IN THE UNITED STATES DISTRICT COURT EASTERN DISTRICT OF ARKANSAS CENTRAL DIVISION

DYLAN BRANDT, et al.,

Plaintiff,

V.

Case No. 4:21-CV-00450-JM

LESLIE RUTLEDGE, et al.,

Defendant.

BRIEF IN SUPPORT OF MOTION TO EXCLUDE EXPERT TESTIMONY
OF MARK REGNERUS

Plaintiffs challenge a law banning gender-affirming medical procedures to treat adolescents with gender dysphoria. They argue that the challenged law prohibits treatments that, based on scientific research and decades of clinical experience, are widely recognized in the medical community as safe and effective. Plaintiffs also allege that by cutting off patients' access to needed care, the challenged law would cause serious harms to the minor plaintiffs and transgender adolescents throughout Arkansas. *See, e.g.*, Mem. Supp. Pls.' Mot. Prelim. Inj. 40–43, 57–61, ECF No. 12. To defend the law, the State asserts an interest in protecting minors from what it contends are unnecessary, harmful, and experimental treatments that, they claim, lack evidence of effectiveness. *See, e.g.*, Defs.' Combined Br. Opp'n Pls.' Mot. Prelim. Inj. 1–2, 34, ECF No. 44. At trial, the Court will be tasked

with resolving factual disputes regarding medical treatments for adolescents with gender dysphoria, which will largely turn on expert testimony.

One of the States' proposed expert witnesses, Prof. Mark Regnerus, offers opinions on a host of medical issues concerning treatments for gender dysphoria—including the state of the research regarding the efficacy of medical treatments for the condition, the actual practices of medical providers in this field, and the ability of minors to consent to the medical interventions prohibited by the state under the Act. But Prof. Regnerus lacks the qualifications necessary to offer those opinions. He is trained exclusively in sociology. According to his profile at the University of Texas, he conducts research "in the areas of sexual behavior, family, marriage, and religion." By his own admission, Prof. Regnerus has no experience or academic training in medicine, mental healthcare, or the treatment of gender dysphoria. And he candidly acknowledges that transgender people have never been a focus of his research.

Prof. Regnerus also opines that the medical organizations, providers, and researchers that support, provide and research medical interventions for gender dysphoria are acting based on ideology rather than science. But these opinions rest

¹ Univ. of Texas at Austin, Dep't of Sociology, Mark Regnerus, https://liberalarts.utexas.edu/sociology/faculty/mdr93 (last accessed June 20, 2022).

on the same medical opinions Prof. Regnerus lacks the qualifications to offer, in addition to anecdotes and unscientific commentary.

Federal Rule of Evidence 702 ensures that expert witnesses opine only on subjects within their field, and that their opinions are based on facts and reliable methodology. Prof. Regnerus has failed to clear that hurdle. His testimony should be excluded in its entirety.

LEGAL STANDARD

Federal Rule of Evidence 702 places a special "gatekeeping role" on district courts. *Daubert* v. *Merrell Dow Pharm., Inc.*, 509 U.S. 579, 597 (1993). To be admissible under Rule 702, expert testimony must satisfy three requirements: "First, evidence based on scientific, technical, or other specialized knowledge must be useful to the finder of fact in deciding the ultimate issue of fact"; "Second, the proposed witness must be qualified to assist the finder of fact"; "Third, the proposed evidence must be reliable or trustworthy in an evidentiary sense, so that, if the finder of fact accepts it as true, it provides the assistance the finder of fact requires." *Lauzon* v. *Senco Prods., Inc.*, 270 F.3d 681, 686 (8th Cir. 2001) (citing *Daubert*, 509 U.S. at 591). "The proponent of the expert testimony must be able to prove its admissibility by a preponderance of the evidence." *Id.* (citing *Daubert*, 509 U.S. at 592).

One of *Daubert's* most important functions is ensuring that witnesses do not speak on matters that go "beyond the expert's expertise." *Am. Auto. Ins. Co.* v. *Omega Flex, Inc.*, 783 F.3d 720, 724 (8th Cir. 2015) (citing *Weisgram* v. *Marley Co.*, 169 F.3d 514, 520–521 (8th Cir. 1999)); *Khoury* v. *Philips Med. Sys.*, 614 F.3d 888, 893 (8th Cir. 2010). "The trial judge must determine whether the testimony has a reliable basis in the knowledge and experience of the *relevant discipline*." *Smith* v. *Rasmussen*, 249 F.3d 755, 758 (8th Cir. 2001) (emphasis added) (quoting *Kumho Tire Co., Ltd.* v. *Carmichael*, 526 U.S. 137, 149 (1999)). Accordingly, courts must exclude testimony whenever the witness is "not well-versed in the particular discipline relevant to their testimony." *Id.* at 759.

Even when a witness is testifying within the bounds of their expertise, the court must separate "expert opinion evidence based on 'good grounds' from subjective speculation that masquerades as scientific knowledge." *Pressley* v. *Lakewood Eng'g and Mfg. Co.*, 553 F.3d 638, 643 (8th Cir. 2009) (quoting *Glastetter* v. *Novartis Pharm. Corp.*, 252 F.3d 986, 989 (8th Cir. 2001)). If the testimony consists only of "vague theorizing based on general principles," it should be excluded. *Pro Serv. Auto., L.L.C.* v. *Lenan Corp.*, 469 F.3d 1210, 1216 (8th Cir. 2006).

ARGUMENT

I. PROF. REGNERUS IS NOT QUALIFIED TO OPINE ON MEDICAL ISSUES CONCERNING THE TREATMENT OF ADOLESCENTS WITH GENDER DYSPHORIA

Under *Daubert*, experts may opine only on matters within their own field of expertise. *See Am. Auto. Ins. Co.*, 783 F.3d at 724; *Khoury*, 614 F.3d at 893. Prof. Regnerus's report offers a range of opinions about medical issues concerning the treatment of adolescents with gender dysphoria that go well beyond his qualifications. Although he may believe that his training in the field of sociology qualifies him to opine on research from other disciplines, *Daubert* requires a meaningful connection between an expert's knowledge and the opinions offered at trial. *See Smith*, 249 F.3d at 758. That connection is completely absent here.

A. Prof. Regnerus Lacks Any Qualifications in Medical Care, Mental Health, Gender Dysphoria, or Transgender People.

Prof. Regnerus's expertise is exclusively in sociology. He has a Bachelor's degree, Master's degree, and PhD in Sociology. Since entering graduate school, he has worked only in sociology as a professor at UT Austin and Calvin College. He has published four books and dozens of peer-reviewed articles on sociological questions. He teaches only sociology courses, and routinely appears to discuss sociology at academic conferences. When asked to describe his "major areas of research," Prof. Regnerus listed "relationship behavior, sexual decisionmaking, . . . sexuality and family formation, marriage, and . . . sociology of

religion," all of which are sociological subjects. *Exhibit 4* – Deposition of Mark Daniel Regnerus, Transcript 44:3–6 ("Dep. Tr.").

By his own admission, Prof. Regnerus has no training or experience in medical care or mental health. *Id.* at 40:16–41:9. During his deposition, he acknowledged that he has never worked in a clinical setting and does not consult with healthcare providers as part of his work. *Id.* at 58:17–20. Prof. Regnerus has not written any peer-reviewed works concerning the effectiveness of medical or mental health treatments, nor does he teach courses on those subjects. *Id.* at 43:12, 52:22–53:1.

Prof. Regnerus's professional experience related to gender dysphoria and transgender people is similarly lacking. His education did not include instruction on "transgender healthcare or [gender] dysphoria," *id.* at 42:9, and he does not teach courses related to gender identity, *id.* at 54:25–55:2. He admitted that transgender people have never been the primary subjects of his work, *id.* at 49:23–50:3, and that he does not know how to diagnose or treat gender dysphoria, *id.* at 100:4–6, 101:23–102:1. His only peer-reviewed work focusing on transgender people in any way is about popular attitudes towards gender-affirming medical interventions. In other words, it is a paper analyzing the personal views of non-medical experts, the vast majority of whom are not transgender. *Id.* at 47:12–17. That work did not study the effectiveness of treatments for gender dysphoria, nor

did it engage with medical research in any way. *Exhibit 1* – Declaration of Mark Regnerus ¶ 56 ("Regnerus Report") (discussing Mark Regnerus & Brad Vermurlen, *Attitudes in The U.S. Toward Hormonal and/or Surgical Interventions for Adolescents Experiencing Gender Dysphoria*, 51(4) Archives of Sexual Behavior 1891 (2022)).

Put simply, Prof. Regnerus lacks any training or experience that would qualify him to speak on healthcare generally or the treatment of gender dysphoria in particular. When asked if it "would be fair to say you don't have academic training, professional experience, or peer-reviewed scholarship related to the efficacy of treatment for gender dysphoria," Prof. Regnerus candidly replied: "True." *Exhibit* 4 – Dep. Tr. 73:23–74:3.

B. Prof. Regnerus's Opinions On Medical Issues Concerning The Treatment of Adolescents With Gender Dysphoria Must be Excluded.

Despite Prof. Regnerus's lack of qualifications concerning medical science, mental health, or the treatment of gender dysphoria, his report is filled with assertions about (1) the research on the efficacy of gender-affirming medical interventions, $Exhibit\ 1$ – Regnerus Report ¶¶ 46-77, (2) the types of research that ought to be conducted about the efficacy of gender affirming medical treatment, id. ¶¶ 70–77, (3) the current practices of medical providers treating adolescent patients for gender dysphoria, id. ¶¶ 98–99, (4) the ability of minors to give informed consent

to medical care, *id.* ¶¶ 120–122, and (5) the connection between adolescent gender dysphoria and suicidality, *id.* ¶¶ 150–162. These claims are well outside Prof. Regnerus's sociological training and experience, and therefore inadmissible under Rule 702. *See Khoury*, 614 F.3d at 893 (holding that expert witnesses cannot opine on topics for which they lack any "training, education, or experience").

1. Opinions about research on the effectiveness of gender-affirming medical care: Prof. Regnerus offers a host of opinions about medical research standards. He devotes an entire section of his report to critiquing existing research that demonstrates the effectiveness of gender-affirming medical care. Exhibit 1 – Throughout these discussions, Prof. Regnerus Regnerus Report ¶¶ 45–69. repeatedly draws conclusions about individual medical studies measuring the effectiveness of hormonal or surgical treatments for gender dysphoria. See, e.g., id. ¶ 57 (stating his view that "a cursory reading of [a medical research study] tells a far less optimistic story than the author's own confident interpretations of the postsurgical data."). And he offers his own views on whether existing medical research shows that gender-affirming medical care benefits patients—going so far as to suggest that his own calculations regarding the efficacy of gender-affirming surgery should "ha[ve] ramifications for the treatment of adult and adolescent patients alike." *Id.* ¶¶ 57–60.

As discussed above, Prof. Regnerus lacks any qualifications in medical care or medical research in general, or the treatment of gender dysphoria specifically. Indeed, during his deposition, he acknowledged that he does not know basic facts about medical care, including facts that would be relevant to his assessment of the state of the science on gender-affirming medical care. For example, despite claiming in his report and during his deposition that any off-label use of drugs is "experimental," Exhibit 1 – Regnerus Report ¶ 70, Prof. Regnerus was unaware of the fact that off-label use of drugs is very common in medicine, as Defendants' medical experts recognized, Exhibit 4 – Dep. Tr. 276:18–20 (admitting that he did not know how common it was for drugs to be used for off-label purposes); see Exhibit 6 – Levine Dep. Tr. 250:14–19; Exhibit 5 – Hruz Dep. Tr. 337:14–18. He also explained that his opinions about how doctors should treat patients when data is uncertain were based only on his "observations of what goes on in the world" and his own "experience with healthcare," rather than "any kind of comprehensive survey" or "scientific study." Exhibit 4 – Dep. Tr. 203:22–204:4.

2. Opinions about research that should be performed: Prof. Regnerus asserts that medical researchers assessing treatments for gender dysphoria should be conducting randomized controlled trials to evaluate the efficacy of that care. $Exhibit\ 1$ – Regnerus Report ¶¶ 70–77. His report attacks the so-called "gender medicine industry" for disagreeing with him about the ethics of randomized

controlled trials in this context, and accuses medical providers of "complicity" and "near lawlessness" for treating patients without first conducting the trials he believes to be necessary. *Id.* ¶¶ 72–76. Despite these broad assertions, Prof. Regnerus stated during his deposition that "it's tough to see [how such a trial would] work in reality," $Exhibit \ 4$ – Dep. Tr. 179:14–15, and acknowledged that he does not know how common it is in medicine for drugs to be used without randomized controlled trials demonstrating effectiveness, *id.* at 276:14–17. Again, he lacks qualifications to opine on medical research.

3. Opinions about how care is currently provided to adolescents with gender dysphoria: Dr. Regnerus claims that healthcare providers treating patients for gender dysphoria are failing to follow the guidance of professional organizations. Specifically, he opines that many clinics are failing to conduct psychological assessments before providing care to minors. Exhibit 1 – Regnerus Report ¶¶ 98–99; Exhibit 2 – Rebuttal Report ¶ 3. When asked to explain the basis for that opinion, Prof. Regnerus confirmed that it was "entirely based on . . . public commentary in newspapers and magazines." Exhibit 4 – Dep. Tr. 247:1–3. He testified that he did not know "how care is provided at any clinics in Arkansas," id. at 244:23–245:1, and had never "observed care being provided in an American clinic," id. at 240:19–21. When asked if he could "name any clinic that is not providing psychological assessments before providing care," Prof. Regnerus replied, "No. But nor can I

name, you know, clinics who are." *Id.* at 242:20–24. As discussed above, Prof. Regnerus lacks qualifications to opine on the treatment of gender dysphoria.

4. Opinions about adolescents' ability to consent to care: Prof. Regnerus repeatedly offers opinions on the psychological capacity and mental health of transgender adolescents. Much of his report discusses research on the ability of teenagers to provide informed consent to medical interventions. See, e.g., Exhibit 1 – Regnerus Report ¶¶ 120–122; see also Exhibit 4 – Dep. Tr. 254:3–9 (testifying that one of his "beefs with this practice" is the "fundamental ability to have informed consent as a 13-year-old about something that you have not experienced"). His report lays out his own assessment of that topic, claiming that adolescents have a "questionable ability to consent." Exhibit 1 – Regnerus Report ¶ 172. As with his other views on medical issues, Prof. Regnerus has no training or experience that would qualify him to offer these views. In addition, he testified that he has no "first-hand experience with the way clinics obtained informed consent" and does not know how clinics in Arkansas do so. Exhibit 4 – Dep. Tr. 296:20–24. When asked to explain the "basis for [his] views on the informed consent process for minors," Prof. Regnerus responded that his knowledge on the topic came "[f]rom people's description of it, from you know, the [Plaintiffs'] expert witnesses." Id. at 284:5–15.

5. Opinions about the relationship between gender dysphoria and suicidality: Prof. Regnerus questions whether gender dysphoria causes increased suicide and suicidality among transgender adolescents. See, e.g., Exhibit 1 – Regnerus Report ¶ 158 ("The evidence for actual suicide risk among gender dysphoria minors is simply unclear."). Throughout his discussion of this topic, he offers opinions about the research on the psychological causes of suicide, and the additional research that he believes would be needed to demonstrate a link between gender dysphoria and suicide. Id. ¶ 160 ("In the absence of data analyses that can control for the effects of other confounding and contributing factors, it becomes very difficult to establish that gender dysphoria is a solitary or primary driver of suicidality."). Once again, Prof. Regnerus lacks the training necessary to evaluate psychological research and has no experience with the diagnosis or treatment of mental health conditions.

Rule 702 requires that experts be "well-versed in the particular discipline relevant to their testimony." *Smith*, 249 F.3d at 759. Here, Prof. Regnerus opines on various medical issues concerning the treatment of gender dysphoria, while lacking the qualifications necessary to make him "well-versed" on those subjects. Prof. Regnerus is not a doctor, does not work in the field of healthcare, has never worked in or observed medical clinics, and has never published research on the effectiveness of medical treatments of any kind, let alone treatments for gender

dysphoria. The complete disconnect between Prof. Regnerus's qualifications and his opinions renders his testimony inadmissible under *Daubert* and Rule 702.

C. General Training in Social Science Does Not Qualify an Expert to Speak on Scientific Research Outside Their Field.

Prof. Regnerus believes that he is qualified to opine on medical research because of his knowledge regarding "basic methodological matters." *Exhibit 1* – Regnerus Report ¶ 3. According to Prof. Regnerus, his sociological training qualifies him to speak to the state of the academic literature in many other disciplines, including medical science, economics, or other social sciences. *Exhibit 4* – Dep. Tr. 121:13–16 (agreeing with the statement "you don't need expertise or training in a particular scientific field to evaluate the quality of the science in that field").

Rule 702, however, is not satisfied simply because an expert has knowledge in some general subject unrelated to the parties' actual dispute. *See Khoury*, 614 F.3d at 893 (holding that even when an expert has "ability or expertise" in one field, his testimony must be excluded when he lacks "training, education, or experience" relevant to the issues in the case). Even when an expert is unquestionably qualified in certain subjects, his testimony must be excluded if those qualifications do not extend to the specific subject matter at issue. *See Am. Auto.*, 783 F.3d at 723 (affirming a district court that limited the testimony of an expert with a "thirty-year academic career, [who] had published hundreds of articles on

metallurgy and arc physics," because he lacked specific qualifications related to "product design and warnings"); *Wheeling Pittsburgh Steel Corp.* v. *Beelman River Terminals, Inc.*, 254 F.3d 706, 715–716 (8th Cir. 2001) (reversing a district court that permitted an expert that was well-qualified in one area to testify on matters beyond his expertise).

The Eighth Circuit has confronted this very problem in a case involving medical treatments for gender dysphoria. In Smith v. Rasmussen, an adult Medicaid recipient sued the Iowa Department of Human Services when the agency denied insurance coverage for a surgical treatment for gender dysphoria. 249 F.3d 755 (8th Cir. 2001). To justify its decision, the agency put forward the testimony of "an experienced, board-certified general psychiatrist, who has treated several patients with sexual disorders," to opine on "the effectiveness and necessity of sex reassignment surgery." Id. at 758. In excluding the expert's testimony on those topics, the district court cited the expert's lack of "expertise in the specialized discipline of gender identity disorder." Id. at 758–759 (emphasis added) (referring to a diagnosis that preceded gender dysphoria). The Eighth Circuit unanimously affirmed that ruling. If the expert in *Smith* was not close enough to the bullseye to offer an opinion on the efficacy of gender-affirming care, then Prof. Regnerus is not even on the board.

Prof. Regnerus has acknowledged that different academic fields use different research standards. He has previously testified about the different research standards applied in sociology and psychology. *Exhibit 8* – March 4, 2014 Trial Tr. 14:2–6, *Deboer v. Snyder*, No. 12-10285 (E.D. Mich. Mar. 4, 2014). He also stated during his deposition that medical researchers employ different standards than sociological researchers. *Exhibit 4* – Dep. Tr. 120:8–13.² Prof. Regnerus's own statements illustrate why the Eighth Circuit has repeatedly held that advanced training in one discipline does not qualify an expert to speak on unrelated topics.

Prof. Regnerus's asserted expertise in "basic methodological matters" is the only qualification he has offered to support his specific opinions on medical research and the effectiveness of treatments for gender dysphoria. *Exhibit 1* – Regnerus Report \P 3. Under the principles long applied in this Circuit, that is not enough.

² In *DeBoer*, Prof. Regnerus opined that psychological research showing that children raised by same-sex parents fared no differently than children raised by opposite-sex parents was methodologically flawed, and that the views of major medical organizations recognizing that conclusion could not be trusted. *Exhibit* 7 – March 3, 2014 Trial Tr. 29–32, *Deboer*, No. 12-10285. He admitted on cross-examination that the research standards used in his field of sociology are different than the standards used in psychological research. *Exhibit* 8 – March 4, 2014 Trial Tr. 13:13–14:22, *Deboer*, No. 12-10285. The district court ultimately decided that his testimony was not credible. *See DeBoer* v. *Snyder*, 973 F. Supp. 2d 757, 765–766 (E.D. Mich. 2014).

II. PROF. REGNERUS'S OPINIONS ABOUT "IDEOLOGICAL CAPTURE" SHOULD ALSO BE EXCLUDED

Prof. Regnerus opines that the "clinical discussion of gender dysphoria has recently become unmoored from empirical assessments," and has been "captured" by "advocates for what is sometimes called 'gender ideology." *Exhibit* I – Regnerus Report ¶ 78. Throughout his discussion of that topic, he claims that organizations, doctors, and researchers who support, provide, and research genderaffirming medical care are acting based on ideology rather than science. But Prof. Regnerus's opinion about "ideological capture" rests on medical opinions he is not qualified to offer.

Prof. Regnerus concludes that ideology is at play only after determining, in his view, that the medical research shows that gender-affirming medical interventions are not effective, $Exhibit\ I$ – Regnerus Report ¶ 86; that minors cannot consent to such treatment, id. ¶ 127; and that treatment is provided on demand, without proper evaluation of patients, id. ¶ 98. Given his assessment of these medical issues related to the treatment of gender dysphoria, it is not surprising that he would look for other factors, besides science, that explain the widespread acceptance of medical interventions to treat gender dysphoria.

Indeed, Prof. Regnerus recognizes that his opinion about ideological capture is inextricably intertwined with his views about medical research:

That any purported 'consensus' on hormonal and surgical interventions at earlier ages should have developed so rapidly among American professional associations—and with so much projected confidence—in the absence of obvious, consistent indicators of treatment efficacy, and amid a surge in cases of gender dysphoria, is suspicious.

Exhibit 1 – Regnerus Report ¶ 86 (emphasis added). As that passage demonstrates, Prof. Regnerus's claim that "American professional organizations" are in the thralls of "ideological capture" is entirely dependent on his belief that those organizations have reached a conclusion about the state of medical science that differs from his own; because he thinks there is an "absence of obvious, consistent indicators of treatment efficacy," everyone who doesn't must be acting based on ideology rather than science.

As discussed in point I, *supra*, Prof. Regnerus is demonstrably unqualified to offer expert opinions on medical issues related to the treatment of gender dysphoria, including whether medical research shows that gender-affirming medical care is effective, how this care is provided, and whether adolescents are able to consent to the care. Because Prof. Regnerus is not qualified to offer expert opinions on the host of medical issues that underlie his views on "ideological capture," he should not be permitted to testify about his conclusions that necessarily depend on these medical judgments. For this reason alone, Prof. Regnerus's testimony related to ideological capture should be excluded.

Prof. Regnerus's opinion that ideological capture is at work with respect to support for gender-affirming medical care also relies on a number of unsupported and unreliable factual claims that should be rejected. *See Pro. Serv. Auto. LLC*, 469 F.3d at 1216 ("In the absence of any record evidence that [the expert] used reliable principles and methods or applied them reliably to the facts of this case to form his opinion, his causation opinion does not satisfy the Rule 702 standards for admissibility."); *Grp. Health Plan, Inc.* v. *Philip Morris USA, Inc.*, 344 F.3d 753, 760 (8th Cir. 2003) (rejecting expert testimony that "entail[ed] a great deal of speculation").

First, Prof. Regnerus's report includes a number of claims about doctors and researchers. He accuses doctors who provide gender-affirming medical care of rushing minors into care without appropriate psychological assessment and providing such care "on demand." *See, e.g., Exhibit 1* – Regnerus Report ¶¶ 96–99; *Exhibit 2* – Rebuttal Report ¶¶ 3, 12, 13. And he accuses researchers of ignoring important research questions, such as transition regret or the demographics of youth identifying as transgender, for ideological reasons. *See, e.g., Exhibit 1* – Regnerus Report ¶ 45 (claiming that researchers are not interested in understanding the purported shift in the number of youth identifying as transgender); *id.* ¶ 109 (asserting that "[t]ransgender activists and their allies in the professions have sought to minimize the experiences of people who regret their transition").

Prof. Regnerus fails to back up these bold claims with any reliable evidence. Instead, on topic after topic, he makes extraordinary claims that rest entirely on anecdotes or unadorned speculation. His claims about the nationwide practices of gender-affirming care providers are based on nothing more than "commentary" and the alleged practices of two clinics. *Id.* ¶ 97–99; *Exhibit 4* – Dep. Tr. 243:20–22. When pressed to explain his views, Prof. Regnerus admitted that he had no firsthand knowledge of how clinics provide gender-affirming medical care or how common it is for clinics to provide treatment in the manner he describes. Exhibit 4 – Dep Tr. 240:19–21, 43:7–10 (when asked at deposition the basis for his statement in his report that psychological assessments of patients are "hardly occurring," he said "I should have said it is unclear in its frequency."). And despite Prof. Regnerus's claims that researchers are ignoring important topics like transition regret or the changing demographics of young identifying as transgender, Exhibit 1 - Regnerus Report ¶¶ 45, 109, his own report cites recent scholarship by one of Plaintiffs' experts on the subject of transition regret, id. ¶ 111 (citing Dr. Turban's 2021 study on detransitioners), while ignoring the discussion of the increase in referrals to gender clinics and the sex ratios of those young patients contained in the most recent draft of WPATH's standards of care, see Exhibit 3 - Karasic Rebuttal Report ¶ 19.

Second, Prof. Regnerus claims that ideological bias is driving the work of major medical organizations that provide guidance on gender affirming medical care, like the Endocrine Society and WPATH. Yet his report is bereft of any analysis distinguishing the Endocrine Society or WPATH from the dozens of comparable organizations that exist throughout the medical community to develop best practices for treatment and advocate on behalf of their patients.

These opinions offered by Prof. Regnerus are "subjective speculation that masquerade[] as scientific knowledge." *Glastetter*, 252 F.3d at 989. In addition to resting on medical opinions he is not qualified to offer, Prof. Regnerus's views on "ideological capture" "entail[] a great deal of speculation [and] involve[] inferences that approach leaps of faith." *Grp. Health Plan*, 344 F.3d at 760. "Where opinion evidence is connected to existing data only by the *ipse dixit* of the expert, a district court may conclude that there is simply too great an analytical gap between the data and the opinion proffered." *Pro Serv. Auto.*, 469 F.3d at 1215. That result is appropriate here, as Prof. Regnerus's report is devoid of any analysis that would close the gap between his sweeping opinions and the limited facts he offers in support. This is an additional reason Prof. Regnerus's testimony about ideological capture should be excluded.

CONCLUSION

Prof. Regnerus's testimony does not reflect the "scientific, technical, or other specialized knowledge" that would make it "useful to the finder of fact." *Lauzon*, 270 F.3d at 686. His opinions concerning medical issues related to the treatment of adolescents with gender dysphoria are well outside his area of expertise, and his opinions concerning ideological capture rely on those opinions he is not qualified to offer, in addition to unsupported assertions. Because Prof. Regnerus is unqualified to offer the opinions in his report, and has failed to base opinions on "good grounds," *Glastetter*, 252 F.3d at 988–89, his testimony should be excluded in its entirety.

Dated: June 22, 2022

/s/ Leslie Cooper

Leslie Cooper
Chase Strangio*
American Civil Liberties Union
Foundation
125 Broad St.
New York, NY 10004
Telephone: (917) 345-1742
lcooper@aclu.org
cstrangio@aclu.org
Attorneys for the Plaintiffs

Beth Echols, Ark. Bar No. 2002203
Christopher Travis, Ark. Bar No. 97093
Drake Mann, Ark. Bar No. 87108
Gill Ragon Owen, P.A.
425 W. Capitol Avenue, Suite 3800
Little Rock, AR 72201
Telephone: (501) 376-3800
echols@gill-law.com
travis@gill-law.com
mann@gill-law.com
On behalf of the Arkansas Civil Liberties
Union Foundation, Inc.
Attorneys for the Plaintiffs

Breean Walas, Ark. Bar No. 2006077 Walas Law Firm, PLLC Sarah Everett, Ark. Bar No. 2017249 Gary Sullivan, Ark. Bar No. 92051 P.O. Box 4591
Bozeman, MT 59772
Telephone: (501) 246-1067
breean@walaslawfirm.com
On behalf of the Arkansas Civil
Liberties Union Foundation, Inc.
Attorneys for the Plaintiffs

Garrard R. Beeney*
Brandyn J. Rodgerson*
Emily T.L. Armbruster*
Alexander S. Holland*
Sullivan & Cromwell LLP
125 Broad Street
New York, NY 10004
Telephone: (212) 558-4000
beeneyg@sullcrom.com
rodgersonb@sullcrom.com
armbrustere@sullcrom.com
hollanda@sullcrom.com
Attorneys for the Plaintiffs

Daniel J. Richardson*
1700 New York Avenue NW
Suite 700
Washington, DC 20006
Telephone: 202-956-7500
richardsond@sullcrom.com

Attorney for Plaintiffs

Arkansas Civil Liberties Union Foundation, Inc. 904 W. 2nd Street Little Rock, AR 72201 Telephone: (501) 374-2842 sarah@acluarkansas.org gary@acluarkansas.org *Attorneys for the Plaintiffs*

Laura Kabler Oswell*
Duncan C. Simpson LaGoy*
Sullivan & Cromwell LLP
1870 Embarcadero Road
Palo Alto, CA 94303
Telephone: (650) 461-5600
oswell@sullcrom.com
simpsond@sullcrom.com
Attorneys for the Plaintiffs

*Admitted pro hac vice

Exhibit 1

IN THE UNITED STATES DISTRICT COURT EASTERN DISTRICT OF ARKANSAS CENTRAL DIVISION

DYLAN BRANDT, et al.,

PLAINTIFFS,

 \mathbf{v} .

No. 4:21-CV-00450-JM

LESLIE RUTLEDGE, et al.,

DEFENDANTS.

DECLARATION OF DR. MARK REGNERUS

Pursuant to 28 U.S.C. 1746, I declare:

I. CREDENTIALS & SUMMARY OF OPINIONS

- 1. I am Professor of Sociology at the University of Texas at Austin. I received my Ph.D. from the University of North Carolina at Chapel Hill in 2000. I became an Assistant Professor of Sociology at UT-Austin in 2002, an Associate Professor in 2007, and a full Professor in 2018.
- 2. I have published numerous articles and four books on sexual relationship behavior and decision-making since 2003.¹ The books, peer-reviewed journal articles, and essays I have written include material on sexual orientation and, more recently, perspectives on transgender medicine. I am an experienced peer reviewer, having reviewed dozens of manuscripts in the past decade on these and related topics—including for top journals in both sociology and sex/sexuality studies (e.g., *Archives of Sexual Behavior*, *Journal of Homosexuality*, etc.). I have extensive survey administration experience as well, having fielded three nationally-representative surveys since 2011, and consulted on survey construction for several others, including the National Study

¹ Regnerus, M. D. (2007). Forbidden fruit: Sex & religion in the lives of American teenagers. Oxford University Press.; Regnerus, M. & Uecker, J. (2011). Premarital sex in America: How young Americans meet, mate, and think about marrying. Oxford University Press.; Regnerus, M. (2017). Cheap sex: The transformation of men, marriage, and monogamy Oxford University Press.; Regnerus, M. (2020). The future of Christian marriage. Oxford University Press.

of Family Growth and the National Longitudinal Study of Adolescent to Adult Health (or Add Health). A more complete review of my professional experience, publications, and research is provided in my curriculum vitae, a copy of which is attached hereto as Exhibit A.

- 3. My experience in the area of transgender research primarily concerns basic methodological matters, involving design, measurement, statistical inference, interpretation of data, and reflections on the research and publication norms that have developed in this new domain in conjunction with media interest and professional and organizational pressures. This leans not only on my knowledge of the research in this domain, but also on the details of quantitative and qualitative research, subjects I have taught to sociology majors at least 20 times since my appointment on the faculty at the University of Texas at Austin.
- 4. I have been retained as an expert witness by the State of Arkansas in connection with this litigation. I have actual knowledge of the matters stated in this report. I base the following opinions on my own knowledge, research, experience, and publications, and the work of other academics and writers. The materials I have used to research and write this report are the standard sources used by other experts in my field. I am receiving \$250 per hour for my time spent preparing this report. My compensation is not dependent upon the outcome of this litigation or the substance of my opinions.
- 5. The focus of this report is on science: scientific evidence, researcher conduct, the culture of scientific organizations, the role of values in scientific inquiry, and a review of the declarations (original and supplemental) submitted by the plaintiffs' witnesses (Deanna Adkins, Armand H. Matheny Antommaria, and Jack Turban) during the preliminary-injunction stage of this litigation. In particular, I focus on the unscientific process by which "affirmative" treatment of transgender-identifying adolescents has come to be the default position advocated by various

professionals and organizations. This is what the sociology of science concerns—an evaluation of how science operates. In this case, I probe how the nascent field of transgender research has, in the United States, come to make premature claims about "standards of care" and profess a level of "consensus" about affirmative care that is not only uncharacteristically rapid for such a new scientific subfield, it's also untrue. The actual practice of many gender clinicians (and surgeons, etc.) continues to shift toward earlier and more invasive treatments, even while the "standards of care" counsel patience. Something is amiss.

- 6. A summary of the key points I discuss in this statement includes:
 - a. The science of the origins and course of gender identity remain in flux.
 - b. The demographics of transgender-identifying adolescents is shifting in ways that are not yet understood.
 - Adolescent gender transition treatments are not supported by randomized clinical trials—an absence that is difficult to account for.
 - d. There is a great deal of evidence that discussion of gender dysphoria and its treatment has been captured by the assumptions of activists promoting what is sometimes called "gender ideology."
 - e. The evidence for suicide risk among gender dysphoric minors is ambiguous at best, and the evidence for claims that treatments for adolescent gender transition lead to sustained improvement in mental health is remarkably weak.
 - f. The practice of "affirmative" treatment for young people with gender dysphoria is characterized by dubious assumptions and questionable value

judgments that increasingly result in a consumer-driven medical culture out of step with science.

- 7. My intention is not to offer a comprehensive literature review of the entire field of research in transgender science—or even that which is focused on minors. That is a task unsuited to this document. Rather, one of the central purposes of my report is to describe how and why any supposition that there is a legitimate scientific consensus about treatment for adolescents is unmerited. The research I cite and discuss is compelling evidence favoring a proper interpretation of this field as "in development" rather than as "settled science."
- 8. In the declaration of Dr. Deanna Adkins, dated June 11, 2021 ("Adkins"), she identifies affirmative care as treatment for gender dysphoria that is "aimed at eliminating the clinically significant distress a patient experiences by helping the patient live in alignment with their gender identity." The same treatment is referred to both in the medical literature and in this report using similar terms, including "gender transition," "gender affirming care," and "affirmative" treatment—an approach that (typically) recommends the hormonal and surgical procedures that Arkansas has prohibited doctors from performing on minors.
- 9. I make no claims here about the most prudent course of treatment for a particular patient, and I have no desire to stoke identity politics or foster moral panic. Instead, as a sociologist, my claims highlight the unscientific processes by which "gender affirming" treatments have come to appear not simply as the dominant approach but increasingly the only permitted approach. And even among its proponents there is growing pressure to skip the psychological evaluations first and move to offer treatments to minors at younger and younger ages. All of this has

² Adkins, D. (2021) Declaration, U.S. District Court, Eastern District of Arkansas, Case No.: 4:21CV450-JM, p. 4.

happened amid a surge in cases of gender dysphoria and transgender identity that emerged suddenly, was unanticipated, and remains demonstrably undertheorized.³ In other words, most scholars have been insufficiently curious about these recent developments and appear instead to be more interested in connecting research strategies and conclusions to fit affirmative care prescriptions. This is the "elephant in the room" that ought to give pause to practitioners and their professional societies. But, instead, many have pressed ahead without sufficient interest in understanding why the current realities have come to be. This is not how medical science works in nearly every other branch. Indeed, medical science is often accused of being too cautious and conservative, preferring—as it typically does—wide and consistent confirmation of stably discernible patient benefits that outweigh the risks involved.

- 10. Since pubertal blockers are already permitted and prescribed for the treatment of precocious puberty in one's natal sex, the plaintiffs' witnesses frame Arkansas's law as discrimination regarding who can access such treatments. But the issues at stake are even more fundamental than a question of fairness. Those fundamental issues include: First, has affirmative care been—and is it now—demonstrably and consistently helpful to minors, in terms of enhanced long-term psychological and physical health? Second, ought minors be permitted to make such consequential, life-altering decisions?
- 11. Lurking in the background are other inexplicable patterns besides a rapid surge in gender dysphoria. Twenty years ago, far more natal males than females exhibited gender dys-

³ Bernadette Wren, who was a senior clinician at the UK Tavistock gender clinic until her retirement, described the situation this way: "There are morally complex, there are clinically complex, there are politically complex issues that we are grappling with and there aren't any easy answers. One of the things about the gender field is you can't plausibly develop a foundational theory of gender identity in which to ground the work." See Gossling, G. (2020). Bernadette Wren: On change. *In mind*. https://100years.tavistockandportman.nhs.uk/bernadette-wren-on-change

phoria. Ten years ago, comparable numbers of natal males and females sought help for it. To-day, the sex ratio has reversed: for every one natal male seeking help, approximately three natal females do. Why? And why aren't certain researchers more interested in understanding this than in shuttling patients (regardless of their natal sex) toward "affirmative" care?

- 12. The plaintiffs' witnesses repeatedly reference current treatment regimens, "consensus," "standards of care," etc. But at a basic level, the question is whether any putative consensus has been formed without undue pressure. The evidence suggests that it has not.
- 13. Meanwhile, there is no global or even Western "consensus" on transgender treatments for adolescents. There is, rather, a coalition of organizations in the United States, Canada, the Netherlands, the United Kingdom, and Australia that use multiple platforms—scientific, medical, legal, and media—to suggest there is a consensus and employ language intended to reinforce the claim of a professional consensus backing "affirmative" care.
- 14. In reality—that is, when you include numerous pediatricians, psychotherapists, some researchers and endocrinologists, together with national health care systems in several European countries—there is no wide, shared consensus about the prudence and intelligence of giving puberty blockers and cross-sex hormones to adolescents. Only professional organizations whose assertions are partial to transgender activists would suggest there is a consensus. Indeed, how could a scholarly consensus emerge so quickly in a domain where research barely existed two decades ago, where much of what has been written is less than 7 years old, and is experiencing a surge in cases? Even some of the most well-known pioneering researchers in the field

acknowledge this: "...in actual practice, no consensus exists whether to use these early medical interventions."

15. Moreover, the consensus that is purported to exist is tentative and fragile, divided over age standards and whether putting patients in the driver's seat of their own care is a good idea.⁵ Although supporters of "affirmative" treatment approaches tend to *formally* endorse the experimental "Dutch protocol," the contemporary practice of American gender clinics is not consistent even with that approach. In the Dutch protocol, baseline health and high functioning are required for adolescent patients to proceed through treatment. Psychiatric co-morbidities and the absence of childhood gender dysphoria (i.e., adolescent-onset only) are grounds for exclusion from subsequent treatment.⁶ American gender clinics, however, increasingly offer treatment ondemand and with a much lower threshold for medical intervention than the Dutch protocol prescribes. That protocol is more rigorous and exclusive than the majority of patients who make up published American transgender research samples—in other words, most of the American patients would not qualify for the (experimental) procedures even under the Dutch protocol. Hence, when Dr. Turban appeals to the results of studies employing the Dutch protocol—including numerous references to Dr. de Vries's research—to support affirmative gender medical treatments, this is sleight of hand, since the momentum in pediatric gender medicine that Turban endorses now disregards central aspects of the Dutch protocol that de Vries has long followed.

⁴ Vrouenraets, L. J., Fredriks, A. M., Hannema, S. E., Cohen-Kettenis, P. T., & de Vries, M. C. (2015). Early medical treatment of children and adolescents with gender dysphoria: An empirical ethical study. *The journal of adolescent health: Official publication of the Society for Adolescent Medicine*, *57*(4), 367–373, p. 367. https://doi.org/10.1016/j.jadohealth.2015.04.004

⁵ Edwards-Leeper, L., & Anderson, E. (2021). The mental health establishment is failing trans kids. *Washington Post*, November 24. https://www.washingtonpost.com/outlook/2021/11/24/trans-kids-therapy-psychologist.

⁶ For a description of the protocol, see: Delemarre-van de Waal, H. A., Cohen-Kettenis, P. T. (2006). Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. *European journal of endocrinology*, *155*(suppl 1):S131–S137.

- 16. In essence, Drs. Adkins, Antommaria, and Turban are endorsing "affirmative" gender treatment based on research conclusions from a literature whose criteria for inclusion has long been quite different—more selective and rigorous—than it is today. To say, as does Thomas Steensma of the Dutch Center of Expertise on Gender Dysphoria, that "more research is really necessary, and very much needed" is an understatement. Moreover, Steensma identifies the experimental nature of it all: "Little research has been done so far on treatment with puberty blockers and hormones in young people. That is why it is also seen as experimental." The nature of the research, given it is "still being evaluated for efficacy, safety, and acceptability," qualifies it as experimental under the American Psychological Association's definition of experimental treatment."
- 17. How do adolescents fare when they are *not* screened for psychiatric co-morbidities? Finnish researchers can answer this question. "Those who had psychiatric treatment needs or problems in school, peer relationships and managing everyday matters outside of home continued to have problems..." Indeed, "[p]sychiatric comorbidities, particularly depression, anxiety disorders and autism spectrum disorders as well as suicidality and self-harming behaviors are common among adolescents seeking gender reassignment." Can "affirmative" treatment help them? We would have to suspend our attention to *any* study conclusions that employ the experimental Dutch protocol in order to make this assessment.

⁷ Tetelepta, B. (2021, February 27). More research is urgently needed into transgender care for young people. Where does the large increase of children come from? *Voorzij*.https://www.voorzij.nl/more-research-is-urgently-needed-into-transgender-care-for-young-people-where-does-the-large-increase-of-children-come-from/

⁸ https://dictionary.apa.org/experimental-treatment

⁹ Kaltiala, R., Bergman, H., Carmichael, P., de Graaf, N. M., Egebjerg Rischel, K., Frisén, L., Schorkopf, M., Suomalainen, L. & Waehre, A. (2020). Time trends in referrals to child and adolescent gender identity services: A study in four Nordic countries and in the UK. *Nordic journal of psychiatry*, 74(3), 213-219. The quotes are from page 213. doi: 10.1080/08039488.2019.1667429. See also Kaltiala-Heino, R., Sumia, M., Työläjärvi, M., & Lindberg, N. (2015). Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development. *Child and Adolescent Psychiatry and Mental Health*, 9(1), 1-9.

18. Fundamentally, the ground has shifted here. Moves to medically treat adolescent gender dysphoria are being endorsed based on conclusions from studies whose sample inclusion criteria were far stricter than is commonly the case in practice today. The American medical establishment is being bamboozled by a bait-and-switch tactic, in service to a politicized movement to open up transgender medicine to adolescent patients who previously would not have been eligible for it.

II. DOCUMENTING GENDER IDENTITY AND EXPLAINING THE RECENT SURGE IN GENDER DYSPHORIA AND TRANSGENDER-IDENTIFYING ADOLESCENTS

19. Transgender self-identifications have surged in the United States, and throughout much of the West, in the past 10 years. What had once comprised around 0.3 percent of the total population as recently as 2011 doubled to 0.6 percent by 2016 (with adolescent transgender self-identification comprising 0.7 percent). Since then, the pace of increase has accelerated further, especially among youth. Population-based survey data from 10 states and nine urban school districts found that an average of 1.8 percent of high school students currently identify as transgender. A study in *Pediatrics*, leaning on a 2016 statewide survey in Minnesota, revealed a figure of 2.7 percent. A 2018 application of the CDC's Youth Risk Behavior Survey to just

¹⁰ The states are as follows: Colorado, Delaware, Hawaii, Maine, Maryland, Massachusetts, Michigan, Rhode Island, Vermont, and Wisconsin; the nine large urban school districts are: Boston, Broward County, Cleveland, Detroit, District of Columbia, Los Angeles, New York City, San Diego, and San Francisco; see Johns, M. M., Lowry, R., Andrzejewski, J., Barrios, L. C., Demissie, Z., McManus, T., Rasberry, C. N., Robin, L., & Underwood, J. M. (2019). Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students - 19 states and large urban school districts, 2017. *MMWR Morbidity and mortality weekly report*, 68(3), 67–71. https://doi.org/10.15585/mmwr.mm6803a3

¹¹ Rider, G. N., McMorris, B. J., Gower, A. L., Coleman, E., & Eisenberg, M. E. (2018). Health and care utilization of transgender and gender nonconforming youth: A population-based study. *Pediatrics*, *141*(3) e20171683. https://doi.org/10.1542/peds.2017-1683

under 5,000 high schoolers in a Northeastern city school district yielded 9.2 percent who reported "incongruence between gender identity and sex assigned at birth." This is no uptick; this is an inexplicable explosion that demands attention.

- 20. Countries like the UK—with a national health system—are better poised to keep centralized statistics about adolescent gender clinic patients. In 2009-10, a total of 32 natal females and 40 natal males were referred to the country's Gender Identity Development Service (or GIDS). A mere five years later, those figures rose to 399 natal females and 250 natal males. At the most recent year of data reporting (2018-19), the numbers had climbed to 1,740 natal females and 624 natal males. Beginning in 2011-12, the share of natal females outnumbered those of natal males, but by 2018-19, the sex ratio of referrals had exploded to 2.8 females for every male. This includes 171 children under age 10, 52 of whom are ages 3-6. A similar sex ratio is reported in North American gender clinics.
- 21. Between 2015 and 2019, there was also a 27% increase among American high school boys in the share that identified as nonheterosexuals (from 4.5 to 5.7 percent). The same estimate among girls was even larger: a 46% increase (from 12.2 to 17.8 percent). But the pace of growth in adolescent transgender self-identifications far eclipses the climb in rates of nonheterosexual orientations.

¹² Kidd, K. M., Sequeira, G. M., Douglas, C., Paglisotti, T., Inwards-Breland, D. J., Miller, E., & Coulter, R. W. S. (2021). Prevalence of gender-diverse youth in an urban school district. *Pediatrics*, 147(6): e2020049823

¹³ Tavistock & Portman NHS Foundation Trust. (2019, 28 June). Referrals to the gender identity development service (GIDS) level-off in 2018-19. https://tavistockandportman.nhs.uk/about-us/news/stories/referrals-gender-identity-development-service-gids-level-2018-19/

¹⁴ Sorbara, J. C., Chiniara, L. N., Thompson, S., & Palmert, M. R. (2020). Mental health and timing of gender-affirming care. *Pediatrics*, *146*(4) e20193600. https://doi.org/10.1542/peds.2019-3600

¹⁵ Rapoport, E., Athanasian, C. E., & Adesman, A. (2021). Prevalence of nonheterosexual identity and same-sex sexual contact among high school students in the US From 2015 to 2019. *JAMA pediatrics*. doi:10.1001/jamapediatrics.2021.1109

- 22. Dr. Turban, in his supplemental declaration submitted during the preliminary injunction phase of this litigation, balks at any use of the term "social contagion" to describe the rapid surge in transgender identity. "In contrast," he writes, "transgender identity has been shown to be primarily influenced by innate biological factors." While I have no reason to contest the presence of biological factors in the etiology of transgender identity, it strains the imagination to suggest there is nothing "social" going on here, especially since we are talking about something that once affected less than 1 in 10,000 children, according to DSM-5 prevalence rates. ¹⁶
- 23. Intersex cases, often used to call attention to transgender cases, are distinctive and occur in roughly one in every 5,000 births, an estimate consonant across three continents.¹⁷ They are considered a type of disorder of sex development (DSD), and are not, as has sometimes been suggested, evidence of a "spectrum" of biological sex.
- 24. The plaintiffs' preliminary-injunction filings in this litigation described gender identity as both "innate" and "immutable," as well as "durable and cannot be altered through medical intervention," citing Dr. Adkins's declaration as its sole support. Although Adkins appears to have characterized gender identity using the term "innate" before, 18 the report she submitted during the preliminary-injunction stage makes no use of that term (nor of "immutable"), instead describing a person's gender identity merely as "fixed." It is fair to say the terminology,

¹⁶ Tavistock & Portman NHS Foundation Trust (2021, June 3). Reply to Freedom of Information request for Charing Cross and GIC waiting and intake figures made by Harry Burns. https://www.whatdotheyknow.com/request/request_for_charing_cross_gic_wa?nocache=incoming-1805111#incoming-1805111

¹⁷ Kim, K. S., & Kim, J. (2012). Disorders of sex development. *Korean journal of urology*, *53*(1), 1-8. doi: 10.4111/kju.2012.53.1.1; Thyen, U., Lanz, K., Holterhus, P. M., & Hiort, O. (2006). Epidemiology and initial management of ambiguous genitalia at birth in Germany. *Hormone research in paediatrics*, *66*(4), 195-203. https://doi.org/10.1159/000094782; Sax, L. (2002). How common is intersex? A response to Anne Fausto-Sterling. *Journal of sex research*, *39*(3), 174-178. https://doi.org/10.1080/00224490209552139

¹⁸ Adkins, D., (2016). Declaration, U.S. District Court, Middle District of North Carolina, Case 1:16-cv-oo236-TDS-JEP https://www.aclu.org/sites/default/files/field_document/AdkinsDecl.pdf.

together with the science of the origins and course of gender identity, remain in flux. Indeed, this fact is acknowledged. The *Standards of Care* (version 7) published by the World Professional Association for Transgender Health (WPATH), for example, recognizes that "[t]erminology in the area of health care for transsexual, transgender, and gender-nonconforming people is rapidly evolving; new terms are being introduced, and the definitions of existing terms are changing." The Endocrine Society's guidelines likewise acknowledge that "[t]erminology and its use vary and continue to evolve."²⁰

- 25. Categorical claims about the immutability of sexual orientation have fared well in recent legal decisions, as University of Utah psychology professor Lisa Diamond observed.²¹ To invoke "immutability" in the absence of a genuine consensus on the etiology of gender dysphoria—especially amid the sudden surge in cases and its sex ratio disparity reversal—suggests political calculation is at work. There is little to suggest that experts in this domain are operating without particular interests.
- 26. Neither adolescent-onset gender dysphoria nor the rise in nonbinary self-identities fit the narrative that gender identity is "immutable" or "durable." Rather, it suggests profound fluidity. What is durable or immutable about a "nonbinary" gender self-identity? Dr. Adkins, on the other hand, maintains that a person's gender identity "is fixed, is not subject to voluntary control, cannot be voluntarily changed, and is not undermined or altered by the existence of other sex-related characteristics that do not align with it," an assertion that seems out of step with the

¹⁹ World Professional Association for Transgender Health. (2012). *Standards of care for the health of transsex-ual,transgender, and gender nonconforming people* [7th Version]. https://www.wpath.org/publications/soc The quote is from p. 95.

²⁰ Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Hassan Murad, M., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T'Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. *The journal of clinical endocrinology & metabolism*, 102, 11, 3869–3903, p. 3874. https://doi.org/10.1210/jc.2017-01658

²¹ Diamond, L. M. & Rosky, C. J. (2016). Scrutinizing "immutability": Research on sexual orientation and its role in legal advocacy for the rights of sexual minorities rights? *Journal of Sex Research*, *53*, 363-391.

American Academy of Pediatrics (AAP) policy statement on the care and support for transgender and gender diverse children and adolescents, which holds that the self-recognition of gender identity "develops over time" and yet "[f]or some people, gender identity can be fluid, shifting in different contexts." Meanwhile, Columbia University sociologist Tey Meadow reports in her article on the production of legal gender classifications: "Many courts look to medical definitions of sex.... yet there is no consensus about when gender change actually happens." ²³

- 27. Accounting for the surge in adolescent transgender cases has been very challenging for two reasons. First, it was an unexpected development. Ten years ago, there was simply no clinical literature on females ages 11 to 21 suffering from gender dysphoria.²⁴ Second, early onset gender dysphoria has been documented for years, but primarily in natal boys—and those typically lacking in extensive comorbidity (that is, co-occurring psychological problems such as anxiety or depression).
- 28. The new surge in adolescent transgender cases cannot be simplistically attributed to "pent-up demand"—that is, by suggesting that gender dysphoria and transgender self-identification exhibited longstanding manifestations that simply went undiagnosed or were entirely stigmatized. If that were true, we should be witnessing a parallel and documentable rise in gender dysphoria among, say, middle-aged adults. But no such rise has been observed. As recently as 2020, a Pew research study noted that only 0.2 percent of Gen X respondents (i.e., 40-55-year-olds) identify as transgender.²⁵ Dr. Turban, in his supplemental declaration, implies that were it

²² Rafferty, J. & Committee on Psychosocial Aspects of Child and Family Health.(2018). Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents, 142 *Pediatrics* 4 e20182162; doi: https://doi.org/10.1542/peds.2018-2162.

²³ Meadow, T. (2010). "A rose is a rose": On producing legal gender classifications, *Gender & society 24*(6), 814–837, p. 824. https://doi.org/10.1177/0891243210385918

²⁴ Shrier, A. (2020). Irreversible damage: The transgender craze seducing our daughters. Regnery Publishing.

²⁵ Jones, J. M. (2021, February 24) LGBT identification rises to 5.6% in latest U.S. estimate. *Gallup*. https://news.gallup.com/poll/329708/lgbt-identification-rises-latest-estimate.aspx

not for longstanding stigma—now diminishing, he admits—a similar surge in transgender self-identification would have materialized among adults as well (page 34). This is unlikely.

- 29. Second, the surge makes for a very sensitive research environment, all the more so given the rapid clinical shift from a "watchful waiting" approach to adolescent gender dysphoria to an "affirmative care" approach in which a swifter move to puberty blockers and cross-sex hormones is suggested. Among "affirmative care" backers, there is a further division that has materialized—between those who would press for psychological evaluations and monitoring, and a more aggressively affirming model characterized by a "trust the patient" (and treat promptly), with few questions asked. This ongoing shift appears to constitute much of the political struggle being witnessed over adolescent gender dysphoria, and it makes research efforts in this domain difficult to monitor, since research conclusions based on data about one approach (watchful waiting) are being used to foster endorsements of altogether different approach ("standard" as well as aggressive affirmative care).
- 30. In an attempt to understand this surge, Brown University public health scientist Lisa Littman explored possible "cluster outbreaks" of what she identified as "rapid onset gender dysphoria" (ROGD) among adolescents, meaning that the dysphoria happens suddenly either during or after puberty among teenagers who displayed no indications of such tendency in their childhood.²⁶ (Others identify this as "adolescent-onset" gender dysphoria.²⁷) The study, which inquired of parents of teens, noted that ROGD tended to occur within groups of friends: more

²⁶ Littman, L. (2018). Rapid-onset gender dysphoria in adolescents and young adults: A study of parental reports. *Plos one*, *13*(8), e0202330. https://doi.org/10.1371/journal.pone.0202330

²⁷ de Vries, A. L. (2020). Challenges in timing puberty suppression for gender-nonconforming adolescents. *Pediatrics*, *146*(4). doi: https://doi.org/10.1542/peds.2020-010611; Sevlever, M., & Meyer-Bahlburg, H. F. (2019). Lateonset transgender identity development of adolescents in psychotherapy for mood and anxiety problems: Approach to assessment and treatment. *Archives of sexual behavior*, *48*(7), 1993-2001. https://doi.org/10.1007/s10508-018-1362-9

than one-third of the friendship groups in the study witnessed half or more of the group identifying as transgender in a similar time frame. This, Littman noted, is about 70 times higher than the expected (0.7%) prevalence rate. Only 13 percent of parents noted no evidence at all of a "social influence."

- 31. Parents of the adolescents in the study tended to describe "a process of immersion in social media, such as 'binge-watching' YouTube transition videos and excessive use of Tumblr, immediately preceding their child becoming gender dysphoric." Littman also observed that 22 percent of adolescents in her study "had been exposed to online advice about what to say to doctors to get hormones." Moreover, "the vast majority of parents were reasonably sure or positive that their child misrepresented their history to their doctor or therapist." A recent study about the surge in adolescent demand for gender dysphoria treatment in the UK and four Nordic countries similarly noted a potential role of social and media influences.³⁰
- 32. Studies like Littman's are exploratory, however, and not designed to discern causation. Professor Littman did not draw hard conclusions from her survey, which was nonrepresentative and relied on an opt-in sampling strategy that is very common in the study of transgender patients. Rather, she documented the associations between what she describes as the phenomenon of ROGD and certain social and psychiatric conditions.
- 33. An outcry on social media emerged after the Littman study was published. The journal's editors pledged to "seek further expert assessment on the study's methodology and analyses." That is, they re-reviewed the study, a very unusual move in the sciences. This post-

²⁸ Littman (2018), p. 3.

²⁹ Littman (2018), p. 36.

³⁰ Kaltiala, R., Bergman, H., Carmichael, P., de Graaf, N. M., Egebjerg Rischel, K., Frisén, L., Schorkopf, M., Suomalainen, L. & Waehre, A. (2020). Time trends in referrals to child and adolescent gender identity services: A study in four Nordic countries and in the UK. *Nordic journal of psychiatry*, 74(1), 40-44. doi: 10.1080/08039488.2019.1667429

publication review resulted in no substantive changes to the study's results, suggesting the motivation was rooted in political rather than scientific concerns. This example highlights the challenging atmosphere for documenting, understanding, and attempting to explain what is going on.

- 34. WPATH mildly criticizes Littman's study in their draft version 8 of their Standards of Care—which became available for preview and comment in December 2021 after 10 years of Version 7. While WPATH claimed Littman's study "contained significant methodological challenges which must be considered as context for the findings," it nevertheless admits much of what Littman revealed, noting that "social influence on gender is salient" and that "by clinical observation an increasing number of youth are coming to self-identify as gender diverse in later adolescence." ³¹
- 35. Dr. Turban's disregard for Professor Littman's inquiry about the social cues of adolescent-onset gender dysphoria is obvious: her work is dismissed because "the scientific current understanding...does not focus on 'social contagion." Perhaps the problem is less with Littman than with purveyors of a "science" that is more interested in safeguarding particular answers than it is with asking questions.
- 36. On page 7 of his report, Dr. Turban favorably cites a study published in a 2015 issue of *Psychoendocrinology* that measured Child Behavior Checklist scores based on parental self-report. Thus, Dr. Turban, whose previous declaration (on page 32) criticizes Littman's reliance on a parental questionnaire, has no trouble with parental self-reports as a measurement technique so long as they support his position.

16

³¹ World Professional Association for Transgender Health. (2021). *Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People* [DRAFT 8th Version]. https://www.wpath.org/publications/sochttps://www.wpath.org/media/cms/Documents/SOC%20v8/SOC8%20Chapters%20for%20Public%20Comment/Letter%20eBlast%20-%20SOC8%20Public%20Comment%20Period%20December%202021%20FINAL.pdf?_t=1638464778

- 37. Dr. Turban seems far less curious about understanding surging gender dysphoria and the sex-ratio reversal than one would expect a purported expert about transgender identity to be. This matters. Professor Littman's exploratory research was lambasted because it introduced the possibility that transgender identity is—at an unknown rate—not innate but developmentally responsive to social cues for an unknown but significant number of cases. If Littman is right, it means greater attention to the diverse origins of gender dysphoria is in order, with likely ramifications for treatment options. But her research is disparaged because this is not in accord with claims of those advocating for aggressively "affirmative" treatment. This isn't how science is supposed to work.
- 38. Dr. Turban's own attempt (beginning on page 33) to explain the surge in gender dysphoria and self-identified transgender cases is odd and under-documented, suggesting that he too—like most researchers in this domain—gives this important matter little thought. He claims that the "increase in referrals" is due to several causes. Among these, Dr. Turban suggests that "parents in the past may have had limited literacy regarding gender diversity," something that has been ameliorated today. In other words, he claims that in the past parents neither had the language nor the interest in aiding their children to live as their authentic selves, except perhaps in "extreme types" of gender dysphoria. But today, he claims, "owing to media attention and the internet, it is easier to access information...making the threshold lower to search for help" (page 34). Dr. Turban thus appeals to the effects of media attention and the internet while simultaneously maintaining that Professor Littman's interest in understanding the role of "social" forces and "transgender-related content" on the internet "is a fringe view not supported by evidence" (page 32). This is an obvious double standard.

- 39. Finally, Dr. Turban attempts to explain why clinics are "seeing more birth-assigned females than males in recent years"—which is a rather mild way of describing what is not a mere uptick but a radical reversal and surge, as I previously described. Dr. Turban begins with the observation that "tomboys" were much more likely to be "accepted in society, whereas feminine boys are ridiculed." Perhaps so. But then he speculates that this phenomenon "likely led to more transgender males being satisfied with pushing gender expression toward more male [sic] without seeking support from a gender clinic..." (page 35). In asserting this, Dr. Turban categorically and anachronistically redefines tomboys as transgender males who simply had no access to a gender clinic. Where are they today? Still hidden—having suppressed their true identity? This explanation beggars belief. Perhaps instead, yesterday's tomboys are largely content to have avoided medical dependency, living without health implications or impairments from lifelong treatments that were, at the time, unavailable. Their gender non-conformity fostered their own resilience.
- 40. Dr. Turban claims that "sex ratios that favor birth-assigned females" among the population of transgender patients is not unprecedented. While I can appreciate the subsequent international citations and consideration of international data, the sample sizes are simply too small (24 total cases of "female-to-male transsexuals" who "came from different parts of Poland" over four years in the study Dr. Turban cites³²) to suggest anything about the sex ratio of transgender Poles in the 1970s. The rate of the much larger number seeking "sexologic" treatment from which this small pool is drawn, however, revealed the standard male-dominated pattern.

³² Godlewski, J. (1988). Transsexualism and anatomic sex ratio reversal in Poland. *Archives of sexual behavior*, *17*(6), 547-548.

- 41. It is also ironic for Dr. Turban to have criticized Littman's use of an opt-in, recruited "anonymous online survey," when he has published extensively—including citations in his previous declaration—from the 2015 United States Transgender Study. The USTS recruited networked, self-identified transgender or nonbinary participants by advertising their survey among "active transgender, LGBTQ, and allied organizations." Now, there's nothing inherently wrong with collecting data using a nonrandom approach like this, and it is common in this domain. The problem, in this case, is when the conclusions based on such data are delivered to the reader in a way that suggests they are consonant with everyone who has identified as transgender or experienced gender identity disorder or dysphoria. Hence, to impugn Littman's strategy is to impugn Dr. Turban's own extensive use of the same method of collecting data from "some anonymous people recruited from the Internet..." (page 32). 35
- 42. That Dr. Turban should commend the Almazan and Keuroghlian study (on page 25 of his initial declaration) is another irony, since it too is based on the USTS. Talk of a "control group" in the Almazan and Keuroghlian study connotes an experimental design, a randomi-

³³ James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality.

³⁴ Littman, L. (2020). The use of methodologies in Littman (2018) is consistent with the use of methodologies in other studies contributing to the field of gender dysphoria research: Response to Restar (2019). *Archives of sexual behavior*, 49(1), 67-77. https://doi.org/10.1007/s10508-020-01631-z

³⁵ See, for example: Turban, J. L., King, D., Li, J. J., & Keuroghlian, A. S. (2021). Timing of social transition for transgender and gender diverse youth, K-12 harassment, and adult mental health outcomes. *Journal of adolescent health*. https://doi.org/10.1016/j.jadohealth.2021.06.001; Turban, J. L., Loo, S. S., Almazan, A. N., & Keuroghlian, A. S. (2021). Factors leading to "detransition" among transgender and gender diverse people in the United States: A mixed-methods analysis. *LGBT health*, 8(4), 273-280. https://doi.org/10.1089/lgbt.2020.0437; Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2020). Pubertal suppression for transgender youth and risk of suicidal ideation. *Pediatrics*, 145(2), e20191725. https://doi.org/10.1542/peds.2019-1725; Turban, J. L., Beckwith, N., Reisner, S. L., & Keuroghlian, A. S. (2020). Association between recalled exposure to gender identity conversion efforts and psychological distress and suicide attempts among transgender adults. *JAMA Psychiatry*, 77(1), 68-76. doi:10.1001/jamapsychiatry.2019.2285; Turban, J. L., King, D., Reisner, S. L., & Keuroghlian, A. S. (2019). Psychological attempts to change a person's gender identity from transgender to cisgender: Estimated prevalence across US States, 2015. *American journal of public health*, 109(10), 1452-1454. https://doi.org/10.2105/AJPH.2019.305237

zation process, and/or some sort of multi-wave analysis in order to establish an obvious time order to events. The USTS and, by extension, the Almazan and Keuroghlian study, offers none of these methodological strengths and characteristics.

- 43. Moreover, the USTS creates the impression that the data collection effort was a population-based random sample, like the US Census. It is not. Indeed, the USTS yields information about the transgender population that is decidedly different from that which can be learned from the 2014 CDC's Behavioral Risk Factor Surveillance System (BRFSS) data, which is the product of a probability sample from 19 states (and Guam).³⁶ When the two are compared, stark differences are revealed, further suggesting that the empirical "truth" about the transgender population is simply difficult to discern—a fact of life in this domain of research. For example:
 - a. Unemployment: 15% in the USTS vs. 8% in the BRFSS
 - b. Sexual orientation: 47% of male-to-female identify as LGB in the USTS vs. 15%
 in the BRFSS; 24% of female-to-male identify as LGB in the USTS vs. 10% in the BRFSS
 - c. Currently married: 18% in the USTS vs. 50% in the BRFSS
 - d. Child in the household under 18: 14% in the USTS vs. 32% in the BRFSS
 - e. General health rated as fair or poor: 22% in the USTS vs. 26% in the BRFSS
- 44. There are two conclusions to draw from this comparison of the USTS and BRFSS samples. First, opt-in samples like the USTS are for understanding processes and possibilities, not populations (as in the BRFSS). Second, Littman's use of an opt-in sample was hardly inappropriate. She sought to understand a process (that of rapid-onset gender dysphoria, or as others

³⁶ Meyer, I. H., Brown, T. N., Herman, J. L., Reisner, S. L., & Bockting, W. O. (2017). Demographic characteristics and health status of transgender adults in select US regions: Behavioral Risk Factor Surveillance System, 2014. *American journal of public health*, 107(4), 582-589. https://doi.org/10.2105/AJPH.2016.303648

call it, late-onset or adolescent-onset gender dysphoria), one that curiously few scholars seem interested in understanding.

45. The general surge—and particular reversal of the anticipated sex ratio—in cases of adolescent gender dysphoria (commonly with comorbid conditions) has not simply escaped scholars and clinicians. Many seem actively hesitant to explore the matter, and quick to criticize those researchers who do. In most other domains of medicine, there is a rush to understand new developments. Professional, political, and cultural interests appear to be at stake here, putting the long-term flourishing of patients at risk.

III. STUDY CONCLUSIONS OF TRANSGENDER TREATMENT EFFECTS ARE DEMONSTRABLY INADEQUATE.

- 46. Despite ample scientific resources—adequate funding, the interest of professional organizations, and competent researchers—the science of gender identity (and transgender outcomes) is often characterized by modest evidence followed by overreaching conclusions. Any talk of "consensus" or of enduring "standards" are baseless assertions. It is more accurate to say the field is rapidly evolving.
- 47. It remains the fact that little is understood about the long-term physical effects of puberty blockers and cross-sex hormones, especially when they are administered during those years that are critical for biological and brain development.³⁷ This is in part a function of (1) how few minors experienced these treatments in the past—a small pool to study, and (2) the fact that the surge in such treatments remains less than a decade old. In other words, too few and too new.

³⁷ Wren, B. (2014). Thinking postmodern and practising in the enlightenment: Managing uncertainty in the treatment of children and adolescents. *Feminism & psychology*, 24(2), 271–291, p. 287. https://doi.org/10.1177/0959353514526223; Heneghan, C., & Jefferson, T. (2019, February 25). *BMJ EBM spotlight*. Gender-affirming hormone in children and adolescents. https://blogs.bmj.com/bmjebmspotlight/2019/02/25/gender-affirming-hormone-in-children-and-adolescents-evidence-review/

- 48. Adolescence is also a crucial period of social development. Artificially holding a child in a pre-pubescent state for several years while his or her peers navigate the social milestones and minefields of adolescence is likely to have at least some "subtle negative psychosocial and self-confidence effects." Indeed, the American Academy of Pediatrics recognizes that "[d]elaying puberty beyond one's peers can also be stressful and can lead to lower self-esteem and increased risk taking." And the Endocrine Society's guidelines recognize "the sense of social isolation from having the timing of puberty be so out of sync with peers."
- 49. But what the research does not tell us is the isolated effect of puberty blockers (and similarly, of subsequent cross-sex hormones), since today gender dysphoria infrequently appears apart from other (possibly confounding) psychiatric conditions and the experience of traumas.⁴¹
- 50. Seven endocrinologists and psychologists recently discussed the clinical characteristics of 79 children presenting to a new gender clinic in Australia, noting a high number of conflicted family situations and documented trauma.⁴² Only five percent of their sample was believed to exhibit "healthy" levels of functioning.
- 51. Despite this, many of the new clinic's patients and their families openly pressed the clinicians to begin medical (hormonal, etc.) treatments, believing that method was the only solution and "that their distress would be completely alleviated if they pursued the pathway of

³⁸ Levine, S. (2020) Declaration, U.S. Circuit Court, Dane County, Wisconsin, Case No.: 20-CV- 454, p.41.

³⁹ Rafferty, J. & Committee on Psychosocial Aspects of Child and Family Health. (2018), p. 5.

⁴⁰ Hembree et al. (2017), p. 3885.

⁴¹ E.g. In Littman (2018), 62 percent of parents reported their child had been previously diagnosed with a psychiatric disorder, while 48 percent reported a traumatic or stressful event occurring prior to the onset of their child's gender dysphoria, p. 13.

⁴² Kozlowska, K., McClure, G., Chudleigh, C., Maguire, A. M., Gessler, D., Scher, S., & Ambler, G. R. (2021). Australian children and adolescents with gender dysphoria: Clinical presentations and challenges experienced by a multidisciplinary team and gender service. *Human Systems*, *1*(1), 70-95. https://doi.org/10.1177/26344041211010777

medical treatment." This frustrated the seven scholar-clinicians: "Lost were our efforts to highlight the many different pathways in which gender variation could be expressed, to explain potential adverse effects of medical treatment, to explore issues pertaining to future fertility and child rearing, and to highlight the importance of ongoing psychotherapy." The authors attributed this now-predictable pattern to information that patients received from (1) their peers, (2) previously encountered health workers, and (3) the internet. Many children, they noted, arrived with "strongly entrenched beliefs and with no interest in further exploring their medical, psychological, social, or familial situation." The study's authors also asserted that many of the patients "did not have the cognitive, psychological, or emotional capacity to understand the decisions they were making."

- 52. These forces complicate treatment of gender dysphoria. A market increasingly characterized by patient demand for puberty blockers and, later, cross-sex hormones does not make for an atmosphere conducive to addressing pertinent co-occurring diagnoses. But this is exactly what is now developing in the "affirmative care" approach—an emerging split between those clinicians who want to (continue to) include psychological evaluations, counseling, and observation prior to hormonal and surgical treatments, and those clinicians—including researchers like Dr. Johanna Olson-Kennedy—who wish to skip those first steps and instead endorse (earlier) procedures.
- 53. As psychotherapist Robert Withers observes, "failure to address relevant psychological issues can result in trans people making unnecessary, permanent changes to their bodies, without adequate scientific justification for doing so." Withers additionally notes that "[m]any

⁴³ Kozlowska et al. (2021). All quotes are from p. 15.

⁴⁴ Withers, R. (2020) Transgender medicalization and the attempt to evade psychological distress. *Journal of analytical psychology*, 65: 865–889, p. 865. https://doi.org/10.1111/1468-5922.12641

of today's young people have also made 'gender affirming' medical treatment their goal. Unfortunately, the evidence base supporting the efficacy of such treatment is extremely poor."⁴⁵

- 54. In his previous declaration Dr. Turban offered the unsubstantiated claim that "[a]ll existing published data...points to the fact that gender-affirming medical interventions improve mental health for transgender adolescents." Such a categorical claim is simply untrue.
- 55. As an example of this erroneous categorical claim, Dr. Turban immediately highlights on the very same page an example of how "research has shown that sexual functioning (along with romantic development) improves" after gender-affirming medical interventions on adolescents. He study he cites reveals no such thing. "Improvement" cannot even be measured here, since the study was a cross-sectional one, not longitudinal. The study, rather, asked transgender youth a series of questions about sexual and romantic experiences and satisfaction (at a mean age of 14, no less). The results revealed that, in comparison to the general population, transgender youth displayed less sexual and romantic experience. It is an odd study to reference in support of his (ironic) claim about state's experts' purported mischaracterizations.
- 56. Large, longitudinal data collection efforts on the psychological health effects of transgender medicine remain rare but do exist. The Swedish Total Population Register, a massive longitudinal survey effort that collected information from over 9.7 million Swedes, is an example. A study based on this data appeared in 2020 in the *American Journal of Psychiatry*, and purported to constitute high-quality evidence in favor of medical transition for gender dysphoric patients.⁴⁷ Its authors tracked dysphoric respondents over time and assessed their subsequent use

⁴⁵ Withers (2020), p. 869.

⁴⁶ Bungener, S. L., Steensma, T. D., Cohen-Kettenis, P. T., & De Vries, A. L. (2017). Sexual and romantic experiences of transgender youth before gender-affirmative treatment. *Pediatrics*, *139*(3) e20162283. https://doi.org/10.1542/peds.2016-2283

⁴⁷ Bränström, R., & Pachankis, J. E. (2020). Reduction in mental health treatment utilization among transgender individuals after gender-affirming surgeries: a total population study. *American journal of psychiatry*, *177*(8), 727-734. https://doi.org/10.1176/appi.ajp.2019.19010080

of mental health treatment (for a mood or anxiety disorder), as well as other related measures (such as hospitalization after a suicide attempt). There was no evidence that initiating hormone treatment paid benefits in reduced subsequent use of mental health treatment, but the authors concluded that "gender-affirming" surgery is associated with reduced demand for subsequent mental health treatment in a sample of persons diagnosed with "gender incongruence."

57. However, a cursory reading of the study itself tells a far less optimistic story than the authors' own confident interpretations of the post-surgical data. From the available published data, I was able to calculate the "Number Needed to Treat," or NNT, which is a measure of clinical impact. It helps relate the actual size of the effect of the treatment back to the realities of clinical practice to aid physicians in decisions about whether a particular treatment is "worth it." A high NNT accompanied by significant risk (in the treatment) is considered high-risk, low payoff. On the other hand, a high NNT accompanied by modest risk (such as prescribing a daily statin pill to reduce risk of a subsequent heart attack) is considered low risk, low payoff. In this study, the NNT appears to be a staggering 49, meaning the beneficial effect of transgender surgery (or more commonly, a series of surgeries) is so small that a clinic may have to perform 49 gender-affirming surgeries before they could expect to witness one additional post-surgical patient's reduction in subsequent mental health assistance. If no other treatment was available, or if the treatment was non-invasive and the hazards were insignificant, clinics might consider surgery a low-risk but low-payoff approach. But even the most common surgeries here (e.g., bi-

⁴⁸ Citrome, L. (2014). Quantifying clinical relevance. *Innovations in clinical neuroscience*, 11(5-6), 26–30.

lateral mastectomy) are considered major surgeries—and particular ones are exceptionally challenging, with elevated likelihood of suffering a complication.⁴⁹ Conducting surgery on 49 patients in order to secure one patient who modestly benefits in slightly less psychological services? It ought to give physicians considerable pause, but in an industry increasing characterized by demand-driven care of patients, it does not.

- 58. The journal received numerous letters pointing out that the study's analysis was flawed and its conclusions unsupported by the data. Almost one year later, the *American Journal of Psychiatry* published seven letters of critique, an editorial note on the subsequent statistical review those critiques prompted, and the resulting correction that nullified the study's claim of a post-surgical mental health benefit. The correction curbed what conclusions the authors had originally made—that "this study provides timely support for policies that ensure coverage of gender-affirming treatments." This example is indicative of a wider trend of "looking" for statistical significance, however weak, to support claims that are consonant with the wishes of transgender medical practitioners.
- 59. The correction the Bränström and Pachankis study merited is far more significant than the "correction" (or more accurately, clarification) of Professor Littman's original study, of which Dr. Turban speaks (on page 31 of his supplemental declaration during the preliminary injunction phase). Simply because Littman's is an opt-in sample is no cause for implying it is

⁴⁹ A recent study revealed that while just over 10 percent of a group of 1,212 adult "transmasculine" patients elected to undergo genital reconstruction surgery, those 129 patients reported 281 complications—more than two per patient, on average—requiring 142 "revisions." The three most common complications? Urethral fistulas or strictures, and worsened mental health. The only documentable benefit? A surge in their "genital self-image." See Robinson, I. S., Blasdel, G., Cohen, O., Zhao, L. C., & Bluebond-Langner, R. (2021). Surgical outcomes following gender affirming penile reconstruction: Patient-reported outcomes from a multi-center, international survey of 129 transmasculine patients. *The journal of sexual medicine*, *18*(4), 800-811. https://doi.org/10.1016/j.jsxm.2021.01.183 ⁵⁰ Bränström, R. & Pachankis, J. E. (2020) Correction to Bränström and Pachankis. *American journal of psychiatry* 177(8): 734. https://doi.org/10.1176/appi.ajp.2020.1778correction

without value, or that—unlike the Bränström and Pachankis study—its conclusions are incommensurate with its data. Professor Littman's study was simply demonstrative—to highlight a surge in adolescent (or late onset) gender dysphoria cases. Four years later, her results are no longer surprising.

- 60. While Dr. Turban is correct to note that the Bränström and Pachankis study concerns adults rather than minors, my discussion of it is intended to highlight the unsettledness of the science here, and to suggest that the line between activists and academics is a rather thin one, provoking contests over the meaning of a study's results. Given that it is arguably the largest longitudinal dataset capable of tracking the long-term effects of hormones and surgery, its lack of positive findings (following the editor's requested correction) has ramifications for the treatment of adult and adolescent patients alike.
- 61. There are some cracks forming in the coerced consensus about aggressively treating youthful gender dysphoria. In just the past two years, three countries' national gender medicine councils have commissioned focused studies on the efficacy of the "affirmative" approach to treating minors. These in-depth reviews by Finland, Sweden, and the UK's National Institute for Health and Care Excellence (NICE) in Britain have all concluded that claims of benefit for medical gender interventions in children are based on "low quality evidence." ⁵¹
- 62. Sweden's review of the evidence base and ethics considerations found "knowledge gaps and uncertain knowledge" to be a "central theme." A summary of their review of the literature reported the following: "No studies explaining the increase of children and

⁵¹ Society for Evidence Based Gender Medicine. (2021, May 5). Sweden's Karolinska ends all use of puberty blockers and cross-sex hormones for minors outside of clinical studies. https://segm.org/Sweden ends use of Dutch protocol

⁵² Swedish National Council on Medical Ethics. (2019, April 26). Letter to the Ministry of Health and Social Affairs re: treatment of gender dysphoria among children and adolescents (unofficial translation), p.2. https://smer.se/wp-content/uploads/2019/04/Skrivelse-konsdysfori-eng-%C3%B6vers%C3%A4ttning.pdf

adolescents seeking [treatment] for gender dysphoria were identified. The literature on management and long-term effects in children and adolescents is sparse, particularly regarding gender affirming surgery. All identified studies are observational, and few are controlled or followed-up over time."⁵³ They conclude by observing that "scientific activity in the field seems high," meaning extensive, but that a "large part of the literature that was considered relevant" was only published after 2017.

- 63. The UK's Royal College of General Practitioners issued a report in mid-2019 asserting that "[t]he significant lack of evidence for treatments and interventions which may be offered to people with dysphoria is a major issue facing this area of healthcare." After the report highlights characteristics of the "affirmative" approach, it notes "a significant lack of robust, comprehensive evidence around the outcomes, side effects and unintended consequences of such treatments for people with gender dysphoria, particularly children and young people, which prevents (general practitioners) from helping patients and their families in making an informed decision."
- 64. The UK NICE pair of reports each concluded that invasive treatment of youth doesn't result in a confident determination of demonstrable success. Those studies, one report notes, "that found differences in outcomes could represent changes that are either of questionable clinical value, or the studies themselves are not reliable and changes could be due to confounding, bias, or chance." The studies "all lack appropriate controls." Moreover, the claims of "clin-

⁵³ Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). (2019). Gender dysphoria in children and adolescents: An overview of the literature. *SBU*. Report No. 307: SBU 2019/427. https://www.sbu.se/en/publications/sbu-bereder/gender-dysphoria-in-children-and-adolescents-an-inventory-of-the-literature/report 307

⁵⁴ Royal College of General Practitioners. (2019). The role of the GP in caring for gender-questioning and transgender patients, RCGP position statement. https://www.rcgp.org.uk/-/media/Files/Policy/A-Z-policy/2019/RCGP-position-statement-providing-care-for-gender-transgender-patients-june-2019.ashx?la=en

ical effectiveness, safety, and cost-effectiveness" of such treatments clearly are not substantiated. Hence, claims of benefit for medical gender interventions in children are based, the reports observe, on "low quality evidence." These assessments offer reasons to be far more cautious about treating underage persons in such a way that permanently alters bodies as a response to problems of the mind.

- 65. Beginning on page 41 of his previous supplemental declaration, Dr. Turban makes much of the fact that the reports from the U.K., Sweden, and Finland "were not peer-reviewed" on his way to suggesting that each report "omits key studies," and/or were "poorly researched," before asserting that he would not recommend relying on their conclusions. A similar claim characterizes his remarks about the Swedish report: "No studies explaining the increase of children and adolescents seeking [treatment] for gender dysphoria were identified.... All identified studies are observational, and few are controlled or followed-up over time." It is plausible that they omitted particular studies, including Dr. Turban's own 2020 USTS-based *Pediatrics* study not as an oversight but intentionally, due to the NICE reports' elevated quality standards.
- 66. A cavalier manner characterizes how Dr. Turban brushes off the conclusions of each of these European medical decision-making bodies, as if admitting any weakness undergirding the "consensus" of American professional societies is potentially fatal to the "aggressive".

⁵⁵ National Institute for Health and Care Excellence (NICE). (2021). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria, p.13. https://www.evidence.nhs.uk/document?id=2334888&returnUrl=search%3fq%3dtransgender%26s%3dDate; National Institute for Health and Care Excellence (NICE). (2021). Evidence review: Gender-affirming hormones for children and adolescents with gender dysphoria. https://www.evidence.nhs.uk/document?id=2334889&returnUrl=search%3Fq%3Dgender%2Bdysphoria

⁵⁶ Society for Evidence Based Gender Medicine. (2021, May 5). Sweden's Karolinska ends all use of puberty block-

⁵⁶ Society for Evidence Based Gender Medicine. (2021, May 5). Sweden's Karolinska ends all use of puberty blockers and cross-sex hormones for minors outside of clinical studies. https://segm.org/Sweden_ends_use_of_Dutch_protocol

⁵⁷ Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). (2019). Gender dysphoria in children and adolescents: An overview of the literature. *SBU*. Report No. 307: SBU 2019/427. https://www.sbu.se/en/publications/sbu-bereder/gender-dysphoria-in-children-and-adolescents-an-inventory-of-the-literature/

affirmative" treatment strategy he represents. Turban simply claims that these too are "outlier views" not supported by the list of professional organizations—which do not even agree among themselves on definitions, terms, and issues such as minors' ability to consent. There's no trust in science here—only in patron professional associations and their client scholars.

- 67. Referring to the UK, Swedish, and Finnish reports, Dr. Turban previously concluded that, together with the other (state's) experts, I "have inflated the importance of these reports..." (page 45). I see nothing to substantiate this. Rather, my modest original intention is to highlight how, despite advocates' rhetoric, there is both individual and organizational dissent to any purported "consensus" about "affirmative" gender treatment for minors.
- 68. One conclusion is increasingly obvious in this dispute. We have rapidly reached a stage in the study of transgender medicine where the phrase "peer review" no longer guarantees quality analyses, apt measures, appropriate samples, thoughtful interpretations, and measured conclusions.
- 69. In sum, the science of transgender medicine—including but not limited to adolescents—does not speak with a univocal voice about the long-term psychological and physical benefits of hormonal and surgical treatment of dysphoria. Much published research in this domain is very recent, relies on nonrepresentative, opt-in samples, "loaded" survey questions, and/or exhibits overreaching conclusions. To suggest the existence of any obvious "consensus" or "standards" from existing research would make little scientific sense.

IV. THE ABSENCE OF RANDOMIZED CLINICAL TRIALS RESEARCH

70. In his previous declaration dated June 11, 2021, plaintiffs' witness Dr. Antommaria claims that, in Arkansas, "adolescents with gender dysphoria are not being subject to...ex-

perimentation."⁵⁸ The FDA, however, has not approved hormonal therapies for treatment of gender dysphoria. Hence, it is undeniable that the protocol of treatments for transgender-identifying youth, including its hormonal regimens, remains at least technically experimental by definition.

- 71. It's not as if hormonal treatments have never been put to a clinical trial. The hormones estradiol and testosterone certainly have. The same is true of GnRH agonists (i.e., puberty blockers), which have been evaluated for adult infertility, prostate cancer, ovarian protection during chemotherapy, and even for tests of male contraceptives. But these drugs have not been tested in randomized clinical trials as treatments for adolescent gender transition procedures. Puberty blockers have been approved only for treatment of precocious puberty.
- 72. Dr. Antommaria is right when he states that, "With respect to study design, randomized trials generally provide "high" quality evidence and observational studies, in comparison, "low." But the entire gender medicine industry merits criticism for complicity in failing to conduct such a rigorous clinical trial. Invasive, and even life-threatening, clinical trials are regularly conducted in the quest for lifesaving treatments among children with serious diseases or conditions.
- 73. Dr. Antommaria maintains that to propose and carry out "randomized placebocontrolled trials (trials that compare pharmacological treatment to no pharmacological treatment) in gender dysphoria are currently unethical." He appeals to the principle of clinical "equipoise," namely, the assumption (underlying the ethics of randomized control groups) that there is no

⁵⁸ Antommaria, A. H. M. (2021). Declaration, U.S. District Court, Eastern District of Arkansas, Case No.: 4:21CV450-JM, p. 11.

⁵⁹ Garner, C. (1994). Uses of GnRH agonists. *Journal of obstetric, gynecologic, & neonatal nursing*, *23*(7), 563-570. https://doi.org/10.1111/j.1552-6909.1994.tb01922.x

⁶⁰ Antommaria (2021), p. 7.

clear "better" intervention present.⁶¹ That is, he maintains that there is no clinical equipoise in the case of treating gender dysphoria; a control group in such a randomized trial would, he believes, receive an inferior, less-effective treatment as compared with the "affirmative" approach.

- 74. But this claim is in no small part a function of the putative "consensus" mentioned above and discussed more fully below. That is, since "affirmative" treatments are sometimes the subject of patient demand and are now endorsed by certain American professional organizations, there is indeed an assumption that clinical equipoise is not present. But that is a situation based not on longitudinal medical and social science research but on media-fostered patient demand and premature professional organizational claims and pressure. In other words, any lack of equipoise is more a psychological or cultural than a scientific development.
- 75. Further, even if (as Dr. Antommaria claims) equipoise were lacking for randomized *placebo-controlled* trials (i.e., trials that compared groups that did and did not receive hormones), that would be no obstacle to randomized trials *without* placebo groups to "compare different types, dosages and methods of administration of active treatments." But no such trials have been conducted.
- 76. This assertion is not, as Dr. Turban states, irrelevant.⁶³ It is yet another piece of evidence demonstrating the many ways in which randomized clinical trials research can be conducted here—but are not. Dr. Turban is correct that such a study "would not answer the question regarding the efficacy or effectiveness of the class of medications in general," but the lack of

⁶¹ Antommaria (2021), p. 8; Cook, C., & Sheets, C. (2011). Clinical equipoise and personal equipoise: two necessary ingredients for reducing bias in manual therapy trials. *Journal of Manual & Manipulative Therapy*, *19*(1), 55-57. doi: 10.1179/106698111X12899036752014

⁶²Haupt, C., Henke, M., Kutschmar, A., Hauser, B., Baldinger, S., Saenz, S. R., & Schreiber, G. (2020). Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. *Cochrane database of systematic reviews*, p. 10. https://doi.org/10.1002/14651858.CD013138.pub2

⁶³ Haupt, C., Henke, M., Kutschmar, A., Hauser, B., Baldinger, S., Saenz, S. R., & Schreiber, G. (2020). Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. *Cochrane database of systematic reviews*, p. 10. https://doi.org/10.1002/14651858.CD013138.pub2

even dosage studies with control groups highlights the near lawlessness that this field of medicine seems to operate with, and provides further evidence of the "ideological capture" that I have thoroughly documented herein.

77. In his own previous response on this topic, Dr. Antommaria continued his appeal to clinical equipoise, adding a pitch for off-label drug use, which "may be well-supported by evidence" and "does not mean that the use is experimental, untested, or unsafe." In the abstract, that is true. But there's a significant gap between "may be" and "is" in particular circumstances. Perhaps a clinical trial really is in order.

V. THE IDEOLOGICAL CAPTURE OF GENDER DYSPHORIA

- 78. There is a great deal of evidence that the clinical discussion of gender dysphoria has recently become unmoored from empirical assessments and instead has been captured by the activist assumptions of those advocating for what is sometimes called "gender ideology." Ideological capture operates not unlike "regulatory capture," a more familiar phrase. The end is the same—the corruption of authority by the successful co-opting of political or professional organizations to serve the aims of a particular interest group. Ideological capture is characterized by incorrigible commitments to certain conclusions regardless of the data and can lead whole organizations to disregard outcomes that are not consistent with the ideologically-motivated sense of rightness. Ideological capture is inimical to the dissent and open debate that is critical to healthy medical and social science.
- 79. Although the plaintiffs in this case have tried to dismiss observations concerning the ideological capture of gender dysphoria as mere "conspiracy theory," it is quite real and a

⁶⁴ Antommaria, A. H. M. (2021), p. 4.

⁶⁵ Chuang, J. A. (2010). Rescuing trafficking from ideological capture: Prostitution reform and anti-trafficking law and policy. *University of Pennsylvania law review*, *158*(6), 1655–1728.

thoroughly documented phenomenon. As I explain below, the ideological capture of gender dysphoria is evidenced by efforts to re-educate people in the use of identity language, by the entrepreneurial explosion of gender clinics across the nation, by pressure-based suppression of open debate (including among most affirmative clinicians and scholars), by inconsistent claims concerning adolescents' ability to give informed consent, by the tacit endorsement of social media "peer education" about transgender life, and even by the Department of Justice's recent inconsistent actions. It has contributed to suppressing any sense of "watchful waiting," a once-standard harm-reduction move that is now accused of fostering suicidality, and has tagged psychological counseling as bordering on "reparative therapy." It fosters the belief that invasive medical—that is, hormonal and surgical—treatments should be performed at earlier ages, as the draft version of WPATH's 8th edition of their Standards of Care reveals.

A. Re-education in the Parlance of Gender Ideology

- 80. To classify something in the social world is to penetrate the imagination, to alter public frameworks of knowledge and discussion, and to shift the perception of everyday life. It is why French sociologist Pierre Bourdieu understood this elite-driven effort as the power of "legitimate naming." In the domains of gender and sexuality—fraught as they are with great moral valence—there is poignant and bitter struggle over words and terms, and the politics of using them or avoiding them. This suggests we are not witnessing a simple quest for better understanding of an emergent population. We are also seeing social and cultural change fostered through scholarship wed to political activism.
- 81. The complaint and reports submitted by the plaintiffs in the preliminary-injunction stage of this case reflect this ideological effort. For example, Adkins' claim that

⁶⁶ Bourdieu, P. (1985). The social space and the genesis of groups. *Theory and society*, 14(6), 723-744.

"[e]veryone has a gender identity" is freighted with dubious ideological assumptions, as the following considerations show. The Endocrine Society guidelines describe "[e]xamples of conditions with similar features" to gender dysphoria, including "body identity integrity disorder (a condition in which individuals have a sense that their anatomical configuration as an able-bodied person is somehow wrong or inappropriate)." Dr. Anne Lawrence, who identifies as transgender, has also noted the parallels between gender dysphoria and body integrity identity disorder (BIID). A person with BIID is able-bodied but identifies as an amputee and reports feeling trapped in a fully functional body. Such persons "often assert [that] their motives for wanting to change their bodies reflect issues of identity."

82. Now, it is one thing to recognize that some people with BIID make such identity claims. But it is something else altogether to say that, because *some people with BIID* make that claim, therefore *everyone* has to be defined in terms of whether they identify as able-bodied, as an amputee, or as something in between. To make this further claim is to advocate a highly disputable ideology that says an able-bodied person's identifying as an amputee is not a disorder at all, but simply one of multiple "functional identities" that an able-bodied person may happen to have. But it is another thing (and altogether inappropriate) to use the terms in which persons experiencing mental distress or a pathology understand themselves as the new prism through which *all persons* must be defined. Claiming that "everyone has a gender identity" is an effort to do precisely that: to define everyone who does *not* suffer gender incongruence in terms of the self-experience of those who do.

⁶⁷ Adkins (2021), p. 3.

⁶⁸ Hembree et al. (2017), p. 3878.

⁶⁹ Lawrence, A. A. (2006). Clinical and theoretical parallels between desire for limb amputation and gender identity disorder. *Archives of sexual behavior*, *35*, 263-78.

⁷⁰ Lawrence (2006), p. 263.

- 83. One of the reasons why advocates include (in their articles, briefs, reports, etc.) sections defining terms is because new words are a source of social change itself. They are not simply illuminating but indoctrinating. Certainly, the challenges of measurement and data collection can benefit from clarification of terms. But they can become vehicles of cultural change themselves by endorsing particular ways of speaking about matters of gender identity that are highly contested. Even official surveys, the root source of so much social science raw data, are not only not exempt from politicization and the fostering of "legitimate naming," but are now a medium of the same.⁷¹
- 84. Plaintiffs' complaint is also saturated with references to "well-established standards of care," "best practices," and lists a litany of terms and statements like these in a section entitled "Standards of Care..." where one might expect to see prescriptions rather than definitions. Such rhetoric fosters a sense that the plaintiffs are attempting to re-educate the reader rather than convince them of the merits of a position through sound argument and evidence. What was meant to map and understand the experience of gender dysphoria—particularly but not only in adolescents—has turned instead to name (new terms and protocols) and shame (the cautious or contrarian voice).
- 85. I concur with psychiatrist Dr. Stephen Levine, who has explained that "clinical work in the gender identity arena, which used to be based on symptoms and social, vocational, and educational dysfunction, is now based on sociopolitical concepts. Cultural forces have provided a new narrative about the vital importance of having strict consonance between one's

⁷¹ The GenIUSS Group. (2014). Best practices for asking questions to identify transgender and other gender minority respondents on population-based surveys. J.L. Herman (Ed.). The Williams Institute.

sexed body and gender identity."⁷² This new narrative is not grounded in evidence-based science but in political activism.

B. The Rapidly Evolving "Consensus"

86. In her report, Dr. Adkins writes, "All of the major medical professional groups in the United States . . . agree that [gender transitioning] is safe, effective, and medically necessary treatment for the health and wellbeing of children and adolescents suffering from gender dysphoria."⁷³ But, despite the fact that American professional associations have endorsed the (general) "affirmative" approach to treating dysphoric adolescents, there is no wide, international consensus about its superiority. Nor is there evidence that the consensus is stable;⁷⁴ rather, there is an uneven evolution among advocates toward affirming treatments "on demand," with decreasing regard for the Dutch protocol's commitment to (1) a slower pace, with more listening and observation, and (2) the refusal to pursue medical treatments in the absence of childhood gender dysphoria and in the presence of psychiatric co-morbidities. That any purported "consensus" on hormonal and surgical interventions at earlier ages should have developed so rapidly among American professional associations—and with so much projected confidence—in the absence of obvious, consistent indicators of treatment efficacy, and amid a surge in cases of gender dysphoria, is suspicious. It suggests, instead, a concerted effort to suppress alternative (or even decade-old) treatment approaches in favor of a demand-driven endorsement of hormonal and surgical treatments.

⁷² Levine, S. B. (2019). Informed consent for transgendered patients. *Journal of sex & marital therapy*, 45(3), 218-229, p. 219.

⁷³ Adkins, D. (2021), p. 6.

⁷⁴ Vrouenraets, L. J., Fredriks, A. M., Hannema, S. E., Cohen-Kettenis, P. T., & de Vries, M. C. (2015).

- 87. Closely connected to the idea of ideological capture is that of a "Castro consensus," wherein a consensus "is viewed as a proxy for truth." Certainly, "when a consensus is fashioned via the independent and free deliberations of many, it is a strong indicator of truth." But "not all consensuses are independent and freely formed." Some are pieced together by "external pressure," while "dependence among individuals can force consensus around an issue, regardless of the underlying truth of the affirmed position." Indeed, simple bias can lead to a purported (and premature) consensus, given that decision-makers (and researchers) "are both human and political." This is an accurate description of what has occurred in the domain of medicine concerned with the treatment of gender dysphoria.
- 88. For instance, WPATH, formed in 1979, has evolved from its beginnings as a group of professionals seeking to understand and assist those with gender dysphoria to acting as a professional association that purports to offer "consensus" clinical guidelines while simultaneously acknowledging that "WPATH is committed to advocacy for . . . changes in public policies and legal reforms." WPATH's treatment recommendations shape the recommendations of other professional organizations; the APA's guidelines, for example, follow WPATH's recommendations and label any approach other than "affirming" to gender dysphoric youth as "unethical."

⁷⁵ Allen, J., Lay, C., & Montanez, G. (2020) A Castro consensus: Understanding the role of dependence in consensus formation, 1-9, p. 1. https://www.researchgate.net/publication/344703449_A_Castro_Consensus_Understanding the Role of Dependence in Consensus Formation

⁷⁶ Socol, Y., Shaki, Y. Y., & Yanovskiy, M. (2019). Interest, bias, and consensus in science and regulation, *Dose-response*, 17, 1-5. https://doi.org/10.1177/1559325819853669

⁷⁷ World Professional Association for Transgender Health (2012), p. 2; Levine, S. B. (2018). Ethical concerns about emerging treatment paradigms for gender dysphoria. *Journal of sex & marital therapy*, 44(1), 29-44; Vrouenraets et al. (2015).

⁷⁸ American Psychological Association. (2015). Guidelines for psychological practice with transgender and gender nonconforming people. *American psychologist*, 70(9), 832-864.

- 89. Despite WPATH's purported "consensus" building, the organization continues to struggle with both the research and clinical communities, as well as their own penchant for establishing—not just recognizing—new ground to cover. Such appears to be the case in the December 2021 preview of their forthcoming Standards of Care version 8, where they devote an entire chapter to "eunuch-identified people," most often natal males who exhibit a "strong urge to live without testicles." If a 17-year-old male presents as "eunuch-identified," this is a valid transgender identity under WPATH guidance, and he should be eligible for "affirming" orchiectomy or more for castration to align his body with his mind. In a 2007 study of this unusual community, researchers noted that the typical time from development of interest to actual castration—physically or chemically—was 18 years. The researchers identified four factors at work in the minds of such persons: sustained abuse during childhood, homosexuality, exposure to animal castration during youth, and religious condemnation of sexuality. The authors noted both BIID and GID among self-identified eunuchs.
- 90. My point about this group is only this. It is beyond ironic that Professor Littman is professionally scourged for observing an exploding number of post-pubertal adolescent dysphoria cases, while WPATH devotes more attention to eunuchs, who as recently as 2015 were considered to be so uncommon as to merit single-case discussion in professional journals.⁸¹
- 91. The WPATH "consensus" is not stable. It is clearly evolving in the direction of aggressive affirmation. In their preview of Standards of Care version 8, WPATH has lowered some of the recommended ages for treatment. No one can suggest anymore that surgery is not

⁷⁹ Hermann, M., & Thorstenson, A. (2015). A rare case of male-to-eunuch gender dysphoria. *Sexual medicine*, *3*(4), 331–333. https://doi.org/10.1002/sm2.81

⁸⁰ Johnson, T. W., Brett, M. A., Roberts, L. F., & Wassersug, R. J. (2007). Eunuchs in contemporary society: Characterizing men who are voluntarily castrated (Part I). *The journal of sexual medicine*, *4*(4), 930-945, https://doi.org/10.1111/j.1743-6109.2007.00521.x.

⁸¹ Hermann, M., & Thorstenson, A. (2015).

being authorized for minors, since WPATH commends age 15 (and above) as appropriate for "chest masculinization" treatment, age 16 for breast augmentation and facial surgeries (e.g., rhinoplasty, tracheal shave, and genioplasty), age 17 for hysterectomy, vaginoplasty, metoidioplasty (or bottom surgery for female-to-male patients), and orchidectomy (the removal of testicles), and 18—the end of status as a minor—for phalloplasty or the construction of a penis in female-to-male transgender patients.⁸²

- 92. Hence, plaintiffs' witness Turban is no longer able to claim, as he did in the *New York Times* in 2020, that "[u]nder current medical guidelines, genital surgeries for transgender patients are never offered before adulthood." It may have been rhetorically useful, but the claim wasn't even true when he wrote it. A 2017 interview-based study of 20 surgeons revealed that vaginoplasties are being performed on minors by surgeons in the United States. While such may have contravened WPATH's previous standards of care, it is no longer true of their forthcoming standards.
- 93. Full gender-affirming surgery in minors, however, now constitutes irreversible surgical sterilization, as even the most ambitious of affirmative clinicians admit.⁸⁴

⁸² World Professional Association for Transgender Health. (2021).

⁸³ Milrod, C., & Karasic, D. H. (2017). Age is just a number: WPATH-affiliated surgeons' experiences and attitudes toward vaginoplasty in transgender females under 18 years of age in the United States. *The journal of sexual medicine*, *14*(4), 624-634.

⁸⁴ Olson-Kennedy, J. (2015). *The future of trans care in the new millennium*. Gender Infinity Annual Conference. https://youtu.be/pO8v--tztSg. What is critical here about the pairing of puberty blockers then cross-sex hormones is that if patients commence puberty blockers early enough, they will not go through puberty (of their natal sex); hence, their gametes do not have enough time to mature (for the purpose of being subsequently harvested for possible future artificial reproduction). See Hudson, J., Nahata, L., Dietz, E., & Quinn, G. P. (2018). Fertility counseling for transgender AYAs. *Clinical practice in pediatric psychology*, *6*(1), 84-92. doi: 10.1037/cpp0000180

- 94. Dr. Turban claimed in his previous supplemental declaration, "Although gender affirming hormones can cause some irreversible changes, such as body fat redistribution and vocal changes, these effects are primarily cosmetic." Vocal changes may not be considered "cosmetic" by many, and fat redistribution is hardly a more significant irreversible change than infertility. For Dr. Turban, infertility seems largely irrelevant. He misrepresents a 2019 study, claiming that "fertility was similar between transgender men who had been on testosterone treatment and cisgender women." In reality, the study is about comparing the pregnancy success rate of assisted reproductive technology—an expensive, demanding process with modest success rates—between self-identified transgender males (natal females) and a parallel group of women. Given that over 98 percent of live births in the United States do not employ assisted reproductive technology. And involve no "fertility preservation" of the sort that WPATH recommends to counseled patients, the reference to "similar" fertility is at best misleading.
- 95. In the short span of a decade, psychiatrists, psychologists, pediatricians, and their patients have been pressed both to think about and to treat child and adolescent dysphoria in one "correct" manner—via the aggressively affirmative approach. Even some early advocates for the Dutch protocol are now concerned about the on-demand, skip-the-counseling version that is

⁸⁵ Turban, J. L., & Keuroghlian, A. S. (2018). Dynamic gender presentations: Understanding transition and "de-transition" among transgender youth. *Journal of the American academy of child & adolescent psychiatry*, *57*(7), 451–453. https://doi.org/10.1016/j.jaac.2018.03.016. The quote is from page 453.

⁸⁶ Turban, J. L. (2021), p. 12.

⁸⁷ Leung, A., Sakkas, D., Pang, S., Thornton, K. & Resetkova, N. (2019). Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine. *Fertility and sterility* 112(5), 858-865. The quote is from page 859.

[&]quot;To be included in this study, the patient had to identify as a transgender man and have completed an ovarian stimulation cycle for oocyte cryopreservation, embryo cryopreservation, or intended uterine transfer. Most couples who desired to conceive did so through reciprocal IVF, whereby the transgender patient provided the oocytes and their cisgender partner carried the pregnancy. The few transgender men who opted to carry the pregnancy themselves underwent several failed intrauterine insemination cycles before proceeding to IVF."

⁸⁸ Centers for Disease Control and Prevention. (2018). ART success rates. https://www.cdc.gov/art/artdata/index.html

emerging.⁸⁹ Psychotherapy has now become more difficult to come by, even disparaged as "conversion" therapies, as discussed below.⁹⁰

C. The Entrepreneurial Explosion of Gender Clinics

- 96. When this contrived consensus meets a free-market health care delivery system, it is no surprise that the result is an explosion in gender clinics. Less than 15 years ago, the United States featured a solitary pediatric gender clinic (Boston Children's Hospital's Gender Management Service, founded in 2007). But today there are over 300 clinics that provide some form of "gender affirmative" care to minors, ranging from full-service operations (i.e., hormone and surgical services) to private practice doctors that will perform surgeries on minors.
- 97. Planned Parenthood clinics, as noted in the organization's recent annual report, are "the second largest provider of hormone therapy to those who identify as transgender/have gender dysphoria." Planned Parenthood's director of health media was recently reported as confirming that the organization offers hormone therapy to transgender patients in 16 states. Mara Keisling, executive director of the National Center for Transgender Equality, remarked about Planned Parenthood that "It's possible they're the largest provider of trans health in the country." Formally, the organization purports to serve only those 18 and older; informally, some facilities report serving 16- and 17-year-olds with "parental consent."

⁸⁹ Edwards-Leeper, L., & Anderson, E. (2021).

⁹⁰ For example, see Turban, J. L., Beckwith, N., Reisner, S. L., & Keuroghlian, A. S. (2020). Association between recalled exposure to gender identity conversion efforts and psychological distress and suicide attempts among transgender adults. *JAMA psychiatry*, 77(1), 68–76. doi:10.1001/jamapsychiatry.2019.2285.

⁹¹ Planned Parenthood Federation of America. (2021). 2019-2020 annual report, p. 11. https://www.plannedparenthood.org/uploads/filer_public/67/30/67305ea1-8da2-4cee-9191-19228c1d6f70/210219-annual-report-2019-2020-web-final.pdf

⁹² Allen, S. (2017, January 10). The attack on Planned Parenthood hurts transgender people, too. *Daily beast*. https://www.thedailybeast.com/the-attack-on-planned-parenthood-hurts-transgender-people-too

 $^{^{93}\} https://www.plannedparenthood.org/planned-parenthood-mass a chusetts/campaigns/gender-affirming-hormone-therapy$

- 98. Planned Parenthood operates its gender services on an "informed consent" basis, with no need for a diagnosis or mental health exam. ⁹⁴ In other words, access to treatment is offered if the patients indicate they understand and accept the possible side effects. "I had no gate-keeping at all," one patient reported. "I had a prescription in my hand the same day I went in." The "affirmative" approach hence leads in short order to patient-driven, on-demand services. ⁹⁵ More natal females than males seek out Planned Parenthood's gender services, which serve as a more stable source of income than abortions. One anonymous employee described them as "cash cows…kept on the hook for the foreseeable future."
- 99. It is clear that clinics make their own decisions about treatment, and are proving even more aggressive than professional organizations' own recommendations. For example, New York's Mount Sinai Center for Transgender Medicine and Surgery (CTMS) operates with a "patient-centered model," and reported that 45 percent of 139 patients seeking vaginoplasty were deemed ready for surgery, well above the 15 percent who met WPATH's criteria for surgery eligibility. If patients seeking surgical treatments are apt to see their odds of getting it tripled, it is only reasonable to believe that providers with fewer restrictions will thrive.
- 100. In a mid-2020 contribution to the *Journal of Medical Ethics*, an Australian attorney and six co-authors make the ethical case for supporting the practice of "ongoing puberty suppression," that is, to "permanently prevent the development of secondary sex characteristics, as a

⁹⁴ Urquhart, E. (2016, January 29). Planned Parenthood is helping transgender patients access hormone therapy. *Slate*. https://slate.com/human-interest/2016/01/how-planned-parenthood-helps-transgender-patients-get-hormone-therapy.html ⁹⁵ Allen (2017).

 ⁹⁶ Shrier, A. (2021, February 8). Inside Planned Parenthood's gender factory: An ex-reproductive health assistant speaks out. Substack: Abigail Shrier, https://abigailshrier.substack.com/p/inside-planned-parenthoods-gender
 ⁹⁷ Lichtenstein, M., Stein, L., Connolly, E., Goldstein, Z. G., Martinson, T., Tiersten, L., Shin, S. J., Pang, J. H., & Safer, J. D. (2020). The Mount Sinai patient-centered preoperative criteria meant to optimize outcomes are less of a barrier to care than WPATH SOC 7 criteria before transgender-specific surgery. *Transgender Health*, *5*(3), 166-172.

way of affirming (one's) gender identity." There is reason to question the clinical stability of an approach that is so rapidly giving young people suffering from significant psychiatric distress the agency to accept experimental medical interventions with irreversible effects, especially in an ideologically-charged atmosphere where medical professionals hold out the treatments to be the child's only hope of leading a peaceful, happy life.

American sexual politics into the medical evaluation and treatment of gender dysphoria. In a study to be published in the *Archives of Sexual Behavior*, a co-author and I observed in a survey of over 5,000 adults that the central framework through which Americans (as well as supplier organizations like Planned Parenthood) perceive the treatment of adolescent transgender patients is that of bodily autonomy and choice. That is, American adults' attitudes about abortion are the strongest predictor of what they think about "affirmative" treatment for minors, even after controlling for religion, political affiliation, voting behavior, and a variety of other factors. ⁹⁹ This makes sense. And we are hardly the first to note it. Years ago journalists observed that the same principles at work in understanding abortion attitudes—about access to and control over one's body—are applied to decision-making about transgender treatments, even invasive ones. By extension, then, it is unsurprising to see how the authority over treatment decisions, including among minors, appear to have shifted from physician to patient. ¹⁰⁰

_

⁹⁸ Notini, L., Earp, B. D., Gillam, L., McDougall, R. J., Savulescu, J., Telfer, M., & Pang, K. C. (2020). Forever young? The ethics of ongoing puberty suppression for non-binary adults. *Journal of medical ethics*, 46(11), 743-752. https://jme.bmj.com/content/46/11/743.abstract

⁹⁹ Regnerus, M. & Vermurlen, B. (Final acceptance October 2021, forthcoming). Approval of hormonal and/or surgical interventions for adolescents experiencing gender dysphoria. *Archives of sexual behavior*.

¹⁰⁰ Urquhart, E. (2016, March 11). Gatekeepers vs. informed consent: Who decides when a trans person can medically transition? *Slate*. https://slate.com/human-interest/2016/03/transgender-patients-and-informed-consent-who-decides-when-transition-treatment-is-appropriate.html

D. Pressure-based Suppression of Open Debate

102. Physicians and researchers have been sanctioned for questioning "affirmative" gender treatment. Some have resigned, some have been demoted, and others fired. (Many have endured social media barrages.) A few examples may prove illuminating. Allan Josephson, chief of the University of Louisville's Division of Child and Adolescent Psychiatry and Psychology for nearly 15 years, was demoted after public remarks he offered criticized aspects of affirmative treatment, saying the "notion that gender identity should trump chromosomes, hormones, internal reproductive organs, external genitalia, and secondary sex characteristics when classifying individuals is counter to medical science."

103. The *Archives of Sexual Behavior*'s editor Kenneth Zucker likewise endured professional and personal scrutiny for his work on the transgender experience. Zucker was head of a Toronto addiction and mental health clinic's "Gender Identity Service" until he was fired in 2015 after an external review by two adolescent psychiatrists found his method insufficiently "affirmative" for transgender-identifying youth. His crime? Too much caution, patience in treatment, and displaying concern for parents and family dynamics. (Zucker won a legal settlement and an apology, 102 and he remains the editor-in-chief of *Archives*, the top sexology journal in the field.) Intimidation of this nature discourages wider interest in this field, narrowing the pool of researchers to those who don't rock the boat or question the purported consensus. This is not how a healthy field of science works.

¹⁰¹ Watkins, M. (2019, March 29). Professor sues U of L, claims he was demoted over comments seen as anti-LGBTQ. *Courier journal*. https://www.courier-journal.com/story/news/2019/03/29/anti-lgbt-comments-university-of-louisville-professor-sues-over-demotion/3300002002/

¹⁰² Rizza, A. (2018, October 7). CAMH to pay more than half a million settlement to head of gender identity clinic after releasing fallacious report. *National post.* https://nationalpost.com/news/camh-reaches-settlement-with-former-head-of-gender-identity-clinic

Hospital in Gothenburg, Sweden, launched the Lundstrom Gender Clinic in 2016. Two years later, she resigned because of her own fears about the lack of evidence for hormonal and surgical treatments. Her decision-making process reveals what others have also noted: "There's a lot of tension between some approaches of gender clinics and the trans community. Patients found it hard to accept that they needed to undergo a full mental health assessment before being referred for medical treatment. Parents would say that nobody ever discussed that other issues...might be implicated in the child's dysphoria." Her patients displayed "many psychiatric symptoms," she notes. Gender dysphoria was just "one part of a complex problem." "Concentrating only on the gender dysphoria meant we might miss other things," she held. "When I realized the complexity [of these cases]...and that health care professionals are still expected to okay gender-affirming treatment despite the lack of evidence that we currently have, it preyed on my conscience." Sämfjord's story contributed to Sweden's recent decision to curb hormonal treatments for adolescents.

105. The controversy over a CBS 60 Minutes segment about detransitioners, which aired on May 23, 2021, provides another sobering illustration of the ideological capture of much of this field of treatment. The popular news program sensed it would be illuminating to have a public discussion about patients who have undergone a gender transition but who wish to detransition back to their natal sex. Yet not only did activists seek to alter the 60 Minutes episode (or prevent it from airing altogether), clinicians did too, including Dr. Johanna Olson-Kennedy, one of the more well-known researchers in the field, who posted on social media that "so many of us

¹⁰³ McCall, B. & Nainggolan, L. (2021, April 23). Transition therapy for transgender teens drives divide. *WebMD*. https://www.webmd.com/children/news/20210427/transition-therapy-for-transgender-teens-drives-divide

worked hard to dissuade them from doing this segment." Lesley Stahl, the segment's correspondent and lead interviewer, reported that she could not remember another story "where comments and criticisms began surfacing from advocates before the piece aired." Other major media outlets are feeling comparable pressure to vet transgender news stories prior to release. 105

106. The 60 Minutes controversy also sheds light on the new fissure between "conventional" affirmative care and the even more aggressive form of patient-driven care that "affirms without question," a position staked out Olson-Kennedy, who perceives little advantage to conducting pre-treatment mental health evaluations, and is known to offer cross-sex hormones to patients as young as 12 years old—a position that puts her at odds even with WPATH's aggressive new Standards of Care. The only thing "settled" about transgender medical science is the advocates' use of that term. In truth, it is perpetually unsettled, and is now shifting toward putting the patient in the driver's seat of their own treatment decisions.

107. A pair of "affirming" clinical psychologists who work with gender dysphoric adolescents, called the *60 Minutes* backlash "unconscionable" and "harmful to detransitioned young people" who are being "made to feel as if their lived experiences are not valid." Moreover, they recognize that silencing detransitioners "will undoubtedly raise questions regarding the objectivity of our field…" Indeed, as explained below, it has.

¹⁰⁴ Zubrow, K. (2021, May 23). Inside the 60 Minutes report on transgender healthcare issues. *CBS News*. https://www.cbsnews.com/news/60-minutes-transgender-health-care-issues-2021-05-23/

¹⁰⁵ Manning, S. (2021, June 26). BBC Pride activists demand right to vet transgender news stories on Radio 4's Today programme after host Justin Webb clashed with Pink News CEO over Stonewall's stance on single-sex spaces. *Daily Mail*. https://www.dailymail.co.uk/news/article-9728735/BBC-Pride-activists-demand-right-vet-transgender-news-stories-Radio-4s-Today-programme.html

¹⁰⁶ Singal, J. (2018, July/August.) When children say they're trans. *The Atlantic Monthly*. https://www.theatlantic.com/magazine/archive/2018/07/when-a-child-says-shes-trans/561749/

¹⁰⁷ Edwards-Leeper & Anderson (2021), paragraph 6.

108. The evidence demonstrates that desistance rates—that is, the share of adolescents who cease identifying as transgender and accept their natal sex—may have been around 90 percent for patients treated with a "watchful waiting" approach. In a review of childhood gender dysphoria, prior studies demonstrated desistence rates ranging from 61% to 98%. This method, however, is now contested in the United States, Canada, Australia, and the UK, and for dysphoric adolescents put on the "gender affirmation" schedule, the reverse has become true. Rather than pressing a pause button for time to think, 98 percent of the adolescents put on puberty blockers at the UK's Tavistock clinic proceeded to cross-sex hormones, thereby triggering irreversible effects. In other words, the "watchful waiting" method consistently predicted desistance because it recognizes the transience of cross-gender identification in minors. But taking an aggressively "affirmative" approach almost guarantees transition.

109. Transgender activists and their allies in the professions have sought to minimize the experiences of people who regret their transition and silence the voices of those who have detransitioned because of the challenges these present to the transgender identity narrative. Serious studies into this increasing phenomenon have been successfully squelched due to pressure from activists, 112 but the fact is that transition regret is real. 113 Recently, a wave of rapid adolescent

¹⁰⁸ Singh, Bradley, and Zucker (2021) recently released a longitudinal study where the desistance rate was 88%. See: Singh, D., Bradley, S. J., & Zucker, K. J. (2021). A follow-up study of boys with gender identity disorder. *Frontiers in psychiatry*, *12*, 1-18. https://doi.org/10.3389/fpsyt.2021.632784

¹⁰⁹ Ristori, J., Steensma, T. D. (2016). Gender dysphoria in childhood, *International review of psychiatry*, 28(1), 13-20.

¹¹⁰ Carmichael et al. (2021)

¹¹¹ de Vries, A. L., Steensma, T. D., Doreleijers, T. A., & Cohen-Kettenis, P. T. (2011). Puberty suppression in adolescents with gender identity disorder: A prospective follow-up study. *The journal of sexual medicine*, 8(8), 2276-2283. https://doi.org/10.1111/j.1743-6109.2010.01943.x

¹¹² Hardy, R. (2017, October 13). How a psychotherapist who has backed transgender rights for years was plunged into a Kafkaesque nightmare after asking if young people changing sex might later regret it. *Daily mail*. https://www.dailymail.co.uk/news/article-4979498/James-Caspian-attacked-transgender-children-comments.html

¹¹³ Djordjevic, M. L., Bizic, M. R., Duisin, D., Bouman, M. B., & Buncamper, M. (2016). Reversal surgery in regretful male-to-female transsexuals after sex reassignment surgery. *The journal of sexual medicine*, *13*(6), 1000-

transitions numbering in the tens of thousands has been accompanied by a surge of young people who have come to see that their transition was not the answer to their problems after all. There are now so many detransitioners that suppression of their stories is becoming impossible. One recent study surveyed 237 detransitioners, both male and female, and noted that over half of the respondents had three mental health co-morbidities, a trait that once nixed their eligibility for aggressive treatments. The majority of the sample, a full 70 percent, said a reason for detransitioning was due to realizing their "gender dysphoria was related to other issues."

- 110. Additionally, 62 percent marked health concerns as a reason for detransitioning, 50 percent said they did not find transition beneficial for their dysphoria, and 45 percent found other ways of dealing with their dysphoria. None of these reasons comport with the trans-affirmative narrative claiming that detransition is primarily due to social pressure or discrimination. 115 "Lack of support from social surroundings (13%), financial concerns (12%) and discrimination (10%)" were the least compelling reasons for detransitioning. 116
- 111. Dr. Turban's recent study of USTS survey data (gathered from an online, opt-in convenience sample) reported far higher levels of "external" rather than "internal" reasons for detransitioning—meaning that motivation for detransitioning was thought to come from the respondent's social environment rather than from internal motivation. This conclusion, however, is a direct result of how the survey question was posed to respondents. External reasons for detransitioning dominated the answer options, including seven "pressure" answers (e.g., pressure

^{1007.} https://doi.org/10.1016/j.jsxm.2016.02.173; Entwistle, K. (2021). Debate: Reality check—Detransitioner's testimonies require us to rethink gender dysphoria. *Child and adolescent mental health*, 26(1), 15-16. doi/epdf/10.1111/camh.12380

¹¹⁴ Vandenbussche, E. (2021). Detransition-related needs and support: A cross-sectional online survey. *Journal of homosexuality*, 1-19. https://doi.org/10.1080/00918369.2021.1919479

¹¹⁵ Turban, J. L., Loo, S. S., Almazan, A. N., & Keuroghlian, A. S. (2021). Factors leading to "detransition" among transgender and gender diverse people in the United States: A mixed-methods analysis. *LGBT health*, 8(4), 273-280. https://doi.org/10.1089/lgbt.2020.0437

¹¹⁶ Vandenbussche (2021), p. 5.

from a parent, pressure from a spouse or partner, pressure from an employer, etc.). Only two vaguely-worded internal answer options were offered: "I realized that gender transition was not for me" and "It was just too hard for me." (Write-in options were nevertheless allowed, but predictably revealed the lowest response frequency.)

112. In a 2021 study published in the *Archives of Sexual Behavior*, public health scientist Lisa Littman surveyed a convenience sample of 100 detransitioners in order to better understand this population. Her survey of detransitioners offered a far wider array of possible reasons for doing so than the USTS did, and revealed what the USTS could not, by design—namely that internal reasons were far more apt to be selected than external ones. Sixty percent of them became "more comfortable identifying as their natal sex," nearly half indicated concerns with "potential medical complications from transitioning," and 38% had come to view their dysphoria as "caused by something specific, such as trauma, abuse, or a mental health condition," each of which are—if the traditional pathway to treatment were followed—supposed to be probed prior to hormonal or medical treatments. 118

113. In the USTS, and hence in Turban's published study of detransitioning, no answer options were offered that would recognize that dysphoria and initial transitioning might have involved "difficulty accepting themselves as homosexual," traumas (including but not limited to sexual trauma), mental health conditions, and peer effects. Littman's survey did not include the first of these—but nevertheless revealed its importance: "Despite the absence of any questions about this topic in the survey, nearly a quarter (23.0%) of the participants expressed the internal-

¹¹⁷ Littman L. (2021). Individuals treated for gender dysphoria with medical and/or surgical transition who subsequently detransitioned: A survey of 100 detransitioners. *Archives of sexual behavior*, *50*(8), 3353–3369. https://doi.org/10.1007/s10508-021-02163-w

¹¹⁸ Ibid., p. 3353.

ized homophobia and difficulty accepting oneself as lesbian, gay, or bisexual narrative by spontaneously describing that these experiences were instrumental to their gender dysphoria, their desire to transition, and their detransition."¹¹⁹

- to have transitioned in the first place. It seldom came from family, however. Open-response answers included: "My gender therapist acted like it [transition] was a panacea for everything;" "[My] [d]octor pushed drugs and surgery at every visit;" "I was dating a trans woman and she framed our relationship in a way that was contingent on my being trans;" "A couple of later trans friends kept insisting that I needed to stop delaying things;" "[My] best friend told me repeatedly that it [transition] was best for me;" "The forums and communities and internet friends." ¹²⁰
- 115. By contrast, only seven percent (collectively) reported in Littman's study that a parent, spouse, or a family member had pressured them to detransition, far below the USTS's report of 36%, 18%, and 26%, respectively.
- 116. Notably, only 24% of those surveyed by Littman had informed the doctor or gender clinic of their detransition, which means that any "official" numbers on detransitioners are apt to be a significant undercount.
- 117. Further, not even all who experience regret or difficulties attributable to their transition will actually seek to physically detransition. There are many reports of individuals having regret but seeking to make the best of the irreversible changes and situation they find themselves in. ¹²¹ Consider the pioneer patient of the experimental Dutch protocol, "B," who was followed

¹¹⁹ Ibid., p. 3362.

¹²⁰ Ibid., p. 3360.

¹²¹ E.g.: Jax, R. (2017). *Don't get on the plane: Why a sex change will ruin your life*. CreateSpace Independent Publishing Platform.; Heyer, W. (2018). *Trans life survivors*. Bowker Identifier Services.; Teller Report. (2020, May 12). Aleksa Lundberg: "I am a gay feminine man with a female body." https://www.tellerreport.com/news/2020-05-12-aleksa-lundberg--%22i-am-a-gay-feminine-man-with-a-female-body%22.SyWGzCjDcU.html

for 22 years until the age of 35. It was reported that "he indicated no regrets about his treatment." However, B "scored high on the measure for depression. Owing to 'shame about his genital appearance and his feelings of inadequacy in sexual matters,' he could not sustain a romantic relationship." One cannot help but wonder whether B could have enjoyed greater lifetime wellbeing if he had not been placed on the medicalized transgender trajectory at the tender age of 13.

118. The scholar/activist authors of a 2020 *JAMA Psychiatry* study, led by plaintiffs' witness Dr. Turban, paint an entire class of cautious therapeutic approaches as intrinsically harmful—conversion attempts—using survey language stated as follows: "Did any professional (such as a psychologist, counselor, or religious advisor) try to make you identify only with your sex assigned at birth (in other words, try to stop you being trans)?" Given the hundreds of questions and items the USTS posed to its respondents six years ago, the fact that it lumps any scenario that does not involve unqualified affirmation (including "watchful waiting") into one imprecise, binary measure is psychometrically irresponsible. ¹²⁴ In other words, it is foisting on people a one-size-fits-all definition. What one can learn from a poor-quality question posed to an opt-in

_

¹²² Cohen-Kettenis, P. T., Schagen, S. E. E., Steensma, T. D., de Vries, A. L.C., & Delemarre-van de Waal, H. A. (2011) Puberty suppression in a gender-dysphoric adolescent: A 22-year follow-up. *Archives of sexual behavior*, 40(4), 843–847, p. 843.

¹²³ Biggs (2019) p. 49; Cohen-Kettenis et al. (2011), p. 845.

¹²⁴ Turban et al. (2020). This study was thoroughly critiqued in: D'Angelo, R., Syrulnik, E., Ayad, S., Marchiano, L., Kenny, D. T., & Clarke, P. (2021). One size does not fit all: In support of psychotherapy for gender dysphoria. *Archives of sexual behavior*, 50(1), 7-16. The authors concluded: "Turban et al.'s (2020) singular endorsement of "affirmative" therapies, which their data failed to substantiate, contributes to the alarming trend to frame any non-"affirming" approaches as harmful. We are deeply concerned that this false dichotomy, reinforced by Turban et al.'s unproven claims of the harms of GICE, will have a chilling effect on the ethical psychotherapists' willingness to take on complex GD patients, which will make it much harder for GD individuals to access quality mental health care. We maintain that availability of a broad range of non-coercive, ethical psychotherapies for individuals with GD is essential to meaningful informed consent, which requires consideration of the full range of treatment options, from highly invasive to non-invasive. Further, given the potential of agenda-free psychotherapy to ameliorate GD non-invasively among young people with GD, withholding this type of intervention, while promoting "affirmation" approaches that pave the way to medical transition, is ethically questionable. We believe that exploratory psychotherapy that is neither "affirmation" nor "conversion" should be the first-line treatment for all young people with GD, potentially reducing the need for invasive and irreversible medical procedures." p. 13

sample of respondents motivated—even recruited—to participate is limited by definition. That such studies seem easily publishable today highlights the extent to which certain medical journals—officially sponsored by the same associations that have claimed a stake in the outcome here—have been "ideologically captured." They seem uninterested in holding transgender research to standards comparable to other divisions of medicine.

- 119. As an aside, one notable development is the explosion in the number of academic journals focused on topics of sexuality and gender identity. There has been, on average, at least one new peer-reviewed journal in the domain of sexuality and gender launched every year for the past 30 years. The supply of journals is certainly in part a function of demand. But it is also invariably the case that where the competition for publication in peer-reviewed journals is tight (and therefore, there is a scarcity of supply), the pathway to publication is more challenging. Hence, the quality of what is published tends to be higher. The opposite happens when there is a large supply of journals: the barrier to publication is lower, and so typically is the quality. This is a problem that pervades the field.
- 120. If counseling can be construed as conversion attempts, this sends a clear message to psychiatrists and psychotherapists alike about their role in the doctor-patient relationship here—as a supplier of whatever the patient wishes to do. In a marketplace where professionals, just like any business, are subject to public reviews of their work, the label of "transphobic" is unwelcome and may have serious adverse professional consequences.
- 121. I concur with Dr. Stephen Levine, who has highlighted the quandary facing professionals attempting to provide "informed" counsel to patients about the biological, social, and

psychological risks posed by any treatment approach.¹²⁵ Such risks are real and ought to be discussed—this is what ethical informed consent does. But a serious, ranging conversation—the "informed" part of obtaining informed consent—could be perceived as an attempt to "convert" the person from pursuing gender affirmation treatments (e.g., hormones, surgery).

- able to live with the body you have strains simple logic as well as the advice of pioneering clinicians that less invasive outcomes were preferable to more aggressive ones. ¹²⁶ In any case, there is no defined psychotherapeutic method for treating gender dysphoria that can be widely characterized and consistently identified as "conversion therapy" in order to be banned. Nor has there been a clinical trial evaluating specific psychotherapeutic methods of counseling gender dysphoria that could potentially demonstrate whether one or more such methods are indeed helpful or harmful.
- 123. On page 36 of his previous supplemental declaration, Dr. Turban contests—by misrepresenting—this claim. I did not state that there are no definitions. Rather, I assert that there is no wide and consistent agreement about what exactly constitutes "conversion therapy." Only his reference to American Academy of Child and Adolescent Psychiatry (AACAP) offers a definition for conversion therapy. The subsequent citations each refer to conversion therapy but do not define it.
- 124. Following the AACAP's policy on conversion therapy, Dr. Turban employs a "frame alignment" move to suggest efforts at conversion therapy for same-sex attraction and

¹²⁵ Levine (2019).

¹²⁶ Smith, Y. L., van Goozen, S. H., & Cohen-Kettenis, P. T. (2001). Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. *Journal of the American Academy of Child & Adolescent Psychiatry*, 40(4), 472-481.

¹²⁷ Snow, D. A., Rochford Jr., E. B., Worden, S. K., & Benford, R. D. (1986). Frame alignment processes, micromobilization, and movement participation. *American sociological review*, 464-481.

gender expression are equivalent, since both—he claims—specifically "aim to promote heterosexuality" (page 36). That is, he links two different movements—the one to suppress gay conversion therapy and the one, noted above, on gender identity "conversion" efforts—in the hopes that overlapping interests, values, beliefs, and goals are complementary. But I am not talking about heterosexuality. I concur with another critic who has observed, "Studies of conversion therapy have been limited to *sexual orientation*, and, moreover, to the sexual orientation of *adults*, not to gender identity and not of children in any case." One British psychotherapist observes this challenge, noting that "[s]ome therapists, trans people, and their allies seem to regard any psychological description of GD as inherently pathologizing and equate it with gay conversion therapy."

125. Here again is evidence that a central framework for understanding the treatment of adolescent transgender patients is not that of mental and physical flourishing, but rather has become that of securing bodily autonomy and patient choice. The ideological capture of much of this field of treatment makes for a very difficult environment for psychological treatment of gender dysphoria in minors.

126. Many other examples of undue pressure could be given, both within and outside the professions. Amazon's decision to withdraw from selling books that so much as suggest the idea that gender dysphoria is (or had been associated with) a mental disorder is one. Public fora for legitimate debate are actively being curbed. Even *reviews* of books are being retracted and

¹²⁸ Cantor, J. M. (2020). Transgender and gender diverse children and adolescents: Fact-checking of AAP policy. *Journal of sex & marital therapy 46*(4): 307-313. The quote is from page 308.

¹²⁹ Withers (2020), p. 865.

¹³⁰ Trachtenberg, J. A. (2018, March 11). Amazon won't sell books framing LGBTQ+ identities as mental illnesses. *Wall street journal*. https://www.wsj.com/articles/amazon-wont-sell-books-framing-lgbtq-identities-as-mental-illnesses-11615511380

withdrawn.¹³¹ Certain conclusions are now penalized both professionally and in the wider social and economic marketplace. To suppose that such external social and political pressures do not affect basic social or medical research on transgender-related matters would be naïve.

E. Inconsistent Claims about Adolescents' Ability to Consent

- 127. A central and persistent concern about hormonal (and subsequent surgical) courses of treatment for gender dysphoria in adolescents is their ability to genuinely consent to treatments that will almost invariably lead to de facto sterilization. Parental consent to sterilization used to be unlawful in many locales, creating ethical dilemmas that commonly required judicial review.¹³²
- 128. These are complicated matters, no doubt. Bernadette Wren, who was a senior clinician at the Tavistock until her retirement in 2020, admits in her diary of reflections to doubts about her field at the UK's gender clinic: "Can children and adolescents realistically consent to these treatments? If yes, how is their competence ensured? If no, is this decision within the scope of parental discretion? And if young people, with or without their parents, are deemed competent, where does the responsibility lie if there are subsequent feelings of regret?" If senior clinicians who have worked in this domain for decades have such fundamental questions, they are certainly worth considering.
- 129. The stakes are high. The bar to informed consent for experimental medical treatments (of any sort) has long been elevated for minors. It is decreasingly so in gender medicine.

 As gender therapist Diane Ehrensaft observes, "continuity of care in gender affirmation" from

¹³¹ Novella, S. & Gorski, D. (2021, June). Retraction notice for Hall, H. (2021, June 15.) Book review: *Irreversible damage: The transgender craze seducing our daughters*, by Abigail Shrier. *Science-based medicine*. https://science-basedmedicine.org/irreversible-damage-the-transgender-craze-seducing-our-daughters/

¹³² For example, it remains illegal in Oregon to sterilize a person under age 15, regardless of parental permission. See also Boynton, M. (1994). Sterilization of minors. *Minn med.* 77(1):23-4. https://pubmed.ncbi.nlm.nih.gov/8127303/

puberty blockers to cross-sex hormones results in "discontinuity in potential capacity to ever create progeny with their own genetic material." In other words, affirmative care eventually means sterilization *as a minor*, under WPATH's proposed new guidance.

- 130. Even researchers and clinicians trained on the experimental Dutch protocol are signaling new allegiances to the "affirm without question" paradigm, after claiming that the recent surge in cases merely reflects hidden demand previously unsurfaced. As an example of this, Dutch child and adolescent psychiatrist Annelou de Vries and six co-authors registered their disappointment with the (original) *Bell v Tavistock* decision, asserting that "minors as young as 12 years of age frequently possess this ability"—that is, the competency to understand the consequences of a decision to begin puberty blockers. 135
- 131. In asserting this, de Vries and her colleagues claim to concur with "all the major medical associations." But even some medical associations offer reasons to doubt that adolescents are competent to consent. The APA recognizes that "adolescents can become intensely focused on their immediate desires, resulting in outward displays of frustration and resentment when faced with any delay in receiving the medical treatment from which they feel they would benefit and to which they feel entitled. This intense focus on immediate needs may create challenges in assuring that adolescents are cognitively and emotionally able to make life-altering de-

¹³³ Ehrensaft, D. (2021, April 7). Fertility issues for transgender and nonbinary youth. Training presentation sponsored by the UC San Francisco Child and Adolescent Gender Center. Discussion and video links available at: https://4thwavenow.com/2021/04/13/tmi-genderqueer-11-year-olds-cant-handle-too-much-info-about-sterilizing-treatments-but-do-get-on-with-those-treatments/

¹³⁴ Arnoldussen, M., Steensma, T.D., Popma, A. *et al.* (2020). Re-evaluation of the Dutch approach: are recently referred transgender youth different compared to earlier referrals?. *European child & adolescent psychiatry*, *29*, 803–811. https://doi.org/10.1007/s00787-019-01394-6.

¹³⁵ de Vries, A. L., Richards, C., Tishelman, A. C., Motmans, J., Hannema, S. E., Green, J., & Rosenthal, S. M. (2021). Bell v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274: Weighing current knowledge and uncertainties in decisions about gender-related treatment for transgender adolescents, *International journal of transgender health*, p. 5. doi: 10.1080/26895269.2021.1904330

cisions to change their name or gender marker, begin hormone therapy (which may affect fertility), or pursue surgery."¹³⁶ For its part, the Endocrine Society guidelines recognize that "no objective tools to make such an assessment [i.e., of an adolescent's competence in decision making] are currently available" and notes that some "believe that . . . abilities (such as good risk assessment) do not develop until well after 18 years."¹³⁷

- 132. The American Medical Association (AMA) presents a curious case about consent. In an April 26, 2021 letter to the National Governors Association (NGA), the AMA wrote to urge the NGA to "oppose state legislation that would prohibit the provision of medically necessary gender transition-related care to minor patients." But this statement is flatly inconsistent with the position the AMA has taken concerning adolescents' abilities in other contexts. In its 2005 amicus brief to the U.S. Supreme Court in *Roper v. Simmons*, a case that concerned capital punishment for crimes committed by minors, the AMA asserted that "[a]dolescents' behavioral immaturity mirrors the anatomical immaturity of their brains. To a degree never before understood, scientists can now demonstrate that adolescents are immature not only to the observer's naked eye, but in the very fibers of their brains." 139
- 133. The AMA brief makes an additional pair of comparative claims about the adolescent brain: "First, adolescents rely for certain tasks, more than adults, on the amygdala, the area of the brain associated with primitive impulses of aggression, anger, and fear. Adults, on the

¹³⁶ American Psychological Association (2015), p. 842.

¹³⁷ Hembree et al. (2017), p. 3884.

¹³⁸ Madara, J. L. (2021, April 26). Official AMA letter to legislators. https://www.ama-assn.org/press-center/press-releases/ama-states-stop-interfering-health-care-transgender-children

¹³⁹ American Medical Association et al. (2005). Brief of Amici Curiae in *Roper v. Simmons*, (U.S. Sup. Ct.), 543 U.S. 551 (No. 03-633), 2004 WL 1633549, p. 10. The AMA was joined in their claims by the American Psychiatric Association, American Society for Adolescent Psychiatry, American Academy of Child & Adolescent Psychiatry, American Academy of Psychiatry and the Law, National Association of Social Workers, Missouri chapter of the National Association of Social Workers, and the National Mental Health Association.

other hand, tend to process similar information through the frontal cortex, a cerebral area associated with impulse control and good judgment. Second, the regions of the brain associated with impulse control, risk assessment, and moral reasoning develop last, after late adolescence."¹⁴⁰ This is widely recognized today in the conventional wisdom that (prefrontal) brain development does not stabilize in human beings until around age 25.

- 134. One of the attorneys who penned the brief in *Roper* on behalf of the AMA and other organizations later reinforced—by referring to the brief itself—that the "ability of adolescents to make cost-benefit calculations, as compared to adults, is deficient. Additionally, their susceptibility to peer pressure is greater because of this impaired judgment. Moreover, adolescents are more volatile than adults, experiencing more extreme emotions that are not as regulated as they are in adults."¹⁴¹
- 135. When it comes to criminal activity, the AMA asserts that minors cannot be trusted to navigate peer pressure, weigh costs and benefits, make clear-minded judgments, and move ahead with life-altering decisions. But when it comes to transgender medicine and its life-altering consequences, the AMA asserts that minors are competent to make such decisions.
- 136. Is a child at the cusp of puberty competent to weigh the risks and consequences that transgender medicine entails? That was the question at stake in *Bell v Tavistock*. In 2020, Keira Bell petitioned the court to review the treatment given to minors and young people, saying she had been rushed to transition, was not given other therapeutic options, and lacked the capacity to understand the long-term implications of her decisions at the time. "I was an unhappy girl who needed help," Bell stated. "Instead, I was treated like an experiment." In its December

¹⁴⁰ American Medical Association et al., p. 11.

¹⁴¹ Haider, A. (2006) *Roper v. Simmons*: The role of the science brief. *Ohio state journal of criminal law 3*: 369-377, p. 372.

¹⁴² Bell, K. (2021, April 7). Keira Bell: My story. *Persuasion*. https://www.persuasion.community/p/keira-bell-my-story

2020 decision, the UK's highest court ruled that children could not give genuine consent to hormonal treatments offered at the National Health Service's gender clinic.

- 137. In its original verdict, the UK High Court also highlighted a "lack of clarity over the purpose of the treatment: in particular, whether it provides a "pause to think" in a "hormone neutral" state or is a treatment to limit the effects of puberty, and thus the need for greater surgical and chemical intervention later."¹⁴³
- 138. When the initial judgment in *Bell v Tavistock* was announced, plaintiff Keira Bell responded, "I am delighted at the judgment of the court today. It was a judgment that will protect vulnerable young people. I wish that it had been made for me before I embarked on the devastating experiment of puberty blockers. My life would be very different today. This time last year I joined this case with no hesitation, knowing what I knew about what had and has been going on at the gender identity clinic. My hope was that outside of the noise of the culture wars the court would shine a light on this harmful experiment on vulnerable children and young people. These drugs seriously harmed me in more ways than one and they have harmed many more particularly young girls and women." 144
- 139. What is certainly clear is that the use of puberty blockers in the present is linked to the potential outcomes of future drugs and surgeries, thus revealing a presumption of medical "path dependence" in these treatment protocols. That is why the court determined that puberty blockers and cross-sex hormones are essentially two parts of "one clinical pathway." Consequently, for minors to be competent to consent to blockers, they would have to adequately understand and consent to the effects of future cross-sex hormones as well.

¹⁴³ Bell & Av. Tavistock & Portman NHS Foundation Trust. (2020), para. 134.

¹⁴⁴ Bell, K. (2020) Keira Bell case: Statements from BBC interview. Transcript available here: https://ourduty.group/2020/12/02/keira-bell-case-statements/

¹⁴⁵ Bell & Av. Tavistock & Portman NHS Foundation Trust. (2020), para. 136.

- 140. In the most recent ruling on the Tavistock's subsequent appeal, the Court of Appeals' opinion did not reflect any change in the evidentiary bases, nor did it draw any conclusions about harm or risk of harm to minors, but instead upheld a legal precedent favoring physicians' discernment of adolescent competence to consent, on a case-by-case basis. (The case is currently proceeding to the UK Supreme Court.)
- Health Authority, presupposes that all clinicians are subject to professional regulation, with established review mechanisms. However, there is growing concern from within the transgender medical community that such established review mechanisms are increasingly disregarded.

 Wren recently reflected that the landscape for treating gender dysphoria in the UK had shifted. There is now "growing resistance from families toward...[a] slow-paced model of care. Young people and their parents, arriving at [Tavistock's GIDS clinic] many months after referral, were becoming more assertive in their demands for validation of their new gender identity and for faster, earlier and simpler access to puberty suspension and cross-sex hormones." Social media sources add motivation, while external providers add competition. Caution and reflection, Wren observed, "were now pitted against online sources of anecdote, emotion and personal history. Private providers waited in the wings, willing to meet these requests with a minimal protocol." Private providers waited in the wings, willing to meet these requests with a minimal protocol."

 $^{^{146}\} http://www.bailii.org/uk/cases/UKHL/1985/7.html\ or\ https://www.judiciary.uk/judgments/bell-and-another-v-the-tavistock-and-portman-nhs-foundation-trust-and-others/$

¹⁴⁷ Wren, B. (2021, Dec. 2). Epistemic injustice. *London review of books*, *43* (23), https://www.lrb.co.uk/the-pa-per/v43/n23/bernadette-wren/diary, paragraph 12. ¹⁴⁸ Ibid.

- 142. Hence, the September 2021 Court of Appeals deference to "Gillick competence," the precedent established in the 1985 case by that name, formally affirms an approach that is increasingly informally ignored—including at the Tavistock clinic, according to Wren.
- psychologists—one of whom identifies as transgender—who work with gender dysphoric adolescents, recently asserted that "we find evidence every single day, from our peers across the country and concerned parents who reach out, that the field has moved from a more nuanced, individualized and developmentally appropriate assessment process to one where every problem looks like a medical one that can be solved quickly with medication or, ultimately, surgery." Formal standards, they claim, are being openly ignored in favor of believing the patient, no matter how young. This, the pair observes, is what gender-affirming medicine has become—skipping the psychological assessment and believing the patient is capable of making all decisions about their own body. They make reference to a popular physician and gender clinic director's claim that gender-affirming medicine means that "you are best equipped to make decisions about your own body,' full stop." ¹⁵⁰
- 144. Sweden and Finland have, on the other hand, scaled back their protocols concerning adolescent transgender treatments after witnessing surging cases and the sex-ratio inversion—far more natal girls than boys seeking medical treatment for gender dysphoria. Finnish guidelines now hold that that identity exploration is a natural phase of adolescence and therefore medical interventions ought to be restricted until their "identity and personality development appear to be stable." Brain development, they observe, continues until early adulthood—about age

¹⁴⁹ Edwards-Leeper & Anderson (2021), paragraph 6.

¹⁵⁰ Ibid., paragraph 13.

- 25—which affects young people's ability to assess the consequences of their decisions on their own future selves for rest of their lives.¹⁵¹
- 145. "Cross-sex identification in childhood, even in extreme cases, generally disappears during puberty," the Finnish document maintains. Moreover, the new guidelines prioritize non-invasive psychotherapeutic interventions as the first course of action, due to "variations in gender identity in minors." Finally, Finnish guidelines similarly recommend further study, citing "a need for more information on the disadvantages of procedures and on people who regret them." ¹⁵³
- 146. Sweden's rollback—in the wake of a 1,500 percent increase in youth gender clinic referrals over a ten-year period—is even more pronounced. Hormonal treatments will no longer be offered to persons under age 18, although clinical trials research on 16-18-year-olds will be allowed. This followed a late 2019 Swedish health system publication and a similar evidence review published in October 2020 that revealed little evidence to suggest that puberty-blocking and hormonal treatments improve the mental health and psychosocial functioning of minors. The literature provides very little knowledge about their safety in the long term. 154

F. The Department of Justice's Dramatic Flip-Flop on Bostock

147. Not to be overlooked in a discussion of matters bearing on the politically-charged nature of issues affecting persons who identify as transgender is the Department of Justice (DOJ) Civil Rights Division's dramatic flip-flop on implementing the U.S. Supreme Court's decision in

¹⁵¹ Council for Choices in Healthcare (COHERE). (2020). Medical treatment methods for dysphoria associated with variations in gender identity in minors – recommendation-summary. Healthcare Services Selection Council (Palko). Government, Finland. https://palveluvalikoima.fi/documents/1237350/22895008/Summary_minors_en.pdf/aaf9a6e7-b970-9de9-165c-abedfae46f2e/Summary_minors_en.pdf

¹⁵² Council for Choices in Healthcare (COHERE) (2020).

¹⁵³ Ibid.

¹⁵⁴ Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) (2019).

Bostock v. Clayton County, Georgia. That decision held that firing an individual because they are transgender violates Title VII of the Civil Rights Act.

- dressing *Bostock*'s implications for various provisions of law, for religious liberty, and for the DOJ's own employment practices. ¹⁵⁵ But a mere five days later—after the inauguration of a new presidential administration—the Civil Rights Division withdrew the memorandum. ¹⁵⁶ The whiplash-inducing speed with which the Civil Rights Division reversed itself after the new administration took over simply highlights the politically-charged nature of the matter.
- 149. I have reviewed the Civil Rights Division's statement of interest filed in this law-suit, which accentuates the point to an even greater degree. The Civil Rights Division's January 17, 2021 memorandum articulated several reasons why the *Bostock* decision did not bear on the Equal Protection Clause. But on June 17, 2021, the Civil Rights Division filed a statement of interest in this lawsuit that repeatedly appeals to *Bostock* in support of the plaintiffs' Equal Protection claim in this lawsuit. The DOJ Civil Rights Division's direct contradiction of the precise legal position that it took only a few months prior renders undeniable the politically-charged nature of matters bearing on individuals who identify as transgender.

VI. ASSESSING THE RISK OF SUICIDE AS MOTIVATION FOR "AFFIRMATIVE" TREATMENT

150. Parents' fears about children's suicide are understandable and ought never to be dismissed. However, such fears should not override scholarly evaluations of suicidality—which

¹⁵⁵ Daukas, J. B. (2021, January 17). Department of Justice memorandum to the Civil Rights Division on the application of *Bostock v. Clayton County*. Although the DOJ removed the January 17 memorandum from the Internet, it is archived online here: https://web.archive.org/web/20210120125231/https://www.justice.gov/crt/page/file/1356531/download

¹⁵⁶ Friel, G. B. (2021, January 22). Department of Justice memorandum to the Civil Rights Division withdrawing the memorandum on the application of *Bostock v. Clayton* County. https://www.justice.gov/crt/page/file/1373621/download

the APA defines as risk of suicide indicated by ideation and intent—with suicide itself.¹⁵⁷ The association of the two (suicide and suicidality) varies notably in subpopulations.¹⁵⁸ Too often, however, suicidal "ideation" is equated with "attempted" suicide, and even seems to be treated as a proxy for suicide.

dorsing the "affirmative" approach to treating dysphoric adolescents. But suicidal ideation and suicidal behavior are not as tightly associated as some surmise. For example, young adults are at least three times as likely to report past-year thoughts of suicide than are adults age 50 and older. But the actual suicide rate among older Americans remains well above that among young adults, and far above children below age 15. New data, collected during the COVID-19 era, complicates matters further, given that young adults ages 18-24 reported suicidal thoughts in the past month at rates 12 times higher than that of respondents age 65 and over, and six times that reported by those between 45 and 64 years old (25.5, 3.8, and 2.0 percent, respectively). 162

¹⁵

¹⁵⁷ https://dictionary.apa.org/suicidality

¹⁵⁸ Han, B., Compton, W. M., Gfroerer, J., & McKeon, R. (2015). Prevalence and correlates of past 12-month suicide attempt among adults with past-year suicidal ideation in the United States. *The journal of clinical psychiatry*, 76(3), 295–302. https://doi.org/10.4088/JCP.14m09287

¹⁵⁹ Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2020). Pubertal suppression for transgender youth and risk of suicidal ideation. *Pediatrics*, *145*, e20191725. https://doi.org/10.1542/ peds.2019-1725. This touted study, however, proves insufficient for the claims it makes. Oxford University sociologist Michael Biggs argues that the study leans on "a low-quality survey which is known to have elicited unreliable answers on puberty blockers." Biggs concludes that Turban's study "provided no evidence to support the recommendation 'for this treatment to be made available for transgender adolescents who want it." See Biggs, M. (2020). Puberty blockers and suicidality in adolescents suffering from gender dysphoria. *Archives of Sexual Behavior*, *49*, 2227-2229. https://link.springer.com/content/pdf/10.1007/s10508-020-01743-6.pdf

¹⁶⁰ Lipari, R. N., Hughes, A., & Williams, M. (2016, June 16). State estimates of past year serious thoughts of suicide among young adults: 2013 and 2014. *The CBHSQ report*, 1-7. Substance Abuse and Mental Health Services Administration (US). PMID: 27854411.

Hedegaard, H., Curtin, S. C., Warner, M. (2021). Suicide mortality in the United States, 1999–2019. NCHS data brief, no. 398. Hyattsville, MD: National Center for Health Statistics. doi: https://dx.doi.org/10.15620/cdc:101761.
 Czeisler, M. É., Lane, R. I., Petrosky, E., Wiley, J. F., Christensen, A., Njai, R., Weaver, M. D., Robbins, R., Facer-Childs, E. R., Barger, L. K., Czeisler, C. A., Howard, M. E. & Rajaratnam, S. M. W. (2020). Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30. MMWR Morbidity & mortality weekly report, 69(32), 1049–1057. doi: http://dx.doi.org/10.15585/mmwr.mm6932a1

Based on thoughts of suicide, then, it could be said that there is a crisis of suicidality among the young. But the crisis of actual suicide affects older Americans to a more significant degree.

- Youth Risk Behavior Survey noted that 19 percent of Americans ages 14-18 report having seriously thought about suicide (i.e., had suicidal ideation) in 2019. Nine percent reportedly attempted suicide. The CDC did not track such rates among youth identifying as transgender, but did note elevated rates among individuals identifying as lesbian, gay, or bisexual. Previous research has noted that between 25 to 30 percent of adolescents identifying as transgender report having attempted suicide during their lifetimes.
- 153. Suicides and attempted suicides among the self-identified transgender population are indeed higher than those in the population at large. It is, however, difficult to determine this subpopulation's scope of suicide risk with accuracy. Moreover, suicide rates have increased strikingly in the general population over the past decade.¹⁶⁵
- 154. Nevertheless, localized estimates of suicidal ideation and attempts among transgender-identifying adolescents vary notably. A 2017 chart review from a Cincinnati gender

¹⁶³ Ivey-Stephenson, A. Z., Demissie, Z., Crosby, A. E, Stone, D. M., Gaylor, E., Wilkins, N., Lowry, R., & Brown, M. (2020). Suicidal ideation and behaviors among high school students - Youth Risk Behavior Survey, United States, 2019. *MMWR Suppl.*, 69(Suppl. 1), 47-55. doi: 10.15585/mmwr.su6901a6. See also: Gender Identity Development Service. (2021). Evidence base: Psychosocial difficulties. https://gids.nhs.uk/evidence-base ¹⁶⁴ Olson, J., Schrager, S. M., Belzer, M., Simons, L. K., & Clark, L. F. (2015). Baseline physiologic and psychosocial characteristics of transgender youth seeking care for gender dysphoria. *Journal of adolescent health*, 57(4), 374–380; Grossman, A.H., Park, J.Y., & Russell, S.T. (2016). Transgender youth and suicidal behaviors: Applying the interpersonal psychological theory of suicide. *Journal of gay & lesbian mental health*, 20(4), 329–349. ¹⁶⁵ Whalen, J. (2018, May 15). Youth suicidal behavior is on the rise, especially among girls. *Wall street journal*. https://www.wsj.com/articles/youth-suicidal-behavior-is-on-the-rise-especially-among-girls-1526443782

clinic noted that among patients (ages 12-22) diagnosed with gender dysphoria, 30 percent reported at least one suicide attempt. (Overall, 58 percent of the Cincinnati clinic patients exhibited at least one additional psychiatric diagnosis.) Two similar studies support these findings, with attempted suicide rates among transgender or dysphoric adolescents of between 26 and 31 percent. Others note lower rates, including 14 percent in a Toronto clinic and 10 percent in an Australian clinic. (168)

155. The UK's Gender Identity Development Service (GIDS) observes that suicide remains "extremely rare" among dysphoric youth, even while noting their rates of self-harm are consonant with those among adolescents in the general population. An extensive, longitudinal "chart study" of all 8,263 adult, adolescent, and child referrals to an Amsterdam gender clinic between 1972 and 2017 documented that 41 natal men (0.8 percent) and 8 natal women (0.3 percent) died by suicide. Among the former, suicide deaths had decreased over time, while it did not change in natal women. Only four suicide deaths were observed among patients referred to the clinic before the age of 18 (0.2 percent), which was a lower risk than among adult patients (0.7 percent).

_

¹⁶⁶ Peterson, C. M., Matthews, A., Copps-Smith, E. and Conard, L. A. (2017). Suicidality, self-harm, and body dissatisfaction in transgender adolescents and emerging adults with gender dysphoria. *Suicide and life-threatening behavior*, 47, 475-482. https://doi.org/10.1111/sltb.12289

¹⁶⁷ Eisenberg, M. E., Gower, A. L., McMorris, B. J., Rider, G. N., Shea, G., & Coleman, E. (2017). Risk and protective factors in the lives of transgender/gender nonconforming adolescents. *Journal of adolescent health*, *61*(4), 521-526. https://doi.org/10.1016/j.jadohealth.2017.04.014; Grossman, A. H. & D'Augelli, A. R. (2007). Transgender youth and life-threatening behaviors. *Suicide and life-threatening behavior*, *37*(5), 527-537. https://guilfordjournals.com/doi/abs/10.1521/suli.2007.37.5.527

¹⁶⁸ Sorbara, J. C., Chiniara, L. N., Thompson, S., & Palmert, M. R. (2020). Mental health and timing of gender-affirming care. *Pediatrics*, *146*(4). https://doi.org/10.1542/peds.2019-3600; Kozlowska et al. (2021).

¹⁶⁹ The median age at first visit, however, was 25. See Wiepjes, C. M., den Heijer, M., Bremmer, M. A., Nota, N. M, de Blok, C. J. M., Coumou, B. J. G., & Steensma, T. D. (2020). Trends in suicide death risk in transgender people: Results from the Amsterdam cohort of Gender Dysphoria study (1972–2017). *Acta psychiatrica Scandinavica*, 141(6), 486-491. https://doi.org/10.1111/acps.13164

- 156. The Tavistock report also revealed that after a year on puberty blockers, a significant increase was noted in responses to the statement "I deliberately try to hurt or kill myself." This finding, however, was not replicated across the duration of the study.¹⁷⁰
- 157. In 2020, the Swedish National Board of Health and Welfare reported that minors with gender dysphoria have a high incidence of "co-occurring psychiatric diagnoses, self-harm behaviors, and suicide attempts compared to the general population" and that suicide mortality rates are higher among people with gender dysphoria than in the general population. They also observe, however, complications in figuring out what is to blame: "At the same time, people with gender dysphoria who commit suicide have a very high rate of co-occurring serious psychiatric diagnoses, which in themselves sharply increase risks of suicide. Therefore, it is not possible to ascertain to what extent gender dysphoria alone contributes to suicide, since these psychiatric diagnoses often precede suicide."
- 158. Hence, the evidence for actual suicide risk among gender dysphoric minors is simply unclear, and not just because completed suicides are far more apt to be documented in terms of demographic characteristics rather than sexual and gender-related ones. Rather, as one psychiatrist aptly notes, "Suicide is rare and noisy," that is, understanding particular causes is challenging. The white male suicide rate, for example, is the highest in the United States by a significant margin. But to suggest that race or sex plays a compelling motivation in suicidal decision-making does not make sense. Complicating matters here is the known, elevated frequency

¹⁷⁰ Biggs (2019).

¹⁷¹ Swedish National Board of Health and Welfare. (2020). The evolution of the diagnosis of gender dysphoria: Prevalence, co-occurring psychiatric diagnoses and mortality from suicide. *Socialstryrelsen*, p. 11.

of "significant psychopathology" among dysphoric adolescents.¹⁷² This makes direct, unmediated claims about the causes of suicidal ideation very difficult.

- 159. An earlier study of 55 transgender youth reported that "nearly half of the sample reported having seriously thought about taking their lives and one quarter reported suicide attempts." Among them, however, "a significantly greater proportion of those who had attempted suicide expressed weight-related body dissatisfaction than those who had not," a finding observed in other studies as well. They also tended to ruminate about how others evaluated their bodies.
- 160. Simply documenting elevated "suicidality" among self-identified transgender youth does not recommend a particular treatment approach. As one psychoanalyst put it, "We treat suicide first of all by keeping people safe, and by helping them become more resilient." Understanding the relationship between gender dysphoria and suicidality is complex; that is, there is an association, but the dysphoria may or may not be a central cause. Research has noted recently that particular aspects of body dissatisfaction may constitute independent risk factors for suicidality among patients with gender dysphoria. In other words, dissatisfaction with appearance—all the more in the age of Instagram and the selfie—may be a factor in the elevated risk of attempted suicide. In the absence of data analyses that can control for the effects of other confounding and contributing factors, it becomes very difficult to establish that gender dysphoria is

¹⁷² Kaltiala-Heino, R., Sumia, M., Työläjärvi, M., & Lindberg, N. (2015). Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development. *Child and adolescent psychiatry and mental health*, *9*(1), 1-9. https://doi.org/10.1186/s13034-015-0042-y

¹⁷³ Grossman & D'Augelli (2007), p. 527.

¹⁷⁴ Day et al. (2019), p. 2; Grossman & D'Augelli (2007).

¹⁷⁵ Day, D. S., Saunders, J. J., & Matorin, A. (2019). Gender dysphoria and suicidal ideation: Clinical observations from a psychiatric emergency service. *Cureus*, *11*(11), e6132. https://doi.org/10.7759/cureus.6132

¹⁷⁶ Shrier (2020), pp. 137-138.

¹⁷⁷ Peterson et al. (2017).

a solitary or primary driver of suicidality, all the more since the majority of gender dysphoric minors never attempt suicide.

- 161. The specter of suicide has nevertheless become a central narrative among supporters of the affirmative treatment approach. Some advocates compare puberty suppression to cancer treatments, claiming that these interventions are as "life-saving" for gender-dysphoric youth as oncology treatments are for those afflicted with cancer. However, the science behind claims that such treatments lead to sustained improvement in mental health—improvement that cannot possibly occur in its absence—is remarkably weak.
- 162. Affirmative clinicians Dr. Edwards-Leeper and her transgender co-author Dr. Erica Anderson have criticized advocates' weaponization of suicidality—a tool they believe to be wielded by the "affirm without question" wing of clinicians, whose argument can be summarized as follows: support the minor's self-diagnosis and put them on the pathway to transition, lest they take their own life. Edwards-Leeper and Anderson have heard enough; the "specter" of suicide "should not be used to push forward unrelated medical treatment without professional care or attention for each patient." 179

¹⁷⁸ In the Tavistock study, children were barred from beginning GnRha treatment if their baseline bone density was too low or agreed to stop treatment if it fell below a certain threshold. In the original Dutch protocol, several participants had to discontinue treatment due to medical complications from the hormone therapy. Did these children die from lack of medicine? Was the progression of their natural puberty and release of sex congruent hormones akin to the progression of metastatic cancer? Of course not. One hopes that these children were rightly encouraged in resilience, rather than surmise that they were doomed to commit suicide because they could not tolerate living in their body apart from transgender medical interventions.

¹⁷⁹ Edwards-Leeper & Anderson, E. (2021), paragraph 15.

VII. THE ROLE OF VALUES IN THE PRODUCTION OF SCIENCE

163. Many scientists have long asserted the reality and importance of the fact/value distinction. That is, there are facts—real things—and then there are values, our opinions or attitudes. The study of transgender medicine undermines any strong confidence in this distinction because what a person values shapes what they discern as facts.

164. Misunderstanding the place of values in science is not just an intellectual problem. It can have practical consequences, especially where science has implications for public health and policy. A trio of philosophers aptly note: "If values play a role in science, then the public and public officials cannot take scientific results as given and scientific authorities as beyond challenge. Responsible public policy will require responsible use of science; responsible use of science will require explicit critical awareness of its value assumptions." ¹⁸⁰

165. Although this report has focused on the scientific evidence, researcher behavior, and the culture of scientific organizations, it is nevertheless easy to observe how values saturate "affirmative" approaches to treating gender dysphoria. This is not a criticism per se. Values necessarily infuse the sciences, including the medical sciences as well. The Endocrine Society openly notes how particular values affect their counsel: "These recommendations place a high value on avoiding an unsatisfactory physical outcome when secondary sex characteristics have become manifest and irreversible, a higher value on psychological well-being, and a lower value on avoiding potential harm from early pubertal suppression." In other words, the Endocrine Society is more concerned with helping young people achieve a certain subjective satisfaction

¹⁸⁰ Kincaid, H., Dupré, J., & Wylie, A., (Eds.). (2007). *Value-free science? Ideals and illusions*. Oxford University Press, pp. 4-5.

¹⁸¹ Hembree et al. (2017), p. 3881.

with their physical appearance than it is avoiding possible harms of experimental medications, the threat of sterilization, or addressing the long-term health and well-being of its young patients.

- 166. The Endocrine Society is not alone here. Even Dr. de Vries and her colleagues, cited earlier as one-time representatives of the (less reckless but still experimental) Dutch protocol, make a play for the same privileging of physical appearance in their criticism of the UK court's *Tavistock* decision: "Our deep concern is that the High Court overlooked . . . the lifelong benefits of having a physical appearance which is congruent with one's gender identity (e.g., no or less breast development and less feminine body shape in an affirmed male and no low voice, Adam's apple, or masculine facial features in an affirmed female)." 182
- 167. Indeed, value-laden questions may outnumber purely clinical ones in this domain. Is the physician's role one of granting the requests of patients in order to fulfill what the latter believe or want to be true, or is the physician's role to treat the gender dysphoria with as little longstanding harm to the wellbeing of the body and mind as possible? Are we to master our feelings and emotions or be subject to them?
- 168. The very experience of social, hormonal, and surgical "transition" is a value leap—the introduction of a new meaning of "life cycle." The "body and its meanings" are now considered "contingent." The concept of "gender identity" requires body dissociation de facto, subjugating material reality to the subjective feelings of youth susceptible to suggestion.
- 169. Dr. Adkins comments on pre-pubertal social transitioning behaviors, including "allowing children to wear clothing, to cut or grow their hair, to use names and pronouns, and to access restrooms and other sex-separated facilities and activities in line with their gender identity

¹⁸² de Vries et al. (2021), p. 4.

¹⁸³ Pyne, J. (2014). Gender independent kids: A paradigm shift in approaches to gender non-conforming children. *The Canadian journal of human sexuality*, 23(1), 1-8, p. 5. https://doi.org/10.3138/cjhs.23.1.CO1

instead of the sex assigned to them at birth."¹⁸⁴ But her description is wrong because these behaviors are not in line with some immutable thing called a "gender identity." Rather, they are in line with current, valued (and culture-specific) expressions of sex-typed behavior. If "gender identity," a concept not invented until mere decades ago, was associated with each of these practices, from where (and why) did such norms arise? Instead of questioning the exclusive validity of two-dimensional, historically contingent gender stereotypes (e.g., the cartoonishly "feminine" Barbie doll or an excessively "masculine" counterpart), many have instead capitulated to (social) media-intensified values about dress, attire, look, and practice. Rather than impugn one's own body, perhaps norms associated with this or that "gender identity" ought to be more flexible.

170. Bernadette Wren, the retired senior clinician from the Tavistock clinic, wrote in 2014 how trendy postmodern ideas about gender had impacted clinicians' work with children and adolescents, namely, by adopting the idea of "all gender as fictional and artificial." After discussing the possible conundrums that arise when directing minors toward irreversible physical changes in light of these conceptions, Wren concluded: "the meaning of trans is constantly shaped and re-shaped, [and] rests on no foundation of truth. The therapist is not burdened with needing to be right or certain, but to offer a reflexive and thoughtful space to help clients explore the architecture and borders of their gendered world view." 185

171. Wren recognizes the value-laden nature of gender medicine for minors: "We are concerned about overstepping what the current evidence can tell us about the safety of our interventions. And we are fully alive to the complexities of informed consent, especially with respect to irreversible bodily change and fertility—and to the possibility of young people having later

¹⁸⁴ Adkins (2021), p. 7.

¹⁸⁵ Wren, B. (2014). Thinking postmodern and practising in the enlightenment: Managing uncertainty in the treatment of children and adolescents. *Feminism & Psychology*, 24(2), 271-291, p. 271 and p. 287, respectively.

misgivings around medical intervention. We see that these are not matters of narrow 'clinical' judgement, but relate to broader social acceptance of the challenges brought by new medical technologies, new ideologies of self-determination and new models of parental responsiveness and love." ¹⁸⁶ Unquestionably, values saturate this domain.

VIII. CONCLUSION

172. The field of adolescent transgender medicine is saturated by conflict over competing values. High quality longitudinal research is rare. Randomized clinical trials research has not occurred. Bait-and-switch tactics are being employed—conclusions from studies based on patients without psychological comorbidities are being applied to patients displaying anxiety disorders, autism spectrum disorders, suicidality, and self-harming behaviors. Protocols are becoming more permissive (and aggressive in "affirmation"), motivated by a market-driven medical culture in which emphasis is placed on liking what one sees in a mirror, or, increasingly, how others respond to a selfie. Careful practitioners are put in a position to only guess at what may result based on research conducted under quite different conditions. To object, however, invites professional censure. Meanwhile, the basics of the explosion in gender dysphoria, especially among natal girls, remain understudied and undertheorized—perhaps now on purpose—even as minors' questionable ability to consent is validated because minors (and their parents) are demanding the experimental treatments. This is not how healthy medical research operates.

173. A premature—and still evolving—"consensus" has been contrived among some professional organizations in this field of medicine. Activists and other interested parties have played a significant role in shaping medical policy, and researchers have taken steps to suppress public discussion and debate and to push medical practice in directions that outpace and even

¹⁸⁶ Wren, B. (2020). Debate: You can't take politics out of the debate on gender-diverse children. *Child and adolescent mental health*, 25(1), 40-42, p. 41. https://doi.org/10.1111/camh.12350

contradict the available evidence. As I have documented, such practices are often openly observ-

able. The pace and extent of ideological capture is staggering.

174. Bernadette Wren, the retired Tavistock senior clinician quoted earlier, helps artic-

ulate the dilemma here. "For some advocates," a term that certainly includes the plaintiffs in this

case, "[a] justice-based approach extends to the demand that all gender-diverse people, including

the young, should have the unquestionable right to make fully autonomous treatment decisions –

the full freedom, we might say, to make their own mistakes."187

175. Based on the current state of the science, giving minors the power to make "fully

autonomous treatment decisions" and "make their own mistakes" here is to abdicate responsibil-

ity and to abandon them to the risks of irreversible and long-term consequences. Medical treat-

ment protocols for youth gender dysphoria are becoming more aggressive, at earlier ages, even

as interest in discerning the long-term presence and stability of the dysphoria before treatment is

diminishing.

176. Given the state of disarray in the science, the activist capture of medical organiza-

tions, and the market motivations shaping medical decision-making in a surging domain, there

are compelling reasons to protect young people by ensuring that they reach adulthood before

submitting to experimental, life-altering gender transition treatments.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on December 10, 2021.

Dr. Mark Regnerus

Mukm

¹⁸⁷ Wren, B. (2021), paragraph 20.

75

MARK REGNERUS

(December 2021)

Department of Sociology The University of Texas at Austin Mail Code A1700 Austin, TX 78712 Office: CLA 3.524 Phone: (512) 232-6307

Email: regnerus@prc.utexas.edu

EDUCATION

Ph.D., Sociology, University of North Carolina at Chapel Hill, 2000.

M.A., Sociology, University of North Carolina at Chapel Hill, 1997.

B.A., Sociology, with high honors, Trinity Christian College, 1993.

PROFESSIONAL APPOINTMENTS

2018–Present: Professor, Department of Sociology, The University of Texas at Austin.

2007–2018: Associate Professor, Department of Sociology, The University of Texas at Austin.

2002–2014: Faculty Research Associate, Population Research Center, The University of Texas at Austin.

2002–2007: Assistant Professor, Department of Sociology, The University of Texas at Austin.

2001–2002: Assistant Professor of Sociology, Department of Sociology and Social Work, and Director, Center for Social Research, Calvin College.

2000–2001: Postdoctoral Research Associate, Carolina Population Center.

PUBLICATIONS

Books

Regnerus, Mark. 2020. *The Future of Christian Marriage*. New York, NY: Oxford University Press. (268 pages)

Reviewed or discussed in *Journal for the Scientific Study of Religion, Publishers Weekly, National Review, Choice, World, Public Discourse,* and *Christianity Today.*

Regnerus, Mark. 2017. *Cheap Sex: The Transformation of Men, Marriage, and Monogamy*. New York, NY: Oxford University Press. (262 pages)

Reviewed in The Atlantic Monthly, Commentary, Washington Post, New York, Humanum, Men & Masculinities, Public Discourse, National Review, Claremont Review of Books, Nevada Appeal, Jet, Contemporary Sociology, and The Globe and Mail.

Regnerus, Mark and Jeremy Uecker. 2011. *Premarital Sex in America: How Young Americans Meet, Mate, and Think about Marrying*. New York, NY: Oxford University Press. (295 pages)

Reviewed in American Journal of Sociology; BYU Studies Quarterly; Commentary; Contemporary Sociology; Culture, Health & Sexuality; First Things; Horizons; INTAMS Review; Journal of Family Theory & Review; Journal of Popular Romance Studies; Journal of Youth and Adolescence; Mercatornet; Public Discourse; Sex Roles; The New Republic; and The New York Times.

Regnerus, Mark D. 2007. Forbidden Fruit: Sex and Religion in the Lives of American Teenagers. New York: Oxford University Press. (304 pages)

Reviewed in American Journal of Sociology, Contemporary Sociology, Journal of Youth and Adolescence, Journal of Sex Research, and The New Yorker.

Peer-Reviewed Journal Articles (including Accepted and In Press)

- Regnerus, Mark and Brad Vermurlen. 2021. "Attitudes toward Hormonal and/or Surgical Interventions for Adolescents Experiencing Gender Dysphoria." Forthcoming, *Archives of Sexual Behavior*.
- Regnerus, Mark. 2020. "Understanding How the Social Scientific Study of Same-Sex Parenting Works," *Annals of Social Science* 12 (3): 43-60. https://doi.org/10.18290/rns20483-3
- Regnerus, Mark, Joseph Price, and David Gordon. 2017. "Masturbation and Partnered Sex: Substitutes or Complements?" *Archives of Sexual Behavior* 46: 2111-2121.
- Regnerus, Mark. 2017. "Is Structural Stigma's Effect on the Mortality of Sexual Minorities Robust? A Failure to Replicate the Results of a Published Study." *Social Science & Medicine* 188: 157-165.
- Regnerus, Mark, David Gordon, and Joseph Price. 2016. "Documenting Pornography Use in America: A Comparative Analysis of Methodological Approaches." *The Journal of Sex Research* 53(7): 873-881.
- Price, Joseph, Rich Patterson, Mark Regnerus, and Jacob Walley. 2016. "How Much More XXX is Generation X Consuming? Evidence of Changing Attitudes and Behaviors Related to Pornography Since 1973." *The Journal of Sex Research* 53(1): 12-20.
- Regnerus, Mark. 2012. "How Different are the Adult Children of Parents who have Same-Sex Relationships? Findings from the New Family Structures Study." *Social Science Research* 41: 752-770.
- Woodberry, Robert D., Jerry Z. Park, Lyman A. Kellstedt, Mark D. Regnerus, and Brian Steensland. 2012. "The Measure of American Religious Traditions: Theoretical and Measurement Considerations." *Social Forces* 91(1): 65-73.
- Uecker, Jeremy E. and Mark D. Regnerus. 2010. "Bare Market: Campus Sex Ratios, Romantic Relationships, and Sexual Behavior." *The Sociological Quarterly* 51: 408-435.
- McFarland, Michael J., Jeremy E. Uecker, and Mark D. Regnerus. 2010. "The Role of Religion in Shaping Sexual Frequency and Satisfaction: Evidence from Married and Unmarried Older Adults." *The Journal of Sex Research* 47: 1-12.
- Stokes, Charles E. and Mark D. Regnerus. 2009. "When Faith Divides Family: Religious Discord and Adolescent Reports of Parent-Child Relations." *Social Science Research* 38: 155-167.

- Hill, Terrence D., Amy M. Burdette, Mark Regnerus, and Ronald J. Angel. 2008. "Religious Involvement and Attitudes Toward Parenting Among Low-Income Urban Women." *Journal of Family Issues* 29(7): 882-900.
- Uecker, Jeremy E., Nicole Angotti, and Mark D. Regnerus. 2008. "Going Most of the Way: 'Technical Virginity' Among American Adolescents." *Social Science Research* 37: 1200-1215.
- Uecker, Jeremy E., Mark D. Regnerus, and Margaret L. Vaaler. 2007. "Losing My Religion: The Social Sources of Religious Decline in Early Adulthood." *Social Forces* 85(4): 1-26.
- Regnerus, Mark D. and Jeremy E. Uecker. 2007. "Religious Influences on Sensitive Self-Reported Behaviors: The Product of Social Desirability, Deceit, or Embarrassment?" *Sociology of Religion* 68(2): 145-163.
- Regnerus, Mark D. and Viviana Salinas. 2007. "Religious Affiliation and AIDS-based Discrimination in Sub-Saharan Africa." *Review of Religious Research* 48(4): 385-401.
- Trinitapoli, Jenny and Mark D. Regnerus. 2006. "Religion and HIV Risk Behaviors among Married Men: Initial Results from a Study in Rural Sub-Saharan Africa" *Journal for the Scientific Study of Religion* 45: 505-528.
- Regnerus, Mark D. and Jeremy Uecker. 2006. "Finding Faith, Losing Faith: The Prevalence and Context of Religious Transformations during Adolescence." *Review of Religious Research* 47: 217-237.
- Regnerus, Mark D. and Amy Burdette. 2006. "Religious Change and Adolescent Family Dynamics." *The Sociological Quarterly* 47: 175-194.
- Regnerus, Mark D. and Laura B. Luchies. 2006. "The Parent-Child Relationship and Opportunities for Adolescents' First Sex." *Journal of Family Issues* 27: 159-183.
- Regnerus, Mark D. and Christian Smith. 2005. "Selection Effects in Studies of Religious Influence." *Review of Religious Research* 47: 23-50.
- Regnerus, Mark D. 2005. "Talking about Sex: Religion and Patterns of Parent-Child Communication about Sex and Contraception." *The Sociological Quarterly* 46: 81-107.
- Regnerus, Mark D., Christian Smith, and Brad Smith. 2004. "Social Context in the Development of Adolescent Religiosity." *Applied Developmental Science* 8: 27-38.
- Regnerus, Mark D. 2003. "Linked Lives, Faith, and Behavior: An Intergenerational Model of Religious Influence on Adolescent Delinquency." *Journal for the Scientific Study of Religion* 42: 189-203.
- Regnerus, Mark D. 2003. "Moral Communities and Adolescent Delinquency: Religious Contexts and Community Social Control." *Sociological Quarterly* 44: 523-554.
- Regnerus, Mark D. 2003. "Religion and Positive Adolescent Outcomes: A Review of Research and Theory." *Review of Religious Research* 44: 394-413.
- Regnerus, Mark D. and Glen H. Elder, Jr. 2003. "Religion and Vulnerability among Low-Risk

- Adolescents." Social Science Research 32: 633-658.
- Regnerus, Mark D. and Glen H. Elder, Jr. 2003. "Staying on Track in School: Religious Influences in High and Low-Risk Settings." *Journal for the Scientific Study of Religion* 42: 633-649.
- Rostosky, Sharon S., Mark D. Regnerus, and Margaret L.C. Wright. 2003. "Coital Debut: The Role of Religiosity and Sex Attitudes in the Add Health Survey." *Journal of Sex Research* 40: 358-367.
- Smith, Christian, Robert Faris, Melinda Lundquist Denton, and Mark D. Regnerus. 2003. "Mapping American Adolescent Subjective Religiosity and Attitudes of Alienation Toward Religion: A Research Report." *Sociology of Religion* 64: 111-133.
- Regnerus, Mark D. 2002. "Friends' Influence on Adolescent Theft and Minor Delinquency: A Developmental Test of Peer-Reported Effects." *Social Science Research* 31: 681-705.
- Smith, Christian, Melinda Denton, Robert Faris, and Mark D. Regnerus. 2002. "Mapping American Adolescent Religious Participation." *Journal for the Scientific Study of Religion* 41: 597-612.
- Ge, Xiaojia, Glen H. Elder, Jr., Mark D. Regnerus, and Christine Cox. 2001. "Pubertal Transitions, Overweight Self Perceptions, and Adolescent Psychosomatic Adjustment: Gender and Ethnic Differences." *Social Psychology Quarterly* 64: 363-375.
- Regnerus, Mark. 2000. "Shaping Schooling Success: A Multi-level Study of Religious Socialization and Educational Outcomes in Urban Public Schools." *Journal for the Scientific Study of Religion* 39: 363-370.
- Steensland, Brian, Jerry Park, Mark Regnerus, Lynn Robinson, Bradford Wilcox, and Robert Woodberry. 2000. "The Measure of American Religion: Toward Improving the State of the Art." *Social Forces* 79: 291-318.
- Regnerus, Mark, David Sikkink, and Christian Smith. 1999. "Voting with the Christian Right: Contextual and Individual Patterns of Electoral Influence." *Social Forces* 77 (4): 1375-1401.
- Regnerus, Mark and Christian Smith. 1998. "Selective Deprivatization among American Religious Traditions: The Reversal of the Great Reversal." *Social Forces* 76: 1347-72.
- Regnerus, Mark, Christian Smith, and David Sikkink. 1998. "Who Gives to the Poor? The Role of Religious Tradition and Political Location on the Personal Generosity of Americans toward the Poor." *Journal for the Scientific Study of Religion* 37: 481-493.

Peer-Reviewed Book Chapters

- Regnerus, Mark D. 2010. "Religion and Adolescent Sexual Behavior." In *Religion, Families, and Health: Population-Based Research in the United States* (Christopher G. Ellison and Robert A. Hummer, editors), pp 61-85. New Brunswick, NJ: Rutgers University Press.
- Regnerus, Mark D. 2005. "Adolescent Delinquency." Pp. 259-276 in Helen Rose Ebaugh (ed.), *Handbook of Religion and Social Institutions*. New York: Kluwer/Plenum.
- Sikkink, David and Mark Regnerus. 1996. "For God and the Fatherland: Protestant Symbolic Worlds and the Rise of German National Socialism." Pp. 133-147 in Christian Smith (ed.), *Disruptive Religion: The Force of Faith in Social Movement Activism*. New York: Routledge.

Non-Peer-Reviewed Journal Articles and Book Chapters

- Regnerus, Mark D. 2020. "Measurement and Analytic Vulnerabilities in the Study of Structural Stigma." (Commentary). *Social Science & Medicine* 244: 112567.
- Regnerus, Mark D. 2019. "Sexual Media as Competition in the Heterosexual Relationship Market" (Commentary). *Archives of Sexual Behavior* 48: 2279-2281.
- Regnerus, Mark. 2019. "Comment on Barbara Risman's review of Cheap Sex: The Transformation of Men, Marriage, and Monogamy." *Contemporary Sociology* 48: 130-131.
- Regnerus, Mark D. 2018. "Reproducing Homes: Intergenerational Transmission of Marriage and Relationship Legacy." In *The Home: Multidisciplinary Reflections* (Antonio Argandoña, editor). Cheltenham, UK: Edward Elgar. 24 pp.
- Regnerus, Mark D. 2015. "The Family as First Building Block." In *The Thriving Society: On the Social Conditions of Human Flourishing* (James R. Stoner, Jr. and Harold James, editors), pp 49-66. Princeton, NJ: The Witherspoon Institute.
- Regnerus, Mark. 2012. "Contemporary Mating Market Dynamics, Sex-Ratio Imbalances, and Their Consequences." *Society* 49: 500-505.
- Regnerus, Mark. 2012. "Parental Same-Sex Relationships, Family Instability, and Subsequent Life Outcomes for Adult Children: Answering Critics of the New Family Structures Study with Additional Analyses." *Social Science Research* 41: 1367-1377.
- Regnerus, Mark D. 2010. "Sexual Behavior in Young Adulthood." The Changing Spirituality of Emerging Adults Project. 16 pp.
- Regnerus, Mark D. 2009. "Imitation Sex and the New Middle Class Morality" (chapter 6 of *Forbidden Fruit*), reprinted in *Speaking of Sexuality: Interdisciplinary Readings, 3rd Edition* (Nelwyn B. Moore, J. Kenneth Davidson, and Terri D. Fisher, editors). New York, NY: Oxford University Press.
- Regnerus, Mark D. and Jeremy E. Uecker. 2007. "How Corrosive Is College to Religious Faith and Practice?" Social Science Research Council. 6 pp.
 - Reprinted as Regnerus, Mark D., and Jeremy E. Uecker. 2008. "College Students Value Religion." *Opposing Viewpoints in Context: America's Youth*. Jamuna Carroll, editor. Farmington Hills, MI: Greenhaven Press. link.galegroup.com/apps/doc/EJ3010300238/OVIC?u=txshracd2598&xid=ea8e31f3. 7 pp.
- Regnerus, Mark D., Christian Smith, and Melissa Fritsch. "Religion in the Lives of American Adolescents: A Review of the Literature." A Research Report of the National Study of Youth and Religion, No. 3. Chapel Hill, NC: University of North Carolina, 2003.
- Regnerus, Mark D. "Living up to Expectations." Report, Center for Research on Religion and Urban Civil

- Society, University of Pennsylvania, 2003.
- Regnerus, Mark D. "Making the Grade: The Influence of Religion upon the Academic Performance of Youth in Disadvantaged Communities." Report, Center for Research on Religion and Urban Civil Society, University of Pennsylvania, 2001.
- Regnerus, Mark. "Challenges to Liberal Protestant Identity and Diversity Work: a Qualitative Study." *Sociological Analysis* 1998, 1: 139-149.

Book Reviews

- Review of: *Nationalizing Sex: Fertility, Fear, and Power*, Richard Togman (New York: Oxford University Press, 2019). In *Review of Politics* 82: 500-502 (2020).
- Review of: *Charitable Choices: Religion, Race, and Poverty in the Post-Welfare Era*, John P. Bartkowski and Helen A. Regis (New York: NYU Press). In *Social Forces* 82: 861-863 (2003).
- Review of: *They Still Pick Me Up when I Fall: The Role of Youth Development and Community Life*, Diana Mendley Rauner (New York: Columbia University Press). In *Social Forces* 79: 1545-1547 (2001).

Select Essays and Op-Eds (all sole-authored)

- "Weak Data, Small Samples, and Politicized Conclusions on LGBT Discrimination." *Public Discourse*, January 12, 2020.
- "New Data Show 'Gender-Affirming' Surgery Doesn't Really Improve Mental Health. So Why are the Study's Authors Saying It Does?" *Public Discourse*, November 13, 2019.
- "Does 'Conversion Therapy' Hurt People who Identify as Transgender? The New JAMA Psychiatry Study Cannot Tell Us." *Public Discourse*, September 18, 2019.
- "Queering Science." First Things, December 2018.
- "The Death of Eros." First Things, October 2017.
- "Can Same-Sex Marriage Really Reduce Teen Suicide?" Public Discourse, February 24, 2017. 4 pp.
- "Hijacking Science: How the 'No Differences' Consensus about Same-Sex Households and Children Works." *Public Discourse*, October 14, 2016. 5 pp.
- "Making Differences Disappear: The Evolution of Science on Same-Sex Households." *Public Discourse*, May 12, 2015. 4 pp.
- "Minecraft over Marriage." First Things, March 31, 2015. 5 pp.
- "The Good-Enough Marriage." First Things, December 4, 2014. 4 pp.
- "The Pornographic Double-Bind." First Things, November 11, 2014. 3 pp.
- "Diversity as Slogan and Reality." First Things, October 9, 2014. 3 pp.
- "Resurrecting the Dead in America." First Things, September 11, 2014. 4 pp.

- "The Government's in Your Bedroom, but This Time It's Okay." *National Review*, July 16, 2014. 3 pp.
- "Right Side of History," or Primed to Say Yes?" National Review, August 20, 2013. 5 pp.
- "Assessing the Australian Study." National Review, June 6, 2013. 3 pp.
- "Sex is Cheap: Why Young Men Have the Upper Hand in Bed, Even When They're Failing in Life." *Slate*, February 25, 2011. (9th-most read *Slate* article of 2011.) 4 pp.
- "Freedom to Marry Young." Washington Post, April 26, 2009. 2 pp.

RESEARCH GRANTS

- Principal Investigator, "The Relationships in America Survey Project." \$328,426 grant from the Austin Institute, January 2014-September 2014. (Approved, 100% under PI's supervision)
- Principal Investigator, "The New Family Structures Study." \$640,000 grant from the Witherspoon Institute, May 2011-August 2013. (Approved, 100% under PI's supervision)
- Principal Investigator, "The New Family Structures Study (supplementary assistance)." \$90,000 grant from the Bradley Foundation, Nov 2011-Nov 2012. (Approved, 100% under PI's supervision)
- Principal Investigator, "The New Family Structures Study." \$55,000 planning grant from the Witherspoon Institute, Oct 2010-June 2011. (Approved, 100% under PI's supervision)
- Principal Investigator, "The New Pentecostals and Political and Social Activism." \$9,565 grant from the National Science Foundation (Dissertation Improvement Grant, for Nicolette Manglos), 2010-2011. (Approved but returned)
- Co-Investigator, "Developing Health Behaviors in Middle Adolescence" (Lynn Rew, PI, The University of Texas at Austin School of Nursing). \$1,276,919 grant from the National Institute of Nursing Research, 2006-2011. (Approved, <5% under Regnerus' supervision). R01-NR009856.
- Principal Investigator, "Testing Differences: The Transfer and Transformation of HIV Testing from the West to Sub-Saharan Africa." \$7,500 grant from the National Science Foundation (Dissertation Improvement Grant, for Nicole Angotti), 2008-2009. (Approved)
- Co-Investigator, "Religious Organizations, Local Norms, and HIV in Africa" (Susan Watkins, PI, University of Pennsylvania). \$864,000 grant from the National Institute of Child Health and Human Development, June 2005-May 2008. (Regnerus is PI of \$279,000 sub-contract to The University of Texas at Austin). R01-HD050142-01.
- Seed grant for "Sex and Emotional Health in Emerging Adulthood." \$4,000 grant from the Population Research Center and \$2,000 grant from the College of Liberal Arts, The University of Texas at Austin, 2007.

SELECT INVITED PRESENTATIONS

"The Future of Christian Marriage."

- University of Mary, Bismarck, ND, April 2021
- Faulkner University, Montgomery, AL, March 2021
- "The Transformation of Men, Marriage, and Monogamy." Universidad Francisco de Vitoria, Madrid, November 2018.
- Author meets critics panel on *Cheap Sex: The Transformation of Men, Marriage, and Monogamy*. Society for the Scientific Study of Religion, Las Vegas, NV, October 2018.
- "The Transformation of Men, Marriage, and Monogamy." Archdiocese of Denver, September 2018.
- Author meets critics panel on *Virgin Nation: Sexual Purity and American Adolescence* (by Sara Moslener, Oxford University Press, 2016). American Academy of Religion, San Antonio, TX, November 2016.
- "Intergenerational Transmission of Marriage and Relationship Legacy." Home Renaissance Foundation, London, United Kingdom, November 2015.
- "The Future of Marriage and Family in America." University of St. Thomas, Houston, TX, March 2015.
- "The New Family Structures Study and the Challenges of Social Science." Brigham Young University, Provo, UT, October 2014.
- "Sex in America: Sociological Trends in American Sexuality." Ethics and Religious Liberty Commission, Nashville, TN, April 2014.
- "Premarital Sex in America." Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, NC, January 2012.
- Book discussion session on *Premarital Sex in America*. Society for the Study of Emerging Adulthood, Providence, RI, October 2011.
- "The Future of Sex and Marriage in American Evangelicalism." National Association of Evangelicals Advisory Board, Washington, D.C., October 2011.
- Heyer Lecture. Austin Presbyterian Theological Seminary, Austin, TX, September 2011.
- Thematic session on "The Cultural War and Red/Blue Divide: Re-examining the Debate Demographically and Behaviorally." American Sociological Association, Las Vegas, NV, August 2011.
- "Sexual Economics: The Forces Shaping How Young Americans Meet, Mate, and Marry." Heritage Foundation, Washington, D.C., May 2011.
- "Marital Realities, Current Mindsets, and Possible Futures." Institute of Marriage and Family Canada, Ottawa, Canada, May 2011.
- Panel on "Teen Pregnancy: What Is California Doing Right?" Zócalo Public Square, Los Angeles, CA, December 2010.
- "Marriage and Parenthood in the Imagination of Young Adults." Baby Makes Three: Social Scientific Research on Successfully Combining Marriage and Parenthood (seminar), Princeton, NJ, June 2010.

- "Saving Marriage Before It Starts." Q Conference, Lyric Opera, Chicago, IL, April 2010.
- "The Price of Sex in Contemporary Heterosexual Relationships." TEDxUT, The University of Texas at Austin, Austin, TX, April 2010.
- "Love and Marriage in the Minds of Emerging Adults." Child Trends and Heritage Foundation, Washington, D.C., October 2009.
- "Forbidden Fruit? Sex and Religious Faith in the Lives of Young Americans." Baylor University, Waco, TX, September 2007.
- "Great Expectations: Culture, Emotion, and Disenchantment in the Sexual Worlds of Young Americans." Bay Area Colloquium on Population, Berkeley, CA, September 2007.

CONFERENCE PRESENTATIONS

- "The Math Behind Declining Christian Marriage," Society for the Scientific Study of Religion, Las Vegas, NV, October 2018.
- "Consent and the Presumption of the Exchange Theory of Relationship Behavior." Paper presented at the annual meeting of the American Political Science Association, Boston, MA, September 2018.
- "Is There a Recession in Marriage among Western Christians?" Paper presented at the annual meeting of the Society for the Scientific Study of Religion, Atlanta, GA, October 2016.
- "Gender and Heterosexual Sex." Panel discussion at the annual meeting of the American Sociological Association, New York, NY, August 2013.
- "The New Family Structures Study: Introduction and Initial Results." Paper presented at the annual meeting of the Population Association of America, San Francisco, CA, May 2012.
- "Religious Distinctions in Nonmarital Romantic Relationship Formation" (with Ellyn Arevalo). Paper presented at the annual meeting of the Society for the Scientific Study of Religion, Milwaukee, WI, October 2011.
- "Premarital Sexual Initiation and Fertility among Pentecostal Adolescents in Brazil." Paper presented at the annual meeting of the Population Association of America, Washington, D.C., April 2011.
- "Red Sex, Blue Sex: Distinguishing Political Culture and Religious Culture in the Sexual Decisions of Young Americans." Paper presented at the annual meeting of the Society for the Scientific Study of Religion, Denver, CO, October 2009.
- "Bare Market: Campus Sex Ratios and Romantic Relationships" (with Jeremy Uecker). Paper presented at the annual meeting of the Population Association of America, Detroit, MI, May 2009.
- "Religion and Sexual Initiation in Brazil" (with Ana Paula Verona). Paper presented at the annual meeting of the Population Association of America, Detroit, MI, April 2009.

ADVISING

Ph.D. Committees in the Department of Sociology (Year Degree Awarded, * Co-Chair/Co-Supervisor, ** Chair/Supervisor)

- 2016 Jennifer McMorris
- 2015 Stanley Kasun
- 2015 Nina Palmo
- 2012 Nicolette Manglos **
- 2012 Catherine McNamee
- 2011 Charles Stokes
- 2010 Nicole Angotti **
- 2010 Georgina Martínez Canizales
- 2010 Viviana Salinas
- 2010 Jeremy Uecker **
- 2010 Ana Paula Verona
- 2008 Margaret Vaaler
- 2008 Sara Yeatman
- 2007 Amy Burdette *
- 2007 Bryan Shepherd
- 2007 Jenny Trinitapoli **
- 2007 Elisa Zhai
- M.A. Committees in the Department of Sociology (Year Degree Awarded, * Co-Chair/Co-Supervisor, ** Chair/Supervisor)
 - 2013 Ellyn Arevalo *
 - 2012 Kristen Redford **
 - 2011 David McClendon **
 - 2010 Aida Ramos Wada
 - 2008 Nicolette Manglos **
 - 2007 Andrea Henderson
 - 2006 Jeremy Uecker **
- Undergraduate Thesis Supervision for Honors, Plan II, BDP (Year Degree Awarded, * Reader, ** Supervisor)
 - 2019 Clarisa Trevino **
 - 2014 Tiffany Fong *
 - 2011 Mary Lingwall **
 - 2008 Hong Nguyen **
- Ph.D. Committees at other universities (Year Degree Awarded)
 - 2018 Yana Mikhaylova, Higher School of Economics, Moscow

DEPARTMENTAL AND UNIVERSITY SERVICE

Member, Executive Committee, Department of Sociology, 2012-2014

Member, Graduate Admissions Committee, Department of Sociology, 2012-2014

Member, Promotion and Tenure Committee, Department of Sociology, 2012-2014

Member, Undergraduate Research Award Selection Committee, College of Liberal Arts, 2010-2012

Guest presenter, Peer Educator Sexual Health courses, University Health Services, 2008-2012

Presenter, Orange Jackets' Week of Women, Tejas Club, Spring 2011

Moderator, Thesis Symposium, Plan II Honors Program, 2011

Member, Graduate Steering Committee, Department of Sociology, 2010-2011

Member, Promotion and Tenure Committee, Department of Sociology, 2010-2011

Member, Executive Committee, Department of Sociology, 2009-2011

Presenter, TEDxUT, The University of Texas at Austin, Spring 2010

Member, Governing Board, Population Research Center, 2009-2010

Member, Graduate Admissions Committee, Department of Sociology, 2009-2010

Presenter, Sexual Health Panel, Tejas Club, Fall 2009

Member, Graduate Steering Committee, Department of Sociology, 2007-2009

Participant and presenter, Faculty Fellows Program, The University of Texas at Austin, 2007-2009

Chair, Religion Faculty Search Committee, Department of Sociology, Fall 2008

Member, Population Junior Faculty Search Committee, Department of Sociology, Fall 2007

Member, Speaker Colloquium Committee, Department of Sociology, Fall 2007

PROFESSIONAL SERVICE AND ORGANIZATIONAL MEMBERSHIP

Co-organizer and session chair, *The Moynihan Report at 50: Reflections, Realities, and Prospects.*Princeton University, Princeton, NJ, October 30-31, 2015

Distinguished Article Award Committee member, American Sociological Association (Religion Section), 2010-2011

• Committee chair, 2011

Editorial Board member, Interdisciplinary Journal of Research on Religion, 2005–2011

Editorial Board member, Journal for the Scientific Study of Religion, 2004–2011

Distinguished Article Award Committee member, Society for the Scientific Study of Religion, 2009-2010

• Committee chair, 2010

Nominating Committee member, Society for the Scientific Study of Religion, 2007-2009

Jack Shand Research Award Committee member, Society for the Scientific Study of Religion, 2005-2007

Council member, American Sociological Association (Religion Section), 2004-2007

Member of:

American Academy of Religion, 2017-2019 Population Association of America, 2004-2018 Society for the Scientific Study of Religion, 1996-present

Ad-hoc reviewer for:

American Journal of Sociology, American Sociological Review, Archives of Sexual Behavior, Biodemography and Social Biology, Gender & Society, Interdisciplinary Journal of Research on Religion, International Journal of Environmental Research and Public Health, Journal for the Scientific Study of Religion, Journal of Adolescent Health, Journal of Behavioral Addictions, Journal of Family Issues, Journal of Health and Social Behavior, Journal of Homosexuality, Journal of Marriage and Family, Journal of Psychology and Christianity, Pediatrics, Perspectives on Psychological Science, Review of Religious Research, Social Forces, Social Problems, Social Psychology Quarterly, Social Science & Medicine, Social Science Quarterly, Social Science Research, Sociological Forum, Sociological Inquiry, The Sociological Quarterly, National Institutes of Health (2007), National Science Foundation (2010, one review), Templeton Foundation (2012, 2019)

Exhibit 2

IN THE UNITED STATES DISTRICT COURT EASTERN DISTRICT OF ARKANSAS CENTRAL DIVISION

DYLAN BRANDT, et al.,

PLAINTIFFS,

v.

No. 4:21-CV-00450-JM

LESLIE RUTLEDGE, et al.,

DEFENDANTS.

REBUTTAL DECLARATION OF DR. MARK REGNERUS

Pursuant to 28 U.S.C. 1746, I declare:

- 1. My credentials, research, and professional qualification are detailed in my declaration in this matter dated December 10, 2021. Here, as there, my opinions are based upon my knowledge and research in the matters discussed. The materials I have used to research and write this report are the standard sources used by other experts in my field. I have actual knowledge of the matters stated in this declaration. My opinions as detailed in this report are based upon my knowledge and direct professional experience in the subject matters discussed. The materials that I have relied upon are the same types of materials that other experts in my field rely upon when forming opinions on the subject. This declaration does not exhaust my opinions.
- 2. I have reviewed the newly submitted declarations by Dr. Deanna Adkins (dated December 9, 2021), Dr. Armand Antommaria (dated December 10, 2021), Dr. Jack Turban (dated December 10, 2021), as well as the declaration submitted by the plaintiffs' additional witness, Dr. Dan H. Karasic (dated December 10, 2021).
- 3. My primary discussion of the medicalization of adolescent gender dysphoria does not concern the pharmacological details of treatment plans. I am not a psychiatrist or pediatric

endocrinologist. Rather, my primary concerns are sociological. The main points of my rebuttal are as follows:

- The protocols for careful mental-health assessments and stringent criteria for eligibility repeatedly invoked by the plaintiffs' witnesses are, in practice, hardly occurring and are being diminished or removed entirely in favor of "informed consent" models in discussions of evolving professional standards of care.
- The plaintiffs' witnesses deny or downplay social and external factors, whereas these influences are undeniable in the recent surge of transgender identification.
- There are open debates, divisions, and concerns now being expressed within the field, even by some gender-affirmative clinicians within the United States, which are not even acknowledged by the plaintiffs' witnesses, much less the concerns and conclusions of vast national health system reviews of research and care that now are protecting youths from being subjected to these medical treatments.
- The medical protocols recommended in the United States for the treatment of adolescents with gender dysphoria are increasingly out of step with developments and changes in numerous countries with progressive policies and decades of research. Where these countries are limiting and/or prohibiting gender medicine for minors in order to protect vulnerable youth, advocates in the United States seek to do the opposite, as reflected by the ideological capture of the professional organizations cited by the plaintiffs' witnesses
- The plaintiffs' witnesses claim that hormonal treatments are largely reversible, and yet only a tiny fraction of patients opt out of subsequent treatment options. If that is true, we are indeed talking about very early decisions with (*de facto*) permanent consequences.

- Strong legal norms once protected minors from consenting to experimental and irreversible procedures. Children's inability to consent to treatments that result in sterilization at ages as young as 10 and 11 is one of the primary reasons that laws such as the SAFE Act are needed.
- The threat of suicide is inflated and increasingly employed to justify these drastic interventions. Meanwhile, the risk of regret over irreversible changes and/or detransition is minimized or ignored.
- In the end, the laws of the state either function as they always have—to protect children and minors from preventable harms—or the state shirks its obligation to them.

I. SOCIOLOGICAL ISSUES

- 4. My concerns are primarily sociological—that is, how social influences are demonstrably evident, but inexplicably ignored, in the rapid "evolution" of protocols, and the swift ideological capture of professional organizations, resulting in suppressed internal rifts now coming to light. Observable radical shifts (e.g., the surge in cases, sex-ratio reversal in cases, disappearing emphasis on psychotherapy in practice, diminishing barriers to medical treatment) are being ignored by many "professionals," including the plaintiffs' witnesses. None of them make reference to any of these troubling developments that are now openly haunting some of their professional peers.¹ They do not wish to debate it, but rather defend only one way forward. To borrow from Admiral Farragut's famous command, it's "Damn the surge. Full speed ahead."
- 5. Social norms are a basic building block of society and a common notion in sociology. They are patterns of behavior and internalized values that are socially enforced.

3

¹ Anderson, E. (2022). When it comes to trans youth, we're in danger of losing our way. *San Francisco Examiner*, January 3, https://www.sfexaminer.com/opinion/are-we-seeing-a-phenomenon-of-trans-youth-social-contagion/; Ghorayshi, A. (2022). Doctors debate whether trans teens need therapy before hormones. *The New York Times*, January 14, https://www.nytimes.com/2022/01/13/health/transgender-teens-hormones html.

Norms simplify life and enable persons to classify (and hence understand) each other's actions, a process that contributes to social order.² While Dr. Karasic insists on page 6 that "[g]ender identity...is not a product of external influence and not subject to voluntary change," his description of the 2013 definition of "Gender Dysphoria in Children" as outlined in the Diagnostic and Statistical Manual Fifth Edition (DSM-5), highlights the profoundly social (and hence external) aspects of gender dysphoria. All but one of the seven criteria Dr. Karasic lists on page 6 concerns social norms: talk of "the other gender," "simulating female attire," "typical masculine clothing," "typical feminine clothing," "cross-gender roles," "activities stereotypically used or engaged in by the other gender," "playmates of the other gender," "typically masculine toys," and "typically feminine toys, games, and activities."

- 6. It's not just the DSM-5. Dr. Karasic himself makes reference to "typically male or typically female" when discussing the definition of gender identity on page 5. To suggest something is "typical" means to accord it a mental image or "type" socially considered common to most cases of a given phenomenon. This is what early sociologist Max Weber identifies as an "ideal type," or (socially) shared mental constructs that help us bring order to reality. (The "ideal" language is no moral claim, but a reflection of wide agreement on key traits.) And yet Dr. Karasic, ignoring universal practice and usage, claims that "the terms biological sex and biological male or female...should be avoided" (page 5). His advice seeks to disable human societies from understanding and classifying each other—a process necessary for social stability.
- 7. My point is not to belabor what constitutes something that is masculine or feminine; rather, I am simply observing that these are all social judgments that vary within and

² Norms. (2013). Oxford Bibliographies Online, Sociology. doi: 10.1093/obo/9780199756384-0091.

³ Britannica, T. Editors of Encyclopaedia (2018, October 10). *ideal type. Encyclopedia Britannica*. https://www.britannica.com/topic/ideal-type.

across societies. And yet they are not arbitrary, but instead helpful to shaping and predicting the behavior of other people. To Judith Butler, author of the book (and phrase) *Gender Trouble* and key contributor to what its critics call "the theory of gender," gender constitutes unconscious, culturally compelled "performance" and is thereby powerfully socially rooted, constructed, and hence malleable. Her influence on contemporary gender matters, including the transgender movement, is extensive. To suggest, as Dr. Karasic does, that gender identity "is not a product of external influence" is to maintain—in the face of evidence to the contrary—that gender is *only* molded by biology, that is, dimorphic sex differences. In doing so, he denies and contradicts what even the draft version of WPATH's SOC 8 acknowledges: "The phenomenon of social influence on gender is salient...as some who have changed their thoughts about their own gender identity have described how social influence was relevant in their experience of their gender during adolescence."

8. Some clinicians perceive a practical dilemma. That is, suppress puberty and treat those teens who identify as transgender with cross-sex hormones in order to avoid presumed distress of having gone through the endogenous (i.e., normal) puberty process of one's natal sex, or consider the possibility that endogenous puberty may alter the experience of gender dysphoria and lead—over time—to the acceptance of one's natal sex. The plaintiffs and their experts assume that a transgender identity is stable over time. (Hence, the vociferous pushback against observations of "rapid-onset" gender dysphoria.) But in a social milieu in which cases of "nonbinary" gender identity are similarly surging, it becomes increasingly difficult to defend the

⁴ Butler, J. Gender Trouble. New York: Routledge, 1990.

⁵ World Professional Association for Transgender Health. (2021). *Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People* [DRAFT 8th Version: Adolescent Chapter].

idea of a stable gender identity—and with it a stable understanding of both (1) what is going on socially among a great many adolescents, and (2) what to do next.

- 9. In my December 2021 declaration, I claimed that ideological capture well explains the professional discussion of gender dysphoria in the United States. This ideological capture is a cousin to the regulatory capture that is occurring in the domain of gender medicine, since there are now strong material incentives to offer treatments that are loosely governed by professional statements and perceptions of legitimate authority (e.g., WPATH, Endocrine Society).⁶ In other words, gender medicine is a new and lucrative line of medicine. Its origins are cultural, rooted in recent notions that men can become women and vice versa by way of social discourse and medical treatments. But the end is the same in both cases—the "capture" of authority by the successful co-opting of professional organizations to serve the aims of a particular interest group.
- 10. This process is accelerated by what could be described as *conceptual veiling*, that is, the construction of new (and extensive) narratives to both diffuse criticism and obtain professional organizations' support for new treatment norms—norms that as little as 10 years ago would have stunned most pediatricians, not to mention the families they serve. Personal stories, not unlike those told by the plaintiffs in this case, are powerful material. And yet they "veil" what is fundamentally going on here—that is, the failure of medical and legal institutions to protect those who are particularly exposed and vulnerable to manipulation and influence by social media content. The evidence suggests this is in no small part responsible for the surge in

⁶ Kwak, J. (2013). Cultural capture and the financial crisis in preventing regulatory capture. In Carpenter, & Moss (Eds.), Preventing regulatory capture: Special interest influence, and how to limit it, pp. 72–98. Cambridge: Cambridge University Press.

⁷ Palea, V. (2021). "'Unreliable accounts: How regulators fabricate conceptual narratives to diffuse criticism' by Karthik Ramanna: A comment on ideological capture." *Accounting, Economics, and Law*, November, 1-8, https://doi.org/10.1515/ael-2021-0054.

teen gender dysphoria. To lurch further in the direction of treatment on demand with mere consent and to enable minors' willful destruction of healthy body parts that are undergoing normal development and maturation is an unprecedented and stunning shift.

II. PROTOCOLS ENDORSED—THEN IGNORED

- 11. Hence, there is a very real gender medicine *industry* today, on a scale that is unparalleled. It is experiencing explosive growth, and there are now somewhere around 300 gender clinics in the United States.⁸ Social media influencers and activists urge clinicians to offer services that self-identified transgender persons ask for, regardless of age. In turn, gender medicine providers and scholars supporting them now engage in what is, in effect even if not in intention, a bait-and-switch maneuver: sell the public on wide access to hormonal and surgical treatments for dysphoric teens based on study results employing the Dutch protocol's very different patient characteristics and far more rigorous mental health safeguards.
- 12. In reality, the Dutch protocol is now all but ignored. Even WPATH's current guidelines—which have evolved considerably away from the Dutch protocol—are increasingly bypassed in favor of an "affirmative" approach whose primary criterion for moving forward to treatment is simple informed consent. That approach no longer scrutinizes dysphoric patients' psychological co-morbidities but instead believes that its treatments can alleviate them. By age 18, this approach is a given. For example, Planned Parenthood Great Plains, whose clinics cover the state of Arkansas, requires no evidence of previous gender-related psychotherapy or a

⁸ E.g. "In 2019, there were over 200 Planned Parenthood facilities in 31 states providing services for patients who identify as transgender." Planned Parenthood. (2020). 2019-2020 Annual Report. Planned Parenthood Federation of America, https://www.plannedparenthood.org/uploads/filer_public/67/30/67305ea1-8da2-4cee-9191-19228c1d6f70/210219-annual-report-2019-2020-web-final.pdf, page 11; Society for Evidence-based Gender Medicine. (2021). "Gender-affirming" hormones and surgeries for gender-dysphoric US youth, *Spotlight Blog*, May 28, https://segm.org/ease_of_obtaining_hormones_surgeries_GD_US#:~:text=There%20are%20over%2060%20pediatric,currently%20estimated%20at%20over%20300.

documented history of gender dysphoria prior to supplying hormone prescriptions. Their website even reads, "You don't need to participate in therapy or provide information from a mental health provider to receive hormone therapy."

- 13. Hence, there is a *de jure* protocol—the WPATH Standards of Care—which all of the plaintiff's experts have taken pains to carefully state and reiterate. But the evidence suggests a quite different *de facto* reality has now emerged, one that is increasingly tailored to patient demands.
- 14. WPATH is, as Dr. Karasic points out on page 8, an organization whose suggested protocols are "endorsed and cited as authoritative" by a series of medical professional organizations.
 - 15. Repeatedly, Dr. Karasic suggests WPATH SOC7's ongoing authority:
 - a. Page 9: "The WPATH SOC 7 and Endocrine Society Guidelines do not recommend genital surgery until a patient has reached adulthood."
 - b. Page 9: "The WPATH SOC 7 states that '[b]efore any physical interventions are considered for adolescents, extensive exploration of psychological, family, and social issues should be undertaken."
 - c. Page 9: "The WPATH SOC 7 makes clear that '[h]ormonal or surgical interventions are appropriate for some adolescents, but not for others.""
 - d. Page 9: "After ongoing work with mental health professionals and when the adolescent has lived in accordance with their gender identity for a significant period of time, they may start treatment with hormones...if and when medically indicated."

8

⁹ See: https://www.plannedparenthood.org/planned-parenthood-great-plains/patient-resources/gender-affirming-care.

- e. Page 10: "The WPATH SOC 7 and the Endocrine Society Guideline further provide that before any medical or surgical interventions are provided to adolescents, a careful mental health assessment should be conducted to ascertain whether the diagnostic criteria for Gender Dysphoria in Adolescents and Adults are met, and the appropriateness of such care for the patient."
- f. Page 12: "[T]here is the additional safeguard of the assessment by a mental health professional, who, in addition to diagnosing gender dysphoria, also reviews the risks and benefits of treatment with the youth and parents."
- g. Page 15: "Gender-affirming medical interventions in accordance with the WPATH SOC 7 and Endocrine Society Guidelines are widely recognized in the medical community as safe, effective, and medically necessary for many adolescents with gender dysphoria."
- 16. Dr. Adkins follows suit in her report, taking pains to reiterate the same claim: "The Endocrine Society and WPATH have published widely accepted guidelines for treating gender dysphoria..." (page 4). She also notes that "[b]efore any medical intervention is initiated, the Endocrine Society Guideline and the WPATH Standards of Care for the Treatment of Gender Dysphoria ("WPATH SOC") provide that extensive mental health evaluations should be conducted" (page 7). On page 8, she further remarks that WPATH SOC 7 maintains that "[b]efore any physical interventions are considered for adolescents, extensive exploration of psychological, family, and social issues should be undertaken The duration of this exploration may vary considerably depending on the complexity of the situation." 10

¹⁰ World Professional Association for Transgender Health (WPATH). (2012). Standards of care for the health of transsexual, transgender, and gender-nonconforming people [7th version] https://www.wpath.org/publications/soc. The quote is from p. 18.

- 17. The key word here, and in five other instances on the same page (8), is "should." Mental health evaluations "should" be conducted, she notes. It does not mean they are required to, or that they will. Dr. Adkins goes on to present (on page 9) the Endocrine Society Guideline's mental health qualifications for eligibility for pubertal suppression. Indeed, at least five pages of Dr. Adkins's report consist of a simple restatement of official protocols—how such organizations believe minors *should* be evaluated and how treatments *should* be administered. The reader is left to presume that this is how treatment happens everywhere. But that is nowhere stated.
- 18. Even Dr. Turban notes (on page 7 of his report) that "gender-affirming genital surgeries are not recommended until adulthood" under the guidelines of both the Endocrine Society and the WPATH's SOC 7. Does this mean he does not object to the SAFE Act's prohibiting these surgeries on minors? On the contrary, Dr. Turban approvingly discusses (on page 7) a study about the benefits of "masculinizing chest surgery" for the relief of what he labels "chest dysphoria" among a small sample of natal female "transmasculine" adolescents. 11 The average age of these post-surgical patients was just under 18 years old, for whom the average time-since-surgery was 19 months. In other words, the mean age at "top" surgery was around 16½ years old. These were minors who were approved for such surgeries in spite of the Endocrine Society and WPATH guidance to the contrary.
- 19. What difference does it make for the plaintiffs' witnesses to repeatedly cite the protocols of professional organizations if practitioners—including plaintiffs' own witnesses—are clearly not interested in adhering to them? It matters a lot, actually. Regulatory capture—the formal co-opting of professional organizations' recommended policy and practice about the

¹¹ Mehringer, J.E., Harrison, J.B., Quain, K.M., et al. (2021). Experience of chest dysphoria and masculinizing chest surgery in transmasculine youth. *Pediatrics*, 147(3):e2020013300.

hormonal and surgical treatment of minors—is not simply driven by material incentives (e.g., new, permanently-dependent patients). It is also driven by "expert knowledge" to help generate the social context for such a radical change, that is, the medical treatment of minors' gender dysphoria on demand, without counseling.¹² This historically unprecedented approach is, without a doubt, at stake in this case.

III. THE RAPID UPTAKE OF AN UNOFFICIAL TREATMENT PROTOCOL

- 20. None of the plaintiffs' witnesses admit that there is a debate among clinicians about whether psychological assessments—a core component of the Dutch protocol—are necessary before proceeding to treat someone with hormones and surgeries. The question is particularly poignant for adolescents. A *New York Times* feature article in January 2022 describes how clinicians are at odds with each other over whether adolescents should be allowed pubertal blockers and cross-gender hormones on demand rather than after a psychological evaluation and several years spent questioning their gender identity. The *New York Times*'s illuminating probe reveals that a journalist is more comfortable with observing (and admitting) that teenagers may be more subject to "emotional distress" and "more vulnerable to peer influence" than the plaintiffs' witnesses have been. 14
- 21. Indeed, there is now open conflict among practitioners of transgender medicine over whether gender dysphoria even need be diagnosed before moving to desired medical treatment.¹⁵ Alex Keuroghlian, a frequent co-author with Dr. Turban and a clinical psychiatrist

¹² Palea, op. cit.

¹³ Ghorayshi, A. (2022). "Doctors Debate Whether Trans Teens Need Therapy Before Hormones," *New York Times*, January 13. https://www.nytimes.com/2022/01/13/health/transgender-teens-hormones html.

¹⁴ Ibid., paragraph 5.

¹⁵ Anderson, *op. cit.*; Edwards-Leeper, L., Anderson, E. (2021). The mental health establishment is failing trans kids. *The Washington Post*, November 24, https://www.washingtonpost.com/outlook/2021/11/24/trans-kids-therapy-psychologist/.

and director of the Massachusetts General Hospital Psychiatry Gender Identity program, told the *Times* reporter that pre-treatment mental health assessment is unnecessary: "I'm really not a believer in requiring that for people," he stated when asked. "Being trans isn't a mental health problem," he later asserted. "To make that a requirement for everybody is inherently unnecessary gatekeeping and also stigmatizing and pathologizing and a waste of resources," Dr. Keuroghlian maintains.¹⁶

- 22. Minors now present themselves as transgender and ask that clinicians respect their self-identity and offer the medical treatments—pubertal blockers, cross-sex hormones, and subsequent surgical options—that they cannot access without the permission of these clinical "gatekeepers." It is the professionals (i.e., the gatekeepers) who are being pressured by patients and activists to offer care to those who ask for it.
- 23. For many practitioners, acquiescence is the path of least resistance. For example, while Dr. Karasic quotes Dr. Kenneth Zucker approvingly (on page 12 of his report), Karasic sought to ban Zucker from presenting his own research at the 2017 USPATH conference. Karasic, who chaired the conference and oversaw the program which included a pair of talks by Zucker, nevertheless gave way to activist critics *during the conference*, apologized to them, and proceeded to cancel Zucker's final scheduled talk. Why? Because Zucker is consistently on record as supporting more rigorous conditions for subjecting minors to gender-transition procedures. Doctors, so the emerging protocol implies, should not be gatekeepers to medical treatment anymore. What are physicians for, then?

¹⁶ Ghorayshi, op. cit., paragraph 33.

¹⁷ Singal, J. (2016). How the fight over transgender kids got a leading sex researcher fired. *The Cut*, February 7, https://www.thecut.com/2016/02/fight-over-trans-kids-got-a-researcher-fired html.

- 24. Already in a 2018 article appearing in the *AMA Journal of Ethics*, a series of practitioners advocated for a shift away from WPATH's SOC7 and toward "an informed consent approach to care as more patient centered and respectful of the patient's sense of agency." The motivation for this is grounded in a conviction about "a person's right of self-determination—and the belief that clinicians will work to facilitate patients' decisions about the course of their own lives and care." This is the aggressively affirmative treatment pathway. It is demand-driven, with fewer "speed bumps."
- 25. Published research using clinic data reflects this shift away from WPATH's current standards toward even easier and faster treatment enrollment (which also disregards the lopsided sex-ratios that follow).¹⁹ In other words, there is increasing support for informed consent as the only threshold for initiating hormone therapy in teenagers.
- 26. Even WPATH's new (draft) 8th Standards of Care mark a significant shift in the direction of an informed consent approach to care as more focused on the patient's sense of agency. More to the point, SOC8 suggests minimum ages that are demonstrably "lower than those in the previous version, for each treatment: 14 for starting hormone therapy, 15 for chest masculinization and at least 17 for more invasive genital operations." That is, cross-sex hormones no later than age 14 and surgeries beginning at age 15. Why do the plaintiffs' expert witnesses spend so much ink restating old standards when newer ones are imminent?

¹⁸ Cavanaugh, T., Hopwood, R., & Lambert, C. (2016). Informed consent in the medical care of transgender and gender-nonconforming patients. *AMA Journal of Ethics*, *18*(11), 1147-1155.

¹⁹ Allen, L. R., Watson, L. B., Egan, A. M., & Moser, C. N. (2019). Well-being and suicidality among transgender youth after gender-affirming hormones. *Clinical Practice in Pediatric Psychology*, 7(3), 302–311, https://doi.org/10.1037/cpp0000288. On page 304, the authors note that their clinic does not require an in-house mental health evaluation prior to treatment: "To avoid unnecessary delays in medical care, our clinic does not require patients to be seen by one of our clinic's mental health professionals if they have an established GD diagnosis and referral from a community mental health professional."

²⁰ Ghorayshi, op. cit., paragraph 30.

- 27. Perhaps anticipating that this shift in actual practice could jeopardize legal goodwill (in this case), the plaintiffs' witnesses go to great lengths to declare that the old protocols are still in place. For example, Dr. Turban repeats the mantra that "[p]rotocols for the provision of such care" have been made clear in the Endocrine Society Guideline and in WPATH's SOC 7 (page 3), and that the "WPATH SOC 7 highlight that an adolescent must be assessed by a mental health professional with specific qualifications prior to initiating any gender-affirming medical interventions" (page 4).
- 28. The plaintiff's expert witnesses still like to cite evidence from studies employing the Dutch protocol—as Dr. Turban does multiple times on pages 4 and 5.²¹ (Dr. Antommaria does the same on pages 15 and 16 of his report.)²² It is a bait-and-switch tactic. Such studies imposed rigorous requirements for study participation, but they are being employed in this case to defend newer and far looser protocols for hormonal treatments on a very different class of adolescents with demonstrable, co-occurring mental health problems.
- 29. Hence, Dr. Turban's citation (on page 5) of the de Vries et al. 2014 *Pediatrics* study, which "found steady improvement in mental health over the course of the study" should be put into context: the participants did not have the type of significant baseline mental health

²¹ The following studies cited on pages 4 and 5 of Dr. Turban's report each employ the Dutch protocol for treatment (and hence study enrollment) eligibility: de Vries, A.L., Steensma, T.D., Doreleijers, T.A., & Cohen-Kettenis, P.T. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. *The Journal of Sexual Medicine*, 8(8), 2276-2283; van der Miesen, A.I., Steensma, T.D., de Vries, A.L., et al. (2020). Psychological functioning in transgender adolescents before and after gender-affirmative care compared with cisgender general population peers. *Journal of Adolescent Health*, 66(6), 699-704; de Vries, A.L., McGuire, J.K., Steensma, T.D., et al. (2014). Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics*, 134(4), 696-704.

²² The following studies cited on pages 15 and 16 of Dr. Antommaria's report each employ the Dutch protocol: de Vries et al. (2011) *op. cit.*; Delemarre-van de Waal H.A., Cohen-Kettenis P.T. (2006). Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. *European Journal of Endocrinology*, *155*(suppl 1): S131–S137; Schagen S.E., Cohen-Kettenis P.T., Delemarre-van de Waal H.A., Hannema S.E. (2016). Efficacy and safety of gonadotropin releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. *Journal of Sexual Medicine*, *13*(7):1125-32.

problems that are consistent with the current surge in dysphoric adolescents presenting at gender clinics around the United States. The *Pediatrics* study sample consisted instead of those "adolescents (who) belonged to a group of 196 consecutively referred adolescents between 2000 and 2008, of whom 140 *had been considered eligible* for medical intervention" (emphasis mine).²³ Eligibility in the Dutch protocol for medical treatment is not by demand, but only after careful psychological scrutiny of the sort that many clinicians and researchers are now actively seeking to drop or disregard.

- 30. As an extension of this, Dr. Turban discusses transition regret (on page 11) among the history of patients in the Amsterdam cohort, and asserts that the regret rate for those who had undergone "gender-affirming surgery" was 0.6% for transgender women and 0.3% for transgender men.²⁴ For a discussion of the medical treatment of minors, this observation is irrelevant, because the Amsterdam cohort adheres to the Dutch protocol, and the 0.6% and 0.3% observations refer to adult gonadectomy regret rates. That is, these are observations made of adults, not minors.
- 31. On p. 13, Dr. Karasic cites a 2021 meta-review²⁵ which found regret rates of 1%. However, the primary studies reviewed were "inherently flawed due to loss to follow up." A more recent review out of the UK found that 20% of patients in the sample had stopped hormone treatment, with half of these citing "regret" or "detransition" as a reason.²⁶ One case note review

²³ de Vries et al. (2014), op. cit., p. 697.

²⁴ Wiepjes C.M., Nota, N.M., de Blok, C.J.M., et al. (2018). The Amsterdam cohort of gender dysphoria study (1972–2015): Trends in prevalence, treatment, and regrets. *Journal of Sexual Medicine*, *15*:582–590.

²⁵ Bustos, V.P., Bustos, S.S., Mascaro, A., Del Corral, G., Forte, A.J., Ciudad, P., Kim, E.A., Langstein, H.N. and Manrique, O.J., 2021. Regret after gender-affirmation surgery: a systematic review and meta-analysis of prevalence. *Plastic and Reconstructive Surgery Global Open*, *9*(3): e3477.

²⁶ Boyd, I., Hackett, T., & Bewley, S. (2022). Care of transgender patients: A general practice quality improvement approach. *Healthcare*, *10*(1), 121. https://doi.org/10.3390/healthcare10010121.

found a detransition rate of 6.9% at one UK clinic.²⁷ Either regret rates have been underestimated in the past or they are increasing. In reality, both are true.

- 32. In the conclusion of Dr. Turban's report, he claims that reports of transition and treatment regrets are unusual, given the "1.4 million transgender people in the United States alone" (page 13). Turban leans on a study employing the (more rigorous) Dutch protocol for support of his claims about modest surgical regret rates, and yet that study claims a transgender prevalence rate of 1 in every 3,600 persons above age 16.28 Meanwhile, Turban's 1.4 million estimate yields a ratio of 1 in every 235 Americans—reminding us again of the bait-and-switch tactic employed here. That is, draw upon conclusions based on a rigorous criterion of inclusion, but then apply its findings to a social setting—the contemporary United States—that now exhibits a baseline rate (of transgender self-identity) at least 15 times larger than that employed in the Dutch protocol-based study sample. And still neither Turban nor any of the other plaintiffs' expert witnesses address whether there is anything different about the two populations.²⁹
- 33. In 2020, Dutch clinician Annelou de Vries acknowledged that the "new developmental pathway" seen in youth presenting as trans at or past puberty without a history of childhood gender dysphoria and often with mental health diagnoses "raises the question whether the positive outcomes of early medical interventions also apply to adolescents who more recently present in overwhelming large numbers for transgender care." Dr. de Vries expressed a need for

²⁷ Hall, R.; Mitchell, L.; Sachdeva, J. Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic: Retrospective case-note review. BJPsych Open 2021, 7, e184.

²⁸ Wiepjes et al. (2018), *op. cit*. The rate quoted is equivalent to the article's reference to 27.7 transgender persons per 100,000 people.

²⁹ Johns, M.M., Lowry, R., Andrzejewski, J., et al. (2019). Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students — 19 states and large urban school districts, 2017. *MMWR Morbidity and Mortality Weekly Report*, 68:67–71, http://dx.doi.org/10.15585/mmwr.mm6803a3.

"caution" and mentioned concern for those later-presenting adolescents that "may detransition." Thomas Steensma warned that clinicians around the world were "blindly adopting" their research, stating that "we don't know whether studies we have done in the past can still be applied to this time" due to the novel type of presentation. 31

- 34. Such an acknowledgement is not lost on other nations' decision-making. Indeed, Sweden's Karolinska Institute—along with four of the country's five other gender clinics—has recently moved away from the original Dutch protocol, allowing pediatric transitions only in strictly controlled trials going forward.
- 35. Similarly, Finland now recommends psychotherapy as the preferred initial treatment for youth presenting with gender dysphoria, even advising clinicians to wait until age 26 (after brain maturation has completed) before administering medical interventions. While still allowing pediatric transitions, Finland has now returned to a stricter adherence to the original Dutch protocol, requiring evidence of childhood onset gender dysphoria, no mental health co-morbidities, and "watchful waiting." Thus, Finland's national recommendations now differ from what WPATH's SOC7 had already endorsed, and are worlds apart from the proposed SOC8 guidelines and the Informed Consent Model.
- 36. Meanwhile, in contrast to the Dutch protocol, a statement by the American Academy of Pediatrics proposes that mental health comorbidities are caused by gender dysphoria rather than the other way around. "[I]f a mental health issue exists, it most often stems from

³⁰de Vries, A. L. C. (2020). Challenges in timing puberty suppression for gender-nonconforming adolescents, *Pediatrics*, *146*(4), e2020010611. The quotes are from p. 1-2.

³¹Tetelepta, B. (2021). More research is urgently needed into transgender care for young people. Where does the large increase of children come from? *Voorzij*, February 27, https://www.voorzij nl/more-research-is-urgently-needed-into-transgender-care-for-young-people-where-does-the-large-increase-of-children-come-from/.

³² "Watchful waiting" was a key component of the original Dutch protocol. See page 61 of: Ehrensaft, D. (2017). Gender nonconforming youth: current perspectives. *Adolescent health, medicine and therapeutics*, 8, 57-67.

stigma and negative experiences rather than being intrinsic to the child," wrote a small cadre of clinicians tasked with articulating policy for all pediatricians ³³ In other words, the emerging scholarly mentality no longer wonders whether minors may come to the conclusion that they are transgender and need hormonal and (later) surgical treatments *because* they are unhappy. They have concluded instead that it is sufficient to take gender dysphoric teens at their word and deduce that they are unhappy *because* of social responses to being transgender. Hence, treatment will alleviate unhappiness by aligning their gender identity with their physical body. The closer the alignment—a socially- and culturally-attuned measure, of course—the better the expected outcome.

37. If there were not a concurrent explosion—and a reversal in the longstanding sex ratio—of cases of gender dysphoria and rates of self-identified transgender teenagers, this transition from a template of caution to one of haste might well have gone unnoticed.

IV. THE CENTRAL ROLE OF A NARRATIVE ABOUT SUICIDALITY

38. The specter of suicide is not simply a motivation undergirding the push toward "affirmative" medical treatment of minors at younger ages. It is the only thing that could possibly justify such drastic interventions. Hence, it is an absolutely essential component of the narrative. Dr. Adkins moves straight to the threat of suicide in her page 19 section on the harms of withholding or terminating transgender treatment among minors with gender dysphoria, and concludes her report (on page 21) by warning that "[w]e barely save some of these young people's lives by getting them on treatment; to take them off mid-treatment where the treatment is working could be life-threatening." This is a narrative widely employed by clinicians, who

³³ Rafferty, J., et al. (2018). Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. *Pediatrics*, *142*(4): e20182162. The quotes are from page 4.

pose the question, "Would you rather have a living son or a dead daughter?"³⁴ While none of the experts employ that particular claim in their reports, its use is widespread and an invention of the perception—as distinct from the reality—of a strong association between gender dysphoria and actual completed suicide (as distinct from suicidality or attempted suicide).

- 39. Throughout the entire seventh edition of WPATH's Standards of Care document, published in 2011 and amounting to 120 pages, the terms "suicide," "suicidal," and "suicidality" appear only four times total—two of which are in the same sentence. The terms appears in no references (i.e., in the titles of journal articles) at all. In the eighth edition, a draft of which is now circulating, the terms appear 31 times in the text of the document, and in 45 references. (For perspective, Dr. Turban uses the terms 21 times in his report's 13 total pages.) Why the skyrocketing interest? It is not because of any surge in actual suicides.
- 40. In a January 2022 article published in the *Archives of Sexual Behavior*, Oxford University sociologist Michael Biggs documents how reports of attempted suicide dramatically exceed the actual rate of completed suicides among adolescent transgender patients.³⁵ To be sure, Biggs notes that the suicide rate is in fact higher—5.5 times higher—than among that observed among adolescents ages 14 to 17 in the UK. And yet some perspective is in order: the actual number of adolescent suicides Biggs uncovers among patients at the UK's GIDS—the world's largest gender clinic—over a decade is four (or 0.03 percent of all patients), which the author notes "is orders of magnitude smaller than the proportion of transgender adolescents who report attempting suicide when surveyed."³⁶

³⁴ Soh, D. (2020). *The end of gender: debunking the myths about sex and identity in our society*. New York: Simon & Schuster. The quote is from page 160.

³⁵ Biggs, M. (2022). Suicide by clinic-referred transgender adolescents in the United Kingdom. *Archives of Sexual Behavior*. https://doi.org/10.1007/s10508-022-02287-7. The quote is from page 4.

³⁶ Ibid., page 4.

- 41. The disparity between suicide "risk" and actual completions is so dramatic that Biggs concludes that "[i]t is irresponsible to exaggerate the prevalence of suicide," adding that Bernadette Wren, a former senior clinician at the GIDS clinic, warned "when inaccurate data and alarmist opinion are conveyed very authoritatively to families we have to wonder what the impact would be on children's understanding of the kind of person they are...and their likely fate."³⁷
- 42. Dr. Biggs notes that completed suicide rates were considerably higher at the Belgian pediatric clinic, despite better average patient psychological function there, as well as at the Amsterdam clinic, a finding he attributed to higher median age (25) at first visit there.³⁸ Suicide rates tend to peak in middle age, an observation that seems lost on participants in this debate. Instead, simple assumptions about the etiology of suicidality among self-identified transgender youth remain the preferred narrative of advocates.³⁹
- 43. Biggs discusses the meaning of self-reporting suicide attempts, citing a pair of small-sample studies of non-heterosexual youth in which half of the studies' respondents who had initially reported a suicide attempt eventually clarified that their attempts had gone no further than imagining or planning suicide. The remainder of actual attempted suicides, he notes, did not typically involve life-threatening situations. The reported attempts, one of the original

³⁷ Wren, B. (2015). Making up people. Presented at the meeting of the European Professional Association for Transgender Health, Ghent, Belgium. A selection of this presentation was quoted in Biggs (2022), page 4.

³⁸ Biggs (2022), op. cit.

³⁹ E.g. Brown, M. (2017). Suicides peak in middle age. So why do we call it a young person's tragedy? *The Guardian*, September 13, *https://www.theguardian.com/commentisfree/2017/sep/13/suicide-middle-aged-young-people-death*; Van Orden et al. (2010) Van Orden, K. A., Witte, T. K., Cukrowicz, K. C., Braithwaite, S. R., Selby, E. A., & Joiner Jr, T. E. (2010). The interpersonal theory of suicide. *Psychological review*, *117*(2), 575-600.

studies noted, instead reflected efforts "to communicate the hardships of lives or to identify with a gay community."

- 44. Biggs notes that elevated prevalence of other conditions, like eating disorders, depression, and autism spectrum conditions—the latter of which occurs at a rate 15 times higher than that found among UK students as a whole—are each known to increase the probability of suicide. Despite Biggs's observation of a profoundly disproportionate rate of autism among GIDS patients, Dr. Turban questioned the connection in print, claiming that "current research has not established an over-representation of GD in those with ASD [Autism Spectrum Disorder] or the converse." Even if there is a link between autism and gender dysphoria, Dr. Turban maintains that it doesn't matter: "they should be provided with access to gender-affirming medical care." Thus, it seems that medical treatments are the go-to prescription. Maslow's "law of the instrument," a form of cognitive bias, is evident here: if the only tool you work with is a hammer, it's tempting to treat everything as if it were a nail.
- 45. Suicide is being weaponized in service to a political end. This is unsurprising. Indeed, it is part of the "conceptual veiling" that aids the capture of professional organizations and, with them, policy shifts and legal protections in practice. Refusing to subject minors with gender dysphoria to puberty blockers, cross-sex hormones, or any of a host of surgical procedures will not kill them—as many seem to imply. It is not akin to withholding insulin from

⁴⁰ Savin-Williams, R. C. (2001). Suicide attempts among sexual-minority youths: Population and measurement issues. *Journal of Consulting and Clinical Psychology*, *69*, 983–991. https://doi.org/10.1037/0022-006X.69.6.983. This is quoted in Biggs (2022), *op. cit.*, page 1.

⁴¹ Ibid

⁴² Turban, J. L., & van Schalkwyk, G. I. (2018). "Gender dysphoria" and autism spectrum disorder: Is the link real? *Journal of the American Academy of Child & Adolescent Psychiatry*, *57*(1), 8-9. The quote is from page 9.

⁴³ Turban, J. L., & van Schalkwyk, G. I. (2018). Drs. Turban and van Schalkwyk reply. *Journal of the American Academy of Child & Adolescent Psychiatry*, *57*(11), 887–889, https://doi.org/10.1016/j.jaac.2018.07.881. The quote is from page 889.

⁴⁴ Maslow, A. (1966). The psychology of science: a reconnaissance. New York: Harper & Row, page 15.

a Type-I diabetic, a move which will indeed lead to death. The two are not comparable processes.

46. Similarly, Dr. Antommaria compares the possibility of adolescents' subsequent treatment-induced infertility with that prompted by cancer. "Parents of children with some types of malignancies may choose treatments that may damage their children's gonads and result in infertility," he writes on page 20 of his report. The same, he notes there and again on page 23, goes for decisions about DSDs (disorders of sex development). Gender dysphoria, however, is not a malignancy, the invasive medical treatment of which is absolutely necessary to preserve life. Nor is it a DSD. A dysphoria is, rather, a psychological state marked by distress, unease, and dissatisfaction. Cancer is not, at bottom, a psychological problem. An intersex condition is likewise physically demonstrable. Moreover, childhood cancers have been and remain extremely rare—affecting 1 in every 6,500 minors per year. DSDs remain comparably rare. 46

The same can no longer be said of gender dysphoria.

V. CONSENT

47. Dr. Antommaria outlines the ethical principles about informed consent, assent, and adolescents' decision-making capacity, as asserted by the Endocrine Society (on page 21 of his report). Is there an age that is too young for informed consent? Small children have difficulty understanding quantity, quality, and time, as well as assigning "causal attributions," that is, understanding that occurrences have both proximal and distal causes. The same goes for reasoning, anticipating the future, the formation of identity, self-reflexivity (or the ability to

⁴⁵ Ries, L.A.G., Eisner, M.P., Kosary, C.L., Hankey, B.F., Miller, B.A., Clegg, L., Edwards, B.K. (eds). (2002). SEER Cancer Statistics Review, 1973-1999. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1973 1999/.

⁴⁶ Witchel, S. F. (2018). Disorders of sex development. *Best practice & research. Clinical obstetrics & gynaecology*, 48, 90–102. https://doi.org/10.1016/j.bpobgyn.2017.11.005.

assess our own judgments), moral awareness, judgment, and truth seeking.⁴⁷ The capacity for each of these develops over time and is quicker in some than in others. Each is related to informed consent here, since adolescents are being asked to decide what their future will look like at a very young age.

- 48. Furthermore, Dr. Antommaria notes that a discussion of "fertility and options for fertility preservation" is recommended by the Endocrine Society as part of "the informed consent process for puberty blockers and sex hormones" (page 21). To speak with a minor about future fertility before beginning puberty blockers is to talk with them about it by around age 11. The Endocrine Society, he continues, "also advises delaying gender-affirming hormone treatment, which results in partly irreversible physical changes, until an adolescent is developmentally capable of providing informed consent." How old is "developmentally capable"? How insignificant is "partly irreversible"? Even the ability to have a serious conversation about the future is decreasingly possible given the move away from physician gatekeeping and toward earlier cross-sex hormone treatment. (WPATH SOC8 recommends age 14.)
- 49. Dr. Adkins discusses (on page 12 of her report) the process of acquiring informed consent from her adolescent patients, noting that those age 12 and over (and a parent or guardian) sign "line by line," but that "a visual presentation" is used "with patients who have limitations on their ability to absorb the information..." Perhaps this concerns minors' grasp of complex medical language. On the other hand, perhaps it signals that Dr. Adkins endorses puberty blockers and cross-sex hormone treatments for minors who either cannot read well or who are too young to understand concepts explained on the printed page. Either way, if pictures

⁴⁷ Smith, C. (2011). *What is a person? Rethinking humanity, social life, and the moral good from the person up.* Chicago: University of Chicago Press.

must replace text, Dr. Adkins's criteria undermine confidence in the ability of minor patients to understand long-term treatment consequences and offer their informed consent.

- 50. Dr. Antommaria writes at some length about principles of informed consent and assent (pages 11-12). The matter of adolescent "medical decision-making capacity" remains central to the concern articulated in the SAFE Act. Antommaria cites Douglas Diekema's 2004 discussion of parental refusals of medical treatment for their minor children.⁴⁸ Diekema nevertheless commences his study with the proposition that minors "are generally considered incompetent to provide legally binding decisions regarding their health care."
- 51. Experimental medicine has historically reinforced the importance of consent and fostered greater protections of those considered most vulnerable—chief among them pregnant women and children. For example, the Institutional Review Board of the Children's Hospital of Philadelphia maintains that "[c]hildren are neither legally nor developmentally capable of consenting to their own treatment or participation in research."
- 52. In discussing the purported absence of clinical equipoise, Dr. Antommaria observes that one particular challenge to conducting a randomized trial is the difficulty of locating a sufficient number of participants willing to risk being randomized into the control wing of the study (page 9). He considers this "inadequate sample size" to constitute an ethical problem. But given that so many studies in this domain rely on modest sample sizes, is Dr. Antommaria sure he wants to consider sample size an issue of ethics? If so, we could disregard perhaps over three-quarters of all published research in this domain. While we're at it, I consider drawing conclusions from recruited opt-in samples (like Dr. Turban does in his publications

⁴⁸ Diekema, D.S. (2004). Parental refusals of medical treatment: The harm principle as threshold for state intervention. *Theoretical Medicine*, 25(4):243-64.

⁴⁹ Children's Hospital of Philadelphia Research Institute, Criteria for IRB approval. https://irb research.chop.edu/criteria-irb-approval. Retrieved: Feb. 10, 2022.

drawing upon the United States Transgender Study, or USTS) dubious at best and borderline unethical—especially if used to draw conclusions or propose policy about an underlying population—despite its large sample size.

53. While Dr. Antommaria discusses at length the varying quality of medical research, the General Assembly's findings that there is "a lack of 'long-term longitudinal studies' on puberty-blocking drugs and a lack of 'randomized clinical trials' of cross-sex hormone therapy" also remains accurate.

VI. CONCLUSIONS

- 54. It is evident by now that there is a widening split between clinicians over how and when to introduce transgender medicine to minor patients. Protocols are shifting to favor younger timelines, and some clinicians are opting to overlook mental health comorbidities and gamble instead that treatments will alleviate them. Given the rapid shift to looser protocols aggressively promoted by many advocates today, what WPATH or the Endocrine Society does or does not currently recommend should be of little or no concern in this case, because the guidance will soon change, and the confederation of medical professional organizations seems very unlikely to contest loosened guidance.
- 55. In the end, this is not about asking a judge to mull over the merits of this or that study's methods, measurements, or conclusions. Debates are hardly unusual in the academy, nor is any single study beyond criticism. Rather, what I have sought to establish—primarily in my December 2021 report and in this rebuttal—is that what is going on in transgender medicine for teenagers is less about tweaking protocols and more about the ideological capture of professional organizations in service to ideas that were unthinkable up until a few years ago. Those ideas are: (1) that minors could consent to their own sterilization by age 14 and surgical removal of normal tissue by age 15, encouraged by strangers on social media; (2) that with the aid of social

collusion the human person can will their own sex change into existence; and (3) that major medical professional associations have—in service to purported respect for human agency—cooperated with activists to put patients in charge of their own diagnosis and treatment prescriptions. To justify all this, the threat of patient suicide has taken center stage, in spite of modest evidence.

- 56. The result is rightfully viewed as scandalous outside of the transgender medicine context. Ordinary Americans maintain critical opinions of treating transgender teenagers with hormones or surgery. This is an example of "déformation professionnelle," or job "conditioning" in which training and socialization processes associated with a profession—in this case the emergence of "gender" medicine—have resulted in a distorted understanding of the human person as a unity of mind and body. That this branch of medicine seems particularly prone to patient activists' emotional involvement in the development and revision of protocols—as compared to, say, cardiology or oncology—offers evidence of (and further fuel for) this professional distortion. As articulated in my own research, this case—and the medical treatment of adolescent gender dysphoria as a whole—has everything to do with a questionable ideological prioritizing of bodily autonomy over bodily integrity. But this choice of values is rarely articulated or reflected upon, to the detriment of young people placed in the medical pipeline of transgender medicine.
- 57. The SAFE Act concerns minors. It makes no claims on the decisions adults wish to make. The law has long recognized the difference, and sought to protect minors from making

⁵⁰ Regnerus, M., Vermurlen, B. (2022). Attitudes in the U.S. toward hormonal and/or surgical interventions for adolescents experiencing gender dysphoria. Archives of Sexual Behavior, https://doi.org/10.1007/s10508-021-02214-2.

⁵¹ The origin of the term is unclear, but is often attributed to the early Russian-American sociologist Pitirim Sorokin, who emigrated to the United States before becoming the inaugural professor of sociology at Harvard.

⁵² Regnerus, Vermurlen (2022), op. cit.

premature judgments that come with strings attached, that is, unintended consequences,

permanent changes, and altered life trajectories. Indeed, there is no shortage of things that the

law prevents minors from doing, even if they wish to. The SAFE Act suggests there are grave

misgivings about the ability of minors—especially but not only those who are very young, such

as ages 11 and 12—to consent to the (rapidly evolving) medical interventions that constitute

transgender medicine. Either the law will extend its protection to minors in these situations—

telling them to wait—or it will leave them exposed to the subtly coercive claims of activists and

their clinicians, whose rapid capture of professional organizations that once protected children is

a stunning accomplishment. Hippocrates would be scandalized. Some priorities, he maintained,

"may outweigh the surgeon's knife and the chemist's drug."

I declare under penalty of perjury that the foregoing is true and correct.

Executed on February 10, 2022.

Mark Regnerus, Ph.D.

Mulyn

27

Exhibit 3

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF ARKANSAS

		X	
Dylan Brandt, et al.,		: : :	
	Plaintiffs,	: : (Case No.: 4:21-CV-00450-JM-01
	v.	:	
LESLIE RUTLEDGE, et al.,		:	
	Defendants.	:	
		:	
		:	
		:	
		X	

EXPERT REBUTTAL REPORT OF DAN H. KARASIC, MD

- 1. I have been retained by counsel for Plaintiffs as an expert in connection with the above-captioned litigation. My background and credentials are set forth in my opening report dated December 10, 2021.
- 2. I reviewed the reports of Dr. Stephen Levine, Dr. Paul Hruz, Prof. Mark Regnerus, and Dr. Patrick Lappert. In this rebuttal report, I respond to some of the central points made in those reports. I do not address each and every assertion made in those reports that I believe are baseless, misleading, or mischaracterizations of the evidence, as there are many. Instead, my aim is to provide an explanation of the erroneous premises upon which their conclusions are based.
 - 3. I reserve the right to supplement my opinions if necessary as the case proceeds.

THE STATE'S EXPERT WITNESSES' DESCRIPTION OF GENDER-AFFIRMING CARE FOR ADOLESCENTS WITH GENDER DYSPHORIA BEARS NO RESEMBLANCE TO THE PREVAILING TREATMENT PROTOCOLS

- 4. The State's experts offer a description of medical care for adolescents with gender dysphoria that bears no resemblance to the widely accepted protocols for treatment articulated in the WPATH Standards of Care 7 ("WPATH SOC") and the Endocrine Society Guideline. Throughout their reports, the State's experts claim that doctors who provide medical interventions to treat gender dysphoria "actively encourage" patients to be transgender, rush to provide medical interventions without psychiatric assessments of patients, disregard other mental health and family issues that could be causing the patient distress, oppose psychotherapy, and fail to inform patients and their families of the risks associated with treatment. (*See, e.g.*, Expert Report of Paul W. Hruz, M.D., PhD. ("Hruz"), ¶¶ 8, 62 (asserting that providers "actively encourage" patients to be transgender); Expert Report of Dr. Mark Regnerus ("Regnerus"), ¶ 95 (asserting that providers provide medication without psychological assessment); Expert Report of Stephen B. Levine, M.D. ("Levine"), ¶ 57 (asserting that providers assume psychological comorbidities need not be addressed); Levine, ¶ 64 (assuming mental health providers do not address family dynamics); Hruz, ¶ 60 (asserting providers do not inform patients of risks of treatments)).
- 5. Dr. Levine calls this the "affirmation therapy model" of care (Levine, ¶ 57), implying that it is an accepted mode of treatment, but the model he describes is not an accepted model and is completely at odds with the protocols provided in the WPATH SOC and the Endocrine Society Guideline:
 - Under the WPATH SOC and Endocrine Society Guideline, affirming care for transgender youth does not mean steering them in any particular direction, but rather supporting them through their period of exploration of gender expression and

increasing self-awareness of their identity. (Coleman, et al., 2012, at 18; Ehrensaft, 2017). The WPATH SOC 7 makes clear that "[h]ormonal or surgical interventions are appropriate for some adolescents, but not for others." (Coleman, et al., 2012, at 16).

- The protocols provide that before any medical or surgical interventions are provided to adolescents, a careful mental health assessment should be conducted to ascertain whether the diagnostic criteria for Gender Dysphoria in Adolescents and Adults are met and the appropriateness of such care for the patient. (Coleman, et al., 2012, at 18; Hembree, et al., 2017, at 3877).
- The protocols provide for the mental health assessment to evaluate other issues that may be causing the patient distress. (Coleman, et al., 2012, at 18 ("Before any physical interventions are considered for adolescents, extensive exploration of psychological, family, and social issues should be undertaken."); Hembree, et al., 2017, at 3876 (clinicians must be able to diagnose psychiatric conditions)).
- The protocols provide that clinicians should ensure than any psychiatric conditions are appropriately treated and that it is important that mental health care is available to patients before, during, and sometimes after transitioning. (Hembree, et al., 2017, at 3876, 3879.)
- The protocols provide for a rigorous informed consent process that includes informing the patient and their parents of side effects of treatment, including the potential loss of fertility. For hormone therapy, in addition to requiring the parents' informed consent, the adolescent must have "sufficient mental capacity . . . to

estimate the consequences of this (partly) irreversible treatment, weigh the benefits and risks, and give informed consent." (Hembree, et al., 2017, at 3878.)

- 6. In sum, the State's experts create a straw man by providing a false description of care under the prevailing protocols and then attack it. They either misunderstand the prevailing protocols or assume, without basis, that all or most gender clinics disregard them. In the case of Prof. Regnerus, it appears to be the latter. (*See* Regnerus, ¶ 5 (recognizing that the standards "counsel patience" but assuming doctors do not follow them)). And while Dr. Levine describes this "model" of care, he acknowledges "I do not know what proportion of practitioners are using" it. (Levine, ¶ 63). As a clinician who, unlike the State's experts, actively works with a multitude of clinicians providing care to transgender youth and adults, I know firsthand that their characterization of treatment is wholly inconsistent with the prevailing practice.
- 7. If there are individual doctors who deviate from the accepted protocols and inappropriately provide care that is harmful to patients, medical licensing boards can address that without denying care to those who have been appropriately assessed and determined to need it. The State's experts point to WPATH president-elect Dr. Marci Bowers "caution[ing] against too rapid transition of adolescents without adequate psychiatric care" (Levine, ¶ 14), and similar comments by Drs. Laura Edwards-Leeper and Erica Anderson. (*See* Regnerus, ¶ 95). These doctors' comments were aimed at improving care, not banning it. After making the comments cited by the State's experts, Dr. Bowers and Dr. Anderson were signatories to a letter from USPATH and WPATH supporting gender-affirming medical care for adolescents with gender dysphoria and opposing legislation like the Act 626. And Dr. Edwards-Leeper and Dr. Anderson

¹ United States Professional Association for Transgender Health and World Professional Association for Transgender Health. (2021). Joint Letter from USPATH and WPATH. *Available at* https://www.wpath.org/media/cms/Documents/Public%20Policies/2021/Joint%20WPATH%20USPATH%20Letter

similarly expressed their full support for gender-affirming care and "disgust" at legislative bans of such care.²

- 8. In painting their false picture of how treatment is provided to adolescents with gender dysphoria, the State's experts use pejorative terms like "gender transition industry" to refer to health care providers who treat these patients. (*See, e.g.*, Levine, ¶85; Hruz, ¶84; Expert Report of Patrick W. Lappert, M.D. ("Lappert"), ¶9). Health professionals across disciplines providing medically necessary care for their gender dysphoric patients, as they do for their other patients, do not constitute an "industry." This suggestion of improper motives on the part of these health-care providers is without basis.
- 9. It is clear from some of the State's experts' reports that their concern is not about the alleged lack of thorough mental health assessments or access to psychotherapy for patients; it is about opposition to transition-related medical care. (*See, e.g.*, Lappert, ¶ 49; Hruz, ¶ 61).

THE STATE'S EXPERT WITNESSES OFFER NO ALTERNATIVE EFFECTIVE TREATMENT FOR ADOLESCENTS WITH GENDER DYPHORIA

- 10. The State's expert witnesses disapprove of existing protocols for treating gender dysphoria in adolescents (and for some of the State's experts, people of any age). (Lappert, ¶ 49; Hruz, ¶ 61. But the alternative treatments they propose lack any evidence of effectiveness.
- 11. Dr. Levine claims there is evidence that psychotherapy can sometimes enable a return to a gender identity that matches sex assigned at birth but offers nothing but anecdotes of "reinvestment" in one's sex assigned at birth. (Levine, ¶ 56 ("I and other clinicians have witnessed reinvestment in the patient's biological sex in some individual patients who are undergoing

^{%20}Dated%20Oct%2012%202021.pdf; see also World Professional Association for Transgender Health. WPATH Public Documents. Available at https://www.wpath.org/policies.

² Laura Edwards-Leeper and Erica Anderson, the Mental Health Establishment is Failing Trans Kids, Washington Post, Nov. 24, 2021, *available at* https://www.washingtonpost.com/outlook/2021/11/24/trans-kids-therapy-psychologist/.

psychotherapy.")). Efforts were made in the past to assist patients to come to identify with their sex assigned at birth but those efforts have proven to be ineffective and harmful and, thus, treatment with the goal of changing a person's gender identity are no longer considered ethical. (Coleman, et al., 2012, at 16; American Psychological Association, 2021).

- 12. Dr. Levine asserts that an alternative to gender-affirming medical care is "to teach coping and resilience skills to gender discordant children." (Levine, ¶ 28). Therapy to promote coping and resilience is certainly appropriate and is an aspect of care for children and adolescents with gender dysphoria. But this type of therapy does not resolve the dysphoria and is not an alternative to medical interventions for adolescents who need them. My initial report discusses the harms that can result from the denial of medically indicated gender-affirming medical care. (Expert Report of Dan H. Karasic, M.D., ¶ 43).
- 13. Dr. Levine also suggests that as an alternative to medical interventions, health care providers can address gender dysphoria by helping patients understand that there are options beyond sex-stereotyped behaviors. (Levine, ¶¶ 28, 29). This represents a misunderstanding of gender dysphoria and its diagnosis and treatment. If a patient's distress relates only to a sense of limitation on behaviors related to gender and they are not experiencing distress about their body, they would not meet the criteria for diagnosis and medical treatment of gender dysphoria.
- 14. Several of the State's experts point to "watchful waiting" as an alternative treatment approach to the existing treatment paradigms outlined in the WPATH SOC and the Endocrine Society Guideline. While "watchful waiting" is an approach for prepubertal children followed by some clinicians, it is not an accepted approach used with adolescents. That is because, while there are studies finding that many prepubertal children diagnosed with Gender Identity Disorder (a precursor diagnosis to Gender Dysphoria in Children) identified with their sex assigned at birth at

a later follow up, there is no evidence that gender dysphoria that continues into adolescence is likely to desist. Some of the State's experts appear to recognize that "watchful waiting" is a treatment modality for prepubertal children and not adolescents. (*See, e.g.*, Levine, ¶ 47 ("When a pre-adolescent child presents with gender dysphoria, a 'watchful waiting' approach seeks to allow for the fluid nature of gender identity in children to naturally evolve."); Hruz, ¶ 64 (stating that "watchful waiting" is "currently the best scientifically supported intervention for young children reporting gender dysphoria.")). Yet they still suggest that "watchful waiting" is an alternative to medical interventions such as hormone therapy for adolescents—*see, e.g.*, Hruz, ¶¶ 64-65; Regnerus, ¶ 29 (suggesting that "a 'watchful waiting' approach to adolescent gender dysphoria" is an accepted protocol)—even though there is no evidentiary support for applying "watchful waiting" to patients once they have started puberty.

- 15. The State's experts rely significantly on the work of Kenneth Zucker in support of "watchful waiting." (*See, e.g.*, Hruz, ¶ 64). But Zucker recognizes the need for medical interventions for gender dysphoria in adolescence and does not suggest that watchful waiting is appropriate for adolescents. (Zucker, et al., 2010). His clinic in Toronto provided puberty blockers and hormone therapy to adolescents with gender dysphoria. (Zucker, et al., 2010). Similarly, the Dutch researchers who coined the term watchful waiting for prepubertal children did the seminal research on medical interventions for those patients whose gender dysphoria persists until adolescence. (de Vries, 2011; Steensma, 2011; de Vries, 2014).
- 16. Dr. Hruz, presumably in an effort to support "watchful waiting" for adolescents, says there is no basis for the assertion made by Plaintiffs' experts that patients who continue to have gender dysphoria after starting puberty typically persist in their transgender identity. (Hruz, ¶ 34E). But all of the research on this topic makes clear that desistance is a prepubertal

phenomenon. (See, e.g., Steensma, 2011). The State's experts have offered no evidence that desistance among adolescence is likely.

- 17. There is no basis for the State's experts' suggestion that providing gender-affirming medical care will cause youth with gender dysphoria who would otherwise desist to, instead, persist. (See, e.g., Levine, ¶ 79). This claim erroneously relies on the assertion that social transition in prepubertal children can cause their gender dysphoria to persist into adolescence. First, contrary to Dr. Levine's suggestion, the fact that there is a correlation between social transition prior to puberty and persistence does not establish that social transition causes persistence of gender dysphoria. As the Steensma study cited by the State's experts reported (see Steensma, 2013), the intensity of gender dysphoria prior to puberty predicted persistence, and children with more intense dysphoria were more likely to socially transition. Second, whatever conclusions can be drawn from these desistance studies about the impact of gender affirmation on the persistence rates in prepubertal children, as discussed above, this research does not apply to adolescents with gender dysphoria, for whom desistance is rare, and the treatments banned by Act 626 are not indicated until adolescence.
- 18. The suggestion that adolescents can just wait until they are 18 years old to get care ignores the harm of not providing the care. Allowing endogenous puberty to advance is not a neutral decision. For many adolescents, the development of secondary sex characteristics that do not match their gender identity can have a severe negative impact on their mental health and can exacerbate lifelong dysphoria because some of those characteristics are impossible to change later through surgeries.

THE STATE'S EXPERTS DRAW INAPPROPRIATE CONCLUSIONS FROM THE NUMBERS AND SEX-RATIOS OF GENDER CLINIC REFERRALS

- 19. The State's experts devote many pages to the increase in the numbers of referrals to gender clinics, and changes in sex ratios of patients. (*See, e.g.*, Hruz, ¶ 51; Levine, ¶ 166). As an initial matter, in their caricature of doctors pushing medical transition, the State's experts say the field is ignoring and avoiding exploration of these developments. (Levine, ¶ 25; Regnerus, ¶¶ 9, 49). That is not the case. Indeed, the draft WPATH SOC, 8th revision Adolescent chapter specifically discusses the increase in referrals to gender clinics and the sex ratios of these young patients. (*See* WPATH SOC Draft for Public Comment Adolescent, Dec. 2021, at 1, 3-4). But the State's experts draw unsupported conclusions about the rise in number of referrals and changes in sex ratios observed in some clinics. They claim this means adolescents are adopting a transgender identity due to "social contagion," leading them to undergo irreversible medical treatments they later regret. This conclusion is baseless.
- 20. The rise in numbers of referrals is hardly surprising given the greater awareness on the part of youth and their parents of what gender dysphoria is and that care is available, as well as the significant increase in the number of clinics available to provide care. In addition, the stigma associated with being transgender, while still significant, has lessened in recent years. Coming out to parents and seeking care are options that did not exist for many youth until recently, so an increase in numbers of referrals to gender clinics is not surprising. While there is a documented increase in clinic referrals, the State's experts' exaggerate the increase by making inappropriate comparisons. For example, Dr. Hruz claims that "it has been reported that in 2018 2% (2 in 100) of high school students identified on surveys as 'transgender'—this is 200 times greater response—a 20,000% increase—over reports during past decades which showed a rate of only .01 percent (one in 10,000 people)." (Hruz, ¶ 76). Prof. Regnerus also references gender dysphoria

"once affect[ing] less than 1 in 10,000 children, according to DSM-V prevalence rates". (Regnerus, ¶ 22). The .01 percent figure in the DSM-5 is based on the small fraction of the population that received care in gender clinics in the Netherlands in 1990. (Bakker, et al., 1993).³ The State's experts compare the number of European gender clinic patients three decades ago to the number of people self-identifying as transgender now as evidence of an exploding number of transgender people, when in fact these numbers were measuring very different things. Put another way, the State's experts are comparing apples to oranges.

An apples to apples comparison of self-identified transgender people over time 21. shows a very different picture. Until the past decade, little data on the number of people identifying as transgender was available. From 2007 to 2009, a question asking whether the respondent identified as transgender was added to a large population-based health survey conducted in Massachusetts, and 0.5% of study participants identified as transgender. (Conron, et al., 2012). Since then, this question was added to large health surveys in other states, and analyses of surveys done in 2014 found that, nationally, 0.5-0.6% of adults identified as transgender, and 0.7% of youth ages 13 to 17 identified as transgender. (Crissman, et al., 2017; Flores, et al., 2016; Herman, et al., 2017). Prof. Regnerus cites Rider et al. (2018) as reporting that 2.7% of youth identified as transgender. (Regnerus, ¶19). However, in that study, the question asked was "Do you consider yourself transgender, genderqueer, genderfluid, or unsure about your gender identity?" The larger number does not demonstrate an increasing number of transgender youth as the survey question captured people who did not identify as transgender. Prof. Regnerus also cites a survey of public high school students disproportionately from large urban school districts, which had 1.8% of youth identifying as transgender. (Johns, et al., 2019). The higher number in this survey, done in 2017,

³ In 2015, the number in the Netherlands had changed to 1 in 3600. (Wiepjes, 2018).

more likely reflects the particular sample than a change over time, versus the lower numbers in Herman et al. (2017), as the time difference was small between the surveys.

- 22. While increases in numbers and changes in sex ratios of patients referred to some gender clinics have been reported, since the number of patients referred to gender clinics reflect only a small fraction of the people identifying as transgender, these changes may reflect changes in referral patterns to clinics rather than changes in the number of people identifying as transgender.
- Sex ratios of patients vary from clinic to clinic and over time. When I was the 23. psychiatrist for the Dimensions Clinic for transgender youth in San Francisco from 2003 to 2020, a consistent majority of my patients were assigned female at birth. Other clinics have had more assigned male at birth patients. The rise in numbers and percentage of patients assigned female at birth observed at some clinics in recent years is not surprising given the historical development of the study of gender dysphoria in youth. The first large American study of gender non-conforming youth was the Feminine Boy Study at UCLA. There was significant societal discomfort with and rejection of boys who departed from sex stereotypes—the director of the study referred to them as "sissy boys" in the book resulting from the study—and these boys often experienced bullying from peers. In this context, boys who were perceived to be effeminate were the population brought in to psychiatrists by their parents and were the population that was initially studied by researchers. (Green, 1987). Parents were not as concerned about gender non-conforming girls as they were more socially accepted. There was also less awareness among the general public of the existence of transgender males and that transitioning was an option for individuals assigned female at birth who were experiencing gender dysphoria. The increase in awareness in recent decades made it

possible for individuals who ultimately came to identify as transgender men to come out and seek care.

24. There is a social or cultural influence on gender in the sense that social and cultural developments make it more possible for youth struggling with gender dysphoria to access care. But there is no evidence that peer influence determines an individual's gender identity. The State's experts point to Lisa Littman's study discussing what she called "rapid onset gender dysphoria," where parents reported that their children who suddenly identified as transgender boys frequently reported consuming social media about transgender issues and having transgender friends. (See e.g., Hruz ¶ 74). While there may be rapid onset parental awareness of a child's transgender status, as is often the case when lesbian and gay youth come out to their parents, that does not mean the gender dysphoria was sudden to the adolescent. In any case, this study does not provide evidence that peers and social media cause individuals to be transgender. As with other marginalized groups, such as lesbian and gay people, it is not unusual to seek out others like you. Nor is it unusual to seek out support and information online. Moreover, the diagnostic criteria for gender dysphoria are rigorous and if there were individuals claiming a transgender identity to fit into a peer group, they would not meet the criteria for a gender dysphoria diagnosis let alone be deemed to need medical interventions.

SOME OF THE STATE'S EXPERT WITNESSES QUARREL WITH THE FIELD OF PSYCHIATRY AND THEIR OPINIONS REFLECT THEIR LACK OF EXPERIENCE IN THE FIELD

25. Gender dysphoria is a psychiatric diagnosis. Some of the State's expert witnesses whose CV's indicate no experience in psychiatry or mental health more generally critique the diagnosis of gender dysphoria for being based on self-reports from patients. (*See, e.g.*, Hruz, ¶¶ 35B, 45 (objecting that gender dysphoria diagnosis is limited to self-report info from patients

without objective data like blood tests or x-rays); Lappert, ¶ 30 ("There is no objective diagnostic test for transgender.")). But clinical interviews with patients are typically used to diagnose other DSM diagnoses and determine treatment. This widely used assessment tool is not unique to gender dysphoria.

- 26. Dr. Hruz candidly acknowledges that his objection is not limited to the gender dysphoria diagnosis and—quite extraordinarily—extends to the entire DSM and the mental health field in general, which he condemns as not being "science-based." (Hruz, ¶ 35A, 48, 50).
- 27. Despite Dr. Hruz's disapproval of the field of psychiatry, and despite his, Dr. Lappert's, and Prof. Regnerus's lack of expertise in the diagnosis or treatment of mental health conditions, all three of these expert witnesses did not hesitate to offer opinions about psychiatric care. For example, some of them compare surgery for gender dysphoria to amputating limbs of patients who have "Body Integrity Identity Disorder (BIID)." (See, e.g., Hruz, ¶ 54). "BIID" is an extremely rare phenomenon, and is not a recognized disorder in the International Classification of Diseases ("ICD") or the DSM. Gender dysphoria, in contrast, is a well-recognized condition with well-established treatments. Dr. Lappert, in opposing gender affirmation surgery, equates it to removing the functioning eyes of a brown-eyed patient who says they identify as blue-eyed and replacing them with blue glass eyes. (Lappert, ¶ 49). Of course, no such phenomenon exists. Comparing such an absurd hypothetical to the well-documented and studied gender dysphoria diagnosis disparages transgender people, and demonstrates Dr. Lappert's lack of expertise and experience in transgender health.

THE STATE'S EXPERT WITNESSES' ATTEMPTS TO DISCREDIT THE WPATH STANDARDS OF CARE AND ALL OF THE PROFESSIONAL GROUPS THAT ACCEPT THEM ARE BASELESS

- 28. The State's expert witnesses characterize WPATH as an ideological, non-scientific, advocacy organization, open to transgender activists outside of the health field. (Hruz, ¶ 64; Levine, ¶¶ 66, 67). Many WPATH members are academics who publish in peer-reviewed journals. Many are academic leaders in endocrinology, internal medicine, plastic surgery, urology, psychiatry, psychology, and other disciplines of the health sciences. WPATH restricts its full membership to those with professional credentials and most members are licensed clinicians. The fact that WPATH engages in advocacy on behalf of its patient population for access to beneficial care is typical of medical associations. For example, the American Psychiatric Association advocates for a wide range of public policy changes to improve access to mental health care, *e.g.*, for migrants and for incarcerated people.⁴
- 29. Dr. Levine asserts "[i]n my experience most current members of WPATH have little ongoing experience with the mentally ill." (Levine, ¶ 73). I do not know what he is basing this on since he has not been involved with WPATH in two decades. But it is simply not true. I have been involved with WPATH for many years and have 35 years of experience treating people with mental illnesses. And there are many others like me in WPATH. Mental health providers make up the largest percentage of WPATH's membership. These mental health professionals are licensed and regulated by state licensing boards, and most provide care to both cisgender and transgender clients—including those with serious mental illness.

⁴ See American Psychiatric Association. (2019). Position Statement on the Care of Medically Vulnerable Migrants in the United States. Available at https://www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Position-Care-of-Medically-Vulnerable-Migrants-in-the-US.pdf; American Psychiatric Association. (2016). Position Statement on Treatment of Substance Use Disorders in the Criminal Justice System. Available at https://www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Position-2016-Substance-Use-Disorders-in-the-Criminal-Justice-System.pdf; see generally American Psychiatric Association Policy Finder, available at https://www.psychiatry.org/home/policy-finder.

- 30. Dr. Levine further claims that "[g]enerally speaking, therapists who encounter gender patients in inpatient psychiatric settings, those educated more thoroughly about the controversies in the field, and mental health professionals who are not members of WPATH do not support the 'affirmation therapy' model." (Levine, ¶ 59). To the extent he is referring to his "model" of therapy that pushes people into adopting a transgender identity and rushes medical interventions and opposes psychotherapy, that would not be surprising and would also be opposed by members of WPATH as it is not a recognized treatment model. If he is referring to the accepted protocols for care, it is unclear what he bases this assertion on, but it is not consistent with my experience. Having been actively involved for three decades as a UCSF professor in the training of psychiatry residents, internal medicine residents and fellows, and medical students, as well as of mental health and medical professionals at conferences around the nation, by my observation, the mainstream views of health professionals on transgender care include widespread acceptance of the WPATH Standards of Care.
- 31. The State's expert witnesses also argue that dissenting views are not tolerated in WPATH. (Levine, ¶ 68). Yet, as a number of them noted, Dr. Marci Bowers recently expressed some criticism about how some in the field are practicing, and she is the President-elect of WPATH. I have attended several WPATH conferences since 2001, and have been a member of the Scientific Committees that have reviewed abstract submissions for the conferences, and the diversity of views presented and discussed has always been notable. For example, as chair of the Scientific Committee for the 2017 USPATH conference, I helped organize a panel of therapists and trainees who had themselves detransitioned, and the presentations and discussion were well-received by attendees.

32. According to Dr. Hruz, it is not just WPATH, but also the American Medical Association, the American Academy of Pediatrics, and the Endocrine Society, that act based on political ideology rather than "evidence-based scientific methodologies." (Hruz, ¶ 84). His unsupported claim that all of these major medical groups are sacrificing adolescents' health to promote a particular ideology is staggering.

GENDER-AFFIRMING MEDICAL CARE CAN HAVE LONG-TERM BENEFITS TO PATIENTS

- 33. Dr. Levine faults Drs. Turban, Antommaria, and Adkins, whose work focuses on pediatric populations, as lacking a "life course" perspective. (Levine, ¶¶ 11-14). I cannot speak for them, but I have treated people ranging from adolescents to the elderly. And many of my patients have remained with me for decades, *e.g.*, where a patient is on medications that need to be monitored, and their medical transition was a positive health care decision not just in the short term but for the course of their lives.
- 34. Dr. Levine's assertion based on anecdotal evidence that regret and "detransition" are "not infrequent" (Levine, ¶ 141, et seq.) is inconsistent with the data. A study of everyone receiving gender-affirming surgery in Sweden over 50 years (1960 to 2010) found a regret rate of 2.2.%, declining over the years. There were ten cases of regret from 1960 to 1980, and only five cases of regret total in the last 30 years that were reviewed, from 1981-2010. (Dhejne, et al., 2014). A meta-analysis of 27 studies which reported regret after gender-affirming surgery found that of 7928 people having gender-affirming surgery, the regret rate was 1%. (Bustos, et al., 2021). Dr. Levine's assertion is also at odds with my clinical experience. I have had some patients who halted their transition due to challenging personal circumstances—e.g., fear of losing family support—but they still had gender dysphoria. And some came back years later to resume their transition. But in 30 years, I have never seen a patient who had undergone hormone therapy and/or surgery

and later came to identify with their sex assigned at birth and, thus, regretted the treatment and wanted to undo its effects

- 35. The State's expert witnesses point to elevated rates of mental health problems and substance use in the transgender community, suggesting that being transgender is the cause of these negative outcomes and, thus, something doctors should try to prevent. (*See e.g.*, Hruz ¶ 61; Levine ¶ 15j). As discussed above, being transgender is not something doctors can prevent. And these comments disregard the significant stigma transgender people continue to face, and stigma is a well-documented risk factor for mental health and substance use issues.
- 36. Apparently in support of the unattainable goal of trying to deter people from being transgender, Dr. Levine makes the wholly unsupported statement that transgender people are not attractive to either sex, are unable "to form lasting relationships and attract a desirable mate," are not loved by others, and do not have friends because people will not be comfortable interacting with them. (Levine, ¶¶ 15j, 133, 135, 151). That may be his own view of transgender people, but it is not at all consistent with clinical experience, including my own. Many transgender people, when appropriately treated, lead fulfilling lives, forming romantic relationships and having families, and having close relationships with friends and extended family.

THE STATE'S EXPERT WITNESSES MISREPRESENT THE AVAILABILITY OF TREATMENT FOR ADOLESCENTS WITH GENDER DYSPHORIA IN EUROPE

37. Dr. Levine asserts that a number of countries have concluded that gender-affirming medical care for minors "must be halted." (Levine, ¶94). But none of the countries he discussed—U.K., Finland, or Sweden—has banned care. One children's hospital in Sweden, in response to the *Bell* v. *Tavistock* court decision in the U.K. (since overruled), made a decision to stop initiating gender-affirming medical interventions to minors outside of the context of research protocols, but to continue to provide care to existing patients. In none of these countries has a law banning

Case 4:21-cv-00450-JM Document 156-3 Filed 06/22/22 Page 19 of 22

transition care to minors been enacted and in none of these countries is gender-affirming care for minors unavailable.

Executed on February 11, 2022

Dan H. Karasic, MD

EXHIBIT A – DAN KARASIC BIBLIOGRAPHY

American Psychological Association. (2021). APA Resolution on Gender Identity Change Efforts. *Available at* https://www.apa.org/about/policy/resolution-gender-identity-change-efforts.pdf.

Bakker A., van Kesteren P. J. M., Gooren L. J. G., et al. (1993). The prevalence of transsexualism in the Netherlands. *Acta Psychiatr Scand*, 87(4), 237-238.

Bustos, V. P., Bustos, S. S., Mascaro, A., Del Corral, G., Forte, A. J., Ciudad, P., Kim, E. A., Langstein, H. N., & Manrique, O. J. (2021). Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence. *Plastic and reconstructive surgery-Global open*, *9*(3), e3477, *available at* https://doi.org/10.1097/GOX.0000000000003477.

Coleman, E., Bockting, W., Botzer, M., *et al.* (2012). Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People (7th Version). The World Professional Association for Transgender Health. *Available at* https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_English2012.pdf?_t=16 13669341.

Conron, K. J., Scott, G., Stowell, G. S., & Landers, S. J. (2012). Transgender health in Massachusetts: results from a household probability sample of adults. *Am. J. Public Health*, *102*(1), 118-122, *available at* https://doi.org/10.2105/AJPH.2011.300315.

Crissman, H. P., Berger, M. B., Graham, L. F., & Dalton, V. K. (2017). Transgender Demographics: A Household Probability Sample of US Adults, 2014. *American Journal of Public Health*, 107(2), 213-215, available at https://doi.org/10.2105/AJPH.2016.303571.

de Vries, A. L., Steensma, T. D., Doreleijers, T. A., & Cohen-Kettenis, P. T. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. *The journal of sexual medicine*, 8(8), 2276-2283, *available at* https://doi.org/10.1111/j.1743-6109.2010.01943.x.

de Vries, A. L. C., McGuire, J. K., Steensma, T. D., Wagenaar, E. C. F., Doreleijers, T. A. H., & Cohen-Kettenis, P. T. (2014). Young Adult Psychological Outcome After Puberty Suppression and Gender Reassignment. *Pediatrics*, *134*(4), 696-704, *available at* https://doi.org/10.1542/peds.2013-2958.

Dhejne, C., Öberg, K., Arver, S., & Landén, M. (2014). An analysis of all applications for sex reassignment surgery in Sweden, 1960-2010: prevalence, incidence, and regrets. *Archives of Sexual Behavior*, 43(8), 1535-1545, *available at* https://doi.org/10.1007/s10508-014-0300-8.

Ehrensaft, D. (2017). Gender nonconforming youth: current perspectives. *Adolescent Health, Medicine and Therapeutics*, 8, 57–67, *available at* https://doi.org/10.2147/AHMT.S110859.

- Flores, A. R., Herman, J. L., Gates, G. J., & Brown, T. N. T. (2016). How Many Adults Identify as Transgender in the United States? *The Williams Institute, available at* https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/.
- Green, R. (1987). *The "Sissy Boy Syndrome" and the Development of Homosexuality*. New Haven, CT: Yale University Press.
- Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S., Meyer, W. J., Murad, M. H., ... T'Sjoen, G. G. (2017). Endocrine treatment of genderdysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*, 102(11), 3869-3903, available at https://doi.org/10.1210/jc.2017-01658.
- Herman, J. L., Flores, A. R., Brown, T. N. T., Wilson, B. D. M., & Conron, K. J. (2017). Age of Individuals Who Identify as Transgender in the United States. *The Williams Institute*, *available at* http://williamsinstitute.law.ucla.edu/wp-content/uploads/Age-Trans-Individuals-Jan-2017.pdf.
- Johns, M. M., Lowry, R., Andrzejewski, J., Barrios, L. C., Demissie, Z., McManus, T., Rasberry, C. N., Robin, L., & Underwood, J. M. (2019). Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students 19 states and large urban school districts, 2017. *Morbidity and Mortality Weekly Report*, 68(3), 67-71, *available at* https://doi.org/10.15585/mmwr.mm6803a3.
- Rider, G. N., McMorris, B. J., Gower, A. L., Coleman, E., & Eisenberg, M. E. (2018). Health and care utilization of transgender and gender nonconforming youth: A population-based study. *Pediatrics*, *141*(3) e20171683, *available at* https://doi.org/10.1542/peds.2017-1683.
- Steensma T. D., Biemond R., de Boer F., & Cohen-Kettenis P. T. (2011). Desisting and persisting gender dysphoria after childhood: A qualitative follow-up study. *Clinical Child Psychology and Psychiatry*, 16(4), 499-516.
- Steensma, T. D., et al. (2013). Factors Associated With Desistence and Persistence of Childhood Gender Dysphoria: A Quantitative Follow-Up Study. *Journal of the American Academy of Child & Adolescent Psychiatry*, 52(6), 582-590.
- Wiepjes, C. M., Nota, N. M., de Blok, C. J., Klaver, M., de Vries, A.L., Wensing-Kruger, S.A., ... & Gooren, L.J. (2018). The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets. *The Journal of Sexual Medicine*, *15*(4), 582-590, *available at* https://doi.org/10.1016/j.jsxm.2018.01.016.
- World Professional Association for Transgender Health. (Dec. 2021). Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People Draft for Public Comment Adolescent (8th Version). *Available at*
- $https://www.wpath.org/media/cms/Documents/SOC\%20v8/SOC8\%20Chapters\%20for\%20Public\%20Comment/SOC8\%20Chapter\%20Draft\%20for\%20Public\%20Comment\%20-\%20Adolescent.pdf?_t=1638406852.$

Zucker, K., *et al.* (2010). Puberty-Blocking Hormonal Therapy for Adolescents with Gender Identity Disorder: A Descriptive Clinical Study. *Journal of Gay & Lesbian Mental Health*, 15:1, 58-82, *available at* http://dx.doi.org/10.1080/19359705.2011.530574.

Exhibit 4

	Page 1
	_
THE UNITED STATES DISTRICT	
FOR THE EASTERN DISTRICT OF	ARKANSAS
CENTRAL DIVISION	
DYLAN BRANDT, by and through	h his mother,
JOANNA BRANDT, et al.,	
Plaintiffs,	
vs.	CASE NO.
	4:21-CV-00450-JM
LESLIE RUTLEDGE, in her off	icial
capacity as the Arkansas	
Attorney General, et al.,	
Defendants.	
Defendants.	
Defendants. ORAL/VIDEOTAPED/	VIDEO CONFERENCE
ORAL/VIDEOTAPED/ DEPOSITION OF MAR	
ORAL/VIDEOTAPED/ DEPOSITION OF MAR	K DANIEL REGNARUS OF THE PLAINTIFFS
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022
ORAL/VIDEOTAPED/ DEPOSITION OF MAR TAKEN ON BEHALF LITTLE ROCK ON MAY 5	K DANIEL REGNARUS OF THE PLAINTIFFS ARKANSAS , 2022

			Dogo 2		Doga 4
1	APPEARANCES		Page 2	1	Page 4 PLAINTIFFS' INDEX OF EXHIBITS
2 3				2	TEARVIETS INDEX OF EXHIBITS
	or the Plaintiffs:				Exhibit Description Descri
4	SULLIVAN & CROMWELL, LLP DANIEL JAMES RICHARDSON			3	Exhibit Description Page
5	BRANDYN RODGERSON (Appearing via video conf.)			4	Exhibit 1 Regnarus Expert Report 11
6	125 Broad Street New York, New York 10004-2498			5	Exhibit 2 Regnarus Rebuttal Expert Report 12
_	212-558-4000			6	Exhibit 3 Declaration of Dr. Regnarus 15
7 8	richardsond@sullcrom.com			7	Exhibit 4 Supplemental Dec. of Dr. Regnarus 15
9	GILL RAGON OWEN			8	Exhibit 5 "Arkansas and the Politics of 77
9	BETH ECHOLS 425 West Capitol Avenue			9	Experimenting on Children."
10	Suite 3800 Little Rock, Arkansas 72201			10	Exhibit 7 11/13/19 "New Data Show" article 81
11	501-376-3800			11	Exhibit 8 "Does Conversion Therapy Hurt People" 207
12	echols@gill-law.com			12	Exhibit 9 Excerpt of bench trial testimony 115
	ACLU OF ARKANSAS			13	Exhibit 14 Attitudes in the U.S., 2020 article 44
13	GARY SULLIVAN CHASE STRANGIO (Appearing via video conf.)			14	Exhibit 18 Findings of Facts and Conclusions of 138
14	LESLIE COOPER (Appearing via video conf.)			15	Law (DeBoer v Snyder)
15	904 West 2nd Street Little Rock, Arkansas 72201			16	, , , , , , , , , , , , , , , , , , ,
16				17	
17	or the Defendants: OFFICE OF THE ARKANSAS ATTORNEY GENERAL			18	* * * * *
10	MICHAEL A. CANTRELL			19	
18	323 Center Street Suite 200				
19	Little Rock, Arkansas 72201 501-682-2401			20	
20	michael.cantrell@arkansasag.gov			21	
21 V	ideo Operator:			22	
22	Mike Tscheimer			23	
23 24				24	
25				25	
			Page 3		Page 5
1	CONTENTS			1	STIPULATIONS
2				2	
3	Pag	ge		3	
4			_	-	
	Examination by Mr. Richardson		7	4	IT IS HEREBY STIPULATED AND AGREED BY and
5	Examination by Mr. Richardson Certificate	328	/	4	
5	Certificate	328 330	/	5	between the parties hereto, through their respective
5 6	Certificate Correction Sheet	330	/	4 5 1 6 a	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL
5 6 7	Certificate		1	4 5 1 6 3 7 1	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the
5 6 7 8	Certificate Correction Sheet	330	/	4 5 1 6 3 7 1 8 3	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena
5 6 7 8 9	Certificate Correction Sheet	330	/	4 5 1 6 3 7 1 8 3 9 1	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of
5 6 7 8 9 10	Certificate Correction Sheet	330	/	4 5 1 6 3 7 1 8 3 9 1 10 0	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of
5 6 7 8 9 10 11	Certificate Correction Sheet	330	/	4 5 1 6 3 7 1 8 3 9 1 10 0	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of
5 6 7 8 9 10 11 12	Certificate Correction Sheet	330	/	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of
5 6 7 8 9 10 11 12 13	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of
5 6 7 8 9 10 11 12 13 14	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of
5 6 7 8 9 10 11 12 13 14 15	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of
5 6 7 8 9 10 11 12 13 14 15 16	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13 14	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13 14 15	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13 14 15 16	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13 14 15 16 17	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18	Certificate Correction Sheet	330	,	4 5 1 6 2 7 1 8 2 9 2 10 0 11 0 12 13 14 15 16 17 18	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 3 10 0 11 0 12 13 14 15 16 17 18 19 20	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Certificate Correction Sheet	330	,	4 5 1 6 3 7 1 8 3 9 1 10 0 11 1 12 13 14 15 16 17 18 19 20 21	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Certificate Correction Sheet	330		4 5 1 6 3 7 1 8 3 9 1 10 0 11 1 12 13 14 15 16 17 18 19 20 21 22	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Certificate Correction Sheet	330		4 5 1 6 3 7 1 8 3 9 1 10 0 11 0 12 13 14 15 16 17 18 19 20 21 22 23	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Certificate Correction Sheet	330		4 5 1 6 3 7 1 8 3 9 1 10 0 11 1 12 13 14 15 16 17 18 19 20 21 22	between the parties hereto, through their respective attorneys, that the videotaped deposition of MARK DANIEL REGNARUS may be taken on behalf of the Plaintiffs on the 5th day of May, 2022, in Little Rock, Arkansas, by Trena K. Bloye, Certified Shorthand Reporter for the State of Oklahoma, by notice pursuant to the Federal Rules of Civil Procedure.

Page 6 Page 8 1 VIDEO OPERATOR: Good morning. We are Q Okay. So this might sound familiar to you. I 2 going on the record at 9:01 a.m. on May 5th, 2022. 2 just have a couple of ground rules off the top. I'll 3 Please note that microphones are sensitive and may pick 3 try not to speak over you today, but I'd appreciate it 4 up whispering and private conversations. Please mute 4 if you let me finish my question so the court reporter 5 your phones at this time. Audio and video recording 5 can make an accurate record. Please answer every 6 will continue to take place unless all parties agree to 6 question verbally. The reporter can't take down things 7 go off the record. 7 like a head nod or a hand gesture. If you need 8 clarification or if a question is ambiguous, just let me This is media unit 1 of the video 9 know and I'll clarify. 9 recorded deposition of Mark Regnarus taken by counsel 10 for Plaintiff in the matter of Dillon Brandt, et al., 10 I don't intend any of my questions to elicit 11 versus Leslie Rutledge, et al, filed in the United 11 information protected by attorney-client privilege. If 12 States District Court, Eastern District of Arkansas, 12 you believe an answer to a question would disclose 13 Central Division, Case Number 4:21-cv-00450-JM. 13 privileged information, just say so. But for all other 14 14 questions, please do answer even if there is an The location of the deposition is 15 Arkansas Attorney General's Office, at 323 Center 15 objection. 16 Street, Suite 200 in Little Rock, Arkansas. My name is 16 I know today is going to be long so I plan to 17 Mark Tscheimer, the court reporter is Trena Bloye, both 17 take breaks every hour, hour-and-a-half or so. But if 18 representing Veritext. I am not related to any party in 18 you need a break at any point, just let me know. I just 19 this action nor am I financially interested in the 19 ask that you finish a question that is asked before the 20 outcome. If there are any objections to proceeding, 20 break. Does that all sound all right? 21 21 please state them at the time of your appearance. A It does. 22 Counsel and all present, including 22 Q All right. Great. Are there any materials you 23 are consulting in connection with your testimony today? 23 remotely, will now state their appearances and 24 affiliations for the record beginning with the noticing 24 A Consulting --25 attorney. 25 Q In person with you? Page 7 Page 9 1 MR. RICHARDSON: This is Daniel James A -- materials? I'm not sure what you mean by 1 2 that. 2 Richardson for the plaintiff. 3 MS. ECHOLS: Beth Echols for the 3 Q Do you have any materials today that you will 4 plaintiff. 4 be looking at? MR. STRANGIO: This is Chase Strangio for 5 A Oh, no. 5 6 the ACLU for the plaintiff. Q Okay. Is there anything that would prevent you 7 MR. CANTRELL: Michael Cantrell, with the 7 from providing complete and accurate testimony today? 8 Arkansas Attorney General's Office for the Defendants. A I don't think so. 9 Q Have you taken any medicines or substances that VIDEO OPERATOR: Madam Reporter, will you 10 please swear in the witness. 10 would impair your ability to testify? 11 11 (The witness was sworn.) 12 VIDEO OPERATOR: Thank you. Please 12 Q All right. What did you do to prepare for your 13 proceed. 13 testimony today? MARK DANIEL REGNARUS, A I went back through my witness reports, 15 after having been first duly sworn, deposes and says in 15 rebuttals, mine, expert witness on the other side, took 16 reply to the questions propounded as follows, to wit: 16 notes on mine, summarized it in brief format and 17 **EXAMINATION** 17 reviewed it a few more times. 18 BY MR. RICHARDSON: 18 Q Okay. Thanks. Did you meet with counsel Q Good morning, Dr. Regnarus. Thanks for being 19 before today? 19 20 here. For the record, can you please just state your 20 A No. I mean, in person? 21 full name. 21 Q In any way to prepare for the testimony today. 22 A Mark Daniel Regnarus. 22 A Just sort of he telling me what it's going to Q Okay. Great. And you have been deposed 23 be like. That's all. 24 before; right? Q Okay. How many times did you all talk? 24 25 A Once. 25 A Twice about the deposition.

	P. 10		D 10
1	Page 10	1	Page 12 MR. RICHARDSON: Okay. And can we get
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	Q Okay. And were those brief conversations?A They were. One was just as I came in.		Exhibit 2 as well, please?
3	Q Okay. Did you review any documents with	3	(Plaintiff's Exhibit 2 was marked for
	counsel?	4	identification and made a part of the
5	A No.	5	record.)
6	Q Okay. And have you spoken with anyone else	6	Q And do you recognize that document?
	other than counsel about your testimony here today?	7	A I do.
8	A I have a research assistant I asked questions	8	Q And is that your rebuttal report?
l	of, go look for things and particular statistics and	9	A Yeah.
	things like that.	10	Q Okay. Great. Do you stand by the statements
11	Q Okay. Are any of those things in addition to		in these two reports?
	what's in your report? Was this research after you	12	A I do.
1	submitted your report?	13	Q Do these reports contain a complete statement
14	A I try to keep up to date what's going on in the	_	of the opinions you intend to provide in this matter?
	field. So, you know, for the report, for today you mean	15	A They do.
1	or for	16	Q Okay. Do these reports contain a complete
17	Q In terms of your preparation for testimony		statement of the opinions you intend to provide in this
	today, was this research assistant involved in helping		matter?
l	you	19	A They do.
20	A No, not for opinion.	20	Q Okay. Do these reports contain a complete
21	Q And anybody else beyond the research assistant		statement of all of the bases and reasons underlying
	that you talked to about your testimony today?		your opinions in this matter?
23	A No.	23	A They do.
24	Q Are you being paid for your work in this case?	24	Q Are there any documents or materials you relied
25	A I am.	25	on to form your opinions that are not cited in these
	Page 11		Page 13
1	Q Did the State pay for your travel today?	1	reports?
2	A I think they will. They said they will.	2	A Could you restate that one?
3	Q Is anyone else compensating you for your work	3	Q Are there any documents or materials you relied
4	in this case?	4	on to form your opinions that are not cited in these
5	A No.	5	reports?
6	Q And is your compensation from the State at all	6	A If I if there are, I don't recall them. You
7	tied to the outcome of this litigation?	7	know, I do a thorough literature review on my way to
8	A No.	8	writing this. Some of them I cite, some of them I
9	Q Okay. You prepared expert reports in	9	don't.
10	connection with that matter; right?	10	Q Okay. But nothing comes to mind?
11	A I did.	11	A No.
12	MR. RICHARDSON: Can you get Exhibit 1,	12	Q Okay. The first document, this is the one
13	please? Okay. Thank you.	13	marked Exhibit 1, that includes your CV; correct?
14	Now mark this Exhibit 1, please.	14	A It does. Yeah, it does.
	110W mark this Exhibit 1, piease.		
15	(Brief off-the-record discussion.)	15	Q Okay. And is that document accurate to your
15 16	•		Q Okay. And is that document accurate to your knowledge?
l	(Brief off-the-record discussion.)		
16	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.)	16 17	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so.
16 17 18 19	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you	16 17 18 19	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you
16 17 18 19	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you recognize this document?	16 17 18 19	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you would add since December?
16 17 18 19 20 21	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you recognize this document? A Yeah. I'm checking to see which which	16 17 18 19 20 21	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you would add since December? A No, I don't think so. I think I had an essay
16 17 18 19 20 21	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you recognize this document? A Yeah. I'm checking to see which which what the date was. Got it.	16 17 18 19 20 21 22	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you would add since December? A No, I don't think so. I think I had an essay or two since then, but nothing in the peer-reviewed
16 17 18 19 20 21 22 23	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you recognize this document? A Yeah. I'm checking to see which which what the date was. Got it. Q So is this your expert report that you	16 17 18 19 20 21 22	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you would add since December? A No, I don't think so. I think I had an essay or two since then, but nothing in the peer-reviewed topic or the book publications.
16 17 18 19 20 21 22 23	(Brief off-the-record discussion.) (Plaintiff's Exhibit 1 was marked for identification and made a part of the record.) Q (By Mr. Richardson) All right. Do you recognize this document? A Yeah. I'm checking to see which which what the date was. Got it.	16 17 18 19 20 21 22 23 24	knowledge? A Let's see. This is from December. You know, it's a little bit updated, but not radically so. Q Okay. Any publications come to mind that you would add since December? A No, I don't think so. I think I had an essay or two since then, but nothing in the peer-reviewed

Page 14 Page 16 A I had an essay in public discourse a couple of 1 Q Okay. Could you look at Exhibit 4, please? 2 months ago. That was about gender and the war in 2 A Okay. 3 Ukraine. Q And do you recognize that document? 4 O Okay. 4 A I think that's -- there might have been one Q And is that the Supplemental Declaration you submitted opposing the preliminary injunction? 6 before that, but that's all that comes to mind. 7 Q Okay. So all that you recall is the essay 8 about the war in Ukraine and gender in Public Discourse? Q Okay. And do you stand by the statements in 8 9 those two declarations? A Yeah. Again --10 Q Okay. 10 A Yes. 11 A -- the thing is if it's not on the paper it 11 Q Okay. Are you aware of any inaccuracies in the 12 escapes my mind. 12 reports or declarations you submitted in this matter? 13 Q Okay. 13 14 Q Is there anything in the reports or 14 A There could be something else, but nothing 15 significant that comes to mind. 15 declarations you would like to amend or correct? Q Okay. So --16 A No, nothing comes to mind. 17 A That's one I do recall that's probably the most 17 Q Have you changed any of your opinions since 18 recent. 18 completing your rebuttal report? 19 Q Okay. Thank you. So are there any relevant 19 A No. 20 qualifications not included on your CV? 20 Q And have you conducted any additional analysis 21 21 relevant to this matter since completing your rebuttal 22 report? 22. Q Okay. And you also submitted declarations 23 opposing the preliminary injunction in this case; 23 A What do you mean by additional analysis? 24 correct? 24 Q Just any work, any research work that you have 25 A You mean the things back in July? 25 done that would be relevant to your opinions in this Page 15 Page 17 Q Yes. 1 1 case? 2 2 MR. RICHARDSON: Can we get Exhibit 3, A Public, written, draft? 3 please? Q Anything that comes to mind, anything that A Right. Okay. And a -- what was the rebuttal, 4 would form your opinions in the case? 5 it was a supplementary document. Are we talking about A I mean, as I said earlier, I have continued 6 that? I think there are two in July. 6 reading in this area and keeping up to date. But since, 7 Q Yes, there should have been two. We will mark 7 February is the rebuttal, I mean, nothing that I could 8 this one as Exhibit 3. 8 sort of say, Oh, here, is a new piece of information or 9 (Plaintiff's Exhibits 3 and 4 were 9 a new set of analyses I have done. 10 marked for identification and made a 10 Q So in terms of keeping up on the research, is 11 11 there anything you've seen that would inform your views part of the record.) 12 A Thank you. Does this contain both of those or 12 in this case that comes to mind that wouldn't be 13 included in those reports. Q That should be the first one you submitted and A Informs my views to shape it differently, you 15 then supplemental will be Exhibit 4. 15 mean? 16 A Okay. 16 Q To shape the opinions expressed in your Q Okay. So looking first at Exhibit 3, you 17 17 reports? 18 recognize that document? A Sure. I -- there are -- as you know, the 19 A Exhibit 3? 19 research in this is pretty dynamic, it's moving fairly 20 Q Exhibit 3, yes. 20 quickly, there is lots of new materials published. I A I go by the date. Looks like that's the 21 have tried my best to keep up with it. So, you know, as 22 December one, yeah. 22 recently as yesterday I read something that I hadn't Q Okay. So that was the report you submitted 23 seen before. But it's not as if I stopped in February, 24 opposing the preliminary injunction in the case. 24 submitted it, and said, you know, I'm not adding 25 A Yeah. 25 anything to my mental file until I talk to you folks.

Page 18 Page 20 1 Q Understood. I just want -- if I'm trying to 1 that? 2 understand the basis for your expert opinions --2 A No. 3 A Right. Q Okay. Any other relevant academic training Q -- are there any reports that would post-date 4 beyond those degrees? 5 the February --Q Okay. And what is your current position? A That would change it significantly you mean? 6 7 7 A Professor of Sociology at University of Texas Q Just inform in any way -- inform your view, 8 change it, reenforce it, whatever that may be? A I don't quite see how that's different from 9 Q Okay. And how long have you been a UT Austin 10 just keeping up with research. 10 professor? 11 Q Okay. So is there any research that comes to 11 A I think I'm finishing my 20th year. 12 mind then? 12 Q And full professor right now; right? A You know, professor Biggs' stuff out of Oxford, 13 A Um-hum. 14 he keeps writing and I find that fairly interesting. 14 Q And before that associate? 15 Q Anything else come to mind? 15 A Associate and assistant. 16 A I try to keep up to date with what Jack Turban 16 Q Okay. Are you also a senior fellow at the 17 has written. Yeah, I try to keep up to date with it. 17 Austin Institute for the Study of Family and Culture? 18 18 O Okay. A I am. 19 A Now, if you want to go through each one of 19 Q Okay. What does the Austin Institute do? 20 those one by one that would be a challenge to me. But 20 A They -- they're kind of a -- they talk about 21 different pieces come out, I ask my research assistant 21 social science of family and marriage and things like 22 to kind of keep her eye on what's new, so she sends me 22 that, probably because that's what one of my strengths 23 things when they come out. 23 is. But they have taken on the flavor of their 24 Q But all of the opinions expressed in your 24 directors over time in their political theorist so they 25 report you stand by? 25 can tack in the direction of content that is more Page 19 Page 21 A I do. 1 towards great books, literature, political thought, 1 Q Can you please describe your academic training? 2 things like that. 3 3 Q Okay. A From what stage? Q Let's say high school. A They tend to -- undergraduates and graduate A High school? I got a high school degree from 5 students at the University of Texas who are interested 6 it's called McBain Rural Agricultural High School in 6 in that -- yeah. So there is a variety of senior 7 McBain, Michigan 1989. Bachelor of Arts in Sociology 7 fellows, some of us don't do much. 8 from Trinity Christian College in Palos Heights, Q Okay. And --9 Illinois in 1993. I guess Master of Arts in Sociology I 9 A I don't frankly do a whole lot for them either, 10 so. 10 think it was 1997, whatever the CV says. And PhD from 11 North Carolina Chapel Hill in 2000, same place. 11 Q And what sort of work does a senior fellow do? 12 Q So I've got the BA from Trinity Christian 12 A Just do what we do. I think they began that a 13 long time ago more for sort of to establish some early 13 College --14 A Yeah. 14 credibility, but they don't -- I don't think they pay Q -- master's from UNC Chapel Hill, PhD from UNC 15 15 senior fellows. So -- well, they don't pay me. 16 Chapel Hill. 16 Q So what is, I mean, in the last year what kind A Correct. 17 17 of work have you done with the Austin Institute? 18 Q All in sociology? 18 A I attend their board meetings because I have a 19 A Everything in sociology, yep. 19 vested interest in, like, what happens at the place. 20 Q Okay. Any other degrees beyond those? 20 Occasionally I will attend events that they host and I'm 21 21 friendly with the people who run the place. So I show 22 Q Any other professional training of any kind? 22 up and just say hi, drop in, see what's going on. 23 A That would end in, like, a certificate or 23 Q Okay. But it's not part of your research 24 something? 24 agenda you work with the Austin Institute? 25 Q Yeah, a certificate program, something like 25 A Part of my research agenda. Like what do you

Page 22 Page 24 1 you mean by that? 1 the book? Q Like any of your research projects, do you work A I suspect it's fine. I just don't recall my 3 with the Austin Institute in any kind of capacity or 3 thoughts of when I looked at it. 4 network? Q Okay. Does the Austin Institute have a view on A I have asked them for funding for surveys. same sex marriage? A I would have to sort of say the same thing 6 They have funded or underwritten two or three surveys 7 about that. 7 that I've done, so they are helpful in that sense. Q Okay. Anything else? 8 Q Okay. A Anything else -- you said related to the 9 A I mean, does the organization of which I am an 10 research --10 unpaid senior fellow have a perspective. It would take 11 Q Or your teaching, anything about your work. 11 on the character of its staff. A Oh, not teaching. They have asked me to lead a O And does the leadership of the Austin Institute 13 four-week seminar, you know, once a week in the evenings 13 have a view on same sex marriage? 14 on the last book I wrote. Public dissemination of 14 A Yes. 15 15 research. I guess quotes don't go well on -- sorry. Q And do you know that view? 16 Public dissemination of research. 16 A Opposed. 17 Q So besides, like, board meetings and book talks 17 Q It's opposed? 18 and things like that, and the funding for certain 18 A Yeah. 19 research projects, nothing else with the Austin 19 Q And do you share that view? 20 Institute comes to mind? 20 21 A No. 21 Q And is the Austin Institute a religious Q Okay. Does the Austin Institute have a view on 22 organization in any way? 22. 23 gender identity? 23 A It is not. 24 MR. CANTRELL: Object to form. 24 Q So no affiliation in any sense? 25 A Do they have a view, like the organization has 25 A No. Page 23 Page 25 1 a view? Q Was this position included in your CV? 1 Q (By Mr. Richardson) Well, yeah, is there an 2 A The position? 3 organizational view? 3 Q Your position as a senior fellow at the Austin A Not that we've ever discussed it explicitly. 4 Institute? 5 The director and his wife have created some materials A Is it? It's in my signature file of most 6 for -- they sell them online -- for kind of how to 6 emails. I don't know if it's in here. I mean, it's not 7 understand gender identity and sexuality, I think. And 7 a professional appointment. It's -- so it is not in my 8 they used to run a few seminars for interested parties 8 CV, no, but it is available online, as you have probably 9 to go through that book. 9 already seen. Q Okay. And can you just briefly summarize the 10 Q Okay. And why is that position not included? 10 11 A It's not a professional appointment. I mean, 11 views in that book? A I would have to give you the briefest of 12 it's a --13 overviews because I'm -- honestly, I have glanced at the 13 Q Okay. 14 book, tried to make sure it, you know, didn't say A These are sort of university-based 15 appointments. I don't think it's ever occurred to me to 15 anything empirically unverifiable. But I'm sure it's 16 critical of modern gender etiology. But it has been a 16 put it in there. Q Okay. Are there other professional activities 17 long time since I looked at that book and I have not 17 18 attended their seminars for it, so -- so insofar as one 18 of any kind not included on your CV? 19 would want to presume that the opinions of the director 19 A Professional activities? 20 and his wife as reflected in that book are the opinions 20 Q Things like being a senior fellow at an 21 of the organization, you could probably feel free to do 21 institute or receiving research funding from an 22 that. 22 organization. 23 Q Do you agree with the content of the book? 23 A I think I'm on Baylor University's -- I want to 24 A I'd have to, you know, take a look at the book. 24 say it's Institute of Religion, Institute for Study of 25 Q Okay. So you have no view on the content of 25 Religion, I think I'm a fellow there that's not on here.

1 It's these pro forma things that I don't include. 1 sociology of religion at UT that had come open, so I

- 2 Q I understand. I just to make sure I have the
- 3 full range.
- 4 A Let me think if there is something else. Give
- 5 me a second. I will try to make my way around that
- 6 space. You may know more than I do on this, so I'll
- 7 agree if it's true.
- 8 Q So nothing else comes to mind besides Baylor?
- 9 A It doesn't, yeah. And that one sort of -- I
- 10 think it's largely -- is it pro forma the term where
- 11 it's -- they want it for their own publicity not because
- 12 I do anything for them.
- 13 Q Okay. So do you attend meetings of that group
- 14 like kind of --
- 15 A I have not attended a formal meeting. I have
- 16 done an informal meeting where we are talking with one
- 17 of the -- just to catch up with one of the staff.
- 18 Q Gotcha. Okay. And do you, like, meet with
- 19 Baylor students as part of that role at all --
- 20 A No.
- 21 Q -- or Baylor faculty?
- 22 A Strictly a handful of faculty.
- 23 Q Okay. And does that faculty group get together
- 24 and meet under that umbrella?
- 25 A I have no idea.

- Page 26 Page 28
 - 2 thought I should apply.
 - 3 Q All right. And did you also work at the
 - 4 Carolina Population Center?
 - 5 A As a post-doc research associate, yeah, for I
 - 6 guess that was a year. I was a pre-doc in it for a year
 - 7 and post-doc in it for a year.
 - 8 Q And what sort of work did you do for the
 - 9 center?
 - 10 A That is -- it's the kind of thing -- like the
 - 11 population center at UT where you have pre-doc,
 - 12 post-docs, and largely they are to pursue their own
 - 13 research interests, and often in conjunction with a
 - 14 advisor type person who you work under. So that's what
 - 15 I did.
 - 16 Q Okay.
 - 17 A Yeah.
 - 18 Q And in your current role as a professor at UT,
 - 19 what do you teach?
 - 20 A I teach -- the last few years I have taught
 - 21 two-two load, two spring, two in the fall. And those
 - 22 have included three sections of "Undergraduate Research
 - 23 Methods" and one, it's called a signature course. It's
 - 24 a unique course that the university, by state
 - 25 law asks -- State Legislature asked, sort of mandated

Page 27

- 1 Q Okay. All right. Thanks. So after graduating
- 2 Trinity Christian College did you work anywhere prior to
- 3 UT?
- 4 A Prior to UT? As in academic jobs or anything?
- 5 Q Anything that comes to mind. Any professional
- 6 work between graduating --
- 7 A Before I -- after I got out of college?
- 8 Q Let's stick to academic jobs.
- 9 A Okay. Because I can go through what I did
- 10 before I got into graduate school.
- 11 Not academic, no. You said after Trinity? UT?
- 12 Q Anything between, you know, finishing your
- 13 education and starting at UT?
- 14 A Calvin College, I was there for a year.
- 15 Q Okay.
- 16 A That's here.
- 17 Q And why did you leave Calvin College?
- 18 A Texas was a nice job, it was at a research
- 19 university and it attracted me. Calvin job was near my
- 20 family. It was to run a research center and help the
- 21 faculty kind of become more research oriented. But no
- 22 sooner did I get there than this Texas position opened
- 23 and I felt like applying, not because I didn't like
- 24 Calvin, but because at the time I was a sociologist of
- 25 religion squarely, and that there were two jobs in

- Page 29
- 1 the university teach. So it's special topics courses 2 that they are interested in so undergraduates get a --
- 3 an experience of small'ish class at a large university
- 4 taught by the professor, so I teach one of those. It's
- 5 called Catholicism and Social Thought.
 - Q Okay.
- 7 A I teach that in the fall.
- 8 Q Okay.
- 9 A I taught it for the last five fall semesters.
- 10 Q Okay. And it's kind of like a seminar, then.
- 11 Is that roughly accurate?
- 12 A Um-hum.
- 13 Q Okay.
- 14 A Correct.
- 15 Q And do you supervise doctoral students?
- 16 A Actively or ever?
- 17 Q Let's say ever, since you joined UT.
- 18 A I have.
- 19 Q Okay.
- 20 A That's listed, I think, in the CV, unless I
- 21 gave you a short version of it. Let me see if it's
- 22 there. Yeah, it's there. Next-to-last page.
- 23 Q Gotcha.
- 24 A I have none currently. Actually, I need to add
- 25 somebody to the plan 2 supervision for honors.

Page 30 Q Oh, down for the undergraduate?

- 2 A Undergraduate thesis supervision for honors.
- 3 Q Okay.

1

- 4 A And I'll have one of those. I just haven't
- 5 updated it.
- 6 Q In terms of the PhD supervision and master's
- 7 supervision, it looks like there hasn't been a master's
- 8 candidate since 2013 and a PhD candidate since 2016. Is
- 9 that correct?
- 10 A It appears that way on here. I'm trying to
- 11 recall if I haven't updated it or not. This is kind of
- 12 part of the CV that I don't spend tons of time on. MA.
- 13 Yeah, that may be accurate. Nobody comes to mind.
- 14 Q Okay. And why have you not served on the
- 15 committee in all that time?
- 16 A I haven't been asked.
- 17 Q So the students sort of -- how does that work?
- 18 The students decide who they want to advise?
- 19 A Yeah, yeah.
- 20 Q Okay. And each committee has, what, like a
- 21 chair and two other people?
- 22 A The MA, I think it's a chair and maybe two
- 23 readers, and the other one is usually a chair and three
- 24 or four readers.
- 25 Q Okay. So in that, you know, the last six years

- Page 32
 1 you could say Catholicism and Socialism Thought is part
- 2 of that, but it's not squarely sociology of religion.
- 3 And then kind of the, I guess, the grandfather of it all
- 4 changed positions.
- So for a while the sociology of religion sort
- 6 of section, we offered a kind comprehensive exam in it
- 7 for years. But, you know, the students kind of
- 8 graduated, the last few are listed there I think. And
- 9 then, you know, the first fellow left and the rest of
- 10 us -- I mean, I drifted into other topics and one didn't
- 11 get tenure and one still teaches a class in it, but --
- 12 so they stopped offering -- the department stopped
- 13 offering a comprehensive exam with our, you know,
- 14 permission, because half of us weren't there anymore.
- 15 Q Yeah.
- 16 A So there aren't really students to supervise in
- 17 religion.
- 18 Q Okay. Thank you. And have you appeared as an
- 19 expert in any other cases besides this one?
- 20 A Expert in any other cases? I did, yes. What's
- 21 the name of it? Something versus U.S. Department of
- 22 Education. Hunter?
- 23 Q Yeah.
- 24 A And was joined by the CCCU, yes.
- 25 Q Okay. So that's Hunter v Department of

Page 31

Page 33

- 1 or so, no students have asked?
- A That is correct.
- 3 Q Why do you think that is?
- 4 A Because they have decided they don't want me on
- 5 their committee.
- 6 Q I mean, it looks like you were on committees
- 7 quite frequently before that. Is there --
- 8 A Well, I was more squarely in the sociology of
- 9 religion up until -- I still dabble in it, the last
- 10 book. But these are mostly Sociology of Religion
- 11 students.
- 12 Q And does the university still have those
- 13 students?
- 14 A Have the students?
- 15 Q Are there still students pursuing the same
- 16 training that these students were --
- 17 A No. And it's not because I changed, but
- 18 because the primary professor who was squarely in
- 19 sociology of religion and who chaired a majority of
- 20 these -- these dissertations left the university in, it
- 21 was probably '11 or '12 I think. I could be wrong.
- 22 So there were one, two, three -- four of us in
- 23 the Sociology of Religion. And one didn't get tenure,
- 24 one kind of dabbles in it still and teaches a class on
- 25 it. I haven't taught a class on it in a while. Well,

- 1 Education. Can you briefly describe the nature of your
- 2 testimony in that case?
- 3 A Briefly describe the nature of my testimony --
- 4 Q Briefly just the views you offered in that case
- 5 as an expert?
- 6 A Do you want to talk about the case first or
- 7 the --
- 8 Q Sure. I mean, just a brief summary of the
- 9 claim and then maybe what your --
- 10 A Yeah. It would be helpful to walk backwards to
- 11 the case itself. This is -- I think the organization is
- 12 called REAP, R-E-A-P. It's an acronym. I can't
- 13 remember what it stands for, probably religious
- 14 something, that organizes a series of plaintiffs who are
- 15 students, current or former, at Christian universities
- 16 and colleges, most of which I think were in the
- 17 coalition for Christian colleges and universities, but
- 18 not all of them.
- 19 And they filed suit against the U.S. Department
- 20 of Education, I believe because it's seeking to end
- 21 their Title IX -- their college's Title IX exemptions
- 22 out of a sense of dissatisfaction with what they call 23 discriminatory treatment about sexuality and gender
- 24 identity in the college conduct codes.
- 25 Q Gotcha.

Page 34 Page 36 1 A So I was approached to consider an expert 1 Q Gotcha. 2 witness report on that topic. A To me, the names are largely irrelevant so I 3 Q Okay. 3 lose track of what the names are. But the Obergafell A So --4 has kind of -- it's memorable, so I don't forget that Q And you were an expert for the defendant in 5 one very easily. Bostock. But there was two cases, the 6 Bostock one and the Harris. 7 A Yes. Q Yeah, R.G & G.R. versus Harris Funeral Homes? A Yeah. That was the one I wrote for. I did not 8 Q Okay. A I always have to stop for a second like 9 write for the Bostock, but I guess they got packaged 10 plaintiffs, defendants. Which one did what? Yes, 10 together. 11 that's correct. 11 Q Okay. So it sounds like there was Masterpiece Q And were you also an expert in a case called 12 Cakes versus Colorado Civil Rights Commission. 13 DeBoer against Snyder? 13 A Yes. Sorry. That's before that. 14 Q Obergafell against Hodges. 15 Q Can you just briefly described that, the nature 15 16 16 of that case? Q United States against Windsor. 17 A That was a -- essentially it was packaged as a 17 A Yeah. 18 same-sex marriage case. I think it did involve an 18 Q And then Bostock v. Clayton County consolidated 19 adoption case at some level at first. State of 19 with --20 Michigan, federal district court in Detroit. I think 20 A Yeah. 21 there were four or five of us as Defendants' witnesses 21 Q -- Harris Funeral Homes. 22 for the State of Michigan. A And if there is another one -- I am blanking on 22 23 it. It might be. No, I don't think so. It was either Q Okay. And anything besides the Hunter case and 24 DeBoer where you served as an expert? 24 four or five. 25 A I don't think so. But if you know one it 25 Q Okay. But nothing else comes to mind besides Page 35 Page 37 1 these? 1 may --2 A It doesn't. Some sort of law search could Q No problem. And have you participated in any 3 other cases without serving as an expert, including as 3 correct that if I'm mistaken. 4 an amicus? Q Okay. So you mentioned that you have degrees A Yeah. I think they have all been supreme court 5 in sociology and nothing else; right? 6 cases, but I could wrong about that. I think I've 7 7 written briefs in the Masterpiece case. I probably Q That's all of your academic training? 8 wrote -- well, wrote or joined? A Um-hum. Q Wrote or joined. 9 Q Okay. Did your academic training include A Yeah. Some of these I joined, some of these I 10 training on how to provide medical care? 11 helped sort of format the main arguments. And I 11 12 probably -- I probably could recall which ones were 12 Q Any training at all in medicine? 13 which, whether I wrote it or joined it. Is it Windsor 13 14 that first one? I think that was the first time I had 14 Q Did it include training on how to test the 15 written an amicus brief. No. I think I joined that 15 efficacy of medical interventions? A The training did not, although I have learned 16 one. 17 Then there was Obergafell and to the 17 about that since. 18 Masterpiece. The one that's now known as -- as the 18 Q Okay. But your formal training through the PhD 19 Georgia County? When I -- in my mind it's the Detroit 19 did not? 20 Funeral Home case. 20 A Well, no. It depends on the -- repeat the Q Okay. 21 question before I answer that, would you? 22 A I don't remember what the exact name of it is. Q Did your academic training include training on 23 It got packaged and now it's known as --23 how to test the efficacy of medical interventions? 24 Q Does Bostock sound right? 24 A Yeah. I mean, it has helped me understand how 25 A Yes. Thank you. 25 to do group differences, of course.

Page 38

O Okay. 1

- A Now, it depends on the kind of medical study
- 3 we're talking about. So some of the plaintiff's expert
- 4 witnesses conduct medical research using group
- 5 differences analyses, those sort of statistics --
- O Yeah.
- 7 A -- that I did get training on. So it all
- 8 depends on what you mean by medical studies.
- Q Okay.
- 10 A Some people are -- they're statistical and
- 11 methodological research training focuses on that, like
- 12 epidemiology. Mine is more on sort of general
- 13 statistical methods, but they overlap enough that I'm
- 14 able to evaluate the research that -- that I talk about.
- 15 Q Okay. So your training includes general social
- 16 science methods training; right?
- 17 A Statistical training.
- 18 Q That sort of -- statistical training.
- 19 A Methods in statistics.
- 20 O Yeah.
- 21 A This is, like, how to collect data.
- 22 Q Um-hum.
- 23
- 24 is a lot of overlap there.
- 25 Q Yeah.

- Page 39
- A There is also statistical training, which is 1
- 2 how to assess, you know, things like efficacy,
- 3 statistical significance, affect sizes, things like
- 4 that.
- 5 O Okay.
- A So there is overlap with that as well. It
- 7 wasn't through a medical school or a medical degree that
- 8 I got that. But they do certainly apply.
- Q Was there a medical focus to the training?
- 10 Were the courses focused on how to --
- A I'll give you an example. 11
- 12 Q Okay.
- A My best friend in graduate school, we both went
- 14 to the same program at UNC. I entered the academic
- 15 career. He entered using the same PhD, same degree,
- 16 entered the sort of medical research field. He's going
- 17 to be more well versed in, I think, it's mostly cardiac
- 18 research than I am, but we lean on a comparable training
- 19 for preparing us.
- Q Understood, yeah. But would any of the courses
- 21 you took or the research you did in your academic
- 22 training have been focused on the efficacy of medical
- 23 interventions?
- A The training? Well, training is often generic.
- 25 It depends on who writes the textbook.

- 1 Q Yeah.
- A You will use textbooks that are written by, um,
- 3 epidemiologists, demographers, sort of pure
- 4 statisticians, things like that. So I don't remember --
- 5 I'm sure I've solved research problems in stats class,
- 6 advanced quantitative methods that were about, you know,
- 7 medical problems.
- Q But not focused on. It would be in the same
- 9 way any subject matter could come up in a course like
- 10 that.

11

- A Not focused in the way if you went to get a
- 12 degree at a department of biostatistics, they are
- 13 probably more focused on that.
- Q Okay. 14
- 15 A Sure.
- 16 Q And it wouldn't have included any training on
- 17 how to diagnose or treat medical conditions?
- 18 A That is correct.
- 19 Q Okay. Did it include any training on how to
- 20 diagnose or treat mental health conditions?
- 21
- 22 Q Okay. Did it include any training on medical
- A Which medical researchers do as well. So there 23 care or psychological treatment for transgender people?
 - 24 A State it again, please.
 - 25 Q Did your training include any training on

Page 41

Page 40

- 1 medical care or psychological treatment for transgender
- 2 people?
- 3 A No. But my training ended in 2000.
- Q Yeah.
- A So fairly early for this topical of matter.
- Q So you feel that in 2000 there would not have
- 7 been anything to study on -- related to transgender
- 8 people?

9

- MR. CANTRELL: Object to form.
- 10 A Not nothing, but sort of -- it was -- a lot of
- 11 this research came after 2000, a lot of which we
- 12 discussed. But that said, that research training would
- 13 not have talked about diagnoses. They may have talked
- 14 about criterion perhaps --
- Q (By Mr. Richardson) Okay. 15
- A -- if I had studied, you know, that. I had a
- 17 professor who I didn't take a class with, but who had
- 18 written -- wrote in gender identity so -- at the
- 19 Carolina Population Center, but I didn't take a class
- 20 from him.
- 2.1 Q So there were courses, then, offered during
- 22 your academic training about gender identity, you just
- 23 didn't take them.
- 24 A No. On gender in general.
- 25 Q Gender in general. Okay.

Page 42	Page 44
1 A Yeah. I'm sure there are courses, or at least	1 Q Okay. Great. How would you describe your
2 a course, I did not take it. It was not in my research	2 major areas of research?
3 interests at the time.	3 A Um, I tend to characterize my research as about
4 Q Did you take any courses on gender?	4 relationship behavior, sexual decisionmaking, some about
5 A I just told you I did not.	5 sexuality and family formation, marriage, and some of
6 Q Okay. And did your academic training involve	6 sociology of religion.
7 education on transgender healthcare or transgender	7 Q So looking at your work on relationships, would
8 dysphoria?	8 it be fair to say that work is primarily focused on
9 A My education, no.	9 heterosexual relationships?
10 Q Okay. Have you published any academic books or	10 A Primarily
11 peer review articles in your career?	11 Q Okay.
12 A Yes.	12 A not exclusively.
13 Q How many would you say just roughly?	13 Q Okay. And have you ever conducted research
14 A You want me to count?	14 related to transgender people?
15 Q You don't need to count. Just a rough estimate	15 MR. CANTRELL: Object to form.
16 is all right.	16 A I have fielded a survey that asks a pair of
17 A I have in my bio online I say 40'ish.	17 questions about that, yeah.
18 Q Forty'ish? Okay.	18 MR. RICHARDSON: Okay. Can I get Exhibit
19 A But I'm sure it's probably not 40 exactly.	19 14, please, Beth? Thank you.
20 Q Okay. And books, what, four or five?	20 (Plaintiff's Exhibit 14 was marked for
21 A Four.	21 identification and made a part of the
22 Q Okay. And did any of those works discuss the	22 record.)
23 effectiveness of medical treatment?	THE WITNESS: Your question was again?
24 A No. Um, books did you say?	24 COURT REPORTER: Hold on, hold on.
25 Q The four books or the peer-reviewed articles.	25 THE WITNESS: Sorry. Your question was
Page 43	Page 45
1 A Only public opinion about the effectiveness.	1 what?
A Only public opinion about the effectiveness. Q Okay.	1 what? 2 Q (By Mr. Richardson) Oh, the last question I
 A Only public opinion about the effectiveness. Q Okay. A One article. 	 1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to
 A Only public opinion about the effectiveness. Q Okay. A One article. Q Okay. So it gauged people's views towards 	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people.
 A Only public opinion about the effectiveness. Q Okay. A One article. Q Okay. So it gauged people's views towards care, but not an assessment whether or not care is 	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this
 A Only public opinion about the effectiveness. Q Okay. A One article. Q Okay. So it gauged people's views towards care, but not an assessment whether or not care is effective? 	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes.
 A Only public opinion about the effectiveness. Q Okay. A One article. Q Okay. So it gauged people's views towards care, but not an assessment whether or not care is effective? A Correct. 	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes. Q And can you just describe the research in that
 A Only public opinion about the effectiveness. Q Okay. A One article. Q Okay. So it gauged people's views towards care, but not an assessment whether or not care is effective? A Correct. Q Do any of those works discuss the effectiveness 	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes. Q And can you just describe the research in that article, please?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care?	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes. Q And can you just describe the research in that article, please? A The research or the conclusions or what?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works?	 1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles.	 1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes. Q And can you just describe the research in that article, please? A The research or the conclusions or what? Q Maybe just a brief summary of the research and your conclusions? A The research question was evaluating what
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end	 what? Q (By Mr. Richardson) Oh, the last question I asked was have you ever conducted research related to transgender people. A The data collection that issued in this article, yes. Q And can you just describe the research in that article, please? A The research or the conclusions or what? Q Maybe just a brief summary of the research and your conclusions? A The research question was evaluating what affected American adults' attitudes towards, as the
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay.	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays.	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria."
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did.
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all?	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff.	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff. 20 Q Okay. And do any of these works address	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right? 20 A Correct.
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff. 20 Q Okay. And do any of these works address 21 treatment for gender dysphoria?	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right? 20 A Correct. 21 Q Okay. And were the people surveyed
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff. 20 Q Okay. And do any of these works address 21 treatment for gender dysphoria? 22 A The peer reviewed stuff you mean?	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right? 20 A Correct. 21 Q Okay. And were the people surveyed 22 transgendered people?
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff. 20 Q Okay. And do any of these works address 21 treatment for gender dysphoria? 22 A The peer reviewed or the books to the extent	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right? 20 A Correct. 21 Q Okay. And were the people surveyed 22 transgendered people? 23 A They were it was a nationally representative
1 A Only public opinion about the effectiveness. 2 Q Okay. 3 A One article. 4 Q Okay. So it gauged people's views towards 5 care, but not an assessment whether or not care is 6 effective? 7 A Correct. 8 Q Do any of those works discuss the effectiveness 9 of psychological care? 10 A The published works? 11 Q The four books or the peer-reviewed articles. 12 A Right. No. I have written essays towards this 13 end 14 Q Okay. 15 A But not peer reviewed essays. 16 Q Gotcha. Do any of these works, the 17 peer-reviewed articles or the academic books, assess the 18 efficacy of medical interventions at all? 19 A Not the peer-reviewed stuff. 20 Q Okay. And do any of these works address 21 treatment for gender dysphoria? 22 A The peer reviewed stuff you mean?	1 what? 2 Q (By Mr. Richardson) Oh, the last question I 3 asked was have you ever conducted research related to 4 transgender people. 5 A The data collection that issued in this 6 article, yes. 7 Q And can you just describe the research in that 8 article, please? 9 A The research or the conclusions or what? 10 Q Maybe just a brief summary of the research and 11 your conclusions? 12 A The research question was evaluating what 13 affected American adults' attitudes towards, as the 14 title says, "Hormonal or Surgical Interventions For 15 Adolescents Experiencing Gender Dysphoria." 16 Q Gotcha. And you tested that through a survey? 17 A I did. 18 Q Okay. And was that the 2018 Post-Mid Term 19 Election Study; is that right? 20 A Correct. 21 Q Okay. And were the people surveyed 22 transgendered people?

- 1 included in this. Let me see what -- we have a -- if
- 2 you see on Table 1.
- 3 Q Yes.
- 4 A Page -- well --
- 5 Q It's not paged.
- A Well, no page. Table 1, far right column,
- 7 percent of N.
- Q Um-hum.
- A Go down to self IDs as transgender. It's the
- 10 fifth from the bottom.
- Q Yeah.
- 12 A 1.7. So 1.7 percent of the population weighted
- 13 in that survey self-identified as transgender.
- Q Okay. The survey, because it's nationally
- 15 representative, it's largely about cisgender people's
- 16 view towards gender-affirming care for transgender
- 17 adolescents.
- 18 A Could you repeat that?
- 19 Q So is the survey largely based on cisgender
- 20 people's approval or disapproval of gender-affirming
- 21 care for transgender people?
- 22 A Yeah, the study -- the survey itself --
- 23 Q Yeah.
- 24 A -- okay, asked all sorts of questions.
- 25 Q Yeah.

Page 47

- A And like any researcher, we take what we're 1
- 2 interested in looking at and includes control variables,
- 3 et cetera. So what emerges was our interest in knowing
- 4 what the people, quote/unquote, thought about hormonal
- 5 and surgical interventions for adolescent transgender
- 7 Q Gotcha.
- A So insofar as that's the question you asked, is
- 9 that right?
- 10 Q Yes, yes.
- 11 A Okay.
- 12 Q So it's fair to say that in your study, the
- 13 vast majority of people surveyed on the question you
- 14 care about were transgender people?
- MR. CANTRELL: Object to form. 15
- 16 A They were not -- they are not transgender,
- 17 correct.
- Q (By Mr. Richardson) Okay. And these were not
- 19 experts you were surveying. These were just regular 20 folks.
- 21 A Regular people.
- Q Okay. Great. And did that paper at all
- 23 discuss the efficacy of the treatment for adolescents
- 24 that's being discussed?
- 25 A No, I don't believe so.

1

- Q Okay. Did you interview or talk with any
- 2 transgender youth as part of that work?
- A For this, no.
- Q Okay. Did you interview or talk with any
- 5 healthcare providers who treat transgender youth as part

Page 48

- 6 of this work?
- A Not as part of this study, no.
- Q Okay. So just stepping back, this is the one
- 9 study that came to mind on transgender people; right?
- 10 Nothing else?
- 11 A Peer reviewed.
- 12 O Nothing peer reviewed or in an academic book.
- 13
- 14 Q So would it be fair to say that transgender
- 15 people and gender dysphoria are not the primary subjects
- 16 of your research?
- 17 A It's fair to say that I have had a more active
- 18 interest in this area in the past, I'd say, three
- 19 years ---
- 20 Q Okay.
- 21 A -- four years. So I'm moving in that
- 22 direction.
- 23 Q Okay. But if I was to focus on the
- 24 peer-reviewed work and the academic books, would it be a
- 25 fair characterization that transgender people are not

Page 49

- 1 the primary focus of those works?
- A I have a variety of research interests --
- 3 Q Yeah.
- A -- and one of the things that's characterized
- 5 my entire career is that I have studied in an area for
- 6 several years, get interested in a different area --
- 7 Q Yeah.
- 8 A -- for several years --
- 9 Q Yeah.
- 10 A So you might say, oh, you have done a lot in
- 11 the relationship behavior, domain, heterosexual
- 12 relationship mostly, again, because I'm mostly geared
- 13 towards what the average American population expresses.
- 14 But that I started in -- 1994 I went to graduate
- 15 school --
- 16 Q Um-hum.
- 17 A -- mostly sociology of religion. I changed a
- 18 little bit of directions toward sexual relationship
- 19 behavior and decisionmaking in 2005'ish, and, you know,
- 20 in the last several years I've turned with a more
- 21 interest in these matters. So that is not yet reflected
- 22 in the academic peer-reviewed publication record.
- Q Okay. So your -- your peer-reviewed
- 24 publication record confining to that, it would be fair
- 25 to say, does not yet reflect a primary interest in

Page 50 Page 52 1 transgender people? 1 Q Okay. Some --A It does not yet reflect my current interest in 2 (Simultaneous crosstalk.) 2 3 it, no. A -- research. Q Understood. And earlier when I asked you your Q So students, they're learning about 5 primary areas of research you said relationship 5 quantitative analysis methods. They are --6 behavior, sexual decisionmaking, sexuality, family A They are learning about quantitative in that 7 class, they are learning about qualitative methods in 7 formation, and the sociology of religion. A That has characterized my publication record. 8 that class. 9 Q And none of those are about transgender people? 9 Q Gotcha. 10 MR. CANTRELL: Object to form. 10 A Um-hum. 11 A I don't make explicit reference or forays of 11 Q Okay. And they'll be looking at different data 12 research into that in my published research until very 12 sets to try things out or to do their own research? I'm 13 just trying to figure out --Q Okay. And when you say published research, if A Right. 14 14 15 15 we're talking about peer-reviewed research --Q -- what they do in this course. (Simultaneous crosstalk.) 16 A Right. 17 Q -- you mean just this one survey? 17 MR. CANTRELL: Object to the form. 18 A Correct. A It depends on how I run the class. But I'll 18 19 Q Okay. Thank you. Okay. So you mention you 19 ask them to analyze existing statistics and conduct 20 currently teach, it was in introductory sociology 20 their own interview data. So different methods teachers 21 course. You teach that three sections a year, and then 21 do a little bit differently. 22 you have the seminar. 22 Q (By Mr. Richardson) Gotcha. So medical 23 23 research would come into play there the same as any A Not an introductory sociology. 24 Q I'm sorry. What was that course? 24 other kind of research, might as like an example they A Research Methods --25 could look at for data? 25 Page 51 Page 53 A Right, but it's not something that I focus on. Q Research Methods course. 1 1 2 A -- for majors. 2 Q Okay. 3 Q Gotcha. Okay. And then you have the 3 A Since they are sociology students they --4 4 upper-level course, Catholicism and Social --A It's not an upper-level course. 5 A -- they would like certain topics more than 5 6 others. So mostly I stick to social research --Q Sorry. I'm --6 7 7 A It's a freshman course. Q Yeah. 8 8 Q All right. Sorry. I'm not in academia so I A -- examples. 9 apologize. Q So sociology students generally don't study at 10 medicine. 10 A Not at all. Q So those are the courses you're currently 11 A That is correct. 11 12 teaching? 12 Q And don't have an interest in looking at A Currently. 13 medical --13 14 Q Okay. 14 A That is correct. Q -- data. So do any of those courses relate to 15 15 A Um-hum. 16 psychology or mental healthcare? 16 Q Do any of those courses relate to medical care? 17 A More overlap in psychology. 17 A Research methods I use a variety of medical 18 Q Okay. And for the same reason, because of the 18 examples in it. Some social, some medical, some 19 political, some religious examples. So we have a 19 methods course? 20 A I'm sorry. 20 section about experimental research, which is not common 21 21 in sociology, but some people do it. So I will use a Q And is this because of the methods course or 22 because of the seminar? 22 medical example --23 A The methods course. 23 Q Okay. 24 Q It's the methods course. 24 A -- occasionally, but not a -- it's not a course 25 that's focused on medical research --25 A Yeah.

Page 54 Page 56 Q Okay. And is that --Q Gotcha. And then in the -- in the seminar 1 2 A You know, it is a social science --2 there is one day on gender identity? Q Yeah. A About a day, yeah. No more than a day. A -- and so there's a good deal of overlap Q Okay. And the emphasis there is about the 5 between psychology and social psychology. 5 views of the Catholic church on gender identity or --6 So more of my examples would come from psychology than A Catholicism in general and understanding what 7 from pure medicine. 7 the teachings of the church say on this and what Q Gotcha. And do these -- would the students be 8 Catholic thinkers of various sorts, how they understand 9 learning how to test the efficacy of a mental health 9 that. 10 treatment as part of this work? 10 Q Okay. And thinking back before your current 11 A No. 11 2-2 course load, have you ever taught courses related to 12 O Okay. Do any of those courses relate to gender 12 gender identity? 13 A No. Q How about gender dysphoria? A Again, as examples I might use one as a measure 14 15 example or a -- a sort of a professional scenario --15 A A course on gender dysphoria? Q Um-hum. 16 Q A course that had gender dysphoria as a primary 17 A -- especially when we're talking about 17 subject to be covered in the course. 18 measurement issues, because I think some of the things 18 A No. Q Okay. And have you ever practiced medicine in 19 about -- for example stigma. There's a lot of 19 20 any way? 20 disagreement about how to measure it, so I use that 21 example with students in the class. 21 A Only at home. Sorry. I mean --22 Q Have you ever provided metal healthcare? Q Okay. But gender dysphoria is not -- not a 23 primary focus of the work? 23 A We're talking about professional? 24 A No. 24 Q Professional. 25 Q And do you teach any courses related to gender 25 A Not professional mental health. A listening Page 55 Page 57 1 identity? 1 ear --2 2 A I don't. Q Yeah. 3 3 Q Okay. And thinking back to earlier courses you A -- with regularity. 4 taught in your career --Q Okay. And have you ever worked in a medical or A I do briefly discuss it in my seminar class. 5 mental health clinical setting of any kind? 5 Q How does that come up? A Uh, Catholicism and social thought, it's one of Q Have you ever consulted with those working in a 8 the domains. I think we cover it no more than one day. 8 medical or mental health clinical setting as part of 9 About how the Catholic church understands gender your professional work? 10 MR. CANTRELL: Object to form. 10 identity, yeah. Q Okay. So looking across the two courses you 11 A Consulted as -- can you give me an example of 11 12 currently teach --12 that looks like? Q (By Mr. Richardson) Sure. Has doctor at a 13 A Um-hum. 13 Q -- there is no primary focus on any of these 14 clinic ever reached out to you for consultation in how 15 issues in the methods course and then there is one day 15 they provide their care? 16 on gender identity in the seminar. A Not in how they provide their care. I'm sure 17 A Say that first part again. Sorry. 17 I've talked to doctors about some of the directions in Q So for the methods course, there is no primary 18 which pediatric medicine is flowing, but not as sort of 19 focus on medical interventions, psychological care, or 19 a here is how you should do your job kind of 20 gender dysphoria? 20 conversation. 21 MR. CANTRELL: Object to form. 21 Q Okay. So those doctors aren't reaching out to 22 A Not a primary focus. 22 you for guidance on how to provide care? 23 Q (By Mr. Richardson) It comes up as an example? 23 A Illumination about trends. 24 A References and, you know, measures, methods and 24 Q So they are reaching out to you to understand 25 that sort of thing. 25 trends in medicine?

Page 58 Page 60 1 A More like trends popularly. Right? A Not that I'm -- you know. 2 Q So help me understand. So a doctor has a 2 Q Okay. 3 patient and they would call you --A I don't think so. A Usually it's not a particular patient. Q Okay. So we have walked through, you know,

- A They are just -- and these are typically social
- 7 exchanges.
- Q Okay. 8
- A It's not like, Hey, I heard that you are good
- 10 at X, Y, and Z. You know, they might seek me out in a
- 11 conversation. Typically I already know these people.
- 12 O Okay.
- 13 A We don't discuss particular patients that I
- 14 have recalled. But some people know that I'm a
- 15 sociologist who is active in this domain and research
- 16 area and, you know, they want to chat.
- 17 Q Okay. So these are -- these are social
- 18 interactions. These aren't doctors formally reaching
- 19 out --
- 20 A Correct.
- 21 Q -- for guidance? Okay. Have you ever been
- 22 part of a group that established or revised medical
- 23 standards?
- 24 A Not medical standards. Survey, research.
- 25 Q Okay. And what were those experiences?

- 13 A Peer reviewed? 14 Q (By Mr. Richardson) Yes.
- 15 A I have things that I have put down in essay
- 16 form --

12

17 Q Yeah.

A Yeah.

11 medical care?

18 A -- things that I have put down in these reports

5 your academic training, your professional experience,

Q Would it be fair to say that you have no

10 peer-reviewed scholarship related to the efficacy of

MR. CANTRELL: Object to form.

9 academic training, professional experience or

6 teaching otherwise, and your peer-reviewed scholarship.

- 19 and, you know, sort of actively working on keeping up to
- 20 date on this research form, not reflected in peer-
- 21 reviewed publications.
- Q Okay. So we'll get to the work outside of the 22
- 23 peer-reviewed context. So would it be fair to say,
- 24 then, that you have academic training, professional
- 25 experience or peer-reviewed scholarship related to the

Page 59

- A Oh, a long time ago I helped consult with the 1
- 2 National Longitudinal Study of Adolescent Health, which
- 3 is now the National Longitudinal Study of Adolescent and
- 4 Adult Health I think.
- 5 COURT REPORTER: Say that one more time.
- 6 I'm sorry. The what?
- 7 THE WITNESS: Sure, sure. I'm sorry.
- 8 The National -- the title today is National Longitudinal
- 9 Study of Adolescent and Adult Health.
- 10 Way back at the beginning of their, I
- 11 think it was their first of second wave of data
- 12 collection. National Study of Family Growth, I have
- 13 consulted on, uh, survey items of theirs. I have
- 14 fielded three surveys of my own, four. But that's not
- 15 really consulting.
- 16 And your original question was --
- 17 Q (By Mr. Richardson) Have you ever been part of
- 18 a group that established or revised medical standards?
- 19 A Medical standards. By medical standards you
- 20 mean like treatment, protocols, things like this?
- Q That would certainly be included. Is there
- 22 anything else that comes to mind on a broader
- 23 definition?
- 24 A I don't think so.
- 25 Q Okay. So that's a no?

- 1 efficacy of medical care?
- 2 MR. CANTRELL: Object to form.
- 3 A Efficacy of medical care.
- Q (By Mr. Richardson) Yes.
- A Well, if you want to talk about -- you know, I
- 6 don't know if you have this example, it's a publication,
- 7 with you, the Hatzenbuehler article, 2016, 2017. I
- 8 guess it's less about medical care and more about my
- 9 assessment of the sort of methodological accuracy of
- 10 their work. He's involved squarely in this domain,
- 11 especially in the study of stigma.
- 12 Q Sorry. When you say "this domain," what do you
- 13 mean by that?
- A The domain of sexual and gender identity --
- 15 Q Okay.
- A -- and health outcomes. Let me take a look at
- 17 my CV. That's about health outcomes, not about
- 18 prescriptions for things. Although, Hatzenbuehler --
- 19 there is often prescriptive interpretations to these
- 20 studies. And so when I -- you know, when I show that
- 21 his 2014 article on structural stigma was not -- I
- 22 couldn't replicate the essential finding, and then he
- 23 admitted that it was, I believe, a coding error or
- 24 something like that.
- 25 Q Okay. And -- I'm sorry. Where is this on your

Page 61

Page 62

1 CV? I'm just trying to follow along here.

- 2 A 2017.
- 3 Q Okay.
- 4 A "Structural Stigma's Effect on the Mortality of
- 5 Sexual Minorities" --
- 6 O Gotcha.
- 7 A -- "Robust. Failure to replicate the results
- 8 of a published study."
- 9 Q Gotcha.
- 10 A So in that original study, if I'm not mistaken,
- 11 and I -- if you have a copy I would appreciate being
- 12 able to look at it. In his original study he'll often
- 13 sort of makes real world or medical recommendations
- 14 based on the findings of his study. So when one comes
- 15 along and can't replicate his study he basically
- 16 declares it invalid and then his study is retracted. I
- 17 didn't make any sort of --
- 18 Q Yeah.
- 19 A -- medical claims about, you know, ignore
- 20 whatever Hatzenbuehler says about structural stigma.
- 21 I'm just saying this study isn't -- isn't correct.
- 22 Q Okay.
- 23 A So I didn't offer medical advice in it,
- 24 although undermining somebody who has, it's tacit, a
- 25 suggestion to, you know, think again before using this

So you can map, you know, when people who are

- 2 participating in the general source survey passed way
- 3 and you look at what they are like, et cetera. And so
- 4 he had made the claim that stigma against sexual
- 5 minorities led to premature deaths. Stigma among your
- 6 neighbors, basically those who lived in the same county
- 7 with you -- which is a generous definition of neighbors.
- 8 Sometimes that's how research works -- led to the
- 9 premature death of sexual minorities by 12 years.
- 10 I read that. This was already in print or had
- 11 been through a peer-reviewed process. One of the
- 12 co-authors did the data merge. He's well familiar with
- 13 public health, all of them, like distinguished positions
- 14 in the academy. And I thought, how is it that you would
- 15 have thought that stigma could knock off more years of
- 16 somebody's life than smoking a pack a day for 20 years.
- 17 So that made me suspicious.
- 18 O Okay.
- 19 A And so I and my research assistant pursued a
- 20 replication of the study. I presume it would be
- 21 replicable. And then able to find, like, how did it do
- 22 this? Let's look at some alternative arrangements. But
- 23 we could not actually replicate the original study,
- 24 especially on the key effect.
- 25 Q Gotcha. And do you think somebody in the

Page 63

- 1 article as a suggestion about medical treatment, but not
- 2 direct advice from me.
- 3 Q Okay. So you've -- so once again, your
- 4 academic training, professional experience,
- 5 peer-reviewed scholarship includes no research from you
- 6 that would be used to assess the effectiveness of a
- 7 medical treatment?
- 8 MR. CANTRELL: Object to form.
- 9 A Only indirectly if people had decided that
- 10 whatever Hatzenbuehler's claim was in this paper was not
- 11 valid.
- 12 Q (By Mr. Richardson) Okay. And Hatzenbuehler,
- 13 do you know his -- is he a -- he or she. Sorry.
- 14 A Public health.
- 15 Q Public health. Okay.
- 16 A Same first name.
- 17 Q So this study from 2017 is, you know,
- 18 Hatzenbuehler had a study saying structural stigma
- 19 caused some kind of harm; correct?
- 20 A Oh, yeah. He said it lopped off an average of
- 21 10 -- no -- 12 years of life from sexual minorities,
- 22 sexual and transgender minorities, but I can't remember
- 23 that for sure. In -- and this is a national study of
- 24 the general social survey, population based, attached to
- 25 the National Death Index.

Page 65

- 1 medical profession would have used Hatzenbuehler's study2 to decide whether a particular treatment protocol was
- 3 appropriate for a patient?
- 4 MR. CANTRELL: Object to form.
- A I wouldn't know that. I just know that there
- 6 is research in this domain that employs data and methods
- 7 that are not as strong as they ought to be and make
- 8 claims about it and seem to have reached into the
- 9 clinical domain.
- 10 Q (By Mr. Richardson) Okay.
- 11 A But I cannot confirm those.
- 12 Q So you don't know what kind of materials
- 13 medical doctors consult to determine treatment
- 14 protocols?
- 15 A Okay. Switching gears here. Could you repeat
- 16 that question?
- 17 Q So when I asked you about Dr. Hatzenbuehler's
- 18 report, if it was used by medical professionals to treat
- 19 patients, you said you don't know.
- 20 A I do not know, no.
- 21 Q And so you don't know if your research
- 22 rebutting his report would have been used by medical
- 23 professionals to treat patients?
- 24 A I don't know that.
- 25 Q And that was the only article you mentioned

Page 66 Page 68 A I said I have no idea. 1 when I asked you for relevant writing about --2 O You have no idea. A I will say one thing, if I may. 3 3 Q Okay. Sure. A Yeah. 4 A His articles were retracted, but it was only Q So you don't know if a doctor would, you know, 5 gain anything from reading either Exhibit 14 or your 5 retracted after I finally wrote the journal publisher, 6 paper rebutting Dr. Hatzenbuehler? 6 because both of our articles remained in print at the 7 MR. CANTRELL: Object to form. 7 same journal, Social Science and Medicine, and, uh, his 8 was quite popular and continued picking up citations at 8 A Since I don't keep active track of citations 9 a pretty good clip, and mine saying there's no evidence 9 for this, I don't know. One can go into the citation 10 that this is -- there is active evidence that this is 10 index, see how it's been cited, both of these papers, by 11 whom. So it's plausible and even possible that it has 11 factually false and he admitted it already in print. 12 And, you know, I wasn't racking up many citations at 12 indirect applicability by peer-reviewed articles that 13 all, so I finally said, These two can't really be in 13 have cited these studies. 14 Q Okay. 14 print at the same time, and eventually the editors 15 A But I have not paid attention to that. 15 agreed and retracted his. Q And that would be peer-reviewed literature in 16 But whether, you know, that changed anybody's 16 17 mind in a clinical setting, I have no idea. 17 medical journals that you have in mind? 18 A Yeah. I mean, it's searchable. Q Okay. So you don't know if your paper would 19 have any utility to a medical provider determining 19 Q Okay. And you don't keep track of --20 A So Social Science and Medicine is a crossover 20 whether or not to provide a certain treatment to a 21 journal between --21 patient? 22 MR. CANTRELL: Object to form. 22 Q Yeah. 23 23 A -- both science -- social science and medicine. A I have no knowledge of that. 24 Q (By Mr. Richardson) And that was the only --24 Q And you don't know if it's being used for that 25 purpose because you don't keep track of what's in 25 A I'm not sure how I could. Page 69 Q And that was the only paper you brought up when 1 medical journals? 1 2 I asked for peer-reviewed scholarship related to the 2 (Simultaneous crosstalk.) 3 efficacy of medical care; correct? 3 A -- my citation index. Q Okay. Do you keep track of what's published in A About the sort of -- from a physician's 5 perspective of this last one we talked about sort of 5 medical journals? 6 popular assessment of medical permissibility, which I A Do I keep track of what's published in medical 7 presume has something to do with perceived efficacy, but 7 journals? 8 it's not about physicians, per se. It's about 8 MR. CANTRELL: Object to form. 9 physicians conduct. 9 Q (By Mr. Richardson) Yeah. 10 Q Okay. So your survey, then, this Exhibit 14, A As I indicated earlier, I asked my research 10 11 is that what you're referring to? 11 assistant to kind of keep an eye on what's coming out 12 A Correct. 12 and send me things that she finds interesting. Q Okay. Your survey, you're saying that, at some 13 Q Okay. 14 level, tells you something about the effectiveness of 14 A So I do keep track some, not for the purpose of 15 gender-affirming care? 15 seeing if my name appears in print, but seeing about A No. It tells readers about what Americans 16 what's going on. 17 think of who ought to be eligible for particular kinds 17 Q Okay. So not to belabor it, but --18 of interventions. 18 A All right. 19 Q Okay. And you just said that a doctor would 19 Q So when I ask you for relevant peer-reviewed 20 consider that kind of public opinion irrelevant 20 scholarship regarding the efficacy of medical treatments 21 when deciding on a treatment protocol? 21 you pointed me towards --MR. CANTRELL: Object to form. 22 22 A Say it like it's -- start slowly, please. 23 A You're saying I said it? 23 Q Peer-reviewed scholarship related to the 24

24 efficacy of medical treatments. You pointed me to

25 Exhibit 14, which is the survey, and a paper you wrote,

25 I thought --

Q (By Mr. Richardson) Correct me if I am wrong.

Page 70 Page 72 1 I believe in 2016 or 2017, refuting Dr. Hatzenbuehler's 1 right. 2 research on stigma; correct? 2 MR. CANTRELL: Okay. I'll continue to A Not refuting. Finding that it was not --3 object. 4 Q Sure. 4 THE WITNESS: So could you repeat that? A It's a mistake. Q (By Mr. Richardson) Would it be fair to say Q Yeah. The inability to replicate 6 you have no academic training, professional experience, 7 Dr. Hatzenbuehler's study. 7 or peer-reviewed scholarship related to the efficacy of 8 psychological care? A Yeah. It was, you know -- correct. 9 Q Okay. So those are the two. Anything else? 9 MR. CANTRELL: Object to form. 10 MR. CANTRELL: Object to form. 10 A Efficacy of psychological care. We're talking 11 A Publications. Influence? Peer reviews? 11 about psychiatry, psychotherapy? 12 O (By Mr. Richardson) Peer-reviewed scholarship 12 O (By Mr. Richardson) The kind of thing that 13 that would relate --13 would be considered by a mental health provider in 14 A Written by me. 14 deciding the appropriate course of treatment. Let's put 15 Q Written by you. 15 it that way. 16 A Okay. You're not counting my work on -- as a A Which could be both psychiatry or psychology; 17 peer reviewer of journal articles in these domains? 17 right? I mean, some of my work, I think tracks the 18 direction of social psychology. But whether 18 O No. sir. 19 A Okay. Because that also happens. 19 providers -- you know, I hear from counselors. Do you 20 Q So those are the two? 20 consider counselors psychological care? I sort of 21 A I believe so. 21 would. 22 Q Okay. And you -- is it correct that you told 22 Q Do you mean like school counselors or what do 23 me that you're not sure if either of those would be 23 you have in mind? 24 relied on by a medical doctor deciding whether or not to 24 A Psychotherapists, people who are -- somebody is 25 on the couch talking to them about their issues. 25 provide certain treatment? Page 73 Page 71 MR. CANTRELL: Object to form. 1 Q Sure. So have they told you they consult your 1 2 A I would not know it if they did. 2 research, your peer-reviewed research? 3 Q (By Mr. Richardson) So you don't know? A I'd say, the book Cheap Sex has been talked 4 A That is correct. 4 about a lot, including by counselors. And whether they 5 Q Okay. And would it be accurate to say that you 5 take it up with their patients I don't know. But that 6 don't have academic training, professional experience, 6 one has had a long track record, and especially with 7 or peer-reviewed scholarship related to the efficacy of 7 regards to people, you know, counselors talking to 8 psychological care? 8 patients or -- about the things that they could learn 9 from that book. MR. CANTRELL: Object to form. 10 A Efficacy of psychological care. So we're 10 Q Gotcha. 11 moving from medical care to psychological care? A So it's a little bit like the last example 12 MR. CANTRELL: Dan, could we take those 12 where I won't know except as if they've reached out to 13 one at time? You're listing a and/or I think --13 me. Some have done so and sort of thanked me for it, MR. RICHARDSON: Well, yeah. If there is 14 you know, it's helped them in talking to people. 15 anything in any category the answer would be yes, I have 15 But -- so a little more demonstrable in terms 16 something. So I think I just want to get a summary of 16 of the things I hear back from people than in the 17 the three things we talked about. Because I asked those 17 medical community, which I wouldn't hear from. Make 18 sense? 18 questions within each topic. So if there is any 19 relevant experience within any three I think the answer 19 Q Yeah, I think so. 20 would be that statement is not accurate. 20 A It's kind of wordy. MR. CANTRELL: I just think it might be 21 Q I'll just put a finer point on it if that's all 22 helpful to ask one at a time. 22 right to help make it a little more concrete. 23 MR. RICHARDSON: Well, I think we walked 23 Would it be fair to say that you don't have 24 through each category. So I just to -- I'm trying to 24 academic training, professional experience, or 25 summarize sort of what we've heard so far if that's all 25 peer-reviewed scholarship related to the efficacy of

Page 74 Page 76 1 treatment for gender dysphoria? Q Okay. But you don't recall any essential 2 MR. CANTRELL: Object to form. 2 interactions of medical professionals where they ask for 3 A True. 3 views on the direction of medicine in this area or 4 MR. RICHARDSON: Okay. I think if it's 4 gender identity broadly? 5 all right with you, now might be a good time for a A Just, you know, in passing sort of like --6 break. Does that sound all right, Doctor? 7 VIDEO OPERATOR: Okay. This will end A -- as a friend of a friend kind of thing. 8 media part 1 and we are off the record at 10:22 a.m. Q Okay. What would you typically say in response 9 9 to a question like that? (A break was had.) 10 VIDEO OPERATOR: We are back on the 10 A Some of the same things I've said in my report. 11 record at 10:35 a.m. This will begin media part 2. 11 You know, I think the research methodology we hear is 12 Please proceed. 12 often problematic, measurements, analytic procedures 13 MR. CANTRELL: Let's go ahead and put on 13 that are questionable, measures that are questionable, 14 the record those who came in. 14 effects and effect sizes that are questionable. 15 MR. SULLIVAN: This is Gary Sullivan with 15 Um, yeah, it's fair to say that I'm -- I find 16 the ACLU of Arkansas for the plaintiffs. 16 the domain of research not what it ought to be and not 17 MS. COOPER: Yes. This is Leslie Cooper 17 what it tends to be in other domains of medicine so far 18 of the ACLU for plaintiffs. 18 as I can tell. MR. RODGERSON: This is Brandyn 19 Q Okay. You mentioned that you've written some 20 Richardson of Sullivan & Cromwell, LLP, for the 20 non-peer-reviewed pieces relevant to transgender people; 21 plaintiffs. 21 right? 22 MR. RICHARDSON: Is that everybody? 22 A Yes. Q (By Mr. Richardson) All right. Great. I'd 23 Q Okay. I'm going to show you Exhibit 5. 24 like to pick up where we were just talking about, but 24 (Plaintiff's Exhibit 5 was marked for identification and made a part of the 25 focus solely on peer-reviewed scholarship that you have 25 Page 75 Page 77 1 authored. 1 record.) 2 2 A Thank you. A Okay. 3 3 Q Do you recognize that document? Q Would it be fair to say that you have no 4 4 peer-reviewed scholarship on the effectiveness of A I do. 5 medical treatment? Q Is this an article you wrote in Public 6 Discourse entitled "Arkansas and the Politics of MR. CANTRELL: Object to form. 7 Experimenting on Children." 7 A Not at present. 8 A Correct. Q (By Mr. Richardson) Okay. Thank you. And 8 9 earlier in a response to a question I asked you Q Does this piece contain any independent 10 research about the effectiveness of medical or 10 mentioned that doctors sometimes will come to you to 11 talk about the overall direction of research. Do you 11 psychological treatment? 12 remember saying that? 12 A I would have to go back and read it --A Socially some may ask me about, you know, 13 14 what's going on, like, culturally about what's going on 14 A -- and give it a three, four-minute skim and 15 then ask that question again? 15 with marriage. Q Will do. 16 Q Do they ever come to you to talk to you about 17 (The witness reviewed the document.) 17 the research of gender identity or gender dysphoria? A Research in particular? I don't recall 18 Q Apologize, professor. How is it coming? 19 conversations towards that end. They may have occurred 19 A I've got about two pages left. When I've 20 written something I usually move on to the next thing 20 socially. 21 21 Q But nothing comes to mind? Q I understand. 22 A So I appreciate the chance of going back to see A Not as, you know, they will leave a message on 23 what I said. 23 my phone saying I'm doctor so-and-so from Houston, I 24 24 wanted to consult with you on the research. Not like (The witness reviewed the document.) 25 Q Is this piece published in Public Discourse? 25 that, no.

Page 78 Page 80 1 A Yes. 1 write, I think it was another Public Discourse piece 2 Q Is Public Discourse a peer-reviewed journal? 2 about calculating the number needed to treat, which is 3 A It's reviewed by the editorial team. 3 an epidemiological statistic and found it rather high. 4 Q Yeah. 4 It's basically a signal of, um -- a signal of small 5 A Which I am on for a particular domain. 5 effect size. And given that that entity was about -- I O But you wouldn't --6 think it was about surgeries, surgery is kind of a 7 7 significant thing. So I thought small effect over ten A So we don't send it out to other people unless 8 years, I think it was, especially in the tenth year, 8 it involves, at least in my domain, unless it involves 9 ninth, tenth year is where you started to see the effect 9 some topic or form of methodology that, at least in my 10 domain, that I don't understand. But I don't typically 10 of surgery on improved medical -- improved use of 11 do that. The other editors might. It's not 11 psychotherapy services if I recall correctly. 12 peer-reviewed in that we send it all to academics, 12 But I thought, well, an entity of 49 is -- is 13 because some of the people who submit stuff are not 13 pretty high. You have to treat 49 people before you can 14 academics. 14 expect to demonstrably help one out in this outcome. Q Okay. So when I asked for peer-reviewed 15 So --Q Okay. But --16 articles and if I look at your CV for peer-reviewed 16 17 articles --17 A It's not peer reviewed, no. I reported it in a 18 A I don't put this in that --18 previous issue of Public Discourse. 19 O Public Discourse --19 O Gotcha. And this NNT calculation doesn't 20 A -- classification. 20 appear in Exhibit 5? 21 Q Gotcha. 21 A No. A link to the one that it refers to does. 22 A Right. 22 MR. RICHARDSON: Gotcha. Okay. 23 23 Can we get Exhibit 7, please, Beth? Q Gotcha. And after having reviewed it does this 24 piece contain any independent research by you about the 24 THE WITNESS: Is that that one? MR. RICHARDSON: Good guess. 25 effectiveness of mental or psychological treatment? 25 Page 79 Page 81 MR. CANTRELL: Object to form. (Plaintiff's Exhibit 7 was marked for 1 1 2 2 A Not so much independent -- actually what kind identification and made a part of the 3 of research? 3 record.) 4 Q Research about the effectiveness of THE WITNESS: I'll need less time with 5 psychological or medical treatment. 5 this, but a couple of minutes still. Thank you. MR. CANTRELL: Form. (The witness reviewed the document.) 7 A So one of the references in here on whatever THE WITNESS: Okay. 8 page -- it doesn't have a page -- a study released last Q (By Mr. Richardson) So you recognize that 9 month in the Journal of Sexual Medicine -- no, not that 9 document? 10 one. I'm sorry. A study appearing in the October 2019 10 A I do. 11 edition of the American Journal of Psychiatry declared Q And this is your article "New Data Show 11 12 that gender-affirming surgery was associated with 12 'Gender-Affirming' Surgery Doesn't Really Improve Mental 13 Health So Why Are the Study's Authors Saying It Does?" 13 reduced demand for subsequent mental health treatment, a 14 sample of Swedish adults diagnosed with gender A Correct. 15 Q Okay. Great. And this has the number to treat 15 incongruence. Although that conclusion eventually 16 succumbed to a correction, the authors' overreaching 16 calculation? 17 claims about the efficacy of surgical treatment on 17 A Correct. 18 subsequent use of mental health services, the original 18 Q And just to clarify, this is also in Public 19 version had already observed no effect of time since 19 Discourse; right? 20 initiating hormone treatment on the likelihood of 20 A Um-hum. 21 subsequently receiving mental health treatment. 2.1 Q And based on the prior definition, Public 22 After the correction the authors admitted that 22 Discourse is not a peer-reviewed journal. 23 surgeries did not yield the anticipated benefit in 23 A Correct. 24 either. 24 Q Have you ever published that number-needed-25 I did not participate in the correction. I did 25 to-treat calculation in a peer-reviewed journal?

Page 82 Page 84 A I did not. 1 Q And they don't include any independent research 2 Q Okay. 2 that was, at all, published in a peer-reviewed journal 3 elsewhere; right? A I thought about writing the editors of the 4 original journal. I didn't, probably because I felt A Could you restate that? 5 like I had already talked about it publically. And the Q They don't include any independent research of 6 clinical impact that you have published elsewhere in a 6 correction that eventually was issued for that study 7 came from a series of other -- in response to a series 7 peer-reviewed journal? A That I have published elsewhere? I think I 8 of other authors, clinicians, researchers who wrote the 9 journal with similar complaints, but of a different 9 make reference to the Hatzenbuehler piece in one of 10 nature. 10 these or some other Public Discourse. So that has 11 Q Okay. But you didn't write to the journal? 11 appeared in public research. 12 A I did not. 12 O Okay. 13 Q Okay. Gotcha. And is Public Discourse 13 A I think a more recent one talked about this 14 published by the Witherspoon Institute? 14 study, also peer-reviewed. (Indicating) 15 A It is. 15 Q A more recent essay you mean? 16 Q Can you describe the Witherspoon Institute to 16 A I think so. 17 me? 17 Q Okay. Do you know the name of that essay? 18 MR. CANTRELL: Object to form. 18 A Not offhand, no. I think I talked about it. 19 A They are not entirely unlike the Austin 19 MR. CANTRELL: Which study were you 20 Institute. They are kind of a philosophical 20 referring to? 21 organization, non-profit that largely, I think, it began 21 MR. RICHARDSON: It's Exhibit 14. 22 to serve the students of Princeton and have grown to 22 MR. CANTRELL: Okay. 23 have influence outside of Princeton. They teach summer 23 THE WITNESS: I thought I did. It would 24 courses on, like, natural law, stuff like that. 24 have been since whatever, October 2021. You can look it Q (By snao) And you are currently affiliated with 25 25 up. Page 83 Page 85 1 the Witherspoon Institute? Q (By Mr. Richardson) Okay. 1 2 A Oh, am I? I don't recall if I am or not. If A Okay. I thought I did, but --3 it is it's sort of in the same non- -- some sort of Q So in those two essays, Exhibit 5 and Exhibit 4 fellow thing, if I am. 4 7, the only measure of clinical impact or medical Q But you are affiliated with Public Discourse? 5 effectiveness was the number-needed-to-treat 5 A Correct, yeah, which is produced out of their 6 calculation; right? 7 shop, yeah. A That's original to me? Q And what is your role with Public Discourse? 8 Q Original to you, yes. 8 9 9 A Original to me, perhaps. Most of what I do is A Contributing editor. 10 Q Okay. And do you have, like, a portfolio? Is 10 evaluate the methods of what I'm reading. 11 that how it's set up? Q Okay. So the only independent research was the 11 12 A I do. 12 number-needed-to-treat calculation? 13 Q And what is that? 13 A I believe so. A I'm in charge of stuff that comes in on 14 Q And that has not appeared in any peer-reviewed 15 publication? 15 sexuality and family. There is like one, two, three --A That has not. 16 five pillars. If somebody submits something in that 16 17 domain I'll see it, other people will see it, and maybe 17 O Okay. 18 three or four of us will read it, talk back to each A But it is, since I -- as I said in here, it's 18 19 other, vote on it independently and then -- I'm not the 19 publically discernible. You don't need the data to do 20 editor, so whether it shows up in print or not, I 20 that. You just need the article to do that. Anybody 21 usually don't even know because I don't pay attention. 21 with medical training could do it. O Okay. So these are two of the 22 Q Okay. Understood. 23 non-peer-reviewed essays you have written on transgender 23 A Medical statistical training. 24 people or gender dysphoria; correct? 24 Q Okay. A Correct. 25 A Because I describe the formula in the footnote.

1 Q Gotcha. Okay. And are there other essays

- 2 related to transgender people or gender dysphoria beyond
- 3 these two?
- 4 A There may be. You would have to sort of scour
- 5 Public Discourse. I don't keep track. I write three or
- 6 four a year. There is probably some mention of it
- 7 somewhere.
- 8 Q Okay. Have you ever written a piece called
- 9 "Queering Science"?
- 10 A I did.
- 11 Q Did that appear in First Things?
- 12 A It did. It sounds like you know some of the
- 13 answers to these questions.
- 14 Q I did my homework a little bit. Is First
- 15 Things maintained by the Institute of Religion and
- 16 Public Life?
- 17 A I do, but I don't really know what their
- 18 organizational aim is, so --
- 19 Q Do you know the mission of that organization?
- 20 A I don't. I just know that, you know, First
- 21 Things is a journal I deal with occasionally. I have
- 22 written occasional stuff in it.
- 23 Q Okay. Would you it surprise you to learn that
- 24 the mission is to oppose the, quote, ideology of
- 25 secularism?

- 1 support that, that objective?
 - 2 MR. CANTRELL: Object to form.
 - 3 A I confess I haven't really thought about that.

Page 88

- 4 Q (By Mr. Richardson) Okay. I just want to
- 5 follow up on the piece "Queering Science." Do you
- 6 remember roughly what that was about?
 - A You know, I do, but, you know, if you have got
- 8 an example I'd sure love to see it.
- 9 Q I'm just curious. Did anything come to mind
- 10 about that piece, about what that -- what your argument
- 11 was in that piece?
- 12 A I think I probably. I think I probably should
- 13 take a look at it first before I make claims about it.
- 14 As I said earlier, one writes things and you move on and
- 15 I don't always remember what I've said. But I seldom
- 16 retract my own words. Do you have that copy of it?
- 17 Q Well, do you just recall anything about it at
- 18 all or --
- 19 A I do recall --
- 20 Q -- about the argument?
- 21 A -- little bits about it, yeah.
- 22 Q Okay. Do you mind sharing what you recall
- 23 about it?
- 24 A I think it's sort of a criticism of what I
- 25 called in this here, ideological capture of professional

- A No. Because, you know first things -- do you
- 2 know what the reference to "first things" are? Like
- 3 first principles. So I'm not surprised that opposition
- 4 to secularism would be, kind of, one of their first
- 5 things, first principle.
- 6 Q And do you share that, that view?
- 7 A Opposition to secularism? I have to think what
- 8 that means. Generally I don't, when I submit something,
- 9 scour the parent organization's mission statement and
- 10 see if I agree with everything. Just it's an -- a
- 11 journal that I subscribe to, read occasionally, like
- 12 lots of things, you see an issue, eh, wait until the
- 13 next issue. But I published in there on occasion.
- 14 Q And so what do you understand "opposition to
- 15 secularism" to mean?
- MR. CANTRELL: Object to form.
- 17 A What do I understand opposition to secularism
- 18 to mean? Probably that they seek to resist
- 19 understandings of the human person and social order and
- 20 maybe political order as -- a post -- things that would
- 21 neglect a perspective that entails sort of the divine
- 22 creation of persons and, you know, I suspect it's 23 another way of saying that it's Judeo-Christian in
- 24 intent.
- 25 Q (By Mr. Richardson) Okay. And do you broadly

- Page 89
 1 organizations and the movement of research methods and
- 2 survey research design and question wording to kind of
- 3 press for a different understanding of the human person
- 4 than most methods and questions had heretofore.
- 5 Q And do you recall, as part of that essay
- 6 "Queering Science" you provided any independent
- 7 research?
- 8 A You know, I'm really going to have to insist on
- 9 seeing a copy of it.
- 10 Q So you don't recall anything?
- 11 A Just like with these, I would like -- can I see
- 12 a copy of it, and I can tell you.
- 13 Q Do you recall writing a piece called "Does
- 14 Conversion Therapy Hurt People Who Identify As
- 15 Transgender"?
- 16 A For Public Discourse?
- 17 Q That would be for Public Discourse, yeah.
- 18 A Yeah.
- 19 Q Okay.
- 20 A That was, I think, a criticism of probably one
- 21 of Jack Turban's articles, yeah.
- 22 Q Okay. And do you recall that including any
- 23 independent research done by you?
- 24 A I'm going to have to ask to see it, like the
- 25 last two.

1 Q So you don't recall, then, any independent

2 research as part of that article?

- 3 A That, I don't know.
- 4 Q So nothing -- does that mean you can't recall
- 5 anything or you don't know if you can recall anything?
- A I would rather look at it first and then I
- 7 could give you an educated answer about it.
- 8 Q Okay. So I guess I'm just trying to think
- 9 across -- across the articles we have discussed with the
- 10 number-needed-to-treat calculation --
- 11 A Um-hum.
- 12 Q -- did you ever submit that kind of research to
- 13 a peer-review journal and it was not published for
- 14 whatever reason or was it never submitted?
- 15 A No. NNT? I just calculated it and included it 16 in this.
- 17 Q Okay.
- 18 A Typically speaking, in hindsight, yeah, I
- 19 probably could have gone to the editor with it. But I
- 20 wrote that first and then I -- you know, well, now it's
- 21 already in print so it's sort of peer-reviewed stuff
- 22 usually it appears first there and then you write about

Q Have you ever submitted the research that was

A The 1NNT thing, um, you know, the calculation

A You know, it's not enough for a research paper,

Q Okay. So for any research you have done on the

13 effectiveness of care for people with gender dysphoria,

A Not in -- you know, not if you're not counting

Q Okay. And that -- and that article, once

A Right. The kind of attitudes may have been

Q And that would be perceptions held by ordinary

21 again, didn't discuss the efficacy of care. It just

24 perceptions of efficacy; however, I do not know.

14 have you ever submitted any of that to a peer-review

A On care of gender dysphoria?

Q On the effectiveness of care.

19 this article on popular opinion about care.

22 surveyed attitudes towards care; right?

7 1NNT would constitute nothing more than a letter to the

23 it.

5

9

10

16

17

18

23

25

8 editor.

11 per se.

15 publication?

- 24 Q Yeah.
- 25 A But I didn't take that order in that case.

1 What was your original question?

3 reflected in those two essays to --

O -- a peer journal?

A Oh, I see.

Q Okay.

1 folks, not experts?

- 2 A Right.
- 3 Q So to your knowledge you have never submitted

Page 92

- 4 research on the effectiveness of care for gender
- 5 dysphoria to a peer-reviewed publication?
- 6 A Not at present.
- 7 Q Okay. When you say "at present," are you
- 8 currently working on research involving the
- 9 effectiveness of care for gender dysphoria?
- 10 A I don't think so, no, not at present.
- 11 O Okay.
- 12 A Okay. Juggling a variety of topical matters
- 13 and I have not constructed any article on that for peer
- 14 review yet.
- 15 Q So nothing in the pipeline about the
- 16 effectiveness of gender-affirming care or other
- 17 treatments for gender disorder?
- 18 A Not in the pipeline, no.
- 19 Q Okay. Gotcha. And earlier you mentioned you
- 20 serve as a peer reviewer sometimes?
- 21 A Um-hum.
- 22 Q Can you discuss that role just broadly for me?
- 23 A General editors or associate editors, depends
- 24 on who is in charge of a particular submission, will ask
- 25 people in the field to review studies that come to them

Page 91

- 1 that they consider good enough to go out for peer review
- 2 before the editors make a decision about it.
- 3 Q Gotcha. And you would provide your -- your
- 4 views on the quality of that work? Is that how it
- 5 typically goes?
- 6 A Right.
- 7 Q Okay. As a peer reviewer have you ever
- 8 reviewed a piece about gender dysphoria?
- 9 A I take a look at my CV. Somewhere in the back
- 10 I believe I listed -- I think I have, but I don't recall
- 11 which journal or what the article was exactly about. We
- 12 did ask for reviews frequently, some I accept, some I
- 13 don't, you know, pursue.
- But I've -- I've been getting content in the
- 15 sexuality and gender domain, more sexuality than gender.
- 16 It would have been in the last three years and, again,
- 17 like lots of these pieces, especially a review, I will
- 18 read it, write my feedback, send it away, forget it,
- 19 list it in here if it's a new journal.
- 20 Q Got it. So you don't recall any specific
- 21 pieces involving gender dysphoria that you were a
- 22 reviewer for?
- 23 A No, but that doesn't mean I didn't do it
- 24 because it's very possible that I did do it. I mean, I
- 25 see Pediatrics is listed in here. I'm not sure why I

24 (Pages 90 - 93)

Page 94 Page 96 1 would get something from Pediatrics. But, again, I 1 or gender dysphoria. 2 don't -- you know, I don't recall offhand. A The PDs above them, New Data Show and Does Q Gotcha. Do you recall reviewing any works 3 Conversion Therapy Help; right? 4 about the efficacy of medical care of any kind? Q I meant the first chronologically. Sorry. The A I would say the exact same thing. 5 first in time would have been --A Oh. Perhaps, unless there is a Public Q So you don't recall anything specific? 7 A If I was asked to do it, it would be not as, 7 Discourse piece that I didn't list on here, and it's 8 you know, an insider to the medical industry, but as a 8 possible because I don't list them all. 9 methodologist. Q Okay. So the first one that you recall or have 10 Q Okay. But just to clarify, you don't recall 10 listed was in 2018? 11 reviewing any --A 2018? Uh, looks like it. 12 A I don't recall. O And does that broadly track what you were Q Okay. Gotcha. So do you recall any other 13 saying earlier about your interest -- the timeline for 14 essays regarding transgender people other than the ones 14 your interest in gender dysphoria? 15 we have discussed that come to mind? 15 MR. CANTRELL: Object to form. A No. But you have a good list. 16 A What is it, 2022? No. In terms of gender 17 Q I'm just curious if anything that you recall 17 essays? Because the Hatzenbuehler piece I read in I 18 coming to mind. 18 think it's 2014 publication. I read it in 2015. I 19 A No. 19 wrote an article, submitted it, and it didn't appear in 20 Q And just to clarify, I asked you about Exhibit 20 print until 2017. So probably 2015'ish. But one starts 21 5, which is the piece "Arkansas and the Politics of 21 reading and it's long before one starts to write. 22 Experimenting on Children." Q (By Mr. Richardson) Okay. Is the Hatzenbuehler 22 23 23 piece you're talking about, do you think that's related A Okay. 24 Q The piece "Queering Science" that was in First 24 to gender dysphoria? 25 Things. 25 A Not explicitly, no. But I started reading more Page 95 Page 97 A Yeah. There may be others, yeah. 1 widely in the area --1 2 Q And there was the piece "New Data Shows Q Okay. 3 Gender-Affirming Surgery Doesn't Really Improve Mental A -- around then. 4 Health." That's Exhibit 7. Q Okay. But the first written work that's 5 explicitly related to gender dysphoria would be the 5 A Okay. Q And then I asked you about the piece "Does 6 piece "Queering Science" in 2018? 7 7 Conversion Therapy Hurt People Who Identify as MR. CANTRELL: Object to form. 8 Transgender." A Again, I -- my recall is failing me, but it's 9 possible. A So did we talk about "Weak Data, Small 10 Samples"? Did you mention that one? 10 Q (By Mr. Richardson) Okay. If I was looking at 11 your CV --11 Q Where would that be? 12 A Public Discourse, January 2020. 12 A Yeah, CV, correct. Q No. Does that involve gender dysphoria? 13 Q -- would that be an accurate starting point? 14 A I don't know. But it's LGBT discrimination. 14 15 15 Probably not gender dysphoria. Q Okay. Thank you. Okay. What is gender 16 Q Okay. 16 dysphoria? 17 A These are select essays. I don't list them 17 A So far as I understand it -- there may be 18 all. 18 different definitions of it -- it's psychological sense 19 19 of a profound distinction between one's body and one's Q Okay. 20 A Write three or four a year. 20 mind regarding gender or the sexed body. Q And this list on -- on your CV, this is page 6, 21 Q So, as you define it, gender dysphoria is the 22 it looks like the first of these was -- would be 22 feeling of a distinction between --23 "Queering Science," which was in December of '18? 23 A Not just a distinction, but, you know, it's 24 A First of what? 24 equated with negative feelings about that distinction. 25 Q The articles that relate to transgender people 25 Q Okay. So how would you define transgender

Page 98 1 people?

- 2 A Again, open to a measurement of distinctions,
- 3 which is the thing that I care about in this domain,
- 4 probably like persons who self-identify as different
- 5 than their natal sex. It may be opposite that, male to
- 6 female, female to male. It may be something not quite
- 7 opposite, like non-binary or something like that.
- 8 And there is different kinds of gender
- 9 identities, so the trans means, like, across identity,
- 10 cross gender.
- 11 Q Gotcha. Okay. What causes gender dysphoria?
- 12 A Causes gender dysphoria? What is coterminous
- 13 with it or what causes it? In my reading of gender
- 14 dysphoria -- and it depends, I think, if it manifests
- 15 itself in childhood or adolescence, I think there can be
- 16 distinctions there. Sort of a -- what causes gender
- 17 dysphoria?
- When I think about cause I think about, like,
- 19 the conditions under which it's more likely to manifest
- 20 itself, which is necessarily like a direct causation.
- 21 In social science and measurement in general causation
- 22 is sort of a specific thing and so we seldom use it in
- 23 terms because we have to say it is this and nothing
- 24 else.
- 25 It seems to develop in some share of children

- Page 100
 1 any particular patient is or is not. However, there has
 - 2 been a great surge in cases, so one does get a little
 - 3 skeptical when he sees a surge in cases.
 - 4 Q But you don't know how clinicians would
 - 5 diagnose gender dysphoria?
 - 6 A I don't.
 - 7 Q Okay. What is gender identity disorder?
 - 8 A Gender identity disorder is -- give me a
 - 9 moment. When we're talking about dysphorias and
 - 10 disorders it's overlapping but distinctive. So far as I
 - 11 know GID is not a common term that people use at
 - 12 present.
 - 13 A disorder is sort of when people have
 - 14 diagnosed that something is positively wrong about a
 - 15 situation as opposed to or as distinct from something is
 - 16 distinctive. Right? So, for example, I noticed in one
 - 17 of the reports somebody making reference to DSD,
 - 18 disorders of sexual development, also differences or
 - 19 disorders.
 - 20 I suspect that indicates a dispute among
 - 21 practitioners about whether something is inherently a
 - 22 problem, a problem for a particular person, or not a
 - 23 problem at all, just reflective of differences in
 - 24 populations. So GID would -- is more of an indicator of
 - 25 an inherent problem. So far as I know it's not used

Page 99

- 1 for, you know, reasons that are not obvious to me. Now,
- 2 I understand that it can emerge more frequently in kids
- 3 who are experiencing emotional distress or household
- 4 upheaval, but not necessarily so. It can develop more
- 5 in children that are autistic, but not necessarily so.
- 6 These are conditions under which it might --
- 7 when you talk about causation, the threshold for saying
- 8 something causes something is pretty rigid and typically
- 9 discerned only in experimental research designs where
- 10 you can sequester or account for other factors so that
- 11 you can establish cause. But in this domain there's not
- 12 a lot of that.
- 13 Q Okay. So is it fair to say that you don't feel
- 14 comfortable offering a causal explanation for gender
- 15 dysphoria?
- 16 A Well, I don't diagnose it. I'm not a
- 17 clinician.
- 18 Q Okay. So do you know how you would diagnose
- 19 gender dysphoria?
- 20 A Not as a clinician might, no.
- 21 Q Okay
- 22 A So when I read materials about gender dysphoria
- 23 I take for granted at some level that they, you know,
- 24 are conducting the diagnoses in the trained manner in
- 25 which they have done so. I don't typically dispute that

- 1 very often as a term, but was fairly recently.
- 2 Q Okay. What is the appropriate way to treat
- 3 adolescents diagnosed with gender dysphoria?
- 4 MR. CANTRELL: Object to form.
- 5 A You are asking a non-clinician this question.
- 6 Appropriate ways to treat adolescents with gender
- 7 dysphoria. I think if I was asked that I would say that
- 8 is up for grabs to some extent. You have the Endocrine
- 9 Society talks about it, guidelines. You have WPATH's
- 10 standards of care.
- 11 Q Sorry to stop you. Did you put "guidelines" in
- 12 quotes just now?
- 13 A Just as a distinction between guidelines and
- 14 standards.
- 15 Q Okay. And how do you see them as distinct?
- 16 A They are two different words. The
- 17 organizations had plenty of chance to coalesce around
- 18 the term that they use. I do think they are similar, so
- 19 far as I can tell, in what they mean by the term. They
- 20 are not demands or orders. So when you say how
- 21 should -- your original question was how to -- are
- 22 adolescents -- adolescents be treated?
- 23 Q What's the appropriate way to treat an
- 24 adolescent with gender dysphoria?
- 25 A Yeah. I don't make that kind of

- 1 recommendation. I think the value of my report is that
- 2 I highlight how there are distinctions in how these
- 3 organizations approach this. And there seems to be an
- 4 emergent dispute between clinicians and caregivers about
- 5 this very question.
- 6 So you can ask me for a solitary response I'd
- 7 say, Well, clinicians don't have a solitary response
- 8 about this.
- 9 Q Okay. But your answer yourself is that --
- 10 (Simultaneous crosstalk.)
- 11 Q Oh, sorry.
- 12 A I don't offer one.
- 13 Q Okay. So you don't know --
- 14 A I observe other people's suggestions and
- 15 disputes. I observe WPATH and Endocrine Society's
- 16 guidelines and standard of care, vice versa. And I
- 17 observe how those have changed over time and I can state
- 18 that it's a dynamic area.
- 19 Q So you have no view on how to treat adolescents
- 20 with gender dysphoria?
- A I have not read about how to treat adolescents.
- 22 In terms of my personal views -- is that what you're
- 23 asking me, my personal view?
- 24 Q I mean, let's take your expert view first. Do
- 25 you have an expert view on --

- Page 104
- 1 significant treatments that put at risk future bodily
- 2 realities at early ages.3 And I can tell that I'm not out of step with
- 4 some clinicians who are worried that those ages are
- 5 becoming earlier as well.
- 6 Q So I just want to make sure I have it in my
- 7 head the right way. I understand that you have an
- 8 expert view that other people's answer to the question
- 9 how to treat adolescents with gender dysphoria might be
- 10 wrong.

16

- 11 A Right.
- 12 Q I am asking your expert position. Am I
- 13 correct that your expert position is they should not
- 14 receive significant treatments?
- 15 MR. CANTRELL: Object to form.
 - A I think that treatments should be -- should not
- 17 sort of happen until they have experienced puberty. I
- 18 know that used to be the standard. Again, this is sort
- 19 of not me writing as an expert.
- 20 But that, you know, I think counseling is
- 21 something I would want to see more of. I think if this
- 22 was my own child I wouldn't want to rush them into
- 23 anything. I would say, Take your time.
- 24 Q (By Mr. Richardson) Okay. I'm just having
- 25 trouble following the expert piece and then the personal

- A I have an expert understanding that there is
- 2 significant evolution in standards of care and
- 3 significant dispute within the community of caregivers
- 4 about what ought to happen and when.
- 5 Q But as an expert, you have no view about how to
- 6 treat gender dysphoria?
- 7 A I think kids should not be rushed into
- 8 significant treatments that will put at risk a future
- 9 that they have not yet experienced.
- 10 Q So your expert view is that adolescents with
- 11 gender dysphoria should not be given significant
- 12 treatments?
- 13 MR. CANTRELL: Object to form?
- 14 Q (By Mr. Richardson) Or is that --
- 15 A Well, if I had an expert opinion I would have
- 16 stated it. If I did you can draw my attention to it.
- My approach as a sociologist is to highlight
- 18 what I call ideological capture, how these professional
- 19 organizations, WPATH, Endocrine Society, et cetera, have
- 20 you been kind of pressed by, for lack of a better term,
- 21 activist groups towards certain answers to the question
- 22 that you pose to me rather than other answers.
- And when I look at it I'm not -- I'm not
- 24 convinced there is an outside analyst of their methods
- 25 and their conclusions that it's a good idea to begin

- Page 105 1 piece. Was the answer to the question for the expert
- 2 piece you don't have an expert opinion about the proper
- 3 course of treatment?
- 4 A Well, if I didn't -- if I didn't state it in
- 5 there then I didn't offer an expert opinion.
- 6 Q So you have no expert opinion on that point?
- 7 A Unless it's stated in there, and I don't recall
- 8 saying that
- 9 Q Okay. And then you said on your personal views
- 10 you would oppose what you called significant treatments;
- 11 is that correct?
- 12 MR. CANTRELL: Object to form.
- 13 A Significant treatments that put at risk their
- 14 bodily integrity.
- 15 Q (By Mr. Richardson) Okay. I just want to pivot
- 16 here.
- 17 A Um-hum.
- 18 Q In your report you use the term "the sociology
- 19 of science."
- 20 A Yes.
- 21 Q Do you remember using that term?
- 22 A In the report? Yeah, I think I used it in the
- 23 "Queering Science" piece, too.
- 24 Q Okay. Can you describe what "the sociology of
- 25 science" means?

- 1 A So when you turn sort of your gaze at the --
- 2 sociology is a science of a sort. Right? It's not like
- 3 physics, but it uses the scientific method in a
- 4 different way. And when you turn your attention at some
- 5 domain in the social world, you know, there's lot of
- 6 things one can learn sociologically. Sociology of race
- 7 ethnicity, sociology of poverty, sociology of family.
- 8 But one can also turn one's sociological attention to
- 9 the norms, values, practices of, uh -- of science.
- 10 Right? So that's what I mean by sociology of science.
- 11 You turn your sort of analytical gaze and interests and
- 12 methods to the conduct of science, of which sociology is
- 13 a part. Right?
- 14 Q Gotcha. And have you published works that you
- 15 would say are in the area of the sociology of science?
- 16 A So one of the things I do in this sociology of
- 17 science domain is criticize the professional
- 18 associations, ASA. I mean, the manner in which science,
- 19 social science is conducted. And I'm sure I have
- 20 critical references to it in the last two books.
- The 2020 Annals of Social Science piece on
- 22 understanding how the social science of the study of
- 23 same sex parenting works. That really is directly on
- 24 sort of assessment of how the discipline operates.
- 25 Q And just to follow up on that. That piece was

- Page 108
- 1 A If so many people -- if the claim was so 2 overreaching and, yet, editors and peer reviewers passed
- 3 on it. It's a -- it's a criticism of how the peer
- 4 review process even works.
- 5 Q Okay.
- A I think it's broken. There's a lot of people
- 7 in my line of work, some of whom have criticized me
- 8 extensively who think the peer review process is broken.
- 9 Q Okay.
- 10 A And there's a move afoot to even post your own
- 11 work pre-peer review. So --
- 12 Q Okay. And so you reference the 2020 piece
- 13 about same sex parenting.
- 14 A Um-hum.
- 15 Q And then the 20, what is that, the 2017 piece
- 16 about structural stigma?
- 17 A Yeah. It's more apparent -- the 2020 piece is
- 18 clearly more about the sociology of science.
- 19 Q Okay. And do either of those pieces relate to
- 20 medical science?
- 21 A 2020 probably does. I'd have to take a look at
- 22 the references I use, because I probably made reference
- 23 to pieces that appear in Pediatrics and things like
- 24 that. Because a fair number of publications in the
- 25 domain that that article concerns are published in

Page 107

- 1 about the discipline's research with respect to one
- 2 empirical question; right?
- 3 A Correct.
- 4 Q The wellbeing of children raised by same sex
- 5 parents?
- 6 A Well, that domain? Right? Because in it is
- 7 all sorts of intricate questions about what does it mean
- 8 to be raised by, what is a household, what is the
- 9 threshold for a household structural change. All sorts 10 of things like this.
- 11 Q Yeah.
- 12 A So that piece is sort of critical of the social
- 13 science conduct of this stuff.
- 14 Q Gotcha. But -- but with respect to -- you
- 15 know, it might include subquestions, but the broad
- 16 question of the wellbeing of children being raised by
- 17 same sex parents.
- 18 A Yes.
- 19 Q Okay.
- 20 A So, for example, the "Structural Stigma" piece
- 21 by Hatzenbuehler.
- 22 Q Okay.
- 23 A This is all critical of wide -- you know, I ask
- 24 a question, why did this pass peer review?
- 25 Q Yeah.

- 1 non-sociology journals, including, like, Clinical
- 2 Psychology, Pediatrics, for example but I would have to
- 3 take a look at the references.
- 4 Q But you don't recall any specific references to
- 5 medical science?
- 6 A No, but I suspect they are in there.
- 7 Q Okay.
- 8 A That would require me to remember the
- 9 references to my studies, let alone some of the details
- 10 of what I have written.
- 11 Q And do either of those two pieces involve the
- 12 sociology of research with respect to transgender
- 13 people?
- 14 A Say that once more time, please.
- 15 Q The sociology of research with respect to
- 16 transgender people.
- 17 A Respect to transgender people. No, I don't
- 18 think so.
- 19 Q Okay. Do you consider yourself an expert on
- 20 the sociology of medicine?
- 21 A What do you mean by "sociology of medicine"?
- Q So you have just described the sociology of
- 23 science, which is applying broad sociological tools --
- 24 A Right.
- 25 Q -- to a field.

Page 110 Page 112 A Sociology of science is the domain of the 1 treatment are? 1 2 science. A I do not. 3 Q Yes. MR. CANTRELL: Object to form. A In which are all these, you know, disciplines. Q (By Mr. Richardson) Do you know of other 5 Sociology of sociology. My advisor wrote a book on the 5 examples besides Arkansas's ban on gender-affirming 6 sociology of sociology. I have not done that, per se. 7 But I write on the sociology of sort of particular 7 A Other examples comparable you mean? 8 research questions --8 Q Other examples of banning medical treatments beyond Arkansas law for gender-affirming care? Q Gotcha. 10 A -- which can span from sociology to family to 10 MR. CANTRELL: Object to form. 11 medicine. 11 A Again, I think in part Arizona is discussing 12 O Gotcha. 12 some law. I'm not sure what the status of that is. You 13 A But sociology of medicine, per se, is not just 13 know, sometimes things will pass the house and senate. 14 I see the media discussing it, but I don't know what the 14 about, like, the efficacy of 3 milliliters of something 15 over five. It's about, sort of, how people fare. And 15 status of these things are, if they become law. 16 so go back to the same sex parenting stuff, you know, Q When you say "these things," you mean other 17 how do children fair across this whole domain of 17 bans on gender-affirming care? 18 measures and outcomes. 18 (Simultaneous crosstalk.) 19 O Okay. 19 A Correct. 20 A So is that sociology of medicine? It's 20 Q Are you aware of any other bans on treatment 21 probably the sociology of health, per se. 21 beyond gender-affirming care? Q Okay. So you consider yourself an expert on A Treatment beyond gender-affirming care. You 22 23 the sociology of health? 23 mean everything else in medicine beyond that? 24 A Expert on sociology of health? I have done 24 Q Other medical treatments that might be 25 work in it. I consider myself more of an expert on 25 provided, yes. Page 111 Page 113 1 sociology of research methodology. MR. CANTRELL: I'm going to object again 2 that Mr. -- Dr. Regnarus is not an attorney and can't 2 Q Gotcha. 3 A The conduct of social science, sometimes 3 provide any legal conclusions. 4 bleeding over into -- outside of social science and into MR. RICHARDSON: I mean, if I asked him 5 health sciences. 5 what's the speed limit, that's a law. I mean, that's Q Gotcha. How common is it in the United States 6 not a legal conclusion to know --7 7 to have laws banning medical treatments? THE WITNESS: It varies. MR. CANTRELL: I'll object. Dr. Regnarus 8 MR. RICHARDSON: -- that there are speed 8 9 is not an attorney. 9 limit states. 10 10 MR. RICHARDSON: This is just the THE WITNESS: Some states don't actually 11 existence of laws banning treatments, not a legal 11 have speed limits for particular stretches of road. 12 question about those laws. 12 MR. RICHARDSON: I understand. My only A I frankly don't know. One piece of our history 13 point is the existence of a law is not a legal analysis. 14 was tarnished by the Tuskegee syphilis study, which was, 14 THE WITNESS: That's a very common --15 15 you know, that should have had a law behind it. And the MR. CANTRELL: I will just object to the 16 Belmont report came out, in part, as a response to that 16 question. 17 17 tragedy, which I may have mentioned the Belmont report MR. RICHARDSON: Understood. 18 THE WITNESS: There are some common laws 18 in my -- one of my reports. A key part of the Belmont report is that the 19 like the speed limit and then there are some that are 20 threshold for participation in significant medical 20 sort of narrowly tailored for particular situations. 21 research, the threshold for including children and 21 MR. RICHARDSON: Understood. 22 pregnant women is elevated, and that remains the case. 22 THE WITNESS: That I would not know. 23 But about your exact question about laws, I --23 Q (By Mr. Richardson) Okay. So my question was

24 do you know of other examples of bans on medical

25 treatment beyond Arkansas's ban on gender-affirming

25

24 that is -- I'm no legal expert.

Q So you don't know how common laws banning

Page 116 Page 114 1 care? 1 this is not necessarily true within the field of 2 MR. CANTRELL: Object to form. 2 psychology; is that right?" And then your response --3 A Again, the Arizona, I don't know what the A Right. 4 status of that is, but it sounds like that was a ban on Q -- was, quote, I know psychologists don't 5 surgical treatment, perhaps. But I do not know the 5 privilege those kinds of samples in a way that 6 current status of that. I've read about it. That's it. 6 sociologists or certainly demographers do." 7 7 There might be -- I mean, one reads in the Do you see that? 8 A I do. 8 newspaper that there are pieces of legislation about 9 LGBTQ stuff that are circulating, but I don't usually 9 MR. CANTRELL: I'm just going to object 10 know about specific ones. 10 to jumping into the middle of a line of questioning 11 Q (By Mr. Richardson) Understood. 11 without any context. 12 A Though I have heard about the Arizona thing, I 12 MR. RICHARDSON: I started with the 13 don't know what the status of it is. 13 question on 13, Mike. Q Okay. Is it the general practice that doctors 14 MR. CANTRELL: Right, and I understand. 15 and patients are free to make medical decisions without 15 But there has been quite a bit of testimony that appears 16 the state overriding those decisions? 16 before this point. 17 MR. CANTRELL: Object to form. 17 Q (By Mr. Richardson) Okay. Do you understand A I think it depends a lot on sort of what that 18 the context of what that question was asking you? 18 19 treatment is. But most of the time treatments are sort 19 A This was in court. Yeah, I do. 20 of considered within reason. I mean, so I don't think 20 Q And then your response was, quote, I know 21 euthanasia, for example, is a treatment that is legal in 21 psychologists don't privilege those kind of samples in 22 most statements. I could be wrong about particular 22 the way that sociologists or certainly demographers do. 23 states. 23 Correct? 24 So when we think about what is against the law, 24 A Correct. 25 I don't think too much is made about the doctor-patient 25 Q What did you mean by that statement? Page 115 Page 117 1 agreement on treatments because there's wide A That sociologist -- or I describe -- or you 2 acknowledgement that, you know, they are both seeking 2 describe, I still agree with that statement. 3 Psychologists will often take a convenience sample. So 3 the same good of a person and have agreements about, 4 like, what that entails. 4 let me give you an example. Q (By Mr. Richardson) Understood. Okay. Just 5 University of Texas, I believe there's a class 5 6 shifting gears a little bit. 6 that all psychology majors have to sign up for, which 7 A Okay. 7 the credit is given for their participation in a whole Q Do research methods vary among different 8 series of surveys conducted by their peers in psychology 8 9 scientific fields? 9 and perhaps the faculty. 10 A They do. 10 So psychologists often offer sort of MR. RICHARDSON: Okay. Can I get Exhibit 11 convenience samples with the underlying presumption, I 11 12 9, please, Beth? 12 guess, that the population of people they are talking to 13 (Plaintiff's Exhibit 9 was marked for 13 is fundamentally similar to the population at large. 14 identification and made a part of the 14 Perhaps if they are talking about, like, psychological 15 15 kinds of things, you know, big five measures, things record.) Q Okay. This is a part of your testimony in 16 16 like that. Any group of 50 to 100 people would be 17 DeBoer against Snyder. 17 similar to what you would find in the wider population. 18 A Okay. 18 I often, sort of, poke at that in my Research 19 Q Do you see down at the bottom on page 13 there, 19 Methods class, I just did a week or two weeks ago, 20 you were asked the question, "In your view, the hallmark 20 saying sociologists, we're not like that, you know, we 21 of a rigorous study is a large representative pool of 21 want to know about things that are generalizable to a 22 participants drawn from a population-based random 22 population at large. I'm not just talking about the 23 sample." And you responded that was correct. 23 population at large like this, but a population of a 24 A Yeah. 24 particular group. Right? 25 25 Q And then you were asked, "But you recognize So one of the things I've criticized, and so

- 1 has professor Biggs from Oxford, is Jack Turban's use of
- 2 the U.S. transgender study, survey, which is a little
- 3 bit like this in that it's a convenience survey of
- 4 people who agreed to answer questions. They were
- 5 solicited by membership in a variety of different
- 6 platforms.
- And that's just -- is that reflective of the
- 8 entire group of transgender persons in the United
- 9 States? I believe one of these pieces I -- or perhaps
- 10 in the report, one of the reports I poked back at
- 11 Dr. Turban about this, as did professor Biggs just
- 12 recently in a response to a letter to the editor for
- 13 publication that Turban was author or co-author of
- 14 saying that, you know, we really thing the USTS is not
- 15 only problematic in its survey questions. Biggs pokes
- 16 at Turban in the analysis and interpretation of data,
- 17 but also for is this a representative sample of the
- 18 transgender population in America. These are not easy
- 19 things to get at, but sociologists do care about that.
- 20 Q So just to follow up --

A That is true.

- 21 A More than psychologists care about it I think.
- 22 Q So when you say that sociologists care more
- 23 about it than psychologists, is the bottom line that a
- 24 study can be useful to a psychologist that might not be
- 25 given a lot of weight by a sociologist?

- Page 120 A And my beefs, including Public Discourse and
- 2 things I've mentioned here, is more about the questions
- 3 they pose, sometimes the statistical methods they
- 4 employ, and sometimes about the interpretations,
- 5 statistical interpretations they give to their -- the
- 6 analyses and the conclusions they draw from those
- 7 analyses.
- Q Understood. So we've got research standards
- 9 that may differ between fields like sociology and
- 10 psychology --
- 11 A Correct.
- 12 O -- and medical research?
- 13
- 14 Q Is it common for researchers in one field to
- 15 critique the state of science in a different field?
- 16 A I don't think it's uncommon. I don't pay a
- 17 wide attention to sort of how economists talk about
- 18 sociologists. But I know they think that our methods
- 19 lack things in terms of especially longitudinal data.
- 20 For example, professor Turban's USTS is not
- 21 longitudinal.
- 22 Q Yeah.
- 23 A Okay. It's hard to collect, costs a lot of
- 24 money, et cetera. But, you know, I have done, published
- 25 work without longitudinal data. Sometimes I do use it

- Page 119
- Q And do you think differences like that are
- 3 common across different scientific fields?
- MR. CANTRELL: Object to form.
- A Probably. I mean, if you think about health
- 6 practitioners, right, they will survey their existing
- 7 patients, right, not possible patients or patients who
- 8 have this condition that are not under their care.
- Yeah, that comes back to sort of sampling
- 10 differences. At the same time, you know, call it
- 11 methodological purism, I think both the interpreters of
- 12 that research and eventually the public at large,
- 13 courtesy if journalists cover it or not, are apt to make
- 14 the leap, assumption that the sample, underlying sample
- 15 is reflective of the population at large. And
- 16 sociologists really care about being cautious about
- 17 that.

1

- 18 Q (By Mr. Richardson) I hear you and I understand
- 19 your opinion about the public at large. I guess my
- 20 question is you mentioned healthcare providers. And is
- 21 it just true that healthcare providers might place
- 22 weight on the kind of research that would not be
- 23 valuable to a sociologist?
- 24 A Certain samples.
- 25 Q Yeah. Okay.

- 1 wherever it's possible. One wants to. It's very
- 2 expensive.
- But economists who often use nationally --
- 4 federal data, which is often longitudinal, they like to
- 5 poke at sociologists.
- Q Gotcha.
- A Perhaps there is a pecking order in the social
- 8 sciences that one can discern from this.
- Q Yeah. So but in your view you don't need
- 10 expertise in a particular field or training in that
- 11 field to evaluate the quality of science in that field.
- 12 A State that once more, please.
- Q Is it your view that you don't need expertise
- 14 or training in a particular scientific field to evaluate
- 15 the quality of the science in that field?
- A Yeah, I think that's true. I don't need that.
- 17 You know, professor Biggs would agree with me if he was
- 18 sitting in this chair.
- 19 Q Okay. So --
- 20 A There is lots of people that can look at the
- 21 kinds of questions one can pose, the analysis one
- 22 conducts. And certainly like, you know, understanding
- 23 that effect size and how to describe that effect size
- 24 and then leap, as did the folks in this piece that I
- 25 highlight (Indicating), to sort of a clinical piece of

Page 122 1 advice. Right?

- So they said that, Ah, this shows that surgery
- 3 is effective using the sort of all Sweden data. And I
- 4 point out in this that, you know, if three people, I
- 5 think it was three or four people had reported something
- 6 different out of the entire population of Sweden, you
- 7 wouldn't see that result. Or if three or four people
- 8 reported something different you might see a stronger
- 9 result. It is very sensitive to sample size.
- And to make a clinical recommendations about
- 11 such a significant thing as a sequence of surgeries
- 12 based on effect size, which is so small as to be
- 13 vulnerable to a handful of cases, I think that's
- 14 methodologically wrong.
- Q Okay. So just to step back, do you think that
- 16 any social scientist with your training could evaluate
- 17 the quality of the evidence in any other scientific
- 18 field?
- 19 A That's a little bit of a stretch.
- 20 Q In what way?
- 21 A So any sociologist?
- 22 Q With your training?
- 23 A With my training. I typically don't weigh in
- 24 on, like, economics as an example --
- 25 Q Okay.

14 not outrageous claims to make, getting by peer review, 15 et cetera, it's a signal of ideological capture of the

17

11

- 16 professional organizations.
 - 18 the quality of evidence in chemistry?
 - 19 A No.

10 uncalled for.

20 Q Why not?

Q Yeah.

- 21 A I'm not a chemist.
- 22 Q And you're not a healthcare provider.
- 23 A I am not a healthcare provider.
- 24 Q What makes those two different?
- 25 A We are dealing in research methods that are not

A Then to -- to sort of back from there and

3 think, Wow, 49 people you have to treat before you

5 the treatment itself is a surgery or a series of

6 surgeries, that doesn't seem to merit the author's

4 should expect one positive outcome in difference, and

7 conclusion that surgery helps people with whatever term

8 they used, gender dysphoria or whatever the term they

9 were working with. I think that was -- that's sort of

But it's indicative of how I would say

13 publishing things in journals that think that these are

Q Okay. So just to step back, could you evaluate

12 researchers with an interest in activism here are

Page 123

- 1 A -- because they -- they -- well, sexual
- 2 economics is more than a theory than a field or domain.
- 3 But if you're dealing with multiple repeated measures,
- 4 and I won't -- I don't weigh in on those; right?
- But when I started looking in on these things I
- 6 was struck by how the field was dominated by a handful
- 7 of researchers using data. You know, my beef is not so
- 8 much with the fact that it's not a representative
- 9 population of the United States. Right? Sometimes they
- 10 are using clinical data. The Swedish data is all
- 11 Sweden, but, you know, they narrowed the focus on
- 12 adults, I think, who had experienced transgender surgery
- 13 or hormonal treatments.
- People with my training could weigh in on other
- 15 areas and other disciplines. It would depend a lot on
- 16 sort of what they understood about that discipline.
- 17 O Yeah.
- 18 A But it's fair to say that some of the claims
- 19 that I have made, one doesn't have to be even
- 20 methodologically all that advanced to recognize it.
- Q So one doesn't need advanced training to make
- 22 the observations you're making?
- A The NNT 49, I mean, that's just a calculation;
- 24 right? It was available and doable from the information
- 25 they provided in the study.

Page 125 1 that different. Survey questions, you know, like the

- 2 USTS, I mean, even professor Biggs and I concur with
- 3 him, he -- Turban didn't even ask a question about
- 4 gender dysphoria to this population of transgender
- 5 persons in the United States, didn't ask a question.
- I could come up with a question on it. How --
- 7 who, other people ask about this stuff. You put one on
- 8 there.
- 9 You know, so there's just -- chemistry is not a
- 10 social science.
- 11 O But economics is?
- 12 A Correct.
- 13 Q And you said you would not feel --
- 14 A And the time order methods that are a lot more
- 15 advanced --
- Q So you would not feel --16
- 17 A -- that I deal with.
- 18 Q So you would not feel comfortable offering an
- 19 expert view on an economic question?
- 20 MR. CANTRELL: Object to form.
- 21 A Not particular kinds of economic questions, but
- 22 about the economics of sex and how it markets in maybe
- 23 markets operate, I think I can hang with that and have,
- 24 and have published a book on it.
- 25 Q (By Mr. Richardson) And the reason you wouldn't

Page 126 Page 128 1 comment beyond that is because, in your view, economics 1 Harvard, wrote a book called States and Social 2 is advanced? 2 Revolutions, a lot about history in there, sociology of MR. CANTRELL: Object to form. 3 history, social movements, revolutions. A No. They ask and answer questions that I'm not So we could do that and some of us do do that. 5 interested in. Some of the models and methods they use 5 My interest has not been in that. But, you know, it is 6 are -- involve methods I don't -- I'm not trained in. 6 a closer leap than chemistry and certainly physics. 7 MR. RICHARDSON: Understood. Okay. Is 7 Whereas most of what I've seen in here are measures and 8 methods that I've been trained in. 8 now a good time for a break for you, Doctor? Q (By Mr. Richardson) And earlier we discussed THE WITNESS: I can keep going. Do you 10 your training and you said you no training in the 10 want to go until lunch? What time do you want to take 11 effectiveness of medical care; correct? 11 lunch? A No training in it. But so when someone like 12 MR. RICHARDSON: You need to change --13 Branstrom and Pachankis write an article in, is it 13 VIDEO OPERATOR: I can do it quick if we 14 American Journal of Psychiatry, I can see their methods, 14 want to keep going. MR. RICHARDSON: Okay. Well, let's do a 15 I can see the questions that they posed, and I can even 15 16 go sort of, Oh, do I like that question? 16 quick five then. Is that all right? 17 If you recall, I say "The authors corrupted 17 THE WITNESS: A quick five. 18 otherwise excellent data and analyses with a skewed 18 MR. RICHARDSON: And then we'll go to 19 interpretation." So I had no troubles with the Swedish 19 lunch. 20 data. They are extremely extensive. I wish our country 20 THE WITNESS: Thanks. 21 21 had such extensive data collection, but, you know, MR. RICHARDSON: Okay. 22 people don't like to be talked to here. 22 VIDEO OPERATOR: This will end media part 23 23 2. We are off the record at 11:58 a.m. Q Do chemists use data sets? 24 24 (A break was had.) A If they do it's not in the, sort of, quite the VIDEO OPERATOR: We are back on the 25 same way or the same kind of variables that we use. 25 Page 127 Page 129 1 record at 12:11 p.m. This will begin media part 3. Q So you don't think they use similar statistical 1 2 Please proceed. 2 methods to measure the outcome of chemical phenomena? 3 MR. RICHARDSON: Thank you. 3 A Perhaps they do. I've never been interested in 4 Q (By Mr. Richardson) How did you hear about 4 chemical phenomena --5 this case? 5 O Okay. A That's a good question. Some news outlet A -- outside of household maintenance. 7 around early April. 7 Q But if they did you would feel comfortable in Q Okay. And how -- who first asked you to work 8 commenting on their quality? 9 on the case as an expert? A I would have to, you know -- the sociology of 10 A He did. (Indicating) 10 health is -- is not a far leap from what I studied and 11 O And that's Mike Cantrell? 11 understood. Chemistry is a leap, so. 12 Q So there's a leap between your field and 12 A Um-hum. 13 chemistry. Is there a leap between your field and 13 Q Are you familiar with the state's other experts 14 medical science? 14 in this case? Start with Dr. Steven Levine. 15 A What do you mean familiar with? 15 A A much closer step. 16 Q Have you ever met Dr. Steven Levine? Q A closer step. Okay. And there's a leap at 17 A I have not. 17 some level between your field and economics, as I 18 Q Okay. Have you ever met Dr. Patrick Lappert? 18 understand it, because you said --19 A Um-hum. 19 A I don't believe so. The name doesn't sound 20 familiar. If I saw a picture, maybe. 20 Q Okay. All right. And so would you feel 21 21 comfortable commenting on the evidence in history? Q Have you met Dr. Paul Hruz? 22 A Once, I believe. 22 MR. CANTRELL: Object to form. 23 Q Okay. And where was that? 23 A I don't think they use the same kinds of 24 A I think that was several years ago, don't ask 24 research methods. Now, sometimes they might. Right? 25 me when, at the Alliance Defending Freedom in 25 For example, Theda Skocpol, professor of Sociology at

Page 130 Page 132 1 Scottsdale. I was at some meeting about research and 1 meeting? 2 people doing research, different people doing different A I think so, yeah. 3 research in areas that they were attended to. Q And do you know if Dr. Lappert was at the Q Okay. 4 meeting? A I think he was there. A I don't know. Again, if I had a photo, maybe, Q Okay. So are you familiar with the group 6 but it doesn't sound familiar. 7 Alliance Defending Freedom? Q Okay. And Dr. Levine? A I have. They have -- they have represented me. A I don't believe so. 8 Q Okay. In what case did they represent you? 9 Q Was Paul McHugh at the meeting? 10 A Internal at University of Texas. 10 A No. 11 Q Oh, okay. 11 Q Have you met Paul McHugh before? 12 A Yeah. 12 A I have. 13 Q And what do you know about the Alliance 13 Q How many times would you say? 14 Defending Freedom generally? 14 A Maybe once. 15 A First Amendment rights group. 15 Q Did you all have a discussion? 16 16 Q Okay. Um --A No. I don't think Paul was -- no, Paul was not 17 A Started by evangelical pastor types. Now it 17 at that meeting. 18 seems generally First Amendment rights for people. Q But you have met Paul McHugh before? 18 19 Q And you said that you attended a meeting hosted 19 A Once. 20 by the Alliance Defending Freedom in Arizona? 20 Q And you didn't have any extensive discussion 21 A I believe so. 21 with him? Q And do you know rough when that was? A No. 22. 22 23 23 A That, I don't recall. Q Okay. Was Dr. Allan Josephson at the meeting? 24 Q Does 2017 sound right? 24 A Is this the fellow from Louisville? 25 A I don't know. It was probably before 2020, but 25 Q Yes. Page 131 Page 133 1 after 2014, but I couldn't tell you when that was. A I think he was at the ADF meeting. 1 Q Okay. That's fine. How did you hear about the 2 Q In Arizona. 3 meeting in Arizona? 3 A I think so. He's the one that kind of got in A Somebody asked me if I wanted to come. 4 trouble at his employer? 5 Q Did you talk to him at the ADF meeting? O And who was that? A That, I don't recall either. A I'm sure I talked to him socially. I do not 7 Q Okay. And as you understood it, what was the 7 remember what I said. 8 purpose of the meeting? Q So you don't recall any conversations with him? 8 A I think they were sort of talking about cases 9 A No. 10 that were circulating and the research that was starting 10 MR. CANTRELL: I'm going to just object. 11 to accumulate in -- I think generally in sexual and 11 I'm not sure what your questions are going toward, but 12 gender identity topics. 12 object on relevance and scope of discovery. Q (By Mr. Richardson) Was Walt Heyer at the 13 Q Okay. 14 A It seemed generic. 14 meeting in 2017? Q Okay. So the meeting was to discuss research A I don't believe so. 15 16 on gender identity at it pertained to work the ADF was 16 Q Okay. 17 doing? 17 A And I don't recall what he looks like, so I A I don't know what motivated their side of it, 18 don't think I met him. 19 but, like, they just wanted to talk to some of us who 19 Q You haven't met him before that meeting? 20 were operating in the research community in this domain. 20 A I don't believe I've met him period. Q Okay. So the purpose was mostly for you all to 21 Q Okay. And had you met Allan Josephson before 22 inform them of your research? 22 that meeting? A I believe so. I think we all took turns 23 A No. 24 talking about what we were working on. 24 Q Okay. And you mentioned that the meeting 25 25 was -- you were presenting to ADF on research you were Q Okay. So it sounds like Dr. Hruz was at this

- 1 doing around gender identity. Was that your role at the
- 2 meeting?
- 3 A Sexual and gender identity. I probably was
- 4 talking about, let's see, Cheap Sex was probably either
- 5 coming or recently out, depends on when the date was.
- 6 And I don't recall if -- when the date was in -- if I
- 7 was talking about the struggles stigma paper or not. I
- 8 don't recall the extent of what I talked about. Around
- 9 the table and share your story, what you're working on.
- 10 Q Okay. Was there a discussion with the group
- 11 about gender identity and gender dysphoria?
- 12 A I don't recall. It seems probable given that
- 13 Paul was there. But I don't recall that discussion.
- 14 Q And by Paul, you mean Paul McHugh?
- 15 A Paul Hruz.
- 16 Q Oh, Paul -- I'm sorry. I got them mixed up.
- 17 Okay. And he would have led that discussion is your
- 18 point?
- 19 A No. Just the fact that he's there, I suspect
- 20 we probably talked about this.
- 21 Q Okay. At this meeting was there any discussion
- 22 about the need for scholarship concerning the effects of
- 23 gender-affirming care for transgender people?
- 24 A I wouldn't have remembered if they had -- they
- 25 weren't funding anything, that's for sure. I mean,
- Page 135

- 1 that's not what they do.
- 2 Q Were attendees asked to produce scholarship --
- 3 A I highly doubt that.
- 4 Q -- related to gender dysphoria?
- 5 A No.
- 6 Q Okay. So would it surprise you that others
- 7 have said that at that meeting there was a discussion
- 8 about the lack of experts willing to testify in cases
- 9 involving transgender issues?
- 10 A I'm not surprised if that was said, yeah.
- 11 Q And that at that meeting attendees were asked
- 12 if they would be willing to serve as experts?
- 13 A Probably.
- 14 Q And would you have been there for that?
- 15 A For that discussion?
- 16 Q For that discussion.
- 17 A If it happened, yes, because I think I stayed
- 18 in the balance of the time.
- 19 Q Okay. But you don't recall specifically
- 20 anybody talking about the lack of experts willing to
- 21 serve in cases involving transgender people?
- 22 A No. It's possible that they did.
- 23 Q Okay. And --
- 24 A That seems, you know, in -- in form for what
- 25 ADF does.

- Page 136
- 1 Q Okay. And so you don't remember specifically
- 2 being asked to serve as an expert in cases involving --
- 3 A I don't --
- 4 Q -- gender?
- 5 A -- but I may well have been asked.
- 6 Q Okay. And you said this meeting took place
- 7 sometime between 2014 and 2022 -- or 2020 you said?
- 8 A Yeah. It was pre COVID but I can't remember
- 9 exactly when.
- 10 Q Okay. And just to clarify, when we spoke
- 11 earlier about the research on your CV involving
- 12 transgender people and gender dysphoria, we said the
- 13 earliest thing on the CV was 2018; is that correct?
- 14 A On gender dysphoria? Are you talking about the
- 15 structural stigma piece?
- 16 Q No. Earlier we were talking your CV and the
- 17 works listed on it. And we asked for the -- when the
- 18 first piece was chronologically that focused on --
- 19 (Simultaneous crosstalk.)
- 20 A -- piece?
- 21 Q A piece of any kind that focused gender
- 22 dysphoria or transgender people. And I think we agreed
- 23 that the 2018 essay "Queering Science" was the first
- 24 one.
- 25 A If you don't count 2017 "Structural Stigma"

- 1 which concerned LGBTQ.
- 2 Q Yes. Primarily focused on transgender people
- 3 or gender dysphoria.
- 4 A Okay. Yeah, perhaps.
- 5 Q So that reflects our earlier discussion; right?
- 6 A Um-hum, maybe.
- 7 Q Okay. And once again, this meeting in Arizona
- 8 was sometime between 2014 and 2020?
- 9 A Yes.
- 10 Q And you -- your testimony is you don't recall
- 11 being asked to serve as an expert, but you may have
- 12 been.
- 13 A That is correct.
- 14 Q And you would have been there for the entire
- 15 discussion?
- 16 A Yes.
- 17 Q Okay. Are you familiar with a group called the
- 18 Witherspoon Institute? I think we talked about them
- 19 earlier.
- 20 A Yeah, we already talked about that.
- 21 Q And you said that you serve as a contributing
- 22 editor for Public Discourse.
- 23 A Correct.
- 24 Q Do you have any other involvement with the
- 25 Witherspoon Institute?

Page 138 Page 140 A Um, their board chair or their president is on 1 Witherspoon Institute? 1 2 the board of Austin Institute. So I'm a senior fellow A I presume so. 3 at the institute, I interact with him with some Q And is the study the New Family Structure 4 regularity. 4 study? Q And has the Witherspoon Institute ever funded A Correct. 6 your research? O Okay. Um --A They were -- they helped fund the 2012 -- 2011, A But the part that is not true is "Regnarus 8 2012 New Family Structure Study. They helped raise 8 obliged." Regnarus was under no compulsion to deliver 9 money for it. 9 anything. I was under self-generated compulsion to 10 Q Okay. 10 collect the best possible random sample study I could on 11 A I mean, they money was sent to the University 11 this, a time when there was only one American study that 12 of Texas and then I used that to conduct a survey. 12 had a random sample, very few outcomes. And I want a Q Okay. And do you recall your involvement with 13 random sample, which is as most people I could find who 14 the Witherspoon Institute being discussed by the 14 had a mother or father had been in a same-sex 15 district court in DeBoer? 15 relationship during some time during their growing up 16 years. 16 A Do I recall it? I'm quite confident it was. 17 MR. RICHARDSON: Okay. Can I get exhibit 17 So that's what I was obliged to do and I told 18 the funder I was going to tell them what I saw in that 18 18, please? data, and that's what I did. 19 (Plaintiff's Exhibit 18 was marked for 20 identification and made a part of the 20 Q Understood. But the funder was the Witherspoon 21 21 Institute in that context? THE WITNESS: Thank you. 22 A Correct. 22. 23 Q (By Mr. Richardson) Okay. And is --23 Q Okay. A This is -- what exactly am I looking at here? 24 24 A I mean, just like the funder of research at UT Q That is the district court's opinion in DeBoer. 25 is the Buffet Foundation. They have vested interests in 25 Page 139 Page 141 A Okay. 1 keeping abortion legal in the United States and have 1 2 colleagues whose entire -- or a good chunk of their Q Can you please turn to page 13 of that opinion? 3 research portfolio is funded by a private foundation. 3 Do you see that paragraph at the bottom? A "The Court finds"? 4 Witherspoon is not really a private foundation. It's an Q "The Court finds," that's the one. Okay. 5 organization. 6 Let's just read together there. "The Court finds Q Okay. And we spoke about this earlier, but 7 Regnarus' testimony entirely unbelievable and not worthy 7 Public Discourse is maintained by the Witherspoon 8 of serious consideration. The evidence adduced at trial 8 Institute. 9 demonstrated that his 2012 'study' was hastily concocted 9 A I think we have said that three times now, yes. 10 at the behest of a third-party funder." 10 Q Okay. And when we talked about your research A He puts in quotations, by the way, study --11 on clinical impact it was limited to an essay published 11 12 Q Yes, study. 12 in Public Discourse; correct? A -- as if he's presuming it's not actually valid 13 A Clinical impact. 14 somehow. 14 Q We talked about the number-needed-to-treat 15 calculation. 15 Q Understood. And then on the next page, on page 16 14 ---16 A Um-hum. 17 A How would he have decided it was hastily 17 Q Okay. And we said that that was the only time 18 you've independently measured the impact of a medical 18 concocted. I mean, I have read this before. But, yes. 19 Okay. Sorry. If you want to continue. 19 treatment. Q Okay. And then on the next page, this is 14, 20 A In print. 21 in that first paragraph the second sentence says, "The 21 Q Yes. Okay. And so the only time you've 22 measured the impact of a clinical treatment was in 22 funder clearly wanted a certain result and Regnarus 23 obliged." 23 Public Discourse? 24 A I see it. 24 A In print, yeah.

Q And Public Discourse is maintained by the

25

Q Is the "funder" being referred to there the

25

Page 142
1 Witherspoon Institute; correct?

- 2 A Um-hum.
- 3 Q Okay. And I want to turn back to -- I just
- 4 want to make sure I understand --
- 5 A I understand.
- 6 Q -- the ADF meeting if that's all right. I
- 7 know it's --
- 8 A I have told you --
- 9 Q I know it's been a few years.
- 10 A -- about what I remember of it.
- 11 O Yeah.
- 12 A But you can continue.
- 13 Q Just to make sure I have this. Were you asked
- 14 to testify in cases involving gender identity or
- 15 transgender people?
- 16 A I don't recall it. I may very well have.
- 17 Q Okay. Thank you. And you also mentioned that
- 18 your affiliation with ADF extends to your work at UT
- 19 Austin; is that correct?
- 20 A They represented me when the university put me
- 21 under a scientific misconduct inquiry stimulated by the
- 22 claims of a blogger from New York City who managed to
- 23 convince the research integrity officer at UT to open up
- 24 this inquiry, a fact that they said was really unusual
- 25 and was dismissed predominantly thereafter.

Page 143

- 1 Q Okay. Can you describe the claim that was made 2 against you?
- 3 A There were eight different, sort of, complaints
- 4 that this person made. I don't recall a single one of
- 5 them, but I responded to every single one of them in the
- 6 meeting that took place at UT, must have been probably
- 7 September of 2012, and the committee then heard those
- 8 answers, recommended to the Provost that the case be
- 9 dismissed, it was accepted.
- 10 Q Okay. So you don't remember the specific
- 11 issues raised by the blogger; correct?
- 12 A Not in particular.
- 13 Q Do you remember the general objection raised by
- 14 the blogger just in terms of the big picture nature of
- 15 the concerns?
- 16 A In his case he had been so hostile publically
- 17 for so long, I don't recall which eight he settled on.
- 18 Q Okay. Did it involve your work on --
- 19 A It was NFS.
- 20 O It was the NFS?
- 21 A Yeah
- 22 Q And you said that investigation concluded with
- 23 the complaint being dismissed and dropped?
- 24 A Yeah.
- 25 Q Okay. Have you ever been the subject of any

- 1 other investigation related to your academic conduct?
- 2 A So in 2014, I think it was 2014 my department
- 3 chair had designated three of my colleagues to conduct
- 4 an evaluation of -- for my every-six-year post-tenure
- 5 review -- it happens every six years to all of us -- and
- 6 they had turned in their review of my teaching research
- 7 and departmental service that said I exceeded
- 8 expectations.
- 9 Department chair at the time was frustrated by
- 10 that and wrote a letter of complaint to the dean saying
- 11 she thinks I failed to meet expectations. So the dean
- 12 has these competing evaluations and appointed an
- 13 associate chair -- no -- associate dean who is a
- 14 colleague of mine in sociology to write a report about
- 15 the NSF study because he said this is what it seems to
- 16 be about.
- 17 So he wrote a report, 30-some-odd pages, I was
- 18 not aware of it. The dean asked me for a meeting fall
- 19 of 2015 -- '14, probably like in September. I remember
- 20 I had kind of a -- fall off to work on other projects
- 21 and I wanted to write this response to the associate
- 22 dean's paper about my NFS.
- 23 And so that was -- you know, the dean got my
- 24 response, his response, seems to have thrown up his
- 25 hands and said, Whatever, you know, we're going to hold
 - Page 145
- 1 these in tension and move forward. So they never even
- 2 settled the case.
- 3 Q Okay. So there was a 2015 -- or 2014 review
- 4 you just described related to the NFS.
- 5 A Right. It was not really like an ethical
- 6 thing.
- 7 Q Got it. So a just a departmental review of
- 8 your work for --
- 9 A It was a college-level review.
- 10 Q College-level review. Okay. And that was just
- 11 part of performance evaluation processes?
- 12 A The department thing was a performance
- 13 evaluation every six years.
- 14 O Yeah.
- 15 A The dean decided to elevate it to, sort of,
- 16 something larger and then just closed the case after
- 17 that.
- 18 Q Okay. Just so I got it, the elevating at
- 19 larger was asking for that 30-page report you talked
- 20 about?
- 21 A Correct.
- 22 Q Understood. Okay.
- 23 A To which I was asked to respond --
- 24 Q Okay. Gotcha.
- 25 A -- which I did.

- 1 Q And then the blogger complaint, which also
- 2 involved the NFS, what was the timeline on that?
- 3 A September 2012 I think, give or take a month.
- 4 Q Okay. And anything else involving reviews of
- 5 your work by your department for performance evaluation 6 purposes?
- 7 A Yeah. There is my promotion case 2017.
- 8 Q And anything else involving investigations --
- 9 A Investigations --
- 10 Q -- of the sort like the blogger complaint about
- 11 academic conduct or the quality of your work or anything
- 12 like that?
- 13 A Not that I'm aware of. If you know something
- 14 you can enlighten me.
- 15 Q Are you familiar with a group called the Ruth
- 16 Institute?
- 17 A Yes.
- 18 Q Did you receive an award from that
- 19 organization?
- 20 A I do. I don't really recall what it was for --
- 21 Q Okay.
- 22 A -- or what they said.
- 23 Q Are you aware that the Ruth Institute describes
- 24 itself as, quote, A global interface coalition equipping
- 25 Christians to defend the family and build a civilization
 - Page 147
- 1 of love, and that, quote, We uphold the ancient
- 2 Christian teachings about marriage, family, and human
- 3 sexuality?
- 4 A Not having studied it, but I'm not surprised
- 5 that's how they describe themselves.
- 6 Q Okay. Would that be --
- 7 A It's a little bit like First Things; right?
- 8 Q Yeah. Would that be a mission you support?
- 9 A Could you read it again, please?
- 10 Q "We uphold the ancient Christian teachings
- 11 about marriage, family, and human sexuality."
- 12 A "Ancient Christian teachings." You know, I
- 13 don't really think about mission statements. I sort of
- 14 look at, like, Well, what is Ruth Institute talking
- 15 about? You know, I have a friend, I think, who does
- 16 some research for them. They have asked me to come
- 17 speak at a conference before, so I come speak. There
- 18 you have it.
- 19 Q Okay.
- 20 A I don't really evaluate the mission statements
- 21 of people who ask me to sort of talk to them.
- 22 Q Understood. Are you aware that the Ruth
- 23 Institute has participated in something called the
- 24 Courage Conference which offers ministry to people
- 25 dealing with same-sex attraction?

- 1 A I'm not aware of that.
 - 2 Q Do you agree that people with homosexual
 - 3 desires should overcome them?
 - 4 A I have no opinion on that really.
 - 5 Q Okay.
 - A Overcome them? You know, some people elect to
 - 7 try to minimize this via, perhaps, behavior and
 - 8 cognitive therapy. If they are unwanted feelings I am
- 9 not opposed to that. But I don't give advice to people
- 10 who are dealing with that issue.
- 11 Q Okay. What is a mixed orientation marriage?
- 12 A It's funny you say that because one of the
- 13 early critics of the NFS insisted that a bunch of these
- 14 cases were mixed orientation marriages. Which for the
- 15 scrutiny, I don't think it's true.
- But I think that's when someone is married to
- 17 someone of a different sexual orientation.
- 18 Q Okay. And did you discuss mixed orientation
- 19 marriages in your expert report in Hunter?
- 20 A Briefly, yes. There is a study that had -- had
- 21 been published. I want to say this is the Yarhouse
- 22 study I think.
- 23 Q Sounds correct.
- 24 A About people manage in those settings. I
- 25 evaluated it. It's a small sample. I probably

Page 149

- 1 mentioned that it was non-representative. And I just
- 2 evaluated it's findings.
- 3 Q Okay. Do you think that the goal for people
- 4 with same sex attraction should be a mixed orientation
- 5 marriage?
- 6 A I have never honestly thought about the goals
- 7 of this.
- 8 Q Okay.
- 9 A I'm a realist. I take at face value what
- 10 people decide to do. So I don't often think about,
- 11 like, "Oh, you should have done something different.
- 12 You should have done this."
- 13 Q Gotcha. Can we turn to your rebuttal report.
- 14 This is Exhibit 2. It should be on page 26.
- 15 A Two, 26.
- 16 Q Yes, sir. Okay. Do you see there in paragraph
- 17 56, I'm just going to read starting at the third
- 18 sentence I suppose. "This is an example of 'déformation
- 19 professionnelle' or job conditioning in which training
- 20 and socialization processes associated with a
- 21 profession, in this case the emergence of 'gender
- 22 medicine,' have resulted in the distorted understanding
- 23 of the human person as a unity of mind and body."
- 24 A Um-hum.
- 25 Q What did you mean by "unity of mind and body"?

A If I can make this reference, then, to this

2 paper.

1

- 3 Q Is this Exhibit 14?
- 4 A Exhibit 14. There is a table in the back that
- 5 kind of describes distinctive world views about human
- 6 body and the relationship to selfhood.
- 7 Q Um-hum.
- 8 A And I describe using the language of James
- 9 Hunter, sociologist from -- well, he's still alive,
- 10 still works. But in Ridley (phonetic) -- a study of I
- 11 think it was about abortion politics back in the 80s or
- 12 90s about different kinds of world views that animate
- 13 people, and one of which is sort of this idea that
- 14 there's a unified -- unity between body and mind. And
- 15 one that's sort of a more dualistic, sort of, you are a
- 16 self that occupies a body; right?
- 17 Q And these are contrasted as the progressive and
- 18 orthodox views; correct?
- 19 A Right. It's not a -- the -- those are the
- 20 terms that Hunter used. I don't know if they are
- 21 quite --
- 22 Q Okay. But so --
- 23 A -- efficacious. But, yeah.
- 24 Q So when you say unity of mind and body in your
- 25 expert report --

Page 151

- 1 A Um-hum.
- 2 Q -- you are reflecting the view that you
- 3 attribute to the orthodox world view in this survey;
- 4 correct?
- 5 A The fact that it's sort of -- it's a mind/body
- 6 dualism.
- 7 Q Gotcha.
- 8 A Sort of a unity.
- 9 Q And -- and your expert view in the report is
- 10 that gender medicine distorts the unity of mind and
- 11 body.
- 12 A They seem to certainly find themselves on the
- 13 progressive side of this, the idea that this true self
- 14 is in the body and that the two may be divergent.
- 15 Q Okay. But on -- on page 26 of your rebuttal
- 16 report you offer as your expert opinion --
- 17 A Um-hum.
- 18 Q -- that gender medicine distorts the unity of
- 19 mind and body?
- 20 A As I said about ideological capture. The
- 21 professional organizations seem intent on understanding
- 22 the human person as a dualism between mind and body,
- 23 and I don't know that that is historic to medicine.
- 24 Q Understood.
- 25 A So I would say it's an example of sort of

Page 150 Page 152

1 professional deformation or conditioning in which

- 2 training and socialization processes associated with a
- 3 provision, right down to medical school, sort of push in
- 4 the -- the direction of understanding the human person
- 5 in a way that's arguably quite distinctive from the way
- 6 people used to treat in medicine or think about the
- 7 human person in medicine.
- R Q Yeah, understood. So but your point, if I'm
- 9 reading paragraph 56 correctly, your point is not that
- 10 they've, you know, picked one of two camps. The point
- 11 is that they picked the wrong camp, that the orthodox
- 12 world view is --
- 13 A You know, I certainly think we are not a mind
- 14 and a self occupying a body. Right?
- 15 Q So your expert opinion aligns with the Orthodox
- 16 World View in Exhibit 14.
- 17 A More so than that.
- 18 O Okay.
- 19 A I would have to go through each of these and
- 20 see them.
- 21 Q So I just want to -- earlier when we talked
- 22 about Exhibit 14 you said that was just a survey of
- 23 ordinary folks with non-expert positions; right?
- 24 A Uh, yeah.
- 25 Q Exhibit 14.

- 1 A Yeah.
 - 2 Q That's the survey.
 - 3 A Right.
 - 4 Q Um, and in your discussion section in Exhibit
 - 5 14 you use this progressive versus orthodox world view
 - 6 to explain support or opposition to gender-affirming
 - 7 care.
 - 8 A I think -- I think we're trying to interpret
 - 9 the data. So why do this many people say this on a
 - 10 survey, why do this many people say that. And if you
 - 11 can -- I will show you -- we didn't come to it with that
 - 1 can -- I will show you -- we did
 - 12 frame in mind --
 - 13 Q Yeah.
 - 14 A -- but table 2 of that Exhibit 14.
 - 15 Q Yeah.
 - 16 A Column 4 and 5, it's all model 4 and then
 - 17 voters only, model 5.
 - 18 Q Yeah.
 - 19 A If you go down to political identity and
 - 20 behavior, the pro-choice coefficient in terms its P
 - 21 value, which you don't see reflected here. But you get
 - 22 a sense of it in the P value.
 - 23 Q Yeah.
 - 24 A Is that it was probably the single best
 - 25 predictor of what people thought about this question.

- 1 Q Understood.
- 2 A The outcome variable. So to me, like when we
- 3 saw that, wow, this sort of comports with Hunter's
- 4 thesis, which was sort of progressive and orthodox. But
- 5 Hunter didn't talk about transgender stuff because that
- 6 really wasn't on the radar when he wrote his original
- 7 work on this.
- 8 So my co-author and I sort of created this
- 9 table of trying to understand, well, what is the
- 10 orthodox and progressive understandings here and can
- 11 they help us understand why people have answered the way
- 12 they did, especially in light of the idea that how they
- 13 characterize themselves as pro-choice or pro-life was
- 14 tightly associated with the answer they gave to the
- 15 question about adolescent treatment of gender dysphoria,
- 16 which, you know, is somewhat striking to us.
- 17 Q Yeah.
- 18 A And so this was an interpretive lens through
- 19 which we discussed this.
- 20 Q And if I read the discussion section right --
- 21 sorry, I'm not an expert, so if this is wrong just tell
- 22 me. But the conclusion was that people with the
- 23 progressive world view would, in the main, support
- 24 gender-affirming care for adolescents. People with the
- 25 orthodox world view would oppose it.
- Page 155

- 1 A Yeah.
- 2 Q And does that help explain why? I mean, is
- 3 your conclusion that that helps explain why they oppose
- 4 it or support it?
- 5 A Yeah. I mean, I talk a little bit about how
- 6 people describe, well, how does this become a culture
- 7 war issue?
- 8 Q Yeah.
- 9 A And this is one of the ways in which it has
- 10 become a culture war issue, is because, quite frankly,
- 11 unbeknownst to me when I did the survey, it's tightly
- 12 associated with how people think about their attitudes
- 13 about abortion. So I was somewhat surprised by that. I
- 14 don't always go in thinking I know exactly -- especially
- 15 in a regression model, like what's going to be
- 16 associated with that.
- 17 Q So --
- 18 A Especially given the fact that after given the
- 19 fact after control for a variety of things, these things
- 20 are still expensive. The study was expensive --
- 21 Q Explanatory.
- 22 A -- was consistently significant and with a
- 23 fairly strong effect.
- 24 Q Understood. So the -- the part of the
- 25 discussion section I'm curious about, though, is the

- 1 idea that the reason someone might oppose
- 2 gender-affirming care for adolescents is because they

Page 156

- 3 have the orthodox world view, even they don't use that
- 4 language for it?
- 5 A Yeah, I think that's probably fair.
- 6 Q Okay. And that was a survey of ordinary people
- 7 and the reason they would oppose gender-affirming care;
- 8 correct?
- 9 A Right. But it's not -- they don't offer that
- 10 explanation. They just answer questions on a survey.
- 11 Q Understood.
- 12 A And we analyze data and effect sizes, we try to
- 13 understand where did this come from.
- 4 Q I understand. But the world view that you
- 15 claim in Exhibit 14 would lead somebody, an ordinary
- 16 person to affirm -- oppose gender-affirming care is what
- 17 you pointed me to when I asked for your expert opinion
- 18 that gender medicine distorts the unity of mind and
- 19 body. And I'm just trying to --
- 20 A Can you just backtrack and say that again?
- 21 Q Sure. We just talked about Exhibit 14 and it
- 22 was discussed that one of the conclusions in Exhibit 14
- 23 is that a person with the orthodox world view with no
- 24 expert background would opposed gender-affirming care
- 25 for adolescents based on that world view.

Page 157

- 1 And when I asked you to explain the statement
- 2 in paragraph 26 of your rebuttal -- paragraph 56.
- 3 A Right.
- 4 Q I'm sorry -- that is your expert view, that
- 5 gender medicine distorts the view of mind and body --
- 6 A Uh --
- 7 Q -- and you pointed me to what that means to
- 8 Exhibit 14.

14

- 9 A When I'm writing this I'm saying -- so, as I
- 10 said, I cite ordinary Americans have critical opinions
- 11 and some are endorsing. But when you look at the
- 12 profession as a whole, right, this is why I conclude the
- 13 rebuttal with a little word about Hippocrates. Right?
 - I think the unity of mind and body, once
- 15 characterized medicine to the whole person, et cetera.
- 16 I think it does not -- and certainly not in gender
- 17 medicine today I think people definitely think one --
- 18 that the mind and the body are quite distinctive things
- 19 and it's their job to help bring the body into alignment
- 20 with the mind.
- 21 Q Yeah. But as I -- as I read paragraph 56 I
- 22 don't see you to be saying, you know, transgender
- 23 medicine has gone awry by picking one interpretation
- 24 within the progressive or orthodox world view. I see 25 you saying it's wrong because the orthodox world view is

Page 158 Page 160

- 1 correct.
- 2 MR. CANTRELL: Object to form.
- 3 Q (By Mr. Richardson) You say, "This is an
- 4 example of job conditioning," and then you say, "It has
- 5 resulted in a distorted understanding of the human
- 6 person as a unity of mind and body."
- 7 A Okay.
- Q And that's your expert view. 8
- A Yes.
- 10 Q And when I asked you what that meant you
- 11 pointed me to the reason an ordinary American might
- 12 oppose gender-affirming care without any expertise?
- 13 MR. CANTRELL: Object to form.
- 14 A Except I -- you know, these ideas animate
- 15 professionals, not just normal people. It's not as if
- 16 health professionals don't have understandings that are
- 17 incontinent with how regular people might think about
- 18 something. I think they were probably more reflective
- 19 on it. Right?
- 20 So we apply the template of these two things to
- 21 explain why regular people will have particular
- 22 attitudes about it. Because they would not be able
- 23 to -- if we asked a follow-up question, Why did you say
- 24 yes or no to this particular question, you know, they
- 25 wouldn't give you an articulation about this.
- Page 159
- I actually think medical professionals probably
- 2 be more articulate about it and I would expect them to
- 3 agree with most, if not all, of the body autonomy
- 4 aspects, which I think is indicative of what I had
- 5 talked about as ideological colonization.
- Q (By Mr. Richardson) So your expert opinion is
- 7 that the medical profession long adhered to an orthodox
- 8 world view.

1

- 9 MR. CANTRELL: Object to form.
- 10 A I don't know what that would necessarily look
- 11 like in early, you know, medicine prior to 1950
- 12 necessarily. But the idea that doctors think that, you
- 13 know, one can be born into the wrong body I think is --
- 14 I would state is relatively new.
- Q (By Mr. Richardson) Okay. And in paragraph
- 16 56 or -- yes, you call that distorting the unity of mind
- 17 and body. When you use the word "distort" there, is
- 18 that a medical judgment? What do you mean by "distort"?
- A Is it a medical judgment? No. An
- 20 understanding of the human person is a philosophic and
- 21 perhaps anthropologic understanding. It's a term
- 22 that -- just to repeat myself, that one can be born into
- 23 the wrong body signals this dualism that I don't think
- 24 characterized most medical professionals.
- 25 Q Okay. Is that -- is it an ethical judgment --

- A Is it an ethical judgment?
- 2 Q -- in any way?
- A No. If I -- all the stuff I have written about
- 4 ideological colonization, um, articulates how particular
- 5 activists, clinicians, researchers, et cetera, have
- 6 helped move the American Academy of Pediatrics, the
- 7 American Medical Association, et cetera, in directions
- 8 that sort of foster this -- this notion.
- So, for example, I talk about in one of those
- 10 reports how the American Medical Association can hold in
- 11 tension its criticism regarding the Supreme Court case
- 12 about capitol punishment for minors. Minors are not
- 13 able -- not mature enough to reflect and the consequence
- 14 of their actions until they are age 25. They don't have
- 15 pre-frontal cortex business (sic.).
- And that's actually a piece of kind of
- 17 conventional wisdom out there. Right? Like half of all
- 18 marriages end in divorce. That's a piece of
- 19 conventional wisdom. You know, your mind isn't
- 20 completely developed until you're age 25. Piece of
- 21 conventional wisdom. But behind that is a fair amount
- 22 of social -- or social and medical science -- medical
- 23 science.
- 24 So I think that you see this happen where they
- 25 can say, Ah, we can't hold youth responsible until they
 - Page 161
- 1 are 25 for capitol crimes in quite the same way as we
- 2 might have. And we also think youth are capable of
- 3 making dramatic distinctions about their physical,
- 4 biological, physiological future well before age 25,
- 5 including, say, 13, 14, 15.
- Holding those two in tension would seem to
- 7 signal that -- you know, the ideological capture of the
- 8 American Medical Association, they once sort of
- 9 protected and liked to see themselves still as
- 10 protecting children and, yet, they are comfortable with
- 11 recommendations that are -- can be rather destructive to
- 12 the body.
- 13 Q I see. So just to step back.
- 14
- 15 Q If there were abundant clinical trials showing
- 16 that gender-affirming medical care improved the mental
- 17 health of adolescents with gender dysphoria, would you
- 18 support providing that care?
- 19 A We're talking about speculation. Like, it
- 20 doesn't exist.
- 21 Q If it did exist --
- 22 A If it did --
- 23 Q -- would you support providing that care?
- 24 A -- exist? You know, I haven't given much
- 25 thought to that because I would be really surprised if

- 1 the kind of clinical trial that people sought -- and 2 we're talking about trials, not only of one method
- 3 versus another method, but like intra-methods, like how
- 4 much dosage of this versus that, the age at which things
- 5 should be done. Right? So WPATH is about to issue
- 5 should be done. Right. 50 W171111 is about to issu
- 6 updated standards of care that bump the ages for its
- 7 recommendations down in age.
- 8 You know, it's not the result of clinical
- 9 trials that compared doing this at one age versus
- 10 another age.
- 11 Q I understand that. I guess my question is if
- 12 there were abundant clinical trials showing that
- 13 gender-affirming medical care improved mental health for
- 14 adolescents with gender dysphoria --
- 15 A Improve -- again, here I get into my
- 16 methodological cap. How did they measure mental
- 17 improvement?
- 18 Q I mean, assume it was a clinical trial that
- 19 satisfied your standards for such a trial.
- 20 A Which are probably pretty high.
- 21 Q Pretty high. Okay.
- 22 A But it's not outrageous. I mean, these are
- 23 clinical trials that they do for cardiac medicine.
- 24 Q I understand. I just want to come back to the
- 25 question if such a trial, if these trials were done

- Page 163
- 1 would you support providing care --
- 2 A Support what?
- 3 Q -- gender-affirming care under those
- 4 circumstances?
- 5 A Gender-affirming care is defined by cross-sex
- 6 hormones, surgery as a minor?
- 7 Q Let's just say puberty blockers and
- 8 gender-affirming hormones.
- 9 A At what age?
- 10 Q At any age supported by the clinical trial.
- 11 A Using the Dutch protocol --
- MR. CANTRELL: Object to speculation.
- 13 A -- or not the Dutch protocol where --
- 14 Q (By Mr. Richardson) Okay. So I just to make
- 15 sure I -- so it sounds like you don't have an answer to
- 16 the question of if there were abundant clinical trials
- 17 what you would --
- 18 A I don't think about -- a whole lot about what's
- 19 not present. Right? Like if those things existed, you
- 20 know, would I be here? I don't know. I -- it's just
- 21 not a realistic situation.
- 22 Q So I'm trying --
- 23 A I do agree that, you know -- I do find myself
- 24 more into the bodily integrity side of this model than
- 25 the bodily autonomy. I think, you know, the barrier to 25

- Page 164
 1 permitting adolescents to undergo surgery on a perfectly
- 2 healthy tissue has got to be awfully high, higher
- 3 barrier than we're currently seeing.
 - Q So given that you fall, in your words, on the
- 5 bodily integrity side, do you have reasons for opposing
- 6 gender-affirming care for adolescents apart from the
- 7 critiques of the literature reflected in your expert
- 8 reports?
- 9 A You know, I hate to disappoint you, but I come
- 10 to these things accepting what is the situation here.
- 11 And I don't often think about, Oh, let's envision a
- 12 world where none of these things happen. Right?
- And so one of the reasons I have agreed to
- 14 write on this topic is reported somewhere in here is
- 15 that I thought it was rationale for the State of
- 16 Arkansas to say this is -- we've got to put a stop to
- 17 this because the situation is kind of -- the medical and
- 18 clinical situation seems to be in disarray. The
- 19 professional organizations are saying one thing. The
- 20 clinicians, even among the affirmatives, are openly
- 21 disputing now in print. You know, something is wrong.
- 22 Q I understand. But when I asked you for your
- 23 views on gender-affirming care for adolescents, you
- 24 pointed me to the idea that you're closer to the bodily
- 25 integrity side.

- 1 A Yes.
- 2 O What does that add?
- 3 A What does that add?
- 4 Q Beyond the critiques of the literature
- 5 reflected in your report.
- 6 MR. CANTRELL: Object to form.
- 7 A What is my support of this add beyond the
- 8 critiques of the --
- 9 Q (By Mr. Richardson) You said that one reason
- 10 you oppose -- or that you think there might be a
- 11 rationale reason to ban care --
- 12 A Right.
- 13 Q -- is the state of the literature surrounding
- 14 that care.
- 15 A Right.
- 16 Q Are there other reasons?
- 17 A Maybe, perhaps.
- 18 Q Can you enlighten me on what those might be?
- 19 A No. If you want to look down here I can look
- 20 at this and say, you know, we're not born into a body
- 21 Q And to clarify, you just gestured to the bodily
- 22 integrity --
- 23 A Right.
- 24 Q -- list of Exhibit 14?
 - A Yeah, the second one in that list.

1 Q Okay.

- 2 A I don't think people are born into a body.
- 3 They are born as a mind-body unity. Right? So anything
- 4 that sort of wishes to radically separate mind from
- 5 body, you know, uh, you know, I cannot speculate about
- 6 some other conditions or something. But it seems like
- 7 it signals a commitment to fundamental approach to the
- 8 human person that I find uncompelling.
- 9 Q Okay. So do you think it's realistic, given
- 10 your comments earlier about the state of the literature,
- 11 that it's realistic that there could be research
- 12 demonstrating the effectiveness of gender-affirming
- 13 care?
- 14 A It could be realistic -- there's already claims
- 15 of such. Right?
- 16 Q Yeah. But when I asked you earlier what if
- 17 randomized controlled trials supported gender-affirming
- 18 care, you said you can't even imagine such a world.
- 19 A It seems unlikely and it's -- your experts,
- 20 when we talk the lack of clinical equipoise.
- 21 Q So you cannot envision what research would look
- 22 like supporting gender-affirming care for adolescents?
- 23 A I don't see it happening and neither do your
- 24 expert witnesses.

1

7

25 O But what would it look like if it did exist?

- Page 166 1 A Um-hum.
 - 2 Q And I'm just looking for what would adequate

Page 168

- 3 research look like in your expert opinion on this
- 4 subject?
- 5 A Adequate research should involve some measure
- 6 of clinical trials of a sort. It seems very difficult
- 7 right now, given that -- you know, I understand what
- 8 Dr. Antommaria talks about while it's very difficult
- 9 when you have one group that is given the treatment that
- 10 so many kids seem to want, affirming treatment, compared
- 11 to some other form of treatment, right, that they are
- 12 not interested in as much, to track them long term.
- 13 It's a difficult medical research situation.
- 14 Q Understood.
- 15 A So that doesn't even happen. But more of it --
- 16 it never really did happen, which is somewhat puzzling
- 17 to me.
- 18 Q But you think it could happen? I think your
- 19 report references that people should be doing randomized
- 20 clinical trials on the subject.
- 21 A Of -- you know, if you can't get it to where
- 22 you have equipoise, like people don't care if they are
- 23 in one or the other, I mean, which is rare. But take,
- 24 for example, my father when he was diagnosed with
- 25 melanoma, 1998. He was offered a clinical trial of the

Page 167

- A What would it look like if it did exist?
- 2 MR. CANTRELL: Object to the form.
- 3 A You know, I'd have to -- if it did exist and it
- 4 used particular methods and samples and had effect sizes
- 5 that were impressive, I would have to sort of wonder am

Q (By Mr. Richardson) You said you wonder that

- 6 I missing something. Right?
- 8 about why --
- 9 A Am I missing something? Because right now all
- 10 I see when I talk about this literature is minor effect
- 11 sizes, a lack of long-term studies.
- 12 You know, for example, you know, it's been
- 13 documented recently that women who undergo menopause
- 14 early, lack in estrogen, et cetera, have greater risk
- 15 for cognitive decline early in life. So we're talking
- 16 about people in this menopause like before age 40. What
- 17 it's like if you forced it on somebody at age, you know,
- 18 17 or 18, whether as a minor or, you know, a young
- 19 adult, like force it. We'd have to track people for a
- 20 long time. Frankly, we ought to be tracking people for
- 21 a long time on this stuff.
- 22 So I don't know if that answers your question.
- 23 Q Well, I suppose I'll reframe it. Your -- your
- 24 expert report is about the purported inadequacy of
- 25 research of effectiveness; right?

- 1 standard treatment, chemotherapy, versus immunotherapy
- 2 they were testing. Right? But the conditions for it
- 3 were different. You know, the second involved a lot
- 4 more time in the hospital, but it was a prospective
- 5 possible -- not so much cure, but it seemed better.
- 6 He picked against it. He said, "I don't want
- 7 to get involved with this," because he didn't want to be 8 in the hospital for so long. Right?
- 9 You have situations where equipoise is
- 10 difficult, but that reached the stage where you could
- 11 still do a clinical trial. Because some people were
- 12 interested enough and said, Okay, I can go with the
- 13 standard --
- 14 Q I see. So trials --
- 15 A You don't know that you're in that standard
- 16 versus the experimental design, um --
- 17 Q Yeah. So I -- so your saying that trials
- 18 should be done in this area. Your expert report says
- 19 that people be should be doing randomized clinical
- 20 trials in this area?
- 21 A We do this in most areas of medicine.
- 22 Q Understood. But when I'm asking you to define
- 23 what a successful trial would look like, you haven't
- 24 given me a definition.
- 25 A Distinctions in outcome, notable distinctions

- 1 in outcome. Right? So Pachankis and Branstrom
- 2 characterize their article, as I recall, almost as sort
- 3 of like this neat experiment -- it's not quite an
- 4 experiment -- but like those who have this and those who
- 5 didn't and you compare the distinctions.
- We can get close with some kinds of data. But
- 7 in that case, you know, if the effect size had been
- 8 remarkable, dramatic, like, Wow, that's something.
- 9 Right? But like many things in this domain, like, they
- 10 are small --
- 11 Q I understand. I guess what I'm --
- 12 A -- given the magnitude of the medical
- 13 invasiveness of the treatments.
- 14 Q Okay. But it sounds like you're saying there
- 15 is at least theoretically possible a randomized clinical
- 16 trial --
- 17 A I would --
- 18 Q -- that would address --
- 19 A -- revisit my presumptions --
- 20 Q Okay.
- 21 A -- at that point.
- 22 Q And if such a trial were performed, would you
- 23 have any reason, apart from your concerns about the
- 24 state of the science, to oppose --
- 25 A The trial?

1

Page 171

- Q -- gender-affirming care?
- 2 A I'm sorry. I misjudged where you were going.
- 3 Q We just talked about the evidence that would be
- 4 adequate to address the concerns you raise in your
- 5 report. If that evidence existed, would you still
- 6 oppose gender-affirming care for adolescents?
- A Since I didn't come to work on this project in
- 8 the absence of an answer to that question, I frankly
- 9 don't know how to approach it. The same question was
- 10 posed to me during the DeBoer v. Snyder.
- 11 I don't really think about non-real options
- 12 that haven't been done. Right? I mean, I have -- like
- 13 I said, I fit with this sort of bodily integrity aspects
- 14 of this, but I didn't sign on to write an expert witness
- 15 report because I only cared about these things. I
- 16 signed on because I had been observing the science of
- 17 this and kind the ideological colonization that had been
- 18 happening and I thought I -- you know, I objected to
- 19 sort of the conduct of medical scientists in this
- 20 domain.
- 21 Q Was the bodily integrity part of your world
- 22 view part of what led you to agree to participate in
- 23 this case?
- 24 A Perhaps. It's not things like I don't sit
- 25 around and think, Oh, given that I held commitments to

Page 172 1 the bodily integrity list, therefore, I should say yes

- 2 to this. I did not anticipate it.
- 2 to this. I did not and tipate it.
- 3 But, yeah, I mean, I don't deny that I think
- 4 these things are true and good.
- 5 Q Okay. So I'm just trying to understand. So
- 6 your report says that certain conclusions follow from
- 7 the weakness of the data in this area?
- 8 A That's my angle here. That's what I do.
- 9 Q I understand. I'm asking if the data changed
- 10 would your conclusion change?
- 11 A It is a possibility that I have not
- 12 entertained, and if the data changed then I entertain
- 13 that possibility.
- 14 Q Okay. So it's a possibility that you would
- 15 adjust your view on this question in response to new
- 16 evidence?
- 17 A As I said earlier, like, if my own children
- 18 were faced with this, and it is a challenging diagnosis,
- 19 et cetera, I think I would counsel them to be patient
- 20 and I would try to sort of help them understand that the
- 21 ramifications of these things, et cetera. But I don't
- 22 think much about what I would tell every other parent.
- 23 Q Okay. Would you counsel them to not pursue
- 24 gender-affirming care?
- 25 MR. CANTRELL: Object to form.

- A I think I would say: Think very hard before
- 2 your children make decisions that you do or don't agree
- 3 with that make permanent changes to their body at a time
- 4 when they're physical and mental development is hardly
- 5 complete.
- 6 Q (By Mr. Richardson) Okay. Sorry to jump all
- 7 over here. I do want to follow up on one thing that you
- 8 said earlier before we break for lunch here.
- 9 You mentioned earlier that you were also
- 10 reviewed by UT for, I think you called it the promotion
- 11 case.
- 12 A Correct.
- 13 Q Can you just describe that --
- 14 A I don't know how we got off that subject a
- 15 while ago.
- 16 Q Yeah, yeah. Sorry.
- 17 A What about it?
- 18 Q Can you describe what you meant by the
- 19 promotion case?
- 20 A Promotion to full professor. There is two
- 21 promotions that you get in your academic career in the
- 22 United States. Assistant to associate with tenure.
- 23 Q Okay.
- 24 A And associate to full.
- 25 Q Okay. And that's what you were referring to

Page 174 Page 176 1 earlier? 1 remarkably weak on the prospect that gender-affirming 2 A The last of those. 2 care improves mental health. 3 Q Was the second. And that resulted in you A All right. Give me a page and --4 becoming a full professor at UT? Q And this will be page 70, paragraph 161. A Correct. A Of --MR. RICHARDSON: Well, I think, if it's O Exhibit 1. 6 6 7 all right with you all, we can wrap for lunch and aim 7 A Seventy? Page 70 you say? 8 for --8 Q Yeah. 9 THE WITNESS: Two. 9 A Speculative suicide; right? 10 VIDEO OPERATOR: -- 45 or something. 10 Q Yeah. And you say, "The science behind claims 11 THE WITNESS: 2:50. 11 that such treatments," referring to puberty suppression, 12 (Simultaneous crosstalk.) 12 "lead to sustained improvements in mental health is 13 VIDEO OPERATOR: Okay. This will remarkably weak." 14 conclude media part 3 and we are off the record at 1:08 A Yeah. Well, that -- between the dashes is 15 rather important. "Improvement that cannot possibly 15 p.m. 16 (A break was had.) 16 occur in its absence" --17 VIDEO OPERATOR: We are back on the 17 Q Okay. 18 record at 2:02 p.m. This begins media part 4. Please 18 A Meaning like, this is sort of where you're 19 proceed. 19 looking for causation because what has been offered to Q (By Mr. Richardson) All right. Welcome back. 20 one group is comparable, except in one domain, the 21 I just want to follow up and some things we were talking 21 treatment to what is offered to another group, groups 22 about before lunch. In terms of this idea of the state 22 that are similar to each other --23 of science that exists right now, is it your view that 23 Q Understood. But you think. 24 randomized controlled trials to test the effectiveness 24 A -- preferably randomly assigned. 25 of gender-affirming care for adolescents with gender 25 Q Understood. So but you think that a trial Page 175 Page 177 1 dysphoria are feasible? 1 could be performed that would address the concern you 2 raise here where you say "the data is remarkably weak"? A Types of them are feasible. 3 3 A Let me read the rest of the section to myself. A Especially if we're talking about dosage So I talk about, like, improvement that can't 5 trials. Certainly, those things are minimally feasible. 5 possibly occurred in its absence, not only am I talking 6 about the lack of clinical trials, but also -- but also 7 A But even if you want to think about how do you 7 the leaps in mental health, what's already out there are 8 counsel nine-year-olds, ten, eleven -- now, different 8 sort of notable, not just sort of tiny effect sizes, 9 forms of counseling, different forms of sort of psych 9 things like that. 10 evaluations that are more extensive than others. I 10 Q Yeah, I understand. 11 mean, there is just lots of ways in which one can do a A We're talking about a major kind of treatment. 11 12 comparison between types of treatment. I think it's 12 One wants to see, kind of heroic affects. Right? With 13 cancer, it's like I don't know what happened to the 13 Swedes or Fins, that in their complaint some things that 14 are going on, said we're only going to do -- going to 14 clinical trial that my father decided not to go in, but 15 deliver treatment while under, I think they said 15 were they dramatically different? 16 research trials or clinical trials. I'm not sure what 16 You know, sometimes they will say, Hey, if it's 17 they are working on exactly. But these things are 17 just one month difference of life it's not worth the 18 feasible, yeah. 18 additional hazards and rigors of the treatment. But 19 Q Yeah, I understand. So your report critiques 19 like in here you want to start -- you want to see a 20 the lack of trials related to both hormone blockers and 20 dramatic improvement --21 gender-affirming hormones? 21 Q I understand. 22 A Could you point that out to me in terms of 22 A -- over the long run. 23 page? 23 Q Yeah. So I'll back up a little bit. Is it

24 feasible to do randomized controlled trials that test

25 the effectiveness of hormone blockers and

Q Oh, sure. Well, I think at one point you

25 call -- let me find it here. You call the evidence

1 gender-affirming hormones?

- 2 A I think it's feasible. I think Dr. Antommaria
- 3 disagrees with me. It depends when you are doing these
- 4 things --
- 5 Q So you think it's feasible in general?
- 6 A It's feasible at least in theory. But I
- 7 recognize the domain in which we're operating, there's
- 8 such a demand for affirmative types of treatment that it
- 9 makes it more difficult to get the condition of
- 10 equipoise where, you know, people are okay with the
- 11 treatment to which they have been assigned or they
- 12 understand, like, you know, this the hazard of being in
- 13 one group versus another group, which is the example I
- 14 used when you opened the questioning is that minimally
- 15 we can do clinical trials on dosing. And I think one
- 16 actually has been done on dosing. I forget for what.
- 17 But even sort of counseling of, say, nine-year-olds or
- 18 something like that. Like do it differently, do it
- 19 twice as long.
- 20 Q Okay.
- 21 A I mean, it's just an example of how these
- 22 things can occur.
- 23 Q Okay. But do you think there could be clinical
- 24 trials beyond just dosing recommendations and content of
- 25 counseling?

1

Page 178 Page 180

- 1 A Adults, children, adolescents, you know, that
- 2 sort of thing.
- 3 Q If multiple studies existed, let's say, on
- 4 hormone therapy, would that change your view about using
- 5 hormone therapy to treat gender dysphoria in
- 6 adolescents?
- 7 MR. CANTRELL: Calls for speculation.
- 8 A It does -- I mean, we're not in that situation,
- 9 so I don't think much about what is possible in the near
- 10 future.
- 11 Q (By Mr. Richardson) Okay.
- 12 A While I strongly encourage the -- you know,
- 13 again, if it's the Swedes or the Fins, but, you know,
- 14 they criticize the research in this area because it's --
- 15 it lacks such studies. I think the Swedes have only, if
- 16 I'm not mistaken, have endorsed treatments using the --
- 17 the original or modified Dutch protocol in a, kind of a
- 18 clinical comparison format.
- 19 Q Okay. Just changing gears here. Do you know
- 20 what HB 1570 is?
- 21 A I'm familiar with it.
- 22 Q If I use terms like "healthcare ban" or
- 23 "Arkansas law," it's referring to the same --
- 24 A Those I'm okay with.
- 25 Q But you know I'm referring to the same thing,

Page 179

- 1 Arkansas law, state of fact.
- 2 A Got it.
- 3 Q Okay. Have you read HB 1570?
- 4 A I have.
- 5 Q Okay. What do you understand HB 1570 to do?
- 6 A To restrict -
- 7 MR. CANTRELL: I'm going to object that
- 8 Dr. Regnarus is not an attorney and can't offer --
- 9 MR. RICHARDSON: Okay. That's noted.
- 10 Thanks.
- 11 A To curb the conduct of treatment of gender
- 12 dysphoria to minors from treatments using hormones and
- 13 surgical methods.
- 14 Q (By Mr. Richardson) And when you say "curb," do
- 15 you understand that it prohibits --
- 16 A Correct.
- 17 Q -- those treatments? Okay.
- 18 Is it your view that the government should
- 19 prohibit doctors from providing gender-affirming medical
- 20 care to minors regardless of the circumstances?
- 21 A Could you, sort of, break that down slowly?
- 22 Q Is it your view the government should --
- 23 A "The government," meaning the State of
- 24 Arkansas?
- 25 Q The State of Arkansas.

Page

- A Beyond -- be specific, please.
- 2 Q So are there randomized control trials that
- 3 could show that receiving gender-affirming care versus
- 4 not receiving gender-affirming improves health?
- 5 A So when you say not receiving -- I'm presuming 6 that one can get everything except one particular thing
- 7 to look at the exact --
- 8 Q Sure. Let's call it hormone blockers.
- 9 A Okay. Fine. So is that the only difference
- 10 between groups?
- 11 Q Is it possible to design a study like that?
- 12 A Possible to design a study like it, yes. Is
- 13 it -- you know, I recognize and I think I even agreed
- 14 with Dr. Antommaria that it's tough to see it work in
- 15 reality.
- 16 Q Okay.
- 17 A And I do care about what is real and what is 18 possible.
- 19 Q Sure. So given that it's at least possible to
- 20 design such a study, if such a study existed would your
- 21 views on gender-affirming care for adolescents change?
- 22 A If a study existed. I would be pleased if a
- 23 study existed. But, really, a domain like this deserves24 multiple studies.
- 25 Q Okay. If multiple studies existed --

1 A Okay.

- Q Should prohibit doctors from providing
- 3 gender-affirming medical care to minors regardless of
- 4 the circumstances?
- MR. CANTRELL: Object to form.
- 6 A "Regardless of the circumstances," what do you
- 7 mean by that?
- Q (By Mr. Richardson) Are there any circumstances
- 9 under which you think that should not be the case?
- A You know, I hate to punt on this, but, you
- 11 know, I look at the situation, I think the situation is
- 12 problematic in terms of, like I said, the ideological
- 13 capture, et cetera, and the internal disputes that are
- 14 going on, the modest science. And, frankly, I think the
- 15 state is merited in saying, "We're going to call a halt
- 16 to this because the situation is untenable."
- 17 Q So is that a yes?
- 18 A Yeah.
- 19 Q Okay. Your report, this is page 4, paragraph 9
- 20 of Exhibit 1.
- 21 A Page 4, paragraph 9. This is December; right?
- Q Yes. Exhibit 1, yeah. Okay. Do you see 22.
- 23 whether you say you make no claims about the most
- 24 prudent course of treatment for a particular patient?
- 25 A Correct.

- Page 183
- Q Is that statement still accurate?
- 2 A Yeah.

1

- 3 Q Does that mean that you recognize that for some
- 4 patients gender-affirming medical care may be
- 5 appropriate?
- MR. CANTRELL: Object to form.
- A It just means that, you know, these are
- 8 individual cases, one -- I might sort of certainly
- 9 empathize. But I look at sort of what's gone on in the
- 10 medical community itself on this, and it would seem to
- 11 be that, you know, it's time for an experiment of sorts.
- 12 Q (By Mr. Richardson) Well, I guess my question
- 13 is: Could gender-affirming medical care ever help any
- 14 single patient?
- 15 A Affirming care?
- 16 Q Could hormone therapy ever help any single
- 17 patient?
- 18 A It sounds like it does in terms of reduction of
- 19 dysphoria.
- 20 Q Okay. So you think that hormone therapy could
- 21 help particular patients?
- A Help meaning like -- you would have to specify
- 23 the outcome.
- 24 Q Improve the mental health of a patient.
- 25 A Mental health as defined by diminished gender

- 1 dysphoria?
- Q Yes.
- A Improved psychological health? I mean, there
- 4 are different domains, some of which are better studied
- 5 than others.
- O Let's take the first one.
- A Dysphoric. The admission of gender dysphoria.
- 8 It's plausible, sure.
- Q Okay. Let's talk about could hormone therapy
- 10 ever help a patients' overall psychological health?
- 11 A Are you talking about minors or adults?
- 12 O Let's do adults first.
- 13 A Okay. What about it?
- Q Could gender-affirming hormone therapy ever 14
- 15 help the psychological condition of an adult patient?
- 16 A Um, probably, yeah.
- 17 Q Okay. And could gender-affirming hormone
- 18 therapy ever help an adolescent with gender dysphoria?
- 19 A It's possible. I think -- I usually
- 20 distinguish in these cases by one's minority status,
- 21 whether you have reached the age of majority and better
- 22 poised to make decisions for yourself. I think we have
- 23 to be, you know, just like the Belmont report and all
- 24 the institutional review boards that I had to go
- 25 through, they seek to protect minors and other protected
- - Page 185

- 1 classes of persons from invasiveness in research.
- Q Okay. But you do think there are individuals
- 3 who may benefit, as adolescents, from hormone therapy?
- A I suspect.
- Q Do you think that cutting off care for a 5
- 6 patient receiving hormone therapy would benefit their
- 7 wellbeing?
- MR. CANTRELL: Object to form.
 - A I have no idea except I understand that they
- 10 would rather not be cut off in care. I understand that
- 11 concern.
- 12 Q (By Mr. Richardson) And when you say you
- 13 understand that concern, is it because you think they
- 14 might be benefitting from that care?
- 15 A It means that I think they want that care and,
- 16 uh, it would be unavailable.
- 17 Q Okay. Could some adolescents who are currently
- 18 receiving gender-affirming medical care be harmed if
- 19 they were required to stop treatment?
- 20 A Could. It's a conceptual, you know. Possible.
- 21 All things are possible.
- 22 Q Do you think it's likely?
- 23 A I do not know.
- 24 Q Okay. Do you support HB 1570?
- 25 A Yes.

Page 186 Page 188 1 Q Okay. And you support the law even though you 1 A All things are possible. 2 believe it's possible that some adolescents currently Q Okay. Are there other medical treatments that 3 benefit from gender-affirming care? 3 you believe patients and doctors should be prohibited 4 MR. CANTRELL: Object to form. 4 from accessing? 5 A Other medical treatments --6 Q (By Mr. Richardson) And you support the law Q Other medical treatments beyond 7 even though you're unsure whether some patients may 7 gender-affirming care. 8 suffer if they stop receiving care? MR. CANTRELL: Object to the form. 9 MR. CANTRELL: Object to form. 9 A I don't think about counter-factuals or 10 A True. 10 non-factuals. 11 Q (By Mr. Richardson) Okay. So if the parents, 11 Q (By Mr. Richardson) So you can't think of any 12 adolescent patient, and doctor --12 other treatments that you would support banning for A This is largely -- sorry to belabor this. 13 adolescents? 14 14 Because my dissatisfaction when I read all this is the MR. CANTRELL: Object to form. 15 you know, we haven't addressed it, but like the surge in 15 A You know, I -- you know, you could perhaps 16 this cases remains largely unexplained. Some of the 16 rattle off some, but I don't actually think about this. 17 plaintiffs' expert witnesses have sought to explain it 17 Q (By Mr. Richardson) Okay. What should the 18 in ways that I think are modest. 18 standards be to determine when it's appropriate for the But, you know, care of minors kind of went government to ban care? 20 along quietly for quite some time and then came this 20 MR. CANTRELL: Again, I'm going to object 21 surge about five or six years ago, maybe a little bit 21 that Dr. Regnarus is not an attorney and can't offer --MR. RICHARDSON: I appreciate that. I'm 22 more, in which case it largely remained unaccounted for. 22 23 And the fact that scholars are uninterested in 23 just asking about what he thinks is appropriate. A What standards are appropriate for --24 explaining that surge, again, fuels this conviction that 24 25 ideological capture has occurred in professional 25 Q (By Mr. Richardson) What standards should Page 187 Page 189 1 societies --1 determine when it's appropriate for the government to Q Understood. I guess I just want to come back 2 ban care? 3 to the question here, which you acknowledge that there 3 A Who would set those standards? 4 are some adolescents could benefit from receiving Q I'm asking your -- your view. 5 gender-affirming care like hormone therapy. A Where would the standards come from? Standards A Could, sure. 6 to which governments are held. 7 Q Okay. And you accept that there are some 7 Q When do you think it would be appropriate to 8 adolescents who would be harmed by no longer receiving 8 ban care? 9 gender-affirming care like hormone therapy? 9 A What kind of care again? 10 10 A Perhaps. Q Any health care. 11 A I am -- I don't know what we mean by -- like, Q Okay. And you, nonetheless, support --11 12 A Depends on how we define "harm." If we define 12 standards that would be set by governments themselves, 13 harm as disappointed, it's not so much harm. 13 courts? Q Well, let's define harm as a reduction (sic.) 14 Q So you think it's appropriate and correct for 15 the state to ban gender-affirming care for adolescents; 15 in gender dysphoria. 16 A A reduction of --16 right? 17 MR. CANTRELL: Object to the form. 17 Q The alleviation of clinical distress --18 (Simultaneous crosstalk.) 18 A I don't disagree with HB 1570, yeah. 19 Q -- caused by --19 Q (By Mr. Richardson) Okay. 20 A -- things like this --20 A Yeah. 21 (Simultaneous crosstalk.) 21 Q And that implies that there are conditions 22 under which you think that sort of ban on care is 22 Q -- gender --23 A -- then we're talking about some degrees of 23 appropriate. 24 subjective judgment. But, yeah, it's possible. 24 A I suppose, yeah.

Q And I'm asking you what those conditions are.

25

Q Okay.

25

- 1 A What those conditions are. It would certainly
- 2 satisfy me more if we had good long-term evidence from
- 3 clinical trials, like I've talked about, in that you
- 4 wouldn't have sort of a rapid surge in patient demand,
- 5 but organizations are entering into and filling the
- 6 gap --
- 7 Q So let's focus on the first thing you said, the
- 8 lack of randomized clinical trials. Would you support a
- 9 system that banned care whenever there were not
- 10 randomized clinical trials to support that care?
- 11 A It depends on sort of the significance of what
- 12 we're talking about. I mean, you can do randomized
- 13 clinical trials on something small. But this is -- this
- 14 is kind of a big deal. This is about life-altering
- 15 circumstances and a minor's biography and history.
- 16 Q Understood. So --
- 17 A Standards have to be pretty high.
- 18 Q So I guess -- so is that a no, that you would
- 19 not support banning care based solely on the absence of
- 20 randomized clinical trials for that care?
- 21 A Please repeat that again slowly.
- 22 Q Would you support banning care solely on the
- 23 basis of a lack of randomized clinical trials supporting
- 24 that care?
- 25 A No.

Page 191

- 1 Q Okay.
- 2 A It would have to be -- you know, that's not
- 3 just the method, it's the measures --
- 4 Q Understood.
- 5 A -- it's the length of time. You know, to see
- 6 the group of scholars in this domain improve their
- 7 analytic capacities, improve their ability to not
- 8 overreach in their conclusions. I mean, like I --
- 9 Q Understood.
- 10 (Simultaneous crosstalk.)
- 11 A -- said, like it should be better. They should
- 12 do better.
- 13 Q Okay. So just to come back to the question.
- 14 The lack of randomized clinical trials alone is not a
- 15 basis to ban medical treatment?
- 16 A Correct, yeah.
- 17 MR. CANTRELL: Object to form.
- 18 Q (By Mr. Richardson) Can you turn to Exhibit 5?
- 19 This is your article "Arkansas and the Politics of
- 20 Experimenting on Children."
- 21 A Okay.
- 22 Q I ask you to look at the second page, please,
- 23 middle paragraph there. Do you see about six lines down
- 24 there's a sentence, "Hutchinson's veto was predicated on
- 25 the idea that it was legislative overreach to obstruct

- 1 the doctor-patient (and family) relationship."
- 2 Do you see that?
- 3 A Yep.
- 4 Q And then you say, "While the legislature's
- 5 primary narrative revolved around longstanding
- 6 objections to medical experimentation on minors." And

Page 192

- 7 then you say, "Both notions have merit to them."
- 8 A Okay.
- Q What did you mean when you said that Governor
- 10 Hutchinson's veto had merit to it?
- 11 A So just for context, I wrote this probably
- 12 after the, you know, what is this -- April 11th. So the
- 13 legislation had recently passed. I was -- my
- 14 information about it came from reading journalistic
- 15 accounts of this, so I'm trusting that the journalists
- 16 had it right.
- 17 So basically I'm saying Hutchinson --
- 18 (Reading) -- was legislative overreach to obstruct the
- 19 doctor-patient (and family) relationship, which,
- 20 typically speaking, matters quite a bit. Right?
- 21 So that's his primary motivation so far as I
- 22 could discern it. And the legislature's primary
- 23 narrative -- well, I think there were several
- 24 narratives -- revolved around their objection to medical
- 25 experimentation on minors.

- 1 Q Okay.
- 2 A But there were other objections to it as far as
- 3 Loculd tell
- 4 Q When you say that Governor Hutchinson's concern
- 5 about overreach into the doctor-patient (and family)
- 6 relationship, you say that has merit generally?
- 7 A Generally, sure.
- 8 Q Okay. What do you mean by that?
- 9 A That's something that should be understood as
- 10 worthy of respect.
- 11 Q Okay. So that --
- 12 A Not worthy of absolute respect, but, like, that
- 13 counts basically, in parentheses.
- 14 Q Okay. And that should be like the default
- 15 position for medical care?
- 16 A No. It's something that shouldn't be ignored;
- 17 right?
- 18 Q Okay.
- 19 A What parents and a kid and the doctor think
- 20 about for each other is like, that's worthy of
- 21 consideration
- 22 Q Okay. And does that ordinarily council in
- 23 favor of letting the doctor and parent and adolescent
- 24 make the choice?
- 25 MR. CANTRELL: Object to form.

- 1 A I suspect it has to do with what they are
- 2 talking about. Right? Historically, yes, because we're
- 3 not usually talking about very dramatic things that are
- 4 life altering.
- 5 Q (By Mr. Richardson) Okay.
- 6 A Although it can, right? I mean, cancer
- 7 treatments. For example, I have family friends whose, I
- 8 don't know, seven or eight-year-old daughter was
- 9 diagnosed with leukemia and the mother -- certainly
- 10 mother, if not the father wrestled with do they want to
- 11 put their child through this rigorous chemotherapy
- 12 schedule. And, you know, the doctor typically, like
- 13 doctors mostly sort of want to improve people's lives,
- 14 they think this is the pathway to doing so. It was the
- 15 standard protocol.
- And but she wrestled with it. And I have no
- 17 idea what the doctor-patient-family interactions were
- 18 about that, but one can recognize that they ought to be
- 19 respected.
- 20 Q Understood. So given the two concerns that you
- 21 say both have merit here --
- 22 A Um-hum.
- 23 Q -- do you think there's some way to balance
- 24 those two concerns with respect to gender-affirming
- 25 care?

1

- Page 195
- 2 Q Okay. What would that look like?
- 3 A I have no idea.
- 4 Q But you think that the two concerns could be
- 5 balanced?
- 6 A The two could be balanced.

A Perhaps, you know.

- 7 MR. CANTRELL: Object to the form.
- 8 A I think like if -- and I've said this in the
- 9 reports. Like if you see, I'd say, better behavior on
- 10 the part of researchers, clinicians, you know, you'd
- 11 have a situation where I think you wouldn't have people
- 12 who are members of professional organizations wondering
- 13 why, you know, they're AAP hierarchy is telling them to
- 14 alter how we treat minors and gender dysphoria.
- 15 I'm losing my train of thought. What was your
- 16 original question?
- 17 Q (By Mr. Richardson) The question was could
- 18 Arkansas have done something differently besides banning
- 19 care to balance the two concerns you mentioned?
- 20 A I'm sure they could have. Again, you know, I
- 21 don't consult on political matters.
- 22 Q But you're offering --
- 23 A Those things could have been different. I
- 24 think they have some sort of penalty to the care
- 25 providers if I'm not mistaken.

1 O Yeah.

- 2 A That could have been different. It could have
- 3 been harsher, it could have been no penalty. Lots of
- 4 things could have been different about the legislation
- 5 I think the Arizona does not ban hormones, but only
- 6 surgery I think. I mean --
- 7 Q Would that system -- would you support that
- 8 sort of law?
- 9 A I don't even know if that's the law.
- 10 Q Well, let's say it was, a law that banned
- 11 surgery but not hormone therapy.
- 12 A Again, I don't think about counterfactuals. I
- 13 deal with what's in front of me.
- 4 Q Well, I understand. But your report suggests
- 15 that, and what you said today, suggests --
- 16 A Right.
- 17 Q -- that a ban on hormone therapy --
- 18 A Yeah
- 19 Q -- is appropriate, and a ban on surgery is
- 20 appropriate.
- 21 A Sure, yeah. I mean, surgery is --
- 22 Q I understand.
- 23 A -- more --
- 24 Q So I'm asking --
- 25 A -- obviously dramatic.

Page 197

- 1 Q So I'm asking, you just suggested an
- 2 alternative from Arizona which would ban some care but
- 3 not others. Is that something you would support?
- 4 A Alternatives are possible.
- 5 O Yes.
- 6 A Would I support it? I haven't thought much
- 7 about it. Just I recognize when I read, I'm like, Okay,
- 8 they decided to do this a little bit differently than
- 9 Arkansas.
- 10 Q Okay. But you think there are options apart
- 11 from Arkansas law short of a total ban that would
- 12 address the legislature's concern that you talk about
- 13 here in your article?
- 14 A I suspect if the Arkansas legislature had seen
- 15 a pathway to, you know, greater -- better science on it
- 16 they might have never pursued it in the first place. I
- 17 don't know. Why did this come up now in 2021 rather
- 18 than in 2020, 2019, 2018.
- 19 I mean, again I think it's part of this sort of
- 20 inexplicable tidal wave of cases. Where did this come
- 21 from? Why aren't the researchers studying this? This
- 22 is the criticism you get from some of the overseas
- 23 countries on this.
- 24 Q Gotcha. Can you turn to the last paragraph of
- 25 that article?

Page 200 Page 198 1 VIDEO OPERATOR: Mr. Richardson, I'm 1 branch has always done clinical trials. It's just like 2 you look at cancer trials, cardiac drug trials. Like 2 hearing noise from your pen. 3 MR. RICHARDSON: Oh, sorry. You want me 3 they're all trials; right? Q Okay. 4 to put this down? 5 VIDEO OPERATOR: Yeah. A National Institute of Health is full of 6 MR. RICHARDSON: Gotcha. 6 clinical trials that people can enroll in if they fit 7 THE WITNESS: Last paragraph? 7 the criteria. 8 Q (By Mr. Richardson) Last paragraph. It's the Q Yeah. So when you say "in every other branch 9 final sentence there. Do you see where it says, "But 9 of medical research except this one," did you attempt to 10 what nobody has at their disposal are the results of 10 exhaustively look at medical branches? 11 kind of rigorous trials that Americans have long 11 A I did not attempt to exhaustively look at them. 12 benefitted from in every other branch of medical 12 Q So was saying "every branch except this one" an 13 research except this one." Do you see that? 13 overstatement, inaccurate? A Yeah. 14 A It's neither of those. It's potentially an 15 Q What did you mean by "rigorous clinical 15 overstatement. 16 Q Potentially an overstatement. Okay. 16 trials"? 17 A I'm not sure I remember my state of mind 17 Is it rare for medical treatments to be 18 exactly when I wrote this, but it's the kind of stuff 18 unsupported by clinical trials? 19 that I've just been describing to you. It's diversity A Is it rare for clinical treatments to be 20 of measures, diversity of longevity of the study itself, 20 unsupported by trials? Can you give me an example? I'm 21 diversity of treatment. There's lots of things that 21 just trying to get my head around --22 could be done here and it's just sort of stunning that 22 Q I'm just asking your view. You talked about 23 they are not, and there seems to be no interest in doing 23 the state of medical research overall. So I'm just 24 so --24 curious, overall is it rare for medical treatments to be 25 Q Okay. 25 unsupported by clinical trials? Page 199 Page 201 A -- which is particularly troubling. A There's degrees of support. I mean, I think 1 2 Q So is it your view that there are clinical 2 Dr. Antommaria highlighted that. What I'm suggesting is 3 I think that's rare to have such invasive treatments 3 trials like you referred to there supporting all 4 treatments that doctors use in this country? 4 that have not been subject to some for of clinical 5 trial. 5 A Say that again. I'm trying to get my head Q Okay. But do you have any idea how often Q Is it your view that there are clinical trials 7 medical treatment are administered to patients without 8 supporting all treatments that doctors use in the 8 the support of a clinical trial? 9 country? 9 A I don't. 10 10 MR. CANTRELL: Object to form. Q Okay. Is it possible that --11 11 A There are a ton of clinical trials going on at A All treatments for --12 Q (By Mr. Richardson) For anything at all. 12 any given time. 13 A -- gender dysphoria? 13 Q Understood. 14 Q No. For anything at all. 14 (Simultaneous crosstalk.) 15 A Forgive me. Say it again now that I've got the 15 A -- looked at them. 16 frame in mind. 16 Q But you don't know how likely it is for Q Yeah. Is it your view that there are clinical 17 treatments to be supported by those types of trials? 18 trials supporting all treatments that doctors use in 18 A Of all possible conditions, that would be an 19 this country? 19 overreach. 20 MR. CANTRELL: Object to form. 20 Q Okay. Is it possible that it's quite common? 21 A No, I suspect not. 21 MR. CANTRELL: Object to form. 22 Q (By Mr. Richardson) Okay. But you say right 22 A I suppose all things are possible. 23 here that, "Americans have long benefitted from in every 23 Q (By Mr. Richardson) So you don't know? 24 other branch of medical research except for this one." 24 A Um, no, I don't. 25 25 A Oh, it doesn't mean like every other medical Q So you don't know how often or how likely it is

Page 202 Page 204 1 for treatment? 1 A No. A You know, I have -- you know, I have kept track Q Is it based on any kind of scientific study of 3 of NIH stuff for family health reasons, et cetera. I 4 realize that there are tons of clinical trials going on A It's observation of what goes on in the world. 5 in significant things and insignificant things, and have Q In just your personal observation? 6 for decades. A How I understand it, um-hum. 7 Q I understand there are a lot of clinical Q So is it typical for doctors to disagree about 8 trials. What I'm asking is how likely is it for care to 8 the appropriate course of treatment? 9 be provided without the support of a clinical trial? A I think internal disputes are common. In this 10 A That would be speculation on my part. 10 case, internal disputes have become so poignant that 11 Q So you don't know? 11 they have spilled over into the popular press, which I A I'm not going to guess. 12 12 think is much less common than disputes among cardiac 13 Q Okay. Is it typical in medicine for there to 13 care physicians. 14 be a consensus that only one type of treatment is the Q Understood. So when you say it's common for 15 appropriate course of treatment? 15 those disagreements to emerge, what is that view based A I think it is uncommon, but, uh, I think 16 on? 17 there's a lot of markers and things like this which 17 A Because as a scientist I know that scientists 18 track people into this is what we needed to do for you. 18 are always kind of disputing each other on sometimes 19 This is -- you know, treatment is kind of framed as 19 large, but oftentimes smaller matters. 20 being individualized or personalized, which I think is Q So that's, once again, not based on any 20 21 probably a stretch. But insofar as we understand 21 scientific research --22 medicine better, genetics, different people there is 22 A Just my participation in the scientific 23 going to be more than one answer to a lot of these kind 23 community and listening and watches other conversations 24 of questions. 24 that are going on in the scientific community. Q Okay. But nothing you've -- you have not 25 Q Okay. So I asked if there was -- if it's 25 Page 205 1 typical for there to be consensus that only one type of 1 written about --2 treatment is appropriate, and you said you think it's 2 A No. 3 uncommon; is that right? 3 Q -- how likely --A Say that once more. A I think --Q I asked is it typical in medicine for there to O -- consensus is for medical professionals. You 6 be a consensus that only one type of treatment is the 6 have not read studies about how likely consensus is for 7 appropriate course of treatment, and you said you think 7 medical professionals. Is that accurate? 8 it's uncommon. A Correct. A It's probably not common that, like, everybody 9 Q Okay. Do you think care should be prohibited 10 would agree that this is the one right way to do things. 10 if there isn't a consensus about the appropriate course Q Okay. And what is that based on, your 11 11 of treatment? 12 assessment of how likely that is? 12 A Should care be prohibited if there is not a 13 consensus? A I would say based on experience with 14 healthcare, you know, doctors will try different things. 14 O Yes. 15 15 Q So just your personal experience with A Uh, no. 16 healthcare? 16 MR. CANTRELL: Object to form. 17 A Also observations. I know that, you know, for 17 Q (By Mr. Richardson) Okay. So a lack of 18 different conditions, heart cardiac conditions they try 18 consensus alone would not be a reason to ban a certain 19 different things. And also for, like, different kinds 19 medical treatment? 20 of cancers occurring in the same place, they treat it 20 A Correct. 21 accordingly, not necessarily with --2.1 Q Okay. What normally happens in medicine when

22 there's a lack of consensus among medical providers?

Q Yeah. What do medical providers usually do

A What happens?

25 when there's a lack of consensus?

23

24

Q This isn't based on any kind of comprehensive

22

24

25

23 survey --

A No, it's not.

O -- of medical care?

Page 206 Page 208 1 A Healthcare providers? Q Okay. I'd like you to turn to, I guess, the 2 Q Doctors, people who treat patients? 2 last two paragraphs at the very end. A I think it's fodder for more study. A The whole thing? Q Okay. Do they typically stop providing care Q The last two paragraphs, yep. Do you see that 5 when there's a lack of consensus? 5 second sentence? A Which paragraph? A It depends on probably what the sort of -- what 7 the situation is. I mean, I would struggle to come up Q It starts "Rarely have researchers been so 8 with an example. But, like, sometimes, you know, entire 8 explicit." See that paragraph down at the bottom of the 9 lines of -- so back in Thalidomide. Right? We figured 9 second-to-last page? 10 out it this was causing birth defects. The whole thing 10 A Okay, yeah. 11 was shelved, the whole thing, immediately. Right? 11 Q Okay. There's a sentence there that says, "If 12 O Okay. 12 this study is really the first study to show adverse 13 A So sometimes that does occur. But oftentimes, 13 mental health outcomes related to conversion therapy, 14 you know, debates resolve over time. 14 how can it be sufficient, even if it were high quality, Q And how common would it be to stop providing 15 to justify government bans." 16 care when there is a lack of consensus in the medical 16 A Um-hum. 17 community? 17 Q Can you explain that statement? A I would be speculating about how often that 18 A Get a little more context here. 18 19 happens. 19 O Okay. 20 Q So you don't know? 20 A I want to read up a couple of paragraphs. 21 A I don't know. 21 Okav. Q Okay. And the example you just raised, I'm 22. 22 Q Okay. Can you explain that statement, please? 23 going to pronounce it wrong. I'm sorry. 23 A If the study is really the first study, which 24 Falidomide (phonetic)? 24 was what Jack Turban had described it as, to show 25 A Thalidomide. 25 adverse mental health outcomes related to conversation Page 207 Page 209 Q Thalidomide? Is that -- Thalidomide? Is that 1 1 therapy, how could it be sufficient, even it were high 2 it? 2 quality, to justify government bans. A Am I now the older person in the room. 3 You know, one should have more than one study 4 Thalidomide was for, uh, a treatment I believe it was 4 on something. And in this case I think his methodology 5 for morning sickness in the 60s -- 50s, 60s, but turned 5 is weak. 6 out to be a source of profound birth defects. Q Okay. And is there --Q Okay. And is that the kind of thing that A His measurement is weak. So I -- to me it's 8 you've -- you know about that experience because you 8 like I look at it like, well, if that's the first study, 9 have researched that topic or is that just general 9 like -- you need more than one weak study to call for 10 knowledge? 10 something to be banned. 11 A Read history, yeah. 11 Q Okay. And why is that? 12 MR. RICHARDSON: Okay. Just general 12 A Because it's weak. 13 knowledge. Okay. 13 Q Is it because there would be uncertainty about 14 Can we get Exhibit 8, please? 14 it? 15 (Plaintiff's Exhibit 8 was marked for A One should be uncertain about something that is 16 measured in the manner in which Turban measures about 16 identification and made a part of the 17 17 it. record.) Q Okay. So is it fair to say that your view is 18 Q (By Mr. Richardson) Do you recognize that 19 document? 19 that care should not be banned when data on the harms of 20 A Did I not include it in our previous 20 that care are uncertain? 21 conversation? I can't recall. 21 MR. CANTRELL: Object to form. Q I think it came up, yes. So is this the 22 A Uncertain as in -- I mean, again, back to 23 article you wrote, let me see, "Does Conversion Therapy 23 Dr. Biggs, he uprated (phonetic) Dr. Turban. And I 24 Hurt People Who Identify As Transgender"? 24 believe in this journal for -- I think it was for this 25 A Yes. 25 study -- but for the use of the USTS and the manner in

- 1 which he asks questions.
- 2 Q (By Mr. Richardson) No. I understand your
- 3 critiques of Dr. Turban and the USTS. I guess what I'm
- 4 asking is you say that because there has only been one
- 5 study showing that conversion therapy is harmful that
- 6 would be an insufficient basis to ban care; is that
- 7 correct? To ban conversion therapy.
- 8 A Typically, yeah. I mean, you want to sort of
- 9 see -- so like in health research perhaps, but also like
- 10 in lots of fields. When I first got into the sociology
- 11 of religion there was this dispute about whether --
- 12 sorry. Take a drink of water -- whether free market in
- 13 religion contributed to, sort of, higher religious
- 14 involvement in a country or not.
- 15 Like there were competing studies on this
- 16 stuff. Right? So only after some time and some
- 17 consistency across studies would you sort of start to
- 18 claim this is actually -- we're starting to see the
- 19 answer to this question.
- 20 Q Okay. So your point is there were competing
- 21 studies. It meant there --
- 22 A There are, but --
- 23 Q They wasn't certainty about it.
- 24 A -- they would be using different measures, et
- 25 cetera, in people.

Page 211

- 1 Q Yeah.
- 2 A Weighted to their measure and not --
- 3 Q Understood. So when they are competing studies
- 4 and uncertainty like that --
- 5 A Sure.
- 6 Q -- is it your point here that under those
- 7 conditions a ban would not be appropriate?
- 8 A I guess it depends on the situation. You know,
- 9 when we're talking about -- and this, I don't think it
- 10 was about minors if I'm not mistaken. Does it? Oh,
- 11 this was about adults if I'm not mistaken, or adults and
- 12 minors.
- I go back to what I've said before, when you're
- 14 dealing with minors the bar has got to be higher.
- 15 Q For providing care or for withholding care?
- 16 A For clear understanding of what's going on,
- 17 for -- depends on the kind of care we're talking about.
- 18 Right? If WPATH standard of care endorses the move for
- 19 surgical treatments down to age 17, which I think the
- 20 age standard of care recommends, that's kind of a big
- 21 deal. I can't believe the spirit of Belmont report
- 22 would endorse a move down into adolescence.
- 23 Q So is it your view that Dr. Turban's research
- 24 that you're talking about in this paper was not about
- 25 minors?

1 A I'd have to -- since the USTS is about adults,

- A Tu have to -- since the USTS is about adults
- 2 but they are retrospectively answering questions. I
- 3 haven't read this in a while so I'd have to -- I think
- 4 it was not about adults. I'm sorry. Not about minors
- 5 alone. They might have included minors.
- 6 Yeah, because if they talk about unemployment
- 7 rates, they wouldn't be talking about unemployment rates
- 8 on minors. So this includes adults and might have been
- 9 limited to adults.
- 10 Q Okay. So just coming back to the point here,
- 11 you said because there was only one study showing that
- 12 conversion therapy was harmful it should not be banned
- 13 and you thought that study was weak.
- 14 A Yes.
- 15 Q Okay. Do you think that there -- are there
- 16 studies showing that gender-affirming care harms minors?
- 17 A Yeah. I mean, Biggs' reanalysis of USTS data
- 18 shows that the -- I mean, this was a comment to -- in a
- 19 journal -- or letter to the editor or commentary --
- 20 showed that, you know, if Turban had controlled for the
- 21 provision of -- I think this was about suicidality --
- 22 had controlled for the provision of estrogen to natal
- 23 male to female patients he would have noted that -- that
- 24 it was actually aggravating to suicide. But he didn't
- 25 control for the provision of estrogen, he only sort of
 - Page 213

- 1 highlighted, if I'm not mistaken, if I recall,
- 2 testosterone is generally positive on mental health.
- 3 But estrogen was aggravating to the mental health of
- 4 natal male to female patients.
- 5 Q Okay. So if we focus on --
- 6 A For comparing -- another thing he didn't do was
- 7 compare adults who didn't want hormone therapy. Because
- 8 a bunch of people in USTS didn't want it. You bring
- 9 those people back into the study and you see that they
- 10 turned out relatively okay as well.
- 11 Q So I guess my question is -- let's focus on
- 12 hormone therapy. Do you think there are studies showing
- 13 that gender-affirming hormone therapy is harmful to
- 14 adolescents?
- 15 A I think there's a variety of studies that show
- 16 either a weak positive or a, you know, an effect that is
- 17 so modest that it doesn't merit invasiveness of the
- 18 treatment.
- 19 Q Okay. But your point here in this article is
- 20 that when there's only one study showing that a certain
- 21 treatment protocol, here conversion therapy, is harmful,
- 22 it shouldn't be banned.
- 23 A Right.
- 24 Q And just to be clear, the conversion therapy
- 25 ban at issue here was for minors.

- A Right. But he's talking to adults. 2 Q Yes. But implication is for a ban on --
- A Reflecting back on their experience while they
- 4 are growing up. Which, of course is, you know, in
- 5 hindsight, like do you remember your experience growing
- 6 up on this stuff. Some will, some won't --
- Q I understand your concerns about the USTS --
- 8 A -- longitudinal --
- 9 Q -- and the study.
- 10 A Okay.

1

- 11 Q What I'm asking about is this was a -- you were
- 12 talking when you say justified government bans, that
- 13 means bans on medical care for minors --
- 14 A Right. Based on one --
- 15 Q -- in that case of conversion therapy.
- 16 A One study alone? No.
- 17 Q Okay. I'm asking, was there a study that shows
- 18 that gender-affirming hormone therapy is harmful to
- 19 adolescents?
- 20 A In terms of -- yeah, I'm not clear on that.
- 21 Q So you don't know if there is a study that
- 22 shows that gender-affirming hormone therapy harms
- 23 adolescents?
- A If you give me time with this I can probably
- 25 pull one out.

1

Page 215

- 2 A Not off the top of my head.

Q But nothing comes to mind?

- 3 Q Okay.
- A I see a lot of studies that are talking about
- 5 modest effects or are conducted with measures that are
- 6 poor or, as in the case with the Swedish study,
- 7 member -- large sample but dragged out over a long
- 8 period of time, which is typically good, but only see
- 9 the effect in, like, the tenth year --
- Q I understand. But so your statement here was
- 11 that when there is only one study showing that a certain
- 12 type of care is harmful --
- 13
- 14 Q -- that does not justify bans on that care for
- 15 minors.
- 16 A I understand.
- 17 Q And you cannot identify for me any study
- 18 showing that gender-affirming hormone therapy is harmful
- 19 to adolescents?
- 20 A Hormone therapy? I could if I had time to work
- 21 through my documents.
- 22 O Okay. But nothing comes to mind?
- 23 A Not offhand.
- 24 Q Okay. So I'm trying to understand how you see
- 25 these two issues. Why is it appropriate to ban

Page 216

- 1 gender-affirming care in the absence of studies showing 2 that they cause harm, but it's not appropriate to ban
- 3 conversion therapy unless there would be multiple
- 4 studies showing some harm? Do you see the question?
- A Plenty -- yeah. Plenty of what I talk about in
- 6 my reports is a matter of informed consent. And I think
- 7 informed consent is very challenging among youth,
- 8 especially when it concerns their future and their
- 9 future reproductive capacity and things like this,
- 10 that -- there is a reason I wrote about informed consent
- 11 because it matters a great deal.
- 12 O But the ban on conversion therapy would apply
- 13 to minors and they would have to consent to care;
- 14 correct?
- 15 A A ban on conversion therapy is usually about
- 16 talk therapy so far as I can tell. Part of my problem
- 17 with the ban on conversion therapy is that, you know,
- 18 linguistically it doesn't make sense because it is about
- the possibility of helping children become more
- 20 comfortable with living in their, you know, with their
- 21 current state.
- 22 Q But do you think that an adolescent could
- 23 consent to conversion therapy or gender identity change
- 24 efforts?
- 25 A I find Turban's definition of what constitutes

- 1 a gender identity change effort, I find it problematic
- 2 in many ways as a measure. And if you want to go
- 3 through it --
- Q We don't -- how would you define conversion
- 5 therapy?
- A It sort of rifts off of conversion therapy for
- 7 sexual orientation. Like conversion therapy for
- 8 transgenders is about sort of, you know, the idea that
- 9 gender identity they use or self-identify as can't
- 10 change and that, uh, the notion that they couldn't be
- 11 comfortable without sort of radically altering their
- 12 bodies via hormones or surgery. Whereas, in some ways,
- 13 like sexual orientation change efforts are trying to get
- 14 people to feel things that they don't feel.
- Q I understand. So I guess --15
- 16 A This is sort of like gender identity change,
- 17 like, well, are you trying to convert them from just
- 18 being more comfortable with their body?
- 19 Q But you accept that whatever it is, it is
- 20 healthcare?
- 21 MR. CANTRELL: Object to form.
- 22 A Part of psychological care.
- 23 Q (By Mr. Richardson) Okay. And could a minor
- 24 give informed consent to that psychological care?
- 25 A So if somebody experiences gender dysphoria, I

Page 218 Page 220 1 mean, typically speaking, even WPATH and Endocrine 1 conversion therapy for minors because there weren't 2 Society, like, they have an idea what should be provided 2 multiple studies showing that care was harmful. 3 to children; right? A One would want multiple studies for anything. Q This is like a straightforward question so I'm Q To ban care for minors; right? That's what 5 sorry for not being clear about it. Could a minor 5 we're talking about --A When we're take talking about this kind of care 6 content --7 A Consent to --7 for minors, it is not of the sort of hormonal or 8 physical --8 Q -- to psychological care involved in conversion 9 9 therapy? Q Understood. 10 A Well, if they can't consent to anything, which 10 A -- nature that --11 like we're talking talk therapy, I mean --11 Q But you just said you want multiple studies. 12 O I'm asking your view. Can a minor consent 12 And when I asked you do you know any studies showing 13 to --13 that gender-affirming hormone therapy harms minors, you 14 did not identify one. 14 A To talk therapy? 15 Q -- to psychological care? 15 A Right. 16 A I suspect, yeah. 16 Q So I'm just trying to get you to explain --17 Q Okay. So I come back to the question, your 17 A And I -- well, I'm explaining it. 18 view seems to be that it is not appropriate to ban 18 O Okay. 19 conversion therapy based on one study showing that it's 19 A The manner in which these studies are performed 20 harmful, but that it is okay to ban gender-affirming 20 is not consistent with the manner in which they are 21 care and you can't think of any study showing that it's 21 being described, so I call it a bait and switch --22 harmful. And I'm just asking what explains that 22 Q I understand. 23 difference and you said informed consent. 23 A -- report. Right? 24 MR. CANTRELL: Object to form. 24 Q So is it fair to say you were --25 A I think of bans, okay, I think about having a 25 A Most of this studies that sort of highlight the Page 219 Page 221 1 preponderance of evidence, not just one study. 1 positive effects were conducted under the Dutch protocol 2 where kids did not have --Q (By Mr. Richardson) Okay. And you think you 3 have a preponderance of evidence showing that Q I understand. 4 gender-affirming hormone therapy --A -- psychological problems, and yet they are A I think a preponderance of evidence that the 5 turned around and the results are shown as evidence that 6 manner in which most of this research is conducted is 6 kids who do have significant psychological coterminous 7 subpar, substandard methodologically and --7 problems should be given treatments. Q I understand your critiques of the field. I Q Okay. So I'll just ask you two separate 9 guess my point is in this piece you say until we have --9 questions. A Just because something is published in a 10 10 A There is a problem with the scientific industry 11 peer-reviewed journal --11 here. 12 Q I understand that. 12 Q I understand. Maybe it will be easier if I 13 just ask it two separate questions. You think that 13 A -- doesn't mean it's good. 14 Q I'm saying your words here -gender-affirming hormone therapy, a ban on that care is 15 15 appropriate for minors even though you cannot recall a (Simultaneous crosstalk.) 16 A That entire industry --16 study showing that it is harmful to minors? 17 17 MR. CANTRELL: Object to form. COURT REPORTER: Hey, one at a time, 18 please. 18 A The studies -- I mean, you're acting as if the 19 A -- has kind of highjacked the peer review 19 studies publication industry --20 process. 20 Q I'm just trying --21 Q (By Mr. Richardson) I am familiar with your 21 (Simultaneous crosstalk.) 22 critiques --22 A -- of their --23 A Okay. 23 Q I'm not talking about --24 Q -- on that point. I'm just asking about your 24 A -- merits. 25 statement that it would not be appropriate to ban 25 Q I'm just asking you to summarize what we've

1 already talked about. You think that a ban on

- 2 gender-affirming hormone therapy for minors is
- 3 appropriate even though you cannot recall a study
- 4 showing that that care harms --
- 5 A Because I can't recall --
- 6 O -- adolescents.
- 7 MR. CANTRELL: Object to form.
- 8 A -- a study whose measures, methods, analyses,
- 9 interpretation and magnitude of gauging risk --
- 10 Q (By Mr. Richardson) Understood.
- 11 A -- meets any standard of statistical and
- 12 epidemiologically decency --
- 13 Q Understood.
- 14 A -- in terms of the way these things are
- 15 conducted. This goes back to the idea that these
- 16 organizations have been highjacked.
- 17 Q I understand. But is the answer -- so that's
- 18 yes?
- 19 A Yes.
- 20 Q Okay. And then the other question, you think
- 21 that a ban on conversion therapy for minors would be
- 22 inappropriate without multiple studies showing that it's
- 23 harmful?
- 24 MR. CANTRELL: Object to form.
- 25 A Again, it's the -- it's not about -- you know,

- Page 222 1 show adverse mental health outcomes related to
 - 2 conversion therapy how can it be sufficient to justify

- 3 government bans?
- 4 A I'm talking back to Jack in this -- this
- 5 article.
- 6 Q Understood. But your point is it's not
- 7 appropriate to ban conversion therapy on the basis of
- 8 only one study because there would be uncertainty about
- 9 it?
- 10 MR. CANTRELL: Object to form.
- 11 A Um, certainly his study.
- 12 Q (By Mr. Richardson) Okay.
- 13 A Right?
- 14 Q Okay. And I just want to come back briefly to
- 15 your critiques of the studies on gender-affirming
- 16 hormone therapy. You're critique about reliance on the
- 17 Dutch protocol, that is a reason for doubting that those
- 18 studies show that care is effective.
- 19 Do those studies show that care is harmful?
- 20 A Um, which studies?
- 21 Q The ones you just referred to.
- 22 A When I'm referring to studies, I'm referring to
- 23 sort of the class of studies that were conducted using
- 24 the Dutch protocol when the sample was comprised of
- 25 patients who did not display psychological problems.
- Page 223
- 1 he's calling for a ban. I'm calling for clarity about
- 2 what is the meaning of conversion therapy because I
- 3 don't buy the --
- 4 Q Understood.
- 5 A -- the basic thesis that it is conversion
- 6 therapy.
- 7 Q I'll try again. So --
- 8 A So he's talking about a ban.
- 9 Q Understood.
- 10 A I'm saying I don't even agree with you about,
- 11 like, what it is you are speaking about. Okay?
- 12 Q Yes.
- 13 A Because bans would have to be sort of, uh --
- 14 Q So you're saying in the absence of greater
- 15 clarity --
- 16 A Clarity and scientific rigor --
- 17 Q -- and certainty about, you do not think that a
- 18 ban on conversion therapy would be appropriate?
- 19 MR. CANTRELL: Object to form.
- 20 A There's not agreement on what constitutes
- 21 conversion therapy.
- 22 Q (By Mr. Richardson) I'm just trying to look at
- 23 this statement right here.
- 24 A Yeah.
- 25 Q So if this study is really the first study to

- Page 225 Q Okay. Let's just follow up on the Dutch
- 2 protocol. Okay?
- 3 A Okay.
- 4 Q The Dutch protocol, you use that in your
- 5 report; right?
- 6 A I do.
- 7 Q And you mean by that a protocol where there's
- 8 more psychological --
- 9 A The scrutiny --
- 10 Q -- screening --
- 11 A -- for screening was notably higher.
- 12 Q Okay.
- 13 A Yeah.
- 14 Q So there is more psychological screening
- 15 involved; right?
- 16 A Right.
- 17 Q And is there also a requirement of childhood
- 18 gender incongruence of some kind. Is that the idea?
- 19 A Yeah, it is.
- 20 Q Okay.
- 21 A That is correct, such that, you know -- go
- 22 ahead.
- 23 Q And your view is that there were studies
- 24 showing that care under those conditions could be
- 25 effective?

- 1 A They seem to be more effective than -- I mean,
- 2 those just aren't the reality for how --
- 3 Q Understood. I'm just trying to --
- 4 A -- we are evaluating applicability for such
- 5 care today.
- 6 Q Okay. So let's just put that to the side, the
- 7 Dutch protocol itself.
- 8 A We can't put it to the side.
- 9 Q I'm just asking for the Dutch protocol itself,
- 10 where there is studies showing that protocol could be
- 11 effective for people with gender dysphoria.
- 12 A I would have to go back and examine them.
- 13 Q Okay.
- 14 A There's been a lot of writing on this domain
- 15 lately.
- 16 Q Okay. Do you think that if doctors in the
- 17 United States are following the Dutch protocol, as you
- 18 understand it --
- 19 A They are not.
- 20 Q -- they should be banned from providing
- 21 gender-affirming care to minors?
- 22 A They're not --
- 23 Q If they were.
- 24 A -- so far as I can tell. You know, if you can
- 25 broker an agreement that that would be possible I

Page 228

- 1 groups who would say we don't need any psychological
- 2 evaluation, let anybody who, sort of, self-identifies as
- 3 opposite gender or something else is free to pursue
- 4 this, which some clinicians and some researchers
- 5 endorse, signaling a major dispute.
- 6 Q Okay. So do you think if providers were
- 7 required to follow the Dutch protocol, that would
- 8 address your concerns?
- 9 A Again, it's not about my concerns. It's about,
- 10 like, the reality has occurred.
- 11 Q I understand.
- 12 A I don't deal with things that are not real.
- 13 Q Let me rephrase. You've raised a number of
- 14 methodological objections to the research involving the
- 15 treatment of gender-affirming gender dysphoria in your
- 16 report.
- 17 A Right.
- 18 Q Would care, according to the Dutch protocol, be
- 19 subject to those same methodological objections?
- 20 A My typical objections are to -- I mean, I
- 21 certainly deal with true Dutch protocol and, sort of a
- 22 much less critical fashion than I do through other forms
- 23 of research and research -- not even research, but
- 24 claims that conclusions from Dutch protocol are
- 25 applicable to all minors.

- 1 suspect we wouldn't even be here and I suspect that this
- 2 matter wouldn't have risen to the attention of the
- 3 Arkansas Legislature. But it's not the reality.
- 4 Q I understand. So I'm saying -- you just said
- 5 that we wouldn't be here if clinics were following the
- 6 Dutch protocol.
- 7 A Because I think people who would be authorized
- 8 for treatment, that number would be a lot smaller. It
- 9 would not even sort of -- I mean, it didn't really come
- 10 to the attention of the public or the legislative eye
- 11 for years. Why are we talking about this now? Because
- 12 of the surge in cases, the flipped-sex ratio of these
- 13 cases.
- 14 Q I understand what you're saying. So do you
- 15 think that if clinics were following the Dutch protocol,
- 16 care should be banned under those circumstances?
- 17 MR. CANTRELL: Object to form.
- 18 A I'm not going to speculate about that. I could
- 19 speculate that it probably -- yeah, we probably wouldn't
- 20 be here if there is scrutiny and their standards were a
- 21 lot higher.
- 22 Q (By Mr. Richardson) So you think the Dutch
- 23 protocol has high standards?
- 24 A Much higher than, sort of, the generalized
- 25 affirmative care, which is, of course, is divided into

- Page 229
- 1 Q Okay. So let's say if the legislature passed a 2 law that said that care had to be provided consistently
- 3 with the Dutch protocol as you understand it. All
- 4 right?
- 5 A Again, they wouldn't -- we wouldn't even get to
- 6 that point --
- 7 Q But say we just --
- 8 A -- because they wouldn't have done it.
- 9 Q Meet me at the hypothetical, please. Okay?
- 10 MR. CANTRELL: Objection to speculation.
- 11 A I don't deal in hypotheticals. I deal in, sort
- 12 of, real situations.
- 13 Q (By Mr. Richardson) So you talk about the Dutch
- 14 protocol at length in your report.
- 15 A Some, yeah.
- 16 Q And I'm asking you, do you think care along the
- 17 lines of the Dutch protocol would benefit patients?
- 18 MR. CANTRELL: Object to the form.
- 19 A Then I would say, you know, perhaps for adults,
- 20 minors, you know, it's very sensitive stuff, but it had
- 21 passed for a long time. These were kind of the
- 22 standards and now they are not. Even though WPATH and
- 23 Dr. Adkins writes at great length endorsing WPATH
- 24 standards of care, at least No. 7, and as if these were
- 25 the standards that people are following.

Page 230 Page 232 1 And as I signaled in my report, I don't think 1 about it. 2 those are the things -- pathways people are following. Q Understood. So I'm just asking, if care was 3 We see internal disputes, you know, indicator of some 3 provided according to the Dutch protocol would you 4 problem. 4 support that system? Q (By Mr. Richardson) So I just want to --MR. CANTRELL: Object to speculation. A It may be the standards of care turn out to be A I think I first need to see how many cases 7 not rules --7 this -- it characterizes. Q I understand. 8 Q (By Mr. Richardson) So if there were a lot of 9 A -- not even norms. 9 people who needed care, you would oppose care under the 10 Q I'm just trying to understand --10 Dutch protocol? 11 A They are suggestions that don't have teeth. A No. It's just like how many people -- what 11 12 And so I think the legislature must have started 12 share of the persons who are receiving care now in the 13 figuring this out and said, "These aren't norms, these 13 affirmative kind of regimen are clinically depressed, 14 aren't standards. Let's give them some rules." 14 anxious, things that would rule them out of the Dutch 15 O I understand. 15 protocol. I don't think we know that. A But that's purely speculation about their 16 Q That's why I'm asking the question. If care 17 mentality and I have no idea how they thought about 17 was provided according to the Dutch protocol would you 18 this. 18 support that system? 19 Q I understand. But you are an expert in this 19 MR. CANTRELL: Object to speculation. 20 case and your expert report focuses on the state of the 20 A I'm going to have to punt on that because even 21 research supporting gender-affirming medical care; 21 about adults, right, and I respect adults' freedoms 22 correct? 22 and -- to do as they please. But we're talking about 23 A It also highlights --23 minors. To see WPATH walking back in time instead of 24 Q Understood. 24 forward ---25 A -- the things going on in the industry and the 25 Q (By Mr. Richardson) So you're not gonna answer Page 231 Page 233 1 weighing of the morality of --1 the question of whether or not you think care according Q I understand. 2 to the Dutch protocol, as you understand it, to be --3 A -- of 13-year-olds going on cross-gender A I have not given it that much thought because 4 hormones. 4 it is not the reality. Q Understood. But I think that it's entirely Q Okay. So you're not going to answer the 5 5 6 appropriate as an expert in this case that you answer a 7 7 hypothetical question about the issues in your report. MR. CANTRELL: Objection. And I'm asking you, if care could only be A I have answered the question. 8 8 9 MR. CANTRELL: I believe the witness has 9 provided according to the Dutch protocol as you 10 understand it, would that be an appropriate system? 10 answered the question. MR. CANTRELL: Same objection. Q (By Mr. Richardson) Okay. I think you said at 11 12 A Perhaps, because I would never have -- my 12 one point you referenced the morality of 13-year-old 13 attention wouldn't have been called to it by sort of 13 girls going on --14 watching the research develop and I would have probably A Yeah. Q -- hormones. 15 ignored it. So I don't weigh in on this because I think 15 16 I need to tell WPATH how to do its job. I weighed in on 16 A Right. 17 this because, even starting essays, because it seems 17 Q What do you mean by the morality? 18 kind of outrageous that we're talking about a wing of 18 A Morality is sort of the weighing of the good 19 American medicine, especially American medicine that 19 and the bad, right and wrong, wise and unwise, prudent, 20 has -- almost seems lawless. 20 imprudent. Q (By Mr. Richardson) I understand. So you said 21 Q And you think --

22

23

24

25

A We are all moral believing animals --

(Simultaneous crosstalk.)

Q And you think it's immoral --

A -- advisor --

24 protocol.

25

22 that you might not have ever become involved in the

A Become involved as in start reading and writing

23 issue if care was provided according to the Dutch

1 Q -- for a --

- 2 A When you talk about immoral, these are moral
- 3 judgments. Right? Do I go so far as to say immoral?
- 4 But they are judgments about what is right and wrong in
- 5 a situation, so I say the morality. The -- the
- 6 weightiness of the judgment, like is it a good or bad
- 7 idea. Right? So I don't juxtapose with morality. I
- 8 juxtapose morality like it is -- when you're talking
- 9 about medicine, you're talking about morality. What's 10 good here.
- 11 Q Okay.
- 12 A What's good to do.
- 13 Q And does your sense of morality inform your
- 14 view of hormone therapy?
- 15 A My sense of morality? Most of what I've talked
- 16 about here is about dealing with reality, not morality.
- 17 Q I understand. But you just referenced the
- 18 morality of a 13-year-old --
- 19 A Yeah.
- 20 Q -- girl going on --
- 21 A Right.
- 22 Q And I'm just trying to understand how does
- 23 that --
- 24 A Juxtaposed with immorality.
- 25 Q Understood.

Page 235

- 1 A It is -- understand, like, what is good for a
- 2 13-year-old kid to do versus this may not be so good.
- 3 Q Okay. What is -- what is your view on that, on
- 4 gender-affirming care?
- 5 A For a 13-year-old? I think it's a little
- 6 young.
- 7 Q For hormone therapy?
- 8 A What kind of hormone therapy are we talking
- 9 about? I mean, by that time you -- I guess, 13, 14, you
- 10 start to see cross-sex hormones. I mean, I think that's
- 11 a little early.
- 12 Q And that's based on a moral judgment?
- 13 A I think it's based on -- well, it's always
- 14 going to be based on a moral judgment. I mean, there's
- 15 no such thing as a pure scientific judgment. Because we
- 16 think, Ah, if this works, it is good to do. Anything
- 17 you're dealing with a good and bad idea, you're dealing
- 18 with morality.
- 19 Q Okay. So your view that starting
- 20 gender-affirming hormone therapy --
- 21 A Just be clear on this. It's like I have
- 22 written extensively about values in science.
- 23 Q Understood.
- 24 A Right? This is where values and science come
- 25 into play because there is always a sense of this is

Page 236

- 1 good to -- you know, to encourage, this is -- this is
- 2 something we don't want to do.
- 3 So, for example, somewhere in one of these
- 4 reports I talk about how Endocrine Society has -- they
- 5 have labeled certain outcomes as valuable to them, good
- 6 ideas; right? And other outcomes as less important to 7 them.
 - Q Yeah, I have seen that part of your report.
- 9 A The long-term flourishing of patients; right?
- 10 O Yeah.
- 11 A Which calls to mind, you know, this research
- 12 about, that I just mentioned earlier, you know, what if
- 13 you go through menopause at age 17 --
- 14 Q I understand. I don't mean to cut you off. I
- 15 just want to come back to the question --
- 16 A Sure.
- 17 Q -- that I asked.
- 18 A All right. This is about values.
- 19 O Yes.
- 20 A Value is good.
- 21 Q Understood. You said that you think providing
- 22 gender-affirming hormone therapy to a 13-year-old would
- 23 be, I think, quote, a little young.
- 24 A Um-hum.
- 25 Q And I asked if that was based on your moral

- 1 judgment. And I just want a yes or no on that.
- 2 A Insofar -- well, you're not going to get a yes
- 3 or no. Insofar as it involves the informed consent of
- 4 minors who haven't experienced puberty perhaps, I think
- 5 it's, you know, it would be wrong to press them forward
- 6 into something that they have not experienced.
- 7 Even -- I forget what her name is. There's a
- 8 live discussion going on among affirmative care about
- 9 what do we do about minors who have not gone through,
- 10 sort of, puberty and, in this case, the sexual
- 11 experiences that people can have at some point after
- 12 puberty that people who have gone through blockers, the
- 13 cross-sex hormones may not experience sexual sensations.
- 14 And they were debating, is this a good idea or maybe
- 15 we're doing this too early. Right? So this is --
- 16 Q Understood.
- 17 (Simultaneous crosstalk.)
- 18 A -- for us to observe it. Like, ah, they're
- 19 having significant debates, which is a good thing, about
- 20 the appropriateness, which means a moral judgment, of
- 21 treatments for teenagers.
- Q Okay. So let me just put a finer point on it.
- 23 A Sure.
- 24 Q If there is a 13-year-old girl who is receiving
- 25 gender-affirming hormone therapy and it is significantly

- 1 reducing her distress and improving her mental health,
- 2 do you think that the hormone therapy is --
- 3 A Which hormone? The blocker or is this on cross
- 4 sex or what?
- 5 Q This is gender-affirming hormone therapy.
- 6 A Okay. Sorry.
- 7 Q So it's significantly reducing her distress,
- 8 improving her mental health. Would you still have a
- 9 moral objection to care?
- 10 A I mean, is she on her way to surgery? Is it,
- 11 you know, is she, like, to stay in that position
- 12 permanently? I mean, this is how old again? Thirteen?
- 13 Q Thirteen, taking your hypo.
- 14 A Thirteen? It's awfully young.
- 15 Q So you would have the same thought that it's,
- 16 as a moral matter, too young.
- 17 A I think people should experience their natal
- 18 puberty.
- 19 Q Okay. So you have the same moral objection to
- 20 care in that circumstance that you shared previously?
- 21 A Yes.
- 22 Q Okay. And so I'm trying to understand your
- 23 view on you talk about values and science, morality. Is
- 24 it your view that the medical appropriateness of
- 25 gender-affirming care is a moral question?

- Page 240
- 1 academically seems to suggest that, you know, it's not
- 2 strict Dutch protocol.
- 3 It's sort of -- affirmative care and the Dutch
- 4 protocol are kind of separate things technically
- 5 speaking.
- 6 Q And I'm trying to understand. You said that's
- 7 based on your read of popular work or --
- A So I have made reference to repeatedly sort of
- 9 the open kind of debate that we read, LA Times,
- 10 Washington Post, Atlanta Monthly. You know, this
- 11 playing out in sort of the court of -- not so much
- 12 public opinion -- but, you know, in long and short form
- 13 journalism.
- So one can see, sort of, what's going on. And
- 15 these are all players in the -- either the research
- 16 community or the former leaders in WPATH. It signals
- 17 that there is a, you know, a significant dispute going
- 18 on.
- 19 Q Okay. So have you ever observed care being
- 20 provided in an American clinic?
- 21 A No.
- 22 Q Have you ever spoke with doctors who provide
- 23 care or gender-affirming care in a clinic?
- 24 A I spoke with pediatricians, but I'm not sure if
- 25 they are providing care themselves. I know they have

Page 239

- 1 A The medical appropriateness of gender-affirming
- 2 care is a moral question? Yes.
- 3 Q It is?
- 4 A Yeah.
- 5 Q Okay. Is it also a scientific question?
- 6 A Yeah.
- 7 Q And are those two separate points?
- 8 A They can be.
- 9 Q Okay. We've talked a bit about your view on
- 10 the practices of American clinics a little bit. I just
- 11 want to look at -- this is your rebuttal report in
- 12 Exhibit 2. Okay. And this is on page 2.
- 13 A The bullet points there.
- 14 Q I think it is. Let me just make sure. Okay.
- 15 It's that first bullet there where you say "Careful
- 16 mental health assessments and stringent criteria for
- 17 eligibility invoked by the plaintiff's witnesses are, in
- 18 practice, hardly occurring." Do you see that?
- 19 A Right.
- 20 Q Okay. What is your basis for thinking that
- 21 that's hardly occurring in American clinics?
- 22 A Hardly occurring? In part, the open disputes
- 23 of gender-affirming care. And, you know, since this
- 24 signals the Dutch protocol in the background, my read of
- 25 the literature and both, sort of, popularly and

- 1 spoken of, you know, patient -- transgender patients 2 or -- uh, that they have seen, but I have not observed.
- 3 Q Okay. And have you ever interviewed a patient
- 4 who received gender-affirming care?
- 5 A No.
- 6 Q Okay. Have you ever reviewed medical records
- 7 of those receiving gender-affirming care to see if
- 8 they conform to the Dutch protocol.
- 9 A I don't think I would be privy to medical
- 10 records.
- 11 Q Okay. Have you done any kind of systemic
- 12 review of what clinics are doing?
- 13 A What familiarity is with the research in this
- 14 domain. How clinics are conducted themselves, I do not
- 15 know.
- 16 Q Okay. But your view is American clinics are
- 17 departing from the Dutch protocol?
- 18 A That is my impression. Not all of them
- 19 necessarily.
- 20 Q Okay.
- 21 A I suspect, again, as we've indicated, there is
- 22 diversity of thought in this.
- 23 Q Okay.
- 24 A Some it looks like, you know, they have kind of
- 25 tightened it, the criteria of eligibility. Others seem,

- 1 as I've highlighted in some of these reports, rebuttals,
- 2 open to sort of no psychological evaluation whatever,
- 3 just taking the patient's word for it.
- 4 Q Okay. And what clinics are not providing
- 5 psychological evaluations?
- 6 A Um, I don't know if I cited them in here.
- 7 But -- so I think I quoted Alex Keuroghlian. I'm
- 8 butchering his last name. Forgive me. But he's based
- 9 in Boston, I want to say Mass General, maybe Harvard
- 10 Family Clinic or Family Institute. He talks -- I don't
- 11 know if he practices this way, but he disparages the
- 12 criterion of psychological health prior to the
- 13 administration of treatment claiming that, you know, why
- 14 are we treating this as, you know, problematic on its
- 15 face.
- 16 Q But just to clarify, you don't know if he
- 17 practices according to that?
- 18 A I do not know if he practices according to
- 19 that.
- 20 Q Okay. So can you name any clinic that is not
- 21 providing psychological assessments before providing
- 22 care?
- 23 A No. But nor can I name, you know, clinics who
- 24 are.
- 25 Q So you can't name any clinics that provide

- 1 Q Okay.
- 2 A I mean, there's a -- one article I did cite,
- 3 whose clinic did not have the criteria of -- and it
- 4 was -- it was a sample from the clinic and they did not
- 5 use -- did not use a sample whose with the psychological

Page 244

Page 245

- 6 evaluation criteria.
- 7 Q Okay. Do you know how care is provided in
- 8 Arkansas?
- 9 A I suspect it is provided in a variety of
- 10 different ways because --
- 11 O Okav.
- 12 A -- when you think about clinic criterion there
- 13 is no rules about it. You have the standards of care,
- 14 which Dr. Adkins claims is, you know, the norm. I have
- 15 no idea why -- I haven't seen evidence that it's the
- 16 norm.
- 17 Q Yeah.
- 18 A Perhaps I haven't seen evidence that it's
- 19 not --
- 20 Q Yeah.
- 21 A -- except that one can infer this from its open
- 22 disputes.
- 23 Q But just to clarify, then, so you don't -- you
- 24 don't know how care is provided at any clinic in
- 25 Arkansas.

- 1 gender-affirming care?
- A I don't study internal clinic behavior, and a
- 3 lot of times I suspect it's not even public. Right?
- 4 Q Okay. So I want to understand, then, on your
- 5 report where you say that there in practice a certain
- 6 kind of treatment is hardly occurring.
- 7 A Okay. Hardly, you know, that is a vague term
- 8 and perhaps I should have said it is unclear in its
- 9 frequency. Because I see lots of commentary about how
- 10 this is -- this is not happening.
- 11 You hear about Planned Parenthood which serves,
- 12 technically, only adults. Some commentary on whether
- 13 they are actually treating adolescents or not, and they
- 14 don't have this eligibility criteria.
- So one gets the impression, okay, and it is an
- 16 impression, that, you know, unless we have long lines at
- 17 gender clinics, and I think we have lines, but not long
- 18 lines like they do in national healthcare services,
- 19 there's a surge in cases. And, uh, so...
- 20 Q So your view about the practice of this sort of
- 21 care is entirely informed by just commentary.
- 22 A Correct.
- 23 Q Not observations of the care.
- 24 A Well, the literature that I attend to typically
- 25 does not talk about -- it's not sort of clinic care.

- 1 A I don't.
 - 2 Q Okay. And if you were to learn that gender
 - 3 clinics in Arkansas provide care with thorough
 - 4 psychological evaluations, would that change your
 - 5 opinion in the case?
 - 6 MR. CANTRELL: Object to speculation.
 - 7 A I don't know. But I have seen enough -- I've
 - 8 read enough of, sort of, WPATH's and Endocrine Society's
 - 9 standards that these are strictly voluntary. It's a
 - 10 dynamic time. I would want to see evidence that those
 - 11 standards of care are being followed.
 - 12 Q (By Mr. Richardson) Understood. But when I
 - 13 asked for a clinic that wasn't following those standards
 - 14 you mentioned only -- I think only Planned Parenthood is
 - 15 the only specific clinic you have mentioned; right? Or
 - 16 the provider of clinics that you mentioned.
 - 17 A Right.
 - 18 Q And they only provide care to adults; right?
 - 19 A Right, uh, formally. Informally I think that's
 - 20 open to question.
 - 21 Q Okay. So what are your views about the care
 - 22 offered at Planned Parenthood based on?
 - 23 A It sounds like it does not involve the
 - 24 documentation of psychological services.Q And what's the basis for that belief?

- 1 A Their website, Planned Parenthood of Great
- 2 Plains.
- 3 Q Okay. Their website says that they --
- 4 A I believe that is correct.
- 5 Q Okay. And they say they provide care to minors
- 6 on the website?
- 7 A No. The minors reference was to an article, I
- 8 forget exactly where that appeared, claiming that, you
- 9 know, kids from high school come over and can get a
- 10 prescription filled. It sounded sort of surreptitious,
- 11 but I do know that plan parent hood does not have that
- 12 as a policy.
- 13 Q So the policy is --
- 14 A It may be a practice, but not a policy. At the
- 15 same time, like, one of my beefs that I've talked about
- 16 in here is, like, there are no rules here, there are
- 17 just suggestions.
- 18 Q Okay. But you think the field is characterized
- 19 by what you call open debate.
- 20 A Yes.
- 21 Q And you think the field is characterized by
- 22 clinics who vary in their practice.
- 23 A Yes.
- Q And if I ask you the basis for why you think
- 25 some clinics are not providing mental health

- Page 248
- 1 is pro forma. Are they doing pro forma psychological 2 care or not? I mean, what is psychological care?
- 3 Because Dr. Turban's conversion therapy sounds an awful
- 4 lot like psychological care at times. Like just sort of
- 5 how do you -- do pediatricians feel free to say, "I
- 6 don't think you should do this?"
- 7 Q Understood. Yeah.
- 8 A You know.
- Q But if you were to find out that a clinic was
- 10 conforming to those sorts of -- was asking those sorts
- 11 of questions you just raised and was providing
- 12 psychological evaluations, that might change your view?
- 13 A Change my view of --
- 14 Q Of whether or not --
- 15 A -- the ban?
- 16 Q -- gender-affirming care should be banned.
- 17 A Um, you know, at the risk of being repetitive,
- 18 there is more than just psych evals here. There is the
- 19 wisdom of minors who have not experienced puberty.
- 20 Q So let's come back to that. Earlier you
- 21 said --
- 22 A Consent of -- that sort of thing.
- 23 Q So earlier you said in this hypothetical about
- 24 a 13-year-old girl in significant distress whose
- 25 healthcare was improving because of gender-affirming

Page 247

- 1 evaluations, that's entirely based on just public
- 2 commentary in newspapers and magazines, things like
- 3 that?
- 4 A Right. It's not from, like, regular people.
- 5 It's from people who used to run WPATH. And, uh,
- 6 this -- for better or worse the sort of medical and
- 7 psychological treatment is playing out in -- more widely
- 8 than it might in this domain than it might in other
- 9 domains of medicine.
- 10 Q Okay. And so when I asked you if -- if you
- 11 were to find out that the clinics in Arkansas were
- 12 providing psychological assessments, would that change
- 13 your view? I think you said you don't know; is that
- 14 correct?
- MR. CANTRELL: Object to speculation.
- 16 A I don't know.
- 17 Q (By Mr. Richardson) Okay. So there is a chance
- 18 that you would have a different view?
- 19 A I would say this is impressive. Do they rule
- 20 out cases who are, you know, don't fit the Dutch
- 21 protocol? The provision of care, but does that affect,
- 22 you know, what happens next?
- I mean, I get the -- from the wider debate
- 24 that's happening in some of these long -- from
- 25 journalistic pieces I get the impression that some of it

- 1 hormone therapy.
- 2 A Right.
- 3 Q You said that you would still object on moral
- 4 grounds because she hadn't experienced puberty yet;
- 5 right?
- 6 A I'd object -- I mean, every objection is on
- 7 moral grounds in general. I mean, whatever -- it's --
- 8 Q Understood. So what if it was --
- 9 A It's saying like it's a moral judgment to say
- 10 this is okay, this is not okay. So --
- 11 Q Understood.
- 12 A -- clinicians, doctors do this all the time, to
- 13 give or not give, to withhold or to -- it's a moral
- 14 judgment.
- 15 Q Understand. One more hypo, then.
- 16 A All right.
- 17 Q Let's keep it the same but the person is now 15
- 18 years old and has gone through a few years of puberty.
- 19 Does that change your view at all?
- 20 A A few years of puberty. Right? Just to punt
- 21 back to this open conversation that was being had by
- 22 clinicians, you know, they are starting to wonder
- 23 whether they should stall longer because, you know, the
- 24 person doesn't know -- and it's a little interesting to
- 25 listen to. Like they don't know -- they don't know what

- 1 it's like to live as a post-pubertal -- people on
- 2 (sic.) post-pubertal minor and experience, sort of,
- 3 relationships and sexuality and et cetera. And so I
- 4 think there's this conversation that's going on. I
- 5 watch it and I'm glad that conversation is happening.
- 6 Q So just to follow --
- 7 A So she is rather young, you know.
- 8 Q So that argument about not experiencing life in
- 9 that way, that would apply to any adolescent
- 10 receiving --
- 11 A Well, I did --
- 12 Q -- care; right?
- 13 A I didn't write this about, you know, minors in
- 14 general.
- 15 Q Understood.
- 16 A Yeah.
- 17 Q So the point is not about not yet experiencing
- 18 puberty.
- 19 A It's not about sort of just being 13 or 15,
- 20 experiencing puberty or informed consent. It is a kind
- 21 of a package.

3

4

7

10

11

9 p.m.

13 Please proceed.

5 every day.

- 22 Q Okay. And just to conclude, those are all
- 23 moral judgments you've said.
- 24 MR. CANTRELL: Object to form.

Q (By Mr. Richardson) Okay.

(A break was had.)

12 record at 3:47 p.m. This will begin media part 5.

15 talked about the possibility of clinical trials to test

17 curious, would you support clinical trials to support

18 the efficacy of care even though it would require

A That's a good question. It seems like

22 trying something out. So I haven't given it a lot of

24 current state of things. But, again, I haven't given it

23 thought, but it certainly -- it is preferential to the

21 something that would make sense if you were actually

19 providing that care to minors?

16 the efficacy of gender-affirming care. I'm just

25 A Everything in this domain from a doctor's

1 prescription is a moral judgment that this is good to

A Morality is something we exude all the time,

8 end media part 4 and we're going off the record at 3:30

MR. RICHARDSON: Okay. Need a break?

VIDEO OPERATOR: All right. This will

VIDEO OPERATOR: We are back on the

Q (By Mr. Richardson) Thank you. So earlier we

Page 252

- 1 Q But all the objections you stated about a minor
- 2 receiving hormone therapy --
- 3 A Not all objections.
- 4 Q Many of the objections you raised.
- 5 A Some of the objections.
- 6 Q Um, that would apply to --
- 7 A It would apply to some --
- 8 Q -- a person --
- 9 A -- you know, that. But, like, you have to
- 10 weigh in that sort of the benefit you gain from clinical
- 11 trials, which, you know, I'm not confident in the least
- 12 will happen because nobody is really calling for them.
- 13 But I will grant your position.
- 14 Q I appreciate it.
- 15 A Then you have to weigh sort of the -- the
- 16 ability to consent to such a thing. Um, yeah, there is
- 17 a lot at play. And it's -- I think about, like, well,
- 18 would these be good trials, are the measures good, all
- 19 sorts of things.
- 20 Again, it would be kind of this conceptual -- I
- 21 think the situation is better than moving forward as is
- 22 with no trials claims about treatment based off of
- 23 cross-sectional data of opt-in internet samples. I
- 24 mean, it's just looking from the outside of medicine as
- 25 a social scientist, it looks like a problem.

Page 251

- 1 Q Understood. So but -- so you support doing
- 2 do. Should I do this? I'm going to do this?

 2 clinical trials in this space where possible?
 - 3 A A clinical trials research is preferential --
 - 4 Q Okay.
 - 5 A -- to what we've had before.
 - 6 Q Understood.
 - 7 A Again, though, you know, I grant Dr. Antommaria
 - 8 his point that it's going to be hard to pull off.
 - 9 Q Understood. But those trials would involve
 - 10 providing gender-affirming hormone therapy to
 - 11 adolescents.
 - 12 A You know, if practitioners, researchers,
 - 13 ethicists, legislators could come together on something
 - 14 like that I probably would be -- it beats not knowing.
 - 15 Q Okay. So in that case care provided in the
 - 16 context of a clinical trial would be appropriate in your
 - 17 judgment?
 - 18 MR. CANTRELL: Object to form.
 - 19 A I'm not sure I would, you know, go so far as to
 - 20 claim that, because it doesn't answer the question of
 - 21 should an adolescent make such decisions, even with
 - 22 their parents' endorsement, about treatments that would
 - 23 cut them off from natal puberty and the revelations that
 - 24 that may have.
 - You know, if we're talking about surgery at 17

64 (Pages 250 - 253)

25 a lot of thought.

- 1 or something like that, you know, I can see ways in
- 2 which one could come to sort of an easier conclusion on
- 3 some of these things. But my beefs with this practice
- 4 go beyond the lack of clinical trials and beyond the
- 5 method of good measures and evaluation to the
- 6 fundamental ability to have informed consent as a
- 7 13-year-old about something that you have not
- 8 experienced, that is, you know, the outcome of natal
- 9 puberty.
- 10 Q (By Mr. Richardson) Okay. So just to clarify,
- 11 so you would -- you would still have objections to care
- 12 provided to adolescent -- let's call it hormone
- 13 therapy --
- 14 A Okay.
- 15 Q -- in the context of a clinical trial?
- 16 A Do I have objections? I think I would have
- 17 misgivings, short of objections. Again, I go back to
- 18 that, I don't make these decisions, I don't get to make
- 19 those decisions.
- 20 Q But you just said you're --
- A I can see a scenario in which, you know, all of
- 22 this could have been avoided had the -- the gender
- 23 medical community decided to pursue treatments in a more
- 24 clinical evaluative manner, and that didn't happen. And
- 25 your asking me like, "Oh, can we go back now and do it,"
 - Page 255
- 1 I have no confidence that will happen.
- 2 Q Okay. So --
- 3 A Are you asking me for a wedge into what would I
- 4 be okay with, when I don't really deal with what would I
- 5 be okay with. I deal with what is happening around
- 6 here, what's even possible. I don't see any space or
- 7 any openness to clinical trials.
- 8 Q Understood. Let's back up a little bit. Okay.
- 9 So you said that -- just a second ago that I think you
- 10 said your beef with this area of research extends beyond
- 11 the lack of clinical trials and beyond the research
- 12 methodological issues --
- 13 A Yeah, and then I talked about --
- 14 Q -- to the informed consent question.
- 15 A Yeah, right.
- 16 Q So those objections would be true even for care
- 17 provided as part of a clinical trial; correct?
- 18 A Yeah.
- 19 Q So your view --
- 20 A Are my objections based on that so absolute
- 21 that I would not permit, I mean, a world in which I was
- 22 in charge, which I'm not? I don't know. Maybe. I
- 23 fundamentally don't think about such things, about what
- 24 would satisfy me.
- 25 Q Okay. So you've talked a bit about the

- Page 256
- 1 practices that some other countries have taken in this
- 2 area --
- 3 A Um-hum.
- 4 Q -- and research in those countries.
- 5 A Um-hum.
- 6 Q I think Sweden, Finland, the UK. Are there
- 7 any --
- 8 A Their references too, yeah.
- 9 Q Are there any practices in those countries that
- 10 you think would be a good way forward for
- 11 gender-affirming care?
- 12 A Let's see. I'm thinking -- the Fins have
- 13 nixed -- if I'm not mistaken, looking at this
- 14 recently -- have nixed surgery until at least age 18. I
- 15 can't recall about the hormone treatments.
- 16 I think the Swedes have said hormone treatments
- 17 can proceed as long as they are in this kind of
- 18 clinical -- I'm not sure if it's actually clinical
- 19 trial, but I think they use clinical research language
- 20 around it.
- To me I look at that as, well, they are being
- 22 more prudent and cautious. And I compare that to the
- 23 United States, I guess Canada too, but I'm more familiar
- 24 with the United States as being imprudent and
- 25 uncautious. So I look at that as, like, well, that's an
 - Page 257
- 1 improvement. But I say, like, that's something that I
- 2 would wholeheartedly endorse, I don't know, because it
- 3 doesn't get past some of these other issues I have with
- 4 the treatment of minors.
- 5 Q Okay. So the issues of the treatment of
- 6 minors, once again, that is your view on informed
- 7 consent for minors and also your view on the morality of
- 8 care for people who have not yet experienced post-
- 9 pubertal life; is that --
- 10 A Yeah.
- 11 Q -- basically right?
- 12 A You add the term "morality" because I said the
- 13 term "morality." But the wisdom and prudence is also
- 14 the same definition of it.
- 15 Q Okay.
- A Whether it's a good idea or not to have not
- 17 experienced your natal puberty before making up these
- 18 decisions. Now, I recognize that plenty of the
- 19 clinicians and researchers totally dispute that, and
- 20 that the Dutch protocol itself has sort of kind of been
- 21 weakened or lightened in part because of demand from
- 22 clinicians and from patients. I don't think it's going
- 23 in the other direction.
- 24 Q Okay. And just to come back to the framework
- 25 you gave for your objections here, you said the

1 objection about the lack of clinical trials.

- 2 A Um-hum.
- 3 Q There's the objection about research and
- 4 methodological concerns. And these are separate
- 5 objections about the wisdom of care for people who have
- 6 not experienced puberty and informed consent.
- 7 A Right, right, yeah.
- Q And those are different objections in your 8
- 9 mind?
- 10 A Right.
- 11 Q I just want to ask also, do you have religious
- 12 objections to gender-affirming care?
- A Religious objections to gender-affirming care?
- 14 Insofar as, you know, in the back of this interpretive
- 15 frame I already agreed that I'm kind of in the bodily
- 16 integrity camp.
- 17 Q And just to clarify, that's Exhibit 14?
- 18 A Is it? Are you asking me?
- 19 Q I'm sorry.
- 20 A Okay. Fine. Are those religious? I don't
- 21 know that those are religious. I'm Catholic. I know
- 22 the Pope isn't a big fan of gender ideology, but, uh --
- 23 Q Do you share that view?
- 24 A It depends on what he means by gender ideology.
- 25 The church hasn't made extensive statement on the

Page 258 1 in the description.

- But, you know, I don't think people can
- 3 actually change their sex insofar as we understand sex,

Page 260

Page 261

- 4 sexual dimorphism of the human organism.
- Q When you say pass for the opposite sex --
- A Like be understood to be somebody of the
- 7 opposite sex.
- 8 Q Okay. And you see that as related to
- 9 transgender people in the sense that you think they are
- 10 attempting to pass --
- 11 A Some transgender persons are attempting to pass
- 12 as the opposite sex, yeah. I mean, Dr. Karasic -- is
- 13 that how you say his name? I wrote in I think the
- 14 rebuttal where he describes this sort of -- the
- 15 normative goals of treatment, which are often to sort of
- 16 feel, appear, understand one's self as a member of the
- 17 opposite sex. So we're talking about, like, the desire
- 18 to do so; right?
- 19 Q Okay. Do you think that anybody who presents
- 20 as the opposite sex is transgender or who wants to
- present as the opposite sex is transgender?
- A Not necessarily, no. 22
- 23 Q So what is the distinction there?
 - A The distinction? I mean, my understanding is
- 25 that there are lots of goals that people have when they

Page 259

24

- 1 matter. These are -- these aren't necessarily
- 2 religious, but they do characterize largely how I
- 3 understand this to be. Um, you know, I don't know that,
- 4 like, my Bishop in Austin, I don't know what his
- 5 thinking is on this, but he wouldn't be out of step, I
- 6 think, with the church. So how much does that influence
- 7 me, I have no idea. I couldn't pick apart these things.
- Q Okay.
- 9 A But it's safe to say my church isn't --
- 10 wouldn't make it easy for me mentally, theologically, to
- 11 sort of endorse these things. But all the things I've
- 12 told you really stand independently so far of that.
- Q Okay. Just to come back, you said the church
- 14 has opposition to gender ideology. What does that term
- 15 mean?
- 16 A That's how they frame -- you know, I'm not a
- 17 good person to ask about that.
- 18 Q Okay.
- 19 A I do think, you know, they would not be fans
- 20 of, or even believers in the idea that one can change
- 21 one's sex.
- 22 Q And is that a view you share?
- 23 A I mean, I think one can pass extremely
- 24 effectively as a member of the opposite sex. Do you
- 25 pass as non-binary? That's a different kind of passing

- 1 pursue this or self-identify as such, some to appear as
- 2 both male and female, neither male, nor female, as a
- 3 member of the opposite sex -- you know, there's a lot of
- 4 goals that people have when they pursue this and some of
- 5 it is idiosyncratic. At the same time I think there's
- 6 some share, a non-insignificant share that seeks to
- 7 appear as somebody as the opposite sex.
- Q Okay. And coming back to this idea of gender
- 9 ideology. I know you said that's not --
- 10 A It's not a term I have used a whole lot I don't
- 11 think.
- 12 Q Okay.
- A I may have used it a few times. But it's sort
- 14 of like the package of -- insofar as I understand what
- 15 the Pope is referring to, like both sort of
- 16 understanding one is ontologically able to change one's
- 17 sex and -- so.
- 18 Q Well, the reason I ask is because it's in your
- 19 Declaration for the preliminary injunction. I think
- 20 this is Exhibit 3. I think it should be paragraph 6D.
- 21 At the beginning you kind of list -- you have a list
- 22 there on page 3.
- 23 A 6D, "There is a great deal of evidence that
- 24 discussion of gender dysphoria has been captured by the
- 25 assumptions of activists promoting what is sometimes

- 1 called 'gender ideology.'"
- 2 Q So what did you understand the term to mean in
- 3 the report?
- 4 A When I said that? Gender ideology, when I am
- 5 referring to it here, is sort of an understanding that
- 6 one can change one's sex, that it is fine and good to
- 7 pursue that if one wants, or, you know, to pursue one's
- 8 personal goals in regarding with hormones and surgery
- 9 and medicine, et cetera, et cetera.
- 10 It's, I think, a short phrase for what some
- 11 call the -- both the provision of the teaching about --
- 12 and it bridges into sort of academic teaching around
- 13 gender performativity (sic.), things like Judith Butler.
- 14 I think the term kind of encompasses this sort of world
- 15 view, physical, psychological, social about sort of the
- 16 malleability of gender or sex.
- 17 Q Okay. And that -- and that is the same meaning
- 18 that you say is part of the Catholic church's teaching
- 19 on gender ideology? Is there a different meaning?
- 20 A I'm trying to think. That is kind of the
- 21 phrase that they use, but some other people have used it
- 22 as well, to characterize -- I think it's the phrase they
- 23 use -- the sort of package of this stuff. Right?

4 that they were not ontologically born as.

A It's kind of a package deal of social,

7 intellectual, academic, psychological, medical,

Q Just to clarify. Transgender identity is not

10 something that, in your words, you were ontologically

MR. CANTRELL: Object to form.

Q (By Mr. Richardson) Well, I'm trying to

A -- is not something you would be ontologically

Q You said that gender identity -- or gender

21 ideology captures the idea that you can change, I think

Q -- what you were ontologically born as.

Q So your view is that --

8 understandings around this stuff.

A Say it once more, please.

15 under -- you just said that this stuff --

A Transgender identity --

Q -- includes --

22 your language was --

A Change one's sex.

A Yeah, made sex.

5

11 born as?

12

13

14

16

17

18

20

23

24

25

19 born as.

- And in some places, you know, there is still
- 25 gender ideology, but, you know, you don't have minors

1 wrestling with medical and surgical decisions. And they

3 would be this notion that people can become something

2 will still, sort of, encompassed in the gender ideology

- 1 Q Am I summarizing that right?
 - 2 A Fine.
 - 3 Q I'm trying to make sure I'm accurate with what

Page 264

Page 265

- 4 you were saying.
- 5 Okay. Is your view that transgender identity,
- 6 then, is not something that is inherently part of a
- 7 person's identity?
- 8 MR. CANTRELL: Object to form.
- 9 A Oh, I think as -- you know, adolescents and
- 10 adults it clearly is, you know, part of how they
- 11 characterize themselves and a very meaningful part. And
- 12 is it true that they are ontologically not their natal
- 13 sex? You know, I'm not sure I would agree with that,
- 14 but I understand that they understand themselves this
- 15 way or may understand themselves this way.
- 16 Q (By Mr. Richardson) Gotcha. Earlier you talked
- 17 about -- I think you called it a surge in cases of
- 18 adolescent --
- 19 A Um-hum.
- 20 Q -- gender dysphoria. Is there evidence of an
- 21 increase in adolescents receiving gender-affirming
- 22 treatment in the United States?
- 23 A I base that on sort of like the growth in
- 24 clinics, basically.
- 25 Q Okay.

Page 263

- A Like in the UK there is kind of one standard
- 2 clinic with a long wait list. So you kind of map the
- 3 surge there. Here, I don't think we keep great clinic
- 4 data. Well, at least, I don't think it's public. But
- 5 there is a far greater number of clinics in the United
- 6 States than there is in other places, probably because
- 7 we don't have a national health service.
- 8 Q Okay. So you think there are explanations,
- 9 then, beyond a number of people seeking care that would
- 10 explain why we have more clinics. You just said because
- 11 we don't have a national health service.
- MR. CANTRELL: Object to form.
- 13 A Okay. Repeat that first part.
- 14 Q (By Mr. Richardson) You just said that one of
- 15 the reason we might have more clinics is because we
- 16 don't have a national health service; right?
- 17 A So, yeah. So we have sort of a free market on
- 18 medicine.
- 19 Q Okay.
- 20 A So it's no surprise that if there is clinics
- 21 growing in number, they are meeting demand, because you
- 22 don't start a clinic when there is no demand.
- 23 Q Okay. So have you done anything to track the
- 24 number of people seeking care at these clinics?
- 25 A Seeking care? I track the number -- I haven't.

67 (Pages 262 - 265)

- 1 Other people have tracked the number of people who are
- 2 claiming on surveys to be transgender, et cetera. But
- 3 exact clinic numbers, I don't know. I'm talking about
- 4 surge in the cases of self-identified transgender.
- 5 Q Okay. Couldn't it be possible that the number
- 6 of people reporting to a single clinic could increase?
- 7 A Sure.
- 8 Q Like I believe that happened in the UK you
- 9 reported talking about something to that effect?
- 10 A Yeah.
- 11 Q Okay. So wouldn't it be possible that the
- 12 number of clinics isn't necessarily related to the
- 13 number of people seeking care?
- 14 A Oh, I disagree. I mean, you don't start a
- 15 clinic if you don't have a base of demand for it.
- 16 Clinics are growing in number because demand is growing
- 17 in number. That's just classic supply and demand.
- 18 Q Okay. So your support for the proposition that
- 19 there is an increase in the number of adolescents
- 20 receiving care in the United States is entirely based on
- 21 the number of clinics?
- 22 A That and sort of the surging numbers of
- 23 self-identified transgender individuals.
- 24 Q Okay. And that's survey data in the United
- 25 States?

Page 267

- A Yes. High schools, CDC's behavioral
- 2 surveillance surveys. We haven't seen those numbers
- 3 turned down by any stretch, only grow.
- 4 Q Okay. Is it your view that an increase in
- 5 incidents of a certain condition typically lead to that
- 6 condition being banned?
- 7 MR. CANTRELL: Object to form.
- 8 A That's a question I have not thought about.
- 9 Q (By Mr. Richardson) Well, is it common, as
- 10 more people need care of a certain kind, to then ban
- 11 that care?
- 12 MR. CANTRELL: Object to form.
- 13 A Need care of a certain kind?
- 14 Q (By Mr. Richardson) Seek care.
- 15 A Seek care of that kind.
- 16 Q Yes.
- 17 A The question is -- say it again, please.
- 18 Q Do you believe that generally when there is an
- 19 increase in the incidents of people seeking medical care
- 20 that we ban that care?
- 21 MR. CANTRELL: Object to form.
- 22 A I really don't have anything to calibrate that
- 23 or gauge that against.
- 24 Q (By Mr. Richardson) Are you aware of other --
- 25 A People demand certain things that then the

Page 268 1 government decides whether it's good to supply or not in

- 2 general. But in medical care, I'm unfamiliar with it.
- 3 Q Okay. Are you aware of a growth in the
- 4 incidence of other medical conditions for which people
- 5 needed care?
- 6 A I think we are seeing growth in sort of
- 7 psychological care, not necessarily medical
- 8 psychological care, but certainly, you know, growth in
- 9 psychotherapy provision and growth in anxiety among 10 youth.
- 11 Q Okay. So just taking anxiety --
- 12 A Depression, things like that. I mean, those
- 13 have surged over the last several years as well, and I
- 14 believe I mentioned that.
- 15 Q To your knowledge has any state responded by
- 16 banning care for anxiety and depression?
- 17 A No.
- 18 Q Okay. Are you aware of -- in the growth of the
- 19 number of people seeking treatment for autism spectrum
- 20 disorder?
- 21 A Seeking treatment? I have heard that is
- 22 growing in diagnosis.
- 23 Q Okay. And do people who are diagnosed with
- 24 that condition receive care associated with that
- 25 condition?

- 1 A I presume so. Though I presume that the care
- 2 does not involve invasive hormones and surgery prior to
- 3 turning 18.
- 4 Q Okay. And are you aware of any state that has
- 5 banned care for that condition?
- 6 A Probably not, given that the acceptable
- 7 treatment of that is not as radical as Arkansas is
- 8 perceiving this one to be.
- 9 Q Understood. So in general, then, an increase
- 10 in the incidence of a condition is not a reason alone to
- 11 ban the treatment for that condition?
- 12 MR. CANTRELL: Object to form.
- 13 A No. Agreed. For my situation it is a reason
- 14 to inquire as to what's happening, what's going on, why
- 15 is this occurring, and get a better understanding of it.
- 16 Which frankly, I'm struck, again, that researchers seem
- 17 insufficiently curious about it. Some of them are
- 18 talking about it now. Some of them realize it needs to
- 19 be talked about.
- 20 But I think I cited Dr. -- I think she's a
- 21 doctor -- Wren of the UK kids clinic formerly, sort of
- 22 reflecting on, sort of, this surge in cases, swap in the
- 23 sex ratio and , you know, wanting to know more about it
- 24 and saying, We owe it to our patients to understand this
- 25 better.

- 1 Q (By Mr. Richardson) I see. So why in this
- 2 context, then, does the increase of the number of
- 3 adolescents seeking care in your view provide a basis
- 4 for banning that care?
- 5 MR. CANTRELL: Object to form.
- 6 A In this case the number of -- the increase in
- 7 cases that is -- has gone, like, undertheorized by
- 8 clinicians and scholars who seem very hesitant to talk
- 9 about it, to me that is yet another signal of an
- 10 industry that is not monitoring itself well and,
- 11 therefore, one wants some reform to come to this.
- 12 O (By Mr. Richardson) So I suppose earlier you
- 13 had raised anxiety and depression among youth as another
- 14 condition that has grown in prevalence in recent years.
- 15 A Yeah, yeah.
- 16 Q Have you examined the state of science around
- 17 those treatments?
- 18 A I've -- not in a systematic way.
- 19 Q Okay.
- 20 A However, I recognize that there's a science
- 21 about giving black box antidepressants. Nobody under
- 22 age 18 -- I could be wrong about that. But certain
- 23 black box, that's what the term is, lest it can become
- 24 suicidal, have the reverse affect.

1 familiar with that term.

6 prescription, go."

11 frequent assessments --

Q Okay.

14 working as designed.

Q Okay.

A Right.

19 younger ages.

Q Yes.

Q So in that --

22 seeking it, it has these risks --

A No. One second. Sorry.

8 receive care?

12

15

16

17

18

23

24

25

25 Q I'm sorry. What does black box mean? I'm not

A You know, if I'm not mistaken, I could be

3 wrong, this should not be given to people under age 18,

4 it ought to be accompanied by careful oversight, careful

Q So they would get assessments before they

10 they are on care, while they are on care -- you know,

A -- because of the risk of the medication not

A For particular kinds of people especially at

Q Okay. So in that context we have a treatment

21 where the need for it is growing, more people are

A It's a treatment. Like there are other

A They should get assessments before care, once

5 oversight instead of just, you know, "Here is a

- Page 272
- 1 treatments I think that we are not pursuing, you know.2 We're not listening to our children very well, we're not
- 3 spending more time with our children. We're basically
- 4 saying a pill is an answer for the more difficult work
- 5 of being with one's child and maybe separating them from
- 6 risk factors and ways in which depression and anxiety
- 7 occur, and so we see a pill as potentially a panacea for
- 8 it.
- 9 Q Okay.
- 10 A I think pills have a place, but I think so do
- 11 those other things that people generally just don't do,
- 12 but clinicians sort of say, you know, I can't prescribe
- 13 mom and dad listen to this kid and have dinner with them
- 14 every night, knock off their, you know, cellphone at
- 15 6:00 p.m. These things might be helpful. They probably
- 16 would be helpful to widespread experience of depression
- 17 and anxiety, but we're not doing that. We're sort of,
- 18 kind of, prescription oriented. But that's --
- 19 Q I gotcha.
- 20 A It's the American way, frankly.
- 21 Q I guess my question is, so you have said there
- 22 is an increased demand for anxiety treatment among
- 23 youth?
- 24 A There's -- for help, yeah.
- 25 Q Yeah. And you said some of the treatments that

Page 271

- 1 are given in that context require, you know,
- 2 psychological evaluations beforehand and then ongoing
- 3 monitoring because they have health risks.
- 4 A Certainly -- well, because the medicine itself
- 5 can not act as intended.
- 6 Q Yes. So they -- they involve a risk and they
- 7 require monitoring to assess that risk.
- 8 A (Nods head.)
- 9 Q Okay. So given that those conditions are
- 10 present, increased demand, need for psychological
- 11 assessment beforehand and risks, do you support banning
- 12 that treatment for anxiety?
- 13 A I don't.
- MR. CANTRELL: Object to form.
- 15 A But I think it certainly should be one thing in
- 16 the arsenal of treating anxiety, not necessarily the
- 17 primary. At the --
- 18 Q (By Mr. Richardson) Okay. So what explains --
- 19 A -- same time -- at the same time it is, you
- 20 know, it's a pill that's -- it's a selective serotonin
- 21 reuptake inhibitor. It should work as designed in that
- 22 way and sort of not radically reorient the human body.
- 23 Q But you said it might lead to suicide; right?
- 24 A It can, right.
- 25 Q That's the risk that you're assessing for?

69 (Pages 270 - 273)

- A Right. They need to monitor that closely. 2 Q And you don't support banning that care for
- 3 minors with anxiety?

1

- A When they say block box, I think that means
- 5 that minors can't have it. I could be wrong about that,
- 6 that it can only be given to 18 and up, but that they
- 7 are very careful about how 18-year-olds and 19-year-olds
- 8 deal with it. Again, not my area of study here.
- But I would rather such black box SSRIs not be
- 10 given to 18, 19, 20-year-olds. They can be given
- 11 effectively, but how do you know it's not going to have
- 12 the reverse effect? That's alarming; right? We would
- 13 like to steer kids away from this.
- Q Okay. 14
- 15 A And I think it involves more than just a pill.
- 16 Q So I'm just trying to understand. So you do
- 17 support a ban to minors receiving that sort of care?
- 18 MR. CANTRELL: Object to form.
- 19 A I haven't thought about it. Again, like I'm
- 20 never in a position to -- for any idea I have of mine to
- 21 become reality. Haven't given it much thought.
- Q (By Mr. Richardson) Okay. But so we have --22.
- 23 A Very wary, though, I will say that.
- Q But you have said that you do support a ban on 24
- 25 gender-affirming care for minors.

- A At the bottom of 30?
- 1 paragraph 70 you talk about --
 - Q Bottom of 30, yes, but it's actually the
 - 4 sentence on the next page. It says, The FDA has not
 - 5 approved hormonal therapies for the treatment of gender

Page 276

- 6 dysphoria. Hence, it is undeniable that the protocol of
- 7 treatments remains technically experimental.
- A Yeah. Okay.
- 9 Q Okay.
- 10 A FDA approval comes when it's -- typically
- 11 when the trials and all this stuff has -- right now it's
- sort of off label if I'm not mistaken. That is my
- understanding, that the FDA has not approved of --
- 14 Q Okay. Well, how common is it, once a drug has
- 15 been approved for one use, for there to be randomized
- 16 controlled trials for alternative uses of that drug?
- 17 A I don't actually know that.
- Q How common is it in medicine for drugs to be 18
- 19 used for off-label purposes?
- 20 A I don't know, but I know that it does occur.
- 21 Q Okay. Do you think it's rare?
- A Probably not rare. But in this case it's, you 22
- 23 know, it's profound in its -- in its outcomes. So I
- 24 don't know if we -- you know, during the COVID era
- 25 people were talking about repurposing different

Page 275

- MR. CANTRELL: Object to form.
- 2 A By, you know, becoming an expert witness, yeah.
- 3 Q (By Mr. Richardson) And part of the reason for
- 4 that in your report is the increase in the number of
- 5 people seeking that care?
- MR. CANTRELL: Object to form.
- A No. I mean, I have mentioned that as sort of
- 8 an unexplained thing. Just the mere fact that it has
- 9 increased is not enough. But it's the fact that it has
- 10 not been talked about enough. It seems like it's a
- 11 source of demand for gender clinics. Our insufficient
- 12 curiosity -- I shouldn't say "our" -- is problematic
- 13 here.

1

- 14 Q (By Mr. Richardson) Okay. Just --
- 15 A I want to know why this is happening.
- Q Understood. But I think you just said this. I
- 17 just want to clarify. So an increase in the number of
- 18 people seeking care is alone not enough to support a ban
- 19 on care?
- 20 A Correct.
- Q Okay. Can we turn to your report again? This
- 22 is Exhibit 1. I think that's the Declaration, the
- 23 preliminary injunction.
- 24 A Exhibit 1.
- 25 Q Exhibit 1, yeah. And this is page 31. So on

- 1 antivirals for fighting COVID. Some of them found they
- 2 may be helpful, some not at all. This would be sort of
- 3 off-label usage in a domain that's comparable.
- Q Okay. So in your view are all off-label uses
- 5 of medicine experimental?
- A I think by FDA definitions they are. I could
- 7 be wrong about that. But I think that's -- the
- 8 definition of an off-label is not that for which it was
- 9 designed.
- 10 Q Okay. And do you think people within the field
- 11 of medicine would agree with that statement?
- 12 A I don't know. I'm not sure.
- Q Okay. Do you think all off-label uses in 13
- 14 medicine should be banned?
- 15 A No. Some of them are fairly tame.
- Q Okay. So the fact that gender-affirming care 16
- 17 involves an off-label use of medication is not alone
- 18 enough to ban care?
- 19 A Its off-label usage is far more significant
- 20 than some more tame off-label uses of -- of particular
- 21 drugs, like these antivirals, while they either
- 22 worked -- they worked or they didn't work. They -- you
- 23 know, they are not sort of harmful, per se. Right?
- 24 It's one thing if we're talking about ineffectual,
- 25 versus effectual, but rather significant in its outcome.

- 1 Q Okay. So once again, what is your basis for
- 2 saying that gender-affirming care is harmful?
- 3 A What is my basis for saying gender-affirming
- 4 care is harmful? Back to what we talked about before.
- 5 Altering the bodies of minors who have a limited sense
- 6 of the, sort of, what they might want in the future
- 7 presumes their ability to give genuinely informed
- 8 consent and disables them from having experienced the
- 9 sort of natal puberty that their body was aiming for in
- 10 service of the pursuit of the moderation of gender
- 11 dysphoria. So different than the off-label use of
- 12 Tamiflu to see if it kills COVID.
- 13 Q Okay. And when you say those things happened
- 14 in service of eliminating gender dysphoria, what
- 15 evidence do you have that that's harmful?
- MR. CANTRELL: Object to form.
- 17 A Harmful as in sort of, you know, is it damaging
- 18 to their psychological health? I'm starting to lose
- 19 track of where we are in this conversation.
- 20 Q (By Mr. Richardson) So you said that what made
- 21 gender-affirming care's off-label usage different was
- 22 that it was harmful.
- 23 A Well, significant in, like, preventing the
- 24 minor from experiencing natal puberty, potentially and
- 25 certainly actively if we move to cross-sex hormones and
 - Page 279
- 1 into surgical procedures for, you know, severing their
- 2 reproductive capacity and their natal sex and locking
- 3 them into a future that they had to choose when they
- 4 were 13, 14, or 15 rather than wait to experience it.
- 5 O Okay.
- 6 A I think right now there is finally some debate
- 7 whether that's a good idea or not from within the
- 8 affirmative medicine community.
- 9 Q Okay. Do you think the changes that happen
- 10 from endogenous puberty are irreversible?
- 11 A Happen from endogenous puberty are
- 12 irreversible? What do you mean?
- 13 Q Would --
- 14 A Example.
- 15 Q Would denying somebody gender-affirming care
- 16 also lock them into a certain future?
- 17 A It would give them the experience of their
- 18 natal body's construction and experience of that prior
- 19 to making the decision about what they want to do in the 20 future.
- 21 Q And would some of those things be irreversible?
- 22 A Uh, yeah, probably so. At the same time we
- 23 also know that sort of in terms of the surgical
- 24 procedures that are -- might be sought, that if you stop
- 25 puberty and reverse it, for example, on a natal male

Page 280 1 prior to growth of the penis that they are -- you know,

- 2 it stunts the ability to create a vaginoplasty in the
- 3 future. And Dr. Karasic has said that himself in an
- 4 article that he wrote about interviews with surgeons.
- 5 So it seems like, you know, one can't have
- 6 everything that one wishes in this domain. I can see
- 7 the affirmative communities are wrestling with what to
- 8 do about this. So --
- 9 Q All right.
- 10 A I'm losing track of your original question.
- 11 Q I'm just asking if some changes from endogenous
- 12 puberty are irreversible, and it sounds like your answer
- 13 is yes.
- 14 A Right. And at the same time, like, you know,
- 15 if you don't go through some aspects of puberty I think
- 16 even the subsequent changes and surgeries sought by
- 17 transgender minors and adults become more difficult if
- 18 one doesn't experience natal puberty.
- 19 Q Gotcha. And you said that one of the surgeries
- 20 you were discussing was vaginoplasty.
- 21 A I believe that was the case about -- with
- 22 regard to the article that Dr. Karasic coauthored.
- 23 Q And would you say that --
- 24 A I would have to refer to it in particular to
- 25 make more commentary about it.
 - Page 281 Q Understood. And would you say that you are an
- 2 expert on the surgical options for vaginoplasty?
- 3 A I am not.
- 4 O Okay.

1

- 5 A I'm basically telling you what an interviewee
- 6 of Dr. Karasic's said --
- 7 Q Understood.
- 8 A -- in Dr. Karasic's article about it --
- 9 Q Okay.
- 10 A -- saying it's kind of unfortunate that the
- 11 position that this failure to go through natal puberty
- 12 puts us in. We don't have much to work with is what he
- 13 said.
- 14 Q Okay. But you're not an expert on that
- 15 subject.
- 16 A I am not.
- 17 Q Okay. I just want to come back a question I
- 18 asked earlier. I want to make sure I have it straight.
- 19 You said the fact that a label -- or use of a
- 20 drug is off label is not itself a reason to ban care:
- 21 correct?
- 22 A That is off label? You know, not in terms of a
- 23 categorical ban I suspect. But, you know, I would
- 24 have -- you know, if you want my opinion on it, which,
- 25 of course, opinions -- again, I don't deal with my

- 1 opinion very often. I don't think about opinion. I
- 2 deal with reality.
- 3 I'd have to sort of look at a whole bunch of
- 4 examples.
- 5 Q Okay. But so you said that you think it could
- 6 be quite common that there are off-label uses of drugs
- 7 for different medical treatments; right?
- 8 A It could be.
- 9 Q Okay.
- 10 A I don't know that it is.
- 11 Q And you wouldn't, based on that fact alone,
- 12 support banning those treatments?
- 13 MR. CANTRELL: Object to form.
- 14 A Just a mere off -- you know -- no, although --
- 15 Q (By Mr. Richardson) Okay.
- 16 A -- you know, lots of times you will see, for
- 17 example, was it -- the treatment for COVID that people
- 18 believed worked and the latest studies didn't confirm
- 19 it. So doctors started banning the procedure, the CDC
- 20 recommended against it. I'm forgetting the name of it.
- 21 So bans happen within clinics. Doctors won't
- 22 prescribe particular things if they are not convinced
- 23 that they work as designed or work as off label. But
- 24 that's a little bit different.
- 25 Q But you would not support a legal ban on all

Page 284

- $1\,$ understands what you're saying if you have to show them
- 2 pictures.
- 3 So I think informed consent practices vary
- 4 widely in their thoroughness.
- 5 Q Okay. And where -- what is your basis for your
- 6 views on the informed consent process for minors?
- 7 A What do you mean what is my basis --
- 8 Q Where does your knowledge of that subject come
- 9 from?
- 10 A Of the -- the -- the knowledge of the subject
- 11 about informed consent?
- 12 Q Yeah.
- 13 A From people's descriptions of it, from, you
- 14 know, these, the opposition -- opposition, you know,
- 15 expert witnesses. You know, I know from experience
- 16 writing protocols for university institutional review
- 17 boards to approve surveys and things like that, you
- 18 know, they have sections on dealing with minors and
- 19 informed consent and what -- not even minors. I mean,
- 20 everybody has to have informed consent. Sometimes it
- 21 can be verbal. Sometimes it can be -- must be written.
- 22 Sometimes it needs to be translated into a language the
- 23 participants and the research can understand.
- 24 All sorts of things are -- so some of it is
- 25 personal experience, some of it -- I teach Research

Page 283

- 1 off-label uses of drugs?
- 2 A No, I don't think that makes sense.
- 3 Q Okay. Do you think that doctors who prescribe
- 4 drugs off label are behaving unethically?
- 5 A It would depend on -- it's not a categorical
- 6 evaluation I would make.
- 7 Q So you wouldn't say yes as a general matter?
- 8 A To all off-label usages of things?
- 9 Q Yeah.
- 10 A No.
- 11 Q Okay. You have mentioned a couple of times the
- 12 ability of minors to consent to care.
- 13 A I have.
- 14 Q Are you familiar with the informed consent
- 15 process for minors?
- 16 A As described by Dr. Adkins perhaps?
- 17 Q In any capacity.
- 18 A Well, I think the forms for it can vary widely.
- 19 In fact, critics of it have described that some places
- 20 and sometimes it's quite pro forma. Very quick, read
- 21 it, sign every page. Other people seem to sort of dwell
- 22 upon it. In her case I think she tries to, sort of,
- 23 even offer visual cues if you can't understand the
- 24 written cues, which I could say that's noble, but it
- 25 also sounds like, I'm not sure this person truly

- 1 Methods. We always have a week on research ethics. And
- 2 informed consent is always the linchpin of one of those
- 3 discussions.
- 4 Q Okay. And have you ever done research that
- 5 involved in seeking informed consent from minors?
- 6 A From minors? I have been involved not as a
- 7 principal investigator, but as a co-investigator.
- 8 Q Okay. And were you involved in, you know,
- 9 crafting the -- sounds like there's kind of survey
- 10 questions that go with this or a way you seek informed
- 11 consent for minors?
- 12 A With informed consent for minors you often have
- 13 to get, you know, it -- read it out to them and their
- 14 parents have to sign, things like that. So I'm familiar
- 15 with it. I haven't done it as a principal investigator.
- 16 I've participated in it as a collaborator,
- 17 co-investigator in the past.
- 18 Q Okay. And did that involve seeking informed
- 19 consent yourself? Like were you the one reading this
- 20 out to a minor?
- 21 A Yeah, I think I did. It's been a long time,
- 22 but I think I did, yeah.
- 23 Q Okay. And do you know what the Applebaum
- 24 criteria is?
- 25 A I don't.

Page 286
1 Q Okay. Just as a general matter, do you think
2 that parents should generally have the right to make
3 medical decisions for their children in consultation
Page 286
1 treatment.
2 It sounds like that reflects a lot of what you
3 have said today about informed consent; right?

- 5 MR. CANTRELL: Object to form.
- 6 A I'd say in general, although I think I wrote in
- 7 one of my reports it is unusual for parents to be given
- 8 permission to consent on behalf of their minor child to
- 9 procedures that would render the child infertile.
- 10 Q (By Mr. Richardson) So do you think the
- 11 government should tell parents which medical procedures
- 12 they can provide to their children?
- 13 MR. CANTRELL: Object to form.
- 14 A Say that again, please.

4 with the child's doctor?

- 15 Q (By Mr. Richardson) Do you think the
- 16 government should tell parents which medical procedures
- 17 they can provide to their children?
- 18 A I think we've been over this before. It
- 19 depends on the procedure and sort of the severity and
- 20 the significance of it and the permanence of it and the
- 21 ramifications of it. And in this case those things are
- 22 all rather significant and serious.
- 23 Q Okay.
- 24 A And insofar as they, you know, render somebody
- 25 permanently infertile prior to age of majority -- you

- 4 A Um-hum.
- 5 Q So do you think a central issue in this case is
- 6 a minor's ability to consent?
- 7 A In part. I mean, it's certainly like, in
- 8 addition to these other things, but it's also sort of
- 9 like is it prudent to permit procedures that would lead
- 10 to the permanent sterilization of minors, whether with
- 11 their consent or not.
- 12 Q Okay. And are you aware that HB 1570 bans
- 13 treatment even when the parents consent as well?
- 14 A I believe I do, yeah.
- 15 Q Okay.
- 16 A Probably -- this is where I sort of write this,
- 17 you know, parental consent of sterilization used to be
- 18 unlawful in many locales creating ethical dilemmas that
- 19 commonly required judicial review, and I cite this --
- 20 Q Understood.
- 21 A -- reference.
- 22 MR. RICHARDSON: Okay. Do you mind if we
- 23 take five and then we'll --
- 24 THE WITNESS: Sure.
- MR. RICHARDSON: I just want to use the

Page 287

- 1 know, I'm aware of doctors who will not give a vasectomy
- 2 to a young adult male who is of age seeking one.
- 3 So, I mean, that's informed consent, but some
- 4 doctors won't do it.
- 5 O And that's left to the doctor to make that
- 6 decision in that context?
- 7 A This is if the -- in this case it was the
- 8 patient pursuing it from a doctor who refused to give
- 9 it.
- 10 Q You think the doctors usually can make
- 11 judgments like that about when informed consent would be
- 12 appropriate on their own?
- 13 MR. CANTRELL: Object to form.
- 14 A I -- whether they can, I think they -- they do
- 15 make those judgments and I suspect it's not too
- 16 difficult to find a doctor who is willing to do so. But
- 17 some won't.
- 18 Q (By Mr. Richardson) Okay. We can turn to your
- 19 report. This is page 56.
- 20 A Which -- it's No. 1?
- 21 Q Number 1, yeah. Thanks. And this is paragraph
- 22 127, just that first sentence. Quote, A central and
- 23 persistent concern about hormonal and subsequent
- 24 surgical courses of treatment for gender dysphoria in
- 25 adolescents is their ability to genuinely consent to

- 1 restroom real quick.
- 2 VIDEO OPERATOR: All right. This will
- 3 end media part 5. We are off the record at 4:38 p.m.
- 4 (A break was had.)
- 5 VIDEO OPERATOR: We are back on the
- 6 record at 4:49 p.m. This will begin media part 6.
- 7 Please proceed.
- 8 Q (By Mr. Richardson) All right. Dr. Regnarus,
- 9 you expressed the view that one reason that
- 10 gender-affirming care for adolescents might be improper
- 11 is that people should be able to go through natal
- 12 puberty and have relationships and gender transition
- 13 might interfere with that.
- 14 A I didn't say relationships, but sort of
- 15 understand the experience of it. And, you know, this is
- 16 not necessarily just me talking. This is some
- 17 affirmative clinicians talking now about the wisdom and
- 18 prudence of that, so.
- 19 Q Understood. But would those concerns stop when
- 20 somebody turns 18?
- 21 A Which concerns?
- 22 Q Your concerns about somebody going through
- 23 natal puberty and being able to live post-pubertal life
- 24 in the way you've described.
- 25 A Right. I know you're asking a significant

- 1 question but I'm still failing to understand. What's
- 2 the --
- 3 Q Maybe I can just rephrase. So earlier we
- 4 talked about the reasons that you might oppose care for
- 5 somebody, you know, age 13, age 15.
- 6 A Um-hum.
- 7 Q And you talked about that person hadn't gone
- 8 through natal puberty and they deserve to sort of live
- 9 past that point in that state I suppose.
- 10 A Yeah.
- 11 Q Is that roughly accurate?
- 12 A Roughly, sure.
- 13 Q Okay. And would those concerns stop when they
- 14 turn 18?
- 15 A Not necessarily. I mean, 18 is sort of this
- 16 legal age of majority, but it is a social construction
- 17 really.
- 18 Q Yeah.
- 19 A As a sociologist I totally can acknowledge
- 20 that.
- 21 Q Okay. So if the bases for your opposition to
- 22 care might extend beyond 18 would you support banning
- 23 care beyond 18 for some people?
- 24 A Banning? I mean, again, I don't think about
- 25 this. In the United States we understand the age of

- Page 292
 - 2 A I don't know.
 - 3 Q -- to receive gender-affirming care?

1 immoral for somebody between 18 and 25 --

- 4 A I haven't -- I haven't given that thought. You
- 5 know, just back to what I said, you know, we allow all
- 6 sorts of behaviors at the age of maturity or close to it
- 7 or shortly thereafter. Smoking, drinking, marriage, I
- 8 mean, that we don't for 13-year-olds or -- you know,
- 9 like marriage. I think most states you have to be 18 or
- 10 17 with permission or things like that.
- We have to have some sort of benchmark of when
- 12 we do this. Some things it's 18, drinking it's 21,
- 13 driving a rental car without great fees is 25.
- 14 Q Okay. And which benchmark do you think would
- 15 make sense in this context?
- 16 A I don't have an opinion on that.
- 17 Q Okay. So earlier --
- 18 (Simultaneous crosstalk.)
- 19 Q I'm sorry. Go ahead.
- 20 A No.
- 21 Q Well, earlier I had asked you if a doctor who
- 22 prescribes a drug for an off-label use is necessarily
- 23 behaving unethically and I believe you said no.
- 24 A Wait. I think this -- you know, again, I'm not
- 25 going to speculate wildly on the nature of the drug or

Page 291

- 1 majority, whether you set it at 18 or not, is when
- 2 adults make decisions for themselves. Even if their
- 3 frontal cortex or prefrontal cortex isn't developed well
- 4 until 25, we seem to sort of set this as the age at
- 5 which people can make decisions by themselves and it
- 6 extends to, like, is it HIPAA or FERPA, I forget which
- 7 one it is, like you have to be -- once you're 18 your
- 8 medical decisions cannot necessarily be discussed with
- 9 your parents. I'm forgetting which one that is. But we
- 10 have decided these things, like, legally at age 18.
- 11 So, you know, I recognize the age of sort of
- 12 majority is a social construction. It kind of is what
- 13 it is. At some point people make their own decisions.
- 14 Whether I think they ought to or not is completely
- 15 irrelevant at that point it seems like.
- 16 Q Okay. But it sounds like the research suggests
- 17 that, in your view, the prefrontal cortex isn't
- 18 developed until 25.
- 19 A Not in my view. If you study Roper v Simmons
- 20 there is an extensive discussion of maturation of the
- 21 human person and the brain and why this is kind of
- 22 important for their, not just their consent, sort of to
- 23 be responsible for one's actions, you know.
- Q So putting the law to the side and kind of the 25 legal line we've drawn at 18, do you think it would be

- 1 the treatment, I mean, or what are we -- I mean, off
- 2 label can be a quack using it to sort of try to cure
- 3 cancer with vitamin C pills, but that -- you know,
- 4 vitamin C is not a -- not an off label. Anyways, but
- 5 you see my point.
- 6 Q I take the point, yeah. So do you think that
- 7 doctors who are providing gender-affirming medical care
- 8 to adolescents are behaving unethically?
- 9 A Do I believe doctors providing gender care to
- 10 adolescents, um, are acting unethically? Within the
- 11 standards of care that seem to govern them, they aren't.
- 12 The -- nevertheless, I think that is problematic and
- 13 unideal conduct.
- 14 Q Is it unethical conduct?
- 15 A Unethical? When you say ethical, you're
- 16 talking about what, immoral? What is the definition
- 17 of --
- 18 Q Let's try immoral. Would it be immoral
- 19 conduct?
- 20 A Ethical or moral, they are all kind of, you
- 21 know, talking about the good, right, reference to the
- 22 good. I think that it's suboptimal to treat adolescents
- 23 with hormones or surgery.
- 24 Q As a matter of fact or value?
- 25 MR. CANTRELL: Object to form.

Page 294 Page 296 A The fact/value distinction is radically Q Do you know how --1 2 overestimated. 2 A It's not -- go ahead. Q (By Mr. Richardson) Okay. So --Q Do you know how gender-affirming clinics in A We get -- we don't get to pick facts that are 4 Arkansas obtain informed consent? 5 separate from values. Right? Values saturate our A I don't. O Okay. 6 facts. For example, when I ask a survey question about 7 what sex are you, you know, I can give them two options, A And I wouldn't presume there is a standard to 8 I can give them more than two options. But the question 9 wording, it's like, What sex are you, do you consider 9 Q And why is that? 10 yourself, is -- implies a valuing of how people 10 A Because I -- so far as I can tell there are 11 understand themselves as sexed. 11 only recommendations out there, not standards. I mean, If I asked a question in a survey, What sex 12 even WPATH standards of care are, at the bottom, 13 were you assigned at birth, both of those signal -- are 13 suggestions. They can be the violated without impunity. 14 value saturated. They might look to be facts, which is Q Okay. So if I asked how many clinics in the 15 establishing people's sex, what they say about it, but 15 United States are using a thorough informed consent 16 process --16 in our facts are embedded values. 17 Q Understood. So let me rephrase it a little 17 A I don't think any of us know this. 18 bit --18 Q But you don't have a guess. 19 VIDEO OPERATOR: I'm sorry. Before you 19 A I don't, no. 20 do that I need to take a quick media break. Just one 20 Q And you don't have any first-hand experience 21 second. 21 with the way these clinics obtain informed consent? 22 A I don't, but to presume that there is a MR. RICHARDSON: Oh, sure. No problem. 22 23 VIDEO OPERATOR: We are going to go off 23 uniformity would make it -- you know, would be likely to 24 the record at 4:57 p.m. 24 be wrong. 25 (A pause was had.) 25 Q And you haven't surveyed clinics --Page 295 Page 297 VIDEO OPERATOR: We're back on the record A I have not. 1 1 2 Q -- as a part of any methodological inquiry? 2 at 4:57 p.m. Please proceed. Q (By Mr. Richardson) So I asked if doctors that A I have not. And I'm not aware of any research 3 4 are providing gender-affirming medical care to 4 on the surveying of clinics about how they understand 5 adolescents are acting unethically. 5 consent. I probably would have come across it in A Um-hum. 6 writing my report. 7 Q And you said that they are not acting to the Q And do you have any basis to doubt clinicians 8 good. Is that -- is that --8 who say that they do a thorough informed consent 9 process? A Oh, well, you know, I first described, you 10 know, within their code of ethics and with regard to the 10 A Doubt? I mean, just sort of, it would be nice 11 Endocrine Society and the WPATH's standards of care, you 11 to know more about what that looks like. 12 know, they're not doing anything that's unethical. 12 Q But you don't -- do you have any reason to 13 think that anybody who said they are providing thorough 13 Q Okay. 14 A But I think treating adolescents with hormones 14 informed consent is lying? 15 or surgery is decidedly suboptimal. 15 A Not out of hand, no. Q Okay. And that view that it is suboptimal has 16 Q So as far as you know most of them may be 17 providing thorough informed consent? 17 a moral component to it? 18 A All treatment decisions have a moral component 18 A They may. 19 to it. 19 Q Just don't know? A I don't, and I don't think anybody knows. 20 Q Including that judgment that it's suboptimal. 20 21 A Yes. 21 Q Okay. I'd like to turn to --22 O Okay. You raised some concern about the 22 A You know, like WPATH, they issue suggestions, 23 informed consent process actually happening at clinics 23 standards of care. But like, what is going on in the 24 regarding gender-affirming care; is that right? 24 clinics, I think there are lots of different clinics

25 under lots of different auspices and authority. You

A Yes.

25

- 1 know, I suspect nobody knows.
- Q Is it unusual for medical associations to
- 3 promulgate standards of care that don't have an
- 4 enforcement mechanism?
- A Is it unusual? One would think they have an
- 6 enforcement mechanism, but I see no evidence of one.
- Q Do most medical standards of care outside of
- 8 the context of gender dysphoria have enforcement
- 9 mechanisms?
- 10 A I don't know.
- 11 Q Can we turn to your report, page 68, paragraph
- 12 158?
- 13 A Same exhibit I'm on?
- 14 Q It should be Exhibit 1, yeah.
- 15 A Okay. Say again. 68?
- 16 Q Sixty-eight.
- 17 A Okay.
- 18 Q And starting at 158 you have a discussion of
- 19 suicide among gender dysphoric minors.
- 20
- 21 Q Do you think suicidal ideation as a condition
- 22 that is important to address?
- 23 A It is a condition important to understand for
- 24 sure.
- 25 Q Okay.

Page 299

- 1 A As I think I have made known in the report or
- 2 somewhere, in the report or rebuttal, I think ideation
- 3 has kind of become this general term that captures risk
- 4 of attempt, and attempt, sort of, obviously may end in
- 5 completion or not completion of suicide.
- Ideation is kind of a, so as far as I can tell,
- 7 it's become a catchall for anything ranging from the
- 8 most severe outcome to, you know, thinking about it;
- 9 right? And lots of adolescents, and frankly lots of
- 10 Americans, think about suicide at one point or another
- 11 and often more than once.
- So I think ideation should be taken seriously,
- 13 but it is well short of an attempt or, God forbid, a
- 14 completion.
- Q So do you think it's important to treat people
- 16 with suicidal ideation, even if that would not have lead
- 17 to a complete --
- 18 A What does it mean to treat with suicidal
- 19 ideation? I think most people get so discouraged,
- 20 upset, whatever, you know, they think about suicide.
- 21 And, frankly, suicide comes in a lot of different forms,
- 22 not in terms of method, but in terms of what's prompting
- 23 it. Right?
- I'm a sociologist, I've read Émile Durkheim. I
- 25 know something about suicide. It's egoistic, anomic,

- 1 and other forms of sudden which are prompted by
- 2 different kinds of things than, kind of, the -- in our
- 3 mind, the idea that, oh, someone is so depressed or
- 4 discouraged that at the end of a long sequence of
- 5 anxiety and depression they take their own life. And 6 there are very different social generations of suicide.
- 7 And in the literature on this stuff, I don't
- 8 see much in the way of nuance around it. I think
- 9 professor Biggs from Oxford notes this and in his study
- 10 of suicide in the UK GIDS Clinic notes that, in reality,
- 11 it's rather uncommon.
- 12 O Okay. So putting completed and attempted
- 13 suicide to the side and just focusing in on people with
- 14 suicidal ideation that never becomes an attempted or
- 15 completed suicide. Do you think that's the sort of
- 16 thing that it would be good to limit or prevent?
- 17 A One -- it's pretty hard to prevent suicidal
- 18 ideation because it's a thought; right?
- 19 Q You don't think people can be treated to reduce
- 20 the frequency of suicidal ideation?
- 21 A Well, I mean, we would have to -- some people
- 22 never really envision suicide despite their
- 23 difficulties. Some people think about it, you know,
- 24 after they perform poorly on a test; right?
- 25 Ideation seems here to be kind of this catchall

Page 301

- 1 from the most severe to the least severe. And I really
- 2 think the least severe kinds of experiences with being
- 3 discouraged about performing badly on an exam, these are
- 4 not realistic likelihood of moving forward towards an
- 5 attempt.
- Q Sure. And I'm saying even if there is nothing
- 7 to suggest there would be an attempted or completed
- 8 suicide in the research, is the mere fact of someone
- 9 having suicidal ideation the sort of thing that --
- A I think if it's a repeated thing then perhaps.
- 11 But to prevent minors in this example from ever thinking
- 12 about, like, Oh, I would be better off dead, that's
- 13 pretty difficult to do because a lot of people give
- 14 fleeting thought to this in their -- in their lives and
- 15 certainly as adolescents.
- Q But do you think there is some people for whom
- 17 it is persistent?
- 18 A I suspect it is.
- 19 Q And do you think they can be treated?
- 20 A In so far as you're trying to prevent a
- 21 thought, like, "Oh, I wish I was dead," right, versus
- 22 the kind of context which gave rise to this, is it
- 23 anxiety that gives rise to suicidal ideation? Is it
- 24 depression that gives rise to suicidal ideation? You
- 25 can attempt to one way or another, which I talked about

- 1 earlier. I'm not sure we're treating that smartly these
- 2 days.
- 3 That's different, though, from the kinds of
- 4 suicidal ideation that are infrequent, you know,
- 5 fleeting, that sort of thing. I feel like -- not feel
- 6 like.
- 7 My read on this literature is that there's a
- 8 preference for evaluating suicidality or suicide
- 9 ideation as kind of a latent term, as a catchall of a
- 10 serious risk if this person is in eminent probability of
- 11 having an attempt as suicide.
- 12 And I don't see together -- professor Biggs, I
- 13 don't see a lot of evidence of the eminent risk of this
- 14 stuff.
- 15 Q Okay. Once again --
- 16 A I agree with --
- 17 Q -- just putting --
- 18 A I agree with you that, yeah, repeated ideation
- 19 is not good and we should help minors and adults who are
- 20 doing this.
- 21 Q Okay. If even if it doesn't lead to a
- 22 completed or attempted suicide, it's a harm in itself
- 23 that should be --
- 24 A Yeah. It's a good thing to treat, right --
- 25 Q Okay.

- Page 303
- 1 A -- by one mechanism or another.
- 2 Q Okay.
- 3 A However, I mean, as I pointed out in this, I
- 4 think the term has been weaponized, certainly not
- $5\,$ we aponized for adults who are far at greater risk for
- 6 attempts and actual completed suicides, despite the fact
- 7 that their ideation patterns for sudden are much lower
- 8 than teenagers.
- 9 Q Okay. But do you believe that suicidal
- 10 ideation is higher for adolescents with gender dysphoria
- 11 than other adolescents?
- 12 A I suspect so, yeah. I mean, it seems to
- 13 have -- I think we saw that in the GIDS study, yeah. So
- 14 I think they do ideate about this more.
- 15 Q Okay. And to your point earlier, treating them
- 16 for that would be beneficial?
- 17 A Correct.
- 18 Q Okay.
- 19 A In some fashion. Right? Yeah.
- 20 Q Okay. And you express some belief, I think
- 21 this is early in your report, that the practitioners and
- 22 researchers involved in gender dysphoria are ignoring
- 23 certain trends.
- 24 A Yes.
- 25 Q I think one of this is desistance as a -- as a

- 1 concept.
- 2 A I don't think I wrote about that at great
- 3 length, but I have mentioned it.
- 4 Q Okay. But do you think it's one of
- 5 the things --
- 6 A Hard to track.
- 7 Q -- one of the things that's being ignored by
- 8 the field?
- 9 A Probably, yeah.
- 10 Q Are you aware if there is any research being
- 11 funded on that topic?
- 12 A So I know that Lisa Lemon did a study of 100
- 13 detransitioners. I don't know if she had external
- 14 funding for it or not. She might have.
- 15 Q Okay. And do people have their work published
- 16 on that topic?
- 17 A At least she does. Not too many people do.
- 18 Q Okay.
- 19 A Detransitioners are somewhat of a mystery, I
- 20 think, but one that the entire industry should seek to
- 21 understand better, not necessarily perceive as a threat.
- 22 So, you know, I think Biggs, professor Biggs was
- 23 criticizing Dr. Turban about the USTS who people who
- 24 aren't -- who are detransitioners I think if they were
- 25 eliminated from the study itself or, if I'm not
 - Page 30

- 1 mistaken, were not included in the sort of threshold for
- 2 completing the survey. I can't remember it. But he
- 3 seemed uninterested in people who had been and then were
- 1 not
- 5 Q Okay. But it would seem like if a field was
- 6 ignoring a certain topic there wouldn't be research
- 7 received on that topic and there wouldn't be papers
- 8 published on that topic; right?
- 9 A No. I think there isn't much published on this
- 10 topic, so I'm grateful for what exists. I think it's a
- 11 healthy sign in a scientific subfield that people are
- 12 taking up somewhat neglected topics like that.
- 13 Q Okay. So what is your basis for saying that
- 14 it's been neglected?
- 15 A Um, in my read of the literature there's just
- 16 not a whole lot out there about it. It's not a
- 17 complaint that it doesn't exist. It's a complaint that
- 18 it's overlooked. We have kind of radically different
- 19 estimates of it, you know.
- 20 Depending on when the detransition occurred,
- 21 you know, I think something I saw lately was -- was it
- 22 the GIDS study, it's closer to between 6 and 20 percent
- 23 than, you know, I think I read the four or -- 2 to 4
- 24 percent in one of the studies that I reported. It was
- 25 kind of not well documented what the, sort of,

1 desistance rate is.

- Plus, you know, when you stop going to a
- 3 clinic, why did you stop going? And do they track you,
- 4 keep track of what's going on. It's a little like,
- 5 what's the term, in survey research where sort of
- 6 longitudinal survey you're tracking people and then
- 7 you're lost to it. Right? You fail to answer the
- 8 fourth wave and they can't contact you and they don't --
- 9 you don't know what happened to that person.
- In this case, did they detransition, did they,
- 11 you know -- are they just not interested in the
- 12 treatment anymore? So kind of keeping really good
- 13 records here is helpful. And I'm sure some
- 14 practitioners think that -- agree with that.
- Q Okay. So do you keep up on research that's
- 16 coming out about desistance? I mean, this view that
- 17 it's being ignored, do you keep tabs on what's out there
- 18 and --
- 19 A I do.
- 20 Q -- what's -- what's in the pipeline?
- 21
- 22 Q Have you seen anything recently about
- 23 desistance?

1

- 24 A It rings a bell, but, you know, if you've got
- 25 one I can tell you whether I've seen it or not.

- Page 306 Page 308 Q Is that research being published?
 - 2 A I haven't seen a lot on it.
 - Q Okay.

1

- A And I usually see sort of the bigger studies
- 5 that come out.
- O Okay.
- A Now, it may be that one has recently come out
- 8 that I wasn't aware of or -- so --
- Q Okay. I guess if I was just asking this
- 10 question generally about is a scientific discipline
- 11 ignoring a certain topic and that that would call into
- 12 question the conclusions of organizations in that space,
- 13 how would I -- how would I know?
- A Right. So give you an example from my report.
- 15 Right? The kind of kerfuffle about 60 Minutes talking
- 16 to detransitioners and kind of the dialogue between some
- 17 of the, sort of, better known affirmative clinician
- 18 researchers to -- not to talk to the media about this.
- 19 And I forget her name, but 60 Minutes host said, I've
- 20 never seen a program try to be killed before it aired,
- you know, rather than criticize after it aired.
- 22 Q But people who work in gender-affirming care
- 23 are researching detransitioners; right?
- 24 A Some, yeah.
- 25 Q All right.

Page 307

Page 309

- Q Okay. You raise a similar concern about social
- 2 contagion as a concept to, right, that the field is sort
- 3 of not paying attention. I guess I have the same
- 4 question. Is there --
- A I think some are paying attention to it. 5
- 7 A I've seen WPATH start talking about it. But,
- 8 you know, sometimes in the expert witness reports from
- 9 the plaintiff's side I can see where they don't want to
- 10 talk about it because we've brought it up and it's, you
- 11 know, dismissed or, kind of in a rebuttal form, poked
- 12 at.
- 13 The idea of a social side to now it might be
- 14 called adolescent onset gender dysphoria. I mean,
- 15 Littman called it rapid onset meaning that it occurred
- 16 fairly quickly during adolescence. Now people very
- 17 critical of her at the beginning, nothing really
- 18 fundamentally changed about her study, and now we hear
- 19 talk about adolescent onset gender dysphoria from other
- 20 sources, so that's a positive in the literature.
- Q So is there research ongoing about that topic?
- 22 It sounds like there is.
- 23 A It does sound like there is.
- 24 Q Okay.
- 25 A I'm glad to see it.

- A I don't think it's a popular line of research,
- 2 but it does exist.
- Q Okay. So if I was looking to understand
- 4 something like this all I would have is, you know,
- 5 anecdotes like a 60 Minutes. I wouldn't have a systemic
- 6 way to evaluate the question?
- A So like Littman, she pulls in 100, I forget
- 8 where she found them, but there are examples of pooling
- 9 together people who say they are detransitioning or have
- 10 detransitioned and kind of exploring the reasons why.
- 11 And I think she does a fairly good job of the span of
- possible reasons for it.
- Q Okay. But if I wanted to understand, for
- 14 instance, like is the field of sociology ignoring the
- 15 connection between drug use and family dissolution?
- 16 A They are not.
- 17 Q They are not, but take me at the hypo there.
- 18 A It would be, you know --
- 19 Q Wouldn't it matter whether or not people are
- 20 pursuing research agendas on that topic and whether or
- 21 not that research is being funded and published,
- 22 wouldn't that be how I would answer that question? A Those are two things, right, the funding to
- 24 publish and the thing before it is --
- 25 Q Research agenda's from scholars.

23

- A Right. I mean, some things cost money to do.
- 2 But like -- in Littman, I don't know if he's funded for
- 3 that. But it doesn't look an expensive thing to do to
- 4 talk to a hundred detransitioners perhaps once. I can't
- 5 remember if she talked to them twice. But, you know,
- 6 it's helpful, I suppose, when funding is earmarked
- 7 towards it. Now, funding isn't usually earmarked that
- 8 narrowly in a discipline.
- And these decisions are made from somewhere.
- 10 Right? You know, what constitutes funding in this area.
- 11 Plus, if you're talking about federal funding then
- 12 you're talking about navigating the peer review process
- 14 And back to my claim about ideological capture.
- 15 And this is not just true of this domain, but the
- 16 federal granting agencies, you know, one could say these
- 17 are -- you know, the claims have been made that these
- 18 are peers that are endorsing each other's research.
- 19 It's this cycle where everybody sort of takes their turn
- 20 on it to keep people funded.
- Whereas, kind of more sort of perhaps cutting
- 22 edge or -- I don't know a better word for it -- research
- 23 that didn't necessarily fit with the paradigm can find
- 24 themselves pushed out of the peer review process at the
- 25 federal system because, you know, people don't like it.
 - Page 311
 - Q But that can suggest --
- 2 A Even though it could be a very viable area of 3 study.
- 4 Q But that suggests that -- you would answer a
- 5 question like that by looking to what is being funded,
- 6 published, researched; right? I mean, that would be the
- 7 way you would do it methodologically, and then you'd get
- 8 into issues about, you know --
- A Right.

1

- 10 Q -- you could draw conclusions about funding
- 11 sources and all of that.
- A True. And also sort of who is interested in
- 13 it. Are they talking? Is there conference proceedings
- 14 that deal with the topic? There's lots of ways that you
- 15 can kind of see what's going on in your field.
- Q Okay. But -- but once again, on the subjects
- 17 of desistance research and social contagion research,
- 18 which I believe you call it --
- 19 A Those are distinctive, though.
- 20 Q Distinctive things, yeah.
- 21 A Right.
- 22 O But you said for both that there is research
- 23 ongoing, there is papers being published.
- 24 A There are people who are curious about it.
- 25 There seems to be research ongoing. I mean, Littman has

- 1 exhibited research on the social contagion idea. I
- 2 don't know that she terms it that. But she was widely
- 3 pilloried and that kind of, I think, surprised her.
- And, you know, Brown sort of stopped things and
- 5 scrutinized it more closely and then decided, Well,
- 6 nothing untoward has happened here so -- but I think
- 7 PLOS, Public Library of Science, PLOS One, the journal
- 8 that was published and issued some sort of, you know --
- 9 that Dr. Turban makes reference to in a disparaging
- 10 fashion, like she had to go through this process that
- 11 Plos One indicated a sort of note of caution, which
- 12 frankly, was ridiculous to have a re-review and a note
- 13 of caution when nothing fundamentally changed about
- 14 analyses or her conclusion, maybe a little bit about the
- 15 language.
- 16 Q Okay. Just a couple of final things here. I
- 17 know we're kind of getting near the end.
- 18 You said that -- I think you referenced a Biggs
- 19 study on detransition; is that right?
- 20 A The 100-case thing? Is that big? That's not
- 21 really big in sociology.
- Q But, you said the Biggs study? 22
- 23 A Biggs --
- 24 Q Yeah. My mistake.
- A -- from Oxford. Detransition. Biggs. Did I 25
 - Page 313

- 1 mention that?
- Q I think it might be in the report. Let me just
- 3 check real fast.
- A Yes, I have. It rings a bell, but not very
- 5 loudly.
- Q Okay. I may circle back there if you don't 6
- 7 mind.
- A Sure. 8
- Q Q Take up your time. Are you familiar with a
- 10 group called Society For Evidence-Based Gender Medicine?
- 11 A A little bit, not a lot.
- 12 Q Are you involved in that organization?
- 13 A No.
- 14 Q Okay. How did you hear about them.
- 15 A I met somebody at a conference somewhere who
- 16 told me that they're involved with it. But -- no, no,
- 17 no. I think my research assistant had mentioned it, and
- 18 then I met somebody who -- that was the second reference
- 19 to it. But SEGM I think they're called.
- 20 Q SEGM, yeah.
- A I don't look at their website much. You know,
- 22 my research assistant mentions things occasionally. But
- 23 I don't -- I don't talk to them. I don't know who runs
- 24 the place, all that stuff.
- 25 Q Do you think that their views are influenced by

1 ideology?

- A I really can't tell you what their views are
- 3 except they're a little more cautious than, say, WPATH.
- 4 I don't know exactly how much more cautious.
- Q Okay. Can you go back to Exhibit 5 here? This
- 6 is your essay, "Arkansas and the Politics of
- 7 Experimenting on Children."
- A Oh, did I mention SEGM in that? It's possible.
- Q Okay. This will be the bottom of --
- 10 A Keep in mind that was a year ago. SEGM had
- 11 probably issued something. They are usually quick out
- 12 of the gate.
- 13 Q Yeah.
- A I don't read it, but, like, they say things 14
- 15 fairly quickly, I know that.
- Q Gotcha. So this will be the bottom of page 4.
- 17 A Got it. For instance --
- 18 Q It says, "Not all medical societies ignore such
- 19 cautions, but the mainstream ones are captured,
- 20 one-sided, and so silencing of all but affirmative care
- 21 voices that alternative professional groups are forced
- 22 to form."
- A Right. Force is kind of a -- not actually
- 24 forced. They feel like they have no choice but to form
- 25 a voice to be heard.

Page 315

- Q Understood. So when you say "mainstream ones," 1
- 2 is that a reference to the AAP, WPATH, and the Endocrine
- 3 Society?
- 4 A Correct.
- Q Okay. And is it your view that WPATH, the
- 6 Endocrine Society, and the AAP are influenced by
- 7 ideology?
- A Well, I mean, they have been captured
- 9 ideologically, which means a small -- smaller set of,
- 10 sort of, activists have managed to convince the American
- 11 Academy of Pediatrics to endorse affirmative medicine
- 12 and all that it entails --
- 13 Q I see.
- 14 A -- which is distinctive from sort of -- well,
- 15 what -- if we were to take a poll of pediatricians in
- 16 the United States, and I have no reason to think that
- 17 the AAP can't pull their membership or do a -- conduct a
- 18 study of their membership, you know, interviewing 500
- 19 pediatricians out of 60,000 or some odd --
- 20 Q Sure.
- A -- to kind of get their sense of this, I think
- 22 that's -- would be a helpful thing to do and they have
- 23 the resources to do it.
- 24 Q So have you --
- 25 A Basically, they didn't do that.

Q Yeah. So have you analyzed SEGM in the same

- 2 way that you have analyzed those organizations?
- A No. I mean, I know they serve -- they're
- 4 antagonistic to the same things I see, but I haven't
- 5 trained my lens on it. My sense is that they are not
- 6 popular perhaps in sort of terms of -- I don't know if
- 7 there is membership to the thing or what. But, you
- 8 know, they seem sort of like a smaller group, though I
- 9 could be wrong.
- 10 Q Okay. So there is no -- you haven't looked at
- 11 them the same way you have looked at the other
- 12 organizations to determine if there is any kind of
- 13 ideological bias involved?
- A Well, if you want to talk about bias, everybody
- 15 is biased.
- 16 Q The same way you have, you know, inquired as to
- 17 the other organizations, you have not done that for
- 18 SEGM?
- 19 A Right. Because I suspect I would find that we
- 20 are probably more on the same page, so -- or at least
- 22 Q Okay. And so would being on the same page you
- 23 mean they are not ideologically motivated?
- 24 A No. I think on the same page as they are not
- 25 crazy about hormonal and surgical treatment for minors.

Page 317

- Q Okay. Do you have any experience with 1
- 2 adolescents diagnosed with gender dysphoria who were
- 3 unable to access gender-affirming care?
- 4 A That's a tight set of criteria.
- 5 O Yeah.
- A Say it again, please.
- Q Do you have any experience with adolescents
- 8 diagnosed --
- 9 A People under 18.
- 10 Q Diagnosed with gender dysphoria.
- A Now, I'm typically not privy to that, but I 11
- 12 have -- okay. That also --
- 13 Q Who were unable to access gender-affirming
- 14 care?
- 15 A Who are interested in accessing it and unable
- 16 to access it?
- 17 Q Yes.
- A I mean, I have some knowledge of kids who were
- 19 assessed as gender dysphoric and in-patient care whose
- 20 parents decided that was wildly different from their
- 21 experience of that child at home and pulled her out of
- 22 the care facility. I mean, I'm not sure if that's quite
- 23 close to what you were talking about.
- 24 Q This is a social interaction, this is somebody
- 25 who --

1 A Correct.

- 2 Q Okay. Like family friends and this is their
- 3 kid or something?
- 4 A (Nods head.)
- 5 Q Okay. So you have never spoken with an
- 6 adolescent who was seeking gender-affirming care for
- 7 gender dysphoria and was not able to obtain it?
- 8 A Correct.
- 9 Q Okay. Do you have any basis to dispute
- 10 clinicians who treat adolescent patients with gender
- 11 dysphoria and see the benefits of that care for their
- 12 patients?
- 13 MR. CANTRELL: Object to form.
- 14 A All right. Say that again slowly, please.
- 15 Q (By Mr. Richardson) Do you have any basis to
- 16 dispute clinicians who treat adolescent patients with
- 17 gender dysphoria and see the benefits of care for those
- 18 patients?

1

9

10

11

16

22

23

25

21 minors.

24 or not.

Q Okay.

A Sure.

12 is lying about the benefits?

17 adolescent with gender dysphoria?

Q Okay. Did you discuss --

- 19 MR. CANTRELL: Object to form.
- 20 A So Dr. Adkins talks a lot about this. And one
- 21 of the ways I criticize her -- I think I criticized her
- 22 in print -- is constantly referring to sort of her
- 23 assessment of her patients, right. You know, since I
- 24 don't have patients and I don't interact with patients,

2 a bit of a loggerhead where she'll say, Ah, I know what

4 I'm kind of not in a position to be privy to those kinds

Q (By Mr. Richardson) Do you not think that

Q So you have no basis to think that Dr. Adkins

A I don't think she's lying about what she sees

14 and perceives. That doesn't solve my disputes with her

A Would you qualify transgender adolescents as

A We did not discuss their diagnoses of dysphoria

19 fitting that? I mean, they would have to give me their

20 diagnosis. You know, I have talked to transgender

15 about all the other things that we've talked about.

Q Okay. So have you ever talked to any

5 of conversations, but privy to the wider literature.

7 clinical experience should inform medical care?

A Oh, you know, I think that's part of it.

3 my patients need and want and benefit from. You know,

25 I assess the literature on this.

- Page 318 Page 320
 - 1 A That would be rather invasive I would say.
 - 2 Q Did you discuss Medicare for gender dysphoria 3 at all?
 - 4 A No.
 - 5 Q Okay. Have you ever read or heard anything
 - 6 about the plaintiff families in this case?
 - 7 A The who?
 - 8 Q Plaintiff families, the Brandts, the Jennens.
 - 9 A Um, I think I did a cursory read back last,
 - 10 whenever that was, June, early July.
 - 11 Q Okay.
 - 12 A But not -- not a detailed read.
 - 13 Q Did you see that they talked about uprooting
 - 14 the families and moving out of the state?
 - 15 A I do recall that.
 - 16 Q Okay. Did you have any reaction to that?
 - 17 A Well, I feel for people. Right? It's -- but,
 - 18 you know, the empathetic part seems that that's a
 - 19 frustrating thing to do and, yet, it's not enough to
 - 20 make me think the treatments are a good idea.
 - 21 Q Okay. Do you recognize that their teen-age
 - 22 children may be harmed if they are forced to stop
 - 23 receiving care?
 - MR. CANTRELL: Object to form.
 - 25 A Harmed in what fashion? This is where I get a

Page 319

- So when Adkins says things like this we come to 1 little frustrated with harm as its generic term meant to
 - 2 signal significant risk of things.
 - 3 Q (By Mr. Richardson) Harm by the clinical
 - 4 distress that accompanies gender dysphoria.
 - 5 A You know, frustrated, sad, upset, yeah,
 - 6 discouraged. I get that that can occur.
 - 7 Q Okay. And you said that you've talked to some
 - 8 transgender adolescents before; right?
 - 9 A Yes.
 - 10 Q How many would you say you?
 - 11 A Not a lot. Sometimes I -- one has subjective
 - 12 assessment of it. But students mostly, in fact, mostly
 - 13 over 18. Sorry.
 - 14 Q So any adolescents?
 - 15 A Yes, but not many.
 - 16 Q Okay. And the context for those conversations,
 - 17 was it --
 - 18 A Social.
 - 19 Q Okay. This wasn't a research setting of any
 - 20 kind or --
 - 21 A No.
 - Q Okay. Do you recall appearing on a program
 - 23 called the Dr. J Show with a host Jennifer Roback Morse?
 - 24 A A show? Vaguely, yeah. This is Zoom era
 - 25 perhaps.

81 (Pages 318 - 321)

Q Okay.

- Q That sounds right. And the host was Jennifer 1
- 2 Roback Morse?
- A Yes.
- Q Okay. Do you recall the host saying "The truth
- 5 will always be at war with transgender people"?
- A I don't recall her saying that. I will say
- 7 that there are moments when you're talking with Jennifer
- 8 Roback Morse that you don't quite know what she is going
- 9 to say.
- 10 Q Okay.
- 11 A It's not my style of operating in this domain.
- 12 O Okay.
- 13 A But, you know, I take responsibility for what I
- 14 say, not for what other people say.
- 15 Q Okay. Do you agree with her statement that
- 16 "The truth is always at war with transgender people"?
- 17 A You know, I'd have to break that down piece by
- 18 piece. It seems like a kind of -- a characterization
- 19 that, you know, is unnecessarily inflammatory with the
- 20 kind of wartime imagery. I don't think about things
- 21 being at war with persons. I try to keep things about
- 22 ideas, right, this is a good idea, this is a bad idea,
- 23 rather than sort of being at war with persons.
- Which is why in all of my research, you know, I
- 25 try hard not to disparage persons. I have to criticize

- Page 324
- 1 empirically more solid research in this domain. When
- 2 we're doing things with samples we're getting estimates
- 3 of the real thing.
- Any time you're dealing with samples and not
- 5 entire censuses of populations you are estimating
- 6 things, which means there is a margin of error, standard
- 7 of errors, deviations. You don't get to know the entire
- 8 truth. You estimate how close it is to the truth.
- 9 Which, of course, is more difficult to do when you don't
- 10 have random samples, but that's a different story.
- 11 Warring. I don't know how to evaluate that
- 12 statement of Jennifer's. I'm not sure what she's
- 13 meaning.
- Q Okay. 14
- 15 A I don't think of myself as warring with
- 16 transgender people.
- 17 Q Okay. So we're getting near the end so I have
- 18 to ask you one of your favorite questions, which is an
- 19 if-you-were-in-charge question.
- 20 If you were in charge would you impose a ban on
- 21 care for all adolescents seeking gender-affirming
- 22 medical treatment or would you prefer a system that
- 23 allows for care in the cases where there is demonstrated
- 24 need and care is regulated by a state medical board?
- 25 MR. CANTRELL: Object to form.

Page 323

- 1 in rebuttal. Right? Sometimes I have no choice but to A What is demonstrated need? This is kind of
- 2 go after people because this is -- but I typically try
- 3 to treat them with dignity, respect, you know, I don't
- 4 think certain kinds of lingo is helpful.
- Q Okay. So just focusing on ideas, then, do you
- 6 think the truth is at war with gender ideology?
- A The truth. What do you mean by the truth?
- 8 Empirical truth?
- Q In the way she meant it, yeah.
- A I'm not sure exactly how she meant it. I would 10
- 11 have to have the context for that discussion. I'm sure
- 12 when she said that I'm like, "Jennifer why do you say
- 13 such things?" But that's her -- her style.
- Q So that's a -- the truth, I mean, it sounds
- 15 like you said -- you just used the descriptor.
- 16 A Empirical?
- 17 Q Yeah. So the empirical truth is at war with
- 18 gender ideology?
- 19 A I'm not sure that's what she was saying,
- 20 though.
- Q Okay. Let's just take it separately then. Do
- 22 you -- do you think that the empirical truth is at war
- 23 with gender ideology?
- A I'm not sure what that means frankly, the
- 25 empirical truth. I'm questing, searching for, like,

- Page 325
- 2 where you go to this sort of medically necessary
- 3 language, which is, of course, somewhat subjective to
- 4 the physician. Right? You know, somebody deems
- 5 something as medically necessary and somebody else would
- 6 not necessarily.
- 7 So if you would, read that to me once more.
- Q (By Mr. Richardson) So I will make it a little
- 9 simpler. If you were in charge would you impose a
- 10 ban --
- 11 A Charge of what?
- 12 Q -- on all gender-affirming care for adolescents
- 13 or prefer a system --
- A So by gender-affirming care we mean the
- 15 psychological aspects of this as well or not?
- 16 Q We mean the procedures banned by HB 1570.
- 17 A So it's for puberty blockers, cross-sex
- 18 hormones, surgeries of different types. Right? I don't
- 19 think they are appropriate for minors.
- 20 Q Okay. So that would be the optimal system in
- 21 your view over any kind of individualized assessments?
- A Well, I think people should have individualized
- 23 assessments. But certain things should be permissible.

24 Certain things should be preferred to other things.

25 But to sort of sever one from, sort of,

Page 326	Page 328
1 experience of puberty I think is imprudent. One does	1 CERTIFICATE
2 not know what one will feel, think, find when that	2
3 occurs. And so I think that conversation is even	3
4 starting to break back into the affirmative care group.	4 I, Trena K. Bloye, Certified Shorthand Reporter
5 I don't expect the conflict with them to diminish any	5 within and for the State of Oklahoma, certify that MARK
6 time soon. I think it's a very live thing. I watch,	6 DANIEL REGNARUS was by me first duly sworn to testify
7 so.	7 the truth, the whole truth, and nothing but the truth,
8 Q Would you say the conflict like that is a sign	8 in the case aforesaid; that the witness chooses to read
9 of a healthy	9 and sign the deposition; that the above and foregoing
10 A Well, I do think	10 videotaped deposition was taken by me in shorthand and
11 Q profession?	11 thereafter transcribed; that the same was taken on May
12 A Open conflict and respect is better than, sort	12 5, 2022, at 9:01 a.m., at the Arkansas Attorney 13 General's Office, 323 Center Street, Suite 200, Little
13 of, what we have seen in the past.	14 Rock, Arkansas, that I am not an attorney for, nor a
14 Q And you think that the current field of	15 relative of any of said parties or otherwise interested
15 transgender healthcare is characterized by open	16 in the event of said action.
	17 IN WITNESS WHEREOF, I have hereunto set my han-
16 conflict? 17 MR. CANTRELL: Object to form.	18 and official seal this 14th day of May, 2022.
3	19
18 A I think we are starting to see signs of more	20
19 open conflict. I think in the past it looks like it	21
20 was, you know, suppressed, probably still is suppressed	22
21 at some level. But how it will end I have no idea.	23
22 Q (By Mr. Richardson) Okay.	OSiana K. Blag
23 A I mean, we're talking about an industry that is	
24 guided by suggestions rather than hard rules.	Trena K. Bloye, CSR
25 Q And do you think that's unusual in medical	25 State of Oklahoma CSR No. 1522
Page 327 1 science?	Page 329 1 MICHAEL A. CANTRELL
2 A When you're dealing with minors I suspect there 3 is a lot more things that involve laws and rules than	2 michael.cantrell@arkansasag.gov 3 May 17, 2022
4 when you're dealing with adults.	4 RE: BRANDT, et al. vs. RUTLEDGE, et al.
	5 5/5/2022, Mark D. Regnarus (#5163547)
5 MR. RICHARDSON: Okay. That's it for me. 6 MR. CANTRELL: I have no questions. But	
_	•
7 we will review and sign.	7 review.
8 VIDEO OPERATOR: Okay. This concludes	8 Within the applicable timeframe, the witness should
9 today's testimony given by Mark Regnarus. The total	9 read the testimony to verify its accuracy. If there are
10 number of media used was six and will be retained by	10 any changes, the witness should note those with the
11 Veritext. We are off the record at 5:39 p.m.	11 reason, on the attached Errata Sheet.
12 (Deposition concluded.)	12 The witness should sign the Acknowledgment of
13	13 Deponent and Errata and return to the deposing attorney.
14	14 Copies should be sent to all counsel, and to Veritext at
15	15 arratae ce(d)varitayt com
15	15 erratas-cs@veritext.com.
16	16
16 17	16 17 Return completed errata within 30 days from
16 17 18	16 17 Return completed errata within 30 days from 18 receipt of testimony.
16 17 18 19	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time
16 17 18 19 20	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time 20 allotted, the transcript may be used as if signed.
16 17 18 19 20 21	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time 20 allotted, the transcript may be used as if signed. 21
16 17 18 19 20 21 22	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time 20 allotted, the transcript may be used as if signed. 21 22 Yours,
16 17 18 19 20 21 22 23	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time 20 allotted, the transcript may be used as if signed. 21 22 Yours, 23 Veritext Legal Solutions
16 17 18 19 20 21 22	16 17 Return completed errata within 30 days from 18 receipt of testimony. 19 If the witness fails to do so within the time 20 allotted, the transcript may be used as if signed. 21 22 Yours,

		Page 330
1	BRANDT, et al. vs. RUTLEDGE, et al.	Tuge 550
	5/5/2022 - Mark D. Regnarus (#5163547)	
3	ERRATA SHEET	
4	PAGELINECHANGE	
5		
	REASON	
7	PAGELINECHANGE	
8		
	REASON	
	PAGELINECHANGE	
11		
	REASON	
	PAGELINECHANGE	
	REASON	
	PAGELINECHANGE	
	DE A CON	
	REASON PAGELINE CHANGE	
	PAGELINECHANGE	
	REASON	
22	NEA BOTT	
	Mark D. Regnarus Date	
25		
		Page 331
1		Page 331
	BRANDT, et al. vs. RUTLEDGE, et al.	Page 331
2	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547)	Page 331
	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT	Page 331
2 3 4	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I	Page 331
2 3 4 5	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any	Page 331
2 3 4 5 6	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as	Page 331
2 3 4 5 6 7	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any	Page 331
2 3 4 5 6 7 8	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is	Page 331
2 3 4 5 6 7 8	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony	Page 331
2 3 4 5 6 7 8 9	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony	Page 331
2 3 4 5 6 7 8 9 10	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me.	Page 331
2 3 4 5 6 7 8 9 10 11 12	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me.	Page 331
2 3 4 5 6 7 8 9 10 11 12	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date	_
2 3 4 5 6 7 8 9 10 11 12 13	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE I	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE I	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE I	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE I	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE II DAY OF	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE II DAY OF	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE II DAY OF	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE II DAY OF	— ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	BRANDT, et al. vs. RUTLEDGE, et al. 5/5/2022 - Mark D. Regnarus (#5163547) ACKNOWLEDGEMENT OF DEPONENT I, Mark D. Regnarus, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Mark D. Regnarus Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE II DAY OF	— ME THIS

[**& - 425**] Page 1

_	144 10 150 2 4	_	2021 04 24 107 17
&	144:19 150:3,4	2	2021 84:24 197:17
& 2:4 36:7 74:20	152:16,22,25	2 4:5 12:2,3 29:25	2022 1:16 5:8 6:2
0	153:5,14 156:15	74:11 128:23	96:16 136:7
00450 1:6 6:13	156:21,22 157:8	149:14 153:14	328:12,18 329:3
	161:5 165:24	239:12,12 305:23	207 4:11
1	235:9 258:17	2-2 56:11	20th 20:11
1 4:4 6:8 11:12,14	279:4	20 64:16 108:15	21 292:12
11:16 13:13 46:2	14th 328:18	274:10 305:22	212-558-4000 2:6
46:6 74:8 176:6	15 4:6,7 161:5	331:15	25 160:14,20 161:1
182:20,22 275:22	249:17 250:19	200 2:18 6:16	161:4 291:4,18
275:24,25 287:20	279:4 290:5	328:13	292:1,13
287:21 298:14	1522 328:25	2000 19:11 41:3,6	26 149:14,15
1.7 46:12	1570 180:20 181:3	41:11	151:15 157:2
1.7. 46:12	181:5 185:24	2005'ish 49:19	2:02 174:18
10 63:21	189:18 288:12	2011 138:7	2:50 174:11
100 117:16 304:12	325:16	2012 138:7,8 139:9	2nd 2:14
309:7 312:20	158 298:12,18	143:7 146:3	3
10004-2498 2:6	161 176:4	2013 30:8	3 4:6 15:2,8,9,17
10:22 74:8	17 167:18 211:19	2014 61:21 96:18	15:19,20 110:14
10:35 74:11	236:13 253:25	131:1 136:7 137:8	129:1 174:14
11 4:4 31:21	292:10 329:3	144:2,2 145:3	261:20,22
11/13/19 4:10	18 4:14 95:23	2015 96:18 144:19	30 144:17 145:19
115 4:12	138:18,19 167:18	145:3	276:2,3 329:17
11:58 128:23	256:14 269:3	2015'ish 96:20	31 275:25
11th 192:12	270:22 271:3	2016 30:8 61:7	323 2:18 6:15
12 4:5 31:21 63:21	274:6,7,10 289:20	70:1	328:13
64:9	290:14,15,22,23	2017 61:7 62:2	328 3:5
125 2:5	291:1,7,10,25	63:17 70:1 96:20	330 3:6
127 287:22	292:1,9,12 317:9	108:15 130:24	331 3:7
12:11 129:1	321:13	133:14 136:25	3800 2:10
13 115:19 116:13	19 274:7,10	146:7	3:47 251:12
139:2 161:5 231:3	1950 159:11	2018 45:18 96:10	
233:12 234:18	1989 19:7	96:11 97:6 136:13	4
235:2,5,9 236:22	1993 19:9	136:23 197:18	4 4:7 15:9,15 16:1
237:24 248:24	1994 49:14	2019 79:10 197:18	153:16,16 174:18
250:19 254:7	1997 19:10	2020 4:13 95:12	182:19,21 251:8
279:4 290:5 292:8	1998 168:25	106:21 108:12,17	305:23 314:16
138 4:14	1nnt 91:6,7	108:21 130:25	40 42:19 167:16
14 4:13 44:19,20		136:7 137:8	40'ish 42:17
67:10 68:5 69:25		197:18	425 2:9
84:21 139:16,20		177.10	
521 157.110,20			

[44 - address] Page 2

	I	I	
44 4:13	7	absolute 193:12	71:5,20 97:13
45 174:10	7 3:4 4:10 80:23	255:20	183:1 205:7 264:3
49 80:12,13 123:23	81:1 85:4 95:4	abundant 161:15	290:11
124:3	229:24	162:12 163:16	acknowledge
4:21 1:6 6:13	70 176:4,7 276:1	academia 51:8	187:3 290:19
4:38 289:3	72201 2:10,15,19	academic 19:2	acknowledgement
4:49 289:6	77 4:8	20:3 27:4,8,11	115:2 331:3
4:57 294:24 295:2	8	37:7,9,22 39:14,21	acknowledgment
5	_	41:22 42:6,10	329:12
5 1:16 4:8 76:23	8 4:11 207:14,15	43:17 48:12,24	aclu 2:12 7:6
76:24 80:20 85:3	80 s 150:11	49:22 60:5,9,24	74:16,18
94:21 153:16,17	81 4:10	63:4 71:6 72:6	acronym 33:12
·	8249 328:23	73:24 144:1	act 273:5
191:18 251:12 289:3 314:5	9	146:11 173:21	acting 221:18
289:3 314:5 328:12	9 4:12 115:12,13	262:12 263:7	293:10 295:5,7
	182:19,21	academically	action 6:19 328:16
5/5/2022 329:5	904 2:14	240:1	actions 160:14
330:2 331:2	90s 150:12	academics 78:12	291:23
50 117:16	9:01 1:17 6:2	78:14	active 48:17 58:15
500 315:18	328:12	academy 64:14	66:10 68:8
501-376-3800 2:11		160:6 315:11	actively 29:16
501-682-2401 2:19	a	accept 93:12 187:7	60:19 278:25
50s 207:5	a.m. 1:17 6:2 74:8	217:19	activism 124:12
5163547 329:5	74:11 128:23	acceptable 269:6	activist 103:21
330:2 331:2	328:12	accepted 143:9	activists 160:5
56 149:17 152:9	aap 195:13 315:2	accepting 164:10	261:25 315:10
157:2,21 159:16	315:6,17	access 317:3,13,16	activities 25:17,19
287:19	ability 9:10 191:7	accessing 188:4	actual 303:6
5:39 327:11	252:16 254:6	317:15	add 13:20 29:24
5th 5:8 6:2	278:7 280:2	accompanied	165:2,3,7 257:12
6	283:12 287:25	271:4	adding 17:24
6 95:21 289:6	288:6	accompanies	addition 10:11
305:22	able 38:14 62:12	321:4	288:8
60 308:15,19 309:5	64:21 158:22	account 99:10	additional 16:20
60,000 315:19	160:13 261:16	accounts 192:15	16:23 177:18
60s 207:5,5	289:11,23 318:7	accumulate	additions 331:6
68 298:11,15	abortion 141:1	131:11	address 43:20
6:00 272:15	150:11 155:13	accuracy 61:9	170:18 171:4
6d 261:20,23	absence 171:8	329:9	170.18 171.4
201.20,23	176:16 177:5	accurate 8:5 9:7	228:8 298:22
	190:19 216:1	13:15 29:11 30:13	220.0 270.22
	223:14	15:15 29:11 30:13	
		ral Calutions	

[addressed - agree] Page 3

addressed 186:15	188:13 189:15	affiliation 24:24	240:23 241:4,7
adduced 139:8	213:14 214:19,23	142:18	243:1 248:16,25
adequate 168:2,5	215:19 222:6	affiliations 6:24	251:16 253:10
171:4	243:13 253:11	affirm 156:16	256:11 258:12,13
adf 131:16 133:1,5	264:9,21 266:19	affirmative 178:8	264:21 274:25
133:25 135:25	270:3 287:25	227:25 232:13	277:16 278:2,3,21
142:6,18	289:10 293:8,10	237:8 240:3 279:8	279:15 289:10
adhered 159:7	293:22 295:5,14	280:7 289:17	292:3 293:7 295:4
adjust 172:15	299:9 301:15	308:17 314:20	295:24 296:3
adkins 229:23	303:10,11 317:2,7	315:11 326:4	308:22 317:3,13
244:14 283:16	319:18 321:8,14	affirmatives	318:6 324:21
318:20 319:1,11	324:21 325:12	164:20	325:12,14
administered	adoption 34:19	affirming 46:16	afoot 108:10
201:7	adult 59:4,9	46:20 67:15 79:12	aforesaid 328:8
administration	167:19 184:15	81:12 92:16 95:3	age 160:14,20
242:13	287:2	112:5,9,17,21,22	161:4 162:4,7,9,10
admission 184:7	adults 45:13 79:14	113:25 134:23	163:9,10 167:16
admitted 61:23	123:12 180:1	153:6 154:24	167:17 184:21
66:11 79:22	184:11,12 211:11	156:2,7,16,24	211:19,20 236:13
adolescence 98:15	211:11 212:1,4,8,9	158:12 161:16	256:14 270:22
211:22 307:16	213:7 214:1	162:13 163:3,5,8	271:3 286:25
adolescent 47:5	229:19 232:21,21	164:6,23 166:12	287:2 290:5,5,16
59:2,3,9 101:24	243:12 245:18	166:17,22 168:10	290:25 291:4,10
154:15 184:18	264:10 280:17	171:1,6 172:24	291:11 292:6
186:12 193:23	291:2 302:19	174:25 175:21	320:21
216:22 250:9	303:5 327:4	176:1 178:1 179:3	agencies 310:16
253:21 254:12	advanced 40:6	179:4,21 181:19	agenda 21:24,25
264:18 307:14,19	123:20,21 125:15	182:3 183:4,13,15	agenda's 309:25
318:6,10,16	126:2	184:14,17 185:18	agendas 309:20
319:17	adverse 208:12,25	186:3 187:5,9	ages 104:2,4 162:6
adolescents 45:15	224:1	188:7 189:15	271:19
46:17 47:23 101:3	advice 62:23 63:2	194:24 212:16	aggravating
101:6,22,22	122:1 148:9	213:13 214:18,22	212:24 213:3
102:19,21 103:10	advise 30:18	215:18 216:1	ago 14:2 21:13
104:9 154:24	advisor 28:14	218:20 219:4	59:1 117:19
156:2,25 161:17	110:5 233:25	220:13 221:14	129:24 173:15
162:14 164:1,6,23	affect 39:3 247:21	222:2 224:15	186:21 255:9
166:22 171:6	270:24	226:21 228:15	314:10
174:25 179:21	affiliated 82:25	230:21 235:4,20	agree 6:6 23:23
180:1,6 185:3,17	83:5	236:22 237:25	26:7 87:10 117:2
186:2 187:4,8		238:5,25 239:1,23	121:17 148:2

[agree - apply] Page 4

19:3 163:23 191:14 272:6,17/22 273:12,16274:3	170.0110.00	T. 10044		252 (15 22
203:10 223:10 264:13 277:11 302:16,18 306:14 322:15 agreed 5:4 66:15 118:4 136:22 164:13 179:13 agreement 115:1 223:20 226:25 agreements 115:3 agricultural 19:6 ah 12:2:1 60:25 235:16 237:18 319:2 166:13 179:11 225:22 292:19 296:2 aim 86:18 174:7 aiming 278:9 aired 308:20,21 al 1:4,8 6:10,11 329:4,4 330:1,1 331:1,1 alarming 278:9 aired 308:20,21 alliane 150:9 alliane 132:23 allan 132:23 133:21 alleviation 187:17 allow 292:5 130:7,13,20 allow 292:5 130:7,13,20 allow 292:5 130:7,13,20 allow 292:5 allow 324:23 alleve 195:14 analyzed 316:1,2 animake 330:23 ancious 309:5 angle 172:8 angle 172:8 animaks 233:22 animaks 233:22 animaks 150:12 animaks 150:12 animaks 150:12 animaks 150:12 animaks 150:12 animaks 233:22 animaks 150:12 animaks 150:14 animaks 150:12 animaks 1	159:3 163:23	altering 190:14	ancient 147:1,10	272:6,17,22
264:13 277:11 302:16,18 306:14 312:15 agreed 5:4 66:15 agreement 115:1 223:20 226:25 agreements 115:3 agricultural 19:6 ah 12:2 160:25 235:16 237:18 319:2 158:11 160:67,10 249:12 23:10 23:10:19 235:16 237:18 319:2 236:16 237:18 319:2 236:16 237:18 319:2 318:18 325:22 292:19 239:10,21 240:20 296:2 241:16 272:20 230:10 230:10,21 241:16 272:20 230:10 230:10,21 241:16 272:20 230:10 230:10,21 241:16 272:20 230:10 230:10,21 241:16 272:20 230:10 230:10,21 241:16 272:20 230:12 306:7 230:10 240:20 240:10 240:20 240:10 240:2				· · · · · · · · · · · · · · · · · · ·
302:16,18 306:14 322:15 314:21 alternatives 197:4 ambiguous 8:8 amended 16:15 amended 16:15 amendment 15:11 223:20 226:25 agreements 115:1 agreements 115:1 agreements 115:3 agreements 115:4 agre				
322:15 agreed 5:4 66:15 118:4 136:22 164:13 179:13 agreement 115:1 223:20 226:25 agreements 115:3 agricultural 19:6 ah 122:2 160:25 235:16 237:18 319:2 ahead 74:13 225:22 292:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10,21 240:20 229:19 239:10 239:10,21 240:20 239:22 311:4 animate 150:12 158:14 239:25 annymore 32:14 306:12 anymore 32:14 306:12 anyways 293:4 apart 164:6 apart 164:15 anymore 32:14 306:12 anyways 293:4 apart 164:6 apart 164:6 apart 164:6 apart 164:6 apart 164:6 apart 164:6 apart 164:15 anymore 32:14 306:12 anyways 293:4 apart 164:6 apart		alternative 64:22	0	
agreed 5:4 66:15 alternatives 197:4 annals 106:21 appearance 228:2 260:19 297:13,20 118:4 136:22 ambiguous 8:8 anomic 299:25 anybody's 66:16 258:15 269:13 amendment answer 8:5,12,14 37:21 71:15,19 30:12 agreement 115:1 130:15,18 37:21 71:15,19 30:12 anyways 293:4 agricultural 19:6 american 45:13 154:14 156:10 170:23 197:10 259:7 235:16 237:18 126:14 140:11 202:23 210:19 259:7 259:7 259:7 ahead 74:13 161:8 231:19,19 222:17 231:6 277:18 3ppearent 108:17 3ppearent 3ppearent 208:17 3ppearent 108:1	302:16,18 306:14	197:2 276:16		anybody 10:21
Table 136:22	322:15	314:21	animate 150:12	85:20 135:20
amend amend amend	agreed 5:4 66:15	alternatives 197:4	158:14	228:2 260:19
258:15 269:13 amendment answer 8:5,12,14 anymore 32:14 agreement 115:1 130:15,18 37:21 71:15,19 306:12 anyways 293:4 agricultural 19:6 america 45:13 49:13 79:11 163:15 171:8 apart 164:6 170:23 197:10 259:7 235:16 237:18 126:14 140:11 202:23 210:19 259:7 259:7 319:2 158:11 160:67,10 222:17 231:6 77:18 3pologize 51:9 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 296:2 241:16 272:20 280:12 306:7 309:22 311:4 309:22 311:4 309:22 31:4 aiming 278:9 americans 45:24 answered 154:11 26:11 26:11 26:11 27:18 apparent 108:17 appear 80:20 86:11 96:19 309:22 31:4 appear 80:20 86:11 96:19 309:22 31:4 appear 80:20 86:11 96:19 309:22 31:4 appear 80:20 32:18	118:4 136:22	ambiguous 8:8	annals 106:21	297:13,20
agreement 115:1 130:15,18 37:21 71:15,19 306:12 agreements 115:3 america 45:25 118:18 105:1 118:4 126:4 apart 164:6 ah 122:2 160:25 49:13 79:11 163:15 171:8 259:7 235:16 237:18 319:2 158:11 160:67,10 202:23 210:19 259:7 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 225:22 292:19 239:10,21 240:20 253:20 272:4 200:22 31:4 309:22 31:4 296:2 241:16 272:20 280:12 306:7 309:22 31:4 409:19 296:2 241:16 272:20 280:12 306:7 309:22 31:4 409:19 409:19 296:2 241:16 272:20 309:22 31:4 409:19 409:23 409:19 409:22	164:13 179:13	amend 16:15	anomic 299:25	anybody's 66:16
223:20 226:25 america 45:25 90:7 102:9 104:8 anyways 293:4 agreements 115:3 america 45:25 90:7 102:9 104:8 apart 164:6 apricultural 19:6 american 45:13 154:14 156:10 170:23 197:10 259:7 235:16 237:18 126:14 140:11 163:15 171:8 259:7 235:16 237:18 126:14 140:11 202:23 210:19 259:7 ahead 74:13 161:8 231:19,19 222:17 231:6 77:18 ahead 74:13 239:10,21 240:20 253:20 272:4 appearent 108:17 296:2 24!:16 272:20 280:12 306:7 309:22 311:4 appearent 108:17 aiming 278:9 americans 45:24 answered 154:11 233:8,10 appearent 108:17 aired 308:20,21 67:16 157:10 233:8,10 answering 212:2 answering 212:2 appearance 6:21 appeared 32:18 84:11 85:14 246:8 appearend 32:18 84:11 85:14 246:8	258:15 269:13	amendment	answer 8:5,12,14	anymore 32:14
agreements 115:3 118:18 105:1 118:4 126:4 apart 164:6 agricultural 19:6 american 45:13 154:14 156:10 170:23 197:10 ah 122:2 160:25 49:13 79:11 163:15 171:8 259:7 235:16 237:18 126:14 140:11 202:23 210:19 apologize 51:9 319:2 158:11 160:6,7,10 222:17 231:6 30:19 222:17 231:6 77:18 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 296:2 241:16 272:20 280:12 306:7 appearent 108:17 aim 86:18 174:7 315:10 309:22 31:4 answered 154:11 233:8,10 appear 80:20 86:11 96:19 aiming 278:9 americans 45:24 answered 154:11 261:1,7 appearent 108:17 appearent 108:17 appear 80:20 86:11 96:19 108:23 260:16 261:1,7 appearance 6:21 appearance 6:21 appearance 6:23 appearance 6:23 appearent<	agreement 115:1	130:15,18	37:21 71:15,19	306:12
agricultural 19:6 american 45:13 154:14 156:10 170:23 197:10 ah 122:2 160:25 49:13 79:11 163:15 171:8 259:7 235:16 237:18 126:14 140:11 202:23 210:19 apologize 51:9 319:2 158:11 160:6,7,10 222:17 231:6 77:18 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 225:22 292:19 239:10,21 240:20 253:20 272:4 apparent 108:17 296:2 241:16 272:20 280:12 306:7 86:11 96:19 aim 86:18 174:7 americans 45:24 answered 154:11 261:1,7 appearance 6:21 ail 1:4,8 6:10,11 198:11 199:23 answering 212:2 answering 212:2 appearance 6:21 appearance 6:21 appearance 6:23	223:20 226:25	america 45:25	90:7 102:9 104:8	anyways 293:4
ah 122:2 160:25 49:13 79:11 163:15 171:8 259:7 235:16 237:18 126:14 140:11 202:23 210:19 apologize 51:9 319:2 158:11 160:6,7,10 222:17 231:6 77:18 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 296:2 241:16 272:20 280:12 306:7 86:11 96:19 aim 86:18 174:7 americans 45:24 aswered 154:11 261:1,7 appearance 6:21 aiming 278:9 americans 45:24 aswered 154:11 261:1,7 appearance 6:21 all :4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:21 appearance 6:23 appearance	agreements 115:3	118:18	105:1 118:4 126:4	apart 164:6
235:16 237:18 319:2 158:11 160:6,7,10 161:8 231:19,19 225:22 292:19 239:10,21 240:20 296:2 241:16 272:20 230:12 306:7 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 230:22 311:4 231:4,8 6:10,11 331:1,1 331:1,1 331:1,1 311:1,	agricultural 19:6	american 45:13	154:14 156:10	170:23 197:10
319:2 158:11 160:6,7,10 222:17 231:6 77:18 ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 225:22 292:19 239:10,21 240:20 253:20 272:4 appear 80:20 296:2 241:16 272:20 280:12 306:7 appear 80:20 aim 86:18 174:7 315:10 309:22 311:4 108:23 260:16 aimed 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:21 331:1,1 amicus 35:4,15 103:21,22 143:8 84:11 85:14 246:8 alarming 274:12 analyses 17:9 38:5 167:22 antagonistic 316:4 appearing 2:5,13 aligns 152:15 120:6,7 126:18 159:21 2:14 79:10 321:22 allow 150:9 analysis 16:20,23 anticipate 172:2 appears 30:10 alleviation 187:17 analyst 103:24 anilytic 76:12 antivirals 277:1 applicability allowe 292:5 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 30:16:12 201:2 253:7 <td< td=""><td>ah 122:2 160:25</td><td>49:13 79:11</td><td>163:15 171:8</td><td>259:7</td></td<>	ah 122:2 160:25	49:13 79:11	163:15 171:8	259:7
ahead 74:13 161:8 231:19,19 232:25 233:5 apparent 108:17 225:22 292:19 239:10,21 240:20 253:20 272:4 appear 80:20 296:2 241:16 272:20 280:12 306:7 86:11 96:19 aim 86:18 174:7 315:10 309:22 311:4 108:23 260:16 aiming 278:9 americans 45:24 answered 154:11 aired 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:21 331:1,1 amicus 35:4,15 103:21,22 143:8 84:11 85:14 246:8 appeared 32:18 alarming 274:12 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 appearing 2:5,13 aligns 150:19 120:6,7 126:18 159:21 anticipate 79:23 appeared 331:7 appeared 331:7 appeared 331:7 appearence 6:15 90:22 116:15 appearence 6:15 90:22 16:15 appearence 6:15 90:22 16:15 appe	235:16 237:18	126:14 140:11	202:23 210:19	apologize 51:9
225:22 292:19 239:10,21 240:20 253:20 272:4 appear 80:20 296:2 241:16 272:20 280:12 306:7 86:11 96:19 aim 86:18 174:7 315:10 309:22 311:4 108:23 260:16 aiming 278:9 americans 45:24 answered 154:11 261:1,7 aired 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:23 329:4,4 330:1,1 299:10 answers 86:13 appearance 6:23 alarming 274:12 amount 160:21 antagonistic 316:4 appearing 2:5,13 alex 242:7 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 alignent 157:19 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 222:8 312:14 159:21 69:15 90:22 allan 132:23 52:5 113:13 anticipate 172:2 applead 331:7 alleviation 187:17 analyst 103:24 270:21 applicability 130:7,13,20 191:7 277:21 applicable 228:25 allows 324:23 156:12<	319:2	158:11 160:6,7,10	222:17 231:6	77:18
225:22 292:19 239:10,21 240:20 253:20 272:4 appear 80:20 296:2 241:16 272:20 306:7 86:11 96:19 aim 86:18 174:7 315:10 309:22 311:4 108:23 260:16 aiming 278:9 americans 45:24 answered 154:11 261:1,7 aired 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:23 329:4,4 330:1,1 299:10 answers 86:13 appearance 6:23 alarming 274:12 amount 160:21 167:22 antagonistic 316:4 2:14 79:10 321:22 aligns 152:15 120:6,7 126:18 anthropologic appears 30:10 69:15 90:22 allian 132:23 52:5 113:13 18:16 121:21 anticipate 172:2 appended 331:7 alleviation 187:17 319:7 277:21 applicability allowe 29:5 analytical 106:11 antivirals 277:1 68:12 226:4 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 316:1,2 anxiety 268:9,11	ahead 74:13	161:8 231:19,19	232:25 233:5	apparent 108:17
aim86:18 174:7315:10309:22 311:4108:23 260:16aiming278:9americans45:24answered154:11261:1,7aired308:20,2167:16 157:10answering212:2appearance6:21al 1:4,8 6:10,11198:11 199:23answering212:2appearances6:23329:4,4 330:1,1299:10answers86:1384:11 85:14 246:8alarming274:12amount160:21103:21,22 143:884:11 85:14 246:8alarming274:12analyses17:9 38:5antagonistic316:4appearing2:5,13aligns152:15120:6,7 126:18anthropologicappears30:10aligns152:15222:8 312:14159:2169:15 90:22allan132:2352:5 113:13anticipate172:2appended331:7133:21118:16 121:21antidepressantsapplebaum285:23alleviation187:17analyst103:24antivirals277:168:12 226:4allore129:25analytical106:11antommaria168:8329:8allotted329:20analytical106:11antommaria168:8329:8allows324:23156:12201:2 253:7158:20 216:12alter195:14analyzed316:1,2anxiety268:9,11250:9 252:6,7	225:22 292:19	239:10,21 240:20	253:20 272:4	
aiming278:9americans45:24answered154:11261:1,7aired308:20,2167:16 157:10233:8,10appearance6:21al1:4,8 6:10,11198:11 199:23answering212:2appearance6:23329:4,4 330:1,1amicus35:4,15103:21,22 143:884:11 85:14 246:8alarming274:12amount160:21167:22appearing2:5,13alex242:7analyses17:9 38:5antagonistic316:4appearing2:5,13aligns152:15120:6,7 126:18anthropologicappears30:10aligns152:15222:8 312:14159:21anticipate172:2allow133:21118:16 121:21anticipated79:23appended331:7alleviation187:17analyst103:24anticipated79:23applebaum285:23alleviation187:17analyst103:24antivirals277:21applicabilityallotted329:20analytical106:11antommaria168:8329:8allow329:25analytical106:11antommaria168:8329:8allows324:23156:12201:2 253:7158:20 216:12alter195:14analyzed316:1,2anxiety268:9,11250:9 252:6,7	296:2	241:16 272:20	280:12 306:7	86:11 96:19
aired 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:21 329:4,4 330:1,1 299:10 answers 86:13 appearance 6:23 alarming 274:12 amicus 35:4,15 103:21,22 143:8 84:11 85:14 246:8 appearing 2:5,13 alex 242:7 analyses 17:9 38:5 antagonistic 316:4 appearing 2:5,13 aligns 152:15 222:8 312:14 anthropologic appears 30:10 alline 150:9 analysis 16:20,23 anticipate 172:2 appears 30:10 alline 150:9 analysis 16:20,23 anticipate 172:2 appeared 321:2 alleviation 187:17 analyst 103:24 anticipate 79:23 applebaum 285:23 alleviation 187:17 analyst 76:12 antivirals 277:1 applicability allows 329:20 analytic 76:12 antivirals	aim 86:18 174:7	315:10	309:22 311:4	108:23 260:16
aired 308:20,21 67:16 157:10 233:8,10 appearance 6:21 al 1:4,8 6:10,11 198:11 199:23 answering 212:2 appearance 6:21 329:4,4 330:1,1 299:10 answers 86:13 appearance 6:21 alarming 274:12 amount 160:21 answers 86:13 appearance 6:21 alex 242:7 amount 160:21 analyses 17:9 38:5 antagonistic 316:4 appearing 2:5,13 aligns 152:15 222:8 312:14 anthropologic appears 30:10 69:15 90:22 allan 132:23 52:5 113:13 18:16 121:21 anticipate 79:23 appended 331:7 alleviation 187:17 analyst 103:24 anticipate 79:23 applebaum 285:23 allowe 157:19 analyst 103:24 anticipate 79:23 applebaum 285:23 allowiation 187:17 analyst 76:12 antivirals 277:1 applicable 228:25:3 allowe 329:20	aiming 278:9	americans 45:24	answered 154:11	261:1,7
329:4,4 330:1,1 299:10 answers 86:13 appeared 32:18 331:1,1 amicus 35:4,15 103:21,22 143:8 84:11 85:14 246:8 alarming 274:12 amount 160:21 167:22 appearing 2:5,13 alex 242:7 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 aligns 152:15 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 analysis 16:20,23 anticipate 179:21 appears 30:10 allan 132:23 52:5 113:13 anticipate 179:23 appended 331:7 alleviation 187:17 analyst 103:24 anticipate 79:23 applebaum 285:23 allowe 19:25 analytic 76:12 antivirals 277:21 applicability allowe 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1	aired 308:20,21	67:16 157:10	233:8,10	appearance 6:21
329:4,4 330:1,1 299:10 answers 86:13 appeared 32:18 331:1,1 amicus 35:4,15 103:21,22 143:8 84:11 85:14 246:8 alarming 274:12 amount 160:21 167:22 appearing 2:5,13 alex 242:7 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 aligns 152:15 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 analysis 16:20,23 anticipate 179:21 appears 30:10 allan 132:23 52:5 113:13 anticipate 179:23 appended 331:7 alleviation 187:17 analyst 103:24 anticipate 79:23 applebaum 285:23 allowe 19:25 analytic 76:12 antivirals 277:21 applicability allowe 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1	al 1:4,8 6:10,11	198:11 199:23	answering 212:2	appearances 6:23
331:1,1amicus35:4,15103:21,22 143:884:11 85:14 246:8alarming274:12amount160:21167:22appearing2:5,13alex242:7analyses17:9 38:5antagonistic316:42:14 79:10 321:22aligns152:15222:8 312:14anthropologic30:1069:15 90:22alive150:9analysis16:20,23anticipate172:2appearing2:5,13allan132:2352:5 113:13anticipate172:2appearer30:10alleviation187:17analyst103:24anticipate79:23appended331:7alliance129:25analytic76:12antivirals277:21applicabilityallotted329:20analytical106:11antommaria168:8329:8allow292:5analyze52:19178:2 179:14apply28:2 39:8allows324:23156:12201:2 253:7158:20 216:12alter195:14analyzed316:1,2anxiety268:9,11		299:10		
alex 242:7 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 alignment 157:19 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 222:8 312:14 159:21 69:15 90:22 alive 150:9 analysis 16:20,23 anticipate 172:2 appended 331:7 alleviation 187:17 analyst 103:24 270:21 applebaum 285:23 alleviation 187:17 analyst 76:12 antivirals 277:21 68:12 226:4 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 aller 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7		amicus 35:4,15	103:21,22 143:8	
alex 242:7 analyses 17:9 38:5 antagonistic 316:4 2:14 79:10 321:22 alignment 157:19 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 222:8 312:14 159:21 69:15 90:22 alive 150:9 analysis 16:20,23 anticipate 172:2 appended 331:7 alleviation 187:17 analyst 103:24 270:21 applebaum 285:23 alleviation 187:17 analyst 76:12 antivirals 277:21 68:12 226:4 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 aller 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	alarming 274:12	amount 160:21	167:22	appearing 2:5,13
alignment 157:19 120:6,7 126:18 anthropologic appears 30:10 aligns 152:15 222:8 312:14 159:21 69:15 90:22 alive 150:9 analysis 16:20,23 anticipate 172:2 16:15 allan 132:23 52:5 113:13 anticipated 79:23 appended 331:7 alleviation 187:17 analyst 103:24 270:21 applicability alliance 129:25 analytic 76:12 antivirals 277:1 68:12 226:4 130:7,13,20 191:7 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	_	analyses 17:9 38:5	antagonistic 316:4	
aligns 152:15 222:8 312:14 159:21 69:15 90:22 alive 150:9 analysis 16:20,23 anticipate 172:2 116:15 allan 132:23 52:5 113:13 anticipated 79:23 appended 331:7 133:21 118:16 121:21 analyst 103:24 antidepressants applicability alliance 129:25 analytic 76:12 antivirals 277:1 68:12 226:4 130:7,13,20 191:7 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 aller 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	alignment 157:19	120:6,7 126:18	_	appears 30:10
allan 132:23 52:5 113:13 anticipated 79:23 appended 331:7 133:21 118:16 121:21 antidepressants applebaum 285:23 alleviation 187:17 analyst 103:24 270:21 applicability alliance 129:25 analytic 76:12 antivirals 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allows 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	aligns 152:15	222:8 312:14		
allan 132:23 52:5 113:13 anticipated 79:23 appended 331:7 133:21 118:16 121:21 antidepressants applebaum 285:23 alleviation 187:17 analyst 103:24 270:21 applicability alliance 129:25 analytic 76:12 antivirals 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	alive 150:9	analysis 16:20,23	anticipate 172:2	116:15
133:21 118:16 121:21 antidepressants applebaum 285:23 alleviation 187:17 analyst 103:24 270:21 applicability alliance 129:25 analytic 76:12 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	allan 132:23	52:5 113:13	_	appended 331:7
alleviation 187:17 analyst 103:24 270:21 applicability alliance 129:25 analytic 76:12 antivirals 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	133:21	118:16 121:21	_	
alliance 129:25 analytic 76:12 antivirals 277:1 68:12 226:4 130:7,13,20 191:7 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	alleviation 187:17	analyst 103:24	_	
130:7,13,20 191:7 277:21 applicable 228:25 allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7	alliance 129:25		antivirals 277:1	
allotted 329:20 analytical 106:11 antommaria 168:8 329:8 allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 329:8 329:8 329:8 329:8 329:8 329:8 allows 329:8				
allow 292:5 analyze 52:19 178:2 179:14 apply 28:2 39:8 allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7		analytical 106:11		
allows 324:23 156:12 201:2 253:7 158:20 216:12 alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7				
alter 195:14 analyzed 316:1,2 anxiety 268:9,11 250:9 252:6,7		•		

applying 27:23	106:15 169:18,20	92:13 93:11 96:19	116:18 145:19
109:23	172:7 180:14	108:25 126:13	169:22 172:9
appointed 144:12	255:10 256:2	170:2 191:19	188:23 189:4,25
appointment 25:7	274:8 310:10	197:13,25 207:23	196:24 197:1
25:11	311:2	213:19 224:5	200:22 202:8
appointments	areas 44:2 50:5	244:2 246:7 280:4	210:4 214:11,17
25:15	123:15 130:3	280:22 281:8	218:12,22 219:24
appreciate 8:3	169:21	articles 42:11,25	221:25 226:9
62:11 77:22	arguably 152:5	43:11,17 66:4,6	229:16 231:8
188:22 252:14	argument 88:10	68:12 70:17 78:16	232:2,16 248:10
approach 102:3	88:20 250:8	78:17 89:21 90:9	254:25 255:3
103:17 166:7	arguments 35:11	95:25	258:18 280:11
171:9	arizona 112:11	articulate 159:2	289:25 308:9
approached 34:1	114:3,12 130:20	articulates 160:4	asks 28:25 44:16
appropriate 65:3	131:3 133:2 137:7	articulation	210:1
72:14 101:2,6,23	196:5 197:2	158:25	aspects 159:4
183:5 188:18,23	arkansas 1:1,7,15	arts 19:7,9	171:13 280:15
188:24 189:1,7,14	2:10,12,15,17,19	asa 106:18	325:15
189:23 196:19,20	4:8 5:8 6:12,15,16	asked 8:19 10:8	assess 39:2 43:17
202:15 203:2,7	7:8 74:16 77:6	22:5,12 28:25	63:6 273:7 318:25
204:8 205:10	94:21 112:9	30:16 31:1 45:3	assessed 317:19
211:7 215:25	164:16 180:23	46:24 47:8 50:4	assessing 273:25
216:2 218:18	181:1,24,25	65:17 66:1 67:2	assessment 43:5
219:25 221:15	191:19 195:18	69:10 71:17 75:9	61:9 67:6 106:24
222:3 223:18	197:9,11,14 227:3	78:15 94:7,20	203:12 273:11
224:7 231:6,10	244:8,25 245:3	95:6 101:7 113:4	318:23 321:12
253:16 287:12	247:11 269:7	115:20,25 129:8	assessments
325:19	296:4 314:6	131:4 135:2,11	239:16 242:21
appropriateness	328:12,14	136:2,5,17 137:11	247:12 271:7,9,11
237:20 238:24	arkansas's 112:5	142:13 144:18	325:21,23
239:1	113:25	145:23 147:16	assigned 176:24
approval 46:20	arkansasag.gov	156:17 157:1	178:11 294:13
276:10	2:20 329:2	158:10,23 164:22	assistant 10:8,18
approve 284:17	arrangements	166:16 202:25	10:21 18:21 20:15
approved 276:5	64:22	203:5 220:12	64:19 69:11
276:13,15	arsenal 273:16	236:17,25 245:13	173:22 313:17,22
april 129:7 192:12	article 4:10,13	247:10 281:18	associate 20:14,15
apt 119:13	43:3 45:6,8 61:7	292:21 294:12	28:5 92:23 144:13
area 17:6 48:18	61:21 63:1 65:25	295:3 296:14	144:13,21 173:22
49:5,6 58:16 76:3	77:5 81:11 85:20	asking 101:5	173:24
97:1 102:18	90:2 91:19,20	102:23 104:12	
49:5,6 58:16 76:3	77:5 81:11 85:20		· · · · · · · · · · · · · · · · · · ·

[associated - bans] Page 6

associated 79:12	188:21 328:12,14	297:3 304:10	badly 301:3
149:20 152:2	329:13	308:8	bait 220:21
154:14 155:12,16	attorneys 5:6	awful 248:3	balance 135:18
268:24	attracted 27:19	awfully 164:2	194:23 195:19
association 160:7	attraction 147:25	238:14	balanced 195:5,6
160:10 161:8	149:4	awry 157:23	ban 112:5 113:25
associations	attribute 151:3	b	114:4 165:11
106:18 298:2	audio 6:5		180:22 188:19
assume 162:18	auspices 297:25	ba 19:12	189:2,8,15,22
assumption	austin 20:8,9,17	bachelor 19:7	191:15 196:5,17
119:14	20:19 21:17,24	back 9:14 14:25	196:19 197:2,11
assumptions	22:3,19,22 24:4,12	48:8 55:3 56:10	205:18 210:6,7
261:25	24:21 25:3 82:19	59:10 73:16 74:10	211:7 213:25
atlanta 240:10	138:2 142:19	77:12,22 83:18	211.7 213.23
attached 63:24	259:4	93:9 110:16	214.2 213.23
329:11	author 118:13,13	118:10 119:9	218:18,20 219:25
attempt 200:9,11	154:8	122:15 124:2,17	220:4 221:14
299:4,4,13 301:5	author's 124:6	128:25 142:3	220:4 221:14 222:1,21 223:1,8
301:25 302:11	authored 75:1	150:4,11 161:13	223:18 224:7
		162:24 174:17,20	
attempted 300:12 300:14 301:7	authority 297:25 authorized 227:7	177:23 187:2	248:15 267:10,20
		191:13 206:9	269:11 274:17,24
302:22	authors 64:12	209:22 211:13	275:18 277:18
attempting 260:10 260:11	79:16,22 81:13	212:10 213:9	281:20,23 282:25
	82:8 126:17	214:3 218:17	324:20 325:10
attempts 303:6	autism 268:19	222:15 224:4,14	banned 190:9
attend 21:18,20	autistic 99:5	226:12 232:23	196:10 209:10,19
26:13 243:24	autonomy 159:3	236:15 248:20	212:12 213:22
attended 23:18	163:25	249:21 251:11	226:20 227:16
26:15 130:3,19	available 25:8	254:17,25 255:8	248:16 267:6
attendees 135:2,11	123:24 329:6	257:24 258:14	269:5 277:14
attention 68:15	avenue 2:9	259:13 261:8	325:16
83:21 103:16	average 49:13	278:4 281:17	banning 111:7,11
106:4,8 120:17	63:20	289:5 292:5 295:1	111:25 112:8
227:2,10 231:13	avoided 254:22	310:14 313:6	188:12 190:19,22
307:3,5	award 146:18	314:5 320:9 326:4	195:18 268:16
attitudes 4:13	aware 16:11	background	270:4 273:11
45:13 91:22,23	112:20 144:18	156:24 239:24	274:2 282:12,19
155:12 158:22	146:13,23 147:22	backtrack 156:20	290:22,24
attorney 1:8 2:17	148:1 267:24	backwards 33:10	bans 112:17,20
6:15,25 7:8 8:11	268:3,18 269:4	bad 233:19 234:6	113:24 208:15
111:9 113:2 181:8	287:1 288:12	235:17 322:22	209:2 214:12,13

[bans - blockers] Page 7

215.14 219.25	hopomina 104.5	holiovona 250.20	biased 316:15
215:14 218:25	becoming 104:5 174:4 275:2	believers 259:20	
223:13 224:3		believing 233:22	big 117:15 143:14
282:21 288:12	beef 123:7 255:10	bell 306:24 313:4	190:14 211:20
bar 211:14	beefs 120:1 246:15	belmont 111:16,17	258:22 312:20,21
barrier 163:25	254:3	111:19 184:23	bigger 308:4
164:3	began 21:12 82:21	211:21	biggs 18:13 118:1
base 264:23	beginning 6:24	bench 4:12	118:11,15 121:17
266:15	59:10 261:21	benchmark	125:2 209:23
based 25:14 46:19	307:17	292:11,14	212:17 300:9
62:14 63:24 81:21	begins 174:18	beneficial 303:16	302:12 304:22,22
115:22 122:12	behalf 1:14 5:7	benefit 79:23	312:18,22,23,25
156:25 190:19	286:8	185:3,6 186:3	binary 98:7
203:11,13,22	behaving 283:4	187:4 229:17	259:25
204:2,15,20	292:23 293:8	252:10 319:3	bio 42:17
214:14 218:19	behavior 44:4	benefits 318:11,17	biography 190:15
235:12,13,14	49:11,19 50:6	319:12	biological 161:4
236:25 240:7	148:7 153:20	benefitted 198:12	biostatistics 40:12
242:8 245:22	195:9 243:2	199:23	birth 206:10 207:6
247:1 252:22	behavioral 267:1	benefitting 185:14	294:13
255:20 266:20	behaviors 292:6	best 17:21 39:13	bishop 259:4
282:11 313:10	behest 139:10	140:10 153:24	bit 13:18 49:18
bases 12:21	belabor 69:17	beth 2:9 7:3 44:19	52:21 73:11 86:14
290:21	186:13	80:23 115:12	115:6 116:15
basic 223:5	belief 245:25	better 103:20	118:3 122:19
basically 62:15	303:20	169:5 184:4,21	147:7 155:5
64:6 80:4 192:17	believe 8:12 33:20	191:11,12 195:9	177:23 186:21
193:13 257:11	47:25 61:23 70:1	197:15 202:22	192:20 197:8
264:24 272:3	70:21 85:13 93:10	247:6 252:21	239:9,10 255:8,25
281:5 315:25	117:5 118:9	269:15,25 301:12	282:24 294:18
basis 18:2 190:23	129:19,22 130:21	304:21 308:17	312:14 313:11
191:15 210:6	131:23 132:8	310:22 326:12	319:2
224:7 239:20	133:15,20 186:2	beyond 10:21	bits 88:21
245:25 246:24	188:3 207:4	19:20 20:4 86:2	black 270:21,23
270:3 278:1,3	209:24 211:21	112:9,21,22,23	270:25 274:9
284:5,7 297:7	233:9 246:4 266:8	113:25 126:1	blanking 36:22
305:13 318:9,15	267:18 268:14	165:4,7 178:24	bleeding 111:4
319:11	280:21 288:14	179:1 188:6 254:4	block 274:4
baylor 25:23 26:8	292:23 293:9	254:4 255:10,11	blocker 238:3
26:19,21	303:9 311:18	265:9 290:22,23	blockers 163:7
beats 253:14	believed 282:18	bias 316:13,14	175:20 177:25
			179:8 237:12
			1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2

[blockers - cantrell] Page 8

227.15	252 1 1 1 2 2 1		10=1=11:15
325:17	263:4,11,19,24	broader 59:22	137:17 146:15
blogger 142:22	bostock 35:24	broadly 76:4	147:23 173:10
143:11,14 146:1	36:5,6,9,18	87:25 92:22 96:12	231:13 262:1
146:10	boston 242:9	broken 108:6,8	264:17 307:14,15
bloye 1:25 5:9	bottom 46:10	broker 226:25	313:10,19 321:23
6:17 328:4,24	115:19 118:23	brought 67:1	calling 223:1,1
board 21:18 22:17	139:3 208:8 276:2	307:10	252:12
138:1,2 324:24	276:3 296:12	brown 312:4	calls 180:7 236:11
boards 184:24	314:9,16	buffet 140:25	calvin 27:14,17,19
284:17	box 270:21,23,25	build 146:25	27:24
bodies 217:12	274:4,9	bullet 239:13,15	camp 152:11
278:5	brain 291:21	bump 162:6	258:16
bodily 104:1	branch 198:12	bunch 148:13	camps 152:10
105:14 163:24,25	199:24 200:1,8,12	213:8 282:3	canada 256:23
164:5,24 165:21	branches 200:10	business 160:15	cancer 177:13
171:13,21 172:1	brandt 1:3,4 6:10	butchering 242:8	194:6 200:2 293:3
258:15	329:4 330:1 331:1	butler 262:13	cancers 203:20
body 97:19,20	brandts 320:8	buy 223:3	candidate 30:8,8
149:23,25 150:6	brandyn 2:5 74:19	c	cantrell 2:17 7:7,7
150:14,16,24	branstrom 126:13		22:24 41:9 44:15
151:5,11,14,19,22	170:1	c 2:1 3:1 293:3,4	47:15 50:10 52:17
152:14 156:19	break 8:18,20 74:6	328:1,1	55:21 57:10 60:12
157:5,14,18,19	74:9 128:8,24	cakes 36:12	61:2 63:8 65:4
158:6 159:3,13,17	173:8 174:16	calculated 90:15	66:22 67:22 68:7
159:23 161:12	181:21 251:6,10	calculating 80:2	69:8 70:10 71:1,9
165:20 166:2,3,5	289:4 294:20	calculation 80:19	71:12,21 72:2,9
173:3 217:18	322:17 326:4	81:16,25 85:6,12	74:2,13 75:6 79:1
273:22 278:9	breaks 8:17	90:10 91:6 123:23	79:6 82:18 84:19
body's 279:18	bridges 262:12	141:15	84:22 87:16 88:2
book 13:23 22:14	brief 9:16 10:1	calibrate 267:22	96:15 97:7 101:4
22:17 23:9,11,14	11:15 33:8 35:15	call 33:22 58:3	103:13 104:15
23:17,20,23,24	45:10	103:18 119:10	105:12 111:8
24:1 31:10 48:12	briefest 23:12	159:16 175:25,25	112:3,10 113:1,15
73:3,9 110:5	briefly 23:10 33:1	179:8 182:15	114:2,17 116:9,14
125:24 128:1	33:3,4 34:15 55:5	209:9 220:21	119:4 125:20
books 21:1 42:10	148:20 224:14	246:19 254:12	126:3 127:22
42:20,24,25 43:11	briefs 35:7	262:11 308:11	120.3 127.22
43:17,23 48:24	bring 157:19	311:18	158:2,13 159:9
106:20	213:8	called 19:6 28:23	163:12 165:6
born 159:13,22	broad 2:5 107:15	29:5 33:12 34:12	163:12 163:6
· ·		86:8 88:25 89:13	
165:20 166:2,3	109:23	105:10 128:1	180:7 181:7 182:5
		10.14	

[cantrell - case] Page 9

	I		I
183:6 185:8 186:4	car 292:13	205:9,12 206:4,16	289:10 290:4,22
186:9 188:8,14,20	cardiac 39:17	209:19,20 210:6	290:23 292:3
189:17 191:17	162:23 200:2	211:15,15,17,18	293:7,9,11 295:4
193:25 195:7	203:18 204:12	211:20 212:16	295:11,24 296:12
199:10,20 201:21	care 37:10 40:23	214:13 215:12,14	297:23 298:3,7
205:16 209:21	41:1 43:5,5,9	216:1,13 217:22	308:22 314:20
217:21 218:24	46:16,21 47:14	217:24 218:8,15	317:3,14,19,22
221:17 222:7,24	51:16 55:19 57:15	218:21 220:2,4,6	318:6,11,17 319:7
223:19 224:10	57:16,22 60:11	221:14 222:4	320:23 324:21,23
227:17 229:10,18	61:1,3,8 67:3,15	224:18,19 225:24	324:24 325:12,14
231:11 232:5,19	71:8,10,11,11 72:8	226:5,21 227:16	326:4
233:7,9 245:6	72:10,20 91:13,16	227:25 228:18	care's 278:21
247:15 250:24	91:17,19,21,22	229:2,16,24 230:6	cared 171:15
253:18 263:12	92:4,9,16 94:4	230:21 231:8,23	career 39:15 42:11
264:8 265:12	98:3 101:10	232:2,9,9,12,16	49:5 55:4 173:21
267:7,12,21	102:16 103:2	233:1 235:4 237:8	careful 239:15
269:12 270:5	112:6,9,17,21,22	238:9,20,25 239:2	271:4,4 274:7
273:14 274:18	114:1 118:19,21	239:23 240:3,19	caregivers 102:4
275:1,6 278:16	118:22 119:8,16	240:23,23,25	103:3
282:13 286:5,13	126:11 134:23	241:4,7 242:22	carolina 19:11
287:13 293:25	153:7 154:24	243:1,21,23,25	28:4 41:19
318:13,19 320:24	156:2,7,16,24	244:7,13,24 245:3	case 1:5 6:13
324:25 326:17	158:12 161:16,18	245:11,18,21	10:24 11:4,24
327:6 329:1	161:23 162:6,13	246:5 247:21	14:23 15:24 17:1
cap 162:16	163:1,3,5 164:6,23	248:2,2,4,16	17:4,12 33:2,4,6
capable 161:2	165:11,14 166:13	250:12 251:16,18	33:11 34:6,12,16
capacities 191:7	166:18,22 168:22	251:19 253:15	34:18,19,23 35:7
capacity 1:7 22:3	171:1,6 172:24	254:11 255:16	35:20 90:25
216:9 279:2	174:25 176:2	256:11 257:8	111:22 129:5,9,14
283:17	179:3,17,21	258:5,12,13 265:9	130:9 143:8,16
capitol 2:9 160:12	181:20 182:3	265:24,25 266:13	145:2,16 146:7
161:1	183:4,13,15 185:5	266:20 267:10,11	149:21 160:11
capture 88:25	185:10,14,15,18	267:13,14,15,19	170:7 171:23
103:18 124:15	186:3,8,19 187:5,9	267:20 268:2,5,7,8	173:11,19 182:9
151:20 161:7	188:7,19 189:2,8,9	268:16,24 269:1,5	186:22 204:10
182:13 186:25	189:10,15,22	270:3,4 271:8,9,10	209:4 214:15
310:14	190:9,10,19,20,22	271:10 274:2,17	215:6 230:20
captured 261:24	190:24 193:15	274:25 275:5,18	231:6 237:10
314:19 315:8	194:25 195:19,24	275:19 277:16,18	245:5 253:15
captures 263:21	197:2 202:8	278:2,4 279:15	270:6 276:22
299:3	203:25 204:3,13	281:20 283:12	280:21 283:22

[case - children] Page 10

206.21.207.7	110.16	17.2 (1.2	-l
286:21 287:7	cautious 119:16	cetera 47:3 64:3	characterize 44:3
288:5 306:10	256:22 314:3,4	103:19 120:24	154:13 170:2
312:20 320:6	cccu 32:24	124:15 157:15	259:2 262:22
328:8	cdc 282:19	160:5,7 167:14	264:11
cases 32:19,20	cdc's 267:1	172:19,21 182:13	characterized
35:3,6 36:5 100:2	cellphone 272:14	202:3 210:25	49:4 50:8 157:15
100:3 122:13	censuses 324:5	250:3 262:9,9	159:24 246:18,21
131:9 135:8,21	center 2:18 6:15	266:2	326:15
136:2 142:14	27:20 28:4,9,11	chair 30:21,22,23	characterizes
148:14 183:8	41:19 328:13	121:18 138:1	232:7
184:20 186:16	central 1:2 6:13	144:3,9,13	charge 83:14
197:20 227:12,13	287:22 288:5	chaired 31:19	92:24 255:22
232:6 243:19	certain 22:18 53:5	challenge 18:20	324:19,20 325:9
247:20 264:17	66:20 70:25	challenging	325:11
266:4 269:22	103:21 119:24	172:18 216:7	chase 2:13 7:5
270:7 324:23	139:22 172:6	chance 77:22	chat 58:16
catch 26:17	205:18 213:20	101:17 247:17	cheap 73:3 134:4
catchall 299:7	215:11 236:5	change 18:6,8	check 313:3
300:25 302:9	243:5 267:5,10,13	107:9 128:12	checking 11:21
categorical 281:23	267:25 270:22	172:10 179:21	chemical 127:2,4
283:5	279:16 303:23	180:4 216:23	chemist 124:21
category 71:15,24	305:6 308:11	217:1,10,13,16	chemistry 124:18
catholic 55:9 56:5	323:4 325:23,24	245:4 247:12	125:9 127:11,13
56:8 258:21	certainly 39:8	248:12,13 249:19	128:6
262:18	59:21 116:6,22	259:20 260:3	chemists 126:23
catholicism 29:5	121:22 128:6	261:16 262:6	chemotherapy
32:1 51:4 55:7	151:12 152:13	263:21,23 330:4,7	169:1 194:11
56:6	157:16 175:5	330:10,13,16,19	child 104:22
causal 99:14	183:8 190:1 194:9	changed 16:17	194:11 272:5
causation 98:20	224:11 228:21	31:17 32:4 49:17	286:8,9 317:21
98:21 99:7 176:19	251:23 268:8	66:16 102:17	child's 286:4
cause 98:18 99:11	273:4,15 278:25	172:9,12 307:18	childhood 98:15
216:2	288:7 301:15	312:13	225:17
caused 63:19	303:4	changes 173:3	children 4:9 77:7
187:19	certainty 210:23	279:9 280:11,16	94:22 98:25 99:5
causes 98:11,12,13	223:17	329:10 331:6	107:4,16 110:17
98:16 99:8	certificate 3:5	changing 180:19	111:21 161:10
causing 206:10	19:23,25	chapel 19:11,15,16	172:17 173:2
caution 312:11,13	certified 5:9 328:4	character 24:11	180:1 191:20
cautions 314:19	certify 328:5	characterization	216:19 218:3
		48:25 322:18	272:2,3 286:3,12

286:17 314:7	156:15 210:18	265:2,3,22 266:3,6	241:14,16 242:4
320:22	253:20 310:14	266:15 269:21	242:23,25 243:17
choice 153:20	claiming 242:13	300:10 306:3	245:3,16 246:22
154:13 193:24	246:8 266:2	clinical 57:5,8	246:25 247:11
314:24 323:1	claims 62:19 65:8	65:9 66:17 84:6	264:24 265:5,10
choose 279:3	79:17 88:13	85:4 109:1 121:25	265:15,20,24
chooses 328:8	123:18 124:14	122:10 123:10	266:12,16,21
christian 19:8,12	142:22 166:14	141:11,13,22	275:11 282:21
27:2 33:15,17	176:10 182:23	161:15 162:1,8,12	295:23 296:3,14
87:23 147:2,10,12	228:24 244:14	162:18,23 163:10	296:21,25 297:4
christians 146:25	252:22 310:17	163:16 164:18	297:24,24
chronologically	clarification 8:8	166:20 168:6,20	clip 66:9
96:4 136:18	clarify 8:9 81:18	168:25 169:11,19	close 170:6 292:6
chunk 141:2	94:10,20 136:10	170:15 175:16	317:23 324:8
church 55:9 56:5,7	165:21 242:16	177:6,14 178:15	closed 145:16
258:25 259:6,9,13	244:23 254:10	178:23 180:18	closely 274:1
church's 262:18	258:17 263:9	187:17 190:3,8,10	312:5
circle 313:6	275:17	190:13,20,23	closer 127:15,16
circulating 114:9	clarity 223:1,15	191:14 198:15	128:6 164:24
131:10	223:16	199:2,7,17 200:1,6	305:22
circumstance	class 29:3 31:24,25	200:18,19,25	coalesce 101:17
238:20	32:11 40:5 41:17	201:4,8,11 202:4,7	coalition 33:17
circumstances	41:19 52:7,8,18	202:9 251:15,17	146:24
163:4 181:20	54:21 55:5 117:5	252:10 253:2,3,16	coauthored
182:4,6,8 190:15	117:19 224:23	254:4,15,24 255:7	280:22
227:16	classes 185:1	255:11,17 256:18	code 295:10
cisgender 46:15	classic 266:17	256:18,19 258:1	codes 33:24
46:19	classification	319:7 321:3	coding 61:23
citation 68:9 69:3	78:20	clinically 232:13	coefficient 153:20
citations 66:8,12	clayton 36:18	clinician 99:17,20	cognitive 148:8
68:8	clear 211:16	101:5 308:17	167:15
cite 13:8 157:10	213:24 214:20	clinicians 82:8	collaborator
244:2 288:19	218:5 235:21	100:4 102:4,7	285:16
cited 12:25 13:4	clearly 108:18	104:4 160:5	colleague 144:14
68:10,13 242:6	139:22 264:10	164:20 195:10	colleagues 141:2
269:20	client 8:11	228:4 249:12,22	144:3
city 142:22	clinic 57:14	257:19,22 270:8	collect 38:21
civil 5:11 36:12	240:20,23 242:10	272:12 289:17	120:23 140:10
civilization 146:25	242:20 243:2,25	297:7 318:10,16	collection 45:5
claim 33:9 63:10	244:3,4,12,24	clinics 227:5,15	59:12 126:21
64:4 108:1 143:1	245:13,15 248:9	239:10,21 241:12	
	1	1	

[college - condition]

Page 12

college 19:8,13	217,11 10	20mnono 170.5	concentual 195.20
27:2,7,14,17 33:24	217:11,18 coming 69:11	compare 170:5 213:7 256:22	conceptual 185:20 252:20
	77:18 94:18 134:5		
145:9,10		compared 162:9	concern 177:1
college's 33:21	212:10 261:8	168:10	185:11,13 193:4
colleges 33:16,17	306:16	comparing 213:6	197:12 287:23
colonization 159:5	comment 126:1	comparison	295:22 307:1
160:4 171:17	212:18	175:12 180:18	concerned 137:1
colorado 36:12	commentary	compensating	concerning 134:22
column 46:6	212:19 243:9,12	11:3	concerns 108:25
153:16	243:21 247:2	compensation	143:15 170:23
come 13:19,24	280:25	11:6	171:4 194:20,24
18:15,21,23 28:1	commenting 127:8	competing 144:12	195:4,19 214:7
40:9 52:23 54:6	127:21	210:15,20 211:3	216:8 228:8,9
55:6 75:10,16	comments 166:10	complaint 143:23	258:4 289:19,21
88:9 92:25 94:15	commission 36:12	144:10 146:1,10	289:22 290:13
125:6 131:4	commitment	175:13 305:17,17	conclude 157:12
147:16,17 153:11	166:7	complaints 82:9	174:14 250:22
156:13 162:24	commitments	143:3	concluded 143:22
164:9 171:7 187:2	171:25	complete 9:7	327:12
189:5 191:13	committee 30:15	12:13,16,20 173:5	concludes 327:8
197:17,20 206:7	30:20 31:5 143:7	299:17 331:8	conclusion 79:15
218:17 224:14	committees 31:6	completed 300:12	113:6 124:7
227:9 235:24	common 51:20	300:15 301:7	154:22 155:3
236:15 246:9	100:11 111:6,25	302:22 303:6	172:10 254:2
248:20 253:13	113:14,18 119:3	329:17	312:14
254:2 257:24	120:14 201:20	completely 160:20	conclusions 4:14
259:13 270:11	203:9 204:9,12,14	291:14	45:9,11 103:25
281:17 284:8	206:15 267:9	completing 16:18	113:3 120:6
297:5 308:5,7	276:14,18 282:6	16:21 305:2	156:22 172:6
319:1	commonly 288:19	completion 299:5	191:8 228:24
comes 13:10 14:6	communities	299:5,14	308:12 311:10
14:15 16:16 17:3	280:7	component 295:17	concocted 139:9
17:12 18:11 22:20	community 73:17	295:18	139:18
26:8 27:5 30:13	103:3 131:20	comports 154:3	concrete 73:22
36:25 55:23 59:22	183:10 204:23,24	comprehensive	concur 125:2
62:14 75:21 83:14	206:17 240:16	32:6,13 203:22	condition 119:8
119:9 215:1,22	254:23 279:8	comprised 224:24	178:9 184:15
276:10 299:21	comparable 39:18	compulsion 140:8	267:5,6 268:24,25
comfortable 99:14	112:7 176:20	140:9	269:5,10,11
125:18 127:7,21	277:3	concept 304:1	270:14 298:21,23
161:10 216:20		307:2	

conditioning	conjunction 28:13	constitute 91:7	contributing 83:9
149:19 152:1	connection 8:23	constitutes 216:25	137:21
158:4	11:10 309:15	223:20 310:10	control 47:2
conditions 40:17	consensus 202:14	constructed 92:13	155:19 179:2
40:20 98:19 99:6	203:1,6 205:5,6,10	construction	212:25
166:6 169:2	205:13,18,22,25	279:18 290:16	controlled 166:17
189:21,25 190:1	206:5,16	291:12	174:24 177:24
201:18 203:18,18	consent 216:6,7,10	consult 59:1 65:13	212:20,22 276:16
211:7 225:24	216:13,23 217:24	73:1 75:24 195:21	convenience 117:3
268:4 273:9	218:7,10,12,23	consultation 57:14	117:11 118:3
conduct 33:24	237:3 248:22	286:3	conventional
38:4 52:19 67:9	250:20 252:16	consulted 57:7,11	160:17,19,21
106:12 107:13	254:6 255:14	59:13	conversation
111:3 138:12	257:7 258:6 278:8	consulting 8:23,24	57:20 58:11
144:1,3 146:11	283:12,14 284:3,6	59:15	207:21 208:25
171:19 181:11	284:11,19,20	contact 306:8	249:21 250:4,5
293:13,14,19	285:2,5,11,12,19	contagion 307:2	278:19 326:3
315:17	286:8 287:3,11,25	311:17 312:1	conversations 6:4
conducted 16:20	288:3,6,11,13,17	contain 12:13,16	10:1 75:19 133:8
44:13 45:3 106:19	291:22 295:23	12:20 15:12 77:9	204:23 319:5
117:8 215:5 219:6	296:4,15,21 297:5	78:24	321:16
221:1 222:15	297:8,14,17	content 20:25	conversion 4:11
224:23 241:14	consequence	23:23,25 93:14	89:14 95:7 96:3
conducting 99:24	160:13	178:24 218:6	207:23 208:13
conducts 121:22	consider 34:1	context 60:23	210:5,7 212:12
conf 2:5,13,14	67:20 72:20 93:1	116:11,18 140:21	213:21,24 214:15
conference 1:12	109:19 110:22,25	192:11 208:18	216:3,12,15,17,23
147:17,24 311:13	294:9	253:16 254:15	217:4,6,7 218:8,19
313:15	consideration	270:2 271:20	220:1 222:21
confess 88:3	139:8 193:21	273:1 287:6	223:2,5,18,21
confidence 255:1	considered 72:13	292:15 298:8	224:2,7 248:3
confident 138:16	114:20	301:22 321:16	convert 217:17
252:11	consistency	323:11	conviction 186:24
confining 49:24	210:17	continue 6:6 72:2	convince 142:23
confirm 65:11	consistent 220:20	139:19 142:12	315:10
282:18	consistently	continued 17:5	convinced 103:24
conflict 326:5,8,12	155:22 229:2	66:8	282:22
326:16,19	consolidated	contrasted 150:17	cooper 2:14 74:17
conform 241:8	36:18	contributed	74:17
conforming	constantly 318:22	210:13	copies 329:14
248:10			
			1

[copy - cs] Page 14

62 11 00 16	1 10615	5616177014	• • • •
copy 62:11 88:16	corrupted 126:17	56:16,17 72:14	criterion 41:14
89:9,12	cortex 160:15	105:3 182:24	242:12 244:12
correct 13:13	291:3,3,17	202:15 203:7	critical 23:16
14:24 16:15 19:17	cost 310:1	204:8 205:10	106:20 107:12,23
29:14 30:9 31:2	costs 120:23	214:4 227:25	157:10 228:22
34:11 36:13 37:3	coterminous 98:12	281:25 324:9	307:17
37:6 40:18 43:7	221:6	325:3	criticism 88:24
45:20 47:17 48:13	couch 72:25	courses 29:1 39:10	89:20 108:3
50:18 53:11,14	council 193:22	39:20 41:21 42:1	160:11 197:22
58:20 62:21 63:19	counsel 6:9,22	42:4 51:11,16	criticize 106:17
67:3,12,24 70:2,8	9:18 10:4,7	53:15 54:12,25	180:14 308:21
70:22 71:4 77:8	172:19,23 175:8	55:3,11 56:11	318:21 322:25
81:14,17,23 83:6	329:14	82:24 287:24	criticized 108:7
83:24,25 97:12	counseling 104:20	court 1:1 6:12,17	117:25 318:21
104:13 105:11	175:9 178:17,25	8:4 34:20 35:5	criticizing 304:23
107:3 112:19	counselors 72:19	44:24 59:5 116:19	critics 148:13
115:23 116:23,24	72:20,22 73:4,7	138:15 139:4,5,6	283:19
120:11,13 125:12	count 42:14,15	160:11 219:17	critique 120:15
126:11 136:13	136:25	240:11	224:16
137:13,23 140:5	counter 188:9	court's 138:25	critiques 164:7
140:22 141:12	counterfactuals	courtesy 119:13	165:4,8 175:19
142:1,19 143:11	196:12	courts 189:13	210:3 219:8,22
145:21 148:23	counting 70:16	cover 55:8 119:13	224:15
150:18 151:4	91:18	covered 56:17	cromwell 2:4
156:8 158:1	countries 197:23	covid 136:8	74:20
173:12 174:5	256:1,4,9	276:24 277:1	cross 98:10 163:5
181:16 182:25	country 126:20	278:12 282:17	231:3 235:10
189:14 191:16	199:4,9,19 210:14	crafting 285:9	237:13 238:3
205:8,20 210:7	counts 193:13	crazy 316:25	252:23 278:25
216:14 225:21	county 35:19	create 280:2	325:17
230:22 243:22	36:18 64:6	created 23:5 154:8	crossover 68:20
246:4 247:14	couple 8:2 14:1	creating 288:18	crosstalk 50:16
255:17 275:20	81:5 208:20	creation 87:22	52:2 69:2 102:10
281:21 303:17	283:11 312:16	credibility 21:14	112:18 136:19
315:4 318:1,8	courage 147:24	credit 117:7	174:12 187:18,21
331:8	course 28:23,24	crimes 161:1	191:10 201:14
correction 3:6	37:25 40:9 42:2	criteria 200:7	219:15 221:21
79:16,22,25 82:6	50:21,24 51:1,4,5	239:16 241:25	233:24 237:17
corrections 331:6	51:7,24 52:15	243:14 244:3,6	292:18
correctly 80:11	53:19,21,23,24	285:24 317:4	cs 329:15
152:9	55:15,18 56:11,15		
	, , , -		

[csr - deformation] Page 15

csr 1:25 328:24,25	damaging 278:17	dealing 123:3	decisions 114:15
cues 283:23,24	dan 71:12	124:25 147:25	114:16 173:2
culturally 75:14	daniel 1:13 2:4 5:6	148:10 211:14	184:22 253:21
culture 20:17	7:1,14,22 328:6	234:16 235:17,17	254:18,19 257:18
155:6,10	dashes 176:14	284:18 324:4	263:1 286:3 291:2
curb 181:11,14	data 4:10 38:21	327:2,4	291:5,8,13 295:18
cure 169:5 293:2	45:5 52:11,20,25	dean 144:10,11,13	310:9
curiosity 275:12	53:15 59:11 64:12	144:18,23 145:15	declaration 4:6
curious 88:9 94:17	65:6 81:11 85:19	dean's 144:22	16:5 261:19
155:25 200:24	95:2,9 96:2	death 63:25 64:9	275:22
251:17 269:17	118:16 120:19,25	deaths 64:5	declarations 14:22
311:24	121:4 122:3 123:7	debate 240:9	16:9,12,15
current 20:6 28:18	123:10,10 126:18	246:19 247:23	declare 331:4
33:15 50:2 56:10	126:20,21,23	279:6	declared 79:11
114:6 216:21	140:19 153:9	debates 206:14	declares 62:16
251:24 326:14	156:12 170:6	237:19	decline 167:15
currently 29:24	172:7,9,12 177:2	debating 237:14	deemed 331:6
50:20 51:11,13	209:19 212:17	deboer 4:15 34:13	deems 325:4
55:12 82:25 92:8	252:23 265:4	34:24 115:17	default 193:14
164:3 185:17	266:24	138:15,25 171:10	defects 206:10
186:2	date 10:14 11:22	dec 4:7	207:6
cursory 320:9	15:21 17:6 18:4	decades 202:6	defend 146:25
cut 185:10 236:14	18:16,17 60:20	december 11:25	defendant 34:5
253:23	134:5,6 330:24	13:17,20,25 15:22	defendants 1:9
cutting 185:5	331:12	95:23 182:21	2:16 7:8 34:10,21
310:21	daughter 194:8	decency 222:12	defending 129:25
cv 1:6 6:13 13:13	day 5:8 55:8,15	decide 30:18 65:2	130:7,14,20
14:20 19:10 25:1	56:2,3,3 64:16	149:10	define 97:21,25
25:8,18 29:20	251:5 328:18	decided 31:4 63:9	169:22 187:12,12
30:12 61:17 62:1	331:15	139:17 145:15	187:14 217:4
78:16 93:9 95:21	days 302:2 329:17	177:14 197:8	defined 163:5
97:11,12 136:11	dead 301:12,21	254:23 291:10	183:25
136:13,16	deal 54:4 86:21	312:5 317:20	definitely 157:17
cycle 310:19	125:17 190:14	decidedly 295:15	definition 59:23
d	196:13 211:21	decides 268:1	64:7 81:21 169:24
d 329:5 330:2,24	216:11 228:12,21	deciding 67:21	216:25 257:14
331:2,4,12	229:11,11 255:4,5	70:24 72:14	277:8 293:16
dabble 31:9	261:23 263:6	decision 93:2	definitions 97:18
dabbles 31:24	274:8 281:25	279:19 287:6	277:6
dad 272:13	282:2 311:14	decisionmaking	deformation 152:1
uau 2/2.13		44:4 49:19 50:6	

[degree - different] Page 16

degree 19:5 39:7	190:11 206:6	designated 144:3	diagnosed 79:14
39:15 40:12	211:8,17 258:24	designed 271:14	100:14 101:3
degrees 19:20 20:4	286:19	273:21 277:9	168:24 194:9
37:4 187:23 201:1	deponent 329:13	282:23	268:23 317:2,8,10
	331:3		
deliver 140:8		designs 99:9 desire 260:17	diagnoses 41:13 99:24 319:23
175:15	deposed 7:23		
demand 79:13	deposes 7:15	desires 148:3	diagnosis 172:18 268:22 319:20
178:8 190:4	deposing 329:13	desistance 303:25	
257:21 265:21,22	deposition 1:13	306:1,16,23	dialogue 308:16 differ 120:9
266:15,16,17	5:6 6:9,14 9:25	311:17	
267:25 272:22	327:12 328:9,10	despite 300:22	difference 124:4
273:10 275:11	depressed 232:13	303:6	177:17 179:9
demands 101:20	300:3	destructive 161:11	218:23
demographers	depression 268:12	detailed 320:12	differences 37:25
40:3 116:6,22	268:16 270:13	details 109:9	38:5 100:18,23
demonstrable	272:6,16 300:5	determine 65:13	119:2,10
73:15	301:24	188:18 189:1	different 18:9,21
demonstrably	describe 19:2 33:1	316:12	49:6 52:11,20
80:14	33:3 44:1 45:7	determining 66:19	82:9 89:3 97:18
demonstrated	82:16 85:25	detransition	98:4,8 101:16
139:9 324:23	105:24 117:1,2	305:20 306:10	106:4 115:8 118:5
325:1	121:23 143:1	312:19,25	119:3 120:15
demonstrating	147:5 150:8 155:6	detransitioned	122:6,8 124:24
166:12	173:13,18	309:10	125:1 130:2,2
deny 172:3	described 34:15	detransitioners	143:3 148:17
denying 279:15	109:22 145:4	304:13,19,24	149:11 150:12
departing 241:17	208:24 220:21	308:16,23 310:4	169:3 175:8,9
department 32:12	283:16,19 289:24	detransitioning	177:15 184:4
32:21,25 33:19	295:9	309:9	195:23 196:2,4
40:12 144:2,9	describes 146:23	detroit 34:20	202:22 203:14,18
145:12 146:5	150:5 260:14	35:19	203:19,19 210:24
departmental	describing 198:19	develop 98:25	244:10 247:18
144:7 145:7	description 4:3	99:4 231:14	258:8 259:25
depend 123:15	260:1	developed 160:20	262:19 276:25
283:5	descriptions	291:3,18	278:11,21 282:7
depending 305:20	284:13	development	282:24 297:24,25
depends 37:20	descriptor 323:15	100:18 173:4	299:21 300:2,6
38:2,8 39:25	deserve 290:8	deviations 324:7	302:3 305:18
52:18 92:23 98:14	deserves 179:23	diagnose 40:17,20	317:20 324:10
114:18 134:5	design 89:2 169:16	99:16,18 100:5	325:18
178:3 187:12	179:11,12,20		
	T7 *4 4 T	1	1

differently 17:14	discerned 99:9	137:15 153:4	294:1
52:21 178:18	discernible 85:19	154:20 155:25	distinctions 98:2
195:18 197:8	discipline 106:24	237:8 261:24	98:16 102:2 161:3
difficult 168:6,8	123:16 308:10	291:20 298:18	169:25,25 170:5
168:13 169:10	310:8	323:11	distinctive 100:10
178:9 272:4	discipline's 107:1	discussions 285:3	100:16 150:5
280:17 287:16	disciplines 110:4	dismissed 142:25	152:5 157:18
301:13 324:9	123:15	143:9,23 307:11	311:19,20 315:14
difficulties 300:23	disclose 8:12	disorder 92:17	distinguish 184:20
dignity 323:3	discouraged	100:7,8,13 268:20	distinguished
dilemmas 288:18	299:19 300:4	disorders 100:10	64:13
dillon 6:10	301:3 321:6	100:18,19	distort 159:17,18
diminish 326:5	discourse 14:1,8	disparage 322:25	distorted 149:22
diminish 320.3	77:6,25 78:2,19	disparages 242:11	158:5
dimorphism 260:4	80:1,18 81:19,22	disparaging 312:9	distorting 159:16
dinner 272:13	82:13 83:5,8	display 224:25	distorts 151:10,18
direct 63:2 98:20	84:10 86:5 89:16	disposal 198:10	156:18 157:5
direction 20:25	89:17 95:12 96:7	dispute 99:25	distress 99:3
48:22 72:18 75:11	120:1 137:22	100:20 102:4	187:17 238:1,7
76:3 152:4 257:23	141:7,12,23,25	103:3 210:11	248:24 321:4
directions 49:18	discovery 133:12	228:5 240:17	district 1:1,1 6:12
57:17 160:7	discrimination	257:19 318:9,16	6:12 34:20 138:15
directly 106:23	95:14	disputes 102:15	138:25
director 23:5,19	discriminatory	182:13 204:9,10	divergent 151:14
directors 20:24	33:23	204:12 230:3	diversity 198:19
disables 278:8	discuss 42:22 43:8	239:22 244:22	198:20,21 241:22
disagree 189:18	47:23 55:5 58:13	319:14	divided 227:25
204:7 266:14	91:21 92:22	disputing 164:21	divine 87:21
disagreement	131:15 148:18	204:18	division 1:2 6:13
54:20	319:22,23 320:2	dissatisfaction	divorce 160:18
disagreements	discussed 23:4	33:22 186:14	doable 123:24
204:15	41:12 47:24 90:9	dissemination	doc 28:5,6,7,11
disagrees 178:3	94:15 126:9	22:14,16	docs 28:12
disappoint 164:9	138:14 154:19	dissertations	doctor 57:13 58:2
disappointed	156:22 291:8	31:20	67:19 68:4 70:24
187:13	discussing 112:11	dissolution 309:15	74:6 75:23 114:25
disapproval 46:20	112:14 280:20	distinct 100:15	128:8 186:12
disarray 164:18	discussion 11:15	101:15	192:1,19 193:5,19
discern 121:8	132:15,20 134:10	distinction 97:19	193:23 194:12,17
192:22	134:13,17,21	97:22,23,24	269:21 286:4
	135:7,15,16 137:5	101:13 260:23,24	287:5,8,16 292:21
	X7 '4 4 T		

[doctor's - earlier] Page 18

doctor's 250:25	170:9 171:20	194:3 196:25	dysphoria 42:8
doctoral 29:15	176:20 178:7	dramatically	43:21 45:15 48:15
doctors 57:17,21	179:23 191:6	177:15	54:13,22 55:20
58:18 65:13 75:10	226:14 241:14	draw 103:16 120:6	56:14,15,16 74:1
114:14 159:12	247:8 250:25	311:10	75:17 83:24 86:2
181:19 182:2	277:3 280:6	drawn 115:22	91:13,16 92:5,9
188:3 194:13	310:15 322:11	291:25	93:8,21 95:13,15
199:4,8,18 203:14	324:1	drifted 32:10	96:1,14,24 97:5,16
204:7 206:2	domains 55:8	drink 210:12	97:21 98:11,12,14
226:16 240:22	70:17 76:17 184:4	drinking 292:7,12	98:17 99:15,19,22
249:12 282:19,21	247:9	driving 292:13	100:5 101:3,7,24
283:3 287:1,4,10	dominated 123:6	drop 21:22	102:20 103:6,11
293:7,9 295:3	dosage 162:4	dropped 143:23	104:9 124:8 125:4
document 11:20	175:4	drug 200:2 276:14	134:11 135:4
12:6 13:12,15	dosing 178:15,16	276:16 281:20	136:12,14,22
15:5,18 16:3 77:3	178:24	292:22,25 309:15	137:3 154:15
77:17,24 81:6,9	doubt 135:3 297:7	drugs 276:18	161:17 162:14
207:19	297:10	277:21 282:6	175:1 180:5
documentation	doubting 224:17	283:1,4	181:12 183:19
245:24	dr 4:6,7 7:19	dsd 100:17	184:1,7,18 187:15
documented	65:17 68:6 70:1,7	dualism 151:6,22	195:14 199:13
167:13 305:25	111:8 113:2	159:23	217:25 226:11
documents 10:3	118:11 129:14,16	dualistic 150:15	228:15 261:24
12:24 13:3 215:21	129:18,21 131:25	duly 7:15 328:6	264:20 276:6
doing 130:2,2	132:3,7,23 168:8	durkheim 299:24	278:11,14 287:24
131:17 134:1	178:2 179:14	dutch 163:11,13	298:8 303:10,22
162:9 168:19	181:8 188:21	180:17 221:1	307:14,19 317:2
169:19 178:3	201:2 209:23,23	224:17,24 225:1,4	317:10 318:7,11
194:14 198:23	210:3 211:23	226:7,9,17 227:6	318:17 319:17,23
237:15 241:12	229:23 244:14	227:15,22 228:7	320:2 321:4
248:1 253:1	248:3 253:7	228:18,21,24	dysphorias 100:9
272:17 295:12	260:12 269:20	229:3,13,17 231:9	dysphoric 184:7
302:20 324:2	280:3,22 281:6,8	231:23 232:3,10	298:19 317:19
domain 49:11	283:16 289:8	232:14,17 233:2	déformation
58:15 61:10,12,14	304:23 312:9	239:24 240:2,3	149:18
65:6,9 76:16 78:5	318:20 319:11	241:8,17 247:20	e
78:8,10 83:17	321:23	257:20	e 2:1,1 3:1 33:12
93:15 98:3 99:11	draft 17:2	dwell 283:21	328:1,1 330:3,3,3
106:5,17 107:6	dragged 215:7	dylan 1:3	ear 57:1
108:25 110:1,17	dramatic 161:3	dynamic 17:19	earlier 17:5 50:4
123:2 131:20	170:8 177:20	102:18 245:10	55:3 69:10 75:9
			33.3 07.10 73.7

[earlier - entertain] Page 19

88:14 92:19 96:13	editorial 78:3	94:4 110:14	empirical 107:2
104:5 126:9	editors 66:14	251:16,18	323:8,16,17,22,25
136:11,16 137:5	78:11 82:3 92:23	effort 217:1	empirically 23:15
137:19 141:6	92:23 93:2 108:2	efforts 216:24	324:1
152:21 166:10,16	educated 90:7	217:13	employ 120:4
172:17 173:8,9	education 27:13	egoistic 299:25	employer 133:4
174:1 236:12	32:22 33:1,20	egoistic 299.23 eh 87:12	employer 133.4 employs 65:6
248:20,23 251:14	42:7,9	eight 143:3,17	encompassed
264:16 270:12	effect 62:4 64:24	194:8 298:16	263:2
281:18 290:3	76:14 79:19 80:5	either 21:9 36:23	
292:17,21 302:1	80:7,9 121:23,23	68:5 70:23 79:24	encompasses 262:14
303:15	122:12 155:23	108:19 109:11	
earliest 136:13		131:6 134:4	encourage 180:12 236:1
	156:12 167:4,10		
early 21:13 41:5 104:2 129:7	170:7 177:8 213:16 215:9	213:16 240:15 277:21 296:8	ended 41:3 endocrine 101:8
148:13 159:11	266:9 274:12	elect 148:6	102:15 103:19
167:14,15 235:11	effective 43:6	election 45:19	218:1 236:4 245:8
237:15 303:21	122:3 224:18	elevate 145:15	295:11 315:2,6
320:10	225:25 226:1,11	elevated 111:22	endogenous
earmarked 310:6	effectively 259:24	elevating 145:18	279:10,11 280:11
310:7	274:11	eleven 175:8	endorse 211:22
easier 221:12	effectiveness	elicit 8:10	228:5 257:2
254:2	42:23 43:1,8 63:6	eligibility 239:17	259:11 315:11
easily 36:5	67:14 75:4 77:10	241:25 243:14	endorsed 180:16
eastern 1:1 6:12	78:25 79:4 85:5	eligible 67:17	endorsement
easy 118:18	91:13,17 92:4,9,16	eliminated 304:25	253:22
259:10	126:11 166:12	eliminating	endorses 211:18
echols 2:9,11 7:3,3	167:25 174:24	278:14	endorsing 157:11
economic 125:19	177:25	emails 25:6	229:23 310:18
125:21	effects 76:14	embedded 294:16	enforcement
economics 122:24	134:22 215:5	emerge 99:2	298:4,6,8
123:2 125:11,22	221:1	204:15	enlighten 146:14
126:1 127:17	effectual 277:25	emergence 149:21	165:18
economists 120:17	efficacious 150:23	emergent 102:4	enroll 200:6
121:3	efficacy 37:15,23	emerges 47:3	entails 87:21
edge 310:22	39:2,22 43:18	eminent 302:10,13	115:4 315:12
edition 79:11	47:23 54:9 60:10	emotional 99:3	entered 39:14,15
editor 83:9,20	61:1,3 67:3,7	empathetic 320:18	39:16
90:19 91:8 118:12	69:20,24 71:7,10	empathize 183:9	entering 190:5
137:22 212:19	72:7,10 73:25	emphasis 56:4	entertain 172:12
	79:17 91:21,24		
1	i .	i .	İ.

entertained	essay 13:21 14:1,7	ethnicity 106:7	evolution 103:2
172:12	60:15 84:15,17	etiology 23:16	exact 35:22 94:5
entire 49:5 118:8	89:5 136:23	euthanasia 114:21	111:23 179:7
122:6 137:14	141:11 314:6	evals 248:18	266:3
141:2 206:8	essays 13:24 43:12	evaluate 38:14	exactly 42:19
219:16 304:20	43:15 83:23 85:3	85:10 121:11,14	93:11 136:9
324:5,7	86:1 91:3 94:14	122:16 124:17	138:24 155:14
entirely 82:19	95:17 96:17	147:20 309:6	175:17 198:18
139:7 231:5	231:17	324:11	246:8 314:4
243:21 247:1	essential 61:22	evaluated 148:25	323:10
266:20	76:1	149:2	exam 32:6,13
entitled 77:6	essentially 34:17	evaluating 45:12	301:3
entity 80:5,12	establish 21:13	226:4 302:8	examination 3:4
envision 164:11	99:11	evaluation 144:4	7:17
166:21 300:22	established 58:22	145:11,13 146:5	examine 226:12
epidemiological	59:18	228:2 242:2 244:6	examined 270:16
80:3	establishing	254:5 283:6	example 39:11
epidemiologically	294:15	evaluations	51:22 52:24 54:15
222:12	estimate 42:15	144:12 175:10	54:19,21 55:23
epidemiologists	324:8	242:5 245:4 247:1	57:11 61:6 73:11
40:3	estimates 305:19	248:12 273:2	88:8 100:16
epidemiology	324:2	evaluative 254:24	107:20 109:2
38:12	estimating 324:5	evangelical 130:17	114:21 117:4
equated 97:24	estrogen 167:14	evenings 22:13	120:20 122:24
equipoise 166:20	212:22,25 213:3	event 328:16	127:25 149:18
168:22 169:9	et 1:4,8 6:10,11	events 21:20	151:25 158:4
178:10	47:3 64:3 103:19	eventually 66:14	160:9 167:12
equipping 146:24	120:24 124:15	79:15 82:6 119:12	168:24 178:13,21
era 276:24 321:24	157:15 160:5,7	everybody 74:22	194:7 200:20
errata 329:11,13	167:14 172:19,21	203:9 284:20	206:8,22 236:3
329:17	182:13 202:3	310:19 316:14	279:14,25 282:17
erratas 329:15	210:24 250:3	evidence 66:9,10	294:6 301:11
error 61:23 324:6	262:9,9 266:2	122:17 124:18	308:14
errors 324:7	329:4,4 330:1,1	127:21 139:8	examples 51:18,19
escapes 14:12	331:1,1	171:3,5 172:16	53:8 54:6,14
especially 54:17	ethical 145:5	175:25 190:2	112:5,7,8 113:24
61:11 64:24 73:6	159:25 160:1	219:1,3,5 221:5	282:4 309:8
80:8 93:17 120:19	288:18 293:15,20	244:15,18 245:10	exceeded 144:7
154:12 155:14,18	ethicists 253:13	261:23 264:20	excellent 126:18
175:4 216:8	ethics 285:1	278:15 298:6	excerpt 4:12
231:19 271:18	295:10	302:13 313:10	

[exchanges - fact] Page 21

exchanges 58:7	expect 80:14 124:4	expert 4:4,5 9:15	explanatory
exclusively 44:12	159:2 326:5	11:9,23 18:2	155:21
exemptions 33:21	expectations	32:19,20 33:5	explicit 50:11
exhaustively	144:8,11	34:1,5,12,24 35:3	208:8
200:10,11	expensive 121:2	38:3 102:24,25	explicitly 23:4
exhibit 4:3,4,5,6,7	155:20,20 310:3	103:1,5,10,15	96:25 97:5
4:8,10,11,12,13,14	experience 29:3	103.1,3,10,13	exploring 309:10
11:12,14,16 12:2,3	60:5,9,25 63:4	104.8,12,13,19,23	express 303:20
13:13 15:2,8,15,17	71:6,19 72:6	110:22,24,25	expressed 17:16
15:19,20 16:1	73:24 203:13,15	110.22,24,23	18:24 289:9
44:18,20 67:10	207:8 214:3,5	129:9 136:2	
68:5 69:25 76:23	237:13 238:17	137:11 148:19	expresses 49:13 extend 290:22
			extend 290:22 extends 142:18
76:24 80:20,23	250:2 272:16	150:25 151:9,16	
81:1 84:21 85:3,3 94:20 95:4 115:11	279:4,17,18	152:15,23 154:21	255:10 291:6
	280:18 284:15,25	156:17,24 157:4	extensive 126:20
115:13 138:17,19	289:15 296:20	158:8 159:6 164:7	126:21 132:20
149:14 150:3,4	317:1,7,21 319:7	166:24 167:24	175:10 258:25
152:16,22,25	326:1	168:3 169:18	291:20
153:4,14 156:15	experienced 103:9	171:14 186:17	extensively 108:8
156:21,22 157:8	104:17 123:12	230:19,20 231:6	235:22
165:24 176:6	237:4,6 248:19	275:2 281:2,14	extent 43:23 101:8
182:20,22 191:18	249:4 254:8 257:8	284:15 307:8	134:8
207:14,15 239:12	257:17 258:6	expertise 121:10	external 304:13
258:17 261:20	278:8	121:13 158:12	extremely 126:20
275:22,24,25	experiences 58:25	experts 47:19 92:1	259:23
298:13,14 314:5	217:25 237:11	129:13 135:8,12	exude 251:4
exhibited 312:1	301:2	135:20 166:19	eye 18:22 69:11
exhibits 4:1 15:9	experiencing	explain 153:6	227:10
exist 161:20,21,24	45:15 99:3 250:8	155:2,3 157:1	f
166:25 167:1,3	250:17,20 278:24	158:21 186:17	f 328:1
305:17 309:2	experiment 170:3	208:17,22 220:16	face 149:9 242:15
existed 163:19	170:4 183:11	265:10	faced 172:18
171:5 179:20,22	experimental	explaining 186:24	facility 317:22
179:23,25 180:3	51:20 99:9 169:16	220:17	fact 123:8 134:19
existence 111:11	276:7 277:5	explains 218:22	142:24 151:5
113:13	experimentation	273:18	155:18,19 181:1
existing 52:19	192:6,25	explanation 99:14	186:23 275:8,9
119:6	experimenting 4:9	156:10	277:16 281:19
exists 174:23	77:7 94:22 191:20	explanations	282:11 283:19
305:10	314:7	265:8	293:24 294:1
			301:8 303:6
			301.0 303.0

[fact - first] Page 22

321:12	families 320:6,8	federal 5:10 34:20	fifth 46:10
factors 99:10	320:14	121:4 310:11,16	fighting 277:1
272:6	family 20:17,21	310:25	figure 52:13
facts 4:14 294:4,6	27:20 44:5 50:6	feedback 93:18	figured 206:9
294:14,16	59:12 83:15 106:7	feel 23:21 41:6	figuring 230:13
factually 66:11	110:10 138:8	99:13 125:13,16	file 17:25 25:5
factuals 188:9,10	140:3 146:25	125:18 127:7,20	filed 6:11 33:19
faculty 26:21,22	147:2,11 192:1,19	217:14,14 248:5	filled 246:10
26:23 27:21 117:9	193:5 194:7,17	260:16 302:5,5	filling 190:5
fail 306:7	202:3 242:10,10	314:24 320:17	final 198:9 312:16
failed 144:11	309:15 318:2	326:2	finally 66:5,13
failing 97:8 290:1	fan 258:22	feeling 97:22	279:6
fails 329:19	fans 259:19	feelings 97:24	financially 6:19
failure 62:7	far 45:24 46:6	148:8	find 18:14 64:21
281:11	71:25 76:17 97:17	fees 292:13	76:15 117:17
fair 44:8 47:12	100:10,25 101:19	fellow 20:16 21:11	140:13 151:12
48:14,17,25 49:24	127:10 192:21	24:10 25:3,20,25	163:23 166:8
60:8,23 72:5	193:2 216:16	32:9 83:4 132:24	175:25 216:25
73:23 75:3 76:15	226:24 234:3	138:2	217:1 247:11
99:13 108:24	253:19 259:12	fellows 21:7,15	248:9 287:16
110:17 123:18	265:5 277:19	felt 27:23 82:4	310:23 316:19
156:5 160:21	296:10 297:16	female 98:6,6	326:2
209:18 220:24	299:6 301:20	212:23 213:4	finding 61:22 70:3
fairly 17:19 18:14	303:5	261:2,2	findings 4:14
41:5 101:1 155:23	fare 110:15	ferpa 291:6	62:14 149:2
277:15 307:16	fashion 228:22	field 10:15 39:16	finds 69:12 139:4
309:11 314:15	303:19 312:10	92:25 109:25	139:5,6
falidomide 206:24	320:25	116:1 120:14,15	fine 24:2 131:2
fall 28:21 29:7,9	fast 313:3	121:10,11,11,14	179:9 258:20
144:18,20 164:4	father 140:14	121:15 122:18	262:6 264:2
false 66:11	168:24 177:14	123:2,6 127:12,13	finer 73:21 237:22
familiar 8:1 64:12	194:10	127:17 219:8	finish 8:4,19
129:13,15,20	favor 193:23	246:18,21 277:10	finishing 20:11
130:6 132:6	favorite 324:18	304:8 305:5 307:2	27:12
137:17 146:15	fda 276:4,10,13	309:14 311:15	finland 256:6
180:21 219:21	277:6	326:14	fins 175:13 180:13
256:23 271:1	feasible 175:1,2,5	fielded 44:16	256:12
283:14 285:14	175:18 177:24	59:14	first 7:15 13:12
313:9	178:2,5,6	fields 115:9 119:3	15:14,17 32:9
familiarity 241:13	february 17:7,23	120:9 210:10	33:6 34:19 35:14
	18:5		35:14 55:17 59:11

[first - frankly] Page 23

63:16 86:11,14,20	focusing 300:13	70:10 71:1,9 72:9	format 9:16 35:11
87:1,2,3,4,5 88:13	323:5	74:2 75:6 78:9	180:18
90:6,20,22 94:24	fodder 206:3	79:1,6 82:18	formation 44:5
95:22,24 96:4,5,9	folks 17:25 47:20	87:16 88:2 96:15	50:7
97:4 102:24 129:8	92:1 121:24	97:7 101:4 103:13	former 33:15
130:15,18 136:18	152:23	104:15 105:12	240:16
136:23 139:21	follow 62:1 88:5	112:3,10 114:2,17	formerly 269:21
147:7 184:6,12	106:25 118:20	119:4 125:20	forms 175:9,9
190:7 197:16	158:23 172:6	126:3 127:22	228:22 283:18
208:12,23 209:8	173:7 174:21	135:24 158:2,13	299:21 300:1
210:10 223:25	225:1 228:7 250:6	159:9 165:6 167:2	formula 85:25
232:6 239:15	followed 245:11	168:11 172:25	forty'ish 42:18
265:13 287:22	following 104:25	182:5 183:6 185:8	forward 145:1
295:9 296:20	226:17 227:5,15	186:4,9 188:8,14	232:24 237:5
328:6	229:25 230:2	189:17 191:17	252:21 256:10
fit 171:13 200:6	245:13	193:25 195:7	301:4
247:20 310:23	follows 7:16	199:10,20 201:21	foster 160:8
fitting 319:19	footnote 85:25	205:16 209:21	found 80:3 277:1
five 29:9 34:21	forays 50:11	217:21 218:24	309:8
36:24 42:20 83:16	forbid 299:13	221:17 222:7,24	foundation 140:25
110:15 117:15	force 167:19	223:19 224:10	141:3,4
128:16,17 186:21	314:23	227:17 229:18	four 22:13 30:24
288:23	forced 167:17	240:12 250:24	31:22 34:21 36:24
flavor 20:23	314:21,24 320:22	253:18 263:12	42:20,21,25 43:11
fleeting 301:14	foregoing 328:9	264:8 265:12	48:21 59:14 77:14
302:5	331:5	267:7,12,21	83:18 86:6 95:20
flipped 227:12	forget 36:4 93:18	269:12 270:5	122:5,7 305:23
flourishing 236:9	178:16 237:7	273:14 274:18	fourth 306:8
flowing 57:18	246:8 291:6	275:1,6 278:16	frame 153:12
focus 39:9 48:23	308:19 309:7	282:13 286:5,13	199:16 258:15
49:1 53:1 54:23	forgetting 282:20	287:13 293:25	259:16
55:14,19,22 74:25	291:9	307:11 314:22,24	framed 202:19
123:11 190:7	forgive 199:15	318:13,19 320:24	framework
213:5,11	242:8	324:25 326:17	257:24
focused 39:10,22	form 12:25 13:4	forma 26:1,10	frankly 21:9
40:8,11,13 44:8	17:4 22:24 41:9	248:1,1 283:20	111:13 155:10
51:25 136:18,21	44:15 47:15 50:10	formal 26:15	167:20 171:8
137:2	52:17 55:21 57:10	37:18	182:14 269:16
focuses 38:11	60:12,16,20 61:2	formally 58:18	272:20 299:9,21
230:20	63:8 65:4 66:22	245:19	312:12 323:24
	67:22 68:7 69:8		

free 23:21 114:15	funding 22:5,18	97:20,21 98:8,10	235:4,20 236:22
210:12 228:3	25:21 134:25	98:11,12,13,16	237:25 238:5,25
248:5 265:17	304:14 309:23	99:14,19,22 100:5	239:1,23 240:23
freedom 129:25	310:6,7,10,11	100:7,8 101:3,6,24	241:4,7 243:1,17
130:7,14,20	311:10	102:20 103:6,11	245:2 248:16,25
freedoms 232:21	funeral 35:20 36:7	104:9 112:5,9,17	251:16 253:10
frequency 243:9	36:21	112:21,22 113:25	254:22 256:11
300:20	funny 148:12	124:8 125:4	258:12,13,22,24
frequent 271:11	future 103:8 104:1	131:12,16 134:1,3	259:14 261:8,24
frequently 31:7	161:4 180:10	134:11,11,23	262:1,4,13,16,19
93:12 99:2	216:8,9 278:6	135:4 136:4,12,14	262:25 263:2,20
freshman 51:7	279:3,16,20 280:3	136:21 137:3	263:20 264:20,21
friend 39:13 76:7	g	142:14 149:21	274:25 275:11
76:7 147:15	g.r. 36:7	151:10,18 153:6	276:5 277:16
friendly 21:21	gain 68:5 252:10	154:15,24 156:2,7	278:2,3,10,14,21
friends 194:7	gan 08.3 232.10 gap 190:6	156:16,18,24	279:15 287:24
318:2	gary 2:13 74:15	157:5,16 158:12	289:10,12 292:3
front 196:13	gaty 2.13 74.13 gate 314:12	161:16,17 162:13	293:7,9 295:4,24
frontal 160:15	gauge 267:23	162:14 163:3,5,8	296:3 298:8,19
291:3	gauged 43:4	164:6,23 166:12	303:10,22 307:14
frustrated 144:9	gauging 222:9	166:17,22 171:1,6	307:19 308:22
321:1,5	gauging 222.9 gaze 106:1,11	172:24 174:25,25	313:10 317:2,3,10
frustrating 320:19	geared 49:12	175:21 176:1	317:13,19 318:6,7
fuels 186:24	gears 65:15 115:6	178:1 179:3,4,21	318:10,17 319:17
full 7:21 20:12	180:19	180:5 181:11,19	320:2 321:4 323:6
26:3 173:20,24	gender 14:2,8	182:3 183:4,13,25	323:18,23 324:21
174:4 200:5	22:23 23:7,16	184:7,14,17,18	325:12,14
fund 138:7	33:23 41:18,22,24	185:18 186:3	general 1:8 2:17
fundamental	41:25 42:4 43:21	187:5,9,15,22	38:12,15 41:24,25
166:7 254:6	45:15 46:16,20	188:7 189:15	56:6 63:24 64:2
fundamentally	48:15 54:12,22,25	194:24 195:14	92:23 98:21
117:13 255:23	55:9,16,20 56:2,5	199:13 212:16	114:14 143:13
307:18 312:13	56:12,14,15,16	213:13 214:18,22	178:5 207:9,12
funded 22:6 138:5	61:14 67:15 74:1	215:18 216:1,23	242:9 249:7
141:3 304:11	75:17,17 76:4	217:1,9,16,25	250:14 268:2
309:21 310:2,20	79:12,14 81:12	218:20 219:4	269:9 283:7 286:1
311:5	83:24 86:2 91:13	220:13 221:14	286:6 299:3
funder 139:10,22	91:16 92:4,9,16,17	222:2 224:15	general's 6:15 7:8
139:25 140:18,20	93:8,15,15,21 95:3	225:18 226:11,21	328:13
140:24	95:13,15 96:1,14	228:3,15,15	generalizable
	96:16,24 97:5,15	230:21 231:3	117:21
	70.10,2177.3,13		

generalized	given 80:5 103:11	god 299:13	252:18,18 254:5
227:24	117:7 118:25	goes 93:5 204:4	256:10 257:16
generally 53:9	134:12 155:18,18	222:15	259:17 262:6
87:8 130:14,18	161:24 164:4	going 6:2 8:16	268:1 279:7
131:11 193:6,7	166:9 168:7,9	9:22 10:14 21:22	293:21,22 295:8
213:2 267:18	169:24 170:12	39:16 69:16 75:14	300:16 302:19,24
272:11 286:2	171:25 179:19	75:14 76:23 77:22	306:12 309:11
308:10	194:20 201:12	89:8,24 113:1	320:20 322:22
generated 140:9	221:7 233:3	116:9 128:9,14	gotcha 26:18
generations 300:6	251:22,24 269:6	133:10,11 140:18	29:23 33:25 36:1
generic 39:24	271:3 273:1,9	144:25 149:17	43:16 45:16 47:7
131:14 321:1	274:6,10,10,21	155:15 171:2	51:3 52:9,22 54:8
generous 64:7	286:7 292:4 327:9	175:14,14,14	56:1 62:6,9 64:25
genetics 202:22	331:9	181:7 182:14,15	73:10 78:21,23
genuinely 278:7	gives 301:23,24	188:20 201:11	80:19,22 82:13
287:25	giving 270:21	202:4,12,23	86:1 92:19 93:3
georgia 35:19	glad 250:5 307:25	204:24 206:23	94:3,13 98:11
gesture 8:7	glanced 23:13	211:16 227:18	106:14 107:14
gestured 165:21	global 146:24	230:25 231:3	110:9,12 111:2,6
getting 93:14	go 6:7 10:9 15:21	232:20 233:5,13	121:6 145:24
124:14 312:17	18:19 22:15 23:9	234:20 235:14	149:13 151:7
324:2,17	27:9 46:9 68:9	237:2,8 240:14,17	197:24 198:6
gid 100:11,24	74:13 77:12 93:1	250:4 251:2,8	264:16 272:19
gids 300:10 303:13	110:16 126:16	253:8 257:22	280:19 314:16
305:22	128:10,18 152:19	269:14 274:11	govern 293:11
gill 2:8,11	153:19 155:14	289:22 292:25	government
girl 234:20 237:24	169:12 177:14	294:23 297:23	181:18,22,23
248:24	184:24 211:13	306:2,3,4 311:15	188:19 189:1
girls 233:13	217:2 225:21	322:8	208:15 209:2
give 23:12 26:4	226:12 234:3	gonna 232:25	214:12 224:3
39:11 57:11 77:14	236:13 253:19	good 6:1 7:19 54:4	268:1 286:11,16
90:7 100:8 117:4	254:4,17,25 271:6	58:9 66:9 74:5	governments
120:5 146:3 148:9	280:15 281:11	80:25 93:1 94:16	189:6,12
158:25 176:3	285:10 289:11	103:25 115:3	governor 192:9
200:20 214:24	292:19 294:23	128:8 129:6 141:2	193:4
217:24 230:14	296:2 312:10	172:4 190:2 215:8	grabs 101:8
249:13,13 278:7	314:5 323:2 325:2	219:13 233:18	graduate 21:4
279:17 287:1,8	goal 149:3	234:6,10,12 235:1	27:10 39:13 49:14
294:7,8 301:13	goals 149:6 260:15	235:2,16,17 236:1	graduated 32:8
308:14 319:19	260:25 261:4	236:5,20 237:14	graduating 27:1,6
	262:8	237:19 251:1,20	

grandfather 32:3	268:18 280:1	happening 166:23	hatzenbuehler's
grant 252:13	guess 19:9 22:15	171:18 243:10	63:10 65:1,17
253:7	28:6 32:3 36:9	247:24 250:5	70:1,7
granted 99:23	61:8 80:25 90:8	255:5 269:14	hazard 178:12
granting 310:16	117:12 119:19	275:15 295:23	hazards 177:18
grants 310:13	162:11 170:11	happens 21:19	hb 180:20 181:3,5
grateful 305:10	183:12 187:2	70:19 144:5	185:24 189:18
great 7:23 8:22	190:18 202:12	205:21,23 206:19	288:12 325:16
12:10 21:1 44:1	208:1 210:3 211:8	247:22	he'll 62:12
47:22 74:23 81:15	213:11 217:15	hard 120:23 173:1	head 8:7 104:7
100:2 216:11	219:9 235:9	253:8 300:17	199:5 200:21
229:23 246:1	256:23 272:21	304:6 322:25	215:2 273:8 318:4
261:23 265:3	296:18 307:3	326:24	health 40:20 54:9
292:13 304:2	308:9	harm 63:19	56:25 57:5,8 59:2
greater 167:14	guidance 57:22	187:12,13,13,14	59:4,9 61:16,17
197:15 223:14	58:21	216:2,4 302:22	63:14,15 64:13
265:5 303:5	guided 326:24	321:1,3	72:13 79:13,18,21
ground 8:2	guidelines 101:9	harmed 185:18	81:13 95:4 110:21
grounds 249:4,7	101:11,13 102:16	187:8 320:22,25	110:23,24 111:5
group 26:13,23	h	harmful 210:5	119:5 127:10
37:25 38:4 58:22	h 330:3	212:12 213:13,21	158:16 161:17
59:18 117:16,24	half 8:17 32:14	214:18 215:12,18	162:13 176:2,12
118:8 130:6,15	160:17	218:20,22 220:2	177:7 179:4
134:10 137:17	hallmark 115:20	221:16 222:23	183:24,25 184:3
146:15 168:9	halt 182:15	224:19 277:23	184:10 189:10
176:20,21 178:13	hand 8:7 296:20	278:2,4,15,17,22	200:5 202:3
178:13 191:6	297:15 328:17	harms 209:19	208:13,25 210:9
313:10 316:8	handful 26:22	212:16 214:22	213:2,3 224:1
326:4	122:13 123:6	220:13 222:4	238:1,8 239:16
groups 103:21	hands 144:25	harris 36:6,7,21	242:12 246:25
176:21 179:10	hang 125:23	harsher 196:3	265:7,11,16 273:3
228:1 314:21	happen 103:4	harvard 128:1	278:18
grow 267:3	104:17 160:24	242:9	healthcare 42:7
growing 140:15	164:17 160:24	hastily 139:9,17	48:5 53:16 56:22
214:4,5 265:21	168:18 252:12	hate 164:9 182:10	119:20,21 124:22
266:16,16 268:22	254:24 255:1	hatzenbuehler	124:23 180:22
271:21	279:9,11 282:21	61:7,18 62:20	203:14,16 206:1
grown 82:22	happened 135:17	63:12,18 68:6	217:20 243:18
270:14	177:13 266:8	84:9 96:17,22	248:25 326:15
growth 59:12	278:13 306:9	107:21	healthy 164:2
264:23 268:3,6,8,9	312:6		305:11 326:9
	312.0		

	1		T
hear 72:19 73:16	heyer 133:13	homework 86:14	hour 8:17,17
73:17 76:11	hi 21:22	homosexual 148:2	house 112:13
119:18 129:4	hierarchy 195:13	honestly 23:13	household 99:3
131:2 243:11	high 19:4,5,5,6	149:6	107:8,9 127:6
307:18 313:14	80:3,13 162:20,21	honors 29:25 30:2	houston 75:23
heard 58:9 71:25	164:2 190:17	hood 246:11	hruz 129:21
114:12 143:7	208:14 209:1	hormonal 45:14	131:25 134:15
268:21 314:25	227:23 246:9	47:4 123:13 220:7	hum 20:13 29:12
320:5	267:1	276:5 287:23	37:8 38:22 46:8
hearing 198:2	higher 164:2	316:25	49:16 51:15 52:10
heart 203:18	210:13 211:14	hormone 79:20	54:16 55:13 81:20
heights 19:8	225:11 227:21,24	175:20 177:25	90:11 92:21
held 91:25 171:25	303:10	179:8 180:4,5	105:17 108:14
189:6	highjacked 219:19	183:16,20 184:9	127:19 129:12
help 27:20 58:2	222:16	184:14,17 185:3,6	137:6 141:16
73:22 80:14 96:3	highlight 102:2	187:5,9 196:11,17	142:2 149:24
154:11 155:2	103:17 121:25	213:7,12,13	150:7 151:1,17
157:19 172:20	220:25	214:18,22 215:18	168:1 194:22
183:13,16,21,22	highlighted 201:2	215:20 219:4	204:6 208:16
184:10,15,18	213:1 242:1	220:13 221:14	236:24 256:3,5
272:24 302:19	highlights 230:23	222:2 224:16	258:2 264:19
helped 35:11	highly 135:3	234:14 235:7,8,20	288:4 290:6 295:6
37:24 59:1 73:14	hill 19:11,15,16	236:22 237:25	298:20
138:7,8 160:6	hindsight 90:18	238:2,3,5 249:1	human 87:19 89:3
helpful 22:7 33:10	214:5	252:2 253:10	147:2,11 149:23
71:22 272:15,16	hipaa 291:6	254:12 256:15,16	150:5 151:22
277:2 306:13	hippocrates	hormones 163:6,8	152:4,7 158:5
310:6 315:22	157:13	175:21 178:1	159:20 166:8
323:4	historic 151:23	181:12 196:5	260:4 273:22
helping 10:18	historically 194:2	217:12 231:4	291:21
216:19	history 111:13	233:15 235:10	hundred 310:4
helps 124:7 155:3	127:21 128:2,3	237:13 262:8	hunter 32:22,25
hereto 5:5 331:7	190:15 207:11	269:2 278:25	34:23 148:19
heretofore 89:4	hodges 36:14	293:23 295:14	150:9,20 154:5
hereunto 328:17	hold 44:24,24	325:18	hunter's 154:3
heroic 177:12	144:25 160:10,25	hospital 169:4,8	hurt 4:11 89:14
hesitant 270:8	holding 161:6	host 21:20 308:19	95:7 207:24
heterosexual 44:9	home 35:20 56:21	321:23 322:1,4	hutchinson 192:17
49:11	317:21	hosted 130:19	hutchinson's
hey 58:9 177:16	homes 36:7,21	hostile 143:16	191:24 192:10
219:17			193:4

[hypo - increase] Page 28

hypo 238:13	identifies 228:2	309:14	improves 176:2
249:15 309:17	identify 89:14	illinois 19:9	179:4
hypothetical	95:7 98:4 207:24	illumination 57:23	improving 238:1,8
229:9 231:7	215:17 217:9	imagery 322:20	248:25
248:23	220:14 261:1	imagine 166:18	imprudent 233:20
hypotheticals	identities 98:9	immediately	256:24 326:1
229:11	identity 22:23	206:11	impunity 296:13
i	23:7 33:24 41:18	immoral 233:23	inability 70:6
idea 26:25 66:17	41:22 55:1,10,16	234:2,3 292:1	inaccuracies 16:11
68:1,2 103:25	56:2,5,12 61:14	293:16,18,18	inaccurate 200:13
150:13 151:13	75:17 76:4 98:9	immorality 234:24	inadequacy
154:12 156:1	100:7,8 131:12,16	immunotherapy	167:24
159:12 164:24	134:1,3,11 142:14	169:1	inappropriate
174:22 185:9	153:19 216:23	impact 84:6 85:4	222:22
191:25 194:17	217:1,9,16 263:9	141:11,13,18,22	incidence 268:4
195:3 201:6 217:8	263:16,20 264:5,7	impair 9:10	269:10
218:2 222:15	ideological 88:25	implication 214:2	incidents 267:5,19
225:18 230:17	103:18 124:15	implies 189:21	include 26:1 37:9
234:7 235:17	151:20 159:5	294:10	37:14,22 40:19,22
237:14 244:15	160:4 161:7	important 176:15	40:25 84:1,5
257:14 244:13	171:17 182:12	236:6 291:22	107:15 207:20
261:8 263:21	186:25 310:14	298:22,23 299:15	included 14:20
274:20 279:7	316:13	impose 324:20	17:13 25:1,10,18
300:3 307:13	ideologically	325:9	28:22 40:16 46:1
312:1 320:20	315:9 316:23	impression 241:18	59:21 90:15 212:5
	ideology 86:24	243:15,16 247:25	305:1
322:22,22 326:21	258:22,24 259:14	impressive 167:5	includes 13:13
ideas 158:14 236:6	261:9 262:1,4,19	247:19	38:15 47:2 63:5
322:22 323:5	262:25 263:2,21	improper 289:10	212:8 263:17
ideate 303:14	314:1 315:7 323:6	improve 81:12	including 6:22
ideation 298:21	323:18,23	95:3 162:15	35:3 73:4 89:22
299:2,6,12,16,19	idiosyncratic	183:24 191:6,7	109:1 111:21
300:14,18,20,25	261:5	194:13	120:1 161:5
301:9,23,24 302:4	ids 46:9	improved 80:10	295:20
302:9,18 303:7,10	ignore 62:19	80:10 161:16	incongruence
identification	314:18	162:13 184:3	79:15 225:18
11:17 12:4 15:10	ignored 193:16	improvement	incontinent
44:21 76:25 81:2	231:15 304:7	162:17 176:15	158:17
115:14 138:20	306:17	177:4,20 257:1	increase 264:21
207:16	ignoring 303:22	improvements	266:6,19 267:4,19
identified 46:13	305:6 308:11	176:12	269:9 270:2,6
266:4,23			

	1	T	T
275:4,17	influenced 313:25	insist 89:8	interest 21:19 47:3
increased 272:22	315:6	insisted 148:13	48:18 49:21,25
273:10 275:9	inform 17:11 18:7	insofar 23:18 47:8	50:2 53:12 96:13
independent 77:9	18:7 131:22	202:21 237:2,3	96:14 124:12
78:24 79:2 84:1,5	234:13 319:7	258:14 260:3	128:5 198:23
85:11 89:6,23	informal 26:16	261:14 286:24	interested 6:19
90:1	informally 245:19	instance 309:14	21:5 23:8 29:2
independently	information 8:11	314:17	47:2 49:6 126:5
83:19 141:18	8:13 17:8 123:24	institute 20:17,19	127:3 168:12
259:12	192:14	21:17,24 22:3,20	169:12 306:11
index 4:1 63:25	informed 216:6,7	22:22 24:4,12,21	311:12 317:15
68:10 69:3	216:10 217:24	25:4,21,24,24	328:15
indicated 69:10	218:23 237:3	82:14,16,20 83:1	interesting 18:14
241:21 312:11	243:21 250:20	86:15 137:18,25	69:12 249:24
indicates 100:20	254:6 255:14	138:2,3,5,14 140:1	interests 28:13
indicating 84:14	257:6 258:6 278:7	140:21 141:8	42:3 49:2 106:11
121:25 129:10	283:14 284:3,6,11	142:1 146:16,23	140:25
indicative 124:11	284:19,20 285:2,5	147:14,23 200:5	interface 146:24
159:4	285:10,12,18	242:10	interfere 289:13
indicator 100:24	287:3,11 288:3	institutional	internal 130:10
230:3	295:23 296:4,15	184:24 284:16	182:13 204:9,10
indirect 68:12	296:21 297:8,14	insufficient 210:6	230:3 243:2
indirectly 63:9	297:17	275:11	internet 252:23
individual 183:8	informs 17:14	insufficiently	interpret 153:8
individualized	infrequent 302:4	269:17	interpretation
202:20 325:21,22	inherent 100:25	integrity 105:14	118:16 126:19
individuals 185:2	inherently 100:21	142:23 163:24	157:23 222:9
266:23	264:6	164:5,25 165:22	interpretations
industry 94:8	inhibitor 273:21	171:13,21 172:1	61:19 120:4,5
219:16 221:10,19	initiating 79:20	258:16	interpreters
230:25 270:10	injunction 14:23	intellectual 263:7	119:11
304:20 326:23	15:24 16:6 261:19	intend 8:10 12:14	interpretive
ineffectual 277:24	275:23	12:17	154:18 258:14
inexplicable	inquire 269:14	intended 273:5	interventions
197:20	inquired 316:16	intent 87:24	37:15,23 39:23
infer 244:21	inquiry 142:21,24	151:21	43:18 45:14 47:5
infertile 286:9,25	297:2	interact 138:3	55:19 67:18
inflammatory	insider 94:8	318:24	interview 48:1,4
322:19	insignificant 202:5	interaction 317:24	52:20
influence 70:11	261:6	interactions 58:18	interviewed 241:3
82:23 259:6		76:2 194:17	

[interviewee - kind] Page 30

interviewee 281:5	136:2,11 142:14	joined 29:17 32:24	justified 214:12
interviewing	146:4,8 228:14	35:8,9,10,13,15	justify 208:15
315:18	irrelevant 36:2	josephson 132:23	209:2 215:14
interviews 280:4	67:20 291:15	133:21	224:2
intra 162:3	irreversible	journal 66:5,7	juxtapose 234:7,8
intricate 107:7	279:10,12,21	68:21 70:17 78:2	juxtaposed 234:24
introductory	280:12	79:9,11 81:22,25	
50:20,23	issue 80:18 87:12	82:4,9,11 84:2,7	k
invalid 62:16	87:13 148:10	86:21 87:11 90:13	k 1:25 5:9 328:4
invasive 201:3	155:7,10 162:5	91:5 93:11,19	328:24
269:2 320:1	213:25 231:23	126:14 209:24	karasic 260:12
invasiveness	288:5 297:22	212:19 219:11	280:3,22
170:13 185:1	issued 45:5 82:6	312:7	karasic's 281:6,8
213:17	312:8 314:11	journalism 240:13	keep 10:14 17:21
investigation	issues 54:18 55:15	journalistic	18:16,17,22 68:8
143:22 144:1	72:25 135:9	192:14 247:25	68:19,25 69:4,6,11
investigations	143:11 215:25	journalists 119:13	69:14 86:5 128:9
146:8,9	231:7 255:12	192:15	128:14 249:17
investigator 285:7	257:3,5 311:8	journals 68:17	265:3 306:4,15,17
285:7,15,17	items 59:13	69:1,5,7 109:1	310:20 314:10
invoked 239:17	ix 33:21,21	124:13	322:21
involve 34:18 42:6	_	judeo 87:23	keeping 17:6,10
95:13 109:11	j	judgment 159:18	18:10 60:19 141:1
126:6 143:18	j 321:23	159:19,25 160:1	306:12
168:5 245:23	jack 18:16 89:21	187:24 234:6	keeps 18:14
253:9 269:2 273:6	118:1 208:24	235:12,14,15	kept 202:2
285:18 327:3	224:4	237:1,20 249:9,14	kerfuffle 308:15
involved 10:18	james 2:4 7:1	251:1 253:17	keuroghlian 242:7
61:10 146:2 169:3	150:8	295:20	key 64:24 111:19
169:7 218:8	january 95:12	judgments 234:3,4	kid 193:19 235:2
225:15 231:22,25	jennens 320:8	250:23 287:11,15	272:13 318:3
285:5,6,8 303:22	jennifer 321:23	judicial 288:19	kids 99:2 103:7
313:12,16 316:13	322:1,7 323:12	judith 262:13	168:10 221:2,6
involvement	jennifer's 324:12	juggling 92:12	246:9 269:21
137:24 138:13	jm 1:6 6:13	july 14:25 15:6	274:13 317:18
210:14	joanna 1:4	320:10	killed 308:20
involves 78:8,8	job 27:18,19 57:19	jump 173:6	kills 278:12
237:3 274:15	149:19 157:19	jumping 116:10	kind 18:22 19:22
277:17	158:4 231:16	june 320:10	20:20 21:16 22:3
involving 92:8	309:11	jurat 3:7	23:6 25:18 26:14
93:21 135:9,21	jobs 27:4,8,25	9	27:21 28:10 29:10
,			30:11 31:24 32:3

[kind - know] Page 31

32:6,7 36:4 38:2	319:4 321:20	104:18,20 106:5	196:9 197:15,17
52:24 57:5,19	322:18,20 325:1	107:15,23 110:4	201:16,23,25
63:19 65:12 67:20	325:21	110:16 111:13,15	202:2,2,11,19
69:11 72:12 73:20	kinds 67:17 98:8	111:25 112:4,13	203:14,17,17
76:7 79:2 80:6	116:5 117:15	112:14 113:6,22	204:17 206:8,14
82:20 87:4 89:2	121:21 125:21	113:24 114:3,5,10	206:20,21 207:8
90:12 91:23 94:4	127:23 150:12	114:13 115:2	209:3 211:8
101:25 103:20	170:6 203:19	116:4,20 117:15	212:20 213:16
116:21 119:22	271:18 300:2	117:20,21 118:14	214:4,21 216:17
126:25 133:3	301:2 302:3 319:4	119:10 120:18,24	216:20 217:8
136:21 144:20	323:4	121:17,22 122:4	220:12 222:25
150:5 160:16	knock 64:15	123:7,11 125:1,9	225:21 226:24
162:1 164:17	272:14	126:21 127:9	229:19,20 230:3
171:17 177:11,12	know 8:9,16,18	128:5 130:13,22	232:15 236:1,11
180:17 186:19	10:15 13:7,17	130:25 131:18	236:12 237:5
189:9 190:14	17:18,21,24 18:13	132:3,5 135:24	238:11 239:23
198:11,18 202:19	22:13 23:14,24	142:7,9 144:23,25	240:1,10,12,17,25
202:23 203:22	24:15 25:6 26:6	146:13 147:12,15	241:1,15,24 242:6
204:2,18 207:7	27:12 30:25 32:7	148:6 150:20	242:11,13,14,16
211:17,20 219:19	32:9,13 34:25	151:23 152:10,13	242:18,23 243:7
220:6 225:18	39:2 40:6 41:16	154:16 155:14	243:16 244:7,14
229:21 231:18	49:19 54:2 55:24	157:22 158:14,24	244:24 245:7
232:13 235:8	58:10,11,14,16	159:10,11,13	246:9,11 247:13
240:4,9 241:11,24	60:1,4,19 61:5,6	160:19 161:7,24	247:16,20,22
243:6 250:20	61:20 62:19,25	162:8 163:20,20	248:8,17 249:22
252:20 256:17	63:13,17 64:1	163:23,25 164:9	249:23,24,25,25
257:20 258:15	65:5,5,12,19,20,21	164:21 165:20	250:7,13 252:9,11
259:25 261:21	65:24 66:12,16,18	166:5,5 167:3,12	253:7,12,19,25
262:14,20 263:6	68:4,4,9,24 70:8	167:12,17,18,22	254:1,8,21 255:22
265:1,2 267:10,13	71:2,3 72:19 73:5	168:7,21 169:3,15	257:2 258:14,21
267:15 272:18	73:7,12,14 75:13	170:7 171:9,18	258:21 259:3,3,4
281:10 285:9	75:22 76:5,11	173:14 177:13,16	259:16,19 260:2
291:12,21,24	83:21 84:17 86:12	178:10,12 179:13	261:3,9 262:7,24
293:20 299:3,6	86:17,19,20,20	180:1,12,13,19,25	262:25 264:9,10
300:2,25 301:22	87:1,2,22 88:7,7	182:10,11 183:7	264:13 266:3
302:9 305:18,25	89:8 90:3,5,20	183:11 184:23	268:8 269:23,23
306:12 307:11	91:6,10,18,24	185:20,23 186:15	271:2,5,10 272:1
308:15,16 309:10	93:13 94:2,8	186:19 188:15,15	272:12,14 273:1
310:21 311:15	95:14 97:23 99:1	189:11 191:2,5	273:20 274:11
312:3,17 314:23	99:18,23 100:4,11	192:12 194:8,12	275:2,15 276:17
315:21 316:12	100:25 102:13	195:1,10,13,20	276:20,20,23,24

[know - lightened] Page 32

276:24 277:12,23	known 35:18,23	latent 302:9	329:23
278:17 279:1,23	299:1 308:17	latest 282:18	legally 291:10
280:1,5,14 281:22	knows 297:20	law 4:15 28:25	legislation 114:8
281:23,24 282:10	298:1	37:2 82:24 111:15	192:13 196:4
282:14,16 284:14	1	112:9,12,15 113:5	legislative 191:25
284:14,15,15,18		113:13 114:24	192:18 227:10
285:8,13,23	1 5:1	180:23 181:1	legislators 253:13
286:24 287:1	la 240:9	186:1,6 196:8,9,10	legislature 28:25
288:17 289:15,25	label 276:12,19	197:11 229:2	197:14 227:3
290:5 291:11,23	277:3,4,8,13,17,19	291:24	229:1 230:12
292:2,5,5,8,24	277:20 278:11,21	law.com 2:11	legislature's 192:4
293:3,21 294:7	281:19,20,22	lawless 231:20	192:22 197:12
295:9,10,12 296:1	282:6,23 283:1,4,8	laws 111:7,11,12	lemon 304:12
296:3,17,23	292:22 293:2,4	111:23,25 113:18	length 191:5
297:11,16,19,22	labeled 236:5	327:3	229:14,23 304:3
298:1,10 299:8,20	lack 103:20	lead 22:12 156:15	lens 154:18 316:5
299:25 300:23	120:19 135:8,20	176:12 267:5	leslie 1:7 2:14 6:11
302:4 304:12,13	166:20 167:11,14	273:23 288:9	74:17
304:22 305:19,21	175:20 177:6	299:16 302:21	lest 270:23
305:23 306:2,9,11	190:8,23 191:14	leaders 240:16	letter 91:7 118:12
306:24 307:8,11	205:17,22,25	leadership 24:12	144:10 212:19
308:13,21 309:4	206:5,16 254:4	lean 39:18	letting 193:23
309:18 310:2,5,10	255:11 258:1	leap 119:14	leukemia 194:9
310:16,17,22,25	lacks 180:15	121:24 127:10,11	level 34:19 51:4,5
311:8 312:2,4,8,17	language 150:8	127:12,13,16	67:14 99:23
313:21,23 314:4	156:4 256:19	127.12,13,10	127:17 145:9,10
314:15 315:18	263:22 284:22		326:21
	312:15 325:3	leaps 177:7	
316:3,6,8,16	lappert 129:18	learn 73:8 86:23	levine 129:14,16
318:23 319:2,3,8 319:20 320:18	132:3	106:6 245:2 learned 37:16	132:7
	large 29:3 115:21		lgbt 95:14
321:5 322:8,13,17	117:13,22,23	learning 52:4,6,7 54:9	lgbtq 114:9 137:1 library 312:7
322:19,24 323:3	119:12,15,19		
324:7,11 325:4	204:19 215:7	leave 27:17 75:22	life 63:21 64:16
326:2,20	largely 26:10	led 64:5,8 134:17	86:16 154:13
knowing 47:3	28:12 36:2 46:15	171:22	167:15 177:17
253:14	46:19 82:21	left 31:20 32:9	190:14 194:4
knowledge 13:16	186:13,16,22	77:19 287:5	250:8 257:9
66:23 92:3 207:10	259:2	legal 111:11,24	289:23 300:5
207:13 268:15	larger 145:16,19	113:3,6,13 114:21	light 154:12
284:8,10 317:18	lately 226:15	141:1 282:25	lightened 257:21
	305:21	290:16 291:25	

[liked - love] Page 33

liked 161:9	litigation 11:7	178:19 190:2	252:24 256:13	
likelihood 79:20	little 1:15 2:10,15	198:11 199:23	309:3 311:5	
301:4	2:19 5:8 6:16	215:7 229:21	looks 15:21 30:7	
	13:18 49:18 52:21	236:9 240:12	31:6 57:12 95:22	
limit 113:5,9,19 300:16			96:11 133:17	
limited 141:11	73:11,15,22 86:14 88:21 100:2 115:6	243:16,17 247:24 256:17 265:2	241:24 252:25	
212:9 278:5	118:2 122:19	285:21 300:4	297:11 326:19	
limits 113:11	147:7 155:5	longer 187:8	lopped 63:20	
linchpin 285:2	157:13 177:23	249:23	lose 36:3 278:18	
line 108:7 116:10	186:21 197:8	longevity 198:20	losing 195:15	
118:23 291:25	208:18 235:5,11	longitudinal 59:2	280:10	
309:1 330:4,7,10	236:23 239:10	59:3,8 120:19,21	lost 306:7	
330:13,16,19	249:24 255:8	120:25 121:4	lot 21:9 38:24	
lines 191:23 206:9	282:24 294:17	214:8 306:6	41:10,11 49:10	
229:17 243:16,17	306:4 312:14	longstanding	54:19 73:4 99:12	
243:18	313:11 314:3	192:5	106:5 108:6	
lingo 323:4	321:1 325:8	look 10:9 16:1	114:18 118:25	
linguistically	328:13	23:24 52:25 61:16	120:23 123:15	
216:18	littman 307:15	62:12 64:3,22	125:14 128:2	
link 80:21	309:7 310:2	78:16 84:24 88:13	163:18 169:3	
lisa 304:12	311:25	90:6 93:9 103:23	202:7,17,23 215:4	
list 93:19 94:16	live 237:8 250:1	108:21 109:3	226:14 227:8,21	
95:17,21 96:7,8	289:23 290:8	121:20 147:14	232:8 243:3 248:4	
165:24,25 172:1	326:6	157:11 159:10	251:22,25 252:17	
261:21,21 265:2	lived 64:6	165:19,19 166:21	261:3,10 288:2	
listed 29:20 32:8	lives 194:13	166:25 167:1	299:21 301:13	
93:10,25 96:10	301:14	168:3 169:23	302:13 305:16	
136:17	living 216:20	179:7 182:11	308:2 313:11	
listen 249:25	llp 2:4 74:20	183:9 191:22	318:20 321:11	
272:13	load 28:21 56:11	195:2 200:2,10,11	327:3	
listening 56:25	locales 288:18	209:8 223:22	lots 17:20 87:12	
204:23 272:2	location 6:14	239:11 256:21,25	93:17 121:20	
listing 71:13	lock 279:16	282:3 294:14	175:11 196:3	
literature 13:7	locking 279:2	310:3 313:21	198:21 210:10	
21:1 68:16 164:7	loggerhead 319:2	looked 23:17 24:3	243:9 260:25	
165:4,13 166:10	long 8:16 20:9	201:15 316:10,11	282:16 297:24,25	
167:10 239:25	21:13 23:17 59:1	looking 9:4 15:17	299:9,9 311:14	
243:24 300:7	73:6 96:21 143:17	44:7 47:2 52:11	loudly 313:5	
302:7 305:15	159:7 167:11,20	53:12 55:11 97:10	louisville 132:24	
307:20 318:25	167:21 168:12	123:5 138:24	love 88:8 147:1	
319:5	169:8 177:22	168:2 176:19		
77 10 17 10 1 1				

[lower - means] Page 34

lower 303:7	manifests 98:14	16:21 40:9 41:5	182:7 183:3 184:3	
lunch 128:10,11	manner 99:24	216:6 227:2	189:11 190:12	
128:19 173:8	106:18 209:16,25	238:16 259:1	191:8 192:9 193:8	
	219:6 220:19,20	283:7 286:1	191.8 192.9 193.8	
174:7,22	254:24		194.0 190.0,21	
lying 297:14		293:24 309:19 matters 49:21	197:19 198:13	
319:12,13	map 64:1 265:2	92:12 192:20	206:7 209:22	
m	margin 324:6 mark 1:13 5:6 6:9	195:21 204:19	210:8 212:17,18	
ma 30:12,22		216:11	,	
madam 7:9	6:17 7:14,22 11:14 15:7 327:9	maturation	218:1,11 219:13 221:18 225:7	
magazines 247:2		291:20	226:1 227:9	
magnitude 170:12	328:5 329:5 330:2			
222:9	330:24 331:2,4,12 marked 11:16	mature 160:13	228:20 233:17	
main 35:11 154:23	12:3 13:13 15:10	maturity 292:6	235:9,10,14	
mainstream	44:20 76:24 81:1	mcbain 19:6,7	236:14 238:10,12 244:2 247:23	
314:19 315:1		mchugh 132:9,11		
maintained 86:15	115:13 138:19 207:15	132:18 134:14	248:2 249:6,7 252:24 255:21	
141:7,25		mean 9:1,20 10:15		
maintenance	markers 202:17	14:25 16:23 17:5	259:15,23 260:12	
127:6	market 210:12	17:7,15 18:6	260:24 262:2	
major 44:2 177:11	265:17	21:16 22:1 24:9	266:14 268:12	
228:5	markets 125:22,23	25:6,11 31:6	270:25 275:7	
majority 31:19	marriage 20:21	32:10 33:8 37:24	279:12 284:7,19	
47:13 184:21	24:5,13 34:18	38:8 43:22 50:17	287:3 288:7	
286:25 290:16	44:5 75:15 147:2	56:21 59:20 61:13	290:15,24 292:8	
291:1,12	147:11 148:11	68:18 72:17,22	293:1,1 296:11	
majors 51:2 117:6	149:5 292:7,9	84:15 87:15,18	297:10 299:18	
making 100:17	marriages 148:14	90:4 93:23,24	300:21 303:3,12	
123:22 161:3	148:19 160:18	101:19 102:24	306:16 307:14	
257:17 279:19	married 148:16	106:10,18 107:7	310:1 311:6,25	
male 98:5,6	mass 242:9	109:21 112:7,16	315:8 316:3,23	
212:23 213:4	master 19:9	112:23 113:4,5	317:18,22 319:19	
261:2,2 279:25	master's 19:15	114:7,20 116:25	323:7,14 325:14	
287:2	30:6,7	119:5 123:23	325:16 326:23	
malleability	masterpiece 35:7	125:2 129:15	meaning 176:18	
262:16	35:18 36:11	134:14,25 138:11	181:23 183:22	
manage 148:24	materials 8:22 9:1	139:18 140:24	223:2 262:17,19	
managed 142:22	9:3 12:24 13:3	149:25 155:2,5	307:15 324:13	
315:10	17:20 23:5 65:12	159:18 162:18,22	meaningful	
mandated 28:25	99:22	168:23 171:12	264:11	
manifest 98:19	matter 6:10 11:10	172:3 175:11	means 87:8 98:9	
	12:14,18,22 16:12	178:21 180:8	105:25 157:7	
77 ' I 101 .'				

[means - mentions] Page 35

183:7 185:15	52:22 53:13 55:19	326:25	melanoma 168:25
214:13 237:20	57:4,8 58:22,24	medically 325:2,5	member 215:7
258:24 274:4	59:18,19,19 60:11	medicare 320:2	259:24 260:16
315:9 323:24	61:1,3,8 62:13,19	medication 271:13	261:3
324:6	62:23 63:1,7 65:1	277:17	members 195:12
meant 96:4 158:10	65:13,18,22 66:19	medicine 37:12	membership
173:18 210:21	67:3,6 68:17 69:1	53:10 54:7 56:19	118:5 315:17,18
321:1 323:9,10	69:5,6,20,24 70:24	57:18,25 66:7	316:7
measure 54:14,20	71:11 73:17 75:5	68:20,23 76:3,17	memorable 36:4
85:4 127:2 162:16	76:2 77:10 79:5	79:9 109:20,21	menopause 167:13
168:5 211:2 217:2	80:10 85:4,21,23	110:11,13,20	167:16 236:13
measured 141:18	94:4,8 108:20	112:23 149:22	mental 17:25
141:22 209:16	109:5 111:7,20	151:10,18,23	40:20 53:16 54:9
measurement	112:8,24 113:24	152:6,7 156:18	56:25 57:5,8
54:18 98:2,21	114:15 120:12	157:5,15,17,23	72:13 78:25 79:13
209:7	126:11 127:14	159:11 162:23	79:18,21 81:12
measurements	141:18 152:3	169:21 202:13,22	95:3 161:16
76:12	159:1,7,18,19,24	203:5 205:21	162:13,16 173:4
measures 55:24	160:7,10,22,22	231:19,19 234:9	176:2,12 177:7
76:13 110:18	161:8,16 162:13	247:9 252:24	183:24,25 208:13
117:15 123:3	164:17 168:13	262:9 265:18	208:25 213:2,3
126:7 191:3	170:12 171:19	273:4 276:18	224:1 238:1,8
198:20 209:16	181:19 182:3	277:5,11,14 279:8	239:16 246:25
210:24 215:5	183:4,10,13	313:10 315:11	mentality 230:17
222:8 252:18	185:18 188:2,5,6	medicines 9:9	mentally 259:10
254:5	191:15 192:6,24	meet 9:18 26:18	mention 50:19
mechanism 298:4	193:15 198:12	26:24 144:11	86:6 95:10 313:1
298:6 303:1	199:24,25 200:9	229:9	314:8
mechanisms 298:9	200:10,17,23,24	meeting 26:15,16	mentioned 37:4
media 6:8 74:8,11	201:7 203:25	130:1,19 131:3,8	65:25 75:10 76:19
112:14 128:22	204:3 205:5,7,19	131:15 132:1,4,9	92:19 111:17
129:1 174:14,18	205:22,24 206:16	132:17,23 133:1,5	119:20 120:2
251:8,12 289:3,6	214:13 230:21	133:14,19,22,24	133:24 142:17
294:20 308:18	238:24 239:1	134:2,21 135:7,11	149:1 173:9
327:10	241:6,9 247:6	136:6 137:7 142:6	195:19 236:12
medical 37:10,15	254:23 263:1,7	143:6 144:18	245:14,15,16
37:23 38:2,4,8,23	267:19 268:2,4,7	265:21	268:14 275:7
39:7,7,9,16,22	282:7 286:3,11,16	meetings 21:18	283:11 304:3
40:7,17,22 41:1	291:8 293:7 295:4	22:17 26:13	313:17
42:23 43:18 51:16	298:2,7 314:18	meets 222:11	mentions 313:22
51:17,18,22,25	319:7 324:22,24		

[mere - months] Page 36

mere 275:8 282:14	127:24 162:3	minimize 148:7	misconduct
301:8	167:4 181:13	ministry 147:24	142:21
merge 64:12	222:8 285:1	minor 163:6	misgivings 254:17
merit 124:6 192:7	michael 2:17 7:7	167:10,18 217:23	misjudged 171:2
192:10 193:6	329:1	218:5,12 250:2	missing 167:6,9
194:21 213:17	michael.cantrell	252:1 278:24	mission 86:19,24
merited 182:15	2:20 329:2	285:20 286:8	87:9 147:8,13,20
merits 221:24	michigan 19:7	minor's 190:15	mistake 70:5
message 75:22	34:20,22	288:6	312:24
met 129:16,18,21	microphones 6:3	minorities 62:5	mistaken 37:3
132:11,18 133:18	mid 45:18	63:21,22 64:5,9	62:10 180:16
133:19,20,21	middle 116:10	minority 184:20	195:25 211:10,11
313:15,18	191:23	minors 47:6	213:1 256:13
metal 56:22	mike 2:22 116:13	160:12,12 181:12	271:2 276:12
method 106:3	129:11	181:20 182:3	305:1
162:2,3 191:3	milliliters 110:14	184:11,25 186:19	mixed 134:16
254:5 299:22	mind 13:10,19,24	192:6,25 195:14	148:11,14,18
methodological	14:6,12,15 16:16	211:10,12,14,25	149:4
38:11 61:9 119:11	17:3,12 18:12,15	212:4,5,8,16	model 153:16,17
162:16 228:14,19	22:20 26:8 27:5	213:25 214:13	155:15 163:24
255:12 258:4	30:13 35:19 36:25	215:15 216:13	models 126:5
297:2	48:9 59:22 66:17	220:1,4,7,13	moderation
methodologically	68:17 72:23 75:21	221:15,16 222:2	278:10
122:14 123:20	88:9,22 94:15,18	222:21 226:21	modern 23:16
219:7 311:7	97:20 149:23,25	228:25 229:20	modest 182:14
methodologist	150:14,24 151:5	232:23 237:4,9	186:18 213:17
94:9	151:10,19,22	246:5,7 248:19	215:5
methodology	152:13 153:12	250:13 251:19	modified 180:17
76:11 78:9 111:1	156:18 157:5,14	257:4,6,7 262:25	mom 272:13
209:4	157:18,20 158:6	274:3,5,17,25	moment 100:9
methods 28:23	159:16 160:19	278:5 280:17	moments 322:7
38:13,16,19 40:6	166:3,4 198:17	283:12,15 284:6	money 120:24
50:25 51:1,17	199:16 215:1,22	284:18,19 285:5,6	138:9,11 310:1
52:5,7,20 53:19,21	236:11 258:9	285:11,12 288:10	monitor 274:1
53:23,24 55:15,18	288:22 300:3	298:19 301:11	monitoring 270:10
55:24 65:6 85:10	313:7 314:10	302:19 316:25	273:3,7
89:1,4 103:24	mine 9:15,16	319:21 325:19	month 79:9 146:3
106:12 115:8	38:12 66:9 144:14	327:2	177:17
117:19 120:3,18	274:20	minute 77:14	monthly 240:10
124:25 125:14	minimally 175:5	minutes 81:5	months 14:2
126:5,6,8,14 127:2	178:14	308:15,19 309:5	

[moral - notable] Page 37

		150 10 10 202 21	
moral 233:22	n	159:10,12 203:21	nevertheless
234:2 235:12,14	n 2:1 3:1,1 5:1	241:19 259:1	293:12
236:25 237:20	46:7	260:22 266:12	new 2:6,6 4:10
238:9,16,19,25	name 6:16 7:21	268:7 273:16	17:8,9,20 18:22
239:2 249:3,7,9,13	32:21 35:22 63:16	289:16 290:15	81:11 93:19 95:2
250:23 251:1	69:15 84:17	291:8 292:22	96:2 138:8 140:3
293:20 295:17,18	129:19 237:7	304:21 310:23	142:22 159:14
morality 231:1	242:8,20,23,25	325:6	172:15
233:12,17,18	260:13 282:20	necessary 325:2,5	news 129:6
234:5,7,8,9,13,15	308:19	331:6	newspaper 114:8
234:16,18 235:18	names 36:2,3	need 8:7,18 29:24	newspapers 247:2
238:23 251:4	narrative 192:5,23	42:15 81:4 85:19	nfs 143:19,20
257:7,12,13	narratives 192:24	85:20 121:9,13,16	144:22 145:4
morning 6:1 7:19	narrowed 123:11	123:21 128:12	146:2 148:13
207:5	narrowly 113:20	134:22 209:9	nice 27:18 297:10
morse 321:23	310:8	228:1 231:16	night 272:14
322:2,8	natal 98:5 212:22	232:6 251:6	nih 202:3
mortality 62:4	213:4 238:17	267:10,13 271:21	nine 175:8 178:17
mother 1:3 140:14		273:10 274:1	ninth 80:9
194:9,10	253:23 254:8	294:20 319:3	nixed 256:13,14
motivated 131:18	257:17 264:12	324:24 325:1	nnt 80:19 90:15
316:23	278:9,24 279:2,18	needed 80:2 81:24	123:23
motivation 192:21	279:25 280:18	85:5,12 90:10	noble 283:24
move 77:20 88:14	281:11 289:11,23	141:14 202:18	nod 8:7
108:10 145:1	290:8	232:9 268:5	nods 273:8 318:4
160:6 211:18,22	national 59:2,3,8,8	needs 269:18	noise 198:2
278:25	59:12 63:23,25	284:22	non 76:20 82:21
movement 89:1	200:5 243:18	negative 97:24	83:3,23 98:7
movements 128:3	265:7,11,16	neglect 87:21	101:5 109:1 149:1
moving 17:19	nationally 45:23	neglected 305:12	152:23 171:11
48:21 71:11	46:14 121:3	305:14	188:10 259:25
252:21 301:4	natural 82:24	neighbors 64:6,7	261:6
320:14	nature 33:1,3	neither 166:23	norm 244:14,16
multiple 123:3	34:15 82:10	200:14 261:2	norm 244:14,16 normal 158:15
_	143:14 220:10		
179:24,25 180:3	292:25	network 22:4 never 90:14 92:3	normally 205:21
216:3 220:2,3,11	navigating 310:12		normative 260:15
222:22	near 27:19 180:9	127:3 145:1 149:6	norms 106:9 230:9
mute 6:4	312:17 324:17	168:16 197:16	230:13
mystery 304:19	neat 170:3	231:12 274:20	north 19:11
	necessarily 98:20	300:14,22 308:20	notable 169:25
	99:4,5 116:1	318:5	177:8
	37. '4. 4. T		

[notably - oh] Page 38

notably 225:11	97:7 101:4 103:13	objections 6:20	305:20 307:15
notary 331:13,19	104:15 105:12	192:6 193:2	occurring 203:20
note 6:3 312:11,12	111:8 112:3,10	228:14,19,20	239:18,21,22
329:10	113:1,15 114:2,17	252:1,3,4,5 254:11	243:6 269:15
noted 181:9	116:9 119:4	254:16,17 255:16	occurs 326:3
212:23 331:7	125:20 126:3	255:20 257:25	october 79:10
notes 9:16 300:9	127:22 133:10,12	258:5,8,12,13	84:24
300:10	158:2,13 159:9	objective 88:1	odd 144:17 315:19
notice 5:10	163:12 165:6	obliged 139:23	offer 62:23 102:12
noticed 100:16	167:2 172:25	140:8,17	105:5 117:10
noticing 6:24	181:7 182:5 183:6	observation 204:4	151:16 156:9
notion 160:8	185:8 186:4,9	204:5	181:8 188:21
217:10 263:3	188:8,14,20	observations	283:23
notions 192:7	189:17 191:17	123:22 203:17	offered 32:6 33:4
nsf 144:15	193:25 195:7	243:23	41:21 168:25
nuance 300:8	199:10,20 201:21	observe 102:14,15	176:19,21 245:22
number 6:13 80:2	205:16 209:21	102:17 237:18	offering 32:12,13
81:15,24 85:5,12	217:21 218:24	observed 79:19	99:14 125:18
90:10 108:24	221:17 222:7,24	240:19 241:2	195:22
141:14 227:8	223:19 224:10	observing 171:16	offers 147:24
228:13 265:5,9,21	227:17 229:18	obstruct 191:25	offhand 84:18
265:24,25 266:1,5	232:5,19 245:6	192:18	94:2 215:23
266:12,13,16,17	247:15 249:3,6	obtain 296:4,21	office 2:17 6:15
266:19,21 268:19	250:24 253:18	318:7	7:8 328:13
270:2,6 275:4,17	263:12 264:8	obvious 99:1	officer 142:23
287:21 327:10	265:12 267:7,12	obviously 196:25	official 1:7 328:18
numbers 266:3,22	267:21 269:12	299:4	oftentimes 204:19
267:2	270:5 273:14	occasion 87:13	206:13
0	274:18 275:1,6	occasional 86:22	oh 9:5 17:8 22:12
	278:16 282:13	occasionally 21:20	30:1 45:2 49:10
o 3:1 5:1	286:5,13 287:13	51:24 86:21 87:11	59:1 63:20 83:2
obergafell 35:17	293:25 318:13,19	313:22	91:4 96:6 102:11
36:3,14	320:24 324:25	occupies 150:16	126:16 130:11
object 22:24 41:9	326:17	occupying 152:14	134:16 149:11
44:15 47:15 50:10	objected 171:18	occur 176:16	164:11 171:25
52:17 55:21 57:10	objection 8:15	178:22 206:13	175:24 198:3
60:12 61:2 63:8	143:13 192:24	272:7 276:20	199:25 211:10
65:4 66:22 67:22	229:10 231:11	321:6	254:25 264:9
68:7 69:8 70:10	233:7 238:9,19	occurred 25:15	266:14 294:22
71:1,9 72:3,9 74:2	249:6 258:1,3	75:19 177:5	295:9 300:3
75:6 79:1 82:18	,	186:25 228:10	301:12,21 314:8
87:16 88:2 96:15			

[oh - okay] Page 39

319:8	70:19,22 71:5	142:17 143:1,10	215:24 217:23
okay 7:23 8:1 9:6	72:2 74:4,7 75:2,8	143:18,25 145:3	218:17,20,25
9:18,24 10:1,3,6	76:1,6,8,19,23	145:10,18,22,24	219:2,23 220:18
10:11 11:9,13	78:15 80:16,22	146:4,21 147:6,19	221:8 222:20
12:1,10,16,20	81:7,15 82:2,11,13	148:5,11,18 149:3	223:11 224:12,14
13:10,12,15,19,24	83:10,22 84:12,17	149:8,16 150:22	225:1,2,3,12,20
14:4,7,10,13,16,19	84:22 85:1,2,11,17	151:15 152:18	226:6,13,16 228:6
14:22 15:4,16,17	85:22,24 86:1,8,23	156:6 158:7	229:1,9 233:5,11
15:23 16:1,2,8,11	87:25 88:4,22	159:15,25 162:21	234:11 235:3,19
18:11,18 19:20	89:19,22 90:8,17	163:14 166:1,9	237:22 238:6,19
20:3,6,9,16,19	91:9,12,20 92:7,11	169:12 170:14,20	238:22 239:5,9,12
21:3,8,23 22:8,22	92:12,19 93:7	172:5,14,23 173:6	239:14,20 240:19
23:10,25 24:4,8	94:10,13,23 95:5	173:23,25 174:13	241:3,6,11,16,20
25:10,13,17 26:13	95:16,19 96:9,22	175:3 176:17	241:23 242:4,20
26:18,23 27:1,9,15	97:2,4,10,15,15,25	178:10,20,23	243:4,7,15 244:1,7
28:16 29:6,8,10,13	98:11 99:13,18,21	179:9,16,25	244:11 245:2,21
29:19 30:3,14,20	100:7 101:2,15	180:11,19,24	246:3,5,18 247:10
30:25 32:18,25	102:9,13 104:24	181:3,5,9,17 182:1	247:17 249:10,10
34:3,8,23 35:21	105:9,15,24	182:19,22 183:20	250:22 251:3,6
36:11,25 37:4,9,18	107:19,22 108:5,9	184:9,13,17 185:2	253:4,15 254:10
38:1,9,15 39:5,12	108:12,19 109:7	185:17,24 186:1	254:14 255:2,4,5,8
40:14,19,22 41:15	109:19 110:19,22	186:11 187:7,11	255:25 257:5,15
41:25 42:6,10,18	113:23 114:14	187:25 188:2,17	257:24 258:20
42:20,22 43:2,4,14	115:5,7,11,16,18	189:19 191:1,13	259:8,13,18 260:8
43:20 44:1,11,13	116:17 119:25	191:21 192:8	260:19 261:8,12
44:18 45:18,21	120:23 121:19	193:1,8,11,14,18	262:17 264:5,25
46:14,24 47:11,18	122:15,25 124:17	193:22 194:5	265:8,13,19,23
47:22 48:1,4,8,20	127:5,16,20 128:7	195:2 197:7,10	266:5,11,18,24
48:23 49:23 50:14	128:15,21 129:8	198:25 199:22	267:4 268:3,11,18
50:19,19 51:3,14	129:18,23 130:4,6	200:4,16 201:6,10	268:23 269:4
51:23 52:1,11	130:9,11,16 131:2	201:20 202:13,25	270:19 271:12,15
53:2,18 54:1,12,22	131:7,13,15,21,25	203:11 204:25	271:20 272:9
55:3,11 56:4,10,19	132:7,23 133:16	205:9,17,21 206:4	273:9,18 274:14
57:4,21 58:5,8,12	133:21,24 134:10	206:12,22 207:7	274:22 275:14,21
58:17,21,25 59:25	134:17,21 135:6	207:12,13 208:1	276:8,9,14,21
60:2,4,22 61:15,25	135:19,23 136:1,6	208:10,11,19,21	277:4,10,13,16
62:3,22 63:3,12,15	136:10 137:4,7,17	208:22 209:6,11	278:1,13 279:5,9
64:18 65:10,15	138:10,13,17,23	209:18 210:20	281:4,9,14,17
66:3,18 67:10,13	139:1,5,19,20	212:10,15 213:5	282:5,9,15 283:3
67:19 68:14,19	140:6,23 141:6,10	213:10,19 214:10	283:11 284:5
69:4,13,17 70:9,16	141:17,21 142:3	214:17 215:3,22	285:4,8,18,23

[okay - original] Page 40

286:1,23 287:18	203:4 204:20	174:10,13,17	options 171:11
288:12,15,22	257:6 263:13	198:1,5 251:7,11	197:10 281:2
290:13,21 291:16	271:9 276:14	289:2,5 294:19,23	294:7,8
292:14,17 294:3	278:1 291:7	295:1 327:8	oral 1:12
295:13,16,22	299:11 302:15	opinion 10:20 43:1	order 87:19,20
296:6,14 297:21	310:4 311:16	67:20 91:19	90:25 121:7
298:15,17,25	325:7	103:15 105:2,5,6	125:14
300:12 302:15,21	one's 97:19,19	119:19 138:25	orders 101:20
302:25 303:2,9,15	106:8 184:20	139:2 148:4	ordinarily 193:22
303:18,20 304:4	259:21 260:16	151:16 152:15	ordinary 91:25
304:15,18 305:5	261:16 262:6,7	156:17 159:6	152:23 156:6,15
305:13 306:15	263:23 272:5	168:3 240:12	157:10 158:11
307:1,6,24 308:3,6	291:23	245:5 281:24	organism 260:4
308:9 309:3,13	ones 35:12 94:14	282:1,1 292:16	organization
311:16 312:16	114:10 224:21	opinions 12:14,17	22:25 23:21 24:9
313:6,14 314:5,9	314:19 315:1	12:22,25 13:4	24:22 25:22 33:11
315:5 316:10,22	ongoing 273:2	16:17,25 17:4,16	82:21 86:19 141:5
317:1,12 318:2,5,9	307:21 311:23,25	18:2,24 23:19,20	146:19 313:12
319:9,16,22,25	online 23:6 25:8	157:10 281:25	organization's
320:5,11,16,21	42:17	oppose 86:24	87:9
321:7,16,19,22	onset 307:14,15,19	105:10 154:25	organizational
322:4,10,12,15	ontologically	155:3 156:1,7,16	23:3 86:18
323:5,21 324:14	261:16 263:4,10	158:12 165:10	organizations 89:1
324:17 325:20	263:18,24 264:12	170:24 171:6	101:17 102:3
326:22 327:5,8	open 28:1 98:2	232:9 290:4	103:19 124:16
oklahoma 5:10	142:23 239:22	opposed 24:16,17	151:21 164:19
328:5,25	240:9 242:2	100:15 148:9	190:5 195:12
old 194:8 233:12	244:21 245:20	156:24	222:16 308:12
234:18 235:2,5	246:19 249:21	opposing 14:23	316:2,12,17
236:22 237:24	326:12,15,19	15:24 16:6 164:5	organizes 33:14
238:12 248:24	opened 27:22	opposite 98:5,7	orientation 148:11
249:18 254:7	178:14	228:3 259:24	148:14,17,18
older 207:3	openly 164:20	260:5,7,12,17,20	149:4 217:7,13
olds 175:8 178:17	openness 255:7	260:21 261:3,7	oriented 27:21
231:3 274:7,7,10	operate 125:23	opposition 87:3,7	272:18
292:8	operates 106:24	87:14,17 153:6	original 59:16
once 7:25 22:13	operating 131:20	259:14 284:14,14	62:10,12 64:23
63:3 91:20 109:14	178:7 322:11	290:21	79:18 82:4 85:7,8
121:12 129:22	operator 2:21 6:1	opt 252:23	85:9 91:1 101:21
132:14,19 137:7	7:9,12 74:7,10	optimal 325:20	154:6 180:17
157:14 161:8	128:13,22,25		195:16 280:10

orthodox 150:18	overriding 114:16	330:13,16,19	286:2,7,11,16
151:3 152:11,15	overseas 197:22	paged 46:5	288:13 291:9
153:5 154:4,10,25	oversight 271:4,5	pages 77:19	317:20
156:3,23 157:24	overstatement	144:17	part 11:17 12:4
157:25 159:7	200:13,15,16	paid 10:24 68:15	15:11 21:23,25
ought 65:7 67:17	overviews 23:13	pair 44:16	26:19 30:12 32:1
76:16 103:4	owe 269:24	palos 19:8	44:21 48:2,5,7
167:20 194:18	owen 2:8	panacea 272:7	54:10 55:17 57:8
271:4 291:14	oxford 18:13	paper 14:11 47:22	58:22 59:17 74:8
outcome 6:20 11:7	118:1 300:9	63:10 66:18 67:1	74:11 76:25 81:2
80:14 124:4 127:2	312:25	68:6 69:25 91:10	89:5 90:2 106:13
154:2 169:25	р	134:7 144:22	111:16,19 112:11
170:1 183:23		150:2 211:24	115:14,16 128:22
254:8 277:25	p 2:1,1 5:1 33:12 153:20,22	papers 68:10	129:1 138:20
299:8	′	305:7 311:23	140:7 145:11
outcomes 61:16,17	p.m. 129:1 174:15	paradigm 310:23	155:24 171:21,22
110:18 140:12	174:18 251:9,12	paragraph 139:3	174:14,18 195:10
208:13,25 224:1	272:15 289:3,6	139:21 149:16	197:19 202:10
236:5,6 276:23	294:24 295:2	152:9 157:2,2,21	207:16 216:16
outlet 129:6	327:11	159:15 176:4	217:22 236:8
outrageous 124:14	pachankis 126:13	182:19,21 191:23	239:22 251:8,12
162:22 231:18	170:1	197:24 198:7,8	255:17 257:21
outside 60:22	pack 64:16	208:6,8 261:20	262:18 264:6,10
82:23 103:24	package 250:21	276:1 287:21	264:11 265:13
111:4 127:6	261:14 262:23	298:11	275:3 288:7 289:3
252:24 298:7	263:6	paragraphs 208:2	289:6 297:2 319:8
overall 75:11	packaged 34:17	208:4,20	320:18
184:10 200:23,24	35:23 36:9	parent 87:9	participants
overcome 148:3,6	page 3:3,7 4:3	172:22 193:23	115:22 284:23
overestimated	29:22 46:4,6 79:8	246:11	participate 79:25
294:2	79:8 95:21 115:19	parental 288:17	171:22
overlap 38:13,24	139:2,15,15,20	parentheses	participated 35:2
39:6 53:17 54:4	145:19 149:14	193:13	147:23 285:16
overlapping	151:15 175:23	parenthood	participating 64:2
100:10	176:3,4,7 182:19	243:11 245:14,22	participation
overlooked 305:18	182:21 191:22	246:1	111:20 117:7
overreach 191:8	208:9 239:12	parenting 106:23	204:22
191:25 192:18	261:22 275:25	108:13 110:16	particular 10:9
193:5 201:19	276:4 283:21	parents 107:5,17	58:4,13 65:2
overreaching	287:19 298:11	186:11 193:19	67:17 75:18 78:5
79:16 108:2	314:16 316:20,22	253:22 285:14	92:24 100:1,22
77.10 100.2	316:24 330:4,7,10	233.22 203.17)2.2 + 100.1,22

110:7 113:11,20	229:17 236:9	108:2,3,8,11	167:20 168:19,22
114:22 117:24	241:1 257:22	124:14 219:11,19	169:11,19 178:10
121:10,14 125:21	269:24 318:10,12	310:12,24	195:11 200:6
143:12 158:21,24	318:16,18,23,24	peers 117:8	202:18,22 206:2
160:4 167:4 179:6	318:24 319:3	310:18	207:24 210:25
182:24 183:21	patrick 129:18	pen 198:2	213:8,9 217:14
271:18 277:20	patterns 303:7	penalty 195:24	226:11 227:7
280:24 282:22	paul 129:21 132:9	196:3	229:25 230:2
particularly 199:1	132:11,16,16,18	penis 280:1	232:9,11 237:11
parties 5:5 6:6	134:13,14,14,15	people 4:11 21:21	237:12 238:17
23:8 328:15	134:16	30:21 38:10 40:23	247:4,5 250:1
party 6:18 139:10	pause 294:25	41:2,8 44:14 45:4	257:8 258:5 260:2
pass 107:24	pay 11:1 21:14,15	45:21,22 46:21	260:9,25 261:4
112:13 259:23,25	83:21 120:16	47:4,13,14,21 48:9	262:21 263:3
260:5,10,11	paying 307:3,5	48:15,25 50:1,9	265:9,24 266:1,1,6
passed 64:2 108:2	pds 96:2	51:21 58:11,14	266:13 267:10,19
192:13 229:1,21	pecking 121:7	63:9 64:1 72:24	267:25 268:4,19
passing 76:5	pediatric 57:18	73:7,14,16 76:20	268:23 271:3,18
259:25	pediatricians	78:7,13 80:13	271:21 272:11
pastor 130:17	240:24 248:5	83:17,24 86:2	275:5,18 276:25
pathway 194:14	315:15,19	89:14 91:13 92:25	277:10 282:17
197:15	pediatrics 93:25	94:14 95:7,25	283:21 289:11
pathways 230:2	94:1 108:23 109:2	98:1 100:11,13	290:23 291:5,13
patient 58:3,4 65:3	160:6 315:11	108:1,6 109:13,16	294:10 299:15,19
66:21 100:1	peer 13:22 42:11	109:17 110:15	300:13,19,21,23
114:25 172:19	42:25 43:11,15,17	117:12,16 118:4	301:13,16 304:15
182:24 183:14,17	43:19,22,23 48:11	121:20 122:4,5,7	304:17,23 305:3
183:24 184:15	48:12,24 49:22,23	123:14 124:3,7	305:11 306:6
185:6 186:12	50:15 60:6,10,13	125:7 126:22	307:16 308:22
190:4 192:1,19	60:20,23,25 63:5	130:2,2,18 134:23	309:9,19 310:20
193:5 194:17	64:11 67:2 68:12	135:21 136:12,22	310:25 311:24
241:1,3 287:8	68:16 69:19,23	137:2 140:13	317:9 320:17
317:19	70:11,12,17 71:7	142:15 147:21,24	322:5,14,16 323:2
patient's 242:3	72:7 73:2,25	148:2,6,9,24 149:3	324:16 325:22
patients 58:13	74:25 75:4 76:20	149:10 150:13	people's 43:4
65:19,23 73:5,8	78:2,12,15,16	152:6 153:9,10,25	46:15,20 102:14
114:15 119:7,7,7	80:17 81:22,25	154:11,22,24	104:8 194:13
183:4,21 184:10	83:23 84:2,7,14	155:6,12 156:6	284:13 294:15
186:7 188:3 201:7	85:14 90:13,21	157:17 158:15,17	perceive 304:21
206:2 212:23	91:5,14 92:5,13,20	158:21 162:1	perceived 67:7
213:4 224:25	93:1,7 107:24	166:2 167:16,19	

[perceives - please]

Page 43

perceives 319:14	166:8 207:3	physician's 67:4	pipeline 92:15,18
perceiving 269:8	249:17,24 252:8	physicians 67:8,9	306:20
percent 46:7,12	259:17 283:25	204:13	pivot 105:15
305:22,24	290:7 291:21	physics 106:3	place 6:6 19:11
perceptions 91:24	302:10 306:9	128:6	21:19,21 119:21
91:25	person's 264:7	physiological	136:6 143:6
perfectly 164:1	personal 102:22	161:4	197:16 203:20
perform 300:24	102:23 104:25	pick 6:3 74:24	272:10 313:24
performance	105:9 203:15	259:7 294:4	places 262:24
145:11,12 146:5	204:5 262:8	picked 152:10,11	265:6 283:19
performativity	284:25	169:6	plains 246:2
262:13	personalized	picking 66:8	plaintiff 6:10 7:2,4
performed 170:22	202:20	157:23	7:6 320:6,8
177:1 220:19	persons 45:25	picture 129:20	plaintiff's 11:16
performing 301:3	87:22 98:4 118:8	143:14	12:3 15:9 38:3
period 133:20	125:5 185:1	pictures 284:2	44:20 76:24 81:1
215:8	232:12 260:11	piece 17:8 77:9,25	115:13 138:19
permanence	322:21,23,25	78:24 80:1 84:9	207:15 239:17
286:20	perspective 24:10	86:8 88:5,10,11	307:9
permanent 173:3	67:5 87:21	89:13 93:8 94:21	plaintiffs 1:5,14
288:10	pertained 131:16	94:24 95:2,6 96:7	2:3 4:1 5:7 33:14
permanently	phd 19:10,15 30:6	96:17,23 97:6	34:10 74:16,18,21
238:12 286:25	30:8 37:18 39:15	104:25 105:1,2,23	186:17
permissibility	phenomena 127:2	106:21,25 107:12	plan 8:16 29:25
67:6	127:4	107:20 108:12,15	246:11
permissible	philosophic	108:17 111:13	planned 243:11
325:23	159:20	121:24,25 136:15	245:14,22 246:1
permission 32:14	philosophical	136:18,20,21	platforms 118:6
286:8 292:10	82:20	160:16,18,20	plausible 68:11
permit 255:21	phone 75:23	219:9 322:17,18	184:8
288:9	phones 6:5	pieces 18:21 76:20	play 52:23 235:25
permitting 164:1	phonetic 150:10	93:17,21 108:19	252:17
persistent 287:23	206:24 209:23	108:23 109:11	players 240:15
301:17	photo 132:5	114:8 118:9	playing 240:11
person 8:25 9:20	phrase 262:10,21	247:25	247:7
28:14 87:19 89:3	262:22	pill 272:4,7 273:20	please 6:3,4,21
100:22 115:3	physical 161:3	274:15	7:10,12,20 8:5,14
143:4 149:23	173:4 220:8	pillars 83:16	11:13,14 12:2
151:22 152:4,7	262:15	pilloried 312:3	15:3 16:1 19:2
156:16,23 157:15	physician 325:4	pills 272:10 293:3	40:24 44:19 45:8
158:6 159:20			69:22 74:12 80:23

109:14 115:12	pokes 118:15	319:4	242:18 256:1,9
121:12 129:2	policy 246:12,13	positions 32:4	284:3
138:18 139:2	246:14	64:13 152:23	practitioners
147:9 174:18	political 20:24	positive 124:4	100:21 119:6
179:1 190:21	21:1 51:19 87:20	213:2,16 221:1	253:12 303:21
191:22 207:14	153:19 195:21	307:20	306:14
208:22 219:18	politics 4:8 77:6	positively 100:14	pre 28:6,11 108:11
229:9 232:22	94:21 150:11	possibility 172:11	136:8 160:15
251:13 263:13	191:19 314:6	172:13,14 216:19	predicated 191:24
267:17 286:14	poll 315:15	251:15	predictor 153:25
289:7 295:2 317:6	pool 115:21	possible 68:11	predominantly
318:14	pooling 309:8	93:24 96:8 97:9	142:25
pleased 179:22	poor 215:6	119:7 121:1	prefer 324:22
plenty 101:17	poorly 300:24	135:22 140:10	325:13
216:5,5 257:18	pope 258:22	169:5 170:15	preferably 176:24
plos 312:7,7,11	261:15	179:11,12,18,19	preference 302:8
plus 306:2 310:11	popular 66:8 67:6	180:9 184:19	preferential
poignant 204:10	91:19 204:11	185:20,21 186:2	251:23 253:3
point 8:18 73:21	240:7 309:1 316:6	187:24 188:1	preferred 325:24
97:13 105:6	popularly 58:1	197:4 201:10,18	prefrontal 291:3
113:13 116:16	239:25	201:20,22 226:25	291:17
122:4 134:18	population 28:4	253:2 255:6 266:5	pregnant 111:22
152:8,9,10 170:21	28:11 41:19 46:12	266:11 309:12	preliminary 14:23
175:22,24 210:20	49:13 63:24	314:8	15:24 16:6 261:19
211:6 212:10	115:22 117:12,13	possibly 176:15	275:23
213:19 219:9,24	117:17,22,23,23	177:5	premature 64:5,9
224:6 229:6	118:18 119:15	post 18:4 28:5,7	preparation 10:17
233:12 237:11,22	122:6 123:9 125:4	28:12 45:18 87:20	prepare 9:12,21
250:17 253:8	populations	108:10 144:4	prepared 11:9
290:9 291:13,15	100:24 324:5	240:10 250:1,2	preparing 39:19
293:5,6 299:10	portfolio 83:10	257:8 289:23	preponderance
303:15	141:3	potentially 200:14	219:1,3,5
pointed 69:21,24	pose 103:22 120:3	200:16 272:7	prescribe 272:12
156:17 157:7	121:21	278:24	282:22 283:3
158:11 164:24	posed 126:15	poverty 106:7	prescribes 292:22
303:3	171:10	practice 114:14	prescription
points 239:7,13	position 20:6 25:1	239:18 243:5,20	246:10 251:1
poised 184:22	25:2,3,10 27:22	246:14,22 254:3	271:6 272:18
poke 117:18 121:5	104:12,13 193:15	practiced 56:19	prescriptions
poked 118:10	238:11 252:13	practices 106:9	61:18
307:11	274:20 281:11	239:10 242:11,17	

prescriptive 61:19	princeton 82:22	159:1 162:20	312:10
present 6:22 75:7	82:23	184:16 192:11	processes 145:11
92:6,7,10 100:12	principal 285:7,15	202:21 203:9	149:20 152:2
163:19 260:21	principle 87:5	206:6 214:24	produce 135:2
273:10	principles 87:3	227:19,19 231:14	produced 83:6
presenting 133:25	print 64:10 66:6	253:14 265:6	profession 65:1
presents 260:19	66:11,14 69:15	269:6 272:15	149:21 157:12
president 138:1	83:20 90:21 96:20	276:22 279:22	159:7 326:11
press 89:3 204:11	141:20,24 164:21	288:16 297:5	professional 19:22
237:5	318:22	304:9 314:11	25:7,11,17,19 27:5
pressed 103:20	prior 27:2,4 81:21	316:20 326:20	54:15 56:23,24,25
presume 23:19	159:11 242:12	problem 35:2	57:9 60:5,9,24
64:20 67:7 140:2	269:2 279:18	100:22,22,23,25	63:4 71:6 72:6
269:1,1 296:7,22	280:1 286:25	216:16 221:10	73:24 88:25
presumes 278:7	private 6:4 141:3	230:4 252:25	103:18 106:17
presuming 139:13	141:4	294:22	124:16 151:21
179:5	privilege 8:11	problematic 76:12	152:1 164:19
presumption	116:5,21	118:15 182:12	186:25 195:12
117:11	privileged 8:13	217:1 242:14	314:21
presumptions	privy 241:9	275:12 293:12	professionals
170:19	317:11 319:4,5	problems 40:5,7	65:18,23 76:2
pretty 17:19 66:9	pro 26:1,10 153:20	221:4,7 224:25	158:15,16 159:1
80:13 99:8 162:20	154:13,13 248:1,1	procedure 5:11	159:24 205:5,7
162:21 190:17	283:20	282:19 286:19	professionnelle
300:17 301:13	probability	procedures 76:12	149:19
prevalence 270:14	302:10	279:1,24 286:9,11	professor 18:13
prevent 9:6	probable 134:12	286:16 288:9	20:7,10,12 28:18
300:16,17 301:11	probably 14:17	325:16	29:4 31:18 41:17
301:20	20:22 23:21 25:8	proceed 7:13	77:18 118:1,11
preventing 278:23	31:21 33:13 35:7	74:12 129:2	120:20 121:17
previous 80:18	35:12,12 40:13	174:19 251:13	125:2 127:25
207:20	42:19 82:4 86:6	256:17 289:7	173:20 174:4
previously 238:20	87:18 88:12,12	295:2	300:9 302:12
primarily 44:8,10	89:20 90:19 95:15	proceeding 6:20	304:22
137:2	96:20 98:4 108:21	proceedings	profit 82:21
primary 31:18	108:22 110:21	311:13	profound 97:19
48:15 49:1,25	119:5 130:25	process 64:11	207:6 276:23
50:5 54:23 55:14	134:3,4,20 135:13	108:4,8 219:20	program 19:25
55:18,22 56:16	143:6 144:19	283:15 284:6	39:14 308:20
192:5,21,22	148:25 153:24	295:23 296:16	321:22
273:17	156:5 158:18	297:9 310:12,24	

progressive	231:24 232:3,10	provision 152:3	psychotherapists
150:17 151:13	232:15,17 233:2	212:21,22,25	72:24
153:5 154:4,10,23	239:24 240:2,4	247:21 262:11	psychotherapy
157:24	241:8,17 247:21	268:9	72:11 80:11 268:9
prohibit 181:19	257:20 276:6	provost 143:8	pubertal 250:1,2
182:2	protocols 59:20	prudence 257:13	257:9 289:23
prohibited 188:3	65:14 284:16	289:18	puberty 104:17
205:9,12	provide 12:14,17	prudent 182:24	163:7 176:11
prohibits 181:15	37:10 57:15,16,22	233:19 256:22	237:4,10,12
project 171:7	66:20 70:25 93:3	288:9	238:18 248:19
projects 22:2,19	113:3 240:22	psych 175:9	249:4,18,20
144:20	242:25 245:3,18	248:18	250:18,20 253:23
promoting 261:25	246:5 270:3	psychiatry 72:11	254:9 257:17
promotion 146:7	286:12,17	72:16 79:11	258:6 278:9,24
173:10,19,20	provided 56:22	126:14	279:10,11,25
promotions	89:6 112:25	psychological	280:12,15,18
173:21	123:25 202:9	40:23 41:1 43:9	281:11 289:12,23
prompted 300:1	218:2 229:2 231:9	55:19 71:8,10,11	290:8 325:17
prompting 299:22	231:23 232:3,17	72:8,10,20 77:11	326:1
promulgate 298:3	240:20 244:7,9,24	78:25 79:5 97:18	public 14:1,8 17:2
pronounce 206:23	253:15 254:12	117:14 184:3,10	22:14,16 43:1
proper 105:2	255:17	184:15 217:22,24	63:14,15 64:13
proposition	provider 66:19	218:8,15 221:4,6	67:20 77:5,25
266:18	72:13 124:22,23	224:25 225:8,14	78:2,19 80:1,18
propounded 7:16	245:16	228:1 242:2,5,12	81:18,21 82:13
prospect 176:1	providers 48:5	242:21 244:5	83:5,8 84:10,11
prospective 169:4	72:19 119:20,21	245:4,24 247:7,12	86:5,16 89:16,17
protect 184:25	195:25 205:22,24	248:1,2,4,12	95:12 96:6 119:12
protected 8:11	206:1 228:6	262:15 263:7	119:19 120:1
161:9 184:25	providing 9:7	268:7,8 273:2,10	137:22 141:7,12
protecting 161:10	161:18,23 163:1	278:18 325:15	141:23,25 227:10
protocol 65:2	181:19 182:2	psychologist	240:12 243:3
67:21 163:11,13	206:4,15 211:15	118:24	247:1 265:4 312:7
180:17 194:15	226:20 236:21	psychologists	331:19
213:21 221:1	240:25 242:4,21	116:4,21 117:3,10	publically 82:5
224:17,24 225:2,4	242:21 246:25	118:21,23	85:19 143:16
225:7 226:7,9,10	247:12 248:11	psychology 53:16	publication 49:22
226:17 227:6,15	251:19 253:10	53:17 54:5,5,6	49:24 50:8 61:6
227:23 228:7,18	293:7,9 295:4	72:16,18 109:2	85:15 91:15 92:5
228:21,24 229:3	297:13,17	116:2 117:6,8	96:18 118:13
229:14,17 231:9		120:10	221:19

publications 13:19	pursued 64:19	44:23,25 45:2,12	110:8 118:4,15
13:23 60:21 70:11	197:16	47:8,13 59:16	120:2 121:21
108:24	pursuing 31:15	65:16 75:9 76:9	125:1,21 126:4,15
publicity 26:11	272:1 287:8	77:15 89:2 91:1	133:11 156:10
publish 309:24	309:20	101:5,21 102:5	202:24 210:1
published 17:20	pursuit 278:10	103:21 104:8	212:2 221:9,13
42:10 43:10 50:12	push 152:3	105:1 107:2,16,24	248:11 285:10
50:14 62:8 69:4,6	pushed 310:24	111:12,23 113:16	324:18 327:6
77:25 81:24 82:14	put 25:16 60:15,18	113:23 115:20	quick 128:13,16
84:2,6,8 87:13	72:14 73:21 74:13	116:13,18 119:20	128:17 283:20
90:13 106:14	78:18 101:11	125:3,5,6,19	289:1 294:20
108:25 120:24	103:8 104:1	126:16 129:6	314:11
125:24 141:11	105:13 125:7	153:25 154:15	quickly 17:20
148:21 219:10	142:20 164:16	158:23,24 162:11	307:16 314:15
304:15 305:8,9	194:11 198:4	162:25 163:16	quietly 186:20
308:1 309:21	226:6,8 237:22	167:22 171:8,9	quite 18:9 31:7
311:6,23 312:8	puts 139:11	172:15 183:12	66:8 98:6 116:15
publisher 66:5	281:12	187:3 191:13	126:24 138:16
publishing 124:13	putting 291:24	195:16,17 210:19	150:21 152:5
pull 214:25 253:8	300:12 302:17	213:11 216:4	155:10 157:18
315:17	puzzling 168:16	218:4,17 222:20	161:1 170:3
pulled 317:21	q	231:7 232:16	186:20 192:20
pulls 309:7	quack 293:2	233:1,6,8,10	201:20 282:6
punishment	qualifications	236:15 238:25	283:20 317:22
160:12	14:20	239:2,5 245:20	322:8
punt 182:10	qualify 319:18	251:20 253:20	quotations 139:11
232:20 249:20	qualitative 52:7	255:14 267:8,17	quote 47:4 86:24
pure 40:3 54:7	quality 93:4	272:21 280:10	116:4,20 146:24
235:15	121:11,15 122:17	281:17 290:1	147:1 236:23
purely 230:16	124:18 127:8	294:6,8,12 307:4	287:22
purism 119:11	146:11 208:14	308:10,12 309:6	quoted 242:7
purported 167:24	209:2	309:22 311:5	quotes 22:15
purpose 68:25	quantitative 40:6	324:19	101:12
69:14 131:8,21	52:5,6	questionable	r
purposes 146:6	queering 86:9	76:13,13,14	r 2:1 33:12 328:1
276:19	88:5 89:6 94:24	questioning	330:3,3
pursuant 5:10	95:23 97:6 105:23	116:10 178:14	r.g 36:7
pursue 28:12	136:23	questions 7:16	race 106:6
93:13 172:23	questing 323:25	8:10,14 10:8	racking 66:12
228:3 254:23	question 8:4,6,8	44:17 46:24 71:18	radar 154:6
261:1,4 262:7,7	8:12,19 37:21	86:13 89:4 107:7	14441 137.0
	0.12,17 37.21		

[radical - received] Page 48

radical 269:7	rattle 188:16	realities 104:2	202:3 290:4
	reached 57:14	reality 179:15	
radically 13:18 166:4 217:11		226:2 227:3	309:10,12
	65:8 73:12 169:10	228:10 233:4	rebuttal 4:5 12:8
273:22 294:1	184:21		15:4 16:18,21
305:18	reaching 57:21,24	234:16 274:21	17:7 149:13
ragon 2:8	58:18	282:2 300:10	151:15 157:2,13
raise 138:8 171:4	reaction 320:16	realize 202:4	239:11 260:14
177:2 307:1	read 17:22 64:10	269:18	299:2 307:11
raised 107:4,8,16	77:12 83:18 87:11	really 32:16 59:15	323:1
143:11,13 206:22	93:18 96:17,18	66:13 81:12 86:17	rebuttals 9:15
228:13 248:11	99:22 102:21	88:3 89:8 95:3	242:1
252:4 270:13	114:6 139:6,18	106:23 118:14	rebutting 65:22
295:22	147:9 149:17	119:16 141:4	68:6
ramifications	154:20 157:21	142:24 145:5	recall 13:6 14:7,17
172:21 286:21	177:3 181:3	146:20 147:13,20	24:2 30:11 35:12
random 115:22	186:14 197:7	148:4 154:6	75:18 76:1 80:11
140:10,12,13	205:6 207:11	161:25 168:16	83:2 88:17,19,22
324:10	208:20 212:3	171:11 179:23	89:5,10,13,22 90:1
randomized	239:24 240:7,9	208:12,23 223:25	90:4,5 93:10,20
166:17 168:19	245:8 283:20	227:9 252:12	94:2,3,6,10,12,13
169:19 170:15	285:13 299:24	255:4 259:12	94:17 96:9 97:8
174:24 177:24	302:7 305:15,23	267:22 290:17	105:7 109:4
179:2 190:8,10,12	314:14 320:5,9,12	300:22 301:1	126:17 130:23
190:20,23 191:14	325:7 328:8 329:9	306:12 307:17	131:6 133:8,17
276:15	331:5	312:21 314:2	134:6,8,12,13
randomly 176:24	readers 30:23,24	reanalysis 212:17	135:19 137:10
range 26:3	67:16	reap 33:12	138:13,16 142:16
ranging 299:7	reading 17:6 68:5	reason 53:18	143:4,17 146:20
rapid 190:4	85:10 96:21,25	90:14 114:20	170:2 207:21
307:15	98:13 152:9	125:25 156:1,7	213:1 221:15
rare 168:23	192:14,18 231:25	158:11 165:9,11	222:3,5 256:15
200:17,19,24	285:19	170:23 205:18	320:15 321:22
201:3 276:21,22	reads 114:7	216:10 224:17	322:4,6
rarely 208:7	real 62:13 171:11	261:18 265:15	recalled 58:14
rate 306:1	179:17 228:12	269:10,13 275:3	receipt 329:18
rates 212:7,7	229:12 289:1	281:20 289:9	receive 104:14
ratio 227:12	313:3 324:3	297:12 315:16	146:18 268:24
269:23	realist 149:9	329:11 330:6,9,12	271:8 292:3
rationale 164:15	realistic 163:21	330:15,18,21	received 241:4
165:11	166:9,11,14 301:4	reasons 12:21 99:1	305:7
		164:5,13 165:16	

receiving 25:21	records 241:6,10	158:18	135:4 144:1 145:4
79:21 179:3,4,5	306:13	reflects 137:5	175:20 208:13,25
185:6,18 186:8	reduce 300:19	288:2	224:1 260:8
187:4,8 232:12	reduced 79:13	reform 270:11	266:12
237:24 241:7	reducing 238:1,7	reframe 167:23	relationship 44:4
250:10 252:2	reduction 183:18	refused 287:8	49:11,12,18 50:5
264:21 266:20	187:14,16	refuting 70:1,3	140:15 150:6
274:17 320:23	reenforce 18:8	regard 280:22	192:1,19 193:6
recognize 11:20	refer 280:24	295:10	relationships 44:7
12:6 15:18 16:3	reference 50:11	regarding 69:20	44:9 250:3 289:12
77:3 81:8 115:25	84:9 87:2 100:17	94:14 97:20	289:14
123:20 178:7	108:12,22 150:1	160:11 262:8	relative 328:15
179:13 183:3	240:8 246:7	295:24	relatively 159:14
194:18 197:7	288:21 293:21	regardless 181:20	213:10
207:18 257:18	312:9 313:18	182:3,6	released 79:8
270:20 291:11	315:2	regards 73:7	relevance 133:12
320:21	referenced 233:12	regimen 232:13	relevant 14:19
recommendation	234:17 312:18	regnarus 1:13 4:4	16:21,25 20:3
102:1	329:6	4:5,6,7 5:7 6:9	66:1 69:19 71:19
recommendations	references 55:24	7:14,19,22 111:8	76:20
62:13 122:10	79:7 106:20	113:2 139:7,22	reliance 224:16
161:11 162:7	108:22 109:3,4,9	140:7,8 181:8	relied 12:24 13:3
178:24 296:11	168:19 256:8	188:21 289:8	70:24
recommended	referred 139:25	327:9 328:6 329:5	religion 25:24,25
143:8 282:20	199:3 224:21	330:2,24 331:2,4	27:25 28:1 31:9
recommends	referring 67:11	331:12	31:10,19,23 32:2,5
211:20	84:20 173:25	regression 155:15	32:17 44:6 49:17
record 6:2,7,24	176:11 180:23,25	regular 47:19,21	50:7 86:15 210:11
7:20 8:5 11:15,18	224:22,22 261:15	158:17,21 247:4	210:13
12:5 15:11 44:22	262:5 318:22	regularity 57:3	religious 24:21
49:22,24 50:8	refers 80:21	138:4	33:13 51:19
73:6 74:8,11,14	reflect 49:25 50:2	regulated 324:24	210:13 258:11,13
77:1 81:3 115:15	160:13	relate 51:16 53:15	258:20,21 259:2
128:23 129:1	reflected 23:20	54:12 70:13 95:25	remained 66:6
138:21 174:14,18	49:21 60:20 91:3	108:19	186:22
207:17 251:8,12	153:21 164:7	related 6:18 22:9	remains 111:22
289:3,6 294:24	165:5	41:7 44:14 45:3	186:16 276:7
295:1 327:11	reflecting 151:2	54:25 56:11 60:10	remarkable 170:8
recorded 6:9	214:3 269:22	60:25 67:2 69:23	remarkably 176:1
recording 6:5	reflective 100:23	71:7 72:7 73:25	176:13 177:2
	118:7 119:15	86:2 96:23 97:5	

[remember - resist] Page 50

remember 33:13	169:18 171:5,15	ronurnosing	138:6 140:24
35:22 40:4 63:22	172:6 175:19	repurposing 276:25	141:3,10 142:23
75:12 88:6,15	182:19 184:23		141.5,10 142.25
,	196:14 211:21	require 109:8	
105:21 109:8		251:18 273:1,7	166:11,21 167:25
133:7 136:1,8	220:23 225:5	required 185:19	168:3,5,13 175:16
142:10 143:10,13	228:16 229:14	228:7 288:19	180:14 185:1
144:19 198:17	230:1,20 231:7	331:13	198:13 199:24
214:5 305:2 310:5	236:8 239:11	requirement	200:9,23 204:21
remembered	243:5 262:3 275:4	225:17	210:9 211:23
134:24	275:21 287:19	research 10:8,12	219:6 228:14,23
remotely 6:23	297:6 298:11	10:18,21 16:24	228:23,23 230:21
render 286:9,24	299:1,2 303:21	17:10,19 18:10,11	231:14 236:11
rental 292:13	308:14 313:2	18:21 21:23,25	240:15 241:13
reorient 273:22	reported 1:25	22:2,10,15,16,19	253:3 255:10,11
repeat 37:20 46:18	80:17 122:5,8	25:21 27:18,20,21	256:4,19 258:3
65:15 72:4 159:22	164:14 266:9	28:5,13,22 38:4,11	284:23,25 285:1,4
190:21 265:13	305:24	38:14 39:16,18,21	291:16 297:3
repeated 123:3	reporter 5:9 6:17	40:5 41:11,12	301:8 304:10
301:10 302:18	7:9 8:4,6 44:24	42:2 44:2,3,13	305:6 306:5,15
repeatedly 240:8	59:5 219:17 328:4	45:3,7,9,10,12	307:21 308:1
repetitive 248:17	reporting 266:6	48:16 49:2 50:5	309:1,20,21,25
rephrase 228:13	reports 9:14 11:9	50:12,12,14,15,25	310:18,22 311:17
290:3 294:17	12:11,13,16,20	51:1,17,20,25 52:3	311:17,22,25
replicable 64:21	13:1,5 16:12,14	52:12,23,24 53:6	312:1 313:17,22
replicate 61:22	17:13,17 18:4	58:15,24 60:20	321:19 322:24
62:7,15 64:23	60:18 100:17	63:5 64:8,19 65:6	324:1
70:6	111:18 118:10	65:21 69:10 70:2	researched 207:9
replication 64:20	160:10 164:8	73:2,2 75:11,17,18	311:6
reply 7:16	195:9 216:6 236:4	75:24 76:11,16	researcher 47:1
report 4:4,5 10:12	242:1 286:7 307:8	77:10 78:24 79:3	researchers 38:23
10:13,15 11:23	represent 130:9	79:4 84:1,5,11	82:8 120:14 123:7
12:8 15:23 16:18	representative	85:11 89:1,2,7,23	124:12 160:5
16:22 18:25 34:2	45:23 46:15	90:2,12 91:2,10,12	195:10 197:21
65:18,22 76:10	115:21 118:17	92:4,8 99:9 107:1	208:7 228:4
102:1 105:18,22	123:8 149:1	109:12,15 110:8	253:12 257:19
111:16,17,19	represented 130:8	111:1,21 115:8	269:16 303:22
118:10 144:14,17	142:20	117:18 119:12,22	308:18
145:19 148:19	representing 6:18	120:8,12 124:25	researching
149:13 150:25	reproductive	127:24 130:1,2,3	308:23
151:9,16 165:5	216:9 279:2	131:10,15,20,22	resist 87:18
167:24 168:19		133:25 136:11	

[resolve - right] Page 51

resource 315:23 respect 107:1,14 109:12,15,17 123:21 323:3 107:24 108:4,8,11 326:12 respectd 194:19 respective 5:5 responde 115:23 responde 115:23 responde 115:23 288:19 310:12,24 143:5 268:15 82:7 102:6,7 111:16 116:2,20 132:21 329:3 181:12 144:21,44 144:21,24 118:12 144:21,24 148:11,12,24 49:22 responsibility 322:13 responsibile 160:25 291:23 restate 13:2 84:4 restrict 181:6 responde 189:2 180:15 291:23 restoom 289:1 restrict 181:6 restrict 88:16 resulted 149:22 158:3 revolved 192:5,24 richardson 2:4 3:4	1 206.14	270.24	1.4. 100.0	222 22 224 12
respect 107:1,14 review 10:3 13:7 revolved 192:5,24 230:5 231:21 109:12,15,17 42:11 90:13 91:14 7:1,2,18 11:12,19 232:8,25 233:11 326:12 12:41 144:5,6 41:15 44:18 45:2 251:3,614 254:10 respected 194:19 145:3,7,9,10 47:18 52:22 55:23 26:14 267:9,14 respond 145:23 241:12 284:16 61:4 63:12 65:10 273:18 274:22 responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 329:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:8 288:22,22 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 responsibility 49:23 50:15 60:6 103:14 104:24 riduculus 312:12 160:25 291:23 66:10,13,21,23,25 105:15 111:10 riduculus 312:12 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 <td< td=""><td>resolve 206:14</td><td>reverse 270:24</td><td>revolutions 128:2</td><td>223:22 224:12</td></td<>	resolve 206:14	reverse 270:24	revolutions 128:2	223:22 224:12
109:12,15,17				
193:10,12 194:24 232:14,25 93:1,17 107:24 108:48,11 12:1 15:2 23:2 25:36,14 254:10 326:12 145:37,9,10 47:18 52:22 55:23 265:14 267:9,14 respected 194:19 145:37,9,10 57:13 59:17 60:14 267:24 270:1,12 respond 145:23 241:12 284:16 61:4 63:12 65:10 273:18 274:22 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 329:7 70:12 71:3,14,23 282:15 286:10,15 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 reviewed 9:17 74:23 75:8 80:22 289:8 294:3,22 295:3 318:15 318:12 144:24 17:15 48:11,12,24 49:22 96:22 97:10 326:22 37:5 326:22 37:5 326:22 37:5 326:22 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:23 326:23 37:5 326:22 39:2			· · · · · · · · · · · · · · · · · · ·	
232:21 323:3 107:24 108:4,8,11 12:1 15:2 23:2 251:3,6,14 254:10 263:14 264:16 263:	, ,			·
326:12 124:14 144:5,6 41:15 44:18 45:2 263:14 264:16 respected 194:19 145:37,9,10 47:18 52:22 55:23 265:14 267:9,14 respond 145:23 241:12 284:16 57:13 59:17 60:14 267:24 270:1,12 responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 312:12 327:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 70:12 71:3,14,23 282:15 286:10,15 82:7 102:6,7 reviewed 9:17 70:12 71:3,14,23 282:15 286:10,15 111:6 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,724 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 49:23 50:15 60:6 60:10,13,21,23,25 66:61,10,13,21,23,25 70:12 71:7 72:7 714:11 110 rideculous 312:12 responsible 63:5 64:11 67:2 68:12,16 69:19,23 113:17,21,23 rideculous 312:12 restate 13:2 84:4 73:2,25 74:25 114:11 115:5,11 rife	*	, , ,	· · · · · · · · · · · · · · · · · · ·	
respected 194:19 145:3,7,9,10 47:18 52:22 55:23 265:14 267:9,14 respective 5:5 184:24 219:19 57:13 59:17 60:14 267:24 270:1,12 respond 145:23 241:12 284:16 61:4 63:12 65:10 273:18 274:22 responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 312:12 327:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 reviewed 9:17 74:23 75:8 80:22 289:8 294:3,22 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 32:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 restrict 18:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restrict 18:6 75:4 76:20 77:17 125:25		· ' '		· · ·
respective 5:5 184:24 219:19 57:13 59:17 60:14 267:24 270:1,12 respond 145:23 241:12 284:16 61:4 63:12 65:10 273:18 274:22 responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 329:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 responsibility 49:23 50:15 60:6 103:14 104:24 326:22 37:5 responsible 63:5 64:11 67:2 105:15 111:10 ridculous 312:12 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 rifts 217:6 restrict 181:6 75:4 76:20 77:17 128:7,12,15,18,21 rifts 211:10,19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 51:8 52:14,16 resu		· · · · · · · · · · · · · · · · · · ·		
respond 145:23 241:12 284:16 61:4 63:12 65:10 273:18 274:22 responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 329:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 reviewed 9:17 74:23 75:8 80:22 289:8 294:3,22 289:8 294:3,22 118:12 144:21,24 43:15,17,19,22.23 85:1 87:25 88:4 19:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 rifts 217:6 rest 32:917:7 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 121:10,19 rifts 217:6 restyle 7:3 result 122:7,9 78:16,23 80:17 129:3	_	· · · ·		·
responded 115:23 288:19 310:12,24 66:24 67:24 69:9 275:3,14 278:20 143:5 268:15 312:12 327:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 reviewed 9:17 74:23 75:8 80:22 289:8 294:3,22 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 restate 13:2 84:4 73:2,25 74:25 125:25 126:9 15:4 18:3 20:12 restrict 18:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12	-			′
143:5 268:15 312:12 327:7 70:12 71:3,14,23 282:15 286:10,15 response 75:9 76:8 329:7 70:12 71:3,14,23 282:15 286:10,15 82:7 102:6,7 reviewed 9:17 72:5,12 74:4,20,22 287:18 288:22,25 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:18 72:5 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 richardsond 2:7 responsibility 49:23 50:15 60:6 10:13,21,23,25 105:15 111:10 326:22 327:5 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 106:25 291:23 richardsond 2:7 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 116:12,17 119:18 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:23,12,15 128:7,12,15,18,21 20:12 27:1 28:3 20:12 27:1 28:3 result	_	241:12 284:16	61:4 63:12 65:10	273:18 274:22
response 75:9 76:8 329:7 72:5,12 74:4,20,22 287:18 288:22,25 82:7 102:6,7 reviewed 9:17 72:5,12 74:4,20,22 289:8 294:3,22 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,1224 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 7esponsible 63:5 64:11 67:2 105:15 111:10 ridiculous 312:12 160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 ridiculous 312:12 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 129:3,4 133:13 35:24 37:5 38:16 resulted 149:22 84:2,7,14 85:14<	responded 115:23	288:19 310:12,24	66:24 67:24 69:9	275:3,14 278:20
82:7 102:6,7 reviewed 9:17 74:23 75:8 80:22 289:8 294:3,22 111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:48,12 ridley 150:10 160:25 291:23 70:12 71:7 72:7 114:11 115:5,11 ridley 150:10 rest a 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 <td>143:5 268:15</td> <td>312:12 327:7</td> <td>70:12 71:3,14,23</td> <td>282:15 286:10,15</td>	143:5 268:15	312:12 327:7	70:12 71:3,14,23	282:15 286:10,15
111:16 116:2,20 13:22 42:25 43:11 80:25 81:8 84:21 295:3 318:15 118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:48,12 ridley 150:10 160:25 291:23 68:12,16 69:19,23 70:12 71:7 72:7 right 7:24 8:20,22 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 9:12 11:10,19 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8	response 75:9 76:8	329:7	72:5,12 74:4,20,22	287:18 288:22,25
118:12 144:21,24 43:15,17,19,22,23 85:1 87:25 88:4 319:6 321:3 325:8 144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 rifts 217:6 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restroom 289:1 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 results 62:7 17:10 219:11 174:6,20 180:11 51:8 52:14,16 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retaced 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewer 70:11 194:5 195:17	82:7 102:6,7	reviewed 9:17	74:23 75:8 80:22	289:8 294:3,22
144:24 172:15 48:11,12,24 49:22 96:22 97:10 326:22 327:5 responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 results 62:7 173:10 219:11 174:6,20 180:11 51:8 52:14,16 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retacted 8:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retrospectively reviewers 70:11 194:	111:16 116:2,20	13:22 42:25 43:11	80:25 81:8 84:21	295:3 318:15
responsibility 49:23 50:15 60:6 103:14 104:24 richardsond 2:7 322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 17	118:12 144:21,24	43:15,17,19,22,23	85:1 87:25 88:4	319:6 321:3 325:8
322:13 60:10,13,21,23,25 105:15 111:10 ridiculous 312:12 responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 9:12 11:10,19 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 resulted 149:22 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retacted 62:16 82:20 93:7,	144:24 172:15	48:11,12,24 49:22	96:22 97:10	326:22 327:5
responsible 63:5 64:11 67:2 112:4 113:4,8,12 ridley 150:10 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retrospectively reviews <td< td=""><td>responsibility</td><td>49:23 50:15 60:6</td><td>103:14 104:24</td><td>richardsond 2:7</td></td<>	responsibility	49:23 50:15 60:6	103:14 104:24	richardsond 2:7
160:25 291:23 68:12,16 69:19,23 113:17,21,23 rifts 217:6 rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retacted 82:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retrospectively reviews 70:11	322:13	60:10,13,21,23,25	105:15 111:10	ridiculous 312:12
rest 32:9 177:3 70:12 71:7 72:7 114:11 115:5,11 right 7:24 8:20,22 restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retracted 62:16 reviewing 94:3,11 194:5 195:17 92:2 93:6 96:3 retrospectively 93:1	responsible	63:5 64:11 67:2	112:4 113:4,8,12	ridley 150:10
restate 13:2 84:4 73:2,25 74:25 116:12,17 119:18 9:12 11:10,19 restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewer 70:11 194:5 195:17 100:16 104:7,11 21:2:2 93:12 146:4 198:1,3,6,8 199:1	160:25 291:23	68:12,16 69:19,23	113:17,21,23	rifts 217:6
restrict 181:6 75:4 76:20 77:17 125:25 126:9 15:4 18:3 20:12 restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 <	rest 32:9 177:3	70:12 71:7 72:7	114:11 115:5,11	right 7:24 8:20,22
restroom 289:1 77:24 78:2,3,12,15 128:7,12,15,18,21 20:12 27:1 28:3 result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retracted 62:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 79:18 205:17 207:12,18	restate 13:2 84:4	73:2,25 74:25	116:12,17 119:18	9:12 11:10,19
result 122:7,9 78:16,23 80:17 129:3,4 133:13 35:24 37:5 38:16 139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 189:19 191:18 92:2 93:6 96:3 retrospectively 70:11 93:12 146:4 198:1,3,6,8 199:12 100:16 104:7,11 212:2 93:12 146:4 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 <	restrict 181:6	75:4 76:20 77:17	125:25 126:9	15:4 18:3 20:12
139:22 162:8 81:6,22,25 83:23 138:17,23 158:3 42:16 43:12 45:19 resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	restroom 289:1	77:24 78:2,3,12,15	128:7,12,15,18,21	20:12 27:1 28:3
resulted 149:22 84:2,7,14 85:14 159:6,15 163:14 46:6 47:9 48:9 158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	result 122:7,9	78:16,23 80:17	129:3,4 133:13	35:24 37:5 38:16
158:5 174:3 90:21 92:5 93:8 165:9 167:7 173:6 51:8 52:14,16 results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	139:22 162:8	81:6,22,25 83:23	138:17,23 158:3	42:16 43:12 45:19
results 62:7 173:10 219:11 174:6,20 180:11 53:1 58:1 69:18 198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	resulted 149:22	84:2,7,14 85:14	159:6,15 163:14	46:6 47:9 48:9
198:10 221:5 241:6 181:9,14 182:8 72:1,17 73:22 retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	158:5 174:3	90:21 92:5 93:8	165:9 167:7 173:6	51:8 52:14,16
retained 327:10 reviewer 70:17 183:12 185:12 74:5,6,23 76:21 retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	results 62:7	173:10 219:11	174:6,20 180:11	53:1 58:1 69:18
retract 88:16 92:20 93:7,22 186:6,11 188:11 78:22 81:19 84:3 retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	198:10 221:5	241:6	181:9,14 182:8	72:1,17 73:22
retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	retained 327:10	reviewer 70:17	183:12 185:12	74:5,6,23 76:21
retracted 62:16 reviewers 108:2 188:17,22,25 85:6 91:22,23 66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	retract 88:16	92:20 93:7,22	186:6,11 188:11	· ·
66:4,5,15 reviewing 94:3,11 189:19 191:18 92:2 93:6 96:3 retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	retracted 62:16	reviewers 108:2	· ·	85:6 91:22,23
retrospectively reviews 70:11 194:5 195:17 100:16 104:7,11 212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	66:4,5,15	reviewing 94:3,11	' '	
212:2 93:12 146:4 198:1,3,6,8 199:12 106:2,10,13 107:2 return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	1 ' '			100:16 104:7,11
return 329:13,17 revised 58:22 199:22 201:23 107:6 109:24 reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	_			·
reuptake 273:21 59:18 205:17 207:12,18 116:2,3,14 117:24 revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	return 329:13,17		· · ·	, ,
revelations 253:23 revisit 170:19 210:2 217:23 119:6,7 122:1	·		205:17 207:12.18	116:2,3,14 117:24
	_			
				· ·
			,	, ,

[right - schedule] Page 52

127:24 128:16	277:23 279:6	328:14	samples 95:10
130:24 137:5	280:9,14 282:7	rodgerson 2:5	116:5,21 117:11
142:6 145:5 147:7	286:2 288:3 289:2	74:19	119:24 167:4
150:16,19 152:3	289:8,25 293:21	role 26:19 28:18	252:23 324:2,4,10
152:14,23 153:3	294:5 295:24	83:8 92:22 134:1	sampling 119:9
154:20 156:9	299:9,23 300:18	room 207:3	satisfied 162:19
157:3,12,13	300:24 301:21	roper 291:19	satisfy 190:2
158:19 160:17	302:24 303:19	rough 42:15	255:24
162:5 163:19	305:8 306:7 307:2	130:22	saturate 294:5
164:12 165:12,15	308:14,15,23,25	roughly 29:11	saturated 294:14
165:23 166:3,15	309:23 310:1,10	42:13 88:6 290:11	saw 129:20 140:18
167:6,9,25 168:7	311:6,9,21 312:19	290:12	154:3 303:13
168:11 169:2,8	314:23 316:19	rule 232:14 247:19	305:21
170:1,9 171:12	318:14,23 320:17	rules 5:10 8:2	saying 62:21 63:18
174:7,20,23 175:6	321:8 322:1,22	230:7,14 244:13	66:9 67:13,23
176:3,9 177:12	323:1 325:4,18	246:16 326:24	75:12,23 81:13
182:21 189:16	rights 36:12	327:3	87:23 96:13 99:7
192:16,20 193:17	130:15,18	run 21:21 23:8	105:8 117:20
194:2,6 196:16	rigid 99:8	27:20 52:18	118:14 144:10
199:22 200:3	rigor 223:16	177:22 247:5	157:9,22,25
203:3,10 206:9,11	rigorous 115:21	runs 313:23	164:19 169:17
210:16 211:18	194:11 198:11,15	rural 19:6	170:14 182:15
213:23 214:1,14	rigors 177:18	rush 104:22	192:17 200:12
218:3 220:4,15,23	rings 306:24 313:4	rushed 103:7	219:14 223:10,14
223:23 224:13	rise 301:22,23,24	ruth 146:15,23	227:4,14 249:9
225:5,15,16	risen 227:2	147:14,22	264:4 269:24
228:17 229:4	risk 103:8 104:1	rutledge 1:7 6:11	272:4 278:2,3
232:21 233:16,19	105:13 167:14	329:4 330:1 331:1	281:10 284:1
234:3,4,7,21	222:9 248:17	S	301:6 305:13
235:24 236:6,9,18	271:13 272:6		322:4,6 323:19
237:15 239:19	273:6,7,25 299:3	s 2:1 3:1 5:1,1	says 7:15 19:10
243:3 245:15,17	302:10,13 303:5	330:3	45:14 62:20
245:18,19 247:4	321:2	sad 321:5	139:21 169:18
249:2,5,16,20	risks 271:22 273:3	safe 259:9	172:6 198:9
250:12 251:7	273:11	sample 45:24	208:11 246:3
255:15 257:11	road 113:11	79:14 115:23	276:4 314:18
258:7,7,10 260:18	roback 321:23	117:3 118:17	319:1
262:23 264:1	322:2,8	119:14,14 122:9	scenario 54:15
265:16 271:16	robust 62:7	140:10,12,13	254:21
273:23,24 274:1	rock 1:15 2:10,15	148:25 215:7	schedule 194:12
274:12 276:11	2:19 5:8 6:16	224:24 244:4,5	

scholars 186:23	223:16 235:15	83:17 87:10,12	268:19,21 270:3
191:6 270:8	239:5 305:11	88:8 89:11,24	271:22 275:5,18
309:25	308:10	91:4 93:25 101:15	285:5,18 287:2
scholarship 60:6	scientist 122:16	104:21 112:14	318:6 324:21
60:10,25 63:5	204:17 252:25	115:19 116:7	seeks 261:6
67:2 69:20,23	scientists 171:19	122:7,8 126:14,15	seen 17:11,23 25:9
70:12 71:7 72:7	204:17	134:4 139:3,24	126:7 197:14
73:25 74:25 75:4	scope 133:12	149:16 152:20	236:8 241:2
134:22 135:2	scottsdale 130:1	153:21 157:22,24	244:15,18 245:7
school 19:4,5,5,6	scour 86:4 87:9	160:24 161:9,13	267:2 306:22,25
27:10 39:7,13	screening 225:10	166:23 167:10	307:7 308:2,20
49:15 72:22 152:3	225:11,14	169:14 177:12,19	326:13
246:9	scrutinized 312:5	179:14 182:22	sees 100:3 319:13
schools 267:1	scrutiny 148:15	191:5,23 192:2	segm 313:19,20
science 20:21	225:9 227:20	195:9 198:9,13	314:8,10 316:1,18
38:16 54:2 66:7	se 67:8 91:11	207:23 208:4,8	seldom 88:15
68:20,23,23 86:9	110:6,13,21	210:9,18 213:9	98:22
88:5 89:6 94:24	277:23	215:4,8,24 216:4	select 95:17
95:23 97:6 98:21	seal 328:18	230:3 232:6,23	selective 273:20
105:19,23,25	search 37:2	235:10 239:18	self 46:9,13 98:4
106:2,9,10,12,15	searchable 68:18	240:14 241:7	140:9 150:16
106:17,18,19,21	searching 323:25	243:9 245:10	151:13 152:14
106:22 107:13	second 26:5 34:9	254:1,21 255:6	217:9 228:2
108:18,20 109:5	59:11 139:21	256:12 260:8	260:16 261:1
109:23 110:1,2	165:25 169:3	270:1 272:7	266:4,23
111:3,4 120:15	174:3 191:22	278:12 280:6	selfhood 150:6
121:11,15 125:10	208:5,9 255:9	282:16 293:5	sell 23:6
127:14 136:23	271:23 294:21	298:6 300:8	semesters 29:9
160:22,23 170:24	313:18	302:12,13 307:9	seminar 22:13
171:16 174:23	section 32:6 51:20	307:25 308:4	29:10 50:22 53:22
176:10 182:14	153:4 154:20	311:15 315:13	55:5,16 56:1
197:15 235:22,24	155:25 177:3	316:4 318:11,17	seminars 23:8,18
238:23 270:16,20	sectional 252:23	320:13 326:18	senate 112:13
312:7 327:1	sections 28:22	seeing 69:15,15	send 69:12 78:7,12
sciences 111:5	50:21 284:18	89:9 164:3 268:6	93:18
121:8	secularism 86:25	seek 58:10 87:18	sends 18:22
scientific 106:3	87:4,7,15,17	184:25 267:14,15	senior 20:16 21:6
115:9 119:3	see 11:21 13:17	285:10 304:20	21:11,15 24:10
121:14 122:17	18:9 21:22 29:21	seeking 33:20	25:3,20 138:2
142:21 204:2,21	46:1,2 68:10	115:2 265:9,24,25	sensations 237:13
204:22,24 221:10	77:22 80:9 83:17	266:13 267:19	

[sense - significant] Page 54

22.7.24.24	. 50.10	62.21.22.61.4.0	227.24.225.10
sense 22:7 24:24	services 79:18	63:21,22 64:4,9	225:24 226:10
33:22 73:18 97:18	80:11 243:18	79:9 100:18 123:1	shown 221:5
153:22 216:18	245:24	131:11 134:3	shows 83:20 95:2
234:13,15 235:25	serving 35:3	148:17 217:7,13	122:2 212:18
251:21 260:9	set 17:9 83:11	237:10,13 260:4	214:17,22
278:5 283:2	189:3,12 291:1,4	sexuality 23:7	sic 160:15 187:14
292:15 315:21	315:9 317:4	33:23 44:5 50:6	250:2 262:13
316:5	328:17	83:15 93:15,15	sickness 207:5
sensitive 6:3 122:9	sets 52:12 126:23	147:3,11 250:3	side 9:15 131:18
229:20	setting 57:5,8	shape 17:14,16	151:13 163:24
sent 138:11 329:14	66:17 321:19	share 24:19 87:6	164:5,25 226:6,8
sentence 139:21	settings 148:24	98:25 134:9	291:24 300:13
149:18 191:24	settled 143:17	232:12 258:23	307:9,13
198:9 208:5,11	145:2	259:22 261:6,6	sided 314:20
276:4 287:22	seven 194:8	shared 238:20	sign 117:6 171:14
separate 166:4	seventy 176:7	sharing 88:22	283:21 285:14
221:8,13 239:7	sever 325:25	she'll 319:2	305:11 326:8
240:4 258:4 294:5	severe 299:8 301:1	sheet 3:6 329:11	327:7 328:9
separately 323:21	301:1,2	shelved 206:11	329:12
separating 272:5	severing 279:1	shifting 115:6	signal 80:4,4
september 143:7	severity 286:19	shop 83:7	124:15 161:7
144:19 146:3	sex 24:5,13 34:18	short 29:21 197:11	270:9 294:13
sequence 122:11	73:3 98:5 106:23	240:12 254:17	321:2
300:4	107:4,17 108:13	262:10 299:13	signaled 230:1
sequester 99:10	110:16 125:22	shorthand 5:9	signaling 228:5
series 33:14 82:7,7	134:4 140:14	328:4,10	signals 159:23
117:8 124:5	147:25 149:4	shortly 292:7	166:7 239:24
serious 139:8	163:5 227:12	show 4:10 21:21	240:16
286:22 302:10	235:10 237:13	61:20 76:23 81:11	signature 25:5
seriously 299:12	238:4 259:21,24	96:2 153:11 179:3	28:23 328:23
serotonin 273:20	260:3,3,5,7,12,17	208:12,24 213:15	signed 171:16
serve 82:22 92:20	260:20,21 261:3,7	224:1,18,19 284:1	329:20
135:12,21 136:2	261:17 262:6,16	321:23,24	significance 39:3
137:11,21 316:3	263:23,25 264:13	showed 212:20	190:11 286:20
served 30:14	269:23 278:25	showing 161:15	significant 14:15
34:24	279:2 294:7,9,12	162:12 210:5	80:7 103:2,3,8,11
serves 243:11	294:15 325:17	212:11,16 213:12	104:1,14 105:10
service 144:7	sexed 97:20	213:20 215:11,18	105:13 111:20
265:7,11,16	294:11	216:1,4 218:19,21	122:11 155:22
278:10,14	sexual 44:4 49:18	219:3 220:2,12	202:5 221:6
,	50:6 61:14 62:5	221:16 222:4,22	237:19 240:17
		<u> </u>	

[significant - sorry] Page 55

	I	I	I
248:24 277:19,25	size 80:5 121:23	317:24 321:18	111:1 120:9 127:9
278:23 286:22	121:23 122:9,12	socialism 32:1	127:25 128:2
289:25 321:2	170:7	socialization	144:14 210:10
significantly 18:6	sizes 39:3 76:14	149:20 152:2	309:14 312:21
237:25 238:7	156:12 167:4,11	socially 75:13,20	solely 74:25
signs 326:18	177:8	133:6	190:19,22
silencing 314:20	skeptical 100:3	societies 187:1	solicited 118:5
similar 82:9	skewed 126:18	314:18	solid 324:1
101:18 117:13,17	skim 77:14	society 101:9	solitary 102:6,7
127:1 176:22	skocpol 127:25	103:19 218:2	solutions 329:23
307:1 316:21	slowly 69:22	236:4 295:11	solve 319:14
simmons 291:19	181:21 190:21	313:10 315:3,6	solved 40:5
simpler 325:9	318:14	society's 102:15	somebody 29:25
simultaneous	small 80:4,7 95:9	245:8	62:24 64:25 72:24
50:16 52:2 69:2	122:12 148:25	sociological 106:8	83:16 100:17
102:10 112:18	170:10 190:13	109:23	131:4 156:15
136:19 174:12	315:9	sociologically	167:17 217:25
187:18,21 191:10	small'ish 29:3	106:6	260:6 261:7
201:14 219:15	smaller 204:19	sociologist 27:24	279:15 286:24
221:21 233:24	227:8 315:9 316:8	58:15 103:17	289:20,22 290:5
237:17 292:18	smartly 302:1	117:1 118:25	292:1 313:15,18
single 143:4,5	smoking 64:16	119:23 122:21	317:24 325:4,5
153:24 183:14,16	292:7	150:9 290:19	somebody's 64:16
266:6	snao 82:25	299:24	somewhat 154:16
sir 70:18 149:16	snyder 4:15 34:13	sociologists 116:6	155:13 168:16
sit 171:24	115:17 171:10	116:22 117:20	304:19 305:12
sitting 121:18	social 20:21 29:5	118:19,22 119:16	325:3
situation 100:15	38:15 51:4,18	120:18 121:5	soon 326:6
163:21 164:10,17	53:6 54:2,5 55:7	sociology 19:7,9	sooner 27:22
164:18 168:13	58:6,17 63:24	19:18,19 20:7	sorry 22:15 34:14
180:8 182:11,11	66:7 68:20,23	28:1 31:8,10,19,23	44:25 50:24 51:6
182:16 195:11	72:18 87:19 98:21	32:2,5 37:5 44:6	51:8 53:20 55:17
206:7 211:8 234:5	106:5,19,21,22	49:17 50:7,20,23	56:21 59:6,7
252:21 269:13	107:12 111:3,4	51:21 53:3,9 54:5	61:12,25 63:13
situations 113:20	121:7 122:16	105:18,24 106:2,6	79:10 96:4 101:11
169:9 229:12	125:10 128:1,3	106:7,7,10,12,15	102:11 134:16
six 30:25 144:4,5	160:22,22 252:25	106:16 108:18	139:19 154:21
145:13 186:21	262:15 263:6	109:1,12,15,20,21	157:4 171:2 173:6
191:23 327:10	290:16 291:12	109:22 110:1,5,5,6	173:16 186:13
sixty 298:16	300:6 307:1,13	110:6,7,10,13,20	198:3 206:23
	311:17 312:1	110:21,23,24	210:12 212:4

[sorry - standard] Page 56

210 7 200 1	405 40 400		101 TY 10-1-
218:5 238:6	197:19 198:22	sorts 46:24 56:8	specifically 135:19
258:19 270:25	206:6 210:8,13,17	107:7,9 183:11	136:1
271:23 292:19	212:25 217:6,8,11	248:10,10 252:19	specify 183:22
294:19 321:13	217:16 220:7,25	284:24 292:6	spectrum 268:19
sort 9:22 17:8	223:13 224:23	sought 162:1	speculate 166:5
21:11,13 24:6	227:9,24 228:2,21	186:17 279:24	227:18,19 292:25
25:14 26:9 28:8	229:11 231:13	280:16	speculating
28:25 30:17 32:5	233:18 237:10	sound 8:1,20	206:18
35:11 37:2 38:5	239:25 240:3,8,11	35:24 74:6 129:19	speculation
38:12,18 39:16	240:14 242:2	130:24 132:6	161:19 163:12
40:3 41:10 54:15	243:20,25 245:8	307:23	180:7 202:10
55:25 57:18 60:19	246:10 247:6	sounded 246:10	229:10 230:16
61:9 62:13,17	248:4,22 250:2,19	sounds 36:11	232:5,19 245:6
67:4,5 71:25	252:10,15 254:2	86:12 114:4	247:15
72:20 73:13 76:5	257:20 259:11	131:25 148:23	speculative 176:9
83:3,3 86:4 87:21	260:14,15 261:13	163:15 170:14	speed 113:5,8,11
88:24 90:21 98:16	261:15 262:5,12	183:18 245:23	113:19
98:22 100:13	262:14,15,23	248:3 280:12	spend 30:12
104:17,18 106:1,2	263:2 264:23	283:25 285:9	spending 272:3
106:11,24 107:12	265:17 266:22	288:2 291:16	spilled 204:11
110:7,15 113:20	268:6 269:21,22	307:22 322:1	spirit 211:21
114:18,19 117:10	272:12,17 273:22	323:14	spoke 136:10
117:18 119:9	274:17 275:7	source 64:2 207:6	141:6 240:22,24
120:17 121:25	276:12 277:2,23	275:11	spoken 10:6 241:1
122:3 123:16	278:6,9,17 279:23	sources 307:20	318:5
124:2,9 126:16,24	282:3 283:21,22	311:11	spring 28:21
131:9 143:3	286:19 288:8,16	space 26:6 253:2	squarely 27:25
145:15 146:10	289:14 290:8,15	255:6 308:12	31:8,18 32:2
147:13,21 150:13	291:4,11,22	span 110:10	61:10
150:15,15 151:5,8	292:11 293:2	309:11	ssris 274:9
151:25 152:3	297:10 299:4	speak 8:3 147:17	staff 24:11 26:17
154:3,4,8 160:8	300:15 301:9	147:17	stage 19:3 169:10
161:8 166:4 167:5	302:5 305:1,25	speaking 90:18	stall 249:23
168:6 170:2	306:5 307:2 308:4	192:20 218:1	stand 12:10 16:8
171:13,19 172:20	308:17 310:19,21	223:11 240:5	18:25 259:12
175:9 176:18	311:12 312:4,8,11	special 29:1	standard 102:16
177:8,8 178:17	315:10,14 316:6,8	specific 93:20 94:6	104:18 169:1,13
180:2 181:21	318:22 322:23	98:22 109:4	169:15 194:15
183:8,9 189:22	325:2,25,25	114:10 143:10	211:18,20 222:11
190:4,11 194:13	326:12	179:1 245:15	265:1 296:7 324:6
195:24 196:8			

[standards - studies] Page 57

standards 58:23 182:15 189:15 status 172:12,15 status 172:12,15 stretches 113:11 58:24 59:18,19,19 198:17 200:23 216:21 230:20 stay 238:11 strict 240:2 strict 240:2 188:18,24,25 269:4 270:16 steer 274:13 strict 240:2 strictity 26:22 190:17 227:20,23 324:24 328:5,25 state 103:16 steer 274:13 stringent 239:16 245:9,11,13 230:6,14 244:13 3tated 103:16 105:7 252:1 sterilization stronge 122:8 298:11 295:11 298:17,22 215:10 288:10,17 steven 129:14,16 strongly 180:12 298:3,7 87:9 116:25 117:2 ster 12:13 ster 12:14,16 structural 61:21 177:19 210:17 219:25 223:23 63:18 64:4,5,15 structural 61:21 265:22 266:14 332:15 324:12 70:2 107:20 136:15,25 307:7 statements 12:10 16:8 114:22 136:15,25 structural 61:21 230:12 282:19 36:16 111:6 113:9 staped 14:20:1 34:9 101:11 31:4,13 296:25 116:12 147:13,20 states 16:10 32:12 13:04		100 15 100 15		
101:10,14 103:2 216:21 230:20 251:24 268:15 188:18,24,25 269:4 270:16 189:35,55,12 290:9 320:14 324:24 328:5,25 124:17 127:15,16 161:13 259:5 124:17 127:15,16 161:13 259:5 124:17 127:15,16 161:13 259:5 124:17 127:15,16 161:13 259:5 128:17,22 17:20 288:10,17 17:19 210:17 27:25 21:1 266:22 235:10 258:25 277:11 326:22 235:10 258:25 277:11 326:22 235:10 258:25 277:11 326:22 235:10 258:25 277:11 307:7 258:25 237:31 230:12 282:19 133:10 114:22 130:17 235:19 133:10 118:9 123:9 125:5 149:17 210:18 128:1 141:1 231:17 235:19 173:22 226:17 231:12 335:19 173:22 226:17 239:13 306:2,3 329:12 329:18 326:4,18 256:23,24 264:22 208:7 296:15 315:16 136:15,25 136:10 38:19 223 31:27 329:25 29:29 236:14 38:10 38:19 223 31:10 282:25 34:19,22 36:14 14:16 136:15 38:10 38:19 223 31:10 38:14 14:16 136:15 1	standards 58:23	182:15 189:15	status 112:12,15	stretches 113:11
120:8 162:6,19 188:18,24,25 269:4 270:16 290:9 320:14 329:15 324:24 328:5,25 329:22,24,25 329:22,24,25 state's 129:13 stated 103:16 105:7 252:1 statement 12:13 298:3,7 stands 33:13 start 69:22 129:14 177:19 210:17 231:25 235:10 258:25 277:11 265:22 266:14 322:15 324:12 statement 12:10 235:16:12 330:12 282:19 statement 12:10 states 1:1 6:12 stipulated 5:4 stipulated 5:3 stipulated 41:16 49:5 states 1:16:12 stipulated 5:4 stipulated 5:4 stipulated 5:4 stipulated 5:3 stipulated 5:4 stipulated 5:3 stipulated 5:3 stipulated 5:4	, ,		·	
188:18,24,25 269:4 270:16 steer 274:13 striking 154:16 189:3,5,5,12 290:9 320:14 324:24 328:5,25 steer 274:13 striking 154:16 190:17 227:20,23 324:24 328:5,25 statef 103:16 161:13 259:5 strong 65:7 155:23 229:22,24,25 stated 103:16 105:7 252:1 stepping 48:8 strongly 180:12 245:9,11,13 293:11 297:23 288:3,7 87:9 116:25 117:2 288:10,17 struck 123:6 298:3,7 87:9 116:25 117:2 stick 27:8 53:6 struck 27:8 53:6 structural 61:21 301:7 219:25 223:23 63:18 64:4,5,15 107:9 2107:20 136:15,25 245:22 235:10 229:25 223:23 63:18 64:4,5,15 107:9 2107:20 136:15,25 307:7 statements 12:10 16:8 114:22 136:16 113:6132; structural 61:21 307:7 statements 12:10 16:8 14:42 stigma's 62:4 structural 61:21 301:1 282:19 16:6 111:6 113:9 stigma's 62:4 structural 61:21 301:1 30:17 states 1:1 6:12 stigma's 62:4 structural 61:21 30	· ·			
189:3,5,5,12 190:9 320:14 324:24 328:5,25 state's 129:13 state's 129:13 state's 129:13 230:6,14 244:13 245:9,11,13 293:11 295:11 statement 12:13 293:14,16 stick 27:8 53:6 62:4,20 63:18 start 69:22 129:14 208:17,22 215:10 219:25 223:23 232:15 324:12 started 49:14 80:9 96:25 116:12 147:13,20 states 1:1 6:12 330:12 282:19 36:16 111:6 113:9 starting 27:13 113:10 114:23 97:13 131:10 118:9 123:9 125:5 149:17 210:18 128:1 141:1 231:17 235:19 173:22 226:17 299:25 292:9 298:18 326:4,18 265:6 266:20,25 299:15 315:16 stright 49:14 20:17 299:25 292:9 299:25 292:9 299:25 292:9 299:25 292:9 299:25 292:9 299:25 292:9 299:25 34:19,22 40:24 102:17 85:23 120:3,5 105:4 114:16 120:15 121:12 statisticians 40:4 statistics 10:9 38:5 strength 230:16 33:15 52:4 stringib 22:13 5trength 230:16 220:18 strongge 122:15 strongge 122:8 strongge 123:6 239:16 38:10 249:10 213:10 249:10 210:10 210:20 210:20 210:10 210:20 210:10 210:20 210:10 210:20 220:12 210:10 210:20 220:12 210:10 210:20 220:12 210:10 210:20 220:12 210:10 210:20 220:12 210:10 220:12 220:12 210:10 220:12 220:	· ·			
190:17 227:20,23 324:24 328:5,25 124:17 127:15,16 161:13 259:5 stronger 122:8 s	· · ·			
229:22,24,25 state's 129:13 stateying 48:8 stronger 122:8 230:6,14 244:13 stated 103:16 stepping 48:8 strongly 180:12 245:9,11,13 105:7 252:1 sterilization 28:10,17 293:11 295:11 296:11,12 297:23 12:17,21 71:20 steven 129:14,16 struck 123:6 298:3,7 87:9 116:25 117:2 steven 129:14,16 struck 27:8 53:6 structural 61:21 298:3,7 87:9 116:25 117:2 stick 27:8 53:6 structural 61:21 3tart 69:22 129:14 208:17,22 215:10 219:25 223:23 63:18 64:4,5,15 70:2 107:20 136:15,25 231:25 235:10 258:25 277:11 108:16 134:7 136:15,25 structural 38:8 140:3 307:7 statements 12:10 108:16 134:7 136:15,25 structural 38:8 140:3 96:25 116:12 147:13,20 statements 12:10 108:16 134:7 students 21:5 students 21:5 149:17 210:18 13:10 114:23 164:16 185:19 30:18 3:1,1,1,13 30:18 3:1,1,1,13 30:18 3:1,1,1,13 30:18 3:1,1,1,13 30:18 3:1,1,1,13 30:18 3:1,1,1,13	1 ' ' '		_	
230:6,14 244:13 stated 103:16 stepping 48:8 strongly 180:12 245:9,11,13 293:11 295:11 statement 12:13 288:10,17 269:16 298:3,7 87:9 116:25 117:2 steven 129:14,16 struck 213:6 298:3,7 87:9 116:25 117:2 steven 129:14,16 structural 61:21 177:19 210:17 219:25 223:23 63:18 64:4,5,15 70:2 107:20 136:15,25 230:22 266:14 32:215 324:12 108:16 134:7 structural 61:21 265:22 266:14 32:215 324:12 136:15,25 structure 138:8 307:7 statements 12:10 statements 12:10 123:5 130:17 states 11:6:12 136:15,25 structure 138:8 123:5 130:17 states 11:6:12 stipulated 5:4 students 21:5 97:13 13:1:0 118:9 123:9 125:5 128:1 141:1 164:16 185:19 32:16 33:15 52:4 298:18 326:4,18 256:23,24 264:22 320:22 stoped	′	1	· · · · · · · · · · · · · · · · · · ·	_
245:9;11,13 105:7 252:1 sterilization 288:10,17 struck 123:6 269:16 298:3;7 87:9 116:25 117:2 steven 129:14,16 structural 61:21	229:22,24,25	state's 129:13	161:13 259:5	stronger 122:8
293:11 295:11 statement 12:13 288:10,17 269:16 structural 61:21 298:3,7 87:9 116:25 117:2 steven 129:14,16 stick 27:8 53:6 62:4,20 63:18 start 69:22 129:14 208:17,22 215:10 61:11,21 62:20 63:18 64:4,5,15 107:9,20 108:16 231:25 235:10 258:25 277:11 70:2 107:20 140:3 structure 138:8 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 statements 12:10 16:8 114:22 108:16 134:7 struggle 206:7 307:7 statements 12:10 16:8 114:22 136:15,25 strugle 206:7 307:7 states 1:1 6:12 36:16 111:6 113:9 stigulated 5:4 students 21:5 96:25 116:12 147:13,20 stipulated 5:4 students 21:5 26:19 29:15 30:17 30:18 31:1,11,13 31:4,15,16 32:7 30:18 31:1,11,13 31:4,15,16 32:7 30:18 31:1,11,13 31:4,15,16 32:7 30:18 31:1,11,13 32:14 22:3	230:6,14 244:13	stated 103:16	stepping 48:8	
296:11,12 297:23 298:3,7 12:17,21 71:20 87:9 116:25 117:2 steven 129:14,16 stick 27:8 53:6 stigma 54:19 structural 61:21 62:4,20 63:18 stands 33:13 start 69:22 129:14 177:19 210:17 231:25 235:10 258:25 277:11 225:25 235:10 258:25 277:11 30:77 307:7 219:25 223:23 23:23 63:18 64:4,5,15 70:2 107:20 136:15,25 structure 138:8 140:3 structure 138:8 140:5 structure 138:8 107:9,20 108:16 136:15,25 structure 138:8 140:3 structure 138:8 140:15 140:30 structure 138:8 140:3 structure 138:8 140:3 structure 138:8 140:5 structure 138:8 107:9,20 108:16 136:15,25 structure 138:8 140:5 103:14,5,15 3:6 structure 138:8 140:3 structure 138:8 140:3 structure 138:8 140:3 structure 138:8 140:3 structure 138:8 140:5 103:14,5,15 3:6 structure 138:8 140:3 140:3 structure 138:8 140:5 103:14,5,15 3:6 structure 138:8 140:5 103:14,5,15 3:4 140:3 140:3 structure 138:8 140:5 103:14,5,15 3:6 structure 138:8 140:5 103:14,5,15 3:4 140:3 140:3 structure 138:8 140:5 140:3 140	245:9,11,13	105:7 252:1	sterilization	struck 123:6
298:3,7 87:9 116:25 117:2 stick 27:8 53:6 62:4,20 63:18 stands 33:13 157:1 183:1 stigma 54:19 62:4,20 63:18 177:19 210:17 219:25 223:23 63:18 64:4,5,15 36:15,25 231:25 235:10 258:25 277:11 70:2 107:20 140:3 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 statements 12:10 16:8 114:22 stigma's 62:4 struggle 206:7 96:25 116:12 147:13,20 stimulated 142:21 students 21:5 students 21:5 123:5 130:17 states 1:1 6:12 stimulated 5:4 stop 34:9 10:11 31:14,15,16 32:7 297:13 131:10 118:9 123:9 125:5 166:8 206:4,15 32:16 33:15 52:4 297:13 131:10 118:9 123:9 125:5 186:8 206:4,15 32:16 33:15 52:4 298:18 326:4,18 256:23,24 264:22 290:13 306:2,3 32:12,12 312:4 studied 41:16 49:5 298:18 326:4,18 statistic 80:3 statistic 80:3 straight 28:18 staight 28:18 studies 38:8 61:20 8tate 5:9 6:21,23 38:13,17,18 39:1,3 38:13,17,18 39:1,3	293:11 295:11	statement 12:13	288:10,17	269:16
stands 33:13 157:1 183:1 stigma 54:19 107:9,20 108:16 start 69:22 129:14 208:17,22 215:10 61:11,21 62:20 136:15,25 177:19 210:17 219:25 223:23 63:18 64:4,5,15 structure 138:8 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 statements 12:10 16:8 114:22 stigma's 62:4 structure 138:8 96:25 116:12 147:13,20 states 1:16:12 stigma's 62:4 struggle 206:7 123:5 130:17 states 1:16:12 stigma's 62:4 struggles 134:7 123:15:130:17 states 1:13:10 114:23 113:10 114:23 </td <td>296:11,12 297:23</td> <td>12:17,21 71:20</td> <td>steven 129:14,16</td> <td>structural 61:21</td>	296:11,12 297:23	12:17,21 71:20	steven 129:14,16	structural 61:21
start 69:22 129:14 208:17,22 215:10 61:11,21 62:20 136:15,25 177:19 210:17 219:25 223:23 63:18 64:4,5,15 structure 138:8 231:25 235:10 258:25 277:11 70:2 107:20 140:3 structure 138:8 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 struggle 206:7 307:7 statements 12:10 136:15,25 struggle 206:7 96:25 116:12 147:13,20 stigma's 62:4 students 21:5 123:5 130:17 states 1:6:12 stipulated 142:21 26:19 29:15 30:17 230:12 282:19 36:16 111:6 113:9 stipulated 5:4 30:18 31:14,15,16 32:7 349:17 210:18 118:9 123:9 125:5 186:8 206:4,15 32:16 33:15 52:4 231:17 235:19 173:22 226:17 290:13 306:2,3 32:12,12 312:4 298:18 326:4,18 265:6 266:20,25 32:12,12 312:4 studied 41:16 49:5 290:25 292:9 290:25 292:9 32:12,12 312:4 32:12,13 32:4 32:12:13 14:4<	298:3,7	87:9 116:25 117:2	stick 27:8 53:6	62:4,20 63:18
177:19 210:17 219:25 223:23 63:18 64:4,5,15 structure 138:8 231:25 235:10 258:25 277:11 70:2 107:20 140:3 140:3 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 statements 12:10 136:15,25 struggles 134:7 started 49:14 80:9 16:8 114:22 stigma's 62:4 students 21:5 96:25 116:12 147:13,20 states 1:1 6:12 stigma's 62:4 students 21:5 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 30:18 31:1,11,13 31:14,15,16 32:7 30:18 31:1,11,13 31:14,15,16 32:7 32:16 33:15 52:4 53:3,9 54:8,21 32:16 33:15 52:4 53:3,9 54:8,21 53:3,9 54:8,21 32:12 22 26:17 290:13 306:2,3 32:0:22 32:12 22 23:12 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:13,17,18 39:1,3 32:13,17,18 39:1,3 32:12,12 312:4	stands 33:13	157:1 183:1	stigma 54:19	107:9,20 108:16
231:25 235:10 258:25 277:11 70:2 107:20 140:3 265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 statements 12:10 136:15,25 struggle 206:7 started 49:14 80:9 16:8 114:22 stigma's 62:4 students 21:5 96:25 116:12 147:13,20 stimulated 142:21 students 21:5 123:5 130:17 states 1:1 6:12 stipulated 5:4 students 21:5 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 32:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 298:18 326:4,18 265:6 23,24 264:22 32:12,12 312:4 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight of 21:3 straight of 21:3 167:11 179:24,25 40:24 102:17 85:23 120:3,5 str	start 69:22 129:14	208:17,22 215:10	61:11,21 62:20	136:15,25
265:22 266:14 322:15 324:12 108:16 134:7 struggle 206:7 307:7 started 49:14 80:9 16:8 114:22 stigma's 62:4 students 12:5 96:25 116:12 147:13,20 stimulated 142:21 26:19 29:15 30:17 123:5 130:17 states 1:1 6:12 stipulated 5:4 30:18 31:1,11,13 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 studies 38:8 61:20 30:7 state 5:9 6:21,23 5tatistic 80:3 straight own 68:13 92:25 109:9 state 5:9 6:21,23 523 120:3,5 512:12	177:19 210:17	219:25 223:23	63:18 64:4,5,15	structure 138:8
307:7 statements 12:10 136:15,25 struggles 134:7 started 49:14 80:9 16:8 114:22 stigma's 62:4 students 21:5 96:25 116:12 147:13,20 states 1:1 6:12 stimulated 142:21 26:19 29:15 30:17 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 290:13 306:2,3 32:12,12 312:4 studied 41:16 49:5 208:7 296:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 8tate 5:9 6:21,23 statistical 38:10 straightforward 167:11 179:24,25 17:	231:25 235:10	258:25 277:11	70:2 107:20	140:3
started 49:14 80:9 16:8 114:22 stigma's 62:4 students 21:5 96:25 116:12 147:13,20 stimulated 142:21 26:19 29:15 30:17 123:5 130:17 states 1:1 6:12 stipulated 5:4 30:18 31:1,11,13 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 290:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistical 38:10 32:12,12 312:4 studies 38:8 61:20 28:25 34:19,22 38:13,17,18 39:1,3 straightforward 180:3,15 20:6 210:15,17,21 211:3 21:16	265:22 266:14	322:15 324:12	108:16 134:7	struggle 206:7
96:25 116:12 147:13,20 stimulated 142:21 26:19 29:15 30:17 123:5 130:17 states 1:1 6:12 stipulated 5:4 30:18 31:1,11,13 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 32:16 33:15 52:4 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 167:11 179:24,25 30:18 31:1,11,13 31:14,15,16 32:7 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4 32:12,12 312:4	307:7	statements 12:10	136:15,25	struggles 134:7
96:25 116:12 147:13,20 stimulated 142:21 26:19 29:15 30:17 123:5 130:17 states 1:1 6:12 stipulated 5:4 30:18 31:1,11,13 230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 32:0:22 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 statistic 80:3 straight 281:18 straight 281:18 167:11 179:24,25 32:25 34:19,22 85:23 120:3,5 strangio 2:13 7:5,5 21:3 21:6 21:3 21:6 40:24 1	started 49:14 80:9	16:8 114:22	stigma's 62:4	students 21:5
230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight Coward 180:3,15 205:6 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 211:3 212:16 213:12,15 215:4 40:24 102:17 85:23 120:3,5 street 25,14,18 213:12,15 215:4 213:12,15 215:4 213:12,15 215:4 213:12,15 215:4 213:12	96:25 116:12	147:13,20	•	26:19 29:15 30:17
230:12 282:19 36:16 111:6 113:9 stop 34:9 101:11 31:14,15,16 32:7 starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 38:19 52:19 stretch 122:19	123:5 130:17	states 1:1 6:12	stipulated 5:4	30:18 31:1,11,13
starting 27:13 113:10 114:23 164:16 185:19 32:16 33:15 52:4 97:13 131:10 118:9 123:9 125:5 186:8 206:4,15 53:3,9 54:8,21 149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 studied 41:16 49:5 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistical 38:10 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 38:13,17,18 39:1,3 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19	230:12 282:19	36:16 111:6 113:9	stop 34:9 101:11	31:14,15,16 32:7
149:17 210:18 128:1 141:1 279:24 289:19 82:22 321:12 231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 127:10 147:4 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 statistical 38:10 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224	starting 27:13	113:10 114:23		32:16 33:15 52:4
231:17 235:19 173:22 226:17 290:13 306:2,3 studied 41:16 49:5 249:22 278:18 256:23,24 264:22 320:22 127:10 147:4 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 statistical 38:10 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	97:13 131:10	118:9 123:9 125:5	186:8 206:4,15	53:3,9 54:8,21
249:22 278:18 256:23,24 264:22 320:22 127:10 147:4 298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 statistical 38:10 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	149:17 210:18	128:1 141:1	279:24 289:19	82:22 321:12
298:18 326:4,18 265:6 266:20,25 stopped 17:23 184:4 starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 statistical 38:10 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 202:21 267:3 224:15,18,19,20	231:17 235:19	173:22 226:17	290:13 306:2,3	studied 41:16 49:5
starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 38:13,17,18 39:1,3 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 straightforward 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	249:22 278:18	256:23,24 264:22	320:22	127:10 147:4
starts 96:20,21 290:25 292:9 32:12,12 312:4 studies 38:8 61:20 208:7 296:15 315:16 story 134:9 324:10 68:13 92:25 109:9 state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 38:13,17,18 39:1,3 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 straightforward 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	298:18 326:4,18	265:6 266:20,25	stopped 17:23	184:4
state 5:9 6:21,23 statistic 80:3 straight 281:18 167:11 179:24,25 7:20 11:1,6 28:24 statistical 38:10 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20				studies 38:8 61:20
7:20 11:1,6 28:24 statistical 38:10 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	208:7	296:15 315:16	story 134:9 324:10	68:13 92:25 109:9
7:20 11:1,6 28:24 statistical 38:10 straightforward 180:3,15 205:6 28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	state 5:9 6:21,23	statistic 80:3	straight 281:18	167:11 179:24,25
28:25 34:19,22 38:13,17,18 39:1,3 218:4 210:15,17,21 40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	· · · · · · · · · · · · · · · · · · ·			,
40:24 102:17 85:23 120:3,5 strangio 2:13 7:5,5 211:3 212:16 105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	1			,
105:4 114:16 127:1 222:11 street 2:5,14,18 213:12,15 215:4 120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20	· · · · · · · · · · · · · · · · · · ·			· · ·
120:15 121:12 statisticians 40:4 6:16 328:13 216:1,4 220:2,3,11 159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20		· · · · · · · · · · · · · · · · · · ·		
159:14 164:15 statistics 10:9 38:5 strengths 20:22 220:12,19,25 165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20			· · ·	· ·
165:13 166:10 38:19 52:19 stretch 122:19 221:18,19 222:22 170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20				
170:24 174:22 stats 40:5 202:21 267:3 224:15,18,19,20				
				· · · · · · · · · · · · · · · · · · ·
, - , -				, , , , , , , , , , , , , , , , , , ,

226:10 282:18	107:13 110:16	287:23	suite 2:10,18 6:16
305:24 308:4	114:9 125:7 154:5	subsequently	328:13
study 20:17 25:24	160:3 167:21	79:21	sullcrom.com 2:7
38:2 41:7 45:19	198:18 202:3	substances 9:9	sullivan 2:4,13
46:22 47:12 48:7	210:16 214:6	substandard	74:15,15,20
48:9 53:9 59:2,3,9	229:20 262:23	219:7	summarize 23:10
59:12 61:11 62:8	263:8,15 276:11	successful 169:23	71:25 221:25
62:10,12,14,15,16	300:7 302:14	succumbed 79:16	summarized 9:16
62:21 63:17,18,23	313:24	sudden 300:1	summarizing
64:20,23 65:1	stunning 198:22	303:7	264:1
70:7 79:8,10 82:6	stunts 280:2	suffer 186:8	summary 33:8
84:14,19 106:22	style 322:11	sufficient 208:14	45:10 71:16
111:14 115:21	323:13	209:1 224:2	summer 82:23
118:2,24 123:25	subfield 305:11	suggest 240:1	supervise 29:15
138:8 139:9,11,12	subject 40:9 56:17	301:7 311:1	32:16
140:3,4,10,11	143:25 168:4,20	suggested 197:1	supervision 29:25
144:15 148:20,22	173:14 201:4	suggesting 201:2	30:2,6,7
150:10 155:20	228:19 281:15	suggestion 62:25	supplemental 4:7
179:11,12,20,20	284:8,10	63:1	15:15 16:5
179:22,23 198:20	subjective 187:24	suggestions	supplementary
204:2 206:3	321:11 325:3	102:14 230:11	15:5
208:12,12,23,23	subjects 48:15	246:17 296:13	supply 266:17
209:3,8,9,25 210:5	311:16	297:22 326:24	268:1
212:11,13 213:9	submission 92:24	suggests 196:14,15	support 88:1
213:20 214:9,16	submit 78:13 87:8	291:16 311:4	147:8 153:6
214:17,21 215:6	90:12	suicidal 270:24	154:23 155:4
215:11,17 218:19	submits 83:16	298:21 299:16,18	161:18,23 163:1,2
218:21 219:1	submitted 10:13	300:14,17,20	165:7 185:24
221:16 222:3,8	11:24 14:22 15:14	301:9,23,24 302:4	186:1,6 187:11
223:25,25 224:8	15:23 16:6,12	303:9	188:12 190:8,10
224:11 243:2	17:24 90:14 91:2	suicidality 212:21	190:19,22 196:7
274:8 291:19	91:14 92:3 96:19	302:8	197:3,6 201:1,8
300:9 303:13	suboptimal 293:22	suicide 176:9	202:9 232:4,18
304:12,25 305:22	295:15,16,20	212:24 273:23	251:17,17 253:1
307:18 311:3	subpar 219:7	298:19 299:5,10	266:18 273:11
312:19,22 315:18	subquestions	299:20,21,25	274:2,17,24
study's 81:13	107:15	300:6,10,13,15,22	275:18 282:12,25
studying 197:21	subscribe 87:11	301:8 302:8,11,22	290:22
stuff 18:13 43:19	subscribed 331:14	suicides 303:6	supported 163:10
43:22 78:13 82:24	subsequent 79:13	suit 33:19	166:17 201:17
83:14 86:22 90:21	79:18 280:16		

[supporting - take] Page 59

	T	I	
supporting 166:22	324:12	survey 44:16	swedish 79:14
190:23 199:3,8,18	surge 100:2,3	45:16 46:13,14,19	123:10 126:19
230:21	186:15,21,24	46:22 50:17 58:24	215:6
suppose 149:18	190:4 227:12	59:13 63:24 64:2	switch 220:21
167:23 189:24	243:19 264:17	67:10,13 69:25	switching 65:15
201:22 270:12	265:3 266:4	89:2 118:2,3,15	sworn 7:11,15
290:9 310:6	269:22	119:6 125:1	328:6 331:14
suppressed 326:20	surged 268:13	138:12 151:3	syphilis 111:14
326:20	surgeons 280:4	152:22 153:2,10	system 190:9
suppression	surgeries 79:23	155:11 156:6,10	196:7 231:10
176:11	80:6 122:11 124:6	203:23 266:24	232:4,18 310:25
supreme 35:5	280:16,19 325:18	285:9 294:6,12	324:22 325:13,20
160:11	surgery 79:12	305:2 306:5,6	systematic 270:18
sure 9:1 17:18	80:6,10 81:12	surveyed 45:21	systemic 241:11
23:14,15 26:2	95:3 122:2 123:12	47:13 91:22	309:5
33:8 40:5,15 42:1	124:5,7 163:6	296:25	t
42:19 57:13,16	164:1 196:6,11,19	surveying 47:19	t 3:1,1 5:1,1 328:1
59:7,7 63:23 66:3	196:21 217:12	297:4	328:1 330:3,3
66:25 70:4,23	238:10 253:25	surveys 22:5,6	table 46:2,6 134:9
73:1 77:13 88:8	256:14 262:8	59:14 117:8 266:2	150:4 153:14
93:25 104:6	269:2 293:23	267:2 284:17	154:9
106:19 112:12	295:15	suspect 24:2 87:22	tabs 306:17
133:6,11 134:25	surgical 45:14	100:20 109:6	tacit 62:24
142:4,13 156:21	47:5 79:17 114:5	134:19 185:4	tack 20:25
163:15 175:16,24	181:13 211:19	194:1 197:14	tailored 113:20
179:8,19 184:8	263:1 279:1,23	199:21 218:16	take 6:6 8:6,17
187:6 193:7	281:2 287:24	227:1,1 241:21	23:24 24:10 41:17
195:20 196:21	316:25	243:3 244:9	41:19,23 42:2,4
198:17 211:5	surging 266:22	281:23 287:15	47:1 61:16 71:12
236:16 237:23	surprise 86:23	298:1 301:18	73:5 88:13 90:25
239:14 240:24	135:6 265:20	303:12 316:19	93:9 99:23 102:24
253:19 256:18	surprised 87:3	327:2	104:23 108:21
264:3,13 266:7	135:10 147:4	suspicious 64:17	104.23 108.21
277:12 281:18	155:13 161:25	sustained 176:12	128:10 146:3
283:25 288:24	312:3	swap 269:22	149:9 168:23
290:12 294:22	surreptitious	swear 7:10	184:6 210:12
298:24 301:6	246:10	sweden 122:3,6	220:6 288:23
302:1 306:13	surrounding	123:11 256:6	293:6 294:20
313:8 315:20	165:13	swedes 175:13	300:5 309:17
317:22 319:10	surveillance 267:2	180:13,15 256:16	313:9 315:15
323:10,11,19,24			322:13 323:21
			344.13 343.41

[taken - textbooks] Page 60

		20127	107.10.01.10.1.7.0
taken 1:14 5:7 6:9	talking 15:5 26:16	284:25	105:18,21 124:7,8
9:9 20:23 256:1	38:3 50:15 54:17	teachers 52:20	159:21 167:11
299:12 328:10,11	56:23 72:10,25	teaches 31:24	168:12 190:2
takes 310:19	73:7,14 74:24	32:11	236:9 243:7
talk 9:24 17:25	96:23 100:9	teaching 22:11,12	257:12,13 259:14
20:20 33:6 38:14	117:12,14,22	51:12 60:6 144:6	261:10 262:2,14
48:1,4 61:5 75:11	131:9,24 134:4,7	262:11,12,18	270:23 271:1
75:16 83:18 95:9	135:20 136:14,16	teachings 56:7	299:3 302:9 303:4
99:7 120:17	147:14 161:19	147:2,10,12	306:5 321:1
131:19 133:5	162:2 167:15	team 78:3	terms 10:17 17:10
147:21 154:5	174:21 175:4	technically 240:4	30:6 73:15 96:16
155:5 160:9	177:5,11 184:11	243:12 276:7	98:23 102:22
166:20 167:10	187:23 190:12	teen 320:21	120:19 143:14
177:4 184:9	194:2,3 211:9,17	teenagers 237:21	150:20 153:20
197:12 212:6	211:24 212:7	303:8	174:22 175:22
216:5,16 218:11	214:1,12 215:4	teeth 230:11	180:22 182:12
218:14 229:13	218:11 220:5,6	tell 76:18 89:12	183:18 214:20
234:2 236:4	221:23 223:8	101:19 104:3	222:14 279:23
238:23 243:25	224:4 227:11	131:1 140:18	281:22 299:22,22
270:8 276:1	231:18 232:22	154:21 172:22	312:2 316:6
307:10,19 308:18	234:8,9 235:8	193:3 216:16	test 37:14,23 54:9
310:4 313:23	253:25 260:17	226:24 231:16	174:24 177:24
316:14	266:3,9 269:18	286:11,16 296:10	251:15 300:24
talked 10:22 41:13	276:25 277:24	299:6 306:25	tested 45:16
41:13 57:17 67:5	289:16,17 293:16	314:2	testify 9:10 135:8
71:17 73:3 82:5	293:21 307:7	telling 9:22 195:13	142:14 328:6
84:13,18 126:22	308:15 310:11,12	281:5	testimony 4:12
133:6 134:8,20	311:13 317:23	tells 67:14,16	8:23 9:7,13,21
137:18,20 141:10	322:7 326:23	template 158:20	10:7,17,22 33:2,3
141:14 145:19	talks 22:17 101:9	ten 80:7 175:8	115:16 116:15
152:21 156:21	168:8 242:10	tend 21:4 44:3	137:10 139:7
159:5 171:3 190:3	318:20	tends 76:17	327:9 329:9,18
200:22 222:1	tame 277:15,20	tension 145:1	331:8
234:15 239:9	tamiflu 278:12	160:11 161:6	testing 169:2
246:15 251:15	tarnished 111:14	tenth 80:8,9 215:9	testosterone 213:2
255:13,25 264:16	taught 28:20 29:4	tenure 31:23	texas 20:7 21:5
269:19 275:10	29:9 31:25 55:4	32:11 144:4	27:18,22 117:5
278:4 290:4,7	56:11	173:22	130:10 138:12
301:25 310:5	teach 28:19,20	term 26:10 45:18	textbook 39:25
319:15,16,20	29:1,4,7 50:20,21	100:11 101:1,18	textbooks 40:2
320:13 321:7	54:25 55:12 82:23	101:19 103:20	

			_
thalidomide 206:9	224:2,7,16 234:14	112:16 117:15,15	15:6 19:10 20:11
206:25 207:1,1,4	235:7,8,20 236:22	117:21,25 118:19	21:12,14 23:7
thank 7:12 11:13	237:25 238:2,5	120:2,19 123:5	25:15,23,25 26:4
14:19 15:12 32:18	248:3 249:1 252:2	124:13 147:7	26:10 29:20 30:22
35:25 44:19 50:19	253:10 254:13	155:19,19 157:18	31:3,21 32:8
75:8 77:2 81:5	thesis 30:2 154:4	158:20 162:4	33:11,16 34:18,20
97:15 129:3	223:5	163:19 164:10,12	34:25 35:5,6,14,15
138:22 142:17	thing 14:11 24:6	170:9 171:15,24	36:23 39:17 54:18
251:14	28:10 55:25 66:2	172:4,21 174:21	55:8 59:4,11,24
thanked 73:13	72:12 76:7 77:20	175:5,13,17 177:9	60:3 62:25 64:25
thanks 7:19 9:18	80:7 83:4 91:6	178:4,22 185:21	67:17 71:13,16,19
27:1 128:20	94:5 98:3,22	187:20 188:1	71:21,23 72:17
181:10 287:21	114:12 118:14	194:3 195:23	73:19 74:4 76:11
theda 127:25	122:11 136:13	196:4 198:21	80:1,6,8 82:21
theirs 59:13	145:6,12 164:19	201:22 202:5,5,17	84:8,13,16,18 87:7
theologically	173:7 179:6 180:2	203:10,14,19	88:12,12,24 89:20
259:10	180:25 190:7	216:9 217:14	90:8 92:10 93:10
theoretically	206:10,11 207:7	222:14 228:12	96:18,23 98:14,15
170:15	208:3 213:6	230:2,25 232:14	98:18,18 101:7,18
theorist 20:24	235:15 237:19	240:4 247:2	102:1 103:7
theory 123:2	248:22 252:16	251:24 252:19	104:16,20,21
178:6	273:15 275:8	254:3 255:23	105:22 108:6,8
therapies 276:5	277:24 300:16	259:7,11,11	109:18 112:11
therapy 4:11	301:9,10 302:5,24	262:13 267:25	114:18,20,24,25
89:14 95:7 96:3	309:24 310:3	268:12 272:11,15	118:21 119:2,5,11
148:8 180:4,5	312:20 315:22	278:13 279:21	120:16,18 121:16
183:16,20 184:9	316:7 320:19	282:22 283:8	122:5,13,15
184:14,18 185:3,6	324:3 326:6	284:17,24 285:14	123:12 124:3,9,13
187:5,9 196:11,17	things 8:6 10:9,10	286:21 288:8	125:23 127:1,23
207:23 208:13	10:11 14:25 18:23	291:10 292:10,12	129:24 130:5
209:1 210:5,7	20:21 21:2 22:18	300:2 304:5,7	131:9,11,23 132:2
212:12 213:7,12	25:20 26:1 39:2,3	309:23 310:1	132:16 133:1,3,18
213:13,21,24	40:4 49:4 52:12	311:20 312:4,16	135:17 136:22
214:15,18,22	54:18 59:20 60:15	313:22 314:14	137:18 141:9
215:18,20 216:3	60:18 61:18 69:12	316:4 319:1,15	144:2 146:3
216:12,15,16,17	71:17 73:8,16	321:2 322:20,21	147:13,15 148:15
216:23 217:5,6,7	76:10 86:11,15,21	323:13 324:2,6	148:16,22 149:3
218:9,11,14,19	87:1,2,5,12,20	325:23,24,24	149:10 150:11
219:4 220:1,13	88:14 94:25 106:6	327:3	152:6,13 153:8,8
221:14 222:2,21	106:16 107:10	think 9:8 11:2	155:12 156:5
223:2,6,18,21	108:23 112:13,15	13:21,21 14:5	157:14,16,17,17

[think - time] Page 62

158:17,18 159:1,4	245:14,19 246:18	319:13 320:9,20	71:19 77:14 83:15
159:12,13,23	246:21,24 247:13	322:20 323:4,6,22	83:18 86:5 93:16
160:24 161:2	248:6 250:4	324:15 325:19,22	95:20 122:4,5,7
163:18,25 164:11	252:17,21 254:16	326:1,2,3,6,10,14	141:9 144:3
165:10 166:2,9	255:9,23 256:6,10	326:18,19,25	threshold 99:7
168:18,18 171:11	256:16,19 257:22	thinkers 56:8	107:9 111:20,21
171:25 172:3,19	259:6,19,23 260:2	thinking 55:3	305:1
172:22 173:1,1,10	260:9,13,19 261:5	56:10 155:14	thrown 144:24
174:6 175:7,12,15	261:11,19,20	239:20 256:12	tidal 197:20
175:24 176:23,25	262:10,14,20,22	259:5 299:8	tied 11:7
178:2,2,5,15,23	263:21 264:9,17	301:11	tight 317:4
179:13 180:9,15	265:3,4,8 268:6	thinks 144:11	tightened 241:25
182:9,11,14	269:20,20 272:1	188:23	tightly 154:14
183:20 184:19,22	272:10,10 273:15	third 139:10	155:11
185:2,5,13,15,22	274:4,15 275:16	149:17	time 6:5,21 20:24
186:18 188:9,11	275:22 276:21	thirteen 238:12,13	21:13 23:17 27:24
188:16 189:7,14	277:6,7,10,13	238:14	30:12,15 35:14
189:22 192:23	279:6,9 280:15	thorough 13:7	42:3 59:1,5 66:14
193:19 194:14,23	282:1,5 283:2,3,18	245:3 296:15	71:13,22 74:5
195:4,8,11,24	283:22 284:3	297:8,13,17	79:19 81:4 96:5
196:5,6,12 197:10	285:21,22 286:1,6	thoroughness	102:17 104:23
197:19 201:1,3	286:10,15,18	284:4	109:14 114:19
202:16,16,20	287:10,14 288:5	thought 21:1 28:2	119:10 125:14
203:2,7 204:9,12	290:24 291:14,25	29:5 32:1 47:4	128:8,10 135:18
205:4,9 206:3	292:9,14,24 293:6	55:7 64:14,15	140:11,15 141:17
207:22 209:4,24	293:12,22 295:14	67:25 80:7,12	141:21 144:9
211:9,19 212:3,15	296:17 297:13,20	82:3 84:23 85:2	167:20,21 169:4
212:21 213:12,15	297:24 298:5,21	88:3 149:6 153:25	173:3 183:11
216:6,22 218:21	299:1,2,10,12,15	161:25 164:15	186:20 191:5
218:25,25 219:2,5	299:19,20 300:8	171:18 195:15	201:12 206:14
221:13 222:1,20	300:15,19,23	197:6 212:13	210:16 214:24
223:17 226:16	301:2,10,16,19	230:17 233:3	215:8,20 219:17
227:7,15,22 228:6	303:4,13,14,20,25	238:15 241:22	229:21 232:23
229:16 230:1,12	304:2,4,20,22,24	251:23,25 267:8	235:9 245:10
231:5,15 232:6,15	305:9,10,21,23	274:19,21 292:4	246:15 249:12
233:1,11,21,23	306:14 307:5	300:18 301:14,21	251:4 261:5 272:3
235:5,10,13,16	309:1,11 312:3,6	thoughts 24:3	273:19,19 279:22
236:21,23 237:4	312:18 313:2,17	threat 304:21	280:14 285:21
238:2,17 239:14	313:19,25 315:16	three 22:6 28:22	313:9 324:4 326:6
241:9 242:7	315:21 316:24	30:23 31:22 48:18	329:19
243:17 244:12	318:21 319:6,8,11	50:21 59:14 71:17	

timeframe 329:8	track 36:3 68:8,19	48:14,25 50:1,9	295:14 302:1
timeline 96:13	68:25 69:4,6,14	63:22 76:20 83:23	303:15
146:2	73:6 86:5 96:12	86:2 89:15 94:14	treatment 33:23
times 9:17,24	167:19 168:12	95:8,25 97:25	40:23 41:1 42:23
132:13 141:9	202:2,18 265:23	109:12,16,17	43:21 47:23 54:10
240:9 243:3 248:4	265:25 278:19	118:2,8,18 123:12	59:20 63:1,7 65:2
261:13 282:16	280:10 304:6	125:4 134:23	65:13 66:20 67:21
283:11	306:3,4	135:9,21 136:12	70:25 72:14 74:1
tiny 177:8	tracked 266:1	136:22 137:2	75:5 77:11 78:25
tissue 164:2	tracking 167:20	142:15 154:5	79:5,13,17,20,21
title 33:21,21	306:6	157:22 207:24	105:3 112:1,20,22
45:14 59:8	tracks 72:17	241:1 260:9,11,20	113:25 114:5,19
today 8:3,16,23	tragedy 111:17	260:21 263:9,16	114:21 124:5
9:3,7,13,19,21	train 195:15	264:5 266:2,4,23	141:19,22 154:15
10:7,15,18,22 11:1	trained 99:24	280:17 319:18,20	168:9,10,11 169:1
59:8 157:17	126:6,8 316:5	321:8 322:5,16	175:12,15 176:21
196:15 226:5	training 19:2,22	324:16 326:15	177:11,18 178:8
288:3	20:3 31:16 37:7,9	transgendered	178:11 181:11
today's 327:9	37:10,12,14,16,18	45:22	182:24 185:19
told 42:5 70:22	37:22,22 38:7,11	transgenders	191:15 198:21
73:1 140:17 142:8	38:15,16,17,18	217:8	201:7 202:1,14,15
259:12 313:16	39:1,9,18,22,24,24	transition 289:12	202:19 203:2,6,7
ton 201:11	40:16,19,22,25,25	translated 284:22	204:8 205:11,19
tons 30:12 202:4	41:3,12,22 42:6	travel 11:1	207:4 213:18,21
tools 109:23	60:5,9,24 63:4	treat 40:17,20	227:8 228:15
top 8:2 215:2	71:6 72:6 73:24	48:5 65:18,23	242:13 243:6
topic 13:23 34:2	85:21,23 121:10	80:2,13 81:15,25	247:7 252:22
71:18 78:9 164:14	121:14 122:16,22	85:5,12 90:10	257:4,5 260:15
207:9 304:11,16	122:23 123:14,21	101:2,6,23 102:19	264:22 268:19,21
305:6,7,8,10	126:10,10,12	102:21 103:6	269:7,11 271:20
307:21 308:11	149:19 152:2	104:9 124:3	271:25 272:22
309:20 311:14	trans 98:9	141:14 152:6	273:12 276:5
topical 41:5 92:12	transcribed	180:5 195:14	282:17 287:24
topics 29:1 32:10	328:11	203:20 206:2	288:1,13 293:1
53:5 131:12	transcript 329:6	293:22 299:15,18	295:18 306:12
305:12	329:20 331:5,8	302:24 318:10,16	316:25 324:22
total 197:11 327:9	transgender 40:23	323:3	treatments 69:20
totally 257:19	41:1,7 42:7,7	treated 101:22	69:24 92:17 103:8
290:19	44:14 45:4,25	300:19 301:19	103:12 104:1,14
tough 179:14	46:9,13,16,21 47:5	treating 242:14	104:16 105:10,13
	47:14,16 48:2,5,9	243:13 273:16	111:7,11 112:8,24

[treatments - uh] Page 64

114:19 115:1	252:18,22 253:2,3	226:3 230:10	66:13 70:9,20
123:13 170:13	253:9 254:4 255:7	234:22 238:22	77:19 83:15,22
176:11 180:16	255:11 258:1	240:6 251:22	85:3 86:3 89:25
181:12,17 188:2,5	276:11,16	262:20 263:14	91:3 101:16
188:6,12 194:7	tried 17:21 23:14	264:3 274:16	106:20 109:11
199:4,8,11,18	tries 283:22	301:20	117:19 124:24
200:17,19,24	trinity 19:8,12	tscheimer 2:22	149:15 151:14
201:3,17 211:19	27:2,11	6:17	152:10 158:20
221:7 237:21	trouble 104:25	turban 18:16	161:6 173:20
253:22 254:23	133:4	118:11,13,16	174:9 194:20,24
256:15,16 270:17	troubles 126:19	125:3 208:24	195:4,6,19 208:2,4
272:1,25 276:7	troubling 199:1	209:16,23 210:3	215:25 221:8,13
282:7,12 320:20	true 26:7 74:3	212:20 304:23	239:7 294:7,8
trena 1:25 5:8	116:1 119:1,21	312:9	309:23
6:17 328:4,24	121:16 140:7	turban's 89:21	type 28:14 202:14
trends 57:23,25	148:15 151:13	118:1 120:20	203:1,6 215:12
58:1 303:23	172:4 186:10	211:23 216:25	types 130:17 175:2
trial 4:12 139:8	228:21 255:16	248:3	175:12 178:8
162:1,18,19,25	264:12 310:15	turn 106:1,4,8,11	201:17 325:18
163:10 168:25	311:12 331:8	139:2 142:3	typical 202:13
169:11,23 170:16	truly 283:25	149:13 191:18	203:1,5 204:7
170:22,25 176:25	trusting 192:15	197:24 208:1	228:20
177:14 201:5,8	truth 322:4,16	230:6 275:21	typically 58:6,11
202:9 253:16	323:6,7,7,8,14,17	287:18 290:14	76:8 78:10 90:18
254:15 255:17	323:22,25 324:8,8	297:21 298:11	93:5 99:8,25
256:19	328:7,7,7	310:19	122:23 192:20
trials 161:15 162:2	try 8:3 10:14	turned 49:20	194:12 206:4
162:9,12,23,25	18:16,17 26:5	144:6 207:5	210:8 215:8 218:1
163:16 166:17	52:12 148:7	213:10 221:5	243:24 267:5
168:6,20 169:14	156:12 172:20	267:3	276:10 317:11
169:17,20 174:24	203:14,18 223:7	turning 269:3	323:2
175:5,16,16,20	293:2,18 308:20	turns 131:23	u
177:6,24 178:15	322:21,25 323:2	289:20	u 5:1
178:24 179:2	trying 18:1 30:10	tuskegee 111:14	u.s. 4:13 32:21
190:3,8,10,13,20	52:13 62:1 71:24	twice 9:25 178:19	33:19 118:2
190:23 191:14	90:8 153:8 154:9	310:5	uh 55:7 59:13 66:7
198:11,16 199:3,7	156:19 163:22	two 12:11 13:22	96:11 106:9
199:18 200:1,2,2,3	172:5 199:5	15:6,7 16:9 22:6	152:24 157:6
200:6,18,20,25	200:21 215:24	27:25 28:21,21,21	166:5 185:16
201:11,17 202:4,8	217:13,17 220:16	28:21 30:21,22	202:16 205:15
251:15,17 252:11	221 20 222 22	21 22 26 5 55 11	202.10 203.13
231.13,17 232.11	221:20 223:22	31:22 36:5 55:11	207:4 217:10

[uh - unexplained]

Page 65

000 10 041 0	1.1	170 11 170 5 0 20	1 4 1 10 1
223:13 241:2	unbeknownst	170:11 172:5,9,20	understood 18:1
243:19 245:19	155:11	175:19 177:10,21	39:20 50:4 85:22
247:5 258:22	unbelievable	178:12 181:5,15	113:17,21 114:11
279:22	139:7	185:9,10,13	115:5 120:8
uk 256:6 265:1	unc 19:15,15	196:14,22 202:7	123:16 127:11
266:8 269:21	39:14	202:21 204:6	128:7 131:7
300:10	uncalled 124:10	210:2 214:7	139:15 140:20
ukraine 14:3,8	uncautious 256:25	215:10,16,24	145:22 147:22
um 20:13 29:12	uncertain 209:15	217:15 219:8,12	151:24 152:8
37:8 38:22 40:2	209:20,22	220:22 221:3,12	154:1 155:24
42:24 44:3 46:8	uncertainty	222:17 226:18	156:11 168:14
49:16 51:15 52:10	209:13 211:4	227:4,14 228:11	169:22 176:23,25
54:16 55:13 76:15	224:8	229:3 230:8,10,15	187:2 190:16
80:4 81:20 90:11	unclear 243:8	230:19 231:2,10	191:4,9 193:9
91:6 92:21 105:17	uncommon 120:16	231:21 233:2	194:20 201:13
108:14 127:19	202:16 203:3,8	234:17,22 235:1	204:14 211:3
129:12 130:16	300:11	236:14 238:22	220:9 222:10,13
137:6 138:1 140:6	uncompelling	240:6 243:4	223:4,9 224:6
141:16 142:2	166:8	249:15 259:3	226:3 230:24
149:24 150:7	undeniable 276:6	260:3,16 261:14	231:5 232:2
151:1,17 153:4	undergo 164:1	262:2 264:14,14	234:25 235:23
160:4 168:1	167:13	264:15 269:24	236:21 237:16
169:16 184:16	undergraduate	274:16 283:23	245:12 248:7
194:22 201:24	28:22 30:1,2	284:23 289:15	249:8,11 250:15
204:6 208:16	undergraduates	290:1,25 294:11	253:1,6,9 255:8
224:11,20 236:24	21:4 29:2	297:4 298:23	260:6 269:9
242:6 248:17	underlying 12:21	304:21 309:3,13	275:16 281:1,7
252:6,16 256:3,5	117:11 119:14	understanding	288:20 289:19
258:2 259:3	undermining	56:6 89:3 103:1	294:17 315:1
264:19 288:4	62:24	106:22 121:22	undertheorized
290:6 293:10	understand 18:2	149:22 151:21	270:7
295:6 298:20	23:7 26:2 37:24	152:4 158:5	underwritten 22:6
305:15 320:9	56:8 57:24 58:2	159:20,21 211:16	unemployment
umbrella 26:24	77:21 78:10 87:14	260:24 261:16	212:6,7
unable 317:3,13	87:17 97:17 99:2	262:5 269:15	unethical 293:14
317:15	104:7 113:12	276:13	293:15 295:12
unaccounted	116:14,17 119:18	understandings	unethically 283:4
186:22	127:18 142:4,5	87:19 154:10	292:23 293:8,10
unavailable	154:9,11 156:13	158:16 263:8	295:5
185:16	156:14 162:11,24	understands 55:9	unexplained
	164:22 168:7	284:1	186:16 275:8
	X X		

6 11 260.2	4 11 100 16	4 110 14 120 20	155 10 212 15
unfamiliar 268:2	untenable 182:16	usts 118:14 120:20	155:19 213:15
unfortunate	untoward 312:6	125:2 209:25	244:9
281:10	unusual 142:24	210:3 212:1,17	various 56:8
unideal 293:13	286:7 298:2,5	213:8 214:7	vary 115:8 246:22
unified 150:14	326:25	304:23	283:18 284:3
uniformity 296:23	unverifiable 23:15	usually 30:23 58:4	vasectomy 287:1
uninterested	unwanted 148:8	77:20 83:21 90:22	vast 47:13
186:23 305:3	unwise 233:19	114:9 184:19	verbal 284:21
unique 28:24	updated 13:18	194:3 205:24	verbally 8:6
unit 6:8	30:5,11 162:6	216:15 287:10	verify 329:9
united 1:1 6:11	upheaval 99:4	308:4 310:7	veritext 6:18
36:16 111:6 118:8	uphold 147:1,10	314:11	327:11 329:14,23
123:9 125:5 141:1	upper 51:4,5	ut 20:9 27:3,4,11	veritext.com.
173:22 226:17	uprated 209:23	27:13 28:1,11,18	329:15
256:23,24 264:22	uprooting 320:13	29:17 140:24	versa 102:16
265:5 266:20,24	upset 299:20	142:18,23 143:6	versed 39:17
290:25 296:15	321:5	173:10 174:4	version 29:21
315:16	usage 277:3,19	utility 66:19	79:19
unity 149:23,25	278:21	v	versus 6:11 32:21
150:14,24 151:8	usages 283:8	v 4:15 32:25 36:18	36:7,12 153:5
151:10,18 156:18	use 40:2 51:17,21	171:10 291:19	162:3,4,9 169:1,16
157:14 158:6	54:14,20 79:18	vaginoplasty	178:13 179:3
159:16 166:3	80:10 98:22	280:2,20 281:2	235:2 277:25
universities 33:15	100:11 101:18	vague 243:7	301:21
33:17	105:18 108:22	vaguely 321:24	vested 21:19
university 20:7	118:1 120:25	valid 63:11 139:13	140:25
21:5 25:14 27:19	121:3 126:5,23,25	valuable 119:23	veto 191:24
28:24 29:1,3	127:1,23 153:5	236:5	192:10
31:12,20 117:5	156:3 159:17	value 102:1 149:9	viable 311:2
130:10 138:11	180:22 199:4,8,18	153:21,22 236:20	vice 102:16
142:20 284:16	209:25 217:9	293:24 294:1,14	video 1:12 2:5,13
university's 25:23	225:4 244:5,5	values 106:9	2:14,21 6:1,5,8
unlawful 288:18	256:19 262:21,23	235:22,24 236:18	7:9,12 74:7,10
unnecessarily	276:15 277:17	238:23 294:5,5,16	128:13,22,25
322:19	278:11 281:19	valuing 294:10	174:10,13,17
unpaid 24:10	288:25 292:22	variable 154:2	198:1,5 251:7,11
unquote 47:4	309:15	variables 47:2	289:2,5 294:19,23
unsupported	useful 118:24	126:25	295:1 327:8
200:18,20,25	uses 106:3 276:16	varies 113:7	videotaped 1:12
unsure 186:7	277:4,13,20 282:6		5:6 328:10
	283:1	variety 21:6 49:2 51:17 92:12 118:5	
		31:17 92:12 118:3	

[view - weight] Page 67

		275.15 17 270.6	264.15 15 270.19
view 18:7 22:22,25	violated 296:13	275:15,17 278:6	264:15,15 270:18
23:1,3,25 24:4,13	visual 283:23	279:19 281:17,18	272:20 273:22
24:15,19 46:16	vitamin 293:3,4	281:24 288:25	285:10 289:24
87:6 102:19,23,24	voice 314:25	307:9 316:14	296:21 300:8
102:25 103:5,10	voices 314:21	319:3	301:25 309:6
104:8 115:20	voluntary 245:9	wanted 75:24	311:7 316:2,11,16
121:9,13 125:19	vote 83:19	131:4,19 139:22	323:9
126:1 151:2,3,9	voters 153:17	144:21 309:13	ways 101:6 155:9
152:12,16 153:5	vs 1:5 329:4 330:1	wanting 269:23	175:11 186:18
154:23,25 156:3	331:1	wants 121:1	217:2,12 244:10
156:14,23,25	vulnerable 122:13	177:12 260:20	254:1 272:6
157:4,5,24,25	W	262:7 270:11	311:14 318:21
158:8 159:8	wait 87:12 265:2	war 14:2,8 155:7	we've 23:4 71:25
171:22 172:15	279:4 292:24	155:10 322:5,16	120:8 164:16
174:23 180:4	walk 33:10	322:21,23 323:6	221:25 239:9
181:18,22 189:4	walked 60:4 71:23	323:17,22	241:21 253:5
199:2,7,17 200:22	walking 232:23	warring 324:11,15	286:18 291:25
204:15 209:18	walt 133:13	wartime 322:20	307:10 319:15
211:23 218:12,18	want 18:1,19	wary 274:23	weak 95:9 176:1
225:23 234:14	23:19 25:23 26:11	washington	176:13 177:2
235:3,19 238:23	30:18 31:4 33:6	240:10	209:5,7,9,12
238:24 239:9	42:14 58:16 61:5	watch 250:5 326:6	212:13 213:16
241:16 243:20	71:16 88:4 104:6	watches 204:23	weakened 257:21
247:13,18 248:12	104:21,22 105:15	watching 231:14	weakness 172:7
248:13 249:19	117:21 128:10,10	water 210:12	weaponized 303:4
255:19 257:6,7	128:14 139:19	wave 59:11 197:20	303:5
258:23 259:22	140:12 142:3,4	306:8	website 246:1,3,6
262:15 263:5	148:21 152:21	way 9:21 13:7	313:21
264:5 267:4 270:3	162:24 165:19	18:7 24:22 26:5	wedge 255:3
277:4 289:9	168:10 169:6,7	30:10 40:9,11	week 22:13,13
291:17,19 295:16	173:7 174:21	56:20 59:10 64:2	117:19 285:1
306:16 315:5	175:7 174:21	72:15 87:23 101:2	weeks 117:19
325:21	185:15 187:2	101:23 104:7	weigh 122:23
views 17:11,14	194:10,13 198:3	106:4 116:5,22	123:4,14 231:15
23:11 33:4 43:4	208:20 210:8	122:20 126:25	252:10,15
56:5 76:3 93:4	213:7,8 217:2	139:11 152:5,5	weighed 231:16
102:22 105:9	220:3,11 224:14	154:11 160:2	weighing 231:1
150:5,12,18	230:5 236:2,15	161:1 194:23	233:18
164:23 179:21	230.3 230.2,13	203:10 222:14	weight 118:25
245:21 284:6	242:9 243:4	238:10 242:11	119:22
313:25 314:2	242:9 243:4 245:10 258:11	250:9 256:10	
	243.10 236.11		

weighted 46:12	wit 7:16	work 10:24 11:3	worried 104:4
211:2	witherspoon	16:24,24 21:11,17	worse 247:6
weightiness 234:6	82:14,16 83:1	21:24 22:2,11	worth 177:17
welcome 174:20	137:18,25 138:5	27:2,6 28:3,8,14	worthy 139:7
wellbeing 107:4	138:14 140:1,20	30:17 44:7,8 48:2	193:10,12,20
107:16 185:7	141:4,7 142:1	48:6,24 54:10,23	wow 124:3 154:3
went 9:14 39:13	withhold 249:13	57:9 60:22 61:10	170:8
40:11 49:14	withholding	70:16 72:17 93:4	wpath 102:15
186:19	211:15	97:4 108:7,11	103:19 162:5
west 2:9,14		110:25 120:25	211:18 218:1
west 2:9,14 whereof 328:17	witness 7:10,11	129:8 131:16	
	9:14,15 34:2		229:22,23 231:16
whispering 6:4	44:23,25 59:7	142:18 143:18	232:23 240:16
wholeheartedly	72:4 77:17,24	144:20 145:8	247:5 296:12
257:2	80:24 81:4,6,7	146:5,11 154:7	297:22 307:7
wide 107:23 115:1	84:23 113:7,10,14	171:7 179:14	314:3 315:2,5
120:17	113:18,22 128:9	215:20 240:7	wpath's 101:9
widely 97:1 247:7	128:17,20 138:22	272:4 273:21	245:8 295:11
283:18 284:4	171:14 174:9,11	277:22 281:12	wrap 174:7
312:2	198:7 233:9 275:2	282:23,23 304:15	wren 269:21
wider 117:17	288:24 307:8	308:22	wrestled 194:10
247:23 319:5	328:8,17 329:8,10	worked 57:4	194:16
widespread	329:12,19	277:22,22 282:18	wrestling 263:1
272:16	witnesses 34:21	working 57:7	280:7
wife 23:5,20	38:4 166:24	60:19 92:8 124:9	write 36:9 80:1
wildly 292:25	186:17 239:17	131:24 134:9	82:11 86:5 90:22
317:20	284:15	175:17 271:14	93:18 95:20 96:21
willing 135:8,12	women 111:22	works 42:22 43:8	110:7 126:13
135:20 287:16	167:13	43:10,16,20 49:1	144:14,21 164:14
windsor 35:13	wonder 167:5,7	64:8 94:3 106:14	171:14 250:13
36:16	249:22	106:23 108:4	288:16
wing 231:18	wondering 195:12	136:17 150:10	writes 39:25 88:14
wisdom 160:17,19	word 157:13	235:16	229:23
160:21 248:19	159:17 242:3	world 62:13 106:5	writing 13:8 18:14
257:13 258:5	310:22	150:5,12 151:3	66:1 82:3 89:13
289:17	wording 89:2	152:12,16 153:5	104:19 157:9
wise 233:19	294:9	154:23,25 156:3	226:14 231:25
wish 126:20	words 88:16	156:14,23,25	284:16 297:6
301:21	101:16 164:4	157:24,25 159:8	written 13:25 17:2
wishes 166:4	219:14 263:10	164:12 166:18	18:17 35:7,15
280:6	wordy 73:20	171:21 204:4	40:2 41:18 43:12
		255:21 262:14	70:14,15 76:19

[written - émile] Page 69

77:20 83:23 86:8	38:6,20,25 39:20	207:11 208:10	years 28:20 30:25
86:22 97:4 109:10	40:1 41:4 42:1	210:8 211:1 212:6	32:7 48:19,21
160:3 205:1	44:17 46:11,22,23	212:17 214:20	49:6,8,20 63:21
235:22 283:24	46:25 49:3,7,9	216:5 218:16	64:9,15,16 80:8
284:21	53:4,7,25 54:3	223:24 225:13,19	93:16 129:24
wrong 31:21 35:6	55:10 56:3 57:2	227:19 229:15	140:16 142:9
67:24 100:14	60:7,17 62:18	233:14 234:19	144:5 145:13
104:10 114:22	63:20 68:3,18,22	236:8,10 239:4,6	186:21 227:11
122:14 152:11	69:9 70:6,8 71:14	244:17,20 248:7	249:18,18,20
154:21 157:25	73:19 76:15 78:4	250:16 252:16	268:13 270:14
159:13,23 164:21	83:6,7 88:21	255:13,15,18	yep 19:19 192:3
206:23 233:19	89:17,18,21 90:18	256:8 257:10	208:4
234:4 237:5	90:24 95:1,1	258:7 260:12	yesterday 17:22
270:22 271:3	97:12,14 101:25	263:25 265:17	yield 79:23
274:5 277:7	105:22 107:11,25	266:10 270:15,15	york 2:6,6 142:22
296:24 316:9	108:17 115:24	272:24,25 275:2	young 167:18
wrote 22:14 35:8,8	116:19 119:9,25	275:25 276:8	235:6 236:23
35:9,13 36:8	120:22 121:9,16	279:22 283:9	238:14,16 250:7
41:18 66:5 69:25	123:17 124:1	284:12 285:21,22	287:2
77:5 82:8 90:20	130:12 132:2	287:21 288:14	younger 271:19
96:19 110:5 128:1	135:10 136:8	290:10,18 293:6	youth 48:2,5
144:10,17 154:6	137:4,20 141:24	298:14 302:18,24	160:25 161:2
192:11 198:18	142:11 143:21,24	303:12,13,19	216:7 268:10
207:23 216:10	145:14 146:7	304:9 306:21	270:13 272:23
260:13 280:4	147:8 150:23	308:24 311:20	Z
286:6 304:2	152:8,24 153:1,13	312:24 313:20	z 58:10
X	153:15,18,23	314:13 316:1	zoom 321:24
x 58:10	154:17 155:1,5,8	317:5 321:5,24	
	156:5 157:21	323:9,17	é
<u>y</u>	161:14 165:25	year 20:11 21:16	émile 299:24
y 58:10	166:16 169:17	27:14 28:6,6,7	
yarhouse 148:21	172:3 173:16,16	50:21 80:8,9 86:6	
yeah 11:21 12:9	175:18,19 176:8	95:20 144:4 175:8	
13:14 14:9 15:22	176:10,14 177:10	178:17 194:8	
15:25 18:17 19:14	177:23 182:18,22	215:9 231:3	
19:25 21:6 23:2	183:2 184:16	233:12 234:18	
24:18 26:9 28:5	187:24 189:18,20	235:2,5 236:22	
28:17 29:22 30:13	189:24 191:16	237:24 248:24	
30:19,19 32:15,23	196:1,18,21 198:5	254:7 274:7,7,10	
33:10 35:5,10	198:14 199:17	292:8 314:10	
36:7,8,17,20 37:24	200:8 205:24		

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.

Exhibit 5

		Page 1
1	THE UNITED STATES DISTRICT COURT	
2	EASTERN DISTRICT OF ARKANSAS	
3	CENTRAL DIVISION	
4		
5	x	
6	DYLAN BRANDT, by and through his	
7	Mother, JOANNA BRANDT, et al.,	
8	Plaintiffs	
9	V. CASE NO. 4:21-CV-00450-JM	
10	LESLIE RUTLEDGE, et al.,	
11	Defendants.	
12	x	
13		
14		
15	REMOTE/ORAL/WEB VIDEOCONFERENCE	
16	VIDEOTAPED DEPOSITION OF	
17	PAUL W. HRUZ, M.D., Ph.D.	
18	May 25, 2022	
19	9:00 a.m. CT	
20		
21		
22		
23		
24	Reported by:	
25	Maureen Ratto, RPR, CCR	

	Daga 2		Dage 4
1	Page 2 * * *	1	Page 4 A P P E A R A N C E S, continued:
2		2	ATTEARANCES, continued.
3	Videotape deposition of Paul W.	3	Co-counsel for Plaintiffs:
4	Hruz, M.D., Ph.D., held virtually via	4	GILL RAGON OWEN, PA
5	Zoom Teleconference, hosted from	5	425 West Capitol Avenue
6	Veritext Legal Solutions, pursuant to	6	Little Rock, Arkansas 72201
7	notice, before Maureen Ratto, Certified	7	BY: BETH ECHOLS, ESQ.
8	Court Reporter, License No. XI01165,	8	echols@gill-law.com
9	Registered Professional Reporter,	9	cenois e gin iaw.com
10	License No. 817125, and Notary Public.	10	Counsel for the Defendants:
11	zionist i (or ell'ize, una i (eur) i denoi	11	SENIOR ASSISTANT ATTORNEY
12	* * *	12	GENERAL, PUBLIC PROTECTION DIVISION
13		13	OFFICE OF ARKANSAS ATTORNEY GENERAL
14		14	323 Center Street
15		15	Little Rock, Arkansas 72201
16		16	BY: AMANDA LAND, ESQ.
17		17	aland@arkansasag.gov
18		18	MICHAEL CANTRELL, ESQ.
19		19	michael.cantrell@arkansasag.gov
20		20	mondon curanisas agrigov
21		21	ALSO PRESENT:
22		22	MICHAEL TSCHIEMER, Legal Video
23		23	Specialist
24		24	Specialist
25		25	
	Page 3		Page 5
1	APPEARANCES:	1	VIDEOGRAPHER: Good morning,
2		1	VIDLOGRAFILER. Good morning,
4		2	we are going on the record at 9:00
3	Counsel for the Plaintiffs:		9
1	Counsel for the Plaintiffs: SULLIVAN & CROMWELL, LLP	2	we are going on the record at 9:00
3		2 3	we are going on the record at 9:00 a.m. Central Time on May 25th,
3 4	SULLIVAN & CROMWELL, LLP	2 3 4	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022.
3 4 5	SULLIVAN & CROMWELL, LLP 125 Broad Street	2 3 4 5	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones
3 4 5 6	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004	2 3 4 5 6	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up
3 4 5 6 7	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ.	2 3 4 5 6 7	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private
3 4 5 6 7 8	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com	2 3 4 5 6 7 8 9	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your
3 4 5 6 7 8 9 10	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ.	2 3 4 5 6 7 8 9 10	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time.
3 4 5 6 7 8 9	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ.	2 3 4 5 6 7 8 9 10 11 12	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record.
3 4 5 6 7 8 9 10	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street	2 3 4 5 6 7 8 9 10 11 12 13	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the
3 4 5 6 7 8 9 10 11 12	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION	2 3 4 5 6 7 8 9 10 11 12	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record.
3 4 5 6 7 8 9 10 11 12 13	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street	2 3 4 5 6 7 8 9 10 11 12 13	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the
3 4 5 6 7 8 9 10 11 12 13 14	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004	2 3 4 5 6 7 8 9 10 11 12 13 14	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of
3 4 5 6 7 8 9 10 11 12 13 14 15	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for
3 4 5 6 7 8 9 10 11 12 13 14 15 16	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie Rutledge, et al filed in the United
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie Rutledge, et al filed in the United States District Court, Eastern
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie Rutledge, et al filed in the United States District Court, Eastern District of Arkansas, Central
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie Rutledge, et al filed in the United States District Court, Eastern District of Arkansas, Central Division 4:21-cv-00450-JM.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	SULLIVAN & CROMWELL, LLP 125 Broad Street New York, New York 10004 BY: BRANDYN RODGERSON, ESQ. rodgersonb@sullcrom.com SOPHIA M. MATTHEWS, ESQ. matthewss@sullcrom.com AMERICAN CIVIL LIBERTIES UNION 125 Broad Street New York, New York 10004 BY: CHASE STRANGIO, ESQ. cstrangio@aclu.org LESLIE COOPER, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	we are going on the record at 9:00 a.m. Central Time on May 25th, 2022. Please note that microphones are sensitive and may pick up whispering and private conversations. Please mute your phones at this time. Audio and video recording will continue to take place unless all parties agree to go off the record. This is Media Unit 1 of the video-recorded deposition of Dr. Paul Hruz taken by counsel for Plaintiff in the matter of Dylan Brandt, et al versus Leslie Rutledge, et al filed in the United States District Court, Eastern District of Arkansas, Central Division 4:21-cv-00450-JM. The location of the deposition

1		1	
	Page 6	1	Page 8
	deposition is also being conducted	1	PAUL W. HRUZ, M.D., Ph.D.
2	remotely using virtual technology.	2	first duly sworn according to law by
3	My name is Mike Tschiemer	3	the Officer, testifies as follows:
4	representing Veritext and I'm the	4	DIRECT EXAMINATION MR. STRANGIO:
5	videographer. The court reporter is	5	VIDEOGRAPHER: Thank you.
6	Maureen Ratto, from the firm of	6	Please proceed.
7	Veritext.	7	Q. Good morning, Dr. Hruz. How
8	I am not related to any party	8	are you this good morning?
9	in this action, nor am I	9	A. Good morning. Doing well.
10	financially interested in the	10	Q. Thank you for being here.
11	outcome.	11	My name is Chase Strangio.
12	If there are any objections to	12	I'm with the ACLU representing the
13	the proceeding, please state them	13	Plaintiffs and I'll be asking you some
14	at the time of your appearance.	14	questions today.
15	Counsel and all present, including	15	Can you just start by stating
16	remotely, will now state their	16	your name for the record, please?
17	appearances and affiliations for	17	A. Paul Hruz.
18	the record, beginning with the	18	Q. And you've had your deposition
19	noticing attorney.	19	taken before, right?
20	MR. STRANGIO: Good morning.	20	A. Correct.
21	This is Chase Strangio from the	21	Q. So you generally know how this
22	ACLU for the Plaintiffs.	22	process goes?
23	MS. COOPER: And also in the	23	A. That is correct.
24	room, Leslie Cooper, with the ACLU	24	Q. I'm just going to run through
25	for Plaintiffs.	25	some basic ground rules that you're
	Page 7	1	Page 9
1	MR. ROGERSON: Also in the	1	PAUL W. HRUZ, M.D., Ph.D.
2	room Brandyn Rogerson with Sullivan	2	probably familiar with, just to make sure
3	& Cromwell for the Plaintiffs.	3	we're on the same page. Is that okay?
4	MS. MATTHEWS: Sophia	4	A. Very good.
5	Matthews, Sullivan & Cromwell also	5	Q. So when answering my questions
6	for Plaintiffs, and we're joined by		
	• •	6	I ask that you respond verbally out loud
7	two of our summer associates.	7	so that the court reporter can hear you
7 8	MS. ECHOLS: Also in the room,	7 8	so that the court reporter can hear you and document your response. Is that okay?
7 8 9	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens	7 8 9	so that the court reporter can hear you and document your response. Is that okay? A. Yes.
7 8 9 10	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm	7 8 9 10	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court
7 8 9 10 11	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer	7 8 9 10 11	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish
7 8 9 10 11 12	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones.	7 8 9 10 11 12	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and
7 8 9 10 11 12 13	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on	7 8 9 10 11 12 13	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same.
7 8 9 10 11 12 13 14	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the	7 8 9 10 11 12 13 14	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good.
7 8 9 10 11 12 13 14 15	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General.	7 8 9 10 11 12 13 14 15	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand
7 8 9 10 11 12 13 14 15 16	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you.	7 8 9 10 11 12 13 14 15 16	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can
7 8 9 10 11 12 13 14 15 16 17	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right	7 8 9 10 11 12 13 14 15 16 17	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you?
7 8 9 10 11 12 13 14 15 16 17	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in.	7 8 9 10 11 12 13 14 15 16 17 18	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes.
7 8 9 10 11 12 13 14 15 16 17 18 19	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael	7 8 9 10 11 12 13 14 15 16 17 18 19	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question
7 8 9 10 11 12 13 14 15 16 17 18 19 20	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael Cantrell, also appearing remotely	7 8 9 10 11 12 13 14 15 16 17 18 19 20	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question I'll assume you understood it. Okay?
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael Cantrell, also appearing remotely for the Defendants. I'm with the	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question I'll assume you understood it. Okay? A. Understood.
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael Cantrell, also appearing remotely for the Defendants. I'm with the Arkansas Attorney General's Office.	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question I'll assume you understood it. Okay? A. Understood. Q. Are you feeling okay today?
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael Cantrell, also appearing remotely for the Defendants. I'm with the Arkansas Attorney General's Office. VIDEOGRAPHER: Anybody else?	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question I'll assume you understood it. Okay? A. Understood. Q. Are you feeling okay today? A. Yes.
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. ECHOLS: Also in the room, Beth Echols with Gill Ragon Owens for the Plaintiffs, and I'm accompanied by our summer associate, Jordan Jones. MS. LAND: Amanda Land, on behalf of the Defendants, with the Office of the Attorney General. VIDEOGRAPHER: Thank you. Doctor, will you raise your right hand to be sworn in. MR. CANTRELL: This Michael Cantrell, also appearing remotely for the Defendants. I'm with the Arkansas Attorney General's Office.	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	so that the court reporter can hear you and document your response. Is that okay? A. Yes. Q. And to help the court reporter, please wait for me to finish asking a question before you answer and I'll try to do the same. A. Very good. Q. And if you do not understand my question, please let me know and I can try to rephrase. Does that work for you? A. Yes. Q. But if you answer my question I'll assume you understood it. Okay? A. Understood. Q. Are you feeling okay today?

	P. 10		D 10
1	Page 10 PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	to answer truthfully and accurately my	2	A. It was receiving quite a bit
3	questions?	3	of attention in the media.
4	A. No.	4	Q. And did you ever speak with a
5	Q. And is there any reason that	5	member of the Arkansas legislature about
6	you don't feel able to give complete and	6	House Bill 1570?
7	truthful testimony today?	7	A. I spoke with a number of
8	A. I'm fine. Thank you.	8	individuals. I don't believe that anybody
9	Q. And today is likely going to	9	was directly a sponsor of the bill.
10	be a long day and so we will need to take	10	Q. But they were members of the
11	breaks.	11	Arkansas legislature?
12	If there comes a time when you	12	A. Not that I recall.
13	feel you need to take a break, please let	13	Q. So you spoke with individuals
14	me know, we will find a good breaking	14	but not members of the Arkansas
15	point. I would just ask that you answer	15	legislature?
16	any pending questions before we break. Is	16	A. Again, recollecting all that
17	that okay?	17	has been going on, I've had numerous
18	A. Understood.	18	conversations with numerous individuals
19	Q. I think that's all for the	19	over an extended period of time. So for
20	basics, if that sounds good to you.	20	me to recall specifically what
21	A. It's good with me.	21	conversations happened in what context,
22	Q. Okay. So can you tell me again	22	whether they were related to this
23	your full name?	23	legislation or other legislation that is
24	A. Paul William Hruz.	24	being put forth throughout the country is
25	Q. And you have been retained by	25	challenging for me and those details.
	Page 11		Page 13
1	Page 11 PAUL W. HRUZ, M.D., Ph.D.	1	Page 13 PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case;	2	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you
2 3	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right?	2 3	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about
2 3 4	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570?
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570?
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act?	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of the bill?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570? A. Again, I had numerous
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of the bill? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570? A. Again, I had numerous conversations with numerous individuals.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of the bill? A. No. Q. Were you aware of the bill	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570? A. Again, I had numerous conversations with numerous individuals. I did not really keep track of who was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of the bill? A. No. Q. Were you aware of the bill when it was pending?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570? A. Again, I had numerous conversations with numerous individuals. I did not really keep track of who was who.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. the Defendants as an expert in this case; is that right? A. That is correct. Q. How did you come to be retained as an expert in this case? A. I was contacted by one of their counsel, I think it was Vincent Wagner, about a year ago asking if I would be willing to serve in this case. Q. And you're aware that this case concerns an Arkansas law called the Safe Act? A. Correct. Q. And when this law was pending as House Bill 1570 did you take a public position on the bill? A. No. Q. Did you testify in support of the bill? A. No. Q. Were you aware of the bill	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anyone who you recall specifically speaking with about HB 1570? A. I'm not aware of any details, so no. Q. So you don't recall any specific individuals? A. That's correct. Q. Do you recall speaking with anyone from the Family Research Council about HB 1570? A. Again, I've had so many conversations over the last couple of years that it's hard for me to remember specific details. Q. Do you remember if you spoke to anyone within the State of Arkansas about HB 1570? A. Again, I had numerous conversations with numerous individuals. I did not really keep track of who was

1	D 14		D 16
1	Page 14 PAUL W. HRUZ, M.D., Ph.D.	1	Page 16 PAUL W. HRUZ, M.D., Ph.D.
2	asking me for my opinion about the nature	2	Complaint as well.
3	of human sexuality; how we define it; how	3	Q. And when you say the
4	we understand that around that time and	4	declarations, do you mean both the
5	that was most of the conversation that I	5	declarations you filed at the preliminary
6	was engaged in.	6	injunction stage and the two reports that
7	Q. And were you involved in	7	you filed during discovery?
8	drafting HB 1570?	8	A. Correct.
9	A. No, but I do recall, either it	9	Q. And did you meet with counsel?
10	was this bill or some of the similar	10	A. I spoke on the telephone.
11	bills, where some individuals had	11	Q. And how many times?
12	contacted me asking me for my	12	A. Two conversations leading
13	professional opinion as far as whether	13	directly to this deposition.
14	there was accuracy in the language that	14	Q. And how long, approximately,
15	was being used to define and recognize	15	were those conversations?
16	what sex is.	16	A. They were each about 90
17	Q. What did you say about the	17	minutes.
18	accuracy in the language of this or	18	Q. And did you speak with anyone
19	similar bills concerning sex and	19	other than your counsel about your
20	sexuality?	20	testimony?
21	MS. LAND: Object to form.	21	A. Only to inform those that
22	A. I have spoken in many	22	needed to know that I would be absent
23	different venues in answer to that	23	today to be able to take the deposition.
24	question and whatever conversation I had	24	Q. But no one about the substance
25	is consistent with those opinions that	25	of your testimony?
	Page 15		Page 17
			1 480 17
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	I've expressed about the nature of sex as	2	PAUL W. HRUZ, M.D., Ph.D. A. That is correct.
2 3	I've expressed about the nature of sex as a biological variable related	2 3	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any
2 3 4	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human	2 3 4	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've
2 3 4 5	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the
2 3 4 5 6	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint?
2 3 4 5 6 7	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the
2 3 4 5 6 7 8	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or
2 3 4 5 6 7 8 9	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week
2 3 4 5 6 7 8 9	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that
2 3 4 5 6 7 8 9 10	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing
2 3 4 5 6 7 8 9 10 11 12	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis.
2 3 4 5 6 7 8 9 10 11 12 13	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can
2 3 4 5 6 7 8 9 10 11 12 13 14	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use
2 3 4 5 6 7 8 9 10 11 12 13 14 15	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it has been a considerable amount of time	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in connection with this matter; is that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it has been a considerable amount of time since I first drafted and submitted them;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in connection with this matter; is that correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it has been a considerable amount of time since I first drafted and submitted them; I was able to review the declarations	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in connection with this matter; is that correct? A. That's my recollection, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it has been a considerable amount of time since I first drafted and submitted them; I was able to review the declarations that were provided to me from both the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in connection with this matter; is that correct? A. That's my recollection, yes. MS. LAND: Chase, give me one
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I've expressed about the nature of sex as a biological variable related intrinsically to the process of human reproduction and the precision of understanding conversations that go on related to disorders of sexual development and similar types of questions. So, again, specifically for this bill I don't have recollection of the conversations but everything that I have opined on that topic is consistent and has been throughout the time I've been involved in this conversation. Q. And what did you do to prepare for your testimony today? A. I reviewed first the declarations that I prepared, since it has been a considerable amount of time since I first drafted and submitted them; I was able to review the declarations	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. That is correct. Q. And did you review any documents, other than those that you've mentioned, the declarations and the Complaint? A. I am continually reviewing the literature. I probably read half dozen or a dozen research papers in the last week or two related to this subject and that is something that I do on an ongoing basis. Q. Okay. I want to see if we can just start by seeing how well we can use this Exhibit Share system and see if we can get a few exhibits admitted. So if you can turn to the Exhibit Share, we're going to be using that for a moment here. So you prepared two reports in connection with this matter; is that correct? A. That's my recollection, yes.

	D 10		D 20
1	Page 18 PAUL W. HRUZ, M.D., Ph.D.	1	Page 20 PAUL W. HRUZ, M.D., Ph.D.
2	make sure I can pull it up.	2	Hruz, you do have it in front of you;
3	MR. STRANGIO: Understood.	3	that's correct, right?
4	We'll go slowly. So I'm just going	4	A. I have it on my computer
5	to because it may take us a	5	screen here, yes.
6	minute on our end too.	6	Q. And do you recognize this
7	(Exhibit Hruz 1, Expert Report	7	document?
8	of Paul Hruz, dated December 10,	8	A. Well, I'm only seeing the
9	2021, was received and marked on	9	first page and I do recognize that as the
10	this date for identification.)	10	report I submitted, yes.
11	Q. So for the first exhibit here	11	Q. Are you able to scroll through
12	marked as Exhibit 1, are you able to see	12	the document?
13	and click on that document?	13	A. I certainly can do that.
14	MR. STRANGIO: I'll wait for	14	Q. To verify, is this a true and
15	you too, Amanda, to make sure we're	15	accurate copy of the report that you
16	ready. We're just marking these for	16	filed in this case?
17	now.	17	A. I certainly won't have the
18	A. I'm not seeing anything come	18	opportunity to read through the entire
19	up.	19	report but I'm scrolling through it
20	Q. It has been uploaded. You just	20	currently and it does look to be the
21	have to refresh the page.	21	document that I submitted. So I'll go
$\begin{vmatrix} 21\\22 \end{vmatrix}$	MS. LAND: It would help if I	22	through the whole thing if you wish me to
23	were in the right folder.	23	do so.
24	A. This is Exhibit 1 titled	24	Q. No. I just want to make sure
25	Expert Report of Paul Hruz.	25	that this looks like an accurate copy of
			•••
1	Page 19 PAUL W. HRUZ, M.D., Ph.D.	1	Page 21 PAUL W. HRUZ, M.D., Ph.D.
2	Q. And do you recognize	2	the December 10, 2021 report you filed
_	Q. This do journe ognize		
3	Amanda, are you all set?		
3 4	Amanda, are you all set? MS. LAND: It's not pulling up	3	and if you go to page, 98 you will see
4	MS. LAND: It's not pulling up	3 4	and if you go to page, 98 you will see your date and signature.
4 5	MS. LAND: It's not pulling up my folder for me.	3 4 5	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance
4 5 6	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed	3 4 5 6	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it
4 5 6 7	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it?	3 4 5 6 7	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted.
4 5 6 7 8	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let	3 4 5 6 7 8	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to
4 5 6 7 8 9	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me.	3 4 5 6 7 8 9	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate
4 5 6 7 8 9 10	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding	3 4 5 6 7 8 9 10	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document?
4 5 6 7 8 9 10	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to	3 4 5 6 7 8 9 10	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all.
4 5 6 7 8 9 10 11 12	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point.	3 4 5 6 7 8 9 10 11 12	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can
4 5 6 7 8 9 10 11 12 13	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What	3 4 5 6 7 8 9 10 11 12 13	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2?
4 5 6 7 8 9 10 11 12 13 14	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean?	3 4 5 6 7 8 9 10 11 12 13 14	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert
4 5 6 7 8 9 10 11 12 13 14 15	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going	3 4 5 6 7 8 9 10 11 12 13 14 15	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February
4 5 6 7 8 9 10 11 12 13 14 15 16	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure	3 4 5 6 7 8 9 10 11 12 13 14 15 16	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked
4 5 6 7 8 9 10 11 12 13 14 15 16 17	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.)
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them. MS. LAND: Do you have them	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this document?
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them. MS. LAND: Do you have them physically? I'll just look at them	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this document? A. Again, from what I can see,
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them. MS. LAND: Do you have them physically? I'll just look at them physically.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this document? A. Again, from what I can see, it, scrolling through, appears to be the
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them. MS. LAND: Do you have them physically? I'll just look at them physically. MR. STRANGIO: Perfect. Beth,	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this document? A. Again, from what I can see, it, scrolling through, appears to be the document that I submitted, correct.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MS. LAND: It's not pulling up my folder for me. MR. STRANGIO: You refreshed it? MS. LAND: Yes. Hold on. Let me. Q. Are you okay just proceeding to mark the exhibits. We're not going to be going through them at this point. MS. LAND: To mark them? What do you mean? MR. STRANGIO: I'm just going to have them just to make sure they're opened and marked for the record and that Dr. Hruz verifies that he recognizes them. MS. LAND: Do you have them physically? I'll just look at them physically.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and if you go to page, 98 you will see your date and signature. A. Okay. Without having a chance to read through the entire document, it does look like the document I submitted. Q. And is there any reason to doubt that it is the true and accurate document? A. Not at all. Q. Okay. Great. Thank you. Can you open now what is marked as Exhibit 2? (Exhibit Hruz 2, Expert Rebuttal Report dated February 10th, 2022, was received and marked on this date for identification.) A. Here we go. Very good. Q. And do you recognize this document? A. Again, from what I can see, it, scrolling through, appears to be the

	D 00		P 24
1	Page 22 PAUL W. HRUZ, M.D., Ph.D.	1	Page 24 PAUL W. HRUZ, M.D., Ph.D.
$\frac{1}{2}$	that correct?	2	studies. Do you recall which studies you
3	A. February 10th, correct.	3	are referring to?
4	Q. And do these reports contain a	4	A. Again, I read dozens of
5	complete statement of the opinions you	5	studies every week. There's a number of
6	intend to provide in this matter?	6	them that would be helpful if we have the
7	A. Well, as I stated in my	7	opportunity and time to be able to
8	declaration, itself, that I'm continually	8	discuss them, but I don't have a list in
9	gathering information and that my	9	front of me and I don't have an ability
10	opinions may be amended based upon new	10	to specifically cite authors and journals
11	information that becomes available and	11	and dates of those journal articles.
12	the necessity to address statements that	12	Q. Understood. Have any of your
13	are made by the Plaintiff experts. But	13	opinions changed since you filed your
14	it is a complete and accurate declaration	14	most recent report on February 10, 2022?
15	of my opinions related to this matter at	15	A. I would say that my opinions
16	the time that I filed it.	16	have not changed. In fact, much of what
17	Q. And since February 10th, 2022,	17	I've read have reinforced the opinions
18	which was the date that you filed the	18	that I have and actually provided even a
19	rebuttal report, have there been any	19	stronger argument for the questions and
20	studies or reports that have been	20	concerns that are raised.
21	published that you believe support your	21	Q. Okay. Thank you. And did you
$\begin{vmatrix} 21\\22\end{vmatrix}$	opinions in this case?	22	write all four reports and declarations
23	A. Yes, indeed. There have been	23	that you submitted in this case?
24	multitude of developments in this rapidly	24	A. This is definitely my work
25	changing field, including declarations by	25	product. The declaration, itself, has
23	changing field, merdaing declarations by	25	product. The decidration, itself, has
1	Page 23	1	Page 25
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into	2	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed
2 3	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this	2 3	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an
2 3 4	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a	2 3 4	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you?
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing,
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions.	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that?
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently. Again, the timing of those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities did defense counsel address with you?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently. Again, the timing of those developments in relation to the timing of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities did defense counsel address with you? MS. LAND: Objection to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently. Again, the timing of those developments in relation to the timing of the filing, I believe several of them,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities did defense counsel address with you? MS. LAND: Objection to the extent that would elicit any
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently. Again, the timing of those developments in relation to the timing of the filing, I believe several of them, these developments have happened since	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities did defense counsel address with you? MS. LAND: Objection to the extent that would elicit any responses that would reveal
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. several European countries calling into question the safety and efficacy of this treatment approach, there have been a number of studies that have been published, many of them with the same weaknesses and limitations of the types of research studies that I cite in my declaration here. And this is an active area of conversation and I've certainly tried my best to keep up-to-date on the conversation primarily related to the scientific questions. Q. And can you list for me the declarations by European countries that you are referring to? A. Certainly I can speak to statements made by Sweden, Finland, the U.K. and France most recently. Again, the timing of those developments in relation to the timing of the filing, I believe several of them,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. been expanded and added to and developed from prior cases that I have served as an expert witness but this is my work product, yes. Q. And did anyone help you? A. I had some organizational help in making sure it was presented in a way that was appropriate for the court and formatting changes and proofing by the defense counsel staff. Q. And when you say proofing, what do you mean by that? A. Checking for errors in grammar and spelling and ambiguity, redundancy, to the best to make it the best product we possibly can to serve this court. Q. And what kind of ambiguities did defense counsel address with you? MS. LAND: Objection to the extent that would elicit any

1	Page 26 PAUL W. HRUZ, M.D., Ph.D.	1	Page 28 PAUL W. HRUZ, M.D., Ph.D.
2	Q. Only answer to the extent, you	2	A. As my role as a
3	know, it's about the type of back and	3	physician-scientist and expert in this
4	forth, not the substance, in particular.	4	field, feeling the need to be able to be
5	A. Again, you know, the details	5	aware of the developments that are
6	I'm not able to recall at this time.	6	occurring in this field and being as
7	Again, this was filed many many months	7	objective as possible and weighing the
8	ago and I've done much since that time.	8	merits of the statements that are being
9	But, again, it was intended to make sure	9	made.
10	that it was as clear as possible and that	10	Q. And was any of that analysis
11	I did not have any for example, I have	11	done in writing?
12	a number of references that I cite from	12	A. The reason I'm hesitating is
13	the peer-reviewed literature to make sure	13	I'm trying to think of the timing of when
14	it is cited correctly. Again, there's	14	I've published. Not not in a
15	quite a bit of information that's	15	manuscript that was peer-reviewed since
16	presented in this rather extensive	16	the time I filed the declaration.
17	document.	17	Q. Any that were not
18	Q. Understood. Are you aware of	18	peer-reviewed?
19	any inaccuracies in any of the reports	19	A. Some writings are currently
20	that you submitted in this case?	20	being prepared.
21	MS. LAND: Object to form.	21	Q. And are you prepared for
22	A. As far as I stand by	22	what?
23	again, I've read over recently the	23	A. Prepared for publication. So
24	declarations and I do not see any	24	as an ongoing effort to bring the science
25	corrections at this time.	25	to the forefront and remain current that
	Page 27		Page 29
1			-
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
	PAUL W. HRUZ, M.D., Ph.D. Q. And is there anything in your	$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	PAUL W. HRUZ, M.D., Ph.D. there is a need to update many of the
2	Q. And is there anything in your		there is a need to update many of the
1		2	there is a need to update many of the for example, the reviews that I
2 3	Q. And is there anything in your reports that you wish to amend at this	2 3	there is a need to update many of the
2 3 4	Q. And is there anything in your reports that you wish to amend at this time?	2 3 4	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data.
2 3 4 5	Q. And is there anything in your reports that you wish to amend at this time?A. No.	2 3 4 5	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data.
2 3 4 5 6	Q. And is there anything in your reports that you wish to amend at this time?A. No.Q. And just to confirm, none of	2 3 4 5 6	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are
2 3 4 5 6 7	 Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since 	2 3 4 5 6 7	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing
2 3 4 5 6 7 8	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report?	2 3 4 5 6 7 8	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is
2 3 4 5 6 7 8 9	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have	2 3 4 5 6 7 8 9	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct?
2 3 4 5 6 7 8 9	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the	2 3 4 5 6 7 8 9	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in
2 3 4 5 6 7 8 9 10	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come	2 3 4 5 6 7 8 9 10	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature
2 3 4 5 6 7 8 9 10 11 12	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration.	2 3 4 5 6 7 8 9 10 11 12	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the
2 3 4 5 6 7 8 9 10 11 12 13	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any	2 3 4 5 6 7 8 9 10 11 12 13	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to
2 3 4 5 6 7 8 9 10 11 12 13 14	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any	2 3 4 5 6 7 8 9 10 11 12 13 14	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this	2 3 4 5 6 7 8 9 10 11 12 13 14 15	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report? A. If by additional analysis you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me. Where do you intend to submit
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report? A. If by additional analysis you mean critical review of the papers that have been published, looking for methodologic flaws, limitation,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me. Where do you intend to submit those current writings? A. It is to be determined. One of the challenges that one experiences in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report? A. If by additional analysis you mean critical review of the papers that have been published, looking for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me. Where do you intend to submit those current writings? A. It is to be determined. One of the challenges that one experiences in attempts to publish in this field is to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report? A. If by additional analysis you mean critical review of the papers that have been published, looking for methodologic flaws, limitation, weaknesses, erroneous conclusions, the answer is yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me. Where do you intend to submit those current writings? A. It is to be determined. One of the challenges that one experiences in attempts to publish in this field is to be able to have comprehensive, accurate
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And is there anything in your reports that you wish to amend at this time? A. No. Q. And just to confirm, none of your opinions have changed since completing your rebuttal report? A. As I stated earlier, I have my opinions have been reinforced by the knowledge and studies that have come forward since I filed this declaration. Q. And have you conducted any excuse me have you conducted any additional analysis relevant to this matter since completing your rebuttal report? A. If by additional analysis you mean critical review of the papers that have been published, looking for methodologic flaws, limitation, weaknesses, erroneous conclusions, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	there is a need to update many of the for example, the reviews that I previously published on this matter to include the latest data. Q. So just to summarize, you are currently in the process of preparing publications to present to journals; is that correct? A. I'm currently involved in systematically reviewing the literature to be able to be up-to-date on the literature that's available, adding to what I've already published for what pertains to this question. Q. And do you have sorry. Excuse me. Where do you intend to submit those current writings? A. It is to be determined. One of the challenges that one experiences in attempts to publish in this field is to

Page 30 PAUL W. HRUZ, M.D., Ph.D. present this and that has not been determined yet. Q. Okay. So shifting gears just a bit, can you tell me what your current job is? A. I'm an Associate Professor of Pediatric Endocrinology at Washington University with a secondary appointment Page 30 1 PAUL W. HRUZ, M.D., Ph.D. 2 understand ways to elicit underl 3 factors that may impact one's ca 4 as depression, anxiety and other 5 health issues. But I am licensed 6 pediatric endocrinology and Boa 7 Certified in pediatric endocrinol 8 general pediatrics. 9 Q. So just to confirm, you'n	Page 32
2 present this and that has not been 3 determined yet. 4 Q. Okay. So shifting gears just a 5 bit, can you tell me what your current 6 job is? 7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 2 understand ways to elicit underl 3 factors that may impact one's ca 4 as depression, anxiety and other 5 health issues. But I am licensed 6 pediatric endocrinology and Box 7 Certified in pediatric endocrinol 8 general pediatrics.	h D
3 determined yet. 4 Q. Okay. So shifting gears just a 5 bit, can you tell me what your current 6 job is? 7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 3 factors that may impact one's ca 4 as depression, anxiety and other 5 health issues. But I am licensed 6 pediatric endocrinology and Box 7 Certified in pediatric endocrinol 8 general pediatrics.	
4 Q. Okay. So shifting gears just a 5 bit, can you tell me what your current 6 job is? 7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 4 as depression, anxiety and other 5 health issues. But I am licensed 6 pediatric endocrinology and Boa 7 Certified in pediatric endocrinol 8 general pediatrics.	
5 bit, can you tell me what your current 6 job is? 6 pediatric endocrinology and Boa 7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 5 health issues. But I am licensed 6 pediatric endocrinology and Boa 7 Certified in pediatric endocrinol 8 general pediatrics.	
6 job is? 6 pediatric endocrinology and Box 7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 6 pediatric endocrinology and Box 7 Certified in pediatric endocrinol 8 general pediatrics.	
7 A. I'm an Associate Professor of 8 Pediatric Endocrinology at Washington 7 Certified in pediatric endocrinol 8 general pediatrics.	
8 Pediatric Endocrinology at Washington 8 general pediatrics.	
	logy and
2. So just to commin, your	e not
10 as Associate Professor of Cellular 10 a psychiatrist?	ic not
11 Biology and Physiology. 11 A. I'm not a licensed I'm	not
12 Q. And how long have you held 12 a Board Certified psychiatrist, c	
that position? 13 Q. Or a psychologist?	offeet.
14 A. Associate or member of the 14 A. That is correct.	
15 faculty I've been a member of the faculty 15 Q. And you don't excuse	me Do
16 at Washington University since 2000, 16 you have any professional exper	
17 after completing my Endocrinology 17 providing mental healthcare?	
18 Fellowship from 1997 to 2000, and I have 18 MS. LAND: Object to for	orm
been Associate Professor since 2011. 19 A. As I've just stated, the	/
20 Q. Just to confirm, you are an 20 psychological care that I provide	e is in
21 endocrinologist; is that correct? 21 the context of my practice of per	
22 A. A pediatric endocrinologist 22 endocrinology and certainly it is	
23 and physician-scientist, correct. 23 relevant topic for me because m	
24 Q. And what conditions do you 24 treatments that we have could be	
25 treat patients for? 25 significantly impacted by comor	
Page 31	Page 33
1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D.	- 1
2 A. I treat patients for diseases, 2 particular depression and anxiet	
3 hormonal diseases from birth, all the way 3 other mood disorders that may i	
4 into probably the early 20s. About half 4 patient's ability to comply with t	the
5 of my patient population has diabetes 5 treatment recommendations that	we make.
6 mellitus, but covers the whole gamut of 6 So that is the extent of my invol	vement
7 pediatric endocrinology, including 7 in psychological care.	
9 the maid diseases mituitemy described 9 0 And you don't have a de	egree
8 thyroid disease, pituitary dysfunction, 8 Q. And you don't have a de	
9 disorders of sexual development, bone 9 related to mental health; is that	
9 disorders of sexual development, bone 9 related to mental health; is that	cine
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 10 related to mental health; is that 10 correct?	
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 11 pediatric endocrinology. 9 related to mental health; is that 10 correct? 11 A. I have a degree in median	g in
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 11 pediatric endocrinology. 12 Q. And you mention you treat 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical and post-medical school training	g in p
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 11 pediatric endocrinology. 12 Q. And you mention you treat 13 patients up to their early 20s. About 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical school training 12 and post-medical school training 13 general pediatrics and fellowship	g in p ogy, in
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 11 pediatric endocrinology. 12 Q. And you mention you treat 13 patients up to their early 20s. About 14 what age do you generally see patients 15 until? 16 A. Generally speaking, and there 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical school training general pediatrics and fellowshif training in pediatric endocrinology. 15 addition to my Ph.D. in biochem 16 Q. And do you have any speaking.	g in p ogy, in nistry.
9 disorders of sexual development, bone 10 abnormalities, and the entire spectrum of 11 pediatric endocrinology. 12 Q. And you mention you treat 13 patients up to their early 20s. About 14 what age do you generally see patients 15 until? 9 related to mental health; is that 10 correct? 11 A. I have a degree in medic 12 and post-medical school training 13 general pediatrics and fellowshi 14 training in pediatric endocrinolog 15 addition to my Ph.D. in biochem	g in p ogy, in nistry. pecific
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical school training general pediatrics and fellowshing training in pediatric endocrinology. 13 general pediatrics and fellowshing addition to my Ph.D. in biochem 15 until? 16 Q. And do you have any speaking related to mental health training related to mental health treatment?	g in p ogy, in nistry. pecific
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical school training general pediatrics and fellowshing and training in pediatric endocrinology. 13 general pediatrics and fellowshing addition to my Ph.D. in biochem 14 training related to mental health training and there 15 A. All medical students recommendations.	g in p pgy, in nistry. pecific
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a psychiatrist, correct? 9 related to mental health; is that 10 correct? 11 A. I have a degree in medical school training general pediatrics and fellowshith training in pediatric endocrinology. 12 and post-medical school training addition to my Ph.D. in biochem 13 addition to my Ph.D. in biochem 14 training related to mental health treatment? 18 treatment? 19 A. All medical students recomposite training related to mental health	g in p pgy, in nistry. pecific eeive issues
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a psychiatrist, correct? A. I have a degree in medical school training general pediatrics and fellowshit training in pediatric endocrinolog addition to my Ph.D. in biochem Q. And do you have any speaking related to mental health treatment? A. All medical students recommendation as part of their normal medical services.	g in p pogy, in nistry. pecific reive issues school
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a psychiatrist, correct? A. I have a degree in medical and post-medical school training general pediatrics and fellowshing training in pediatric endocrinology. A. I have a degree in medical and post-medical school training general pediatrics and fellowshing training in pediatric endocrinology. A. Ald do you have any special training related to mental health treatment? A. All medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part o	g in p pogy, in nistry. pecific reive issues school
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a psychiatrist, correct? A. I am not a licensed psychological assessment relates to my related to mental health; is that correct? 1. A. I have a degree in medic and post-medical school training general pediatrics and fellowshi training in pediatric endocrinolog addition to my Ph.D. in biochem 15 dedition to my Ph.D. in biochem 16 Q. And do you have any sp 17 training related to mental health 18 treatment? 19 A. All medical students rec 20 training related to mental health 21 as part of their normal medical se 22 curriculum, all throughout reside 23 fellowship training. It is also	g in p pogy, in nistry. pecific reive issues school ency and
disorders of sexual development, bone abnormalities, and the entire spectrum of pediatric endocrinology. Q. And you mention you treat patients up to their early 20s. About what age do you generally see patients until? A. Generally speaking, and there A. Generally speaking, and there have been exceptions, I will follow them through college, if they so desire. Q. And you are not a psychiatrist, correct? A. I have a degree in medical and post-medical school training general pediatrics and fellowshing training in pediatric endocrinology. A. I have a degree in medical and post-medical school training general pediatrics and fellowshing training in pediatric endocrinology. A. Ald do you have any special training related to mental health treatment? A. All medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part of their normal medical students recommendated to mental health as part o	g in p pgy, in nistry. pecific reive issues school ency and

	Page 34		Page 30
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	the specialty which one works in.	2	trying to find in my declaration where
3	Q. And beyond what is provided to	3	that paragraph is located.
4	all medical students within the context	4	Q. The Whittaker case?
5	of their various specialties, do you have	5	A. The Whittaker case, correct.
6	any other specific training related to	6	Q. So we have those four cases.
7	mental health?	7	Are there any others?
8	A. If you're if are you	8	A. I'm trying to remember. I'm
9	asking whether I've had certification or	9	sure you'll tell me.
10	formal fellowship training or residency	10	Q. Well, if you don't recall,
11	training in psychiatry or psychology?	11	that's fine. I'm just trying to get a
12	Q. Yes. Any of those.	12	sense of which ones you recall.
13	A. No.	13	A. Very good.
14	Q. And you mention that you've	14	Q. And what about the Tavistock
15	been deposed before, right?	15	case in the United Kingdom, were you
16	A. Yes, I have.	16	deposed in that case?
17	Q. How many times?	17	A. I was not.
18	A. I listed the cases in my	18	Q. And how did you come to be
19	declaration there and not all of the	19	involved in that case?
20	cases was I deposed in, but most of the	20	A. One of the attorneys from the
21	ones related to this topic of gender	21	U.K. contacted me, asking me if they
22	dysphoria. I've undergone depositions, I	22	could use some of the published
23	can't count the exact number.	23	literature that I have contributed to
24	Q. So if I could just run	24	this question to assist them in that
25	through. So you were deposed in the	25	litigation.
	Page 35		Page 3
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct?	2	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which
2 3	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct.	2 3	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness
2 3 4	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case?	2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed?
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case?	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case?	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case,	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota,	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one. A. Yes. Correct.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I have not been deposed in that case. I did
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one. A. Yes. Correct. Q. Other than those three cases,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I have not been deposed in that case. I did file a declaration in that case for the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one. A. Yes. Correct. Q. Other than those three cases, were you deposed in any other cases that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I have not been deposed in that case. I did file a declaration in that case for the question of summary judgment.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one. A. Yes. Correct. Q. Other than those three cases, were you deposed in any other cases that you recall?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I have not been deposed in that case. I did file a declaration in that case for the question of summary judgment. Q. Are there any other cases you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Adams case; is that correct? A. That is correct. Q. And in the Bruce case? A. Sorry. Which case? Q. The Bruce case. A. Is that the South Dakota case? Q. That is the South Dakota case, yes. A. I'm more familiar if you tell me the location than the Q. Understood. So Bruce case in South Dakota, Adams case in Florida, the Kadel case in North Carolina? A. Are you talking the the more recent one here? I'm trying to think of the name. I have, yes. Q. The healthcare one. A. Yes. Correct. Q. Other than those three cases, were you deposed in any other cases that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. Are there other cases in which you were involved as an expert witness but where you were not deposed? A. Yes. For example, the Vancouver case was a similar circumstance where they asked for permission to use the published literature that I had put forward for their case. I'm trying to recall if there were any others. Those are the two that come to mind. Q. What about in the current Alabama case challenging Alabama's recent law restricting care for adolescents with gender dysphoria, are you involved as an expert in that case? MS. LAND: Object to form. A. So I have not submitted, or I have not been deposed in that case. I did file a declaration in that case for the question of summary judgment.

	D 20		D 40
1	Page 38 PAUL W. HRUZ, M.D., Ph.D.	1	Page 40 PAUL W. HRUZ, M.D., Ph.D.
2	A. Yes.	2	of my practice relates to that.
3	Q. And what cases are those?	3	Q. Have you ever treated a
4	A. There is a case in Arizona and	4	patient with gender dysphoria with
5	one very recently in Washington State.	5	puberty suppression for their gender
6	Q. And what is the case in	6	dysphoria?
7	Arizona?	7	A. As clearly stated in my
8	A. Snyder is one of the litigants	8	declaration, the basis by which I have
9	in that case.	9	not participated in gender-affirming care
10	Q. What does it concern?	10	is based upon my conclusion that there is
11	A. It is a similar to the North	11	not sufficient evidence to warrant the
12	Carolina question.	12	consideration of risks and benefits
13	Q. Regarding health insurance	13	providing that care. And to be
14	coverage?	14	consistent with my professional judgment,
15	A. Right.	15	I have not engaged in any not just
16	Q. And what about the Washington	16	related to gender dysphoria any care
17	State case?	17	which I have deemed not to be justified.
18	A. It is also a question about	18	Q. So you have never treated a
19	insurance coverage.	19	patient with gender-affirming care; is
20	Q. Any other matters?	20	that correct?
21	A. No.	21	MS. LAND: Object to form.
22	Q. Have you ever reached out to	22	A. As I just stated, I have
23	someone and offered to serve as an expert	23	treated patients with gender dysphoria.
24	witness in a case?	24	I have not engaged in gender-affirming
25	A. No.	25	medical care for the purpose of gender
	Page 39		Page 41
1	Page 39 PAUL W. HRUZ, M.D., Ph.D.	1	Page 41 PAUL W. HRUZ, M.D., Ph.D.
1 2	=	1 2	PAUL W. HRUZ, M.D., Ph.D.
	PAUL W. HRUZ, M.D., Ph.D.		PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding
2	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a	2	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported
2 3	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes.	2 3	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding
2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity?	2 3 4	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity?	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them?
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus,	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus,	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know,
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender dysphoria or were you treating them for other conditions?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals. Q. And so have you ever provided any treatments to patients aimed at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender dysphoria or were you treating them for other conditions? MS. LAND: Object to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals. Q. And so have you ever provided any treatments to patients aimed at treating their gender dysphoria?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender dysphoria or were you treating them for other conditions?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals. Q. And so have you ever provided any treatments to patients aimed at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender dysphoria or were you treating them for other conditions? MS. LAND: Object to form. A. Well, I'm trying to understand	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals. Q. And so have you ever provided any treatments to patients aimed at treating their gender dysphoria? MS. LAND: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. Have you ever treated a patient with gender dysphoria? A. Yes. Q. And in what capacity? A. In my role as a pediatric endocrinologist. Q. And what treatment did you provide to them? A. There's been quite a few, actually. I treated a patient with dyslipidemia, one with diabetes mellitus, actually several with diabetes mellitus, one with thyroid abnormalities and probably many more as well. Q. So for the patients that you've treated who have gender dysphoria, have you ever treated their gender dysphoria or were you treating them for other conditions? MS. LAND: Object to form. A. Well, I'm trying to understand your question. So I'm a pediatric	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. affirmation, based upon my understanding of the relative risks and purported benefits of this treatment approach. Q. When you say you have treated patients with gender dysphoria, what treatment did you provide them? MS. LAND: Object to form. A. I've actually already answered that. I provided care for underlying issues. For example, many of the patients at my institution are hospitalized because of of, you know, psychiatric issues and if they have underlying conditions like diabetes, that certainly needs to be cared for and I provided that care for these individuals. Q. And so have you ever provided any treatments to patients aimed at treating their gender dysphoria? MS. LAND: Objection to form. A. As I've already stated, the

	D 40		5 44
1	Page 42 PAUL W. HRUZ, M.D., Ph.D.	1	Page 44 PAUL W. HRUZ, M.D., Ph.D.
2	gender affirmation is based upon my	$\frac{1}{2}$	A. So are you asking me if I've
3	conclusions that there is not sufficient	3	referred somebody for care that I've
4		4	•
	evidence on the safety and efficacy of		already deemed as not justified by the
5	this treatment.	5	available scientific evidence?
6	Q. Do you believe that there are	6	Q. I asked about whether you
7	other medical interventions, other than	7	referred them for a diagnosis, which I
8	gender-affirming care, that one could	8	believe you mentioned was done by
9	provide to treat a patient with gender	9	psychological or psychiatric
10	dysphoria aimed at their gender	10	professionals.
11	dysphoria?	11	So my question was whether, in
12	A. I certainly do believe that	12	the course of your treatment of a
13	there are, yes.	13	patient, say, with diabetes you ever
14	Q. And what are those?	14	referred them for a potential evaluation
15	A. Again, many of these	15	for a diagnosis of gender dysphoria?
16	individuals have comorbidities, including	16	MS. LAND: Object to form.
17	depression, anxiety, eating disorders,	17	A. I don't recall a specific
18	substance abuse. All of these require	18	example where I've referred somebody for
19	and can benefit from psychological	19	psychological assessment related to
20	intervention and certainly would advocate	20	gender dysphoria. However, I have
21	that they receive that care.	21	encountered patients in my primary care
22	Q. So it's your position the way	22	clinic I'm trying to remember if I
23	excuse me.	23	ever where we've had conversations
24	So it's your position that the	24	about referring them onto a psychologist.
25	way to treat the gender dysphoria would	25	Whether it's directly related to gender
	Page 43		Page 45
1	Page 43 PAUL W. HRUZ, M.D., Ph.D.	1	Page 45 PAUL W. HRUZ, M.D., Ph.D.
1 2			
	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is	1 2	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues
2 3	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct?	1 2 3	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that
2 3 4	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form.	1 2 3 4	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization	1 2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these	1 2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and	1 2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I	1 2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and	1 2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most	1 2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is	1 2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific	1 2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care?
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that	1 2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria?	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and generally those of my colleagues that do	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a role for an endocrinologist in treating
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and generally those of my colleagues that do participate in that care rely heavily	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a role for an endocrinologist in treating gender dysphoria?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and generally those of my colleagues that do participate in that care rely heavily upon the psychological and psychiatric	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a role for an endocrinologist in treating gender dysphoria? A. I believe that there are many
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and generally those of my colleagues that do participate in that care rely heavily upon the psychological and psychiatric assessments to make that diagnosis.	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a role for an endocrinologist in treating gender dysphoria? A. I believe that there are many scientific questions that remain
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. be to treat underlying comorbidities; is that correct? MS. LAND: Object to form. A. That is a mischaracterization of my opinion. I state that these psychological care is helpful and necessary for these individuals. As I state very clearly in my declaration, and it's consistently stated, there is much uncertainty about what the most efficacious approach is and there is certainly a need for proper scientific study to be done to address that question. Q. And have you ever diagnosed anyone as having gender dysphoria? A. I have never been called upon to diagnose a gender dysphoria and generally those of my colleagues that do participate in that care rely heavily upon the psychological and psychiatric	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria or the underlying issues related to depression and anxiety that were impacting their successful care of their diabetes mellitus or other endocrine conditions, I have done that. Q. And do you, yourself, provide any of the care that you consider appropriate for gender dysphoria to patients with gender dysphoria? MS. LAND: Object to form. A. Can you be more specific about what you're asking as far as care? I have already declared in my declaration the role of an endocrinologist in treating endocrine diseases and that's where I focus my practice. Q. Do you believe that there is a role for an endocrinologist in treating gender dysphoria? A. I believe that there are many

1	Page 46 PAUL W. HRUZ, M.D., Ph.D.	1	Page 48 PAUL W. HRUZ, M.D., Ph.D.
$\frac{1}{2}$	a pediatric endocrinologist or	2	ambiguity about how one is going to be
3	endocrinologists, in general, to care for	3	able to live their lives with in a
4	the medical needs of a patient that has	4	sexual manner most effectively and most
5	been deliberately medicalized in needing	5	fulfilling, and that is a topic of
6	hormone treatments. For example, a	6	conversations that I've been involved
7	patient who has undergone gonadectomy is	7	with.
8	depended upon a hormone administration	8	Q. And have you been have you
9	for regular health, and that is an area	9	personally prescribed treatment for
10	where an endocrinologist would be need to	10	individuals with disorders of sexual
11	be involved.	11	development aimed at bringing their body
12	Q. Have you ever been present for	12	into alignment with their gender
13	a discussion between a provider and a	13	identity?
14	patient about treatment options for	14	MS. LAND: Object to form.
15	gender dysphoria?	15	A. I would broaden the question.
16	A. In the context I usually I	16	To adequately answer your
17	practice in at the Children's Hospital	17	question, it has to be considered in the
18	where I'm practicing individually, yes, I	18	greater context of how care is delivered
19	would say that in the context of	19	to individuals that have VSDs and focus
20	disorders of sexual development, which	20	of the care is to; one, understand the
21	I've been involved with throughout my	21	basis for which the disorder of sexual
22	career, there have certainly been	22	development occurred, their functional
23	questions related to gender issues in	23	ability related to that, including
24	in those affected patients.	24	fertility and engagement in sexual acts
25	There is actually a	25	as they mature throughout life.
	Page 47		Page 49
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	multidisciplinary clinic at my	2	And so it is a much broader
3	institution which I regularly participate	3	question than focusing specifically on
4	in discussions on these patients with	4	gender identity. It includes all aspects
5	disorders of sexual development and that	5	of their human sexuality and all geared
6	does include questions about gender	6	at allowing them, in these rare
7	identity and how to best care for these	7	situations where people are born with
8	individuals.	8	this ambiguity, to have the best outcome.
9	Q. And so for patients with	9	Q. In these rare situations, as
10	disorders of sexual excuse me for	10	you describe them, of individuals with
11	patients with disorders of sexual	11	disorders of sexual development, is their
12	development who are also experiencing, as	12	gender identity part of the consideration
13	you characterize, gender issues, have you	13	that excuse me. Let me back up.
14	been present for discussions around	14	In patients with disorders of
15		1	sexual development, is treatment does
13	gender-affirming treatment options?	15	sexual development, is treatment does
16	gender-affirming treatment options? MS. LAND: Objection to form.	15 16	treatment take into account an
			•
16	MS. LAND: Objection to form.	16	treatment take into account an
16 17	MS. LAND: Objection to form.A. So to adequately answer your	16 17	treatment take into account an individual's gender identity?
16 17 18	MS. LAND: Objection to form. A. So to adequately answer your question it would be necessary to provide	16 17 18	treatment take into account an individual's gender identity? A. As part of comprehensive care
16 17 18 19 20 21	MS. LAND: Objection to form. A. So to adequately answer your question it would be necessary to provide the context of care that's provided for	16 17 18 19	treatment take into account an individual's gender identity? A. As part of comprehensive care it is necessary to consider aspects of
16 17 18 19 20 21 22	MS. LAND: Objection to form. A. So to adequately answer your question it would be necessary to provide the context of care that's provided for patients with disorders of sexual	16 17 18 19 20	treatment take into account an individual's gender identity? A. As part of comprehensive care it is necessary to consider aspects of biological function, psychological
16 17 18 19 20 21 22 23	MS. LAND: Objection to form. A. So to adequately answer your question it would be necessary to provide the context of care that's provided for patients with disorders of sexual development in our multidisciplinary	16 17 18 19 20 21	treatment take into account an individual's gender identity? A. As part of comprehensive care it is necessary to consider aspects of biological function, psychological function, which includes gender identity.
16 17 18 19 20 21 22	MS. LAND: Objection to form. A. So to adequately answer your question it would be necessary to provide the context of care that's provided for patients with disorders of sexual development in our multidisciplinary model, which does include attention to	16 17 18 19 20 21 22	treatment take into account an individual's gender identity? A. As part of comprehensive care it is necessary to consider aspects of biological function, psychological function, which includes gender identity. Q. You're currently affiliated

1	Page 50		Page 52
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	A. That is correct.	2	the exact dates. It was I don't want
3	Q. And St. Louis Children's	3	to guess, but it was several years after
4	Hospital is the pediatric teaching	4	that.
5	hospital for that School of Medicine; is	5	Q. So more than five years ago
6	that correct?	6	from today, you would say?
7	A. That is correct.	7	A. It started more than five
8	Q. And do you work at the St.	8	years ago, yes.
9	Louis Children's Hospital?	9	Q. And the Transgender Center
10	A. I have my clinic in the	10	treats adolescent patients with gender
11	Children's Hospital and I attend on the	11	dysphoria; is that correct?
12	wards, in patient wards at St. Louis	12	A. Correct.
13	Children's Hospital, yes.	13	Q. And as part of that treatment
14	Q. And is there a transgender	14	they prescribe pubertal suppression to
15	clinic at the St. Louis Children's	15	treat gender dysphoria at the clinic?
16	Hospital called the Washington University	16	A. That is my understanding
17	Transgender Center?	17	there, they do prescribe GnRH agonists.
18	A. Yes.	18	Q. And what about cross-sex
19	Q. And what is your connection to	19	hormones to treat gender dysphoria for
20	the Transgender Center?	20	adolescents at the clinic?
21	A. This relates directly to how I	21	A. Do you mean the administration
22	became involved in the entire	22	of testosterone to biological females and
23	conversation that has led for me to be.	23	estrogen to biological males? The answer
24	Here this morning with you.	24	is yes.
25	While I was Chief of the Division of	25	Q. So the hospital where you work
_			
	Page 51		Page 53
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at	2	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that
2 3	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a	2 3	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that
2 3 4	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me	2 3 4	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct?
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation,
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri?
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them actually engaging in topics related to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for speculation.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them actually engaging in topics related to gender dysphoria.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for speculation. A. It's a hypothetical question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them actually engaging in topics related to gender dysphoria. Q. And you said that these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for speculation. A. It's a hypothetical question. I can certainly share what I would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them actually engaging in topics related to gender dysphoria. Q. And you said that these discussions started in 2012. When was the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for speculation. A. It's a hypothetical question. I can certainly share what I would perceive as the best path forward if that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Endocrinology and Metabolism at Washington University in 2012 I had a colleague of mine that approached me asking to start a gender clinic. That necessitated that I investigate the proposal that was being made, put forward, the basis for establishing that clinic. And in that capacity spend a considerable amount of effort beginning my investigation of the available medical literature and have continued to I've continued to assist many of our fellows in their fellowship training. I served for many years as the Fellowship Program Director and I am no the Associate Fellowship Program Director and oversee the research activities that our fellows do, with several of them actually engaging in topics related to gender dysphoria. Q. And you said that these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. currently provides the treatments that you oppose in this lawsuit; is that correct? A. They provide the care that is covered by the topic of this legislation, correct. MS. LAND: Object to form on that previous question. Q. And are you aware that a law similar to HB 1570 has been introduced in the State of Missouri? A. I am aware, yes. Q. And if Missouri were to pass a law like Arkansas what would happen to the current patients at the transgender patients at your hospital? MS. LAND: Objection to form and vague and calls for speculation. A. It's a hypothetical question. I can certainly share what I would

	D 54		D 5/
1	Page 54 PAUL W. HRUZ, M.D., Ph.D.	1	Page 56 PAUL W. HRUZ, M.D., Ph.D.
2	colleagues over the last decade.	2	excuse me. Let me back up.
3	That there is a certainly a	3	So going back to Missouri and
4	need to engage in the proper scientific	4	the Transgender Center, is it your
5	investigation into the most effective	5	position that all of the patients that
6	treatments that minimize risk and	6	are currently under the hospital's care
7	maximize benefit. And much of that care	7	would benefit from having their current
8	to be transitioned, like it has been in	8	treatment cut off?
9	European countries such as Sweden,	9	MS. LAND: Object to form.
10	relegated to investigational use under	10	A. I would not characterize that
11	the auspices of IRB approval and	11	in the way that you phrased it.
12	supervision to make sure that the best	12	Q. How would you characterize it?
13	standards of care are delivered under	13	MS. LAND: Object to form.
14	that experimental setting.	14	A. Can you please rephrase your
15	Q. So if a law like that were to	15	question for me?
16	pass in Missouri the best course would be	16	Q. Is it your position so if
17	to transfer those patients into clinical	17	Missouri passed a law like Arkansas and
18	research settings; is that correct?	18	all the patients under the care of the
19	MS. LAND: Object to form.	19	Transgender Center at St. Louis
20	A. That is a very that is an	20	Children's Hospital could no longer
21	overstatement of my opinion on that.	21	receive their treatment, is it your
22	There are many aspects of the	22	position that they would benefit from
23	care of these individuals that would need	23	having that treatment terminated?
24	to be considered on an individual basis	24	MS. LAND: Object to form.
25	to continue their psychological care to	25	A. Again, I don't accept the
	Page 55		Page 57
1	DAIII W HDIIZ M D DL D		
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	address their comorbidities such as	2	premise of that question. That again,
2 3	address their comorbidities such as depression, anxiety, eating disorders and	2 3	premise of that question. That again, as I stated very clearly in my
2 3 4	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are	2 3 4	premise of that question. That again, as I stated very clearly in my declaration that my concern with the
2 3 4 5	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population.	2 3 4 5	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not
2 3 4 5 6	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my	2 3 4 5 6	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is
2 3 4 5 6 7	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the	2 3 4 5	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not
2 3 4 5 6 7 8	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would	2 3 4 5 6 7 8	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand
2 3 4 5 6 7 8 9	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur.	2 3 4 5 6 7 8 9	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in
2 3 4 5 6 7 8 9	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the	2 3 4 5 6 7 8 9 10	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns
2 3 4 5 6 7 8 9 10	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow	2 3 4 5 6 7 8 9 10	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain.
2 3 4 5 6 7 8 9 10 11 12	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments	2 3 4 5 6 7 8 9 10 11 12	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent
2 3 4 5 6 7 8 9 10 11 12 13	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research?	2 3 4 5 6 7 8 9 10 11 12 13	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those
2 3 4 5 6 7 8 9 10 11 12 13 14	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form.	2 3 4 5 6 7 8 9 10 11 12 13 14	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most
2 3 4 5 6 7 8 9 10 11 12 13 14 15	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal	2 3 4 5 6 7 8 9 10 11 12 13 14 15	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I will defer to those that have the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would you support to arrive at those answers?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I will defer to those that have the competence to be able to say so.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would you support to arrive at those answers? A. I think that there are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I will defer to those that have the competence to be able to say so. Q. Would you support would you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would you support to arrive at those answers? A. I think that there are numerous hypotheses that have been put
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I will defer to those that have the competence to be able to say so. Q. Would you support would you support the law to the extent it would	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would you support to arrive at those answers? A. I think that there are numerous hypotheses that have been put forward both as to the etiology, the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	address their comorbidities such as depression, anxiety, eating disorders and all of the other comorbidities that are experienced by this patient population. That would certainly continue. It's my understanding that that the legislation that is being proposed would allow for that to occur. Q. Are you aware that the legislation in Arkansas would not allow for the continuation of any treatments even for purposes of clinical research? MS. LAND: Object to form. A. You're asking me a legal question and I'm testifying as a physician-scientist and medical expert. So any questions that are related to implications from the legal aspect, I will defer to those that have the competence to be able to say so. Q. Would you support would you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	premise of that question. That again, as I stated very clearly in my declaration that my concern with the care that is being delivered, it has not been demonstrated that there is sufficient benefit versus risk of the affirmation approach and that would stand whether or not legislation was passed in the State of Missouri. Those concerns would remain. I think the most prudent approach would be able to answer those existing questions about what is the most appropriate care to alleviate suffering in this vulnerable population and I would certainly support efforts to arrive at those very important answers. Q. But what type of efforts would you support to arrive at those answers? A. I think that there are numerous hypotheses that have been put

	D 50		D (1)
1	Page 58 PAUL W. HRUZ, M.D., Ph.D.	1	Page 60 PAUL W. HRUZ, M.D., Ph.D.
2	directed toward alleviating suffering in	2	made, so you do believe that the state of
3	these patients.	3	the science could benefit from, say,
4	I think that all of the	4	randomized controlled trials in the
5	hypotheses that have been put forward	5	future under the support and supervision
6	need to be considered and to the extent	6	of an institutionalized review board
7	that they're followed with the safeguards	7	wherein one population received the
8	that are present under institutional	8	gender-affirming medical treatments and
9	review boards and all of the controls	9	another population did not; is that your
10	that are done in the conduct of human	10	position?
11	research, that there are many questions	11	MS. LAND: Object to form.
12	that could be asked in a rigorous manner	12	A. So if you wish for me to
13	elevating the science to the state where	13	provide the proper context for my opinion
14	we would be able to have answers to the	14	on the conduct of research in this field,
15	questions about causal relationships	15	I think it's very important to recognize
16	between intervention and outcome and a	16	the fundamental basics of how research is
17	greater knowledge of the relative risks	17	normally performed, and much of the
18	and the purported or real benefits of	18	discussion is lacking in that
19	that intervention.	19	understanding. That science, as it's
20	Q. So help me understand. So you	20	normally conducted, usually begins with a
21	would support, for example, a rigorous	21	hypothesis, and there can often be
22	assessment under the oversight of a	22	multiple hypotheses approached. One
23	institutional review board of, say, for	23	should not dismiss outright any
24	example, treating natal female with	24	hypothesis that is being put forward.
25	testosterone to alleviate gender	25	One weighs the relative merits of a
_			
	Page 59		Page 61
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. dysphoria?	2	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a
2 3	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way	2 3	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then
2 3 4	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not	2 3 4	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones,
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really have those answers that we don't have	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find evidence. You begin with the presumption
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really have those answers that we don't have yet.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find evidence. You begin with the presumption that there is no difference in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really have those answers that we don't have yet. Q. Just to clarify, not speaking	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find evidence. You begin with the presumption that there is no difference in the treatment versus the control arm and seek
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really have those answers that we don't have yet. Q. Just to clarify, not speaking about what has been done, but speaking	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find evidence. You begin with the presumption that there is no difference in the treatment versus the control arm and seek to find evidence to disprove that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria? A. I think that to date the way that studies have been conducted have not allowed us to reach a valid conclusions and any effort to be able to answer that question, in comparison to alternative approaches, would be as we would in any other area of medicine, be certainly valid and necessary to investigate. Due to the state of where things are at that, for example, thinking about a randomized controlled trial, it may necessitate individuals that are given the hormonal treatments that are for gender affirmation in comparison to alternative approaches being able to do this in a randomized controlled manner where we can look at outcomes and really have those answers that we don't have yet. Q. Just to clarify, not speaking	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. hypothesis, which is always based upon a basic scientific premise, and one then designs a trial to be able to answer the question as to whether the hypothesis is valid or invalid. In fact, the way science is normally conducted is in a state of inherent skepticism one needs to look at the evidence available to disapprove the null hypothesis. So if one puts forward a hypothesis that gender-affirming hormonal care, specifically cross-sex hormones, testosterone to a biological female or estrogen to a biological male, is going to have a defined outcome that is measurable and in a way that can be objectively assessed, one needs to find evidence. You begin with the presumption that there is no difference in the treatment versus the control arm and seek

1	Page 62 PAUL W. HRUZ, M.D., Ph.D.	1	Page 64 PAUL W. HRUZ, M.D., Ph.D.
1 2	always conducted. It's not the way that	$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	MS. LAND: Object to form.
$\begin{vmatrix} 2 \\ 3 \end{vmatrix}$	· · · · · · · · · · · · · · · · · · ·	3	•
4	it's being conducted in this field right	4	A. So, again, we would need to be
5	now and there are many many deficiencies	5	specific about what you're asking. I'm
	that I have outlined in my declaration		not entirely sure. That's a rather broad
6 7	and the basis for those objections to the way the science is being conducted. And	6 7	statement. But I think in any area of
	•	8	scientific investigation there are many
8	that, again, very lengthy answer, and I	9	hypotheses that can be put forward and
9	apologize for the lengthy answer, is only	l	many treatment approaches that can be
10	the surface of the necessary	10	proposed, not all of them have the same
11	considerations that need to be made in	11	merit, as in my time in reviewing NIH
12	performing the proper research in this	12	studies, over my career serving on NIH
13	field.	13	study sections, one of the tasks that we
14	Q. If I understand your position	14	have is to be able to assess the merits
15	is that there are questions that still	15	of proposed research, not all research
16	need answering with respect to treatment	16	proposed research studies get funded for
17	of gender dysphoria; is that correct?	17	a variety of reasons. Many times they're
18	A. That is absolutely correct.	18	based upon a flawed premise an
19	MS. LAND: Object to form.	19	incorrectly proposed hypothesis or
20	Q. And that in order to answer	20	inadequate study methodology to address
21	those questions we need to conduct more	21	the question at hand.
22	research; is that correct?	22	Q. I think I think I think
23	A. I've said that repeatedly	23	I understand. I don't mean to cut you
24	throughout the time that I've been	24	off, but it seems like we're launching
25	involved in this conversation, that the	25	into a sort of an area that is not
-			
	Page 63	1	Page 65
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic	2	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going
2 3	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and	2 3	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you.
2 3 4	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has	2 3 4	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college?
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin,
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them;	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct?	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the validity of those hypotheses that are	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at the Medical College of Wisconsin, after I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the validity of those hypotheses that are generated.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at the Medical College of Wisconsin, after I received my Ph.D. and M.D. degrees. I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the validity of those hypotheses that are generated. Q. And among those hypotheses,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at the Medical College of Wisconsin, after I received my Ph.D. and M.D. degrees. I went to the University of Washington in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the validity of those hypotheses that are generated. Q. And among those hypotheses, that would include providing treatment	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at the Medical College of Wisconsin, after I received my Ph.D. and M.D. degrees. I went to the University of Washington in Seattle where I trained in general
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. current literature has major methodologic flaws, weaknesses and limitations and that as a physician-scientist who has worked in the area of conducting research investigations throughout my entire career, we need to elevate the science to the way it is conducted in other fields. Q. And in order to conduct that research there needs to be a way to provide different forms of treatment to the patient population and compare them; is that correct? A. I would I would narrow that down a little bit, that there needs to be an unbiased consideration of valid hypotheses that are based on plausible scientific premises and then the design of scientific trials that can address the validity of those hypotheses that are generated. Q. And among those hypotheses,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. responsive to the question. So I'm going to move us on, if that's okay with you. Can you describe your educational background for me, beginning with college? A. I received my undergraduate from Marquette University in the field of chemistry as a major. I then, following college, did my M.D. and Ph.D. training at the Medical College of Wisconsin, where I did my Ph.D. research in the area of biochemistry studying inborn air of metabolism, doing structure and function studies about an enzyme involved in ketogenesis that included my general medical education. Following the completion of the medical scientist training program at the Medical College of Wisconsin, after I received my Ph.D. and M.D. degrees. I went to the University of Washington in

	D ((D (0
1	Page 66 PAUL W. HRUZ, M.D., Ph.D.	1	Page 68 PAUL W. HRUZ, M.D., Ph.D.
2	decision to pursue subspeciality training	2	types of research, bench research,
3	in pediatric endocrinology, and that is	3	literature research, and a limited number
4	when I arrived at Washington University	4	of clinical studies and certainly have
5	in St. Louis in 1997, where I completed	5	gained through those experiences an
6	that fellowship training and chose to	6	expertise in being able to critically
7	remain at Washington University following	7	evaluate the conduct of research studies
8	completion of that training to the	8	and the critical evaluation of research
9	present date.	9	papers.
10	Q. And do you have any education	10	Q. And have you submitted any
11	or training related specifically to	11	proposals for funding for research
12	gender dysphoria?	12	related to gender dysphoria?
13	MS. LAND: Object to form.	13	A. I have had several
14	A. I would say that physicians	14	conversations with my colleagues at
15	never complete their education by the	15	Washington University about how clinical
16	time they graduate from the fellowship	16	trials can and should be conducted. To
17	training. If they stop their education	17	date there has these studies have not
18	at that point in time they're not going	18	been adopted or submitted.
19	to be very good physicians. There is	19	We did put together proposals
20	ongoing maintenance of certification that	20	related to the area of disorders of
21	is required, there is ongoing learning	21	sexual development as part of that
22	that needs to be required that is	22	multidisciplinary team. We were at one
23	required.	23	time our center was part of a large
24	The training that I have in	24	network of other institutions providing
25	understanding issues related to gender	25	similar care.
1			
	Page 67		Page 69
1	Page 67 PAUL W. HRUZ, M.D., Ph.D.	1	Page 69 PAUL W. HRUZ, M.D., Ph.D.
2		2	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship
2 3	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on	2 3	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director
2 3 4	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the	2 3 4	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria?
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally?	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers, and that is a type of research that is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals. They've been funded by institutional
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers, and that is a type of research that is highly valued in the academic community,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals. They've been funded by institutional funds and I think there's been one of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers, and that is a type of research that is highly valued in the academic community, and many people have that as the primary	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals. They've been funded by institutional funds and I think there's been one of our fellows has submitted research grants
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers, and that is a type of research that is highly valued in the academic community, and many people have that as the primary focus of their scholarly activity	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals. They've been funded by institutional funds and I think there's been one of our fellows has submitted research grants to get that funded. They're in the early
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dysphoria occurred after I finished my fellowship training while I was on faculty, again, as I was Chief of the Division of Pediatric Endocrinology at Washington University and that education has included the extensive review of the literature that I've brought to this declaration that I've provided for this case. Q. And have you conducted any research related to gender dysphoria personally? A. Yes. Q. And what is that research? A. It's reflected in the publications that I have of critically analyzing the relevant scientific literature, doing reviews of the papers, and that is a type of research that is highly valued in the academic community, and many people have that as the primary	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. In my role as Fellowship Associate, Fellowship Program Director I've helped to guide the research that's being conducted by several of our fellows, but to date I have not received NIH funding for that purpose. Q. And when you mentioned you guided research of your of any research of fellows related to gender dysphoria? A. Yes. Two of our fellows currently are involved in research projects that are related to the area of gender dysphoria. Q. And those are is that research that is being funded by the NIH? A. I believe there's been I'm not sure where there's been proposals. They've been funded by institutional funds and I think there's been one of our fellows has submitted research grants

1	2		D 50
1	Page 70 PAUL W. HRUZ, M.D., Ph.D.	1	Page 72 PAUL W. HRUZ, M.D., Ph.D.
$\frac{1}{2}$	there is not a NIH R01 level research	2	Q. And what age what ages does
3	grant that's granted in this area.	3	that research cover?
4	Q. And what is first, what is	4	A. It's covering the adolescent
5	your role in guiding that research with	5	group of patients that are receiving
6	the fellows?	6	these hormones. It is a randomized trial
7	A. One of my tasks as a	7	of various forms of estrogen to compare
8	fellowship Associate Fellowship	8	side-effects that occur in receiving that
9	Director is to be able to make sure that	9	intervention.
10	the research that is being conducted has	10	Q. And you are supervising the
11	that the fellows are trained on the	11	fellow in that clinical trial?
12	way that research is conducted, that has	12	A. I am serving my role as
13	sufficient scientific rigor, that they're	13	Associate Fellowship Director. I am not
14	able to focus their question, develop	14	the primary mentor. There are a number of
15	their hypotheses, develop their research	15	other individuals on the Scholastic
16	methodology. This is usually done in the	16	Oversight Committee.
17	context of a primary mentor, which I am	17	I do sit in on the meetings
18	not for either of those fellows, and a	18	where they propose their research. I was
19	Scholastic Oversight Committee that	19	actually involved as they were selecting
20	provides guidance.	20	their mentors and putting together their
21	So I provide lectures and	21	Scholastic Oversight Committee. I have
22	training and review, for example, as the	22	listened to and provided feedback when
23	fellows are getting ready to submit a	23	they prepared for presentation at
24	grant, a research presentation at a	24	national meetings and will be reviewing
25	national meeting or to submit a	25	the manuscript that comes out of this
	Page 71		Page 73
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	manuscript to be able to help them to	2	research as they complete their
3	elevate the quality of their research to	3	fellowship training, which is a
J		l	1 0,
	meet the basic standards that we expect	4	requirement of all fellowship training
4	meet the basic standards that we expect in all of their areas of medicine.	5	requirement of all fellowship training that they engage and have a work product
4 5	in all of their areas of medicine.	5	that they engage and have a work product
4	in all of their areas of medicine. Q. And just going back a minute,	l	that they engage and have a work product related to their scholarly activity. That
4 5 6 7	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing	5 6 7	that they engage and have a work product related to their scholarly activity. That is my role.
4 5 6 7 8	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender	5 6 7 8	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up
4 5 6 7 8 9	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria.	5 6 7 8 9	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your
4 5 6 7 8 9 10	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you	5 6 7 8	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up
4 5 6 7 8 9 10 11	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington	5 6 7 8 9 10	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe
4 5 6 7 8 9 10 11 12	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential	5 6 7 8 9 10 11 12	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99?
4 5 6 7 8 9 10 11 12 13	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender	5 6 7 8 9 10 11	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe
4 5 6 7 8 9 10 11 12 13 14	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right?	5 6 7 8 9 10 11 12 13 14	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues.
4 5 6 7 8 9 10 11 12 13 14 15	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're	5 6 7 8 9 10 11 12 13	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a
4 5 6 7 8 9 10 11 12 13 14	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited	5 6 7 8 9 10 11 12 13 14 15	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues.
4 5 6 7 8 9 10 11 12 13 14 15 16 17	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is	5 6 7 8 9 10 11 12 13 14 15 16 17	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited	5 6 7 8 9 10 11 12 13 14 15 16 17 18	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time. Q. And what is that what is	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're still seeing you. At least we
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time. Q. And what is that what is the subject of that clinical trial?	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're still seeing you. At least we haven't failed that.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time. Q. And what is that what is the subject of that clinical trial? A. It is assessing various forms	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're still seeing you. At least we haven't failed that. Do you, Amanda, want to look
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time. Q. And what is that what is the subject of that clinical trial? A. It is assessing various forms of estrogen and risks associated with	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're still seeing you. At least we haven't failed that. Do you, Amanda, want to look on with the hardcopy that you had?
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	in all of their areas of medicine. Q. And just going back a minute, you discussed you were discussing clinical trials to treat gender dysphoria. If I understood correctly, you and your colleagues at Washington University have been exploring potential clinical trials to treat gender dysphoria; is that right? A. I would say that they're actually conducting a very limited clinical trial, one of my fellows is conducting a clinical trial at the current time. Q. And what is that what is the subject of that clinical trial? A. It is assessing various forms	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that they engage and have a work product related to their scholarly activity. That is my role. Q. Understood. Can you open up Exhibit 1 for me again, which is your reports, initial report in this case and scroll to the back because I believe that's where your CV is, at page 99? A. I'm having connectivity issues. Q. We can also hand over a hardcopy if that would be useful. MS. LAND: It disconnected from the internet. MR. STRANGIO: Oh, good. We're still seeing you. At least we haven't failed that. Do you, Amanda, want to look

1	D 74		D 76
1	Page 74 PAUL W. HRUZ, M.D., Ph.D.	1	Page 76 PAUL W. HRUZ, M.D., Ph.D.
2	MS. LAND: I was talking about	2	Q. Have you published so among
3	Dr. Hruz has disconnected from the	3	these articles, have any of the writings
4	laptop that he has.	4	that you've done on the treatment of
5	THE WITNESS: I have it now.	5	gender dysphoria or transgender people
6	Q. So this is your CV dated	6	been published in peer-reviewed journals?
7	7/7/21, which is attached. Do you see	7	A. Yes.
8	that, starting around page 99?	8	Q. Which ones are those?
9	A. I'm scrolling down. I haven't	9	A. The Linacre is a peer-reviewed
10	quite gotten there yet. Okay. I am here.	10	journal. The other papers have been
11	Q. Okay. And then so do you	11	undergone extensive editorial review.
12	have an updated CV since the one you	12	But I will state that this question came
13	submitted here?	13	up previously in other depositions that
14	A. I probably I didn't bring	14	I've had related to The Linacre and since
15	it with me.	15	the time that I've been previously
16	Q. Well, could you provide that	16	deposed, I, myself, have served as a peer
17	to us?	17	reviewer for other papers in the Linacre,
18	A. I certainly can. I don't think	18	it's a very it's the longest standing
19	it's yes, I can do that for you.	19	ethics journal in the United States, very
20	Q. So I just want to ask you	20	well respected and it does undergo, I can
21	about a few things in your CV related to	21	guarantee from my experience in being a
22	articles concerning gender dysphoria	22	peer reviewer, that a paper submitted to
23	and/or transgender people.	23	that do undergo peer review.
24	Sort of looking at the various	24	Q. Is that a scientific journal?
25	types of publications here, are these, to	25	A. It is an ethics journal.
	Page 75		Page 77
	E		
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
		1 2	PAUL W. HRUZ, M.D., Ph.D. Q. And is it a Catholic ethics
1 2 3	PAUL W. HRUZ, M.D., Ph.D. your knowledge, all of your publications related to the treatment of gender	1	
2	your knowledge, all of your publications	2	Q. And is it a Catholic ethics
2 3	your knowledge, all of your publications related to the treatment of gender	2 3	Q. And is it a Catholic ethics journal?
2 3 4	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people?	2 3 4	Q. And is it a Catholic ethics journal? MS. LAND: Object to form.
2 3 4 5	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here.	2 3 4 5	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for
2 3 4 5 6	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the	2 3 4 5 6	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to
2 3 4 5 6 7	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there	2 3 4 5 6 7	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association.
2 3 4 5 6 7 8	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper	2 3 4 5 6 7 8	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to
2 3 4 5 6 7 8 9	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis.	2 3 4 5 6 7 8 9	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5.
2 3 4 5 6 7 8 9 10 11 12	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria.	2 3 4 5 6 7 8 9 10 11 12	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry.
2 3 4 5 6 7 8 9 10 11 12 13	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published	2 3 4 5 6 7 8 9 10 11 12 13	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me.
2 3 4 5 6 7 8 9 10 11 12 13 14	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re:
2 3 4 5 6 7 8 9 10 11 12 13 14 15	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment of gender dysphoria or transgender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.) A. I only see two exhibits.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment of gender dysphoria or transgender issues?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.) A. I only see two exhibits. Q. We're working on it on our
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment of gender dysphoria or transgender issues? A. No, other than what I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.) A. I only see two exhibits. Q. We're working on it on our end. This time it's definitively our
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment of gender dysphoria or transgender issues? A. No, other than what I mentioned before about the manuscripts	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.) A. I only see two exhibits. Q. We're working on it on our end. This time it's definitively our fault. So Exhibit 3 should be there now.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	your knowledge, all of your publications related to the treatment of gender dysphoria or transgender people? A. Let me get to that part here. So there are a couple of articles in the NCBC Quarterly, a Linacre article, there is a book chapter, and there is a paper that was published in the New Atlantis. I think those are the primary publications that I have currently related to gender dysphoria. Q. Any that have been published since this version of your CV, any post July 2021? A. Nothing that is currently available, no. Q. And anything that you're currently working on related to treatment of gender dysphoria or transgender issues? A. No, other than what I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. And is it a Catholic ethics journal? MS. LAND: Object to form. A. It is an ethics journal for which the publisher has affiliation to the Catholic Medical Association. Q. Okay. I think we're going to have to refresh, open up Exhibit 5. A. Exhibit 5? I don't see an Exhibit 5. Q. Sorry. Exhibit 3. Sorry. Excuse me. (Exhibit Hruz 3, Abstract re: The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria by Paul W. Hruz was received and marked on this date for identification.) A. I only see two exhibits. Q. We're working on it on our end. This time it's definitively our

	D 70		P 00
1	Page 78 PAUL W. HRUZ, M.D., Ph.D.	1	Page 80 PAUL W. HRUZ, M.D., Ph.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	Q. So we'll mark this Exhibit 3.	2	That was my first meeting with
3	And do you recognize this document?	3	my two coauthors. I was introduced to
4	A. I'm looking at the first page	4	them. We had a number of conversations
5	and I do recognize this, yes.	5	initially about how we would address,
6	Q. And scrolling through this	6	first identifying what the relevant
7	document, does this appear to be a copy	7	questions were, how we would address a
8	of your article, The Use of Cross-Sex	8	discussion of those questions in relation
9	Steroids in the Treatment of Gender	9	to what we do and do not know about
10	Dysphoria?	10	pubertal blockade, and through a very
11	A. That is correct.	11	extensive back-and-forth process we
12	Q. And this was published in the	12	this is the product of that conversation.
13	National Catholic Bioethics Quarterly in	13	Q. Did you first meet your
14	2017, correct?	14	coauthors, Lawrence Mayer and Paul
15	A. Correct.	15	McHugh, in the context of writings this
16	Q. And we'll come back to the	16	piece, is that what you just stated?
17	articles. I'm just going to try to mark	17	A. That is my recollection.
18	some exhibits right now based on	18	Again, it was many years ago, but I don't
19	publications in your CV.	19	recall that I had ever been introduced to
20	So now you can go back and if	20	them prior to that time.
21	you can look for Exhibit 4?	21	Q. And based on our prior
22	(Exhibit Hruz 4, article from	22	conversations, the New Atlantis is not a
23	New Atlantis entitled Growing	23	peer-reviewed scientific journal; is that
24	Pains, was received and marked on	24	correct?
25	this date for identification.)	25	A. It is rigorously editorially
	Page 79		Page 81
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up.	2	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the
2 3	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize	2 3	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than
2 3 4	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document?	2 3 4	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article?	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to contribute my expertise in the question	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is being presented, I would assume that the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to contribute my expertise in the question of pubertal blockade.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is being presented, I would assume that the editors of this journal did provide an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to contribute my expertise in the question of pubertal blockade. I was contacted I'm trying	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is being presented, I would assume that the editors of this journal did provide an opportunity to be able to check the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to contribute my expertise in the question of pubertal blockade. I was contacted I'm trying to remember the actual person that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is being presented, I would assume that the editors of this journal did provide an opportunity to be able to check the accuracy of the statements that were made
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Okay. It just came up. Q. Okay. Great. Do you recognize this document? A. This appears to be the article in the New Atlantis, Growing Pains. Q. And this is an article that you published in the New Atlantis in 2017 with Lawrence Mayer and Paul McHugh; is that correct? A. That is correct. That's what it looks like right here, yes. Q. And how did you come to publish this article? A. I was let's see. That was way back. I'm trying to remember how we actually came about that. I was asked if I would participate, because of my role as a pediatric endocrinologist, to contribute my expertise in the question of pubertal blockade. I was contacted I'm trying	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reviewed. I, again, for all of the these types of publications, other than The Linacre, where I served, myself, as a peer reviewer, I'm not privy to the exact extent of that review process. It was I know it was very extensively editorially reviewed because we had to address many comments that were made for clarification throughout the drafting of this document. Q. But I'm using the "peer review" as sort of the term of art in the scientific context. So it was not a peer-reviewed scientific journal; is that correct? A. Well, again, how you define peers, those that have the expertise to be able to assess the information that is being presented, I would assume that the editors of this journal did provide an opportunity to be able to check the

	Dage 92		Page 94
1	Page 82 PAUL W. HRUZ, M.D., Ph.D.	1	Page 84 PAUL W. HRUZ, M.D., Ph.D.
2	they were accurate and relevant. So in	2	Experimental Approaches to Alleviating
3	that respect peer-reviewed. But, again,	3	Gender Dysphoria in Children?
4	as I stated, I have not reviewed for the	4	A. It appears to be so, yes.
5	New Atlantis. I don't know the editorial	5	Q. And it was published in the
6	and review process. To the best of my	6	National Catholic Bioethics Quarterly; is
7	knowledge, it is a different review	7	that correct?
8	process than for many of the other papers	8	A. That is correct.
9	that I have written.	9	Q. We are going to come back to
10	Q. Do you distinguish between	10	these documents. I just wanted to get
11	generally between peer-reviewed and	11	them marked as exhibits.
12	non-peer-reviewed publications in your CV	12	How are you doing, Dr. Hruz?
13	or other aspects of your professional	13	Do you want to keep going?
14	A. Yeah. In general, I	14	A. I would prefer to keep going.
15	distinguish in my CV those that I was	15	Q. Okay. Let's keep going.
16	invited to be able to be able to submit a	16	Have you given any
17	publication, to one where it was a fruit	17	presentations about gender dysphoria,
18	of my own research. And I have broken	18	transgender or related people at any
19	that out into invited reviews versus	19	scientific or medical conferences?
20	other papers and that is reflected in my	20	A. Yes.
21	CV.	21	Q. Can you tell me about those?
22	Q. Okay. Thank you. Sorry. One	22	A. I have delivered I don't
23	second. To your knowledge, is the	23	know the exact number. I've delivered
24	sorry. Excuse me.	24	grand rounds presentations to a number of
25	Is the New Atlantis recognized	25	major universities; I presented at the
	Page 83		Page 85
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical	2	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association
2 3	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field?	2 3	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to
2 3 4	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general?
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5.	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.)	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.) A. Okay. I do see it now.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same type of information that I've included
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.) A. Okay. I do see it now. Q. So this do you recognize	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same type of information that I've included addressing the methodologic weaknesses,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.) A. Okay. I do see it now. Q. So this do you recognize this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same type of information that I've included addressing the methodologic weaknesses, flaws, concerns, questions about
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.) A. Okay. I do see it now. Q. So this do you recognize this document? A. From what I can see, yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same type of information that I've included addressing the methodologic weaknesses, flaws, concerns, questions about etiology, epidemiology, intervention
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. as a peer-reviewed journal in the medical field? MS. LAND: Object to form. A. I'm not sure how one assesses that. I don't know of my colleagues in my department of pediatrics at Washington University, I'm not aware of any of my colleagues that have published in this journal. Q. Okay. Can you go back to Exhibit Share, I think it's marked as Exhibit 5. (Exhibit Hruz 5, article from NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD was received and marked on this date for identification.) A. Okay. I do see it now. Q. So this do you recognize this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. National Catholic Medical Association meeting; I've given presentations to I'm just trying to think through all of the different presentations I've given over the years, quite a few. Q. And for the grand rounds presentations, what were the topics? A. Generally, the so related to gender dysphoria or in general? Q. Related to gender dysphoria. A. Yeah. All of the presentations I've made have been primarily focused on the scientific evidence related to questions in this field of medical intervention, related to many of the topics that are covered within my declaration. So it's essentially the same type of information that I've included addressing the methodologic weaknesses, flaws, concerns, questions about

	D 06		D 00
1	Page 86 PAUL W. HRUZ, M.D., Ph.D.	1	Page 88 PAUL W. HRUZ, M.D., Ph.D.
2	needs to be put forward to elevate this	2	A. All of the papers that I have
3	field to the same degree of rigor that we	3	written on this topic that have been
4	have seen in other areas of medicine.	4	completed are reflected in my CV.
5	VIDEOGRAPHER: This is the	5	Q. So none have been rejected
6	videographer. Sometime within the	6	from a journal?
7	next ten minutes we'll need to take	7	A. They've all been published as
8	a media break.	8	reflected in my CV.
9	MR. STRANGIO: Let's go ahead	9	Q. They may have been published
10	and take a five minute break now. I	10	elsewhere but were they previously
11	think this would be a good time.	11	submitted to a journal in which they were
12	Thank you.	12	rejected?
13	VIDEOGRAPHER: This will end	13	A. I have not had a paper that's
14	media part 1 and we're off the	14	been outright rejected. I've certainly
15	record at 10:20 a.m.	15	had requests to review and revise the
16	(Recess is taken.)	16	manuscripts that I've submitted as part
17	VIDEOGRAPHER: We are back on	17	of the normal review process.
18	the record at 10:31 a.m. This will	18	Q. And as to those papers, were
19	begin media part 2. Please proceed.	19	they ultimately published elsewhere from
20	Q. Going back, I just have one or	20	where you initially submitted them?
21	two followup questions about the various	21	A. No.
22	papers we were discussing.	22	Q. Okay. Do you believe there are
23	Have you submitted papers to	23	some people that have a gender identity
24	journals that have not been accepted?	24	that differs from their natal sex?
25	A. Unfortunately, yes.	25	MS. LAND: Object to form.
	Page 87		Page 89
1	Page 87 PAUL W. HRUZ, M.D., Ph.D.	1	Page 89 PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender	2	
2 3	PAUL W. HRUZ, M.D., Ph.D.	2 3	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question
2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well,
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case?	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form.	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria?
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV,	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've submitted any papers to journals related	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly adolescents that have a gender identity
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've submitted any papers to journals related to gender dysphoria, transgender people,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly adolescents that have a gender identity that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've submitted any papers to journals related to gender dysphoria, transgender people, gender identity that have not been	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly adolescents that have a gender identity that differs from their biological sex.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've submitted any papers to journals related to gender dysphoria, transgender people, gender identity that have not been accepted?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly adolescents that have a gender identity that differs from their biological sex. Q. And for the population of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And papers on gender dysphoria? A. No. Q. Papers on transgender individuals? A. No. Q. And papers on any of the issues related to the care that is the subject matter of this case? MS. LAND: Object to form. A. All of the manuscripts that I have completed are reflected in my CV, excluding the ones that are currently in preparation. Q. Okay. Do you believe that sorry. Going back, that wasn't the question. I asked whether you've submitted any papers to journals related to gender dysphoria, transgender people, gender identity that have not been	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Well, there is many elements of the way that you phrased that question that I wouldn't accept. If you were asking me well, maybe I should have you rephrase the question so I can understand it properly. Q. Do you believe that there are people who have a gender identity I'll take that back. How would you describe someone with gender dysphoria? A. Thank you. I would say that I do not deny that there are individuals that experience a gender identity that is discordant with their biological sex. Q. And that there are adolescents who would fit this description? A. There are certainly adolescents that have a gender identity that differs from their biological sex.

1	D 00		P 02
1	Page 90 PAUL W. HRUZ, M.D., Ph.D.	1	Page 92 PAUL W. HRUZ, M.D., Ph.D.
2	their biological sex, that that	2	dozen over a period of several decades,
3	discordance can cause severe distress?	3	all show consistent findings that the
4	MS. LAND: Object to form.	4	vast majority of those individuals will,
5	A. So I would say that there is	5	if no intervention is engaged upon, have
6	an association with gender dysphoria and	6	a spontaneous realignment of their gender
7	distress. There are many factors that	7	identity with their biological sex. That
8	lead to that distress.	8	is what the literature shows.
9	Q. Is the discordance between	9	Q. But some will not?
10	one's gender identity and biological sex	10	MS. LAND: Object to form.
11	one of the factors in your opinion that	11	A. So the numbers range anywhere
12	leads to the distress?	12	from just above 50% up to 98%. Most
13	MS. LAND: Object to form and	13	estimates are about 85 to 87%. Since
14	vague.	14	that number is not 100, that means there
15	A. So what we know about people	15	is a percentage that will have
16	that experience gender dysphoria is that	16	persistence.
17	it is a well, we don't fully know the	17	There is no biological test,
18	etiology. We know that there are many	18	there is no reliable indicator to
19	contributing factors. And as I've often	19	determine which of those individuals will
20	said, and I believe I said in my	20	have that experience of persistence or
21	declaration, the actual nature and degree	21	desistance or whether there are factors
22	of those contributing factors are going	22	that influence that outcome.
23	to likely differ between individuals that	23	Q. And is there any evidence
24	have that experience.	24	showing that this desistance to
25	Q. But I asked you the question;	25	biological sex is likely for individuals
	P 01		
	Page 91		Page 93
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender	2	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender
2 3	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor	2 3	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty?
2 3 4	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress?	2 3 4	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form,	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between gender and biological sex come to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts making that claim and, in fact, found
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between gender and biological sex come to identify with their birth sex by	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts making that claim and, in fact, found that the references made reference to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between gender and biological sex come to identify with their birth sex by adolescents?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts making that claim and, in fact, found that the references made reference to other references that made reference to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between gender and biological sex come to identify with their birth sex by adolescents? A. I can refer and as I have	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts making that claim and, in fact, found that the references made reference to other references that made reference to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. is the discordance between gender identity and biological sex one factor leading to distress? MS. LAND: Object to form, asked and answered. A. Again, when you're looking at a complex trait that has multifactorial etiologies, there are many contributing factors. There is I would say definitively there is an association between having a sex-discordant gender identity and those that experience distress and that is by definition in the DSM-V, what we mean by gender dysphoria. Q. And so is it your view that a significant percentage of prepubertal children who have a discordance between gender and biological sex come to identify with their birth sex by adolescents?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. There are many claims that are made on either little or no scientific data, that that is the case. And when I've investigated the bases for those assertions I've come up empty with research studies that actually validate that assertion. It is known that in the current context of affirming gender identity, that the vast majority of these individuals will have that experience of persistence. As I believe in either in my declaration or one of my rebuttals went at length to trace back the claims that were made by the plaintiff experts making that claim and, in fact, found that the references made reference to other references that made reference to

	D 0.4		D 0/
1	Page 94 PAUL W. HRUZ, M.D., Ph.D.	1	Page 96 PAUL W. HRUZ, M.D., Ph.D.
2	asking you I would like you to stay	2	based upon scientific evidence. These are
3	focused on the questions that I'm asking.	3	assertions that are being made repeatedly
4	So you so you said that	4	in the absence of that information that
5	there is that there is evidence of	5	there are individuals so as a
6	persistence once an individual reaches	6	developmental process I think there is
7	adolescents. Is that a fair summary of	7	clear evidence that that stage of puberty
8	what you said?	8	is important as far as the response that
9	MS. LAND: Objection to form.	9	an individual has with the bodily changes
10	A. If one takes as evidence of	10	of sexual maturation from the prepubertal
11	persistence those that receive	11	reproductive incompetent state to that of
12	gender-affirming interventions, including	12	being productively mature and competent,
13	puberty blockers, that proceed on to get	13	and in that experience there are many
14	cross-sex hormones, the current evidence	14	changes that occur. It occurs in the
15	suggests in the published papers that the	15	setting not only of the biological
16	vast majority of those that are affirmed	16	changes that occur but also in the
17	in their gender identity will go on to	17	psychosocial dimension with what we refer
18	those interventions.	18	to as adolescence. And there are
19	The question of whether that	19	multiple factors that affect one's
20	is sustained throughout one's lifetime,	20	experience at that time of life.
21	the percentage of individuals that	21	And, again, in my
22	generally have a later desistance is	22	investigation of the claims that are made
23	quite unknown.	23	that those that have persistence into
24	I'm happy to discuss many of	24	puberty will not desist is not supported
25	the limitations and challenges in the	25	by the available evidence. There is an
	Page 95		Page 97
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an	2	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that
2 3	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that	2 3	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion.
2 3 4	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty?	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's really hard to make that assertion. So
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's really hard to make that assertion. So one when one enters into an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any evidence?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's really hard to make that assertion. So one when one enters into an intervention, they're no longer
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any evidence? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's really hard to make that assertion. So one when one enters into an intervention, they're no longer spontaneous. So the question is really
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any evidence? MS. LAND: Objection to form. A. So in my investigation of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individualswell, you said spontaneous and it's really hard to make that assertion. So one when one enters into an intervention, they're no longer spontaneous. So the question is really a; how to refute a negative. So that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any evidence? MS. LAND: Objection to form. A. So in my investigation of the claims of persistence or desistance	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individuals well, you said spontaneous and it's really hard to make that assertion. So one when one enters into an intervention, they're no longer spontaneous. So the question is really a; how to refute a negative. So that those that have desistance aren't going
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. existing literature to arrive at an adequate understanding of what that frequency is. Q. And is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Objection to form and vague. A. So if you are asking the question of how many people undergo gender-affirmation interventions Q. That's not what I'm asking. Just as a general matter, is there any evidence of spontaneous desistance by individuals who continue to experience gender dysphoria after the onset of puberty; just is there any evidence? MS. LAND: Objection to form. A. So in my investigation of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. absence of credible data to support that assertion. Q. But going back to the question; is there any evidence that spontaneous desistance by untreated individuals who continue to experience gender dysphoria after the onset of puberty? MS. LAND: Object to form. A. You're asking in a way that I would acknowledge the literature in this area has major limitations and cannot be definitively answered. But there are certainly reports of individuals, in fact, there are reports of individualswell, you said spontaneous and it's really hard to make that assertion. So one when one enters into an intervention, they're no longer spontaneous. So the question is really a; how to refute a negative. So that

	Page 98		Page 100
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	establishment, so there is no way to	2	Q. And do you still believe what
3	assess that number if they don't come to	3	you wrote there? Sorry. Excuse me.
4	attention.	4	Is that still your view, that
5	Q. Can I ask you to go back to	5	there is some evidence that gender
6	Exhibit 4, please, what's previously	6	dysphoria and cross-identification become
7	marked as Exhibit 4, Growing Pains.	7	more persistent if they last into
8	A. Again, I'm locked out here. I	8	adolescence?
9	don't know why it's locking me out.	9	A. So with the caveats of the
10	Which exhibit is it	10	limitations and methodologic weaknesses
11	Q. Exhibit 4, this is your	11	of the papers that have been published in
12	Growing Pains article, and if you could	12	that area, again, as I write these papers
13	turn to the second page, second	13	I think as a physician-scientist it's
14	paragraph.	14	important to be very objective, to be
15	A. "Of particular concern"?	15	able to acknowledge the published
16	Q. The paragraph beginning "Of	16	literature. But in this type of format
17	particular concern", about midway down.	17	it is merely pointing that there are
18	So there you wrote, "Most	18	published papers making that claim, in
19	children with gender identity problems	19	the context of that statement did not
20	come to accept the gender associated with	20	allow a full elucidation of the
21	their sex and stop identifying as the	21	deficiencies or problems related to that.
22	opposite sex. There is some evidence,	22	Q. But as a general matter, there
23	however, that gender dysphoria and	23	is some evidence that
24	cross-gender identification become more	24	cross-identification and gender dysphoria
25	persistent if they last into	25	become more persistent if they the last
	Page 99		Page 101
1			
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly?	2	PAUL W. HRUZ, M.D., Ph.D. into adolescence?
2 3	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll	2 3	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form.
2 3 4	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the	2 3 4	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know,
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence,
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there?	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47,
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E?
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child Psychology and Psychiatry in 2011.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise otherwise.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child Psychology and Psychiatry in 2011. Q. Were you thinking of any other	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise otherwise. A. Okay. You said page 47?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child Psychology and Psychiatry in 2011. Q. Were you thinking of any other evidence at that time?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise otherwise. A. Okay. You said page 47? Q. Sorry. It's actually page 46.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child Psychology and Psychiatry in 2011. Q. Were you thinking of any other evidence at that time? A. I don't recall at that time.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise otherwise. A. Okay. You said page 47? Q. Sorry. It's actually page 46. A. Okay. I'm on page 46 now. You
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. adolescence." Did I read that correctly? A. You read that correctly. I'll go back to reference 7, which is the basis for that statement. And I'm trying to I'll need to go to that reference to be able to refresh my memory, as I wrote that while I'm doing that I'm happy to Q. So one question was what evidence are you referring to there? A. That's why I'm going to the references, so you anticipated that precisely. Okay. So reference 7 talks about a paper from Child in Clinical Child Psychology and Psychiatry, published in 2000 and the Steensma paper that was also published in Clinical Child Psychology and Psychiatry in 2011. Q. Were you thinking of any other evidence at that time?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. into adolescence? MS. LAND: Object to form. A. So without, you know, specifically analyzing the quality of that evidence and the strength of that evidence to say there is evidence, whether it's of poor quality or questionable quality, that is correct. Q. Okay. And can you go back to Exhibit 1, which is your report? I'm going to ask you to turn to page 47, paragraph 34E? A. Is there a way for me to jump to the specific pages or do I have to scroll down? Q. I believe you have to scroll down. I do not have the technological knowledge to advise otherwise. A. Okay. You said page 47? Q. Sorry. It's actually page 46.

	D 103		D 104
1	Page 102 PAUL W. HRUZ, M.D., Ph.D.	1	Page 104 PAUL W. HRUZ, M.D., Ph.D.
2	A. So you mentioned you	2	current literature is of low quality and
3	directed me to 34E and, in fact, the	3	inadequate to address the safety and
4	statement that I just made and the	4	efficacy of the affirmation model and
5	response to that prior question about	5	because of that there is a need for
6	examining the evidence that is presented	6	ongoing higher quality scientific
7	by the plaintiff experts is very well	7	studies.
8	contained within that paragraph, where I	8	Q. And how would excuse me.
9	trace back what they reference and then	9	Let me take that back.
10	the references that are present within	10	How would a study be conducted
11	that book chapter and then the article,	11	in light of in Arkansas, for example,
12	itself, that was referenced in the	12	in light of the current ban on treatment
13	referenced chapter. So that will point	13	there?
14	you directly to the my previous	14	MS. LAND: Object to form and
15	comments.	15	vague.
16	Q. Okay. Thank you. I'm actually	16	A. How long do you want me to go
17	going to move on. Sorry I had you open	17	on in that? To my knowledge, I'm not
18	the wrong exhibit.	18	aware of any research that is being done
19	If you go back and open	19	in this state, although, there may be
20	Exhibit 5, which is Experimental Approach	20	that I'm not aware of.
21	to Alleviating Gender Dysphoria in	21	So you are asking me how, when
22	Children.	22	I question the low quality of evidence
23	A. Okay.	23	and make that conclusion, similar to what
24	Q. And I'm in the abstract here.	24	is made in other areas, including several
25	I'm on page 1. So this was published in	25	European countries, that the bar that is
1			
	Page 103		Page 105
1	Page 103 PAUL W. HRUZ, M.D., Ph.D.	1	Page 105 PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center;	2	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement
2 3	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct?	2 3	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be
2 3 4	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal?	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas'
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my declaration, yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this deposition, I am testifying as a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my declaration, yes. Q. So you believe that more	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this deposition, I am testifying as a physician-scientist and medical expert on
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my declaration, yes. Q. So you believe that more research is generally needed in this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this deposition, I am testifying as a physician-scientist and medical expert on the scientific literature in this field.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my declaration, yes. Q. So you believe that more research is generally needed in this field?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this deposition, I am testifying as a physician-scientist and medical expert on the scientific literature in this field. Questions related to legal
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. the National Catholic Bioethics Center; is that correct? A. The NCBC Quarterly, correct. Q. And is that a medical journal? A. It is an ethics journal. Q. So it's not a medical journal. A. It's an ethics journal. MS. LAND: Object to form. Q. And in the abstract here you write, "There is an urgent need for high-quality research to establish the overall risks and benefits of the current treatment paradigm." That's about midway through the abstract. Is that did I read that correctly? A. You did. Q. And do you agree with that? A. As reflected in my declaration, yes. Q. So you believe that more research is generally needed in this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. normally established for the engagement of new medical practice that needs to be achieved, are you asking me what type of studies would need to be done to elevate this from the category of lower, very low quality evidence to something that approaches a higher standard? Is that what you're asking? Q. No. That's not what I'm asking. Let's say all states in the United States had laws like Arkansas' laws, so this care could never be provided, would it be possible to conduct any research into the efficacy of the treatment? MS. LAND: Object to form. A. As I stated earlier in this deposition, I am testifying as a physician-scientist and medical expert on the scientific literature in this field.

	P. 100		P. 100
1	Page 106 PAUL W. HRUZ, M.D., Ph.D.	1	Page 108 PAUL W. HRUZ, M.D., Ph.D.
2	languages in the various proposals that	2	that the current paradigm is based on low
3	are being put forward throughout the	3	quality scientific evidence, in many
4	country vary, I would not be able to	4	cases no scientific evidence, and have
5	answer that. I would defer to the legal	5	chosen to put a pause on the practice of
6	counsel to be able to make that.	6	that outside of the experimental setting.
7	However, there are many things	7	So, again, it is a move in the
8	in medicine where when new therapies are	8	right direction to acknowledge what I've
9	being proposed and we engage in the	9	been saying for many years, that have
10	proper method of scientific research that	10	been noted by other leaders in the field,
11	can be done under the auspices of an	11	that we need to get answers.
12	institutional review board with all of	12	The question of what is the
13	the safeguards in place to protect the	13	most efficacious approach, either
14	study subjects.	14	alternatives that increase the efficacy
15	Q. So you've mentioned Sweden a	15	and reduce the risk, is something that
16	few times. So in Sweden are you aware	16	absolutely needs to be considered.
17	that patients with gender dysphoria are	17	Q. Would you support a law that
18	able to receive treatment with hormone	18	prohibited clinical research trials into
19		19	the efficacy of hormone therapy to treat
20	therapy in a clinical trial setting, for example?	20	gender dysphoria in adolescents?
21	MS. LAND: Object to form.	21	MS. LAND: Object to form.
22	A. So my understanding of the	$\begin{vmatrix} 21\\22\end{vmatrix}$	A. Your question actually
23	policy statements made in Sweden, which	23	addresses really the rationale as to
24	<u> </u>	24	•
25	were first adopted by the Karolinska Institute and later adopted by the entire	25	why my understanding as to why this legislation was put forward. It is a
23	· ·	23	legislation was put forward. It is a
1	Page 107	1	Page 109
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology	2	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical
2 3	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this	2 3	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and
2 3 4	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors	2 3 4	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach?	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place,
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that you support the approach that is being	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you favor a law that banned clinical trials
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that you support the approach that is being taken in Sweden, that the care is being	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you favor a law that banned clinical trials into the efficacy of hormone therapy to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that you support the approach that is being taken in Sweden, that the care is being provided in clinical research trials?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you favor a law that banned clinical trials into the efficacy of hormone therapy to treat gender dysphoria in adolescents?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that you support the approach that is being taken in Sweden, that the care is being provided in clinical research trials? MS. LAND: Object to form,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you favor a law that banned clinical trials into the efficacy of hormone therapy to treat gender dysphoria in adolescents? MS. LAND: Object to form,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. country, prioritizes psychology assessment and necessitates that if this care is going to be provided to minors that it needs to be done in the setting of an experimental trial. Q. And do you support that approach? A. As adequately and extensively discussed in my declaration, I said repeatedly that there is a need for higher quality evidence. The only way that you're going to gain higher quality evidence is to conduct clinical research to address those relevant questions. How those studies are done is a topic of much discussion but that it needs to be done is absolutely clear. Q. So is your answer yes, that you support the approach that is being taken in Sweden, that the care is being provided in clinical research trials?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reflection of a failure of the medical institution to do the normal controls and process of evaluating new treatments. Ideally, and as it is in other areas of medicine, there would not be a need for legislation because the type of research would be done, as it is done in other areas where the safeguards are in place, where things are rigorously tested, where people proceed with the utmost of caution in the absence of information. So the ideal scenario would be for this field of medical intervention to return to the basic principles that are present in all of medicine, which we claim to be valued for evidence-based, recognizing how those studies are done. Q. So my question was, would you favor a law that banned clinical trials into the efficacy of hormone therapy to treat gender dysphoria in adolescents?

	D 110		P 112
1	Page 110 PAUL W. HRUZ, M.D., Ph.D.	1	Page 112 PAUL W. HRUZ, M.D., Ph.D.
2	light of the fact that we have inadequate	2	fields, and that is the way that it
3	scientific evidence, that I would	3	should be done. So, you know, to opine
4	advocate for not gaining scientific	4	that we shouldn't do research studies,
5	evidence? The answer to	5	when we need the research studies, is
6	Q. That wasn't my question.	6	is it's an interesting question that
7	A. I think it would be an	7	you've asked. I thought I answered it
8	egregious failure to not put forward	8	directly.
9	alternative hypotheses and design	9	Q. What is the problem saying
10	clinical trials.	10	whether you support or oppose a law that
11	The whole practice of medicine	11	bans research studies?
12	is designed to alleviate suffering in our	12	MS. LAND: Object to form of
13	patients, to correct disease processes	13	that question.
14	that are present when we encounter them.	14	A. As I said previously, I'm a
15	And to say that we're not going to	15	physician-scientist and a pediatric
16	investigate ways to do our job I think	16	endocrinologist, I'm not a lawyer, I'm
17	would be a failure of us as physician-	17	not a politician and I'm opining in this
18	scientists and clinicians.	18	case related to questions of scientific
19	Q. So you would not favor a law	19	evidence and defer to those that are
20	that banned clinical research trials into	20	politicians and lawyers to be able to
21	the efficacy of treatment in this area?	21	really interpret the basis.
22	MS. LAND: Object to form,	22	I would say that it's a
23	asked and answered.	23	failure of the medical establishment to
24	A. I'm struggling to understand	24	do its job as the basis for which these
25	why you're still asking that question	25	type of legislative efforts are put
		_	
	Page 111		Page 113
1	Page 111 PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that	2	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our
2 3	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater	2 3	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in
2 3 4	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not	2 3 4	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today;
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through clinical trials?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form, asked and answered.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through clinical trials? MS. LAND: Object to form,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form, asked and answered. A. There is a need for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through clinical trials? MS. LAND: Object to form, asked and answered.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form, asked and answered. A. There is a need for understanding better the etiology, the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through clinical trials? MS. LAND: Object to form, asked and answered. A. I will say again the way this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form, asked and answered. A. There is a need for understanding better the etiology, the natural history, the effects of various
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. when I've already answered the fact that there is an urgent need to gain greater information. It's maybe I'm not understanding your question in the way that I've answered previously, that there is inadequate information and there is a need for more information. So if you are asking me that in light of the fact we need more information, and I would support not getting that information, that is what the question sounds like. Maybe I'm not understanding the question correctly. Q. I don't believe you answered my question directly which is simply; would you be opposed to a law that prohibited the ability to get this information that you desire through clinical trials? MS. LAND: Object to form, asked and answered.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. forward and that it would be best for our profession if we engaged upon research in the way that it should be done and then there would be no need to have any legislation related to that. Q. Okay. So you support the ability of the medical profession to do more research in this area? MS. LAND: Object to form. A. I have stated very clearly in my declaration that we need to do more research of high quality in the way that science needs to be conducted. Q. And I'm asking you here today; it is your view that more research is needed into the treatment for gender dysphoria in adolescence? MS. LAND: Object to form, asked and answered. A. There is a need for understanding better the etiology, the

	D 114		P 116
1	Page 114 PAUL W. HRUZ, M.D., Ph.D.	1	Page 116 PAUL W. HRUZ, M.D., Ph.D.
2	relative risks of the interventions that	2	what is contained within my declaration
3	are being put forward.	3	about my concerns about the assumptions
4	Q. Okay. I'm going to ask you	4	that are made from the DSM, and how those
5	one second.	5	statements are made, there are many that
6	One thing in your report you	6	assume erroneously that this is put
7	mention a few times that treatment of	7	together as a scientifically validated
8	gender dysphoria is different from other	8	process.
9	conditions because you cannot objectively	9	As I stated very clearly in my
10	verify the diagnose or symptoms; is that	10	declaration, that is not the way that
11	an accurate description of your position?	11	document is proposed. It's actually
12	A. As stated very clearly in my	12	the DSM is more of a dictionary of
13	declaration, it differs from other	13	various conditions and it's often and
14	conditions in that it relies entirely	14	we see that very clearly in relation to
15	upon the patient's expressed experience.	15	gender dysphoria how the evolution of
16	There is no validated biological tool or	16	even the terminology that we use to
17	test that can be done to assess the	17	express this condition is there was
18	veracity of that claim, to objectively	18	to my knowledge, there was absolutely
19	know what is being said.	19	zero scientific evidence that was put
20	So I think in that area it	20	forward to support the transition from
21	is and the uniqueness, actually,	21	"gender identity" to "disorder" to
22	doesn't exist with the fact of a patient	22	"gender dysphoria", and to the new
23	report, but the fact that it has been	23	designation that they're proposing of
24	effectively politicized and put forward	24	"gender incongruence".
25	that this is a reliable form of	25	These was voted upon by the
	Page 115		Page 117
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we	2	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals.
2 3	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know.	2 3	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not
2 3 4	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any	2 3 4	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists?	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine?	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny that at all. I actually have referred my	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions that have been made over time, especially
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny that at all. I actually have referred my patients many times to psychologists.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions that have been made over time, especially and most uniquely in those changes that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny that at all. I actually have referred my patients many times to psychologists. Q. And do you consider the DSM to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions that have been made over time, especially and most uniquely in those changes that have been made without new scientific
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny that at all. I actually have referred my patients many times to psychologists. Q. And do you consider the DSM to be a non-scientific publication?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions that have been made over time, especially and most uniquely in those changes that have been made without new scientific data, mostly reflecting cultural changes
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. evaluation, which is contrary to what we can know. Q. Do any of your patients, any of your current patients, have mental health diagnoses? A. Yes. Unfortunately, quite a few of them do. Q. And are any of your patients also seeing psychologists or psychiatrists? A. Yes, they are. Q. And do you consider psychiatry to be a legitimate field in medicine? MS. LAND: Object to form. A. I think psychology and psychiatry provide very valuable, when done properly, provide very valuable assistance to our patients. I don't deny that at all. I actually have referred my patients many times to psychologists. Q. And do you consider the DSM to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. members that put together these manuals. And that is it's not that there is not utility in having that, the DSM, but it is certainly not of the rigor that other areas it can't be considered science. Q. And that's a critique as to the DSM as a whole? A. Well, I think the purpose of the DSM, in general, relates to that cataloguing of conditions. It doesn't say that there are not references that can be used to demonstrate the existence of the experiences that people have. But in the end, there are it's a voting process that is actually used to be able to determine what is put in that manual and how those decisions are made. And we can see that very clearly in the revisions that have been made over time, especially and most uniquely in those changes that have been made without new scientific

	D 110		D 120
1	Page 118 PAUL W. HRUZ, M.D., Ph.D.	1	Page 120 PAUL W. HRUZ, M.D., Ph.D.
2	generally to the DSM as a whole? That's	2	Q. But separate and apart from
3	my question.	3	the response, is it your opinion that
4	MS. LAND: Object to form,	4	reliance on patient's self-report for
5	asked and answered.	5	diagnosis is unique to gender dysphoria?
6	A. I would say that the manual,	6	MS. LAND: Objection to form,
7	again, for its purpose, in general, has	7	vague.
8	that for its purpose and we need to	8	A. Again, there are so many
9	understand that for the DSM. There are	9	because of why don't you restate your
10	many different	10	question just so I focus that.
11	Q. Not just related to gender	11	Q. How about I be more specific.
12	dysphoria, you're speaking about the DSM	12	Is anxiety based on self-report?
13	as a whole?	13	A. There are objective measures
14	A. I would say that there are	14	of anxiety that can be monitored, as far
15	levels of evidence that is available for	15	as physiologic responses, including heart
16	the different components of the DSM.	16	rate and blood pressure and physical
17	But, in general, the decisionmaking	17	findings that can be used to corroborate
18	process of how to categorize and portray	18	that experience of anxiety.
19	this as evidence in the revisions that	19	Q. So anxiety is not based on
20	have been made, I would say that that	20	self-report at all?
21	applies generally to the DSM.	21	MS. LAND: Object to form,
22	Q. And is it your opinion that	22	asked and answered.
23	reliance on patients' self-report for	23	A. I did not say that. I said
24	diagnosis is unique to gender dysphoria?	24	there are objective physiologic
25	MS. LAND: Object to form.	25	correlates that help in correlating with
	Page 119		Page 121
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	A. I would say that our response	2	that reported experience.
			* *
3	to the patient's self-report is unique to	3	Q. What about, are there what
3 4	the condition. And I've used in the past,	3 4	Q. What about, are there what about migraines?
3 4 5	the condition. And I've used in the past, and others do as well, of analogous	3 4 5	Q. What about, are there what about migraines?A. Again, there are physiologic
3 4 5 6	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the	3 4 5 6	Q. What about, are there what about migraines?A. Again, there are physiologic responses that can be very much verified.
3 4 5 6 7	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified	3 4 5 6 7	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very
3 4 5 6 7 8	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact.	3 4 5 6 7 8	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well,
3 4 5 6 7 8 9	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is	3 4 5 6 7 8 9	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood
3 4 5 6 7 8 9	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a	3 4 5 6 7 8 9	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes.
3 4 5 6 7 8 9 10	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively	3 4 5 6 7 8 9 10	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that
3 4 5 6 7 8 9 10 11 12	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the	3 4 5 6 7 8 9 10 11 12	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes.
3 4 5 6 7 8 9 10 11 12 13	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the	3 4 5 6 7 8 9 10 11 12 13	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to
3 4 5 6 7 8 9 10 11 12 13 14	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that	3 4 5 6 7 8 9 10 11 12 13 14	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1
3 4 5 6 7 8 9 10 11 12 13 14 15	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not	3 4 5 6 7 8 9 10 11 12 13 14 15	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will
3 4 5 6 7 8 9 10 11 12 13 14 15 16	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time,
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58,
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you use examples you have to recognize the	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58, midway through. And here the sentence
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you use examples you have to recognize the limitations. But that is a unique aspect	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58, midway through. And here the sentence begins, "This is a source of potentially
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you use examples you have to recognize the limitations. But that is a unique aspect that we don't critically question the	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58, midway through. And here the sentence begins, "This is a source of potentially profound unreliability." Do you see that?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you use examples you have to recognize the limitations. But that is a unique aspect that we don't critically question the assertion that is being made in relation	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58, midway through. And here the sentence begins, "This is a source of potentially profound unreliability." Do you see that? A. Is it midway down the page.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the condition. And I've used in the past, and others do as well, of analogous conditions where we don't accept the patient's perception as being verified fact. The perfect example of that is in the example of anorexia nervosa, a patient that is objectively undernourished, that comes in with the perception that they are overweight, the clinician does not accept that self-report as being true and will not propose interventions that allow that patient to lose weight. That's one example that is often used. I think it's any time you use examples you have to recognize the limitations. But that is a unique aspect that we don't critically question the	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. What about, are there what about migraines? A. Again, there are physiologic responses that can be very much verified. There are and this is used very frequently in research studies as well, which include pain responses, blood pressure, heart rate, blood flow changes. There are physiologic correlates to that experience, yes. Q. Can I have you turn to paragraph going back to Exhibit 1 here, this is your report, I think I will get you to the right place this time, paragraph 46. A. Paragraph 46? Q. We're moving to page 58, midway through. And here the sentence begins, "This is a source of potentially profound unreliability." Do you see that?

Page 124 PAUL W. HRUZ, M.D., Ph.D. preceding sentence so I can get the context? A. Okay. Q. Absolutely. A. Okay. sentence that I'm focused on here. You write that, "There's profound unreliability in patient care as the physicians are poor lie detectors' often no more reliable in discerning false reports than flipping a coin and sometimes much worse." Did I read that correctly? A. You read that correctly. Q. And what is your basis for believing that there is a problem of slase reports when it comes to gender dysphoria? MS. LAND: Objection to form. A. So if you back up and read the entire tometext of that paragraph, I begin entire to is so unique in that there is no PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far ar she reliability as far as being able to detecrit that are being made and the unique aspect of this actually to focus to interest that are being made and the unique suspect of this actually to focus to the restant that are being made and the unique suspect of this actually to focus to the recitor of the actual experience that they are very good at being able to determine the veracity of the statements made by the realist provider as the provider saying or that they's intentionally try into the decive their physicians? Paul W. HRUZ, M.D., Ph.D. Page 125 PAUL W. HRUZ, M.D., Ph.D. Page 125 PAUL W. HRUZ, M.D., Ph.D. The provided some example of that in the literature to illustrate that popini. The provided some example of that in the literature that actually proves that, that one's confidence in being able to the correct in one's ability to find out whether there is veracity or the statements that are being made example of that in the published literature refute that and the popinic literature that actually proves extensive ilerature that actually proves that, that one's confidence in being able to the correct in one's a		7. 400		D 404
2 preceding sentence so I can get the context? 4 Q. Absolutely. 5 A. Okay. 6 Q. So just to read to you the sentence that I'm focused on here. You unreliability in patient care as the relevant science documents that physicians are poor 'lie detectors' often no more reliable in discerning false correctly? 10 reports than flipping a coin and some correctly? 11 A. You read that correctly. 12 A. You read that correctly. 13 false reports when it comes to gender dysphoria? 14 MS. LAND: Objection to form. 15 believing that there is a problem of false reports when it comes to gender dysphoria? 16 A. You read that correctly. 17 Q. And what is your basis for peliciving that there is a problem of false reports when it comes to gender dysphoria? 18 believe that patients are lying about the their gender dysphoria? 19 C. Let's take them each in turn. 10 are claiming is true? Is that what you're saying or that they're intentionally try in to deceive their physician? 11 believing that there is a problem of false reports when it cornectly. 12 A. So perhaps, you know, whether what they question is, you know, whether what they are claiming is true? Is that way you're saying or that they're intentionally try in to deceive their physician? 19 C. Let's take them each in turn. 10 A. There are claiming is true? Is that way you're saying or that they're intentionally try in to deceive their physician? 10 Let's take them each in turn. 11 belief with a there is a problem of false reports when it correctly? 11 MS. LAND: Objection to form. 12 A. So perhaps, you know, whether what they euclain is, you know, whether what they assaying or that they? intentionally try to deceive their physician? 12 MS. LAND: Objection to form. 13 False reports when it comes to gender decive their physician? 14 MS. LAND: Objection to form. 15 Edieve that partable, whether they decive their physician? 16 A. The aware of examples where it's bene circulated on social media in dividual about speak to their provider to be able to have acces	1	Page 122	1	Page 124
3 context? 4 Q. Absolutely. 5 A. Okay. 6 Q. So just to read to you the 7 sentence that I'm focused on here. You 8 write that, "There's profound 9 unreliability in patient care as the 10 relevant science documents that 11 physicians are poor lie detectors' often 12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And what is your base for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is again, 25 this is unique in that there is no 26 relevant there is a problem of 27 and hard is your base for 28 declaration to support this assertion as 29 able to detect veracity or falsehood in 29 statements that are being made and the 20 unique aspect of this actually to focus 21 upon is many of the people that are 22 providing this care have the inherent 23 that there is a catually upon the word of the actually the evidence that is present in 29 that the was every good at being 20 able to determine the veracity of the 21 statements made by their patients. And 22 actually, Linculde in my 23 declaration to support this assertion as 24 far as the reliability as far as being 25 able to detect veracity or falsehood in 26 statements that are being made and the 27 unjon is many of the people that are 28 providing this care have the inherent 29 providing this care have the inherent 20 point. 21 There is actually much more 22 extensive literature refute that and 23 that, that one's confidence in being able 24 to be correct in one's ability to find 25 that none's confidence in being able 26 to be correct in one's ability to find 26 the rigented day one to the rigented the refreshed and the unique aspect of this actually to focus 3 that, none's confidence in being able 3 to declevation none's ability to find 3 the firm year and th				
4 Q. Absolutely. 5 A. Okay. 6 Q. So just to read to you the 7 sentence that I'm focused on here. You 8 write that, "There's profound 9 unreliability in patient care as the 10 relevant science documents that 11 physicians are poor 'lie detectors' often 12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And do you have any reason to believe that a relability in patient care as the 18 published literature refute that and 19 unreliability in patient care as the 10 relevant science documents that 11 physicians are poor 'lie detectors' often 12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 18 false reports when it comes to gender 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Object to frum. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is - again, 25 this is unique in that there is no 26 deceive their physician? 27 MS. LAND: Object to form. 28 A. I'm aware of examples where 29 it's been circulated on social media 29 particular end or whether it was actually to at least ask a hypothesis as to whether 20 a place of this actually to focus 21 upon is many of the people that are 22 providing this care have the inherent 23 belief that they are very good at being 24 able to determine the veracity of the 25 statements made by their patients. And 26 actually the evidence that is present in 27 the published literature refute that and 28 that in the literature refute that and 29 point. 20 disceive that patients are lead the 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 25 deceive their patients are leading it and it i	1			
5 A. Okay. Q. So just to read to you the sentence that I'm focused on here. You write that, "There's profound urneliability in patient care as the relevant science documents that physicians are poor lie detectors' often no more reliable in discerning false reports than flipping a coin and sometimes much worse." Did I read that correctly? A. You read that correctly. Q. And what is your basis for believing that there is a problem of selieving that there is a problem of she believing that there is a problem of she intercontext of that paragraph, I begin by talking about that this is - again, this is unique in that there is no Page 123 PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity of falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And for actually, 1- irrectly and a declaration to support this assertion as far as the reliability as far as being able to detect wareity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And for actually, 1- irrectly of the statements made by their patients. And for actually the evidence that is present in frepublished literature refute that and the published literature refute that and the provider of the care and the statements made by their patients. And for the reliability of form. Page 123 PAUL W. HRUZ, M.D., Ph.D. There is actually much more that in the litera	1			
6 Q. So just to read to you the 7 sentence that I'm focused on here. You 8 write that, "There's profound 9 unreliability in patient care as the 10 relevant science documents that 11 relevant science documents that 12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 25 by talking about that this is again, 26 this is unique in that there is no 27 Page 123 28 made by that patient. And then I go onto 29 and, actually, I include in my 20 declaration to support this assertion as 21 a far as the reliability as far as being 22 a bale to detect veracity or falsehood in 23 statements that are being made and the 24 unique aspect of this actually to focus 29 providing this care have the inherent 210 belief that they are very good at being 211 a belief that they are very good at being 212 that in the literature refute that and 213 c) Let's take them each in turn. 214 I be there any reason to believe that 225 providing this care have the inherent 226 point. 28		- ·		
8 write that, "There's profound write that wite that they were their physician? "A. So perhaps, you know, whether was the you know, whether was they caused with they are claiming is true? Is that what you're are claiming is true? Is that what you're saying or that they're intentionally try to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that was eimentionally trying to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that w		· · · · · · · · · · · · · · · · · · ·		
8 write that, "There's profound point in the politic in patient care as the reliability in patient care as the reliability in patient. And then I go onto and confirm or refute the assertion that is satements that are being made and the unique aspect of this actually to providing this care have the inherent belief that they are very good at being at the they's corrective their physician? A. So perhaps, you know, the question is, you know, whether what they are claiming is true? Is that what you're saying or that they're intentionally try to deceive their physician? Q. Let's take them each in turn. Is there any reason to believe that patients are intentionally trying to deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where if deceive their physician? MS. LAND: Object to form. A. I'm aware of examples where indeceive their physician? MS. LAND: Object to form. A. I'm aware of examples where indeceive their physician? MS. LAND: Object to form. A. I'm aware of examples where indeceive their physician? MS. LAND: Object to form. A. I'm aware of examples where indeceive their physician? MS. LAND: Object to form. A. I'm aware of examples where indeceive their physician? MS. LAND: Object to form. A. I'm aware				
9 unreliability in patient care as the 10 relevant science documents that 11 relevant science documents that 12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 19 point. 20 There is actually much more 21 extensive literature that actually proves 22 that, that one's confidence in being able 24 to be correct in one's ability to find 25 the correct in one's ability to find 26 the visual than the previous that individual should speak to their provider to deceive their physician? 27 the decieve their physician? 28 the ther any reason to believe that 29 patients are intentionally trying to deceive their physician? 29 the decieve their physician? 20 patients are intentionally trying to deceive their physician? 20 patients are intentionally trying to deceive their physician? 21 PAUL W.HRUZ, M.D. Ph.D. 22 that individual sh	1			•
10 relevant science documents that 11 physicians are poor lie detectors' often 11 12 no more reliable in discerning false 12 to deceive their physicians 12 to deceive their physicians 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 14 to correctly? 15 to correctly? 16 A. You read that correctly. 16 A. You read that correctly. 16 A. You read that correctly. 16 believing that there is a problem of 18 A. I'm aware of examples where 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the entire context of that paragraph, I begin 23 this is unique in that there is no 25 this is unique in that there is no 26 this is unique in that there is no 27 The paragraph 10 this paragraph 10 t	1			
11 physicians are poor 'lie detectors' often no more reliable in discerning false reports than flipping a coin and sometimes much worse." Did I read that correctly? 12 A. You read that correctly. 13 Q. Let's take them each in turn. 14 Is there any reason to believe that patients are intentionally trying to deceive their physician? 17 Q. And what is your basis for believing that there is a problem of believing that there is a problem of believing that there is a problem of dase reports when it comes to gender daysphoria? 19 A. So if you back up and read the entire context of that paragraph, I begin by talking about that this is — again, this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far ar sthe reliability as far as being able to detect veracity or falsehood in unique aspect of this actually to focus 10 unique aspect of this actually to focus 11 belief that they re very good at being able to determine the veracity of the statements made by their patients. And 16 actually the evidence that is present in the published literature refute that and 18 I didn't — I provided some example of that in the literature to illustrate that 20 prior. 10 There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find		* *		- · · · · · · · · · · · · · · · · · · ·
12 no more reliable in discerning false 13 reports than flipping a coin and 14 sometimes much worse." Did I read that 15 correctly? 16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion and, actually, 1 include in my 6 declaration to support this assertion as able to detect veracity or falsehood in 9 statements that are being made and the unique aspect of this actually to focus 10 upon is many of the people that are providing this care have the inherent to belief that they are very good at being able to determine the veracity of the 15 statements made by their patients. And actually the evidence that is present in the published literature refute that and 18 I didn't I provided some example of that in the literature to illustrate that point. 21 There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find 22 to be correct in one's ability to find 23 to deceive their physician? 4 Let's take them each in turn. 4 Let's take them each in turn. 4 Deceive their physician? 4 A. I'm aware of examples where it's been circulated on social media platforms the exact language that an individual should speak to their provider to be able to have access to whether 22 that was acreased to speak to their provider with a texaset language that an individual should speak to				
reports than flipping a coin and sometimes much worse." Did I read that sometimes may read that sometimes may read that sometimes where it's been circulated on social media platforms the exact language that an individual should speak to their provider to be able to have access to gender-affirming care, which is often recited verbatim, and would lead one to at least ask a hypothesis as to whether. 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 2 objective b	1			
14 sometimes much worse." Did I read that correctly? 15		-		
15 correctly? 16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 15 belief that they are very good at being 16 actually, the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 fath in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 25 diagnary and read the 26 decive their physician? 30 MS. LAND: Object to form. 4 A. I'm aware of examples where 18 individual should speak to their provider 10 to be able to have access to 22 gender-affirming care, which is often 24 recited verbatim, and would lead one to 25 at least ask a hypothesis as to whether 26 at least ask a hypothesis as to whether 27 that was being done to obtain a 28 particular end or whether it was actually 29 that was being done to obtain a 29 particular end or whether it was actually 20 that was being done to obtain a 21 particular end or whether it was actually 22 that a was being done to obtain a 23 particular end or whether it was actually 24 that was being done to obtain a 25 that individual had. 26 So is that a you know, I 27 mean, these are social m	1			-
16 A. You read that correctly. 17 Q. And what is your basis for 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 10 providing this care have the inherent 11 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 19 that in the literature to illustrate that 20 point. 21 deceive their physician? MS. LAND: Object to form. 22 A. I'm aware of examples where it's been circulated on social media platforms the exact language that an individual should speak to their provider recited verbatim, and would lead one to at least ask a hypothesis as to whether 22 that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual should speak to their provider recited verbatim, and would lead one to at least ask a hypothesis as to whether 24 to be able to have access to 25 gender-affirming care, which is often recited verbatim, and would lead one to at least ask a hypothesis as to whether 25 that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual shad. So is that a you know, I mean, these are social media reports with the limi	1			
17 Q. And what is your basis for believing that there is a problem of 18 believing that there is a problem of 19 false reports when it comes to gender 20 dysphoria? 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin 24 by talking about that this is again, 24 this is unique in that there is no 25 this is unique in that there is no 26 piective biological correlates to 27 confirm or refute the assertion that is 3 confirm or refute the assertion that is 3 able to detect veracity or falsehood in 29 statements that are being made and the 30 unique aspect of this actually to focus 10 upon is many of the people that are 11 able to determine the veracity of the 31 actually the evidence that is present in 41 the published literature refute that and 17 the published literature refute that and 18 I didn't I provided some examples of this belief that the literature to illustrate that 20 point. 20 A. So if you back up and read the 22 to be able to have access to 23 gender-affirming care, which is often 24 to be able to have access to 25 at least ask a hypothesis as to whether 25 at least ask a hypothesis as to whether 26 at least ask a hypothesis as to whether 27 at least ask a hypothesis as to whether 28 that was being done to obtain a 25 particular end or whether it was actually a reflection of the actual experience 26 that individual had. 30 is that a - you know, I 30 mean, the wind and actually a reflection of the actual experience 30 that was being 40 mether it was actually 40 a reflection of the actual experience 30 that was being 41 able to detect veracity or falsehood in 40 the statements are social media reports with 41 the limitations. But there are examples 41 that have been demonstrated by others 42 that have been demonstrated by others 43 that not all patients are providing 44 objective data to for practitioner. 45 that one determine the veracity of the 45 that have been demonstrated by others 46 that would lead to at leas		•		• • •
18 believing that there is a problem of false reports when it comes to gender dysphoria? 20 dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the entire context of that paragraph, I begin by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 10 upon is many of the people that are 21 providing this care have the inherent 22 belief that they are very good at being 14 able to determine the veracity of the 31 that in the literature refute that and 15 that in the literature refute that and 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 18 A. I'm aware of examples where it's been circulated on social media individual should speak to their provider to be able to have access to gender-affirming care, which is often recited verbatim, and would lead one to at least ask a hypothesis at least ask a hypothesis as to whether Page 125 PAUL W. HRUZ, M.D., Ph.D. 4 that was being done to obtain a particular end or whether it was actually a reflection of the actual exact ask a hypothesis that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objectiv				
19 false reports when it comes to gender dysphoria? 21 MS. LAND: Objection to form. 22 A. So if you back up and read the 23 entire context of that paragraph, I begin by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of that the the inherent 20 point. 19 it's been circulated on social media 20 platforms the exact language that an individual should speak to their provider to be able to have access to 20 gender-affirming care, which is often recited verbatim, and would lead one to at least ask a hypothesis as to whether 21 that was being done to obtain a 20 particular end or whether it was actually a reflection of the actual experience 21 that individual had. 21 that was being done to obtain a 21 particular end or whether it was actually a 22 reflection of the actual experience 23 that never being made and the 32 particular end or whether it was actually 4 a reflection of the actual experience 33 that individual had. 4 reflection of the actual experience 34 that individual had. 4 reflection of the actual experience 34 that individual had. 4 reflection of the actual experience 35 that individual had. 4 reflection of the actual experience 34 that individual had. 4 reflection of the actual experience 35 that never being able and the 36 particular end or whether it was actually 4 a reflection of the actual experience 35 that never being and the 37 mean, these are social media reports wit				ŭ ,
20 dysphoria? 20				
MS. LAND: Objection to form. A. So if you back up and read the entire context of that paragraph, I begin by talking about that this is again, this is unique in that there is no Page 123 PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being table to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and If din't I provided some example of that in the literature to illustrate that point. MS. LAND: Objection to form. 21 individual should speak to their provider to be able to have access to gender-affirming care, which is often recited verbatim, and would lead one to at least ask a hypothesis as to whether Page 125 PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual should speak to their provider at least ask a hypothesis as to whether Page 125 PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading	1			
A. So if you back up and read the entire context of that paragraph, I begin by talking about that this is again, 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 this is unique in that there is no 25 that individual had. 30 particular end or whether it was actually a reflection of the actual experience that individual had. 30 particular end or whether it was actually a reflection of the actual experience that individual had. 30 particular end or whether it was actually a reflection of the actual experience that individual had. 30 particular end or whether it was actually a reflection of the actual experience that individual had. 31 particular end or whether it was actually a reflection of the actual experience that individual had. 32 particular end or whether it was actually a reflection of the actual experience that individual had. 32 particular end or whether it was actually a reflection of the actual experience that individual had. 44 that individual had. 45 particular end or whether it was actually a reflection of the actual experience that individual had. 45 particular end or whether it was actually a reflection of the actual experience that individual had. 46 particular end or whether it was actually a reflection of the actual experience that individual had. 46 particular end or whether it was actually a reflection of the actual experience that individual had. 46 particular end or whether it was actually a reflection of the actual experience that indi		• •		
23 entire context of that paragraph, I begin 24 by talking about that this is again, 25 this is unique in that there is no Page 123 1 PAUL W. HRUZ, M.D., Ph.D. 2 objective biological correlates to 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 recited verbatim, and would lead one to at least ask a hypothesis as to whether 24 recited verbatim, and would lead one to at least ask a hypothesis as to whether 24 recited verbatim, and would lead one to at least ask a hypothesis as to whether 24 recited verbatim, and would lead one to at least ask a hypothesis as to whether 25 that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. 6 So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysph				
by talking about that this is again, this is unique in that there is no Page 123 PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in unique aspect of this actually to focus unique aspect of this actually to focus providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. Page 123 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.				
this is unique in that there is no Page 123 PAUL W. HRUZ, M.D., Ph.D. page 125 PAUL W. HRUZ, M.D., Ph.D. page 126 PAUL W. HRUZ, M.D., Ph.D. page 127 PAUL W. HRUZ, M.D., Ph.D. page 128 PAUL W. HRUZ, M.D., Ph.D. page 125 that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing this care have the inherent belief that they are very good at being the belief that they are very good at being that are providing that an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. There is actually much more that actually proves that, that one's confidence in being able to be correct in one's ability to find the transfer of the actua	1			
Page 123 PAUL W. HRUZ, M.D., Ph.D. Page 125 Pate 14 a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that individual had. So is that a you know, I mean, these are social media reports with the limitations. But here are social media reports with the limitations. But here are social media reports with the limitations. But here are social media reports with the limitations. But here are social medi			25	at least ask a hypothesis as to whether
PAUL W. HRUZ, M.D., Ph.D. pojective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't — I provided some example of that in the literature to illustrate that point. PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a — you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a — you know, I mean, these are social media reports with the limitations. But there are examples that not all patients are providing that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of				
2 that was being done to obtain a 3 confirm or refute the assertion that is 4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 2 that was being done to obtain a 3 particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing objective data to for practitioner. 12 with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a provider with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.		Page 123		Page 125
confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being statements that are being made and the unique aspect of this actually to focus providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that, that one's confidence in being able to be correct in one's ability to find are flection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.	1		1	
4 made by that patient. And then I go onto 5 and, actually, I include in my 6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that individual had. 6 So is that a you know, I 7 mean, these are social media reports with 8 the limitations. But there are examples 9 that have been demonstrated by others 10 that would lead to at least a hypothesis 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 19 problem with adolescents intentionally 10 misleading their providers in order to 11 objection to form. 12 objective data to for practitioner. 13 belief that they are very good at being 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.		PAUL W. HRUZ, M.D., Ph.D.		PAUL W. HRUZ, M.D., Ph.D.
and, actually, I include in my declaration to support this assertion as far as the reliability as far as being statements that are being made and the unique aspect of this actually to focus unique aspect of this actually to focus providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves that in declaration to support this assertion as far as the reliability as far as being mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? There is actually much more extensive literature that actually proves that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that not all patients are providing that not all patients are examples that not all patients are providing that not all patients are providing that not all patients are providing that not all patients are providers that not all patients are providing that not all patients are providers th	2	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to	2	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a
6 declaration to support this assertion as 7 far as the reliability as far as being 8 able to detect veracity or falsehood in 9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 6 So is that a you know, I 7 mean, these are social media reports with 8 the limitations. But there are examples 10 that have been demonstrated by others 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is	2 3	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually
far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus unique aspect of this actually to focus tupon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto	2 3 4	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience
9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that have been demonstrated by others 10 that would lead to at least a hypothesis 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 20 point. 20 problem with adolescents intentionally 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 9 that have been demonstrated by others 10 that would lead to at least a hypothesis 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 to be correct in one's ability to find MS. LAND: Objection to form.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had.
9 statements that are being made and the 10 unique aspect of this actually to focus 11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that have been demonstrated by others 10 that would lead to at least a hypothesis 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 20 point. 20 problem with adolescents intentionally 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 9 that have been demonstrated by others 10 that would lead to at least a hypothesis 11 that not all patients are providing 12 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 to be correct in one's ability to find MS. LAND: Objection to form.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I
11 upon is many of the people that are 12 providing this care have the inherent 13 belief that they are very good at being 14 able to determine the veracity of the 15 statements made by their patients. And 16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 21 Inthat not all patients are providing 22 objective data to for practitioner. 13 They come to their provider 14 with an intended goal of having access to 15 this form of intervention, and they will 16 like to do whatever they can to have that 17 result and attempt to facilitate that by 18 making these types of statements. 19 Q. So it's your view there is a 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with
providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and If it in the literature to illustrate that point. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to objective data to for practitioner. They come to their provider their provider that an intended goal of having access to this form of intervention, and they will nearly with an attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples
belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that, that one's confidence in being able to be correct in one's ability to find MS. LAND: Objection to form.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others
able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves that, that one's confidence in being able to determine the veracity of the veracity of the with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis
able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves that, that one's confidence in being able to the vidence that veracity of the with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing
16 actually the evidence that is present in 17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 26 like to do whatever they can to have that 27 result and attempt to facilitate that by 28 making these types of statements. 29 Problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner.
17 the published literature refute that and 18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 27 result and attempt to facilitate that by 28 making these types of statements. 29 problem with adolescents intentionally 20 misleading their providers in order to 21 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider
18 I didn't I provided some example of 19 that in the literature to illustrate that 20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 28 making these types of statements. 19 Q. So it's your view there is a 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to
that in the literature to illustrate that point. There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find 20	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will
20 point. 21 There is actually much more 22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 20 problem with adolescents intentionally 21 misleading their providers in order to 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that
There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find 21 misleading their providers in order to cobtain treatment for gender dysphoria; is that right? 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by
22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements.
22 extensive literature that actually proves 23 that, that one's confidence in being able 24 to be correct in one's ability to find 22 obtain treatment for gender dysphoria; is 23 that right? 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a
24 to be correct in one's ability to find 24 MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to
25 out whether there is veracity or 25 A. I would not state in a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PAUL W. HRUZ, M.D., Ph.D. objective biological correlates to confirm or refute the assertion that is made by that patient. And then I go onto and, actually, I include in my declaration to support this assertion as far as the reliability as far as being able to detect veracity or falsehood in statements that are being made and the unique aspect of this actually to focus upon is many of the people that are providing this care have the inherent belief that they are very good at being able to determine the veracity of the statements made by their patients. And actually the evidence that is present in the published literature refute that and I didn't I provided some example of that in the literature to illustrate that point. There is actually much more extensive literature that actually proves that, that one's confidence in being able to be correct in one's ability to find	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PAUL W. HRUZ, M.D., Ph.D. that was being done to obtain a particular end or whether it was actually a reflection of the actual experience that individual had. So is that a you know, I mean, these are social media reports with the limitations. But there are examples that have been demonstrated by others that would lead to at least a hypothesis that not all patients are providing objective data to for practitioner. They come to their provider with an intended goal of having access to this form of intervention, and they will like to do whatever they can to have that result and attempt to facilitate that by making these types of statements. Q. So it's your view there is a problem with adolescents intentionally misleading their providers in order to obtain treatment for gender dysphoria; is that right? MS. LAND: Objection to form.

	P. 104		P. 120
1	Page 126 PAUL W. HRUZ, M.D., Ph.D.	1	Page 128 PAUL W. HRUZ, M.D., Ph.D.
2	categorical manner that it applies to all	2	health professionals to subjectively make
3	patients that present to their providers.	3	life-changing decisions in gender
4	But I will assert, as I did in my	4	dysphoria cases, such mental health
5	declaration, that the provider that is	5	professionals often unreliably
6	encountering the patients in their office	6	overestimate their ability to offer such
7	has no basis objectively to know whether	7	'crystal ball' assessments and
8	that patient is sincere and or not,	8	predictions. Few of these professionals
9	whether that is an accurate	9	seem aware of the research showing the
10	representation of their internal feelings	10	grave limitations on the experience,
11	or not.	11	judgment and methodologies of mental
12	Q. And do you have any reason to	12	health professionals." Did I read that
13	believe that the Plaintiffs in this case	13	right?
14	are intentionally misleading their	14	A. You did indeed read that
15	providers about their gender dysphoria?	15	correctly.
16	MS. LAND: Objection to form.	16	Q. What is a poorly qualified
17	A. I have no basis. I am not	17	social worker or other mental health
18	again, I am serving as an expert in this	18	professional?
19	case to present my expertise as a	19	A. So somebody that well,
20	physician-scientist in the literature.	20	let's put it this way, the amount of
21	I've not been directly	21	training that is provided for many of the
22	involved in the care of these patients, I	22	social workers that engage in essentially
23	have not seen their medical records and	23	checking the boxes for the DSM diagnosis
24	I'm not in a position to be able to make	24	of gender dysphoria, their experience is
25	that determination.	25	limited to reading the DSM and applying
	Page 127		Page 129
1	Page 127 PAUL W. HRUZ, M.D., Ph.D.	1	Page 129 PAUL W. HRUZ, M.D., Ph.D.
2		1 2	-
1	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective		PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and	2 3 4	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is the bottom of page 61.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from the reports of people that I have spoken
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is the bottom of page 61. A. I have that at hand.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from the reports of people that I have spoken to, as I've done my due diligence in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is the bottom of page 61. A. I have that at hand. Q. So I'm going to read here.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from the reports of people that I have spoken to, as I've done my due diligence in trying to understand all the aspects of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is the bottom of page 61. A. I have that at hand. Q. So I'm going to read here. You write, "As the gender transition	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from the reports of people that I have spoken to, as I've done my due diligence in trying to understand all the aspects of this condition, I have repeatedly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. Given your concerns about the lack of objective a lack of objective criteria to verify gender dysphoria and your concerns about potentially misleading providers, are there any circumstances in which you believe that treatment for gender dysphoria in adolescents could be effectively studied? MS. LAND: Objection to form. A. That is a very broad question and I don't know if you have an hour for me to go through to adequately answer that question or if you want to focus the question. Q. Yeah. I don't have an hour for you to go through, so I'll just move on. Okay. If I could have you turn to paragraph 50 on page 61, and this is the bottom of page 61. A. I have that at hand. Q. So I'm going to read here.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that criteria. Many of them have not even a fraction of the knowledge of the existing scientific literature, much of which I provided in my declaration. They accept it at face value as fact without ever critically evaluating the merits of the approach. And I know this from conversations that I've had with many that are providing that service. When I directly challenge them, if they know the research that I have mentioned in my declaration, they are entirely unaware of that. Q. And you said many are doing this. How many? A. I have not systematically surveyed nor am I aware of the absolute number. What I have become aware of from the reports of people that I have spoken to, as I've done my due diligence in trying to understand all the aspects of

Page 130 Page 132 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 being unaware beyond the actual check base in making that, and actually to 3 3 boxes for the DSM diagnosis. So that has challenge them when they make statements 4 been my experience. 4 that are not supported by scientific evidence. And I've uniformly, when I've 5 Q. And who have you spoken to? 5 A. I've spoken to dozens of had those conversations, are struck by 6 6 7 people over the last ten years. 7 the lack of knowledge beyond, for 8 Q. So dozens of people over the 8 example, the WPATH statements to know the 9 last ten years. And that is the only 9 basis for which those statements are 10 basis for your assertion that there are 10 being made. 11 poorly trained mental health 11 It is something that is highly 12 professionals providing these 12 concerning to me, and that I continue to 13 evaluations? 13 engage in the dialogue to be able to 14 MS. LAND: Object to form. 14 bring this to light. 15 A. So if you're asking a 15 Q. Do you remember the name of question, has there been a scientific 16 16 anyone that you challenged in this 17 study that has directly assessed the regard? 17 18 percentage of individuals that have 18 MS. LAND: Object to form. adequate qualifications that are aware of 19 19 A. I would have to -- I mean, 20 the scientific literature in the field, 20 it's happened over so many times and so 21 the limitations of the research that's 21 many conversations. I believe my ability 22 22 to pick out isolated circumstances with being done versus those that are merely 23 reading the DSM-V and providing a letter 23 the context of when -- which those 24 for patients, I'm not aware of that 24 conversations occurred and the details of 25 literature. 25 those conversations. I think would lead Page 131 Page 133 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 O. And what was the context of to error, and I prefer to stay objective 3 3 the discussions that you had with mental to provide the best service to this health professionals about these 4 court. 4 5 5 evaluations? Q. And so you can't remember the 6 name of anyone that you had one of these 6 A. They have come under multiple different settings for multiple different 7 7 conversations with? 8 purposes. 8 MS. LAND: Objection to form. 9 As I have stated previously, 9 A. I can certainly remember many 10 10 my task, when this was first put forward individuals I've spoken to, but the by a member of my faculty in 2012, was to circumstances by which I've spoken to 11 11 12 be able to understand the approach that 12 them for, the questions that were being 13 was being proposed, to be able to gather 13 asked, the context of the questions 14 information relevant to making an 14 differed markedly and that certainly 15 assessment about whether this was a 15 influences one's ability to assess that prudent course of action and this did 16 16 conversation. 17 include talking to as many individuals as 17 In the context of this 18 possible. 18 deposition I think it would be misleading 19 It's something that I've 19 to be able to draw attention to any one 20 continued to do over the last decade and 20 of those conversations without having the 21 21 very much welcome conversations with ability to engage in the full context of 22 people that are advocating for this form 22 that conversation. 23 of medical intervention, to be able to 23 Q. So you're unwilling today to 24 listen very carefully to their 24 recall even a single name of someone you 25 experience, to assess other knowledge 25 had what you describe as these highly

	7. 404		D 404
1	Page 134 PAUL W. HRUZ, M.D., Ph.D.	1	Page 136 PAUL W. HRUZ, M.D., Ph.D.
2	concerning conversations with?	2	MS. LAND: Objection to form.
3	MS. LAND: Objection to form,	3	A. That is not correct. I did not
4	asked and answered.	4	say that. I said that people that have
5	A. I would say I'm not unwilling,	5	the relevant they are members of the
6	I'm incapable of doing that in a way that	6	relevant scientific community that have
7	would serve this court.	7	expertise to be able to critically
8	Q. Who would be appropriately	8	evaluate the literature, recognize the
9	qualified to evaluate someone for gender	9	strengths and limitations.
10	dysphoria?	10	So that is a general statement
11	MS. LAND: Object to form.	11	of the qualifications of the relevant
12	A. So, again, those that are	12	scientific community. And I would draw
13	typically charged with caring for	13	just looking at my own experience in
14	individuals that have the difficulties	14	reviewing clinical trials and research
15	that are experienced in the setting of	15	papers, I think that would be the
16	sex, gender identity discordance would be	16	standard that I would expect of anybody
17	the psychological profession. But there	17	that would want to opine in that area.
18	are many different levels of expertise in	18	Q. And among those currently
19	these areas.	19	assessing adolescents with gender
20	The ones that would be most	20	dysphoria, what percentage would you say
21	reliable would be the ones that have	21	currently meet that standard, based on
22	there are members of the relevant	22	your best estimate?
23	scientific community that have the	23	A. Again, I don't have an
24	ability to objectively, in a	24	objective research study to know, but I
25	non-idealogical, non-biased manner look	25	would say that it is a minority of
	Page 135		Page 137
1		1	= -
1 2	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that		PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that	1 2 3	= -
	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically	2	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that
2 3	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that	2 3	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones
2 3 4	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are	2 3 4	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly—I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly—I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment".
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out individual names.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment". Q. So for a patient who has
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly—I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out individual names. Q. So individuals who would be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment". Q. So for a patient who has received proper assessment and been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly—I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out individual names. Q. So individuals who would be qualified would be those who have	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment". Q. So for a patient who has received proper assessment and been recommended for treatment with, say,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly—I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out individual names. Q. So individuals who would be qualified would be those who have published in the area and who recognize	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment". Q. So for a patient who has received proper assessment and been recommended for treatment with, say, pubertal suppression for gender dysphoria, after proper assessment would you support the provision of treatment?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. at the evidence that's available that have been involved in critically assessing the literature and there are individuals that have those qualifications. Q. Can you think of any individuals that have those qualifications? A. You know, there's certainly I have to go through my database of hundreds of papers that I reviewed and many of them are authors of those papers that acknowledge the limitations in the literature that give me the evidence that they are critically asking these questions. And so I would have to go back to my records to be able to pull out individual names. Q. So individuals who would be qualified would be those who have published in the area and who recognize the limitations of the existing research;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. patients. And I would say that the ones that I am most aware of are the ones that are being cared for are not within the United States. Q. For those that are receiving proper assessment and evaluation, do you support the provision of treatment for those individuals sorry. Excuse me. Let me rephrase. For individuals who are receiving proper assessment, as you just described it in or outside the United States, do you support a provision of treatment for those patients? MS. LAND: Objection, form. A. So you'd have to specify what you mean by "treatment". Q. So for a patient who has received proper assessment and been recommended for treatment with, say, pubertal suppression for gender dysphoria, after proper assessment would

	D 120		P. 140
1	Page 138 PAUL W. HRUZ, M.D., Ph.D.	1	Page 140 PAUL W. HRUZ, M.D., Ph.D.
2	A. I think this goes back to what	2	A. I stated that I don't have the
3	I've already answered previously about	3	literature, the study has not been
4	the state of knowledge and about the	4	conducted to be able to assess that, but
5	relative risks and benefits of the	5	I think it is a substantial portion.
6	treatment paradigm.	6	And, you know, to put a number on that,
7	There are many other aspects	7	I'm not aware of any research studies
8	of which would be considered treatment	8	that allow one to make a definitive
9	that would not fall under the category of	9	assessment on that. I do know that there
10	the interventions that I have concluded	10	are, based on percent-wise of the number
11	are not supported by the available	11	of people that have expressed their
12	scientific evidence.	12	concerns, that it's a significant number.
13	Q. So it's not just the	13	Q. So you don't so you don't
14	assessment process that you're concerned	14	know the percentage?
15	about; is that correct?	15	MS. LAND: Object to form.
16	MS. LAND: Object to form.	16	A. Percentage of what?
17	A. As I said previously, there	17	Q. You don't know the percentage
18	are questions about etiology, diagnosis,	18	of patients who are not receiving an
19	risks, benefits, long-term outcomes and	19	adequate assessment based on your
20	the availability of alternative	20	assessment of what is happening?
21	approaches, all that I have concerns	21	MS. LAND: Object to form.
22	about.	22	A. Let me broaden this, okay,
23	Q. So taking just the assessment	23	because I think it's important. And it's
24	alone, that is if that were done	24	not you know, the concern I have is in
25	properly, as you've described it, you	25	the whole assessment process, itself.
	Page 139		Page 141
1	Page 139 PAUL W. HRUZ, M.D., Ph.D.	1	Page 141 PAUL W. HRUZ, M.D., Ph.D.
1 2		1 2	= -
	PAUL W. HRUZ, M.D., Ph.D.		PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that	2	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in
2 3	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct?	2 3	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but
2 3 4	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form,	2 3 4	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions. Q. So previously you said, going	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase "proper assessment", there are many
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions. Q. So previously you said, going back a few questions, you said a minority	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase "proper assessment", there are many dimensions to what is necessary for a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions. Q. So previously you said, going back a few questions, you said a minority of patients are receiving proper	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase "proper assessment", there are many dimensions to what is necessary for a proper assessment beyond the DSM check
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions. Q. So previously you said, going back a few questions, you said a minority of patients are receiving proper assessments in the United States; is that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase "proper assessment", there are many dimensions to what is necessary for a proper assessment beyond the DSM check box diagnosis.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. would still have concerns; is that correct? MS. LAND: Object to form, asked and answered. A. In the context of the ability so this is why it's critically important to be able to do properly controlled studies. So that if you take a patient population that is heterogeneous, as far as underlying precipitating factors, etiologies, and even ability to since there is not an ability to accurately identify the veracity of the claims that are being made, it is essential then in that setting to be able to conduct the research in a randomized manner to be able to make valid conclusions. Q. So previously you said, going back a few questions, you said a minority of patients are receiving proper	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So if one followed the DSM in checking the boxes for the criteria but failed to assess underlying psychological comorbidity, oftentimes which predated any evidence of onset of gender dysphoria, and to critically evaluate whether that might be contributory to the experience that that individual experienced, you know, that is an important component of what would be necessary for valid assessment. And the way that the standards have been put forward are to essentially check the boxes for the diagnostic criteria to be able to give them the label of gender dysphoria, and that is inadequate for an assessment. When you use the phrase "proper assessment", there are many dimensions to what is necessary for a proper assessment beyond the DSM check

	D 140		D 144
1	Page 142 PAUL W. HRUZ, M.D., Ph.D.	1	Page 144 PAUL W. HRUZ, M.D., Ph.D.
2	Arkansas are treating patients with	2	A. I have knowledge what is
3	gender dysphoria?	3	stated in the Complaint and the
4	MS. LAND: Objection to form.	4	practitioners that have made public
5	A. Are you asking if I've ever	5	disclosures.
6	practiced medicine in Arkansas? I have	6	My knowledge is that they
7	not.	7	claim to follow the WPATH guidelines,
8	Q. Do you have any specific	8	which there is much that can be said
9	knowledge about how clinicians in	9	about that guideline, and how it is being
10	Arkansas are treating patients with	10	implemented, and all of the difficulties
11	gender dysphoria?	11	that are presented by those
12	MS. LAND: Objection to form.	12	recommendations.
13	A. So are you asking me; have I	13	Q. And which practitioners in
14	read the consent forms of all of the	14	Arkansas are you referring to?
15	practitioners in Arkansas? Have I I'm	15	A. I believe that there's one in
16	familiar with what is made in the	16	the Complaint that was listed. I'd have
17	Complaint, as far as the assertions that	17	to go back to the actual Complaint. But
18	are being made about following the WPATH	18	I'm talking specifically about the
19	guidelines, but that's the extent.	19	assertions that are being made.
20	I've not practiced medicine in	20	I've heard repeatedly in the
21	Arkansas and I can only rely upon the	21	case here about statements about
22	evidence that's been presented to me to	22	referring to these medical group
23	this point in time.	23	guidelines as being followed. And if
24	Q. So you have no knowledge	24	they are being followed, in the absence
25	beyond the Complaint about how the	25	of exploring alternative hypotheses, I
	Page 143		Page 145
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	treatment for how adolescent patients	2	would not consider that to be adequate
3	with gender dysphoria are treated in	2 3	would not consider that to be adequate assessment.
3 4	with gender dysphoria are treated in Arkansas?	2 3 4	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can
3 4 5	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form.	2 3 4 5	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70?
3 4 5 6	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word	2 3 4 5 6	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero?
3 4 5 6 7	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive	2 3 4 5 6 7	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're
3 4 5 6 7 8	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of	2 3 4 5 6 7 8	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental
3 4 5 6 7 8 9	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would	2 3 4 5 6 7 8 9	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And
3 4 5 6 7 8 9	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about	2 3 4 5 6 7 8 9	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender
3 4 5 6 7 8 9 10	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment".	2 3 4 5 6 7 8 9 10	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this
3 4 5 6 7 8 9 10 11 12	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an	2 3 4 5 6 7 8 9 10 11 12	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental
3 4 5 6 7 8 9 10 11 12 13	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender	2 3 4 5 6 7 8 9 10 11 12 13	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations
3 4 5 6 7 8 9 10 11 12 13 14	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas?	2 3 4 5 6 7 8 9 10 11 12 13 14	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the
3 4 5 6 7 8 9 10 11 12 13 14 15	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the
3 4 5 6 7 8 9 10 11 12 13 14 15 16	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal knowledge about what the evaluation	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with that sentence?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal knowledge about what the evaluation process you have no personal knowledge	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with that sentence? A. I do.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal knowledge about what the evaluation process you have no personal knowledge about the evaluation process for patients	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with that sentence? A. I do. Q. And what is your basis for
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal knowledge about what the evaluation process you have no personal knowledge about the evaluation process for patients with gender dysphoria in the State of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with that sentence? A. I do. Q. And what is your basis for saying that patients are not properly
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	with gender dysphoria are treated in Arkansas? MS. LAND: Objection to form. A. Again, you used the word "treatment", which is a comprehensive statement that includes a lot of different dimensions. So I would appreciate you be more specific about what you mean by "treatment". Q. Have you ever sat in on an evaluation of a patient for gender dysphoria in the State of Arkansas? MS. LAND: Objection to form. A. I do not practice in Arkansas and I have not been present in a gender clinic in the State of Arkansas. Q. Okay. So you have no personal knowledge about what the evaluation process you have no personal knowledge about the evaluation process for patients	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	would not consider that to be adequate assessment. Q. Okay. Still on Exhibit 1, can we turn to paragraph 60 on page 70? A. Six-zero? Q. Six-zero, yes. And here you're describing here some of the fundamental purposes of the practice of medicine. And towards the end you write, "The gender transition industry violates this essential principle by using experimental treatments on vulnerable populations without properly informing them of the actual risks and limitations of the treatments." Did I read that correctly? A. That is the sentence as it is written, yes. Q. And do you still agree with that sentence? A. I do. Q. And what is your basis for

	D 146		D 140
1	Page 146 PAUL W. HRUZ, M.D., Ph.D.	1	Page 148 PAUL W. HRUZ, M.D., Ph.D.
$\frac{1}{2}$	A. It is based upon the	$\frac{1}{2}$	MS. LAND: Object to form.
3	everything that's contained within my	3	
4	declaration, as because of the	4	A. If you are asking questions about consent, this is a broad question
5	deficiencies of the evidence that's	5	that requires a discussion of multiple
6	presented, it is not it's a question	6	elements related to the ability of both
7	that is not answered. So it is not	7	parents and children to consent to these
8	available to be able to know the actual	8	procedures and it would be important to
9	risks and limitations of the treatment	9	be able to be more specific in addressing
10	when they've not been investigated in a	10	each of those components to be able to
11	rigorous manner, as I've stated	11	arrive at a proper understanding of the
12	repeatedly.	12	important factors and why I believe that
13	Q. Your view is; based on the	13	these individuals have not been properly
14	current state of the science, it would be	14	consented.
15	impossible for someone to be properly	15	Q. I'm not asking why you believe
16	informed of the risks and limitations of	16	it. I'm asking do you believe that they
17	the treatment?	17	have not been properly consented?
18	MS. LAND: Object to form.	18	MS. LAND: Object to form.
19	A. I am not aware of anyone that	19	A. Again, we need to discuss the
20	presents this in the proper context as an	20	individual criteria for informed consent
21	experimental approach with unproven	21	to be able to answer that question. It's
22	efficacy and major risks, which is what	22	a broad question that you've asked.
23	the scientific evidence currently shows.	23	In the field of ethics it's
24	Q. If someone were presented with	24	critically important that one consider
25	the if someone were presented with the	25	all of the contributing factors.
1			
	Page 147		Page 149
1	Page 147 PAUL W. HRUZ, M.D., Ph.D.	1	Page 149 PAUL W. HRUZ, M.D., Ph.D.
1 2	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D.
1 2 3	=	1 2 3	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your
2	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and	2	PAUL W. HRUZ, M.D., Ph.D.
2 3	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment,	2 3	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly
2 3 4	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and	2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right?
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed?
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical trials relative to this form of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they, themselves, are not able to give consent.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical trials relative to this form of intervention.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they, themselves, are not able to give consent. That was actually a topic that was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical trials relative to this form of intervention. Q. So the only way to be informed	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they, themselves, are not able to give consent. That was actually a topic that was directly addressed in the Keira Bell case
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical trials relative to this form of intervention. Q. So the only way to be informed of the risks of treatment would be to be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they, themselves, are not able to give consent. That was actually a topic that was directly addressed in the Keira Bell case in the U.K. And it's not just myself
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. information as being an experimental treatment and consented to that, and their parent consented to that treatment, would that change your view on this question of properly informed? MS. LAND: Objection to form. A. So are you asking if a parent came and would be willing to be enrolled in a randomized controlled trial under the IRB auspices, I would certainly agree with that. Q. And do you have any basis to believe that the Plaintiffs in this case were not properly informed of the risks and limitations of treatment? MS. LAND: Objection to form. A. I'm not aware of any of the Plaintiffs that were enrolled in clinical trials relative to this form of intervention. Q. So the only way to be informed	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. So here you said in your report that people have not been properly informed of the actual risks and limitations of the treatment; that's your position, right? A. That is correct. Q. And how could they be properly informed? A. Again, if you want to have a discussion I would be very happy to go through in great detail about all of the necessary elements that would be required for them to be able to adequately consent. And I would actually argue that because of the children, themselves, that are affected by this, because of the underlying factors, the state of their psychological development, they, themselves, are not able to give consent. That was actually a topic that was directly addressed in the Keira Bell case

Page 150 Page 152 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 left to give assent and the parents, to give informed consent to treat gender 3 3 themselves, are often sought to give the dysphoria with hormone therapy in 4 consent and they often, themselves, 4 adolescents? 5 5 present with inadequate information. MS. LAND: Object to form. They certainly aren't -- so if they -- I 6 6 A. I think it is certainly 7 don't know of any parent -- I actually 7 possible for an individual or a parent to 8 know of specific examples of parents that 8 consent enrolling their child in an 9 were not given the experimental nature of 9 experimental protocol, informing them 10 the approach and they were essentially 10 that it is an experimental approach with 11 told that if they did not affirm their 11 an uncertain outcome, that would be 12 child that they would commit suicide and, 12 possible. 13 really, the basis for them to challenge 13 Q. And so your knowledge of 14 that is very difficult for a parent to be 14 practice is based on your conversations 15 able to do that. 15 with the dozens of people in the field but you can't name any of them right now? 16 I have not yet encountered one 16 17 of the people that is putting forward MS. LAND: Objection to form, 17 18 this treatment approach to address that 18 asked and answered. 19 question, and I'm not going to answer a 19 A. The basis for me not giving 20 hypothetical about whether there is 20 individual names is because it would be 21 anybody out there in the world that does 21 misleading without the proper context of 22 this. I don't have knowledge of that. 22 the conversations that were made to be 23 But I would say that I stand by my 23 able to use that as a basis for that 24 statement that because of the limitations 24 opinion. 25 of the knowledge we have, they are not 25 I've already stated repeatedly Page 151 Page 153 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 being informed of the lack of evidence here as far as the basis for my concern, 3 3 and the significant risk before being and that's very adequately stated in my 4 asked to engage in this intervention. 4 declaration as well. O. Is it possible to provide 5 5 Q. Can you turn to, still on information sufficient to enable a family 6 Exhibit 1, paragraph 71, page 81, and 6 7 7 to give informed consent to hormone this is related to something you just 8 therapy to treat gender dysphoria in 8 mentioned. This is toward the bottom of 9 adolescents? 9 paragraph 71, beginning with, "In 10 10 addition". Do you see that sentence? MS. LAND: Object to form. A. Again, that's a very broad and A. I'm not there yet. Give me a 11 11 hypothetical question, and because of the 12 12 minute. Yes. "So in addition", I'm 13 nature of the ethics I think it would be 13 there. 14 erroneous to make that. There are many 14 You say, "In addition, parents 15 factors that potentially could be present 15 are often manipulated and coerced by in a theoretical manner, but to be able misinformed political activists or 16 16 17 to opine on that in a hypothetical 17 providers who threaten them with dire situation is fraught with much difficulty 18 18 warnings that the only two operations are treatment or suicide." Did I read that 19 and possible for misinterpretation. 19 20 Q. I mean -- sorry. I think it's 20 correctly? appropriate to ask you as an expert what 21 21 A. You did. 22 you think is possible in a hypothetical 22 What is the basis for that 23 context. 23 statement? 24 So is it possible to provide 24 A. I've seen many things that are information sufficient to enable a family 25 25 published on -- by people that are

Page 154 Page 156 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 advocating for this affirmation approach problem of suicidality in this patient 3 3 that use that exact same language and population. 4 I've heard this repeatedly. And it's 4 It has not been demonstrated actually -- you can find this very 5 5 that it is definitively the cause of that readily on social media, on blog posts suicidality. And to make statements that 6 6 7 and even within papers, themselves. And, 7 if one does not provide this care that 8 again, I do provide a reference in my 8 your child will commit suicide fits 9 declaration with some evidence. There is 9 within that category. Q. And when you say that they're 10 certainly more that I can use to cite 10 11 that. There are many people that are 11 "often manipulated and coerced", what 12 using the -- the concern over suicide 12 does "often" mean? 13 risk to justify. 13 A. There is a plethora of 14 There's very clear examples, 14 examples that one can find with even a 15 for example, where people have made 15 casual survey of what can be available almost verbatim statements; would you publicly. It doesn't take much effort to 16 16 17 rather have a live child of a particular 17 find that. 18 sex or gender identity or a dead one of 18 Q. Do you believe that more than 19 the other? 50% of the time providers are 19 20 Those are coercive and 20 manipulating and coercing their patients into receiving this treatment? 21 manipulative. They don't adequately 21 22 reflect the fact that suicide rates 22 MS. LAND: Object to form. 23 remain markedly elevated with the data 23 A. You are asking a question 24 that we have available after affirmative 24 about actual magnitude within the absence 25 therapy. Again, with the limitations of 25 of any scientific data to make that Page 155 Page 157 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 the literature that is present, they 2 assertion and I have no basis to be able 3 don't reflect the fact of the basis for 3 to put a firm number on it, but it is a 4 why that exists. And that is what I'm 4 very common observation. 5 5 referring to in that statement I made in O. So there is no scientific data 6 my declaration. 6 to put a firm number on your assertion 7 7 Q. So you have political that it's happening often? 8 activists or providers. Do you believe 8 MS. LAND: Objection to form. that political activists and providers 9 A. I am not aware of an objective 10 are acting in comparable manners here? 10 scientific tool that's been generated to MS. LAND: Object to form. adequately, in a population-based manner, 11 11 A. Well, many of the people that survey all those that are providing this 12 12 13 are the ones administering this care are 13 care to determine the precise methods 14 not only medical providers. They are, 14 that they use in recommending this form 15 themselves, political activists, one in 15 of intervention. 16 the same people. And I think that many Q. Do you have any basis to 16 people adopt the language that has been believe that the parent Plaintiffs in 17 17 put forward by the political activists in this case were manipulated or coerced 18 18 19 presenting this to their patients. into consenting to treatment for their 19 Q. And what do you mean by 20 20 children? 21 "manipulated and coerced" in this 21 MS. LAND: Object to form. 22 context? 22 A. Again, I've stated my 23 knowledge of the Plaintiffs in this case A. I think it's erroneous to make 23 and the limitations of that knowledge 24 the claim that the affirmative approach 24 has been demonstrated to solve the 25 and, therefore, would not be able to

Page 158 1 PAUL W. HRUZ, M.D., Ph.D.	D 160
	Page 160 PAUL W. HRUZ, M.D., Ph.D.
2 comment specifically on their experience. 2 r	eport.
3 MR. STRANGIO: Amanda, I just 3	A. Well, essentially that is
. 3	again, each of these approaches begin
	with various scientific premises and have
	contrasting goals of the treatment
	approach.
8 end and take a quick lunch after 8	The expectant management has
	- you know, the premise there is that
	he vast majority of prepubertal children
	vill have a spontaneous realignment of
	heir gender identity with their sex with
	ime, and it's to provide ongoing support
, ,	or perhaps underlying comorbidities, but
	not to intervene in any way to influence
	hat natural history outcome.
videographer within the next 15	Q. Is that what you call the
	vatchful waiting treatment modality in
	our report?
20 MR. STRANGIO: So why don't we 20	A. Correct. Expectant means
	pasically watching or waiting.
for lunch now, if we have to do 15 22	Q. So going through the three
23 minutes. And then come back in 23	general approaches it's; one, conversion
	or reparative approach; two, watchful
	vaiting or expectant management approach;
Page 159	Page 161
1 PAUL W. HRUZ, M.D., Ph.D. 1	PAUL W. HRUZ, M.D., Ph.D.
2 MS. LAND: Yes. 2 a	and three, the gender-affirming approach.
3 VIDEOGRAPHER: Okay. It's 3 I	Oo I have that right, the three that you
4 11:47 and this will end media part 4 d	lescribe?
5 2 and we're off the record. 5	A. That is correct.
2 and we're on the record.	
6 (Lunch recess is taken.)	
6 (Lunch recess is taken.) 6	
6 (Lunch recess is taken.) 6	Q. Okay. So I just want to sort
6 (Lunch recess is taken.) 6 7 VIDEOGRAPHER: We are back on 7 or 8 the record at 12:20 p.m. This will 8	Q. Okay. So I just want to sort of address each in turn.
6 (Lunch recess is taken.) 6 7 VIDEOGRAPHER: We are back on 7 or 8 8 the record at 12:20 p.m. This will 8 9 begin media part 3. We can proceed. 9 or 10 Q. I'm still at what we've marked 10 we	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to
6 (Lunch recess is taken.) 6 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 to 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 11 is	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex?
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 condition of the process of the proc	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex"
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 11 is 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 16 of 7 of	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand.	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex.
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 co 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 To could a serve the same and the s	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 con 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 16 vince the sack on 17 con 18 described three approaches for treating 18 described three approaches for treating 19 described three approaches for treating	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 18 gender dysphoria in children and 18 gender dysphoria in children and	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex.
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 con 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three 20 approaches that I mentioned as far as the	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that is successful, that one will not then be
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 9 con 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three 20 approaches that I mentioned as far as the 21 expectant management, the reparative 21 respectant management, the reparative	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that is successful, that one will not then be medicalized, have all of the inherent
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three 20 approaches that I mentioned as far as the 21 expectant management, the reparative 22 approach and the gender-affirming 22 respectant management is to see the same and the gender-affirming 22 respectant management is taken.)	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" as got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that is successful, that one will not then be medicalized, have all of the inherent lisks long-term that go along with the
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three 20 approaches that I mentioned as far as the 21 expectant management, the reparative 22 approach, correct. 23 approach, correct.	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" has got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that is successful, that one will not then be medicalized, have all of the inherent lisks long-term that go along with the offirmative approach, and that is deemed
6 (Lunch recess is taken.) 7 VIDEOGRAPHER: We are back on 8 the record at 12:20 p.m. This will 9 begin media part 3. We can proceed. 10 Q. I'm still at what we've marked 11 as Exhibit 1. If I could ask you to turn 12 to page 72, paragraph 62. I'm not going 13 to be reading here, but just trying to 14 understand. 15 So in your report you 16 described three approaches for treating 17 gender dysphoria in children and 18 adolescents; is that right? 19 A. Yes. There are three 20 approaches that I mentioned as far as the 21 expectant management, the reparative 22 approach and the gender-affirming 23 approach, correct. 24 Q. What is the expected	Q. Okay. So I just want to sort of address each in turn. So for the first, the conversion or therapy approach, is that where a clinician encourages a patient to dentify with their natal sex? A. Again, the term "natal sex" as got lots of connotations. I would like to talk about sex or biological sex. But, indeed, yes, that is an approach where there is a desire to have one have that experience of realignment with their gender identity with their sex. The premise there is if that is successful, that one will not then be medicalized, have all of the inherent lisks long-term that go along with the

Page 162 Page 164 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 Q. And how in this approach would A. I would say that to have the 3 3 they encourage them to identify with experience of realignment, not to force 4 their biological sex? 4 them but allow them to experience that on 5 5 A. There is a wide variety of their own. 6 ways that that has been done. Probably 6 Q. And having the experience of 7 the pioneer in that approach is that by 7 realignment as a goal is unique to the 8 Ken Zucker, and he has extensive 8 conversion approach? 9 9 literature. It really is a wide variety MS. LAND: Object to form. 10 10 of approaches that people have advocated A. First, I think that the term 11 for. And so -- but I think where it's 11 "conversion" has been influenced by much 12 distinguished from the expectant or 12 idealogy and I prefer to use the term 13 watchful waiting approach or the 13 "reparative therapy". 14 affirmative approach is that it states as 14 "Conversion" is in the 15 a premise that there is a desired goal to 15 declaration so it's very clear to the 16 allow that child to have that experience 16 court what we're speaking of. But I 17 think there are many erroneous of realignment. 17 18 Q. And you would put Ken Zucker 18 assumptions when one thinks about, you know, that particular -- the means that 19 in the conversion or reparative category? 19 20 MS. LAND: Object to form. 20 are used to achieve that end. But as a 21 A. If you read through his 21 whole, it is an approach that seeks to 22 approach, he -- it was probably a 22 allow that individual to experience that 23 combination of an expectant approach and 23 realignment of gender identity with sex. 24 a reparative approach. And he's not the Q. And to what age does -- to 24 25 only one that have put a focus on trying 25 what age patients does this approach Page 163 Page 165 PAUL W. HRUZ, M.D., Ph.D. 1 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 to identify underlying precipitating apply? A. I don't know that there's 3 factors that may have led an individual 3 4 to experience a sex-discordant gender 4 necessarily -- again, when we think about 5 5 identity, prior traumas, relationships these as broad categories, there are many with their peers or their parents. And 6 ways of which this has been applied. 6 7 7 to be able to explore those, to be able As a pediatric endocrinologist 8 to address those underlying issues in the 8 talking specifically relevant to this process of addressing those underlying 9 litigation, we're talking about children, 10 issues that predate any sex-discordant 10 and I think that that would cover the gender identity to allow that individual entire timeframe that the pediatric 11 11 12 then to have that reintegration process. 12 practitioner would be engaged in this. 13 So I wouldn't characterize 13 Q. Might this approach apply to a 14 he's the only one, and there are many 14 17-year-old? 15 different approaches that fit within that 15 A. It certainly could. It could category, but it's based upon the apply at any age if it has not -- again, 16 16 scientific premise that is present, as when you think about the changing 17 17 far as what has led to the gender demographics of this condition, there are 18 18 19 dysphoria and the desired outcome. 19 patients that present prepubertally, 20 Q. And just to clarify, the 20 there are patients that present during 21 21 desired outcome within the conversion or the adolescent years, and there are 22 reparative approach is for the patient to 22 patients that present later. And there 23 realign their gender identity with their are people that will choose or at least 23 24 biological sex; is that correct? 24 advocate for each of these approaches, MS. LAND: Object to form. 25 25 with the exception perhaps of the

	D 1//		P. 160
1	Page 166 PAUL W. HRUZ, M.D., Ph.D.	1	Page 168 PAUL W. HRUZ, M.D., Ph.D.
2	affirmative well, it does include the	$\frac{1}{2}$	A. Okay. The goal of the watch
3	affirmative approach in prepubertal	3	and wait approach is to accompany the
4	children as well because of the social	4	person essentially if you think about
5	affirmation component of that.	5	this in terms of medical interventions,
6	So I think it applies to the	6	that if you have an outcome in which 85%
7	population in general and as it's being	7	of individuals will spontaneously have
8	thought of, as far as different treatment	8	their realignment of their gender
9	modalities, can apply across the	9	identity with their sex and not be
10	spectrum.	10	subjected to the risks and questionable
11	Q. And that's including to	11	benefits of the affirmation approach,
12	adults?	12	that any intervention that one would
13	A. As far as well, we're not	13	propose it would need to establish
14	talking about that here in this	14	non-inferiority, meaning that that
15	litigation here. And my speaking on this	15	outcome it has to be at least as good as
16	is focused on the question of of the	16	that observation of outcomes.
17	pediatric experience, but there are	17	So it really tries to maximize
18	individuals that seek that type of	18	the benefit, while minimizing risk. And,
19	intervention in adults.	19	again, there are many areas of medicine
20	Q. And the second is what you	20	where one does not have an outcome that
21	refer to here I think as neutral or	21	is 100% effective and we seek to
22	watchful waiting and what you refer to	22	alleviate suffering in the most patients
23	today as expected management. And this	23	that we can, while minimizing risk in any
24	approach is where clinicians wait and see	24	intervention that we do. And I think that
25	how the patient identifies as they grow;	25	that's the basis for that approach,
	Page 167		Page 169
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. is that correct?	2	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience
2 3	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct.	2 3	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any
2 3 4	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any,	2 3 4	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question,	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens?
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those individuals will have desistance or this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been once they reached an age of majority,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those individuals will have desistance or this experience of spontaneous realignment of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been once they reached an age of majority, that they would be allowed to be able to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those individuals will have desistance or this experience of spontaneous realignment of their gender identity with their sex.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been once they reached an age of majority, that they would be allowed to be able to move forward with those interventions. In
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those individuals will have desistance or this experience of spontaneous realignment of their gender identity with their sex. Q. And what is the goal of this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been once they reached an age of majority, that they would be allowed to be able to move forward with those interventions. In that, again, you're trying to maximize
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. is that correct? A. That is correct. Q. And what treatment, if any, happens while the waiting process is in process? A. That's a very good question, and it involves addressing all of the associated comorbidities. So if there is underlying depression or anxiety or substance abuse or eating disorders, that those can be addressed in the ways that we normally address, you know, those conditions. The difference is that not knowing is, again, as I said previously, that there is no way reliably for many biological test or predictive value that will allow us to know which of those individuals will have desistance or this experience of spontaneous realignment of their gender identity with their sex.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. knowing that if there is that experience of spontaneous realignment that any intervention that might affect that in a way of leaning to persistence would be considered inferior because of the risks with that. Q. And so if a patient under this approach if a patient continues to experience significant distress related to the incongruence between their gender identity and biological sex into adolescence, what happens? A. So if you're specifically referring to the model of Ken Zucker or others, they would argue that if this experience of persistence occurs that once they reach a stage of their life, and in the past historically it had been once they reached an age of majority, that they would be allowed to be able to move forward with those interventions. In

	Page 170		Page 172
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	benefit are different, they infer the	2	with puberty blockers or hormone therapy
3	individual at a younger age. That is the	3	if the gender dysphoria persisted into
4	argument that is made.	4	adolescence; is that right?
5	Q. And you're aware that at Ken	5	MS. LAND: Objection to form.
6	Zucker's clinic in Toronto, once patients	6	A. So by definition, if one
7	reached adolescence under this watchful	7	engages in puberty blockers and cross-sex
8	waiting proposal if their distress	8	hormones we're moving away from the
9	continued they would be treated with	9	expectant approach, we're actually
10	pubertal suppression and hormone therapy?	10	providing an intervention.
11	A. As I mentioned before, that	11	It is often argued that
12	that that is the approach that	12	pubertal blockade is a neutral
13	Dr. Zucker has put forward. And, again,	13	intervention. I have many reasons that
14	in the time that this was being done in	14	I've stated in my declaration and in the
15	Canada in the clinic that he was	15	New Atlantis paper why I have concluded
16	operating, you know, there was a very	16	that that is an erroneous assertion. But
17	different patient demographic than we're	17	nevertheless, that you're starting to
18	experiencing right now. And so there are	18	provide interventions that have
19	factors that need to be considered about	19	consequences and then you shift the
20	the relative risk and benefit	20	dynamics of that natural history
21	historically from what we're encountering	21	observation, and I think that there is
22	currently. And I think that	22	evidence to suggest very strongly that by
23	epidemiology, precipitating factors, you	23	providing pubertal blockade you are no
24	know, all of those are necessary.	24	longer in a neutral category, that you're
25	But your statement about what	25	having consequences on that rate of
	Page 171		Page 173
1	Page 171 PAUL W. HRUZ, M.D., Ph.D.	1	Page 173 PAUL W. HRUZ, M.D., Ph.D.
2		2	
2 3	PAUL W. HRUZ, M.D., Ph.D.	2 3	PAUL W. HRUZ, M.D., Ph.D.
2 3 4	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about	2 3 4	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children?	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into adulthood. So there are examples one	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical interventions that still can be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into adulthood. So there are examples one could find of each of these approaches,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical interventions that still can be performed. It's not to say that we don't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into adulthood. So there are examples one could find of each of these approaches, in a variety of populations.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical interventions that still can be performed. It's not to say that we don't provide any care for these individuals.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into adulthood. So there are examples one could find of each of these approaches, in a variety of populations. Q. And just beyond Zucker, more	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical interventions that still can be performed. It's not to say that we don't provide any care for these individuals. It merely says that we're not making any
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Dr. Zucker had advocated is accurate, as far as if there was persistence, would then recommend, still with concern about the relative risk involved, that his conclusion was that there may be circumstances where that would be again, risk/benefit-wise to be pursued. Q. And as the broader medical community understands it, is watchful waiting generally an approach applied to prepubertal children? MS. LAND: Objection to form, vague. A. So the expectant approach, as I said, takes various forms. All of these interventions are engaged upon at all stages of life, prepubertally, during adolescence and puberty and into adulthood. So there are examples one could find of each of these approaches, in a variety of populations.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. desistance. Q. So at any point that a medical intervention is provided, then the watchful waiting approach is no longer the modality; is that your is that your understanding? A. That is not correct. I've already said previously that psychological care for underlying comorbidities can be provided under the expectant approach. There is no desire to change whatever trajectory will occur but there is a desire to alleviate suffering, providing that psychological support, for example, if they have depression or eating disorders or anxiety. So those are medical interventions that still can be performed. It's not to say that we don't provide any care for these individuals.

Page 174 Page 176 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 to experience whatever outcome would Dutch Protocol. 3 3 occur for a variety of factors. Q. But here you're summarizing it 4 Q. Under the watchful waiting 4 as actively encouraging children to embrace transgender identity with social 5 approach, how long do you wait before 5 providing pharmacological interventions? transitioning. But under the Dutch 6 6 7 MS. LAND: Objection to form. 7 Protocol my understanding was that social 8 A. That's a broad question. There 8 transitioning was not encouraged; isn't 9 are many different approaches that use 9 that right? 10 different time points. So I think many 10 A. Exactly. And I think that's a 11 will, because of the erroneous 11 wonderful point. I think when you look at 12 assumptions about the quoted statistic 12 how this has evolved since that original 13 about persistence when one has continued 13 Dutch study and the way it's being used 14 dysphoria during the adolescent years, 14 to justify this approach, you correctly 15 that they will advocate at that point to 15 have identified that there has been a 16 move from the expectant approach to the 16 movement away from that point of initial 17 affirmative approach. 17 caution and actually at a very early age 18 As I've already stated, there 18 to affirm individuals requires the social affirmation phase. And that's much of 19 are problems with that assertion and 19 20 difficulties in saying that that is -- at 20 what's been the subject of other areas of 21 that point shifts the dynamics as far as 21 litigation related to gender dysphoria, 22 relative risk and benefit. 22 about whether that involves the 23 Q. So I'm going -- turning your 23 participation of parents, teachers, 24 attention to the same Exhibit 1, coaches, and other members of one's 24 25 paragraph 62, page 72, this is an 25 social community in engaging in that, and Page 175 Page 177 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 explanation of the affirmative approach. 2 including name change, preferred pronoun 3 3 It's at the bottom of the page, the usage and bathroom access. And that all third, it's affirming -- here -- it's the 4 fits under the affirming approach, based 4 last sentence before the bottom of page 5 5 upon a different premise than we see in 6 6 the other two approaches. 7 7 You write, "The third It is based upon the premise 8 affirming approach is to actively 8 -- again, you see this stated many encourage children to embrace transgender 9 different ways as far as this condition 10 identity with social transitioning, 10 being innate and immutable -- that there followed by hormone therapy leading to is a biological basis that, again, has 11 11 12 surgical interventions and lifelong 12 not been proven by science, and that this 13 sterilization." Did I read that 13 is the prudent approach to be able to 14 14 actively encourage social transition. correctly? 15 A. You have correctly read that 15 Q. So just to be clear, this is statement in my declaration. your definition, it's not the one that 16 16 17 Q. And where did this definition 17 came from the Dutch Protocol or anywhere 18 come from? 18 else of what the so-called affirming 19 A. Well, it's a summary of the 19 approach is? 20 approach that is being used. And so it is 20 A. It is not my definition. It is a way to summarize the various treatment 21 the practice that is being put forward by 21 22 approaches. And many people would refer 22 the WPATH and other advocacy groups very 23 to the first Dutch study, the de Vries 23 vocally and, in fact, leading to 24 paper, for this approach in children. So 24 discouragement of anything that is it's why it's often referred to as the 25 25 contrary to that social affirmation.

	D 170		P 190
1	Page 178 PAUL W. HRUZ, M.D., Ph.D.	1	Page 180 PAUL W. HRUZ, M.D., Ph.D.
2	So it's not something that I	2	MS. LAND: Objection to form.
3	generated on my own. It's a summary of	3	A. Having a therapist tell them
4	the approach to intervention that is	4	that they will love their child no matter
5	being widely applied within the United	5	what is a statement that has nothing to
6	States under the auspices of the WPATH	6	do with a desired outcome of a
7	and other advocacy groups.	7	transgendered identity. It is something
8	Q. And what does it mean to	8	that all parents would not necessarily
9	actively encourage a child to embrace	9	need to be told that. But what would be
10	transgender identity?	10	actively encouraging them is to tell the
11	A. It means exactly that, it	11	parents that it is necessary that they
12	means to encourage them to "come out"	12	use the preferred pronouns, allow them to
13	within their social networks or at	13	cross-dress, allow them to use bathroom
14	schools, it's to encourage and support	14	access, allow them to adopt the social
15	them, making affirmative statements about	15	role of their desired or their gender
16	gender identity and in many cases	16	identity, that would be the affirmative
17	encouraging that. And that is being done	17	approach.
18	at very early ages. There are clear	18	Q. And what is your basis for
19	examples that are well documented within	19	believing that clinicians are telling
20	the not peer-reviewed literature but in	20	parents that it is necessary to engage in
21	the internet and stories of these types	21	say, for example, using a preferred
22	of efforts by advocacy groups to	22	pronoun?
23	encourage this affirmation.	23	A. I don't have to rely on my
24	Q. And if a child who was, let's	24	opinion. It's very readily available if
25	say, seven, biological male, told the	25	anyone does a very casual search of what
	,, <u>B</u> ,		
	D 170		D 101
1	Page 179 PAUL W HRUZ M D Ph D	1	Page 181 PAUL W HRIIZ M D Ph D
1 2	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl	2	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups
2 3	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family	2 3	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is
2 3 4	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no	2 3 4	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity?	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity,
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to?
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity?	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old biological male told their family that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address this question when it arises. And,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old biological male told their family that they felt like a girl, and the therapist	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address this question when it arises. And, again, it doesn't take much effort to be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old biological male told their family that they felt like a girl, and the therapist encouraged the family to tell the child	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address this question when it arises. And, again, it doesn't take much effort to be able to find that information.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old biological male told their family that they felt like a girl, and the therapist encouraged the family to tell the child that they would love them no matter what,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address this question when it arises. And, again, it doesn't take much effort to be able to find that information. Q. Do you think providing a child
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. child's family that they felt like a girl and the therapist encouraged the family to tell the child they would love them no matter what, is that actively encouraging a transgender identity? MS. LAND: Objection to form. A. I would say any parent would say that they love their child no matter what, that there's a non sequitur in that question. Q. So is that a no, that's not actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. Please state the question so I can adequately answer it. Q. So if a seven-year-old biological male told their family that they felt like a girl, and the therapist encouraged the family to tell the child	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. has been written about by advocacy groups and that is exactly what they say. It is not my opinion, it is verifiable by a wealth of information that can be found on various advocacy sites. Q. And when you say that it's readily available on the internet that advocacy groups are actively encouraging kids to embrace a transgender identity, what are you referring to? A. If you like I can provide you with dozens of examples of that. I would refer you to many of the publications of books that have been presented to children in that area, the directives that are being given and they are, again, available online as far as for people that access these websites to address this question when it arises. And, again, it doesn't take much effort to be able to find that information.

	D 100		P 104
1	Page 182 PAUL W. HRUZ, M.D., Ph.D.	1	Page 184 PAUL W. HRUZ, M.D., Ph.D.
2	seven-year-old with a book that includes	2	description of children struggling with
3	a transgender character is actively	3	gender identity issues where they present
4	encouraging a transgender identity?	4	the child with various accounts with
5	MS. LAND: Objection to form.	5	parents, caregivers and peers. Is that an
6	A. I think you mischaracterize	6	example of a story where the desired goal
7	the publications that are available,	7	is a transgender identity?
8	because if you look carefully at those	8	A. It depends. Again, we're
9	examples, they do much more than just	9	talking in generalities and it might be
10	presenting the child that experiences a	10	better to actually provide you with
11	transgender identity. They have many	11	specific examples of that so we can
12	aspects that are presented in there of	12	actually look at the literature. I don't
13	the affirmation approach that I'm	13	have that in front of me, but it's
14	discussing, that we're discussing	14	certainly easy to find and we can
15	currently.	15	certainly go through those publications
16	Q. And how do those how do	16	and address specifically in that
17	those children's books do that?	17	individual publication whether or not
18	A. I've seen them present either,	18	that occurs.
19	you know, fictionalized stories of	19	I think the general message
20	children that are struggling with gender	20	that is being put forward is that this is
21	identity issues, where they present the	21	a desired outcome, that it is the only
22	child in a fictionalized account of their	22	approach in many cases or the best
23	response to engaging with various	23	approach to address this sex-discordant
24	parents, caregivers and peers. There is	24	gender identity.
25	many different types of examples of that	25	Q. Can you think of any
	Page 183		Page 185
1	Page 183 PAUL W. HRUZ, M.D., Ph.D.	1	Page 185 PAUL W. HRUZ, M.D., Ph.D.
1 2	=	1 2	= -
1	PAUL W. HRUZ, M.D., Ph.D.		PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. that can be readily found.	2	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this
2 3	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively	2 3	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I
2 3 4	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity?	2 3 4	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form,	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity?
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome,	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome,	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague. A. Let me understand the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back. Okay. You mentioned Ken Zucker
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague. A. Let me understand the question. So	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back. Okay. You mentioned Ken Zucker a few times. Which approach does he fall
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague. A. Let me understand the question. So Q. Let me rephrase. You had said	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back. Okay. You mentioned Ken Zucker a few times. Which approach does he fall into?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague. A. Let me understand the question. So Q. Let me rephrase. You had said your example of a children's book that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back. Okay. You mentioned Ken Zucker a few times. Which approach does he fall into? A. I would say he has a hybrid
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that can be readily found. Q. And is that actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. As I said, again, we're talking about an approach of social affirmation. And if one is portraying this as a desired goal, again, the scientific premise or the intent of the intervention is to lead to that outcome, that would constitute the affirmation approach. Q. And is a desired goal the same as something that is not to be that is not to be shamed? MS. LAND: Objection to form, vague. A. Let me understand the question. So Q. Let me rephrase. You had said	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. children's book that fit this A. I would say the book I would say the book I Am Jazz is probably the most recognized book in that category. Q. You would say that I Am Jazz actively encourages transgender identity? A. I would say MS. LAND: Objection to form. A. I would say that of the three approaches that we're discussing, it falls closest to the affirmation approach as compared to the watchful waiting or the reparative approaches. Q. Do you think a children's book that shows a transgender child being affirmed in their gender identity necessarily falls to I take that back. Okay. You mentioned Ken Zucker a few times. Which approach does he fall into?

1	Page 186 PAUL W. HRUZ, M.D., Ph.D.	1	Page 188 PAUL W. HRUZ, M.D., Ph.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	actually I think as a as a as a	$\frac{1}{2}$	influence the calculus that one uses in
3	very respected individual in this field	3	assessing the, you know, how one would
4	has considered all of the options. I	4	approach this.
5	think some of his earlier work could be	5	The other factor that I have
6	easily construed to be in the reparative	6	to stress, as I've already said in my
7	model. I think he makes scientific	7	declaration and I believe several times
8	premises that there may be underlying	8	today already, is that the demographics
9	psychological distress and issues that	9	of what we're seeing right now is
10	need to be addressed that could assist an	10	drastically different than the time that
11	individual to experience that alignment	11	Dr. Zucker was performing his research.
12	of their gender identity with their sex,	12	And it's becoming even, you know, the
13	and then and I think he still holds	13	categories that would fit into his
14	that there are circumstances in which	14	affirmative paradigm as a last resort
15	that is still true. Yet one has	15	and, in fact, he often says it as that,
16	proceeded far enough along that pathway	16	is very different.
17	which they're not able to basically pull	17	And as far as risk and
18	themselves back, even with addressing the	18	benefit, what's not known is this
19	underlying comorbidities, where in his	19	explosion of adolescent biological
20	experience the likelihood that that	20	females now presenting with gender
21	ongoing approach would have success has	21	dysphoria without having any prepubertal
$\begin{vmatrix} 21\\22\end{vmatrix}$	changed and then would shift over into a	22	experience of that is vastly different
$\begin{vmatrix} 22 \\ 23 \end{vmatrix}$	-	23	than the population of prepubertal males
$\begin{vmatrix} 23 \\ 24 \end{vmatrix}$	more of an affirmation approach. And I think, again, as a	24	that he encountered in his clinic in
25	respected member of the relevant	25	Canada when he was performing that
23	<u> </u>	23	
1	Page 187 PAUL W. HRUZ, M.D., Ph.D.	1	Page 189 PAUL W. HRUZ, M.D., Ph.D.
$\frac{1}{2}$	scientific community, I think he	$\frac{1}{2}$	research.
3	acknowledges the limitations in each of	3	Q. So if you if you had so
4	those approaches. He will acknowledge	4	if a patient who begins a cross-sex
5	much better than many of the other people	5	identification at, let's say, age 2 and
6			
()	•		
	that are currently engaged in this	6	is persistent until they're 15-years-old,
7	that are currently engaged in this discussion about the unknowns and I think	6 7	is persistent until they're 15-years-old, at which point they come to clinic for
7 8	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a	6 7 8	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting
7 8 9	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis.	6 7 8 9	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient?
7 8 9 10	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the	6 7 8 9 10	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I
7 8 9 10 11	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with	6 7 8 9 10 11	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm
7 8 9 10 11 12	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's	6 7 8 9 10 11 12	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example,
7 8 9 10 11 12 13	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the	6 7 8 9 10 11 12 13	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that
7 8 9 10 11 12 13 14	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that?	6 7 8 9 10 11 12 13 14	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the
7 8 9 10 11 12 13 14 15	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state	6 7 8 9 10 11 12 13 14 15	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that
7 8 9 10 11 12 13 14 15 16	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on	6 7 8 9 10 11 12 13 14 15 16	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance.
7 8 9 10 11 12 13 14 15 16 17	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about	6 7 8 9 10 11 12 13 14 15 16 17	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting
7 8 9 10 11 12 13 14 15 16 17 18	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits	6 7 8 9 10 11 12 13 14 15 16 17 18	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if
7 8 9 10 11 12 13 14 15 16 17 18 19	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot	6 7 8 9 10 11 12 13 14 15 16 17 18	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying
7 8 9 10 11 12 13 14 15 16 17 18 19 20	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot provide a definitive conclusion about	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying comorbidities in providing that care to
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot provide a definitive conclusion about which approach is going to be the most	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying comorbidities in providing that care to that individual, and then allowing them
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot provide a definitive conclusion about which approach is going to be the most effective in the most number of patients.	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying comorbidities in providing that care to that individual, and then allowing them again, this whole question that we
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot provide a definitive conclusion about which approach is going to be the most effective in the most number of patients. If it were possible to	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying comorbidities in providing that care to that individual, and then allowing them again, this whole question that we discussed earlier about about consent,
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that are currently engaged in this discussion about the unknowns and I think appropriately phrases the question as a risk/benefit type of analysis. Q. And do you disagree with the approach well, do you disagree with what you just described as Zucker's approach? Do you disagree with the advisability of that? A. As I said before, at the state of knowledge that we have right now, on the knowledge about etiology, about natural history, about risks and benefits of the current paradigm, one cannot provide a definitive conclusion about which approach is going to be the most effective in the most number of patients.	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	is persistent until they're 15-years-old, at which point they come to clinic for assessment, what does watchful waiting look like for that patient? A. Well, I can restate what I stated previously because that paradigm still applies in that specific example, that the scientific premise there is that there is no goal to influence in the watchful waiting approach whether that person has persistence or desistance. It is geared toward assisting that individual in providing support if they do experience underlying comorbidities in providing that care to that individual, and then allowing them again, this whole question that we

	D 100		D 102
1	Page 190 PAUL W. HRUZ, M.D., Ph.D.	1	Page 192 PAUL W. HRUZ, M.D., Ph.D.
2	about what the long-term outcome is going	2	A. So the question is; which do I
3	to be for that individual, I think you	3	support?
4	know, that there's disagreement among the	4	I am a physician-scientist
5	relevant scientific community as to the	5	that believes that our goal in pursuing
6	particular point in one's life where one	6	any medical intervention, and
7	is able to make that decision, where the	7	particularly in that area of gender
8	risk/benefit ratio is changed. Many have	8	dysphoria, is to do the best we can to
9	strongly	9	alleviate suffering without inducing
10	Q. I'm sorry I'm sorry to	10	harms, so having the best risk/benefit
11	interrupt. I think I think that you	11	ratio. And as I said repeatedly, it's
12	got a little far afield from the question	12	put forward that the affirmative approach
13	because what I was what I meant to ask	13	has been established, it's the preferred
14	here is for the watchful waiting	14	approach and, in fact, many would argue
15	approach.	15	is the only approach. And I would argue
16	So it doesn't make a	16	very strongly that the scientific
17	difference at what age the person first	17	evidence does not allow one to make that
18	presents with a gender discordant	18	conclusion and that there is a need to
19	identity; is that your view?	19	conduct adequate scientific investigation
20	MS. LAND: Object to form.	20	to pursue alternative approaches that
21	A. So the approach, itself,	21	would. Some of them would fit under the
22	doesn't change but the consideration of	22	category of the expectant or the
23	which of the three potential approaches	23	reparative models.
24	has, you know, weighing out relative	24	Q. And so just, what is your view
25	risks and benefits, does change with the	25	on the treatment approach that minimizes
	Page 191		Page 193
1	Page 191 PAUL W. HRUZ, M.D., Ph.D.	1	Page 193 PAUL W. HRUZ, M.D., Ph.D.
2		2	
1	PAUL W. HRUZ, M.D., Ph.D.	l	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the	2	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't had the biological changes of sexual	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best outcome for this individual, lifelong, to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't had the biological changes of sexual maturity.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best outcome for this individual, lifelong, to—if there is an approach that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't had the biological changes of sexual maturity. Q. And which of the three	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best outcome for this individual, lifelong, to if there is an approach that is sustained, long-term, that does not carry
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't had the biological changes of sexual maturity. Q. And which of the three treatment modalities that you described,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best outcome for this individual, lifelong, to if there is an approach that is sustained, long-term, that does not carry medical risk, it's preferable to a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. age of the patient. So the paradigm with the scientific premise and the goal and the overall approach can happen at any age. However, it is it does differ in the age that the child presents. And once they reach adulthood many would argue that, you know, to continue with a watchful approach, if there is a desire for that individual to switch over to the affirmative approach, based upon relative risks and benefits and, you know, and ability to obtain as best as possible the consent, that is a different proposition than doing it to an adolescent with an immature brain that is going through all of the traumas of adolescence or a prepubertal child that actually hasn't had the biological changes of sexual maturity. Q. And which of the three	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. suffering the most, based on the current state of the science? MS. LAND: Objection, vague. A. So your question is quite broad. The alleviating suffering, there are many ways to look at that. Many focus on the immediate effect of alleviation of stress and dysphoria, but others will weigh more heavily long-term effects. There are many things that we propose in medicine that may have a short-term benefit in alleviating distress that ultimately have long-term consequences that do not have sustained effects or in fact have more significant adverse effects over time. So I would look at this question broadly, looking at the best outcome for this individual, lifelong, to if there is an approach that is sustained, long-term, that does not carry

Page 194 Page 196 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 over time. reparative approach that has the 3 3 scientific premise that sex and gender Q. Going back to this question, 4 if you -- if you had a patient who began 4 identity are an integrated whole, and 5 cross-sex identification, let's say there 5 that many of the precipitating factors 6 is a patient who began -- who is a 6 are identifiable and addressable. And 7 biological male and begins to identify as 7 the watchful waiting approach takes an 8 female at 2, age 2, and continues that 8 agnostic approach saying; we don't know 9 identification until they are 9 and, therefore, we're going to take a 10 10 14-years-old and they come to a clinic cautious approach and try to achieve the 11 for assessment; what is your, your, Dr. 11 least invasive outcome that one can 12 Hruz's view on what watchful waiting 12 possibly have. 13 would look like for this particular 13 So if one looks at each of 14 individual? 14 those different premises in the model, 15 MS. LAND: Objection to form. 15 one can apply that in an individual 16 A. So your question, in the 16 patient. And the way that one approaches 17 specific example of a two-year-old child that will actually then allow one to 17 18 presenting with sex-discordant gender 18 segregate it into these broad categories. 19 identity with persistence to the age of 19 And I should say that there 20 15, I think in that situation, as I've 20 are circumstances where, you know, this 21 described more generally for the watch 21 segregation into three different 22 22 and wait approach, it does necessitate treatment approaches doesn't truly 23 exploration of the social dynamics of 23 reflect the complexity of the situation, 24 the heterogeneity that we see within that child, underlying conflicts within 24 25 the family, within peer groups, 25 individuals, understanding, to the best Page 195 Page 197 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 investigation as to whether there are best we can, about potential etiologic 3 3 other conditions like autism, which is factors that led to this sex/gender 4 highly associated with sex/gender 4 identity discordance certainly can 5 5 identity discordance, to be able to influence how to approach this one explore those factors and to address 6 individual patient. 6 7 7 those factors and then to be able to use Q. And do you agree with the 8 that information to provide the best care 8 premise of reparative therapy -- excuse 9 to that individual. 9 10 10 Q. So it's a type of assessment Do you agree with the premise that would be needed? It's not a duration of the reparative therapy approach that 11 11 12 of time in watchful waiting, as you just 12 sex and gender identity are an integrated 13 described it? 13 whole? 14 A. I'm not sure I fully follow 14 A. I have always stated this as a 15 the question. But I think that if you 15 -- as a hypothesis, as an alternative divide out those different approaches for hypothesis to what is being put forward 16 16 17 the underlying scientific premise and, 17 by the affirmation approach. And, again, 18 you know, to elaborate, the affirmative 18 not all scientific premises are created 19 approach has the premise that 19 equally, but it is a starting point for 20 sex-discordant gender identity is a part 20 understanding this question of 21 21 of normal human variation, that is innate sex-discordant gender identity. 22 and immutable. You see many variations 22 Q. And is it your view that 23 sex-discordant -- sex/gender identity of that, many will argue contrary to 23 24 that, and still try to use the 24 discordance is not a part of human 25 affirmative model. There is the 25 identity?

	Page 198		Page 200
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	MS. LAND: Objection to form.	2	that it's often presented with, as you
3	A. There are many statements that	3	understand it?
4	are made by from an idealogic basis	4	A. The desired outcome of
5	that are contrary to science. And when	5	presenting the publication to the child?
6	one looks at, as a physician-scientist	6	Q. Correct.
7	and as a pediatric endocrinologist, it is	7	A. Again, as I said, I would have
8	you know, looking at sex as being	8	to know more about the hypothetical
9	inherently binary is really had not	9	situation to be able to know what that
10	been controversial until the idealogy had	10	intent was.
11	been introduced. And that to say there	11	Q. Well, you just said it's often
12	is variations of sex, as I've said in	12	presented with a desired outcome, so I'm
13	many of the forums that I've spoken,	13	just curious what you meant by that.
14	there are two and only two gonads that	14	A. If that's the only information
15	participate in the process of	15	that's presented to a child and then
16	reproduction, there is not variability in	16	there is a conversation with the parents
17	a continuum of that. The relationship	17	subsequent to that telling them that they
18	between sex and gender are distinct but	18	need to adopt preferred pronouns,
19	they're not entirely severable.	19	bathroom use and dress, that could be
20	If we think about what we	20	constituted as an endorsement of the
21	mean, again, using the terms gender and	21	affirmative approach.
22	gender identity, has adopted many	22	Q. Do you think the book I Am
23	different definitions over time, as	23	Jazz should be banned?
24	opposed to the objective scientific	24	MS. LAND: Objection to form
25	biological understanding of the word sex.	25	and relevance.
	Page 199		Page 201
1	Page 199 PAUL W. HRUZ, M.D., Ph.D.	1	Page 201 PAUL W. HRUZ, M.D., Ph.D.
2		1 2	-
	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be		PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately	2	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this
2 3	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be	2 3	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner, with a genuine sense of uncertainty, it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone presents anything other than a book like
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner, with a genuine sense of uncertainty, it could potentially not constitute that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone presents anything other than a book like I Am Jazz, for example, if one presented
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner, with a genuine sense of uncertainty, it could potentially not constitute that. The setting that it's often presented is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone presents anything other than a book like I Am Jazz, for example, if one presented to a preschool child a book that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner, with a genuine sense of uncertainty, it could potentially not constitute that. The setting that it's often presented is with a desired outcome, and so it depends	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone presents anything other than a book like I Am Jazz, for example, if one presented to a preschool child a book that presented human sexuality contrary to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So in order to adequately address that question one needs to be using the terms in the same way and that is not always the case. Q. Do you think if the mental health provider gives a family a copy of the book I Am Jazz, that that is actively encouraging a transgender identity? MS. LAND: Objection to form, asked and answered. A. You know, I think that that's an overly simplistic portrayal of what actually goes on. I have no idea, you know, the circumstances of any individual of presenting that. If it was presented concomitantly with other publications that present it in a different manner, with a genuine sense of uncertainty, it could potentially not constitute that. The setting that it's often presented is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. A. Again, I am serving in this case as a physician-scientist and focusing as best I can on the scientific studies, but acknowledging much of the discussion is going on in public. I think that all the information is I don't support banning differing points of view, but I do encourage active discussion based upon relevant scientific facts, consideration of alternative hypotheses, so that the conversations of the information that's being presented is not necessarily the problem, it is the assertion that it is the only approach and that anything contrary to that is harmful. And that is explicitly stated by a number of the political advocacy groups that if anyone presents anything other than a book like I Am Jazz, for example, if one presented to a preschool child a book that

	Page 202		Page 204
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	is of high concern to be able to engage	2	information at an age-appropriate level
3	in the proper dialogue related to this	3	to allow them to integrate that
4	very complex question.	4	information at a time of their life where
5	Q. Do you think presenting	5	previously they had not had that exposure
6	children with books that include same-sex	6	in historically those types of
7	couples actively encourages gay identity?	7	questions did not come up in, you know,
8	MS. LAND: Objection to form	8	the sexualization of prepubertal children
9	relevancy and scope.	9	was not a topic that needed to be even
10	A. Well, okay, so are you asking	10	addressed in a hypothetical manner as
11	this in terms of the association between	11	you're proposing right now. It is the
12	the desisting patients and same-sex	12	many cultural shifts that have occurred
13	attraction as it's relevant to this case?	13	that have necessitated that discussion.
14	Q. No. I'm asking generally about	14	Q. So portraying a children with
15	how children's books actively encourage	15	same-sex couple parents can be
16	things.	16	inappropriate for a child?
17	So I'm trying to understand if	17	MS. LAND: Objection to form,
18	you believe that presenting a child with	18	asked and answered.
19	a book that includes same-sex parent	19	A. I will refer you to my answer
20	family actively encourages gay identity?	20	to the question on transgender identity
21	MS. LAND: Objection to form,	21	and the response is the same.
22	relevancy and scope.	22	Q. So what age is too young to
23	A. I would draw you back to my	23	see a same-sex couple families in books?
24	response to the prior question and use	24	A. That question cannot be
25	the exact same understanding, the context	25	answered because
	Page 203		Page 205
1	Page 203 PAUL W. HRUZ, M.D., Ph.D.	1	Page 205 PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being	2	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form.
2 3	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the	2 3	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical
2 3 4	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child?
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the context it is, the involvement of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and gender identity but, again, these
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the context it is, the involvement of the parents in that discussion. And I think	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and gender identity but, again, these questions are being asked in a manner
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the context it is, the involvement of the parents in that discussion. And I think that children, as a whole, are being	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and gender identity but, again, these questions are being asked in a manner that does not adequately allow one to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the context it is, the involvement of the parents in that discussion. And I think that children, as a whole, are being bombarded by very strong idealogical	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and gender identity but, again, these questions are being asked in a manner that does not adequately allow one to assess the context by which these
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. of which that literature is being presented to that child and I think the answer would be the same. Q. So assuming that the child also has many examples of books with different-sex parents and this being one example of the book with same-sex parents, is that actively encouraging a gay identity? MS. LAND: Objection to form, asked and answered. A. The situation you're presenting is quite broad and there are situations where those types of materials are not appropriate to be presented to a child of any perspective, and situations where it might be relevant, depending on the age at which it's presented, the context it is, the involvement of the parents in that discussion. And I think that children, as a whole, are being	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. MS. LAND: Objection to form. A it's a hypothetical question that it's far too broad for me to be able to opine on. Q. Do you believe that presenting a same-sex couple family do you believe that portraying a same-sex couple family is sexualizing information for a child? MS. LAND: Objection to the form of that question and scope. A. To understand the basis for your question, and I'm getting a little bit lost in your line of questioning as relates to this bill and the topic of gender dysphoria, unless you are asking this question in relation to the association of sexual orientation and gender identity but, again, these questions are being asked in a manner that does not adequately allow one to

	D 200		P. 200
1	Page 206 PAUL W. HRUZ, M.D., Ph.D.	1	Page 208 PAUL W. HRUZ, M.D., Ph.D.
2	make a blanket statement without	2	A. It would be much easier to
3	considering the circumstances is not	3	give me an example and have me opine on
4	possible.	4	that. But if you look through the use of
5	Q. So we mentioned a few times	5	the GRADE system there for example, as
6	about the what your view of the	6	a pediatric endocrinologist we have
7	evidence supporting the banned	7	many in the treatment of diabetes we
8	interventions under the Arkansas law is.	8	have treatment approaches that are being
9	I just want to ask you a few questions	9	proposed based upon limited evidence and
10	about that.	10	usually when we engage with when we
11	Are there other treatments	11	look specifically at the degree of
12	that you provide that are supported by	12	evidence that we have, that we proceed
13	only low or very low quality evidence as	13	with caution, that we don't that we
14	defined by the GRADE system?	14	design the appropriate clinical studies,
15	A. I think that the availability	15	that we consider this in terms of
16	of low quality evidence is not unique to	16	alternative approaches, and all of these
17	the field of gender medicine. What is	17	things are generally unique.
18	unique about the field of gender medicine	18	Q. So taking the diabetes
19	is the confidence that's asserted about	19	example, when, you know, there are
20	proceeding with this form of intervention	20	treatments that are supported by only low
21	in light of that uncertainty and without	21	quality evidence and prescribing them is
22	efforts to answer the questions and	22	something that is done routinely; is that
23	elevate the quality of that science and,	23	right?
24	in fact, a desire to prevent one from	24	A. Not not in the way that
25	actually engaging in those studies.	25	we're talking about. So, again, it
	Page 207		Page 209
1	Page 207 PAUL W. HRUZ, M.D., Ph.D.	1	Page 209 PAUL W. HRUZ, M.D., Ph.D.
1 2		1 2	= -
1	PAUL W. HRUZ, M.D., Ph.D.	l	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we	2	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are
2 3	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are	2 3	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have	2 3 4	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many respects unique to the field of gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing fertility in a child that hasn't the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many respects unique to the field of gender medicine.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing fertility in a child that hasn't the capacity to understand what they're going
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many respects unique to the field of gender medicine. Q. Can you give me examples of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing fertility in a child that hasn't the capacity to understand what they're going through and giving up without proper
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many respects unique to the field of gender medicine. Q. Can you give me examples of other treatment that is supported by low	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing fertility in a child that hasn't the capacity to understand what they're going through and giving up without proper evidence has a much higher bar in being
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. So it's not the fact that we don't have other situations, there are many areas of medicine where we have uncertainty, where we are making recommendations based on low quality evidence. There is ample historical evidence for guidelines that have been put forward by that type of evidence that later had been proven to be completely wrong and the guidelines are completely reversed. So it's not the fact that there is low quality evidence, it's the strength of the assertion that this is the preferred and only approach to proceed to not adequately inform patients about the low quality evidence. All of those factors I think are in many respects unique to the field of gender medicine. Q. Can you give me examples of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. influences the recommendations that are being made and the relative risks and benefits of intervention. If we have a low quality study that advocates, you know, a particular diet, that's vastly different than a recommendation that company potentially sterilize a child. Again, there are many factors that influence the ability to make recommendations based upon low quality evidence. But the higher the risk the greater the bar is to be able to engage in that practice. And I would say, in particular, in relating to the affirmative approach, when you have an intervention that has the likely outcome of impairing or completely abolishing fertility in a child that hasn't the capacity to understand what they're going through and giving up without proper

Page 210 Page 212 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 by which guidelines are put forward with MS. LAND: Objection to form, 3 3 lower quality evidence, with not the same asked and answered. 4 degree of risk that is being put forward. 4 A. In situations where the Q. Do you ever make treatment 5 5 relative risk is minor and the potential recommendations based on low quality 6 6 benefit is substantial, that I have made 7 7 recommendations based upon low quality evidence? 8 MS. LAND: Objection to form, 8 evidence. 9 asked and answered. 9 That is not -- so but -- but 10 10 A. As I said, that all in a general sense, independent of gender 11 recommendations that are made for 11 dysphoria, if there is high risk, 12 12 uncertain benefit and low quality patients are based upon a discussion of 13 relative risks and benefits. And where 13 evidence, I will not recommend that. 14 there is low quality evidence the patient 14 Q. Do you use puberty blockers to 15 needs to know that, and they need to know 15 treat precocious puberty in your 16 about alternatives that are possible as 16 practice? 17 17 well. A. Yes. 18 Again, that's unique in the 18 Q. And do you believe that 19 gender field that alternative approaches 19 puberty blockers are safe to treat 20 are not presented to patients as -- in 20 precocious puberty? 21 the proper context based upon the level 21 A. It depends what you mean by 22 of evidence that's available. 22 "safe". But the treatment of precocious 23 Q. But I'm not asking about the 23 puberty is intended to restore an 24 individual to the state that they would gender field. I'm asking you in your 24 25 practice, after advising patients of the 25 normally have in the absence of the Page 211 Page 213 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 relative risks and benefits, do you ever condition of central precocious puberty. 3 3 make treatment recommendations based on Q. Are there randomized 4 low quality evidence? 4 controlled studies evaluating the 5 5 MS. LAND: Objection to form, long-term use of puberty blockers to asked and answered. 6 treat precocious puberty? 6 7 7 A. I cannot remember a situation A. So, again, broad question. We 8 with -- that has that degree of risk of 8 can talk about specific aspects of the 9 inducing, you know, permanent sterility, 9 scientific literature that's available 10 lifelong osteopenia, with persistent 10 for the treatment of precocious puberty, suicidal ideation markedly above the which includes studies about the efficacy 11 11 12 background population where I've in suppressing the gonadal -- pituitary 12 13 advocated for a treatment based on low 13 gonadal access, the affects on height, 14 quality evidence. 14 bone age advancement, bone density, 15 Q. That wasn't my question. My 15 metabolic risks and all these other question wasn't anything related to any 16 16 aspects. 17 specific risk, just based on in your 17 Again, it's a different story practice, not the gender field that you 18 18 to be able to propose an intervention 19 don't practice in, as you said. 19 that restores somebody to the state that 20 So based on your practice, 20 they would normally have than to induce a 21 21 after advising your patients of the pathologic state that would not normally 22 relative risks and benefit, and I don't 22 be present. 23 want to know what they are, have you ever 23 So in the area of the use of 24 made treatment recommendations based on 24 GnRH agonists or puberty blockers to 25 low quality evidence? 25 treat central precocious puberty, there

Page 214 Page 216 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 is data, that is not necessarily side-effects. 3 3 randomized controlled, there are cohort So yes, I would say there are 4 studies that have been done for those 4 a number of studies that have followed 5 that have received GnRH agonists and 5 patients long-term, again, for the specific outcome measures that are 6 those that have not on their final 6 7 height, their age of menarche, and other 7 relevant in treating that condition. 8 factors, that drive the prescribing of 8 Q. Do any of these studies follow 9 this class of medication for that 9 these patients into middle or old age to 10 10 assess bone health? purpose. 11 And so, again, this is a great 11 A. I believe there are a few. Let 12 example of your earlier question about 12 me say, to put it in proper context why relative risk and benefit in applying 13 13 bone density issues are quite important, 14 that to the case of central precocious 14 is that there are many people that try to 15 puberty, where the calculation of 15 extend the use of a puberty blockade in 16 relative risk and benefit is vastly 16 patients that had precocious puberty 17 different than, for example, doing that longer than is currently recommended for 17 18 same intervention to suppress normal 18 a desire to maximize height. And many 19 timed puberty. 19 oftentimes that was in patients that were 20 Q. Are there long-term cohort 20 diagnosed later with more advanced bone 21 studies evaluating the safety for puberty 21 ages. 22 blockers to treat central precocious 22 It's well documented that peak 23 puberty? 23 bone mineral density is achieved during 24 24 the adolescent years, into the early 20s. A. The best studies I'm aware of 25 address the question -- so the indication 25 That is the only time in life where you Page 215 Page 217 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 -- so let me backup. have the opportunity to achieve maximal 3 3 bone density. And those that have low The indications for 4 prescribing puberty blockers in central 4 bone density moving at that phase of life 5 are at markedly elevated risk of 5 precocious puberty is both to preserve a final height and to allow an individual 6 osteoporosis later in life. 6 to experience puberty at a time that 7 7 Those long-term studies are 8 their psychological development is 8 available. It is the basis for why the appropriate to be able to navigate the 9 recommendations are very specific as far 10 changes of biological puberty and those 10 as how long to continue that duration of outcomes have been measured to the point intervention. 11 11 12 of following children to a final adult 12 Q. Can pubertal suppression 13 height and to be able to follow those 13 impair fertility? 14 children as far as their psychological 14 A. It depends. So there is no 15 functioning to the age where puberty is 15 evidence that if you treat central 16 allowed to progress in concert with their precocious puberty with a GnRH agonist 16 17 it's going to impair long-term fertility. peers. 17 It's a difficult calculus when 18 There is also data available 18 19 for the extension of puberty blockers 19 you disrupt normally timed puberty and, 20 beyond the normal age of puberty for a 20 generally speaking, the reversibility 21 21 occurs in the reengagement of the desire to even further maximize height, 22 for example, studies showing that when 22 pituitary gonadal access following 23 you delay puberty beyond the normal time cessation of that therapy no matter what 23 24 of initiation, that you have adverse 24 time one intervenes. 25 effects on bone density and other 25 The concern are primarily for

Page 218 Page 220 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 those individuals that go from puberty Q. But that wasn't my question, 3 3 blockers to cross-sex hormones. And in because there are some that don't, even 4 that situation you have not allowed the 4 under your theory. 5 gonads to fully mature and then you 5 So my question is, for those expose them to hormones that they are not -- so are you aware of any evidence that 6 6 7 designed to see, the gonad, and the 7 would suggest that pubertal suppression 8 expected effect of that is to induce 8 on its own, without the subsequent 9 infertility and in many cases lifelong 9 administration of cross-sex hormones, 10 sterility. And that is an expected 10 impairs fertility? 11 effect. 11 MS. LAND: Objection to form, 12 12 asked and answered. In fact, what I'm aware of in 13 the consent form process that is one area 13 A. I don't think we have 14 that is explicitly addressed. It has been 14 sufficient evidence to definitively 15 addressed in a number of publications 15 answer that. with that concern to propose efforts to 16 16 There are many people that artificially preserve fertility in the 17 have expressed concerns about whether 17 18 situation where it's been intentionally 18 there may be effects. But I would say 19 disrupted. So I think that the context of 19 that in the setting of GnRH agonists 20 when these drugs are given and it relates 20 alone, given at the time of normal 21 specifically to the effects of the sex 21 puberty, has pleiotropic effects. There 22 steroid hormones in the context of the 22 are many different things that are 23 sexual maturity of the developing gonad. 23 influenced. And one of the concerns 24 Q. But so does the pubertal 24 that, it's not been established, but 25 blockade on its own, without the 25 there are concerns that there may be Page 219 Page 221 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 subsequent administration of cross-sex effects but it's -- it would -- I don't 3 3 hormone, cannot cause -- does that impair think there's evidence to say that it is 4 4 guaranteed to lead to a permanent fertility? 5 5 sterility. These drugs have been used in MS. LAND: Objection to form. 6 Q. The pubertal blockade on its 6 postpubertal individuals in the treatment 7 7 own, without the subsequent of cancers, prostate cancer and breast 8 administration of cross-sex hormones, 8 cancer, for example, where the gonads 9 does that impair fertility? 9 have already been allowed to fully mature 10 10 A. You have stated that in a very and we've been able to shut down the definitive way and I would not state it normal signalling from the pituitary 11 11 12 in that way. I think we do not know. gland to the gonads. And we know in 12 13 Q. Are you currently aware of any 13 that situation that when you stop the 14 evidence suggesting that pubertal 14 pubertal blocker that the function will 15 suppression without subsequent 15 occur. administration of cross-sex hormones 16 16 The question, and the reason I 17 impairs fertility? 17 cannot answer it in the definitive manner MS. LAND: Objection to the 18 18 that you propose, is that when you are 19 form asked and answered. 19 engaging in administering this medication 20 20 in an adolescent who is going through A. I am aware of the studies that 21 21 biological puberty, there are many 98 to 100% of the individuals that get --22 that get pubertal blockade go onto 22 factors about the timing, when it is 23 cross-sex hormones, so that your 23 introduced, the duration for which it is 24 hypothetical situation is not the reality 24 introduced and the other interventions 25 of what's going on. 25 that are occurring concomitantly with

	D 222		2 201
1	Page 222	1	Page 224
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D. that sexed individual vastly exceed what
3	that. And there have been no properly controlled trials to definitively or	3	would physiologically be achieved, often
4	even, you know, in a reliable manner	4	reaching concentrations that we would see
5	provide causative treatment outcome	5	in endocrine secreting tumors. And there
6	conclusions to be made.	6	are very significant consequences, some
7	Q. Do oral contraceptives have	7	of which are known, many of them that
8	risks?	8	which are not known in that practice. So
9	A. You're talking synthetic	9	they are not the same thing.
10	estrogen and progesterones that are used	10	Q. So the types of blood clots
11	to disrupt the normal feedback regulatory	11	that are a risk in the context of oral
12	mechanism of the ovary and pituitary	12	contraceptives are the not the same type
13	gland?	13	of blood clots that you identify as a
14	Q. Yes.	14	risk in treating gender dysphoria with
15	A. Yes, they do have effects.	15	estrogen?
16	Q. And do they have risks?	16	A. Do you mean the same type of
17	A. Yes, they do.	17	risk as far as being they're both
18	Q. And are the risks do oral	18	related to thromboembolic stroke, but the
19	contraceptives have excuse me. What	19	risk of exposure to that hormone is not
20	are the risks?	20	the same when given to a male versus
21	A. There are risks of blood	21	given to a female. The net effect of
22	clots, blood pressure, metabolic effects	22	leading to thrombosis that could lead to
23	and cancer risks. The cancer risk is a	23	stroke, that could lead to neurological
24	mixed bag. Some of them are actually	24	impairment or death is real, but the
25	beneficial and some are adverse. There	25	incidence of that occurring is directly
	Page 223		
	rage 225		Page 225
1		1	Page 225 PAUL W. HRUZ, M.D., Ph.D.
1	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated	1 2	PAUL W. HRUZ, M.D., Ph.D.
1 2 3	PAUL W. HRUZ, M.D., Ph.D.		-
2	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated	2	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those
2 3	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and	2 3	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature
2 3 4	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian	2 3 4	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria?	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly?
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due to the differing epigenetics, leading to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National Catholic Bioethics Quarterly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due to the differing epigenetics, leading to differential genetic expression that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National Catholic Bioethics Quarterly Submission Guidelines, was received
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due to the differing epigenetics, leading to differential genetic expression that leads to different consequences of that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National Catholic Bioethics Quarterly Submission Guidelines, was received and marked on this date for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due to the differing epigenetics, leading to differential genetic expression that leads to different consequences of that steroid exposure. In the cross-sex	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National Catholic Bioethics Quarterly Submission Guidelines, was received and marked on this date for identification.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. are very well-documented risks associated with the use of synthetic estrogen and progesterone to regulate ovarian function. Q. And are these some of the same risks you describe in the use of estrogen to treat gender dysphoria? A. No. Q. Why not? A. Because when you're treating gender dysphoria you are giving sex hormones to so giving estrogen to a male is not the same thing to giving estrogen to a female. Giving testosterone to a female is not the same thing as giving it to a male. There's there is very well-established sex-based differences in every cell of the body due to the differing epigenetics, leading to differential genetic expression that leads to different consequences of that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. related to the mechanism by which those drugs are acting within the sexed nature of the human being due to, again, these epigenetic difference. Q. Can I ask you to go back and open Exhibit 3? This is The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. Do you see that up? A. I do have that up. Q. Just to reconfirm, this was published by the National Catholic Bioethics Quarterly? A. That is the journal where it was published, correct. Q. Okay. I am going to ask you to know open what has been marked as Exhibit 6. (Exhibit Hruz 6, National Catholic Bioethics Quarterly Submission Guidelines, was received and marked on this date for

	D 226		P 220
1	Page 226 PAUL W. HRUZ, M.D., Ph.D.	1	Page 228 PAUL W. HRUZ, M.D., Ph.D.
2	A. I seem to recall that it was	2	Q. What does it mean to be
3	brought to my attention at a prior	3	"consonant with the magisterium of the
4	deposition.	4	Catholic Church?"
5	Q. So you have seen it?	5	MS. LAND: Object to form.
6	A. My recollection, yes.	6	A. Again, I want to be clear in
7	Q. And these are the submission	7	serving as an expert in this case that I
8	guidelines for the National Catholic	8	am a physician-scientist and pediatric
9	Bioethics Quarterly, which is where your	9	endocrinologist, not a theologian. But
10	article, The Use of Cross-Sex Steroids	10	what it means is that there are teachings
11	was published; is that correct?	11	of the church that that the teaching
12	A. The paper was published in the	12	authority of the church put forward.
13	NCBC Quarterly; that's correct.	13	Q. Is your article consonant with
14	Q. And just reading from the top,	14	the magisterium of the Catholic church?
15	this says that, "The National Catholic	15	MS. LAND: Object to form.
16	Bioethics Quarterly is the official	16	A. Again, I'm not opining as a
17	journal of the National Catholic	17	theologian. I have no reason to doubt
18	Bioethics Center, an organization	18	that it is. But even if it were not,
19	dedicated to research and the analysis of	19	based upon the paragraph that you read
20	moral issues arising in healthcare and	20	and the publication criteria, it would
21	the life sciences. The NCBQ seeks to	21	have still allowed it to be for
22	foster intellectual inquiry on moral	22	publication in this journal.
23	issues by publishing articles that	23	Q. Going back to your article,
24	address the ethical, philosophical,	24	which is marked as Exhibit 3, and this is
25	theological and clinical questions raised	25	in abstract. So I'm reading from the
	mediogical and emineal questions raised		in destruct. So I in reading from the
	D 005		D 000
1	Page 227 PAUL W HRUZ M D Ph D	1	Page 229 PAUL W HRUZ M D. Ph.D.
1 2	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and	2	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective,
2 3	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the	2 3	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this
2 3 4	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ	2 3 4	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular	2 3 4 5 6 7 8 9 10 11	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly?	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly. Q. Were you aware of this mission	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your article for publication there?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly. Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically reading the paragraph that you just read,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?" A. I'd be happy to very much
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly. Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically reading the paragraph that you just read, but it was my understanding that this was	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?" A. I'd be happy to very much explain the context of the statement.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically reading the paragraph that you just read, but it was my understanding that this was an ethics journal, that this was an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?" A. I'd be happy to very much explain the context of the statement. This relates to many of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically reading the paragraph that you just read, but it was my understanding that this was an appropriate venue to write the paper that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?" A. I'd be happy to very much explain the context of the statement. This relates to many of the errors that are put forward in describing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. by the rapid pace of modern medical and technological progress inspired by the harmony of faith and reason. The NCBQ unites faith in Christ to reasoned and rigorous reflection on the findings of empirical and experimental sciences. While the NCBQ is committed to publishing material that is consonant with the magisterium of the Catholic Church, it remains open to other faiths and secular viewpoints in the spirit of informed dialogue." Did I read that correctly? A. You indeed read that correctly? Q. Were you aware of this mission of the journal when you submitted your article for publication there? A. I don't recall specifically reading the paragraph that you just read, but it was my understanding that this was an ethics journal, that this was an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. middle, "From an ethical perspective, this practice administering" then this part is not quoted but referring back to administering cross-sex hormones to treat gender dysphoria "distorts a proper view of human nature and violates bodily integrity by directly inducing sterility. The use of exogenous cross-sex hormones reenforces rather than alleviates underlying psychiatric dysfunction while significantly increasing the risk of other medical morbidities." Did I read that correctly? A. Yes, you've read that correctly. Q. Can you explain to me what you mean by "this practice distorts a proper view of human nature?" A. I'd be happy to very much explain the context of the statement. This relates to many of the

	D 220		D 222
1	Page 230 PAUL W. HRUZ, M.D., Ph.D.	1	Page 232 PAUL W. HRUZ, M.D., Ph.D.
2	As a physician-scientist one	$\frac{1}{2}$	question of potential, you know, good
3	recognizes sex as inherently directed	3	versus harm and then does put it within
4	toward the biological process of	4	the context of what we know about the
5	reproduction, and that is certainly true	5	human person at multiple levels.
6	in humans. And that the assertions	6	My focus is primarily on the
7	idealogically that are made that try to	7	biology, but a reader of this journal
8	distort that basic it can be viewed at	8	article may come from a different
9	multiple levels, some of which might fall	9	perspective and gain additional insight
10	into the area of theology or philosophy,	10	into that important the contribution
11	but my expertise as a physician-	11	that I tried to make in this article.
12	scientist, it even violates the basic	12	Q. And does medical ethics,
13	understanding of what we mean by sex at	13	generally speaking, have a position on
14	the level of what its inherent purpose	14	the proper view of human nature?
15	is.	15	A. Your question is quite broad.
16	In the ethical or	16	I would say there are again, we think
17	philosophical tradition the term telos is	17	about the way medicine is conducted or
18	often used to refer to what is the end or	18	science is performed, that there are
19	purpose of a particular trait and that	19	varying premises that are put forward,
20	the statement that is made in this paper	20	and the merits of those premises are not
21	is to convey that by many of the	21	equal, but we all begin with underlying
22	idealogical assertions that are made	22	premises, and that includes understanding
23	people are ignoring the basic fundamental	23	of questions of anthropology. It is the
24	reality of the purpose of sexuality in	24	basis for which various hypotheses can be
25	relation to human reproduction.	25	generated, and it can serve as a
	Page 231		Page 233
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	Q. What do you mean by "from an	2	framework by which one designs and
3	ethical perspective" in this context?	3	conducts research studies to, again,
4	A. Ethics, again, is directed	4	achieve the long-term goal to provide
5	quite broadly about doing good and	5	good and avoid harm.
6	avoiding harm. And there is a danger in	6	Q. Do you think having a gender
7	distorting that fundamental understanding	7	identity different from one's biological
8	of the human person if one does not	8	sex violates a proper view of human
9	understand that reproductive purpose.	9	nature?
10	So that, when we talk about	10	MS. LAND: Objection to form.
11	ethics, this is something that's not	11	A. The statement in this article
12	unique, you know, to the discussion of	12	is related to the assertion that sex has
13	the NCBC. There are ethics boards that	13	nothing to do with reproduction. And that
14	are present in all hospitals, there are	14	is what the idealogy is putting forward.
15	ethical issues that arise from time to	15	And many of the hypotheses that are
16	time based upon varied complicated	16	putting forward, or I should say even
17	situations making decisions about how to	17	more fundamental to that, the scientific
18	best act. It's always directed at trying	18	premises that are at play in those that
19	to promote the good and preventing harm,	19	make hypotheses related to this area very
20	and that is the purpose of when we think	20	frequently distort that understanding of
21	about the field of ethics, and I think	21	the human person, they distort the nature
1			
22	it's vitally important to recognize that.	22	of sex in that reproductive goal.
23	That is why this particular	23	VIDEOGRAPHER: This is the
1	· ·		

	D 224		D 404
1	Page 234 PAUL W. HRUZ, M.D., Ph.D.	1	Page 236 PAUL W. HRUZ, M.D., Ph.D.
2	media break.	$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	nature?
3	MR. STRANGIO: Okay. Just I'll	$\frac{2}{3}$	MS. LAND: Objection to form.
4	go another five, if that's okay.	4	A. Again, are you asking
5	Q. Do you think being transgender	5	again, my perspective as a
6	violates a proper view of human nature?	6	physician-scientist and thinking about
7	MS. LAND: Object to form.	7	the biological purpose of sex, I would
8	A. You're saying being	8	say that if you look at the way the body
9	transgender? Are you referring to having	9	is designed from a sexual standpoint, the
10	the experience of a sex-discordant gender	10	sexual organs that are present, the
11	identity?	11	physical form of the body and the
12	Q. Is that how you understand	12	physical activity that occurs in sexual
13	being transgender?	13	union, if you look at the interaction
14	A. I I would say that people	14	between a male and a female, there is an
15	experience a transgender a gender	15	obvious relationship between that sexual
16	identity that is discordant with their	16	anatomy and the potential to generate new
17	sex and that is ethically and morally	17	human life. That is not true for other
18	neutral, as far as the experience they	18	types of interactions in which the sexual
19	have.	19	organs are engaged in a manner that has
20	Q. Is sexual activity between	20	does not have that reproductive
21	same-sex couples consistent with the	21	potential.
$\begin{vmatrix} 21\\22\end{vmatrix}$	proper view of human nature?	22	Q. Does that mean that yes,
23	MS. LAND: Objection to form,	23	same-sex relationships do violate a
24	relevance and scope.	24	proper view of human nature?
25	A. So speaking with my expertise	25	MS. LAND: Objection, asked
	The boopeaning with my expertise		1715. Et il (B. Gojection, ushed
	D 225		B 227
1	Page 235	1	Page 237
1 2	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric	2	PAUL W. HRUZ, M.D., Ph.D. and answered.
2 3	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of	2 3	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so
2 3 4	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one	2 3 4	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex,	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality,
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct?
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form,	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality,
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking?	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom,
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has to be that that question has to be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one understands that that biological purpose,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has to be that that question has to be understood in the context of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one understands that that biological purpose, as far as the nature of the human being,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has to be that that question has to be understood in the context of the underlying understanding of human	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one understands that that biological purpose, as far as the nature of the human being, that is very evident, that the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has to be that that question has to be understood in the context of the underlying understanding of human sexuality.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one understands that that biological purpose, as far as the nature of the human being, that is very evident, that the interaction of a male with a female is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. as a physician-scientist and pediatric endocrinologist, with the goal of treating endocrinologic diseases, if one maintains the biological purpose of sex, the purpose of reproduction will not occur with a same-sex union. Q. And what about non-procreative sex, generally? MS. LAND: Objection to form, relevance and scope. A. I guess, what are you asking? Q. Does that violate a proper view of human nature, having non-procreative sex? A. I would say that there are many sexual acts that occur, not every single sexual encounter leads to the production of new human life. So it has to be that that question has to be understood in the context of the underlying understanding of human	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. and answered. A. So you're asking about so human nature and we're talking specifically I assume about sexuality, correct? Q. As you use it in your article is what I'm talking about. A. And in my article I'm talking about the understanding of sexuality, human sexuality for its reproductive purpose, which is well established in science and it's not just unique to humans, it's across the animal kingdom, where there are distinct definitions of what constitutes as male and female in participation in that reproductive process. In that context that if one understands that that biological purpose, as far as the nature of the human being, that is very evident, that the

	Daga 220		Page 240
1	Page 238 PAUL W. HRUZ, M.D., Ph.D.	1	Page 240 PAUL W. HRUZ, M.D., Ph.D.
2	MR. STRANGIO: I think we can	2	difficulties that these patients
3	stop here for the videographer and	3	experience.
4	take a five minute break. Let's go	4	Q. But it's your view that it
5	off the record.	5	reinforces underlying psychiatric
6	VIDEOGRAPHER: This will end	6	dysfunction?
7	media part 3 and we are off the	7	A. My opinion is that there is
8	record at 1:47 p.m.	8	evidence here that leads them to proceed
9	(Recess is taken.)	9	on to later interventions. And that is
10	VIDEOGRAPHER: We are back on	10	borne out by the studies that are coming
11	the record at 1:59 p.m. This will	11	out right now of those that are going
12	begin media part 4. Please proceed.	12	proceeding on to later stage
13	Q. So in the passage that we were	13	interventions, once they've been
14	last discussing you wrote, "The use of	14	affirmed, beginning with the puberty
15	exogenous cross-sex hormones reinforces	15	blockade and then proceeding onto
16	rather than alleviates underlying	16	cross-sex hormones.
17	psychiatric dysfunction." What is your	17	Q. Are there any studies besides
18	basis for saying that?	18	the Heil-Gorman study that you believe
19	A. I would draw your attention to	19	show that hormone therapy has these
20	the existing literature. For example,	20	negative effects?
21	the paper by Steensma, looking at the	21	A. Certainly. I'll draw your
22	effects of pubertal blockade and	22	attention to the Bränström study that was
23	progression under cross-sex hormones, the	23	discussed at length within my
24	evidence that is evolving right now that	24	declaration. Again, this is a
25	the changing demographics of people,	25	population-based study that concluded
	Page 239		Page 241
1	Page 239 PAUL W. HRUZ, M.D., Ph.D.	1	Page 241 PAUL W. HRUZ, M.D., Ph.D.
1 2		1 2	-
1	PAUL W. HRUZ, M.D., Ph.D.	l	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding	2	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that
2 3	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those	2 3	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance?	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones showing that there was no benefit in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study, the PLoS ONE Swedish study of Dane, which
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones showing that there was no benefit in reducing mental health needs.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study, the PLoS ONE Swedish study of Dane, which showed outcomes long-term in a patient
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones showing that there was no benefit in reducing mental health needs. So there is objective	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study, the PLoS ONE Swedish study of Dane, which showed outcomes long-term in a patient population-based sample. And we can talk
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones showing that there was no benefit in reducing mental health needs. So there is objective information that suggests proceeding with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study, the PLoS ONE Swedish study of Dane, which showed outcomes long-term in a patient population-based sample. And we can talk about that you'd like, about the data,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. again, it solidifies an understanding rather than if we think, go back to those three approaches that we discussed earlier, that it puts forward a path for many individuals that makes it very difficult for them to have other outcomes once this is engaged upon. Q. So by psychiatric dysfunction here you're referring to gender identity sex discordance? A. No. I'm talking about the constellation of factors that affect the wellbeing of these individuals and their underlying suffering. If, for example, I can address the Heil-Gorman paper that looked at psychiatric medication use and need for psychotherapy following gender affirmation for cross-sex hormones showing that there was no benefit in reducing mental health needs. So there is objective	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. even in the original publication that cross-sex hormones provided no benefit long-term in the psychological functioning of these individuals. It made a false claim initially that surgeries had benefit, but as a result of that paper being published and multiple physician-scientists drawing attention to the inaccuracies and falsehoods in the way the data was analyzed ultimately led to the conclusion that neither cross-sex hormones or gender-affirming surgeries improved the psychological health of these individuals and there are others as well. Those are two studies I think that I cited within my declaration. And you can even draw upon the earlier study, the PLoS ONE Swedish study of Dane, which showed outcomes long-term in a patient population-based sample. And we can talk

Page 242 Page 244 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 lack of benefit. neutral or actually adverse. 3 3 Q. Can we turn back to your Q. Do you think a lack of benefit 4 is the same as making patients worse? 4 paper, Exhibit 3, page 662, top of the MS. LAND: Object to form. 5 5 page, it's a sentence that begins "In stark contrast." 6 A. So, again, you have to know 6 7 the evidence that we have because many --7 A. Okay. 8 most of the studies were not randomized 8 Q. The sentence, "In stark 9 controlled studies. You can't -- and if 9 contrast to Pope St. John Paul II's 10 10 teaching on the theology of the body they're not controlled you can't assess the intervention, itself, on the outcome. 11 11 which illuminates teleological 12 You can only state that the outcome was 12 complementarity between male and female 13 not improved. 13 forms and an inseparable unity of body, 14 This example in the Bränström 14 mind and soul it is now openly argued 15 paper, when they actually did have the 15 that the mind alone can and in some 16 information available of those that 16 circumstances should determine or at 17 received and those that did not receive least influence reality in medical 17 18 the gender-affirming affirmation there 18 practice." Did I read that right? 19 was actually a worsening of the reported 19 A. You did indeed read that 20 effects. Now, it's not a completely 20 correctly. 21 accurate, you know, presentation because 21 Q. How does Pope John Paul 22 there could be factors of how they were 22 II's -- how Pope St. John Paul II's 23 segregated into the two groups. 23 teaching come into scientific analysis? 24 24 MS. LAND: Object to form. So I think there is evidence 25 that actually it increases, but certainly 25 A. Again, I will draw attention Page 243 Page 245 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 does not improve. You can see that to the fact that I am serving the court 3 3 actually in the Turban paper as well from in this case as a physician-scientist and 4 Pediatrics in 2000 when the claim was 4 pediatric endocrinologist and not as a 5 5 made, not by the author but by the media, philosopher or a theologian. 6 that the exposure to pubertal blockade 6 It's relevant to consider that 7 7 reduced suicide. teaching in relation to our prior 8 What that paper showed is that 8 conversation about the nature of human 9 9 lifetime suicidality was different, sexuality in male and female forms. 10 10 ignoring the fact that it may have been What is put forward in that 11 the basis by which a patient was offered teaching is the complementarity between 11 12 or not offered puberty blockers. But when male and female forms and it can be 12 13 you looked in the actual raw data of that 13 readily apparent to a casual bystander 14 paper you could see that recent, meaning 14 that merely by looking at the appearance 15 last year's suicidal attempts, were 15 of the human body, that there is a 16 actually higher in those that actually 16 complementarity for unity where the male 17 received that gender-affirmation parts go in relation to the female parts. 17 18 And that is the relevant aspect that's treatment. 18 19 19 important about the statement in relation The nature of the way that 20 study was done only allowed for 20 to how we're engaging in medical 21 21 associative data to be gained, it could practice. 22 not give a causal relationship, it was 22 So that this addresses 23 completely erroneous, and the claim said 23 directly the conversation that we had in 24 that it was beneficial and, in fact, the 24 the previous line of questioning in our 25 raw data suggests that it was either 25 last session, by which the failure to see

Page 246 Page 248 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 that the purpose of sexuality, the actual take into account biological reality, as 3 3 form of the human body in relation to you've described it? 4 that sexual act leads to distortions. 4 MS. LAND: Object to form. 5 The argument being moving away from an 5 A. If your question is; do we 6 empiric observation of what we can see 6 need to operate medicine according to 7 from the biological form to assertions 7 reality? The answer is yes. 8 that are made purely on ideological 8 Q. I think if I'm looking exactly 9 grounds that what one believes determines 9 at the transcript it's, "Would any 10 10 reality. And that as a medically prudent approach to treatment 11 physician-scientist one needs to be aware 11 of gender dysphoria need to take into 12 of that and to question the veracity of 12 account biological reality with respect 13 that world view. 13 to male and female forms, as you've just 14 Q. Are these views about the 14 described it?" 15 complementarity of male and female forms 15 MS. LAND: Object to form, 16 medical opinions? 16 asked and answered. 17 17 MS. LAND: Object to form. A. Are you asking broadly about 18 A. I would say they're objective 18 any medical intervention or specifically 19 biological facts. 19 related to questions that impact human 20 Q. And are Pope St. John Paul 20 sexuality? 21 II's teachings recording complementarity 21 Q. I'm asking specifically about 22 -- excuse me. Let me take that back. 22 treatment for gender dysphoria. Let's be 23 Does Pope St. John Paul II's 23 more specific. 24 teaching inform your treatment for 24 For example, would your 25 treatment of gender dysphoria? 25 assessment of the treatment of gender Page 247 Page 249 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 MS. LAND: Object to form. dysphoria in the context of, say, 3 3 A. I will restate the important prescribing hormone therapy to an 4 adolescent biological male need to take 4 aspects in relation to this question 5 5 about the most prudent approach to into account the biological reality of addressing and alleviating suffering in 6 male and female forms, as you've just 6 7 7 people that experience gender dysphoria described them? 8 needs to be grounded in the biological 8 MS. LAND: Object to form. 9 9 A. I will go back to how I have reality. 10 10 repeatedly described the way that The teachings, themselves, that go far beyond the biological scientific investigation is conducted; to 11 11 understanding are -- are -- can have begin with scientific premises that lead 12 12 13 value for those that choose to explore 13 to the generation of testable hypotheses 14 that in relation to philosophical and 14 in the design and conduct of the research 15 theological dimensions. But I think 15 study. merely on the biological level it is 16 16 This is a question related to 17 relevant to how we understand how this I 17 scientific premise and I think it is 18 would say relativistic understanding that 18 directly relevant to the merit of any 19 is based not upon scientific fact, but 19 hypotheses that are put forward that will 20 20 lead to the conduct of the trials. rather based on idealogy, has allowed 21 21 these assertions, these idealogical So I think it needs to be --22 assertions to have been made. 22 one needs at least to be aware that there 23 Q. And as you described it, would 23 are different premises that are at play 24 any medically prudent approach to 24 and they can be competing premises. There 25 treatment of gender dysphoria need to 25 can be people that begin with a

Page 250 Page 252 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 non-scientific idealogical premise that the ones that are able to understand and 3 3 directs the generation of their incorporate that holistic view of the 4 hypothesis. It doesn't mean it needs to 4 human person in every encounter that they 5 5 be rejected but it should be considered have. 6 in the context by which that hypothesis 6 Q. And can we go to page 671 of 7 is being put forward. And a hypothesis 7 this same article? 8 that claims that you can have benefit in 8 Okay. A. 9 altering the appearance of the human 9 Q. And this is just under Future 10 10 body, based upon a premise that ignores Directions here. The second clause after the biological reality, will have 11 11 the comma but first sentence you write, 12 consequences as to the merit of that 12 "It is clear that the use of cross-sex hypothesis, and the likelihood by which 13 13 hormones for the treatment of gender 14 one will be able to disprove the null 14 dysphoria is immoral." Is that a medical 15 hypothesis as a scientific study is 15 assessment? 16 conducted. 16 MS. LAND: Object to form. 17 A. It is an ethical assessment In my experience in working on 17 18 the NIH study section we often will 18 based upon the scientific evidence and 19 evaluate that because we don't want to 19 the medical aspects related to my 20 spend millions of dollars on a study that 20 analysis of this question of the use of 21 shows an effect that was likely to not be 21 this intervention. Q. Is it a medical ethics 22 proven based upon a faulty premise. 22 23 Q. Okay. I may come back to that. 23 assessment? 24 But for now I'm going to ask you, so is 24 MS. LAND: Object to form, 25 the unity of body, mind and soul a 25 asked and answered. Page 251 Page 253 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 medical concept? A. Again, you know, we don't 3 3 MS. LAND: Objection to form, conduct medicine in a vacuum. We 4 4 always -- again, to reiterate, when we're 5 5 A. Well, I'd say your question is talking about ethics we're trying to 6 fairly broad, but I think --6 maximize good and avoid bad. 7 7 Q. I'm referring back to what you So the assessment of based 8 wrote, which is that "inseparable unity 8 upon the analysis that was conducted as of body, mind and soul", is that a 9 the basis for this manuscript, the 10 10 medical concept? conclusion that was made is that there is A. So any practitioner is going a disproportionate harm in relation to 11 11 to approach their patient who's present 12 12 benefit. And that is how it is stated. 13 in their clinic and be able to look at 13 As far as whether you say moral or 14 that person holistically, they need to 14 ethical, that conclusion it's not 15 understand and respect their values, they 15 supported based on the evidence that's need to understand and address 16 16 available. 17 psychological functioning, they need to 17 Q. Is it your view that it's 18 recognize and understand biological 18 morally wrong to administer cross-sex 19 variation. All those elements; body, 19 hormones to treat gender dysphoria 20 soul and unity are components by which 20 regardless of a patient's age? 21 every single practitioner that engages in 21 MS. LAND: Object to form. 22 medical practice, whether they're aware 22 A. Again, I will say that if 23 of it or not, has to address, some more we're going to adequately address the 23 24 effectively than others. 24 question we need to see this in terms of 25 The best physicians I know are 25 risk versus benefit, which changes

1	D 051		D 056
1	Page 254 PAUL W. HRUZ, M.D., Ph.D.	1	Page 256 PAUL W. HRUZ, M.D., Ph.D.
2	throughout the lifetime. It is different	$\frac{1}{2}$	we were reading, the next sentence
3	in any individual. It differs for a	3	begins, "Nevertheless".
4	variety of factors, that there are many	4	"Nevertheless, there remains a
5	situations where the same intervention is	5	need for ethically permissible
6	done for a particular purpose or a	6	alternative interventions in attempting
7	differing purpose, so it's let me	7	to address this pressing knowledge
8	phrase it this way, that when you are	8	deficit. The limits of bodily
9	assessing the ethics of any act there is	9	manipulation must be recognized and
10	a component of it; what is the actual	10	upheld."
11	nature of the act; what is the intention	11	What did you mean by "the
12	of the act; and what is the circumstance	12	limits of bodily manipulation must be
13	surrounding that act?	13	recognized and upheld?"
14	That is a basic fundamental	14	A. The statement about limits of
15	paradigm that people use in generating	15	bodily limitation is to recognize the
16	ethical decisions that's used every day	16	consequence of the affirmative approach
17	in hospitals throughout the country on	17	and we've already addressed some of
18	ethics boards to try and make decisions	18	those. I think the most pressing is the
19	about complex cases. And so that to make	19	effect on a lifelong fertility in these
20	a definitive statement in any one	20	individuals and, in particular, as we're
21	individual, without consideration of all	21	discussing care to adolescents, that the
22	of those aspects of what is necessary for	$\begin{vmatrix} 21\\22\end{vmatrix}$	induction of sterility in these patients
23	making an ethical choice, it just	23	is not insignificant.
24	requires attention to all of those	24	In fact, for the in the
25	components and the specifics. And the one	25	ethical analysis it involves the lifetime
-	Page 255	-	Page 257
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	that's most problematic all the time are	2	of the patient. And there's actually good
3	the circumstances.	3	data that suggests or that shows that
4		4	when one is presented with a likelihood
	we can objectively look at the		
	We can objectively look at the nature of what is being done and the	1	of inducing lifelong sterility and you
5	nature of what is being done and the	5	of inducing lifelong sterility and you offer artificial means to preserve
	nature of what is being done and the intent of what's being done and then	1	offer artificial means to preserve
5 6 7	nature of what is being done and the intent of what's being done and then there are many differing opinions and	5 6 7	offer artificial means to preserve fertility in an adolescent, fewer than 5%
5 6	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last	5 6	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer.
5 6 7 8	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component.	5 6 7 8	offer artificial means to preserve fertility in an adolescent, fewer than 5%
5 6 7 8 9	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the	5 6 7 8 9	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after
5 6 7 8 9 10	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component.	5 6 7 8 9 10	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the
5 6 7 8 9 10 11	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy,	5 6 7 8 9 10 11	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and
5 6 7 8 9 10 11 12	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw	5 6 7 8 9 10 11 12	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask
5 6 7 8 9 10 11 12 13	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that.	5 6 7 8 9 10 11 12 13	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological
5 6 7 8 9 10 11 12 13	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some	5 6 7 8 9 10 11 12 13 14	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a
5 6 7 8 9 10 11 12 13 14 15	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy	5 6 7 8 9 10 11 12 13 14 15	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have
5 6 7 8 9 10 11 12 13 14 15 16	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is	5 6 7 8 9 10 11 12 13 14 15 16	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children.
5 6 7 8 9 10 11 12 13 14 15 16 17	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical?	5 6 7 8 9 10 11 12 13 14 15 16 17	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less
5 6 7 8 9 10 11 12 13 14 15 16 17 18	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical? MS. LAND: Object to form.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less than 5% and 50%, as far as desire for
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical? MS. LAND: Object to form. A. I would say one needs to	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less than 5% and 50%, as far as desire for children, highlights the important
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical? MS. LAND: Object to form. A. I would say one needs to consider all of those aspects of the	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less than 5% and 50%, as far as desire for children, highlights the important consequence of bodily manipulation that
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical? MS. LAND: Object to form. A. I would say one needs to consider all of those aspects of the ethics to make that decision. And I would	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less than 5% and 50%, as far as desire for children, highlights the important consequence of bodily manipulation that leads to permanent sterility. It's a very
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	nature of what is being done and the intent of what's being done and then there are many differing opinions and factors that will influence that last component. Q. Is it your view, based on the risks and benefits of hormone therapy, that that would make let me withdraw that. Okay. So in your view, in some circumstances providing hormone therapy for adults with gender dysphoria is ethical? MS. LAND: Object to form. A. I would say one needs to consider all of those aspects of the ethics to make that decision. And I would think that it would be wrong to make a	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	offer artificial means to preserve fertility in an adolescent, fewer than 5% will accept that offer. When you look at the scientific studies as to in adults after they've had full brain maturation and psychosocial development and you ask them; do you desire to have biological children? Approximately 50% have a strong desire to be able to have biological children. So the difference between less than 5% and 50%, as far as desire for children, highlights the important consequence of bodily manipulation that leads to permanent sterility. It's a very relevant topic and very important in

	D 250		D 200
1	Page 258 PAUL W. HRUZ, M.D., Ph.D.	1	Page 260 PAUL W. HRUZ, M.D., Ph.D.
2	intervention that could affect fertility	2	population. I've mentioned that, I
3	to be a bodily manipulation?	3	believe in my declaration, that many of
4	MS. LAND: Object to form.	4	these patients experience significant
5	A. So I would say yes, as far as	5	anxiety. Cognitive behavioral therapy
6	bodily manipulation. But I would not say	6	has been shown to be very effective in
7	that it is inherently immoral or	7	alleviating anxiety. It's not been
8	unethical to do that.	8	rigorously studied in this patient
9	In fact, in the very first	9	population in terms of how that might
10	sentence of this conclusion paragraph, I	10	influence outcomes in these patients.
11	outline the ethical principles that could	11	So there's these are just
12	potentially be used to justify that	12	examples, but there are many more and
13	disruption of bodily function, the	13	there are a multitude of alternative
14	principles totality and double effect.	14	hypotheses and treatment approaches that
15	Q. In that same sentence you	15	could be pursued if one would accept that
16	refer to "ethically permissible	16	the scientific basis for the
17	alternative interventions." What would	17	affirmation-only approach has not been
18	those be?	18	proven and has significant limitations
19	A. Well, again, I think that many	19	and one would engage in the proper
20	of the alternative hypotheses that have	20	research to address all of these
21	been put forward to provide benefit for	21	alternative hypotheses.
22	these individuals that suffer from gender	22	Q. And are these alternative
23	dysphoria, many of which have not been	23	hypotheses for minors or adults or both?
24	explored in the rigorous scientific	24	A. They could be for both. Again,
25	manner for which they deserve, could	25	the merits of the hypotheses are going to
	Page 259		Page 261
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of	2	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and
2 3	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk	2 3	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating
2 3 4	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize	2 3 4	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses?
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but,
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence that you just referred to?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety, body dysmorphia, you know, things that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence that you just referred to? A. The emerging evidence related
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety, body dysmorphia, you know, things that predated the onset of gender dysphoria	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence that you just referred to? A. The emerging evidence related to the lack of long-term benefit of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety, body dysmorphia, you know, things that predated the onset of gender dysphoria where that is present.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence related to the lack of long-term benefit of the affirmation approach.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety, body dysmorphia, you know, things that predated the onset of gender dysphoria where that is present. There are many modern	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence related to the lack of long-term benefit of the affirmation approach. Q. Do you have personal religious
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. potentially fall within the category of ethically permissible. Again, as we talk about ethics, we're trying to maximize good and avoid bad for the affected individuals Q. I just asked sorry to interrupt but it was a simple question. What are those alternative interventions in your view? A. Sorry. Thank you. So, for example, they're not exhaustive, but I would say primary psychological approaches that would fall under the other treatment paradigms, whether that is reparative or watch and wait, to address underlying psychological distress, to be able to identify and treat underlying depression, anxiety, body dysmorphia, you know, things that predated the onset of gender dysphoria where that is present.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. differ depending on the circumstance and the group and all sorts of mitigating factors but they certainly could apply to both. Q. And are they all just hypotheses? A. I would say that they're because they've not been rigorously studied, until you do the studies they remain hypotheses. There is emerging evidence that would support that. That is but, again, as I said repeatedly, this is an area of medical interventions that is based upon very limited quality evidence, so it's still experimental. Q. And what is the emerging evidence related to the lack of long-term benefit of the affirmation approach.

	Page 262		Page 264
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	relevance.	2	in my entire life, in my professional
3	A. So you are asking what are the	3	career, ever experienced that conflict
4	bases of my scientific premises that I	4	and I doubt very highly that that would
5	use in formulating	5	ever occur. But I, again, am a
6	Q. No. I'm not asking about the	6	physician-scientist and I follow the
7	basis of your scientific premise. I'm	7	facts where they lead.
8	just asking about your personal religious	8	Q. So I just since we're
9	views.	9	allowed to ask sorry I just want to
10	A. I have religious views. I	10	ask again because you didn't answer the
11	think everyone does. If one does not,	11	question; do you have personal religious
12	they are ignoring reality.	12	views about gender transition separate
13	Q. So what are your personal	13	from what you explained about your
14	religious views about gender transition?	14	medical views?
15	MS. LAND: Objection to form,	15	MS. LAND: Objection to form,
16	relevance and scope.	16	asked and answered.
17	A. I am a physician-scientist,	17	A. It doesn't occur in a vacuum.
18	and I'm a pediatric endocrinologist. I	18	So my religious views cannot be
19	look at all of again, this gets back	19	disassociated from my scientific views.
20	to your question earlier about the	20	But I've already answered your question
21	relationship between faith and reason.	21	that I do have religious views.
22	And I have repeatedly stated in many	22	Q. And what are they?
23	venues that there is no contradiction	23	MS. LAND: Objection to form,
24	between faith and reason. Yet my focus	24	asked and answered.
25	is on science, which would fall in the	25	A. They are in consonant from
			•
	Page 263		Page 265
1	PAUL W. HRUZ, M.D., Ph.D.	1	Page 265 PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. category of reason.	1 2	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I
2 3	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any	1 2 3	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my
2 3 4	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by	1 2 3 4	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand	1 2 3 4 5	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding.	1 2 3 4 5 6	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and	1 2 3 4 5 6 7	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition?
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a	1 2 3 4 5 6 7 8	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form,
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment	1 2 3 4 5 6 7 8	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert	1 2 3 4 5 6 7 8 9	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in	1 2 3 4 5 6 7 8 9 10	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology	1 2 3 4 5 6 7 8 9 10 11 12	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy.	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a	1 2 3 4 5 6 7 8 9 10 11 12 13 14	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of cross-sex hormone therapy to treat gender	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that understanding of that teleologic
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of cross-sex hormone therapy to treat gender dysphoria, would you support the	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that understanding of that teleologic relationship again where the science that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of cross-sex hormone therapy to treat gender dysphoria, would you support the treatment even though it's still distorts	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that understanding of that teleologic relationship again where the science that I've seen thus far has been entirely in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of cross-sex hormone therapy to treat gender dysphoria, would you support the treatment even though it's still distorts biological reality, as you describe it?	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that understanding of that teleologic relationship again where the science that I've seen thus far has been entirely in concert with statements that are made
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. category of reason. So that I don't see any conflict between what I can know by science versus what others can understand on the basis of a faith understanding. But they're not mutually exclusive and everything that I have seen from a rigorous attempt at unbiased assessment of the scientific evidence is in concert with those statements that are made in nonscientific rounds related to theology or philosophy. Q. So let's say there were a dozen studies, including randomized trials that met the standards that you believe for rigorous assessment and institutional review board oversight that demonstrated the effectiveness of cross-sex hormone therapy to treat gender dysphoria, would you support the treatment even though it's still distorts	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 265 PAUL W. HRUZ, M.D., Ph.D. what I've learned from science that I described in very much detail within my declaration and throughout this deposition. Q. What are they with respect to gender transition? MS. LAND: Objection to form, asked and answered. A. I would say there is an intrinsic teleologic relationship between male and female for the purpose of reproduction. That's a basic scientific fact. It can also be understood from a theological or philosophical perspective. They are not in conflict with each other. There are approaches to medical care that seek to preserve the integrity of the human person, and that understanding of that teleologic relationship again where the science that I've seen thus far has been entirely in

	D 000		P. 200
1	Page 266 PAUL W. HRUZ, M.D., Ph.D.	1	Page 268 PAUL W. HRUZ, M.D., Ph.D.
2	All of the things that I put	2	of engaging in medical interventions,
3	forward are not in contradiction, yet	3	given the inability of children to give
4	and thus, in no way have felt any	4	informed consent, are certainly relevant.
5	conflict in putting forward my scientific	5	Q. But generally speaking, your
6	understanding based upon the scientific	6	concerns about the treatment are not
7	premises for hypotheses that any	7	based on age alone?
8	physician-scientist would attempt to do	8	A. That is correct.
9	to address a very complex and important	9	Q. And if Arkansas had proposed a
10	problem.	10	law banning hormone treatment and
11	Q. Okay. So are there any medical	11	surgical treatment with gender dysphoria
12	treatments are there any	12	in patients of any age, would you support
13	pharmacological treatments that you	13	that?
14	support to treat adults with gender	14	MS. LAND: Objection to form
15	dysphoria based on the current state of	15	and scope.
16	the science?	16	A. Again I will reiterate that I
17	MS. LAND: Objection, form.	17	am serving this court as a
18	A. Well, again, my perspective	18	physician-scientist and pediatric
19	are you asking in my clinical experience	19	endocrinologist. I don't profess to be a
20	or in my research that I have done in the	20	politician or a legislator and,
21	medical literature?	21	therefore, I leave to those that are.
$\begin{vmatrix} 21\\22\end{vmatrix}$	I would say that the same	$\begin{vmatrix} 21\\22\end{vmatrix}$	However, I would say that they
23	objections that I have for the quality of	23	*
23		24	are not the same situation when you address the engagement of this
25	the evidence. In fact, really the most solid evidence that we have on long-term	25	affirmation approach in adults versus
23	solid evidence that we have on long-term	25	arrimation approach in addits versus
1	Page 267	1	Page 269
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not	2	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon
2 3	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term	2 3	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in
2 3 4	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this	2 3 4	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of benefits, there are different factors as	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the same factors at play.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of benefits, there are different factors as far as and we do this all the time in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the same factors at play. Q. And what is your understanding
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of benefits, there are different factors as far as and we do this all the time in medicine as far as the ability to do	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the same factors at play. Q. And what is your understanding of what social transition is?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of benefits, there are different factors as far as and we do this all the time in medicine as far as the ability to do things in children versus in adults the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the same factors at play. Q. And what is your understanding of what social transition is? A. Well, we've already addressed
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. outcomes actually apply to adults, not children. We don't have the long-term studies on the long-term effects of this gender-affirming approach when it's applied to children, and it is the basis for the concern that when we look at the adult population, that is where the evidence suggests actually doesn't suggest, it actually demonstrates that there remains a very significant morbidity. It's often quoted and I think correctly from the Swedish study where the completed suicide rate is 19.1 times the background population. So I would say that the same concerns that I have apply to the adult population. Now, where it differs is that in context of the risks and the lack of benefits, there are different factors as far as and we do this all the time in medicine as far as the ability to do	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. children. And primarily it's based upon completed psychosocial development in adults, where it's still evolving in children into the early 20s. And we allow adults to do things that we don't allow children to do. For example, we allow knowing the risks of smoking leading to lung cancer is something that we recognize occurs equally in children and adults. We allow adults to buy cigarettes, we don't allow children to buy cigarettes. It's a distinction that we make in many other areas. And even though I have concerns about the relative risk and benefit and the efficacy of that approach, it does not mean those two populations, from a legislative standpoint, would have the same factors at play. Q. And what is your understanding of what social transition is?

	D 450		5 45
1	Page 270 PAUL W. HRUZ, M.D., Ph.D.	1	Page 272 PAUL W. HRUZ, M.D., Ph.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	name, pronouns, bathroom access, dress,	2	hypotheses about how social affirmation
$\begin{vmatrix} 2 \\ 3 \end{vmatrix}$	you know, in their interactions with	3	might influence the overall health
4	society.	4	long-term and trajectory that they have?
5	Q. Do you think permitting social	5	I do have hypotheses based
6	transition is harmful in adolescents?	6	upon the existing evidence that would
7	MS. LAND: Object to form and	7	lead me to raise that hypothesis. Again,
8		8	it's not a neutral intervention and it
9	scope. A. So in the context of the three	9	may influence the natural trajectory of
10		10	
11	different paradigms we need to consider the relative merits of those different	11	what is going forward. Q. Your answer referred to the
12		12	-
13	approaches and I would say that social affirmation is not a neutral	13	Endocrine Society guidelines referenced
14	intervention.	13	prepubertal children. I'm asking about adolescents.
15		15	
16	Q. What is what do you think		So do you have a hypothesis
17	about social transition? Do you think social transition is harmful in	16 17	that based on existing evidence that social transition in adolescents is
18	adolescents?	18	harmful?
19		19	
20	MS. LAND: Objection to form	20	MS. LAND: Objection, form, asked and answered.
21	and vague.A. Looking at the scientific	21	A. I would extend the statement I
22	evidence there are many concerns. And	22	made about the Endocrine Society
23	this is if you look at the Endocrine	23	guidelines and to extend that into the
24	Society guidelines specifically for that	24	adolescent period, that the social
25	same concern, they caution against social	25	affirmation is not a neutral intervention
23	same concern, they caution against social	25	arrifination is not a neutral intervention
1	Page 271	1	Page 273
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for	2	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be
2 3	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns	2 3	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that
2 3 4	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal	2 3 4	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents?	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form,	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis.
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's an objective which I do as a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are different factors. And to raise the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's an objective which I do as a physician-scientist rather than base	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are different factors. And to raise the hypothesis in prepubertal versus
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's an objective which I do as a physician-scientist rather than base opinions on just, you know, gut beliefs.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are different factors. And to raise the hypothesis in prepubertal versus adolescent children to adults, that would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's an objective which I do as a physician-scientist rather than base opinions on just, you know, gut beliefs. If you are going to address it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are different factors. And to raise the hypothesis in prepubertal versus adolescent children to adults, that would require three distinct hypotheses and I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. affirmation in prepubertal children for the same reason that I have concerns about whether it may alter the normal trajectory. So I would say that it's not a neutral intervention, and it needs to be understood as such. Q. So are you opposed to social transition excuse me. Do you believe that social transition and not a neutral intervention is harmful in adolescents? MS. LAND: Objection, form, asked and answered. A. Well, again, you use the word "believe" and as a physician-scientist I tend to avoid that term. I look at; is there evidence that actually, you know, influences the potential outcome? That's an objective which I do as a physician-scientist rather than base opinions on just, you know, gut beliefs.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. and there are many questions that can be asked about what the influence of that is. And, again, if I'm going to be a physician-scientist, just unlike many of the ideologists that are engaged in this field, who have a preconceived conclusion and then look for evidence to support that conclusion, I don't operate science that way. I look at the hypothesis and try to find objective evidence to really support or refute that hypothesis. Q. Would you extend that to adults? A. One can so one can one can extend the hypothesis to adults but, as I stated previously, they are a different population and there are different factors. And to raise the hypothesis in prepubertal versus adolescent children to adults, that would

	Page 274		Page 276
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	done to be able to obtain a conclusion on	2	just trying to remember the context here.
3	the effect.	3	Q. And would it help if I
4	Q. I'm going to ask you to go	4	reminded you that it involved a teacher
5	back, we are going to upload another	5	and the use of pronouns in a classroom?
6	exhibit. This I will mark as Exhibit 7.	6	A. Yes. That's very helpful for
7	(Exhibit Hruz 7, Amicus Brief	7	me.
8	re: Nicholas Meriwether was	8	Q. Based on your recollection, do
9	received and marked on this date	9	you agree with what you submitted to the
10	for identification.)	10	court as amicus?
11	Q. Is it showing up for you?	11	MS. LAND: Objection, form and
12	A. This is the Sixth Circuit	12	scope.
13	Court of Appeals, Meriwether?	13	A. I'm going to have to read
14	Q. Yes.	14	through the entire document to refresh my
15	A. Okay.	15	memory. I apologize for that, but it's
16	Q. Are you familiar with the case	16	been a while and so much that has
17	of Meriwether versus the Trustees of	17	happened since then.
18	Shawnee State University?	18	Q. You don't need to read through
19	A. I'm trying to refresh my	19	the whole document.
20	memory on this. It's not immediately	20	Would you agree, based on what
21	coming to mind, so I'll have to scroll	21	you've seen on the front page, that you
22	through here.	22	did, in fact, sign the brief?
23	Q. It's okay. You can scroll and	23	MS. LAND: If we're going to
24	just so your name is listed on the	24	be asking questions about this
25	disclosure statement and then the table	25	document he needs time to review
	Page 275		Page 277
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that.	2	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it.
2 3	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind	2 3	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around
2 3 4	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the	2 3 4	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end.	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016?	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me.	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one here. So I'm just trying to I have a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to proceed.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one here. So I'm just trying to I have a number of things that I've been involved	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to proceed. Q. Okay. If I could ask you to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one here. So I'm just trying to I have a number of things that I've been involved with. But this what I'm reading	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to proceed. Q. Okay. If I could ask you to turn to page 23.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one here. So I'm just trying to I have a number of things that I've been involved with. But this what I'm reading through, what I'm seeing through here	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to proceed. Q. Okay. If I could ask you to turn to page 23. A. Page 3?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. of contents that follows that. A. I think of this in my mind I'm trying to figure out find where the date of this was to be able the place it in the context of my research here. Maybe it's at the very end. Q. It was filed June 6, 2020. You can see that at the top, the first page. A. 2016? Q. 2020. A. 2020. Okay. I have it in front of me. Q. Do you recall joining this amicus brief in support of the plaintiff, Dr. Meriwether? A. Again, I'm trying to remember. I'm aware of several amici that I signed onto. I'm just trying to place this one here. So I'm just trying to I have a number of things that I've been involved with. But this what I'm reading	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. it. He's not remembering it. A. I believe that this is around the time where I had about ten other things going on. I just want to make sure that I am remembering this correctly before we get into specific questions here. I'm looking through the document, and at least scrolling through there, there's the statements that are being made, generally speaking, are in agreement with the things that I've included in my declaration. Q. Go ahead. Continue. A. I'm just trying to I'm only on page 26 right now and I'm not reading the whole thing. I'm just trying to scroll through here. I'm ready to proceed. Q. Okay. If I could ask you to turn to page 23.

1	Page 278	1	Page 280
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
	section. This paragraph reads, "This	2	in. And we're going to find long-term
3	idealogical displacement of science leads	3	likely that it is going to have
4	to the position evidently asserted by the	4	significant consequences.
5	Complainant in this case, namely that	5	Q. Do you think an adult person
6	what he feels and thinks about himself	6	who has a sex-discordant gender
7	constitutes the truth about him, which	7	identity's use of pronouns consistent
8	the University would force the entire	8	with their gender identity is ignoring
9	campus community to accept and to treat	9	science?
10	as real. By so weaponizing Complainant's	10	MS. LAND: Objection. Object
11	solecism the University endangers the	11	to form.
12	integrity of scientific knowledge and	12	A. You have to the statement
13	research." Do you still agree with that	13	is being made in the context of what is
14	general idea?	14	being asked.
15	MS. LAND: Objection to form	15	So it is my recollection,
16	and scope and relevance.	16	although I would have to read the
17	A. So, again, I wanted to be able	17	document in its entirety and be able to
18	to read this in the context, but in	18	place it within the context of the way
19	general, you know, speaking to what we've	19	that the science is made, my
20	already discussed, that I think it's	20	recollection, based upon a review very
21	absolutely essential for one to	21	superficially of a document that was
22	understand that when one is making an	22	generated several years ago, is I
23	argument in the area an idealogical	23	would agree with the statement that there
24	statement that is contrary to science or	24	are dangers in forcing scientists to
25	ignores science, that there are inherent	25	operate on idealogical principles without
	Page 279		Page 281
			Fage 201
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
1 2		2	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality.
	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have	2 3	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate
2	PAUL W. HRUZ, M.D., Ph.D. dangers in that.	2	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality.
2 3	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have	2 3	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate
2 3 4	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions,	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely,
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science.
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity?
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form.
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these idealogical assumptions. And that's I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological nature of the person that presents in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these idealogical assumptions. And that's I would say that that is a significant	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological nature of the person that presents in front of them? Is that the question you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these idealogical assumptions. And that's I would say that that is a significant danger. It extends far beyond the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological nature of the person that presents in front of them? Is that the question you are asking?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these idealogical assumptions. And that's I would say that that is a significant danger. It extends far beyond the question of gender dysphoria into the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological nature of the person that presents in front of them? Is that the question you are asking? Q. I'm not asking about anyone
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. dangers in that. It's something that I have repeatedly addressed in other questions, to see this displacement. And I think the term "idealogical displacement of science" is an accurate way to describe some of the corruption or distortion of the natural scientific method that we have long held as academicians and there are definitely dangers associated with that. And it's not only the fact that one can hold a contrary opinion that is not in concert with science, but there is a growing requirement that those that want to maintain the scientific basis of, you know, looking at objective, verifiable information, which is the domain of science, to adopt these idealogical assumptions. And that's I would say that that is a significant danger. It extends far beyond the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. reference to objective reality. Q. Sorry. I was asking separate and apart from this document entirely, you had just previously stated a concern about ignoring science. So my question is generally, for an adult person with a sex-discordant gender identity, does it ignore science for that person to use a pronoun consistent with their gender identity? MS. LAND: Objection, form. A. Okay. If I'm understanding your question correctly, you're asking whether a scientist that is being required to use preferred pronouns that convey an understanding of human sexuality, that is different than what can be observed from the biological nature of the person that presents in front of them? Is that the question you are asking?

	D 000		D 204
1	Page 282 PAUL W. HRUZ, M.D., Ph.D.	1	Page 284 PAUL W. HRUZ, M.D., Ph.D.
2	sex-discordant gender identity themself	2	Q. If a person asked if a
3	uses pronouns consistent with their	3	person with a sex-discordant gender
4	gender identity, does that ignore	4	identity asked you to use their gender
5	science?	5	identity preferred pronouns, would you do
6	MS. LAND: Objection, form,	6	it?
7	vague.	7	MS. LAND: Objection to form,
8	A. You know, that the reasons	8	relevance and scope.
9	for why an individual may do that or not	9	A. I can share with you my
10	is not something that I would be able to	10	experience that I've encountered in my
11	judge in relation to this particular	11	clinical practice where the circumstances
12	amicus brief. It is in relation to	12	have arisen. And what I have discovered
13	requiring somebody else to use those same	13	that as a physician there are when I'm
14	pronouns.	14	confronted with a medical problem I often
15	So what is going on here so	15	need to generate a differential diagnosis
16	I have no way to judge the basis for	16	and effective treatment plan. That
17	which another individual, from their own	17	necessitates one recognizing the sexed
18	personal standpoint, wants to use	18	nature of the individual that is
19	whatever term they want to use.	19	presenting for my care. And this is not
20	Q. If a science professor	20	my opinion, this is well recognized by
21	addresses a person with a sex-discordant	21	our National Institute of Health. In
22	gender identity with their preferred	22	fact, the Endocrine Society as a whole
23	pronouns, are they ignoring science?	23	has put out a statement of recognizing
24	MS. LAND: Objection to form.	24	sex as a biological variable.
25	A. Again, I would use the same	25	If one uses pronouns that
_			
	Page 283		Page 285
1	Page 283 PAUL W. HRUZ, M.D., Ph.D.	1	Page 285 PAUL W. HRUZ, M.D., Ph.D.
2	=	1 2	= -
	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I	2	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason,
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage.
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the specifics by which one is addressing that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from medical records and documenting a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the specifics by which one is addressing that question can be influenced upon the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from medical records and documenting a patient's physiologic characteristics, in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the specifics by which one is addressing that question can be influenced upon the circumstances, whether it's an individual	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from medical records and documenting a patient's physiologic characteristics, in interactions with the person and their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the specifics by which one is addressing that question can be influenced upon the circumstances, whether it's an individual request, whether it's in relation to a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from medical records and documenting a patient's physiologic characteristics, in interactions with the person and their parents, let's say, would you use their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. response to the individual that I previously answered in the last question. The relevant question that I am able to answer is if one were to ask you know, I mean, I can only explain it from my standpoint of what is being conveyed by that. There are many people that are recognizing the ask to be able to use preferred pronouns that do not accept that that is conveying a reality of the person that is requesting that pronoun usage. Some will argue that that it may be something that can be compassionate for that individual. Some will argue otherwise. So I think, you know, the question is fairly broad and the specifics by which one is addressing that question can be influenced upon the circumstances, whether it's an individual	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. suggest an identity for that person that is not that is discordant with the biology that is present, it alters one's thinking often in generating those hypotheses and can lead to errors. And therefore, there is a practical reason, it's not based on idealogy, it's based on best principles of medical practice as to why some individuals may think that it's not a good idea to ignore the biological reality of the individual, despite the request for preferred pronoun usage. Q. And separate and apart from medical records and documenting their physiological characteristics (Internet disruption.) Sorry. I wasn't sure if that was happening okay. Separate and apart from medical records and documenting a patient's physiologic characteristics, in interactions with the person and their

Page 286 Page 288 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 effects of that practice, whether it's in suffering. To effectively do that one 3 3 writing, reading or a conversation that needs to establish a relationship with a 4 can have significant effect on the way 4 patient. 5 5 that one approaches the care of that Many times in pediatric endocrinology we address areas of a very 6 patient. 6 Different practitioners will 7 sensitive nature; we ask them to do 7 8 have different conclusion about it. My 8 things that are very challenging; there 9 own personal experience that I've 9 needs to be an establishment of trust; 10 encountered is it does change the way one 10 there needs to be, you know, ability not 11 looks at that individual and many times 11 only to give them the technical advice 12 leads to potential for error in making 12 but to be able to give them the 13 that objective assessment for the best 13 encouragement and the motivation to 14 care for that individual. And, again, 14 accept the recommended form of 15 this is independent of questions related 15 intervention. And so to make a statement 16 to gender dysphoria. 16 about in that context of weighing the 17 Q. So you wouldn't refer to the relative factors about whether it's going 17 18 patient based on their preferred pronoun, 18 to be a benefit or detriment to that 19 if I'm understanding from what you just 19 individual patient will differ based upon 20 said? 20 the circumstances of that patient. 21 MS. LAND: Objection to form 21 Q. And have you ever used the 22 22 preferred pronouns of one of your and asked and answered. 23 A. So you are making an absolute 23 patients with gender dysphoria? 24 statement that I would not make. I would A. Everything I just shared to 24 you is my experience, was based upon 25 state that my experience is that in 25 Page 287 Page 289 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 making -- you know, providing the best 2 using those pronouns. I would have no 3 3 care for an individual and, again, it experience of being able to make the 4 affects the circumstances by which you're 4 statement that it changes the way I think 5 about a patient if I have not engaged in 5 interacting with that patient, you know 6 -- for example, you know that there are 6 that, and that has been my experience. 7 certain ways that I interpret laboratory 7 Q. So you have used preferred 8 studies based upon normal reference 8 pronouns -ranges that are different between males 9 MS. LAND: Objection to -and females and this can occur 10 10 Q. -- in reference to a patient? independent of hormone exposure. MS. LAND: -- form. Objection 11 11 12 12 There are screening tests that to form. 13 I recommend for my patients that are 13 A. I had a very lengthy answer to dependent upon the sex nature of that 14 14 your question that answered the question 15 individual. And in those circumstances 15 that you just asked. So did I not make where that is -- and many times it creeps myself clear? 16 16 17 up in areas where I would not have 17 Q. I don't think that you did. 18 You said I made an absolute statement expected. 18 19 19 before and you couldn't make absolute. The net effect of using those 20 pronouns changes the way one thinks about 20 So I'm asking you a specific question 21 that individual and may lead to medical 21 which is; as to the patients that you 22 errors. And it's on that basis. It's not 22 have actually had, have you ever referred 23 to a patient with a sex-discordant gender an absolute statement. 23 24 You know, the desire for any 24 identity by their preferred pronoun? MS. LAND: Objection to form. 25 physician, again, is to alleviate 25

Page 290 Page 292 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 A. The basis by which I can make in being able to use those pronoun 3 3 the statement that it alters the way one usages. And many times one can avoid 4 thinks about a patient is based on my own 4 using pronouns altogether. I have no 5 personal experience of using that 5 problem using a preferred name, and many language and seeing the effects of using 6 6 times that's how we resolve that. 7 those pronouns in changing the way I 7 The other way that we address 8 think about that patient. 8 this, and many of the patients accept 9 Q. So -- so -- excuse me. Using 9 this very well, that we have a discussion 10 10 a patient's preferred pronouns has about the condition they have and about the best way that we can approach it. 11 affected the way you think about the 11 12 12 Most of my colleagues that do patient? 13 A. It is essential for me in my 13 engage in the practice of using preferred 14 practice in generating treatment plans, 14 pronouns very frequently make errors in 15 differential diagnoses, to acknowledge 15 -- because they're attempting to think 16 sex-based differences and disease about this individual in their sexed 16 17 susceptibility in responses to treatment. 17 identity in relation to disease. We've 18 The bigger example of this is 18 had conversations about that as well. 19 actually in the area of disorders of 19 Most patients will accept that 20 sexual development. Decades ago when I 20 and they will understand that if you 21 first started working with DSDs, there 21 provide the basis for why you are or are 22 was a belief that making a definitive 22 not using those specific pronouns. 23 determination of the sexed identity of 23 Q. So are you saying you have in 24 that individual would be irreversible and 24 the past used the preferred pronouns and 25 we would engage in entire conversations 25 found that it had effects that you were Page 291 Page 293 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 where we would use gender neutral terms concerned about and so now you don't use 3 3 to be able to avoid that. That was a preferred pronouns but you do utilize 4 4 these other methods that you just standard practice in pediatric 5 5 endocrinology when I had my fellowship described? training in the early phases of my 6 6 A. Again, I will state once again 7 7 training. that there is not a set definitive 8 We've subsequently learned 8 approach to addressing these patients 9 that that concern is not validated and 9 that I use, that I try to approach them 10 10 that we can certainly share with the with compassion to enter into patients the basis for the genital conversation to build trust with them in 11 11 12 ambiguity that occurs and that we can 12 the way that best serves them, that also 13 have that conversation in relation to all 13 includes being able to recognize and 14 14 diagnose a disease and provide the most of the other aspects of understanding the 15 sexed identity of that individual and how 15 effective therapy. they are going to live their life. That will depend upon the 16 16

patient, the circumstances, the nature of

many different approaches that have been

attempted. I've found that some are more

effective than others. And I would say

with them in a very effective manner by

using gender neutral terms, which could

the majority of the patients that I interact with now I am able to interact

my interaction and so there's -- there's

17

18

19

20

21

22

23

24

25

17

18

19

20

21

22

23

24

25

But there are many

circumstances in which I've, I would say,

address individuals in relation to gender

topic, independent of DSDs, with gender

experimented with differing ways to

identity to try to provide the best care

conclusions that I've reached on the

dysphoria is that there are clear risks

to those individuals. And the

	D 204		P. 206
1	Page 294 PAUL W. HRUZ, M.D., Ph.D.	1	Page 296 PAUL W. HRUZ, M.D., Ph.D.
2	include a preferred name, you know,	2	it's presented before me.
3	talking to the parent in other ways, that	3	Q. So you mentioned your
4	conveys my concern for why they are here	4	approach.
5	in my clinic, how I can best serve them	5	Is your approach to generally
6	without distorting my ability to provide	6	avoid pronoun uses when dealing with
7	effective care by ignoring the biological	7	these individuals?
8	sexed nature of the individual that's in	8	MS. LAND: Objection to form.
9	front of me.	9	A. As I've already stated, that I
10	Q. What about outside your	10	would not make a definitive statement. It
11	medical and clinical practice, just	11	depends on the circumstances of the
12	interacting with, say, a colleague who is	12	individual and the role that I have in
13	who has a sex-discordant gender	13	that conversation.
14	identity, would you honor that person's	14	I have found most often, and
15	request to use their preferred pronouns?	15	this is most often not even a conscious
16	MS. LAND: Objection to form,	16	deliberate attempt, that I don't find
17	scope and relevance of that	17	myself presented with a situation where
18	question.	18	I'm required to do so.
19	A. You know, it's a very vague	19	I do remember many times in
20	question. I'd have to look back at my	20	patient case conferences where a
21	conversations with other individuals.	21	transgendered individual is being
22	But I would say that same principle of	22	discussed and having difficulty following
23	maintaining respect is present, you know,	23	the conversation, in particular, using
24	in all my conversations with individuals.	24	the pronoun "they", as it's being
25	And there are many circumstances where	25	presented and thinking in terms of plural
	Page 295		Page 297
1			
1 1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
1		1 2	
2 3	it's not necessary to make this an issue. I think there are many people		PAUL W. HRUZ, M.D., Ph.D. versus singular, and that's just an observation which I think many of my
2	it's not necessary to make this an issue.	2	versus singular, and that's just an
2 3	it's not necessary to make this an issue. I think there are many people	2 3	versus singular, and that's just an observation which I think many of my
2 3 4	it's not necessary to make this an issue. I think there are many people that want to make it an issue when it	2 3 4	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared
2 3 4 5	it's not necessary to make this an issue. I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue	2 3 4 5	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a
2 3 4 5 6	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial	2 3 4 5 6	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just
2 3 4 5 6 7	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have	2 3 4 5 6 7	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to
2 3 4 5 6 7 8	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone	2 3 4 5 6 7 8	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to
2 3 4 5 6 7 8 9 10	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day.	2 3 4 5 6 7 8 9	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is
2 3 4 5 6 7 8 9 10 11 12	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my	2 3 4 5 6 7 8 9 10 11 12	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a
2 3 4 5 6 7 8 9 10 11 12 13	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends	2 3 4 5 6 7 8 9 10 11 12 13	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns
2 3 4 5 6 7 8 9 10 11 12 13 14	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and	2 3 4 5 6 7 8 9 10 11 12 13 14	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals	2 3 4 5 6 7 8 9 10 11 12 13 14 15	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to do the analyses. And in all of those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts with people you know, I'm a physician
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to do the analyses. And in all of those interactions I've not encountered any	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts with people you know, I'm a physician and I spend most of my time much of my
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to do the analyses. And in all of those interactions I've not encountered any hostility in my approach to be able to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts with people you know, I'm a physician and I spend most of my time much of my time in the clinical arena, and it's not
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to do the analyses. And in all of those interactions I've not encountered any hostility in my approach to be able to deal with them with respect and but also	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts with people you know, I'm a physician and I spend most of my time much of my time in the clinical arena, and it's not surprising to me that what I've done in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	I think there are many people that want to make it an issue when it doesn't necessarily need to be an issue to be able to have those collegial interactions, to be able to even have those random associations that everyone has every day. I've not been confronted with somebody that demands that I use any particular pronoun. Most of my interactions with colleagues and friends and those that I have spoken with, and I've spoken to a number of individuals that experience sex-discordant gender identity throughout the time that I've been doing my due diligence about understanding the condition and trying to do the analyses. And in all of those interactions I've not encountered any hostility in my approach to be able to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	versus singular, and that's just an observation which I think many of my colleagues that I work with have shared similar difficulties. But it's not a rigorous idealogical statement, it's just merely a; what is the best way to approach that person, that allows us to have those interactions in a way that is most fruitful. Q. And what would be sorry. Why don't you want to use a transgender person's preferred pronouns outside of the medical context, say, in a social setting? MS. LAND: Objection to form. A. I don't think that I said that. So but I find myself you know, that the way that one interacts with people you know, I'm a physician and I spend most of my time much of my time in the clinical arena, and it's not

	Page 298		Page 300
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	not an idealogical assertion, it's merely	2	through and read it again.
3	what is in the best you know, it's	3	Q. Do you want to just quickly
4	just the way that I act, and I have not	4	scan through the document to refresh your
5	found it to be a problem.	5	recollection of the case?
6	I think in the line of	6	A. Thank you. Yes, I do.
7	questioning that others I'm not	7	(Deponent reviews the
8	necessarily saying that you are want	8	document.)
9	to make it a big issue and it's not. It	9	A. I'm almost at the end of it
10	is something that is it's important,	10	here. So thank you for allowing me to
11	it's important to recognize in medical	11	review it. Okay. Yes.
12	care and I think it actually can	12	Q. And I'm actually going to have
13	influence interactions in other settings	13	you look at the very last paragraph of
14	as well to understand. But it's you	14	the document on page 22.
15	know, you're asking the question in a	15	A. Okay.
16	more dogmatic stance and that is not the	16	Q. So it concludes, "We agree
17	way that I look at it.	17	with the American College of
18	Q. Do you recall speaking to a	18	Pediatrician's conclusion that
19	trans man outside the medical context and	19	conditioning children into believing that
20	using the honorific "Mr."?	20	a lifetime of impersonating someone of
21	MS. LAND: Objection to form	21	the opposite sex, achievable only through
22	and relevance.	22	chemical and surgical interventions, is a
23	A. Again, you know, similar to	23	form of child abuse." Did I read that
24	previous to questions about various	24	correctly?
25	conversations, I've had so many	25	A. You did read that correctly.
	Page 299		Page 301
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so	2	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that
2 3	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know	2 3	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement?
2 3 4	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit.	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope.
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.)	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017.	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto. Q. Do you recall the case that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And if you understand abuse as harm, then I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto. Q. Do you recall the case that this brief was filed in?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And if you understand abuse as harm, then I think that would be in concert with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto. Q. Do you recall the case that this brief was filed in? A. Very briefly. It was so many	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And if you understand abuse as harm, then I think that would be in concert with everything that I've said in my
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto. Q. Do you recall the case that this brief was filed in? A. Very briefly. It was so many years ago but I believe it was one of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And if you understand abuse as harm, then I think that would be in concert with everything that I've said in my declaration as far as the concerns about
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. conversations with so many people in so many different settings that I don't know that I can actually answer that question. Q. Okay. I'm going to mark another exhibit. (Exhibit Hruz 8, amicus brief re: Gloucester County School Board v. Deirdre Grimm, was received and marked on this date for identification.) Q. This is going to be Exhibit 8. This is an amicus brief filed at the United States Supreme Court January 2017. Do you recognize this document? A. I'm surprised that that's an older amicus and I actually remember this more. I think it was the very first amicus that I ever filed or signed onto. Q. Do you recall the case that this brief was filed in? A. Very briefly. It was so many	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. Q. And do you agree with that statement? MS. LAND: Objection to the form of that question and it's outside the scope. A. At the time that this was put forward I do remember actually the conversation about the terminology that was used. The message that it's conveying, as far as being harmful to the children based upon the evidence that was available at that time and really has been reinforced over time, is accurate. But I do remember there was a conversation about the exact wording. But I think it conveys the reality of the concern that it is harming children. And if you understand abuse as harm, then I think that would be in concert with everything that I've said in my

Page 302 Page 304 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 who consents to gender-affirming hormone risks, as I've stated in my declaration, 3 3 therapy for their adolescent child is then we need to acknowledge that. 4 engaging in a form of child abuse? 4 Q. And are the practitioners who 5 5 MS. LAND: Objection to are prescribing -- is it your belief that 6 the practitioners who are prescribing the 6 relevance and scope. 7 A. So I would say that there are 7 gender-affirming hormone therapy to many factors that influence a parent's 8 8 adolescents with gender dysphoria are 9 acceptance of the affirmative approach. 9 engaging in child abuse? 10 Most often what I have encountered are 10 MS. LAND: Objection to 11 parents who have significant concerns 11 relevance and scope. 12 about this approach but are told by the 12 A. It's a very broad question and we would have to have specific examples 13 practitioners that this is a necessary 13 14 intervention and that they will be 14 of specific practitioners with specific 15 harming their children if they do not go 15 information about the information that ahead with affirmation. So that's -- and 16 16 they're presenting to the parents to be 17 you couldn't accuse a parent who is being able to make a conclusion based on that. 17 18 told by their medical professional that 18 I would not care to make a general they're supposed to do this is without a 19 19 assertion. 20 basis for them questioning this. Again, 20 I do -- I am aware there are in relation to our conversation earlier 21 21 circumstances by which idealogically 22 22 oriented individuals are encouraging the about consent and the information that is 23 shared with these individuals, that could 23 affirmation approach without the 24 presentation of the lack of evidence or not constitute that the parents, 24 25 themselves, were abusing the children. 25 the poor quality evidence that would Page 303 Page 305 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 certainly raise questions about -- you However, there are situations 3 3 know, in relation to harming that child. that I'm aware of and, in fact, that I participated in litigation where patients 4 Q. Are you aware that Governor of 4 are -- parents are going through a 5 Texas issued a directive declaring that 5 divorce and they are playing the child 6 treating minors with gender dysphoria 6 off in that divorce proceeding in a way 7 with hormone therapy and puberty blockers 7 8 that is, by an objective observer, could 8 is a form of child abuse? be characterized as certainly not helping 9 MS. LAND: Objection to form, 10 10 and probably harming that child. It's relevance and scope. listed in my declaration, the Texas case A. I am familiar with what you 11 11 12 that I was involved in, where some of are referring to only from what's 12 13 those dynamics were present. 13 presented in the media. 14 Again, you know, to be able to 14 Q. And were you asked by the 15 make a definitive conclusion in any one 15 State of Texas to be an expert in that 16 situation there are many factors. I would 16 case? say some parents are proceeding based 17 17 A. No. upon erroneous information and that would 18 18 Q. Is it your view that someone 19 not constitute abuse. But certainly if 19 with a sex-discordant gender identity who 20 they're using it for other motives or, 20 lives in accordance with that gender 21 you know, from an idealogical 21 identity is impersonating someone of the perspective, the net effect, if the 22 22 opposite sex? 23 concerns that I have related to the 23 A. I probably wouldn't currently 24 affirmative approach are leading to harm, 24 use that language. I'm certainly aware of -- this is a general area of concern in 25 you know, lack of benefit and significant 25

1	D 207		P 200
1	Page 306 PAUL W. HRUZ, M.D., Ph.D.	1	Page 308 PAUL W. HRUZ, M.D., Ph.D.
2	the entire conversation of the way that	2	A. I was aware of the news
3	words are being used, some in a helpful	3	reports when this came out and the links
4	way but often in a harmful way, and I	4	that came out on the internet. First time
5	think it works throughout the	5	I saw it was after this came out and,
6	conversation.	6	yeah, that was the first time I saw it.
7	You know, "impersonation"	7	Q. And this is new guidance from
8	implies knowledge, you know, conclusions	8	the Florida Department of Health entitled
9	that one would make about the motivation	9	Treatment of Gender Dysphoria For
10	for an individual acting in that manner.	10	Children and Adolescents, dated April
11	And I think that as a general statement	11	20th, 2022; is that right?
12	most of the time that that information is	12	A. That's correct.
13	not available.	13	Q. And you see in the first
14	They are certainly acting in a	14	bullet under the general under the
15	way that is discordant with the	15	bullets it says, "Social gender
16	biological reality of their bodies and	16	transition should not be a treatment
17	there is some accuracy in the statement	17	option for children or adolescents." Do
18	but there is also ways that it could be	18	you see that?
19	misinterpreted.	19	A. I do see that.
20	So there are probably other	20	
21	2 2	21	Q. And I'm reading that correctly?
22	ways that one could convey that important	22	·
23	point. But I think that, you know, those		J ,
1	that choose to use that language are	23	yes.
24 25	attempting to acknowledge the fact that	24 25	Q. Based on your expert medical
23	the way that they are acting is	23	opinion do you think social transition
1	Page 307	1	Page 309
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity	2	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited?
2 3	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective.	2 3	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form.
2 3 4	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go	2 3 4	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit.	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video?	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes.	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9.	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for identification.)	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects of that. This looks like to be a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for identification.) Q. It should be up now. Have you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects of that. This looks like to be a definitive conclusion.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for identification.) Q. It should be up now. Have you seen this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects of that. This looks like to be a definitive conclusion. I will state that in my search
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for identification.) Q. It should be up now. Have you seen this document? A. Yes, I have.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects of that. This looks like to be a definitive conclusion. I will state that in my search for randomized controlled trials on
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. discordant with their sexual identity from a biological perspective. Q. I'm going to ask you to go back for another exhibit. Mike, how are we doing on the video? VIDEOGRAPHER: We need to take a break within 15 minutes. MR. STRANGIO: Okay. I'll just do one more line of questioning and we'll take a break. So this will be Exhibit 9. (Exhibit Hruz 9, statement from Florida Department of Health re: Treatment of Gender Dysphoria for Children and Adolescents dated April 20, 2022, was received and marked on this date for identification.) Q. It should be up now. Have you seen this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. for minors should be prohibited? MS. LAND: Object to form. A. Well, my opinion on social gender transition is contained within my declaration and I've already discussed at length in our deposition today my concern that it's not a neutral intervention, but it is listed here as a fairly definitive statement. I think that there are certainly serious questions that can be raised about the influence of social gender transition and the effects it has on individuals. And as we discussed already, you know, that is how I would approach the question from a physician-scientist standpoint, by generating hypotheses about the effects of that. This looks like to be a definitive conclusion. I will state that in my search

	D 210		D 212
1	Page 310 PAUL W. HRUZ, M.D., Ph.D.	1	Page 312 PAUL W. HRUZ, M.D., Ph.D.
2	certainly have concerns that the	2	have full opportunity, as far as my
3	investigation of the effects has not been	3	understanding, to be able to receive the
4	adequately studied.	4	care in all of the other areas that we've
5	Q. Do you think that parents	5	already discussed here, in addressing
6	should ever be let me take that back.	6	underlying psychological comorbidities
7	MR. STRANGIO: I think let's	7	and other difficulties. You know, that
8	take a break here.	8	there's much that can be provided for
9	VIDEOGRAPHER: This will end	9	these individuals to support them and to
10	video part 4 and we are off the	10	continue to strive for that goal of
11	record at 3:18 p.m.	11	achieving significant and sustained
12	(Recess is taken.)	12	alleviating of their distress.
13	VIDEOGRAPHER: We are back on	13	Q. But as to an individual
14	the record at 3:27 p.m. This will	14	patient it would have to be a
15	begin media part 5. Please proceed.	15	case-by-case basis in order to determine
16	Q. Okay. So are you aware that	16	what medical treatment was in their best
17	there are three minor Plaintiffs in this	17	interests?
18	case that are currently receiving hormone	18	A. I would say
19	therapy to treat gender dysphoria?	19	MS. LAND: Objection to form.
20	A. I was given a copy of the	20	A I have already opined in
21	Complaint, yes.	21	this case here that, based upon the
22	Q. And in your view excuse me.	22	evidence of significant risks and
23	In your view would you say	23	unproven benefits, that any care that
24	that it's in the best interests of all	24	should be that to be provided to these
25	of these minor Plaintiffs to	25	individuals would best be served in the
	Page 311		Page 313
1	Page 311 PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are	2	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar
2 3	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving?	2 3	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be
2 3 4	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden.
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment,
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model.	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation,	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative model is based on low quality scientific	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would continue to have access to various forms
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative model is based on low quality scientific evidence with significant risks and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would continue to have access to various forms of intervention with limitations about
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative model is based on low quality scientific evidence with significant risks and unproven benefits. And what is entirely	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would continue to have access to various forms of intervention with limitations about what type of intervention that may be
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative model is based on low quality scientific evidence with significant risks and unproven benefits. And what is entirely unexplored are alternative means of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would continue to have access to various forms of intervention with limitations about what type of intervention that may be until they reach the age of majority, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. discontinue the care they are receiving? MS. LAND: Object to form. A. You know, I think that I'm not able to comment on the specific Plaintiffs, not having evaluated all of the medical records. And that was really my participation as an expert witness is related to the scientific literature and the relative risks and benefits in this affirmative treatment model. So, therefore, I don't have a basis to make a treatment recommendation, nor is that something that I would be able to do in this area. All I can say is that based upon the scientific information that's available right now, the affirmative model is based on low quality scientific evidence with significant risks and unproven benefits. And what is entirely	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. setting of an experimental trial, similar to the way it is being proposed to be done in Sweden. Q. But as to an individual with respect to discontinuation of treatment, would that be a case-by-case basis to determine what would be in their best interests? MS. LAND: Object to form. A. So I think you're asking about specifics. So there's much that should so it's not so the way that the question is being phrased, at least as I interpret it, maybe incorrectly, is that you're proposing that we abandon all treatment. And I don't think that that's the intent nor the effect of the legislation, that these individuals would continue to have access to various forms of intervention with limitations about what type of intervention that may be

Page 316 Ph.D. those d n the enetics may be se the o cause nis in people nink you can taking es in a dn't want to been that is is
those d n the enetics may be se the o cause nis in people nink you can taking es in a dn't want to been that
d n the enetics may be se the o cause nis in people nink you can taking es in a dn't want to been
the enetics may be se the co cause his in people hink you can taking es in a dn't want to been that
enetics may be se the to cause nis in people nink you can taking es in a dn't want to been
may be se the o cause nis in people nink you can taking es in a dn't want to been
the to cause or cause or cause or people or can taking es in a dn't want to been
the o cause nis in people nink you can taking es in a dn't want to been
o cause nis in people nink you can taking es in a dn't want to been
o cause nis in people nink you can taking es in a dn't want to been
nis in people nink you can taking es in a dn't want to been
people nink you can taking es in a dn't want to been
nink you can taking es in a dn't want to been
taking es in a dn't want to been
es in a dn't want to been that
dn't want to been
been
hat
10 10
gation,
ieve that
ieve that
now, to
Page 317
Ph.D.
support
to work
ply into
re
tself, or
aspects
ed to be
ed anyway,
ation.
imes that
this
ove
to treat
to treat t mean that
t mean that
t mean that tment is
t mean that tment is form.
t mean that tment is form.
t mean that tment is form. I've in the
t mean that tment is form.
t mean that tment is form. I've in the
r ts a ii tl

Page 318 Page 320 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 conclude from them, particularly the ones potential that we may uncover what those 3 3 that are cross-sectional, is there may be factors might be, so that we would have a 4 an association between intervention and 4 better prognostic value in who would not be harmed and who might actually achieve 5 an outcome measure. 5 6 6 What we're not certain about benefit. 7 is that there is a causal relationship 7 Q. Can I stop you there? So 8 between the two, that we've not been able 8 there are people who might achieve 9 to establish there's benefit. And when 9 benefit from the medical interventions? 10 A. So as a physician-scientist I 10 you look at any experimental protocol, 11 any intervention at all, there is 11 don't begin with the preconceived 12 heterogeneity in response. 12 conclusion. I ask a hypothesis and I test 13 One of the concerns that I 13 the information. 14 have about the literature is that we 14 So if I'm going to opine on 15 don't fully understand the etiology of 15 what the effect is, I need to recognize that as we're going to conduct a 16 sex-discordant gender identity. Based 16 17 upon the evidence that I've seen, it scientific investigation the reason --17 18 would be most reasonable to put forward a 18 the whole reason that we have equipoise and we actually conduct the scientific 19 hypothesis that it is a multifactorial 19 20 condition, where the emergence of gender 20 investigation is because we don't know for certain what that outcome is going to 21 dysphoria occurs by different reasons to 21 22 different -- in nature and degree in any 22 be. So that's the way all science is 23 one individual. 23 done. If there was no reason to doubt 24 24 When one looks at some of the that you knew the outcome, there would be 25 studies that have been done in small 25 no reason to perform the study. Page 319 Page 321 PAUL W. HRUZ, M.D., Ph.D. 1 1 PAUL W. HRUZ, M.D., Ph.D. 2 patient populations, there is a very 2 Q. Have you read the expert 3 immediate concern about generalized 3 reports of Dr. Karasic and Dr. Adkins in 4 ability of findings. And there is no 4 this case? method here to be able to determine who 5 5 A. Yes, I have. would and would not benefit, you know, 6 Q. And are you aware that they 6 7 from an intervention, who would or would 7 report that hormone therapy had a 8 not suffer a particular adverse outcome 8 significant positive impact on the mental 9 9 health of their patients? effect. 10 10 A. Anecdotal, unsupported, weak You can look at, for example, science. There is much I can say about the risk of stroke, a three to five fold 11 11 increase in males that get estrogen, that those assertions that are being made, not 12 12 13 that doesn't mean there's 100% to the 13 only, you know, just their -- for 14 patients that have that effect. If there 14 example, Dr. Adkins makes many statements 15 are a way to predict who would have that 15 that she's not verified with any adverse effect, you know, both from a scientific information and those things 16 16 physiologic or pathophysiologic 17 17 that she does cite have very serious 18 mechanism, that would be incredibly 18 methodologic flaws. 19 useful. We don't have a biological test 19 So that, you know, to even 20 or even a way to predict who would and 20 make the conclusion that there is a 21 would not respond. 21 causal relationship between what was done 22 If the trials are conducted in 22 and the effect is not possible. You know, 23 the rigorous manner that they need to be the lowest level of scientific evidence 23 24 performed, there may -- there's 24 is the case report. And these anecdotal potential, there's no guarantee, there is 25 25 stories are, at best, means for

Page 322 Page 324 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 hypothesis generation, and they cannot be interventions, or whether they completed 3 3 used to make a definitive conclusions suicide. 4 about causal relationships between 4 So from that vantage point, to 5 5 intervention outcomes. That's well -- to not dismiss their personal 6 observation, but merely to question the 6 recognized in science. And for one to 7 rely upon an opinion on a personal 7 conclusions that are reached by that 8 8 experience that is not controlled and personal observation, I would say, at 9 there is no way to be able to know the 9 best, those anecdotal reports can be used 10 factors that led to that observation. 10 to generate testable hypotheses using the 11 whether it has anything to do with the 11 more rigorous methods to be able to 12 intervention, itself, is highly 12 establish a causal relationship between 13 problematic. 13 the intervention and outcome. Q. But do you have any reason to 14 14 Q. And what strong scientific 15 dispute the anecdotal observation that 15 non-anecdotal evidence exists they have made? 16 16 demonstrating the effectiveness of 17 A. If they have an anecdotal psychological interventions alone to 17 18 observation that they observe an outcome 18 treat gender dysphoria in adolescents? I have every reason to question what is 19 A. I will be the first to be able 19 20 the basis for that outcome and whether it 20 to acknowledge that this is an area that 21 had anything to do with the intervention. 21 has been understudied and underutilized 22 The way it's being presented, 22 and that if one is to pursue these modern 23 the experience is the experience but we 23 psychological tools that have not been 24 don't know why, we don't know the 24 applied to the area of gender dysphoria, 25 circumstances, and we don't -- and then 25 that that is a part of what I propose in Page 323 Page 325 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 the investigation scientifically. the other -- and this is covered in my 3 3 declaration quite clearly, you know We do have evidence that's 4 they're looking at relatively short time 4 based upon established studies about the points. And I think that there is 5 5 comorbidities, you know, the evidence of short-term alleviating of 6 effectiveness, for example, I mentioned 6 7 of cognitive behavioral therapy in 7 anxiety that -- and that's what they're 8 likely reporting, in the absence of 8 alleviating anxiety. We do have 9 9 long-term followup. approaches to addressing underlying 10 10 They certainly have -- well, depression. We do have very longstanding I'm not going to speak for them evidence in treating, independent of 11 11 specifically. But in the studies that gender dysphoria, those that experience 12 12 13 have been conducted where they have tried 13 anorexia. We do have emerging evidence 14 to do this in a longitudinal manner, 14 on how to best care for individuals that 15 there have been very very significant 15 have autism spectrum disorder, many number of patients that are lost to 16 questions that still remain in that 16 followup. There is no way to assess what 17 17 domain. those outcomes were, whether those 18 18 So what is needed is to be 19 19 patients were dissatisfied with the care able to take that experience, in other 20 they received and chose not to return to 20 conditions, to use that in the generation 21 their providers, which is actually 21 of testable hypotheses and apply that to surprising because many of the 22 22 the care of individuals that have sex 23 interventions tether them to the medical discordant gender identity. And if the 23 24 establishment and require them to 24 hypothesis is proven correct, that there 25 continue to receive hormonal 25 is benefit in pursuing those types of

	D 227		D 220
1	Page 326 PAUL W. HRUZ, M.D., Ph.D.	1	Page 328 PAUL W. HRUZ, M.D., Ph.D.
2	interventions, that the addressing of	2	approach. And there is a need across the
3	underlying psychological distress that	3	entire spectrum of scientific
4	might have been from prior sexual or	4	investigation to elevate the quality of
5	physical abuse, dysfunctional family	5	the science that is being put forward.
6	relationships, disordered peer	6	Q. Are there studies indicating
7	interactions, experiences that predated	7	that there are interventions that can
8	the onset of gender dysphoria, that that	8 cause a minor to desist and end up	
9	would have a means to address the	9	identifying with their biological sex?
10	underlying dysphoria. And I would say	10	A. I would say that many of the
11	that even if the dysphoria, itself,	11	so the literature that I'm most
12	cannot be entirely mitigated, and the	12	familiar with is looking at the natural
13	evidence suggests with the affirmation	13	history.
14	approach that there is a continuing	14	If you look at again, we
15	morbidity, whether there is improved	15	mentioned previously Dr. Zucker and his
16	efficacy in alleviation of suffering with	16	program and the experience that he's had
17	the mitigation of risk. So that is	17	in having some individuals that have that
18	really, I've been trying to convey that	18	realignment of their gender identity with
19	to this court throughout this proceeding	19	their sex has occurred, but I think all
20	and in my declaration.	20	of those studies have limitations and
21	There is much more I can say	21	weaknesses and, you know, I think that
22	about that but this is how I view this	22	there is evidence.
23	and this is the conclusions I have	23	Is it the best evidence or is
24	reached in addressing that question.	24	there opportunity to study this in a more
25	Q. But at this time there is no	25	rigorous way? And I've said consistently
	Page 327		Page 329
1	Page 327 PAUL W. HRUZ, M.D., Ph.D.	1	Page 329 PAUL W. HRUZ, M.D., Ph.D.
1 2		1 2	
2 3	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are	2 3	PAUL W. HRUZ, M.D., Ph.D.
2	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that	2 3 4	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right?	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions.
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria;	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right?	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions.
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either?
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form.
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available.	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know,	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there are case reports within that literature	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even consider the alternative hypotheses in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there are case reports within that literature that actually showed patients that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even consider the alternative hypotheses in the other treatment paradigms. There has
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there are case reports within that literature that actually showed patients that actually showed benefit.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even consider the alternative hypotheses in the other treatment paradigms. There has been a mischaracterization of those other
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there are case reports within that literature that actually showed patients that actually showed benefit. Is it quality science? It has	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even consider the alternative hypotheses in the other treatment paradigms. There has been a mischaracterization of those other treatment approaches by many individuals
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. scientific evidence demonstrating that psychological interventions alone are effective at treating gender dysphoria; is that right? MS. LAND: Objection to form, asked and answered. A. I would not say that there is no evidence. I would say there is the same limitations in the quality of evidence that is available. I would stress that in the WPATH guidelines, SOC 7, you know, there's many statements that are made in that Standard of Care document where they make claims that alternative approaches are have been demonstrated to be ineffective and are harmful. And if one actually looks at those studies, there are case reports within that literature that actually showed patients that actually showed benefit.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. that I think there is tremendous opportunity to be able to engage in these areas of investigation to get answers to those questions. Q. So at this time would you say that your preferred treatment approach is not supported by any of the best evidence either? MS. LAND: Objection to form. A. I don't recall that I have shared with you a preferred treatment approach. I've presented three potential treatment approaches or at least paradigms. I presented to you the limitations of the claim that the affirmative model is the necessary model that needs to be put forward. I've shared with you the lack of evidence to even consider the alternative hypotheses in the other treatment paradigms. There has been a mischaracterization of those other

	P. 220		D 222
1	Page 330 PAUL W. HRUZ, M.D., Ph.D.	1	Page 332 PAUL W. HRUZ, M.D., Ph.D.
2	with methods that everyone would	2	Nevertheless, because it's
3	acknowledge are unethical. I'm talking	3	unanswered which approach is going to
4	specifically about the reference to	4	have the most significant and sustained
5	conversion therapy.	5	long-term benefit for a patient, that
6	So there is many areas that	6	there needs to be an ability to put
7	need investigation. And so if I were to	7	forward a variety of alternative
8	opine, based upon the low quality of	8	hypotheses.
9	evidence that we have, that there is a	9	Q. So you're giving me an answer
10	preferred method, then I would be falling	10 about how we assess the relative risks	
11	into the same danger, the trap, the error	and benefits moving forward.	
12	that the Plaintiff experts are putting	12	What is your view on how
13	forward about having a conclusion and	12 what is your view on now 13 patients should be treated right now?	
14	looking for evidence to support their	14	MS. LAND: Objection to form,
15	conclusion.	15	asked and answered.
16	I look at science in a more	16	A. You know, I will reiterate
17	objective manner, and look for the	17	what I've said previously, that there are
18	scientific evidence that supports the	18	many areas of established recognized
19	veracity of the hypotheses that are put	19	benefits of addressing underlying
20	forward.	20	comorbidity, investigating and searching
21	Q. Do you have a view of how	21	for potential precipitating factors that
22	adolescents with gender dysphoria should	22	may include underlying autism, underlying
23	be treated?	23	psychological distress from family
24	MS. LAND: Objection to form,	24	dynamics, from prior abuse, from many
25	asked and answered.	25	other aspects. Those are all
	Page 331		Page 333
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	A. So I will again reiterate that	2	interventions that can be engaged and
_	there is the question shout the	l _	11 1 111 1 21 21 4
3			really should be engaged with within the
3 4	preferred approach in treating	3 4	current knowledge base that we have at
1		l	
4	preferred approach in treating	4	current knowledge base that we have at
4 5	preferred approach in treating individuals that experience	4 5	current knowledge base that we have at this time to alleviate suffering in those
4 5 6	preferred approach in treating individuals that experience sex-discordant gender identity needs to	4 5 6	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are
4 5 6 7	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of	4 5 6 7	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term
4 5 6 7 8	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be	4 5 6 7 8	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions.
4 5 6 7 8 9 10 11	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of	4 5 6 7 8 9	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general
4 5 6 7 8 9 10	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term	4 5 6 7 8 9	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be
4 5 6 7 8 9 10 11	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is	4 5 6 7 8 9 10 11	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're
4 5 6 7 8 9 10 11 12	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for	4 5 6 7 8 9 10 11 12	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we
4 5 6 7 8 9 10 11 12 13	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is	4 5 6 7 8 9 10 11 12 13	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put
4 5 6 7 8 9 10 11 12 13 14	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search	4 5 6 7 8 9 10 11 12 13 14	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low
4 5 6 7 8 9 10 11 12 13 14 15	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is.	4 5 6 7 8 9 10 11 12 13 14 15	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as
4 5 6 7 8 9 10 11 12 13 14 15 16	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that	4 5 6 7 8 9 10 11 12 13 14 15 16	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of
4 5 6 7 8 9 10 11 12 13 14 15 16 17	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological	4 5 6 7 8 9 10 11 12 13 14 15 16 17	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological assessment have inherently, in the	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal and surgical interventions in the
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological assessment have inherently, in the approach or lack the concerns about the	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal and surgical interventions in the experimental setting.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological assessment have inherently, in the approach or lack the concerns about the bodily effects, often irreversible, that	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal and surgical interventions in the experimental setting. Q. Is it your view that a patient
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological assessment have inherently, in the approach or lack the concerns about the bodily effects, often irreversible, that is consequent to using hormonal and	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal and surgical interventions in the experimental setting. Q. Is it your view that a patient sorry. Let me restart that. Let me
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	preferred approach in treating individuals that experience sex-discordant gender identity needs to include an assessment of relative risk and relative benefit, and it needs to be done not only in the context of short-term benefit but long-term sustainability, the influence that is least damaging and most beneficial for the most number of patients. That is what I would advocate for is the search for what that intervention is. Many of the hypotheses that are put forward for psychological assessment have inherently, in the approach or lack the concerns about the bodily effects, often irreversible, that is consequent to using hormonal and surgical interventions. So at the	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	current knowledge base that we have at this time to alleviate suffering in those affected individuals while we are searching for effective long-term solutions. So that is the general framework that I believe needs to be engaged in and one of the and we're actually seeing this more in Europe as we move forward. Exactly what I've put forward is in recognition of the low quality evidence is being put forward as a prudent approach; the prioritization of psychological assessment over hormonal and surgical interventions in the experimental setting. Q. Is it your view that a patient sorry. Let me restart that. Let me back up.

1	Page 334		Page 336	
1	PAUL W. HRUZ, M.D., Ph.D.	$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	PAUL W. HRUZ, M.D., Ph.D.	
2	A. I'm very careful about using universal statements like that and I	$\frac{2}{3}$	been able to find means to be able to	
3	don't think that's the case in what I've	4	navigate that gender dysphoria and with	
5		5	significant benefit, in the absence of	
	seen, but it's a substantial number of		the affirmative approach.	
6 7	patients and that have varying degrees of this of these comorbidities.	6 7	Q. So my understanding is that your current recommendation is similar or	
8	Q. And in your description of	8	is to follow the approach of Sweden and	
9	what we can do right now you mentioned	1		
10	treating comorbidities.	10	•	
11	When there are no	11	You are aware in Sweden and	
12	comorbidities, how should the gender	12	those other countries if gender dysphoria	
13	dysphoria, itself, be treated in an	13	is not resolved by the psychological	
14	individual with no comorbidities no child	14	interventions puberty blockers and	
15	trauma and an intact, healthy family?	15	hormone therapies can be provided, right?	
16	MS. LAND: Object to form.	16	MS. LAND: Objection, form.	
17	A. You are asking how we treat	17	A. Under an experimental	
18	sex-discordant gender identity when there	18	protocol.	
19	is no dysphoria?	19	Q. And do you disagree with that	
20	Q. I'm asking when the only	20	approach?	
21	diagnosis is gender dysphoria, there is	21	A. I repeatedly stated my desire	
22	no comorbidities, and there is no history	22	to see the elevation of the science and	
23	of trauma or childhood sexual abuse, what	23	that the provision of that type of care	
24	would you recommend as a current	24	within the setting of an experimental	
25	treatment for that individual with the	25	protocol under the supervision of an	
-			protocor under une supervision or un	
1	Page 335	1	Page 337	
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.	
2	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria?	2	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review	
2 3	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form.	2 3	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated.	
2 3 4	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis	2 3 4	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that	
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach?	
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form.	
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the	
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation.	
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression,	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do	
2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label?	
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form,	
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope.	
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the	
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or	2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is	
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold	2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication.	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one has in peer relationships. One can	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there is very well established data in the	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one has in peer relationships. One can certainly assist that individual in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one has in peer relationships. One can certainly assist that individual in even if it's not possible to eliminate	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there is very well established data in the adult population and there have not been clinical trials that are done in the	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one has in peer relationships. One can certainly assist that individual in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there is very well established data in the adult population and there have not been	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. gender dysphoria? MS. LAND: Objection to form. A. As an investigative hypothesis and, you know, experimental approach I would adopt or recommend adopting the approach that Sweden has taken and the European countries, prioritizing even if there is not diagnoseable depression, diagnosable anxiety disorder, there can still be potential benefit and psychological support to be able to allow an individual again, if you think about the field of psychiatry or psychology, you know, there are threshold criteria to establish a diagnosis, but that is often presented on a spectrum and there are certainly opportunity to address underlying difficulties that one has in peer relationships. One can certainly assist that individual in even if it's not possible to eliminate the gender dysphoria, the again, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. institutional review board. A review board is what is indicated. Q. So you agree with that approach? MS. LAND: Objection, form. A. I've repeatedly stated the rationale for experimental investigation. Q. In your current practice do you ever prescribe medications off label? MS. LAND: Objection, form, relevance, scope. A. So the question related to the prescribing of drug off-label. It is very common in medical practice with the appropriate recognition for the basis for which one is using the off-label indication. Many times in pediatrics there is very well established data in the adult population and there have not been clinical trials that are done in the pediatric population. There are	

	D 220		P 246
1	Page 338 PAUL W. HRUZ, M.D., Ph.D.	1	Page 340 PAUL W. HRUZ, M.D., Ph.D.
2	established, where there indeed have been	2	proceed with the utmost of caution when
3	randomized controlled studies of the	3	you have greater risk and unproven
4	intervention in other patient populations		
5	that we can draw upon. The use of	5 Now, in this particular area	
6	Q. This was just a yes or no	6	we have not only seen significant risks,
7	question. I don't need a full background.	7	we have seen evidence that's mounting
8	Yes or no; do you prescribe	8 that there is no benefit and that there	
9	medication off-label in your current	9 may be potential harms. It's not entirely	
10	practice?	10 neutral. And what I would like to see as	
11	A. I think it's necessary	11	a minimum of being able to see a study
12	MS. LAND: Objection	12	that is adequately powered with the
13	A. It's necessary in pediatrics	13	proper experimental design, with enough
14	on frequent occasions to be able to	14	power to be able to establish a
15	prescribe medicines that have not been	15	conclusion about the causal relationship
16	specifically approved for the use in	16	between the intervention and the outcome
17	children but have been approved for other	17	and be able to show that that had the
18	indications with good knowledge of the	18	intended benefit. And I think that those
19	risks and benefits.	19	trials are often done initially as pilot
20	Q. Okay. So as a general I'll	20	trials that are extended into larger
21	stop there.	21	trials to be able to increase the power
22	Let's take another five minute	22	to be able to increase the
23	break if we could. Thanks.	23	generalizability.
24	VIDEOGRAPHER: We're off the	24	So I would like to see a study
25	record at 3:57 p.m.	25	that was done with that rigor, that is
	Page 339		Page 341
1	PAUL W. HRUZ, M.D., Ph.D.	1	PAUL W. HRUZ, M.D., Ph.D.
2	(Recess is taken.)	2	has a properly designed control group,
3	VIDEOGRAPHER: We are back on	3	that has definable definitive hypothesis
4	the record at 4:12 p.m. Please	4	and outcome measure that one can get that
5	proceed.	5	information for. And I should stress
6	Q. So Dr. Hruz, what kind of data	6	that, to be able to conduct that clinical
7	would you need to see demonstrating the	7	trial, it is not, as it's often
8	effectiveness of gender-affirming medical	8	portrayed, that you have a control group
9	care in adolescents in order to be	9	that you do nothing to. That is not the
10	willing to deem it appropriate care?	10	way science is done.
11	MS. LAND: Objection to form.	11	Science is conducted by which
12	A. Okay. We'll come back to,	12	you take all of the variables that are
13	maybe flesh out a little bit more some of	13	present in your study population, both
14	the things that I said previously.	14	the control and the intervention group,
15	I think that there needs to be	15	and you make both groups equal with the
16	a recognition of relative benefit versus	16	exception of what's called the
17	relative risk and the approach that needs	17	independent variable, the thing that
	relative fish and the approach that needs	1	
18		18	you're going to intervene with that's
18 19	to be put forward needs to have	18 19	you're going to intervene with that's going to be different between the
1	to be put forward needs to have consideration of alternative hypotheses	1	going to be different between the
19	to be put forward needs to have	19	
19 20	to be put forward needs to have consideration of alternative hypotheses of other interventions in comparison to that.	19 20	going to be different between the treatment group and the control group. I've not seen those studies
19 20 21	to be put forward needs to have consideration of alternative hypotheses of other interventions in comparison to that. So, you know, I think that	19 20 21	going to be different between the treatment group and the control group. I've not seen those studies designed in this patient population. I've
19 20 21 22	to be put forward needs to have consideration of alternative hypotheses of other interventions in comparison to that.	19 20 21 22	going to be different between the treatment group and the control group. I've not seen those studies

	5 00		D 044
1	Page 342 PAUL W. HRUZ, M.D., Ph.D.	1	Page 344 PAUL W. HRUZ, M.D., Ph.D.
2	medications, suicidality current, not	2	the alternative hypotheses that have been
3	lifetime, in this population after	3	proposed, would like to see a controlled
4	they've achieved affirmative care.	4	trial where one compares the affirmative
5	If it were demonstrated that	5	approach with a primary, you know,
6	we had that evidence available, again,	6	psychological approach, which isn't being
7	with caution, depending on the strength	7	done. That would be a very important
8	of that information, that as we do in	8	study.
9	other areas of medicine, that	9	Even asking simple questions
10	acknowledging the data that's available,	10 at this point in time about the effect of	
11	that we would be able to engage in that	pubertal blockade on persistence is	
12	particular intervention. If we're	12	certainly a trial that can ethically be
13	and, again, there are so many different	13	conducted. There is actually existing
14	caveats to that as it pertains to gender	14	data from previously published papers
15	dysphoria that have not been yet	15	that wasn't controlled, randomized, where
16	explored.	16	one has compared delay in pubertal
17	So it doesn't mean that you	17	blocker initiation versus immediate,
18	have to have a definitive answer with a	18	showing that both groups showed benefit.
19	gold standard study that was done in a	19	The way that that's a paper
20	thousand patients, you know, with	20	by Costa that I think I mentioned in my
21	generalizability to the entire	21	declaration. This is a paper that, based
22	population. That's not what I would	22	upon very inadequate data, allows one to
23	propose.	23	ask a hypothesis that if both
24	But there has been a failure	24	intervention groups if both the group
25	of the medical establishment to, you	25	that did and did not receive the puberty
	Page 343		Page 345
1	Page 343 PAUL W. HRUZ, M.D., Ph.D.	1	Page 345 PAUL W. HRUZ, M.D., Ph.D.
1 2	PAUL W. HRUZ, M.D., Ph.D.	1 2	PAUL W. HRUZ, M.D., Ph.D.
	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of		PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received
2	PAUL W. HRUZ, M.D., Ph.D.	2	PAUL W. HRUZ, M.D., Ph.D.
2 3	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing	2 3	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean
2 3 4	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard.	2 3 4	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar
2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of	2 3 4 5	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global
2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data	2 3 4 5 6	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a
2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually	2 3 4 5 6 7	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able
2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model.	2 3 4 5 6 7 8	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period
2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data.
2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few	2 3 4 5 6 7 8 9	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned
2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one	2 3 4 5 6 7 8 9 10	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take
2 3 4 5 6 7 8 9 10 11 12 13 14	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few	2 3 4 5 6 7 8 9 10 11 12	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment
2 3 4 5 6 7 8 9 10 11 12 13 14 15	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you	2 3 4 5 6 7 8 9 10 11 12 13	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached this as a physician-scientist, again, in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't have that information and we have much
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached this as a physician-scientist, again, in the way we approach all areas of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't have that information and we have much information that leads to questions
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached this as a physician-scientist, again, in the way we approach all areas of medicine, that one needs to take the lead	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't have that information and we have much information that leads to questions whether that really is achieving the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached this as a physician-scientist, again, in the way we approach all areas of medicine, that one needs to take the lead of the evidence that's available.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't have that information and we have much information that leads to questions whether that really is achieving the effect that one says is being achieved.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. know, apply the basic principles of evidence-based medicine in this regard. And because of the emerging data showing the significant risk, the lack of long-term benefit, and emerging data showing that there may be actually significant effects of that intervention, in that setting I think that the ethics prevent one from endorsing that model. Q. So if you had that, say, one of those and let's say you had a few of those rigorous studies that is designed, as you describe, that did show benefit to patients, then would you prescribe puberty blockers and hormone therapy to treat gender dysphoria? MS. LAND: Objection to form. A. As I have always approached this as a physician-scientist, again, in the way we approach all areas of medicine, that one needs to take the lead	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	PAUL W. HRUZ, M.D., Ph.D. blocker, but both groups received psychological support had a similar regression, either regression to the mean or improvement in overall global functioning, that that would be in a controlled trial that one could be able to propose a study for a defined period of time to begin getting this data. The type of data that needs to be generated is acknowledged to take significant time. And as I've mentioned previously, if the science were to show that this is the only effective treatment that has proven benefit and acceptable risk profile, that would be on par with other areas of medicine where we engage in this intervention. At the current moment we don't have that information and we have much information that leads to questions whether that really is achieving the

Page 346 Page 348 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 to treat gender dysphoria? acceptable and the desired outcome was 3 achieved, and we do this in many other 3 MS. LAND: Objection to form. 4 A. I would choose the option that 4 areas, and we can apply many of those 5 5 had the least risk and maximal benefit. ethical principles that I mentioned that we didn't discuss, including, for 6 I've said that repeatedly and I will say 6 7 7 example, the principle of totality or it again. 8 If there was two 8 double effect in assessing whether to 9 9 engage in that that -- again, you know, interventions, both that were efficacious 10 10 looking at the scientific premise is in alleviating gender dysphoria, one 11 resulted in a loss of sexual function, 11 going to influence the likelihood of 12 exposure to risks of osteopenia, stroke, 12 whether we're able to see that. But if 13 metabolic effects, and the other did not 13 it's done rigorously, then that's what we 14 have any of those consequent effects by 14 do in medicine. And we do this in all 15 not being exposed to those treatments, 15 other areas of medicine and we certainly 16 the superior and preferred treatment 16 have interventions. 17 group would be the one that has the lower 17 If you think about the 18 risk. 18 treatment of people with cancer, there 19 19 are many interventions that we do that Where it becomes more 20 difficult is if the intervention is not 20 have very significant risks, but it's 21 equal as far as the response and weighing 21 necessary in that circumstance -- and, 22 the relative risks and benefits, and that 22 again, I would say that in most of those 23 would have to be determined after the 23 cases we are doing this in the conduct of 24 24 research trials, in the rigorous manner trial and the information is available to 25 weigh those relative risks and benefits. 25 that I am proposing, where there can be Page 347 Page 349 1 PAUL W. HRUZ, M.D., Ph.D. 1 PAUL W. HRUZ, M.D., Ph.D. 2 2 harms that are induced, but they're At the current moment, what we 3 3 have available is a model that claims engaged with a better knowledge of the 4 relative risks and benefits because 4 erroneously that the conclusion has 5 5 already been reached and that alternative they've had the higher quality clinical 6 approaches have been proven to be 6 studies performed. 7 7 ineffective. And those are false Q. Do you support surgical 8 statements that need to be addressed. 8 interventions to change the appearance of an infant's genitals when the infant has 9 And so that is how I approach that 9 10 10 certain disorders of sexual development? question. Q. And as we've been discussing, MS. LAND: Objection to form. 11 11 12 if the data were to show in the future, 12 A. So your question is related to 13 understanding it could take a long time, 13 the care of individuals with disorders of 14 that these interventions did improve the 14 sexual development and I didn't have a 15 health and wellbeing of adolescents with 15 chance previously with your question to gender dysphoria, would you support them, address that aspect of the evolution of 16 16 even though they could be based on a care over time. But together, with the 17 17 18 premise that ignores the biological question related to how we refer to the 18 19 reality as you have previously described 19 individual, the initial presumption was 20 20 that we needed to definitively alter the it? 21 21 MS. LAND: Objection to form. appearance of the genitalia to conform to 22 A. Again, the goal of medicine is 22 our best understanding of sexual 23 to alleviate suffering. And if it was 23 identity. And it's clearly not the 24 proven that this was the most effective 24 paradigm that is used currently. And I 25 intervention, that the risks were 25 think the best recommendations are to

	Page 350		Daga 252
1	PAUL W. HRUZ, M.D., Ph.D.	1	Page 352 CERTIFICATE
2	defer those surgeries until later in	2	I, MAUREEN M. RATTO, a
3	life.	3	Registered Professional Reporter, do
4	The only exceptions would be	4	hereby certify that prior to the
5	if there are medical reasons that would	5	commencement of the examination, PAUL
6	necessitate earlier surgery. For	6	W. HRUZ, M.D., Ph.D. was sworn by me to
7	example, an area of disordered sexual	7	testify the truth, the whole truth and
8	development that would lead to markedly	8	nothing but the truth.
9	increased risk of cancer or infection,	9	I DO FURTHER CERTIFY that the
	•	10	foregoing is a true and accurate
10	urinary retention, there are conditions	11	transcript of the proceedings as taken
11	where you need to intervene.	12	stenographically by and before me at
12	But for the goal of changing	13	the time, place and on the date
13	the appearance of the genitalia to allow	14	hereinbefore set forth.
14	the function to coincide with the sexual	15	I DO FURTHER CERTIFY that I am
15	identity of that individual, I think	16	neither a relative nor employee nor
16	most, including our institution that	17	attorney nor counsel of any of the
17	participates in that care, recognizes	18	parties to this action, and that I am
18	that that is a decision that does not	19	neither a relative nor employee of such
19	need to be made in the newborn period.	20	attorney or counsel, and that I am not
20	That it is apparent both from	21	financially interested in this action.
21	understanding the natural history of the	22	
22	condition as the child ages but also to	23	
23	acknowledge the other factors and		Mauronkatta
24	allowing for that consent for that	24	Maureen Katto Maureen M. RATIO, RPR
25	procedure to have that procedure done at	25	License No. 817125
	Page 351		Page 353
1	PAUL W. HRUZ, M.D., Ph.D.	1	INDEX
2	a later stage of life.	2	WITNESS: PAUL W. HRUZ, M.D., 7
3	MR. STRANGIO: I think we are	3	Ph.D.
4	all set on this end.	4	DIRECT EXAMINATION MR. STRANGIO 8
5	Thank you for your time, Dr.	5	
6	Hruz. I'll pass the witness.	6	EXHIBITS
7	MS. LAND: Can we take a five	7	Exhibit Hruz 1, Expert Report of 18
8	minute break?	8	Paul Hruz, dated December 10,
9	VIDEOGRAPHER: We're off the	9	2021,
10	record at 4:26 p.m.	10	Exhibit Hruz 2, Expert Rebuttal 21
11	(Recess is taken.)	11	Report dated February 10th,
12	VIDEOGRAPHER: We're back on	12	2022,
13	the record at 4:33 p.m. Please	13	Exhibit Hruz 3, Abstract re: The 77
14	proceed.	14	Use of Cross-Sex Steroids in the
15	MS. LAND: Thank you. No	15	Treatment of Gender Dysphoria by
16	further questions from us but we	16	Paul W. Hruz
17	would like to review and sign.	17	Exhibit Hruz 4, article from New 78
18	VIDEOGRAPHER: Okay. This will	18	Atlantis entitled Growing Pains,
1		l	_
1			
		l	
1		l	= =
	angonino de 1100 pinis)		
		l	
25		25	Catholic Bioethics Quarterly
19 20 21 22 23 24	complete the deposition. We're off the record at 4:33 p.m. (The proceedings were adjourned at 4:33 p.m.)	19 20 21 22 23 24	Exhibit Hruz 5, article from 83 NCBC entitled Experimental Approaches to Alleviating Gender Dysphoria in Children by Paul W. Hruz, MD Exhibit Hruz 6, National 225

	Page 354		Page 356
1	Submission Guidelines,	1	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al.
2	Exhibit Hruz 7, Amicus Brief re: 274	2	Paul Hruz , M.D. (#5163582)
3	Nicholas Meriwether	3	ERRATA SHEET
4	Exhibit Hruz 8, amicus brief re: 299		PAGELINECHANGE
5	Gloucester County School Board	5	
6	v. Deirdre Grimm,		REASON
7 8	Exhibit Hruz 9, statement from 307		PAGELINECHANGE
9	Florida Department of Health re: Treatment of Gender Dysphoria	8	
10	for Children and Adolescents		REASON
11	dated April 20, 2022		PAGELINECHANGE
12	dated April 20, 2022		DEACON
13			REASONPAGELINECHANGE
14			FAGE LINE CHANGE
15			REASON
16			PAGELINECHANGE
17		17	
18			REASON_
19			PAGELINECHANGE
20		20	
21		21	REASON
22		22	
23		23	
24		24	Paul Hruz , M.D. Date
25		25	
	Page 355		Page 357
1	Page 355 Amanda Land, Esq.,	1	Page 357 Brandt, Dylan Et Al v. Rutledge, Leslie Et Al.
1 2			
	Amanda Land, Esq.,		Brandt, Dylan Et Al v. Rutledge, Leslie Et Al.
2	Amanda Land, Esq., aland@arkansasag.gov	2	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582)
2 3	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022	2 3 4	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT
2 3 4	Amanda Land, Esq., aland@arkansasag.gov	2 3 4 5	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I
2 3 4 5 6	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review.	2 3 4 5 6	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any
2 3 4 5 6	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should	2 3 4 5 6 7	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as
2 3 4 5 6 7 8 9	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are	2 3 4 5 6 7	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz, M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz, M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is
2 3 4 5 6 7 8 9	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the	2 3 4 5 6 7 8	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz, M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz, M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me.
2 3 4 5 6 7 8 9 10	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet.	2 3 4 5 6 7 8 9 10	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz, M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz, M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me.
2 3 4 5 6 7 8 9 10 11 12	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of	2 3 4 5 6 7 8 9 10 11 12	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date
2 3 4 5 6 7 8 9 10 11 12 13	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney.	2 3 4 5 6 7 8 9 10 11 12 13	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz, M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz, M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz, M.D. Date *If notary is required
2 3 4 5 6 7 8 9 10 11 12 13 14	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at	2 3 4 5 6 7 8 9 10 11 12 13 14	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz, M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz, M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz, M.D. Date *If notary is required
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony. If the witness fails to do so within the time	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony. If the witness fails to do so within the time allotted, the transcript may be used as if signed.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony. If the witness fails to do so within the time allotted, the transcript may be used as if signed. Yours,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony. If the witness fails to do so within the time allotted, the transcript may be used as if signed.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Amanda Land, Esq., aland@arkansasag.gov June 3, 2022 RE: Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. 5/25/2022, Paul Hruz, M.D. (#5163582) The above-referenced transcript is available for review. Within the applicable timeframe, the witness should read the testimony to verify its accuracy. If there are any changes, the witness should note those with the reason, on the attached Errata Sheet. The witness should sign the Acknowledgment of Deponent and Errata and return to the deposing attorney. Copies should be sent to all counsel, and to Veritext at erratas-cs@veritext.com. Return completed errata within 30 days from receipt of testimony. If the witness fails to do so within the time allotted, the transcript may be used as if signed. Yours,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Brandt, Dylan Et Al v. Rutledge, Leslie Et Al. Paul Hruz , M.D. (#5163582) ACKNOWLEDGEMENT OF DEPONENT I, Paul Hruz , M.D., do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Paul Hruz , M.D. Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20

[& - ability] Page 1

0	2	244:4 277:23	662 244:4
&	2	353:13 355:3	671 252:6
& 3:4 7:3,5	2 21:13,14 86:19	30 158:24 355:17	
0	159:5 189:5 194:8	307 354:7	7
00450 1:9 5:21	194:8 353:10	323 4:14 5:24	7 99:4,15 274:6,7
1	20 158:6 307:18	34e 101:13,24	327:13 353:2
	354:11 357:15	102:3	354:2
1 5:13 18:7,12,24 19:24 73:9 86:14	200 5:25	3:18 310:11	7/7/21 74:7
	2000 30:16,18	3:27 310:14	70 145:5
101:11 102:25	99:18 243:4	3:57 338:25	71 153:6,9
121:14 145:4	2011 30:19 99:20		72 159:12 174:25
153:6 159:11	2012 51:3,23	4	175:6
174:24 353:7	131:11	4 78:21,22 98:6,7	72201 4:6,15
10 18:8 21:2 24:14	2016 275:10	98:11 238:12	77 353:13
353:8	2017 78:14 79:8	310:10 353:17	78 353:17
100 92:14 168:21	299:14	425 4:5	8
219:21 319:13	2019 83:25	46 101:22,23	8 299:7,12 353:4
10004 3:6,14	2020 275:8,11,12	121:17,18	354:4
10:20 86:15	2021 18:9 21:2	47 101:12,21	81 153:6
10:31 86:18	75:15 353:9	4:12 339:4	817125 2:10
10th 21:16,25 22:3	2022 1:18 5:4	4:21 1:9 5:21	352:25
22:17 353:11	21:16,25 22:17	4:26 351:10	83 353:19
11:47 159:4	24:14 307:18	4:33 351:13,20,22	85 92:13 168:6
125 3:5,13	308:11 353:12	5	87 92:13
12:20 159:8	354:11 355:3		
14 194:10	20s 31:4,13 216:24	5 77:9,10,11 83:13	9
15 158:17,22	269:5	83:14 102:20	9 307:13,14 354:7
189:6 194:20	20th 308:11	257:7,18 310:15	90 16:16
307:9	21 353:10	353:19	98 21:3 92:12
1570 11:16 12:6	22 300:14	5/25/2022 355:5	219:21
13:4,12,19 14:8	225 353:24	50 92:12 127:19	99 73:12 74:8
53:11	23 277:22,24	156:19 257:14,18	a
17 165:14	25 1:18	5163582 355:5	a.m. 1:19 5:3
17425 352:23	25th 5:3	356:2 357:2	
18 353:7	26 277:17	58 121:19,24	86:15,18
19.1 267:14	274 354:2	6	abandon 313:16
1997 30:18 66:5	299 354:4	6 225:18,19 275:8	ability 9:25 24:9
1:47 238:8	3	353:24	33:4 48:23 111:18
1:59 238:11	_	60 145:5	113:8 123:24
	3 77:12,14,23 78:2	61 127:19,20	128:6 132:21
	159:9 225:7	62 159:12 174:25	133:15,21 134:24
	228:24 238:7		139:6,13,14 148:6

[ability - actively] Page 2

149:24 191:14	293:13,23 295:6,7	academic 67:21	320:5,8
209:10 267:22	295:22 303:14	academicians	achieved 105:4
288:10 294:6	304:17 311:6,16	279:10	216:23 224:3
319:4 332:6	312:3 313:25	accept 56:25 89:4	342:4 345:23
able 10:6 15:22	312.3 313.23	98:20 119:6,14	348:3
16:23 18:12 20:11	318:8 319:5 322:9	129:6 257:8	
24:7 26:6 28:4	324:11,19 325:19	260:15 278:9	achieving 223:24 312:11 316:2
29:12,23,25 33:24	329:3 335:12	283:11 288:14	345:22
48:3 55:21 57:13	336:2,2 338:14		acknowledge
58:14 59:6,17	340:11,14,17,21	292:8,19	97:12 100:15
61:4 64:14 68:6	340:11,14,17,21	acceptable 345:15	108:8 135:14
70:9,14 71:2	342:11 345:7	acceptance 302:9	187:4 290:15
81:19,22 82:16,16 99:7 100:15 106:4	348:12 abnormalities	accepted 86:24 87:23	304:3 306:24
	31:10 39:14	0,1-0	324:20 330:3 350:23
106:6,18 112:20		access 124:22	000.00
117:16 123:8,14	abolishing 209:19	125:14 177:3	acknowledged
123:23 124:22	abrupt 316:9	180:14 181:19	345:11
126:24 131:12,13	abruptly 316:17	213:13 217:22	acknowledgement
131:23 132:13	absence 96:4 97:2	270:2 313:20	357:3
133:19 135:18	109:12 144:24	accompanied 7:11	acknowledges
136:7 139:8,17,19	156:24 212:25	accompany 168:3	187:3
140:4 141:16	323:8 336:4	account 49:16	acknowledging
146:8 148:9,10,21	absent 16:22	182:22 248:2,12	201:5 342:10
149:14,20 150:15	absolute 129:18	249:5	acknowledgment
151:16 152:23	286:23 287:23	accounts 184:4	355:12
157:2,25 163:7,7	289:18,19	accuracy 14:14,18	aclu 6:22,24 8:12
169:21 177:13	absolutely 62:18	81:23 306:17	aclu.org 3:16,18
181:22 186:17	107:18 108:16	355:9	act 11:13 231:18
189:24 190:7	116:18 122:4	accurate 20:15,25	246:4 254:9,11,12
195:5,7 200:9	278:21	21:9 22:14 29:23	254:13 298:4
202:2 203:25	abstract 77:14	82:2 114:11 126:9	acting 155:10
205:5,25 209:13	102:24 103:10,15	171:2 242:21	225:3 306:10,14
209:24 213:18	228:25 353:13	279:7 301:15	306:25
215:9,13 221:10	abuse 42:18	352:10	action 6:9 131:16
250:14 251:13	167:11 300:23	accurately 10:2	352:18,21
252:2 257:15	301:20 302:4	139:14	active 23:9 201:10
259:18 274:2	303:19 304:9	accuse 302:17	actively 175:8
275:5 278:17	305:8 326:5	achievable 300:21	176:4 177:14
280:17 282:10	332:24 334:23	achieve 164:20	178:9 179:5,13,24
283:5,10 288:12	abusing 302:25	196:10 217:2	180:10 181:9
289:3 291:3 292:2		233:4 316:23	182:3 183:3,24
		1	1

185:8 199:8 202:7	addressed 149:22	172:4 191:18	advancement
202:15,20 203:9	167:12 186:10	adolescent 52:10	213:14
activists 153:16	204:10 218:14,15	72:4 143:2 165:21	adverse 193:17
155:8,9,15,18	256:17 269:23	174:14 188:19	215:24 222:25
activities 51:18	279:4 347:8	191:16 216:24	244:2 319:8,16
activity 67:23 73:6	addresses 108:23	221:20 249:4	advice 288:11
234:20 236:12	231:25 245:22	257:7 272:24	advisability
acts 48:24 235:17	282:21	273:22 302:3	187:14
actual 79:23 90:21	addressing 85:21	adolescents 37:15	advise 101:19
125:4 130:2	148:9 163:9 167:8	52:20 89:17,20	advising 210:25
144:17 145:15,24	186:18 247:6	91:22 94:7 108:20	211:21
146:8 149:4	283:20 293:8	109:22 125:20	advocacy 177:22
156:24 243:13	312:5 325:9 326:2	127:9 136:19	178:7,22 181:2,6
246:2 254:10	326:24 332:19	151:9 152:4	181:9 201:19
adams 35:2,14	adequate 95:3	159:18 256:21	advocate 42:20
added 25:2	130:19 140:19	270:6,18 271:12	110:4 165:24
adding 29:13	145:2 192:19	272:14,17 304:8	174:15 331:14
addition 33:15	adequately 47:17	307:17 308:10,17	advocated 162:10
153:10,12,14	48:16 107:9	324:18 330:22	171:2 211:13
additional 27:15	127:13 149:14	339:9 347:15	advocates 209:5
27:18,25 232:9	153:3 154:21	354:10	advocating 131:22
additions 357:6	157:11 179:18	adopt 155:17	154:2
address 22:12	199:2 205:22	180:14 200:18	affect 96:19 169:4
25:20 33:25 43:14	207:17 253:23	279:19 335:6	239:13 258:2
55:2 63:19 64:20	259:25 310:4	adopted 68:18	affiliated 49:22
80:5,7 81:9 104:3	340:12	106:24,25 198:22	affiliation 77:6
107:15 150:18	adjourned 351:22	adopting 335:6	affiliations 6:17
161:7 163:8	adkins 321:3,14	adult 215:12	affirm 150:11
167:13 181:19	administer 253:18	267:8,17 280:5	176:18
184:16,23 195:6	administering	281:8 337:21	affirmation 41:2
199:3 214:25	155:13 221:19	adulthood 171:20	42:2 57:8 59:16
226:24 239:16	229:3,5	191:8	95:13 104:4 154:2
251:16,23 253:23	administration	adults 166:12,19	166:5 168:11
256:7 259:17	46:8 52:21 219:2	255:16 257:10	176:19 177:25
260:20 266:9	219:8,16 220:9	260:23 266:14	178:23 182:13
268:24 271:23	223:24	267:2,23 268:25	183:9,13 185:13
288:6 291:20	admitted 17:16	269:4,6,11,12	186:23 197:17
292:7 314:2 326:9	adolescence 96:18	273:15,17,22	239:19 242:18
335:19 349:16	99:2 100:8 101:2	advance 313:25	243:17 260:17
addressable 196:6	113:18 169:13	advanced 216:20	261:22 268:25
	170:7 171:19		270:13 271:2

	T		
272:2,25 302:16	ages 72:2 178:18	193:6,14 247:6	327:16 329:20
304:23 315:7	216:21 350:22	260:7 312:12	332:7 339:19
326:13	agnostic 196:8	323:6 325:8	344:2 347:5
affirmative	ago 11:9 26:8 52:5	346:10 353:21	alternatives
154:24 155:24	52:8 80:18 280:22	alleviation 193:9	108:14 210:16
161:23 162:14	290:20 299:23	326:16	alters 285:4 290:3
166:2,3 174:17	329:25	allotted 355:20	altogether 292:4
175:2 178:15	agonist 217:16	allow 55:9,11	amanda 4:16 7:13
180:16 188:14	agonists 52:17	100:20 119:16	18:15 19:3,24
191:12 192:12	213:24 214:5	140:8 162:16	73:22 158:3 355:1
195:18,25 200:21	220:19	163:11 164:4,22	ambiguities 25:19
209:17 256:16	agree 5:12 103:18	167:19 180:12,13	ambiguity 25:15
301:24 302:9	107:25 145:19	180:14 192:17	48:2 49:8 291:12
303:24 311:12,19	147:11 197:7,10	196:17 204:3	amend 27:3
327:25 329:17	276:9,20 278:13	205:22 215:6	amended 22:10
336:5 342:4 344:4	280:23 300:16	269:6,7,8,12,13	american 3:12
affirmed 94:16	301:2 337:4	295:24 335:12	300:17
185:18 240:14	agreement 277:13	350:13	amici 275:18,25
affirming 40:9,19	ahead 86:9 158:6	allowed 59:5	amicus 274:7
40:24 41:25 42:8	277:15 302:16	121:25 169:21	275:15 276:10
47:15 60:8 61:13	aimed 41:20 42:10	215:16 218:4	282:12 299:7,13
93:13 94:12	48:11	221:9 228:21	299:17,19 354:2,4
124:23 159:22	air 65:13	243:20 247:20	amount 15:20
161:2 175:4,8	al 1:7,10 5:17,18	264:9	51:10 128:20
177:4,18 241:14	355:4,4 356:1,1	allowing 49:6	ample 207:7
242:18 267:5	357:1,1	173:25 189:21	analogous 119:5
302:2 304:7 339:8	alabama 37:14	269:25 300:10	analyses 295:20
afield 190:12	alabama's 37:14	350:24	analysis 27:15,18
age 31:14 72:2	aland 4:17 355:2	allows 297:8	27:25 28:10 187:9
164:24,25 165:16	alignment 48:12	344:22	226:19 244:23
169:20 170:3	186:11	alter 271:4 349:20	252:20 253:8
176:17 189:5	alleviate 57:15	altering 250:9	256:25
190:17 191:2,5,7	58:25 110:12	alternative 59:7	analyzed 241:12
194:8,19 203:19	168:22 173:15	59:17 110:9	analyzing 67:18
204:2,22 213:14	192:9 287:25	138:20 144:25	101:5
214:7 215:15,20	314:19 333:5	192:20 197:15	anatomy 236:16
216:9 253:20	347:23	201:12 208:16	anecdotal 321:10
268:7,12 313:23	alleviates 229:10	210:19 256:6	321:24 322:15,17
agenda 229:25	238:16 341:23	258:17,20 259:9	324:9,15 335:24
agendas 117:24	alleviating 58:2	260:13,21,22	animal 237:14
	83:16 84:2 102:21	311:23 314:18	

[anorexia - approaches]

Page	5
------	---

• 440.40	40 6 0	1 11=0=	10610107711
anorexia 119:10	answers 57:18,20	apply 117:25	196:10 197:5,11
325:13	58:14 59:20	165:2,13,16 166:9	197:17 200:21
answer 9:12,19	108:11 329:4	196:15 261:4	201:16 207:16
10:2,15 14:23	339:25	267:2,17 325:21	209:17,25 247:5
26:2 27:23 47:17	anthropology	343:2 348:4	247:24 248:10
48:16 52:23 57:13	232:23	applying 128:25	251:12 256:16
59:6 61:4 62:8,9	anticipated 99:13	214:13	260:17 261:22
62:20 106:5	anxiety 32:4 33:2	appointment 30:9	267:5 268:25
107:19 110:5	42:17 45:3 55:3	appreciate 143:10	269:17 292:11
127:13 148:21	120:12,14,18,19	approach 23:4	293:8,9 295:22
150:19 179:18	167:10 173:18	41:4 43:12 57:8	296:4,5 297:8
203:4 204:19	259:19 260:5,7	57:13 102:20	301:24 302:9,12
206:22 220:15	323:7 325:8	107:8,20 108:13	303:24 304:23
221:17 248:7	335:10	129:8 131:12	309:17 326:14
264:10 272:11	anybody 7:23 12:8	146:21 150:10,18	328:2 329:7,13
283:5 289:13	136:16 150:21	152:10 154:2	331:4,19 332:3
299:4 332:9	anyway 317:9	155:24 159:22,23	333:16 335:5,7
342:18	apart 120:2 281:4	160:7,24,25 161:2	336:5,8,20 337:5
answered 41:9	285:14,19	161:9,15,23 162:2	339:17 343:21
87:25 91:6 97:14	apologize 62:9	162:7,13,14,22,23	344:5,6 347:9
107:24 109:24	276:15	162:24 163:22	approached 51:4
110:23 111:2,6,15	apparent 245:13	164:8,21,25	60:22 343:19
111:22 112:7	350:20	165:13 166:3,24	approaches 57:25
113:20 118:5	appeals 274:13	168:3,11,25 169:9	59:8,17 64:9
120:22 134:4	appear 78:7	170:12 171:11,15	83:16 84:2 85:24
138:3 139:5 146:7	appearance 6:14	171:25 172:9	105:8 113:24
152:18 179:16	245:14 250:9	173:5,12 174:5,16	138:21 159:16,20
183:6 199:11	349:8,21 350:13	174:17 175:2,8,20	160:4,23 162:10
203:12 204:18,25	appearances 6:17	175:24 176:14	163:15 165:24
210:9 211:6 212:3	appearing 7:20	177:4,13,19 178:4	171:21 174:9
219:19 220:12	appears 21:22	180:17 182:13	175:22 177:6
237:2 248:16	79:5 84:4	183:8,14 184:22	185:12,15 187:4
252:25 264:16,20	appended 357:7	184:23 185:13,21	190:23 192:20
264:24 265:9	applicable 355:8	185:24 186:21,23	195:16 196:16,22
271:14 272:20	applied 165:6	187:11,13,21	208:8,16 210:19
283:3 286:22	171:11 178:5	188:4 189:15	239:4 259:14,24
289:14 317:21,22	267:6 324:24	190:15,21 191:5	260:14 265:17
327:7 330:25	applies 118:21	191:10,12,24	270:12 286:5
332:15	126:2 166:6	192:12,14,15,25	293:19 325:9
answering 9:5	189:12	193:21 194:22	327:16 329:14,23
62:16		195:19 196:2,7,8	331:25 347:6

353:21	arena 297:22,24	78:17 226:23	235:12 236:4
appropriate 25:9	argue 149:15	artificial 257:6	237:3 248:17,21
45:9 57:15 151:21	169:16 191:8	artificially 218:17	262:3,6,8 266:19
203:16 204:2	192:14,15 195:23	asked 37:7 44:6	272:13 276:24
208:14 215:9	283:14,17	58:12 79:17 87:19	281:3,14,22,23,24
227:23 231:24	argued 172:11	87:25 90:25 91:6	289:20 298:15
337:16 339:10	244:14	107:24 109:24	313:11 331:23
appropriately	argument 24:19	110:23 111:22	334:17,20 344:9
134:8 187:8	170:4 246:5	112:7 113:20	aspect 55:19
approval 54:11	278:23	118:5 120:22	119:21 123:10
approved 338:16	arisen 284:12	133:13 134:4	245:18 349:16
338:17	arises 181:20	139:5 148:22	aspects 49:4,19
approximately	arising 226:20	151:4 152:18	54:22 82:13
16:14 257:14	arizona 38:4,7	179:16 183:6	129:22 138:7
april 307:18	arkansas 1:2 4:6	199:11 203:12	182:12 213:8,16
308:10 354:11	4:13,15 5:20,23	204:18 205:21	247:4 252:19
area 23:10 46:9	5:25 7:22 11:12	210:9 211:6 212:3	254:22 255:20
55:25 59:9 63:5	12:5,11,14 13:18	219:19 220:12	291:14 317:7
64:6,25 65:12	53:15 55:11 56:17	236:25 248:16	332:25
68:20 69:14 70:3	104:11 105:13	252:25 259:7	assent 150:2
97:13 100:12	142:2,6,10,15,21	264:16,24 265:9	assert 126:4
110:21 113:9	143:4,14,16,18,24	271:14 272:20	asserted 206:19
114:20 135:22	144:14 206:8	273:3 280:14	278:4
136:17 181:16	268:9 314:6	284:2,4 286:22	assertion 93:11
192:7 213:23	arkansasag.gov	289:15 305:14	97:3,18 119:23
218:13 230:10	4:17,19 355:2	314:13 327:7	123:3,6 130:10
233:19 261:15	arm 61:22	330:25 332:15	157:2,6 172:16
278:23 290:19	arrive 57:17,20	asking 8:13 9:12	174:19 201:15
305:25 311:16	95:2 148:11	11:9 14:2,12 34:9	207:15 233:12
324:20,24 340:5	arrived 66:4	36:21 44:2 45:13	298:2 304:19
350:7	art 81:13	51:5 55:15 64:4	assertions 93:9
areas 71:5 86:4	article 75:7 78:8	79:24 89:5 94:2,3	96:3 142:17
104:24 109:5,9	78:22 79:5,7,14	95:11,14 97:11	144:19 230:6,22
117:6 134:19	83:14,24 98:12	104:21 105:4,9,11	246:7 247:21,22
168:19 176:20	102:11 226:10	109:25 110:25	321:12
207:4 269:15	227:18 228:13,23	111:9 113:15	assess 64:14 81:19
287:17 288:6	232:8,11 233:11	130:15 135:16	98:3 114:17
312:4 329:4 330:6	237:7,9 252:7	142:5,13 147:8	131:25 133:15
332:18 342:9	353:17,19	148:3,15,16	140:4 141:4
343:21 345:17	articles 24:11	156:23 202:10,14	205:23 216:10
348:4,15	74:22 75:6 76:3	205:17 210:23,24	242:10 323:17

[assess - ball] Page 7

	I		I
332:10	associations 295:8	author 243:5	246:11 249:22
assessed 61:19	associative 243:21	authority 228:12	251:22 275:18
130:17	assume 9:20 81:20	authors 24:10	303:3 304:20
assesses 83:5	116:6 237:5	135:13	305:4,24 308:2
assessing 71:22	assuming 203:5	autism 195:3	310:16 321:6
135:4 136:19	assumptions	325:15 332:22	336:11
188:3 254:9	116:3 164:18	availability	b
257:23 348:8	174:12 279:20	138:20 206:15	b 353:6
assessment 31:23	atlantis 75:9 78:23	available 22:11	back 19:25 26:3
44:19 58:22 107:3	79:6,8 80:22 82:5	29:13 44:5 51:11	49:13 51:25 56:2
131:15 137:7,12	82:25 172:15	61:10 75:17 96:25	56:3 71:6 73:11
137:20,23 138:14	353:18	118:15 135:2	73:25 78:16,20
138:23 140:9,19	attached 74:7	138:11 146:8	79:16 80:11 83:11
140:20,25 141:12	355:11	154:24 156:15	84:9 86:17,20
141:18,20,22	attempt 125:17	180:24 181:8,18	87:17 89:10 93:18
145:3 189:8	263:9 266:8	182:7 210:22	97:4 98:5 99:4
194:11 195:10	296:16	213:9 215:18	
248:25 252:15,17	attempted 293:20	217:8 242:16	101:10 102:9,19
252:23 253:7	attempting 256:6	253:16 301:14	104:9 121:14
263:9,17 286:13	292:15 306:24	306:13 311:19	122:22 135:18
331:7,18 333:17	attempts 29:22	314:15 327:11	138:2 139:21
assessments 43:23	243:15	342:6,10 343:23	144:17 158:23
128:7 139:23	attend 50:11	346:24 347:3	159:7 185:19
assist 36:24 51:13	attendant 315:13	355:6	186:18 194:3
186:10 335:21	attention 12:3	avenue 4:5	202:23 225:6
assistance 115:19	47:22 98:4 133:19	avoid 233:5 253:6	228:23 229:4
assistant 4:11	174:24 226:3	259:5 271:17	238:10 239:3
assisting 189:17	238:19 240:22	291:3 292:3 296:6	244:3 246:22
associate 7:12	241:10 244:25	avoiding 231:6	249:9 250:23
30:7,10,14,19	254:24	aware 11:11,22,25	251:7 255:25
51:17 69:3 70:8	attorney 4:11,13	13:5 26:18 28:5	262:19 274:5
72:13	5:23 6:19 7:15,22	53:10,13 55:10	294:20 307:5
associated 71:23	25:24 352:17,20	83:8 104:18,20	310:6,13 333:22
98:20 167:9 195:4	355:13	106:16 124:18	339:3,12 351:12
223:2 279:11	attorneys 36:20	128:9 129:18,19	background 65:5
associates 7:7	attraction 202:13	130:19,24 137:3	211:12 267:15
association 77:7	audio 5:10	140:7 146:19	338:7
85:2 90:6 91:12	auspices 54:11	147:18 157:9	backup 215:2
202:11 205:19	106:11 147:11	170:5 214:24	bad 253:6 259:5
318:4	178:6	218:12 219:13,20	bag 222:24
		220:6 227:16	ball 128:7

[ban - best] Page 8

ban 104:12	318:16 325:4	153:9 240:14	170:2,20 171:8
			170:2,20 171:8
banned 109:20	330:8 343:3,24	begins 60:20	
110:20 200:23	344:21 347:17	121:21 189:4	188:18 190:8
206:7	bases 93:8 262:4	194:7 244:5 256:3	192:10 193:13
banning 201:8	basic 8:25 61:3	behalf 7:14	211:22 212:6,12
268:10	71:4 109:15 230:8	behavioral 260:5	214:13,16 239:20
bans 112:11	230:12,23 254:14	325:7	241:3,7 242:2,3
bar 104:25 209:13	265:13 343:2	belief 123:13	250:8 253:12,25
209:23 267:24	basically 160:21	290:22 304:5	258:21 261:21
base 132:2 271:21	186:17	beliefs 271:22	269:16 288:18
333:4	basics 10:20 60:16	believe 12:8 22:21	303:25 314:15
based 22:10 40:10	basis 17:12 40:8	23:22 42:6,12	318:9 319:6 320:6
41:2 42:2 61:2	41:24 48:21 51:8	44:8 45:19,22	320:9 325:25
63:17 64:18 78:18	54:24 62:6 99:5	60:2 69:18,25	327:22 331:8,10
80:21 96:2 108:2	112:21,24 122:17	73:11 87:16 88:22	332:5 335:11
109:17 120:12,19	126:7,17 130:10	89:8 90:20 93:16	336:4 337:25
136:21 140:10,19	132:9 145:22	100:2 101:17	339:16 340:4,8,18
146:2,13 152:14	147:13 150:13	103:21,25 111:15	343:6,15 344:18
157:11 163:16	152:19,23 153:2	124:5,14 126:13	345:15 346:5
177:4,7 191:12	153:22 155:3	127:7 132:21	benefits 40:12
193:2 201:10	157:2,16 168:25	144:15 147:14	41:4 58:18 103:13
207:6 208:9	177:11 180:18	148:12,15,16	138:5,19 168:11
209:11 210:6,12	198:4 205:13	155:8 156:18	187:18 190:25
210:21 211:3,13	217:8 232:24	157:17 188:7	191:13 209:4
211:17,20,24	238:18 243:11	202:18 205:6,8	210:13 211:2
212:7 223:18	253:9 260:16	212:18 216:11	255:11 267:20
228:19 231:16	262:7 263:6 267:6	240:18 260:3	311:11,22 312:23
240:25 241:22	279:16 282:16	263:17 271:10,16	331:25 332:11,19
247:19,20 250:10	287:22 290:2	277:3 299:23	338:19 346:22,25
250:22 252:18	291:11 292:21	301:25 333:10,23	349:4
253:7,15 255:10	302:20 311:14	believes 192:5	best 23:11 25:16
261:16 266:6,15	312:15 313:7	246:9	25:16 29:25 47:7
268:7 269:2 272:5	322:20 337:16	believing 122:18	49:8 53:23 54:12
272:16 276:8,20	bathroom 35:24	180:19 300:19	54:16 82:6 113:2
280:20 285:8,8	177:3 180:13	bell 149:22	133:3 136:22
286:18 287:8	200:19 270:2	bench 68:2	184:22 191:14
288:19,25 290:4	299:24	beneficial 222:25	192:8,10 193:19
290:16 301:13	becoming 188:12	243:24 331:12	195:8 196:25
303:17 304:17	began 194:4,6	benefit 42:19 54:7	197:2 201:4
308:24 311:17,20	beginning 6:18	56:7,22 57:7 60:3	214:24 231:18
312:21 314:14	51:10 65:5 98:16	168:18 169:24	251:25 271:25
	X7 '4 4 T		

[best - brought] Page 9

285:9 286:13	163:24 167:18	blood 120:16	boxes 128:23
287:2 291:21	169:12 177:11	121:9,10 222:21	130:3 141:3,15
292:11 293:12	178:25 179:20	222:22 224:10,13	brain 191:17
294:5 297:7 298:3	188:19 191:20	board 32:6,12	257:11
310:24 312:16,25	194:7 198:25	58:23 60:6 106:12	brandt 1:6,7 5:17
313:8 314:9,20	215:10 221:21	263:18 299:8	355:4 356:1 357:1
317:25 321:25	230:4 233:7 235:5	337:2,3 354:5	brandyn 3:7 7:2
324:9 325:14	236:7 237:20	boards 58:9	break 10:13,16
328:23 329:8	246:7,19 247:8,11	231:13 254:18	86:8,10 158:19,21
349:22,25	247:16 248:2,12	bodies 306:16	234:2 238:4 307:9
beth 4:7 7:9 19:23	249:4,5 250:11	bodily 96:9 229:7	307:12 310:8
better 113:22	251:18 257:13,16	256:8,12,15	338:23 351:8
184:10 187:5	263:23 281:19	257:20 258:3,6,13	breaking 10:14
320:4 349:3	284:24 285:11	331:20	breaks 10:11
beyond 34:3 130:2	294:7 306:16	body 48:11 223:19	breast 221:7
132:7 141:22	307:3 314:6	236:8,11 244:10	brief 274:7 275:15
142:25 171:23	319:19 328:9	244:13 245:15	276:22 282:12
215:20,23 247:11	347:18	246:3 250:10,25	299:7,13,21 354:2
279:22	biology 30:11	251:9,19 259:20	354:4
biased 134:25	232:7 285:4	bombarded	briefly 299:22
big 298:9	birth 31:3 91:21	203:23	bring 28:24 74:14
bigger 290:18	bit 12:2 26:15 30:5	bone 31:9 213:14	132:14
bill 11:16,17,20,22	63:15 205:15	213:14 215:25	bringing 48:11
12:6,9 14:10	339:13	216:10,13,20,23	broad 3:5,13 64:5
15:11 205:16	blanket 206:2	217:3,4	127:11 148:4,22
bills 14:11,19	blockade 79:21	book 75:8 102:11	151:11 165:5
binary 198:9	80:10 172:12,23	182:2 183:23	174:8 193:6
biochemistry	216:15 218:25	185:2,3,4,5,16	196:18 203:14
33:15 65:13	219:6,22 238:22	199:8 200:22	205:4 213:7
bioethics 78:13	240:15 243:6	201:20,22 202:19	232:15 251:6
84:6 103:2 225:13	344:11	203:8	283:19 304:12
225:20 226:9,16	blocker 221:14	books 181:15	314:12
226:18 353:25	344:17 345:2	182:17 202:6,15	broaden 48:15
biological 15:3	blockers 94:13	203:6 204:23	140:22
49:20 52:22,23	172:2,7 212:14,19	born 49:7	broader 49:2
61:15,16 71:24	213:5,24 214:22	borne 124:2	171:9 283:24
89:16,22 90:2,10	215:4,19 218:3	240:10	broadly 193:19
91:3,20 92:7,17	243:12 305:7	bottom 127:20	231:5 248:17
92:25 96:15	336:14 343:16	153:8 175:3,5	broken 82:18
114:16 123:2	blog 154:6	box 141:23	brought 67:8
161:14 162:4			226:3

[bruce - certainly] Page 10

1 25 4 6 12	(1.14.69.25.97.0	67.10.25.72.10	227 10 229 4 14
bruce 35:4,6,13	61:14 68:25 87:9	67:10,25 73:10	227:10 228:4,14
bränström 240:22	105:14 107:4,21	87:10 93:7 112:18	353:25
242:14	122:9 123:12	126:13,19 144:21	causal 58:15
build 293:11	124:23 126:22	147:14 149:22	243:22 318:7
bullet 308:14	155:13 156:7	157:18,23 199:5	321:21 322:4
bullets 308:15	157:13 173:10,22	201:3 202:13	324:12 340:15
buy 269:12,13	189:20 195:8	214:14 228:7	causative 222:5
bystander 245:13	256:21 265:18	245:3 274:16	cause 90:3 156:5
c	284:19 286:5,14	278:5 296:20	219:3 316:10
c 3:1 4:1 352:1,1	287:3 291:21	299:20 300:5	328:8
calculation 214:15	294:7 298:12	303:11 305:16	caution 109:11
calculus 188:2	304:18 311:2	310:18 312:15,15	176:17 208:13
217:18	312:4,23 317:3	312:21 313:7,7	270:25 340:2
call 160:17	323:19 325:14,22	321:4,24 327:20	342:7
called 11:12 43:18	327:15 336:23	334:4 335:25	cautious 196:10
50:16 177:18	339:9,10 342:4	cases 25:3 34:18	caveats 100:9
341:16	349:13,17 350:17	34:20 35:21,22	342:14
calling 23:2	cared 41:17 137:4	36:6 37:2,23 38:3	ccr 1:25
calls 53:19	career 46:22 63:7	108:4 128:4	cell 223:19
campus 278:9	64:12 185:25	178:16 184:22	cellular 30:10
canada 170:15	264:3	218:9 254:19	center 4:14 5:24
188:25	careers 67:24	299:24 348:23	50:17,20 52:9
cancer 221:7,8	69:24	casual 156:15	56:4,19 68:23
222:23,23 269:10	careful 334:2	180:25 245:13	103:2 226:18
348:18 350:9	carefully 131:24	cataloguing	central 1:3 5:3,20
cancers 221:7	182:8	117:11	213:2,25 214:14
cantrell 4:18 7:19	caregivers 182:24	categorical 126:2	214:22 215:4
7:20	184:5	categories 165:5	217:15
capacity 39:5 51:9	caring 134:13	187:25 188:13	certain 69:25
209:21	carolina 35:15	196:18	287:7 318:6
capitol 4:5	38:12	categorize 118:18	320:21 349:10
care 32:3,20 33:7	carries 193:24	category 105:6	certainly 20:13,17
37:15 40:9,13,16	carry 193:22	138:9 156:9	23:10,17 29:24
40:19,25 41:10,18	case 1:9 11:2,6,10	162:19 163:16	32:22 41:17 42:12
41:25 42:8,21	11:12 20:16 22:22	172:24 185:6	42:20 43:13 45:25
43:7,21 44:3,21	24:23 26:20 35:2	192:22 259:2	46:22 53:22 54:3
45:4,8,13 46:3	35:4,5,6,7,8,13,14	263:2	55:6 57:17 59:9
47:7,19 48:18,20	35:14,24 36:4,5	catholic 77:2,7	68:4 74:18 88:14
49:18 53:5 54:7	36:15,16,19 37:6	78:13 84:6 85:2	89:19 97:15 99:24
54:13,23,25 56:6	37:9,14,17,20,21	103:2 225:12,20	117:5 133:9,14
	38:4,6,9,17,24	226:8,15,17	135:10 147:11
56:18 57:5,15			

[certainly - clear] Page 11

150:6 152:6	357:6	334:14 350:22	circuit 274:12
154:10 165:15	changing 22:25	child's 179:2	circulated 124:19
184:14,15 187:25	128:3 165:17	childhood 334:23	circumstance 37:6
197:4 230:5	238:25 290:7	children 83:17	199:24 254:12
240:21 242:25	350:12	84:3 91:19 98:19	261:2 348:21
261:4 268:4	chapter 75:8	102:22 148:7	circumstances
291:10 303:9,19	102:11,13	149:16,25 157:20	127:7 132:22
305:2,24 306:14	character 182:3	159:17 160:10	133:11 171:7
309:12 310:2	characteristics	165:9 166:4	186:14 196:20
317:8 323:10	285:16,21	171:12 175:9,24	199:15 206:3
335:18,21 344:12	characterize	176:4 181:16	244:16 255:3,15
348:15	47:13 56:10,12	182:20 184:2	283:22 284:11
certification 34:9	163:13	202:6 203:22	287:4,15 288:20
66:20	characterized	204:8,14 215:12	291:18 293:17
certified 2:7 32:7	303:9	215:14 257:14,16	294:25 296:11
32:12	charged 134:13	257:19 267:3,6,23	304:21 322:25
certify 352:4,9,15	chase 3:15 6:21	267:25 268:3	cite 23:8 24:10
cessation 217:23	8:11 17:23	269:2,5,7,11,13	26:12 154:10
316:9	check 81:22 130:2	271:2 272:13	321:17
challenge 129:11	141:14,22 158:4	273:22 300:19	cited 26:14 241:18
132:3 150:13	checking 25:14	301:13,19 302:15	civil 3:12
challenged 132:16	81:24 128:23	302:25 307:17	claim 93:20
challenges 29:21	141:3	308:10,17 338:17	100:18 109:17
94:25	chemical 300:22	353:22 354:10	114:18 144:7
challenging 12:25	chemistry 65:9	children's 46:17	155:24 241:6
37:14 288:8	chief 50:25 67:4	50:3,9,11,13,15	243:4,23 329:16
chance 21:5	child 99:16,17,19	56:20 182:17	claiming 124:10
349:15	150:12 152:8	183:23 185:2,16	claims 93:5,18
change 147:5	154:17 156:8	202:15	95:23 96:22
173:13,24 177:2	162:16 178:9,24	choice 254:23	139:15 250:8
190:22,25 286:10	179:4,9,22 180:4	choose 165:23	327:16 347:3
349:8 356:4,7,10	181:23 182:10,22	247:13 306:23	clarification 81:10
356:13,16,19	184:4 185:17	346:4	clarify 59:22
changed 24:13,16	191:7,19 194:17	chose 66:6 323:20	163:20
27:7 186:22 190:8	194:24 200:5,15	chosen 108:5	class 214:9
changes 25:10	201:22 202:18	christ 227:5	classroom 276:5
96:9,14,16 117:21	203:3,5,17 204:16	church 227:10	clause 252:10
117:23 121:10	205:10,25 209:8	228:4,11,12,14	clear 26:10 96:7
191:20 215:10	209:20 300:23	cigarettes 269:12	107:18 154:14
253:25 287:20	302:3,4 303:6,10	269:13	164:15 177:15
289:4 355:10	304:9 305:3,8		178:18 228:6
	I .	1	1

252:12 289:16	157:18	comments 81:9	complainant
291:25	coercing 156:20	102:15	278:5
clearly 40:7 43:9	coercive 154:20	commit 150:12	complainant's
57:3 113:11	cognitive 260:5	156:8	278:10
114:12 116:9,14	325:7	committed 227:8	complaint 15:25
117:19 241:25	cohort 214:3,20	committee 70:19	16:2 17:6 142:17
323:3 349:23	coin 122:13	72:16,21	142:25 144:3,16
click 18:13	coincide 350:14	common 157:4	144:17 310:21
client 25:24	colleague 51:4	337:15	complementarity
clinic 44:22 47:2	294:12	community 67:21	244:12 245:11,16
50:10,15 51:5,9	colleagues 43:20	134:23 136:6,12	246:15,21
51:24 52:15,20	54:2 68:14 71:11	171:10 176:25	complete 10:6
143:18 170:6,15	83:6,9 292:12	187:2 190:5 278:9	22:5,14 66:15
188:24 189:7	295:13 297:4	comorbidities	73:2 351:19 357:8
194:10 251:13	college 31:18 65:6	42:16 43:2 55:2,4	completed 66:5
294:5	65:10,11,20	160:14 167:9	87:13 88:4 267:14
clinical 54:17	300:17	173:11 186:19	269:3 324:2
55:13 68:4,15	collegial 295:6	189:20 312:6	355:17
71:8,13,17,18,21	combination	325:5 334:7,10,12	completely 207:10
72:11 99:16,19	162:23	334:14,22	207:11 209:19
106:19 107:14,22	come 11:5 18:18	comorbidity 32:25	242:20 243:23
108:18 109:20	27:11 36:18 37:12	141:5 332:20	completing 27:8
110:10,20 111:20	78:16 79:13 84:9	333:25	27:16 30:17
136:14 147:19,24	91:20 93:9 98:3	company 209:8	completion 65:18
208:14 226:25	98:20 125:13	comparable	66:8
266:19 284:11	131:6 158:23	155:10	complex 91:8
294:11 297:22,24	175:18 178:12	compare 63:12	202:4 254:19
337:22 341:6	189:7 194:10	72:7	266:9
349:5	204:7 232:8	compared 63:24	complexity 196:23
clinician 119:14	244:23 250:23	185:14 344:16	complicated
161:10	339:12	compares 344:4	231:16
clinicians 110:18	comes 10:12 72:25	comparison 59:7	comply 33:4
141:25 142:9	119:12 122:19	59:16 339:20	component 141:11
166:24 180:19	coming 19:25	compassion	166:5 254:10
closest 185:13	240:10 274:21	293:10	255:9
clots 222:22	comma 252:11	compassionate	components
224:10,13	commencement	283:16	118:16 148:10
coaches 176:24	352:5	competence 55:21	251:20 254:25
coauthors 80:3,14	comment 158:2	competent 96:12	269:24
coerced 153:15	311:6	competing 249:24	comprehensive
155:21 156:11			29:23 49:18 143:7

[comparer consistent	[computer - consistent]			
computer 20:4	concludes 300:16	279:24 283:25	189:23 191:15	
concentrations	conclusion 40:10	320:16,19 341:6	218:13 268:4	
224:4	104:23 171:6	348:23	302:22 350:24	
concept 251:2,10	187:20 192:18	conducted 6:1	consented 147:3,4	
concern 38:10	241:12 253:10,14	27:13,14 59:4	148:14,17	
57:4 98:15,17	258:10 273:7,9	60:20 61:8 62:2,3	consenting 157:19	
140:24 153:2	274:2 286:8	62:7 63:8 67:11	consents 302:2	
154:12 171:4	300:18 303:15	68:16 69:5 70:10	consequence	
202:2 217:25	304:17 309:21	70:12 104:10	256:16 257:20	
218:16 267:7	320:12 321:20	113:14 140:4	consequences	
270:25 281:5	330:13,15 340:15	232:17 249:11	172:19,25 193:15	
291:9 294:4	347:4	250:16 253:8	223:22 224:6	
301:19 305:25	conclusions 27:22	309:25 319:22	250:12 280:4	
309:7 319:3	42:3 59:5 139:19	323:13 341:11	consequent	
341:24	222:6 291:23	344:13	331:21 346:14	
concerned 138:14	306:8 322:3 324:7	conducting 63:5	consider 45:8	
293:2	326:23	71:16,18 267:24	49:19 115:13,22	
concerning 14:19	concomitantly	conducts 233:3	145:2 148:24	
74:22 132:12	199:18 221:25	conferences 84:19	208:15 245:6	
134:2	condition 116:17	296:20	255:20 257:25	
concerns 11:12	119:4 129:23	confidence 123:23	270:10 329:20	
24:20 57:10 85:22	165:18 177:9	206:19	considerable	
116:3 127:2,5	213:2 216:7	confirm 27:6	15:20 51:10	
138:21 139:2	292:10 295:19	30:20 32:9 123:3	consideration	
140:12 149:24	318:20 329:25	conflict 263:4	40:12 49:12 63:16	
220:17,23,25	350:22	264:3 265:16	190:22 201:11	
267:16 268:6	conditioning	266:5	254:21 339:19	
269:15 270:22	300:19	conflicts 194:24	considerations	
271:3 301:23	conditions 30:24	conform 349:21	62:11	
302:11 303:23	39:20 41:16 45:6	confronted 284:14	considered 48:17	
310:2 318:13	114:9,14 116:13	295:10	54:24 58:6 108:16	
331:19	117:11 119:6	connection 17:20	117:6 138:8 169:6	
concert 215:16	167:14 195:3	50:19	170:19 186:4	
263:10 265:23	316:2 325:20	connectivity 73:13	250:5	
279:14 301:21	333:25 350:10	connotations	considering 206:3	
315:21	conduct 27:25	161:13	255:24	
concerted 173:24	58:10 60:14 62:21	conscious 296:15	consistent 14:25	
conclude 318:2	63:9 68:7 105:15	consent 142:14	15:13 40:14 92:3	
concluded 138:10	107:14 111:24	148:4,7,20 149:15	234:21 275:24	
172:15 240:25	139:17 192:19	149:20 150:4	280:7 281:11	
	249:14,20 253:3	151:7 152:2,8	282:3	
	I .	l .		

	200.16 207.14	41 (1.22	226.10
consistently 43:10	288:16 297:14	control 61:22	326:18
328:25	298:19 307:24	341:2,8,14,20	conveyed 283:8
consonant 227:9	331:9	controlled 59:13	conveying 283:12
228:3,13 264:25	continually 17:7	59:18 60:4 139:9	301:12
constellation	22:8	147:10 213:4	conveys 294:4
239:13	continuation	214:3 222:3 242:9	301:18
constitute 183:13	55:12,24	242:10 309:23	cooper 3:17 6:23
199:21 302:24	continue 5:11	322:8 338:3 344:3	6:24
303:19	54:25 55:6 93:2	344:15 345:7	copies 355:14
constituted 200:20	95:7,17 97:7	controls 58:9	copy 20:15,25
constitutes 237:16	132:12 191:9	109:3	78:7 199:7 310:20
278:7	217:10 277:15	controversial	correct 8:20,23
construed 186:6	312:10 313:20	198:10	11:4,14 13:9 16:8
contacted 11:7	317:3 323:25	conversation 14:5	17:2,21 20:3
14:12 36:21 79:22	continued 4:1	14:24 15:15 23:10	21:23 22:2,3 29:9
79:24	51:12,13 131:20	23:12 50:23 62:25	30:21,23 31:20
contain 22:4	170:9 174:13	80:12 133:16,22	32:12,14 33:10
contained 102:8	continues 169:9	200:16 245:8,23	35:2,3,20 36:5
116:2 146:3 309:5	194:8	286:3 291:13	40:20 43:3 50:2,6
contents 275:2	continuing 326:14	293:11 296:13,23	50:7 52:11,12
context 12:21	continuum 198:17	301:9,17 302:21	53:4,7 54:18
27:24 32:21 33:25	contraceptives	306:2,6	62:17,18,22 63:13
34:4 46:16,19	222:7,19 224:12	conversations 5:8	63:25 78:11,14,15
47:19 48:18 60:13	contradiction	12:18,21 13:14,21	79:10,11 80:24
70:17 80:15 81:14	262:23 266:3	13:25 15:6,12	81:16 84:7,8
93:13 100:19	contrary 115:2	16:12,15 44:23	101:9 103:3,4
122:3,23 131:2	177:25 195:23	48:6 68:14 80:4	110:13 123:24
132:23 133:13,17	198:5 201:17,23	80:22 129:9	135:24 136:3
133:21 139:6	278:24 279:13	131:21 132:6,21	138:15 139:3,24
146:20 151:23	contrast 244:6,9	132:24,25 133:7	149:7 159:23
152:21 155:22	contrasting 160:6	133:20 134:2	160:20 161:5
202:25 203:20	contribute 79:20	152:14,22 201:13	163:24 167:2,3
205:23 210:21	contributed 36:23	205:24 290:25	173:8 200:6
216:12 218:19,22	contributing	292:18 294:21,24	225:15 226:11,13
224:11 229:21	90:19,22 91:9	298:25 299:2	237:6 268:8
231:3 232:4	148:25 317:6	conversion 160:23	308:12 325:24
235:21 237:19	contribution	161:9 162:19	357:8
249:2 250:6	232:10	163:21 164:8,11	corrections 26:25
267:19 270:9	contributory	164:14 330:5	357:6
275:6 276:2	141:8	convey 230:21	correctly 26:14
278:18 280:13,18		281:17 306:21	71:10 99:2,3

[correctly - decade] Page 15

100 15 111 11	240 45 254 42	277.17	7 044 00
103:16 111:14	268:17 274:13	cs 355:15	dane 241:20
122:15,16 128:15	276:10 299:14	cstrangio 3:16	danger 231:6
145:16 153:20	326:19	ct 1:19	279:22 330:11
175:14,15 176:14	cover 72:3 165:10	cultural 117:23	dangers 279:2,11
227:13,15 229:14	coverage 38:14,19	204:12	280:24
229:16 244:20	covered 33:24	curious 200:13	data 29:5 93:7,25
267:13 277:6	53:6 85:17 323:2	current 28:25	97:2 117:23
281:14 300:24,25	covering 72:4	29:19 30:5 37:13	125:12 154:23
308:21	covers 31:6	53:16 56:7 63:2	156:25 157:5
correlates 120:25	created 197:18	71:19 93:13 94:14	189:24 214:2
121:11 123:2	credible 97:2	103:13 104:2,12	215:18 241:11,23
correlating 120:25	creeps 287:16	108:2 115:5	243:13,21,25
corroborate	criminal 147:24	146:14 187:19	257:3 337:20
120:17	criteria 127:4	193:2 266:15	339:6 342:10
corruption 279:8	129:2 141:3,15	333:4 334:24	343:4,6 344:14,22
costa 344:20	148:20 228:20	336:7 337:9 338:9	345:9,10 347:12
council 13:11	335:16	342:2 345:19	database 135:11
counsel 3:3 4:3,10	critical 27:19 68:8	347:2	date 18:10 21:4,17
5:15 6:15 11:8	critically 67:17	currently 20:20	22:18 23:11 29:12
16:9,19 25:11,20	68:6 119:22 129:7	28:19 29:7,10	59:3 66:9 68:17
106:6 352:17,20	135:3,16 136:7	37:24 49:22 53:2	69:6 77:18 78:25
355:14	139:7 141:7	56:6 69:13 75:11	83:19 225:22
count 34:23	148:24	75:16,19 87:14	274:9 275:5
countries 23:2,15	critique 117:7,25	136:18,21 146:23	299:10 307:19
54:9 104:25 335:8	cromwell 3:4 7:3,5	170:22 182:15	352:13 356:24
336:9,12	cross 52:18 61:14	187:6 189:25	357:12
country 12:24	77:15 78:8 94:14	216:17 219:13	dated 18:8 21:15
106:4 107:2	98:24 100:6,24	305:23 310:18	74:6 307:17
254:17	172:7 180:13	314:24 349:24	308:10 353:8,11
county 299:8	189:4 194:5 218:3	curriculum 33:22	354:11
354:5	219:2,8,16,23	cut 56:8 64:23	dates 24:11 52:2
couple 13:14 75:6	220:9 223:23	cv 1:9 5:21 73:12	day 10:10 254:16
204:15,23 205:7,8	225:8 226:10	73:24 74:6,12,21	295:9 357:15
couples 202:7	229:5,9 238:15,23	75:14 78:19 82:12	days 355:17
234:21	239:19,24 240:16	82:15,21 87:13	de 175:23
course 44:12	241:3,13 252:12	88:4,8	dead 154:18
54:16 131:16	253:18 263:20	d	deal 295:23
court 1:1 2:8 5:19	316:15 318:3	d 353:1	dealing 296:6
6:5 9:7,10 25:9,18	353:14	dakota 35:7,8,13	death 224:24
133:4 134:7	crystal 128:7	damaging 331:12	decade 54:2
164:16 245:2		damaging 331.12	131:20

[decades - describing]

Page	16)
1 450	10	•

decades 92:2	dedicated 226:19	318:22	dependent 287:14
290:20 329:25	deem 339:10	degrees 65:21	depending 203:18
deceive 124:12,16	deemed 40:17	334:6	261:2 342:7
december 18:8	44:4 161:23 357:6	deirdre 299:9	depends 184:8
21:2 353:8	deeply 317:4	354:6	199:23 212:21
decision 66:2	defendants 1:11	delay 215:23	217:14 296:11
190:7 255:21	4:10 7:14,21 11:2	344:16	315:4
350:18	defense 15:24	deliberate 296:16	deponent 300:7
decisionmaking	25:11,20	deliberately 46:5	355:13 357:3
118:17	defer 55:20 106:5	delivered 48:18	deposed 34:15,20
decisions 47:24	112:19 350:2	54:13 57:5 84:22	34:25 35:22 36:16
117:18 128:3	deficiencies 62:4	84:23	37:4,20 76:16
231:17 254:16,18	100:21 146:5	demands 295:11	deposing 355:13
declaration 22:8	deficit 256:8	demographic	deposition 1:16
22:14 23:9 24:25	definable 341:3	170:17	2:3 5:14,22 6:1
27:12 28:16 34:19	define 14:3,15	demographics	8:18 16:13,23
36:2 37:21 40:8	81:17	165:18 188:8	105:20 133:18
43:9 45:15 57:4	defined 61:17	238:25	226:4 265:5 309:7
62:5 67:9 85:18	206:14 345:8	demonstrate	314:3 351:19
90:21 91:24 93:17	definitely 24:24	117:13	depositions 34:22
103:20 107:10	103:25 279:11	demonstrated	76:13
113:12 114:13	definition 91:15	57:6 125:9 155:25	depression 32:4
116:2,10 123:6	172:6 175:17	156:4 263:19	33:2 42:17 45:3
126:5 129:5,13	177:16,20	327:17 342:5	55:3 167:10
146:4 153:4 154:9	definitions 198:23	demonstrates	173:17 259:19
155:6 164:15	237:15	241:25 267:10	325:10 335:9
172:14 175:16	definitive 140:8	demonstrating	describe 49:10
188:7 240:24	187:20 219:11	324:16 327:2	65:4 89:11 133:25
241:18 260:3	221:17 254:20	339:7	161:4 223:7
265:4 277:14	255:23 290:22	demonstration	263:23 279:7
301:23 303:11	293:7 296:10	341:23	343:14
304:2 309:6 323:3	303:15 309:9,21	density 213:14	described 137:13
326:20 344:21	322:3 341:3	215:25 216:13,23	138:25 159:16
declarations 15:19	342:18	217:3,4	187:12 191:23
15:22 16:4,5 17:5	definitively 77:22	deny 89:14 115:19	194:21 195:13
22:25 23:15 24:22	91:12 97:14 156:5	department 49:23	247:23 248:3,14
26:24	220:14 222:3	83:7 307:15 308:8	249:7,10 265:3
declare 357:4	349:20	354:8	293:5 347:19
declared 45:14	degree 33:8,11	depend 293:16	describing 145:8
declaring 305:5	86:3 90:21 208:11	depended 46:8	229:23
	210:4 211:8		
		ral Solutions	

description 89:18	detectors 122:11	diagnoses 115:6	286:7,8 287:9
114:11 184:2	determination	290:15	293:19 299:3
334:8	126:25 290:23	diagnosis 43:23,25	318:21,22 329:25
deserve 258:25	determine 92:19	44:7,15 118:24	331:25 341:19
design 63:18	117:17 123:14	120:5 128:23	342:13
110:9 208:14	157:13 244:16	130:3 138:18	differential
249:14 340:13	312:15 313:8	141:23 284:15	223:21 284:15
designation	319:5	334:21 335:16	290:15
116:23	determined 29:20	diagnostic 141:15	differing 95:24
designed 110:12	30:3 346:23	dialogue 132:13	201:9 223:20
218:7 236:9 341:2	determines 246:9	202:3 227:13	254:7 255:7
341:22 343:14	detriment 288:18	dictionary 116:12	291:19
designs 61:4 233:2	develop 70:14,15	diet 209:6	differs 88:24
desirable 161:24	developed 25:2	differ 90:23 191:6	89:22 114:13
desire 31:18	developing 218:23	261:2 288:19	254:3 267:18
111:19 161:16	development 15:8	differed 133:14	difficult 150:14
173:13,15 191:10	31:9 46:20 47:5	difference 61:21	217:18 239:7
206:24 215:21	47:12,21 48:11,22	167:15 190:17	346:20
216:18 257:13,15	49:11,15 68:21	225:5 257:17	difficulties 134:14
257:18 287:24	149:19 215:8	differences 223:19	144:10 174:20
336:21	257:12 269:3	290:16 331:24	240:2 297:5 312:7
desired 162:15	290:20 349:10,14	different 14:23	335:19
163:19,21 180:6	350:8	63:11 82:7 85:5	difficulty 151:18
180:15 183:10,15	developmental	114:8 118:10,16	296:22
184:6,21 199:23	96:6	131:7,7 134:18	dig 317:4
199:25 200:4,12	developments	143:9 163:15	diligence 129:21
269:25 348:2	22:24 23:21,23	166:8 170:2,17	295:18
desist 96:24 328:8	28:5	174:9,10 177:5,9	dimension 96:17
desistance 92:21	diabetes 31:5	182:25 187:25	dimensions
92:24 94:22 95:6	39:12,13 41:16	188:10,16,22	141:21 143:9
95:17,23 97:6,23	44:13 45:5 208:7	191:15 195:16	247:15
167:20 173:2	208:18	196:14,21 198:23	dire 153:17
189:16	diagnosable	199:19 203:7	direct 8:4 353:4
desisting 202:12	335:10	209:7 213:17	directed 58:2
despite 285:12	diagnose 43:19	214:17 220:22	102:3 230:3 231:4
detail 149:12	114:10 293:14	223:22 232:8	231:18
265:3	diagnoseable	233:7 237:24	direction 108:8
details 12:25 13:5	335:9	243:9 249:23	directions 252:10
13:16 26:5 132:24	diagnosed 43:16	254:2 267:20	directive 305:5
detect 123:8	216:20	270:10,11 273:19	directives 181:16
		273:20,25 281:18	
		· · · · · · · · · · · · · · · · · · ·	

[directly - domain]

Page 18

	1		
directly 12:9	289:23 294:13	disordered 326:6	169:10 170:8
16:13 44:25 50:21	295:16 305:19	350:7	186:9 193:14
102:14 111:16	306:15 307:2	disorders 15:7	259:18 312:12
112:8 126:21	318:16 325:23	31:9 33:3 42:17	326:3 332:23
129:11 130:17	331:6 334:18	46:20 47:5,10,11	district 1:1,2 5:19
149:22 224:25	discouragement	47:20 48:10 49:11	5:20
229:8 245:23	177:24	49:14 55:3 68:20	divide 195:16
249:18	discovered 284:12	167:11 173:18	dividing 95:24
director 51:16,17	discovery 16:7	290:19 349:10,13	division 1:3 4:12
69:3 70:9 72:13	discuss 24:8 94:24	displacement	5:21 50:25 67:5
directs 250:3	148:19 348:6	278:3 279:5,6	divorce 303:6,7
disagree 187:10	discussed 71:7	disproportionate	doable 158:7
187:11,13 336:19	107:10 189:23	253:11	doctor 7:17 93:24
disagreement	239:4 240:23	disprove 61:23	document 9:8
190:4	278:20 296:22	250:14	18:13 20:7,12,21
disapprove 61:10	309:6,15 312:5	dispute 93:25	21:6,7,10,20,23
disassociated	314:3 316:18	322:15	26:17 78:3,7 79:4
264:19	discussing 71:7	disrupt 217:19	81:11 83:22
discerning 122:12	86:22 182:14,14	222:11 315:8	116:11 276:14,19
disclosure 274:25	185:12 238:14	316:17	276:25 277:10
disclosures 144:5	256:21 347:11	disrupted 218:19	280:17,21 281:4
disconnected	discussion 46:13	disruption 258:13	299:15 300:4,8,14
73:17 74:3	60:18 80:8 107:17	285:17 316:11	307:22 327:15
discontinuation	148:5 149:11	dissatisfied 323:19	documented
313:6	187:7 201:6,10	distinct 198:18	178:19 216:22
discontinue 311:2	203:21 204:13	237:15 273:23	223:2
314:9	210:12 231:12	distinction 269:14	documenting
discontinuing	292:9	distinguish 82:10	285:15,20
314:23	discussions 47:4	82:15	documents 17:4
discordance 89:25	47:14 51:23 131:3	distinguished	84:10 122:10
90:3,9 91:2,19	disease 31:8	162:12	dogmatic 298:16
134:16 195:5	110:13 290:16	distort 230:8	doing 8:9 65:14
197:4,24 239:11	292:17 293:14	233:20,21	67:19 84:12 99:8
discordant 89:16	diseases 31:2,3	distorting 231:7	129:15 134:6
91:13 163:4,10	39:24 45:17 235:4	294:6	191:16 214:17
184:23 190:18	dismiss 60:23	distortion 279:8	231:5 295:18
194:18 195:20	324:5	distortions 246:4	307:6 348:23
197:21,23 234:10	disorder 48:21	distorts 229:6,18	dollars 250:20
234:16 280:6	116:21 325:15	263:22	domain 279:19
281:8 282:2,21	335:10	distress 90:3,7,8	325:17
284:3 285:3		90:12 91:4,15	
		val Calutions	

[double - effective] Page 19

7 77 250 11	7 70 11 100 01	100 (01 100 01	
double 258:14	due 59:11 129:21	100:6,24 102:21	e
348:8	223:19 225:4	106:17 108:20	e 3:1,1 4:1,1 352:1
doubt 21:9 228:17	295:18	109:22 113:18	352:1 353:1,6
264:4 320:23	duly 8:2	114:8 116:15,22	356:3,3,3
dozen 17:8,9 92:2	duration 195:11	118:12,24 120:5	earlier 27:9
263:15	217:10 221:23	122:20 124:6	105:19 186:5
dozens 24:4 130:6	dutch 175:23	125:22 126:15	189:23 214:12
130:8 152:15	176:2,6,13 177:17	127:4,8 128:4,24	239:5 241:19
181:13	dylan 1:6 5:16	134:10 136:20	262:20 302:21
dr 5:15 8:7 19:18	355:4 356:1 357:1	137:23 141:7,17	350:6
19:25 74:3 84:12	dynamics 169:25	142:3,11 143:3,14	early 31:4,13
158:13 170:13	172:20 174:21	143:23 151:8	69:23 176:17
171:2 188:11	194:23 303:13	152:3 159:17	178:18 216:24
194:11 275:16	332:24	163:19 172:3	269:5 291:6
321:3,3,14 328:15	dysfunction 31:8	174:14 176:21	easier 208:2
339:6 351:5	229:11 238:17	188:21 192:8	easily 186:6
drafted 15:21	239:9 240:6	193:10 205:17	eastern 1:2 5:19
drafting 14:8	dysfunctional	212:11 223:8,12	easy 184:14
81:10	326:5	224:14 225:9	eating 42:17 55:3
drastically 188:10	dyslipidemia	229:6 246:25	167:11 173:18
draw 133:19	39:12	247:7,25 248:11	echols 4:7,8 7:8,9
136:12 202:23	dysmorphia	248:22 249:2	editorial 76:11
238:19 240:21	259:20	252:14 253:19	82:5
241:19 244:25	dysphoria 34:22	255:16 258:23	editorially 80:25
338:5	37:16 39:3,17,19	259:21 263:21	81:8
drawing 241:9	40:4,6,16,23 41:6	266:15 268:11	editors 81:21
dress 180:13	41:21 42:10,11,25	279:23 286:16	editors 81.21 education 65:17
200:19 270:2	43:17,19,25 44:15	288:23 291:25	66:10,15,17 67:6
drive 214:8	44:20 45:2,9,10	304:8 305:6	educational 65:5
drug 337:14	45:21 46:15 51:21	307:16 308:9	effect 193:9 218:8
drugs 218:20	52:11,15,19 59:2	310:19 314:8,25	218:11 224:21
221:5 225:3	62:17 66:12 67:2	315:12 317:6,16	250:21 256:19
dsds 290:21	67:12 68:12 69:11	318:21 324:18,24	258:14 274:3
291:24	69:15 71:9,14,25	325:12 326:8,10	286:4 287:19
dsm 91:16 115:22	74:22 75:4,12,20	326:11 327:4	303:22 313:18
116:4,12 117:4,8	76:5 77:16 78:10	330:22 333:24	
117:10 118:2,9,12	83:17 84:3,17	334:13,19,21	319:9,14,16 320:15 321:22
118:16,21 128:23	85:10,11 87:3,21	335:2,23 336:3,12	344:10 345:23
128:25 130:3,23	89:12 90:6,16	342:15 343:17	348:8
141:2,22	91:16 93:3 95:7	346:2,10 347:16	
	95:18 97:8 98:23	353:15,22 354:9	effective 54:5
		·	168:21 187:22

[effective - entirely] Page 20

260:6 284:16	elaborate 195:18	encouraged 176:8	engage 54:4 73:5
293:15,21,24	elements 89:2	179:3,22	106:9 128:22
294:7 316:19	148:6 149:13	encouragement	132:13 133:21
327:4 333:7	251:19	288:13	151:4 180:20
345:14,25 347:24	elevate 63:7 71:3	encourages	202:2 208:10
effectively 48:4	86:2 105:5 206:23	161:10 185:8	209:13 260:19
114:24 127:9	328:4	202:7,20	290:25 292:13
251:24 288:2	elevated 154:23	encouraging	329:3 339:23
effectiveness	217:5	176:4 178:17	342:11 345:17
263:19 324:16	elevating 58:13	179:5,13,24	348:9
325:6 339:8	elevation 336:22	180:10 181:9	engaged 14:6
effects 57:24 72:8	elicit 25:22 32:2	182:4 183:4,24	40:15,24 92:5
113:23 193:11,16	eliminate 335:22	199:9 203:9	113:3 165:12
193:17 215:25	elucidation 100:20	304:22	171:17 187:6
216:2 218:21	embrace 175:9	endangers 278:11	236:19 239:8
220:18,21 221:2	176:5 178:9	endocrine 39:25	273:6 289:5 333:2
222:15,22 238:22	181:10	45:6,16 224:5	333:3,11 349:3
240:20 242:20	emergence 318:20	270:23 272:12,22	engagement 48:24
267:4 286:2 290:6	emerging 261:12	284:22	105:2 268:24
292:25 309:14,19	261:18,20 325:13	endocrinologic	engages 172:7
310:3 331:20	343:4,6	235:4	251:21
343:8 346:13,14	empiric 246:6	endocrinologist	engaging 51:20
efficacious 43:12	empirical 227:7	30:21,22 39:7,24	176:25 182:23
108:13 346:9	employee 352:16	45:16,20 46:2,10	206:25 221:19
efficacy 23:3 42:4	352:19	79:19 112:16	245:20 268:2
104:4 105:16	empty 93:9	165:7 198:7 208:6	302:4 304:9
108:14,19 109:21	enable 151:6,25	228:9 235:3 245:4	enrolled 147:9,19
110:21 146:22	encounter 110:14	262:18 268:19	147:24
213:11 269:17	235:18 252:4	endocrinologists	enrolling 152:8
317:12,14 326:16	encountered	46:3	enter 293:10
effort 28:24 51:10	44:21 129:24	endocrinology	enters 97:19
59:6 156:16	150:16 188:24	30:8,17 31:7,11	entire 20:18 21:6
173:24 181:21	284:10 286:10	31:24 32:6,7,22	31:10 50:22 63:6
efforts 57:17,19	295:21 302:10	33:14 51:2 66:3	106:25 122:23
112:25 178:22	encountering	67:5 288:6 291:5	165:11 264:2
206:22 218:16	126:6 170:21	endogenous	276:14 278:8
egregious 110:8	encourage 162:3	315:18	290:25 306:2
either 14:9 70:18	175:9 177:14	endorsement	328:3 342:21
93:6,16 108:13	178:9,12,14,23	200:20	entirely 64:5
182:18 243:25	201:10 202:15	endorsing 343:10	114:14 129:13
329:9 345:4			198:19 265:22

[entirely - exact] Page 21

201 4 211 22	1.00.4	255 21 255 22	105 0 15 100 10
281:4 311:22	168:4	255:21 257:23	135:2,15 138:12
326:12 340:9	establish 103:12	259:4 267:25	141:6 142:22
entirety 280:17	168:13 288:3	343:9	146:5,23 151:2
entitled 78:23	318:9 324:12	etiologic 197:2	154:9 172:22
83:15,25 308:8	335:16 340:14	etiologies 91:9	192:17 206:7,13
353:18,20	established 105:2	139:12	206:16 207:7,8,9
enzyme 65:15	192:13 220:24	etiology 57:23	207:14,18,24
epidemiology	223:18 237:12	85:23 90:18	208:9,12,21
85:23 170:23	325:4 332:18	113:22 138:18	209:12,23 210:3,7
epigenetic 225:5	337:20 338:2	187:17 318:15	210:14,22 211:4
epigenetics 223:20	establishing 51:8	europe 333:12	211:14,25 212:8
316:5	establishment	european 23:2,15	212:13 217:15
equal 232:21	98:2 112:23 288:9	54:9 104:25 335:8	219:14 220:6,14
341:15 346:21	323:24 342:25	336:9	221:3 238:24
equally 197:19	estimate 136:22	evaluate 68:7	240:8 242:7,24
269:11	estimates 92:13	134:9 136:8 141:7	252:18 253:15
equipoise 320:18	estrogen 52:23	250:19	261:12,16,19,20
errata 355:11,13	61:16 71:23,24	evaluated 311:7	263:10 266:24,25
355:17	72:7 222:10 223:3	evaluating 109:4	267:9 270:22
erratas 355:15	223:7,13,15	129:7 213:4	271:18 272:6,16
erroneous 27:22	224:15 315:23	214:21	273:8,12 301:13
151:14 155:23	319:12	evaluation 44:14	304:24,25 311:21
164:17 172:16	et 1:7,10 5:17,18	68:8 115:2 137:7	312:22 314:14
174:11 243:23	355:4,4 356:1,1	143:13,20,22	318:17 321:23
303:18	357:1,1	evaluations	323:6 324:15
erroneously 116:6	ethical 226:24	130:13 131:5	325:3,11,13
347:4	229:2 230:16	evaluator 119:25	326:13 327:2,9,11
error 133:2	231:3,15 252:17	evidence 40:11	328:22,23 329:8
286:12 330:11	253:14 254:16,23	42:4 44:5 61:10	329:19 330:9,14
errors 25:14	255:17 256:25	61:20,23 85:15	330:18 333:15
229:23 285:6	258:11 348:5	92:23 94:5,10,14	340:7 342:6 343:3
287:22 292:14	ethically 234:17	95:5,16,20 96:2,7	343:23
especially 117:20	256:5 258:16	96:25 97:5 98:22	evident 237:22
esq 3:7,9,15,17 4:7	259:3 344:12	99:11,22,25 100:5	evidently 278:4
4:16,18 355:1	ethics 76:19,25	100:23 101:6,7,7	evolution 116:15
essential 139:16	77:2,5 103:6,8	102:6 104:22	349:16
145:12 278:21	148:23 151:13	105:7 107:12,14	evolved 176:12
290:13	227:22 231:4,11	108:3,4 109:17	evolving 238:24
essentially 85:19	231:13,21,24	110:3,5 112:19	269:4
128:22 141:14	232:12 252:22	116:19 118:15,19	exact 34:23 52:2
150:10 160:3	253:5 254:9,18	123:16 132:5	81:5 84:23 124:20
	X7 '4 4 T		

[exact - explain] Page 22

202:25 301:17 350:4 324:15 experienced 55:5 exactly 176:10 excluding 87:14 exclusive 263:7 238:15 exogenous 229:9 134:15 141:10 264:3 248:8 333:13 excuse 27:14 expert 71:4 68:5 89:21 117:14 264:3 examining 102:6 example 26:11 104:8 137:9 160:8.20,25 expect 71:4 182:10 326:7 experiences 29:21 29:3 37:5 41:12 181:24 197:8 160:8.20,25 47:12 170:18 experimental 44:18 46:6 58:21 222:19 246:22 172:9 173:12 54:14 83:15 84:2 47:10 170:18 experimental 19:9,10,18 exhaustive 259:13 exhibit 17:15,17 18:7,11,12,24 experience 32:16 experimental 18:4:15 173:17 18:7,11,12,24 287:18 150:9 152:9,10 227:7 261:17 18:4:15 173:17 18:7,11,12,24 28:18 150:9 152:9,10 227:7 261:17 18:4:16 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 336:17,24 337:8 20:13 20:22 83:14 98:6,71,10 97:71 14:15 336:17,24 337:8	129:24 154:3	exceptions 31:17	exists 155:4	331:5
exactly 176:10 excluding 87:14 exclusive 263:7 expanded 25:2 expanded 25:2 experiences 29:21 248:8 333:13 excuse 27:14 expanded 25:2 experiences 29:21 examination 8:4 29:17 32:15 42:23 expertant 159:21 68:5 89:21 117:14 352:5 353:4 47:10 49:13 56:2 expertant 159:21 182:10 326:7 experiencing examining 102:6 77:13 82:24 100:3 expectant 159:21 182:10 326:7 experiencing 47:12 170:18 26:14 17:12 170:18		-		
178:11 181:3		excluding 87:14	exogenous 229:9	_
examination 8:4 352:5 353:4 47:10 49:13 56:2 77:13 82:24 100:3 6xample 29:17 32:15 42:23 77:13 82:24 100:3 104:8 137:9 160:8,20,25 160:8,20,25 160:8,20,25 160:8,20,25 160:12,23 171:15 160:8,20,25 160:8,20,25 160:12,23 171:15 160:8,20,25 160:12,23 171:15 160:8,20,25 160:12,23 171:15 160:8,20,25 160:12,23 171:15 160:8,20,25 172:9 173:12 160:8,20,25 174:16 192:22 expected 159:24 166:23 218:8,10 174:16 192:22 expected 159:24 166:23 218:8,10 174:16 192:22 expected 159:24 166:23 218:8,10 174:16 192:22 102:0 107:6 experimental 54:14 83:15 84:2 102:0 107:6 experimental 227:7 261:17 313:2 318:10 227:7 261:17 313:18 13:19 220:18 21:2,12 291:19 experi 11:2,6 18:7 18:25 21:14 25:4 28:3 37:3,17 18:25 21:14 25:4 28:3 37:3,17 18:15 17:12 12:12 28:16:12 12:12 28:13 18:13 28:18 10:21 16:13 28:18 10:21 17:14 18:12 17:11		_		264:3
examination 8:4 29:17 32:15 42:23 expect 71:4 68:5 89:21 117:14 352:5 353:4 47:10 49:13 56:2 136:16 182:10 326:7 example 26:11 104:8 137:9 160:8,20,25 expectant 159:21 47:12 170:18 29:3 37:5 41:12 181:24 197:8 162:12,23 171:15 162:8,20,25 47:12 170:18 44:18 46:6 58:21 222:19 246:22 172:9 173:12 154:14 83:15 84:2 102:20 107:6 104:11 106:20 310:22 exhaustive 259:13 expected 159:24 102:20 107:6 119:9;10,18 exhaustive 259:13 exhibit 17:15,17 287:18 166:23 218:8,10 146:21 147:2 154:15 173:17 18:7,11,12,24 experience 32:16 227:7 261:17 150:9 152:9,10 184:6 189:12 73:9 77:9,10,11 76:21 89:15,24 313:2 318:10 333:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 29:19 29:19 29:19 248:24 259:12 145:4 153:6 130:4 131:25	248:8 333:13	excuse 27:14	expanded 25:2	experiences 29:21
352:5 353:4 47:10 49:13 56:2 136:16 182:10 326:7 examining 102:6 77:13 82:24 100:3 expectant 159:21 experiencing 29:3 37:5 41:12 181:24 197:8 162:12,23 171:15 47:12 170:18 experimental 44:18 46:6 58:21 222:19 246:22 172:9 173:12 122:19 173:12 54:14 83:15 84:2 19:9,10,18 exhaustive 259:13 exhibit 17:15,17 166:23 218:8,10 146:21 147:2 183:18 132:8 exhibit 17:15,17 287:18 150:9 152:9,10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:2 318:10 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 97:7 114:15 239:15 242:14 102:18,20 121:14 120:18 121:2,12 experimented 239:15 242:14 102:18,20 121:14 125:4 128:10,24 experimented 290:18 315:23 225:7,17,19 158:2 16:17 38:23 55:17 290:18 315:23 225:7,17,19 158:2 16:17 38:23 55:17 <td>examination 8:4</td> <td>29:17 32:15 42:23</td> <td>_</td> <td>_</td>	examination 8:4	29:17 32:15 42:23	_	_
example 26:11 104:8 137:9 160:8,20,25 47:12 170:18 29:3 37:5 41:12 181:24 197:8 162:12,23 171:15 54:14 83:15 84:2 44:18 46:6 58:21 222:19 246:22 172:9 173:12 54:14 83:15 84:2 58:24 59:12 70:22 27:9 290:9 174:16 192:22 102:20 107:6 104:11 106:20 310:22 expected 159:24 108:6 145:12 119:9;10,18 exhaustive 259:13 166:23 218:8,10 146:21 147:2 123:18 132:8 exhibit 17:15,17 287:18 150:9 152:9,10 150:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 79:20 93:2,15 336:17,24 337:8 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 18:25 21:14 25:4 249:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17	352:5 353:4	47:10 49:13 56:2	•	182:10 326:7
29:3 37:5 41:12 44:18 46:6 58:21 58:24 59:12 70:22 104:11 106:20 119:9,10,18 123:18 132:8 123:18 132:8 123:18 132:8 124:15 173:17 180:21 183:23 19:24 21:13,14 19:24 21:13,14 19:17 201:21 201:19 290:9 214:12,17 215:22 218 238:20 221:19 246:22 271:9 290:9 216:23 171:15 287:18 289:15.24 297:7 26:1:17 299:12.21 299:12.23:15,71 299:13.23:15,71 299:13.23:15,71 299:13.23:16:13 299:13.23:16:13 28:23.23:12 28:23.23 28:23.23 28:20.27:26:16 28:24.24:44:4 28:24.24:24:44:4 28:24.24:24:44:4 28:24.24:24:44:4 28:24.24:24:44:4 28:24.24:44	examining 102:6	77:13 82:24 100:3	expectant 159:21	experiencing
44:18 46:6 58:21 222:19 246:22 172:9 173:12 54:14 83:15 84:2 58:24 59:12 70:22 310:22 174:16 192:22 102:20 107:6 104:11 106:20 310:22 expected 159:24 102:20 107:6 119:9,10,18 exhaustive 259:13 166:23 218:8,10 146:21 147:2 123:18 132:8 exhibit 17:15,17 18:7,11,12,24 experience 32:16 150:9 152:9,10 184:6 189:12 73:9 77:9,10,11 76:21 89:15,24 313:2 318:10 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 336:17,24 337:8 203:8 208:3,5,19 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 experimented 291:19 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 166:17 167:21 305:15 308:24	example 26:11	104:8 137:9	160:8,20,25	47:12 170:18
58:24 59:12 70:22 271:9 290:9 174:16 192:22 102:20 107:6 104:11 106:20 310:22 expected 159:24 108:6 145:12 119:9,10,18 exhaustive 259:13 166:23 218:8,10 146:21 147:2 123:18 132:8 exhibit 17:15,17 287:18 150:9 152:9,10 154:15 173:17 18:7,11,12,24 experience 32:16 227:7 261:17 180:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 166:13 14:9 35:3 35:1 examples 119:20	29:3 37:5 41:12	181:24 197:8	162:12,23 171:15	experimental
104:11 106:20	44:18 46:6 58:21	222:19 246:22	172:9 173:12	54:14 83:15 84:2
119:9,10,18 exhaustive 259:13 166:23 218:8,10 146:21 147:2 123:18 132:8 119:24 21:13,14 287:18 150:9 152:9,10 154:15 173:17 18:7,11,12,24 287:18 227:7 261:17 180:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 29:19 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 159:11 174:24 136:13 141:9 18:25 21:14 25:4 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 166:17 167:21 305:15 308:24 150:8 154:14 353:13,17,19,24 186:11,2	58:24 59:12 70:22	271:9 290:9	174:16 192:22	102:20 107:6
123:18 132:8 exhibit 17:15,17 287:18 150:9 152:9,10 154:15 173:17 18:7,11,12,24 experience 32:16 227:7 261:17 180:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 29:11 239:15 242:14 102:18,20 121:14 125:4 128:10,24 29:119 248:24 259:12 145:4 153:6 159:11 174:24 130:4 131:25 18:25 21:14 25:4 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 24:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10	104:11 106:20	310:22	expected 159:24	108:6 145:12
154:15 173:17 18:7,11,12,24 experience 32:16 227:7 261:17 180:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 experimented 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 299:12 307:5,13 166:17 167:21 305:15 308:24 150:8 154:14 354:2,4,7 189:19 215:7 23:10 expertise 68:6	119:9,10,18	exhaustive 259:13	166:23 218:8,10	146:21 147:2
180:21 183:23 19:24 21:13,14 76:21 89:15,24 313:2 318:10 184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 experimented 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 229:12 307:5,13 166:17 167:21 105:21 126:18 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 305:15 308:24 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 <td>123:18 132:8</td> <td>exhibit 17:15,17</td> <td>287:18</td> <td>150:9 152:9,10</td>	123:18 132:8	exhibit 17:15,17	287:18	150:9 152:9,10
184:6 189:12 73:9 77:9,10,11 90:16,24 91:14 333:19 335:5 194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 experimented 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 29:17 77:20 78:18 240:3 247:7 266:19 284:10	154:15 173:17	18:7,11,12,24	experience 32:16	227:7 261:17
194:17 201:21 77:12,14,23 78:2 92:20 93:2,15 336:17,24 337:8 203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 29:17,20 78:18 240:3 247:7 126:19 134:	180:21 183:23	19:24 21:13,14	76:21 89:15,24	313:2 318:10
203:8 208:3,5,19 78:21,22 83:12,13 95:7,18 96:13,20 340:13 353:20 214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,67 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 250:17 260:4 136:7 230:11 209:25 260:12 84:11 250:17 260:4 234:25 304:13	184:6 189:12	73:9 77:9,10,11	90:16,24 91:14	333:19 335:5
214:12,17 215:22 83:14 98:6,7,10 97:7 114:15 experimented 221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 126:19 134:18 126:19 134:18 209:25 260:12 84:11 250:17 260:4 234:25 experts 22:13 304:13 exist 114:22 286:9,25 288:25 experts 22:13 95:2 129:4 135:23 295:16 315:25	194:17 201:21	77:12,14,23 78:2	92:20 93:2,15	336:17,24 337:8
221:8 238:20 98:11 101:11 120:18 121:2,12 291:19 239:15 242:14 102:18,20 121:14 125:4 128:10,24 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 19:11 77:20 78:18 240:3 247:7 126:19 134:18 209:25 260:12 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exce	203:8 208:3,5,19	78:21,22 83:12,13	95:7,18 96:13,20	340:13 353:20
239:15 242:14 102:18,20 121:14 125:4 128:10,24 expert 11:2,6 18:7 248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 290:25 260:12 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21 </td <td>214:12,17 215:22</td> <td>83:14 98:6,7,10</td> <td>97:7 114:15</td> <td>_</td>	214:12,17 215:22	83:14 98:6,7,10	97:7 114:15	_
248:24 259:12 145:4 153:6 130:4 131:25 18:25 21:14 25:4 269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21 <td>221:8 238:20</td> <td>98:11 101:11</td> <td>120:18 121:2,12</td> <td>291:19</td>	221:8 238:20	98:11 101:11	120:18 121:2,12	291:19
269:8 287:6 159:11 174:24 136:13 141:9 28:3 37:3,17 290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21	239:15 242:14	102:18,20 121:14	1	_
290:18 315:23 225:7,17,19 158:2 161:17 38:23 55:17 319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 322:8,23,23 explain 229:17,21				
319:10 321:14 228:24 244:4 162:16 163:4 105:21 126:18 325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 330:12 238:20 272:6,16 322:8,23,23 explain 229:17,21	269:8 287:6	159:11 174:24	136:13 141:9	· · · · · · · · · · · · · · · · · · ·
325:6 348:7 350:7 274:6,6,7 299:6,7 164:3,4,6,22 151:21 228:7 examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21		1 ' '	158:2 161:17	38:23 55:17
examples 119:20 299:12 307:5,13 166:17 167:21 305:15 308:24 124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21		228:24 244:4	162:16 163:4	
124:18 125:8 307:14 353:7,10 169:2,10,17 174:2 311:9 321:2 353:7 150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21				
150:8 154:14 353:13,17,19,24 186:11,20 188:22 353:10 156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21	_	,		
156:14 171:20 354:2,4,7 189:19 215:7 expertise 68:6 178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21		· · · · · · · · · · · · · · · · · · ·	' '	
178:19 181:13 exhibits 17:16,25 234:10,15,18 79:20 81:18 182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21			·	
182:9,25 184:11 19:11 77:20 78:18 240:3 247:7 126:19 134:18 203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21		' '		_
203:6 207:22 84:11 250:17 260:4 136:7 230:11 209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 30:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21		· · · · · · · · · · · · · · · · · · ·	, ,	
209:25 260:12 exist 114:22 266:19 284:10 234:25 304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21				
304:13 existence 117:13 286:9,25 288:25 experts 22:13 exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21				
exceed 224:2 existing 57:14 289:3,6 290:5 93:19 102:7 exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21				
exception 165:25 95:2 129:4 135:23 295:16 315:25 330:12 341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21			· · · · · · · · · · · · · · · · · · ·	_
341:16 238:20 272:6,16 322:8,23,23 explain 229:17,21			· · · · · · · · · · · · · · · · · · ·	
, , , , , , , , , , , , , , , , , , ,	_			
1 044 10 1 007 10 10 000 17 1 000 7	341:16			_
344:13 325:12,19 328:16 283:7		344:13	325:12,19 328:16	283:7

[explained - lemaie]			1 uge 23
explained 183:25	81:6 142:19	264:7	174:21 177:9
264:13	f	faculty 30:15,15	181:18 186:16
explanation 175:2	_	67:4 131:11	188:17 190:12
explicitly 201:18	f 352:1	failed 73:21 141:4	205:4 215:14
218:14	face 129:6	fails 355:19	217:9 224:17
exploration	facilitate 125:17	failure 109:2	234:18 237:21
194:23	fact 24:16 61:7	110:8,17 112:23	247:11 253:13
explore 163:7	93:20 97:16 102:3	245:25 342:24	257:18 258:5
195:6 247:13	110:2 111:2,10	fair 94:7	265:22 267:21,22
explored 258:24	114:22,23 119:8	fairly 251:6	279:22 301:12,23
342:16	129:6 154:22	283:19 309:9	312:2 316:14
exploring 71:12	155:3 177:23	faith 227:4,5	346:21
144:25	188:15 192:14	262:21,24 263:6	fault 77:23
explosion 188:19	193:16 206:24	faiths 227:11	faulty 250:22
expose 218:6	207:2,13 218:12	fall 138:9 185:21	favor 109:20
exposed 316:4	243:10,24 245:2	230:9 259:2,14	110:19
346:15	247:19 256:24	262:25	february 21:15,25
exposure 204:5	258:9 265:14	falling 330:10	22:3,17 24:14
223:23 224:19	266:24 276:22	falls 185:13,19,24	353:11
243:6 287:11	279:12 284:22	false 122:12,19	feedback 72:22
346:12	303:3 306:24	241:6 347:7	222:11
express 116:17	factor 91:3 188:5	falsehood 123:8	feel 10:6,13
expressed 15:2	factors 32:3 90:7	124:2	feeling 9:22 28:4
114:15 140:11	90:11,19,22 91:10	falsehoods 241:11	feelings 126:10
220:17	92:21 96:19	familiar 9:2 35:10	feels 278:6
expression 223:21	139:12 148:12,25	142:16 274:16	fellow 72:11
extend 216:15	149:18 151:15	305:11 328:12	fellows 51:13,19
272:21,23 273:14	163:3 170:19,23	families 204:23	69:6,10,12,22
273:17	174:3 195:6,7 196:5 197:3	family 13:11	70:6,11,18,23
extended 12:19		151:6,25 179:2,3	71:17
340:20	207:19 209:9	179:20,22 194:25	fellowship 30:18
extends 279:22	214:8 221:22 239:13 242:22	199:7 202:20	33:13,23 34:10
extension 215:19	254:4 255:8,24	205:7,9 326:5	51:14,16,17 66:6
extensive 26:16	254:4 255:8,24 261:4 267:20	332:23 334:15	66:16 67:3 69:2,3
67:7 76:11 80:11	269:20 273:20	far 14:13 26:22	70:8,8 72:13 73:3
123:22 162:8	288:17 302:8	45:13 96:8 105:24	73:4 291:5
343:25	303:16 317:5	120:14 123:7,7	felt 179:2,21 266:4
extensively 81:7	320:3 322:10	129:25 139:11	female 58:24
107:9	332:21 350:23	142:17 153:2	61:15 194:8
extent 25:22 26:2	facts 119:24	159:20 163:18	223:15,16 224:21
33:6 55:23 58:6	201:11 246:19	166:8,13 171:3	236:14 237:16,23
	201.11 240.19		

[female - form] Page 24

	I	1	
244:12 245:9,12	find 10:14 36:2	florida 35:14	56:9,13,24 60:11
245:17 246:15	61:19,23 123:24	307:15 308:8	62:19 64:2 66:13
248:13 249:6	154:5 156:14,17	354:8	77:4 83:4 87:11
265:12 314:7	171:21 181:22	flow 121:10	87:24 88:25 90:4
females 52:22	184:14 273:12	focus 45:17 48:19	90:13 91:5 92:10
188:20 237:25	275:4 280:2	67:23 70:14	93:4 94:9 95:9,21
287:10 315:23	296:16 297:18	120:10 123:10	97:10 101:3 103:9
fertility 48:24	336:2	127:14 162:25	103:24 104:14
209:20 217:13,17	findings 92:3	193:8 232:6	105:18 106:21
218:17 219:4,9,17	120:17 227:6	262:24	107:23 108:21
220:10 256:19	319:4	focused 85:14	109:23 110:22
257:7 258:2	fine 10:8 36:11	94:3 122:7 166:16	111:21 112:12
fewer 257:7	158:15	focusing 49:3	113:10,19 114:25
fictionalized	finish 9:11	201:4	115:15,24 118:4
182:19,22	finished 67:2	fold 319:11	118:25 120:6,21
field 22:25 28:4,6	finland 23:18	folder 18:23 19:5	122:21 124:7,17
29:22 60:14 62:3	firm 6:6 157:3,6	follow 31:17 144:7	125:15,24 126:16
62:13 65:8 83:3	first 8:2 15:18,21	195:14 215:13	127:10 130:14
85:16 86:3 103:23	18:11 20:9 70:4	216:8 264:6 336:8	131:22 132:18
105:22 108:10	78:4 80:2,6,13	followed 58:7	133:8 134:3,11
109:14 115:14	106:24 131:10	141:2 144:23,24	136:2 137:16,25
130:20 148:23	161:8 164:10	175:11 216:4	138:16 139:4,25
152:15 186:3	175:23 190:17	following 65:9,18	140:15,21 142:4
206:17,18 207:20	252:11 255:23	66:7 142:18	142:12 143:5,15
210:19,24 211:18	258:9 275:9	215:12 217:22	143:25 146:18
231:21 273:7	290:21 299:18	239:18 296:22	147:7,17,20 148:2
313:25 335:14	308:4,6,13 324:19	follows 8:3 275:2	148:18 151:10
fields 63:8 112:2	fit 89:18 163:15	followup 86:21	152:5,17 155:11
figure 275:4	185:2 188:13	323:9,17	156:22 157:8,14
file 37:21	192:21	force 164:3 278:8	157:21 162:20
filed 5:18 16:5,7	fits 156:8 177:4	forced 281:24	163:25 164:9
20:16 21:2 22:16	five 52:5,7 86:10	forcing 280:24	167:25 171:13
22:18 23:24 24:13	234:4 238:4	forefront 28:25	172:5 174:7 179:7
26:7 27:12 28:16	319:11 338:22	foregoing 352:10	179:15 180:2
275:8 299:13,19	351:7	357:5	182:5 183:5,18
299:21	flawed 64:18	form 14:21 26:21	185:10 190:20
filing 23:22	flaws 27:21 63:3	32:18 37:18 39:21	191:25 194:15
final 214:6 215:6	85:22 321:18	40:21 41:8,22	198:2 199:10
215:12	flesh 339:13	43:4 44:16 45:11	200:24 202:8,21
financially 6:10	flipping 122:13	47:16 48:14 53:8	203:11 204:17
352:21		53:18 54:19 55:14	205:2,12 206:20

[form - gender] Page 25

207:25 210:8	245:9,12 246:15	france 23:19	future 59:25 60:5
211:5 212:2	248:13 249:6	fraught 151:18	252:9 347:12
218:13 219:5,19	313:20	frequency 95:4	g
220:11 228:5,15	formulating 262:5	frequent 338:14	gain 107:13 111:3
233:10 234:7,23	forth 12:24 26:4	frequently 121:8	232:9
235:10 236:3,11	80:11 352:14	233:20 292:14	gained 68:5
242:5 244:24	forums 198:13	friends 295:13	243:21
246:3,7,17 247:2	forward 27:12	front 20:2 24:9	gaining 110:4
248:4,15 249:8	37:9 51:8 53:23	184:13 275:12	gamut 31:6
251:3 252:16,24	57:23 58:5 60:24	276:21 281:21	gather 131:13
253:21 255:18	61:12 64:8 86:2	294:9	gather 131.13
258:4 261:25	106:3 108:25	fruit 82:17	gathering 22.7 gay 202:7,20
262:15 263:24	110:8 113:2 114:3	fruitful 297:10	203:10
264:15,23 265:8	114:24 116:20	fulfilling 48:5	geared 49:5
266:17 268:14	131:10 141:14	full 10:23 100:20	189:17
270:7,19 271:13	150:17 155:18	133:21 257:11	gears 30:4
272:19 276:11	169:22 170:13	312:2 338:7	gender 34:21
278:15 280:11	171:25 177:21	339:25	37:16 39:3,17,18
281:12 282:6,24	184:20 192:12	fully 90:17 195:14	40:4,5,9,16,19,23
284:7 286:21	197:16 207:9	218:5 221:9	40:24,25 41:6,21
288:14 289:11,12	210:2,4 228:12	318:15	41:25 42:2,8,9,10
289:25 294:16	229:23 232:19	function 49:20,21	42:25 43:17,19,25
296:8 297:16	233:14,16 239:5	65:14 221:14	44:15,20,25 45:9
298:21 300:23	245:10 249:19	223:5 258:13	45:10,21 46:15,23
301:5 302:4 305:8	250:7 258:21	315:8,17 346:11	47:6,13,15,23
305:9 309:3 311:4	266:3,5 272:10	350:14	48:12 49:4,12,17
312:19 313:10	301:8 318:18	functional 48:22	49:21 51:5,21
314:11 315:2	328:5 329:18	functioning	52:10,15,19 58:25
317:19 327:6	330:13,20 331:17	215:15 241:5	59:16 60:8 61:13
329:10 330:24	332:7,11 333:13	251:17 345:6	62:17 66:12,25
332:14 334:16	333:14,15 339:18	fundamental	67:12 68:12 69:10
335:3 336:16	foster 226:22	60:16 145:8	69:15 71:8,13,25
337:6,11 339:11	found 93:20 181:5	230:23 231:7	74:22 75:3,12,20
343:18 346:3	183:2 292:25	233:17 254:14	76:5 77:16 78:9
347:21 349:11	293:20 296:14	funded 64:16	83:16 84:3,17
formal 34:10	298:5 309:24	69:17,20,23	85:10,11 87:2,21
format 100:16	founded 51:24	funding 68:11	87:22 88:23 89:9
formatting 25:10	four 24:22 36:6	69:7	89:12,15,20,21,25
forms 63:11 71:22	fraction 129:3	funds 69:21	90:6,10,16 91:2
72:7 142:14	framework 233:2	further 215:21	91:13,16,20 92:6
171:16 244:13	333:10	351:16 352:9,15	93:2,13 94:12,17
			75.2,15 77.12,17

[gender - go] Page 26

	I	I	T
95:7,13,18 97:8	252:13 253:19	333:9 338:20	girl 179:2,21
98:19,20,23,24	255:16 258:22	general's 5:23	give 10:6 17:23
100:5,24 102:21	259:21 261:24	7:22	135:15 141:16
106:17 108:20	262:14 263:20	generalities 184:9	149:20 150:2,3
109:22 113:17	264:12 265:7	generalizability	151:7 152:2
114:8 116:15,21	266:14 267:5	340:23 342:21	153:11 207:22
116:22,24 118:11	268:11 279:23	generalized 319:3	208:3 243:22
118:24 120:5	280:6,8 281:9,11	generally 8:21	268:3 288:11,12
122:19 124:6,23	282:2,4,22 284:3	31:14,16 43:20	given 59:15 84:16
125:22 126:15	284:4 286:16	82:11 85:9 94:22	85:3,5 127:2
127:4,8,23 128:3	288:23 289:23	103:22 118:2,21	150:9 181:17
128:24 134:9,16	291:2,20,24	171:11,24 194:21	218:20 220:20
136:19 137:22	293:25 294:13	202:14 208:17	224:20,21 268:3
141:6,16 142:3,11	295:16 302:2	217:20 232:13	310:20 357:9
143:3,13,17,23	304:7,8 305:6,19	235:9,25 268:5	gives 199:7
145:10 151:8	305:20 307:16	277:12 281:7,25	giving 71:24
152:2 154:18	308:9,15 309:5,14	296:5	152:19 209:22
159:17,22 160:12	309:24 310:19	generate 236:16	223:12,13,14,15
161:2,18 163:4,11	314:8,25 315:7,12	284:15 324:10	223:17 332:9
163:18,23 164:23	317:16 318:16,20	generated 63:21	gland 221:12
167:22 168:8	324:18,24 325:12	157:10 178:3	222:13
169:11 172:3	325:23 326:8	232:25 280:22	global 345:5
176:21 178:16	327:4 328:18	345:11	gloucester 299:8
180:15 182:20	330:22 331:6	generating 254:15	354:5
184:3,24 185:18	333:24 334:12,18	285:5 290:14	gnrh 52:17 213:24
186:12 188:20	334:21 335:2,23	309:19	214:5 217:16
190:18 192:7	336:3,12 339:8	generation 249:13	220:19
194:18 195:4,20	342:14 343:17	250:3 322:2	go 5:12 15:6 18:4
196:3 197:3,12,21	346:2,10 347:16	325:20	20:21 21:3,18
197:23 198:18,21	353:15,21 354:9	genetic 223:21	78:20 83:11 86:9
198:22 205:17,20	general 4:12,13	genital 47:25	94:17 98:5 99:4,6
206:17,18 207:20	7:15 32:8 33:13	291:11	101:10 102:19
210:19,24 211:18	46:3 65:16,23	genitalia 349:21	104:16 123:4
212:10 223:8,12	82:14 85:10 95:15	350:13	127:13,17 135:11
224:14 225:9	100:22 117:10	genitals 349:9	135:17 144:17
229:6 233:6	118:7,17 136:10	genuine 199:20	149:11 158:6
234:10,15 239:10	160:23 166:7	getting 70:23	161:22 184:15
239:18 241:14	184:19 212:10	111:12 205:14	218:2 219:22
242:18 243:17	278:14,19 279:25	314:4 345:9	225:6 234:4 238:4
246:25 247:7,25	304:18 305:25	gill 4:4,8 7:9	239:3 245:17
248:11,22,25	306:11 308:14		247:11 249:9

[go - health] Page 27

252:6 274:4	273:4 274:4,5	great 21:12 79:3	h
277:15 299:25	276:13,23 277:5	149:12 214:11	h 353:6 356:3
302:15 307:4	280:2,3 282:15	greater 48:18	half 17:8 31:4
goal 125:14	288:17 291:16	58:17 111:3	hand 7:18 19:24
162:15 164:7	299:5,12 300:12	209:13 340:3	64:21 73:15 91:25
167:23 168:2	303:5 307:4 315:9	grimm 299:9	127:21 189:25
183:10,15 184:6	316:20 320:14,16	354:6	happen 53:15
189:14 191:4	320:21 323:11	ground 8:25	191:5
192:5 233:4,22	332:3 341:18,19	grounded 247:8	happened 12:21
235:3 312:10	348:11	grounds 246:9	23:23 132:20
316:24 347:22	gold 342:19	group 72:5 144:22	276:17
350:12	gonad 218:7,23	261:3 341:2,8,14	happening 140:20
goals 160:6	gonadal 213:12,13	341:20,20 344:24	157:7 285:18
goes 8:22 138:2	217:22 315:8,16	346:17	happens 167:5
199:14	gonadectomy 46:7	groups 177:22	169:13
going 5:2 8:24	gonads 198:14	178:7,22 181:2,9	happy 94:24 99:9
10:9 12:17 17:18	218:5 221:8,12	194:25 201:19	149:11 229:20
17:24 18:4 19:11	good 5:1 6:20 8:7	242:23 341:15	hard 13:15 97:18
19:12,15 48:2	8:8,9 9:4,14 10:14	344:18,24 345:2	hardcopy 73:16
56:3 61:16 65:2	10:20,21 21:18	grow 166:25	73:23
66:18 71:6 73:24	36:13 66:19 73:19	growing 78:23	harm 231:6,19
77:8 78:17 84:9	86:11 123:13	79:6 98:7,12	232:3 233:5
84:13,14,15 86:20	158:10 167:7	279:15 353:18	253:11 301:20
87:17 90:22 97:4	168:15 231:5,19	guarantee 76:21	303:24 314:22
97:23,25 99:12	232:2 233:5 253:6	319:25	harmed 320:5
101:12 102:17	257:2 259:5	guaranteed 221:4	harmful 201:17
107:4,13 110:15	285:11 338:18	guess 52:3 235:12	270:6,17 271:12
114:4 121:14	gorman 239:16	guidance 70:20	272:18 301:12
127:22 139:20	240:18	308:7	306:4 327:18
150:19 159:12	gotten 74:10	guide 69:4	harming 301:19
160:22 174:23	governor 305:4	guided 69:9	302:15 303:10
187:21 190:2	grade 206:14	guideline 144:9	305:3
191:17 194:3	208:5	guidelines 142:19	harmony 227:4
196:9 201:6	graduate 66:16	144:7,23 207:8,11	harms 192:10
209:21 217:17	grammar 25:14	210:2 225:21	315:4 340:9 349:2
219:25 221:20	grand 84:24 85:7	226:8 270:24	hb 13:4,12,19 14:8
225:16 228:23	grant 70:3,24	272:12,23 327:13	53:11
240:11 250:24	granted 70:3	354:1	health 32:5 33:9
251:11 253:23	grants 69:22	guiding 70:5	33:17,20 34:7
255:25 260:25	grave 128:10	gut 271:22	38:13 46:9 113:25
271:23 272:10			115:6 128:2,4,12

[health - hruz] Page 28

	316:12 321:7	52:1 53:1 54:1
131·4 100·7 higher 104·6		
131.4 199.7 Ingliet 104.0	336:15 343:16	55:1 56:1 57:1
216:10 239:21 105:8 107:12,13 ho	rmones 52:19	58:1 59:1 60:1
241:15 272:3 209:12,23 243:16	51:14 72:6 94:14	61:1 62:1 63:1
284:21 307:15 267:24 349:5	172:8 218:3,6,22	64:1 65:1 66:1
308:8 321:9 highlights 257:19	219:8,16,23 220:9	67:1 68:1 69:1
347:15 354:8 highly 67:21	223:13 229:5,9	70:1 71:1 72:1
healthcare 32:17 132:11 133:25 2	238:15,23 239:19	73:1 74:1,3 75:1
35:19 226:20 195:4 264:4	239:24 240:16	76:1 77:1,14,17
healthy 334:15 322:12	241:3,13 252:13	78:1,22 79:1 80:1
hear 9:7 historical 207:7	253:19 315:10,19	81:1 82:1 83:1,14
heard 144:20 historically	316:4,10,15	83:18 84:1,12
154:4 169:19 170:21 ho	spital 46:17	85:1 86:1 87:1
heart 120:15 204:6 5	50:4,5,9,11,13,16	88:1 89:1 90:1
121:10 history 57:24 5	52:25 53:17 56:20	91:1 92:1 93:1
heavily 43:21 113:23 160:16 ho	spital's 56:6	94:1 95:1 96:1
193:11 172:20 187:18 ho	spitalized 41:14	97:1 98:1 99:1
height 213:13 328:13 334:22 ho	spitals 231:14	100:1 101:1 102:1
214:7 215:6,13,21 350:21 2	254:17	103:1 104:1 105:1
216:18 hold 19:8 279:13 ho	sted 2:5	106:1 107:1 108:1
heil 239:16 240:18 holds 186:13 ho	stility 295:22	109:1 110:1 111:1
held 2:4 30:12 holistic 252:3 ho	ur 127:12,16	112:1 113:1 114:1
279:10 holistically 251:14	158:5	115:1 116:1 117:1
help 9:10 18:22 honor 294:14 ho	use 11:16 12:6	118:1 119:1 120:1
25:6,7 58:20 71:2 honorific 298:20 hr	uz 1:17 2:4 5:15	121:1 122:1 123:1
120:25 276:3 hormonal 31:3	7:25 8:1,7,17 9:1	124:1 125:1 126:1
helped 69:4 59:15 61:13	10:1,24 11:1 12:1	127:1 128:1 129:1
helpful 24:6 43:7 323:25 331:21	13:1 14:1 15:1	130:1 131:1 132:1
276:6 306:3 333:17 1	16:1 17:1 18:1,7,8	133:1 134:1 135:1
helping 303:9 hormone 46:6,8	18:25 19:1,18	136:1 137:1 138:1
317:18 106:18 108:19 2	20:1,2 21:1,14	139:1 140:1 141:1
hereinbefore 109:21 151:7	22:1 23:1 24:1	142:1 143:1 144:1
352:14 152:3 170:10 2	25:1 26:1 27:1	145:1 146:1 147:1
hereto 357:7 172:2 175:11	28:1 29:1 30:1	148:1 149:1 150:1
hesitating 28:12 219:3 223:24,25	31:1 32:1 33:1	151:1 152:1 153:1
heterogeneity 224:19 240:19	34:1 35:1 36:1	154:1 155:1 156:1
196:24 318:12 249:3 255:11,15	37:1 38:1 39:1	157:1 158:1,13
heterogeneous 263:20 268:10	40:1 41:1 42:1	159:1 160:1 161:1
139:11 287:11 302:2	43:1 44:1 45:1	162:1 163:1 164:1
high 103:12 304:7 305:7	46:1 47:1 48:1	165:1 166:1 167:1
113:13 202:2 310:18 314:23	49:1 50:1 51:1	168:1 169:1 170:1

[hruz - identity] Page 29

171:1 172:1 173:1	292:1 293:1 294:1	281:17	200:8 204:10
174:1 175:1 176:1	295:1 296:1 297:1	humans 230:6	205:3 219:24
177:1 178:1 179:1	298:1 299:1,7	237:14	i
180:1 181:1 182:1	300:1 301:1 302:1	hundreds 135:12	idea 199:14
183:1 184:1 185:1	303:1 304:1 305:1	hybrid 185:23	278:14 285:11
186:1 187:1 188:1	306:1 307:1,14	hypergonadal	ideal 109:13
189:1 190:1 191:1	308:1 309:1 310:1	315:9	ideally 109:5
192:1 193:1 194:1	311:1 312:1 313:1	hypogonadal	idealogic 198:4
195:1 196:1 197:1	314:1 315:1 316:1	316:13	idealogical 117:24
198:1 199:1 200:1	317:1 318:1 319:1	hypogonadism	134:25 203:23
201:1 202:1 203:1	320:1 321:1 322:1	315:13,25	229:25 230:22
204:1 205:1 206:1	323:1 324:1 325:1	hypotheses 57:22	247:21 250:2
207:1 208:1 209:1	326:1 327:1 328:1	58:5 60:22 63:17	278:3,23 279:6,20
210:1 211:1 212:1	329:1 330:1 331:1	63:20,22 64:8	280:25 297:6
213:1 214:1 215:1	332:1 333:1 334:1	70:15 110:9	298:2 303:21
216:1 217:1 218:1	335:1 336:1 337:1	144:25 201:12	idealogically
219:1 220:1 221:1	338:1 339:1,6	232:24 233:15,19	230:7 304:21
222:1 223:1 224:1	340:1 341:1 342:1	249:13,19 258:20	
225:1,19 226:1	343:1 344:1 345:1	260:14,21,23,25	idealogy 164:12 198:10 233:14
227:1 228:1 229:1	346:1 347:1 348:1	261:7,11 266:7	247:20 285:8
230:1 231:1 232:1	349:1 350:1 351:1	271:24 272:2,5	ideation 211:11
233:1 234:1 235:1	351:6 352:6 353:2	273:23 285:6	identifiable 196:6
236:1 237:1 238:1	353:7,8,10,13,16	309:19 324:10	identification
239:1 240:1 241:1	353:17,19,23,24	325:21 329:20	18:10 21:17 77:19
242:1 243:1 244:1	354:2,4,7 355:5	330:19 331:16	78:25 83:19 98:24
245:1 246:1 247:1	356:2,24 357:2,4	332:8 339:19	100:6,24 189:5
248:1 249:1 250:1	357:12	344:2	
251:1 252:1 253:1	hruz's 194:12	hypothesis 60:21	194:5,9 225:23 274:10 299:11
254:1 255:1 256:1	human 14:3 15:4	60:24 61:2,5,11	307:20
257:1 258:1 259:1	49:5 58:10 195:21	61:13,24 64:19	identified 176:15
260:1 261:1 262:1	197:24 201:23	124:25 125:10	identifies 166:25
263:1 264:1 265:1	225:4 229:7,19,24	197:15,16 250:4,6	
266:1 267:1 268:1	230:25 231:8	250:7,13,15 272:7	identify 91:21 139:14 161:11
269:1 270:1 271:1	232:5,14 233:8,21	272:15 273:11,13	
272:1 273:1 274:1	234:6,22 235:14	273:17,21 318:19	162:3 163:2 194:7
274:7 275:1 276:1	235:19,22,25	320:12 322:2	224:13 259:18
277:1 278:1 279:1	236:17,24 237:4	325:24 335:4	identifying 80:6 98:21 328:9
280:1 281:1 282:1	237:11,21 245:8	341:3 344:23	
283:1 284:1 285:1	245:15 246:3	hypothetical	identity 47:7,23
286:1 287:1 288:1	248:19 250:9	53:21 150:20	48:13 49:4,12,17 49:21 87:22 88:23
289:1 290:1 291:1	252:4 265:19	151:12,17,22	
		- 1 C -14:	89:9,15,20,21

90:10 91:3,14	ignoring 230:23	231:22 232:10	104:24 120:15
92:7 93:14 94:17	243:10 262:12	245:19 247:3	166:11 177:2
98:19 116:21	280:8 281:6	257:19,22 266:9	263:15 348:6
134:16 154:18	282:23 294:7	298:10,11 306:21	350:16
160:12 161:18	ii's 244:9,22,22	344:7	incompetent
163:5,11,23	246:21,23	impossible 146:15	96:11
164:23 167:22	illuminates 244:11	improve 243:2	incongruence
168:9 169:12	illustrate 123:19	347:14	116:24 169:11
175:10 176:5	immature 191:17	improved 241:14	incorporate 252:3
178:10,16 179:6	immediate 193:8	242:13 326:15	incorrectly 64:19
179:14,25 180:7	319:3 344:17	improvement	313:15
180:16 181:10	immediately	345:5	increase 108:14
182:4,11,21 183:4	274:20	inability 268:3	319:12 340:21,22
183:25 184:3,7,24	immoral 252:14	inaccuracies	increased 350:9
185:8,18 186:12	258:7	26:19 241:10	increases 242:25
190:19 194:19	immutable 177:10	inadequate 64:20	increasing 229:12
195:5,20 196:4	195:22	104:3 110:2 111:7	incredibly 319:18
197:4,12,21,23,25	impact 32:3	141:17 150:5	independent
198:22 199:9	248:19 321:8	344:22	212:10 286:15
202:7,20 203:10	impacted 32:25	inappropriate	287:11 291:24
204:20 205:20	impacting 45:4	204:16	317:10 325:11
233:7 234:11,16	impair 9:25 33:3	inborn 65:13	341:17
239:10 280:8	217:13,17 219:3,9	incapable 134:6	indicated 337:3
281:9,11 282:2,4	impairing 209:19	315:18	indicating 328:6
282:22 284:4,5	impairment	incidence 224:25	indication 214:25
285:2 289:24	224:24	include 29:5 47:6	337:18
290:23 291:15,21	impairs 219:17	47:22 63:23 121:9	indications 215:3
292:17 294:14	220:10	123:5 131:17	338:18
295:17,25 305:19	impersonating	166:2 202:6 294:2	indicator 92:18
305:21 307:2	300:20 305:21	331:7 332:22	individual 54:24
318:16 325:23	impersonation	included 65:16	94:6 96:9 124:21
328:18 331:6	306:7	67:7 85:20 183:25	125:5 135:19
334:18 349:23	implemented	277:14	141:9 148:20
350:15	144:10	includes 49:4,21	152:7,20 163:3,11
identity's 280:7	implications 55:19	143:8 182:2	164:22 170:3
ideological 246:8	implies 306:8	202:19 213:11	184:17 186:3,11
ideologists 273:6	important 57:18	232:22 269:24	189:18,21 190:3
ignore 281:9	60:15 96:8 100:14	293:13	191:11 193:20
282:4 285:11	139:8 140:23	including 6:15	194:14 195:9
ignores 250:10	141:11 148:8,12	22:25 31:7 42:16	196:15 197:6
278:25 347:18	148:24 216:13	48:23 94:12	199:15 212:24
210.23 341.18	140.24 210:13	40.23 94.12	199.13 414.24

			_
215:6 224:2 254:3	311:24 312:9,25	85:20 96:4 109:12	inquiry 226:22
254:21 269:25	313:19 315:6,16	111:4,7,8,11,12	inseparable
282:9,17 283:2,16	315:22 316:8	111:19 131:14	244:13 251:8
283:22 284:18	325:14,22 328:17	147:2 150:5 151:6	insight 232:9
285:12 286:11,14	329:23 331:5	151:25 181:5,22	insignificant
287:3,15,21	333:6 335:25	195:8 200:14	256:23
288:19 290:24	349:13	201:8,13 204:2,4	insofar 55:25
291:15 292:16	induce 213:20	205:9 239:23	inspired 227:3
294:8 296:12,21	218:8	242:16 279:18	institute 106:25
306:10 312:13	induced 349:2	302:22 303:18	284:21
313:5 315:20	inducing 192:9	304:15,15 306:12	institution 41:13
318:23 334:14,25	211:9 229:8 257:5	311:18 320:13	47:3 109:3 350:16
335:13,21 349:19	induction 256:22	321:16 341:5	institutional 58:8
350:15	industry 127:24	342:8 345:20,21	58:23 69:20
individual's 49:17	145:11	346:24	106:12 263:18
individually 46:18	ineffective 327:18	informed 145:24	337:2
individuals 12:8	347:7	146:16 147:6,15	institutionalized
12:13,18 13:8,21	infant 349:9	147:22 148:20	60:6
14:11 41:18 42:16	infant's 349:9	149:4,9 151:2,7	institutions 68:24
43:8 47:8 48:10	infection 350:9	152:2 227:12	insufficient
48:19 49:10 54:23	infer 170:2	268:4	317:13
59:14 72:15 87:6	inferior 169:6	informing 145:14	insurance 38:13
89:14,24 90:23	inferiority 168:14	152:9	38:19
92:4,19,25 93:15	infertility 218:9	inherent 61:9	intact 334:15
94:21 95:6,17	influence 92:22	123:12 161:21	integrate 204:3
96:5 97:7,15,16	160:15 188:2	230:14 278:25	integrated 196:4
130:18 131:17	189:14 197:5	inherently 198:9	197:12
133:10 134:14	209:10 244:17	230:3 258:7	integrity 229:8
135:5,8,20 137:9	255:8 260:10	331:18	265:19 278:12
137:11 148:13	272:3,9 273:3	initial 73:10	intellectual 226:22
166:18 167:20	298:13 302:8	176:16 349:19	intend 22:6 29:18
168:7 173:22	309:13 331:11	initially 80:5	intended 26:9
176:18 196:25	348:11	88:20 241:7	125:14 212:23
218:2 219:21	influenced 164:11	340:19	340:18
221:6 239:6,14	220:23 283:21	initiating 316:12	intent 183:11
241:5,15 256:20	influences 133:15	initiation 215:24	200:10 255:6
258:22 259:6	209:2 271:19	344:17	313:18
285:10 291:20,22	inform 16:21	injunction 16:6	intention 254:11
294:21,24 295:15	207:17 246:24	innate 177:10	intentionally
296:7 302:23	information 22:9	195:21	124:11,15 125:20
304:22 309:15	22:11 26:15 81:19		126:14 218:18
	1	<u> </u>	<u> </u>

[interact - judge] Page 32

interact 293:23,23	214:18 217:11	invalid 61:6	issue 295:2,4,5
	242:11 248:18	invasive 196:11	298:9
interacting 287:5 294:12			issued 305:5
	252:21 254:5	investigate 51:6	
interaction 236:13	257:24 258:2	59:10 110:16	issues 32:5 33:20
237:23,24 293:18	270:14 271:6,11	investigated 93:8	33:25 41:11,15
interactions	272:8,25 288:15	146:10	45:2 46:23 47:13
236:18 270:3	302:14 309:8	investigating	47:23 66:25 73:14
285:22 295:7,13	311:24 313:21,22	332:20	75:21 87:9 105:24
295:21 297:9,25	315:5 318:4,11	investigation	163:8,10 182:21
298:13 326:7	319:7 322:5,12,21	51:11 54:5 64:7	184:3 186:9
interacts 297:19	324:13 331:15	95:22 96:22	216:13 226:20,23
interest 314:9	338:4 340:16	192:19 195:2	231:15
interested 6:10	341:14 342:12	249:11 310:3	j
352:21	343:8 344:24	316:22,22 320:17	january 299:14
interesting 112:6	345:18,25 346:20	320:20 325:2	jazz 185:4,7 199:8
interests 310:24	347:25	328:4 329:4 330:7	200:23 201:21,24
312:17 313:9	interventions 42:7	337:8	jm 1:9 5:21
314:20	85:25 94:12,18	investigational	joanna 1:7
internal 126:10	95:13 114:2	54:10	job 30:6 110:16
internet 73:18	119:16 138:10	investigations	112:24
178:21 181:8	168:5 169:22	63:6 279:24	john 244:9,21,22
285:17 308:4	171:17 172:18	investigative	246:20,23
interpret 112:21	173:20 174:6	335:4	joined 7:6
287:7 313:15	175:12 206:8	invited 82:16,19	joining 275:14
interrupt 190:11	221:24 240:9,13	involved 14:7	jones 7:12
259:8	256:6 258:17	15:15 29:10 36:19	jordan 7:12
intervene 160:15	259:9 261:15	37:3,16 46:11,21	journal 24:11
341:18 350:11	268:2 300:22	48:6 50:22 62:25	29:25 76:10,19,24
intervenes 217:24	314:19 315:7	65:15 69:13 72:19	76:25 77:3,5
intervention 42:20	317:15 320:9	126:22 135:3	80:23 81:15,21
58:16,19 72:9	323:23 324:2,17	171:5 275:21	83:2,10 88:6,11
85:16,23 92:5	326:2 327:3 328:7	276:4 303:12	103:5,6,7,8
97:20,24 109:14	331:22 333:2,18	involvement 31:22	225:14 226:17
125:15 131:23	336:14 339:20,24	33:6 203:20	227:17,22,25
147:21 151:4	346:9 347:14	involves 167:8	228:22 231:25
157:15 166:19	348:16,19 349:8	176:22 256:25	232:7
168:12,24 169:4	intrinsic 265:11	irb 54:11 147:11	journals 24:10
172:10,13 173:4	intrinsically 15:4	irreversible	29:8 76:6 86:24
178:4 183:12	introduced 53:11	290:24 331:20	87:20
192:6 206:20	80:3,19 198:11	isolated 132:22	judge 282:11,16
209:4,18 213:18	221:23,24		Juuge 202.11,10

[judgment - land] Page 33

	I	T	
judgment 37:22	165:3 167:13,19	104:17 116:18	91:5 92:10 93:4
40:14 128:11	170:16,24 182:19	129:3 131:25	94:9 95:9,21
july 75:15	188:3,12 189:24	132:7 138:4	97:10 101:3 103:9
jump 101:14	190:4,24 191:9,13	141:25 142:9,24	103:24 104:14
june 275:8 355:3	195:18 196:8,20	143:20,21 144:2,6	105:18 106:21
justified 40:17	198:8 199:12,15	150:22,25 152:13	107:23 108:21
44:4	200:8,9 204:7	157:23,24 187:16	109:23 110:22
justify 154:13	208:19 209:6	187:17 256:7	111:21 112:12
176:14 258:12	210:15,15 211:9	278:12 306:8	113:10,19 115:15
k	211:23 219:12	333:4 338:18	115:24 118:4,25
kadel 35:14	221:12 222:4	349:3	120:6,21 122:21
karasic 321:3	225:17 231:12	known 85:24	124:7,17 125:24
karolinska 106:24	232:2,4 242:6,21	93:12 188:18	126:16 127:10
keep 13:22 23:11	251:25 253:2	224:7,8	130:14 132:18
_	259:20 263:4	1	133:8 134:3,11
84:13,14,15 keira 149:22	270:3 271:18,22	label 141:16	136:2 137:16,25
ken 162:8,18	273:24 278:19		138:16 139:4,25
169:15 170:5	279:17 282:8	337:10,14,17 338:9	140:15,21 142:4
185:20	283:6,18 285:25	labeled 201:25	142:12 143:5,15
kenosha 35:25	287:2,5,6,24	laboratory 287:7	143:25 146:18
	288:10 294:2,19	lack 127:3,3 132:7	147:7,17 148:2,18
ketogenesis 65:16 kids 181:10	294:23 297:19,20	151:2 242:2,3	151:10 152:5,17
kind 25:19 339:6	298:3,15,23 299:3	261:21 267:19	155:11 156:22
	303:14,21,25	303:25 304:24	157:8,21 158:10
kingdom 36:15 237:14	305:3 306:7,8,22	315:16 329:19	159:2 162:20
knew 320:24	309:16 311:5	331:19 343:5	163:25 164:9
know 8:21 9:16	312:7 316:25	lacking 60:18	167:25 171:13
10:14 16:22 26:3	317:17 319:6,16	land 4:16 7:13,13	172:5 174:7 179:7
26:5 41:14 80:9	320:20 321:13,19	14:21 17:23 18:22	179:15 180:2
81:7 82:5 83:6	321:22 322:9,24	19:4,8,13,20	182:5 183:5,18
84:23 90:15,17,18	322:24 323:3	25:21 26:21 32:18	185:10 190:20
98:9 101:4 112:3	325:5 327:13	37:18 39:21 40:21	191:25 193:4
	328:21 332:16		194:15 198:2
114:19 115:3	335:5,15 339:22	41:8,22 43:4	199:10 200:24
124:8,9 125:6	342:20 343:2	44:16 45:11 47:16	202:8,21 203:11
126:7 127:12	344:5 348:9	48:14 53:8,18	204:17 205:2,11
129:8,11 132:8	knowing 167:16	54:19 55:14 56:9	207:25 210:8
135:10 136:24	169:2 269:8	56:13,24 60:11	211:5 212:2 219:5
140:6,9,14,17,24	knowledge 27:11	62:19 64:2 66:13	219:18 220:11
141:10 146:8	58:17 75:2 82:7	73:17 74:2 77:4	228:5,15 233:10
150:7,8 158:21	82:23 101:19	83:4 87:11,24	234:7,23 235:10
160:9 164:19		88:25 90:4,13	·

[land - linacre] Page 34

	I	I	I
236:3,25 242:5	launching 64:24	led 50:23 163:3,18	171:18 190:6
244:24 246:17	law 8:2 11:12,15	197:3 241:12	204:4 216:25
247:2 248:4,15	37:15 53:10,15	322:10	217:4,6 226:21
249:8 251:3	54:15 55:23 56:17	left 150:2	235:19 236:17
252:16,24 253:21	108:17 109:20	legal 2:6 4:22	264:2 291:16
255:18 258:4	110:19 111:17	55:15,19 105:23	317:8 350:3 351:2
261:25 262:15	112:10 206:8	106:5 355:23	lifelong 175:12
263:24 264:15,23	268:10	legislation 12:23	193:20 211:10
265:8 266:17	law.com 4:8	12:23 53:6 55:8	218:9 256:19
268:14 270:7,19	lawrence 79:9	55:11 57:9 105:24	257:5
271:13 272:19	80:14	108:25 109:7	lifetime 94:20
276:11,23 278:15	laws 105:13,14	113:6 311:25	243:9 254:2
280:10 281:12	lawsuit 53:3	313:19 317:10	256:25 300:20
282:6,24 284:7	lawyer 112:16	legislative 112:25	342:3
286:21 289:9,11	lawyers 112:20	269:19	light 104:11,12
289:25 294:16	lcooper 3:18	legislator 268:20	110:2 111:10
296:8 297:16	lead 90:8 124:24	legislature 12:5,11	132:14 206:21
298:21 301:4	125:10 132:25	12:15	likelihood 186:20
302:5 304:10	183:12 221:4	legitimate 115:14	250:13 257:4
305:9 309:3 311:4	224:22,23 239:24	length 93:18	348:11
312:19 313:10	249:12,20 264:7	240:23 309:7	limitation 27:21
314:11 315:2	272:7 285:6	lengthy 62:8,9	256:15
317:19 327:6	287:21 343:22	289:13	limitations 23:7
329:10 330:24	350:8	leslie 1:10 3:17	63:3 94:25 97:13
332:14 334:16	leaders 108:10	5:17 6:24 355:4	100:10 119:21
335:3 336:16	leading 16:12 91:4	356:1 357:1	125:8 128:10
337:6,11 338:12	175:11 177:23	letter 130:23	130:21 135:14,23
339:11 343:18	223:20 224:22	level 70:2 204:2	136:9 145:15,25
346:3 347:21	269:9 303:24	210:21 230:14	146:9,16 147:16
349:11 351:7,15	leads 90:12 223:22	247:16 321:23	149:5 150:24
355:1	235:18 240:8	levels 118:15	154:25 157:24
language 14:14,18	246:4 257:21	134:18 223:25,25	187:3 241:24
124:20 154:3	278:3 286:12	230:9 232:5 316:3	260:18 313:21
155:17 290:6	345:21	liberties 3:12	327:10,24 328:20
305:24 306:23	leaning 169:5	license 2:8,10	329:16
languages 106:2	learned 265:2	352:25	limited 68:3 71:16
laptop 17:25 74:4	291:8	licensed 31:21	128:25 208:9
large 68:23	learning 66:21	32:5,11	261:16
larger 340:20	leave 268:21	lie 122:11	limits 256:8,12,14
latest 29:5	lectures 70:21	life 48:25 96:20	linacre 75:7 76:9
		128:3 169:18	76:14,17 81:4
		1014	

[line - m.d.] Page 35

line 95:25 205:15	llp 3:4	294:20 298:17	lower 105:6 210:3
245:24 298:6	located 36:3	300:13 316:14	346:17
307:11 356:4,7,10	location 5:22	318:10 319:10	lowest 321:23
356:13,16,19	35:11	328:14 330:16,17	lunch 158:5,8,22
linking 329:24	locked 98:8	looked 239:17	159:6
links 308:3	locking 98:9	243:13	lung 269:9
list 23:14 24:8	long 10:10 16:14	looking 27:20	lying 124:5
listed 34:18	30:12 104:16	74:24 78:4 91:7	m
144:16 274:24	113:25 138:19	136:13 193:19	m 3:9 352:2,24
303:11 309:9	161:22 174:5	198:8 238:21	m.d. 1:17 2:4 7:25
listen 131:24	190:2 193:11,15	245:14 248:8	8:1 9:1 10:1 11:1
listened 72:22	193:22 213:5	270:21 277:9	12:1 13:1 14:1
literature 17:8	214:20 216:5	279:17 323:4	15:1 16:1 17:1
26:13 29:11,13	217:7,10,17 233:4	328:12 330:14	18:1 19:1 20:1
36:23 37:8 51:12	241:4,21 261:21	348:10	21:1 22:1 23:1
63:2 67:8,19 68:3	266:25 267:3,4	looks 20:25 79:12	24:1 25:1 26:1
92:8 95:2 97:12	272:4 279:10	196:13 198:6	27:1 28:1 29:1
100:16 104:2	280:2 323:9	286:11 309:20	30:1 31:1 32:1
105:22 123:17,19	331:10 332:5	318:24 327:19	33:1 34:1 35:1
123:22 126:20	333:7 343:6	lose 119:17	36:1 37:1 38:1
129:4 130:20,25	347:13	loss 346:11	39:1 40:1 41:1
135:4,15 136:8	longer 56:20	lost 205:15 323:16	42:1 43:1 44:1
140:3 155:2 162:9	97:20 172:24	lot 143:8	45:1 46:1 47:1
178:20 184:12	173:5 216:17	lots 161:13	48:1 49:1 50:1
203:2 213:9	longest 76:18	loud 9:6	51:1 52:1 53:1
238:20 241:25	longitudinal	louis 49:25 50:3,9	54:1 55:1 56:1
266:21 311:10	323:14	50:12,15 56:19	57:1 58:1 59:1
318:14 327:20	longstanding	66:5	60:1 61:1 62:1
328:11 343:25	325:10	love 179:4,9,23	63:1 64:1 65:1,10
litigants 38:8	look 19:21 20:20	180:4	65:21 66:1 67:1
litigation 36:25	21:7 51:25 59:19	low 104:2,22	68:1 69:1 70:1
165:9 166:15	61:9 73:22,24	105:6 108:2	71:1 72:1 73:1
176:21 303:4	78:21 134:25	206:13,13,16	74:1 75:1 76:1
little 4:6,15 5:25	176:11 182:8	207:6,14,18,23	77:1 78:1 79:1
63:15 93:6 190:12	184:12 189:9	208:20 209:5,11	80:1 81:1 82:1
205:14 314:4	193:7,18 194:13	210:6,14 211:4,13	83:1 84:1 85:1
339:13	208:4,11 236:8,13	211:25 212:7,12	86:1 87:1 88:1
live 48:3 154:17	251:13 255:4	217:3 311:20	89:1 90:1 91:1
291:16	257:9 262:19	330:8 333:14	92:1 93:1 94:1
lives 48:3 305:20	267:7 270:23	335:24	95:1 96:1 97:1
	271:17 273:8,11		98:1 99:1 100:1
			70.1 77.1 100.1

[m.d. - marked] Page 36

101:1 102:1 103:1	224:1 225:1 226:1	347:1 348:1 349:1	319:12
104:1 105:1 106:1	227:1 228:1 229:1	350:1 351:1 352:6	man 298:19
107:1 108:1 109:1	230:1 231:1 232:1	353:2 355:5 356:2	management
110:1 111:1 112:1	233:1 234:1 235:1	356:24 357:2,4,12	159:21,25 160:8
113:1 114:1 115:1	236:1 237:1 238:1	magisterium	160:25 166:23
116:1 117:1 118:1	239:1 240:1 241:1	227:10 228:3,14	manipulated
119:1 120:1 121:1	242:1 243:1 244:1	magnitude 156:24	153:15 155:21
122:1 123:1 124:1	245:1 246:1 247:1	maintain 279:16	156:11 157:18
125:1 126:1 127:1	248:1 249:1 250:1	295:24	manipulating
128:1 129:1 130:1	251:1 252:1 253:1	maintaining	156:20
131:1 132:1 133:1	254:1 255:1 256:1	294:23	manipulation
134:1 135:1 136:1	257:1 258:1 259:1	maintains 235:5	256:9,12 257:20
137:1 138:1 139:1	260:1 261:1 262:1	maintenance	258:3,6
140:1 141:1 142:1	263:1 264:1 265:1	66:20	manipulative
143:1 144:1 145:1	266:1 267:1 268:1	major 63:2 65:9	154:21
146:1 147:1 148:1	269:1 270:1 271:1	84:25 97:13	manner 48:4
149:1 150:1 151:1	272:1 273:1 274:1	146:22	58:12 59:18 126:2
152:1 153:1 154:1	275:1 276:1 277:1	majority 92:4	134:25 139:18
155:1 156:1 157:1	278:1 279:1 280:1	93:14 94:16	146:11 151:16
158:1 159:1 160:1	281:1 282:1 283:1	160:10 169:20	157:11 199:19
161:1 162:1 163:1	284:1 285:1 286:1	293:22 313:23	204:10 205:21
164:1 165:1 166:1	287:1 288:1 289:1	making 25:8	221:17 222:4
167:1 168:1 169:1	290:1 291:1 292:1	93:20 100:18	236:19 258:25
170:1 171:1 172:1	293:1 294:1 295:1	125:18 131:14	293:24 306:10
173:1 174:1 175:1	296:1 297:1 298:1	132:2 173:23	316:16 319:23
176:1 177:1 178:1	299:1 300:1 301:1	178:15 207:5	323:14 330:17
179:1 180:1 181:1	302:1 303:1 304:1	231:17 242:4	348:24
182:1 183:1 184:1	305:1 306:1 307:1	254:23 278:22	manners 155:10
185:1 186:1 187:1	308:1 309:1 310:1	286:12,23 287:2	manual 117:17
188:1 189:1 190:1	311:1 312:1 313:1	290:22	118:6
191:1 192:1 193:1	314:1 315:1 316:1	male 61:16 178:25	manuals 117:2
194:1 195:1 196:1	317:1 318:1 319:1	179:20 194:7	manuscript 28:15
197:1 198:1 199:1	320:1 321:1 322:1	223:14,17 224:20	71:2 72:25 253:9
200:1 201:1 202:1	323:1 324:1 325:1	236:14 237:16,23	manuscripts
203:1 204:1 205:1	326:1 327:1 328:1	244:12 245:9,12	75:23 87:12 88:16
206:1 207:1 208:1	329:1 330:1 331:1	245:16 246:15	mark 19:11,13
209:1 210:1 211:1	332:1 333:1 334:1	248:13 249:4,6	78:2,17 274:6
212:1 213:1 214:1	335:1 336:1 337:1	265:12	299:5
215:1 216:1 217:1	338:1 339:1 340:1	males 52:23 71:24	marked 18:9,12
218:1 219:1 220:1	341:1 342:1 343:1	188:23 237:25	19:17 21:13,16
221:1 222:1 223:1	344:1 345:1 346:1	287:9 315:24	77:18 78:24 83:12

83:18 84:11 98:7 64:23 91:16 125:7 42:7 46:4 51:11 71:5 86:4 106:8 109:6,16 110:11 228:24 274:9 143:11 151:20 65:11,17,19,20 115:14 142:6,20 129:10 307:19 115:14 142:6,20 17:7 83:2 84:19 145:9 168:19 145:22 169:13 143:12 16:23 113:12 16:23 113:12 16:23 143:12 16:23 143:14 15:25 143:14 15:25 143:14 15:25 143:14 15:25 143:14 15:25 143:14 15:25				_
228:24 274:9 143:11 151:20 65:11,17,19,20 115:14 142:6,20 299:10 307:19 155:20 156:12 77:7 83:2 84:19 145:9 168:19 markedly 133:14 178:8 198:21 85:2,16 97:25 193:12 206:17,18 154:23 211:11 212:21 224:16 103:5,7 105:3,21 207:4,21 232:17 217:5 350:8 228:2 229:18 109:2,14 111:25 248:6 253:3 marking 18:16 230:13 231:2 112:23 113:8 267:22 342:9 marquette 65:8 236:22 250:4 126:23 131:23 343:3,22 345:17 material 205:24 256:11 269:18 144:22 155:14 347:22 348:14,15 227:9 283:6 317:16 168:5 171:9 173:3 mecticines 338:15 matter 5:16 17:20 224:31 229:13 232:12 mecting 70:5 29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 matters 33:2 178:11,12 228:10 252:12,10,22 mellitus 31:6 matters 33:0 178:11,12 228:10 25:2:2 20:12 30:12,13 45:5 matterbws	83:18 84:11 98:7	64:23 91:16 125:7	42:7 46:4 51:11	71:5 86:4 106:8
299:10 307:19 155:20 156:12 77:7 83:2 84:19 145:9 168:19 markedly 133:14 178:8 198:21 85:2,16 97:25 193:12 206:17,18 154:23 211:11 212:21 224:16 103:5,7 105:3,21 207:4,21 232:17 217:5 350:8 228:2 229:18 109:2,14 111:25 248:6 253:3 marking 18:16 230:13 231:2 112:23 113:8 267:22 342:9 material 205:24 256:11 269:18 144:22 155:14 347:22 348:14,15 227:9 283:6 317:16 168:5 171:9 173:3 medicines 338:15 materials 203:15 319:13 342:17 173:19 192:6 mect 16:9 71:4 80:13 136:21 224:4 87:10 95:15 319:13 342:17 173:19 192:6 80:13 136:21 mect 16:9 71:4 80:13 136:21 mect 197:14 80:13 136:21 mect 16:9 71:4 80:13 136:21 mect 16:9 71:4 80:13 136:21 mect 16:9 71:4 80:13 136:21 mect 197:24 80:25 80:2 85:3 80:2 85:3 </td <td>159:10 225:17,22</td> <td>132:19 137:18</td> <td>55:17,24 60:8</td> <td>109:6,16 110:11</td>	159:10 225:17,22	132:19 137:18	55:17,24 60:8	109:6,16 110:11
markedly 133:14 178:8 198:21 85:2,16 97:25 193:12 206:17,18 154:23 211:11 212:21 224:16 103:5,7 105:3,21 207:4,21 232:17 217:5 350:8 228:2 229:18 109:2,14 111:25 248:6 253:3 marking 18:16 230:13 231:2 112:23 113:8 267:22 342:9 maturatial 205:24 256:11 269:18 144:22 155:14 343:3,23 23 345:17 227:9 283:6 317:16 168:5 171:9 173:3 medicines 338:15 matter 5:16 17:20 224:4 193:23 227:2 medicines 338:15 229:4 87:10 95:15 243:14 244:17 245:20 80:13 136:21 29:4 87:10 95:15 243:14 246:16 248:18 meetings 70:25 100:22 179:5,9,23 178:11,12 228:10 257:6 311:23 257:25 261:15 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 30:14,15 131:11 257:11 30:25 320:13 226:21 30:14,15 131:11 mattre with with with with with with with with	228:24 274:9	143:11 151:20	65:11,17,19,20	115:14 142:6,20
154:23 211:11	299:10 307:19	155:20 156:12	77:7 83:2 84:19	145:9 168:19
217:5 350:8	markedly 133:14	178:8 198:21	85:2,16 97:25	193:12 206:17,18
marking 18:16 230:13 231:2 112:23 113:8 267:22 342:9 marquette 65:8 236:22 250:4 126:23 131:23 343:3,22 345:17 material 205:24 256:11 269:18 144:22 155:14 347:22 348:14,15 227:9 283:6 317:16 168:5 171:9 173:3 medicines 338:15 matter 5:16 17:20 345:4 193:23 227:2 medicines 338:15 22:6,15 27:16 meaning 168:14 229:13 232:12 80:13 136:21 meeting 70:25 23:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 meeting 70:25 180:4 217:23 means 92:14 246:16 248:18 meeting 70:25 matters 38:20 178:11,12 228:10 255:2,10,22 mellitus 31:6 matterws 3:9 7.4 257:6 311:23 257:25 261:15 39:12,13 45:5 member 12:5 mature 48:25 meant 190:13 28:12 08:21 294:11 297:14 136:25 176:24 members 12:10,14 218:23 measures </td <td>154:23 211:11</td> <td>212:21 224:16</td> <td>103:5,7 105:3,21</td> <td>207:4,21 232:17</td>	154:23 211:11	212:21 224:16	103:5,7 105:3,21	207:4,21 232:17
marquette 65:8 236:22 250:4 126:23 131:23 343:3,22 345:17 material 205:24 256:11 269:18 144:22 155:14 347:22 348:14,15 materials 203:15 mater 5:16 17:20 345:4 173:19 192:6 meet 16:9 71:4 matter 5:16 17:20 345:4 193:23 227:2 80:13 136:21 29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 100:22 179:5,9,23 means 92:14 246:16 248:18 meeting 70:25 matters 38:20 178:11,12 228:10 257:6 311:23 257:6 311:23 257:25 261:15 meetings 72:17,24 matthews 3:9 7:4 257:6 311:23 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 30:14,15 131:11 257:11 200:13 285:20 287:21 17:2 134:22 maturety 191:21 241:4 308:24 311:8 274:20 276:15 maureen 1:25 2:7 6:6 352:2,24 216:6 339:8,24 342:25 339;	217:5 350:8	228:2 229:18	109:2,14 111:25	248:6 253:3
material 205:24 256:11 269:18 144:22 155:14 347:22 348:14,15 227:9 283:6 317:16 168:5 171:9 173:3 medicines 338:15 materials 203:15 319:13 342:17 173:19 192:6 meet 16:9 71:4 22:6,15 27:16 meaning 168:14 229:13 232:12 meeting 70:25 29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 100:22 179:5,9,23 means 92:14 246:16 248:18 meetings 72:17,24 180:4 217:23 160:20 164:19 251:2,10,22 mellitus 31:6 matthews 3:9 7:4 257:6 311:23 257:25 261:15 39:12,13 45:5 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 186:25 member 12:5 mature 48:25 meant 190:13 285:20 287:21 117:2 134:22 136:21 memory 99:7 maturity 191:21 341:4 308:24 311:8 32:23 337:15 menory 99:7 23:23 measures <t< td=""><td>marking 18:16</td><td>230:13 231:2</td><td>112:23 113:8</td><td>267:22 342:9</td></t<>	marking 18:16	230:13 231:2	112:23 113:8	267:22 342:9
227:9 283:6 317:16 168:5 171:9 173:3 medicines 338:15 materials 203:15 319:13 342:17 173:19 192:6 meet 16:9 71:4 22:6,15 27:16 meaning 168:14 229:13 232:12 meeting 70:25 29:4 87:10 95:15 243:14 244:17 245:20 80:28 5:3 180:4 217:23 means 92:14 246:16 248:18 meetings 72:17,24 180:4 217:23 160:20 164:19 251:2,10,22 melitus 31:6 matters 38:20 178:11,12 228:10 257:25 261:15 meetings 72:17,24 matthews 3:9 7:4 257:6 311:23 257:25 261:15 meetings 72:17,24 7:5 321:25 326:9 264:14 265:18 39:12,13 45:5 member 12:5 7:5 321:25 326:9 266:11,21 268:2 member 12:10,14 257:11 200:13 285:20 287:21 117:2 134:22 96:12 218:5 221:9 measure 318:5 38:14 308:24 311:8 274:20 276:15 maximize 54:7	marquette 65:8	236:22 250:4	126:23 131:23	343:3,22 345:17
materials 203:15 319:13 342:17 173:19 192:6 meet 16:9 71:4 matter 5:16 17:20 345:4 193:23 227:2 80:13 136:21 22:6,15 27:16 meaning 168:14 229:13 232:12 meeting 70:25 29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 100:22 179:5,9,23 means 92:14 244:17 245:20 meeting 70:25 180:4 217:23 160:20 164:19 246:16 248:18 meetings 72:17,24 matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:97:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 30:14,15 131:11 257:11 200:13 285:20 287:21 17:2 134:22 maturity 19:12 341:4 298:11,19 302:18 member 12:10,14 218:23 measured 215:11 measured 215:11 308:24 311:8 274:20 276:15 maximal <t< td=""><td>material 205:24</td><td>256:11 269:18</td><td>144:22 155:14</td><td>347:22 348:14,15</td></t<>	material 205:24	256:11 269:18	144:22 155:14	347:22 348:14,15
matter 5:16 17:20 345:4 meaning 168:14 to 22:6,15 27:16 and 22:6,15 27:16 to 29:4 87:10 95:15 to 243:14 to 29:4 87:10 95:15 to 243:14 to 29:4 87:10 95:15 to 243:14 to 244:17 245:20 to 246:16 248:18 to 244:17 245:20 to 246:16 248:18 to 25:12,10,22 to 25:14,19,22 to 25:12,10,22 to 25:12,10,2,2 to 25:12,10,22 to 25:12,10,2,2 to 25:12,10,22 to 25:12,10,2	227:9	283:6 317:16	168:5 171:9 173:3	medicines 338:15
22:6,15 27:16 meaning 168:14 229:13 232:12 meeting 70:25 29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 100:22 179:5,9,23 means 92:14 246:16 248:18 meetings 72:17,24 180:4 217:23 160:20 164:19 251:2,10,22 mellitus 31:6 matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 186:25 member 12:5 maturetion 96:10 200:13 284:14 285:9,15 members 12:10,14 96:12 218:5 221:9 measurable 61:18 294:11 297:14 136:5 176:24 136:5 176:24 maturity 191:21 341:4 308:24 311:8 274:20 276:15 menory 99:7 maximal 217:2 216:6 339:8,24 342:25 33:9,17,20 34:7 15:5 127:25 methins 51:3 12:3 86:8,14,19 124:19	materials 203:15	319:13 342:17	173:19 192:6	meet 16:9 71:4
29:4 87:10 95:15 243:14 244:17 245:20 80:2 85:3 100:22 179:5,9,23 means 92:14 246:16 248:18 meetings 72:17,24 180:4 217:23 160:20 164:19 251:2,10,22 mellitus 31:6 matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 matthewss 3:10 meant 190:13 266:11,21 268:2 members 12:10,14 257:11 200:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 298:11,19 302:18 members 12:10,14 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 maureen 1:25 2:7 measures 120:13 323:23 337:15 menarche 214:7 maximal 217:2 319:18 161:21 130:11 131:3 168:17 169:23 86:8,14,19 124:19 248:10 199:6 239:21 255:21 226:18 86:8,14,19 124:19 </td <td>matter 5:16 17:20</td> <td>345:4</td> <td>193:23 227:2</td> <td>80:13 136:21</td>	matter 5:16 17:20	345:4	193:23 227:2	80:13 136:21
100:22 179:5,9,23 means 92:14 246:16 248:18 meetings 72:17,24 180:4 217:23 160:20 164:19 251:2,10,22 mellitus 31:6 matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 186:25 maturation 96:10 meant 190:13 285:20 287:21 186:25 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measured 318:5 298:11,19 302:18 274:20 276:15 maturity 191:21 341:4 308:24 311:8 274:20 276:15 maximal 217:2 323:23 337:15 menarche 214:7 maximal 217:2 319:18 350:5 15:5 127:25 maximal 217:2 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 <td< td=""><td>22:6,15 27:16</td><td>meaning 168:14</td><td>229:13 232:12</td><td>meeting 70:25</td></td<>	22:6,15 27:16	meaning 168:14	229:13 232:12	meeting 70:25
180:4 217:23 160:20 164:19 251:2,10,22 mellitus 31:6 matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 matthewss 3:10 336:2 266:11,21 268:2 186:25 maturation 96:10 meant 190:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 members 12:10,14 218:23 measured 215:11 308:24 311:8 274:20 276:15 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 menarche 214:7 maximal 217:2 mesures 120:13 323:23 337:15 339:17,20 34:7 maximal 217:2 319:18 16:21 339:17,20 34:7 maximize 54:7 319:18 16:21 130:11 131:3 <td>29:4 87:10 95:15</td> <td>243:14</td> <td>244:17 245:20</td> <td>80:2 85:3</td>	29:4 87:10 95:15	243:14	244:17 245:20	80:2 85:3
matters 38:20 178:11,12 228:10 252:14,19,22 39:12,13 45:5 matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 matthewss 3:10 336:2 266:11,21 268:2 186:25 maturation 96:10 meant 190:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 memory 99:7 maturity 191:21 341:4 308:24 311:8 298:11,19 302:18 memory 99:7 matureen 1:25 2:7 measures 120:13 323:23 337:15 menarche 214:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 medically 247:24 199:6 239:21 253:6 259:4 125:7 154:6 medication 9:25 mention	100:22 179:5,9,23	means 92:14	246:16 248:18	
matthews 3:9 7:4 257:6 311:23 257:25 261:15 member 12:5 7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 matthewss 3:10 336:2 266:11,21 268:2 186:25 maturation 96:10 200:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 memory 99:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 menache 214:7 maximal 217:2 323:23 337:15 mental 32:4,17 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication	180:4 217:23	160:20 164:19	251:2,10,22	mellitus 31:6
7:5 321:25 326:9 264:14 265:18 30:14,15 131:11 matthewss 3:10 336:2 266:11,21 268:2 186:25 maturation 96:10 meant 190:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 memory 99:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 30:11 131:3 168:17 169:23 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medicalion 9:25<	matters 38:20	178:11,12 228:10	252:14,19,22	39:12,13 45:5
matthewss 3:10 336:2 266:11,21 268:2 186:25 maturation 96:10 meant 190:13 284:14 285:9,15 members 12:10,14 257:11 200:13 285:20 287:21 117:2 134:22 members 12:10,14 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 136:5 176:24 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 memory 99:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 menarche 214:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 169:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 metion 31:12 mayer 79:9 80:14 158:19 159:4,9 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5	matthews 3:9 7:4	257:6 311:23	257:25 261:15	member 12:5
maturation 96:10 meant 190:13 284:14 285:9,15 members 12:10,14 257:11 200:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 maureen 1:25 2:7 measures 120:13 323:23 337:15 menarche 214:7 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 mental 32:4,17 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 <td>7:5</td> <td>321:25 326:9</td> <td>264:14 265:18</td> <td>30:14,15 131:11</td>	7:5	321:25 326:9	264:14 265:18	30:14,15 131:11
257:11 200:13 285:20 287:21 117:2 134:22 mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 218:23 measured 215:11 312:16 320:9 menarche 214:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine	matthewss 3:10	336:2	266:11,21 268:2	186:25
mature 48:25 measurable 61:18 294:11 297:14 136:5 176:24 96:12 218:5 221:9 measure 318:5 308:24 311:8 274:20 276:15 18:23 measured 215:11 312:16 320:9 menarche 214:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 <t< td=""><td>maturation 96:10</td><td>meant 190:13</td><td>284:14 285:9,15</td><td>members 12:10,14</td></t<>	maturation 96:10	meant 190:13	284:14 285:9,15	members 12:10,14
96:12 218:5 221:9 measure 318:5 298:11,19 302:18 memory 99:7 maturity 191:21 341:4 308:24 311:8 274:20 276:15 maureen 1:25 2:7 measures 120:13 312:16 320:9 menarche 214:7 6:6 352:2,24 messures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 medica 5:13 12:3 medically 247:24 199:6 239:21 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean <th< td=""><td>257:11</td><td>200:13</td><td>285:20 287:21</td><td>117:2 134:22</td></th<>	257:11	200:13	285:20 287:21	117:2 134:22
maturity 191:21 341:4 308:24 311:8 274:20 276:15 218:23 measured 215:11 312:16 320:9 menarche 214:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 mention 31:12 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15	mature 48:25	measurable 61:18	294:11 297:14	136:5 176:24
218:23 measured 215:11 312:16 320:9 menarche 214:7 maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 <th< td=""><td>96:12 218:5 221:9</td><td>measure 318:5</td><td>298:11,19 302:18</td><td>memory 99:7</td></th<>	96:12 218:5 221:9	measure 318:5	298:11,19 302:18	memory 99:7
maureen 1:25 2:7 measures 120:13 323:23 337:15 mental 32:4,17 6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25	maturity 191:21			274:20 276:15
6:6 352:2,24 216:6 339:8,24 342:25 33:9,17,20 34:7 maximal 217:2 mechanism 350:5 115:5 127:25 346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25	218:23			
maximal217:2mechanism350:5115:5 127:25346:5222:12 225:2medicalized46:5128:4,11,17maximize54:7319:18161:21130:11 131:3168:17 169:23media5:13 12:3medically247:24199:6 239:21215:21 216:1886:8,14,19 124:19248:10321:8253:6 259:4125:7 154:6medication9:25mention31:12mayer79:9 80:14158:19 159:4,9214:9 221:1934:14 114:7mchugh79:9203:24 234:2239:17 338:9mentioned17:580:15238:7,12 243:5medications23:25 44:8 69:8md83:18 353:23305:13 310:15337:10 342:275:23 102:2mean16:4 19:14medical33:12,19medicine33:11106:15 129:12,25	maureen 1:25 2:7	measures 120:13	323:23 337:15	mental 32:4,17
346:5 222:12 225:2 medicalized 46:5 128:4,11,17 maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25	6:6 352:2,24	216:6	339:8,24 342:25	33:9,17,20 34:7
maximize 54:7 319:18 161:21 130:11 131:3 168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25	maximal 217:2			115:5 127:25
168:17 169:23 media 5:13 12:3 medically 247:24 199:6 239:21 215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25				
215:21 216:18 86:8,14,19 124:19 248:10 321:8 253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25	maximize 54:7			
253:6 259:4 125:7 154:6 medication 9:25 mention 31:12 mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25			_	
mayer 79:9 80:14 158:19 159:4,9 214:9 221:19 34:14 114:7 mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25		· '		
mchugh 79:9 203:24 234:2 239:17 338:9 mentioned 17:5 80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25				
80:15 238:7,12 243:5 medications 23:25 44:8 69:8 md 83:18 353:23 305:13 310:15 337:10 342:2 medicine 33:11 106:15 129:12,25		· · · · · · · · · · · · · · · · · · ·		
md 83:18 353:23 305:13 310:15 337:10 342:2 75:23 102:2 mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25				
mean 16:4 19:14 medical 33:12,19 medicine 33:11 106:15 129:12,25		· · · · · · · · · · · · · · · · · · ·		
25:13 27:19 52:21 33:21 34:4 40:25 49:24 50:5 59:9 153:8 159:20		· · · · · · · · · · · · · · · · · · ·		
	25:13 27:19 52:21	33:21 34:4 40:25	49:24 50:5 59:9	153:8 159:20

170:11 185:20	methods 157:13	minutes 16:17	moment 17:18
206:5 260:2 296:3	293:4 324:11	86:7 158:6,18,23	345:19 347:2
317:11 325:6	330:2	158:24 233:25	monitored 120:14
328:15 334:9	michael 4:18,22	307:9	months 26:7
344:20 345:12	7:19	mischaracterizat	mood 33:3
348:5	michael.cantrell	43:5 329:22	moral 226:20,22
mentor 70:17	4:19	mischaracterize	253:13
72:14	microphones 5:5	182:6	morally 234:17
mentors 72:20	middle 216:9	misinformed	253:18
merely 100:17	229:2	153:16	morbidities
130:22 173:23	midway 98:17	misinterpretation	229:13
245:14 247:16	103:14 121:20,23	151:19	morbidity 267:12
297:7 298:2 324:6	121:24	misinterpreted	326:15 341:25
merit 64:11	migraines 121:4	306:19	morning 5:1 6:20
249:18 250:12	migrate 17:24	misleading 125:21	8:7,8,9 50:24
merits 28:8 60:25	mike 6:3 307:6	126:14 127:6	mother 1:7
64:14 129:7	millions 250:20	133:18 152:21	motivation 288:13
232:20 260:25	mind 37:12	mission 227:16	306:9
270:11	244:14,15 250:25	missouri 53:12,14	motives 303:20
meriwether 274:8	251:9 274:21	54:16 56:3,17	mounting 340:7
274:13,17 275:16	275:3	57:10	move 65:3 102:17
354:3	mine 51:4	mitigated 326:12	108:7 127:17
message 184:19	mineral 216:23	mitigating 161:24	169:22 171:25
301:11	minimize 54:6	261:3	174:16 333:13
messages 203:24	169:24	mitigation 314:17	movement 176:16
met 263:16	minimizes 192:25	326:17	moving 121:19
metabolic 213:15	minimizing	mixed 222:24	172:8 217:4 246:5
222:22 346:13	168:18,23	modalities 166:9	332:11
metabolism 51:2	minimum 340:11	191:23	multidisciplinary
65:14	minor 212:5	modality 160:18	47:2,21 68:22
method 106:10	310:17,25 314:5	167:24 173:6	multifactorial
279:9 319:5	328:8	model 47:22 104:4	91:8 318:19
330:10	minority 136:25	169:15 186:7	multiple 60:22
methodologic	139:21	195:25 196:14	96:19 131:6,7
27:21 63:2 85:21	minors 107:4	311:12,20 329:17	148:5 230:9 232:5
100:10 321:18	260:23 305:6	329:17 343:10	241:9
methodologies	309:2 314:23	347:3	multitude 22:24
128:11	minute 18:6 71:6	models 192:23	260:13
methodology	86:10 153:12	modern 227:2	mute 5:8
64:20 70:16	238:4 338:22	259:23 324:22	mutually 263:7
	351:8		
128:11 methodology	86:10 153:12 238:4 338:22	modern 227:2	mute 5:8

[n - normally] Page 39

n	231:13 353:20	253:24 256:5	neutral 166:21
n	ncbq 226:21 227:4	270:10 273:25	172:12,24 234:18
n 3:1 4:1 353:1	227:8	276:18 284:15	244:2 270:13
name 6:3 8:11,16	necessarily 165:4	295:5 304:3 307:8	271:6,11 272:8,25
10:23 35:18	180:8 185:19	315:15 317:8	291:2 293:25
132:15 133:6,24	201:14 214:2	319:23 320:15	309:8 340:10
152:16 177:2	295:5 298:8	328:2 330:7 338:7	never 40:18 43:18
270:2 274:24	necessary 43:8	339:7 347:8	66:15 105:14
292:5 294:2	47:18 49:19 59:10	359.7 547.8	263:25
names 135:19	62:10 141:12,21	needed 16:22	nevertheless
152:20	149:13 170:24	103:22 113:17	
narrow 63:14		195:11 204:9	172:17 256:3,4 332:2
natal 58:24 88:24	180:11,20 254:22 295:2 302:13	316:20 325:18	
161:11,12			new 3:6,6,14,14 22:10 75:9 78:23
national 70:25	329:17 338:11,13	349:20	
72:24 78:13 84:6	348:21 357:6	needing 46:5 needs 41:17 46:4	79:6,8 80:22 82:5
85:2 103:2 225:12	necessitate 59:14		82:25 105:3 106:8
225:19 226:8,15	194:22 350:6	61:9,19 63:10,15	109:4 116:22
226:17 284:21	necessitated 51:6	66:22 86:2 105:3	117:22 172:15
353:24	204:13	107:5,18 108:16	235:19 236:16
natural 57:24	necessitates 107:3	113:14 199:3	308:7 353:17
113:23 160:16	284:17	210:15 239:21	newborn 350:19
172:20 187:18	necessity 22:12	246:11 247:8	news 308:2
272:9 279:9	need 10:10,13	249:21,22 250:4	nicholas 274:8
328:12 350:21	28:4 29:2 43:13	255:19 271:6	354:3
nature 14:2 15:2	46:10 47:24 54:4	276:25 288:3,9,10	nih 64:11,12 69:7
90:21 150:9	54:23 58:6 62:11	329:18 331:6,8	69:17 70:2 250:18
151:13 225:3	62:16,21 63:7	332:6 333:10	non 82:12 115:23
229:7,19 232:14	64:3 86:7 99:6	339:15,17,18	134:25,25 168:14
233:9,21 234:6,22	103:11 104:5	343:22 345:10	179:10 235:8,15
235:14 236:2,24	105:5 107:11	negative 97:22	250:2 324:15
237:4,21 243:19	108:11 109:6	240:20	nonscientific
245:8 254:11	111:3,8,10 112:5	neither 241:13	263:12
255:5 281:20	113:5,12,21 118:8	352:16,19	normal 33:21
284:18 287:14	148:19 158:18	nervosa 119:10	88:17 109:3
288:7 293:17	168:13 170:19	net 224:21 287:19	195:21 214:18
294:8 299:25	180:9 186:10	303:22	215:20,23 220:20
318:22	192:18 200:18	network 68:24	221:11 222:11
navigate 215:9	210:15 233:25	networks 178:13	271:4 287:8 315:8
336:3	239:18 247:25	neurological	normally 60:17,20
ncbc 75:7 83:15	248:6,11 249:4	224:23	61:8 105:2 167:13
103:4 226:13	251:14,16,17		212:25 213:20,21
103.7 220.13			

[normally - office] Page 40

217:19	111:21 112:12	198:2 199:10	330:17
north 35:15 38:11	113:10,19 115:15	200:24 202:8,21	objectively 61:19
notary 2:10	115:24 118:4,25	203:11 204:17	114:9,18 119:11
357:13,19	120:21 124:17	205:2,11 207:25	126:7 134:24
note 5:5 355:10	130:14 132:18	210:8 211:5 212:2	255:4
noted 108:10	134:11 137:25	219:5,18 220:11	observation 157:4
357:7	138:16 139:4	233:10 234:23	168:16 172:21
notice 2:7	140:15,21 146:18	235:10 236:3,25	246:6 297:3
noticing 6:19	148:2,18 151:10	251:3 262:15	322:10,15,18
null 61:11 250:14	152:5 155:11	263:24 264:15,23	324:6,8
number 12:7 23:5	156:22 157:21	265:8 266:17	observe 322:18
23:25 24:5 26:12	162:20 163:25	268:14 270:19	observed 281:19
34:23 68:3 72:14	164:9 167:25	271:13 272:19	observer 303:8
80:4 84:23,24	190:20 191:25	276:11 278:15	observing 63:24
92:14 98:3 129:19	228:5,15 234:7	280:10 281:12	obtain 125:2,22
140:6,10,12 157:3	242:5 244:24	282:6,24 284:7	191:14 274:2
157:6 187:22	246:17 247:2	286:21 289:9,11	obvious 236:15
201:18 216:4	248:4,15 249:8	289:25 294:16	obviously 158:5
218:15 275:21	252:16,24 253:21	296:8 297:16	occasions 338:14
295:15 323:16	255:18 258:4	298:21 301:4	occur 53:24 55:9
331:13 334:5	261:25 270:7	302:5 304:10	72:8 96:14,16
numbers 92:11	280:10 309:3	305:9 312:19	173:14 174:3
numerous 12:17	311:4 313:10	317:19 327:6	221:15 235:7,17
12:18 13:20,21	314:11 315:2	329:10 330:24	264:5,17 287:10
57:22	334:16	332:14 335:3	occurred 48:22
0	objection 25:21	336:16 337:6,11	67:2 132:24
object 14:21 26:21	41:22 47:16 53:18	338:12 339:11	204:12 328:19
32:18 37:18 39:21	94:9 95:9,21	343:18 346:3	occurring 28:6
40:21 41:8 43:4	120:6 122:21	347:21 349:11	221:25 224:25
44:16 45:11 48:14	124:7 125:24	objections 6:12	occurs 96:14
53:8 54:19 55:14	126:16 127:10	62:6 266:23	169:17 184:18
56:9,13,24 60:11	133:8 134:3 136:2	objective 28:7	217:21 236:12
62:19 64:2 66:13	137:16 139:25	100:14 119:24	269:11 291:12
77:4 83:4 87:11	142:4,12 143:5,15	120:13,24 123:2	318:21
87:24 88:25 90:4	143:25 147:7,17	125:12 127:3,3	offer 128:6 257:6
90:13 91:5 92:10	152:17 157:8	133:2 136:24	257:8
93:4 97:10 101:3	171:13 172:5	157:9 198:24	offered 38:23
103:9,24 104:14	174:7 179:7,15	239:22 246:18	243:11,12
105:18 106:21	180:2 182:5 183:5	271:20 273:12	office 4:13 5:24
107:23 108:21	183:18 185:10	279:17 281:2	7:15,22 126:6
109:23 110:22	193:4 194:15	286:13 303:8	

001	1 22 2 00 10	240 5 250 12	
officer 8:3	one's 32:3 90:10	240:7 279:13	osteoporosis 217:6
official 226:16	94:20 96:19	284:20 308:25	outcome 6:11 49:8
oftentimes 141:5	123:23,24 133:15	309:4 322:7	58:16 61:17 92:22
216:19	176:24 190:6	opinions 14:25	152:11 160:16
oh 73:19	233:7 285:4	22:5,10,15,22	161:24 163:19,21
okay 9:3,8,20,22	ones 34:21 36:12	24:13,15,17 27:7	168:6,15,20
9:24 10:17,22	76:8 87:14 134:20	27:10 246:16	173:24 174:2
17:13 19:10 21:5	134:21 137:2,3	255:7 271:22	180:6 183:12
21:12 24:21 30:4	155:13 252:2	opportunity 20:18	184:21 190:2
65:3 74:10,11	318:2	24:7 81:22 217:2	193:20 196:11
77:8,24 79:2,3	ongoing 17:11	312:2 313:24	199:23,25 200:4
82:22 83:11,20	28:24 66:20,21	316:21 328:24	200:12 209:18
84:15 87:16 88:22	104:6 160:13	329:3 335:18	216:6 222:5
99:15 101:10,21	186:21	oppose 53:3	242:11,12 271:19
101:23,25 102:16	online 181:18	112:10	318:5 319:8
102:23 113:7	onset 93:3 95:8,19	opposed 111:17	320:21,24 322:18
114:4 122:5	97:8 141:6 259:21	198:24 271:8	322:20 324:13
127:18 140:22	326:8	opposite 98:22	340:16 341:4
143:19 145:4	open 21:13 73:8	300:21 305:22	348:2
158:12,13 159:3	77:9 102:17,19	optimal 316:23	outcomes 59:19
161:6 168:2	225:7,17 227:11	option 308:17	63:24,25 138:19
185:20 202:10	opened 19:17	346:4	168:16 215:11
225:16 234:3,4	opening 77:25	options 46:14	239:7 241:21
244:7 250:23	openly 244:14	47:15 186:4	260:10 267:2
252:8 255:14,25	operate 248:6	oral 1:15 222:7,18	322:5 323:18
266:11 274:15,23	273:9 280:25	224:11	outline 258:11
275:12 277:21	operating 170:16	order 62:20 63:9	outlined 62:5
281:13 285:18	operations 153:18	125:21 199:2	outright 60:23
299:5 300:11,15	opine 112:3	312:15 339:9	88:14
307:10 310:16	136:17 151:17	organization	outset 331:23
338:20 339:12	205:5 208:3	226:18	outside 108:6
351:18	320:14 330:8	organizational	137:13 294:10
old 165:14 179:19	opined 15:13	25:7	297:14 298:19
182:2 189:6	312:20	organs 236:10,19	301:6
194:10,17 216:9	opining 112:17	orientation 205:19	ovarian 223:4
older 299:17	228:16	oriented 304:22	ovary 222:12
once 94:6 169:18	opinion 14:2,13	original 15:25	overall 103:13
169:20 170:6	43:6 54:21 60:13	176:12 241:2	113:25 191:5
191:7 239:8	90:11 118:22	osteopenia 211:10	272:3 345:5
240:13 293:6	120:3 152:24	346:12	overestimate
	180:24 181:4		128:6

[overly - patients] Page 42

overly 100.12	239:16 241:8	200.16 202.7 0 21	pass 53:14 54:16
overly 199:13 oversee 51:18		200:16 203:7,9,21 204:15 285:23	351:6
	242:15 243:3,8,14		
oversight 58:22	244:4 344:19,21	302:11,24 303:5	passage 238:13
70:19 72:16,21	papers 17:9 27:19	303:17 304:16	passed 56:17 57:9
263:18	67:19 68:9 76:10	310:5	path 53:23 239:5
overstatement	76:17 82:8,20	part 33:21 49:12	pathologic 213:21
54:21	86:22,23 87:2,5,8	49:18 52:13 68:21	pathophysiologic
overweight 119:13	87:20 88:2,18	68:23 75:5 86:14	319:17
owen 4:4	93:23 94:15 99:24	86:19 88:16 159:4	pathway 186:16
owens 7:9	100:11,12,18	159:9 195:20	patient 31:5 39:3
p	135:12,13 136:15	197:24 229:4	39:11 40:4,19
p 3:1,1 4:1,1	154:7 344:14	238:7,12 310:10	42:9 44:13 46:4,7
p.m. 159:8 238:8	par 345:16	310:15 324:25	46:14 50:12 55:5
238:11 310:11,14	paradigm 103:14	participate 41:24	63:12 114:22
338:25 339:4	108:2 138:6	43:21 47:3 79:18	119:11,17 122:9
351:10,13,20,22	187:19 188:14	79:25 198:15	123:4 126:8
pa 4:4	189:11 191:3	participated 40:9	137:19 139:10
pace 227:2	254:15 349:24	303:4	143:13 156:2
page 9:3 18:21	paradigms 259:15	participates	161:10 163:22
20:9 21:3 73:12	270:10 329:15,21	350:17	166:25 169:8,9
74:8 78:4 98:13	paragraph 36:3	participation	170:17 189:4,9
101:12,21,22,23	98:14,16 101:13	176:23 237:17	191:2 194:4,6
102:25 121:19,23	102:8 121:14,17	311:9	196:16 197:6
127:19,20 145:5	121:18 122:23	particular 26:4	210:14 241:21
153:6 159:12	127:19 145:5	33:2 98:15,17	243:11 251:12
174:25 175:3,5	153:6,9 159:12	125:3 154:17	257:2 260:8 286:6
244:4,5 252:6	174:25 227:20	164:19 190:6	286:18 287:5
275:9 276:21	228:19 258:10	194:13 209:6,16	288:4,19,20 289:5
277:17,22,23,24	277:25 278:2	230:19 231:23	289:10,23 290:4,8
300:14 356:4,7,10	300:13	254:6 256:20	290:12 293:17
356:13,16,19	parent 147:4,8	257:23 282:11	296:20 312:14
pages 101:15	150:7,14 152:7	295:12 296:23	315:11 319:2
pain 121:9	157:17 179:8	319:8 340:5	332:5 333:20
pains 78:24 79:6	202:19 294:3	342:12 343:24	338:4 341:22
98:7,12 353:18	301:25 302:17	particularly 192:7	patient's 33:4
paper 75:8 76:22	parent's 302:8	318:2	114:15 119:3,7
81:24 88:13 99:16	parents 148:7	parties 5:12	120:4 253:20
99:18 172:15	150:2,8 153:14	352:18	285:21 290:10
175:24 226:12	163:6 176:23	parts 245:17,17	patients 30:25
227:23 230:20	180:8,11,20	party 6:8	31:2,13,14 39:16
	182:24 184:5		40:23 41:6,13,20
231:24 238:21			

[patients - pediatric]

Page	43

_			_
44:21 45:10 46:24	27:1 28:1 29:1	149:1 150:1 151:1	269:1 270:1 271:1
47:4,9,11,20	30:1 31:1 32:1	152:1 153:1 154:1	272:1 273:1 274:1
49:14 52:10 53:16	33:1 34:1 35:1	155:1 156:1 157:1	275:1 276:1 277:1
53:17 54:17 56:5	36:1 37:1 38:1	158:1 159:1 160:1	278:1 279:1 280:1
56:18 58:3 72:5	39:1 40:1 41:1	161:1 162:1 163:1	281:1 282:1 283:1
106:17 110:13	42:1 43:1 44:1	164:1 165:1 166:1	284:1 285:1 286:1
115:4,5,9,19,21	45:1 46:1 47:1	167:1 168:1 169:1	287:1 288:1 289:1
118:23 123:15	48:1 49:1 50:1	170:1 171:1 172:1	290:1 291:1 292:1
124:5,15 125:11	51:1 52:1 53:1	173:1 174:1 175:1	293:1 294:1 295:1
126:3,6,22 130:24	54:1 55:1 56:1	176:1 177:1 178:1	296:1 297:1 298:1
137:2,15 139:22	57:1 58:1 59:1	179:1 180:1 181:1	299:1 300:1 301:1
140:18 142:2,10	60:1 61:1 62:1	182:1 183:1 184:1	302:1 303:1 304:1
143:2,22 145:23	63:1 64:1 65:1	185:1 186:1 187:1	305:1 306:1 307:1
155:19 156:20	66:1 67:1 68:1	188:1 189:1 190:1	308:1 309:1 310:1
164:25 165:19,20	69:1 70:1 71:1	191:1 192:1 193:1	311:1 312:1 313:1
165:22 168:22	72:1 73:1 74:1	194:1 195:1 196:1	314:1 315:1 316:1
170:6 173:25	75:1 76:1 77:1,17	197:1 198:1 199:1	317:1 318:1 319:1
187:22,24 202:12	78:1 79:1,9 80:1	200:1 201:1 202:1	320:1 321:1 322:1
207:17 210:12,20	80:14 81:1 82:1	203:1 204:1 205:1	323:1 324:1 325:1
210:25 211:21	83:1,17 84:1 85:1	206:1 207:1 208:1	326:1 327:1 328:1
216:5,9,16,19	86:1 87:1 88:1	209:1 210:1 211:1	329:1 330:1 331:1
240:2 242:4	89:1 90:1 91:1	212:1 213:1 214:1	332:1 333:1 334:1
256:22 260:4,10	92:1 93:1 94:1	215:1 216:1 217:1	335:1 336:1 337:1
268:12 287:13	95:1 96:1 97:1	218:1 219:1 220:1	338:1 339:1 340:1
288:23 289:21	98:1 99:1 100:1	221:1 222:1 223:1	341:1 342:1 343:1
291:11 292:8,19	101:1 102:1 103:1	224:1 225:1 226:1	344:1 345:1 346:1
293:8,22 303:4	104:1 105:1 106:1	227:1 228:1 229:1	347:1 348:1 349:1
314:21 319:14	107:1 108:1 109:1	230:1 231:1 232:1	350:1 351:1 352:5
321:9 323:16,19	110:1 111:1 112:1	233:1 234:1 235:1	353:2,8,16,22
327:21 331:13	113:1 114:1 115:1	236:1 237:1 238:1	355:5 356:2,24
332:13 333:24	116:1 117:1 118:1	239:1 240:1 241:1	357:2,4,12
334:6 342:20	119:1 120:1 121:1	242:1 243:1 244:1	pause 108:5
343:15	122:1 123:1 124:1	244:9,21,22 245:1	peak 216:22
paul 1:17 2:3 5:15	125:1 126:1 127:1	246:1,20,23 247:1	pediatric 30:8,22
7:25 8:1,17 9:1	128:1 129:1 130:1	248:1 249:1 250:1	31:7,11,24 32:6,7
10:1,24 11:1 12:1	131:1 132:1 133:1	251:1 252:1 253:1	32:21 33:14 39:6
13:1 14:1 15:1	134:1 135:1 136:1	254:1 255:1 256:1	39:23 46:2 50:4
16:1 17:1 18:1,8	137:1 138:1 139:1	257:1 258:1 259:1	66:3 67:5 79:19
18:25 19:1 20:1	140:1 141:1 142:1	260:1 261:1 262:1	112:15 165:7,11
21:1 22:1 23:1	143:1 144:1 145:1	263:1 264:1 265:1	166:17 198:7
24:1 25:1 26:1	146:1 147:1 148:1	266:1 267:1 268:1	208:6 228:8 235:2
			1

[pediatric - ph.d.] Page 44

0.45, 4.050, 10	205.2.205.20	70.00	45 1 46 1 45 1
245:4 262:18	295:3 297:20	person 79:23	45:1 46:1 47:1
268:18 288:5	299:2 316:12	168:4 189:16	48:1 49:1 50:1
291:4 337:23	320:8 348:18	190:17 231:8	51:1 52:1 53:1
pediatrician's	perceive 53:23	232:5 233:21	54:1 55:1 56:1
300:18	percent 140:10	251:14 252:4	57:1 58:1 59:1
pediatrics 32:8	percentage 91:18	265:19 280:5	60:1 61:1 62:1
33:13 49:23 65:24	92:15 94:21	281:8,10,20,25	63:1 64:1 65:1,10
83:7 243:4 337:19	130:18 136:20	282:21 283:13	65:12,21 66:1
338:13	140:14,16,17	284:2,3 285:2,22	67:1 68:1 69:1
peer 26:13 28:15	perception 119:7	297:8	70:1 71:1 72:1
28:18 76:6,9,16	119:13	person's 294:14	73:1 74:1 75:1
76:22,23 80:23	perfect 19:23	297:13	76:1 77:1 78:1
81:5,12,15 82:3	119:9	personal 143:19	79:1 80:1 81:1
82:11,12 83:2	perform 320:25	143:21 261:23	82:1 83:1 84:1
178:20 194:25	performed 60:17	262:8,13 264:11	85:1 86:1 87:1
317:7 326:6	173:21 232:18	282:18 286:9	88:1 89:1 90:1
335:20	319:24 349:6	290:5 322:7 324:5	91:1 92:1 93:1
peers 81:18 163:6	performing 62:12	324:8	94:1 95:1 96:1
182:24 184:5	188:11,25	personally 48:9	97:1 98:1 99:1
215:17	period 12:19 92:2	67:13	100:1 101:1 102:1
pending 10:16	272:24 345:8	perspective	103:1 104:1 105:1
11:15,23	350:19	203:17 229:2	106:1 107:1 108:1
people 13:25 49:7	permanent 211:9	231:3 232:9 236:5	109:1 110:1 111:1
67:22 74:23 75:4	221:4 257:21	265:15,25 266:18	112:1 113:1 114:1
76:5 84:18 87:21	permissible 256:5	271:24 303:22	115:1 116:1 117:1
88:23 89:9 90:15	258:16 259:3	307:3	118:1 119:1 120:1
95:12 109:11	permission 37:7	pertains 29:15	121:1 122:1 123:1
117:14 123:11	permits 127:24	342:14	124:1 125:1 126:1
129:20,25 130:7,8	permitting 270:5	ph.d. 1:17 2:4 7:25	127:1 128:1 129:1
131:22 136:4	persisted 172:3	8:1 9:1 10:1 11:1	130:1 131:1 132:1
140:11 149:3	persistence 92:16	12:1 13:1 14:1	133:1 134:1 135:1
150:17 152:15	92:20 93:16 94:6	15:1 16:1 17:1	136:1 137:1 138:1
153:25 154:11,15	94:11 95:23 96:23	18:1 19:1 20:1	139:1 140:1 141:1
155:12,16,17	169:5,17 171:3	21:1 22:1 23:1	142:1 143:1 144:1
162:10 165:23	174:13 189:16	24:1 25:1 26:1	145:1 146:1 147:1
175:22 181:18	194:19 341:24	27:1 28:1 29:1	148:1 149:1 150:1
187:5 216:14	344:11	30:1 31:1 32:1	151:1 152:1 153:1
220:16 230:23	persistent 98:25	33:1,15 34:1 35:1	154:1 155:1 156:1
234:14 238:25	100:7,25 189:6	36:1 37:1 38:1	157:1 158:1 159:1
247:7 249:25	211:10	39:1 40:1 41:1	160:1 161:1 162:1
254:15 283:9		42:1 43:1 44:1	163:1 164:1 165:1

[ph.d. - point] Page 45

166:1 167:1 168:1	289:1 290:1 291:1	phrases 187:8	place 5:11 106:13
169:1 170:1 171:1	292:1 293:1 294:1	physical 120:16	109:9 121:16
172:1 173:1 174:1	295:1 296:1 297:1	236:11,12 326:5	275:5,19 280:18
175:1 176:1 177:1	298:1 299:1 300:1	physically 19:21	352:13
178:1 179:1 180:1	301:1 302:1 303:1	19:22	plaintiff 5:16
181:1 182:1 183:1	304:1 305:1 306:1	physician 28:3	15:24 22:13 93:19
184:1 185:1 186:1	307:1 308:1 309:1	30:23 31:25 55:17	102:7 275:15
187:1 188:1 189:1	310:1 311:1 312:1	63:4 100:13	330:12
190:1 191:1 192:1	313:1 314:1 315:1	105:21 110:17	plaintiffs 1:8 3:3
193:1 194:1 195:1	316:1 317:1 318:1	112:15 124:12,16	4:3 6:22,25 7:3,6
196:1 197:1 198:1	319:1 320:1 321:1	126:20 192:4	7:10 8:13 126:13
199:1 200:1 201:1	322:1 323:1 324:1	198:6 201:3 228:8	147:14,19 157:17
202:1 203:1 204:1	325:1 326:1 327:1	230:2,11 235:2	157:23 310:17,25
205:1 206:1 207:1	328:1 329:1 330:1	236:6 241:9 245:3	311:7
208:1 209:1 210:1	331:1 332:1 333:1	246:11 262:17	plan 284:16
211:1 212:1 213:1	334:1 335:1 336:1	264:6 266:8	plans 290:14
214:1 215:1 216:1	337:1 338:1 339:1	268:18 271:16,21	platforms 124:20
217:1 218:1 219:1	340:1 341:1 342:1	273:5 284:13	plausible 63:17
220:1 221:1 222:1	343:1 344:1 345:1	287:25 297:20	play 233:18
223:1 224:1 225:1	346:1 347:1 348:1	309:18 320:10	249:23 269:20
226:1 227:1 228:1	349:1 350:1 351:1	343:20	playing 303:6
229:1 230:1 231:1	352:6 353:3	physicians 66:14	please 5:5,8 6:13
232:1 233:1 234:1	pharmacological	66:19 122:11	8:6,16 9:11,16
235:1 236:1 237:1	174:6 266:13	251:25	10:13 56:14 86:19
238:1 239:1 240:1	317:15	physiologic	98:6 179:17
241:1 242:1 243:1	phase 176:19	120:15,24 121:5	238:12 310:15
244:1 245:1 246:1	217:4	121:11 285:21	339:4 351:13
247:1 248:1 249:1	phases 291:6	316:3 319:17	pleiotropic 220:21
250:1 251:1 252:1	philosopher 245:5	physiological	plethora 156:13
253:1 254:1 255:1	philosophical	285:16	plos 241:20
256:1 257:1 258:1	226:24 230:17	physiologically	plural 296:25
259:1 260:1 261:1	247:14 265:15,24	224:3	point 10:15 19:12
262:1 263:1 264:1	philosophy 230:10	physiology 30:11	59:25 66:18
265:1 266:1 267:1	263:13	pick 5:6 132:22	102:13 123:20
268:1 269:1 270:1	phones 5:9	piece 80:16	142:23 169:25
271:1 272:1 273:1	phrase 141:19	pilot 340:19	173:3 174:15,21
274:1 275:1 276:1	254:8 271:25	pioneer 162:7	176:11,16 189:7
277:1 278:1 279:1	phrased 56:11	pituitary 31:8	190:6 197:19
280:1 281:1 282:1	89:3 313:14	213:12 217:22	215:11 306:22
283:1 284:1 285:1	317:23	221:11 222:12	324:4 344:10
286:1 287:1 288:1			
			<u> </u>

[pointing - preparing]

Page 46

Dointing 100:17 Doints 174:10 62:14 14:11 210:25 21:128 21:20 22:20 21:20 22:20 21:20 22:2				
201:9 323:5	pointing 100:17	56:5,16,22 60:10	177:21 209:14	predictive 167:18
policy 106:23 232:13 278:4 positive 321:8 possible 26:10 244:18 245:21 preferred 177:2 political 153:16 possible 26:10 251:22 284:11 180:12,21 192:13 287:105:15 285:9 286:2 200:18 207:16 220:14 291:4 228:116 282:22 220:18 292:13 294:11 283:11 284:5 285:13,24 286:18 politicians 112:20 191:14 206:4 politicized 114:24 politicized 114:24 politicized 114:24 possibly 25:17 poror 101:8 122:11 335:22 possibly 25:17 pororly 127:24 post 33:12 75:14 post 13:12 89:23 139:10 156:3 190:23 197:2 125:5 57:16 60:7,9 63:12 89:23 139:10 156:3 190:23 197:2 240:25 241:22 236:16,21 271:19 240:25 241:22 236:16,21 271:19 230:23 292:13 294:11 331:4 346:16 predimary 16:5 precipitating 13:11 189:13 14:22 342:3,22 populations 145:13 171:22 236:12 319:25 320:2 precise 157:13 post 33:12 4 332:21 335:11 341:22 342:3,22 populations 145:13 171:22 259:2 populations 145:13 171:22 259:2 populations 145:13 171:22 259:2 populations 145:13 171:22 powered 340:12 powered 340:12 portray 118:18 portrayal 199:13 postion 11:17 postion 128:8 position 11:17 postion 23:10 predictions 128:8 preparing 29:7 precision 128:8 preparing 29:7 points 174:10	62:14 114:11	210:25 211:18,19	prefer 84:14 133:2	
Desiritical 153:16 Possible 26:10 251:22 284:11 180:12.21 192:13 285:7,9,15,18 28:7 105:15 285:9 286:2 200:18 207:16 281:16 282:22 200:18 207:16 281:16 282:22 200:18 207:16 281:16 282:22 200:18 207:16 281:16 282:22 200:18 207:16 281:16 282:22 200:18 207:16 281:16 282:22 200:14 291:4 283:11 284:5 286:20 politicized 114:24 210:16 321:22 politicized 114:24 210:16 321:22 postibly 25:17 poor 101:8 122:11 304:25 possibly 25:17 post 33:12 75:14 post 33:14 346:16 precliminary 16:5 preceding 122:2 precipitating 15:7:11 166:7 212:5 232:2 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 236:16,21 271:19 170:23 196:5 196:3 197:8,10 249:17 250:2,10	201:9 323:5	126:24 149:6	211:20 212:16	164:12
political 153:16 155:7,9,15,18 28:7 105:15 28:9 286:2 290:14 291:4 281:16 282:22 politician 112:17 268:20 151:22,24 152:7 292:13 294:11 283:11 284:5 politicians 112:20 politicized 114:24 210:16 321:22 337:9,15 338:10 285:13,24 286:18 poor 101:8 122:11 304:25 possibly 25:17 196:12 post 33:12 75:14 pope 244:9,21,22 246:20,23 possibly 25:17 postpubertal 221:6 221:6 postpubertal 221:6 postpubertal 221:6 postpubertal 221:6 postpubertal 221:5 23:2 postpubertal 24:15 297:13 319:25 30:2 postpubertal 240:25 241:22 260:2,9 267:8,15 260:16,221 271:19 236:16,221 271:19 236:16,221 271:19 237:21,23 341:13 337:21,23 341:13 337:21,23 341:13 331:24 332:21 331:24 332:21 335:11 postpubertal 24:15 141:4,13 postpubertal 24:15 141:4,13 postpubertal 24:15 141:4,13 postpubertal 24:15 297:13 226:16,221 271:19 236:	policy 106:23	232:13 278:4	224:8 229:3,18	preferable 193:23
155:7,9,15,18	283:24	positive 321:8	244:18 245:21	preferred 177:2
131:18 151:5,19	political 153:16	possible 26:10	251:22 284:11	180:12,21 192:13
politician 112:17 151:22,24 152:7 292:13 294:11 283:11 284:5 politicians 112:20 152:12 187:23 337:9,15 338:10 285:13,24 286:18 politicized 114:24 210:16 321:22 practiced 142:6 288:22 289:7,24 poor 101:8 122:11 335:22 practicing 46:18 292:24 293:3 poorly 127:24 196:12 postibly 25:17 196:12 practitioner 294:2,15 297:13 128:16 130:11 post 33:12 75:14 postpubertal 25:11,21 331:4 346:16 preditioners 292:24 293:3 329:7,12 330:10 331:4 346:16 preditioners preditioners <t< td=""><td>155:7,9,15,18</td><td>28:7 105:15</td><td>285:9 286:2</td><td>200:18 207:16</td></t<>	155:7,9,15,18	28:7 105:15	285:9 286:2	200:18 207:16
152:12 187:23 337:9,15 338:10 285:13,24 286:18	201:19	131:18 151:5,19	290:14 291:4	281:16 282:22
politicians 112:20 191:14 206:4 practiced 142:6 288:22 289:7,24 poor 101:8 122:11 335:22 practicing 46:18 292:24 293:3 poor 101:8 122:11 335:22 practitioner 292:24 293:3 poorly 127:24 196:12 post 33:12 75:14 practitioners 294:2,15 297:13 population 31:5 post 33:12 75:14 post 33:12 75:14 practitioners preliminary 16:5 population 31:5 posts 154:6 286:7 302:13 64:18 160:9 331:4 346:16 premise 57:2 61:3 population 155:15 57:16 60:7,9 potential 44:14 304:4,6,14 precing 12:22 16:19 162:15 premise 57:2 61:3 157:11 166:7 212:52 32:2 precing 122:2 139:12 163:2 139:12 163:2 16:19 162:15 188:23 211:12 236:16,21 271:19 170:23 196:5 139:12 163:2 196:3 197:8,10 240:25 24:22 248:12 23:2 331:24 precise 157:13 precisely 99:14 249:14 183:18 160:5 186:18 </td <td>politician 112:17</td> <td>151:22,24 152:7</td> <td>292:13 294:11</td> <td>283:11 284:5</td>	politician 112:17	151:22,24 152:7	292:13 294:11	283:11 284:5
politicized 114:24 poor 210:16 321:22 335:22 possibly 142:20 practicing 290:10 292:5,13 292:5,13 292:24 293:3 poor 101:8 122:11 304:25 possibly 25:17 poorly 127:24 196:12 possibly 125:12 165:12 25:11,21 230:10 329:7,12 330:10 292:5,13 299:24 293:3 pope 244:9,21,22 246:20,23 population post 33:12 75:14 postubertal 221:6 posts 154:6 potential 44:14 71:12 161:25 potential 44:14 71:12 161:25 potential 44:14 71:12 161:25 potential 44:14 71:12 161:25 preceding 122:2 precipitating 157:11 166:7 212:5 232:2 postubertal 240:25 241:22 260:2,9 267:8,15 267:17 273:19 329:13 331:24 260:2,9 267:8,15 39:25 320:2 260:2,9 267:8,15 39:25 320:2 populations 145:13 171:22 269:18 319:2 338:4 potentially 139:25 320:2 potentially 139:21 333:24 precisely 99:14 precision 15:5 potentially 12:20,22 213:2,6 21:15 23:10,25 214:14 232:19,20,22 233:18 249:12,23 34:18 portrayal 199:13 portrayal 199:13 portrayed 341:8 portrayed 341:8 portraying 183:9 204:14 205:8 position 11:17 10:11 143:16 142:20 predictioner 125:12 165:12 251:11,21 25:11,21 predict 319:15,20 predictions 128:8 preparing 29:7 290:10 292:5,13 29:24:23:29:13 29:12,15 20:11 329:12,16 25:11,21 precitioner 125:12 29:24:23:3 294:2,15 297:13 329:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:7,12 330:10 32:13 33:12 163:2 139:12 163:2 139:12 163:2 139:12 163:2 139:12 163:2 139:12 163:2 19:14 195:17,19 19:63 197:8,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,20 22:23:2,6 23:18 249:17 250:2,20 22:23:2,6 23:18 249:17 23:19 249:17 250:2,20 22:23:2,6 23:18 249:17 23:19 24:14 22:15 14:	268:20	152:12 187:23	337:9,15 338:10	285:13,24 286:18
poor 101:8 122:11 335:22 possibly 25:17 practicing 46:18 292:24 293:3 294:2,15 297:13 poorly 127:24 196:12 possibly 25:17 125:12 165:12 329:7,12 30:10 pope 244:9,21,22 post 33:12 75:14 practitioner 125:11 121 331:4 346:16 preliminary 16:5 premise 57:2 61:3 post 57:10:60:7 post 154:6 post 71:12 161:25 preceding 122:2 premise 57:2 61:3 64:18 160:9 64:18	politicians 112:20	191:14 206:4	practiced 142:6	288:22 289:7,24
Description Procession Pr	politicized 114:24	210:16 321:22	142:20	290:10 292:5,13
poorly 127:24 196:12 125:12 165:12 329:7,12 330:10 pope 244:9,21,22 post 33:12 75:14 practitioners preliminary 16:5 246:20,23 221:6 142:15 144:4,13 premise 57:2 61:3 population 31:5 posts 154:6 286:7 302:13 64:18 160:9 63:12 89:23 71:12 161:25 preeding 122:2 premise 57:2 61:3 139:10 156:3 190:23 197:2 precipitating 183:11 189:13 183:11 189:13 157:11 166:7 212:5 232:2 precipitating 183:11 189:13 157:11 166:7 212:5 232:2 precipitating 183:11 189:13 240:25 241:22 286:12 314:22 332:21 170:23 196:5 196:3 197:8,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 precisely 99:14 precisely 99:14 precisely 99:14 precisely 99:14 precise 157:13 precise 63:18 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:5 186:8 160:	poor 101:8 122:11	335:22	practicing 46:18	292:24 293:3
128:16 130:11		possibly 25:17		294:2,15 297:13
pope 244:9,21,22 246:20,23 postpubertal 221:6 practitioners 142:15 144:4,13 premise 57:2 61:3 population 31:5 55:5 57:16 60:7,9 63:12 89:23 potential 44:14 71:12 161:25 preceding 122:2 163:2 161:19 162:15 163:17 177:5,7 139:10 156:3 157:11 166:7 240:25 241:22 260:2,9 267:8,15 37:21,23 341:13 331:24 37:21,23 341:13 341:22 342:3,22 populations 286:12 314:22 32:2 17:19 170:23 196:5 196:3 197:8,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,20 22:15 240:24 342:3,22 populations precion 15:5 precious 212:15 160:5 186:8 196:14 197:18 232:19,20,22 23:18 249:12,23 23:18 249:12,23 23:18 249:12,23 23:18 249:12,23 249:24 262:4 portion 140:5 power 340:14,21 practical 285:7 portrayal 199:13 portrayal 199:13 portrayal 199:13 portrayed 341:8 portraying 183:9 204:14 205:8 position 11:17 powered 340:12 practical 285:7 predate 163:10 prepared 15:16 prepared 15:19 17:19 28:20,21,23 predict 319:15,20 predictions 128:8 preparing 29:7 position 11:17 postpubertal 221:6 posts 154:6 prepared 12:2 186:13 30:4,4,6,14 preceding 122:2 163:2 163:2 17:16:25 preceding 122:2 163:2 19:12:20; 249:12 163:2 19:13 10:13 10:13 10:13 10:13 10:13 10:25 10:25 10:13	poorly 127:24	196:12	125:12 165:12	329:7,12 330:10
246:20,23 221:6 posts 154:6 potential 44:14 304:4,6,14 preceding 122:2 161:19 162:15 161:19 162:15 163:17 177:5,7 139:10 156:3 190:23 197:2 precipitating 183:11 189:13 191:4 195:17,19 183:11 189:13 191:4 195:17,19 183:11 189:13 191:4 195:17,19 196:3 197:8,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,10 249:17 250:2,20 260:22 262:7 347:18 348:10 337:21,23 341:13 332:21 335:11 332:21 335:11 precision 15:5 precision 15:5 precision 15:5 precision 15:5 166:14 197:18 232:19,20,22 233:18 249:12,23 233:18 249:12,23 249:24 262:4 249:24 262:4 249:24 262:4 249:24 262:4 249:24 262:4 249:24 262:4 249:24 262:4	128:16 130:11	post 33:12 75:14	251:11,21	331:4 346:16
population 31:5 posts 154:6 286:7 302:13 64:18 160:9 55:5 57:16 60:7,9 71:12 161:25 preceding 122:2 163:17 177:5,7 139:10 156:3 190:23 197:2 precipitating 183:11 189:13 157:11 166:7 212:5 232:2 139:12 163:2 191:4 195:17,19 188:23 211:12 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 premises 63:18 337:21,23 341:13 340:9 potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 199:21 209:8 214:22 215:5 233:18 249:12,23 238:4 258:12 259:2 power 340:14,21 preconceived 273:7 320:11 preparation 87:15 portrayal 199:13 portrayal 199:13 portcical 285:7 predated 141:5 prepared 15:19 204:14 205:8 46:17 105:3 108:5 predict 319:15,20	pope 244:9,21,22	postpubertal	practitioners	preliminary 16:5
55:5 57:16 60:7,9 potential 44:14 304:4,6,14 161:19 162:15 63:12 89:23 71:12 161:25 preceding 122:2 163:17 177:5,7 139:10 156:3 190:23 197:2 precipitating 183:11 189:13 157:11 166:7 212:5 232:2 139:12 163:2 191:4 195:17,19 188:23 211:12 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precocious 212:15 160:5 186:8 populations potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 power 340:14,21 preconceived 273:7 320:11 prepared 15:16 portrayal 199:13 practical 285:7	246:20,23	221:6	142:15 144:4,13	premise 57:2 61:3
63:12 89:23 71:12 161:25 preceding 122:2 163:17 177:5,7 139:10 156:3 190:23 197:2 precipitating 183:11 189:13 157:11 166:7 212:5 232:2 139:12 163:2 191:4 195:17,19 188:23 211:12 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 power 340:14,21 preconceived 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predated 141:5 prepared 15:19 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 <td>population 31:5</td> <td>posts 154:6</td> <td>286:7 302:13</td> <td>64:18 160:9</td>	population 31:5	posts 154:6	286:7 302:13	64:18 160:9
139:10 156:3	55:5 57:16 60:7,9	potential 44:14	304:4,6,14	161:19 162:15
157:11 166:7 212:5 232:2 139:12 163:2 191:4 195:17,19 188:23 211:12 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 potentially 121:21 127:5 151:15 212:20,22 213:2,6 196:14 197:18 145:13 171:22 199:21 209:8 214:22 215:5 233:18 249:12,23 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portrayal 199:13 practical 285:7 predated 141:5 prepared 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8	63:12 89:23	71:12 161:25	preceding 122:2	163:17 177:5,7
188:23 211:12 236:16,21 271:19 170:23 196:5 196:3 197:8,10 240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 potentially 121:21 127:5 151:15 212:20,22 213:2,6 196:14 197:18 145:13 171:22 199:21 209:8 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portray 118:18 powered 340:14,21 preconceived 273:7 320:11 preparation 87:15 portrayed 341:8 practical 285:7 predated 141:5 prepared 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	139:10 156:3	190:23 197:2	precipitating	183:11 189:13
240:25 241:22 286:12 314:22 332:21 249:17 250:2,10 260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portray 118:18 powered 340:14,21 preconceived 266:7 portrayal 199:13 practical 285:7 predated 141:5 prepared 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	157:11 166:7	212:5 232:2	139:12 163:2	191:4 195:17,19
260:2,9 267:8,15 319:25 320:2 precise 157:13 250:22 262:7 267:17 273:19 329:13 331:24 precisely 99:14 347:18 348:10 337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 potentially 121:21 127:5 151:15 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portray 118:18 power 340:14,21 preconceived 266:7 portrayal 199:13 practical 285:7 predated 163:10 prepared 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 prepared 15:19 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	188:23 211:12	236:16,21 271:19	170:23 196:5	196:3 197:8,10
267:17 273:19 329:13 331:24 precisely 347:18 348:10 337:21,23 341:13 340:9 precision 15:5 premises 63:18 341:22 342:3,22 populations potentially 121:21 12:20,22 213:2,6 196:14 197:18 160:5 186:8 196:14 197:18 232:19,20,22 23:19,20,22 23:19,20,22 23:18 249:12,23 233:18 249:12,23 233:18 249:12,23 233:18 249:12,23 233:18 249:12,23 249:24 262:4 249:24 262:4 266:7 preconceived 266:7 preparation 87:15 prepared 15:16 prepared 15:16 prepared 15:19 17:19 28:20,21,23 24:14 205:8 259:21 326:7 predict 319:15,20 72:23 preparing 29:7	240:25 241:22	286:12 314:22	332:21	249:17 250:2,10
337:21,23 341:13 332:21 335:11 precision 15:5 premises 63:18 341:22 342:3,22 populations potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predated 141:5 prepared 15:19 portraying 183:9 32:21 40:2 45:18 259:21 326:7 predict 319:15,20 72:23 position 11:17 110:11 143:16 predict 319:15,20 preparing 29:7	260:2,9 267:8,15	319:25 320:2	precise 157:13	250:22 262:7
341:22 342:3,22 340:9 precocious 212:15 160:5 186:8 populations 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portray 118:18 powered 340:12 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predated 163:10 prepared 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	267:17 273:19	329:13 331:24	precisely 99:14	347:18 348:10
populations potentially 121:21 212:20,22 213:2,6 196:14 197:18 145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	337:21,23 341:13	332:21 335:11	precision 15:5	premises 63:18
145:13 171:22 127:5 151:15 213:10,25 214:14 232:19,20,22 269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	341:22 342:3,22	340:9	precocious 212:15	160:5 186:8
269:18 319:2 199:21 209:8 214:22 215:5 233:18 249:12,23 338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portray 118:18 powered 340:12 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	populations	potentially 121:21	212:20,22 213:2,6	196:14 197:18
338:4 258:12 259:2 216:16 217:16 249:24 262:4 portion 140:5 power 340:14,21 preconceived 266:7 portray 118:18 powered 340:12 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portrayed 341:8 practice 31:24 predated 141:5 prepared 15:19 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	145:13 171:22	127:5 151:15	213:10,25 214:14	232:19,20,22
portion 140:5 power 340:14,21 preconceived 266:7 portray 118:18 powered 340:12 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portrayed 341:8 practice 31:24 predated 141:5 prepared 15:19 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	269:18 319:2	199:21 209:8	214:22 215:5	233:18 249:12,23
portray 118:18 powered 340:12 273:7 320:11 preparation 87:15 portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 110:11 143:16 predictions 128:8 preparation 87:15	338:4	258:12 259:2	216:16 217:16	249:24 262:4
portrayal 199:13 practical 285:7 predate 163:10 prepare 15:16 portrayed 341:8 practice 31:24 predated 141:5 prepared 15:19 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 predictions 128:8 preparing 29:7	portion 140:5	power 340:14,21	preconceived	266:7
portrayed 341:8 practice 31:24 predated 141:5 prepared 15:19 portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 predictions 128:8 preparing 29:7	portray 118:18	powered 340:12	273:7 320:11	preparation 87:15
portraying 183:9 32:21 40:2 45:18 259:21 326:7 17:19 28:20,21,23 204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 position 11:17 predictions 128:8 preparing 29:7	portrayal 199:13	practical 285:7	predate 163:10	prepare 15:16
204:14 205:8 46:17 105:3 108:5 predict 319:15,20 72:23 predictions 11:17 predict 319:15,20 preparing 29:7	portrayed 341:8	*	•	prepared 15:19
position 11:17 110:11 143:16 predictions 128:8 preparing 29:7	1 2	32:21 40:2 45:18	259:21 326:7	17:19 28:20,21,23
	204:14 205:8	46:17 105:3 108:5	predict 319:15,20	72:23
	position 11:17	110:11 143:16	predictions 128:8	preparing 29:7
30:13 42:22,24 145:9 152:14	30:13 42:22,24	145:9 152:14		

prepubertal 91:18	presented 25:8	167:16 173:9	292:5 298:5
96:10 160:10	26:16 81:20 84:25	189:11 204:5	317:24
166:3 171:12	102:6 142:22	273:18 281:5	problematic
188:21,23 191:19	144:11 146:6,24	283:3 328:15	201:25 255:2
204:8 271:2	146:25 181:15	332:17 339:14	322:13
272:13 273:21	182:12 199:17,22	344:14 345:13	problems 98:19
prepubertally	200:2,12,15	347:19 349:15	100:21 174:19
95:25 165:19	201:14,21,23,24	primarily 23:12	procedure 350:25
171:18	203:3,16,19	85:14 217:25	350:25
preschool 201:22	205:25 210:20	232:6 269:2	procedures 148:8
prescribe 52:14	257:4 296:2,17,25	primary 44:21	proceed 8:6 86:19
52:17 207:24	305:13 322:22	67:22 70:17 72:14	94:13 109:11
337:10 338:8,15	329:13,15 335:17	75:10 259:13	159:9 207:17
343:16	presenting 155:19	344:5	208:12 238:12
prescribed 48:9	182:10 188:20	principle 145:12	240:8 277:20
prescribing	194:18 199:16	294:22 348:7	310:15 339:5
208:21 214:8	200:5 202:5,18	principles 109:15	340:2 351:14
215:4 249:3 304:5	203:14 205:6	258:11,14 280:25	proceeded 186:16
304:6 337:14	284:19 304:16	285:9 343:2 348:5	proceeding 6:13
present 4:21 6:15	presents 146:20	prior 25:3 80:20	19:10 206:20
29:8 30:2 46:12	190:18 191:7	80:21 102:5 163:5	239:23 240:12,15
47:14 58:8 66:9	201:20 281:20	202:24 226:3	303:7,17 326:19
102:10 109:16	preserve 215:5	245:7 326:4	proceedings
110:14 119:25	218:17 257:6	332:24 352:4	351:21 352:11
123:16 124:3	265:18	prioritization	process 8:22 15:4
126:3,19 143:17	pressing 256:7,18	333:16	29:7 80:11 81:6
150:5 151:15	pressure 120:16	prioritizes 107:2	82:6,8 88:17 96:6
155:2 163:17	121:10 222:22	prioritizing 335:8	109:4 116:8
165:19,20,22	presumption	336:10	117:15 118:18
182:18,21 184:3	61:20 349:19	private 5:7	138:14 140:25
199:19 213:22	prevent 206:24	privilege 25:24	143:21,22 163:9
231:14 236:10	343:10	privy 81:5	163:12 167:5,6
251:12 259:22	preventing 231:19	probably 9:2 17:8	198:15 218:13
285:4 294:23	previous 53:9	31:4 39:15 74:14	230:4 237:18
303:13 341:13	102:14 245:24	162:6,22 185:4	processes 110:13
presentation	298:24	303:10 305:23	procreative 235:8
70:24 72:23	previously 29:4	306:20	235:15
242:21 304:24	76:13,15 88:10	problem 112:9	producing 315:18
presentations	98:6 111:6 112:14	122:18 125:20	product 24:25
84:17,24 85:3,5,8	129:25 131:9	156:2 201:15	25:5,17,25 73:5
85:13	138:3,17 139:20	266:10 284:14	80:12

[production - psychiatrist]

Page 48

production 235:19	292:2 295:12	345:8	provided 15:23
productively	296:6,24	proposed 55:8	24:18 34:3 41:10
96:12	pronouns 180:12	64:10,15,16,19	41:18,19 47:19
profess 268:19	200:18 270:2	106:9 111:24	67:9 72:22 105:15
profession 113:3,8	276:5 280:7	116:11 131:13	107:4,22 123:18
134:17	281:16 282:3,14	208:9 268:9 313:3	128:21 129:5
professional 2:9	282:23 283:11	344:3	173:4,11 241:3
14:13 32:16 40:14	284:5,25 285:24	proposing 85:25	312:8,24 315:21
82:13 128:18	287:20 288:22	116:23 204:11	317:9,9 336:15
264:2 302:18	289:2,8 290:7,10	313:16 348:25	provider 46:13
352:3	292:4,14,22,24	proposition	124:21 125:13
professionals	293:3 294:15	191:15	126:5 199:7
44:10 128:2,5,8	297:13	prostate 221:7	providers 125:21
128:12 130:12	proofing 25:10,12	protect 106:13	126:3,15 127:6
131:4	proper 43:13 54:4	protection 4:12	153:17 155:8,9,14
professor 30:7,10	60:13 62:12	protocol 152:9	156:19 171:25
30:19 282:20	106:10 137:7,12	176:2,7 177:17	323:21
profile 337:25	137:20,23 139:22	318:10 336:18,25	provides 53:2
345:16	141:20,22 146:20	protocols 316:19	70:20
profound 121:22	148:11 152:21	prove 317:13	providing 32:17
122:8	202:3 209:22	proven 177:12	40:13 63:23 68:24
progesterone	210:21 216:12	207:10 250:22	123:12 125:11
223:4	229:6,18 232:14	260:18 325:24	129:10 130:12,23
progesterones	233:8 234:6,22	345:15 347:6,24	157:12 172:10,23
222:10	235:13,25 236:24	proves 123:22	173:16 174:6
prognostic 320:4	260:19 340:13	provide 22:6	181:23,25 189:18
program 51:16,17	properly 89:7	32:20 39:9 41:7	189:20 255:15
65:19 69:3 328:16	115:18 138:25	42:9 45:7 47:18	287:2 317:2
progress 215:16	139:8 145:14,23	53:5 60:13 63:11	provision 137:8
227:3	146:15 147:6,15	70:21 74:16 81:21	137:14,24 336:23
progression	148:13,17 149:3,8	115:17,18 133:3	prudent 57:12
238:23	222:2 341:2	151:5,24 154:8	131:16 177:13
prohibit 55:24	proposal 51:7	156:7 160:13	209:24 247:5,24
prohibited 108:18	170:8	172:18 173:22	248:10 333:16
111:18 309:2	proposals 68:11	181:12 184:10	psychiatric 41:15
projects 69:14	68:19 69:19 106:2	187:20 195:8	43:22 44:9 229:11
promote 231:19	propose 72:18	206:12 222:5	238:17 239:9,17
pronoun 177:2	119:16 168:13	233:4 258:21	239:25 240:5
180:22 281:10	193:12 213:18	291:21 292:21	341:25
283:13 285:13	218:16 221:18	293:14 294:6	psychiatrist 31:20
286:18 289:24	324:25 342:23	315:19	32:10,12

navahiotriata	nubortaller 05:25	00.19 10 100.11	140:6 141:13
psychiatrists 115:11	pubertally 95:25 puberty 40:5 93:3	99:18,19 100:11 100:15,18 102:25	
	94:13 95:8,19	123:17 135:22	155:18 157:3,6
psychiatry 34:11 99:17,20 115:13	96:7,24 97:9	153:25 225:12,15	162:18,25 170:13 177:21 184:20
115:17 335:14	171:19 172:2,7	226:11,12 241:8	192:12 197:16
psychological	212:14,15,19,20	309:25 344:14	207:9 210:2,4
31:23 32:20 33:7	212:14,13,19,20	publisher 77:6	216:12 228:12
42:19 43:7,22	212.23 213.2,3,0	publishing 226:23	229:23 232:3,19
44:9,19 49:20	213.10,24,23	227:8	245:10 249:19
54:25 134:17	214.13,19,21,23	pull 18:2 135:18	250:7 258:21
141:4 149:19	215:4,5,7,10,13	186:17	266:2 284:23
173:10,16 186:9	215.19,20,23	pulling 19:4	301:7 318:18
215:8,14 241:4,15	217:19 218:2	puring 19.4 purely 246:8	328:5 329:18
251:17 259:14,17	220:21 221:21	purported 41:3	330:19 331:17
259:24 312:6	240:14 243:12	58:18	332:6 333:13,15
317:2 324:17,23	305:7 336:14	purpose 40:25	339:18
326:3 327:3	343:16 344:25	69:7 117:9 118:7	puts 61:12 239:5
331:17 332:23	public 2:10 4:12	118:8 214:10	putting 72:20
333:17 332:23	11:16 144:4 201:6	230:14,19,24	150:17 233:14,16
336:10,13 344:6	283:24 357:19	231:9,20 235:5,6	266:5 330:12
345:3	publication 28:23	236:7 237:12,20	
psychologist 31:22	82:17 115:23	246:2 254:6,7	q
32:13 44:24	184:17 200:5	265:12	qualifications
psychologists	227:18,24 228:20	purposes 41:25	130:19 135:6,9
115:10,21	228:22 241:2	55:13 131:8 145:9	136:11
psychology 34:11	publications 29:8	229:24	qualified 127:25
99:17,20 107:2	67:17 74:25 75:2	pursuant 2:6	128:16 134:9
115:16 335:15	75:11 78:19 81:3	pursue 66:2	135:21
psychosocial	82:12 181:14	192:20 324:22	quality 71:3 101:5
96:17 257:12	182:7 184:15	pursued 171:8	101:8,9 103:12
269:3	199:18 218:15	260:15	104:2,6,22 105:7
psychotherapy	publicly 156:16	pursuing 192:5	107:12,13 108:3
239:18	publish 29:22	325:25	113:13 206:13,16
pubertal 52:14	79:14	put 12:24 37:8	206:23 207:6,14
79:21 80:10	published 22:21	51:7 57:22 58:5	207:18,24 208:21
137:22 170:10	23:6 27:20 28:14	60:24 64:8 68:19	209:5,11 210:3,6
172:12,23 217:12	29:4,14 36:22	86:2 106:3 108:5	210:14 211:4,14
218:24 219:6,14	37:8 75:9,13 76:2	108:25 110:8	211:25 212:7,12
219:22 220:7	76:6 78:12 79:8	112:25 114:3,24	261:16 266:23
221:14 238:22	83:9,25 84:5 88:7	116:6,19 117:2,17	304:25 311:20
243:6 344:11,16	88:9,19 94:15	128:20 131:10	327:10,23 328:4
,	·		330:8 333:15

[quality - reading] Page 50

	T		
335:24 349:5	214:12,25 220:2,5	248:19 273:2	rate 120:16
quarterly 75:7	221:16 232:2,15	276:24 277:7	121:10 172:25
78:13 84:6 103:4	235:20 246:12	279:4 286:15	267:14
225:13,20 226:9	247:4 248:5	298:24 305:2	rates 154:22
226:13,16 353:25	249:16 251:5	309:12 314:2	ratio 190:8 192:11
question 9:12,16	252:20 253:24	325:16 329:5	rationale 108:23
9:19 14:24 23:3	259:8 262:20	344:9 345:21	337:8
29:15 36:24 37:22	264:11,20 279:23	351:16	ratto 1:25 2:7 6:6
38:12,18 39:23	281:7,14,21 283:3	quick 158:8	352:2,24
43:15 44:11 47:18	283:4,19,21,24	quickly 300:3	raw 243:13,25
48:15,17 49:3	289:14,14,20	quite 12:2 26:15	reach 59:5 169:18
53:9,21 55:16	294:18,20 298:15	39:10 74:10 85:6	191:8 313:23
56:15 57:2 59:7	299:4 301:5	94:23 115:7 193:5	reached 38:22
61:5 64:21 65:2	304:12 309:17	203:14 216:13	169:20 170:7
70:14 76:12 79:20	313:14 314:13	231:5 232:15	291:23 315:6
87:18 89:3,7	315:3 317:21,23	323:3	324:7 326:24
90:25 94:19 95:12	322:19 324:6	quoted 174:12	347:5
97:5,21 99:10	326:24 331:3,23	229:4 267:12	reaches 94:6
102:5 104:22	337:13 338:7	r	reaching 224:4
108:12,22 109:19	347:10 349:12,15	r 3:1 4:1 352:1	read 17:8 20:18
110:6,25 111:5,13	349:18	356:3,3	21:6 24:4,17
111:14,16 112:6	questionable	r01 70:2	26:23 99:2,3
112:13 115:25	101:9 168:10	ragon 4:4 7:9	103:16 121:25
118:3 119:22	questioning	raise 7:17 272:7	122:6,14,16,22
120:10 124:9	205:15 245:24	273:20 305:2	127:22 128:12,14
127:11,14,15	298:7 302:20	raised 24:20	142:14 145:16
130:16 146:6	307:11	226:25 309:13	153:19 162:21
147:6 148:4,21,22	questions 8:14 9:5	raising 149:24	175:13,15 227:13
150:19 151:12	10:3,16 13:24	random 295:8	227:14,20 228:19
156:23 166:16	15:9 23:13 24:19	randomized 59:13	229:13,15 244:18
167:7 174:8	45:23 46:23 47:6	59:18 60:4 72:6	244:19 276:13,18
179:11,17 181:20	55:18 57:14 58:11	139:18 147:10	278:18 280:16
183:21 187:8	58:15 62:15,21	213:3 214:3 242:8	300:2,23,25 321:2
189:22 190:12	80:7,8 85:15,22	263:15 309:23	355:9 357:5
192:2 193:5,19	86:21 94:3 105:23	338:3 344:15	reader 232:7
194:3,16 195:15	107:15 112:18	range 92:11	readily 154:6
197:20 199:3	133:12,13 135:17	ranges 287:9	180:24 181:8
202:4,24 204:20	138:18 139:21	rapid 227:2	183:2 245:13
204:24 205:4,12	148:3 204:7	rapidly 22:24	reading 128:25
205:14,18 211:15	205:21 206:9,22	rare 49:6,9	130:23 159:13
211:16 213:7	226:25 232:23	12.0,2	226:14 227:20
	1	1	

228:25 256:2	356:21	339:2 351:11	288:14
275:22 277:17	reasonable 318:18	recited 124:24	recommending
286:3 308:20	reasoned 227:5	recognition	157:14
343:25	reasons 64:17	107:25 333:14	reconfirm 225:11
reads 278:2	172:13 282:8	337:16 339:16	record 5:2,12 6:18
ready 18:16 70:23	318:21 350:5	recognize 14:15	8:16 19:18 86:15
277:19	rebuttal 21:15,25	19:2 20:6,9 21:19	86:18 159:5,8
real 58:18 224:24	22:19 27:8,16	60:15 78:3,5 79:3	238:5,8,11 310:11
278:10	353:10	83:21 119:20	310:14 338:25
realign 163:23	rebuttals 93:17	135:22 136:8	339:4 351:10,13
realignment 92:6	recall 12:12,20	231:22 251:18	351:20
160:11 161:17	13:3,7,10 14:9	256:15 269:10	recorded 5:14
162:17 164:3,7,23	24:2 26:6 35:23	293:13 298:11	recording 5:10
167:21 168:8	36:10,12 37:10	299:15 320:15	246:21
169:3 328:18	44:17 80:19 99:23	recognized 82:25	records 126:23
reality 124:3	133:24 226:2	185:5 256:9,13	135:18 285:15,20
219:24 230:24	227:19 275:14	284:20 322:6	311:8
244:17 246:10	298:18 299:20	332:18	reduce 108:15
247:9 248:2,7,12	329:11	recognizes 19:19	reduced 243:7
249:5 250:11	receipt 355:18	230:3 350:17	reducing 239:21
262:12 263:23	receive 33:19	recognizing	redundancy 25:15
281:2 283:12	42:21 56:21 94:11	109:18 283:10	reenforces 229:10
285:12 301:18	106:18 242:17	284:17,23	reengagement
306:16 347:19	312:3 323:25	recollecting 12:16	217:21
really 13:22 59:19	344:25	recollection 15:11	refer 91:23 96:17
97:18,21 108:23	received 18:9	17:22 80:17 226:6	166:21,22 175:22
112:21 150:13	21:16 60:7 65:7	276:8 280:15,20	181:14 204:19
162:9 168:17	65:21 69:6 77:17	300:5	230:18 258:16
198:9 266:24	78:24 83:18	recommend 171:4	286:17 349:18
273:12 301:14	137:20 214:5	212:13 287:13	reference 93:21
311:8 326:18	225:21 242:17	334:24 335:6	93:22 99:4,6,15
333:3 345:22	243:17 274:9	recommendation	102:9 154:8 281:2
reason 10:5 21:8	299:9 307:18	209:7 311:14	287:8 289:10
28:12 124:4,14	323:20 345:2	336:7	330:4
126:12 221:16	receiving 12:2	recommendations	referenced 102:12
227:4 228:17	72:5,8 137:6,12	33:5 144:12 207:6	102:13 272:12
262:21,24 263:2	139:22 140:18	209:2,11 210:6,11	355:6
271:3 285:7	156:21 310:18	211:3,24 212:7	references 26:12
320:17,18,23,25	311:3 314:7,24	217:9 349:25	81:24 93:21,22
322:14,19 355:11	recess 86:16 159:6	recommended	99:13 102:10
356:6,9,12,15,18	238:9 310:12	137:21 216:17	117:12

referred 43:24	reintegration	245:19 246:3	relevancy 202:9
44:3,7,14,18	163:12	247:4,14 253:11	202:22
115:20 175:25	reiterate 253:4	282:11,12 283:23	relevant 27:15
261:19 272:11	268:16 331:2	291:13,20 292:17	32:23 67:18 80:6
289:22	332:16	302:21 305:3	82:2 107:15
referring 23:16	rejected 88:5,12	relationship	122:10 131:14
24:3 44:24 99:11	88:14 250:5	198:17 236:15	134:22 136:5,6,11
144:14,22 155:5	related 6:8 12:22	243:22 262:21	165:8 186:25
169:15 181:11	15:3,7 17:10	265:11,21 288:3	190:5 201:11
229:4 234:9	22:15 23:12 33:9	318:7 321:21	202:13 203:18
239:10 251:7	33:17,20 34:6,21	324:12 340:15	216:7 245:6,18
305:12	39:25 40:16 44:19	relationships	247:17 249:18
reflect 154:22	44:25 45:3 46:23	58:15 163:5	257:22 268:4
155:3 196:23	48:23 51:20 55:18	235:24 236:23	283:4
reflected 67:16	66:11,25 67:12	317:7 322:4 326:6	reliability 123:7
82:20 87:13 88:4	68:12,20 69:10,14	335:20	reliable 92:18
88:8 103:19	73:6 74:21 75:3	relative 41:3	114:25 122:12
reflecting 117:23	75:12,19 76:14	58:17 60:25 114:2	134:21 203:25
reflection 109:2	84:18 85:9,11,15	138:5 147:20	222:4
125:4 227:6	85:16 87:9,20	170:20 171:5	reliably 167:17
refresh 18:21 77:9	100:21 105:23	174:22 190:24	reliance 118:23
99:7 274:19	112:18 113:6	191:12 209:3	120:4
276:14 300:4	118:11 148:6	210:13 211:2,22	relies 114:14
refreshed 19:6	153:7 169:10	212:5 214:13,16	religious 261:23
refute 97:22 123:3	176:21 202:3	269:16 270:11	262:8,10,14
123:17 273:13	211:16 224:18	288:17 311:11	264:11,18,21
regard 132:17	225:2 233:12,19	331:7,8,24 332:10	rely 43:21 142:21
343:3	248:19 249:16	337:24 339:16,17	180:23 322:7
regarding 38:13	252:19 261:20	346:22,25 349:4	remain 28:25
regardless 253:20	263:12 286:15	352:16,19	45:23 57:11 66:7
registered 2:9	303:23 311:10	relatively 323:4	154:23 261:11
352:3	337:13 349:12,18	relativistic 247:18	325:16
regression 345:4,4	relates 31:23 40:2	relegated 54:10	remains 227:11
regular 46:9	50:21 115:25	relevance 200:25	256:4 267:11
regularly 47:3	117:10 205:16	234:24 235:11	remember 13:15
regulate 223:4	218:20 229:22	262:2,16 278:16	13:17 36:8 44:22
regulatory 222:11	relating 209:16	284:8 294:17	79:16,23 132:15
reinforced 24:17	relation 23:21	298:22 302:6	133:5,9 211:7
27:10 301:15	80:8 116:14	304:11 305:10	275:17 276:2
reinforces 238:15	119:23 205:18	337:12	296:19 299:17
240:5	230:25 245:7,17		301:8,16

remembering	reporting 323:8	62:12,22 63:5,10	response 9:8 96:8
277:2,6	reports 16:6 17:19	64:15,15,16 65:12	102:5 119:2 120:3
reminded 276:4	22:4,20 24:22	67:12,15,20 68:2	182:23 202:24
remote 1:15	26:19 27:3 37:24	68:2,3,7,8,11 69:4	204:21 283:2
remotely 6:2,16	73:10 97:15,16	69:9,10,13,17,22	318:12 346:21
7:20	122:13,19 125:7	69:24 70:2,5,10	responses 25:23
rendered 315:9,17	129:20 308:3	70:12,15,24 71:3	85:24 120:15
reparative 159:21	321:3 324:9	72:3,18 73:2	121:6,9 290:17
160:24 162:19,24	327:20 335:24,25	82:18 93:10	316:6
163:22 164:13	representation	103:12,22 104:18	responsive 65:2
185:15 186:6	126:10	105:16 106:10	restart 333:21
192:23 196:2	representing 6:4	107:14,22 108:18	restate 120:9
197:8,11 259:16	8:12	109:7 110:20	189:10 247:3
repeatedly 62:23	reproduction 15:5	111:25 112:4,5,11	restore 212:23
96:3 107:11	198:16 230:5,25	113:3,9,13,16	restores 213:19
129:23 144:20	233:13 235:6	121:8 128:9	restricting 37:15
146:12 152:25	265:13	129:12 130:21	result 125:17
154:4 192:11	reproductive	135:23 136:14,24	241:8
249:10 261:14	96:11 231:9	139:18 140:7	resulted 346:11
262:22 279:4	233:22 236:20	188:11 189:2	retained 10:25
336:21 337:7	237:11,17	226:19 233:3	11:6
346:6	request 283:23	249:14 260:20	retention 350:10
rephrase 9:17	285:13 294:15	266:20 267:25	return 109:15
56:14 89:6 137:10	requesting 283:13	275:6 278:13	323:20 355:13,17
183:22	requests 88:15	327:24 348:24	reveal 25:23
report 18:7,25	require 42:18	residency 33:22	reverse 316:14
20:10,15,19 21:2	273:23 323:24	34:10	reversed 207:12
21:15,25 22:19	required 31:25	resolution 239:25	reversibility
24:14 27:8,17	66:21,22,23	resolve 292:6	217:20
73:10 97:25	149:13 281:16	resolved 336:13	review 15:22 17:3
101:11 114:6,23	296:18 316:7	resort 188:14	27:19 29:24 58:9
118:23 119:3,15	357:13	respect 62:16 82:3	58:23 60:6 67:7
120:4,12,20	requirement 73:4	248:12 251:15	70:22 76:11,23
121:15 149:3	279:15	265:6 294:23	81:6,13 82:6,7
159:15 160:2,19	requires 148:5	295:23 313:6	88:15,17 106:12
321:7,24 353:7,11	176:18 254:24	317:14	263:18 276:25
reported 1:24	requiring 282:13	respected 76:20	280:20 300:11
121:2 242:19	research 13:11	186:3,25	337:2,2 351:17
reporter 2:8,9 6:5	17:9 23:8 51:18	respects 207:20	355:7
9:7,11 352:3	54:18 55:13,25	respond 9:6	reviewed 15:18,25
	58:11 60:14,16	319:21	26:13 28:15,18

76:6,9 80:23 81:2	261:9 348:13	346:25 347:25	says 173:23
81:8,15 82:3,4,11	risk 54:6 57:7	348:20 349:4	188:15 226:15
82:12 83:2 135:12	108:15 151:3	rock 4:6,15 5:25	308:15,22 345:23
178:20	154:13 168:18,23	rodgerson 3:7	scan 300:4
reviewer 76:17,22	169:24,25 170:20	rodgersonb 3:8	scenario 109:13
81:5	171:5,8 174:22	rogerson 7:1,2	129:24
reviewing 17:7	187:9 188:17	role 28:2 39:6	scholarly 67:23
29:11 64:11 72:24	190:8 192:10	45:15,20,25 69:2	73:6
136:14	193:23,25 209:12	70:5 72:12 73:7	scholastic 70:19
reviews 29:3	210:4 211:8,17	79:19 180:15	72:15,21
67:19 82:19 300:7	212:5,11 214:13	296:12	school 33:12,21
revise 88:15	214:16 217:5	roman 277:25	49:24 50:5 299:8
revisions 117:19	222:23 224:11,14	room 6:24 7:2,8	354:5
118:19	224:17,19 229:12	rounds 84:24 85:7	schools 178:14
right 7:17 8:19	253:25 269:16	263:12	science 28:24
11:3 18:23 20:3	314:16,17 315:11	routinely 127:24	58:13 60:3,19
34:15 38:15 49:25	319:11 326:17	208:22	61:7,25 62:7 63:7
62:3 71:14 75:24	331:7 337:25	rpr 1:25 352:24	113:14 117:6
78:18 79:12 108:8	339:17 340:3	rules 8:25	122:10 146:14
121:16 125:23	343:5 345:16	run 8:24 34:24	177:12 193:3
128:13 149:6	346:5,18 350:9	rutledge 1:10 5:18	198:5 206:23
152:16 159:18	risks 40:12 41:3	355:4 356:1 357:1	232:18 237:13
161:3 170:18	58:17 71:23	S	262:25 263:5
172:4 176:9	103:13 114:2	s 3:1 4:1 353:6	265:2,21 266:16
187:16 188:9	138:5,19 145:15	356:3	273:9 278:3,24,25
204:11 208:23	145:24 146:9,16	safe 11:13 212:19	279:7,14,19 280:9
238:24 240:11	146:22 147:15,23	212:22	280:19 281:6,9
244:18 277:17	149:4 161:22,25	safeguards 58:7	282:5,20,23
308:11 311:19	168:10 169:6	106:13 109:9	320:22 321:11
327:5 332:13	187:18 190:25	safety 23:3 42:4	322:6 327:23
334:9 336:15	191:13 209:3	104:3 214:21	328:5 330:16
rigor 70:13 86:3	210:13 211:2,22	sample 241:22	335:24 336:22
117:5 340:25	213:15 222:8,16	sat 143:12	341:10,11 345:13
rigorous 58:12,21	222:18,20,21,23	saw 308:5,6	sciences 226:21
146:11 227:6	223:2,7 255:11	saying 108:9	227:7
258:24 263:9,17	267:19 269:9	112:9 124:11	scientific 23:13
297:6 319:23	291:25 304:2	145:23 174:20	43:13 44:5 45:23
324:11 328:25	311:11,21 312:22	196:8 234:8	54:4 61:3 63:18
343:13 348:24	315:14 331:24	238:18 292:23	63:19 64:7 67:18
rigorously 80:25	332:10 338:19	298:8	70:13 76:24 80:23
109:10 260:8	340:6 346:12,22		81:14,15 84:19

[scientific - set] Page 55

05.14.02.6.06.2	220.2 12 225.2	41 210.2	107.04
85:14 93:6 96:2	230:2,12 235:2	sectional 318:3	segregate 187:24
104:6 105:22	236:6 245:3	sections 64:13	196:18
106:10 108:3,4	246:11 262:17	secular 227:11	segregated 242:23
110:3,4 112:18	264:6 266:8	see 17:13,15 18:12	segregation
115:23 116:19	268:18 271:16,21	21:3,21 26:24	196:21
117:22 129:4	273:5 281:15	31:14 74:7 77:10	selecting 72:19
130:16,20 132:4	309:18 320:10	77:20,24 79:15	self 118:23 119:3
134:23 136:6,12	343:20	83:20,23 116:14	119:15 120:4,12
138:12 146:23	scientists 110:18	117:19 121:22	120:20
156:25 157:5,10	241:9 280:24	153:10 159:25	senior 4:11
160:5 163:17	scope 202:9,22	166:24 177:5,8	sense 36:12
183:11 186:7	205:12 234:24	195:22 196:24	199:20 212:10
187:2 189:13	235:11 262:16	204:23 218:7	sensitive 5:6 288:7
190:5 191:4	268:15 270:8	224:4 225:9 243:2	sent 355:14
192:16,19 195:17	276:12 278:16	243:14 245:25	sentence 121:20
196:3 197:18	284:8 294:17	246:6 253:24	122:2,7 145:17,20
198:24 201:4,11	301:6 302:6	263:3 275:9 279:5	153:10 175:5
213:9 233:17	304:11 305:10	308:13,18,19	244:5,8 252:11
244:23 247:19	337:12	315:11 336:22	256:2 258:10,15
249:11,12,17	screen 20:5	339:7 340:10,11	separate 120:2
250:2,15 252:18	screening 287:12	340:24 344:3	264:12 281:3
257:10 258:24	scroll 20:11 73:11	348:12	285:14,19
260:16 262:4,7	101:16,17 274:21	seeing 17:14 18:18	sequitur 179:10
263:10 264:19	274:23 277:19	20:8 73:20 115:10	serious 309:12
265:13 266:5,6	scrolling 20:19	188:9 275:23	321:17
270:21 271:24	21:22 74:9 78:6	290:6 333:12	serve 11:10 25:17
278:12 279:9,16	277:10	seek 61:22 97:24	38:23 134:7
279:24 283:25	search 180:25	166:18 168:21	232:25 294:5
311:10,18,20	309:22 314:18	265:18	served 25:3 35:25
316:22 320:17,19	331:14	seeking 29:24	51:15 76:16 81:4
321:16,23 324:14	searching 332:20	seeks 164:21	312:25
327:2 328:3	333:7	226:21	serves 293:12
330:18 348:10	seattle 65:23	seen 86:4 126:23	service 129:10
scientifically	second 17:24	153:24 182:18	133:3
116:7 325:2	82:23 98:13,13	225:25 226:5	serving 64:12
scientist 28:3	114:5 166:20	263:8 265:22	72:12 126:18
30:23 55:17 63:4	252:10	276:21 307:22,24	201:2 228:7 245:2
65:19 100:13	secondary 30:9	318:17 334:5	268:17
105:21 112:15	secreting 224:5	340:6,7 341:21,23	session 245:25
126:20 192:4	section 250:18	seeping 279:25	set 19:3 293:7
198:6 201:3 228:8	278:2	1 6	351:4 352:14

[setting - situation] Page 56

gotting 54.14	220.2 12 222.9 12	237:11 245:9	sign 276:22
setting 54:14	230:3,13 233:8,12	246:2 248:20	
96:15 106:19	233:22 234:10,17		351:17 355:12
107:5 108:6	234:21 235:5,7,9	281:18	signalling 221:11
134:15 139:17	235:15,24 236:7	sexualization	signature 21:4
199:22 220:19	236:23 238:15,23	204:8	352:23
297:15 313:2	239:11,19,24	sexualizing 205:9	signed 275:18
316:5 333:19	240:16 241:3,13	shamed 183:17	299:19 355:20
336:24 343:9	252:12 253:18	share 17:15,17	significant 91:18
settings 54:18	263:20 280:6	53:22 83:12 284:9	140:12 151:3
131:7 298:13	281:8 282:2,21	291:10	169:10 193:17,25
299:3	284:3,24 287:14	shared 288:24	224:6 260:4,18
seven 178:25	289:23 290:16	297:4 302:23	267:11 279:21
179:19 182:2	294:13 295:16	329:12,18	280:4 286:4
severable 198:19	300:21 305:19,22	sharing 53:25	302:11 303:25
severe 90:3	315:10,18 316:3	shawnee 274:18	311:21 312:11,22
sex 14:16,19 15:2	316:10,15 318:16	sheet 355:11	313:24 314:16
52:18 61:14 77:15	325:22 328:9,19	shift 172:19	315:10 316:11
78:8 88:24 89:16	331:6 334:18	186:22	321:8 323:15
89:22 90:2,10	353:14	shifting 30:4	332:4 336:4 340:6
91:3,13,20,21	sexed 224:2 225:3	shifts 174:21	341:25 343:5,8
92:7,25 94:14	284:17 290:23	204:12	345:12 348:20
98:21,22 134:16	291:15 292:16	short 113:24	significantly 32:25
154:18 160:12	294:8	193:13,24 323:4,6	229:12
161:11,12,14,14	sexual 15:7 31:9	331:10	similar 14:10,19
161:18 162:4	46:20 47:5,10,11	show 92:3 240:19	15:8 37:6 38:11
163:4,10,24	47:20 48:4,10,21	340:17 343:14	53:11 68:25
164:23 167:22	48:24 49:11,15	345:13 347:12	104:23 297:5
168:9 169:12	68:21 96:10	showed 241:21	298:23 313:2
172:7 184:23	191:20 205:19	243:8 327:21,22	336:7 345:3
186:12 189:4	218:23 234:20	344:18	simple 259:8
194:5,18 195:4,20	235:17,18 236:9	showing 92:24	344:9
196:3 197:3,12,21	236:10,12,15,18	128:9 215:22	simplistic 199:13
197:23,23 198:8	246:4 290:20	239:20 274:11	simply 111:16
198:12,18,25	295:25 307:2	343:4,7 344:18	sincere 126:8
202:6,12,19 203:7	326:4 334:23	shown 260:6	single 133:24
203:8 204:15,23	346:11 349:10,14	shows 92:8 146:23	235:18 251:21
205:7,8 218:3,21	349:22 350:7,14	185:17 250:21	singular 297:2
219:2,8,16,23	sexuality 14:3,20	257:3	sit 72:17
220:9 223:12,18	49:5 201:23	shut 221:10	sites 181:6
223:23,25 225:8	229:24 230:24	side 72:8 216:2	situation 151:18
226:10 229:5,9	235:23 237:5,10		194:20 196:23

[situation - state] Page 57

200:9 203:13	solve 155:25	120:11 141:24	spontaneous 92:6
211:7 218:4,18	somebody 44:3,18	142:8 143:10	95:6,16 97:6,17
219:24 221:13	128:19 213:19	148:9 150:8	97:21 160:11
268:23 296:17	282:13 295:11	184:11 189:12	167:21 169:3
303:16	sophia 3:9 7:4	194:17 211:17	
situations 49:7,9	-	213:8 216:6 217:9	spontaneously 168:7
203:15,17 207:3	sorry 29:16 35:5	248:23 277:7	st 49:25 50:3,8,12
212:4 231:17	77:12,12 82:22,24 87:17 100:3	289:20 292:22	50:15 56:19 66:5
254:5 303:2			
337:24	101:22,25 102:17 137:9 151:20	304:13,14,14 311:6 314:5	244:9,22 246:20 246:23
six 145:6,7	190:10,10 259:7	specifically 12:20	staff 25:11
sixth 274:12	259:11 264:9	13:3 15:10 24:10	stage 16:6 96:7
skepticism 61:9	281:3 285:17	49:3 61:14 66:11	169:18 240:12
slowly 18:4	297:11 333:21	101:5 144:18	315:5,6 351:2
small 318:25	sort 64:25 74:24	158:2 165:8	stages 69:24
smoking 269:9	81:13 161:6	169:14 184:16	171:18
snyder 38:8	sorts 261:3	208:11 218:21	stance 298:16
soc 327:13	sought 150:3	227:19 237:5	stand 26:22 57:8
social 124:19	soul 244:14	248:18,21 270:24	150:23
125:7 127:25	250:25 251:9,20	323:12 330:4	standard 105:8
128:17,22 154:6	sounds 10:20	338:16	136:16,21 291:4
166:4 175:10	111:13	specifics 254:25	327:15 342:19
176:5,7,18,25	source 121:21	283:20 313:12	standards 54:13
177:14,25 178:13	sources 203:25	specify 137:17	71:4 141:13
180:14 183:8	south 35:7,8,13	spectrum 31:10	263:16
194:23 203:24	speak 12:4 16:18	166:10 325:15	standing 76:18
269:22 270:5,12	23:17 124:21	328:3 335:17	standpoint 236:9
270:16,17,25	323:11	speculation 53:20	269:19 282:18
271:8,10 272:2,17	speaking 13:3,10	spelling 25:15	283:7 309:18
272:24 297:15	31:16 59:22,23	spend 51:9 250:20	stark 244:6,8
308:15,25 309:4	118:12 164:16	297:21	start 8:15 17:14
309:13	166:15 217:20	spill 297:24	51:5
society 270:4,24	232:13 234:25	spirit 227:12	started 51:23 52:7
272:12,22 284:22	268:5 277:12	spoke 12:7,13	290:21
solecism 278:11	278:19 298:18	13:17 16:10	starting 74:8
solid 266:25	specialist 4:23	spoken 14:22	172:17 197:19
solidifies 239:2	specialties 34:5	129:20 130:5,6	state 6:13,16
solution 193:24	specialty 34:2	133:10,11 198:13	13:18 38:5,17
solutions 2:6	specific 13:8,16	295:14,15	43:6,9 53:12
333:8 355:23	33:16 34:6 44:17	sponsor 12:9	57:10 58:13 59:11
	45:12 64:4 101:15		60:2 61:8 76:12
	1	1	1

[state - subject] Page 58

		T	
96:11 104:19	287:23 288:15	steroids 77:15	studies 22:20 23:5
125:25 138:4	289:4,18 290:3	78:9 225:8 226:10	23:8 24:2,2,5
143:14,18,23	296:10 297:6	353:14	27:11 59:4 64:12
146:14 149:18	301:3 306:11,17	stop 66:17 98:21	64:16 65:15 68:4
179:17 187:15	307:14 309:10	221:13 238:3	68:7,17 91:25
193:3 212:24	317:20 354:7	320:7 338:21	93:10 104:7 105:5
213:19,21 219:11	statements 22:12	stories 178:21	107:16 109:18
242:12 266:15	23:18 28:8 81:23	182:19 321:25	112:4,5,11 121:8
274:18 286:25	106:23 116:5	story 184:6 213:17	139:9 140:7 201:5
293:6 305:15	123:9,15 124:2	strangio 3:15 6:20	206:25 208:14
309:22	125:18 132:3,8,9	6:21 8:4,11 18:3	213:4,11 214:4,21
stated 22:7 27:9	144:21 154:16	18:14 19:6,15,23	214:24 215:22
32:19 40:7,22	156:6 178:15	73:19 86:9 158:3	216:4,8 217:7
41:23 43:10 57:3	198:3 263:11	158:12,20 234:3	219:20 233:3
80:16 82:4 105:19	265:23 277:11	238:2 307:10	240:10,17 241:17
113:11 114:12	321:14 327:14	310:7 351:3 353:4	242:8,9 257:10
116:9 131:9 140:2	334:3 347:8	street 3:5,13 4:14	261:10 263:15
144:3 146:11	states 1:1 5:19	5:24	267:4,25 273:25
152:25 153:3	76:19 105:12,13	strength 101:6	287:8 317:12,25
157:22 172:14	137:5,14 139:23	207:15 342:7	318:25 323:12
174:18 177:8	162:14 178:6	strengths 136:9	325:4 327:19
189:11 197:14	299:14	stress 188:6 193:9	328:6,20 329:24
201:18 219:10	stating 8:15	327:12 341:5	338:3 341:21
253:12 262:22	statistic 174:12	strive 312:10	343:13 349:6
273:18 281:5	stay 94:2 133:2	stroke 224:18,23	study 43:14 64:13
296:9 304:2	steensma 99:18	319:11 346:12	64:20 104:10
336:21 337:7	238:21	strong 203:23	106:14 130:17
statement 22:5	stenographically	257:15 324:14	136:24 140:3
64:6 99:5,25	352:12	stronger 24:19	175:23 176:13
100:19 102:4	stepwise 316:16	strongly 172:22	209:5 240:18,22
136:10 143:8	sterile 315:17	190:9 192:16	240:25 241:19,20
150:24 153:23	sterility 211:9	struck 132:6	241:24 243:20
155:5 170:25	218:10 221:5	structure 65:14	249:15 250:15,18
175:16 180:5	229:8 256:22	struggling 110:24	250:20 267:13
206:2 229:21	257:5,21	182:20 184:2	283:25 320:25
230:20 233:11	sterilization	students 33:19	328:24 340:11,24
245:19 254:20	175:13	34:4	341:13 342:19
255:23 256:14	sterilize 209:8	studied 127:9	344:8 345:8
272:21 274:25	steroid 218:22	259:25 260:8	studying 65:13
278:24 280:12,23	223:23 316:3,10	261:10 310:4	subject 17:10
284:23 286:24			71:21 87:10

[subject - t] Page 59

176.00		111.11 110.10	250.6
176:20	sufficient 40:11	111:11 112:10	surgery 350:6
subjected 168:10	42:3 57:7 70:13	113:7 116:20	surgical 175:12
subjectively 128:2	151:6,25 220:14	123:6 137:8,14,24	268:11 300:22
subjects 106:14	suggest 172:22	160:13 173:16	331:22 333:18
submission 225:21	220:7 267:10	178:14 189:18	349:7
226:7 354:1	285:2	191:24 192:3	surprised 299:16
submit 29:18	suggesting 219:14	201:8 261:13	surprising 297:23
70:23,25 82:16	suggests 94:15	263:21 266:14	323:22
submitted 15:21	239:23 243:25	268:12 273:8,13	surrounding
20:10,21 21:7,23	257:3 267:9	275:15 312:9	254:13
24:23 26:20 37:19	326:13	317:2 327:25	survey 156:15
37:25 68:10,18	suicidal 211:11	330:14 335:12	157:12
69:22 74:13 75:25	243:15	336:10 345:3,24	surveyed 129:18
76:22 86:23 87:20	suicidality 156:2,6	347:16 349:7	susceptibility
88:11,16,20	243:9 342:2	supported 96:24	290:17
227:17,24 276:9	suicide 150:12	132:4 138:11	sustainability
subscribed 357:14	153:19 154:12,22	206:12 207:23	331:11
subsequent	156:8 243:7	208:20 253:15	sustained 94:20
200:17 219:2,7,15	267:14 324:3	329:8	193:16,22,25
220:8	suite 5:24	supporting 206:7	312:11 332:4
subsequently	sullcrom.com 3:8	supports 330:18	sweden 23:18 54:9
291:8	3:10	supposed 302:19	106:15,16,23
subspeciality 66:2	sullivan 3:4 7:2,5	suppress 214:18	107:21 313:4
substance 16:24	summarize 29:6	suppressing	335:7 336:8,11
26:4 42:18 167:11	175:21	213:12	swedish 241:20
substantial 140:5	summarizing	suppression 40:5	267:13
212:6 334:5	176:3	52:14 137:22	switch 191:11
success 186:21	summary 37:22	170:10 217:12	sworn 7:18 8:2
successful 45:4	94:7 175:19 178:3	219:15 220:7	352:6 357:14
161:20	summer 7:7,11	supreme 299:14	symptoms 114:10
suffer 258:22	superficially	sure 9:2 18:2,15	synthetic 222:9
319:8	280:21	19:16 20:24 25:8	223:3
suffering 57:15	superior 346:16	26:9,13 36:9	system 17:15
58:2 110:12	supervising 72:10	54:12 64:5 69:19	39:25 206:14
168:22 173:15	supervision 54:12	70:9 83:5 195:14	208:5
192:9 193:2,6	60:5 336:25	277:5 285:18	systematically
239:15 247:6	support 11:19	317:17	29:11 129:17
288:2 314:20	22:21 55:22,23	surface 62:10	t
326:16 333:5	57:17,20 58:21	surgeries 241:7,14	-
347:23	59:24 60:5 97:2	350:2	t 352:1,1 353:6
	107:7,20 108:17		356:3,3
	X7 '4 4 T		

[table - think] Page 60

table 274:25	teachers 176:23	terminated 56:23	theological 226:25
take 5:11 10:10,13	teaching 50:4	terminology	247:15 265:15,24
11:16 16:23 18:5	228:11 244:10,23	116:16 301:9	theology 230:10
49:16 86:7,10	245:7,11 246:24	terms 168:5	244:10 263:12
89:10 104:9	teachings 228:10	198:21 199:4	theoretical 151:16
124:13 139:9	246:21 247:10	202:11 208:15	theory 220:4
156:16 158:8,18	team 68:22	253:24 260:9	therapies 106:8
181:21 185:19	technical 288:11	291:2 293:25	336:15
196:9 233:25	technological	296:25	therapist 179:3,21
238:4 246:22	101:19 227:3	test 92:17 114:17	180:3
248:2,11 249:4	technology 6:2	167:18 319:19	therapy 106:19
307:8,12 310:6,8	teleconference 2:5	320:12	108:19 109:21
325:19 338:22	teleologic 265:11	testable 249:13	151:8 152:3
341:12 343:22	265:20	324:10 325:21	154:25 161:9
345:11 347:13	teleological	tested 109:10	164:13 170:10
351:7	244:11	testifies 8:3	172:2 175:11
taken 5:15 8:19	telephone 16:10	testify 11:19 352:7	197:8,11 217:23
86:16 107:21	tell 10:22 30:5	testifying 55:16	240:19 249:3
159:6 238:9	35:10 36:9 84:21	105:20	255:11,15 260:5
310:12 335:7	179:4,22 180:3,10	testimony 10:7	263:20 293:15
339:2 351:11	telling 180:19	15:17 16:20,25	302:3 304:7 305:7
352:11	200:17	355:9,18 357:8	310:19 314:7,23
takes 94:10	telos 230:17	testosterone 52:22	321:7 325:7 330:5
171:16 196:7	ten 86:7 130:7,9	58:25 61:15	343:17
talk 161:14 213:8	233:25 277:4	223:15 314:7	thing 20:22 114:6
231:10 241:22	tend 271:17	315:24	223:14,16 224:9
259:3	term 81:13 113:24	tests 287:12	277:18 341:17
talking 35:16 74:2	113:25 138:19	tether 323:23	things 59:12 74:21
101:24 122:24	161:12,22 164:10	texas 303:11 305:5	106:7 109:10
131:17 144:18	164:12 190:2	305:15	153:24 193:12
165:8,9 166:14	193:11,13,15,22	text 308:22	202:16 208:17
183:8 184:9	193:24 213:5	thank 7:16 8:5,10	220:22 259:20
208:25 222:9	214:20 216:5	10:8 21:12 24:21	266:2 267:23
237:4,8,9 239:12	217:7,17 230:17	82:22 86:12 89:13	269:6 275:21
253:5 294:3 330:3	233:4 241:4,21	102:16 259:11	277:5,13 288:8
talks 99:15	261:21 266:25	300:6,10 351:5,15	321:16 339:14
task 131:10	267:3,4 271:17	thanks 338:23	think 10:19 11:8
tasks 64:13 70:7	272:4 279:6 280:2	themself 282:2	28:13 35:18 45:25
tavistock 36:14	282:19 323:6,9	theologian 228:9	57:12,21 58:4
teacher 276:4	331:10,10 332:5	228:17 245:5	59:3 60:15 64:6
	333:7 343:6		64:22,22,22 69:21

[think - training] Page 61

				_
	74:18 75:10 77:8	295:3 297:3,17	15:14,20 22:16	292:3,6 296:19
	83:12 85:4 86:11	298:6,12 299:18	24:7 26:6,8,25	316:18 317:11
	96:6 100:13 110:7	301:18,21 306:5	27:4 28:16 62:24	337:19
	110:16 114:20	306:11,22 308:25	64:11 65:25 66:16	timing 23:20,21
	115:16 117:9	309:11 310:5,7	66:18 68:23 71:19	28:13 158:4
	119:19 121:15	311:5 313:11,17	76:15 77:22 80:20	221:22
	132:25 133:18	316:13 323:5	86:11 96:20 99:22	titled 18:24
	135:7 136:15	328:19,21 329:2	99:23 117:20	today 8:14 9:22
	138:2 140:5,23	334:4 335:13	119:19 121:16	10:7,9 15:17
	151:13,20,22	338:11 339:15,22	142:23 156:19	16:23 52:6 113:15
	152:6 155:16,23	340:18 343:9	158:25 160:13	133:23 166:23
	162:11 164:10,17	344:20 348:17	169:25 170:14	188:8 309:7
	165:4,10,17 166:6	349:25 350:15	174:10 188:10	told 150:11 178:25
	166:21 168:4,24	351:3	193:17 194:2	179:20 180:9
	170:22 172:21	thinking 59:12	195:12 198:23	302:12,18
	174:10 176:10,11	99:21 236:6 285:5	204:4 215:7,23	tool 114:16 157:10
	181:23,25 182:6	296:25	216:25 217:24	tools 324:23
	184:19,25 185:16	thinks 164:18	220:20 231:15,16	top 226:14 244:4
	186:2,5,7,13,24	278:6 287:20	233:24 255:2	275:9
	187:2,7 190:3,11	290:4	267:21 276:25	topic 15:13 32:23
	190:11 194:20	third 175:4,7	277:4 295:17	34:21 48:5 53:6
	195:15 198:20	thought 112:7	297:21,22 301:7	88:3 107:17
	199:6,12 200:22	166:8	301:14,15 306:12	149:21 204:9
	201:7 202:5 203:3	thousand 342:20	308:4,6 316:25	205:16 257:22
	203:21 206:15	threaten 153:17	323:4 326:25	291:24
	207:19 218:19	three 35:21	329:6 333:5	topics 51:20 85:8
	219:12 220:13	159:16,19 160:22	344:10 345:9,12	85:17
	221:3 231:20,21	161:2,3 185:11	347:13 349:17	toronto 170:6
	232:16 233:6	190:23 191:22	351:5 352:13	totality 258:14
	234:5 238:2 239:3	196:21 239:4	355:19	348:7
	241:17 242:3,24	270:9 273:23,24	timed 214:19	trace 93:18 102:9
	247:15 248:8	277:24 310:17	217:19	track 13:22
	249:17,21 251:6	319:11 329:13	timeframe 165:11	tradition 230:17
	255:22 256:18	threshold 335:15	355:8	trained 65:23
	258:19 262:11	thromboembolic	times 16:11 34:17	70:11 130:11
	267:12 270:5,15	224:18	64:17 106:16	training 33:12,14
	270:16 275:3	thrombosis	114:7 115:21	33:17,20,23 34:6
	278:20 279:5	224:22	132:20 185:21	34:10,11 51:14
	280:5 283:18	thyroid 31:8 39:14	188:7 206:5	65:10,19 66:2,6,8
	285:10 289:4,17	time 5:3,9 6:14	267:14 286:11	66:11,17,24 67:3
	290:8,11 292:15	10:12 12:19 14:4	287:16 288:5	70:22 73:3,4
\Box				

[training - try] Page 62

100.01.001.65	4 20 25 21 2	106 10 110 21	
128:21 291:6,7	treat 30:25 31:2	106:18 110:21	treats 52:10
trait 91:8 230:19	31:12 39:24 42:9	113:17,24 114:7	tremendous 329:2
trajectory 173:14	42:25 43:2 52:15	125:22 127:8	trend 279:25
271:5 272:4,9	52:19 71:8,13	137:8,15,18,21,24	trial 59:13 61:4
trans 298:19	108:19 109:22	138:6,8 143:2,7	71:17,18,21 72:6
transcript 248:9	151:8 152:2	143:11 146:9,17	72:11 106:19
352:11 355:6,20	212:15,19 213:6	147:3,4,16,23	107:6 147:10,25
357:5,8	213:25 214:22	149:5 150:18	313:2 341:7 344:4
transfer 54:17	217:15 223:8	153:19 156:21	344:12 345:7
transgender 50:14	229:5 253:19	157:19 160:6,18	346:24
50:17,20 52:9	259:19 263:20	166:8 167:4	trials 60:4 63:19
53:17 56:4,19	266:14 278:9	175:21 191:23,24	68:16 71:8,13
74:23 75:4,20	310:19 314:8,24	192:25 196:22	107:22 108:18
76:5 84:18 87:5	315:22 317:15	207:23 208:7,8	109:20 110:10,20
87:21 175:9 176:5	324:18 334:17	210:5 211:3,13,24	111:20 136:14
178:10 179:6,13	343:17 346:2	212:22 213:10	147:20 222:3
179:25 181:10	treated 39:2,11,17	221:6 222:5 225:8	249:20 263:16
182:3,4,11 183:4	39:18 40:3,18,23	243:18 246:24,25	309:23 319:22
183:24 184:7	41:5 143:3 170:9	247:25 248:10,22	337:22 340:19,20
185:8,17 199:9	330:23 332:13	248:25 252:13	340:21 348:24
204:20 234:5,9,13	334:13	259:15 260:14	tried 23:11 232:11
234:15 297:13	treating 39:19	263:22 268:6,10	323:13
transgendered	41:21 45:16,20	268:11 284:16	tries 168:17
180:7 296:21	58:24 142:2,10	290:14,17 307:16	true 20:14 21:9
transition 116:20	159:16 216:7	308:9,16 311:12	119:15 124:10
127:23 145:11	223:11 224:14	311:14 312:16	186:15 230:5
177:14 261:24	235:4 305:6	313:6,17 314:10	236:17 352:10
262:14 264:12	315:25 325:11	316:6,12 317:13	357:8
265:7 269:22	327:4 331:4	317:17 329:7,12	truly 196:22
270:6,16,17 271:9	334:10	329:14,21,23	trust 288:9 293:11
271:11 272:17	treatment 23:4	334:25 341:20	trustees 274:17
308:16,25 309:5	33:5,18 39:8 41:4	345:14 346:16	truth 278:7 352:7
309:14,24	41:7 42:5 44:12	348:18 353:15	352:7,8
transitioned 54:8	46:14 47:15 48:9	354:9	truthful 10:7
transitioning	49:15,16 52:13	treatments 32:24	truthfully 10:2
175:10 176:6,8	56:8,21,23 57:25	41:20 46:6 53:2	try 9:13,17 78:17
trap 330:11	61:22 62:16 63:11	54:6 55:12 59:15	124:11 195:24
trauma 334:15,23	63:23 64:9 75:3	60:8 109:4 145:13	196:10 216:14
traumas 163:5	75:19 76:4 77:16	145:16,25 206:11	230:7 254:18
191:18	78:9 103:14	208:20 266:12,13	273:12 291:21
	104:12 105:17	346:15	293:9
	X7 '4 4 T		

[trying - unity] Page 63

trying 28:13 35:17	types 15:8 23:7	259:17,19 312:6	350:21
36:2,8,11 37:10	68:2 74:25 81:3	316:5 325:9 326:3	understands
39:22 44:22 79:16	125:18 178:21	326:10 332:19,22	171:10 237:20
79:22 85:4 99:5	182:25 203:15	332:22 335:19	understood 9:20
124:15 129:22	204:6 224:10	undernourished	9:21 10:18 18:3
159:13 162:25	236:18 325:25	119:12	24:12 26:18 35:12
169:23 202:17	typically 134:13	understand 9:15	71:10 73:8 235:21
231:18 253:5		14:4 32:2 39:22	265:14 271:7
259:4 274:19	u	48:20 58:20 62:14	understudied
275:4,17,19,20	u.k. 23:19 36:21	64:23 89:7 93:24	324:21
276:2 277:16,18	149:23	110:24 118:9	underutilized
295:19 326:18	ultimately 88:19	129:22 131:12	324:21
tschiemer 4:22 6:3	193:14 241:12	159:14 183:20	unethical 258:8
tumors 224:5	unanswered 45:24	200:3 202:17	330:3
turban 243:3	332:3	205:13 209:21	unexplored
turn 17:17 98:13	unaware 129:13	231:9 234:12	311:23
101:12 121:13	130:2	247:17 251:15,16	unfortunately
124:13 127:18	unbiased 29:24	251:18 252:2	86:25 115:7
145:5 153:5	63:16 263:9	263:5 278:22	uniformly 132:5
159:11 161:7	uncertain 152:11	292:20 298:14	union 3:12 235:7
244:3 277:22	212:12	301:20 318:15	236:13
turning 174:23	uncertainty 43:11 199:20 206:21	understanding	unique 118:24
two 7:7 16:6,12	207:5	15:6 41:2 52:16	119:3,21 120:5
17:10,19 37:11	uncover 320:2	55:7 60:19 66:25	122:25 123:10
69:12 77:20 80:3	undergo 76:20,23	95:3 105:25	164:7 206:16,18
86:21 153:18	95:12	106:22 108:24	207:20 208:17
160:24 177:6	undergone 34:22	111:5,14 113:22	210:18 231:12
194:17 198:14,14	46:7 76:11	148:11 173:7	237:13
237:25,25 241:17	undergraduate	176:7 196:25	uniquely 117:21
242:23 269:18	65:7	197:20 198:25	uniqueness 114:21
277:24 318:8	underlying 32:2	202:25 227:21	unit 5:13
346:8	41:10,16 43:2	230:13 231:7	united 1:1 5:18
type 26:3 57:19	45:2 93:25 139:11	232:22 233:20	36:15 76:19
67:20 85:20	141:4 149:18	235:22 237:10	105:13 137:5,13
100:16 105:4	160:14 163:2,8,9	239:2 247:12,18	139:23 178:5
109:7 112:25	167:10 173:10	263:6,25 265:20	299:14
166:18 187:9	186:8,19 189:19	266:6 269:21	unites 227:5
195:10 207:9	194:24 195:17	281:13,17 286:19	unity 244:13
224:12,16 313:22	229:11 232:21	291:14 295:19,25	245:16 250:25
336:23 345:10	235:22 238:16	312:3 336:6	251:8,20
	239:15,25 240:5	347:13 349:22	
1	237.13,23 2TU.3		

[universal - video] Page 64

universal 334:3	212:14 213:5,23	282:7 294:19	varying 232:19
universities 84:25	216:15 223:3,7	valid 59:5,10 61:6	334:6
university 30:9,16	225:7 226:10	63:16 139:19	vast 92:4 93:14
49:24 50:16 51:3	229:9 237:7	141:12	94:16 160:10
65:8,22 66:4,7	238:14 239:17	validate 93:10	vastly 188:22
67:6 68:15 71:12	252:12,20 254:15	validated 114:16	209:6 214:16
83:8 274:18 278:8	262:5 269:25	116:7 291:9	224:2 237:24
278:11	271:15 276:5	validity 63:20	venture 273:24
unknown 94:23	280:7 281:10,16	valuable 115:17	venue 227:23
unknowns 187:7	282:13,18,19,25	115:18	venues 14:23
unproven 146:21	283:10 284:4	value 129:6	262:23
311:22 312:23	285:23 291:2	167:18 247:13	veracity 114:18
314:15 340:3	292:2 293:2,9	320:4	123:8,14,25
unreliability	294:15 295:11	valued 67:21	139:15 246:12
121:22 122:9	297:12 299:24	109:17	330:19
unreliably 128:5	305:24 306:23	values 251:15	verbally 9:6
unsupported	325:20 338:5,16	vancouver 37:6	verbatim 124:24
321:10	341:25 353:14	vantage 324:4	154:16
untreated 97:6	useful 73:16	variability 198:16	verifiable 119:24
unwilling 133:23	319:19	variable 15:3	181:4 279:18
134:5	uses 188:2 282:3	284:24 341:17	verified 119:7
update 29:2	284:25 296:6	variables 341:12	121:6 321:15
updated 74:12	usually 46:16	variation 195:21	verifies 19:18
upheld 256:10,13	60:20 70:16	251:19	verify 20:14
upload 274:5	149:25 208:10	variations 195:22	114:10 127:4
uploaded 18:20	utility 117:4	198:12	355:9
urgent 103:11	utilize 293:3	varied 231:16	veritext 2:6 6:4,7
111:3	utmost 109:11	variety 64:17	355:14,23
urinary 350:10	340:2	162:5,9 171:22	veritext.com.
usage 177:3	V	174:3 254:4 332:7	355:15
283:14 285:13	v 1:9 91:16 130:23	various 34:5 57:25	version 75:14
usages 292:3	277:25 299:9	71:22 72:7 74:24	versus 5:17 57:7
use 17:14 36:22	354:6 355:4 356:1	86:21 106:2	61:22 82:19
37:7 54:10 77:15	357:1	113:23 116:13	130:22 224:20
78:8 116:16	vacuum 253:3	160:5 171:16	232:3 253:25
119:20 141:19	264:17	175:21 181:6	263:5 267:23
152:23 154:3,10	vague 53:19 90:14	182:23 184:4	268:25 273:21
157:14 164:12	95:10 104:15	232:24 298:24	274:17 297:2
174:9 180:12,13	120:7 171:14	313:20	339:16 344:17
195:7,24 200:19	183:19 193:4	vary 106:4	video 4:22 5:10,14
202:24 208:4	251:4 270:20		307:7 310:10
	231.4 270.20		

videoconference	virtually 2.4	99:1 100:1 101:1	222:1 223:1 224:1
1:15	virtually 2:4 vitally 231:22	102:1 103:1 104:1	225:1 226:1 227:1
videographer 5:1	vitally 231.22 vocally 177:23	105:1 106:1 107:1	228:1 229:1 230:1
6:5 7:16,23 8:5	voted 116:25	103.1 100.1 107.1	231:1 232:1 233:1
,		111:1 112:1 113:1	234:1 235:1 236:1
86:5,6,13,17	voting 117:15		
158:16,17 159:3,7	vries 175:23 vsds 48:19	114:1 115:1 116:1	237:1 238:1 239:1
233:23,24 238:3,6		117:1 118:1 119:1	240:1 241:1 242:1
238:10 307:8	vulnerable 57:16	120:1 121:1 122:1	243:1 244:1 245:1
310:9,13 338:24	145:13	123:1 124:1 125:1	246:1 247:1 248:1
339:3 351:9,12,18	W	126:1 127:1 128:1	249:1 250:1 251:1
videotape 2:3	w 1:17 2:3 7:25	129:1 130:1 131:1	252:1 253:1 254:1
videotaped 1:16	8:1 9:1 10:1 11:1	132:1 133:1 134:1	255:1 256:1 257:1
view 91:17 100:4	12:1 13:1 14:1	135:1 136:1 137:1	258:1 259:1 260:1
113:16 125:19	15:1 16:1 17:1	138:1 139:1 140:1	261:1 262:1 263:1
146:13 147:5,25	18:1 19:1 20:1	141:1 142:1 143:1	264:1 265:1 266:1
190:19 192:24	21:1 22:1 23:1	144:1 145:1 146:1	267:1 268:1 269:1
194:12 197:22	24:1 25:1 26:1	147:1 148:1 149:1	270:1 271:1 272:1
201:9 206:6 229:7	27:1 28:1 29:1	150:1 151:1 152:1	273:1 274:1 275:1
229:19 232:14	30:1 31:1 32:1	153:1 154:1 155:1	276:1 277:1 278:1
233:8 234:6,22	33:1 34:1 35:1	156:1 157:1 158:1	279:1 280:1 281:1
235:14,25 236:24	36:1 37:1 38:1	159:1 160:1 161:1	282:1 283:1 284:1
240:4 246:13	39:1 40:1 41:1	162:1 163:1 164:1	285:1 286:1 287:1
252:3 253:17	42:1 43:1 44:1	165:1 166:1 167:1	288:1 289:1 290:1
255:10,14 259:10	45:1 46:1 47:1	168:1 169:1 170:1	291:1 292:1 293:1
305:18 310:22,23	48:1 49:1 50:1	171:1 172:1 173:1	294:1 295:1 296:1
326:22 330:21	51:1 52:1 53:1	174:1 175:1 176:1	297:1 298:1 299:1
332:12 333:20	54:1 55:1 56:1	177:1 178:1 179:1	300:1 301:1 302:1
viewed 230:8	57:1 58:1 59:1	180:1 181:1 182:1	303:1 304:1 305:1
viewpoints 227:12	60:1 61:1 62:1	183:1 184:1 185:1	306:1 307:1 308:1
views 246:14	63:1 64:1 65:1	186:1 187:1 188:1	309:1 310:1 311:1
261:24 262:9,10	66:1 67:1 68:1	189:1 190:1 191:1	312:1 313:1 314:1
262:14 264:12,14	69:1 70:1 71:1	192:1 193:1 194:1	315:1 316:1 317:1
264:18,19,21	72:1 73:1 74:1	195:1 196:1 197:1	318:1 319:1 320:1
vincent 11:8	75:1 76:1 77:1,17	198:1 199:1 200:1	321:1 322:1 323:1
violate 235:13,25	78:1 79:1 80:1	201:1 202:1 203:1	324:1 325:1 326:1
236:23	81:1 82:1 83:1,17	204:1 205:1 206:1	327:1 328:1 329:1
violates 145:11	84:1 85:1 86:1	207:1 208:1 209:1	330:1 331:1 332:1
229:7 230:12	87:1 88:1 89:1	210:1 211:1 212:1	333:1 334:1 335:1
233:8 234:6	90:1 91:1 92:1	213:1 214:1 215:1	336:1 337:1 338:1
virtual 6:2		216:1 217:1 218:1	339:1 340:1 341:1
	93:1 94:1 95:1	219:1 220:1 221:1	342:1 343:1 344:1
	96:1 97:1 98:1		

[w - wpath] Page 66

	I	I	
345:1 346:1 347:1	watch 168:2	322:9,22 323:17	wide 162:5,9
348:1 349:1 350:1	194:21 259:16	328:25 341:10	widely 178:5
351:1 352:6 353:2	watchful 160:18	343:21 344:19	william 10:24
353:16,22	160:24 162:13	ways 32:2 110:16	willing 11:10
wagner 11:9	166:22 170:7	162:6 165:6	79:24 147:9
wait 9:11 18:14	171:10,24 173:5	167:12 177:9	339:10
166:24 168:3	174:4 185:14,24	193:7 287:7	wisconsin 65:11
174:5 194:22	189:8,15 190:14	291:19 294:3	65:20
259:17	191:10 194:12	306:18,21	wise 140:10 171:8
waiting 160:18,21	195:12 196:7	we've 44:23	wish 20:22 27:3
160:25 162:13	watching 160:21	159:10 221:10	60:12
166:22 167:5	way 25:8 31:3	256:17 269:23	withdraw 255:12
170:8 171:11,24	42:22,25 56:11	278:19 291:8	witness 25:4 37:3
173:5 174:4	59:3 61:7,18,25	292:17 312:4	38:24 74:5 311:9
185:14,25 189:8	62:2,7 63:8,10	314:2 318:8	351:6 353:2 355:8
189:15 190:14	70:12 79:16 89:3	347:11	355:10,12,19
194:12 195:12	97:11 98:2 101:14	weak 321:10	witnesses 15:24
196:7	107:12 111:5,23	weaknesses 23:7	wonderful 176:11
want 17:13 20:24	112:2 113:4,13	27:22 63:3 85:21	word 143:6
52:2 73:22 74:20	116:10 128:20	100:10 328:21	198:25 271:15
84:13 104:16	134:6 141:13	wealth 181:5	wording 301:17
127:14 136:17	147:22 160:15	weaponizing	words 306:3
149:10 158:4	167:17 169:5	278:10	work 9:17 24:24
161:6 206:9	175:21 176:13	web 1:15	25:4,24 50:8
211:23 228:6	196:16 199:4	websites 181:19	52:25 73:5 186:5
250:19 264:9	208:24 219:11,12	week 17:9 24:5	297:4 317:3
277:5 279:16	232:17 236:8	weigh 193:10	worked 63:5
282:19 295:4	241:11 243:19	346:25	worker 128:17
297:12 298:8	249:10 254:8	weighing 28:7	workers 127:25
300:3 316:16	266:4 271:25	190:24 288:16	128:22
wanted 84:10	273:10 279:7	346:21	working 37:24
278:17	280:18 282:16	weighs 60:25	75:19,24 77:21
wants 282:18	286:4,10 287:20	weight 119:17	250:17 290:21
wards 50:12,12	289:4 290:3,7,11	welcome 131:21	works 34:2 306:5
warnings 153:18	292:7,11 293:12	wellbeing 239:14	world 150:21
warrant 40:11	297:7,9,19 298:4	347:15	246:13
washington 30:8	298:17 303:7	went 65:22 93:18	worse 122:14
30:16 38:5,16	306:2,4,4,15,25	west 4:5	242:4
49:24 50:16 51:3	313:3,13 315:22	whispering 5:7	worsening 242:19
65:22 66:4,7 67:6	316:23 317:22	whittaker 36:4,5	wpath 132:8
68:15 71:11 83:7	319:15,20 320:22		142:18 144:7
	X7 ' T		

[wpath - zucker's] Page 67

177:22 178:6	Z
327:13	zero 116:19 145:6
write 24:22	145:7 309:24
100:12 103:11	zoom 2:5
122:8 127:23	zucker 162:8,18
145:10 175:7	169:15 170:13
227:23 252:11	171:2,23 185:20
writing 28:11	188:11 328:15
286:3	zucker's 170:6
writings 28:19	187:12
29:19 76:3 80:15	107.12
written 82:9 88:3	
145:18 181:2	
wrong 102:18	
207:11 253:18	
255:22	
wrote 98:18 99:8	
100:3 238:14	
251:8	
X	
x 1:5,12 353:1,6	
xi01165 2:8	
y	
yeah 82:14 85:12	
127:16 308:6	
year 11:9 165:14	
179:19 182:2	
194:17	
year's 243:15	
years 13:15 51:15	
52:3,5,8 80:18	
85:6 108:9 130:7	
130:9 165:21	
174:14 189:6	
194:10 216:24	
280:22 299:23	
york 3:6,6,14,14	
young 204:22	
younger 170:3	

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.

Exhibit 6

	Page 1
1	THE UNITED STATES DISTRICT COURT
2	EASTERN DISTRICT OF ARKANSAS
3	CENTRAL DIVISION
4	CASE NO. 4:21-CV-00450-JM
5	x
6	DYLAN BRANDT, by and through his
7	Mother, JOANNA BRANDT, et al.,
8	Plaintiffs,
9	v.
10	LESLIE RUTLEDGE, in her official
11	capacity as the Arkansas
12	Attorney General, et al.,
13	Defendants.
14	x
15	CONTAINS CONFIDENTIAL PORTIONS
16	
17	REMOTE/ORAL/WEB VIDEOCONFERENCE
18	VIDEOTAPED DEPOSITION OF
19	STEPHEN B. LEVINE, M.D.
20	May 26, 2022
21	9:20 a.m. CDT
22	
23	
24	Reported by:
25	Maureen Ratto, RPR, CCR

	D 4
Page 2	Page 4 1 APPEARANCES, continued:
2	2 Co-counsel for Plaintiffs:
3 Videotape deposition of Stephen B.	3 GILL RAGON OWEN, PA
4 Levine, M.D. held virtually via Zoom	
5 Teleconference, hosted from Veritext	
	,
6 Legal Solutions, pursuant to notice,	6 BY: BETH ECHOLS, ESQ.
7 before Maureen Ratto, Certified Court	7 echols@gill-law.com
8 Reporter, License No. XI01165,	8
9 Registered Professional Reporter,	9 Counsel for the Defendants:
10 License No. 817125, and Notary Public.	10 SENIOR ASSISTANT ATTORNEY
11	11 GENERAL, PUBLIC PROTECTION DIVISION
12 ***	12 OFFICE OF ARKANSAS ATTORNEY GENERAL
13	13 323 Center Street
14	14 Little Rock, Arkansas 72201
15	15 BY: MICHAEL CANTRELL, ESQ.
16	16 michael.cantrell@arkansasag.gov
17	17 AMANDA LAND, ESQ.
18	18 aland@arkansasag.gov
19	19
20	20 ALSO PRESENT:
21	21 JASON ELY, Legal Video Specialist
22	22
23	23
24	24
25	25
Page 3	Page 5
1 APPEARANCES:	1 VIDEOGRAPHER: Good morning.
2 Counsel for the Plaintiffs:	2 We are going on the record at 9:25
3 SULLIVAN & CROMWELL, LLP	3 a.m. on May 26th, 2022.
4 125 Broad Street	4 This is Media Unit 1 of the
5 New York, New York 10004	5 video-recorded deposition of
6 BY: BRANDYN RODGERSON, ESQ.	6 Dr. Stephen Levine taken by counsel
7 rodgersonb@sullcrom.com	7 for Plaintiff in the matter of
8 EMILY ARMBRUSTER, ESQ.	8 Dylan Brandt, et al versus Leslie
9 armbrustere@sullcrom.com	9 Rutledge, et al, filed in the
10 SOPHIA MATTHEWS, ESQ.	10 United States District Court,
11 matthewss@sullcrom.com	11 Eastern District of Arkansas, Case
12	12 No. 4:21-CV-00450-JM.
13 AMERICAN CIVIL LIBERTIES UNION	Will counsel please identify
14 125 Broad Street	14 themselves for the record?
15 New York, New York 10004	15 MS. COOPER: Leslie Cooper,
16 BY: LESLIE COOPER, ESQ.	16 from the ACLU for Plaintiffs
17 lcooper@aclu.org	17 appearing in New York.
18 CHASE STRANGIO, ESQ.	MR. STRANGIO: Chase Strangio,
19 cstrangio@aclu.org	19 from the ACLU for Plaintiffs, also
20	20 appearing in New York.
21 ACLU OF ARKANSAS	21 MR. ROGERSON: Brandyn
22 904 West 2nd Street	22 Rogerson, from Sullivan Cromwell
23 Little Rock, Arkansas 72201	23 for the Plaintiffs, appearing in
24 BY: GARY SULLIVAN, ESQ.	24 New York.
25 gsullivan@aclu.org	25 MS. ARMBRUSTER: Emily
	1410. AMMIDINUS LEIN. EIIIIIV

1 Armbruster, from Sullivan & 1 STEPHEN B. LEVINE, M.D. 2 Cromwell, for the Plaintiffs. 3 MS. MATTHEWS: Sophia 4 Matthews, Sullivan & Cromwell, for 5 the Plaintiffs in New York. And 6 I'm joined by one of our summer 7 associates. 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 17 A. Okay.
2 Cromwell, for the Plaintiffs. 3 MS. MATTHEWS: Sophia 4 Matthews, Sullivan & Cromwell, for 5 the Plaintiffs in New York. And 6 I'm joined by one of our summer 7 associates. 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 2 one another. So if you can let me finish 3 my question before you begin to answer, 4 then even if you anticipate the end of my 5 question it makes for a much cleaner 6 record if you let me finish the question 7 and you then answer and I will do my best 8 to wait until you completed your answer 9 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
3 my question before you begin to answer, 4 Matthews, Sullivan & Cromwell, for 5 the Plaintiffs in New York. And 6 I'm joined by one of our summer 7 associates. 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 3 my question before you begin to answer, 4 then even if you anticipate the end of my 5 question it makes for a much cleaner 6 record if you let me finish the question 7 and you then answer and I will do my best 8 to wait until you completed your answer 9 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
4 Matthews, Sullivan & Cromwell, for 5 the Plaintiffs in New York. And 6 I'm joined by one of our summer 7 associates. 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 4 then even if you anticipate the end of my 5 question it makes for a much cleaner 6 record if you let me finish the question 7 and you then answer and I will do my best 8 to wait until you completed your answer 9 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
the Plaintiffs in New York. And I'm joined by one of our summer associates. VIDEOGRAPHER: Mr. Cantrell, can we get your appearance here? MS. ECHOLS: Beth Echols, li Bill Ragon Owen, for the Plaintiffs, in Little Rock. MR. CANTRELL: I'm Michael Cantrell, with the Arkansas Attorney General's Office, for the Defendants. VIDEOGRAPHER: Mr. Cantrell, square for a much cleaner record if you let me finish the question and you then answer and I will do my best to wait until you completed your answer before asking another question. Okay? A. Okay. Defore asking another question of the your testimony needs to be typed, that you answer verbally, so nods can't be depicted up by the court reporter and also before asking another question of the your answer before asking another question of the your
6 I'm joined by one of our summer 7 associates. 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: Mr. Cantrell, 7 and you then answer and I will do my best 8 to wait until you completed your answer 9 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
7 and you then answer and I will do my best 8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 and you then answer and I will do my best 18 to wait until you completed your answer 19 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
8 VIDEOGRAPHER: Mr. Cantrell, 9 can we get your appearance here? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: Mr. Cantrell, 18 to wait until you completed your answer 9 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
9 before asking another question. Okay? 10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 19 before asking another question. Okay? 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
10 MS. ECHOLS: Beth Echols, 11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 10 A. Okay. 11 Q. And it's important because 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
11 Bill Ragon Owen, for the 12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 18 Q. And it's important because 19 your testimony needs to be typed, that 10 you answer verbally, so nods can't be 11 picked up by the court reporter and also 12 words like a-hum are hard to transcribe. 13 So just be mindful of that, please, okay? 14 A. Okay.
12 Plaintiffs, in Little Rock. 13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 18 your testimony needs to be typed, that 19 your testimony needs to be typed, that 10 your testimony needs to be typed, that 11 your testimony needs to be typed, that 12 your testimony needs to be typed, that 13 you answer verbally, so nods can't be 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
13 MR. CANTRELL: I'm Michael 14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 18 you answer verbally, so nods can't be 19 picked up by the court reporter and also 19 words like a-hum are hard to transcribe. 19 So just be mindful of that, please, okay? 10 A. Okay.
14 Cantrell, with the Arkansas 15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 18 picked up by the court reporter and also 19 picked up by the court reporter and also 19 picked up by the court reporter and also 10 picked up by the court reporter and also 11 picked up by the court reporter and also 12 picked up by the court reporter and also 13 picked up by the court reporter and also 14 picked up by the court reporter and also 15 words like a-hum are hard to transcribe. 16 So just be mindful of that, please, okay? 17 A. Okay.
15 Attorney General's Office, for the 16 Defendants. 17 VIDEOGRAPHER: The witness 18 words like a-hum are hard to transcribe. 19 So just be mindful of that, please, okay? 10 A. Okay.
16 Defendants. 16 So just be mindful of that, please, okay? 17 VIDEOGRAPHER: The witness 17 A. Okay.
17 VIDEOGRAPHER: The witness 17 A. Okay.
18 will now be sworn in by the 18 Q. If I ask a question that is
19 reporter. 19 not clear to you or you need
20 * * * * 20 clarification, please just ask and I will
21 STEPHEN B. LEVINE, M.D., having been 21 try to ask the question in a clearer way.
22 first duly sworn according to law by 22 But if you answer the question I will
23 the Officer, testifies as follows: 23 assume that you've understood it. Okay?
24 DIRECT EXAMINATION BY MS. COOPER: 24 A. Okay.
25 MS. COOPER: We did not hear 25 Q. And we will likely need to
Page 7 Pag
1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D.
2 sound when Dr. Levine said "I do". 2 take some breaks during the course of the
3 THE WITNESS: I do. 3 day. I will certainly call some but if
4 Q. Thank you. Good morning, Dr. 4 there is any point which you need a break
5 Levine. 5 just let me know and if I have a pending
6 I know we've met before but 6 question we'll just ask that you answer
7 it's been a very long time so I'll 8 reintroduce myself. 7 that question and I'll try to find a good 8 breaking point, okay?
8 reintroduce myself. 8 breaking point, okay? 9 My name is Leslie Cooper and 9 A. Okay.
10 I'm with the ACLU, counsel for 10 Q. Is there anything that would
11 Plaintiffs, and I'll be taking your 11 prevent you from providing competent or
12 deposition this morning or today. 12 complete and competent testimony today?
13 So let's start out, just for 13 A. I can't think of anything.
14 the record, can you please state your 14 Q. Okay. Is there any material
15 full name? 15 you're consulting in connection with your
16 A. Stephen Barrett Levine. 16 deposition today, anything in front of
17 Q. So I know you've been deposed 17 you?
18 a number of times before, but just so 18 A. Nothing is in front of me.
19 we're clear, I'll go through the 19 Q. Okay. Did you do anything to
20 groundrules so that we make sure we get a 20 prepare for the deposition today?
21 clean record and the court reporter is 21 A. Yes.
22 able to transcribe my questions and your 22 Q. What did you do?
23 answers. 23 A. I reread my original expert
So first ground rule is let's 24 opinion report, I read some of the other
25 both do our best to avoid speaking over 25 Plaintiffs' experts report, I reread my

1	Page 10 STEPHEN B. LEVINE, M.D.	1	Page 12 STEPHEN B. LEVINE, M.D.
1	recent article on informed consent,	2	VIDEOGRAPHER: We're going
	things like that.	3	back on the record. The time is
4	It's hard for me to answer	4	9:59.
1	that question explicitly because I'm	5	Q. Thank you. When we left off I
	constantly reading things on this		was asking about anything you did to
	subject.		prepare for the deposition. I just have
8	Q. You mention you read some of		one last question about that.
	the Plaintiffs' expert reports. Which	9	Did you speak with anyone
	ones?		other than counsel about your testimony
11	A. I read part of Dr. Adkins'		today?
	report again and I read Dr. Anton Maria.	12	A. No.
13	Q. Is that it?	13	MR. CANTRELL: Give us one
14	A. I read a very brief report	14	second. We had a technical issue.
15	from like a three-page report from I	15	A. No.
	think an endocrinologist. Hutchison was	16	Q. I want to ask some questions
17	it perhaps?	17	about your background as a psychiatrist
18	Q. Did you read a report from	18	and your treatment of patients.
19	Dr. Karasic?	19	I understand you've been a
20	A. I originally read Karasic's	20	psychiatrist for quite some time. Can you
1	report but I didn't do it in preparation		give me an idea of approximately how many
1	for today.	22	patients you've treated in your career?
23	Q. Okay. And what about	23	A. Well, if my career begins when
1	Dr. Turban's report?		I was finished my residency, I have been
25	A. I didn't read that yesterday	25	practicing psychiatry full-time since
	Page 11		Page 13
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.
2	STEPHEN B. LEVINE, M.D. either, but I've read it in the past.		STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually
2 3	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with	3	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've
2 3 4	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition?	3 4	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a
2 3 4 5	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did.	3 4 5	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that
2 3 4 5 6	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that?	3 4 5 6	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and
2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning.	3 4 5 6 7	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll
2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that	3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with
2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare?	3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head.
2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right.	3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like
2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to	3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than
2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having	3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound
2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again.	3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right?
2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off	3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's	3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy.	3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the record? I think it's more than	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12 months a year?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the record? I think it's more than that.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12 months a year? A. Five and a half days a week
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the record? I think it's more than that. VIDEOGRAPHER: Off the record	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12 months a year? A. Five and a half days a week for most of those years.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the record? I think it's more than that. VIDEOGRAPHER: Off the record at 9:32.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12 months a year? A. Five and a half days a week for most of those years. Q. Okay. So say in the past year,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	stephen B. Levine, M.D. either, but I've read it in the past. Q. Okay. Did you meet with counsel to prepare for your deposition? A. I did. Q. When did you do that? A. 7:30 this morning. Q. Was that the only meeting that you had to prepare? A. That's right. MS. COOPER: I just want to pause for a moment. We're having some sound issues again. Can we do we need to go off the record to clear this up? It's been fuzzy. THE WITNESS: I spoke very softly the last time. MS. COOPER: Can we go off the record? I think it's more than that. VIDEOGRAPHER: Off the record	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. 1973, July 1st. I've never actually counted up the numbers of patients I've seen, but I work an average of 35 hours a week with patients. So you multiply that by four and then multiply that by 12 and then multiply that by 49, I think you'll have the answer. I'm not that good with math anymore in my head. Q. All right. So sounds like we're talking about potentially more than a thousand patients. Does that sound right? A. I trust your math. Q. Okay. And can you give me an approximate number of patients you see within a year? Is it the same math that you just described, about 35 patient hours a week with four days a week, 12 months a year? A. Five and a half days a week for most of those years.

Page 14 Page 16 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 -- I've worked from ten a.m. to six p.m. 2 A. Well, I run teaching 3 only five days a week, and most of those 3 conferences and sometimes a child is 4 hours are spent with patients. 4 presented with a parent at a teaching Q. Okay. In your practice, do I 5 conference, so... 6 understand right, most of your patients Q. So, but of your patients that 7 you've seen and treated, there's about 7 are adults? A. Teenagers and adults. 8 six prepubertal children total, all of Q. And by teenager, do you mean 9 whom were there for gender 10 under 18 or would you include 18 and 10 identity-related issues? 11 19-year-olds in that? 11 A. Yes. 12 12 A. No. I see sometimes 15, 16, Q. So that's a good pivot to 13 17-year-olds. 13 focusing in on your treatment of patients 14 Q. And I believe you recently 14 with gender dysphoria or gender 15 testified that you've seen about 50 15 identity-related issues. And I know 16 adolescent minor patients in your career. 16 you've been asked about that at a number 17 Is that still about right? 17 of depositions, so I just want to follow A. All these are guesstimates, 18 up a little bit to make sure I have that 19 Ms. Cooper. I don't think I've changed my 19 clear. 20 estimate since the last deposition. 20 Can you give me an approximate 21 Q. Okay. So it would be fair to 21 number of adult patients you've 22 say the overwhelming majority of your 22 personally treated in the past year that 23 patients are adults and a small, much 23 have gender dysphoria? 24 smaller number are minors? 24 A. I am hesitating because of the 25 That's correct. 25 word "treatment" or "treated". Page 15 Page 17 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 Q. Speaking of prepubertal Do you mean how many people 3 children, I believe you most recently 3 I've actually seen with a gender problem 4 that I saw testified that you've seen 4 versus somebody I'm actively regularly 5 trying to help with one problem or 5 about six prepubertal children. Is that 6 about right still? 6 another or do you mean all of the above? 7 A. That's about right, still. 7 Q. Thank you. That's a good 8 O. And that's for any condition? 8 question. Let's break it down. A. No. Those are all So how many patients have you 10 seen in the past year who have had a 10 gender-identified children. 11 11 gender problem, I think is the language Q. Okay. A. I'm sorry. I hear about other 12 you used? 12 13 children, I mean children with other 13 A. I would guess about ten. 14 problems, since adults often talk about 14 Q. And of those ten, how many 15 troubles with their children. 15 would you put in that other category of 16 regularly treating? Q. But as far as your own 17 patients, you've seen about six 17 A. Well, regularly treated 18 prepubertal children and all of them had 18 sometimes means regularly twice a year, 19 gender identity-related issues; is that 19 sometimes it means once a week, sometimes 20 right? 20 it means someone coming for a three or 21 A. That is right. 21 four hour consultation and there the 22 Q. You didn't see prepubertal 22 evaluation and the treatment get all 23 children for other conditions? 23 mixed up. 24 A. Not generally. 24 So I would say about the ten, 25 Q. Ever? 25 to use a concept of treatment of trying

Page 18 Page 20 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 to influence in one way or another, 2 about your supervision of others, but 3 before we get to that. So I've just 3 clarify something, to be helpful to the 4 asked you about in the past year. 4 patient. I've always tried to be 5 Can you give me an 6 approximation of the number of patients 6 helpful. So I would say I've been 7 treating 100% of those people, but many 7 you've seen with gender dysphoria in the 8 of them come for a one-time evaluation or 8 past five years? A. I would say that I have 9 a followup. 10 10 contacts with families or patients So I think in the last year 11 probably most everyone I've seen has been 11 directly with gender dysphoria about ten 12 for a short-term intensive followup and 12 times a year. And I don't think that has 13 three or four of them may have been just 13 changed much in the last five years. 14 coming back every six months or three Q. And are some of those patients 15 months, something like that. Obviously, I 15 people who -- let me rephrase that. 16 don't keep track of these numbers. Do I correctly assume it's not Q. Understood. And when you say a 17 necessarily ten new patients each year, 17 18 short-term intensive followup, is that 18 that some of them are ongoing over a 19 course of more than one year? 19 different than an evaluation? 20 A. Well, it's someone I've 20 Some of them, yes. 21 evaluated years before, you see. 21 Q. Okay. And have patients with 22 gender dysphoria always been, you know, a 22 Q. And then they come back for 23 another evaluation several years later? 23 similar percentage of your practice, 24 these small numbers? A. No. They come back for 25 25 medication or some emotional issue They've never been the Page 19 Page 21 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 they're having. 2 majority of my practice. It's varied from 3 Q. I see but -- I'm sorry. Go 3 year to year. You need to understand that 4 I used to be -- I started the first 4 ahead. 5 gender identity clinic in Cleveland, Ohio 5 A. Someone, some 40-year-old 6 trans person just had renal cancer and he 6 in 1974. And so in those days we were 7 came to discuss -- she came to discuss 7 keeping track of the numbers of people 8 that process. 8 and by 1989 we had -- I think we had 325 9 evaluations done and we stopped keeping Q. I see. So of the patients who 10 you were providing sort of ongoing 10 track when we stopped keeping track. 11 therapy for, would it be about three or Would you repeat the question, 12 four in the past year who have had gender 12 please? I don't think I answered it. 13 dysphoria? Q. Well, no, thank you. I was 13 A. Most of my work in the past 14 asking whether the -- whether gender 15 year has been supervising other people 15 dysphoria patients have always been a 16 who have had patients with gender 16 similar percentage of your entire patient 17 dysphoria. 17 pool? Q. I'll ask you about that. But 18 A. My specialty from 1973 on was 19 before we do that, of your own patients 19 human sexual problems, and gender 20 is it about three or four that you've 20 problems were just one of five or six 21 seen that you're doing ongoing therapy 21 different categories of problems that 22 with in the past year? 22 I've been involved with. A. I think it would be closer to 23 23 So I would say not more than 24 two to three. 24 15% of my time over the course of my 25 Q. Okay. And I will be asking 25 career has been spent with gender

Page 22 Page 24 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 problems. The rest of the time has been 2 to gender dysphoria. And so I would say 3 spent with other ways that human beings 3 -- are you asking for a number? 4 suffer sexually. 4 Q. Yeah. Q. So let's turn to your 5 A. I would say at any given time 6 supervision of the work of others dealing 6 there's probably a dozen people in our 7 practice with a gender identity issue. 7 with gender issues. Whose work do you supervise in Q. The Transgender Team or -- the 9 Gender Diversity Team is the proper name 9 this area? 10 for it: is that correct? 10 A. I've always supervised all the 11 staff that has worked with me and so I've 11 A. Yes. 12 always had a staff from 1973 on. So 12 Q. Are they affiliated with any 13 basically, I've been the senior person 13 other institution besides your private 14 and on these -- so everyone who got 14 practice? 15 presented to our gender clinic eventually A. No. 15 16 got presented to me and many of the times 16 Q. Not with any university? 17 I've interviewed those people. A. No. I am but they are not. 17 I now currently supervise six 18 Q. And those folks who you 19 people in the transgender team. Actually 19 supervise who have seen about 12 patients 20 someone just got added, so it would be 20 at any given time with gender identity 21 seven. And I also now supervise a 21 issues, are they a mixture of minors and 22 psychiatrist, child psychiatrist in New 22 adults? 23 York who calls me for supervision every 23 A. Are you asking about the 24 patients or the staff? 24 two weeks and we talk about her teenage 25 gender patients. 25 Q. The patients. Page 23 Page 25 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 1 2 Q. So your staff at your Yes. A. 3 3 practice, you said there's seven people Q. And when you described these 4 on the trans team? 4 other clinicians present a case to you 5 once a month, what does that mean, to 5 A. Yes. 6 O. What is the trans team? 6 present a case? A. We call it their Gender A. Well, they spend about 30 8 Diversity Program. And so children, 8 minutes telling us the story of their 9 teenagers and adults with these issues 9 patients and then the group of us discuss 10 present to our general outpatient mental 10 the meaning of the story and we try to 11 health practice. 11 help the therapist understand what is 12 going on a little more clearly and 12 Q. And all seven providers in 13 that group see patients with gender 13 sometimes we give guidance about what to 14 identity-related issues? 14 do next. That's what it means. 15 A. Yes. 15 Q. And do you have -- well, let Q. And approximately how many 16 me ask it differently. 17 patients with gender dysphoria has that 17 For all of the patients who 18 team seen in the past year, say? 18 are being seen by these seven people on A. I don't -- I don't exactly 19 the -- in the Gender Diversity Program, 20 know, but they present cases to me at 20 do you have cases of every one of those 21 patients presented to you? 21 this point once a month. It used to be a 22 little bit further -- I mean more often, 22 A. Well, I have -- I have 23 but in the last six months it's been once 23 clinicians of varying vintages of 24 a month. So almost every one of them has 24 experience and so perhaps the most 25 patient or two who have some relationship 25 experienced person focuses mostly on

Page 26 Page 28 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 you were to put together the other 2 children and young teenagers. I'm not so 3 sure she feels it's necessary to present. 3 patients in your practice who have gender 4 In general, we ask our 4 dysphoria-related issues, how many in a 5 professionals, our colleagues to present 5 year? 6 cases that present problems for them, 6 A. For the entire staff? 7 either diagnostic problems or therapeutic 7 O. Yeah 8 problems or ethical problems. A. I have no confidence in the So the more experienced person 9 answer to that question. Since -- if 10 doesn't necessarily feel the need to 10 there are 12 at any given time, I would 11 present to us. Generally speaking, we 11 imagine that over the course of a year 12 encourage our staff when they're 12 there may be as many as 20. Our patients 13 uncomfortable with the processes that are 13 tend to stay, you see, so it may be 20, 14 happening between them and their 14 25. 15 patients, we ask them to present. That's 15 Come to think of it -- I'm 16 always been the case in our conferences. 16 hesitating because for some reason within 17 You should understand that I 17 the last year I ran some data on -- let 18 run two conferences a week and have done 18 me back up. 19 19 that since 1977 for staff for these My computer system that keeps 20 purposes. When the professional is 20 track of diagnoses only goes back to 21 uncomfortable for any reason in dealing 21 2017. And I think we had 182 people with 22 with a patient, we ask that person to 22 a diagnosis, one of the gender identity 23 present to the staff. 23 diagnoses. And I think there was 24 something like 60 that were my patients. While I am the leader of the 25 staff, many -- the rest of the staff is 25 But, again, please, I'm not sure I Page 27 Page 29 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 present and so we have a group discussion 2 remember these numbers correctly. 3 about what the issue is. Q. Okay. Understood. And just 4 going back to the supervision and your Q. And who was that experienced 5 role in supervising the care of these 5 person you mentioned who focuses on 6 children and younger teens? 6 patients, do I understand correctly that 7 you hear about issues with these patients 7 A. Who is it? 8 O. Yes. What is their name? 8 only when the clinician has problems or A. Her name is Anna Novak. 9 issues that they want to discuss with 10 others in the practice; is that right? 10 Q. She's the person in your A. The therapist is asked to 11 practice who sees the most minors with 12 gender dysphoria; is that correct? 12 clarify what question they would like the 13 A. I would say so, yes. 13 conference to address. So that is the 14 Q. You mentioned -- I'm just 14 ideal way the conference begins; I'm 15 trying to get a sense of the patients in 15 having a problem with this aspect or that 16 your practice. 16 aspect, so we then try to address that 17 You mentioned that at any 17 aspect. 18 given time there's about 12 people, Q. So you are not necessarily 19 patients in your practice who are dealing 19 brought into the care decisions for all 20 with gender identity issues. 20 of the patients with gender dysphoria Can you tell me over the 21 issues at your practice; is that right? 21 22 course of a year how many patients that 22 A. No. I am -- well, in some 23 sense, yes, I am talking about the care 23 would be? You mentioned that for 24 and decisions that are made, but it's a 25 yourself it might be about ten. But if 25 lot more subtle then I think your

Page 30 Page 32 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 question implies. 2 the child or of the teenager, the Q. But it wouldn't be for all 3 adolescent. So I don't know, you know, 4 care decisions for all patients, it would 4 how to answer your question. I don't 5 be -- only be for one that there is an 5 really consider the evaluation of a 6 issue that the clinician wants to discuss 6 teenager or adolescent complete without 7 with the group; is that right? 7 an evaluation of their family A. These are all credentialed 8 circumstances. And some of that 9 professionals. They make many many 9 evaluation work is done without the 10 decisions that they never consult anyone 10 patient, the teenager present. 11 about. So I want you to understand 12 Q. So focusing in now, I was 12 that I'm answering your question in terms 13 asking generally about patients with 13 of that whole system, the family system, 14 gender dysphoria, sort of lumping 14 not simply the 14-year-old. 15 together adults and minors, and if we can 15 Q. Understood. So if the patient 16 just focus in on minors now. 16 is the 14-year-old I understand you would 17 Of the I think you said 17 likely see the patient as well as the 18 approximately ten people you've seen in 18 patient's parent and that would count as 19 one evaluation, right? 19 the past year, and I think you said two 20 to three in a recurring way, how many of 20 A. Yes. And sometimes it's more 21 those gender dysphoria patients were 21 than one session with the parent. 22 minors? 22 Q. But one -- sorry. That would A. A minor being somebody in the 23 count at one minor patient who you were 24 teenage years? 24 treating? 25 Q. Under 18. 25 A. One family. I think about a Page 31 Page 33 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. A. Yes. I would say the majority 2 patient and a family as one. 3 of them in the past 12 months, have been Q. Okay. So then in terms of the 4 number of minor patients, and including 4 teenagers. 5 their family, to estimate how many you've Q. So again, that's about ten 6 seen in the past five years, does that 6 total and two or three who you saw in a 7 regular way? 7 sound good? A. Yes. A. It would be -- I was just 9 clarifying the number 50 for you. Q. And then if we can expand that 10 to the past five years of the patients 10 Q. Okay. So that sounds about 11 that you've seen who have gender 11 right. In the past five years, and most 12 dysphoria, can you give me an idea how 12 of them being a single evaluation, and 10 13 many are minors? 13 to 15 being ongoing treatment? A. I think you should multiply A. Again, I want to use the word 15 times five of the answer I've previously 15 guesstimate here. 16 gave. Q. A-hum. How many prepubertal 17 Q. So would that be a total of 17 children with gender dysphoria have you 18 about 50 who you may have seen perhaps 18 seen in the last year, if any? 19 once and 10 to 15 who you've seen in an A. In the last year, prepubertal? 20 ongoing relationship; does that sound 20 I think none. 21 right? 21 Q. And in the last five years 22 Yes. Part of the -- part of my 22 would that be the six you mentioned or 23 were they spread out over time? 23 hesitation here is I sometimes hear about 24 minors from their parents or I spend time A. I don't think that I can 25 with parents as part of the evaluation of 25 answer that question. I think -- you

Page 34	Page 36
1 STEPHEN B. LEVINE, M.D.	1 STEPHEN B. LEVINE, M.D.
2 know.	2 A. I think she's primarily
3 Q. That's fine. You mentioned you	3 interested in the forming a
4 supervise a New York psychologist, I	4 psychotherapeutic relationship with these
5 think you said psychiatrist, a child	5 people and talking about their
6 psychiatrist?	6 development and their motives and their
7 A. A child psychiatrist.	7 options. She is not an affirmative care
8 Q. What's their name?	8 doctor. She is much more psychodynamic;
9 A. Pardon me?	9 "I want to investigate this with the
10 Q. What is that person's name?	10 patient" doctor.
11 A. Must I answer that?	11 Q. Does she refer any of her
MR. CANTRELL: We can	12 patients for hormone therapy?
designate information confidential.	13 A. Some of her patients are on
MS. COOPER: We can	14 hormone therapy. I don't I would guess
15 temporarily designate it	15 she's not the person to refer. She
16 confidential and discuss that	16 doesn't discriminate against patients,
17 later.	17 she doesn't try to stop them, she tries
18 A. Her name is Dr. Miriam	18 to recognize that it's their option and
19 Goodman. I'm sorry. That's not right.	19 they need to consider their motives for
20 Grossman, Miriam Grossman.	20 it and their fears about it and the
21 Q. And is that a common thing to	21 consequences of it.
22 do in your field, to supervise somebody	MR. CANTRELL: Leslie, we will
23 from another practice somewhere?	23 designate the testimony about this
24 A. Oh, yes.	child psychiatrist as confidential.
25 Q. And I understand she pays you	25 MS. COOPER: All right. We can
Page 35	Page 37
1 STEPHEN B. LEVINE, M.D.	1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 for that supervision?	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine.
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes.	 STEPHEN B. LEVINE, M.D. review that later, but fine. Q. And I believe at a recent
 STEPHEN B. LEVINE, M.D. for that supervision? A. She does, yes. Q. And that's a typical thing 	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you
 STEPHEN B. LEVINE, M.D. for that supervision? A. She does, yes. Q. And that's a typical thing that's done? 	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor
 STEPHEN B. LEVINE, M.D. for that supervision? A. She does, yes. Q. And that's a typical thing that's done? A. Well, I don't know how 	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is
 STEPHEN B. LEVINE, M.D. for that supervision? A. She does, yes. Q. And that's a typical thing that's done? A. Well, I don't know how typical. You know, usually experienced 	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision,	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision?
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months,	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months.	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation.
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria?	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor?
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria.	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor?
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria.	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry.
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender 19 dysphoria does she see that you supervise	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry. 19 Q. And you don't remember her
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender 19 dysphoria does she see that you supervise 20 that care?	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry. 19 Q. And you don't remember her 20 last name?
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender 19 dysphoria does she see that you supervise 20 that care? 21 A. I think she's probably talked	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry. 19 Q. And you don't remember her 20 last name? 21 A. It's I think Katz.
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender 19 dysphoria does she see that you supervise 20 that care? 21 A. I think she's probably talked 22 to me about six people. 23 Q. Does she have a view about the 24 appropriateness of ever providing hormone	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry. 19 Q. And you don't remember her 20 last name? 21 A. It's I think Katz. 22 Q. Do you no longer supervise 23 her? 24 A. She said she would get back to
1 STEPHEN B. LEVINE, M.D. 2 for that supervision? 3 A. She does, yes. 4 Q. And that's a typical thing 5 that's done? 6 A. Well, I don't know how 7 typical. You know, usually experienced 8 people don't want to pay for supervision, 9 but she read some of my papers and she 10 sought me out and we've been talking 11 every two weeks for probably six months, 12 maybe eight months. 13 Q. And she treats patients with 14 gender dysphoria? 15 A. Now her specialty is 16 adolescents with gender dysphoria. 17 Q. And approximately how many 18 patients who are adolescents with gender 19 dysphoria does she see that you supervise 20 that care? 21 A. I think she's probably talked 22 to me about six people. 23 Q. Does she have a view about the	1 STEPHEN B. LEVINE, M.D. 2 review that later, but fine. 3 Q. And I believe at a recent 4 deposition you mentioned that you 5 supervised another, I think a counselor 6 who was not part of your practice; is 7 that right? Was there a second person you 8 supervised, paid you for supervision? 9 A. There is, but I don't recall 10 that that supervision was about a gender 11 well, it wasn't directly about a 12 gender case. Oftentimes, there are hidden 13 gender issues behind the presentation. 14 Q. What is the name of that 15 counselor? 16 A. Again, I'm not even sure I 17 remember her last name. Her first name is 18 Sherry. 19 Q. And you don't remember her 20 last name? 21 A. It's I think Katz. 22 Q. Do you no longer supervise 23 her?

Page 38 Page 40 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 from her in about four months. 2 able to assess somebody for gender Q. And she hasn't had any 3 dysphoria to be able to do that? 4 patients with gender dysphoria issues A. I don't understand your 5 that she's discussed with you; is that 5 question but I forgot -- I didn't answer 6 your previous question completely. 6 right? 7 Since 2006 I have supervised A. Well, she has a patient who 8 doesn't like sexual behavior with her 8 the Gender Identity Team at the 9 husband. And so part of that 9 Massachusetts Department of Corrections, 10 investigation is helping her to know what 10 all of their inmates who have gender 11 questions to ask involves the subtle 11 dysphoria, so that's been 16 years. And 12 aspects of one's sexual identity. 12 the supervision of those cases have been 13 Q. Have you diagnosed any minor 13 ongoing and very numerous. I forgot that. 14 patients with gender dysphoria? 14 So the number of people I A. Ms. Cooper, patients come in 15 supervise on the treatment of gender 15 16 dysphoria, these are adults, but they 16 and tell the doctor that they have gender 17 dysphoria. This idea of diagnosing people 17 number in the hundreds at this point. And 18 with gender dysphoria seems really formal 18 I'm sorry, I forgot that when you were 19 asking me the question. 19 and physician-like. But the truth is 20 people come in and they tell you what 20 Q. Thank you. 21 they have and that's -- they know the 21 So would you repeat the last A. 22 diagnostic criteria for gender dysphoria. 22 question, please? 23 And so the answer is yes, I have Q. Sure. You had -- I had 24 previously asked you if you diagnosed any 24 diagnosed people with gender dysphoria, 25 but that really isn't such a difficult 25 patients with gender dysphoria and I Page 39 Page 41 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 process, since the patient tells you they 2 believe you said yes, but that they 3 have it. And then you ask them a question 3 actually know themselves or diagnose 4 or two and then -- and then they meet 4 themselves. 5 5 criteria generally. Are you saying that one Sometimes when they don't meet 6 doesn't need to be a mental health 7 criteria it's because they feel like they 7 provider to be able to assess whether 8 have gender dysphoria for the last three 8 somebody has gender dysphoria? 9 months and as you know that the criteria A. Well, I'm sure the primary 10 is six months. 10 care physician, the nurse practitioner, 11 the cardiac surgeon, a physician, someone 11 MR. CANTRELL: Leslie, just 12 who has a license, who has a credential 12 for the record, I want it to be 13 clear that we were designating as 13 to make psychiatric diagnoses, which 14 confidential the discussion of both 14 would be any physician, could make a 15 of the individuals who Dr. Levine 15 diagnosis. But the diagnosis is based on 16 patient's self-report and to some extent 16 has supervised. 17 MS. COOPER: Outside of his 17 what the doctor or the licensee practice? Ms. Katz and Dr. Goodman, 18 perceives. And so one doesn't have to be 18 19 that's who you are referring to, 19 a mental health professional to make the 20 20 diagnosis. This is part of the problem, right? 21 MR. CANTRELL: The two, the 21 you know. 22 two individuals, yes. 22 Q. Does your -- you mention that 23 23 you meet with the parents too. Does that MS. COOPER: Okay. 24 Q. So is it your view you don't 24 contribute to your assessment whether 25 need to be a mental health provider to be 25 somebody meets criteria for gender

Page 42 Page 44 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 dysphoria, what's reported by the 2 Q. Have you ever had patients, 3 parents? 3 adult or minors, who come to you because 4 4 maybe they already had a gender dysphoria A. Of course. Q. So you touched on -- I'm 5 diagnosis, maybe they didn't, but their 6 sorry. You mention that if a patient 6 goal is to get a diagnosis that -- and a 7 doesn't meet criteria it's usually 7 letter to be able to get hormone therapy? 8 because it's just been three months and 8 Have you ever had patients like that? 9 the diagnostic criteria is six months. 9 A. Oh, yes. Oh, yes. 10 10 Is that the only time you've O. Yes. And does that include 11 ever concluded that a patient did not 11 minors? 12 meet diagnostic criteria, is that the 12 A. Well, minors have asked for 13 length of time wasn't sufficient under --13 that, yes. It includes minors. 14 MR. CANTRELL: Object to form. Q. Is it fair to assume that if a 15 A. The purpose of a psychiatric 15 minor has asked for that that you would 16 evaluation is to get a picture of the 16 not provide a gender dysphoria diagnosis 17 if you did not think they met the 17 person as a whole and not just the aspect 18 of that person's gender identity. And 18 criteria? 19 19 oftentimes the diagnosis of a patient MR. CANTRELL: Object to form. 20 carries much more serious concerns than 20 A. I think you better repeat that 21 the gender identity issues or the sexual 21 question for me. There was something 22 identity or the orientation issues or the 22 about that question that seemed strange 23 paraphilic issues of the patients. It has 23 to me. 24 to do with their general mental health, 24 Q. Okay. Is it correct that if a 25 their depression, their suicidality, 25 minor comes to you seeking a diagnosis Page 43 Page 45 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 their self-harming, their anxiety states, 2 and a letter for approval for hormone 3 their social isolation, their autism, 3 therapy, that if you did not believe that 4 that minor had gender dysphoria and met 4 their developmental physical activities, 5 their bedwetting, so forth. 5 the diagnostic criteria you would not So it's very important to 6 give them that diagnosis; is that 7 understand that I'm trying to get the 7 correct? 8 people I supervise to see the patient as A. I would not write a letter in 9 a whole, not just as a gendered person 9 support of hormone therapy if I didn't 10 believe that they had gender dysphoria. 10 because the treatment and the decisions 11 Is that answer to your question? 11 that ultimately are made by the family 12 Q. It does answer. Thank you. 12 has to do not simply with gender identity 13 but with how the person is doing in 13 And have you ever had a 14 general in the world. So that's the 14 patient come in asking for a letter for 15 answer to the question. It's much more 15 hormone therapy where you did not feel 16 they had gender dysphoria? 16 comprehensive. 17 Sometimes I make the diagnosis 17 A. Well, the patient tells me 18 that he or she has gender dysphoria. I 18 that it's apparent that the person has 19 some kind of gender identity problem of 19 often see other issues and oftentimes 20 some duration. But I'm also very 20 their parents see other issues. 21 sensitive to the other -- the other 21 So I generally don't meet a 22 emotional difficulties that they're 22 person and write a letter for hormones. I 23 having at the same time or often what 23 meet a person and I meet a person and I 24 preceded those; the diagnosis or the 24 meet a person and I meet a person and 25 crystallization of a trans identity. 25 then eventually I, if I feel it's in

Page 46 Page 48 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 their best interests and they understand 2 adolescents tend to not be insistent on a 3 the pros and cons of this, and they 3 letter right now. But have you ever had 4 understand the nature of what is known 4 an adolescent patient at whatever point 5 and what is not known, and they 5 in time, whether it was immediately or 6 understand what the problems are of adult 6 into the therapeutic relationship, asked 7 transsexual people, then I will sometimes 7 for a letter and you did not feel it was 8 write a letter for them. 8 appropriate to provide that? A. You know, a person comes to Q. And are there people for whom 10 you would not write a letter, in -- let 10 mind who was talking to me about getting 11 me ask that in a clearer way. 11 a letter from me eventually. Then in the Have there been people who 12 course of about six months of talking had 12 13 have sought a letter where you declined 13 confessed to me that he is already taking 14 to write a letter? 14 testosterone. And so I would not have 15 A. Yes. 15 given that person a letter at that point, 16 Q. And were any of them 16 in part, because that person had five 17 adolescents, minors? 17 psychiatric hospitalizations by the time A. Well, actually the adolescent 18 he or she, depending on where they were 19 at the time, before they were 16 years of 19 tells me that they would like to take 20 hormones. They often don't tell me I want 20 age. But then at 17 surreptitiously was 21 a letter now. Adults have told me I want 21 taken testosterone but withheld that 22 a letter now, but teenagers generally 22 information from me for a while. 23 don't say those things to me. They say So I guess the answer to your 24 they would like to have hormones or they 24 question is there would be people with 25 would like to have their genitals or 25 gender dysphoria, claimed to have gender Page 47 Page 49 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 1 2 breasts redone and they agree to talk to 2 dysphoria that I would not give a letter 3 me over time. And sometimes -- well, I 3 for hormones at that point. I think 4 that's the answer to your question. Does 4 could speak more directly to older people 5 who are very insistent, this is the only 5 it seem like --6 thing they want from me and they don't 6 Q. Yes. I think you've answered 7 get the letter from me, they get the 7 my question. Thank you. 8 letter sometimes from some of my staff, Have you ever had an 9 but it's not exactly with my blessing. 9 adolescent patient who you believed was 10 But they're independent people and so I 10 asserting a trans identity based on 11 have nothing to -- you know. It's their 11 social influence? 12 clinical judgment. 12 A. Oh, yes. 13 Q. Staying within the patients 13 Q. Can you tell me about -- how 14 who are minors, then do I understand 14 many times has that happened? 15 correctly that it's never been an 15 A. Well, if you know anything 16 adolescent who has sought a letter that 16 about -- and I'm sure you do -- about 17 you've declined to provide, only adults; 17 adolescents and their involvement with 18 is that right? 18 the internet and how teenagers going 19 MR. CANTRELL: Object to form. 19 through early puberty and having angst A. I -- again, I'm not grasping 20 about their body and their future body 20 21 and their degree of beauty or 21 your question. 22 Q. Let me try to ask it 22 handsomeness or masculinity or femininity 23 and how people spend what they do calling 23 differently. Has there ever been an 24 "research" which means emersion in trans 25 adolescent -- I understand that you say 25 websites and listening to trans guru and

Page 50 Page 52 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 orientation and intention. And there 2 trans animae. So this is a very common 3 experience, I would say a universal 3 often are excursions into one or more 4 experience, in my clinical experience. 4 combinations of those three dimensions. So that would be the cultural 5 And so social media has helped many 6 influences of the typical trans teenager 6 people define themselves as, in some way, 7 as an atypical sexual identity before 7 that we hear about in our clinic. And as 8 far as I can see talking to colleagues 8 they've had any social experience, 9 nationally and internationally, it's the 9 intimate experience, romantic experience 10 and even social experience with peers and 10 same thing. 11 Q. And of those patients, 11 friendship patterns. So social media must 12 understanding that many of them look at a 12 be considered as one of the developmental 13 lot of social media, did you believe any 13 influences on trans teenage gender 14 of them were influenced to become 14 identity. 15 transgender or identify as transgender 15 Q. And you have supported 16 who would not have otherwise --16 patients' social transition; is that 17 MR. CANTRELL: Object to form. 17 right? 18 Q. -- except for social media? 18 A. I -- yes. 19 A. Well, in order to answer that 19 Q. And you've counseled some 20 question I have to speculate. You're 20 parents to support the transgender 21 really asking me; do I understand that 21 identification of their children? 22 social media, cultural exposure, 22 A. I've tried to at times, yes. 23 education or miseducation or Q. And looking at your patients 24 who have had gender dysphoria, have most 24 indoctrination is an influence in some 25 teenager's new identification as a trans 25 of them medically transitioned in some Page 51 Page 53 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 way? 2 person? Then I would speculate yes. 3 Q. And has there been any patient MR. CANTRELL: Object to form. 4 you had who you felt that was what was A. I think you need to clarify 5 going on and did not diagnose them with 5 the question if you're only talking about 6 gender dysphoria as a result? 6 minors. Because if you're talking about A. That would not be a reason not 7 adults, the answer is very different. 8 to diagnose them. That's a question about 8 Q. All right. Let's break it 9 where this came from or the developmental 9 down. I think that's helpful. 10 influences on the patient's Let's start with adults. Of 10 11 crystallization of their identity as a 11 your adult gender dysphoria patients, 12 trans person. 12 have most of them medically transitioned 13 You know, their identity 13 in some way, either hormone therapy or 14 before they were a trans person have 14 surgery or both? A. Yes. If I could just modify 15 oftentimes had -- they were something --15 16 first they thought themselves to be 16 "most", guessing, because some people 17 bisexual or lesbian or homosexual and 17 come to me thinking about it and then --18 they were gay or not gay any longer or 18 and some people come to me already on it 19 and some people I've written letters for 19 not lesbian any longer. So you see that 20 adolescence is normally a change, a 20 hormones for and surgery. 21 change phenomenon over six, seven years. Q. And of the patients, the adult 21 22 And people assume different identities, 22 patients with gender dysphoria that you 23 different dimensions of sexual identity. 23 have seen in the past year -- and I'm There are three dimensions of 24 trying to go back to find what your 25 sexual identity; gender identity, 25 estimate was of that number, I believe

Page 54 Page 56 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 you said about ten, but a smaller number 2 O. Okay. A. And my brain does not work in 3 3 of whom you saw on a regular basis -- of 4 those patients, how many did not have any 4 12-month intervals. So I've already 5 medical transition? 5 illustrated that I forgot a whole series A. I don't think in the past 6 of work that I do in answering your 7 year, I don't think in the past year I've 7 question. So your continuing to ask me 8 -- I've not seen anyone who was 8 these numbers continues to make me feel 9 contemplating medical transition but had 9 uncertain about my answers. 10 not transitioned. You know, I may have Q. All right. Let me try asking 10 11 been 18 months ago or 24 months ago, you 11 it a different way. 12 know, I can't -- I'm sorry. I think the 12 Of the approximately ten or so 13 answer is probably zero or close to zero. 13 adolescent patients you've seen with 14 Q. And actually, now I'm 14 gender dysphoria, how many had medically 15 reviewing my notes, and I think, tell me 15 transitioned in some way? 16 if I'm getting this right, that most of A. Had medically transitioned? Is 17 your patients, when you said you had 17 that what you --18 about ten gender dysphoria patients in 18 Q. Yes, medically. 19 the past year, two to three of whom were 19 A. Well, can I ask you if the 20 on a recurring basis, that most of those 20 person who is surreptitiously taking 21 patients were minors; is that right? 21 testosterone, would that be a medical 22 A. Meaning, yeah, adolescents, 22 transition person? 23 right. 23 Q. Sure. Let me ask it 24 24 differently. Q. Under 18? 25 25 Of the approximately ten Yeah. Page 55 Page 57 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Okay. And so of those 2 adolescents you've seen with gender 3 adolescent patients, have most of those 3 dysphoria in the past year, how many of 4 them were taking hormone therapy, one way 4 patients also medically transitioned? A. No. Most of them expressed the 5 or the other? 6 desire to one day have medical transition 6 A. I think two. 7 and most of their patients' parents are Q. So one of them was the patient 8 horrified by it, about it and we were --8 you mentioned who was surreptitiously 9 the teenager and I were talking. 9 taking testosterone; is that right? 10 Q. So of that ten that you've 10 A. Yes. But I think you should 11 seen altogether, and I know that's a 11 understand that it is possible to get 12 rough number because that includes 12 hormones in ways that are not medically 13 adults, is there any way to tease out, by 13 approved and that this is one of the 14 the way, just for clarity of our 14 great temptations that trans people have 15 conversations, of the approximately ten 15 when they're 15 and 16. And there is 16 people you've seen in the past year for 16 another patient that was discovered to 17 gender dysphoria, how many of them were 17 have been trying to import estrogen from 18 China and it was discovered by his 18 minors or under 18? A. I think we already established 19 parents. And it leaves me with the 19 20 that they were mostly minors. 20 feeling that even though some of the 21 Q. Okay. But you can't say if it 21 people I've seen said they weren't on 22 was all? 22 hormones, there's at least the A. You know, you're pursuing a 23 possibility that they prematurely 24 line of numerical questioning that I 24 transitioned without medical approval. 25 already told you is a guess. 25 So this is just one of the

	D 50		P (0)
1	Page 58	1	Page 60 STEPHEN B. LEVINE, M.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	STEPHEN B. LEVINE, M.D. great uncertainties we have in this field	_	taking hormone therapy but you don't know
l .	about people telling the truth when they		for sure; is that right?
l .	go see a mental health professional with	4	A. Well, to my knowledge they're
5	this issue.		not taking hormone therapy.
6	Q. Okay. So did you have any, of	6	Q. Okay.
_	your ten or so adolescent patients you've	7	A. And one can never be sure
	seen for gender dysphoria in the past	· '	about any particular patient whether one
	year, have medically approved hormone		gets the whole truth.
l .	therapy?	10	Ms. Cooper, while you're
11	A. Yes, one of them got hormones	11	•
	got after 45 minutes with the first	12	
l .	doctor and I guess you would say that	13	MS. COOPER: Yes. Let's go off
l .	that was medically approved.	14	the record.
15	Q. So that was someone who saw	15	VIDEOGRAPHER: Going off the
l .	another doctor, got approved for hormones	16	record. The time is 11:00.
l .	by that other doctor and then saw you	17	(Recess is taken.)
	later?	18	VIDEOGRAPHER: Going back on
19	A. Yes.	19	the record. The time is 11:06.
20	Q. So of the ten or so	20	Q. When we spoke earlier you
	adolescents you've seen for gender		mentioned someone in your practice, I
l .	dysphoria, or who have had gender	22	• •
l .	dysphoria in the past year, you mentioned	23	that right?
l .	one that you know of surreptitiously	24	A. N-o-v-a-k.
	receiving hormones, you know of one who	25	Q. And is she a social worker?
_			
	Page 59		Page 61
1	Page 59 STEPHEN B. LEVINE, M.D.	1	Page 61 STEPHEN B. LEVINE, M.D.
l		1 2	
l	STEPHEN B. LEVINE, M.D.		STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S,
2	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval	2	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S,
2 3 4	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor.	2 3	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor.
2 3 4	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you	2 3 4	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced
2 3 4 5 6	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy?	2 3 4 5 6	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced
2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one	2 3 4 5 6	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other
2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents	2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in
2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second	2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the
2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that	2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender
2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person.	2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right?
2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just	2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with
2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There	2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well,
2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk to me the more I remember.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with gender dysphoria than Anna Novak?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk to me the more I remember. Q. Good.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with gender dysphoria than Anna Novak? A. Nobody.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk to me the more I remember. Q. Good. A. So that would be I guess four	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with gender dysphoria than Anna Novak? A. Nobody. Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk to me the more I remember. Q. Good. A. So that would be I guess four of people.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with gender dysphoria than Anna Novak? A. Nobody. Q. Okay. A. Although, most of the patients
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	STEPHEN B. LEVINE, M.D. was approved in the 45 minute approval process from another doctor. Are there any others who you know were receiving hormone therapy? A. Yes. And there was the one actually that person is sadly now deceased who tried to import hormones and I don't know whether the parents discovered the first time or the second time, and so I'm just not sure about that particular person. Oh, and I just I just again you're jogging my memory. There was another person that went to the University of Pittsburgh and had a one-hour evaluation and was given a testosterone prescription. So I forgot about that. You see the longer you talk to me the more I remember. Q. Good. A. So that would be I guess four	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. A. She's a Social Worker-S, supervisor. Q. What does that mean? A. That means she's experienced and has the license to supervise other people in social work. Q. And is she I believe is the person you said is most experienced in your practice, of your staff, for the treatment of adolescents with gender dysphoria; is that right? A. No. In particular, with children and young adults, yes. Well, it's true what you said but I just want to add also children. Q. A-hum. Is there anyone else on your staff, besides yourself, that is more experienced with adolescents with gender dysphoria than Anna Novak? A. Nobody. Q. Okay.

	Page 62		Pa	ge 64
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.	gc 04
2	diagnosis of gender dysphoria among her	2	Q. How many of those letters have	
1	patients where appropriate?	3	you co-signed for adolescent minor	
4	A. Yes.		patients?	
5	Q. And is she able to recommend	5	A. Very few. Over the course of	
6	treatment for those patients?	6	*	
7	A. Well, of course.	7	MS. COOPER: I'd like to mark	
8	Q. The fact that she's a social	8	our first exhibit, which is tab 1.	
9	worker doesn't preclude her from having	9	(Exhibit Levine 1, Declaration	
10	that ability to do that?	10	of Stephen B. Levine, MD, dated	
11	MR. CANTRELL: Object to form.	11	February 23, 2022, was received and	
12	A. Well, if there is a problem,	12	marked on this date for	
13	you know, she will present her case to	13	identification.)	
14	the group. But when she's seeing	14	Q. We'll get to have some	
15	children, the treatment is you know,	15	practice with Exhibit Share. I'll let you	
16	relates to the child's problems, the	16	know when we have it uploaded.	
17	family relationships. So she sees the	17	THE WITNESS: What are we	
	parents, she sees the child and when	18	doing?	
	and that's true for her when her patient	19	MR. CANTRELL: She's marking	
20	is a teenager as well.	20	an exhibit and we're waiting for it	
21	The treatment is to the extent	21	to be uploaded.	
	of the valuation and the	22	MS. COOPER: It should be	
1	psychotherapeutic relationship, so she is	23	available now. You have to hit the	
	certainly able to recommend treatment.	24	refresh button on your screen.	
25	Q. And for any of her adolescent	25	MR. CANTRELL: You can scroll	
	Page 63			ge 65
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.	ge 65
2	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone	2	STEPHEN B. LEVINE, M.D. up and down.	ge 65
2 3	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy?	2 3	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert	ge 65
2 3 4	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her	2 3 4	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report.	ge 65
2 3 4 5	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the	2 3 4 5	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to	ge 65
2 3 4 5 6	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go	2 3 4 5 6	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1?	ge 65
2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and	2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes.	ge 65
2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the	2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this	ge 65
2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak	2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document?	ge 65
2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended	2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do.	ge 65
2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I	2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you	ge 65
2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist	2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia?	ge 65
2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her	2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes.	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing	2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022,	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing	2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right?	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes.	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. up and down. THE WITNESS: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for a minor patient. Has she in the past?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted text there. Let me know when you've found	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for a minor patient. Has she in the past? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted text there. Let me know when you've found that.	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for a minor patient. Has she in the past? A. Yes. Q. And you've approved those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted text there. Let me know when you've found that. A. I have it.	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for a minor patient. Has she in the past? A. Yes. Q. And you've approved those letters?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted text there. Let me know when you've found that. A. I have it. Q. Okay. I'm just going to read	ge 65
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	STEPHEN B. LEVINE, M.D. patients, have they been provided hormone therapy? A. In recent years, no, from her recommendation. I think some of the families and some of the families then go to another to an endocrinologist and get the treatment. I'm not aware in the last couple of years whether Mrs. Novak has sent anyone for or recommended hormone therapy treatment because I generally sign letters with the therapist for hormones and I don't recall her bringing a letter to me. But we are doing treatment, you understand, we're doing treatment. Q. I understand. So you say in the last few years you don't recall her bringing a letter for hormone therapy for a minor patient. Has she in the past? A. Yes. Q. And you've approved those	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	stephen B. Levine, M.D. up and down. The Witness: That's my expert opinion report. Q. Dr. Levine, are you able to see what's been marked as Exhibit 1? A. I can see it, yes. Q. And do you recognize this document? A. I do. Q. Is this the declaration you filed in the case BPJ in West Virginia? A. Yes. Q. And that was in February 2022, according to the first page there; is that right? A. Yes. Q. If you can scroll down to paragraph 6 you'll see some highlighted text there. Let me know when you've found that. A. I have it.	ge 65

Page 66 Page 68 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 dysphoria, you need this treatment, it's 2 practice treating patients who suffered 3 from gender dysphoria I have at one time 3 medically necessary. 4 or another recommended or prescribed or 4 So in a sense I've 5 supported social transition, cross-sex 5 recommended, I've gone along with, I've 6 hormones and surgery for particular 6 said, well, if this is what you want to 7 patients, but only after extensive 7 do and I've assured myself, I've talked 8 diagnostic and psychotherapeutic work." 8 to you about my concerns about this, and 9 Did I read that correctly? 9 I've agreed that if you go through 10 therapy and we think about this together, 10 A. Yes. 11 Q. Just a couple of questions 11 and it's your decision, you have autonomy 12 about terminology here. 12 about this, then I write a letter, I When you say "prescribed", can 13 recommend. 14 you tell me what you're referring to? Do 14 I don't recommend in the 15 you mean actually writing prescriptions 15 former sense, I recommend in the latter 16 or is something else? 16 sense, that I've been with you for a long 17 17 time, and I respect your right to make A. I mean writing a letter so the 18 endocrinologist can evaluate the 18 this decision. 19 patient's physical status and make a 19 Q. Thank you. And I see in some 20 decision whether hormones are 20 of your reports and depositions you've 21 used the word "approved" patients for 21 contraindicated or not. 22 hormone therapy. Is that the same or do 22 Q. And when you say 23 "recommended", is that something 23 you mean something different by that? A. No. You know, it's hard to --24 different? 25 A. Different than what? 25 it's efficient to use a word like Page 67 Page 69 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Than writing a letter for 2 "approved" or "recommended" or 3 somebody. I'm just trying to understand 3 "prescribed", without writing a paragraph 4 what you mean by these terms. 4 about the limitations of that. Maybe there is no difference, O. But just to make sure I'm 6 but I want to understand if there is a 6 understanding what you're referring to 7 meaningful difference when you say 7 when you would write a letter for 8 "recommended", "prescribed" and you also 8 somebody after having a relationship with 9 have the word "supported" in that 9 them and determine that you've satisfied 10 sentence, do those terms have different 10 yourself that you can write that letter 11 meanings here? 11 for them to take to an endocrinologist; 12 is that right? A. Well, I guess I'm hedging the 13 meanings of these words by using "or". 13 A. Yes. Q. Okay. You've also approved, Q. Okay. 14 15 A. Really, what I really am 15 using the term in the same way, some of 16 saying is that it's the patient's choice 16 your gender dysphoria patients, adult 17 at this point and I recognize that I've 17 patients that is for surgery; is that 18 done what I can to educate the person 18 right? 19 about this and if the pattern wants to do 19 A. Yes. 20 this, as the person does, then I write a 20 And when is the last time you Ο. 21 letter with my imprimatur as MD and 21 did that? 22 psychotherapist and experienced person in 22 A. Probably 16 months ago, 17, 18 23 the field. 23 months ago. It's not like I've seen the 24 MS. COOPER: Okay. I'd like to mark as the next exhibit what is 25 person and I said, oh, you have gender 25

	Page 70		Page 7
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.
2	tab 3.		hormones very quickly and we are much
3	We'll let you know when it's		more cautious. We will give adolescents
4	uploaded. That's now available. Let		hormones but not as quickly as the
5	me know when you can see that.	5	Standards of Care would like."
6	(Exhibit Levine 2, excerpt of	6	Did I read that correctly?
7	the deposition of Stephen B.	7	A. Umm.
8	Levine, MD re: Reiyn Keohane v.	8	Q. Is that a yes?
9	Julie Jones was received and marked	9	A. That is a yes. I'm trying not
10	on this date for identification.	10	to be funny.
11	THE WITNESS: It's a different	11	Q. Okay.
12	exhibit now?	12	A. I just want to compliment you
13	MR. CANTRELL: Yes. It's a	13	in your capacity to read.
14	different exhibit.	14	Q. Thank you so much.
15	Q. Are you able to see Exhibit 2,	15	So when you say there, just
16 I	Or. Levine?	16	for clarity, "I don't exactly follow the
17	A. I can see it, yes.	17	Standards", do I understand correctly you
18	Q. And do you recognize this as a	18	are referring to the WPATH Standards of
	leposition you gave in the case of Reiyn	19	Care, 7th Edition?
20 H	Keohane versus Julie Jones May of 2017?	20	A. Yes, you are correct.
21	A. Actually, the last time I was	21	Q. And when you say "we're much
	sked about this I didn't remember giving		more cautious" well, actually let me
	deposition. I only remembered being in		ask it let me backup.
	he courtroom at the trial but I presume,	24	At the beginning of the
25 I	just don't remember the deposition.	25	sentence you say in your "Center", is
	Page 71		Page 7
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.
2	STEPHEN B. LEVINE, M.D. Q. You remember being a witness	2	STEPHEN B. LEVINE, M.D. that your medical practice that you're
2 3 i	STEPHEN B. LEVINE, M.D. Q. You remember being a witness n that case; is that correct?	2 3	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to?
2 3 i	STEPHEN B. LEVINE, M.D. Q. You remember being a witness n that case; is that correct? A. Yes, I do.	2 3 4	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In
2 3 i 4 5	STEPHEN B. LEVINE, M.D. Q. You remember being a witness n that case; is that correct? A. Yes, I do. Q. Okay. If you could please	2 3 4 5	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what?
2 3 i 4 5 6 s	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please acroll down to page 59, and I think we've	2 3 4 5 6	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage
2 3 i 4 5 6 s 7 c	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only	2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence
2 3 i 4 5 6 s 7 c 8 h	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay?	2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just
2 3 i 4 5 6 s 7 c 8 h	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah.	2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that
2 3 i 4 5 6 s 7 c 8 f 9	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to	2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice?
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r	STEPHEN B. LEVINE, M.D. Q. You remember being a witness In that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to lead the surrounding text to make sure	2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes.
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do	2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please acroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue	2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you,
2 3 ii 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take	2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text,	2 3 4 5 6 7 8 9 10 11 12 13 14 15	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 1	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents,
2 3 i 4 5 6 s 7 c 6 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 17	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 17 18 c 1	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.)	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says?
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 17 18 c 19	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes.
2 3 ii 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 ii 17 18 c 19 20	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I Q. Okay. I'm just going to read	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes. Q. And just, again, going back to
2 3 i 4 5 6 s 7 c 6 s 7 c 6 s 10 11 r 12 t 13 y 14 s 15 a 16 i 17 18 c 19 20 21 r	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I Q. Okay. I'm just going to read now the highlighted passage that says,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes. Q. And just, again, going back to terminology, the phrase "we will give
2 3 i 4 5 6 s 7 c 6 s 7 c 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 17 18 c 19 20 21 r 22 "	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I Q. Okay. I'm just going to read now the highlighted passage that says, and so in my Center I recommend	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes. Q. And just, again, going back to terminology, the phrase "we will give adolescents hormones", do you mean
2 3 i 4 5 6 s 7 c 8 h 9 10 11 r 12 t 13 y 14 s 15 a 16 i 17 18 c 19 20 21 r 22 " 23 F	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I Q. Okay. I'm just going to read now the highlighted passage that says, and so in my Center I recommend only of the surrounding text on the proposed that says, and so in my Center I recommend only of the surrounding text on the proposed that says, and so in my Center I recommend only of the surrounding text on the proposed that says, and so in my Center I recommend only of the surrounding text of the surrounding text of the surrounding text, and so in my Center I recommend only of the surrounding text of the surround	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes. Q. And just, again, going back to terminology, the phrase "we will give
2 3 ii 4 5 6 s 7 c 6 s 7 c 6 s 7 c 7 c 8 ii 9 10 11 r 12 ii 13 y 14 s 15 a 16 ii 17 18 c 6 19 20 21 r 22 " 23 r 24 e	STEPHEN B. LEVINE, M.D. Q. You remember being a witness in that case; is that correct? A. Yes, I do. Q. Okay. If you could please scroll down to page 59, and I think we've only provided excerpts because we only have one passage to show you. Okay? A. Yeah. Q. And I want to give you time to read the surrounding text to make sure that the context is clear to you. But do you see that I've highlighted in blue some text on page 59? Why don't you take a moment to read the surrounding text, including that and then we'll review it. (Deponent reviews the document.) A. Okay. I think I Q. Okay. I'm just going to read now the highlighted passage that says, and so in my Center I recommend	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	stephen B. Levine, M.D. that your medical practice that you're referring to? A. Repeat the last sentence. In the what? Q. Sure. At the first passage there I'm sorry the first sentence there "And so in my Center". And I just want to clarify, in your Center, is that your medical practice? A. Yes. Q. Okay. And do I understand correctly that you are saying that you, in your practice, in your center are much more cautious in terms of timing and when you would give hormones to adolescents, compared to what the WPATH Standards of Care 7 says? A. Yes. Q. And just, again, going back to terminology, the phrase "we will give adolescents hormones", do you mean approve or write a letter, as you

Page 74 Page 76 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 Q. I think you mentioned a few I'm not certain. If the answer 3 is affirmative, like one, two or three, 3 minutes ago that over the course of your 4 career or I guess -- strike that. I want 4 it certainly is an unusual thing. 5 to be more precise. I think our center is known to I believe you testified over 6 be a place for people who want to think 7 the past 20 years or so you've approved 7 about this when they have gender 8 hormones for a handful of adolescents; is 8 dysphoria. We do occasionally see people, 9 that correct? 9 they are not necessarily adolescents, 10 A. Yes. 10 they could be 20, 21, 25, 26, 40, who 11 Q. Okay. And when was the last 11 feel like they want to have, you know, 12 they know what they want. But what's 12 time you did that? 13 happened, in 19 -- I would say for 20 13 A. In August 2020. The reason I 14 remember that is that in March 2021 this 14 years in the Cleveland metropolitan area 15 person died and so it's fixed in my mind 15 we were the only show in town that had 16 these sequences. 16 expertise and interest in this problem. 17 17 But subsequently other places have arisen Q. And is this a patient who died 18 by suicide? 18 and places associated with hospitals and A. Well, it's not clear. He died 19 individuals who are, quote, "gender 20 of a heroin overdose and probably with 20 specialists" in town. And so, generally 21 fentanyl, but when I was seeing him there 21 speaking, when adolescents want hormone 22 treatment and they have their parents 22 was no hint he was on heroin. He only went on heroin when he 23 consent or they go somewhere else. So our 24 center these days selects people who want 24 went to college and, as a trans person, 25 and couldn't find a roommate. And then 25 a more thoughtful, conservative, careful, Page 75 Page 77 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 eventually found a trans roommate that he 2 slow approach. 3 didn't get along with, and then he didn't So I would say that my career 4 study, this kid who was brilliant, and 4 experience has to be divided into when we 5 then he left college and then started at 5 were the only show in town and when we 6 a new college and by the time he --6 became known as the place who is more 7 before he transferred to the new college 7 conservative. 8 he, unknown to me and to his parents, he Q. I think you mentioned before 9 was using heroin. And I think he had one 9 that Ms. Novak at least has approved some 10 Narcon revival in his home before he died 10 minor patients for hormone therapy; is 11 that right? 11 in his dorm room at Ohio State. 12 A. Yes. Yes. 12 So whether this is suicide or 13 just a product of bad judgment because of Q. And any other providers at 13 14 his pain, his ongoing pain, and then he 14 your center? 15 died of a drug overdose, I'm not sure. 15 A. We're just talking about Q. And when was the last time you 16 minors now? 17 were asked to provide a letter for 17 O. Yes. 18 hormone therapy for an adolescent? Was it A. I think I'm the one that sees 19 that patient? 19 most of the minors, Mrs. Novak and 20 20 myself. Well, we have a child A. I think that was the last 21 time, yes. 21 psychiatrist who participates in the 22 Q. And have any of the providers 22 evaluation of these adolescents, but 23 that you supervise recommended or 23 basically she doesn't do the 24 approved anyone under 18 for hormone 24 psychotherapy. She does sort of diagnosis 25 therapy in the last five years? 25 of anxiety and depression and autism and

Page 78 Page 80 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 so forth. 2 treatment programs at three special 3 Q. So between you and Mrs. Novak 3 gender programs in Cleveland, when people 4 there have been a handful of cases in the 4 want hormones they often go to those 5 past, say, five years where you have 5 places and they get their hormones. 6 approved hormone therapy for minors; is 6 Those places don't often even ask us for 7 that right? 7 a letter of recommendation. A. These are particularly So the scene in my region is 9 fraught, difficult circumstances, yes. 9 perhaps different than the scene in Q. Can you say what you mean by 10 Little Rock or New York and so forth. And 10 11 that? 11 -- that's all. 12 A. Well, many of the people with 12 Q. Have you ever written letters 13 gender dysphoria have what others call 13 of authorization for minor patients to --14 comorbid conditions. And sometimes we 14 minor patients with gender dysphoria to 15 have very disturbed people who are very 15 receive puberty blockers? 16 insistent and we don't seem to be able to 16 A. To what puberty blockers? 17 get anywhere in understanding their lives 17 To receive puberty blockers. Q. 18 with them until they get what they want, 18 A. Never. 19 so to speak. 19 Q. What about Mrs. Novak or 20 So as I've said in some of my 20 others in your practice? 21 publications, the ethical problems 21 A. Never. 22 involved with these patients are 22 Q. Have you ever written a letter 23 sometimes very complicated and one has to 23 of authorization for any minor patient 24 make decisions that one is uneasy about. 24 for top surgery? 25 I, for one, am very sensitive 25 A. Meaning less than 18? Page 79 Page 81 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 to the long-term consequences of Yes. Q. 3 3 medicalizing this problem because I'm A. Never. 4 perhaps more aware of anyone in my unit 4 And what about others in your 5 of the literature in this field. So I 5 practice? 6 find myself being ethically comfortable 6 A. As far as I know, never. 7 talking with and not immediately giving 7 Q. And as patients come to you 8 hormones to people immediately, meaning 8 now, going forward, current patients and 9 quickly. I don't mean in 40 minutes or 60 9 potentially new patients who are minors 10 with gender dysphoria, would you consider 10 minutes, I mean over a course of months. 11 writing a letter for them, if after that 11 So I think that's the answer to your 12 careful, lengthy, exploratory period, you 12 question. 13 13 felt it was appropriate? Q. Understood. But just in terms 14 of timeframe, I'm trying to get an 14 MR. CANTRELL: Object to form. 15 understanding, that I think you testified 15 A. Ms. Cooper, as I said before, 16 both you and Mrs. Novak have approved 16 I view gender dysphoria as one aspect of 17 minor, some minor patients for hormone 17 a person's life, and I'm very sensitive 18 therapy, and has that happened within the 18 to finding other aspects of a person's 19 past five years? 19 life, in particular, when they're 20 20 dysfunctional or highly symptomatic, as A. What I'm saying -- I'm not 21 sure. I think -- I think it probably has 21 some of the patients that we get to see 22 on rare occasion. 22 are, as most of the patients that we get 23 to see happen to be. So it's not a matter What you need to understand, 24 given the reputation that we have and the 24 of, here is the diagnosis, here is the 25 availability of specialized gender 25 treatment. It's, here is the person who

Page 82 Page 84 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 has gender dysphoria, who is autistic, 2 theoretically, if various factors were in 3 who is self-harming, who is not going to 3 place, could see approving you said 4 school. And when I look at the whole 4 someone who was 18 for hormone therapy. 5 person I can't -- it's such a different 5 Have you now ruled out for 17-year-olds 6 thing than what you're asking me. 6 in the similar scenario you described? You're asking me about when 7 MR. CANTRELL: Object to form. 8 gender dysphoria exists in a whole 8 A. I haven't in an absolute sense 9 person, do I recommend hormones or 9 ruled out, but I am particularly inclined 10 surgery? 10 to be wanting to delay the use of these 11 Q. That is not what I meant to 11 medications and certainly of surgeries 12 ask you. So maybe I should clarify the 12 until I believe the person has had enough 13 question. 13 maturity and enough life experience to 14 A. Thank you. 14 realize what the consequences of this 15 Q. I understand from your 15 will be in the short term and in the 16 testimony that you have for some patients 16 long-term. 17 written letters approving them for 17 So I am biased to provide 18 hormone therapy. 18 psychotherapeutic treatment as opposed to 19 I'm just trying to understand 19 hormonal treatment and I'm much quicker 20 whether that is something that you would 20 to recommend psychotherapeutic treatment 21 still consider at any point for future 21 than I am medical or surgical treatment 22 patients? Or put another way, have you 22 in minors, and in majors as well. 23 taken that off the table and would no Q. And by "majors", I assume you 24 longer consider that, regardless of the 24 mean adults, just for the record; is that 25 circumstances? 25 correct? Page 83 Page 85 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 MR. CANTRELL: Object to form. A. For the record. A. Those are two questions. So 3 Q. For the record. 3 4 I'll answer the first question. So in the past when you have 5 approved people under 18 for hormone On a theoretical basis, if I 6 therapy, had you determined that they had 6 had an opportunity to consider the whole 7 patient and the family and had an 7 the maturity to understand all the 8 opportunity to address the adversities in 8 implications that you were describing and 9 the person's past and improve some 9 you made the judgment that it was 10 things, and if I thought that this person 10 appropriate to author that letter? 11 was cognitively free enough from the MR. CANTRELL: Object to form. 11 12 psychopathology to make an informed 12 A. I don't think so. That's what 13 decision and was 18-years-old, I could 13 I mean, these things are ethically 14 theoretically say I will write a letter 14 fraught. One cannot be sure a 15 in support of hormone therapy. That was 15 15-year-old, a 16-year-old, a 18-year-old 16 the answer to your first question. 16 is mature enough. These are fraught --17 That doesn't happen very 17 these cause anguish in the souls of the 18 often. And as I already told you, the 18 doctors. Or if they don't, I worry why 19 last time I did that I've had to deal 19 they don't. 20 with the parents grieving in my office. 20 Q. When you've written letters 21 Now, if you could repeat the 21 for adolescents in the past, did you 22 second question, I'll answer that. 22 first determine that they had Q. Well, let's drop that one. I 23 long-standing stable -- a long-standing 24 want to follow up here. 24 stable gender identity? 25 25 Now, you mention that you MR. CANTRELL: Object to form.

D 06	D 00
Page 86 STEPHEN B. LEVINE, M.D.	Page 88 1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 A. Yes. I would be very	2 So when we socially transition
3 disinclined to write a letter for	3 a child or a teenager, that pretty much
4 hormones if somebody had this for six	4 increases that increases their chance
5 months or seven months.	5 of getting medically transitioned in the
6 MS. COOPER: Let's mark as	6 future with all those consequences.
7 Exhibit 3, tab 4, please.	7 So what I'm saying is parents
8 (Exhibit Levine 3, article re:	8 need to be more fully understanding of
9 Reconsidering Informed Consent	9 what science knows and what science
written by Stephen B. Levine, MD,	10 doesn't know, you see. And they need to
in the Journal of Sex & Marital	11 understand what we're worried about with
Therapy, was received and marked on	12 adults who have already made this
this date for identification.)	13 transition and what the indicators of
14 Q. It should be available now.	14 their dysfunction is as a group. So
15 A. Exhibit 3, I'll open 3?	15 that's what informed consent, that's what
16 Q. Yes. Let me know when you're	16 this is about, you see.
17 able to see it.	Are we, number one, evaluating
18 A. I'm there.	18 these children correctly? Number two, do
19 Q. Do you recognize this	19 the doctors know the facts in this field?
20 document, Doctor?	20 And three, are people being told what
21 A. I do.	21 science knows and what science doesn't?
22 Q. Is this your article	22 And four, what do parents understand
23 Reconsidering Informed Consent for	23 what the what the social, medical and
24 Trans-Identified Children, Adolescents	24 psychological problems are of adults who
25 and Young Adults?	25 have been well transitioned have been
Page 87	Page 89
1 STEPHEN B. LEVINE, M.D.	1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is.	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what
 STEPHEN B. LEVINE, M.D. A. Yes, it is. Q. And this was published in 	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about.
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct?	 STEPHEN B. LEVINE, M.D. long transitioned. You see, that's what this article is about. Q. Okay. And is it a description
 STEPHEN B. LEVINE, M.D. A. Yes, it is. Q. And this was published in this year, 2022, correct? A. March 17th. 	 STEPHEN B. LEVINE, M.D. long transitioned. You see, that's what this article is about. Q. Okay. And is it a description of the process for informed consent that
 STEPHEN B. LEVINE, M.D. A. Yes, it is. Q. And this was published in this year, 2022, correct? A. March 17th. Q. I've read the article and as I 	 STEPHEN B. LEVINE, M.D. long transitioned. You see, that's what this article is about. Q. Okay. And is it a description of the process for informed consent that you would apply with patients who are
 STEPHEN B. LEVINE, M.D. A. Yes, it is. Q. And this was published in this year, 2022, correct? A. March 17th. Q. I've read the article and as I understand it, and tell me if I'm getting 	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition?
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part?
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right?	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes.	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay.	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition.	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition?
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you.	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes,
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly.
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime 20 consequences. To add hormones as	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly. 20 Q. You anticipated my next
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime 20 consequences. To add hormones as 21 additional lifetime consequences and to	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly. 20 Q. You anticipated my next 21 question, whether that process includes
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime 20 consequences. To add hormones as 21 additional lifetime consequences and to 22 remove bodily tissues that are healthy,	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly. 20 Q. You anticipated my next 21 question, whether that process includes 22 the parents. So that's a "yes"?
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime 20 consequences. To add hormones as 21 additional lifetime consequences and to 22 remove bodily tissues that are healthy, 23 have also have additional psychological	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly. 20 Q. You anticipated my next 21 question, whether that process includes 22 the parents. So that's a "yes"? 23 A. The parents are the only
1 STEPHEN B. LEVINE, M.D. 2 A. Yes, it is. 3 Q. And this was published in 4 this year, 2022, correct? 5 A. March 17th. 6 Q. I've read the article and as I 7 understand it, and tell me if I'm getting 8 this right, that you are recommending 9 some specifics of an informed consent 10 process that you think providers should 11 undertake before authorizing hormone 12 therapy for medical transition for 13 minors; is that right? 14 A. And surgical transition, yes. 15 Q. Surgical transition. Okay. 16 A. And social transition. 17 Q. Okay. Thank you. 18 A. So let's be clear. To socially 19 transition a person has enormous lifetime 20 consequences. To add hormones as 21 additional lifetime consequences and to 22 remove bodily tissues that are healthy,	1 STEPHEN B. LEVINE, M.D. 2 long transitioned. You see, that's what 3 this article is about. 4 Q. Okay. And is it a description 5 of the process for informed consent that 6 you would apply with patients who are 7 adolescents seeking social transition or 8 medical transition? 9 A. I'm sorry. Would you repeat 10 that, the first part? 11 Q. Sure. What you describe in 12 this article, is it a process for 13 obtaining informed consent that you would 14 apply with patients who are minors 15 seeking social transition or medical 16 transition? 17 A. Yes. It would be a process 18 with the parents and the minor. Yes, 19 exactly. 20 Q. You anticipated my next 21 question, whether that process includes 22 the parents. So that's a "yes"?

Page 90 Page 92 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Right. And you would gauge, 2 economist and a methodologist, she's an 3 according to your recommendation in this 3 expert in analyzing material relating to 4 article, gauge whether the minor 4 health and she works for a health 5 comprehends all the information that 5 organization, but I don't think she's 6 you're providing them; is that right? 6 affiliated with a university, if that's MR. CANTRELL: Object to form. 7 what you're asking. A. To the extent that one can Q. No. I was just trying to 9 understand her background. And what do 9 accurately assess whether a minor can, a 10 13-year-old, a 14-year-old can appreciate 10 you know about Julia Mason? 11 a list of medical and psychosocial and A. She's a pediatrician who has 12 psychosexual problems of being 30. You 12 some experience with gender patients and 13 see, that's why we want to emphasize the 13 conservative, "let's be thoughtful about 14 parents, not the child. 14 this" approach. She doesn't -- I don't I don't really think the 15 think she agrees with some of her 15 16 typical 14-year-old has the capacity. 16 colleagues in pediatrics who think social 17 They have the passion; they have the 17 transition of six-year-olds is a good 18 zeal; they have the "I can't live without 18 idea. 19 19 this" quality; they have the overvalued Q. And I understand that she's 20 idea. They don't have the life 20 also affiliated with SEGM. Is it okay if 21 experience to appreciate what this means. 21 I use those initials? 22 Q. I see your coauthors listed 22 A. SEGM. I think we -- we call it 23 here are E. Abbruzzese. Am I saying that 23 SEGM. 24 right? I'm going to spell it for the Q. SEGM, happy to use that. Is 24 25 court reporter Abbruzzese 25 she also affiliated with SEGM? Page 91 Page 93 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 1 2 2 A-b-b-r-u-z-z-e-s-e? A. I think she -- yes. Q. How did you come to partner 3 A. Yes. 3 4 with these two authors on this paper? 4 Q. That's one. And the other is 5 Julia W. Mason; is that correct, they're A. People have read some of my 6 your coauthors of this paper? Okay. 6 writing and asked me to join. Sometimes I 7 A. Your reading skills continue 7 get invitations for this or that based on 8 to be excellent. 8 what people have read that I've written Q. Who is E. Abbruzzese? 9 and E invited me to be part of a A. Who is she? 10 10 psychotherapy group of mental health Q. Well, does that person go by E 11 professions who were looking at the 12 possibility of alternate approaches to 12 or is that a full name? 13 A. She prefers to go by E. 13 this because many of them have seen 14 Q. Okay. I see on this paper her 14 negative consequences in patients to 15 affiliation listed is SEGM, the -- I'm 15 transitions premature -- what they call 16 premature transitions. 16 going to say that wrong. 17 A. I'll say it for you. 17 So I joined a Q. Say it for me. Thank you. 18 18 once-every-two-weeks, one-and-a-half-hour A. The Society For Evidence-Based 19 19 discussion on the internet with people 20 from Australia and England and Ireland 20 Gender Medicine. Q. That is the affiliation. Do 21 and Canada and various parts in the 22 you know if E. Abbruzzese is affiliated 22 United States. And so we talked about --23 with any university or any other 23 we were talking about these issues and 24 organization as well? 24 talking about cases and talking about the 25 difficulties in doing various forms of 25 Well, she is -- she's a health

Page 94 Page 96 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 work and talking about the general trust 2 them I never heard back from them. But I 3 -- thrust of how science has been ignored 3 did write a letter authorizing a 4 and a treatment fashion has taken over, 4 mastectomy for a 26-year-old engaged 5 and there has been a political 5 person, who is living together with her 6 indoctrination that's been amazingly 6 fiancé, his fiancé. 7 successful, and there's been a confusion Q. I believe you testified in 8 of medical science with political 8 another case that you've written letters 9 concepts and civil rights. 9 for gender-dysphoric adults more than 50 10 So we got together to start 10 times; is that right? 11 talking about these issues and people A. Over the course of a lifetime, 12 were impressed that I have written of the 12 you know, I just use the word guesstimate 13 issues that they were talking about, so 13 again to remind you of my previous 14 testimony. 14 they invited me to join the discussion. 15 And during those discussions it was 15 In 1974, 1984 and 1994 the 16 proposed, since I have had this interest 16 field was very different. Our 17 in informed consent and feeling like 17 understanding was very very different. 18 there has been ethical problem in not 18 The situation, the landscape has changed 19 having the elements of informed consent, 19 dramatically. 20 that SEGM decided they would like me to 20 In the early years, in the 21 write a paper on this subject. And 21 early decades we were dealing primarily 22 starting I would say in January 2021 I 22 with adults and primarily with male 23 began writing a paper and SEGM actually 23 adults. But now the landscape, as you 24 gave me a grant to, \$5,000, for the 24 well know, is a very different thing. 25 effort to develop a paper. 25 Q. But is that right, that you've Page 95 Page 97 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 That paper occupied me for, I 2 -- does that sound about right, that 3 would say, 15 months of my time, and I 3 you've recommended or approved surgery at 4 probably worked at the level of getting 4 least 50 times? 5 \$2 an hour for the amount of time I spent A. Well, if we could count it and 6 in developing this paper. So that's sort 6 it turned out to be 36 or 61 it wouldn't 7 of the background. 7 surprise me. Q. Okay. Thank you. Have you Q. Okay. Fair enough. So we've 9 written letters of authorization for 9 talked about letters authorizing hormone 10 adult gender dysphoria patients to get 10 therapy. What do you say in these 11 gender-confirming surgeries? 11 letters? 12 A. I recently wrote a paper --12 A. What I say in these letters is 13 sorry. I wrote a letter of support most 13 very different than what I've seen 14 recently for two people; one, the woman I 14 recommended in these letters. 15 mentioned who developed renal cancer for 15 Q. What do you say? 16 an orchiectomy, which she never went A. I talk about the evaluation 16 17 through with, not because of the cancer 17 that I've done, I talk about the person, 18 but for other reasons; and I wrote a 18 I talk about their strengths, their 19 letter for a mastectomy to a 26-year-old 19 weaknesses or their limitations, I talk 20 person who is engaged to a woman and I 20 about their symptoms bearing, I talk 21 had interviewed both the patient three 21 about their reasons for doing this, I 22 times and the fiancé. And I got a 22 talk about my unease, if I have unease, 23 promise from that person that I would see 23 and I usually have unease. You see, so I 24 them back three months after their 24 give a picture. So I've heard from 25 people that these are the most 25 mastectomy. And despite my contacting

Page 98 Page 100 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 comprehensive and helpful letters I've 2 The answer to your question, I 3 think in a briefer way, is that of course 3 ever received from anybody. I've written a book written by 4 I wouldn't write a letter thinking it's 5 -- published by the American Psychiatric 5 going to harm them. I do -- I guess what 6 Association on transgender healthcare and 6 I said is sometimes I'm not sure it's 7 I saw the sample letters that people were 7 going to benefit them. 8 recommending and, basically; I have seen Q. You mention some people are 9 this person and I think they're 9 lost to followup. Is that a common thing 10 cognitively prepared for this, they 10 in medical care in the United States? 11 understand the limitations and it's my MR. CANTRELL: Object to form. 12 recommendation that they be given 12 A. It's not a common thing in 13 hormones. 13 ideal medical care, but it's certainly a 14 This is not the letter that I 14 common thing in trans care. 15 have ever written or co-signed. The Q. So it's not a common thing 16 letters that we write talk about the 16 with your other kinds of patients who you 17 elements of the evaluation and the whole 17 have for other conditions? 18 person and that we have discussed these A. Oh, I'm sure you can find 19 matters with the patient, and they're 19 countless examples where there is a short 20 usually a minimum of three page, two to 20 intervention with a patient and the 21 three page letter. 21 doctor never sees the patient again, of 22 Q. And do you say in the letters 22 course. But this is a chronic condition, 23 that you believe that treatment is likely 23 you know, gender dysphoria. It's not 24 to benefit the patient? 24 really a curable condition for most 25 A. No. I generally say that the 25 people. And if you recall the important Page 99 Page 101 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 study published by Sweden in 19 -- in 2 patient believes that it's going to 3 benefit them and that we do not see any 3 2011, the recommendation was for lifelong 4 reason to stand in the way of this and, 4 psychiatric care. It's easy to make 5 recommendations like that. Those things 5 therefore, we are referring this patient 6 for hormone therapy. 6 usually don't happen. Q. Would you ever approve a Q. Just to go back then, when you 8 letter or do a letter if you felt that 8 write these letters for patients with 9 gender dysphoria to approve hormone 9 treatment would be harmful to the person? A. If it was not going to benefit 10 treatment, you don't say whether or not 10 11 the person, is that what you said? 11 you think the treatment will be 12 O. I said would be harmful to the 12 beneficial to them? 13 person. 13 MR. CANTRELL: Object to form. 14 A. No. I say the patient wants A. Well, I have -- I can remember 15 a particular person, it was actually -- I 15 hormone treatment. I say that I've had an 16 think it was for surgery, that we weren't 16 opportunity to discuss hormone treatment 17 sure that this was going to help the 17 and his or her life in more detail; these 18 person, but we didn't know what else to 18 are things I know about this person; here 19 do for this person, and we outlined our 19 are the person's strengths, for example, 20 concerns about the mental state of this 20 high intelligence; and here are the 21 person's limitations, chronic depression, 21 person. So the person underwent surgery 22 and then we never heard back from them 22 social isolation, anxiety states, 23 again. It's the typical thing in the 23 tendency to be dependent on marijuana; 24 United States, people are lost to 24 and the patient and I have had a year, 25 followup. 25 year and a half of opportunities and I've

Page 102 Page 104 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 met with them 23 times or 30 times or 18 2 other symptoms of mental illness. 3 times, and the person is now 18 years of 3 So this is part of the ethical 4 age and still persists in wanting to have 4 problem, Ms. Cooper, that the surgeon 5 hormone surgery and I promised the person 5 wants to assume that the ethics have been 6 that I would write a letter for them if 6 worked out by the endocrinologist and the 7 they cooperated with me to discuss this 7 endocrinologist wants to assume that the 8 and at great length and the patient has 8 ethics problem and the criteria have been 9 met my criteria and she still wants to 9 worked out by the mental health 10 take estrogen, and so I'm writing this 10 professional. 11 letter informing you that she has done 11 So everyone is sort of passing 12 her psychiatric preliminary work and, no, 12 the buck here to the mental health 13 I'm not saying I think this is going to 13 professional and that's why, you know, 14 benefit the person. 14 very conservative people, like myself, 15 O. Are these letters needed 15 need to take time and thoughtfulness and 16 because some endocrinologist won't 16 need to have a relationship with the 17 provide the care without a letter from a 17 patient and the family and we need to 18 mental health provider? 18 represent accurately what science knows 19 and what science doesn't know, and we A. Well, that's not always true, 20 I'm sad to report. But generally 20 need to accurately represent what are the 21 speaking, the people who say that they 21 problems, the well-known problems of the 22 follow the Standards of Care from WPATH 22 marginalized, vulnerable, often substance 23 do require a mental health assessment. 23 abusing, and chronically suicidal people 24 They don't -- they don't really define 24 in adult life are. So that's my 25 what that should be or how comprehensive 25 long-winded answer to your question. Page 103 Page 105 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 or how sophisticated, but they do want a MS. COOPER: This is a good 3 3 letter from a mental health professional. time for a break. Does this work as 4 4 The reason they want a letter a good lunch break time for folks? 5 5 is they don't want to take ethical MR. CANTRELL: Sure. 6 responsibility for making this decision, 6 MS. COOPER: Let's go off the 7 this is a fraught, difficult decision, 7 record. 8 they want -- they want to say, well, the 8 VIDEOGRAPHER: Going off the 9 psychiatrist or the social worker or the 9 record. The time is 12:05. 10 mental health professional said it's 10 (Lunch recess is taken.) 11 okay, therefore, I'm just doing this, and 11 VIDEOGRAPHER: Back on the 12 I'm just going to assure myself that the 12 record. The time is 12:46. 13 patient knows what the side-effects are Q. I understand that for at least 13 14 and knows when to call me or when to go 14 some of your minor patients who have 15 to the emergency room if this happens or 15 gender dysphoria they're being treated 16 that happens, you see. But the ultimate 16 with psychotherapy alone, without, to 17 decision whether I should give hormones 17 your knowledge, any hormone therapy, 18 or not is made by the mental health 18 correct? 19 professional. And as you may or may not 19 A. I think that's true for most 20 know, many endocrinologists have felt 20 of them, yes. 21 very uneasy about this on an ethical 21 Q. And what is your approach to 22 basis because they don't know whether 22 psychotherapy to address gender dysphoria 23 gender dysphoria is a mental illness or 23 with these patients? 24 not, even though some people say it's 24 MR. CANTRELL: Object to form. 25 not, because many of these people have A. Would you like me to talk 25

Page 106 Page 108 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 about the general principles I think of 2 don't have to change the gender identity 3 psychotherapy with patients? Is that what 3 if we address the underlying processes, 4 the question is about? 4 whereby, the person decided that they Q. Fair enough. Let me ask it 5 must be trans, if we can address their 6 differently. 6 social isolation, their uneasiness with Is it fair for me to assume 7 their body, the fact that they've been 8 that based on your past testimony that at 8 sexual abused or something terrible has 9 least some of your minor patients with 9 happened in their family, we can deal 10 gender dysphoria have comorbidities, 10 with those processes. We let the child 11 psychological comorbidities; is that 11 then decide over time, as they proceed 12 correct? 12 during adolescence, to try on various, as 13 A. That's correct. 13 most adolescents do have different 14 O. Are there some who don't? 14 passions and sometimes the gender 15 15 dysphoria begins to fade away and they A. I don't think I met one yet. Q. Over your career, you're 16 develop a different identity, maybe a 16 17 saying; is that right? 17 lesbian identity or a gay male identity, 18 A. Yes. 18 or they get interested in some other 19 Q. Are there people who have 19 topic entirely unrelated. 20 gender dysphoria outside of your patient 20 So the psychotherapy is; one, 21 pool who have gender dysphoria but don't 21 an attempt to understand the motivations; 22 have comorbidities? 22 two, to understand the adversities and A. That depends on the evaluator. 23 the things that the person is troubling 24 Q. Okay. What I'm trying to 24 with and to address those things; and 25 understand is what kind of psychotherapy 25 three, to recognize that this person is Page 107 Page 109 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 can address the gender dysphoria, 2 more than their gender identity, and that 3 understanding there may be psychotherapy 3 every human being is more complex than 4 needed to address other issues for other 4 their one aspect of their identity. 5 patients, but how can psychotherapy 5 As you may know, Toni Morrison 6 address the gender dysphoria? 6 has said there are hundreds of pieces of A. That's an excellent question 7 me, when someone asked her. And there 8 and it probably requires an hour's answer 8 are many pieces of your identity and my 9 but I will try to be succinct. 9 identity and we try to introduce patients 10 10 to their richness, their complexity and One concept is that one's 11 identity is the product of other 11 not to have them reduce everything in 12 processes. In other words, if I can use a 12 their life to one thing. 13 big word, it's a epiphenomena. And so 13 In other words, we're 14 what we're interested in is the 14 thoughtful and all this thoughtfulness 15 antecedents to the crystallization of 15 must depend upon a trusting relationship 16 this particular identity. And we're 16 between the patient, the family and the 17 interested in understanding the 17 doctor. 18 developmental challenges that this child 18 Now, one other thing that 19 has had from birth on or even during from 19 happens in psychotherapy is what you --20 the last exhibit you put up is the 20 pregnancy on. 21 informed consent process. So without 21 And so we try to address the 22 vulnerabilities that the child has and 22 trying to proselytize, without trying to 23 help them deal with the underlying 23 warn or to scare, we just try to 24 challenges. Assuming that we don't have 24 represent what is known and what is not 25 to try to cure the gender identity, we 25 known and to -- even though we recognize

Page 110 Page 112 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 that patients may be certain, most human Q. And you're using the word 3 desist. Is this person you were talking 3 beings -- it's dangerous for most human 4 beings to be certain about anything. You 4 about, in the examples you're talking 5 say, I'm certain I've fallen in love with 5 about, prepubertal kids or are these 6 you and I'm going to marry you and I 6 adolescents and adults? 7 can't live without you and two years A. Adolescents. I've seen 8 later after I married you I want to 8 prepubertal children desist as well. 9 divorce you. So we distrust certainty in Q. So of your patients with 10 all human beings. So these are -- that's 10 gender dysphoria how many who are 11 my four-minute summary of my issues on 11 adolescents who are older have come to 12 identify with their natal sex? 12 psychotherapy. 13 I also try to represent in the 13 A. Have come to identify with 14 process of that therapy what science 14 what? 15 knows and these days, now that we have 15 O. That are natal sex, with 16 countries that have said psychotherapy 16 psychotherapy alone. 17 ought to be the first approach because 17 I don't know. 18 the outcomes are not very clear when we 18 How many that you are aware 19 do medical, as the first approach, these 19 of? 20 people need to know that. 20 A. How many am I aware? I'm aware 21 Q. Okay. Thank you. That was 21 of a six-year-old who has desisted. 22 helpful. 22 Q. I'm talking adolescent and Of your gender dysphoria 23 older. 24 patients who have been treated with 24 A. Okay. I'm trying to think. 25 psychotherapy alone, whether adolescents 25 I've certainly reviewed case histories of Page 111 Page 113 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 or adults, have any come to identify as 2 people who have desisted. Q. Your patients, I'm asking. 3 their natal sex? A. I know your question. I'm A. I think in late January of 5 this year parents came to me about their 5 just trying to review a lifetime of 6 15-year-old and we talked about their 6 experience. 7 concerns about announcement that he's a 7 Well, the one who comes to 8 trans woman and we -- the parents and I 8 mind who saw me first with his parents 9 who wouldn't come back because he said he 9 talked about this and they came back to 10 see me about three weeks ago and their 10 hated me and then he came back to me 11 son seems to be more comfortable being a 11 three months later and said that what I 12 son now. And so, I've never seen their 12 said during that initial evaluation has 13 son personally, I've done the parent 13 haunted him and he hated me and now he 14 guidance. 14 thinks I was right and he has returned to 15 So I think if you take my work 15 living as a male. So that's one. I often 16 as both with parents alone, with kids 16 think about him. 17 alone, with parents and kids together, 17 I am dealing with another 18 I've seen people desist and I've 18 child, teenager, who has moved a little 19 certainly talked to other people, 19 bit away from the trans world into the 20 colleagues who do psychotherapy that 20 sadomasochistic world and is experiencing 21 they've seen people desist sometimes 21 the pleasures of masochistic kink. I 22 before medical treatment and sometimes 22 have seen --23 during medical treatment and sadly Q. Before you move on, that 24 sometimes after medical surgical 24 person no -- their gender identity is 25 treatment. 25 different than it was?

Page 114 Page 116 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 feminine in their behavioral expressions. A. I think -- I think the gender 3 identity is weakening about that, right. 3 It's really hard for me to 4 And another person who -- the one that I 4 answer this because I don't see the world 5 made mention to before, who had five 5 simply as trans or non-trans. And I guess 6 hospitalizations or four psychiatric 6 I'm a student of the human psychology and 7 hospitalizations, who was taking 7 human psyche and I like to talk about 8 testosterone, I'm not sure that the 8 that every human being has a mosaic of 9 degree of certainty about the stability 9 sexual identity identifications. We're 10 of this gender identity seemed to be 10 not what we appear, we are not 11 weakening when I enabled this person to 11 subjectively what we socially present 12 psychotherapy to get his GED and then he 12 ourselves to be. And so I'm used to 13 moved out of state to go to art school. 13 talking about, say, just taking males, 14 So I'm not -- I'm not exactly sure. I 14 for example, I'm used to talking about 15 can't say that's one who's desisted, but 15 feminine expressions and feminine 16 I've watched this -- I've watched the 16 features in males and sometimes their 17 certainty become uncertainty, which I 17 struggle or misunderstanding or lack of 18 consider to be a much more reasonable 18 understanding about the normality of 19 human position, to be uncertain about 19 having a sexual identity mosaic of 20 things, especially when one is an 20 masculine and feminine, gay and straight, 21 adolescent. 21 and kink and non-kinky aspirations, 22 Q. What about adults, have you 22 sexual intentions. 23 had any adults come to identify with So I can't really answer that 24 their natal sex, your gender dysphoria 24 question because I don't see the world in 25 patients? 25 the terms that you're using. Page 115 Page 117 STEPHEN B. LEVINE, M.D. 1 1 STEPHEN B. LEVINE, M.D. A. I've seen prisoners reidentify Q. Are any of your patients who 3 several times. I've seen the phenomenon 3 have received hormone therapy, have you 4 of trans in prison and bisexual and 4 seen benefits to their mental health as a 5 result of that treatment? 5 straight out of prison. Let me see about adults. I've A. Have I seen people benefit 7 certainly seen adults who have thought --7 from the results of my treatment? 8 who have come to me with this who are 8 Q. From hormone therapy. 9 terribly ambivalent and may have been A. I've seen people being very 10 playing at this process, who then go back 10 happy instantly upon swallowing their 11 first treatment and for months, as 11 into not playing, not expressing it. 12 they're looking for breast development or 12 You need to understand that 13 it's not a rare thing for people to have 13 looking for oily skin and lowering of the 14 a mosaic of combination of male and 14 voice, they're immensely happy, 15 female identifications in their psyche 15 absolutely. 16 and sometimes they give voice to or give 16 You know, in medicine, 17 behavioral expression to the feminine and 17 especially in mental health medicine, we 18 sometimes to the masculine, and they have 18 have an enormous influence of the placebo 19 considerable conflict about that. And 19 effect. Depressed people get a pill and 20 many adults who come to see me discuss 20 they start feeling better and the 21 these things with me. So they're not 21 question is, and why we do controlled 22 necessarily out as a trans person and 22 studies, is we try to separate the 23 desist but they fluctuate between 23 placebo effect in the control group from 24 masculine expressions or masculine 24 the true drug effect, you see. 25 acceptance of their body and wishes to be 25 So it's clearly, since we

Page 118 Page 120 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 don't -- since we don't have any 2 testified to, I've already told you this, 3 controlled studies in this field of 3 but in terms of their functional 4 taking hormones and so many people are so 4 capacities in the world there is not 5 much happier once they're getting 5 evidence that that really improves them. 6 hormones because they wanted hormones for Now, I know some people are 7 years, for example, they're happy or 7 improved but I also have seen patients 8 happier. The question is, are they 8 who take hormones and get terribly 9 functioning better? Is there mental 9 depressed. You see, that's why we need 10 health better a year later or six months 10 the science, because the doctors' 11 later or five years later? 11 experience is so much heavily colored by 12 Q. That's my question for you. Do 12 the last patient he's seen, you see. So 13 you know whether any of your patients, 13 it's not focusing on the issue of, what 14 after six months or a year, five years, 14 have you seen, Dr. Levine? It's what do 15 their mental health was better after 15 we know from the collective scientific 16 taking hormones? 16 experience in this field. And that's why 17 A. Well, it depends what you mean 17 we're having a contentious argument in 18 by mental health. 18 this courtroom, I mean in this issue, Q. Whatever you meant when you 19 because science tells us one thing and 20 just said it. 20 people have other opinions. Doctors often 21 A. Well, if you mean are they 21 have other opinions from the science. And 22 happy they're taking -- are they happy 22 as far as I can see, many of these 23 taking hormones? Many are happy taking 23 doctors don't know the science, they 24 hormones, they're happy with the 24 don't ---25 feminization, they're happy with the 25 Q. When you say you've known --Page 119 Page 121 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 masculinization. 2 you know some people have improved, how 3 do you know that? Q. Do you think it relieved their 4 distress and anxiety for some patients? A. Because I see them, because A. Well, you know, the U.K., 5 they liked the hormones, because they 6 Finland, Sweden, France have all tried to 6 like being feminized, for example, and 7 -- and the Cochrane Reviews, they've all 7 they like being masculinized, whether 8 tried to assess the answer to your 8 they're still cutting themselves or still 9 question, and it's not clear that these 9 not going to school or not working or 10 still getting depressed or if you talk to 10 people have better mental health after 11 taking hormones for a long period of 11 -- if you talk to anyone who runs an 12 time. 12 inpatient service, psychiatric service, 13 13 they're frequently getting people who are Q. I'm asking about your 14 patients, not the research. You're a 14 trans identified who are on hormones who 15 psychiatrist. Can you not evaluate their 15 are in there for depression or suicide 16 mental health and whether it's improving 16 attempt and so forth. So, look, it's not 17 or deteriorating or staying the same? 17 that if you give hormones and everyone is 18 guaranteed to be happy. 18 MR. CANTRELL: Objection, 19 Q. That's not my question. My argumentative. 20 20 question is have any of your patients who A. Well, listen, I'm a 21 psychiatrist, I'm informed by the 21 received mental health improvement as a 22 science. Please, I think all doctors need 22 result of hormones? And as a psychiatrist 23 to be informed by the science. And I 23 I thought psychiatrists could evaluate 24 certainly can evaluate certain aspects of 24 the state of someone's mental health. 25 a person's life. And I've already 25 MR. CANTRELL: Object to form.

Page 122 Page 124 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 A. I have -- I have people who 2 masculine and now that I'm treated with 3 have been on hormones for years and who 3 hormones I'm happier. But the question 4 are functioning they think better. 4 is, are they functioning better and are Now, I can just tell you since 5 they mentally well? You see many times 6 we tell ourselves the patient is improved 6 I'm psychiatrist seeing one patient, it's 7 taken me three or four years to convince 7 but we don't tell ourselves the patient 8 one person that he was worth more than he 8 is healthy, they're just less depressed. 9 was getting paid for in his job and Q. Are there any who are healthy 10 during all this time I've been giving him 10 who you believe that hormone therapy 11 hormones and finally he went from getting 11 contributed to that? 12 \$30,000 a year in his job to a new job at 12 A. Well, I've certainly heard 13 \$90,000 and he's much happier at \$90,000 13 many accounts of people, sort of public 14 than he is at 30,000. And if you're not 14 figures who say that they are -- the 15 careful you might have concluded it's the 15 hormones have really helped them 16 hormones that's making him happier, when 16 considerably. So I believe -- I believe 17 I tell you it's the work that we have 17 that's possible, yes. I don't get to see 18 done to convince him that he's 18 that that often myself, but I hear public 19 undervaluing himself because of his 19 pronouncements like that very frequently. 20 negative self views, you see. 20 People stand up at microphones sometimes 21 So if you ask me simply, have 21 and tell you how much better they are. 22 I had a patient who is better off on Q. Have you seen that ever in 22 23 hormones than he was before he was on 23 your patients, that they are -- again, 24 their mental health is better? I'm 24 hormones, I would say yes. But whether 25 it's to be attributed to hormones is an 25 sorry. Was that a yes? Page 123 Page 125 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 entirely different question. A. No, that wasn't a yes. That Q. So you don't know whether --3 was a non-answer. That was an I'm 4 is it fair to say then you don't know 4 thinking. 5 whether hormones have helped any of your 5 O. Oh. 6 patients? 6 A. Well, I'm thinking about a 7 A. It's fair to say many of my 7 person who's happy expressing himself as 8 patients are happy taking hormones, and 8 a woman, but who is very unhappy because 9 happiness is an improvement, you see. 9 two of his three children won't talk to 10 That doesn't mean they're not still 10 him. 11 depressed, it's that they're happier, 11 So you see we have to separate 12 they're happy with. They still may be 12 the happiness about gender expression 13 anxious, they still may be smoking 13 from the general overall unhappiness or 14 cigarettes, they still may be heavily 14 happiness of a person. And I don't expect 15 using drugs, they still may be depressed 15 hormones to take care of everything that 16 but they say they're happier taking 16 ails a person, you see. 17 hormones. 17 That's one of the reasons why

32 (Pages 122 - 125)

18 I caution young people that they are much

19 more complicated and rich and varied and

20 dimensional than simply gender identity.

21 That's one of the reasons why I think all

22 mental health professionals have to slow

23 down and not rush to medicalize people.

25 ago you believe it's possible that

Q. When you said a few minutes

21

Q. Has hormones reduced any of

A. Temporarily it does, yes, but

19 those symptoms like anxiety and

20 depression for any of your patients?

23 then there is the effect of I always

22 that's probably the placebo effect. And

24 wanted to experiment, I've always had a

25 mosaic that's heavily feminine or heavily

Page 126 Page 128 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 hormone therapy can contribute to 2 gender-affirming medical care for minors, 3 positive mental health improvements but 3 and I wanted to ask, do you believe that 4 it's not something you see very often, I 4 the risks of gender-affirming medical 5 want to ask a couple of questions about 5 care outweigh the benefits for all minors 6 with gender dysphoria? 6 that. A. If you take out the word "all" 7 Is that because you don't 8 generally get to follow the patients up 8 from that question it would be easier for 9 or is that because most of your patients 9 me to answer. 10 who get hormone therapy don't see a 10 Would you mind rephrasing that 11 benefit, in your experience? 11 question without the word --12 MR. CANTRELL: Object to form. Q. I think this is what -- yes. I 12 13 A. Well, what we suffer from in 13 think I can. 14 this field and what I suffer from as a 14 Again, you've talked about the 15 doctor, is that we don't have followup 15 risks and benefits of gender-affirming 16 medical care for minors and the need to 16 and we don't have systematic or systemic 17 discuss that fully, right, with patients 17 long-term followup which is, of course, 18 what science requires to know to answer 18 and their families. 19 these questions that you're getting at. 19 So my questions is, is it your 20 I think the answer to your 20 view that in every case of a minor with 21 question is both, it's not either/or, 21 gender dysphoria that the risks of that 22 it's just both. You know, I'm a mental 22 medical treatment will outweigh the 23 health professional, when people feel 23 benefits? 24 24 that they're happy -- people never come MR. CANTRELL: Object to form. 25 to a mental health professional because 25 A. Again, I think you put in a Page 127 Page 129 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 their life is going great. They come to 2 phrase of three words there that make it 3 similar to "all". If I can rephrase -- I 3 us in crisis, they come to us in despair, 4 they come to us in demoralization, they 4 don't know if I'm allowed --5 come to us sometimes in sort of 5 O. Go ahead. 6 life-threatening circumstances. 6 A. It's not just Dr. Levine who So, again, I'm working with 7 has estimated that the risks are 8 the whole person here and you're just 8 considerable and the benefits are 9 trying to, you see, cut off a little 9 unclear. Independent reviews by people 10 piece of that whole person and ask a 10 who are capable of analyzing published 11 studies, and not all physicians or 11 little dimension of them. 12 Ph.D.'s are equally capable of analyzing 12 Q. Is it fair to say you're less 13 likely to hear about the success stories 13 reports, independent reviews, two from 14 because they're doing great and they 14 the U.K., one from Sweden, and one from 15 wouldn't have reason to come see you 15 Finland, and I'm not sure whether France 16 again? 16 did an independent review or just changed 17 A. That's right. Successful 17 their policy in February of this year, 18 people don't need to see me, successful 18 but these countries who are much more 19 in that way. And if they went to another 19 controlled and have much more information 20 doctor and they're getting hormones and 20 than we do in United States with 50 21 they're living happily ever after, they 21 separate states, these independent, 22 don't come to visit Dr. Levine. 22 carefully -- carefully reviewed these 23 people who are skilled in looking at Q. Now, you've talked about the 24 risks and benefits, you know, having to 24 methodologies, they have said that the 25 look at the risks and benefits of 25 risks outweigh the benefits and have

Page 130 Page 132 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 encouraged their country to no longer 2 14-year-old or the removing the breasts 3 create these rapid -- these many 3 of a 14-year-old or 13-year-old, these 4 treatments of choice or what used to be 4 things have long-term risks for people 5 called best practices for youth. 5 and for their families, and the fact that So it's not just a matter of 6 there is one patient out of ten or one 7 me, based on my clinical experience. 7 patient out of thirty, you know, who 8 Although, my clinical experience is -- my 8 benefits from it and say the rest are 9 accumulated clinical experience does 9 either unclear or they have -- they 10 cause me to be cautious. You need to 10 regret. Public policy requires we not 11 understand that I base a great deal -- I 11 look at a case alone but we look at a 12 take a great deal -- I give a great deal 12 series of cases and public policy should 13 of respect to commissions that have 13 rest upon what science knows. And that's 14 independently assessed the data and found 14 what I think you and I are discussing, 15 the data to be lacking and the benefits 15 what does science know about this. 16 to be unclear in the long run, and the O. My question --17 risk in the long run to outweigh those 17 You want to make this what Dr. 18 benefits. 18 Levine believes, but Dr. Levine is trying 19 19 to represent here what science knows, you And so that's how I answer 20 your question. Science has answered this 20 see, and how many cases --21 question as best that we can, given the 21 Q. I think we're getting far 22 fact that it's May 2022. In June 2022 we 22 afield. My question was not about public 23 may have better information, which would 23 policy. 24 24 either support or make us change our The question was whether the 25 views. But based on today's knowledge, 25 reason you would not agree that the Page 131 Page 133 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 especially informed by science, I would 2 benefit -- the risks outweigh the 3 say that the risks tend to outweigh the 3 benefits in all cases for all minors, was 4 because you didn't want to say that 4 benefits and now we have this whole 5 that's true for every minor; is that 5 phenomenon of detransition of people who 6 have transitioned with the help of the 6 correct? I'm not asking you about public 7 medical profession who are now saying, I 7 policy. 8 regret this or I'm detransitioning. And 8 MR. CANTRELL: Object to form. 9 you know that data as well as I do. A. I object that when you talk 10 about "all minors" --Q. Yes. So the problem with my 11 earlier question was the word "all" and 11 Q. You can't agree --12 "that in every case." A. If you want me to agree that 12 13 So do I understand that your 13 there is a case somewhere that may 14 testimony is that the benefits -- sorry 14 benefit in the short run, and even in the 15 -- the risks of gender-affirming medical 15 median-term run and possibly in the long 16 care for minors tend to outweigh the 16 run who might be happy with a transition 17 benefits, but that you would not agree 17 that they've made, there must be patients 18 that that's true in every case? 18 like that, of course. Of course there 19 MR. CANTRELL: Object to form. 19 are. 20 A. When it comes to public policy 20 Q. Okay. That was my question. 21 we can't let one case be the -- generate 21 And you talked about the European 22 public policy. If science has said that 22 countries determining that risks outweigh 23 the risks are exceeding the benefits, and 23 the benefits. I believe perhaps you're 24 the risk includes tragedies and, for 24 referring to the statement out of Sweden

25 when you reference that. Is that what

25 example, permanent sterility of a

Page 134 Page 136 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 you had in mind? 2 that they banned it. I think they've 3 A. Did you say Sweden? 3 recommended this. And to recommend 4 4 psychotherapy is to imply that Q. Yes. 5 A. Yes. Sweden is one of them. 5 puberty-blocking hormones and cross-sex 6 hormones should not be the initial Q. And tell me what other country 7 has said the risks outweigh the benefits, 7 approach to these kids. 8 have actually said that? 8 Q. So you are not aware then or 9 is it your understanding that Finland A. Finland. 10 allows minors to receive gender-affirming 10 O. Finland said that? 11 A. Yes. 11 medical care if the psychotherapy as a 12 Q. Who else said that? 12 first approach is not successful in 13 A. I think the NICE report from 13 resolving the condition? 14 England and the Cass report and I'm 14 A. I don't know. 15 actually -- I'm actually a member of the 15 MR. CANTRELL: Object to form. 16 Cochrane Group who's evaluating these 16 A. I'm not -- I don't know the 17 subjects. But as the report is not out 17 details of, like, how long they have to 18 yet I'm not permitted to talk about that. 18 have psychotherapy and what the 19 parameters of success would be. I think Q. And you're aware, right, that 20 in Finland, U.K., France and Sweden, that 20 it's a big policy statement if a 21 they have not banned gender-affirming 21 country -- if a country says this is how 22 care for minors, right? 22 we, as a country, are going to approach A. I'm aware that Sweden has said 23 this within our standardized universal 24 that and Finland has said that they think 24 medical system, which is so different 25 no one should have this treatment until 25 than what we do in the United States, so Page 135 Page 137 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 about 26 and that -- and Sweden has said 2 different. 3 minors can have gender-affirming care if 3 Q. So it your understanding that 4 the U.K. does not allow gender-affirming 4 it's part of a scientific protocol, as 5 part of an experiment, what we would call 5 hormone therapy for minus? 6 an IRB or government-approved experiment. A. I know the U.K. did not go so 7 That's very different than, this is an 7 far as to disallow it but it's certainly 8 acceptable treatment for all kids that 8 -- their recommendations have certainly 9 claim to be gender dysphoric. 9 slowed the number of people getting it. 10 Q. So you would agree with 10 As you are well aware there 11 Sweden's approach to allow the treatment 11 was -- there were two -- there was a 12 in the context of clinical trials but not 12 lawsuit that pretty much prohibited --13 separately? 13 there was a lawsuit that the High Court 14 of London in I think 2019, December 17th, 14 A. Yes. 15 Q. And -- sorry. 15 said no one less than 16 could have A. I would agree. 16 16 cross-sex hormone or puberty blockers and 17 And your understanding is that 17 anyone from 17, 16 or 17 had to have 18 Finland bans care for anyone under 26 18 court approval. And that was -- that 19 gender-affirming medical care? 19 last part was reversed in 2020, I think 20 MR. CANTRELL: Object to form. 20 in September, where it said that doctors 21 A. My memory may not be correct, 21 had to decide, not courts. 22 but Finland has recommended that the 22 I think the impact of the 23 first approach to gender-dysphoric youth 23 first two decisions was that the rapid 24 should be a psychotherapeutic approach 24 use of puberty blockers and cross-sex 25 and not a medical approach. I'm not sure 25 hormones diminished dramatically in the

Page 138 Page 140 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 U.K. 2 to be boys when they go through puberty 3 and no one has fully explained this 3 Q. Have you read the Cass report 4 out of the U.K.? 4 tsunami of increased incidents, that the 5 A. I have in the past, yes. 5 medical professions' sort of best Q. Okay. And is it your 6 practices approach to giving medical 7 understanding that that report recommends 7 treatment to all these people before we 8 increasing access to gender-affirming 8 understand the motivations, both the 9 medical care for minors? 9 social sources of the motivations and the 10 MR. CANTRELL: Object to form. 10 psychological sources of the motivations 11 A. I don't, I don't recall that. 11 in the person of the children, that this 12 has caused Sweden, Finmark -- Finland, 12 Q. Is it your understanding that 13 France is prohibiting gender-affirming 13 France and the U.K. and some elements in 14 medical care for minors? 14 the United States to have some caution A. No. It's my understanding that 15 about what we're doing because we 15 16 France, in February, also recommended 16 recognize that adolescence is a time 17 psychotherapy as the first approach. 17 that's a six-, seven-year process of Q. And that they would permit 18 trying to define what one's identity is. 19 gender-affirming medical care as an 19 And one's identity at 13 is not the same 20 alternative approach if psychotherapy is 20 as one's identity as 15 or 16 or 20. And 21 not sufficient? 21 so these are changeable phenomena. And 22 MR. CANTRELL: Object to form. 22 the idea that we're making permanent a 23 A. I don't know that one way or 23 13-year-old or 14's gender identity by 24 medicalizing that identity, you see, and 24 the other. 25 When we were talking about the 25 supporting that identity, these countries Page 139 Page 141 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 risks and benefits, I got the sense from 2 and these scientific -- the scientific 3 what you're saying that you, your 3 scrutiny has said all this is a stop sign 4 understanding from the research is that 4 for how we're taking care of people. And so the risks are 5 in the vast majority of cases that the 5 6 risks would outweigh the benefits of 6 uncertain, the detransition numbers are 7 care; is that right? 7 increasing, the benefits have not been 8 A. I'll repeat. 8 demonstrated and, therefore, the risks Q. Sure. I understood from your 9 outweigh the benefits. That is what I 10 past testimony that your view is that the 10 believe is science talking to you. 11 risks of gender-affirming medical care Q. And you said the 12 for minors outweighs the benefits of such 12 detransitioning is increasing. 13 care in the vast majority of cases? 13 Are you aware of any data 14 MR. CANTRELL: Object to form. 14 comparing rates of detransition now to 15 A. No, you misunderstood. I said 15 some time in the past? 16 "I will repeat." I didn't ask you to A. No, but we're getting reports 17 of detransition. Do you know that March 17 repeat. I'm sorry. We miscommunicated. 18 18 12th of this year was National and Q. Oh. 19 International Detransition Day? 19 A. The scientific review of the 20 literature indicates that the long-term O. I understand you have some 21 patients who have detransitioned; is that 21 benefits are unclear. There are 22 considerable concerns about the long-term 22 correct? 23 harms and as there has been an 23 A. I have already testified to 24 that, right. 24 increasing, a dramatic increase in the 25 number of girls assigned at birth wanting 25 Detransition -- well, I don't

Page 142 Page 144 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 know if we did that today, but I know you Q. Okay. And did detransitioning 3 improve their mental health in these two 3 talked about desisted which I know may be 4 an overlap term. 4 cases? Let me be clear. Have you had 5 A. Yes. Oh, yes. 6 patients detransition after having 6 Q. I understand from your 7 writings and testimony, and tell me if 7 received medical transition? A. I know of those people, yes. 8 I'm not saying this correctly, that you 9 have concerns about I think what you've Q. And have any of them 10 retransitioned after detransitioning? 10 called rapid affirmation, where doctors A. Do you know that I wrote a 11 prescribe medical transition too quickly. 12 Is that a fair statement? 12 paper about one case? 13 Q. I do. But I'm asking do you 13 A. Yes. That's a fair statement. 14 know anyone who retransitioned after they 14 Q. And I understand from your 15 detransitioned? 15 Reconsidering Informed Consent paper you A. I've heard that that happens 16 think it's important for clinicians to 17 sometimes, yes. The answer to your 17 take the time to really get to know the 18 question is I think I know of a prisoner 18 patient and also to make sure to 19 like that who detransitioned when 19 thoroughly inform patients, and when 20 released and got readmitted to 20 they're minors their parents, of the 21 incarceration and then returned to living 21 risks associated with care and what is 22 as a trans person. I wouldn't swear to 22 known in the science; is that correct? 23 that. I'm not certain, in other words. A. That's correct, yes. It's also Q. And your patients who 24 correct that it's important for the 25 detransition, was it always because they 25 doctors to know, to actually know what Page 143 Page 145 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 came to identify with their natal sex or 2 science knows and to separate their 3 were there other reasons? 3 personal beliefs from what science knows. 4 I would have you add that to your 4 A. I'm sorry? 5 Q. I can speak up. 5 summary. Of your patients who 6 Q. Okay. And is it your 7 detransitioned, was it always due to them 7 understanding that all clinicians who are 8 coming to identify with their natal sex 8 providing care to minors with gender 9 or were there other reasons for the 9 dysphoria -- actually, me ask that 10 medical detransition? 10 differently. 11 Is it your understanding that MR. CANTRELL: Objection. 12 all clinicians who are referring minors 12 A. Two come to mind and they 13 detransitioned to reidentify with their 13 for gender-affirming medical care or 14 natal sex assigned at birth. 14 providing themselves gender-affirming 15 Q. You've had two of your 15 medical care to minors, are doing it 16 patients detransition, is that what 16 without taking the time to do the 17 you're saying? 17 thorough evaluations and provide the 18 18 thorough information for informed A. Yes. 19 Q. Have you had just two or have 19 consent? 20 there been others? 20 MR. CANTRELL: Object to form. 21 A. Well, that's one -- one I 21 A. Ms. Cooper, if you use the 22 wrote a paper about and one I already 22 word "all" in any one of your questions I 23 talked to you about. And at the moment I 23 cannot answer it yes or no because I 24 can't think of a third but, you know, I'm 24 object to the idea that the heterogeneity 25 of everything can be summarized as all or 25 slow to retrieve memories these days.

D 146	D 140
Page 146 STEPHEN B. LEVINE, M.D.	Page 148 1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 none.	1 STEPHEN B. LEVINE, M.D. 2 recommended having going on hormones.
	3 So I have these experiences
3 Q. All right. Let me ask you a 4 question.	4 and these experiences have helped me
5 Is it true that is it your	5 write these two papers over the years
6 understanding that a majority of	6 about informed consent. I'm not I'm
7 clinicians are providing care without	7 not testifying about all or none or
8 taking time to evaluate fully the	8 12.7%. I'm telling you, this is what I
9 patients and thoroughly engage in the	9 think are the standards.
10 informed consent process that you say is	Now, I can tell you that as of
11 important?	11 this morning 27,000 people downloaded
12 MR. CANTRELL: Object to form.	12 this article since March the 17th. So
13 A. What I am saying in the	13 it's not about my accusation in this
14 Reconsidering Informed Consent paper is	14 percentage of people. I'm trying to set
15 that these are the elements of informed	15 the standards. I'm trying to have it
16 consent. I'm not sure how this	16 based on science, and science is limited
17 practitioner or this clinic does it	17 here. And because it's limited we need
18 because there are 50 or more clinics in	18 informed consent, and because we need
19 the United States and many more clinics	19 informed consent, it has to be honest,
20 around the world.	20 and it has to separate the doctor's
21 I'm trying to set the	21 belief from what science knows. So your
22 standards for informed consent. I can't	22 line of questioning somehow is is
23 make a judgment of whether it's 38% or	23 missing my point.
24 79%. I'm trying to articulate the	24 Q. Do you have any knowledge
25 standards that would help somebody	25 about how gender-affirming medical care
Page 147	Page 149
Page 147 STEPHEN B. LEVINE, M.D.	Page 149 1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas?
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer,	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%.	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere.
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors?
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that.
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients 20 and I hope it will change the process	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's 20 been marked as Exhibit 3, your
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients 20 and I hope it will change the process 21 whereby I won't have to have patients	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's 20 been marked as Exhibit 3, your 21 Reconsidering Informed Consent paper, and
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients 20 and I hope it will change the process 21 whereby I won't have to have patients 22 come to see me saying, my son went to	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's 20 been marked as Exhibit 3, your 21 Reconsidering Informed Consent paper, and 22 if we can scroll down to page 2. Are you
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients 20 and I hope it will change the process 21 whereby I won't have to have patients 22 come to see me saying, my son went to 23 this clinic and after one hour they said	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's 20 been marked as Exhibit 3, your 21 Reconsidering Informed Consent paper, and 22 if we can scroll down to page 2. Are you 23 there? There's some blue highlighted
1 STEPHEN B. LEVINE, M.D. 2 ethically make the recommendation to a 3 family about this matter, period. These 4 are the ethical requirements, this paper 5 argues, for how to do this, considering 6 that science does not have the answer, 7 people doctors have to inform people 8 about the state of science, the state of 9 our knowledge, you see. And so I'm not 10 I can't answer your question by 11 majority, all or 12.6%. 12 I'm saying this paper 13 articulates what I hope will be the 14 standard for understanding informed 15 consent obligations for the individual 16 practitioner and, therefore, I hope it 17 will change how various institutions and 18 programs and individual doctors think 19 about this and approach their patients 20 and I hope it will change the process 21 whereby I won't have to have patients 22 come to see me saying, my son went to	1 STEPHEN B. LEVINE, M.D. 2 is provided to minors in Arkansas? 3 A. No, I'm not an expert. But I 4 don't think that there is any studies 5 going on in Arkansas, or least not that 6 I've heard of. And Arkansas, I think, has 7 a children's clinic and probably has 8 individual practitioners, but I don't 9 want to represent myself as very 10 knowledgeable about what's happening in 11 Arkansas. I think what's happening in 12 Arkansas is probably not that different 13 from what's happening elsewhere. 14 Q. You don't know what kind of 15 protocols the doctors there follow in 16 terms of providing this treatment to 17 minors? 18 A. No. I'm ignorant of that. 19 Q. Let's look again at what's 20 been marked as Exhibit 3, your 21 Reconsidering Informed Consent paper, and 22 if we can scroll down to page 2. Are you

Page 150 Page 152 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 have articulated. Q. I'm going to jump to the 3 second paragraph that's highlighted. If 3 Many times doctors and systems 4 you want to take a minute to 4 think they are doing informed consent, 5 contextualize where that is, I'll give 5 but in our view they're not doing a 6 thorough informed consent. 6 you a moment to do that. 7 A. Okay. For example, if somebody Q. I want to read that second 8 mentions to the family of a 13-year-old 9 blue highlighted paragraph. Just follow 9 that they could do fertility preservation 10 with me. "Social transition, hormonal 10 or we can take sperm and take eggs and 11 interventions and surgery have profound 11 save them and, therefore, we've covered 12 implications for the course of the lives 12 the informed consent process about this 13 of young patients and their families. It 13 sterilizing effect of surgery or 14 is incumbent upon professionals that 14 hormones. I don't really think most 15 these consequences be thoroughly, 15 families can consider what this means. 16 patiently clarified over time prior to 16 And, for example, if the family is on the 17 undertaking any element of transition. 17 lower socioeconomic group and is on 18 The informed consent process does not 18 Medicaid, they're not going to be able to 19 preclude transition, it merely educates 19 afford or maintain at 15 years of 20 the family about the state of the science 20 payments to a fertility -- to a freezer 21 underpinning the decision to transition. 21 where these things are spent. 22 Social transition, hormones and surgeries 22 So the issue really is, can a 23 are unproven in the strict scientific 23 family understand what the doctor is 24 talking about? And I've been familiar 24 sense and as such to be ethical require a 25 thorough and fully informed consent 25 with what I consider to be perfunctory Page 151 Page 153 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 process." 2 informed consent processes. Okay. I'm not going to ask So the answer to your question 4 you if I read that right because I'm 4 is, if the doctor does the process over going to just assume that I did. 5 time, over a long period of time, and A couple of questions about 6 works with the parents to understand the 7 this. I want to make sure I understand. 7 implications of what we're talking about 8 I think this is sort of a version of what 8 and the parents and the doctor all think 9 you've been saying in the last few 9 that this circumstance with this family, 10 minutes. But do I understand correctly 10 with the absence of major 11 that in your view it is ethical to 11 psychopathology, or with the fact that 12 there hasn't been sexual abuse of the 12 provide gender-affirming hormone therapy 13 to minor patients if the doctors do 13 child that the family is trying to cover 14 engage in that thorough evaluation 14 up, you see, then I think yes, yes, we 15 process you've described and do engage in 15 can do this. But I want to be careful 16 that thorough informed consent process 16 because of the long-term consequences for 17 that fully informs patients and their 17 everyone in the family, not just the 18 parents of the risks and the state of the 18 patient. 19 science? Is that a fair description of So if you force me I could say 20 your view? 20 yes, I believe -- I wrote the paragraph, 21 21 I believe in the paragraph, you see. But MR. CANTRELL: Object to form. 22 A. The answer to your question is 22 I want -- I'm urging caution and you are 23 yes, presuming that the doctors actually 23 telling me that I am -- I am supporting, 24 do these things and whether they would 24 and you could give puberty blockers to 25 meet the criteria that I and my coauthors 25 kids if you did informed consent, and I'm

Page 154 Page 156 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 saying, whoa, whoa, whoa. I'm saying the 2 standards and I think higher standard for 3 standards for informed consent are very 3 how care is provided to adolescents and 4 high and I don't think they're being met 4 younger people with this diagnosis. Yes, 5 throughout the world. And you know this 5 I'm trying to benefit those people. 6 has gone through peer review, this is not Q. And in this article you don't 7 just Levine's opinion. 7 take the position that gender-affirming Q. In this article then, I mean, 8 -- let me ask it differently. 9 is it fair to say you're offering -- I 9 You don't argue in this 10 think you said you want this to be the 10 article that gender-affirming medical 11 standard that practitioners follow what 11 care should be categorically prohibited 12 you describe in this article; is that 12 for minors, right? 13 right? 13 A. No. I am saying that given the 14 A. I'm saying that we have a 14 uncertainties that science has clarified, 15 field called medical ethics. It's an 15 that it behooves the physician to; number 16 umbrella under which physicians need to 16 one, know what science has clarified; it 17 behooves the physician to separate his 17 operate. So I am emphasizing the umbrella 18 here. That's what I'm saying. It's an 18 personal beliefs, his personal passionate 19 umbrella. It's a legal and it's an 19 beliefs from what science knows and to be 20 ethical and it's a moral umbrella that 20 a trustworthy informer of the family over 21 people should know what they're getting 21 time what is known and what is not known; 22 into. 22 and what the implications are of social I think there is a long legal 23 transition, puberty-blocking hormones, 24 precedent in the United States law that 24 you know, cross-sex hormones and various 25 says doctors just can't do anything, they 25 surgical interventions. And I think the Page 155 Page 157 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 need to teach the people what they're 2 doctors, especially the pediatricians, 3 about to do and get their consent. That's 3 the doctors who are focused in pediatric 4 been evolving in the law for, you know 4 age groups need to pay attention to what 5 better than I do, for decades. 5 we know about adults with whom they've 6 had very little experiences. And after I'm just reminding the world 7 of -- I'm sorry, I'm sounding very 7 they turn 18 pediatricians generally do 8 narcicisstic -- but my colleagues and I 8 not get involved with people. 9 are reminding the world of the standards So the thing is that the 10 of informed consent and we're trying to 10 pediatric world tends to not be as 11 refine them and define them and we hope 11 conversant with the adult world of the 12 to have an influence on being safe and 12 trans people as they need to be in order 13 not harming people. 13 to inform parents of what the Q. Is it fair to say part of your 14 implications are. 15 aim is to try to improve how care is 15 Q. So is it your view then if 16 provided to minors with gender dysphoria 16 parents are truly fully informed in the 17 by writing this article? 17 way you say they need to be, that the A. Sorry. If you take your hand 18 parents should be the ones to make the 19 away from your mouth --19 decision about whether their adolescent 20 Q. Sorry. I will try to speak 20 children undergo gender-affirming medical 21 closer to the mic as well. 21 care? 22 Through this article are you 22 MR. CANTRELL: Object to form. 23 trying to improve how care is provided to 23 A. Gee, I thought I made these 24 minors with gender dysphoria? 24 things clear repeatedly already today. 25 But the parents have to give legal 25 A. I'm hoping to set the

D 1	Po 160
Page 1 STEPHEN B. LEVINE, M.D.	Page 160 1 STEPHEN B. LEVINE, M.D.
2 consent, the parents are in charge, you	2 is there to inform, not to recommend.
3 see. Those views have to be taken into	3 I think if it's truly an
4 consideration. The parents the ideal	4 informed consent, you see, the doctor
5 set of parents knows the patient better	5 tells the facts and because things are
6 than the doctor will ever know the	6 uncertain, the patient get that is the
7 patient, right?	7 unit patient, that is the parents and the
8 The legal requirements for the	8 child, they get to decide based upon an
9 parents to make this decision are in	9 accurate set of facts, and the facts
10 place because they have a brain	10 include that we don't know about these
11 maturational process and life experience	11 things, you see.
12 process and fertility process, pregnancy	Now, I am different than
13 process, raising children process that	13 pediatricians. Pediatricians feel
14 the child or the teen doesn't have. And	14 obligated sometimes to recommend a
15 of course their judgment is crucial here.	15 treatment, whereas, I feel the obligation
16 But in order for them to make this very	16 is to recommend the options and have
17 difficult decision this is not an easy	17 to inform people of the options and help
18 decision for any parent, you see. In	18 the parents to decide which is best for
19 order to make this decision, they have to	19 their family unit. It's different than
20 be informed.	20 "the doctor recommends", you see. Now, I
And the problem is that many	21 think I'm different than many
22 of the doctors believe passionately, they	22 pediatricians because I have that view.
23 believe passionately in what they're	MS. COOPER: How is everyone
24 doing, but they don't know what science	24 doing in terms of breaking? This
25 says or they don't accept what science	looks like a fine time to break if
Page 1	Page 161
Page 1 STEPHEN B. LEVINE, M.D.	Page 161 1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour,	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper.	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record.	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.)
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02. 13 Q. Dr. Levine, is it right that
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02. 13 Q. Dr. Levine, is it right that 14 in this case you've been asked to provide
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care?	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02. 13 Q. Dr. Levine, is it right that 14 in this case you've been asked to provide 15 expert testimony about the state of the
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form.	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02. 13 Q. Dr. Levine, is it right that 14 in this case you've been asked to provide 15 expert testimony about the state of the 16 scientific evidence about
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if	1 STEPHEN B. LEVINE, M.D. 2 they need one or if you need to go 3 on. 4 THE WITNESS: My bladder would 5 like one minute. 6 MS. COOPER: Let's take a 7 break. 8 VIDEOGRAPHER: Going off the 9 record. The time is 1:51. 10 (Recess is taken.) 11 VIDEOGRAPHER: Back on the 12 record. The time is 2:02. 13 Q. Dr. Levine, is it right that 14 in this case you've been asked to provide 15 expert testimony about the state of the 16 scientific evidence about 17 gender-affirming medical care for minors?
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide expert testimony about the state of the scientific evidence about gender-affirming medical care for minors? A. Yes.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide expert testimony about the state of the scientific evidence about gender-affirming medical care for minors? A. Yes. Q. And that's what you've
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents 20 and the child and the doctor, that's a	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide expert testimony about the state of the scientific evidence about gender-affirming medical care for minors? A. Yes. Q. And that's what you've discussed in your reports in this case?
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents 20 and the child and the doctor, that's a 21 team, right, the parent, the child, the	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide scientific evidence about regender-affirming medical care for minors? A. Yes. Q. And that's what you've discussed in your reports in this case? A. Well, you read the report.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents 20 and the child and the doctor, that's a 21 team, right, the parent, the child, the 22 doctor, that's a unit, that's a team and	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide scientific evidence about gender-affirming medical care for minors? A. Yes. Q. And that's what you've discussed in your reports in this case? A. Well, you read the report. Q. So that's a "yes"?
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents 20 and the child and the doctor, that's a 21 team, right, the parent, the child, the 22 doctor, that's a unit, that's a team and 23 sometimes the doctor is a set of	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that tin this case you've been asked to provide scientific evidence about regender-affirming medical care for minors? A. Yes. Q. And that's what you've discussed in your reports in this case? A. Well, you read the report. Q. So that's a "yes"? A. I hope it's a yes.
1 STEPHEN B. LEVINE, M.D. 2 says or they say, well, this study is BS, 3 you see. But that's what I think I've 4 been saying to you over an hour, 5 Ms. Cooper. 6 Q. Okay. And again, just 7 sometimes we need to get things clear for 8 the record. 9 Then assuming that the doctors 10 provide that full information that you've 11 described as necessary, is it your view 12 that the decision should be left with the 13 parents for the care of their minor child 14 with respect to gender-affirming medical 15 care? 16 MR. CANTRELL: Object to form. 17 A. In that individual case, if 18 the state allows this to happen, then it 19 is, yes, the answer is yes, the parents 20 and the child and the doctor, that's a 21 team, right, the parent, the child, the 22 doctor, that's a unit, that's a team and	they need one or if you need to go on. THE WITNESS: My bladder would like one minute. MS. COOPER: Let's take a break. VIDEOGRAPHER: Going off the record. The time is 1:51. (Recess is taken.) VIDEOGRAPHER: Back on the record. The time is 2:02. Q. Dr. Levine, is it right that this case you've been asked to provide scientific evidence about gender-affirming medical care for minors? A. Yes. Q. And that's what you've discussed in your reports in this case? A. Well, you read the report. Q. So that's a "yes"?

Page 162 Page 164 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Arkansas law at issue in this case? 2 are currently on these treatments. 3 A. I did, yes. So that's a psychological and 4 Q. So you understand that the law 4 medical problem that needs to be solved 5 prohibits gender-affirming medical 5 if the law goes into effect. But I do 6 interventions for minors which suffer 6 think the intent of the law is not so 7 from gender dysphoria in all cases, 7 much with the people who are currently 8 regardless of circumstances? 8 being treated, but the people who might 9 MR. CANTRELL: Object to form. 9 be treated after the law goes into 10 A. I think that's what the law 10 effect. That's my understanding. 11 says at this point in the history of the Q. Okay. When you talk about the 12 problem of the people who already are 12 law, yes. 13 Q. Can you say what you mean by, 13 17-year-olds and have been on hormone 14 "at this point in the history of the 14 therapy for a few years, do you think it 15 law?" 15 would be a problem to require them to A. Well, you know, if you 16 discontinue hormone therapy? 17 interpret the law as any doctor -- every 17 MR. CANTRELL: Object to form. 18 doctor has to stop prescribing hormones 18 A. I think there's a physiologic 19 to people who have been on hormones for 19 problem and I think there's a 20 two years or three years, I really don't 20 psychological problem and I think the 21 think that's going to happen. I think the 21 team of doctors that include, I hope 22 law will be modified or that doctors will 22 still, a mental health professional, 23 get together and recommend a process 23 although I doubt if any of them have a 24 whereby people can be discontinued from 24 mental health professional, I think that 25 hormones. 25 team of the endocrinologist or the Page 163 Page 165 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 I do think the writing of the 2 primary care doctor or the pediatrician 3 law was more about the future than it is 3 and the mental health professional who's 4 been interested in gender dysphoria, will 4 about the current situation and that the 5 have to get together and to think about 5 current patients on hormones who are in 6 the process, say, 17-year-olds, 17 and a 6 how best to do this, to live within the 7 half-year-olds, I don't think the law 7 law. 8 will be literally interpreted for those 8 Now, if it's six months 9 people as they will be interpreted for 9 before, you know, the person is 18, 10 the 13-year-old who comes with gender 10 they'll find some solution. And then if 11 dysphoria, who then would be offered in 11 the child is 16 and they're two years, 12 Arkansas a different kind of approach. 12 there will be a different kind of 13 I don't really think Arkansas 13 solution to it. And so, it's not like the 14 is trying to stop the treatment of kids 14 medical profession can't respond to this 15 with gender dysphoria. I think they're 15 law, to live within the law and I don't 16 trying to stop the treatments with 16 really think that the Attorney Generals 17 scientifically unclear value and dangers 17 -- of the people in the Attorney 18 with children with gender dysphoria. 18 General's Office and the Prosecutor's So as far as I understand, the 19 Office are going to be unsympathetic to 20 law says that we, we physicians in 20 the situations that you and I are making 21 reference to. 21 Arkansas must desist from giving these 22 treatments, but I think doctors are going 22 The law, itself, you see, I 23 to get together, and perhaps even with 23 think is primarily about the future. But 24 the blessing or of another law in 24 it does have a problem now for what are 25 Arkansas, to deal with the patients who 25 we going to do with these kids? And I

Page 166 Page 168 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 trust the medical profession -- I trust 2 identity, which has been stable for four 3 the medical profession to be sensitive to 3 years, is not going to disappear because 4 the physical and the psychological and 4 the child is not on hormones for six 5 the social needs of these children, and 5 months or can be on a lesser dose of 6 they'll find a way. 6 hormones, you see. Q. You talk about finding 7 Now, spironolactone, for 8 solutions that stay within the confines 8 example, is not a hormone, but it's 9 of the law. Do you mean find solutions 9 commonly used to suppress androgens and 10 about how to detransition them in a way 10 to increase estrogen in the body. So 11 that stays within the confines of the law 11 they'll figure out how to deal with this 12 or to find a way to not detransition? 12 if the law becomes the law, you see. 13 MR. CANTRELL: Object to form. 13 The doctors will work with the 14 A. No. I don't imply it's going 14 law and they'll find a way. The law 15 to cause them to detransition. Gender 15 doesn't apply to 18-year-olds. And so, I 16 just think the law, itself, is aimed at 16 identity is a psychological thing. It 17 isn't dependent on taking hormones, you 17 preventing treatments that are not 18 see. 18 scientifically established for young 19 Q. Let me rephrase that question 19 people. 20 then, understanding why that was 20 But this is a group that you 21 confusing. 21 and I are now talking about that will be 22. 22 -- will require some additional thinking, When you were talking about 23 the medical community coming up with 23 which the law does not provide for at 24 solutions, do vou mean solutions about 24 this point. But I trust the medical 25 how to take them off of the hormone 25 profession and their belief in if the Page 167 Page 169 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 therapy or solutions about how to not 2 patient, in fact, is -- is doing better, 3 take them off the hormone therapy? I'm 3 they may come to realize the person is 4 not sure what you meant by "solutions". 4 still not doing better and maybe the MR. CANTRELL: Object to form. 5 5 treatment for the last three years hasn't A. I'm saying that since medicine 6 really amounted to an upgrade in 7 improvement, so the family and the 7 ideally is on a case-by-case basis, the 8 team of physicians who are involved with 8 patient and the law sort of will be 9 this, which I hope will be the endocrine 9 cooperating to make an individual 10 expert, and that may be the pediatrician, 10 decision that you may eventually call 11 him or herself, and the mental health 11 detransition. But I don't know what that 12 professional, and the team that has been 12 will be, it's uncertain. 13 involved, let's say there's a children's 13 Q. If you have a 16-year-old 14 hospital that does this in Little Rock, 14 who's been on hormone therapy and by all 15 you know, those people will get together 15 accounts the patient, parent and doctor 16 and will think about this, both as a 16 agree that has been a beneficial 17 policy; that is how we're going to 17 treatment, and then the law goes into 18 generally approach this and how we're 18 effect tomorrow and the doctors can't 19 going to individually approach this for 19 continue to provide hormone therapy for 20 this case versus that case, and they will 20 two more years while the patient is a 21 find a solution. And it is not -- it 21 minor, could that cause harm to that 22 doesn't necessarily mean detransitioning 22 minor, psychologically --23 the child. It may mean decreasing their MR. CANTRELL: Object to form. 23 24 hormones or using something else or 24 Q. -- physically? 25 reassuring the family that gender Theoretically, it could cause 25

Page 170 Page 172 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 banning new treatments. 2 distress. It would cause the family to 3 have to find a solution. It may be to go 3 Q. And are some of those, the 4 to Kentucky or Missouri or Oklahoma or it 4 ones that are considering it, like 5 Arkansas, banning continued care for 5 may, if it's a politically active family, 6 it may cause a conversation with the 6 those already receiving treatment? 7 legislature who will provide a secondary 7 MR. CANTRELL: Object to form. 8 bill, a bill that perhaps can pass very 8 A. I'm sorry. The two of you 9 quickly that only applies to those 9 heard that better than I did. 10 16-year-olds, like those kids like you Q. When you -- you mentioned you 10 11 are just making reference to, that would 11 had some concerns about what's going on 12 be much more, you know, thoughtful about 12 in other states. Are there proposals 13 how do we deal with the already 13 you're concerned about that, like 14 transitioned people who are doing well. 14 Arkansas, would prohibit not just So if there are already 15 forward-looking treatment for new 15 16 transitioned kids who are not doing well, 16 patients but treatment being continued 17 this may be, in fact, a benefit. But 17 for those currently receiving 18 there are kids who -- I will presume with 18 gender-affirming hormone therapy? 19 MR. CANTRELL: Object to form. 19 you that there are children who are doing 20 better or who are functioning well in 20 A. What I'm saying is that the 21 their new role and who want to continue, 21 social circumstances of children who are 22 and I think solutions will be found. You 22 gender dysphoric but haven't been 23 know, I would prefer this law to have 23 socialized into a new gender or haven't 24 made provisions already for that but that 24 been given one of the hormone treatments 25 wasn't in -- I wasn't consulted. 25 is one set of issues. And what you are Page 171 Page 173 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. Q. And just to clarify, when you 2 raising appropriately is, what about the 3 say you would prefer that the law would 3 children who already have spent years in 4 have made provisions already for that, 4 treatment, what are we to do about those 5 you mean, are you suggesting some kind of 5 people? And I am trying to be kind and 6 a carveout for adolescents who are 6 understanding and compassionate about the 7 already receiving gender-affirming 7 situations and those families. 8 hormone therapy? I don't think this is a reason A. I would have liked the law to 9 to ban the law, so to speak. I think 10 have talked about the present -- the 10 it's a reason to think about those people 11 future treatments of this as of the time 11 as a separate category of people, and to 12 be compassionate about them and 12 the law was passed and recognizing the 13 social, psychological circumstances of 13 compassionate to the doctors and 14 the children who already have been 14 compassionate to the parents, and to make 15 stabilized in their new social gender, 15 an individual -- to make -- as I already 16 their new gender, to think about those 16 said, I think there are two dimensions to 17 kids. I don't think the law has thought 17 the response to that group of people; 18 about those kids sufficiently. So I'm a 18 one, is the teams of doctors who have 19 little concerned about that, and it's not 19 been involved with this need to get 20 just in Arkansas, you know. 20 together and think about what is 21 Q. Where else are you concerned 21 necessary in general for this group of 22 about that? 22 people; and then the individual doctors A. Well, as you know better than 23 taking care of this child and these set 24 I, other states are considering or have 24 of parents, you see, need to think about, 25 -- you know, are considering similar 25 what are we going to do in this case? And

Page 176 Page 174 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 I have more optimism that the good nature 2 different what we're going to do with Tom 3 Burch. Am I clear? I think so. 3 of that process, the medical process, 4 they'll find solutions for this, you see. Q. So going back then to your 5 And I hope one of the solutions will be 5 reports that discuss the scientific 6 to approach the legislature to create --6 evidence regarding gender-affirming 7 to not put doctors in harm's way if they 7 medical care for adolescents, by 8 -- if they're taking care of people who 8 submitting those reports in this case was 9 they've previously committed to this 9 it your intention to express support for 10 banning gender-affirming medical care 10 treatment. 11 If someone is taking four 11 across the board for minors? 12 years of an anti-cancer drug, and it's 12 MR. CANTRELL: Object to form. 13 now proven that this anti-cancer drug has 13 A. You are talking about this 14 negative -- negative consequences, well, 14 article? 15 the doctors can easily stop that, you Q. No. No. Sorry. Your reports 15 16 see. But here we're imposing -- we 16 that you submitted in this case, your 17 recognize that if we stop the cancer 17 expert reports, your declarations. 18 drug, there's a certain benefit to it and 18 MR. CANTRELL: Object to form. THE WITNESS: You want me to 19 there is a certain risk to it and the 19 20 doctors will modify that decision based 20 answer this? 21 upon their understanding of the risks and 21 MR. CANTRELL: You can answer. 22 the benefits of the drug. What else can 22 Q. Actually, let me back up. I 23 we do? 23 don't want there to be confusion here. 24 So, you know, we want our You recall submitting expert 25 doctors to be preoccupied with the 25 reports in this case, correct? Page 175 Page 177 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 welfare of the child, of our patients, Of course. 3 3 and I believe that doctors are Q. Okay. And so my question 4 preoccupied with that. So we'll find a 4 relates to those reports. 5 way. We'll find a way. It's not just, 5 By submitting those reports in 6 okay, it's going to stop and then doctors 6 this case was it your intention to 7 are going to turn their back on these 7 express support for banning 8 people. I don't think that's going to 8 gender-affirming medical care across the 9 happen at all. 9 board for minors in Arkansas? Q. Now, in your view, would it be 10 MR. CANTRELL: Object to form. 11 best for an individual case-by-case 11 A. I thought that the Attorney 12 determination to be made for what to do 12 General's Office hired me to give the 13 with each of those teens who is already 13 state -- to articulate the state of 14 on gender-affirming medical care? 14 science in this field. That's what I was 15 MR. CANTRELL: Object to form. 15 hired to do. I am not a proponent or an A. You know, I've already 16 opponent to this, to the law. 17 answered that question. I'll do it a 17 I have already told you my 18 third time. 18 concerns about the law. I'm not a 19 I think it will take two 19 legislator, I'm not a politician, I don't 20 forms; one, what are we going to do in 20 consider myself an expert in public state 21 general about this problem because it's 21 policy, policy on state levels. 22 new; and two, what are we going to do 22 I do feel my expertise is in 23 about John Jones? They can be separate. 23 my knowledge of the state of science in 24 I mean, John Jones is going to fall 24 this field, and I believe I'm being hired 25 within the umbrella but it's going to be 25 to testify only to that.

Page 178 Page 180 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 I don't present -- I don't 2 position is scientifically and 3 personally, based on my experience, there 3 presume that I'm an expert in the wisdom 4 of the law. I hope I have a certain 4 are considerable concerns, legitimate 5 concerns about the long-term implications 5 degree of cogency and grasp of the state 6 of science, and that's what I believe 6 of what we're doing by medicalizing a 7 I've been hired to testify to. Is that an 7 child's gender identity, you see, because 8 answer to your question? 8 it makes -- it causes permanent damage. Q. I think it was. And from 9 Generally, "this above all, do 10 earlier in the deposition we talked about 10 no harm" is the major medical principle 11 your articles Reconsidering Informed 11 of ethics. And the penis is normal, the 12 Consent, and your views about how care 12 breast tissue is normal, menstruation is 13 should be provided in this area. So I 13 normal, you see, and interfering with 14 just want to make sure I understand 14 these things on the hope that the 15 correctly. 15 long-term outcome will lead to mental 16 healthy, highly functional, loving Is it your position, not that 17 care -- sorry. I'll start again. Is it 17 people. The hope. The science says, 18 your position -- I'm sorry. I'm asking 18 well, what is the evidence that your hope 19 this in a very awkward way. 19 has been realized? 20 Do I understand correctly that 20 So my position is, as long as 21 it is not that you oppose ever providing 21 you believe this, that it's an important 22 gender-affirming medical care to minors, 22 thing to do and there are things like 23 but that it should be done with a lot 23 true transsexual people, which I'm not 24 more caution and according to standards 24 sure exists, you see, then if you're 25 that you articulate in your revisiting 25 going to do these things, at least you Page 179 Page 181 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 informed consent article? 2 should do it within the ethical framework 3 MR. CANTRELL: Object to form. 3 that this article discusses. A. It's my position that there 4 4 I don't know if I'm ever going 5 are serious, serious concerns about the 5 to be able to answer your question. 6 wisdom of medicalizing gender identity in MS. COOPER: Can we mark 6 7 a child and in a adolescent, and that the 7 exhibit tab 17 as the next exhibit. 8 evidence that this is beneficial to the 8 (Exhibit Levine 4, transcript re: Presentation on Healthcare 9 child, him or herself, and to the family 9 10 you see, in the long run and that it 10 Models For Transgender Adolescents, 11 improves the ability to function dated March 12, 2020, was received 11 12 socially, vocationally, educationally, 12 and marked on this date for 13 and sexually, these things are -- there 13 identification.) 14 are indications that these things are not 14 Q. Okay. That should be up. 15 health-promoting. 15 Dr. Levine, this is a So given the state of science 16 transcript of testimony from a 17 I have concerns about the wisdom of this 17 legislative hearing in Pennsylvania. 18 and I hope that the doctors have the Do you recall testifying in 18 19 2020 at a legislative hearing in 19 concerns about the wisdom of this 20 treatment and apparently, the legislature 20 Pennsylvania? 21 has concerns about the wisdom of these 21 A. Yes, I do recall that. 22 treatments as well. 22 Q. And am I right that that was 23 about state medical insurance coverage So if you understand my 24 testimony, I think you keep asking me 24 for gender-affirming medical care for 25 about, you know, what is my position? My 25 minors? Is that the issue you were

Page 182 Page 184 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 talking about? 2 Q. Okay. Just making sure we're A. I think there was a health 3 3 on the same page. 4 subcommittee and they were trying to 4 So at the top of 59 I want to 5 decide whether Medicaid should cover 5 ask about a passage that says, "I'm not 6 asking the committee to outlaw sexual 6 these treatments. 7 assignment surgery, I'm not asking the 7 Q. For minors; is that right? 8 A. Yes, for minors. 8 committee to outlaw the judicious use of Q. Okay. If you could scroll down 9 endocrine treatment, I'm just raising 10 with me to page 59, please. 10 questions for you about the wisdom of 11 encouraging puberty blocking, the way I A. Okay. 59, yes. You didn't 12 highlight this page. 12 understand it happens in urban centers 13 that process many many kids, increasing 13 Q. No. Sorry. Actually, let's go 14 to 58 because I want to make sure 57 --14 numbers of children." I'll stop there. 15 A. 57? 15 What did you mean by "the 16 judicious use of endocrine treatments" Q. Yes. If you could read, 17 there's an exchange between Dr. Levine 17 there? 18 and Representative Cox where he asks a 18 A. Ms. Cooper, I know you're a 19 question at the bottom of page 57. Do you 19 very intelligent person. And "judicious" 20 see that? Starting with, "If I might, 20 is a word you understand. So I'm a little 21 Mr. Chairman"? 21 perplexed that you are asking me what I 22 22 meant by "the judicious use of endocrine A. Yes. Okay. I'm there. Q. I just want to make sure you 23 treatment." 24 can have the context. So why don't you 24 I guess you mean, am I saying 25 read there through page 59. 25 that doctors need to be thoughtful, make Page 183 Page 185 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. A. I have now read to the top of 2 good judgment? Yes, that's what I mean. 3 page 59. Do you want me to read through We've already spent a great 4 59? 4 deal of time of what goes into judicious, 5 Q. Yes, please. 5 informed consent, based on science, based 6 A. Okay. 6 on the families' education and ability to 7 (Deponent reviews the 7 comprehend, based on the psychopathology 8 document.) 8 of the family, the psychopathology of the 9 9 family, the psychopathology of what the A. Okay. Q. So I wanted to ask you, this 10 child has endured in life and is still 10 11 was about whether to cover 11 suffering from. That's what I mean by 12 gender-affirming medical care for minors 12 judicious. 13 as part of the state Medicaid coverage? 13 Now, I'm not saying that there A. Well, Ms. Cooper, this is the 14 is no child that a therapist might 15 first time since March 12th, 2020 I read 15 actually think it may not harm, it may 16 not help, but I think it's worth a try, 16 those words, so you'll forgive whatever I 17 say next because I'm not exactly, you 17 that would be judicious. That would be 18 know -- this was me two years ago and six 18 judicious as of March 12th, 19 -- 2020. 19 months ago. I've had a lot of experience 19 Q. Is it different now? 20 in the last 26 months. I've reviewed a 20 A. I think it may be different 21 now that we've had additional reviews 21 lot of data in the last 26 months. 22 Q. But the topic you're talking 22 about the risk/benefit ratios, but still 23 about is gender-affirming medical care 23 I would always want -- I would always 24 for minors, right? 24 want the word judicious to modify what 25 A. Right. 25 doctors do.

Page 186 Page 188 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 So I would never say -- I 2 experiences and loving and falling in 3 mean, I'm not going to delete that word 3 love and having sexual experiences and 4 and I don't think when you get medical 4 entering into a romantic relationship 5 care you would want your doctor to be 5 with or without sex and understanding the 6 non-judicious. So it's judicious. 6 complexities of it, the nuances of it, 7 and to realize that I'm more than my Now, the question is, is it 8 really judicious to take a 13-year-old 8 gender identity, and my body responds 9 and put them on hormones, say, puberty 9 with pleasure in ways that I didn't know 10 blockers, and then a year later put them 10 that I had before. That these things are 11 on either testosterone or estrogen. 11 -- these things can change a child's 12 attitude towards the self, which is what 12 Today, given the science, it would 13 probably be even less judicious than it 13 gender dysphoria is, you know, it's a 14 was two years ago to do that. And again, 14 problem in one's attitude towards the 15 science is ever-changing, facts are 15 bodily self and the psychological self, 16 ever-evolving, and who knows what a year 16 as represented in your own gender, your 17 from now we will know. 17 concepts about your own gender. I don't think if we get new 18 So judicious also means the 19 knowledge it won't be from the United 19 judicious use of the doctor as a 20 States, it will be from other countries 20 maturational promoting agent, you see. 21 who are more apt to be cautious and to do 21 So much of the psychotherapy of these 22 studies like Sweden, for example. 22 children are -- is aimed at facilitating Q. You give the example of a 23 maturation and not getting stuck on one 24 13-year-old, that maybe today it wouldn't 24 issue, vou see. 25 not be judicious to provide certain 25 So I think there the tradition Page 187 Page 189 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 medical transition treatment to a 2 of psychotherapy and the state of science 3 13-year-old. 3 comes together to perform a powerful 4 argument that we should not be giving, 4 Could it in your view be 5 judicious in 2022 to ever provide hormone 5 especially when there is high pressure on 6 therapy to a 16-year-old? 6 institutions to process or have what I 7 MR. CANTRELL: Object to form, 7 call high throughput, move kids through 8 8 the system very quickly. I think that's A. Well, it wouldn't be judicious 9 a very strong argument to not giving 10 hormones to the average 16-year-old who's 10 if it was outlawed in the state. It 11 wouldn't be judicious to put the doctor 11 been identified for two years as a trans 12 person, you see. They can keep their 12 into some kind of jeopardy. 13 Q. Let's put that aside. As a 13 identity as a trans person, they can keep 14 medical question? 14 that identity, but they need to have this 15 A. As a medical question, if we 15 process that will help them participate 16 had a chance to do what Dr. Levine 16 in the world as though they're a more 17 suggests, not just today but in papers 17 complicated person than just a trans 18 I've written about understanding all the 18 person. 19 things I've already said several times, I 19 So I think science and 20 think it is possible that there may be a 20 psychology and the knowledge of 21 case or two that we could be planning for 21 psychological development through 22 ultimate endocrine treatment in the 22 adolescence all come together to say 23 caution, caution, careful, don't harm 23 future. I don't know that it has to 24 happen at 16, for example. I think at 16 24 this kid, just because he wants this. 25 it's possible to begin to have intimate 25 MS. COOPER: I'd like to mark

	7 400		D 400
1	Page 190 STEPHEN B. LEVINE, M.D.	1	Page 192 STEPHEN B. LEVINE, M.D.
2	tab 8 as the next exhibit.	$\frac{1}{2}$	Q. I wanted to just ask you to
3	(Exhibit Levine 5, transcript		read with me, I'm going to read the
4	· · · · · · · · · · · · · · · · · · ·		answer highlighted. You say "Because
5	December 21, 2020 re: Juli Claire		categorical" actually, sorry. I'm
6			going to go up to the first prior answer,
7	Services was received and marked on		"Listen, I'm going to answer all your
8	this date for identification.)		questions. I don't believe generally in
9	Q. Exhibit 5 is now up. Are you		categorical bans of hormone treatment and
1	able to open the document?		surgical treatment for individual
11	A. Did you ask me a question?		patients. Why is that? Because
12	·		categorical bans is an absolute thing and
13	A. Yes.		I've already established that people have
14	Q. This is a transcript of a		different needs and I don't want to
15	deposition of you taken in the case		deprive certain people, even though I
1	Claire against Florida Department of		think it's a bad idea for other people.
1	Management Services. Do you recall being		That's what I take when you say
	deposed in that case?		categorical bans."
19	•	19	And I understand this was a
20	Q. Okay. According to the cover	20	case about adults that you were talking
21	page here that was in December of 2020;	21	about, so I don't want to confuse things.
22	is that correct?	22	But is that still your view in general,
23	A. I trust the accuracy of that.	23	about what you said there, that you don't
24	Q. Can you please scroll down,	24	believe generally in categorical bans of
25	it's page 152 I put to point you to.	25	hormone therapy for certain patients?
	Page 191		Page 193
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.
2	A. 152, I'm almost there. I'm	2	MR. CANTRELL: And just for
3	surprised. And you highlighted it.	3	the record, the question beginning
4	Q. All right. Let's I want to	4	where right before you started
5			
5	make sure I give you time to read the	5	reading, Leslie, says "Let's move
6	relevant context.	6	it to adults."
6 7	relevant context. If you go to page 151, the	6 7	it to adults." MS. COOPER: Yes. That's what
6 7 8	relevant context. If you go to page 151, the first question at the bottom I think is	6 7 8	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before,
6 7 8 9	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you	6 7 8 9	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly.
6 7 8 9 10	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152.	6 7 8 9 10	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just
6 7 8 9 10 11	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin?	6 7 8 9 10 11	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear
6 7 8 9 10 11 12	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151.	6 7 8 9 10 11 12	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that.
6 7 8 9 10 11 12 13	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time."	6 7 8 9 10 11 12 13	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear.
6 7 8 9 10 11 12 13 14	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go	6 7 8 9 10 11 12 13 14	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay.
6 7 8 9 10 11 12 13 14 15	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page.	6 7 8 9 10 11 12 13 14 15	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware,
6 7 8 9 10 11 12 13 14 15 16	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number.	6 7 8 9 10 11 12 13 14 15 16	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose
6 7 8 9 10 11 12 13 14 15 16 17	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the	6 7 8 9 10 11 12 13 14 15 16 17	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the
6 7 8 9 10 11 12 13 14 15 16 17 18	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.)	6 7 8 9 10 11 12 13 14 15 16 17 18	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex
6 7 8 9 10 11 12 13 14 15 16 17 18	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop,	6 7 8 9 10 11 12 13 14 15 16 17 18	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop, with the highlight?	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it sometimes gender-confirming or
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop, with the highlight? Q. You can finish page 152. I	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it sometimes gender-confirming or gender-conforming surgeries. Two
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop, with the highlight? Q. You can finish page 152. I don't know if you need to read the	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it sometimes gender-confirming or gender-conforming surgeries. Two studies by profound advocates of sex
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop, with the highlight? Q. You can finish page 152. I don't know if you need to read the lawyer's objection. The end of your	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it sometimes gender-confirming or gender-conforming surgeries. Two studies by profound advocates of sex assignment surgery began by saying it's
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	relevant context. If you go to page 151, the first question at the bottom I think is the beginning of this question. If you can read that through page 152. A. Where do you want me to begin? Q. Very bottom of page 151. A. "I am mindful of the time." Q. That's the question. Let's go to the next page. A. Bates number. (Deponent reviews the document.) A. Where did you want me to stop, with the highlight? Q. You can finish page 152. I don't know if you need to read the lawyer's objection. The end of your testimony on that page.	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	it to adults." MS. COOPER: Yes. That's what I was trying to clarify before, perhaps not clearly. MR. CANTRELL: Okay. I just wanted to make sure we were clear on that. MS. COOPER: We're clear. MR. CANTRELL: Okay. A. Ms. Cooper, I've been aware, based on two recent studies, whose prefaces have said it's unclear what the mental health benefits are of sex reassignment surgeries, they call it sometimes gender-confirming or gender-conforming surgeries. Two studies by profound advocates of sex

Page 194 Page 196 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 the mental health benefits of these 2 I'm for informed consent and for people 3 treatments, these surgical treatments 3 whose brains are mature, as mature as 4 actually are. 4 they're going to be. They get to decide, 5 you see. Both of the studies -- one of 6 the studies, the most well known of the 6 So this was before, and I hold 7 the right to continue to evolve as a 7 studies is the Bränström-Panchankis Study 8 in the August American Journal of 8 professional in my understanding of 9 Psychiatry, both of these studies have 9 things. It's my right to mature as a 10 been roundly attacked and the conclusions 10 professional. It's my right to change my 11 of the study have been agreed upon by 11 mind and it's my right to phrase things 12 others to not be based upon the data that 12 differently from every two years or every 13 the study is purported to demonstrate. 13 two days, you see. Because, like 14 And so the idea that the treatment of 14 children, all adults mature, continue to 15 adults is well established is -- is not 15 mature theoretically and professionals 16 correct. The science is unclear even in 16 mature. 17 this arena of adults. And this is very 17 Q. So is your view no longer --18 very relevant to the treatment of all 18 where you say, "I don't believe generally 19 in categorical bans on hormone treatment 19 transgender people when, after 60 years 20 of experimenting or at least offering 20 or surgical treatment for individual 21 these treatments, we can't be certain of 21 patients", is that no longer your view 22 after the new information you've learned 22 the mental health benefits and we are 23 aware of the high risk of suicides in 23 in the last two years? 24 A. I'm not in favor of 24 adults after the complete package of 25 medical treatment of the trans people. So 25 categorical bans on surgery for Page 195 Page 197 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 in 2000 when I made this testimony I 2 transgender adults. I'm not in favor of 3 didn't have access to those two studies. 3 categorical bans. I'm just in favor of 4 4 the judicious -- of physicians doing So now I know that I'm even 5 judicious decisionmaking based on correct 5 more uncertain of the long-term wisdom of 6 doing these things with people just 6 information. And I do think physicians 7 because they want to. However, adults are 7 need not to disregard studies that they 8 responsible, they're old enough to be 8 don't happen to agree with because it is 9 responsible for making decisions. And I 9 not in keeping with their zeitgeist. So 10 try to help them understand the data, but 10 maybe ask me that question again. 11 if they still want to do this, they still Q. Well, I was asking whether 12 want to have their breasts removed or 12 your opinion where you state here, "I 13 they still want to have their 13 don't believe generally in categorical 14 vaginoplasty, you see, if they understand 14 bans of hormone treatment or surgical 15 that their pleasure in masturbation, for 15 treatment for individual patients", 16 example, using their penis will disappear 16 whether that has changed? 17 and I can't guarantee they will be able 17 A. Well, actually I think it 18 to have orgasm with masturbation or with 18 makes more sense to categorically ban 19 a partner when they female genitalia --19 puberty-blocking hormones in young people 20 female-looking genitalia. Well, they get 20 than it does genital surgeries in 21 to choose that, I don't get to ban that 21 40-year-olds. 22 for them, you see. 22 Q. You would not at this point 23 favor categorical ban of hormone So I'm not exactly 24 categorically against things, as I've 24 treatment or surgical treatment for 25 testified I hope articulately already. 25 adults for gender dysphoria?

Page 198 Page 200 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 A. That's right. 2 dysphoria, do I understand correctly that 3 Q. And you think it might make 3 you would support the thorough informed 4 more sense to categorically ban puberty 4 consent process that you outlined in your 5 blockers for minors with gender 5 article for that kind of treatment? 6 dysphoria? 6 MR. CANTRELL: Object to form, 7 7 A. Right. asked and answered. Q. And what about hormone 8 A. I think I already expressed my 9 treatment for minors with gender 9 ambivalence of categorical bans and I've 10 already told you about the requirements 10 dysphoria? 11 for informed consent, but I think what I 11 A. I think it makes -- I think 12 need to tell you now is that I believe 12 there is a very strong argument, which 13 I've already tried to tell you the 13 that if doctors and parents and children 14 science has made, that this is -- the 14 knew, were given the facts on the ground, 15 risks are too great to promote this as a 15 there probably would not be as much of a 16 standard treatment and certainly 16 need for a law, you see, because I think 17 the evidence suggests that the risk to 17 promoting this as a standard or what is 18 called best practices, unquote -- quote 18 this child is too great, and the 19 best unquote practices. 19 consequence is not just for the child, 20 The idea that promoting this 20 the consequence is for the parent to have 21 as the best practice is not only 21 a mentally ill child or mentally ill 22 scientifically not correct, it's 22 adult is -- and that sometimes happens, 23 ethically not correct. And if it's 23 you know, because we don't really pay 24 ethically not correct, then it might not 24 attention to the underlying mental 25 be legally correct. 25 illness of the child. We say that all Page 199 Page 201 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. Q. But putting aside the question 2 gender identities are normal but they 3 of promoting hormone therapy as best 3 have comorbidity. Their comorbidity may 4 practice, I'm just asking about 4 determine their mental illness at 22 and 5 categorically banning it for minors with 5 then for the parents they have a 6 gender dysphoria, are you in favor of 6 22-year-old child who is failing to 7 that or does that fit into where you say 7 launch and they may be happy taking 8 -- let me ask it again. 8 hormones, you see, but they're not MR. CANTRELL: Object to form. 9 functioning very well. 10 MS. COOPER: I'm striking it. 10 So what I'm saying is, we --A. Ms. Cooper, can I just ask you 11 it's not a matter of categorical bans 11 12 to face me when you --12 alone, it's a matter of understanding 13 Q. I'm sorry. 13 what the profile of a child is and too 14 A. Because when your face is 14 many doctors have focused only on the 15 down, and I'm hard of hearing, I miss 15 gender dysphoria and they have believed 16 that the best practice is hormones. And 16 every third word. 17 Q. I'm sorry. Yeah, we don't 17 because they don't know the facts, people 18 like state legislators are worrying about 18 want that. 19 19 what they're doing to the next generation You talked about, for adult 20 of children. 20 treatment, you're not favor in And so that's where we are. 21 categorical bans you're for informed 21 22 consent, I think is the way that you put 22 And I don't know how to say this more 23 it. 23 clearly. You know, I think my attorney 24 And so my question is, for 24 just said asked and answered. I think we 25 hormone therapy for minors with gender 25 could have said that three times already

Page 202 Page 204 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 doctor's state of knowledge, not with 2 or four times. This is a really fraught 3 area. All of us are concerned about this. 3 this doctor's state of belief --Q. I'm wondering, since you've 4 Q. But a doctor -- sorry. 5 talked about -- you've got your article 5 A. -- because beliefs are 6 about revisiting informed consent, 6 determined not simply by scientific 7 describing what I think you said would be 7 knowledge, they're determined by many 8 -- you feel is an appropriate standard to 8 other factors, including what someone 9 be applied when considering 9 above them that they respect has taught 10 gender-affirming medical care for minors, 10 them, which may not be true at all, what 11 would in your view, if Arkansas passed a 11 I like refer to as the chain of trust in 12 law or regulation that required 12 medical education. And we all have to 13 clinicians to follow that kind of 13 trust what we're taught, but we know the 14 rigorous process, would that be a better 14 soul of science is skepticism but we have 15 choice than banning care across the board 15 to learn so many things about so many 16 no matter how that care is provided? 16 disorders that we just practically trust 17 MR. CANTRELL: Object to form. 17 what we're taught. A. Maybe I'm getting too 18 So I'm saying that people in 19 fatigued. I don't think I grasped what 19 this arena often have strong beliefs that 20 you were just asking me. 20 they're on the side of angels and that 21 Q. Okay. So I understand from 21 there's more benefit than there are harms 22 your testimony that the concern you have 22 and that's not what science knows, and 23 is providers not being cautious and 23 they don't know that. 24 providing gender-affirming medical care 24 So what I'm saying is, when 25 too quickly without thoroughly evaluating 25 you've asked that question you must Page 203 Page 205 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 and getting to know the patients and 2 include that the doctors need to know 3 without thoroughly informing families of 3 what the truth is as scientifically 4 everything you feel they need to know 4 established, and that's whatever you said 5 about the risks and state of science, 5 accurate minus that point. Q. So if the doctor knows what 6 that's a concern you've repeatedly 7 raised? 7 the truth is, as you understand it, do 8 A. Can I stop you there? 8 you believe a doctor could provide that 9 9 informed consent process to a family and Q. Yes. 10 a family could choose to provide 10 A. Yes. That's right. But you 11 want to add one thing to your statement, 11 gender-affirming medical care to a minor? 12 I'm also concerned that the doctors don't 12 MR. CANTRELL: Object to form, 13 know what the state of science is. So 13 vague. A. If there isn't a law 14 their interactions with the patients, 14 15 meaning the family and the patient, are 15 prohibiting it then I think, yes, under 16 based upon a positive view of the 16 certain circumstances. If a team of 17 potential of having a problem-free life 17 doctors have had a thoughtful 18 in the face of this child's history where 18 deliberation process among themselves and 19 among the family, I think it's possible 19 there are all these comorbidities. So if 20 the doctor does not know the facts on the 20 to make this judicious decision. And 21 table circa May 26, 2022, then they can't 21 whether it would prove right or wrong, 22 really give informed consent and if you 22 the doctor may not know because it may 23 understand my article, which I think you 23 prove right in two months and be wrong in 24 really do, these are the requirements for 24 two years. And so that's where science 25 informed consent. It begins with the 25 comes in. We say, where is the long-term

Page 206 Page 208 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 expert is in the state of science. 2 followup, folks? And the answer is, in 3 America we don't have any. It's not about support of a 4 So we don't know whether this 4 law or against a law or whether an 5 judicious decision to say yes to hormones 5 insurance company should do this or 6 has proven to be, in fact, judicious or 6 should not. 7 it may have been judicious then but Q. Let me ask you differently. 8 whether it's right in two years or five 8 Have you testified about legislation that 9 years, we don't know. And you know if 9 bans gender-affirming medical care for 10 this were your child you would want to 10 minors in any state? 11 know what other people who went on 11 MR. CANTRELL: Object to form. 12 hormones five and ten years ago, how are 12 A. Have I testified in favor --13 they doing? And the answer, if you ask 13 Q. Have you testified in any 14 that to your doctor, for your child, the 14 state legislative --15 doctor should say I don't know, I don't 15 A. No. 16 know. 16 Q. -- process? 17 A. No. You have already seen my Q. Could doctors have clinical 17 18 experience that would allow them to see 18 Pennsylvania thing. I thought I was just 19 benefits to those kids in five years? 19 giving information. I wasn't testifying 20 A. Well, if it's a pediatrician 20 for or against something. 21 or pediatric endocrinologist who then 21 Q. You didn't testify in Alabama 22 punts the child to an adult 22 about -- relating to a law about 23 endocrinologist or adult internist or 23 gender-affirming medical care there? 24 primary care doctor, they wouldn't know. 24 A. No. 25 I mean. I've had -- I've talked to a 25 Q. Have you been asked to give Page 207 Page 209 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 doctor who thinks he's helping people 2 testimony related to a similar measure in 3 live long, happy, successful, vocational 3 your state of Ohio? 4 and romantic lives and he's a child A. Yes, and I refused. 5 5 psychiatrist who doesn't see kids after O. Why did you refuse? 6 17 or 18. So he just believes it. He just A. Because I'm not an expert in 6 7 believes it. Okay. What's the basis of 7 these things. I think -- I refused 8 it? Well, I'm doing this, I have to 8 because this is what I know and I don't 9 believe it, I believe it. But he's 9 want to be used for political -- I don't 10 teaching that to parents. 10 want to be a pawn in political purposes. Q. Have you ever been asked to 11 These things are highly politicized. It 12 testify in support of a law banning 12 makes thinking very unclear. 13 gender-affirming medical care for minors? 13 I've come to learn that my 14 MR. CANTRELL: Object to form. 14 testimonies are public things that I 15 A. I have been asked to give the 15 never imagined would be reading my expert 16 opinion reports, are reading my expert 16 state of science in states that have --17 are considering limiting insurance 17 opinion reports and calling me names 18 coverages. And I don't know the answer 18 based on what they think. They call me 19 sometimes anti-trans or something. So I 19 to your question of -- maybe in -- no one 20 has asked me to testify in favor of 20 don't want to be part of the public fray 21 banning a law. Everyone has asked me, 21 but unfortunately I guess I am. 22 because I've been very clear with these 22 Q. Do you think a law like 23 people, the only thing I'm relatively 23 Arkansas, if it passed in Ohio, would be 24 knowledgeable about or what you would 24 beneficial to your minor patients with 25 called qualified as a Daubert qualified 25 gender dysphoria?

Page 210 Page 212 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 A. If they pass this -- you say 2 people the conservative treatment that 3 if they passed it in Ohio? 3 might benefit them and then when they're 4 Q. Right. 4 older, if they want to do this, then 5 A. Then I would say that it might 5 they're responsible for themselves to do 6 be very beneficial for the future of 6 it. 7 trans-identified children in getting them 7 The state has an interest, I 8 what I consider to be reasonable 8 think, in protecting the vulnerable young 9 appropriate care, because they have a 9 and clearly, the transgendered 10 psychological problem and they would then 10 populations are vulnerable people. 11 be treated like any other psychological 11 They're not healthy people. 12 problem by reviewing the patient's Q. So and in this case of 12 13 history and approaching the problems that 13 gender-affirming hormone therapy for 14 the child has psychologically with or 14 minors, you would prefer a categorical 15 without some medication, like an 15 ban on care to an individual case-by-case 16 antidepressant or anti-anxiety agent and 16 determination with proper informed 17 we would have the same problem that you 17 consent? 18 and I have discussed for 20 minutes about 18 A. I would prefer that a higher 19 what to do with the children who already 19 quality mental health approach, first 20 have been supported by the medical 20 approach, be done with these children 21 profession and I would urge then the Ohio 21 because I believe that if a high quality 22 legislature to have a bill that would 22 therapeutic process involving the 23 take into consideration that which you 23 children and the family process, that we 24 and I have already discussed --24 would be able to help children find more 25 Q. So you wouldn't -- sorry. 25 comfort in how to live, than being Page 211 Page 213 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 A. -- benefiting from what we're 2 preoccupied solely with transforming 3 talking about today. 3 their bodies. Q. So if they did have a bill So all this business about 5 that they amended to say it doesn't apply 5 categorical bans, I think because science 6 to minors who are already currently 6 is so uncertain and because other people 7 receiving such treatment, you wouldn't 7 feel profoundly, based on knowledge and 8 have any concerns about that law, you 8 intuition, that this is not a good thing 9 think that would be in the best interests 9 to do to remove the breasts of 13- and 10 of minors with gender dysphoria in Ohio? 10 14-year-old girls no matter what they MR. CANTRELL: Object to form. 11 say. We wouldn't take a 14-year-old who 11 12 12 says, I don't ever want to have children A. You see, based on the 13 assumption behind your question is that 13 and remove her ovaries. We wouldn't 14 these treatments are really beneficial, 14 sterilize a 15-year-old girl or boy 15 that they're really helpful, that they 15 because they didn't -- they don't want to 16 cure many things and that they prevent 16 have children if that were cis. But we 17 suffering from depression and anxiety and 17 can somehow do that if they're trans and 18 substance abuse and suicidality, you see. 18 that doesn't make a lot of sense to many That's what is behind your 19 people. 20 question, that there is something really 20 Q. If somebody -- actually, 21 positive about that. And these damn 21 strike that. 22 states that are trying to get rid of 22 MR. CANTRELL: Leslie, are we 23 this, these are -- these are actions to 23 getting close a break? 24 harm people, you see. Whereas, I think 24 MS. COOPER: In a couple of 25 they are actions trying to give these 25 minutes I think we can.

Page 214 Page 216 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 Q. So do I understand then that 2 Swedish study from 2011 and the Bränström 3 your view is that if a minor patient, 3 study in 2020 that demonstrated these 4 their parents and their doctor agree that 4 problems with suicide, you see. 5 hormone therapy would be beneficial to So what happens is if we're 6 the patient, and the family is provided a 6 going to inform the -- if the doctor or 7 thorough informed consent process about 7 the pediatrician informs the patient 8 the risks basis -- the risks and benefits 8 about the benefits of hormones, you'll 9 feel better, it will stabilize your 9 of treatment and the state of the 10 evidence, that the government should 10 sexual -- your gender identity, you see, 11 override that decision that the parents 11 your voice will get lower or you will 12 make? 12 grow breasts, and the risks are you'll 13 MR. CANTRELL: Object to form, 13 get a blood clot or you'll weight gain or 14 asked and answered. 14 your blood counts will go up, you see, 15 A. There is something about that 15 and your serum cholesterol will go up and 16 long question that --16 your high triglycerides, they don't say 17 17 these things will predispose you to death Q. Let me break it down. 18 A. -- I think you left something 18 from cardiovascular disease, it's not a 19 out. 19 lifecycle -- it's not a lifecycle 20 Q. Maybe I did. Let me restate 20 perspective. It's about the known medical 21 effects of hormones. That's not informed 21 it. Thank you. 22. So if a minor patient, their 22 consent, that's only a part of informed 23 parents and their doctor agree that 23 consent. And that's why I don't like how 24 hormone therapy is appropriate for the 24 you phrased that sentence because it's 25 patient, after the family is fully 25 about, oh, well, we talk about the risk Page 215 Page 217 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 informed about the risks and benefits of 2 and benefits of the treatment. You're not 3 treatment, do you think the government 3 talking about the risk of the treatment 4 should override that medical decision 4 because you don't have a lifetime 5 made by the parents? 5 perspective. And when you give -- when MR. CANTRELL: Same 6 you give a 15-year-old hormones you're 7 objections. 7 changing their life trajectory and you're A. All right. The risk and 8 shortening their lives. 9 benefits of treatment is what stopped me Q. It sounds like you're of the 10 the first time because I happen to know 10 view that these treatments can never be 11 that the risk of benefit treatment is 11 beneficial. So why did you write an 12 article about how to approach it through 12 that the benefits are not really written 13 down, but the risks are thromboembolism, 13 informed consent rather than an article 14 you know, weight gain, future 14 about banning the treatment? MR. CANTRELL: Object to form, 15 cardiovascular disease, right. They're 15 16 not talking about the risks that I'm 16 argumentative. 17 talking about, you see. They're not 17 A. I wrote an article to be 18 talking about the long-term life course 18 helpful, to represent what doctors know 19 outcomes. They're not talking about the 19 and what doctors don't know. And I leave 20 elevated suicide rate. 20 it to the medical profession and for 21 I've never seen an informed 21 anyone else who wants to read the 22 consent that talked about the elevated 22 article, like lawyers and legislatures, 23 to think about the implications of this. 23 suicide rate of adults who are fully 24 transitioned. I've never -- I've never 24 I'm not -- I don't have the 25 heard of a doctor talking about the 25 wisdom to ban everything. I don't know

Page 218 Page 220 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 who benefits and who doesn't benefit. I 2 take a pause and think about this. 3 don't know the rate of unhappiness at I know lawyers have to win and 4 five years. I don't know -- I don't know 4 lose cases. But on a larger sense, I'm 5 how society is to answer the question; 5 trying to influence everyone to 6 understand what science is. And you guys 6 how many negative outcomes versus 7 positive outcomes would make us want to 7 can fight it out. 8 continue or want to ban the treatment? Q. Would you be comfortable if 9 every state in the country passed a law For example, if I ask you the 10 question, if you were a legislator or a 10 banning gender-affirming medical care for 11 governor, if 15% of people are harmed and 11 minors? 12 50% are benefited and the rest, the 35% 12 MR. CANTRELL: Object to form, 13 are neutral, they don't know the answer, 13 calls for speculation. 14 would you ban it? And what happens if 60% 14 A. You see, I think medical care 15 are harmed but 40 are helped, would you 15 includes psychological care. So I don't 16 ban it? You see, at what level? It's not 16 even think that your statement makes any 17 doctors who could decide this, you know, 17 sense. 18 it's legislatures or governors, 18 Q. Let me rephrase the question. 19 politicians can decide these things. But 19 Would you feel comfortable with a law 20 you see as a doctor our medical 20 banning gender-affirming hormone therapy 21 profession does not know what the actual 21 for minors with gender dysphoria? 22 rate of harm is. And when these -- these 22 MR. CANTRELL: Same 23 reviews in other countries have said it 23 objections. 24 24 looks like the risk of harm exceeds the A. I would say based on what I 25 benefit, the benefits be cautious. 25 know today, that there would be a certain Page 219 Page 221 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 1 2 Now, in ten years we may know 2 prudence to that and yet a certain 3 that this treatment helps 83%, harms 10% 3 imprudence to that, and I don't know how 4 and 7% unclear. Well, if we -- if we knew 4 to balance those two things and I don't 5 that 83% of people benefited, I would be 5 really think, given what my -- what the 6 in favor of taking certain kids who met 6 state of science has and where we are, 7 certain criteria and putting them on this 7 that it's up to us to make that decision. 8 path. But if it were reversed and only I'm generally not -- I'm 9 13% were helped and 87% or 80% were 9 generally not for statements like "all" 10 harmed, then I would say don't do this, 10 or "always" and "never". I've been a 11 don't do this, please. I'm looking at --11 doctor too long to know that even great 12 we're talking about millions of people 12 adversities today sometimes have good 13 here. 13 outcomes and good things today have bad 14 Q. So given what we know how, 14 outcomes. 15 you're comfortable with your report being 15 So it's really hard for me to 16 used to help the state support and defend 16 take these kind of positions that I think 17 a ban on care for minors --17 you're trying to box me into. So please, 18 please respect the complexity of my 18 MR. CANTRELL: Object to form. 19 Q. -- ban on gender-affirming 19 views, at least as I experience them. 20 medical care for minors? Q. And just to wrap up and we can 20 21 21 take a break, is some of your discomfort MR. CANTRELL: Object to form. 22 A. I believe my report is helping 22 in answering these -- hold on. We're 23 you to think about the problem that 23 having an audio problem message. Can you 24 you're trying to defend. I believe I'm 24 hear me? 25 helping everyone who reads the report to 25 A. I hear you fine.

Page 222 Page 224 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Is your discomfort with the 2 turned to the black market to try to 3 sort of "all" questions that as a general 3 access hormone therapy and you mentioned 4 matter medical decisions would be made on 4 that that was a source of concern. Can 5 a case-by-case basis as opposed to 5 you say why that was concerning or would 6 blanket rule about care? 6 be concerning? A. Because the patient was lying MR. CANTRELL: Object to form. 7 A. If I may go back to breast 8 to his parents and the patient had taken 9 cancer for a minute, these case-by-case 9 his 12-year-old sister and sort of 10 colluded with her to keep this private 10 decisions are part of a larger umbrella 11 of what science knows. 11 and somehow he used her in this scheme 12 So what science knows about 12 and the parents were not only mad at the 13 the treatment of a particular form of 13 son for surreptitiously getting hormones 14 breast cancer has to be modified because 14 from China, but of his younger, more 15 this woman with breast cancer or this man 15 naïve sister and putting her into a 16 loyalty of conflict between the love for 16 with breast cancer has an associated 17 her parents and the love for her brother, 17 medical problem. So that treatment is on 18 a case-by-case basis. But that's an 18 and they found that to be morally 19 reprehensible. 19 exception to the umbrella of how we treat 20 breast cancer. And that applies to 20 Q. Did you have any physical 21 everything. That applies to depression, 21 health concerns for your patients taking 22 that applies to schizophrenia, that 22 black market hormones? 23 applies to eczema. 23 A. Absolutely. 24 24 MS. COOPER: This would be a Q. Like? 25 fine time to take a break. How much 25 One, that person is the person Page 223 Page 225 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 who ultimately died of probably fentanyl. time would you like? Let's go out 3 off the record. 3 O. So is there --4 4 VIDEOGRAPHER: Going off the A. So there is the naivete of the 5 record. The time is 3:17. 5 person who thinks I'm taking estrogen, 6 I'm taking heroin, they think they know 6 (Recess is taken.) 7 VIDEOGRAPHER: Going back on 7 what they're taking and heroin -- I'm 8 the record. The time is 3:31. 8 sorry -- words -- opioids are a perfect 9 MS. COOPER: Can we go off? 9 example of the dangers that society faces 10 10 when we don't do science, when we just do Sorry. I forgot to do something. 11 VIDEOGRAPHER: Time is 3:32. 11 what somebody or some group of people 12 12 think is the best thing to do and we We're off the record. 13 13 don't allow science to lead us. And now (Discussion is held off the 14 14 we have these incredible death rates from record.) 15 VIDEOGRAPHER: Back on the 15 opioids throughout America, which is not 16 abating, by the way. 16 record. The time is 3:32. 17 Q. Dr. Levine, do you think the 17 But this is a perfect example, 18 Arkansas law were to go into effect that 18 I think, that all of us need to worry 19 adolescents currently receiving care will 19 about when science does not lead 20 find some way to get access to hormone 20 therapeutics. 21 therapy? 21 Q. Going back to hormone therapy, 22 MR. CANTRELL: Object to form. 22 do you have any concerns that adolescents 23 in Arkansas who are currently receiving 23 A. I think some will. Q. You mentioned earlier in the 24 hormone therapy under a doctor's care, if 25 day at least one of your patients had 25 they had had to stop doing that because

Page 226 Page 228 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 the law took effect, would pursue 2 thinking that they're transgender. 3 Q. So I'm not sure if that 3 hormones from the black market? 4 MR. CANTRELL: Object to form, 4 answers my question. 5 calls for speculation. 5 Have you made a decision to no 6 longer provide letters --6 A. I think some would get some 7 benefit from it because it would cause A. Oh, I'm sorry. No, I haven't 7 8 them to rethink their situation and some 8 made that decision. 9 people would use black market and some Q. So would it be a case-by-case 10 people would get a friend's oral 10 basis, if there were a patient that you 11 contraceptives, there will be all kinds 11 felt it was appropriate for you would 12 of ways of dealing with this and not all 12 consider doing it, say, a 17-year-old or 13 necessarily bad and certainly not all 13 16-year-old? 14 necessarily good. 14 MR. CANTRELL: Object to form. 15 Q. But using black market 15 A. I don't have a -- yes. The 16 hormones without a doctor's supervision, 16 answer to your question is yes. 17 is that necessarily bad? Q. Do you think it would be 17 18 A. Yes. 18 beneficial to have clinical trials on the 19 19 safety and effectiveness of Q. We talked several hours ago I 20 think at this point about you and your 20 gender-affirming medical care for minors? 21 colleague, Ms. Novak, having written 21 A. Absolutely, yes. 22 letters of authorization for some minors 22 Q. And does that mean you would 23 to receive gender-affirming hormone 23 favor allowing minors to receive 24 therapy. I don't think I asked a followup 24 treatment in the context of -- let me ask 25 question. If you or Ms. Novak were --25 you in a better way. Page 227 Page 229 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 well, let me ask it differently. You would be supportive of Have you made a decision to no 3 clinical trials that would, as I 4 longer consider hormone therapy for 4 understand it, necessarily mean that some 5 anybody who has not reached their 18th 5 minors would be receiving 6 birthday since you provided those 6 gender-affirming medical care as part of 7 letters? 7 those trials, correct? A. I've made a decision to be A. I'm all in favor of a 9 very cautious and to put a period of time 9 national, multisite, carefully designed 10 in therapy between me and the letter. 10 study to answer the questions that we've 11 That's the decision I've made. I've also 11 been struggling over for the last four 12 made the decision, based upon two parents 12 hours and 30 minutes. I have great 13 I've seen who wanted their child to be 13 respect for the processes of science, 14 given puberty blockers, that oftentimes 14 even though I know that science too has 15 it is the mother who needs therapy rather 15 limitations. But the limitations of 16 than the child. 16 science are far less than the limitations 17 So my policy, and I think and 17 of individual doctors and their 18 my team, none of us are interested in 18 passionate beliefs. 19 providing puberty-blocking hormones based Q. So just to make sure I 20 upon our limited experience with this. 20 understand it, a clinical trial 21 And I think, generally speaking, we want 21 necessarily entails minor patients being 22 to have the evaluation psychotherapy 22 provided that treatment and then compared 23 process, that I've already described to 23 to a control group that would not be 24 you, as a matter of therapeutic approach 24 providing the hormone therapy, do I 25 to children, adolescent children who are 25 understand that correctly?

Page 230 Page 232 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 exception for minors who participate in A. A clinical trial, it begins 3 with a question and it -- it begins with 3 clinical trials? 4 a question and then it has a primary 4 MR. CANTRELL: Object to form. 5 endpoint and then a set of secondary 5 A. I don't think that's what's in 6 endpoints. And it has a means of 6 that law. I think if we had that study 7 evaluating those -- the primary and 7 the prosecutors would bless that study. 8 secondary endpoints that are agreed upon 8 Q. Right. So you think the law 9 in advance, and in addition, it has a 9 allows for those kind of clinical trials, 10 decision about when that -- those primary 10 that's your reading of the law? 11 endpoints are going to be looked into, A. I don't think in America --12 and when the secondary endpoints are 12 what I just said about the study is not 13 going to be looked into, and there is an 13 an idea that is part of the dialogue of 14 informed consent process to enter into 14 -- the culture war dialogue that's going 15 the treatment process, and it has 15 on in America. It's much more a European 16 different groups, or what we call in 16 concept. It's like science doesn't matter 17 in this subject, it's only therapeutic 17 methodology, different arms of the study, 18 you see, and it often -- it sometimes has 18 fashion and it's only the passionate 19 a placebo-controlled period, and then an 19 conviction of doctors that matter here. 20 arm where it divides into more placebo or 20 So I think that if we could --21 this kind of treatment, and then this 21 if on a national basis or on a multistate 22 kind of treatment, you see. 22 basis we could get together a group of So I think in order to get the 23 research centers to do this, places like 24 numbers that scientists would respect as 24 Arkansas would sign onto it and if we 25 having a robust what we call "N" or 25 needed an exception -- if we needed a Page 231 Page 233 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 numbers we would have to have a 2 ruling from the Attorney General of this 3 multistate or multicenter study using the 3 state or that state, I can't imagine the 4 same protocol, approved by what's called 4 Attorney General would say no to a study. 5 an IRB, and that is a review body, to see 5 Because I think this law is saying you, 6 to the efficacy of the study, the wisdom 6 doctors, are not studying this subject 7 of the study and the morality of the 7 and, therefore, we're going to ban this 8 study, the ethics of the study. I'm all 8 because there is a lot of indications 9 in favor of that, because that's the way 9 that we're harming our youth, you see. 10 we advance, you see. And we also -- that 10 But if you give them the science and say 11 study has to have a prolonged followup. 11 we can restrict this, we can restrict the 12 So an individual place, you 12 treatment to families who qualify for the 13 know, an individual child clinic can 13 protocol so we can answer the question in 14 publish its results, but it can't do the 14 five years and it's going to take three, 15 same thing as a multisite study can do. 15 four, five years to begin the first step 16 And in the United States this is so 16 in answering the question, then I think 17 cryingly necessary. And the trouble is 17 probably whatever state you're talking 18 the government has to fund this. These 18 about would be very susceptible, would be 19 are very expensive things but it's 19 amenable to this. 20 certainly a worthy study to undertake. 20 Now, I don't have a crystal 21 And yes, that is something I would be 21 ball and maybe I don't understand the 22 advocate, that's something I would 22 politics of various states, obviously I 23 don't, but that's my opinion or that's my 23 advocate for. Q. And are you aware that the 24 speculation. 25 Arkansas law in this case doesn't make an 25 So if you were involved or if

Page 234 Page 236 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 somebody were to ask you about a law like 2 identification for genetically male boys, 3 this would you favor having an exception 3 adolescents, and men or return to female 4 for participation in clinical trials? 4 identification for genetically female 5 MR. CANTRELL: Object to form. 5 girls, adolescents, and women." 6 A. If -- if some legislator asked I know you wrote this about a 7 me for my opinion I would be happy to 7 year ago. Is that still your view, is 8 share a similar opinion that I just gave 8 that still correct? A. Well, there has been more 9 you. 10 MS. COOPER: Okay. Let's mark 10 anecdotal evidence since that time but in 11 tab 10, please. 11 the strict scientific way, in the way 12 12 that you and I were just talking about, a (Exhibit Levine 6, Declaration 13 future study for medical intervention, we 13 of Dr. Stephen B. Levine, dated 14 July 2021, was received and marked 14 still have the same paucity of 15 on this date for identification.) 15 information, we have still only anecdotal 16 A. You're preparing a new 16 reports, even though some people collect 17 a series of cases in their anecdotal 17 exhibit? Q. Yes. We'll let you know. Okay. 18 reports but they still are scientifically 19 anecdotal only. 19 It's available now. If you can open 20 Exhibit 6. 20 The field of psychotherapy 21 21 finds it more difficult to do controlled A. It's open. 22 studies but there have been controlled Q. Okay. Great. We're looking at 22 23 Exhibit 6. Do you recognize this 23 studies than medication treatments. 24 document? 24 Because medication treatments often have 25 25 to do with this drug versus various doses A. I do. Page 235 Page 237 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 1 Q. Is this a declaration you 2 of drugs or drugs versus placebo. It's, 3 submitted in this case back in July of 3 you know, hard to do placebo-controlled. 4 '21? In psychotherapy studies 5 placebo controls are really weightless 5 A. Yes. Q. If we can scroll all the way 6 placebo. But the answer is yes, it's 7 still -- actually, I wrote the same thing 7 down to paragraph 35, let me know when 8 you found that. 8 in the article that was published six A. I just bypassed it. 35. 9 weeks ago, so... Q. Why don't you take a moment to 10 Q. But it's not outdated, I just 11 read the full paragraph. If you could 11 wanted to check; is that right? 12 just read the paragraph. 12 A. Sorry. I didn't understand 13 A. Sorry. Say that again? 13 your question. 14 Q. If you could just read the 14 MR. CANTRELL: We're having a 15 full paragraph. 15 little bit of trouble understanding A. To myself, item 35? Just that 16 you. I'm not sure what has 17 paragraph, right? 17 happened. Q. Just that paragraph. Have you MS. COOPER: Okay. I'll try 18 19 finished reading? 19 again. So far so good? 20 A. I've read it. 20 THE WITNESS: As long as your Q. I want to read together just 21 head is straight. You see when you 21 22 the first sentence, "To my knowledge, 22 look down I have trouble. 23 there is no credible scientific evidence Q. I need a little podium. 23 24 beyond anecdotal reports that 24 So I just wanted to confirm 25 that, and I think you have, that the 25 psychotherapy can enable a return to male

Page 238 Page 240 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 statement that there is no credible 2 A. Okay. Q. And in this paragraph -- well, 3 3 scientific evidence beyond anecdotal 4 reports that psychotherapy can enable a 4 why don't you take a minute to read the 5 return to male identification for 5 paragraph. A. Actually, I'm pretty familiar 6 genetically male boys, adolescents or men 6 7 or return to female identification for 7 with that. 8 genetically female girls, adolescents and 8 Q. Okay. Yes, we discussed 9 women, that that's still the state of the 9 different types of scientific evidence, 10 science? 10 correct? 11 A. Yes. I just came from a 11 A. It's a hierarchy of the 12 symposium two days ago where two people 12 trustworthy evidence, the risk or the 13 talked about their psychotherapy helping 13 chances the evidence will prove to be 14 people to desist, what we call desist or 14 factually valid. In that sense it's a 15 detransition through psychotherapy. So 15 hierarchy. 16 these are, again, anecdotal reports. Q. Understood. The anecdotal 17 Basically psychiatry has a lot of those 17 evidence you described a few moments ago 18 anecdotal reports. 18 regarding psychotherapy, helping patients 19 have a return to their natal gender 19 Q. Who were those clinicians or 20 those that spoke about their experience? 20 identity, is that -- does that fit within 21 A. You want their names? 21 B, a single case or a series of cases 22 22 what could be called anecdotal evidence? Q. Yes, please. 23 A. One was Sasha Ayad and the 23 Is that how you would describe that? 24 other was Lisa Marchiano. A. Well, you see A and B are 25 MS. COOPER: Can we mark as 25 pretty low. But at least when someone Page 239 Page 241 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 the next exhibit tab 6? 2 publishes a case history, especially case 3 (Exhibit Levine 7, Declaration 3 history that's not a paragraph but an of Stephen B. Levine, MD dated 4 extended case history, where the readers 4 5 can understand the dynamic forces 5 December 9, 2021 was received and 6 involved in the patient's life, that's 6 marked on this date for 7 identification.) 7 much better than a person like me 8 Q. You can refresh and it will be 8 pontificating, or a patient like one of 9 there, Exhibit 7. 9 your Plaintiffs' experts pontificating A. It's not there yet. 10 based on what they think exists in the 10 Q. So Exhibit 7, do you recognize 11 world. 12 that as a declaration that you submitted 12 So I know lay people don't 13 in this case -- I'm scrolling down to the 13 understand this, but they think he's an 14 signature block, on page 93, December 9th 14 expert, you know, he's a doctor, he's an 15 2021? 15 expert. But lay people often don't 16 understand the limitations of what 16 A. I don't have the date in front 17 of me, but I trust you. 17 doctors know or experts know. But you Q. If you go to page 93 you can 18 have a different sense of what expert 19 see. I'm sorry, page 93 on the document. 19 means in the law. You have to qualify to 20 A. Oh, that's the date. That's 20 be an expert in the law. But in terms of 21 reliability of information, a single case 21 what you had me see. Q. I just wanted you to look at 22 history and even a series of case 23 that and understand what you're looking 23 histories, is still anecdotal evidence. 24 at here. Now, I'd like you to go to Q. And that's the category that 25 paragraph 88. 25 the evidence you talked about regarding

Page 244 Page 242 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 psychotherapy, allow return to --2 received hormone blocking --A. Well, it's also the same kind 3 puberty-blocking hormones. And based on 4 of evidence that passionate believers in 4 the results of those studies there was 5 the hormone therapy have, based on their 5 total inconsistency from one study to 6 case experience, even if they write it 6 another about the results. There was --7 up, so to speak. 7 there was no appreciation that along with Q. Well, I wasn't asking about 8 puberty blocking agents, other things 9 that. I'm just asking about your -- the 9 were being given to the patient, like 10 evidence you talked about regarding --10 antidepressants, for example. There was 11 that you call anecdotal evidence about 11 very little appreciation of the effects 12 returning to your natal -- having a 12 of maturation and there was no control 13 gender identity that matches your natal 13 group to effect -- to see how kids mature 14 sex, that is the level of evidence we 14 between, say, 11 and 14. And so the 15 have at this point, correct? 15 results of that cohort study, which is A. Are you talking about my case 16 higher than a case report because it's a 17 history that I published? 17 series of cases and multiple studies of a Q. No. I'm talking about the body 18 series of cases from various centers, the 19 of existing scientific evidence showing 19 results were that, at best, the results 20 that psychotherapy can cause a return to 20 of puberty-blocking hormones were 21 your gender identity that matches your 21 inconclusive and they certainly didn't 22 sex assigned at birth, is that limited to 22 demonstrate with scientific certainty 23 ---23 that puberty-blocking hormones were 24 A. Yeah, sometimes that's called 24 beneficial. 25 --25 So you can see that even if Page 243 Page 245 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Let me finish the question, 2 you go from up to a cohort study, but if 3 I'm sorry, just for the record. 3 the cohort study doesn't have a control That would fall within under 4 group, I guess it's not really -- it's a 5 B, a single case or series of cases what 5 series of cases without a control group, 6 could be called anecdotal evidence? 6 it really doesn't -- it doesn't give you 7 A. Yes. 7 a lot of certainty that this is correct. Q. Okay. Now, you had started to 8 And you see, in our field of 9 transgender care, we don't have -- we 9 talk about the research we have on --10 maybe not the research but the use of 10 don't have E, and I'm not even sure -- we 11 hormone therapy to treat minors with 11 don't have a cohort study with a serious 12 gender dysphoria. 12 control group. And so we're really left 13 Which categories of research 13 at the level somewhere B+ perhaps or C-, 14 or evidence do we have that shows or 14 because we don't have a control group. 15 addresses -- let me ask that again. I 15 This is still a low level, Ms. Cooper, 16 muddled it. I'm sorry. 16 this is not -- this is not robust. 17 What categories of your 17 Q. So you don't have cohort 18 categories A through G, that you conclude 18 studies, B? 19 here, do we have assessing A. We don't have cohort studies 19 20 gender-affirming medical care for minors? 20 with control groups. A. Well, if you look at some of 21 Q. By B you meant cohort study 22 the reviews for puberty-blocking 22 with control group, is that in the 23 hormones. I think one of the reviews 23 definition of cohort study that would be 24 looked at ten studies. These were cohort 24 involved? 25 studies, that is groups of people who 25 Maybe I haven't stated that

Page 246 Page 248 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 correctly. Maybe I should have said a A. I presume you know, 3 cohort study with a control group. But 3 Ms. Cooper, that I am a psychiatrist, 4 that's generally -- you know, anything --4 right? 5 you see from A to -- A to D is just, it's 5 Q. I do. 6 not robust. It's not -- it's not 6 A psychiatrist. And you know 7 powerful. And one study is not powerful. 7 that psychotherapy, psychiatrists my age, 8 We need multiple studies from various 8 my vintage, have been trained in doing 9 times and various places from various 9 therapy with people and some of it is 10 perspectives and we have that potential 10 short-term and some of it is long-term. 11 in gender medicine. We have Australia and 11 And psychiatrist -- the psychotherapeutic 12 Canada and Amsterdam and Sweden, we have 12 process in therapy has never really been 13 Boston, we have other cities throughout 13 submitted to the rigors of randomized 14 America. This could be done. This could 14 controlled studies. 15 be done. And it's not being done. 15 So of course the answer to Anyway, that's not your 16 your question is that I do therapies that 17 question, I guess, so ask your question. 17 are not based on randomized controls. Q. It's fine. Now, double-blind Q. Do you treat patients with 19 clinical trial, that couldn't be done, 19 medication? 20 right, for gender-affirming hormone 20 A. Oh, of course I treat patients 21 therapy, right? Could it be blinded? How 21 with medications, and the medications 22 would that be possible? 22 that are FDA approved for certain A. May I answer that question in 23 indications are the result -- the modern 24 detail? 24 ones, not the ones that were accepted 50 25 25 years ago, in practice 50 years ago --Q. Let's get started and see. Page 247 Page 249 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 A. Well, it's going to take some 2 but the modern ones are all the process 3 time. I don't know if you want me to take 3 of double-blind placebo triple trials, 4 all this time. I'll be happy to answer --4 the kinds of control trials that I O. Let me ask a different 5 already described to you, multisite, 6 question. Do you think it could be 6 different cultures, different dose 7 blinded? 7 toggles (sic) and so forth. 8 A. Yes. 8 Q. Do you never prescribe 9 Q. Okay. That's fine. 9 off-label drugs, drugs for off-label use? 10 MR. CANTRELL: Object to form. 10 Are there treatments that you 11 provide to patients -- well, let me ask A. Yes. There are times that I've 11 12 prescribed drugs for off-label use. That 12 it differently. 13 Do you only provide treatments 13 is not the same as making me say that all 14 to patients that have the benefit of 14 drugs off-label are equally judicious. 15 randomized controlled clinical trials? 15 Q. Understood. So in your view 16 the fact that a drug is being used for 16 MR. CANTRELL: Object to form, 17 vague. 17 off-label purpose doesn't, by itself, 18 mean it's an improper use of the drug? Q. Let me restate that. You're 19 right. It was vague. 19 A. Does it mean what? Do you only provide treatments 20 Q. It doesn't, by itself, mean 20 21 to patients that are supported by 21 that there is anything wrong with using 22 evidence that includes randomized 22 the drug for that purpose? 23 controlled clinical trials? A. If we want to use that gross MR. CANTRELL: Same 24 24 generalization that you made, of course objections. 25 25 you're right.

Page 250 Page 252 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 Q. Well, help inform me. Let me 2 insomnia is a lot different than giving 3 somebody a drug that stops their 3 ask it more precisely. I think you just said you have 4 menstruation, for example. So we need to 5 be judicious about not comparing apples 5 used drugs for off-label uses; is that 6 to zebras. 6 right? A. I think you and I are 7 Q. I want to switch topics and 8 misunderstanding each other at this 8 talk about the desistance literature. 9 point. Yes, I said that. Do you know what I mean when I Q. Okay. I understand. I'm not 10 refer to the desistance literature? 11 talking about randomized controlled 11 A. The persistence literature, is 12 clinical trials. I'm just asking about 12 that what you said? 13 off-label drug use. 13 Q. The desistance literature. 14 A. Well, I think you know in 14 MR. CANTRELL: Desistance. 15 medicine off-label drug use is very 15 A. Desistance, the desistance 16 common in probably every field, including 16 literature? 17 psychiatry. The wisdom of that depends 17 Q. Yes. Does that -- you 18 on the drug and what's known about it, 18 understand what I'm referring to when I 19 what the benefits and the risks are. 19 talk about that body of research? 20 O. Does the fact that a use of 20 A. Yes. 21 the drug is off-label necessarily mean 21 Q. I'm just making sure. I just 22 it's an experimental use of the drug? 22 have a few questions about that. A. Just that alone does not mean Is it correct that these 24 it's experimental. It just means that it 24 studies found that most prepubertal 25 doesn't have the rigor of a scientific 25 children who had been diagnosed with Page 251 Page 253 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 basis for its use. 2 gender identity disorder, I believe, had So if I use an off-label drug 3 desisted by puberty; is that correct? 4 to get someone to go to sleep at night, A. If you and I are referring to 5 because I have experience that the drug 5 the same body of studies, then that's 6 is helpful in 50% of the time that I give 6 correct. I'm not sure what studies you're 7 it approximately, and I don't really 7 referring to, but I am aware of a group 8 think much harm will come unless they 8 of studies that have shown that under 9 have nightmares and then they won't use 9 certain circumstances, non-intervention. 10 the drug again, that's a very different 10 that 11 of 11 studies have shown that 11 thing than using an off-label drug that's 11 children desist, the majority of children 12 going to change the physiology of a 12 desist by the time they're somewhere in 13 person's life permanently or at least for 13 adolescence. Sometimes that's referred to 14 a very long period of time. 14 puberty, but I really think it's later in 15 Q. Okay. 15 adolescence, since puberty is a variable A. So I know where you're going 16 period of time. 17 here, that hormones are used on an 17 Q. And a number of these studies 18 were done by Ken Zucker; is that correct? 18 off-label basis and the FDA has not 19 approved them, and they've never been 19 A. A number of studies? 20 treated to a randomized 20 O. Some of these studies were 21 placebo-controlled trial. But of course, 21 done by Ken Zucker; is that correct? 22 the implications of using a mild 22 A. Yes. Yes. He was one of the 23 antidepressant that's soporific to help 23 coauthors of several followup studies, 24 people to sleep that has not been 24 yes. 25 approved for insomnia but is used for 25 Q. Did any of these studies show

Page 254 Page 256 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 that youth who continue to have gender 2 has gender dysphoria, say, at age 14, 3 that that would be likely to desist? 3 dysphoria in adolescence were likely to 4 desist? A. Well, I happen to know of a A. I think the literature of 5 woman who had gender dysphoria, who now 6 has lived as a woman, a cis woman for 6 desistance about the people who begin 7 their gender identity, their transgender 7 years and years and years. And the 8 identity in adolescence is really far 8 reason she's sort of studied this subject 9 less clear and less developed than what 9 and is sort of an expert in this subject 10 the cross-gender identified younger 10 is that she persisted when during your 11 children, that's what those 11 studies 11 adolescence for a while. And I happen to 12 referred to. 12 know, which I think you probably are 13 Q. I think my question maybe 13 aware of, the previous studies among --14 wasn't clear because I meant to convey 14 among male-identified homosexual men, 15 something differently. 15 that two-thirds of them have a history of If you're talking about just 16 having very strong feminine 17 the population of people who had gender 17 identifications when they were children. 18 dysphoria from early childhood, the 18 And I don't know if they all had gender 19 studies that looked at -- actually, let 19 dysphoria because when they were younger 20 me take that back. 20 we weren't really looking at that term, 21 For individuals who have 21 we didn't even have this concept. But 22 feminine -- among homosexual adult males, 22 gender dysphoria from early childhood and 23 continue to have gender dysphoria after 23 many of them recognize that they had a 24 puberty begins, is there any evidence 24 long period of time when they wanted to 25 indicating a likelihood of desistance in 25 be a girl, and that they behaved in Page 255 Page 257 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 that population of patients? 2 feminine ways. A. You mean if with childhood Now, most of these people, and 4 I can tell you from Richard Green's study 4 onset gender dysphoria, we'll just take 5 published in 1988, The Sissy Boy 5 those 11 studies and summarize them 6 inaccurately as, say, 22% persist, okay? 6 Syndrome, I think the numbers were -- he 7 You're asking me, is there any evidence 7 followed for 15 years 88 children who 8 that I'm aware of among those 22 kids who 8 were cross-gender identified. The sample 9 persist, do any of those children 9 came from both New York and from 10 subsequently desist? Is that the question 10 California, he actually worked in both 11 you asked me? 11 places bi-coastally. And 86 of those 12 children grew up to be non-cross-gender 12 Q. Let's start there, if you 13 could answer that question? 13 identified, two of them declared A. I don't know the answer to 14 themselves to be transgender and I think 15 that question. But I want to be clear, 15 like a handful declared themselves to be 16 that's what I thought you were asking. 16 heterosexual, but the majority of those 17 Q. Okay. 17 cross-gender identified children grew up A. So I'm asking you, was that 18 to be homosexual in their orientation to 19 the question you were asking me? 19 men, to their same cisgender people. 20 Q. It wasn't exactly but I 20 So that was the Richard Green 21 understand that that's what you were 21 study from 1988, and I think that begins 22 answering, so I will ask differently. 22 to answer your question. But none of Are you aware of any evidence 23 those children were, you know, affirmed 24 indicating that somebody who has gender 24 socially trans, you know, no pediatrician 25 dysphoria from early childhood and still 25 said you ought to live as a little girl,

Page 258 Page 260 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 you know, and nobody was giving 2 treatment, and another 20% were lost to 3 puberty-blocking hormones. 3 followup, some of whom may have come back Q. But they were first assessed 4 for treatment later. And there was a 5 during pre-pubertal childhood, right, you 5 second study by Boyd, et al, the first 6 would agree? 6 one I mentioned is by Hall, and that's a A. They were all identified as 7 group of people who were started on 8 cross-gender identified little boys who 8 hormones on an average age of 20 and in a 9 wanted to be little girls, yeah. 9 five-year followup almost 30% of those Q. So you mention there is a 10 people had desisted. 11 woman you know who desisted after 11 So we're beginning to get 12 adolescence and has been studying the 12 information about the rate of desistance 13 issue. 13 which in some people's language is the 14 My question was, is there any 14 rate of error, although, I'm not sure 15 evidence that it's likely that people who 15 that is the right language. It's the 16 start experiencing gender dysphoria in 16 error rate of making -- the patient 17 early childhood and continue to 17 decides it was an error, even though some 18 experience it in early adolescence are 18 of them say, well, it wasn't really -- I 19 likely to desist, the way we have that 19 don't want to do this anymore but I don't 20 evidence about prepubertal kids? 20 regret having taken hormones for X years 21 A. I can only answer that 21 because it's helped me decide who I am 22 question tangentially. 22 and what I want to be now. You are aware that there are So you know these are very 24 increasing numbers of people who are 24 difficult, complicated, nuanced kind of 25 coming out of the woodwork saying that 25 distinctions that we're making about Page 259 Page 261 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 they have detransitioned and many of 2 regret and desistance and so forth. 3 those children, many of those adults or Q. Can I ask you -- I think I 4 didn't hear, when you said the rate of 4 older people, older teenagers, many of 5 those kids -- I mean, I don't know what 5 desistance in that second study you 6 proportion of those children were 6 mentioned by Boyd, what percentage was 7 cross-gender identified as children, many 7 that? I just didn't hear. 8 of them probably were -- had onset of A. I think up to 30% of people 9 transgender identities shortly after 9 were no longer taking treatment with 10 puberty. 10 hormones after five years. Q. The connection busted up right But I think the answer to your 12 as you said that. Can you repeat it? 12 question, in a tangential way, is I'm 13 aware that people detransition after A. I said this is the Boyd, et al 13 14 prolonged periods of time of medical 14 study from the U.K. published in this 15 treatment or even just certain 15 year, I think. And I forget the numbers 16 non-medical but cross-gender identified 16 at this point, but actually it's quoted 17 identities. But I can't -- I can tell you 17 in my paper, and the specific numbers are 18 in my paper. But my general recollection 18 about two recent studies that were 19 published and I became aware of them in 19 is that there was a five-year followup. 20 the beginning of this year, so it's not 20 The average age of entering -- of getting 21 hormones was 20 and by 25 there was a 21 in my report, they're both from the U.K. 22 and one of them was a 16-month followup 22 large, very impressively large dropout 23 rate from hormone treatment. And the 23 after being started on hormones and at 16 24 months there were a total of 10% of the 24 authors stated that, given the 25 kids had desisted from their hormone 25 uncertainties about this, and the

Page 262 Page 264 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 difficulties in following up people, it 2 for affirmative care of adolescence 3 may very well be that we have vastly 3 actually consider it to be an 4 underestimated the number of people who 4 alternative. It's where there is 5 discontinue hormones just because we 5 disagreement, you know. 6 don't have these careful followup 6 And just to go back to the 7 studies. I believe the Boyd, et al study 7 earlier part of your question, watchful 8 was basically getting hormones in primary 8 waiting can mean sometimes do nothing but 9 care settings. 9 followup the patient in three months or Q. And you believe it was a 30% 10 six months, whatever, regularly, to see 11 rate of desistance from the numbers they 11 how this works out, sometimes -- that 12 had? 12 would be one form of watchful waiting. 13 A. I think, you know, I could 13 The other form of watchful waiting would 14 look it up on my paper, but that's what 14 be to take the parents in and talk to the 15 --15 parents and leave the kid alone and then 16 Q. That's okay. Is that right, 16 help the parents deal with their 17 you don't remember? 17 intrafamilial issues. The third form of A. That's what I remember but, 18 watchful waiting might be to not deal 19 you know, who knows what people remember 19 with the child's gender identity, but to 20 accurately. 20 deal only in a therapeutic process with 21 Q. Do you remember whether it was 21 the other issues, the other developmental 22 a majority or a minority of the --22 challenges that the child has, but just A. No. It was about 30. It 23 leave the gender identity alone with the 24 wasn't 60. It was 30. Maybe it was 28-7, 24 assumption that perhaps gender identity 25 is an epiphenomenon of some other 25 you know. Page 263 Page 265 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. Q. Are you familiar with the 2 underlying problem. And if we can deal 3 watchful waiting approach to minors with 3 with the underlying problem, perhaps the 4 gender dysphoria? 4 child can one day make a clearer decision 5 about how he or she wants to live his 5 A. I know that term, yes. Q. And do you understand -- what 6 gendered life. 7 do you understand that term to mean? 7 So that's my understanding of 8 Let's make sure we're on the same page. 8 watchful waiting. So I said three, but A. Well, I think -- I think you 9 sometimes I say it as two versions, but I 10 know from my expert opinion. I describe 10 made a third version for you today 11 this in my report. So do you want me to 11 because I wanted to emphasize sometimes 12 repeat that? 12 the child is not getting treated at all, 13 Q. Fair enough. I don't need you 13 but the parents are getting treated. And 14 then sometimes the parent and the child 14 to do that. 15 As described in your report, 15 is treated, but we're not focusing on 16 is that an approach that is recognized as 16 gender, per se. Whereas, if you do 17 applying to prepubertal children with 17 give -- you know, socialize a child, 18 you're certainly treating them for their 18 gender dysphoria? A. Well, it depends on the 19 gender. 20 practitioner. Watchful waiting was 20 Q. Just one moment, I'm going to 21 certainly a concept that began with the 21 show you an exhibit. 22 child onset gender dysphoria realm. It 22 Has Ken Zucker been a leading 23 has been -- it's a concept that's applied 23 proponent of watchful waiting in the 24 to adolescents as well, but it certainly 24 field? 25 is not a concept of people who advocate 25 Ken Zucker recently told me he

Page 268 Page 266 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 -- he thinks he coined the term and he 2 within a relatively short period may also 3 was embarrassed about it. 3 be a common outcome for post-pubertal 4 Q. Why was he embarrassed? 4 youths who exhibit recently described A. It wouldn't be a term he would 5 'rapid onset gender disorder.' I observe 6 an increasingly vocal online community of 6 use today, I think would be my 7 speculation. When he said that, I said I 7 young women who have reclaimed a female 8 didn't think you actually coined the term 8 identity after claiming a male gender 9 "watchful waiting", because he's a 9 identity at some point during their teen 10 psychologist and I'm a physician. And 10 years. A recent review of 11 watchful waiting is a term that I think 11 detransitioning claimed to have 12 grew up in medicine and in surgery and it 12 identified 16,000 entries in a search of 13 has a great deal to do with men's 13 proliferating websites devoted to this 14 prostate cancer, and when it's mild 14 topic. However, data on outcomes for this 15 enough we say that we're going to watch 15 age group with and without therapeutic 16 interventions is not yet available to my 16 -- we're going to practice watchful 17 waiting, we're not going to have an 17 knowledge." 18 intervention, we're going to get a --18 So a couple of questions. That 19 perhaps you're familiar with the PSA 19 16,000 number, that's not 16,000 stories 20 test, we're going to do a digital exam 20 of detransition, is it? 21 and a PSA test every six months. And 21 A. No. Those are 16,000 people 22 it's only if your PSA or you get a nodule 22 that Dr. Exposito-Campos identified as 23 in your prostate that we will intervene 23 being members of various groups with that 24 surgically or through radiation. 24 title. That doesn't tell us that each of 25 So that has a long tradition 25 those persons have detransitioned. They Page 267 Page 269 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 in prostate medicine, in the urology 2 could be parents of kids, they could be 3 field. And I wouldn't be surprised --3 kids who are thinking about 4 detransitioning, they could be people who 4 you know, in the leukemia field we have 5 certain kinds of slow-growing leukemic 5 have detransitioned, but that's still a 6 processes that we just watch. And 6 large number. And it raises the question 7 certainly in probably every field we have 7 for you and I to think about, is 8 watchful waiting for one condition or 8 detransition is an issue that needs to be 9 another. 9 thought about very carefully because some 10 of those people who would detransition 10 Certainly in child psychology 11 there are situations where we watch and 11 might regret having undergone these 12 we wait and see if people outgrow 12 medical treatments or these psychological 13 whatever the issue is. 13 adaptations. Q. Let's go back to Exhibit 7, 14 So it's just another 15 you may have that up, paragraph 78. 15 indication that I would say to all of us, A. I didn't -- I didn't 16 let's be careful here, this could be a 17 understand any word you just said. 17 dangerous thing. Q. That's terrible. Exhibit 7, if Q. That 16,000 number doesn't 19 you could go back to Exhibit 7, paragraph 19 tell you anything about the number of 20 78. 20 stories of detransitioners that are 21 I'll read it together since it 21 included there, is there? Does it? 22 is just the highlighted paragraph. It 22 Let me ask you differently. 23 says, "Desistance, (a patient's willing 23 The number 16,000 doesn't tell you 24 reacceptance of their biological sex 24 about how many detransitioners are in 25 through normal developmental processes) 25 that group, does it?

Page 270 Page 272 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 A. I think I just said that. Q. Let's take a look. 3 A. I don't have -- I have that 3 Okay. Just making sure we're 4 article at home. 4 clear. 5 Let's go to paragraph 70 in 5 Q. We'll pull it up. Maybe let's 6 the same Exhibit 7. Let me know you're 6 mark that as Exhibit 8, please. 7 there. 7 (Exhibit Levine 8, Canadian 8 8 Gender Report, dated October 1, A. Yes. 9 9 Q. Why don't you just read the 2019 was received and marked on 10 paragraph to yourself. 10 this date for identification.) 11 A. I read it. A. Shall I go to that? 11 Q. It's not quite there yet. All 12 Q. Looking at the last sentence 12 13 of the paragraph that's highlighted it 13 right. It's available now. 14 says, "Two separate valuations, one from 14 A. Oh, MacRichards not McFarland. 15 Canada and one from U.K., reviewed 15 Sorry. 16 WPATH's guidelines and found them 16 Q. If you read with me, we're 17 looking at Exhibit 8, which is just, for 17 untrustworthy." And you have there a 18 footnote, number 43 that cites a study by 18 the record, a document with a heading 19 S. Dahlen, et al and then another one 19 Canadian Gender Report. And then on the 20 after that it says see also 20 bottom of the first page it says, "The 21 https://genderreport.CA/bias-not-evidence 21 following investigative report was 22 -dominate-standard-of-care. 22 contributed by@Lisa MacRichards (a 23 A. That's right. 23 pseudonym)." And then goes on to say, 24 24 "Lisa MacRichards works at a Canadian Q. I'd like to focus on the 25 second one. I just had some questions 25 hospital and holds a Master of Science Page 271 Page 273 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 about that. 2 degree from the University of British 3 Is that the report from Canada 3 Columbia", and some other text. 4 that you were referring to? So do you not understand -- is A. Yes. 5 Lisa MacRichards her real name? Did I 5 Q. And you've reviewed that 6 read that wrong or misunderstand? 7 report, I take it? 7 A. I presume this is the same A. I've read that report, yes. 8 thing. The one I have at home doesn't Q. Okay. Was it published by a 9 exactly look like this, but I presume 10 scientific organization? 10 it's the same. A. The author was a journalist Q. So by reading, do you 12 understand that to mean that Lisa 12 and I don't think it was published by a 13 scientific organization. But if you read 13 MacRichards is not her real name? 14 that review, it's very cogent and it's A. I didn't remember when I told 15 not -- in a different language form it 15 you this initially that it wasn't her 16 says much of the same thing as the 16 real name, but it probably says that in 17 Dahlen, et al study. 17 my report too. Q. Do you know anything about the 18 Q. Does that give you any concern 19 author? 19 about relying on a report if somebody is 20 publishing it anonymously? 20 A. No. A. Actually, the Dahlen report 21 Q. The author was anonymous, 22 right? 22 gives me no concerns. The Dahlen report 23 A. No. No. 23 is a group of, a team of methodologists 24 Q. No? 24 from different field who are expert in 25 Her name is I think McFarland. 25 reviewing standards of care.

Page 274 Page 276 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 Q. I understand, but I'm asking 2 Standards of Care on the 7th Edition are 3 you about this one. 3 good enough, you see. A. But you see, the -- there are So the fact that there's a 5 other people who looked at and tried to 5 Lisa MacRichards to me is not just a big 6 live with and understand the Standards of 7 Care and have found them wanting. And so Q. Okay. You mentioned you 7 8 I could have easily just given the Dahlen 8 distinguish this from peer-reviewed 9 report, but I thought it would strengthen 9 academic settings. 10 it a little bit if we see that someone 10 What does that mean to be a 11 else has thought about this from a 11 peer-reviewed academic study? I think 12 different continent, also looking at 12 that was the term you used. A. You're asking me what does 13 this. 14 I could probably give more 14 "peer-reviewed" mean? 15 examples of people who don't follow the 15 O. Yeah, what does that mean? 16 Standards of Care but to me the most That means when a person --17 important thing is that this report, 17 I'll use myself, for example -- when a 18 whatever its limitations are, that it's 18 person submits an article to a journal, 19 that it's first read by the editor and if 19 not a scientific peer-reviewed journal, 20 so to speak, it just happens to say 20 it is viewed to be a reasonable 21 similar things as the peer-reviewed 21 submission, the editor usually sends it 22 scientific report says. 22 out to three people who have some And so, I don't know why --23 knowledge of the subject area, and those 24 are called the peer reviewers. Hopefully, 24 whoever Lisa MacRichards really is -- I 25 don't know why she wants to use a 25 they're really peers and, hopefully, they Page 275 Page 277 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 pseudonym. In my experience when people 2 know something about the subject 3 work for clinics that do trans care they 3 material. And then those people write a 4 sometimes, and they're objecting to it, 4 critique, which then the editor puts 5 rather than quit their jobs, as many 5 together. So there are usually three 6 people at the Tavistock Clinic quit over 6 reviewers to a paper, then the author, 7 many years, I think they lost 60 7 myself, gets back after several months, 8 psychologists over five or ten years 8 sometimes after nine months or ten 9 because of the trans care. So they 9 months, we get back three critiques, 10 developed a pseudonym and they write --10 three evaluations, independent 11 they do research and they write what they 11 evaluations, anonymous evaluations, I 12 think. And I think that's probably what 12 don't know who's doing it, and they often 13 Lisa MacRichards -- maybe her real name 13 have criticisms and suggestions. 14 is McFarland, I don't know. So that's Now, they're asked to make a 15 decision, and they independently make the 15 what I think. 16 following decision; reject; have major So it does give me concern but 17 it doesn't -- it wouldn't make me think 17 revision; have minor revision, those are 18 that that disqualifies this idea. I 18 the choices they're usually given. And if 19 the paper is not rejected it is -- if the 19 think even the committee that's doing the 20 WPATH standards have reasons to criticize 20 paper is rejected, the author gets 21 the 7th Edition of the Standards of Care. 21 reasons for the deficiencies of the study 22 So the idea that the Standards 22 or whatever the paper is, and they may 23 decide to send it to a different journal. 23 of Care are what God has said and this is 24 the truth and this is science, even the 24 But if it's major revision, then between

25 the three reviewers and the editor

25 people in WPATH don't think that the

Page 278 Page 280 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 they're told exactly what's wrong with 2 reviewer who believes in affirmative care 3 the paper, even though it has merit, and 3 and you look at the Panchankis article, 4 how they can fix the paper. And if it has 4 you say, look what the authors say, look 5 minor revisions, a similar thing happens 5 what they found, it's just -- it confirms 6 there are less points and they're 6 what I believe about that. So they're not 7 relatively -- they don't go to the heart 7 very critical about it. 8 of the matter but they are much more to So the peer review does not 9 round out the article. And so that's peer 9 guarantee factualness, it's just a way we 10 have to increase the likelihood of being 10 review. 11 So what happens is then I, as 11 correct, reasonable science. 12 the journal writer, as the manuscript 12 In the Panchankis -- the 13 writer then responds to the reviewer and 13 Bränström-Panchankis study is a beautiful 14 we make changes, oftentimes we make 14 case in point, that there is something 15 changes in track changes mode, so that 15 wrong within this field that we can't be 16 the reviewers and the editor can see what 16 critical of certain work that's 17 we've changed and we have to justify the 17 affirmative to trans care. 18 changes. And sometimes we agree with the 18 Now, you probably know that 19 reviewer and sometimes we disagree. And 19 there were seven letters to the editor 20 if we disagree, we have to state why we 20 that were so, so correct in pointing out 21 disagree. 21 the deficiencies that Dr. Kalin, the 22 22 editor, then sent this out to two So we send that back and then 23 the reviewers get that material from us, 23 additional reviewers, this would be 24 from me, us, and they then decide to 24 reviewer four and reviewer five. And 25 reject, to have another major 25 those two people looked at this study and Page 279 Page 281 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 modification, to a minor modification or 2 said that the results of this study, the 3 acceptance. 3 conclusions of the study could not be 4 based on the data that were presented, 4 And that's the process of peer 5 and that led to Dr. Kalin publishing the 5 review, as I understand it, and as I have 6 experienced it in the 152-or-so articles 6 seven original letters, which I think 7 that I have published. 7 that were 12 authors, but the two Q. Does publication in a journal 8 independent statistical authors, which 9 that uses the peer-review process, is 9 were not published, and Dr. Kalin wrote a 10 that considered more reliable scientific 10 little article about the process and 11 evidence than material published 11 about the concerns about the paper, and 12 then the two original authors were asked 12 elsewhere? 13 MR. CANTRELL: Object to form. 13 to write a response to all this and they A. I don't think I understand. 14 wrote what some people call a retraction, 14 15 Can I repeat the question to see if I 15 but when people are -- don't like that 16 understand? 16 term, they wrote that more research was 17 Q. I'll ask it differently. 17 necessary in order to reach the Does the peer-review process 18 conclusions that we reached in this 19 help insure that the research is 19 paper, that our paper did not prove -- we 20 reliable? 20 understand it did not prove our 21 A. Well, as you can tell from the 21 conclusions. 22 Bränström Panchankis study, sometimes 22 Q. I want to ask about the 23 egregious errors are not picked up by the 23 peer-review process. 24 reviewers, you see. 24 A. I think I just explained it. 25 You did. In your field or 25 The trouble is if you're a

Page 282 Page 284 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 among scientists is it understood which 2 concerns about the rapidity of 3 journals are the peer-reviewed journals 3 affirmative care and the lack of 4 and which are not? 4 evidence. That's why they named it The A. Oh, all the journals are 5 Society For Evidence-Based Gender 6 Medicine. It's not about medicine, in 6 peer-reviewed. There are newspapers 7 that -- you know, like there is something 7 particular, it's confined to this 8 called Psychiatric Times. Psychiatric 8 particular topic. 9 Times asks me sometimes to write an 9 So many -- you know, I don't 10 article and they sometimes send it out to 10 know if you consider me a scientist, but 11 someone else to say it's okay or the 11 so there are many people who, like me, 12 editor says, oh, you have to write it 12 are interested in this, are clinically 13 differently. That is not what I call peer 13 involved and who are interested in 14 review. You know, the Psychiatric Times 14 exploring the scientific basis of this 15 doesn't want to get sued or lose 15 subject because we, from our clinical 16 readership or something outrageous, so 16 work, have developed the kind of worry 17 they check with someone else. And if you 17 about what we're doing to people. 18 look closely they have a board, an 18 So I don't know if you would 19 editorial board that they send those 19 agree that this is a scientific 20 papers to for a quick "okay". But it's 20 organization. You probably would think 21 very different than peer-reviewed, as I 21 that the American Psychiatric Association 22 originally described, and which failed in 22 is a scientific organization, and they 23 the process of Bränström and Panchankis. 23 would like to think they're a scientific 24 organization, but other people know that Q. People in your field know the 25 difference between peer-reviewed in a 25 it's a trade organization as well, who Page 283 Page 285 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 1 2 scientific journal and different kinds of 2 then talks about science and presents 3 publications? 3 scientific studies. 4 A. Yes, I hope so. I think I So, you know, the question you 5 answered your question, right? 5 just asked needs to be examined closely, 6 and what you mean and what I mean and Q. You did. I'm going to switch 7 gears now. 7 what the culture means and how naïve all 8 of us can be about what is science and I want to talk about SEGM, as 9 you called them, and you cited to a 9 what is not science. 10 publication, I believe in paragraph 8, 10 Q. Does SEGM have a position 11 SEGM -- I'm going to back to your report, 11 about whether gender-affirming medical 12 care for minors should be prohibited 12 I'm sorry, Exhibit 7. 13 13 across the board? A. Exhibit 7? 14 Q. Yes. I believe you cited in A. Should be prohibited across 15 paragraph 8 ---15 the board? Actually, I don't think so. I A. Sorry. What paragraph are you 16 think what SEGM -- I don't know that 17 talking about? 17 anyone can say what SEGM -- it has --Q. Let's close that. I made a 18 18 let's say it has 100 members. I don't 19 mistake. 19 think there's a uniformity of belief 20 system among the hundred members, except 20 I want to understand a little 21 bit more about SEGM. Are they a 21 that there is reason to be skeptical 22 scientific organization? 22 about what is going on and to be worried 23 about what is going on and to wonder 23 MR. CANTRELL: Object to form. A. Well, it's a group of 24 whether compassion lies in supporting or 25 clinicians and scientists who share 25 not supporting these kind of

Page 288 Page 286 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 interventions. There is a kind of 2 knowledge and the latest recommendations 3 uncertainty and a uniformity of desire 3 that a group of people together, had put 4 for better study and better reasoning and 4 together. 5 to separate advocacy from science. 5 I just think that was an That is what I think that 6 extremely ambitious thing. And if you can 7 look at how many years delayed the WPATH 7 these people have in common, or I should 8 say we people since, you know, they paid 8 8th Standards of Care are, and it's 9 me money to write that article. So but I 9 probably three years past due, how 10 don't think you're right if you are 10 difficult it is to formulate guidelines 11 asserting that SEGM is against all 11 in this controversial area. 12 12 care --So I don't know exactly what 13 Q. That's not what I'm asking. 13 happened because I'm not privileged to 14 I'm definitely not asserting. I'm asking. 14 the -- you know, I'm not a decisionmaker A. Well, it's my opinion that 15 or policy maker in SEGM. I was sometimes 15 16 they don't have a policy that they're 16 used to participate in this process. But 17 against all trans care for youth. 17 we worked together on it and then I think they are saying where 18 suddenly we weren't working on it 19 is the science? And when the science is 19 anymore. So I don't really know the 20 not there we ought to be cautious. 20 answer. 21 Please be cautious, world, please, is 21 Q. So was there even a framework 22 developed for what the guidelines would 22 probably what they would say. Q. Are you still involved with 23 look like? 24 SEGM? 24 A. Well. SEGM was interested in 25 25 the psychotherapeutic approach and how to A. Not today, I mean, currently Page 287 Page 289 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 involved with SEGM? You know, because we 2 guide mental health professionals, how to 3 wrote an article, I sometimes write to my 3 think about doing psychotherapy. We first 4 had to say there are scientific 4 second and third author and say, do you 5 know how many people have looked at this 5 limitations and if we're going to have an 6 lately? You know, there's 27,000. 6 alternate treatment we're just not saying 7 That's in the top 1% of any article ever 7 whatever your past experience is, go to 8 written, and this article must be having 8 psychotherapy because we don't know what 9 an impact everywhere. 9 that was going to result in. 10 10 Q. I understood from a previous So what we were trying to do 11 deposition that you gave that you have 11 was illustrate processes of therapy and 12 been on a committee to develop treatment 12 then principles of therapy. So this is 13 guidelines with SEGM. Is that still in 13 very hard to teach how to do 14 the works? 14 psychotherapy, Ms. Cooper, because 15 A. No. 15 generally speaking, we want to -- we can 16 only give overriding, overarching 16 Q. What happened with that? 17 A. I think SEGM had too many 17 principles like, pay attention to the 18 quality of the relationship, or what 18 ideas. They didn't have the manpower, 19 the energy and the time to -- they were 19 should you do about the name, what name 20 going to publish -- they were going to 20 should you address the patient by? But 21 publish in some undisclosed --21 when you're lost -- when you have in a 22 unclarified form guidelines for primary 22 private confidence psychotherapeutic 23 care physicians and guidelines for mental 23 session you never know exactly what's 24 health professionals where people could 24 going to happen. We can't tell you what 25 get updates on the latest scientific 25 to do in every circumstance.

Page 290 Page 292 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 So generally we have to have a 2 for transgender youth? 3 certain faith system, in the power of a 3 A. That's a nice paraphrase of 4 good relationship, a trustworthy, 4 it, yes. 5 respectable relationship that illuminates 5 Q. Would you describe it 6 what people feel, what they've been 6 differently? I can't remember the exact 7 through and what they're conflicted about 7 title. 8 and what they're worried about. 8 A. It wasn't what you just said 9 What all psychotherapists 9 but it's close enough. 10 share is the belief that that's a Q. And who were your 10 11 maturation -- if you can meet those 11 co-presenters? 12 criteria that's a maturation stimulating 12 A. I mentioned two of them 13 process and we think that's important for 13 already and the fourth one was Kenneth 14 13, 15 and 17 and 27-year-olds who have 14 Zucker. 15 this psychological pain called gender 15 Q. And the another two, was that 16 dysphoria. And we actually think it's not 16 Sasha Ayad and Lisa Marchiano? 17 different than if someone who didn't have 17 A. Yes. 18 gender dysphoria, but had the pain of Q. Well, was it a symposium? Did 18 19 anxiety or the pain of depression or the 19 I use the right word when I said that? 20 pain of feeling that they're low status 20 That's what the APA calls it. 21 in their peer group, you see, we would 21 Q. How big was the audience for 22 want to do the same thing. And we, SEGM 22 this program? 23 people, or at least the psychotherapy 23 A. I'm sorry. What was that? 24 24 section of SEGM people were very Q. How big was the audience for 25 concerned, very concerned that somehow 25 this program? Page 291 Page 293 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 when a kid announces a trans identity he A. Well, you know, I'm such a --3 or she is disqualified based on WPATH's 3 it was a big room. There were -- there 4 was 11 rows, there was approximately 100 4 pronouncement in 2013, that he is 5 disqualified from needing this process, 5 people there. 6 which we think is ridiculous. Q. Okay. And was this part of a 7 MS. COOPER: I was going to 7 larger conference where there was a 8 suggest we take a break now. Can we 8 series of presentations on other issues 9 9 related to gender dysphoria? do that? 10 MR. CANTRELL: Okay. 10 A. Yes. This is the annual 11 American Psychiatric Association 11 MS. COOPER: Let's take five 12 minutes good? 12 conference and there were a few symposia 13 13 on gender issues, because the theme was MR. CANTRELL: Sure. 14 14 Social Determinants of Mental Health Or (Recess is taken.) 15 VIDEOGRAPHER: Going off the 15 Mental Illness. And the APA has gone out 16 record the time is 4:58. 16 of its way to specialize and to welcome 17 (Recess is taken.) 17 all forms of mental cultural diversity. 18 VIDEOGRAPHER: Going back on 18 And that was the theme and this was just 19 the record. The time is 5:15. 19 one of perhaps 50 different symposia that 20 were held during a four-day period. 20 Q. Dr. Levine, did you present 21 this month at a symposium at the APA 21 Q. So they were not all on gender 22 conference? 22 dysphoria-related issues but some were? 23 A. Two days ago. 23 A. Most were not gender 24 Q. Two days ago? And was that a 24 dysphoria, but there were a handful of 25 symposium on reexamining best practices 25 papers relating to that.

Page 294 Page 296 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 trust -- you want me to talk about what I Q. And just for clarity, I think 3 ---3 you said it was the American Psychiatric 4 Association conference; is that right? It 4 Q. Sure. 5 wasn't the American Psychological 5 A. So I talked about the 6 Association? 6 processes of people at high places, 7 sometimes institutions, sometimes 7 A. Yes, you're right. 8 Q. I get confused with the APAs. 8 researchers, policymakers, creating a 9 Did -- excuse me. Let me back up. 9 diagnosis and creating a treatment and Sasha Ayad and Lisa Marchiano, 10 the reason we do that is we're trying to 11 are those both members of SEGM? 11 -- we can recognize suffering based on 12 12 people's patterns, and so we create A. Yes. 13 Q. And Ken Zucker presented as 13 diagnoses and we offer treatments. 14 well, you said? 14 Hopefully some of those treatments are 15 A. Yes. 15 based on science, and then we trickle Q. And did any of these 16 those things down to educators and 17 presenters, including yourself, suggest 17 educators, in turn, follow this chain of 18 halting hormonal therapies to treat 18 trust down to our students and mostly our 19 minors with gender dysphoria? 19 students are medical students, our 20 A. That didn't come up in the 20 psychology students, our social work 21 symposium. 21 students that have some familiarity with 22 Q. What did come up? What kind of 22 the soul of science, which is skepticism, 23 recommendations were made? 23 which says; show me what is the evidence 24 for this. A. Well, I spoke first for about 25 eight minutes, and then Ken Zucker -- and 25 So this is the chain of trust Page 295 Page 297 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 I'll tell you what I spoke about if 2 that educates physicians, we'll just pick 3 you're interested -- and Ken Zucker then 3 on physicians for a minute. And I said 4 the chain of trust is never entirely 4 talked about the evidence for the 5 epidemiological shift towards -- across 5 trustworthy and sometimes the chain of 6 the world towards more children claiming 6 trust is not trustworthy at all because 7 an identity, a trans identity, but the 7 science changes what is the truth or what 8 predominance of female girls at birth, 8 is the therapy and what is the problem 9 what you might call assigned-at-birth 9 and what suffering we're going to 10 girls, and then Dr. Marchiano --10 associate, we're going to focus on. 11 Dr. Marchiano talked about the state of So I started out with the 12 science in this field and the limitations 12 concept of a chain of trust is how 13 of, for example, the DeVries study from 13 medical education works. And I need to 14 what we call the Dutch protocol, which, 14 remind everybody that the chain of trust 15 you know, I wrote about in the paper and 15 is never always trustworthy because 16 she talked about detransitioning and what 16 today's facts are not tomorrow's facts. 17 that means. So she spoke for about 20 17 So then I talked about ten 18 minutes on those topics about the 18 ideas that are -- I talked about the 19 limitations of science in the field and 19 difference between affirmative treatment, 20 then Sasha Ayad spoke for the last few 20 which I don't have to tell you about, and 21 minutes about what you and I have already 21 alternate treatment, which I hope I'm 22 made mention of, which is how to conceive 22 beginning to tell you it exists, you see. 23 So I made those distinctions. And then I 23 of -- how to do therapies, the principles 24 of psychotherapy for transgender youth 24 gave a slide with ten ideas that many 25 and what I spoke about was the chain of 25 people who, in my experience, are in the

Page 298 Page 300 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 affirmative treatment activity process, 2 hormone therapy to minors? 3 they actually believe, for example, that A. As Dr. Zucker said during the 4 it is biologically determined, that it's 4 symposium, you know, he sometimes have 5 fixed for life or immutable and that the 5 prescribed puberty blockers to children 6 but certainly I think you summarize what 6 treatments have already been proven to 7 decrease suicide and increase people's 7 all four of us believe. 8 social functioning. Anyway, I had ten Q. Would you say that all four of 9 things that I believe I've heard and I've 9 you would be considered dissenting views 10 read, which I don't believe science has 10 in the APA world? 11 established. 11 MR. CANTRELL: Object to form. 12 So I talked about those ten 12 A. We have dissenting views from 13 things. And then I talked about the rise 13 the APA's positions, is that what you 14 in what I like to call the transgender 14 mean? 15 treatment industry and saying that there 15 O. Well, let me ask it 16 are now -- you know, there used to be 16 differently. 17 very few centers in the 1970s and 1980s, 17 Would you say all four of you 18 there were very few little pockets of 18 on the panel have views that are 19 clinical work and now there are over 50 19 considered dissenting from the views of 20 centers in the United States that 20 the major medical associations, including 21 specialize in affirmative care. In 21 the American Psychiatric Association? 22 Cleveland, for example, we have three of 22 MR. CANTRELL: Object to form, 23 them whose name tells you that they're 23 vague. 24 24 interested in affirmative care. A. Well, there are 28,000 25 25 psychiatrists in the APA, I think. So And so that's all I had to say Page 299 Page 301 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 and because I was really -- the basic --2 certainly I don't -- I mean, there are --3 that was my introductory way of saying, 3 people in the audience came up to us and 4 isn't this a time for a paradigm shift? 4 say, gee, thank you for saying these 5 Can we, based upon science, the 5 things, I didn't have the courage to say 6 limitations of science, can we say that 6 these things, and there is so much worry 7 this idea of affirmative care is proven 7 that people were going to be harmed, 8 and is the best thing to do? Can we have 8 their reputation would be harmed if they 9 -- can we open our minds to the 9 express any dissenting view. 10 possibility that the best practices are 10 The APA, in 2010, in 2010 11 not necessarily the best practices and we 11 declared that there is no such thing as 12 need to be somewhat skeptical and could 12 an abnormal gender identity and was very 13 we even imagine that we have another 13 supportive of all this affirmative care. 14 paradigm shift? 14 And that was really before some of the 15 And that was my introduction 15 seminal studies have showed up. 16 to Dr. Zucker and Dr. Ayad -- Ms. Ayad So they had a political view 16 17 and Dr. Marchiano. And then we had 17 because the APA has made a terrible 18 questions, I mean discussion. That was it 18 mistake in this -- before 1973 when they 19 -- actually, it was supposed to be 90 19 called homosexual people to be 20 minutes but it lasted I think almost 115 20 psychopathology, that was a form of I 21 think they called it a psychopathic 21 minutes. 22 22 personality disorder or something, I O. And Ken Zucker, Lisa Ayad and 23 don't remember exactly. But they were 23 Lisa Marchiano are people who you would 24 describe as supporting a more cautious 24 extremely embarrassed about their 25 approach with respect to providing 25 position that they maintained for years

	D 202		P 204
1	Page 302 STEPHEN B. LEVINE, M.D.	1	Page 304 STEPHEN B. LEVINE, M.D.
	and years and years.	2	Q. And you've not reviewed his
3	You know, all of us in		expert report in this case?
	medicine are a little bit aware of	4	A. If I have I don't remember it.
	mistakes that we've made about social	5	Q. So you never heard of him
	issues. You know, the American		before?
1	Psychiatric the American Medical	7	A. Given my memory, put a little
1	Association used to support eugenics.		asterisk about that, please.
	And, of course, you and I have already	9	Q. Let me ask it differently. Is
1	talked about the mistake of the opioid		it someone you know who works in the area
1	crisis and I can go on and on, and so		of treatment for gender dysphoria?
1	could you, about the	12	A. What is his first name?
13	Q. Maybe we can switch gears.	13	Q. Mark.
14	A about the misadventures.	14	A. No. Mark, no, I don't know
15	But answer to your specific question, the	15	that person. At least at 5:30 I don't
	APA was aware that we were presenting		know that person.
	ideas that were not in keeping with the	17	Q. Do you know who Patrick
	official policies of the APA.	18	Lappert is?
19	In fact, they made that	19	A. Patrick, last?
20	announcement and they asked people I	20	Q. L-a-p-p-e-r-t.
21	mean, they sent a special moderator to	21	A. That name sounds more familiar
22	our session, unbeknownst to me and I	22	but I don't associate it with anything.
23	didn't have any special monitor I	23	No, I don't know.
24	didn't see any APA monitors in any of the	24	Q. If I were to mention that he
25	other sessions I attended during you	25	also submitted an expert report for the
	Page 303		Page 305
1	Page 303 STEPHEN B. LEVINE, M.D.	1	Page 305 STEPHEN B. LEVINE, M.D.
2	STEPHEN B. LEVINE, M.D. know, during the days I was there, but		
2 3	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of	2	STEPHEN B. LEVINE, M.D.
2 3	STEPHEN B. LEVINE, M.D. know, during the days I was there, but	2	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you
2 3 4 5	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful	2 3 4 5	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr.
2 3 4 5 6	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be	2 3 4 5 6	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert?
2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that	2 3 4 5 6 7	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know
2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not	2 3 4 5 6 7 8	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z?
2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of	2 3 4 5 6 7 8 9	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes.
2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA.	2 3 4 5 6 7 8 9 10	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him
2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking	2 3 4 5 6 7 8 9 10 11	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally?
2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody	2 3 4 5 6 7 8 9 10 11 12	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I
2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on.	2 3 4 5 6 7 8 9 10 11 12 13	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case.
2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know	2 3 4 5 6 7 8 9 10 11 12 13 14	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at
2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an expert witness for the State of Arkansas	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist. Q. Gotcha. Is he someone you know
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an expert witness for the State of Arkansas in this case. Does that help ring a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist. Q. Gotcha. Is he someone you know to be an expert in the field of gender
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an expert witness for the State of Arkansas in this case. Does that help ring a bell?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist. Q. Gotcha. Is he someone you know to be an expert in the field of gender dysphoria, treatment of gender dysphoria
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an expert witness for the State of Arkansas in this case. Does that help ring a bell? A. R-e-g-n-u-s?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist. Q. Gotcha. Is he someone you know to be an expert in the field of gender dysphoria, treatment of gender dysphoria in adolescents?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	STEPHEN B. LEVINE, M.D. know, during the days I was there, but this woman appeared, who was the head of the program, and she made a little announcement that this was a respectful institution and that people needed to be talk nice, and the APA was aware that some of the ideas expressed here were not in keeping with the official policy of the APA. So while we were all talking the group was extremely polite and nobody interrupted and so forth and so on. Q. Switching gears, do you know who Mark Regnerus is? A. Sorry. Who? Margaret? Q. Mark Regnerus. A. No, I don't know that name. Q. R-e-g-n-e-r-u-s. He is an expert witness for the State of Arkansas in this case. Does that help ring a bell?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	STEPHEN B. LEVINE, M.D. State of Arkansas, would that help you remember who he is? A. I don't remember reading an expert report by Dr. Lappert. Is it Dr. Lappert? Q. Yes. Okay. Do you know Dr. Paul Hruz, H-r-u-z? A. Yes. Q. And do you know him personally? A. I've met Dr. Hruz somewhere, I think on another case. Q. Did you ever meet Dr. Hruz at any professional conference? A. I don't think we go to the same conferences. Q. Why is that? A. I'm a psychiatrist. Q. Gotcha. Is he someone you know to be an expert in the field of gender dysphoria, treatment of gender dysphoria

Page 306 Page 308 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 ahead with hormone treatments without 2 you know about Michael Biggs? 3 adequate scientific foundation. That's A. He's from the U.K. and he's 4 what I know of Dr. Hruz. 4 someone who has a great capacity to Q. Did you read his report that 5 analyze data and to recognize, you know, 6 he submitted in this case? 6 reasonableness and he's someone who digs 7 into data in a far deeper way than most A. I think I probably did 8 somewhere, nine, ten months ago, yeah. 8 human beings can do and don't have the Q. Was there anything that he 9 capacity to do. 10 opined that you disagreed with? 10 So I've been very interested MR. CANTRELL: Object to form. 11 in what he has said about various 12 A. You may or may not know that 12 articles, in particular, about 13 I've spent a lot of time editing reports. 13 Dr. Turban's articles, which many of us 14 I'm the senior editor of a major textbook 14 have enormous skepticism about, enormous 15 in sexual ideas, sexual health called 15 skepticism about. 16 Handbook of Clinical Sexuality For Mental 16 So he recently published a 17 letter to the editor about suicide and 17 Health Professionals. And so I'm used very much to 18 gender -- teens with gender dysphoria and 19 taking experts and helping them write 19 looked at the data from the Tavistock 20 more clearly and more succinctly and more 20 Clinic and came up with a rate of suicide 21 powerfully. And I often ask people, what 21 that was surprisingly low, considering 22 does this mean? Could you say that more 22 all the claims that we have to give 23 clearly? 23 hormones to kids because they're going to 24 So probably when I read other 24 kill themselves if they don't. And he 25 experts' reports, and let's not pick on 25 found that in looking at all the data Page 307 Page 309 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Dr. Hruz specifically, I could say that 2 over the years that there were four known 3 about many of the expert reports on 3 suicides of people who registered to the 4 Tavistock Clinic over a ten-year period 4 either side, I wouldn't have said it 5 exactly that way. So I don't remember 5 and two of those kids were in treatment 6 right now whether I disagree with 6 with hormones and two of them were on the 7 something he said. 7 waitlist. And he calculated the rates, I certainly know that a few 8 the suicide rate there and it was .03%, 9 experts have rebutted some of his 9 which is so different than, you see, what 10 concepts. You know, some of your experts 10 everyone is afraid of. Because people 11 don't think that I know what I'm talking 11 have a hard time -- maybe if you're in 12 psychiatry you don't have a hard time 12 about either, or should I say more 13 respectfully, they disagree with 13 with this, but outside of psychiatry, 14 something I said. 14 people, when they hear about suicidality, 15 Q. I mean, is there anything in 15 they don't make these distinctions. 16 particular you have in mind where you say 16 Q. I just want to interrupt 17 our experts rebutted some of Dr. Hruz's 17 because I didn't mean to ask you about 18 concepts? 18 Michael Biggs' work --19 MR. CANTRELL: Object to form. A. I'm sorry. I'm sorry. 19 20 Q. -- about his background. 20 A. I think in order to answer So do you understand, is he a 21 that question I would have to read his 21 22 report again. 22 doctor or psychiatrist? 23 Q. All right. In your reports in A. No. He's not a psychiatrist, 24 this case I saw some references to 24 he's not a MD. He has a Ph.D. in 25 Sociology. 25 publications by Michael Biggs. What do

Page 310 Page 312 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 Q. Is he someone you consider to A. Occasionally -- I'm sorry. 3 You reminded me, I can order blood tests 3 be an expert on treatment of gender 4 and certainly -- and I take a medical 4 dysphoria? 5 A. No. He's an expert on the 5 history. Being a doctor it's important 6 analysis of data. 6 for me to take a medical history, in 7 Q. And is he a member of SEGM? 7 part, because I know what certain 8 A. I don't know. 8 diseases mean, whereas, social workers Q. Do you know if he's opposed to 9 may not know. 10 any provision of gender-affirming medical 10 Q. So would a blood test be able 11 care for minors? 11 to detect something like anxiety or 12 A. I don't know. 12 depression? 13 Q. Switching gears, as a 13 A. Not a blood test, no. 14 psychiatrist, is it fair to say you treat 14 Q. Any physiological tests? 15 a range of mental health conditions in 15 A. Well, you can run an EKG and 16 your patients? 16 you can take a person's pulse, you can A. Yes. 17 17 see their body shake. I mean, I have 18 patients who shake in front of me. I 18 Q. Would that include depression? 19 A. Of course. 19 don't need a blood test to see they're 20 Q. Anxiety? 20 nervous, I can hear what they do when 21 21 they're nervous, you know. So -- and when A. Of course. 22 22 they're depressed, you know, there are Q. Bipolar disorder? 23 A. I'm sorry. What was that? 23 certain -- their face looks depressed, 24 Q. Bipolar disorder. 24 their posture looks depressed, their 25 A. Which kind of disorder. 25 attitudes looks depressed, their Page 311 Page 313 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 2 self-concepts sound depressed. Q. Bipolar. 3 MR. CANTRELL: She's saying So that's all part of the 4 4 first thing a doctor does, first thing we bipolar. 5 learn in how to do physical diagnosis is 5 A. Oh, bipolar. Yes. 6 to observe the patient. So we learn a lot 6 Q. Are there any -- strike that. 7 When you are diagnosing 7 by looking at the patient. 8 patients with these conditions, do you Q. Are there objective -- have 9 rely on self-report of the patients? 9 you used the term objective and 10 A. Of course I do. 10 subjective to refer to methods of 11 diagnosing a condition? Is that Q. Is there any other evidence 12 you can look to to verify the evidence 12 terminology you use? 13 provided in the patient's self-report? A. Well, the patient talks about 13 14 14 their subjectivity and we're interested, A. Yes. 15 Q. Can you tell me what kinds of 15 at least in psychiatry, we're interested 16 things? 16 in how they think and how they feel and 17 A. I can talk to a spouse, I 17 how they suffer from what the problem is. 18 could talk to a parent, I could do a 18 And objectively we look at them and we 19 psychological test, I could fill out a 19 hear how they speak and observe what they 20 do with their bodies and their eyes and 20 form and have them fill out a form, I can 21 read their medical history, I can talk to 21 their posture while we're talking. We 22 the previous therapist. I think that's 22 also can have these questionnaires or do 23 most of what I can do. 23 psychological tests as a more objective Q. Is there any kind of 24 appraisal. 25 physiological verification? 25 For example, when I do a

Page 314 Page 316 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 forensic report for somebody who's 2 paradoxes in psychiatry. We live with 3 paradoxes and contradictions. 3 committed or is accused of a crime, I 4 always provide psychological testing to 4 It is -- you know, the APA 5 verify my impressions or to see what I've 5 declared in 2010 that there is no such 6 missed, so to speak. So there are things 6 thing as an abnormal gender identity, and 7 that are objective and we gather 7 the policy from the DSM-IV was 8 information that is patient narrative. 8 inconsistent with that. 9 But, again, we also -- we're also being 9 Now, the DSM-V has said, well, 10 paid what some of my patients call big 10 gender identity, per se, is not an 11 bucks, we get the big bucks for making 11 abnormality, but if people are distressed 12 judgments about what the person says and 12 then they have a psychiatric diagnosis. 13 thinks and feels, and we sometimes 13 You see, if you are going to 14 provide an alternate view of -- and then 14 ask me if I have issues with the DSM-V 15 we watch -- sometimes this is called an 15 diagnosis of gender dysphoria, you really 16 interpretation -- and we watch the 16 need to ask me if I have issues about 17 patient's response to our alternate view, 17 psychiatric diagnosis, in general, and 18 and then we see that patient over time 18 then we would have to talk about that at 19 and we see how our alternate view may 19 great length. And you don't want me to 20 land on fertile ground and help a person 20 spend an hour talking about that. And 21 shift their subjectivity. 21 then we could get to the specifics about 22 I mean, a lot of people say --22 gender dysphoria as a diagnosis and why 23 I don't mean to sound too proud about 23 the DSM -- why the ICD-11 has went out of 24 this -- but a lot of people say, it was 24 its way to not make it a psychiatric 25 so very helpful talking to you, Dr. 25 diagnosis, and how they think that that's Page 315 Page 317 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Levine, you've really helped me today, I 2 a major step forward, and which I think 3 feel much better leaving after 50 minutes 3 it helps everyone deny the importance of 4 than I did when I walked in here. That's 4 self-harm and suicidality and depression 5 why I get paid the big bucks, so to 5 and anxiety. Because that's something 6 speak, you know. 6 separate from gender identity, you see. So I don't know if you want to 7 It's a comorbidity. As though a person 8 call this objective. I'm comfortable with 8 can have six different diagnoses. I 9 the subjectivity, the patient's 9 laugh when I sometimes get patients who 10 subjectivity and my subjectivity and the 10 come from others who gave six psychiatric 11 relationship between the two of those 11 diagnoses, it's one person and they have 12 subjectivities. 12 six different problems. And you see, 13 Q. Do you take issue with the DSM 13 this is the diagnostic problem, this is 14 diagnosis of gender dysphoria? 14 the diagnostic foolishness I think that 15 MR. CANTRELL: Object to form, 15 we have in separating things out. It's 16 just one person struggling with life, you 16 vague. 17 A. What issue would you be 17 see. 18 referring to? 18 Q. Do you think that gender Q. Do you think that gender 19 dysphoria is diagnosed only based on 20 dysphoria is appropriately considered a 20 patient's self-report? 21 MR. CANTRELL: Object to form. 21 psychiatric condition? 22 A. Oh. Well, in the DSM-V there 22 A. By whom? Q. By the -- by you, by whoever 23 is a psychiatric condition. In the 23 24 ICD-11 it is a condition that affects 24 is doing --25 sexual health. This is one of the great 25 A. If you are asking about me

Page 318 Page 320 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 versus -- you didn't ask about me. You 2 is, is that -- is the reliance on 3 asked about, do I think gender dysphoria 3 patient's self-report and report from 4 is diagnosed by a patient's self-report? 4 family members unique in the psychiatric 5 Well, of course, it begins with patient's 5 field to the diagnosis of gender 6 self-report and it also requires a sense, 6 dysphoria? 7 the doctor's sense of what is gender MR. CANTRELL: Object to form. 7 8 dysphoria and where does it come from and 8 A. Oh, I see. I see where you've 9 how long has it existed and who is this 9 been going here. 10 person, you see, and is this person 10 Self-report is a very 11 mentally ill, apart from the gender 11 important component in the diagnosis of 12 dysphoria problem, you see. 12 any psychiatric condition. In the field of gender 13 So you know, one can be 13 14 psychotic and have gender dysphoria or 14 dysphoria, in the beginning of the 15 one can be a little anxious and have 15 history of the gender dysphoria we 16 recognized in the '70s and '80s that many 16 gender dysphoria, and those are different 17 kettles of fish. 17 people lied to us because they read the Q. And I think we talked about 18 textbook description and they wanted 19 hormones, for example, and they gave us 19 this earlier, do you look to information 20 from the parents when diagnosing a minor 20 textbook descriptions of their gender 21 dysphoria. So we trying to distinguish 21 with gender dysphoria? 22 A. Why, of course. 22 in the '70s and '80s in adults between Q. Is the reliance on self-report 23 people who had -- looking at men, for 24 from patients and information from family 24 example, men who evolved into trans 25 members unique to the diagnosis of gender 25 identities from transvestitic fetishism Page 319 Page 321 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 dysphoria? 2 or cross-married, heterosexual 3 MR. CANTRELL: Object to form. 3 cross-dressers from people who had what 4 4 we thought back then was true gender 5 dysphoria. We didn't call it gender 5 O. Is that true of other 6 psychiatric conditions? 6 dysphoria in those days, true A. Yes. For example, if somebody 7 transsexualism. 8 is having cognitive troubles, and say, It turns out now that 9 oh, I'm not having any troubles, I just 9 children, teenagers spend so much time on 10 got lost on the way home last night, I'd 10 social media and so much time on trans 11 be happy to talk to their spouse or their 11 social media, and that there are people 12 son or their daughter or their other 12 telling teenagers what to tell the 13 doctor, whatever. 13 doctor, that now we have the problem of; Of course, I mean, this is --14 do we believe the patient's subjective 15 you know, this is standard medical stuff. 15 report? Is there -- is the patient 16 It doesn't require just being a 16 telling us the truth as they experience 17 psychiatrist. The internist does the 17 themselves or are they telling us what we 18 same thing, the pediatrician does the 18 think we need to hear in order to 19 same thing, even the neurosurgeon does 19 recommend affirmative care? And this is 20 the same thing. 20 one of the reasons why we need to have a Q. Well, I'm asking because there 21 conservative, slow report to figure out 21 22 have been critiques by others that the 22 the truth because people lie to doctors 23 diagnosis of gender dysphoria is not 23 when they want something, and transgender 24 valid because it is only based on 24 people are no exceptions to the human 25 patient's self-report. And my question 25 potential to lie to doctors to achieve

Page 322 Page 324 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 So I don't know -- he made mention of 2 some goal that they have in mind. And so 3 doctors can't treat people like they're 3 several different issues he wanted to 4 liars, but they have to understand that 4 talk to me about. 5 it may not be the whole truth. So I don't know -- I can just 6 report to you some somebody called me So that when someone says it's 7 not valid because it's only self-report, 7 about -- he called me a weak ago Friday, 8 I think the substance of that claim is 8 tomorrow would be a week, last Friday he 9 that it may not always be true, just 9 called but I've been -- I was on my way 10 self-report and, therefore, it's 10 to the APA meeting. 11 important to get multiple sources of Q. What issues did he say he 12 information sometimes and it's important, 12 wanted to talk about? 13 Levine would say it's important to know 13 A. He didn't say, but I presumed 14 that person over time because stories 14 it was something about trans world. 15 change. 15 People don't ask me to be expert 16 witnesses about schizophrenia. 16 Q. Are there other mental health 17 conditions that you can diagnose only Q. Do you think parents of a 17 18 based on self-report and report from 18 minor on hormone therapy should be deemed 19 others who know the patient? 19 child abusers? 20 A. I think that's how it works. 20 MR. CANTRELL: Object to form. 21 Q. That's how psychiatry works? 21 A. That's sort of a -- let me see 22 A. Yes. I think the answer to 22 if I got that question. Do I think the 23 your question; are there other 23 parents who support a child being on 24 conditions, the answer is simply yes. But 24 hormones should be accused of child 25 I'm so long-winded here. 25 abuse? Page 323 Page 325 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. Are you familiar with the Q. 3 3 decision in Texas to investigate families Is that your question? 4 of children who are -- actually, not 4 5 children. I'll start that again. 5 A. I would say that's sort of a Are you aware of a decision in 6 laughable idea. 7 Texas to deem gender-affirming medical 7 Q. Why do you say that? 8 care for minors to be child abuse? A. Because I've spent almost 9 seven hours to you explaining the answer A. I read the papers. Q. So you are aware of that from 10 10 to that question. 11 the news; is that right? 11 Q. Yeah, tell me how I missed it. 12 So it's a laughable idea 12 A. The dear Governor of Texas. 13 Q. You are aware; is that 13 because you don't consider parents who 14 access gender-affirming medical care for 14 correct? 15 A. I read the papers. I'm aware. 15 their minor children to be engaged in an 16 I don't know if I'm as aware as you are 16 act of child abuse? 17 but I'm aware somewhat of this idea. 17 A. I don't think they're Q. Have you been asked to provide 18 knowingly abusing their child. I think 19 they often are misinformed because of the 19 expert testimony in litigation in Texas 20 over that policy? 20 principles I outlined in our article. I A. Actually, last week somebody 21 don't think they've been informed and I 22 from the Attorney General's Office called 22 don't think we should punish parents by 23 me and I said there is no possibility I 23 taking their child away. And I've, by 24 could talk to you until -- for another 24 the way, seen that where social agencies 25 couple of weeks because I'm so damn busy. 25 take children away, custody of children

Page 326 Page 328 1 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 law there and they said, well, thank you 2 away from 14-year-old kids who object to, 3 you know, the use of affirmative care on 3 very much, Dr. Levine, we'll get back to 4 their 14-year-old. 4 you. So I haven't heard since that time The culture is somewhat 5 from them. 6 hyperbolic about this subject, you see, 6 Q. What concerns did you explain 7 and people need to calm down about this. 7 to them? 8 The Governor needs to calm down about A. I don't remember the details 9 this, I mean the Governor of Texas. And 9 of the Alabama law, only that it made me 10 you know, these principles have something 10 uncomfortable. I particularly -- I think 11 to do with the election cycle. And I'm 11 there was something like revocation of 12 talking about science here. And I'm not 12 licenses or ten years in prison, 13 an expert on election cycles, but I am a 13 something that I thought was Draconian. I 14 citizen, you know, I do vote, I do make 14 think there was -- I think they were 15 up my mind about what happens in the 15 threatening to send doctors to prison. 16 political sphere. But I really want you 16 And I'm aware that there are many 17 to talk to me about what I know about 17 controversies in medicine. And it's only 18 science. 18 in this area -- or in the abortion area 19 19 and this area that we have such passion If you're asking me about my 20 opinions about various political things, 20 as a nation. And when we think about 21 I'll be happy to tell you, but I don't 21 taking a cultural resource like 22 think, you know, that's what you got me 22 physicians that communities depend upon 23 here for. But maybe I don't understand 23 for their physical and mental health and 24 why you have me here. 24 putting them in prison because they have 25 Q. Do I take it from your answer 25 a different view some medical issue, I Page 327 Page 329 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 that if you were asked to serve as an 2 just think that's over the top. 3 expert witness on behalf of the State of Q. Are you aware that the 4 Arkansas law provides that doctors who 4 Texas to help them defend their policy of 5 investigating parents for child abuse for 5 provide gender-affirming medical care to 6 providing gender-affirming hormone 6 minors would be deemed to be acting in 7 therapy that you would decline that? 7 violation of medical ethics and could 8 MR. CANTRELL: Object to form. 8 have their licenses taken away by the 9 A. Oh, yes. 9 State Medical Board? Q. Was that an "oh, yes", did I 10 10 MR. CANTRELL: Object to form. 11 hear that right? 11 A. That is not -- that is not my 12 reading of the law. I do know that there 12 A. Yes. At this moment I would 13 decline that, if that's how they phrased 13 is a kind of threat of reporting to the 14 it, yeah. 14 State Medical Board, but I don't really 15 Q. I can't remember if I asked 15 think that law mandates the removal of 16 you this already. Have you been asked to 16 their medical license. 17 offer expert testimony in the case 17 Q. A consequence of the law, if 18 involving the felony ban on 18 that is what the law means, would that be 19 gender-affirming medical care in Alabama? 19 a concern of yours? 20 A. I was in discussions with the 20 MR. CANTRELL: Object to form. 21 21 Attorney General, one of the Assistant And Dr. Levine is not an attorney 22 Attorney Generals of Alabama, about a 22 so he, of course, can't answer 23 month ago and I had a conference call and 23 legal -- can't give a legal 24 I explained some of my concerns about 24 opinion.

MS. COOPER: Of course.

25

25 that, about what I understood to be the

Page 330 Page 332 1 STEPHEN B. LEVINE, M.D. 1 STEPHEN B. LEVINE, M.D. 2 Q. I'm not asking for your legal 2 support a policy that would discipline 3 opinion. I'm asking if the state law does 3 doctors who provide this care by taking 4 actually mean that some doctors could 4 away their medical licenses? 5 have their licenses taken away if they 5 MR. CANTRELL: Object to form. 6 6 provide gender-affirming medical care to A. I'm actually not here to 7 minors, would that cause you concern? 7 support policy, but to let science lead A. So, listen, you may not know 8 policy. 9 9 this but the State Medical Board of Ohio Q. You mentioned that there are 10 has used me as an evaluator of doctors 10 others in your medical practice who 11 who have gotten into trouble over many 11 provide care for minors with gender 12 years. They've used me since I would say 12 dysphoria. 13 1990, and they have me -- when people 13 Are they aware of your 14 renew their licenses, they have to listen 14 participation in this case and other 15 to a 20-minute talk by me. And that's in 15 cases involving issues related to this 16 the last year, not for 30 years. They've 16 treatment? 17 used me for consultations for errant 17 A. I'm sorry. Which group of 18 doctors. 18 people are you asking me about? 19 Q. The doctors in your -- the I've been witnessing for 30 20 years how state medical boards operate, 20 providers in your practices. 21 our state medical -- the Ohio State 21 A. Yes. Yes. I think they may not 22 Medical Board operates. And so when 22 be aware of Arkansas, per se, but they're 23 doctors are accused of things they get a 23 aware that I do function as an expert 24 very careful evaluation. 24 witness in some states, sometimes. 25 So just because the Arizona 25 Q. And is it your experience that Page 331 Page 333 STEPHEN B. LEVINE, M.D. STEPHEN B. LEVINE, M.D. 2 law says something, words something that 2 they agree with the opinions you have 3 is vaguely threatening, it really doesn't 3 offered in these cases? 4 mean that, practically speaking, that A. I don't think they know the 5 they will lose their license. 5 opinions that I offer in these cases. I I don't think the law remands 6 don't think any one of them have read any 7 or demands that the Arkansas State 7 expert opinion report I ever wrote. I 8 Medical Board removes their license. I 8 mean, if you look at the length of this 9 think, if I remember reading it 9 report you got to be a lawyer to read 10 correctly, they could report them to the 10 this. No one else in their right mind 11 State Medical Board. 11 would read these reports or maybe a 12 parent would read this report. 12 Q. I'm not asking your analysis 13 of the statute. I am asking if doctors Q. Would you agree there is 13 14 were to lose their licenses because they 14 disagreement among doctors and other 15 provided gender-affirming medical therapy 15 healthcare providers about the 16 to minors, would that be a concern to 16 appropriate way to treat adolescents with 17 you? 17 gender dysphoria? 18 18 MR. CANTRELL: Object to form. MR. CANTRELL: Object to form. 19 A. If we leave it as simply as 19 A. I think I must be getting 20 you just said, it would be a concern to 20 tired because I'm having a hard time 21 me. But I think what I was trying to tell 21 grasping what you're asking me. Would I 22 you is it's more complicated, the 22 agree to what? 23 process. The devil is in the details and Q. That there is -- I'll ask it 24 not in the statement that you made. 24 again because maybe you didn't hear all 25 Q. And fair to say you would not 25 of it.

Page 334 STEPHEN B. LEVINE, M.D.	Page 336 STEPHEN B. LEVINE, M.D.
2 Would you agree that among	2 hearts and revascularize the
3 doctors and other healthcare providers	3 atherosclerotic blood vessels and there
4 there are diverse views about the	4 was a controversy and people couldn't
5 appropriate treatment for gender	5 decide. So people did a study and found
6 dysphoria in adolescents?	6 out if you treat this medically you don't
7 A. Yes. I would agree to that.	7 need to have open heart surgery. And
8 Q. Some oppose the use of	8 then we further then had controversies
9 hormonal interventions to treat gender	9 about should we put a stent in rather
10 dysphoria and some support it; is that a	10 than using medication.
11 fair statement?	So medicine advances because
12 A. Oh, I'm aware that, you know,	12 there are disagreements. There are
13 your Plaintiffs' experts support it and	13 disagreements in psychiatry. There are
14 they represent many people in those	14 disagreements in every field. You see,
15 50-some units across America who are	15 trans care is the only is the most
16 actively providing hormone treatment for	16 controversial, most passionate thing. The
17 teenagers. Yes, I'm aware.	17 passion comes from patients who want it
18 Q. Are there other psychiatric	18 and the passion comes from doctors who
19 conditions about which there is	19 believe compassionately, wholeheartedly
20 substantial disagreement in the field	20 that this is helping them, and they don't
21 about the appropriate course of	21 want to know that the suicide rates after
22 treatment?	22 all they do, after all this treatment
23 A. Of course.	23 have not improved, you see.
Q. Can you give me an example or	So controversy I want to
25 two?	25 teach people that controversy is how we
Page 335	Page 337
Page 335 STEPHEN B. LEVINE, M.D.	Page 337 STEPHEN B. LEVINE, M.D.
	-
1 STEPHEN B. LEVINE, M.D.	1 STEPHEN B. LEVINE, M.D.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction.	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09.
A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.)
A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out 20 all the time. I say, embrace the	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.) 20 VIDEOGRAPHER: Back on the
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out 20 all the time. I say, embrace the 21 controversy. Of course, there are	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.) 20 VIDEOGRAPHER: Back on the 21 record. The time is 6:21.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out 20 all the time. I say, embrace the 21 controversy. Of course, there are 22 controversies. That's how science	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.) 20 VIDEOGRAPHER: Back on the 21 record. The time is 6:21. 22 CROSS-EXAMINATION BY MR. CANTRELL:
A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out 20 all the time. I say, embrace the 21 controversy. Of course, there are 22 controversies. That's how science 23 advances, you see.	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.) 20 VIDEOGRAPHER: Back on the 21 record. The time is 6:21. 22 CROSS-EXAMINATION BY MR. CANTRELL: 23 Q. Just one question, Dr. Levine.
1 STEPHEN B. LEVINE, M.D. 2 A. Well, some people think that 3 high-dose antipsychotic drugs are the 4 treatment, lots of people disagree about 5 which drugs to use. I wrote a book in 6 2020 called Psychotherapeutic Approaches 7 to Sexual Problems. And on the 10th and 8 final chapter of the book I urged the 9 readers to not run away from controversy 10 but to embrace controversy and understand 11 what the controversy is about and to 12 recognize that the reason there is a 13 controversy is that we don't have enough 14 science to answer the question, and that 15 would help us pay attention to subsequent 16 studies to move us in the direction. 17 You see, what's happened in 18 this field is people got polarized and 19 they try to cancel the opposing views out 20 all the time. I say, embrace the 21 controversy. Of course, there are 22 controversies. That's how science	1 STEPHEN B. LEVINE, M.D. 2 advance knowledge and we we don't have 3 to we have to acknowledge the 4 controversy and we have to be balanced 5 enough to understand the opposing points 6 of view and then conceptualize how in the 7 world or some of us have to 8 conceptualize how in the world are we 9 going to advance and get the answer to 10 the contentious issue. But defining the 11 contentious issue is the first step to 12 progress. 13 MS. COOPER: With that I can 14 pass the witness. 15 MR. CANTRELL: Okay. Let's 16 take a short break. 17 VIDEOGRAPHER: Going off the 18 record. The time is 6:09. 19 (Recess is taken.) 20 VIDEOGRAPHER: Back on the 21 record. The time is 6:21. 22 CROSS-EXAMINATION BY MR. CANTRELL:

	Page 338		Page 340
1		1	STEPHEN B. LEVINE, M.D.
2			child. And so we say, go ahead and give
3	J J 1		them hormones and hopefully you'll follow
4			the patient and we'll follow the patient.
5		5	So I don't really like the
6	think she has any authority or legitimacy	6	word that we recommended or Anna Novak
	or credentials to approve surgery or		recommended or Anna Novak approved it.
	hormones. She's a social worker. She's a	8	What we're really saying is
9	very competent person and she's very	9	that we've done what we can, to the best
	experienced in this area and we depend	10	of our ability with this family and they
	very much on Anna Novak to evaluate		have autonomy in decisionmaking about
	families and parents and the life history		this.
	of children with this problem and to	13	I think that's a lot different
	enter into a substantial, ongoing	14	than happens in many clinics, when you
	relationship. And if, in doing what we		hear about someone, and maybe this isn't
	have earlier said today is the process of	16	the modal experience, but it is certainly
	informed consent and having a growing	17	a common enough experience that people
18	understanding of what the dynamics in the	18	get I want testosterone and by the end
19	family are, if the parents decide, having	19	of the first visit they have a
20	recognized the various forms of treatment	20	prescription. Is that an answer?
21	options that are available, if the	21	MR. CANTRELL: That's an
22	parents decide that they would like to go	22	answer, Dr. Levine. And with that,
23	ahead with, say, cross-sex hormones then	23	we'll pass the witness. But we
24	Anna will write a letter to the she	24	will review and sign.
25	will present it to me or to the group and	25	MS. COOPER: No more
	Page 339		Page 341
1	STEPHEN B. LEVINE, M.D.	1	STEPHEN B. LEVINE, M.D.
	if there is a consensus agreement about	2	questions.
	this, considering what we all know about	3	VIDEOGRAPHER: This concludes
1	the situation, and we have no we have	4	the video deposition. The time is
	no reason to believe that this is going	5	6:25. Going off the record.
	to be a disaster, even though we have no	6	(The proceedings were
	reason to believe that there is going to	7	adjourned at 6:25 p.m.)
1	have a favorable outcome, we will write a	8	
1	letter to the endocrinologist about our	9	
	understanding of this case and that we	10	
1	we give our permission for the not the	11	
1	urologist, but the endocrinologist to	12	
	provide those hormones.	13	
14	1 1	14	
		15	
15	might say, well, don't you approve it?		
15 16	But Anna Novak doesn't prove it. If	16	
15 16 17	But Anna Novak doesn't prove it. If anyone approves it, it's my signature	16 17	
15 16 17 18	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the	16 17 18	
15 16 17 18 19	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only	16 17 18 19	
15 16 17 18 19 20	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only a great deal of information about the	16 17 18 19 20	
15 16 17 18 19 20 21	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only a great deal of information about the patient and the family, it gives them the	16 17 18 19 20 21	
15 16 17 18 19 20 21 22	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only a great deal of information about the patient and the family, it gives them the idea that we have concerns, of course,	16 17 18 19 20 21 22	
15 16 17 18 19 20 21 22 23	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only a great deal of information about the patient and the family, it gives them the idea that we have concerns, of course, the parents are aware of our concerns,	16 17 18 19 20 21 22 23	
15 16 17 18 19 20 21 22 23 24	But Anna Novak doesn't prove it. If anyone approves it, it's my signature with the MD degree that legitimizes the it gives the endocrinologist not only a great deal of information about the patient and the family, it gives them the idea that we have concerns, of course,	16 17 18 19 20 21 22	

1	Page 342 CERTIFICATE	1	Page 344 Stephen B. Levine, M.D. Monday,
$\frac{1}{2}$	I, MAUREEN M. RATTO, a		•
$\frac{2}{3}$	Registered Professional Reporter, do	2	December 21, 2020 re: Juli
	hereby certify that prior to the	3 Claire v. Florida Department of	
	commencement of the examination,	4 Management Services	
	STEPHEN B. LEVINE, M.D. was sworn by me	5 Exhibit Levine 6, Declaration of 234	
	to testify the truth, the whole truth	6	Dr. Stephen B. Levine, dated
	and nothing but the truth.	7	July 2021
9	I DO FURTHER CERTIFY that the	8	Exhibit Levine 7, Declaration of 239
1	foregoing is a true and accurate	9	Stephen B. Levine, MD dated
	transcript of the proceedings as taken	l	December 9, 2021
	stenographically by and before me at	11	Exhibit Levine 8, Canadian 272
13		12	Gender Report, dated October 1,
	hereinbefore set forth.	13	2019
15	I DO FURTHER CERTIFY that I am	14	
	neither a relative nor employee nor	15	
17		16	
	parties to this action, and that I am	17	
	neither a relative nor employee of such	18	
	attorney or counsel, and that I am not	19	
	financially interested in this action.	20	
22	•	21	
23	Maureen Ratto	22	
		23	
24	MAUREEN M. RATTO, RPR	24	
25	License No. 817125	25	
	Page 343		Page 345
1	INDEX	1	MICHAEL CANTRELL, ESQ.
2	WITNESS: STEPHEN B. LEVINE, M.D. 6	2	michael.cantrell@arkansasag.gov
3	DIRECT EXAMINATION BY MS. COOPER 6	3	June 8, 2022
4	CROSS-EXAMINATION BY 337	4	RE: BRANDT, et al. vs. RUTLEDGE, et al.
5	MR. CANTRELL	5	5/26/2022, Stephen B. Levine (#5163591)
6		6	The above-referenced transcript is available for
7	EXHIBITS	7	review.
8	Exhibit Levine 1, Declaration of 64	8	Within the applicable timeframe, the witness should
9	Stephen B. Levine, MD, dated	9	read the testimony to verify its accuracy. If there are
10	February 23, 2022		any changes, the witness should note those with the
11	Exhibit Levine 2, excerpt of the 70	11	reason, on the attached Errata Sheet.
12	deposition of Stephen B. Levine,	12	The witness should sign the Acknowledgment of
13	MD re: Reiyn Keohane v. Julie	13	Deponent and Errata and return to the deposing attorney.
14	Jones		Copies should be sent to all counsel, and to Veritext at
15	Exhibit Levine 3, article re: 86	l	erratas-cs@veritext.com.
16	Reconsidering Informed Consent	16	
17	written by Stephen B. Levine,	17	Return completed errata within 30 days from
18	MD, in the Journal of Sex &	l	receipt of testimony.
19	Marital Therapy	19	If the witness fails to do so within the time
20	Exhibit Levine 4, transcript re: 181	20	allotted, the transcript may be used as if signed.
21	Presentation on Healthcare	21	- ·
22	Models For Transgender	22	Yours,
23	Adolescents, dated March 12,	23	Veritext Legal Solutions
24	2020	24	_
	Exhibit Levine 5, transcript of 190	25	
25	Zimion Zevime e, transcript or 170		

		Page 346
	BRANDT, et al. vs. RUTLEDGE, et al.	
2	5/26/2022 - Stephen B. Levine (#5163591)	
3	ERRATA SHEET	
	PAGELINECHANGE	
5		
6	REASON	
7	PAGELINECHANGE	
8		
9	REASON	
10	PAGELINECHANGE	
11		
	REASON	
	PAGELINECHANGE	
	REASON	
	PAGELINECHANGE	
	TAGECHANGE	
	REASON	
	PAGELINECHANGE	
	REASON	
22		
23		
24	Stephen B. Levine Date	
25		
		Page 347
1		Page 347
	BRANDT, et al. vs. RUTLEDGE, et al.	Page 347
2	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591)	Page 347
2	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT	Page 347
2 3 4	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I	Page 347
2 3 4 5	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any	Page 347
2 3 4 5 6	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as	Page 347
2 3 4 5 6	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any	Page 347
2 3 4 5 6 7	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as	Page 347
2 3 4 5 6 7 8	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is	Page 347
2 3 4 5 6 7 8	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony	Page 347
2 3 4 5 6 7 8 9	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony	Page 347
2 3 4 5 6 7 8 9 10	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me.	Page 347
2 3 4 5 6 7 8 9 10 11 12	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date	Page 347
2 3 4 5 6 7 8 9 10 11 12 13	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required	_
2 3 4 5 6 7 8 9 10 11 12 13 14	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M.	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M.	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M.	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M.	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	BRANDT, et al. vs. RUTLEDGE, et al. 5/26/2022 - Stephen B. Levine (#5163591) ACKNOWLEDGEMENT OF DEPONENT I, Stephen B. Levine, do hereby declare that I have read the foregoing transcript, I have made any corrections, additions, or changes I deemed necessary as noted above to be appended hereto, and that the same is a true, correct and complete transcript of the testimony given by me. Stephen B. Levine Date *If notary is required SUBSCRIBED AND SWORN TO BEFORE M DAY OF	_

[**& - 30**] Page 1

&	14 32:14,16 90:10	168:15 207:6	216:3 335:6
	90:16 132:2,3	181 343:20	343:24 344:2
& 3:3 6:1,4 86:11	213:10,11 244:14	182 28:21	2021 74:14 94:22
343:18	256:2 326:2,4	18th 227:5	234:14 239:5,15
0	14's 140:23	19 14:11 76:13	344:7,10
00450 1:4 5:12	15 14:12 21:24	101:2 185:18	2022 1:20 5:3
03 309:8	31:19 33:13 57:15	190 343:25	64:11 65:14 87:4
1	85:15 95:3 111:6	1970s 298:17	130:22,22 187:5
	140:20 152:19	1973 13:2 21:18	203:21 343:10
1 5:4 64:8,9 65:6	213:14 217:6	22:12 301:18	345:3
272:8 287:7 343:8	218:11 257:7	1974 21:6 96:15	21 76:10 190:5
344:12	290:14	1977 26:19	235:4 344:2
10 31:19 33:12	151 191:7,12	1980s 298:17	22 201:4,6 255:6,8
219:3 234:11	152 190:25 191:2	1984 96:15	23 64:11 102:2
259:24	191:10,21 279:6	1988 257:5,21	343:10
100 18:7 285:18	16 14:12 40:11	1989 21:8	234 344:5
293:4	48:19 57:15 69:22	1990 330:13	239 344:8
10004 3:5,15	85:15 137:15,17	1994 96:15	24 54:11
10th 335:7	140:20 165:11	1:51 161:9	25 28:14 76:10
11 244:14 253:10	169:13 170:10	1st 13:2	261:21
253:10 254:11	187:6,24,24		26 1:20 76:10
255:5 293:4	189:10 228:13	2	95:19 96:4 135:2
315:24 316:23	259:22,23	2 70:6,15 95:5	135:18 183:20,21
115 299:20	16,000 268:12,19	149:22 343:11	203:21
11:00 60:16	268:19,21 269:18	20 28:12,13 64:6	26th 5:3
11:06 60:19	269:23	74:7 76:10,13	27 290:14
12 13:6,19 24:19	17 14:13 48:20	140:20 210:18	27,000 148:11
27:18 28:10 31:3	69:22 84:5 137:17	260:2,8 261:21	287:6
56:4 181:11 224:9		295:17 330:15	272 344:11
281:7 343:23	137:17 163:6,6 164:13 181:7	347:15	28,000 300:24
12.6 147:11	207:6 228:12	2000 195:2	28-7 262:24
12.7 148:8	290:14	2006 40:7	2:02 161:12
125 3:4,14	17425 342:23	2010 301:10,10	2.02 101.12 2nd 3:22
12:05 105:9	17425 342:23 17th 87:5 137:14	316:5	
12:46 105:12	148:12	2011 101:3 216:2	3
12th 141:18		2013 291:4	3 70:2 86:7,8,15,15
183:15 185:18	18 14:10,10 30:25	2017 28:21 70:20	149:20 343:15
13 90:10 132:3	54:11,24 55:18 69:22 75:24 80:25	2019 137:14 272:9	30 25:7 90:12
140:19,23 152:8		344:13	102:2 229:12
163:10 186:8,24	83:13 84:4 85:5	2020 74:13 137:19	260:9 261:8
187:3 213:9 219:9	85:15 102:2,3	181:11,19 183:15	262:10,23,24
290:14	157:7 165:9	185:18 190:5,21	330:16,19 345:17
		I	

[30,000 - act] Page 2

30,000 122:12,14	184:4	87 219:9	324:25 325:16
323 4:13	5:15 291:19	88 239:25 257:7	327:5
325 21:8	5:30 304:15	8th 288:8	abused 108:8
337 343:4	6	9	abusers 324:19
35 13:4,18 218:12	6 65:19 234:12,20	9 239:5 344:10	abusing 104:23
235:7,9,16	234:23 239:2	90 299:19	325:18
36 97:6			academic 276:9,11
38 146:23	343:2,3 344:5 60 28:24 79:9	90,000 122:13,13 904 3:22	accept 158:25
3:17 223:5			acceptable 135:8
3:31 223:8	193:24 194:19	93 239:14,18,19	acceptance 115:25
3:32 223:11,16	218:14 262:24	9:20 1:21	279:3
4	275:7	9:32 11:23	accepted 248:24
	61 97:6	9:59 12:4	access 138:8 195:3
4 86:7 181:8	64 343:8	9th 239:14	223:20 224:3
343:20	6:09 337:18	a	325:14
40 19:5 76:10 79:9	6:21 337:21	a.m. 1:21 5:3 14:2	accounts 124:13
197:21 218:15	6:25 341:5,7	abating 225:16	169:15
425 4:4	7	abbruzzese 90:23	accumulated
43 270:18	7 73:18 219:4	90:25 91:9,22	130:9
45 58:12 59:2	239:3,9,11 267:14	ability 62:10	accuracy 190:23
49 13:7	267:18,19 270:6	179:11 185:6	345:9
4:21 1:4 5:12	283:12,13 344:8	338:3 340:10	accurate 160:9
4:58 291:16	70 270:5 343:11	able 7:22 40:2,3	205:5 342:10
5	70s 320:16,22	41:7 44:7 61:25	accurately 90:9
5 190:3,9 343:25	72201 3:23 4:5,14	62:5,24 65:5	104:18,20 262:20
5,000 94:24	78 267:15,20	70:15 78:16 86:17	accusation 148:13
5/26/2022 345:5	79 146:24	152:18 181:5	accused 314:3
346:2 347:2	7:30 11:7	190:10 195:17	324:24 330:23
50 14:15 31:18	7th 71:24 72:19	212:24 312:10	achieve 321:25
33:9 96:9 97:4	275:21 276:2	abnormal 301:12	acknowledge
129:20 146:18	8	316:6	337:3
218:12 248:24,25		abnormality	acknowledgement
251:6 293:19	8 190:2 272:6,7,17	316:11	347:3
298:19 315:3	283:10,15 344:11	abortion 328:18	acknowledgment
334:15	345:3	absence 153:10	345:12
5163591 345:5	80 219:9	absolute 84:8	aclu 3:21 5:16,19
346:2 347:2	80s 320:16,22	192:12	7:10
57 182:14,15,19	817125 2:10 342:25	absolutely 117:15	aclu.org 3:17,19
58 182:14		224:23 228:21	3:25
59 71:6,14 182:10	83 219:3,5	abuse 153:12	act 325:16
182:11,25 183:3,4	86 257:11 343:15	211:18 323:8	
,			

[acting - aimed] Page 3

4. 220.6	11 4 25 16	1 44 02 0	202 7 207 14
acting 329:6	adolescents 35:16	adversities 83:8	323:7 325:14
action 342:18,21	35:18,25 46:17	108:22 221:12	327:6,19 329:5
actions 211:23,25	48:2 49:17 54:22	advocacy 286:5	330:6 331:15
active 170:5	57:2 58:21 61:11	advocate 231:22	afford 152:19
actively 17:4	61:19,24 71:25	231:23 263:25	afield 132:22
334:16	72:3 73:16,22	advocates 193:22	afraid 309:10
activities 43:4	74:8 76:9,21	affiliated 24:12	age 48:20 102:4
activity 298:2	77:22 85:21 86:24	91:22 92:6,20,25	157:4 248:7 256:2
actual 218:21	89:7 108:13	affiliation 91:15	260:8 261:20
adaptations	110:25 112:6,7,11	91:21	268:15
269:13	156:3 171:6 176:7	affirmation	agencies 325:24
add 61:16 87:20	181:10 223:19	144:10	agent 188:20
145:4 193:24	225:22 236:3,5	affirmative 36:7	210:16
203:11	238:6,8 263:24	76:3 264:2 280:2	agents 244:8
added 22:20	305:23 333:16	280:17 284:3	ago 54:11,11 69:22
addition 230:9	334:6 343:23	297:19 298:2,21	69:23 74:3 111:10
additional 87:21	adult 16:21 44:3	298:24 299:7	125:25 183:18,19
87:23 168:22	46:6 53:11,21	301:13 321:19	186:14 206:12
185:21 280:23	69:16 95:10	326:3	226:19 236:7
additions 347:6	104:24 157:11	affirmed 257:23	237:9 238:12
address 29:13,16	199:19 200:22	affirming 128:2,4	240:17 248:25,25
83:8 105:22 107:2	206:22,23 256:22	128:15 131:15	291:23,24 306:8
107:4,6,21 108:3,5	adults 14:7,8,23	134:21 135:3,19	324:7 327:23
108:24 289:20	15:14 23:9 24:22	136:10 137:4	agree 47:2 131:17
addresses 243:15	30:15 40:16 46:21	138:8,13,19	132:25 133:11,12
adequate 306:3	47:17 53:7,10	139:11 145:13,14	135:10,16 169:16
adjourned 341:7	55:13 61:14 84:24	148:25 151:12	197:8 214:4,23
adkins 10:11	86:25 88:12,24	156:7,10 157:20	258:6 278:18
adolescence 51:20	96:9,22,23 111:2	159:14 161:17	284:19 333:2,13
108:12 140:16	112:6 114:22,23	162:5 171:7	333:22 334:2,7
189:22 253:13,15	115:6,7,20 157:5	172:18 175:14	agreed 68:9
254:3,8 256:11	192:20 193:6	176:6,10 177:8	194:11 230:8
258:12,18 264:2	194:15,17,24	178:22 181:24	agreement 339:2
adolescent 14:16	195:7 196:14	183:12,23 202:10	agrees 92:15
32:3,6 46:18	197:2,25 215:23	202:24 205:11	ahead 19:4 129:5
47:16,25 48:4	259:3 320:22	207:13 208:9,23	306:2 338:23
49:9 55:3 56:13	advance 230:9	212:13 219:19	340:2
58:7 62:25 64:3	231:10 337:2,9	220:10,20 226:23	ails 125:16
75:18 112:22	advances 335:23	228:20 229:6	aim 155:15
114:21 157:19	336:11	243:20 246:20	aimed 168:16
179:7 227:25		285:11 310:10	188:22
117.1 221.23		203.11 310.10	100.22

[al - applying] Page 4

al 1:7,12 5:8,9	analysis 310:6	142:17 145:23	anxiety 43:2 77:25
260:5 261:13	331:12	147:6,10 151:22	101:22 119:4
262:7 270:19	analyze 308:5	153:3 159:19	123:19 210:16
271:17 345:4,4	analyzing 92:3	176:20,21 178:8	211:17 290:19
346:1,1 347:1,1	129:10,12	181:5 192:4,6,7	310:20 312:11
alabama 208:21	androgens 168:9	206:2,13 207:18	317:5
327:19,22 328:9	anecdotal 235:24	218:5,13 228:16	anxious 123:13
aland 4:18	236:10,15,17,19	229:10 233:13	318:15
allotted 345:20	238:3,16,18	237:6 246:23	anybody 98:3
allow 135:11	240:16,22 241:23	247:4 248:15	227:5
137:4 206:18	242:11 243:6	255:13,14 257:22	anymore 13:9
225:13 242:2	angels 204:20	258:21 259:11	260:19 288:19
allowed 129:4	angst 49:19	288:20 302:15	anyway 246:16
allowing 228:23	anguish 85:17	307:20 322:22,24	298:8
allows 136:10	animae 50:2	325:9 326:25	apa 291:21 292:20
159:18 232:9	anna 27:9 60:22	329:22 335:14	293:15 300:10,25
alternate 93:12	61:20 337:25	337:9 340:20,22	301:10,17 302:16
289:6 297:21	338:11,24 339:16	answered 21:12	302:18,24 303:7
314:14,17,19	340:6,7	49:6 130:20	303:10 316:4
alternative 138:20	announcement	175:17 200:7	324:10
264:4	111:7 302:20	201:24 214:14	apa's 300:13
altogether 55:11	303:5	283:5	apart 318:11
amanda 4:17	announces 291:2	answering 32:12	apas 294:8
amazingly 94:6	annual 293:10	56:6 221:22	apparent 43:18
ambitious 288:6	anonymous	233:16 255:22	apparently 179:20
ambivalence	271:21 277:11	answers 7:23 56:9	appear 116:10
200:9	anonymously	228:4	appearance 6:9
ambivalent 115:9	273:20	antecedents	appeared 303:3
amenable 233:19	answer 8:3,7,8,13	107:15	appearing 5:17,20
amended 211:5	8:22 9:6 10:4 13:8	anti 174:12,13	5:23
america 206:3	28:9 31:15 32:4	209:19 210:16	appended 347:7
225:15 232:11,15	33:25 34:11 38:23	anticipate 8:4	apples 252:5
246:14 334:15	40:5 43:15 45:11	anticipated 89:20	applicable 345:8
american 3:13	45:12 48:23 49:4	antidepressant	applied 202:9
98:5 194:8 284:21	50:19 53:7 54:13	210:16 251:23	263:23
293:11 294:3,5	76:2 79:11 83:4	antidepressants	applies 170:9
300:21 302:6,7	83:16,22 100:2	244:10	222:20,21,22,23
amount 95:5	104:25 107:8	antipsychotic	apply 89:6,14
amounted 169:6	116:4,23 119:8	335:3	168:15 211:5
amsterdam	125:3 126:18,20	anton 10:12	applying 263:17
246:12	128:9 130:19		

appraisal 313:24	251:19,25 340:7	arkansasag.gov	281:12 285:5
appreciate 90:10	approves 339:17	4:16,18 345:2	302:20 318:3
90:21	approving 82:17	arm 230:20	323:18 327:2,15
appreciation	84:3	armbruster 3:8	327:16
244:7,11	approximate	5:25 6:1	asking 8:9 12:6
approach 77:2	13:16 16:20	armbrustere 3:9	19:25 21:14 24:3
92:14 105:21	approximately	arms 230:17	24:23 30:13 40:19
110:17,19 135:11	12:21 23:16 30:18	art 114:13	45:14 50:21 56:10
135:23,24,25	35:17 55:15 56:12	article 10:2 86:8	82:6,7 92:7 113:3
136:7,12,22	56:25 59:24 251:7	86:22 87:6 89:3	119:13 133:6
138:17,20 140:6	293:4	89:12 90:4 148:12	142:13 178:18
147:19 163:12	approximation	154:8,12 155:17	179:24 184:6,7,21
167:18,19 174:6	20:6	155:22 156:6,10	197:11 199:4
212:19,20 217:12	apt 186:21	176:14 179:2	202:20 242:8,9
227:24 263:3,16	area 22:9 76:14	181:3 200:5 202:5	250:12 255:7,16
288:25 299:25	178:13 202:3	203:23 217:12,13	255:18,19 274:2
approaches 93:12	276:23 288:11	217:17,22 237:8	276:13 286:13,14
335:6	304:10 328:18,18	272:4 276:18	317:25 319:21
approaching	328:19 338:10	278:9 280:3	326:19 330:2,3
210:13	arena 194:17	281:10 282:10	331:12,13 332:18
appropriate 48:8	204:19	286:9 287:3,7,8	333:21
62:3 81:13 85:10	argue 156:9	325:20 343:15	asks 182:18 282:9
202:8 210:9	argues 147:5	articles 178:11	aspect 29:15,16,17
214:24 228:11	argument 120:17	279:6 308:12,13	42:17 81:16 109:4
333:16 334:5,21	189:4,9 198:12	articulate 146:24	aspects 38:12
appropriately	argumentative	177:13 178:25	81:18 119:24
173:2 315:20	119:19 217:16	articulated 152:2	aspirations 116:21
appropriateness	arisen 76:17	articulately	asserting 49:10
35:24	arizona 330:25	195:25	286:11,14
approval 45:2	arkansas 1:2,11	articulates 147:13	assess 40:2 41:7
57:24 59:2 137:18	3:21,23 4:5,12,14	aside 187:13 199:2	90:9 119:8
approve 73:23	5:11 6:14 149:2,5	asked 16:16 20:4	assessed 130:14
99:7 101:9 338:4	149:6,11,12 162:2	29:11 40:24 44:12	258:4
338:7 339:15	163:12,13,21,25	44:15 48:6 70:22	assessing 243:19
approved 57:13	171:20 172:5,14	75:17 93:6 109:7	assessment 41:24
58:9,14,16 59:2	177:9 202:11	161:14 200:7	102:23
63:22 68:21 69:2	209:23 223:18	201:24 204:25	assigned 139:25
69:14 74:7 75:24	225:23 231:25	207:11,15,20,21	143:14 242:22
77:9 78:6 79:16	232:24 303:20	208:25 214:14	295:9
85:5 97:3 135:6	305:2 329:4 331:7	226:24 234:6	assignment 184:7
231:4 248:22	332:22	255:11 277:14	193:23

[assistant - b] Page 6

assistant 4:10	329:21 342:17,20	137:10 141:13	78:1 79:1 80:1
327:21	345:13	193:15 194:23	81:1 82:1 83:1
associate 297:10	attributed 122:25	231:24 253:7	84:1 85:1 86:1,10
304:22	atypical 52:7	255:8,23 256:13	87:1 88:1 89:1
associated 76:18	audience 292:21	258:23 259:13,19	90:1 91:1,2,2 92:1
144:21 222:16	292:24 301:3	302:4,16 303:7	93:1 94:1 95:1
associates 6:7	audio 221:23	323:6,10,13,15,16	96:1 97:1 98:1
association 98:6	august 74:13	323:17 328:16	99:1 100:1 101:1
284:21 293:11	194:8	329:3 332:13,22	102:1 103:1 104:1
294:4,6 300:21	australia 93:20	332:23 334:12,17	105:1 106:1 107:1
302:8	246:11	339:23	108:1 109:1 110:1
associations	author 85:10	awkward 178:19	111:1 112:1 113:1
300:20	271:11,19,21	ayad 238:23	114:1 115:1 116:1
assume 8:23 20:16	277:6,20 287:4	292:16 294:10	117:1 118:1 119:1
44:14 51:22 84:23	authority 338:6	295:20 299:16,16	120:1 121:1 122:1
104:5,7 106:7	authorization	299:22	123:1 124:1 125:1
151:5	80:13,23 95:9	b	126:1 127:1 128:1
assuming 107:24	226:22	b 1:19 2:3 6:21 7:1	129:1 130:1 131:1
159:9	authorizing 87:11	8:1 9:1 10:1 11:1	132:1 133:1 134:1
assumption	96:3 97:9	12:1 13:1 14:1	135:1 136:1 137:1
211:13 264:24	authors 93:4	15:1 16:1 17:1	138:1 139:1 140:1
assure 103:12	261:24 280:4	18:1 19:1 20:1	141:1 142:1 143:1
assured 68:7	281:7,8,12	21:1 22:1 23:1	144:1 145:1 146:1
asterisk 304:8	autism 43:3 77:25	24:1 25:1 26:1	147:1 148:1 149:1
atherosclerotic	autistic 82:2	27:1 28:1 29:1	150:1 151:1 152:1
336:3	147:25	30:1 31:1 32:1	153:1 154:1 155:1
attached 345:11	autonomy 68:11	33:1 34:1 35:1	156:1 157:1 158:1
attacked 194:10	340:11	36:1 37:1 38:1	159:1 160:1 161:1
attempt 108:21	availability 79:25	39:1 40:1 41:1	162:1 163:1 164:1
121:16	available 64:23	42:1 43:1 44:1	165:1 166:1 167:1
attended 302:25	70:4 86:14 234:19	45:1 46:1 47:1	168:1 169:1 170:1
attention 157:4	268:16 272:13	48:1 49:1 50:1	171:1 172:1 173:1
200:24 289:17	338:21 345:6	51:1 52:1 53:1	174:1 175:1 176:1
335:15	avenue 4:4	54:1 55:1 56:1	177:1 178:1 179:1
attitude 188:12,14	average 13:4	57:1 58:1 59:1	180:1 181:1 182:1
attitudes 312:25	189:10 260:8	60:1 61:1 62:1	183:1 184:1 185:1
attorney 1:12 4:10	261:20	63:1 64:1,10 65:1	186:1 187:1 188:1
4:12 6:15 165:16	avoid 7:25	66:1 67:1 68:1	189:1 190:1,4
165:17 177:11	aware 63:8 79:4	69:1 70:1,7 71:1	191:1 192:1 193:1
201:23 233:2,4	112:18,20,20	72:1 73:1 74:1	194:1 195:1 196:1
323:22 327:21,22	134:19,23 136:8	75:1 76:1 77:1	197:1 198:1 199:1

[b - believe] Page 7

			T
200:1 201:1 202:1	316:1 317:1 318:1	218:8,14,16	222:18 228:10
203:1 204:1 205:1	319:1 320:1 321:1	219:17,19 233:7	232:21,22 251:2
206:1 207:1 208:1	322:1 323:1 324:1	327:18	251:18 284:14
209:1 210:1 211:1	325:1 326:1 327:1	banned 134:21	bates 191:16
212:1 213:1 214:1	328:1 329:1 330:1	136:2	bearing 97:20
215:1 216:1 217:1	331:1 332:1 333:1	banning 172:2,5	beautiful 280:13
218:1 219:1 220:1	334:1 335:1 336:1	176:10 177:7	beauty 49:21
221:1 222:1 223:1	337:1 338:1 339:1	199:5 202:15	bedwetting 43:5
224:1 225:1 226:1	340:1 341:1 342:6	207:12,21 217:14	began 94:23
227:1 228:1 229:1	343:2,7,9,12,17	220:10,20	193:23 263:21
230:1 231:1 232:1	344:1,6,9 345:5	bans 135:18 192:9	beginning 72:24
233:1 234:1,13	346:2,24 347:2,4	192:12,18,24	191:9 193:3
235:1 236:1 237:1	347:12	196:19,25 197:3	259:20 260:11
238:1 239:1,4	back 12:3 18:14	197:14 199:21	297:22 320:14
240:1,21,24 241:1	18:22,24 28:18,20	200:9 201:11	begins 12:23 29:14
242:1 243:1,5	29:4 37:24 53:24	208:9 213:5	108:15 203:25
244:1 245:1,13,18	60:18 73:20 95:24	barrett 7:16	230:2,3 254:24
245:21 246:1	96:2 99:22 101:7	base 130:11	257:21 318:5
247:1 248:1 249:1	105:11 111:9	based 41:15 49:10	behalf 327:3
250:1 251:1 252:1	113:9,10 115:10	91:19 93:7 106:8	behaved 256:25
253:1 254:1 255:1	161:11 175:7	130:7,25 148:16	behavior 38:8
256:1 257:1 258:1	176:4,22 222:8	160:8 174:20	behavioral 115:17
259:1 260:1 261:1	223:7,15 225:21	180:3 185:5,5,7	116:2
262:1 263:1 264:1	235:3 254:20	193:16 194:12	behooves 156:15
265:1 266:1 267:1	260:3 264:6	197:5 203:16	156:17
268:1 269:1 270:1	267:14,19 277:7,9	209:18 211:12	beings 22:3 110:3
271:1 272:1 273:1	278:22 283:11	213:7 220:24	110:4,10 308:8
274:1 275:1 276:1	291:18 294:9	227:12,19 241:10	belief 148:21
277:1 278:1 279:1	321:4 328:3	242:5 244:3	168:25 204:3
280:1 281:1 282:1	337:20	248:17 281:4	285:19 290:10
283:1 284:1 285:1	background 12:17	284:5 291:3	beliefs 145:3
286:1 287:1 288:1	92:9 95:7 309:20	296:11,15 299:5	156:18,19 204:5
289:1 290:1 291:1	backup 72:23	317:19 319:24	204:19 229:18
292:1 293:1 294:1	bad 75:13 192:16	322:18	believe 14:14 15:3
295:1 296:1 297:1	221:13 226:13,17	basic 299:2	37:3 41:2 45:3,10
298:1 299:1 300:1	balance 221:4	basically 22:13	50:13 53:25 61:8
301:1 302:1 303:1	balanced 337:4	77:23 98:8 238:17	74:6 84:12 96:7
304:1 305:1 306:1	ball 233:21	262:8	98:23 124:10,16
307:1 308:1 309:1	ban 173:9 195:21	basis 54:3,20 83:5	124:16 125:25
310:1 311:1 312:1	197:18,23 198:4	103:22 167:7	128:3 133:23
313:1 314:1 315:1	212:15 217:25	207:7 214:8 222:5	141:10 153:20,21

[believe - break] Page 8

158:22,23 175:3	131:4,14,17,23	biggs 307:25 308:2	336:3
177:24 178:6	132:8 133:3,23	309:18	blue 71:13 149:23
180:21 192:8,24	134:7 139:2,6,12	bill 6:11 170:8,8	150:9
196:18 197:13	139:21 141:7,9	210:22 211:4	board 176:11
200:12 205:8	174:22 193:18	biological 267:24	177:9 202:15
207:9,9 212:21	194:2,22 206:19	biologically 298:4	282:18,19 285:13
219:22,24 253:2	214:8 215:2,9,12	bipolar 310:22,24	285:15 329:9,14
262:7,10 280:6	216:8 217:2 218:2	311:2,4,5	330:9,22 331:8,11
283:10,14 298:3,9	218:25 250:19	birth 107:19	boards 330:20
298:10 300:7	best 7:25 8:7 46:2	139:25 143:14	bodies 213:3
321:14 336:19	130:5,21 140:5	242:22 295:8,9	313:20
339:5,7	160:18 165:6	birthday 227:6	bodily 87:22
believed 49:9	175:11 198:18,19	bisexual 51:17	188:15
201:15	198:21 199:3	115:4	body 49:20,20
believers 242:4	201:16 211:9	bit 16:18 23:22	108:7 115:25
believes 99:2	225:12 244:19	113:19 237:15	168:10 188:8
132:18 207:6,7	291:25 299:8,10	274:10 283:21	231:5 242:18
280:2	299:11 339:25	302:4	252:19 253:5
bell 303:22	340:9	black 224:2,22	312:17
beneficial 101:12	beth 4:6 6:10	226:3,9,15	book 98:4 335:5,8
169:16 179:8	better 44:20	bladder 161:4	boston 246:13
209:24 210:6	117:20 118:9,10	blanket 222:6	bottom 182:19
211:14 214:5	118:15 119:10	bless 232:7	191:8,12 272:20
217:11 228:18	122:4,22 124:4,21	blessing 47:9	box 221:17
244:24	124:24 130:23	163:24	boy 213:14 257:5
benefit 98:24 99:3	155:5 158:5 169:2	blind 246:18 249:3	boyd 260:5 261:6
99:10 100:7	169:4 170:20	blinded 246:21	261:13 262:7
102:14 117:6	171:23 172:9	247:7	boys 140:2 236:2
126:11 133:2,14	202:14 216:9	block 239:14	238:6 258:8
156:5 170:17	228:25 241:7	blockers 80:15,16	bpj 65:12
174:18 185:22	286:4,4 315:3	80:17 137:16,24	brain 56:3 158:10
204:21 212:3	beyond 235:24	153:24 186:10	brains 196:3
215:11 218:2,25	238:3	198:5 227:14	brandt 1:6,7 5:8
226:7 247:14	bi 257:11	300:5	345:4 346:1 347:1
benefited 218:12	bias 270:21	blocking 136:5	brandyn 3:6 5:21
219:5	biased 84:17	156:23 184:11	break 9:4 17:8
benefiting 211:2	big 107:13 136:20	197:19 227:19	53:8 60:12 105:3
benefits 117:4	276:5 292:21,24	243:22 244:2,3,8	105:4 160:25
127:24,25 128:5	293:3 314:10,11	244:20,23 258:3	161:7 213:23
128:15,23 129:8	315:5	blood 216:13,14	214:17 221:21
129:25 130:15,18		312:3,10,13,19	222:25 291:8

[break - care] Page 9

227.16	220.16.25.220.14	00.7 100.11	20000111001
337:16	230:16,25 238:14	90:7 100:11	capacities 120:4
breaking 9:8	242:11 281:14	101:13 105:5,24	capacity 1:11
160:24	282:13 295:9,14	119:18 121:25	72:13 90:16 308:4
breaks 9:2	298:14 314:10	126:12 128:24	308:9 338:3
breast 117:12	315:8 321:5	131:19 133:8	capitol 4:4
180:12 222:8,14	327:23	135:20 136:15	cardiac 41:11
222:15,16,20	called 130:5	138:10,22 139:14	cardiovascular
breasts 47:2 132:2	144:10 154:15	143:11 145:20	215:15 216:18
195:12 213:9	198:18 207:25	146:12 151:21	care 29:5,19,23
216:12	231:4 240:22	157:22 159:16	30:4 35:20 36:7
brief 10:14	242:24 243:6	162:9 164:17	41:10 72:5,19
briefer 100:3	276:24 282:8	166:13 167:5	73:18 100:10,13
brilliant 75:4	283:9 290:15	169:23 172:7,19	100:14 101:4
bringing 63:14,19	301:19,21 306:15	175:15 176:12,18	102:17,22 125:15
british 273:2	314:15 323:22	176:21 177:10	128:2,5,16 131:16
broad 3:4,14	324:6,7,9 335:6	179:3 187:7 193:2	134:22 135:3,18
brother 224:17	calling 49:23	193:10,14 199:9	135:19 136:11
brought 29:19	209:17	200:6 202:17	138:9,14,19 139:7
bränström 194:7	calls 22:23 220:13	205:12 207:14	139:11,13 141:4
216:2 279:22	226:5 292:20	208:11 211:11	144:21 145:8,13
280:13 282:23	calm 326:7,8	213:22 214:13	145:15 146:7
bs 159:2	campos 268:22	215:6 217:15	148:25 155:15,23
buck 104:12	canada 93:21	219:18,21 220:12	156:3,11 157:21
bucks 314:11,11	246:12 270:15	220:22 222:7	159:13,15 161:17
315:5	271:3	223:22 226:4	165:2 172:5
burch 176:3	canadian 272:7,19	228:14 232:4	173:23 174:8
business 213:4	272:24 344:11	234:5 237:14	175:14 176:7,10
busted 261:11	cancel 335:19	247:16,24 249:10	177:8 178:12,17
busy 323:25	cancer 19:6 95:15	252:14 279:13	178:22 181:24
button 64:24	95:17 174:12,13	283:23 291:10,13	183:12,23 186:5
bypassed 235:9	174:17 222:9,14	300:11,22 306:11	202:10,15,16,24
c	222:15,16,20	307:19 311:3	205:11 206:24
c 3:1 4:1 245:13	266:14	315:15 317:21	207:13 208:9,23
342:1,1	cantrell 4:15 6:8	319:3 320:7	210:9 212:15
calculated 309:7	6:13,14 12:13	324:20 327:8	219:17,20 220:10
california 257:10	34:12 36:22 39:11	329:10,20 331:18	220:14,15 222:6
call 9:3 23:7 78:13	39:21 42:14 44:19	332:5 333:18	223:19 225:24
92:22 93:15	47:19 50:17 53:3	337:15,22 340:21	228:20 229:6
103:14 135:5	62:11 64:19,25	343:5 345:1	243:20 245:9
169:10 189:7	70:13 81:14 83:2	capable 129:10,12	262:9 264:2
193:19 209:18	84:7 85:11,25		270:22 273:25
173.17 207.18			

[care - child] Page 10

		I	T
274:7,16 275:3,9	231:25 235:3	caution 125:18	245:7
275:21,23 276:2	239:13 240:21	140:14 153:22	certified 2:7
280:2,17 284:3	241:2,2,4,21,22	178:24 189:23,23	certify 342:4,9,15
285:12 286:12,17	242:6,16 243:5	cautious 72:3,22	chain 204:11
287:23 288:8	244:16 280:14	73:15 130:10	295:25 296:17,25
298:21,24 299:7	303:21 304:3	186:21 202:23	297:4,5,12,14
301:13 310:11	305:13 306:6	218:25 227:9	chairman 182:21
321:19 323:8	307:24 327:17	286:20,21 299:24	challenges 107:18
325:14 326:3	332:14 339:10	ccr 1:25	107:24 264:22
327:19 329:5	cases 23:20 25:20	cdt 1:21	chance 88:4
330:6 332:3,11	26:6 40:12 78:4	center 4:13 71:22	187:16
336:15	93:24 132:12,20	72:25 73:8,9,14	chances 240:13
career 12:22,23	133:3 139:5,13	76:5,24 77:14	change 51:20,21
14:16 21:25 74:4	144:4 162:7 220:4	centers 184:12	108:2 130:24
77:3 106:16	236:17 240:21	232:23 244:18	147:17,20 188:11
careful 76:25	243:5 244:17,18	298:17,20	196:10 251:12
81:12 122:15	245:5 332:15	central 1:3	322:15 346:4,7,10
153:15 189:23	333:3,5	certain 76:2 110:2	346:13,16,19
262:6 269:16	cass 134:14 138:3	110:4,5 119:24	changeable 140:21
330:24	categorical 192:5	142:23 174:18,19	changed 14:19
carefully 129:22	192:9,12,18,24	178:4 186:25	20:13 96:18
129:22 229:9	196:19,25 197:3	192:15,25 194:21	129:16 197:16
269:9	197:13,23 199:21	205:16 219:6,7	278:17
carries 42:20	200:9 201:11	220:25 221:2	changes 278:14,15
carveout 171:6	212:14 213:5	248:22 253:9	278:15,18 297:7
case 1:4 5:11 25:4	categorically	259:15 267:5	345:10 347:6
25:6 26:16 37:12	156:11 195:24	280:16 290:3	changing 186:15
62:13 65:12 70:19	197:18 198:4	312:7,23	217:7
71:3 96:8 112:25	199:5	certainly 9:3	chapter 335:8
128:20 131:12,18	categories 21:21	62:24 76:4 84:11	charge 158:2
131:21 132:11	243:13,17,18	100:13 111:19	chase 3:18 5:18
133:13 142:12	category 17:15	112:25 115:7	check 237:11
159:17 161:14,20	173:11 241:24	119:24 124:12	282:17
162:2 167:7,7,20	cause 85:17	137:7,8 198:16	child 16:3 22:22
167:20 173:25	130:10 166:15	226:13 231:20	32:2 34:5,7 36:24
175:11,11 176:8	169:21,25 170:2,6	244:21 263:21,24	62:18 77:20 88:3
176:16,25 177:6	226:7 242:20	265:18 267:7,10	90:14 107:18,22
187:21 190:15,18	330:7	300:6 301:2 307:8	108:10 113:18
192:20 212:12,15	caused 140:12	312:4 340:16	147:24,25 153:13
212:15 222:5,5,9,9	causes 180:8	certainty 110:9	158:14 159:13,20
222:18,18 228:9,9		114:9,17 244:22	159:21 160:8

[child - collective] Page 11

165:11 167:23	259:3,6,7 263:17	claire 190:5,16	246:19 247:15,23
168:4 173:23	295:6 300:5 321:9	344:3	250:12 284:15
175:2 179:7,9	323:4,5 325:15,25	clarification 8:20	298:19 306:16
185:10,14 200:18	325:25 338:13	clarified 150:16	clinically 284:12
200:19,21,25	children's 149:7	156:14,16	clinician 29:8 30:6
201:6,13 206:10	167:13	clarify 18:3 29:12	clinicians 25:4,23
206:14,22 207:4	china 57:18	53:4 73:9 82:12	144:16 145:7,12
210:14 227:13,16	224:14	171:2 193:8	146:7 202:13
231:13 263:22	choice 67:16 130:4	clarifying 33:9	238:19 283:25
264:22 265:4,12	202:15	clarity 55:14	clinics 146:18,19
265:14,17 267:10	choices 277:18	72:16 294:2	275:3 340:14
323:8 324:19,23	cholesterol 216:15	clean 7:21	close 54:13 213:23
324:24 325:16,18	choose 195:21	cleaner 8:5	283:18 292:9
325:23 327:5	205:10	clear 7:19 8:19	closely 282:18
340:2	chronic 100:22	11:15 16:19 39:13	285:5
child's 62:16	101:21	71:12 74:19 87:18	closer 19:23
180:7 188:11	chronically	110:18 119:9	155:21
203:18 264:19	104:23	142:5 157:24	clot 216:13
childhood 254:18	cigarettes 123:14	159:7 176:3	coastally 257:11
254:22 255:3,25	circa 203:21	193:11,13 207:22	coauthors 90:22
258:5,17	circumstance	254:9,14 255:15	91:6 151:25
children 15:3,5,10	153:9 289:25	270:4	253:23
15:13,13,15,18,23	circumstances	clearer 8:21 46:11	cochrane 119:7
16:8 23:8 26:2	32:8 78:9 82:25	265:4	134:16
27:6 33:17 52:21	127:6 162:8	clearly 25:12	cogency 178:5
61:14,16 62:15	171:13 172:21	117:25 193:9	cogent 271:14
86:24 88:18 112:8	205:16 253:9	201:23 212:9	cognitive 319:8
125:9 140:11	cis 213:16 256:6	306:20,23	cognitively 83:11
157:20 158:13	cisgender 257:19	cleveland 21:5	98:10
163:18 166:5	cited 283:9,14	76:14 80:3 298:22	cohort 243:24
170:19 171:14	cites 270:18	clinic 21:5 22:15	244:15 245:2,3,11
172:21 173:3	cities 246:13	50:7 146:17	245:17,19,21,23
184:14 188:22	citizen 326:14	147:23 149:7	246:3
196:14 200:13	civil 3:13 94:9	231:13 275:6	coined 266:2,8
201:20 210:7,19	claim 135:9 322:8	308:20 309:4	colleague 226:21
212:20,23,24	claimed 48:25	337:25	colleagues 26:5
213:12,16 227:25	268:11	clinical 47:12 50:4	50:8 92:16 111:20
227:25 252:25	claiming 268:8	130:7,8,9 135:12	155:8
253:11,11 254:11	295:6	206:17 228:18	collect 236:16
255:9 256:17	claims 308:22	229:3,20 230:2	collective 120:15
257:7,12,17,23		232:3,9 234:4	

[college - confuse] Page 12

	I		
college 74:24 75:5	common 34:21	compliment 72:12	concluded 42:11
75:6,7	50:2 100:9,12,14	component 320:11	122:15
colluded 224:10	100:15 250:16	comprehend	concludes 341:3
colored 120:11	268:3 286:7	185:7	conclusions
columbia 273:3	340:17	comprehends 90:5	194:10 281:3,18
combination	commonly 168:9	comprehensive	281:21
115:14	communities	43:16 98:2 102:25	condition 15:8
combinations 52:4	328:22	computer 28:19	100:22,24 136:13
come 18:8,22,24	community	conceive 295:22	267:8 313:11
28:15 38:15,20	166:23 268:6	concept 17:25	315:21,23,24
44:3 45:14 53:17	comorbid 78:14	107:10 232:16	320:12
53:18 81:7 93:3	comorbidities	256:21 263:21,23	conditions 15:23
111:2 112:11,13	106:10,11,22	263:25 297:12	78:14 100:17
113:9 114:23	203:19	concepts 94:9	310:15 311:8
115:8,20 126:24	comorbidity 201:3	188:17 307:10,18	319:6 322:17,24
127:2,3,4,5,15,22	201:3 317:7	313:2	334:19
143:12 147:22	company 208:5	conceptualize	conference 16:5
169:3 189:22	compared 73:17	337:6,8	29:13,14 291:22
209:13 251:8	229:22	concern 202:22	293:7,12 294:4
260:3 294:20,22	comparing 141:14	203:6 224:4	305:15 327:23
317:10 318:8	252:5	273:18 275:16	conferences 16:3
comes 44:25 48:9	compassion	329:19 330:7	26:16,18 305:17
113:7 131:20	285:24	331:16,20	confessed 48:13
163:10 189:3	compassionate	concerned 171:19	confidence 28:8
205:25 336:17,18	173:6,12,13,14	171:21 172:13	289:22
comfort 212:25	compassionately	202:3 203:12	confidential 1:15
comfortable 79:6	336:19	290:25,25	34:13,16 36:24
111:11 219:15	competent 9:11,12	concerning 224:5	39:14
220:8,19 315:8	338:9	224:6	confined 284:7
coming 17:20	complete 9:12	concerns 42:20	confines 166:8,11
18:14 143:8	32:6 194:24 347:8	68:8 99:20 111:7	confirm 237:24
166:23 258:25	completed 8:8	139:22 144:9	confirming 95:11
commencement	345:17	172:11 177:18	193:20
342:5	completely 40:6	179:5,17,19,21	confirms 280:5
commissions	complex 109:3	180:4,5 211:8	conflict 115:19
130:13	complexities 188:6	224:21 225:22	224:16
committed 174:9	complexity 109:10	273:22 281:11	conflicted 290:7
314:3	221:18	284:2 327:24	conforming
committee 184:6,8	complicated 78:23	328:6 339:22,23	193:21
275:19 287:12	125:19 189:17	conclude 243:18	confuse 192:21
	260:24 331:22		

[confused - correct] Page 13

confused 294:8	consider 32:5	continent 274:12	conversant 157:11
confusing 166:21	36:19 81:10 82:21	continue 91:7	conversation
confusion 94:7	82:24 83:6 114:18	169:19 170:21	170:6
176:23	152:15,25 177:20	196:7,14 218:8	conversations
connection 9:15	210:8 227:4	254:2,23 258:17	55:15
261:11	228:12 264:3	continued 4:1	convey 254:14
cons 46:3	284:10 310:2	172:5,16	conviction 232:19
consensus 339:2	325:13	continues 56:8	convince 122:7,18
consent 10:2 76:23	considerable	continuing 56:7	cooper 3:16 5:15
86:9,23 87:9	115:19 129:8		5:15 6:24,25 7:9
88:15 89:5,13,24	139:22 180:4	contraceptives 226:11	11:11,19 14:19
94:17,19 109:21		contradictions	34:14 36:25 38:15
144:15 145:19	considerably 124:16	316:3	
144:13 143:19	consideration	contraindicated	39:17,23 60:10,13 64:7,22 69:24
146:10,14,16,22	158:4 210:23	66:21	81:15 86:6 104:4
147:13 148:0,18	considered 52:12	contribute 41:24	105:2,6 145:21
150:18,25 151:16		126:2	159:5 160:23
,	279:10 300:9,19		161:6 181:6
152:4,6,12 153:2	315:20	contributed	
153:25 154:3	considering 147:5	124:11 272:22	183:14 184:18
155:3,10 158:2	171:24,25 172:4	control 117:23	189:25 193:7,13
160:4 178:12	202:9 207:17	229:23 244:12	193:15 199:10,11
179:2 185:5 196:2	308:21 339:3	245:3,5,12,14,20	213:24 222:24
199:22 200:4,11	constantly 10:6	245:22 246:3	223:9 234:10
202:6 203:22,25	consult 30:10	249:4	237:18 238:25
205:9 212:17	consultation 17:21	controlled 117:21	245:15 248:3
214:7 215:22	consultations	118:3 129:19	289:14 291:7,11
216:22,23 217:13	330:17	230:19 236:21,22	329:25 337:13
230:14 338:17	consulted 170:25	237:3 247:15,23	340:25 343:3
343:16	consulting 9:15	248:14 250:11	cooperated 102:7
consequence	contacting 95:25	251:21	cooperating 169:9
200:19,20 329:17	contacts 20:10	controls 237:5	copies 345:14
consequences	contains 1:15	248:17	correct 14:25
36:21 79:2 84:14	contemplating	controversial	24:10 27:12 44:24
87:20,21,24 88:6	54:9	288:11 336:16	45:7 71:3 72:20
93:14 150:15	contentious	controversies	74:9 84:25 87:4
153:16 174:14	120:17 337:10,11	328:17 335:22,24	91:5 105:18
conservative	context 71:12	336:8	106:12,13 133:6
76:25 77:7 92:13	135:12 182:24	controversy 335:9	135:21 141:22
104:14 212:2	191:6 228:24	335:10,11,13,21	144:22,23,24
321:21	contextualize	336:4,24,25 337:4	176:25 190:22
	150:5		194:16 197:5

[correct - day] Page 14

	I		I
198:22,23,24,25	42:4 48:12 62:7	151:25 219:7	cut 127:9
229:7 236:8	64:5 65:25 74:3	290:12	cutting 121:8
240:10 242:15	79:10 89:25 96:11	critical 280:7,16	cv 1:4 5:12
245:7 252:23	100:3,22 126:17	criticisms 277:13	cycle 326:11
253:3,6,18,21	133:18,18 150:12	criticize 275:20	cycles 326:13
280:11,20 323:14	158:15 177:2	critique 277:4	d
347:8	215:18 248:15,20	critiques 277:9	d 246:5 343:1
corrections 40:9	249:24 251:21	319:22	dahlen 270:19
347:6	302:9 310:19,21	cromwell 3:3 5:22	271:17 273:21,22
correctly 20:16	311:10 318:5,22	6:2,4	274:8
29:2,6 47:15 66:9	319:14 329:22,25	cross 66:5 136:5	damage 180:8
72:6,17 73:13	334:21,23 335:21	137:16,24 156:24	damn 211:21
88:18 144:8	339:22	254:10 257:8,12	323:25
151:10 178:15,20	court 1:1 2:7 5:10	257:17 258:8	
200:2 229:25	7:21 8:14 90:25	259:7,16 321:2,3	dangerous 110:3 269:17
246:2 331:10	137:13,18	337:22 338:23	
counsel 3:2 4:2,9	courtroom 70:24	343:4	dangers 163:17
5:6,13 7:10 11:4	120:18	crucial 158:15	225:9
12:10 342:17,20	courts 137:21	cryingly 231:17	data 28:17 130:14
345:14	cover 153:13	crystal 233:20	130:15 131:9
counseled 52:19	182:5 183:11	crystallization	141:13 183:21
counselor 37:5,15	190:20	43:25 51:11	194:12 195:10
count 32:18,23	coverage 181:23	107:15	268:14 281:4
97:5	183:13	cs 345:15	308:5,7,19,25
counted 13:3	coverages 207:18	cstrangio 3:19	310:6
countless 100:19	covered 152:11	cultural 50:5,22	date 64:12 70:10
countries 110:16	cox 182:18	293:17 328:21	86:13 181:12
129:18 133:22	create 130:3 174:6	culture 232:14	190:8 234:15
140:25 186:20	296:12	285:7 326:5	239:6,16,20
218:23	creating 296:8,9	cultures 249:6	272:10 342:13
country 130:2	credential 41:12	curable 100:24	346:24 347:12
134:6 136:21,21	credentialed 30:8	cure 107:25	dated 64:10
136:22 220:9	credentials 338:7	211:16	181:11 234:13
counts 216:14	credible 235:23	current 81:8 163:4	239:4 272:8 343:9
couple 63:9 66:11	238:2	163:5	343:23 344:6,9,12
126:5 151:6	crime 314:3	currently 22:18	daubert 207:25
213:24 268:18	crisis 127:3 302:11	164:2,7 172:17	daughter 319:12
323:25	criteria 38:22 39:5	211:6 223:19	day 9:3 55:6
courage 301:5	39:7,9 41:25 42:7	225:23 286:25	141:19 223:25
course 9:2 20:19	42:9,12 44:18	custody 325:25	265:4 293:20
21:24 27:22 28:11	45:5 102:9 104:8	cusiouy 323.23	347:15
21.24 27.22 28:11	45.5 102.9 104.8		
	1	I	I

[days - desist] Page 15

dovg 12.10.21.24	169:10 174:20	define 52:6 102:24	70.10 22 25
days 13:19,21,24 14:3 21:6 61:24	205:20 206:5	140:18 155:11	70:19,23,25 178:10 190:15
76:24 110:15	203.20 200.3		287:11 341:4
143:25 196:13	221:7 227:3,8,11	defining 337:10	343:12
	, ,	definitely 286:14	
238:12 291:23,24	227:12 228:5,8	definition 245:23	depositions 16:17
303:2 321:6	230:10 265:4	degree 49:21	68:20
345:17	277:15,16 323:3,6	114:9 178:5 273:2	depressed 117:19
deal 83:19 107:23	decisionmaker	339:18	120:9 121:10
108:9 130:11,12	288:14	delay 84:10	123:11,15 124:8
130:12 163:25	decisionmaking	delayed 288:7	312:22,23,24,25
168:11 170:13	197:5 340:11	delete 186:3	313:2
185:4 264:16,18	decisions 29:19,24	deliberation	depression 42:25
264:20 265:2	30:4,10 43:10	205:18	77:25 101:21
266:13 276:6	78:24 137:23	demands 331:7	121:15 123:20
339:20	195:9 222:4,10	demonstrate	211:17 222:21
dealing 22:6 26:21	declaration 64:9	194:13 244:22	290:19 310:18
27:19 96:21	65:11 234:12	demonstrated	312:12 317:4
113:17 226:12	235:2 239:3,12	141:8 216:3	deprive 192:15
dear 323:12	343:8 344:5,8	demoralization	describe 89:11
death 216:17	declarations	127:4	154:12 240:23
225:14	176:17	deny 317:3	263:10 292:5
decades 65:25	declare 347:4	department 40:9	299:24
96:21 155:5	declared 257:13	190:6,16 344:3	described 13:18
deceased 59:8	257:15 301:11	depend 109:15	25:3 73:24 84:6
december 137:14	316:5	328:22 338:10	151:15 159:11
190:5,21 239:5,14	decline 327:7,13	dependent 101:23	227:23 240:17
344:2,10	declined 46:13	166:17	249:5 263:15
decide 108:11	47:17	depending 48:18	268:4 282:22
137:21 160:8,18	decrease 298:7	depends 106:23	describing 85:8
182:5 196:4	decreasing 167:23	118:17 250:17	202:7
218:17,19 260:21	deem 323:7	263:19	description 89:4
277:23 278:24	deemed 324:18	deponent 71:17	151:19 320:18
336:5 338:19,22	329:6 347:6	183:7 191:17	descriptions
decided 94:20	deeper 308:7	345:13 347:3	320:20
108:4 339:24	defend 219:16,24	deposed 7:17	designate 34:13,15
decides 260:17	327:4	190:18	36:23
decision 66:20	defendants 1:13	deposing 345:13	designating 39:13
68:11,18 83:13	4:9 6:16	deposition 1:18	designed 229:9
103:6,7,17 150:21	deficiencies	2:3 5:5 7:12 9:16	desire 55:6 286:3
157:19 158:9,17	277:21 280:21	9:20 11:4 12:7	desist 111:18,21
158:18,19 159:12		14:20 37:4 70:7	112:3,8 115:23
·			

[desist - disaster] Page 16

163:21 238:14,14	detransitioned	44:25 45:6 62:2	differently 25:16
253:11,12 254:4	141:21 142:15,19	77:24 81:24 156:4	47:23 56:24 106:6
255:10 256:3	143:7,13 259:2	296:9 313:5	145:10 156:8
258:19	268:25 269:5	315:14 316:12,15	196:12 208:7
desistance 252:8	detransitioners	316:17,22,25	227:2 247:12
252:10,13,14,15	269:20,24	318:25 319:23	254:15 255:22
252:15 254:6,25	detransitioning	320:5,11	269:22 279:17
260:12 261:2,5	131:8 141:12	diagnostic 26:7	282:13 292:6
262:11 267:23	142:10 144:2	38:22 42:9,12	300:16 304:9
desisted 112:21	167:22 268:11	45:5 66:8 317:13	difficult 38:25
113:2 114:15	269:4 295:16	317:14	78:9 103:7 158:17
142:3 253:3	develop 94:25	dialogue 232:13	236:21 260:24
258:11 259:25	108:16 287:12	232:14	288:10
260:10	developed 95:15	died 74:15,17,19	difficulties 43:22
despair 127:3	254:9 275:10	75:10,15 225:2	93:25 262:2
despite 95:25	284:16 288:22	difference 67:5,7	digital 266:20
detail 101:17	developing 95:6	282:25 297:19	digs 308:6
246:24	development 36:6	different 18:19	dimension 127:11
details 136:17	117:12 189:21	21:21 51:22,23	dimensional
328:8 331:23	developmental	53:7 56:11 66:24	125:20
detect 312:11	43:4 51:9 52:12	66:25 67:10 68:23	dimensions 51:23
deteriorating	107:18 264:21	70:11,14 80:9	51:24 52:4 173:16
119:17	267:25	82:5 96:16,17,24	diminished 137:25
determinants	devil 331:23	97:13 108:13,16	direct 6:24 343:3
293:14	devoted 268:13	113:25 123:2	direction 335:16
determination	devries 295:13	135:7 136:24	directly 20:11
175:12 212:16	diagnose 41:3 51:5	137:2 149:12	37:11 47:4
determine 69:9	51:8 322:17	160:12,19,21	disagree 278:19
85:22 201:4	diagnosed 38:13	163:12 165:12	278:20,21 307:6
determined 85:6	38:24 40:24	176:2 185:19,20	307:13 335:4
204:6,7 298:4	252:25 317:19	192:14 230:16,17	disagreed 306:10
determining	318:4	240:9 241:18	disagreement
133:22	diagnoses 28:20	247:5 249:6,6	264:5 333:14
detransition 131:5	28:23 41:13	251:10 252:2	334:20
141:6,14,17,19,25	296:13 317:8,11	271:15 273:24	disagreements
142:6,25 143:10	diagnosing 38:17	274:12 277:23	336:12,13,14
143:16 166:10,12	311:7 313:11	282:21 283:2	disallow 137:7
166:15 169:11	318:20	290:17 293:19	disappear 168:3
238:15 259:13	diagnosis 28:22	309:9 317:8,12	195:16
268:20 269:8,10	41:15,15,20 42:19	318:16 324:3	disaster 339:6
	43:17,24 44:5,6,16	328:25 340:13	

[discipline - dr] Page 17

dissiplins 220.2	diamagand 107.7	313:4 319:13	152.4 5 150.24
discipline 332:2 discomfort 221:21	disregard 197:7	321:13	152:4,5 158:24 160:24 169:2,4
	dissenting 300:9		·
222:2 discontinue	300:12,19 301:9 distinctions	doctor's 148:20	170:14,16,19 180:6 193:25
		204:2,3 225:24	
164:16 262:5	260:25 297:23	226:16 318:7	195:6 197:4
discontinued	309:15	doctors 85:18	201:19 206:13
162:24	distinguish 276:8	88:19 119:22	207:8 225:25
discovered 57:16	320:21	120:10,20,23	228:12 248:8
57:18 59:10	distress 119:4	137:20 144:10,25	275:19 277:12
discriminate	170:2	147:7,18 149:15	284:17 289:3
36:16	distressed 316:11	151:13,23 152:3	317:24 338:15
discuss 19:7,7 25:9	district 1:1,2 5:10	154:25 157:2,3	dominate 270:22
29:9 30:6 34:16	5:11	158:22 159:9	dorm 75:11
101:16 102:7	distrust 110:9	162:22 163:22	dose 168:5 249:6
115:20 128:17	disturbed 78:15	164:21 168:13	335:3
176:5	diverse 334:4	169:18 173:13,18	doses 236:25
discussed 38:5	diversity 23:8 24:9	173:22 174:7,15	double 246:18
98:18 161:20	25:19 293:17	174:20,25 175:3,6	249:3
210:18,24 240:8	divided 77:4	179:18 184:25	doubt 164:23
337:24	divides 230:20	185:25 200:13	downloaded
discusses 181:3	division 1:3 4:11	201:14 203:12	148:11
discussing 132:14	divorce 110:9	205:2,17 206:17	dozen 24:6
discussion 11:24	doctor 36:8,10	217:18,19 218:17	dr 5:6 7:2,4 10:11
27:2 39:14 93:19	38:16 41:17 58:13	229:17 232:19	10:12,19,24 34:18
94:14 223:13	58:16,17 59:3	233:6 241:17	39:15,18 65:5
299:18	86:20 100:21	321:22,25 322:3	70:16 120:14
discussions 94:15	109:17 126:15	328:15 329:4	127:22 129:6
327:20	127:20 152:23	330:4,10,18,23	132:17,18 161:13
disease 215:15	153:4,8 158:6	331:13 332:3,19	181:15 182:17
216:18	159:20,22,23,25	333:14 334:3	187:16 223:17
diseases 312:8	160:4,20 162:17	336:18	234:13 268:22
disinclined 86:3	162:18 165:2	document 65:9	280:21 281:5,9
disorder 253:2	169:15 186:5	71:18 86:20 183:8	291:20 295:10,11
268:5 301:22	187:11 188:19	190:10,12 191:18	299:16,16,17
310:22,24,25	203:20 204:4	234:24 239:19	300:3 305:5,5,8,12
disorders 204:16	205:6,8,22 206:14	272:18	305:14 306:4
disqualified 291:3	206:15,24 207:2	doing 19:21 43:13	307:2,17 308:13
291:5	214:4,23 215:25	63:14,15 64:18	314:25 328:3
disqualifies	216:6 218:20	93:25 97:21	329:21 337:23
275:18	221:11 241:14	103:11 127:14	340:22 344:6
	309:22 312:5	140:15 145:15	

emphasize 90:13	entering 188:4	ethical 26:8 78:21	214:10 235:23
265:11	261:20	94:18 103:5,21	236:10 238:3
emphasizing	entire 21:16 28:6	104:3 147:4	240:9,12,13,17,22
154:17	entirely 108:19	150:24 151:11	241:23,25 242:4
employee 342:16	123:2 297:4	154:20 181:2	242:10,11,14,19
342:19	entries 268:12	ethically 79:6	243:6,14 247:22
enable 235:25	epidemiological	85:13 147:2	254:24 255:7,23
238:4	295:5	198:23,24	258:15,20 270:21
enabled 114:11	epiphenomena	ethics 104:5,8	279:11 284:4,5
encourage 26:12	107:13	154:15 180:11	295:4 296:23
encouraged 130:2	epiphenomenon	231:8 329:7	311:11,12
encouraging	264:25	eugenics 302:8	evolve 196:7
184:11	equally 129:12	european 133:21	evolved 320:24
endocrine 167:9	249:14	232:15	evolving 155:4
184:9,16,22	errant 330:17	evaluate 66:18	186:16
187:22	errata 345:11,13	119:15,24 121:23	exact 292:6
endocrinologist	345:17	146:8 338:11	exactly 23:19 47:9
10:16 63:7 66:18	erratas 345:15	evaluated 18:21	71:24 72:16 73:25
69:11 102:16	error 260:14,16,17	evaluating 88:17	89:19 114:14
104:6,7 164:25	errors 279:23	134:16 202:25	183:17 195:23
206:21,23 339:9	especially 114:20	230:7	255:20 273:9
339:12,19	117:17 131:2	evaluation 17:22	278:2 288:12
endocrinologists	157:2 189:5 241:2	18:8,19,23 31:25	289:23 301:23
103:20	esq 3:6,8,10,16,18	32:5,7,9,19 33:12	307:5
endpoint 230:5	3:24 4:6,15,17	42:16 59:17 77:22	exam 266:20
endpoints 230:6,8	345:1	97:16 98:17	examination 6:24
230:11,12	established 55:19	113:12 151:14	337:22 342:5
endured 185:10	168:18 192:13	227:22 330:24	343:3,4
energy 287:19	194:15 205:4	evaluations 21:9	examined 285:5
engage 146:9	298:11	145:17 277:10,11	example 101:19
151:14,15	estimate 14:20	277:11	116:14 118:7
engaged 95:20	33:5 53:25	evaluator 106:23	121:6 131:25
96:4 325:15	estimated 129:7	330:10	152:7,16 168:8
england 93:20	estrogen 57:17	eventually 22:15	186:22,23 187:24
134:14	102:10 168:10	45:25 48:11 75:2	195:16 218:9
enormous 87:19	186:11 225:5	169:10	225:9,17 244:10
117:18 308:14,14	et 1:7,12 5:8,9	everybody 297:14	252:4 276:17
entails 229:21	260:5 261:13	evidence 91:19	295:13 298:3,22
enter 230:14	262:7 270:19	120:5 161:16	313:25 319:7
338:14	271:17 345:4,4	176:6 179:8	320:19,24 334:24
	346:1,1 347:1,1	180:18 200:17	

	120 - 00 170 11		
examples 100:19	130:7,8,9 158:11	experts 9:25 241:9	276:4 302:19
112:4 274:15	180:3 183:19	241:17 306:19,25	factors 84:2 204:8
exceeding 131:23	206:18 221:19	307:9,10,17	facts 88:19 160:5,9
exceeds 218:24	227:20 238:20	334:13	160:9 186:15
excellent 91:8	242:6 251:5	explain 328:6	200:14 201:17
107:7	258:18 275:2	explained 140:3	203:20 297:16,16
exception 222:19	289:7 297:25	281:24 327:24	factually 240:14
232:2,25 234:3	321:16 332:25	explaining 325:9	factualness 280:9
exceptions 321:24	340:16,17	explicitly 10:5	fade 108:15
excerpt 70:6	experienced 25:25	exploratory 81:12	failed 282:22
343:11	26:9 27:4 35:7	exploring 284:14	failing 201:6
excerpts 71:7	61:5,9,19 67:22	exposito 268:22	fails 345:19
exchange 182:17	279:6 338:10	exposure 50:22	fair 14:21 44:14
excursions 52:3	experiences 148:3	express 176:9	97:8 106:5,7
excuse 294:9	148:4 157:6 188:2	177:7 301:9	123:4,7 127:12
exhibit 64:8,9,15	188:3	expressed 55:5	144:12,13 151:19
64:20 65:6 69:25	experiencing	200:8 303:8	154:9 155:14
70:6,12,14,15 86:7	113:20 258:16	expressing 115:11	263:13 310:14
86:8,15 109:20	experiment	125:7	331:25 334:11
149:20 181:7,7,8	123:24 135:5,6	expression 115:17	faith 290:3
190:2,3,9 234:12	experimental	125:12	fall 175:24 243:4
234:17,20,23	250:22,24	expressions	fallen 110:5
239:2,3,9,11	experimenting	115:24 116:2,15	falling 188:2
265:21 267:14,18	194:20	extended 241:4	familiar 152:24
267:19 268:4	expert 9:23 10:9	extensive 66:7	240:6 263:2
270:6 272:6,7,17	65:3 92:3 149:3	extent 41:16 62:21	266:19 304:21
283:12,13 343:8	161:15 167:10	90:8	323:2
343:11,15,20,25	176:17,24 177:20	extremely 288:6	familiarity 296:21
344:5,8,11	178:3 208:2 209:6	301:24 303:12	families 20:10
existed 318:9	209:15,16 241:14	eyes 313:20	63:6,6 128:18
existing 242:19	241:15,18,20	f	132:5 150:13
exists 82:8 180:24	256:9 263:10	f 342:1	152:15 173:7
241:10 297:22	273:24 303:20	face 199:12,14	185:6 203:3
expand 31:9	304:3,25 305:5,21	203:18 312:23	233:12 323:3
expect 125:14	307:3 310:3,5	faces 225:9	338:12
expensive 231:19	323:19 324:15	facilitating 188:22	family 32:7,13,25
experience 25:24	326:13 327:3,17	fact 62:8 108:7	33:2,5 43:11
50:3,4,4 52:8,9,9	332:23 333:7	130:22 132:5	62:17 83:7 104:17
52:10 77:4 84:13	expertise 76:16	150.22 152.5	108:9 109:16
90:21 92:12 113:6	177:22	170:17 206:6	147:3 150:20
120:11,16 126:11		249:16 250:20	152:8,16,23 153:9
		Z47.10 ZJU.ZU	

[family - follow] Page 21

153:13,17 156:20 290:20 figure 160:19 167:25 feels 26:3 314:13 321		1:8 192:6
160:19 167:25 feels 26:3 314:13 321		
		2:19 215:10
		3:15 235:22
,		3:4 260:5
·	′	2:20 276:19
		9:3 294:24
	'	4:12 313:4,4
320:4 338:19 195:19,20 236:3,4 finan	cially 342:21 33'	7:11 340:19
339:21,25 340:10 238:7,8 268:7 find	9:7 53:24 fish	318:17
far 15:16 50:8 295:8 74:2	25 79:6 100:18 fit 1	199:7 240:20
81:6 120:22 feminine 115:17 165	:10 166:6,9,12 five	13:21,24 14:3
132:21 137:7	:21 168:14 20:	8,13 21:20
163:19 229:16 123:25 256:16,22 170	:3 174:4 175:4 31:	10,15 33:6,11
237:19 254:8 257:2 175	:5 212:24 33:	21 48:16 65:25
308:7 femininity 49:22 223	:20 75:	25 78:5 79:19
fashion 94:4 feminization finding	ng 81:18	4:5 118:11,14
232:18 118:25 166	:7 200	5:8,12,19 218:4
fatigued 202:19 feminized 121:6 finds	236:21 233	3:14,15 260:9
favor 196:24 fentanyl 74:21 fine	34:3 37:2	1:10,19 275:8
197:2,3,23 199:6 225:2 160	:25 221:25 280	0:24 291:11
199:20 207:20 fertile 314:20 222	:25 246:18 fix	278:4
208:12 219:6 fertility 152:9,20 247	:9 fixed	74:15 298:5
228:23 229:8 158:12 finish	8:2,6 191:21 flori	da 190:6,16
231:9 234:3 fetishism 320:25 243	:2 344	4:3
favorable 339:8 fiancé 95:22 96:6 finish	ed 12:24 fluct	uate 115:23
fda 248:22 251:18 96:6 235	:19 focu s	s 30:16 270:24
fears 36:20 field 34:22 58:2 finlar	d 119:6 29°	7:10
features 116:16 67:23 79:5 88:19 129	:15 134:9,10 focu s	sed 157:3
february 64:11 96:16 118:3 134	:20,24 135:18 20	1:14
65:14 129:17 120:16 126:14 135	:22 136:9 focu s	ses 25:25 27:5
138:16 343:10	:12 focu s	sing 16:13
feel 26:10 39:7 236:20 245:8 finma		12 120:13
45:15,25 48:7 250:16 265:24 first	6:22 7:24 26:	5:15
	37:17 51:16 folks	24:18 105:4
	2 59:10 64:8 200	5:2
		w 16:17 71:24
	6 85:22 89:10 72:	16 83:24
		2:22 126:8
	· · · · · · · · · · · · · · · · · · ·	9:15 150:9
		4:11 202:13
		4:15 296:17

[follow - gender] Page 22

340:3.4 187:7 199:9 200:6 four 13:6,19 17:21 170:20 20:19 following 262:2 207:14 208:11 18:13 19:12,20 38:2 59:22 88:22 found 231:18 follows 6:23 217:15 219:18,21 110:11 114:6 funny 72:10 further 23:22 followup 18:9,12 220:12 222:7,13 174:11 202:2 336:8 342:9,15 further 23:22 18:18 99:25 100:9 223:22 226:4 229:11 233:15 future 49:20 82:21 18:18 99:25 100:9 223:22 226:4 229:11 233:15 future 49:20 82:21 18:18 99:25 100:9 223:22 226:4 229:11 233:15 future 49:20 82:21 18:18 99:25 100:9 228:14 232:4 300:7,8,17 309:2 717:11 187:23 260:26 26:4:9 279:13 283:23 288:21 framework 181:2 236:13 260:26 26:4:9 307:19 311:20,20 315:15 317:21 fraw 20:20 free 83:11 203:17 fores 241:5 329:10,20 331:18 forms 93:25 free 81:1 freezer 152:20 form 42:14 44:19 47:19 50:17 53:3 forms 93:25 friendship 52:11 friendship 52:11 130:13 ged 14:12 ge 15:10,19			T	
following 262:2 207:14 208:11 38:2 59:22 88:22 fund 231:18 fundy 72:10 follows 62:3 217:15 219:18,21 122:7 168:2 fund 231:18 fund 232:22 336:23 fund 232:22 336:23 fund 232:23 336:23 fund 231:18 fund 231:18 fund 231:18 fund 232:13 fund 232:13 fund 232:13 fund 232:13 fund 232:13 fund 232:14 gain 233:13 gain<	340:3,4	187:7 199:9 200:6	four 13:6,19 17:21	170:20 201:9
272:21 277:16			· · · · · · · · · · · · · · · · · · ·	
follows 6:23 followup 223 (17:15 219:18,21) 122:7 168:2 174:11 202:2 236:12 222:7,13 further 23:22 336:8 342:9,15 18:18 99:25 100:9 126:15,17 206:2 226:24 231:11 223:22 226:4 228:14 232:4 236:13 23:25 229:11 233:15 280:24 293:20 further 23:22 336:8 342:9,15 260:3.9 261:19 260:3.9 261:19 260:60 264:9 279:13 283:23 287:22 300:11,22 301:20 306:11 288:21 5 (20:20 306:11 fourth 292:13 288:21 88:6 163:3 165:23 171:11 187:23 foothote 270:18 301:20 306:11 307:19 311:20,20 315:15 317:21 7 (abc) 13:18 307:19 311:20,20 129:15 134:20 138:13,16 140:13 fraught fuzzy 11:16 foregot 261:15 60rest 329:10,20 331:18 329:10,20 331:18 fray 209:20 free 83:11 203:17 freezer 223:14 232:4 238:12 103:17 forgot 40:15 3:13 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 50:17 53:3 338:20 6rest 6ridship 52:11 front 9:12 159:10 235:11,15 239:16 312:18 full 108:17 116:20 gears 283:14 20:13 303:14 20:13 210:6 215:14 216:13 226:13 42:14 216:13 226:12 42:18 223:13 42:19 42:19 223:10 22:19 223:10 223:10 223:10 223:10 223:10 223:11 223:11 223:11 223:11<	_			
Trail Trai				_
18:18 99:25 100:9 223:22 226:4 229:11 233:15 280:24 293:20 226:14 231:11 234:5 247:16 300:7.8,17 309:2 171:11 187:23 260:3,9 261:19 264:17 271:15 framework 181:2 288:21 framework 181:2 288:11 29:15 134:20 138:13,16 140:13 framework 181:2 288:11 29:15 134:20 138:13,16 140:13 framework 181:2 288:11 29:15 134:20 138:13,16 140:13 framework 181:2 288:21 framework 181:2 288	follows 6:23	·	122:7 168:2	
126:15,17 206:2 228:14 232:4 230:24 293:20 300:7,8,17 309:2 171:11 187:23 260:3,9 261:19 264:17 271:15 262:6 264:9 279:13 283:23 288:21 236:13 260:3,9 261:19 267:6 264:9 279:13 283:23 288:21 236:13 236:13 249:20 300:11,22 249:10 20 306:11 307:19 311:20,20 307:19 311:20,20 337:5 347:5 324:20 327:8 319:3 320:7 347:5 324:20 327:8 329:10,20 331:18 6orgot 40:5,13,18 56:5 59:18 223:10 6ormal 38:18 6orgot 40:5,13,18 56:5 59:18 223:10 6orm 42:14 44:19 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 101:13 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 136:15 138:10,22 136:15 138:10,22 136:15 138:10,22 136:15 138:10,22 136:15 138:10,22 136:15 138:10,22 136:15 136:15 136:15 136:10,22 136:15 136:15	followup 18:9,12	220:12 222:7,13	174:11 202:2	336:8 342:9,15
226:24 231:11 253:23 259:22 260:3,9 261:19 262:6 264:9 foolishness 317:14 foreigoing 342:10 347:5 foregoing 342:10 347:5 foregoing 342:10 347:5 forejoing 183:16 forget 261:15 forget 261:15 form 42:14 44:19 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 101:3 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 139:14 145:20 136:15 138:10,22 139:14 145:20 130:23 36:13 130:33 32:7 324:20 327:8 formal 38:18 formal 38:18 formal 38:18 former 68:15 form 42:14 44:19 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 101:3 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 139:14 145:20 146:12 151:21 157:22 159:16 162:9 164:17 166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3	18:18 99:25 100:9	223:22 226:4	229:11 233:15	future 49:20 82:21
253:23 259:22	126:15,17 206:2	228:14 232:4	280:24 293:20	88:6 163:3 165:23
260:3,9 261:19	226:24 231:11	234:5 247:16	300:7,8,17 309:2	171:11 187:23
262:6 264:9 279:13 283:23 288:21 fuzzy 11:16 foolishness 317:14 287:22 300:11,22 fance 119:6 129:15 134:20 g force 153:19 307:19 311:20,20 315:15 317:21 315:15 317:21 fraught 78:9 85:14 g foregoing 342:10 347:5 324:20 327:8 fraught 78:9 85:14 85:16 103:7 202:2 gary 3:24 gain 215:14 216:13 forget 261:15 forget 261:15 formal 38:18 formal 38:18 free 83:11 203:17 free 83:11 203:17 gauge 90:2,4 gather 314:7 gauge 90:2,4 gather 314:7 gauge 90:2,4 gary 3:24 gather 314:7 gauge 90:2,4 gather 314:7 gauge 90:2,4 gather 314:7 gary 51:18,18 108:17 116:20 gears 283:7 gauge 90:2,4 gary 51:18,18 gary 51:18,18 gary 51:18,18 gary 3:24 gather 314:7 gauge 90:2,4 gary 51:18,18 gary 51:18,1	253:23 259:22	249:10 264:12,13	fourth 292:13	210:6 215:14
foolishness 317:14 287:22 300:11,22 france 119:6 g footnote 270:18 301:20 306:11 307:19 311:20,20 129:15 134:20 g 243:18 303:19,23 303:24 g foregoing 342:10 315:15 317:21 315:15 317:21 fraught 78:9 85:14 g 24:18 303:19,23 303:24 gain 215:14 216:13 gary 3:24 gain 215:14 216:13 gary 3:24 gather 314:7 gain 215:14 216:13 gary 3:24 gather 314:7 gain 215:14 216:13 gary 3:24 gather 314:7 gary 3:24 gather 314:7 gather 314:7 gary 3:24 gather 314:7 gary 3:25:14 gary<	260:3,9 261:19	264:17 271:15	framework 181:2	236:13
footnote 270:18 301:20 306:11 129:15 134:20 g 243:18 303:19,23 g 243:18 303:19,23 g 243:18 303:19,23 303:24 g 243:18 303:19,23 303:24 g 243:18 303:19,23 303:24 g 243:18 303:19,23 303:24 g a 215:14 216:13 g 303:24 g a 215:14 216:13 g 303:24 g g 243:18 303:19,23 303:24 g a g e e e e e e e e e e e e e e e e e	262:6 264:9	279:13 283:23	288:21	fuzzy 11:16
footnote 270:18 force 301:20 306:11 307:19 311:20,20 307:19 311:20,20 307:19 311:20,20 315:15 317:21 319:3 320:7 347:5 324:20 327:8 forensic 315:15 317:21 319:3 320:7 324:20 327:8 forensic 315:15 317:21 319:3 320:7 324:20 327:8 forensic faught 78:9 85:14 85:16 103:7 202:2 fray 209:20 free 83:11 203:17 gary 3:24 gain 215:14 216:13 gary 3:24 g	foolishness 317:14	287:22 300:11,22	france 119:6	g
force 153:19 forces 241:5 foregoing 342:10 347:5 forensic 314:2 forgive 183:16 forgot 40:5,13,18 56:5 59:18 223:10 form 42:14 44:19 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 101:13 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 139:14 145:20 146:12 151:21 157:10 179:3 175:15 176:12,18 175:10 179:3 175:10 179:3 175:10 179:3 175:10 179:3 175:15 176:12,18 175:10 179:3 175:10 179:3 175:15 176:12,18 175:10 179:3 175:10 179:3 115:15 317:2 1315:15 317:2 1315:15 317:2 1311:13:17 35:14 35:16,18 37:10,12 37:13 38:4,14,16 38:18,22,24 39:8	footnote 270:18	301:20 306:11	129:15 134:20	
forces 241:5 315:15 317:21 fraught 78:9 85:14 85:16 103:7 202:2 fray 209:20 gain 215:14 216:13 gary 3:24 209:20 free 83:11 203:17 freezer 152:20 freezer 152:	force 153:19	307:19 311:20,20	138:13,16 140:13	
storegoing 342:10 319:3 320:7 85:16 103:7 202:2 216:13 forensic 314:2 324:20 327:8 fray 209:20 free 83:11 203:17 gary 3:24 forgive 183:16 formal 38:18 former fee 83:11 203:17 gauge 90:2,4 gauge 10:2,1 gauge 11:2,1 10:1,1 10:1,1 10:1,1 10:1,1 10:1,1 10:1,1 10:1,1 10:1,1	forces 241:5	315:15 317:21	fraught 78:9 85:14	
34/:5 324:20 327:8 fray 209:20 gary 3:24 gather 314:7 gauge 90:2,4 gather 314:7 gauge 90:2,4 gather 314:7 gauge 90:2,4 gauge 10:8-18 108:17 116:20 gauge 10:8-18 108:17 116:20 gauge 114:12	foregoing 342:10	319:3 320:7	85:16 103:7 202:2	•
forget 261:15 forgive 183:16 forgot 40:5,13,18 56:5 59:18 223:10 form 42:14 44:19 47:19 50:17 53:3 62:11 81:14 83:2 84:7 85:11,25 90:7 100:11 101:13 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 139:14 145:20 146:12 151:21 157:12 159:16 162:9 164:17 166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3	347:5	324:20 327:8	fray 209:20	
forget 261:15 332:5 333:18 formal 38:18 formal 38:18 formal 38:18 formal 38:18 formal 38:18 formal 38:18 formal formal 38:18 former 68:15 forming 36:3 forming 38:10	forensic 314:2	329:10,20 331:18	free 83:11 203:17	
forgive 183:16 formal 38:18 frequently 121:13 gattle 90:2,4 gay 51:18,18 108:17 116:20 gars 290:2,4 gay 51:18,18 108:17 116:20 gars 290:2,4 gay 51:18,18 108:17 116:20 gars 290:2,4 gay 51:18,18 108:17 116:20 116:20 118:21	forget 261:15	332:5 333:18	freezer 152:20	
forgot 40:5,13,18 former 68:15 124:19 friday 324:7,8 former 108:17 116:20 gears 283:7 302:13 303:14 310:13 form 42:14 44:19 forms 93:25 friend's 226:10 friendship 52:11 front 9:16,18 gears 283:7 302:13 303:14 310:13 62:11 81:14 83:2 formulate 288:10 front 9:16,18 239:16 312:18 ged 114:12 gee 157:23 301:4 gender 15:10,19 16:9,14,14,23 17:3 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:11 19:12,16 20:7,11,22 21:5,14 21:19,25 22:7,15 17:10 22:25 23:7,13,17 17:16 214:25 21:19,25 22:7,15 22:25 23:7,13,17 22:25 23:7,13,17 24:2,7,9,20 25:19 27:12,20 28:3,22 29:20 30:14,21 35:16,18 37:10,12 35:16,18 37:10,12 35:16,18		formal 38:18	frequently 121:13	0 0
56:5 59:18 223:10 forming 36:3 friday 324:7,8 finday 324:7,8 gears 283:7 form 42:14 44:19 forms 93:25 friend's 226:10 friendship 52:11	_	former 68:15		
form 42:14 44:19 forms 93:25 friend's 226:10 302:13 303:14 302:13 303:14 47:19 50:17 53:3 62:11 81:14 83:2 338:20 friendship 52:11 form 9:16,18 ged 114:12 ged 114:12 ged 114:12 ged 114:12 ged 157:23 301:4 gender 15:10,19 16:9,14,14,23 17:3 17:11 19:12,16 gender 15:10,19 16:9,14,14,23 17:3 17:11 19:12,16 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 21:19,25 22:7,15 22:25 23:7,13,17 157:16 214:25 215:23 150:25 151:17 157:16 214:25 215:23 150:25 151:17 22:25 23:7,13,17 24:2,7,9,20 25:19 27:12,20 28:3,22 29:20 30:14,21 33:11 33:17 35:14 33:11 33:17 35:14 310:13 30:14 30:13 30:14 30:13 30:14 30:13 30:14 30:13 30:14 30:13 30:14 310:13 30:14 30:13 30:14 30:13 30:14 310:13 30:14 310:13 30:14 20:7,12,22 20:7,11,22 21:5,14	56:5 59:18 223:10	forming 36:3	friday 324:7,8	
47:19 50:17 53:3 175:20 293:17 62:11 81:14 83:2 338:20 84:7 85:11,25 formulate 288:10 90:7 100:11 forth 43:5 78:2 101:13 105:24 80:10 121:16 121:25 126:12 249:7 261:2 133:8 135:20 303:13 342:14 139:14 145:20 forward 81:8 146:12 151:21 157:22 159:16 162:9 164:17 166:13 167:5 169:23 172:7,19 274:7 280:5 175:10 179:3 308:25 336:5 foundation 306:3 functioning 118:9 123:4 124:4 310:13 ged 114:12 gec 157:23 301:4 gender 15:10,19 16:9,14,14,23 17:3 17:11 19:12,16 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 21:19,25 22:7,15 22:25 23:7,13,17 24:2,7,9,20 25:19 27:12,20 28:3,22 29:20 30:14,21 31:11 33:17 35:14 35:16,18 37:10,12 37:13 38:4,14,16 38:18,22,24 39:8	form 42:14 44:19	forms 93:25	friend's 226:10	0
62:11 81:14 83:2 338:20 formulate 288:10 ged 114:12 90:7 100:11 forth 43:5 78:2 80:10 121:16 239:16 312:18 ged 157:23 301:4 101:13 105:24 80:10 121:16 249:7 261:2 91:12 159:10 235:11,15 16:9,14,14,23 17:3 128:24 131:19 303:13 342:14 forward 81:8 172:15 317:2 found 65:20 75:2 140:3 146:8 150:25 151:17 20:7,11,22 21:5,14 139:14 145:20 130:14 170:22 130:14 170:22 215:23 157:16 214:25 24:27,9,20 25:19 166:13 167:5 252:24 270:16 332:23 function 179:11 332:23 31:11 33:17 35:14 169:23 172:7,19 308:25 336:5 functioning 118:9 37:13 38:4,14,16 177:10 179:3 foundation 306:3 122:4 124:4 38:18,22,24 39:8	47:19 50:17 53:3	175:20 293:17	friendship 52:11	
84:7 85:11,25 formulate 288:10 239:16 312:18 gee 157:23 301:4 90:7 100:11 forth 43:5 78:2 80:10 121:16 91:12 159:10 235:11,15 121:25 126:12 249:7 261:2 303:13 342:14 235:11,15 16:9,14,14,23 17:3 133:8 135:20 forward 81:8 172:15 317:2 140:3 146:8 150:25 151:17 20:7,11,22 21:5,14 139:14 145:20 found 65:20 75:2 157:16 214:25 22:25 23:7,13,17 24:2,7,9,20 25:19 157:22 159:16 224:18 235:8 function 179:11 332:23 27:12,20 28:3,22 166:13 167:5 274:7 280:5 308:25 336:5 functional 120:3 35:16,18 37:10,12 175:15 176:12,18 foundation 306:3 122:4 124:4 38:18,22,24 39:8	62:11 81:14 83:2	338:20	front 9:16,18	
90:7 100:11 forth 43:5 78:2 full 7:15 12:25 gender 15:10,19 101:13 105:24 249:7 261:2 303:13 342:14 235:11,15 16:9,14,14,23 17:3 17:11 19:12,16 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 21:19,25 22:7,15 22:25 23:7,13,17 22:25 23:7,13,17 24:2,7,9,20 25:19 27:12,20 28:3,22 27:12,20 28:3,22 29:20 30:14,21 332:23 332:23 308:13 38:4,14,16 35:16,18 37:10,12 37:13 38:4,14,16 37:13 38:4,14,16 38:18,22,24 39:8	84:7 85:11,25	formulate 288:10	239:16 312:18	•
101:13 105:24 121:25 126:12 128:24 131:19 133:8 135:20 136:15 138:10,22 139:14 145:20 146:12 151:21 157:22 159:16 162:9 164:17 166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3 180:10 121:16 249:7 261:2 249:7 261:2 303:13 342:14 140:3 146:8 150:25 151:17 157:16 214:25 215:23 160:9,14,14,23 17:3 17:11 19:12,16 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 20:7,11,22 21:5,14 21:19,25 22:7,15 22:25 23:7,13,17 24:2,7,9,20 25:19 27:12,20 28:3,22 29:20 30:14,21 33:11 33:17 35:14 35:16,18 37:10,12 37:13 38:4,14,16 38:18,22,24 39:8	90:7 100:11	forth 43:5 78:2	full 7:15 12:25	0
121:25 126:12 249:7 261:2 303:13 342:14 17:11 19:12,16 128:24 131:19 303:13 342:14 140:3 146:8 140:3 146:8 150:25 151:17 150:25 151:17 157:16 214:25 157:16 214:25 157:12 20:25 23:7,13,17 157:16 214:25 157:16 214:25 157:12 20:25 23:7,13,17 157:12 20:25 23:7,13,17 157:16 214:25 157:16 214:25 157:12 20:25 23:7,13,17 157:12 20:25 23:7,13 157:12 20:25 23:7,1	101:13 105:24	80:10 121:16	91:12 159:10	_
128:24 131:19 303:13 342:14 fully 88:8 128:17 133:8 135:20 136:15 138:10,22 172:15 317:2 140:3 146:8 20:7,11,22 21:5,14 139:14 145:20 172:15 317:2 150:25 151:17 22:25 23:7,13,17 146:12 151:21 130:14 170:22 215:23 24:2,7,9,20 25:19 157:22 159:16 224:18 235:8 function 179:11 29:20 30:14,21 166:13 167:5 274:7 280:5 functional 120:3 35:16,18 37:10,12 175:15 176:12,18 308:25 336:5 functioning 118:9 38:18,22,24 39:8	121:25 126:12	249:7 261:2	235:11,15	
133:8 135:20 forward 81:8 140:3 146:8 21:19,25 22:7,15 136:15 138:10,22 139:14 145:20 150:25 151:17 22:25 23:7,13,17 146:12 151:21 130:14 170:22 215:23 24:2,7,9,20 25:19 157:22 159:16 224:18 235:8 224:18 235:8 224:18 235:8 27:12,20 28:3,22 166:13 167:5 274:7 280:5 308:25 336:5 functional 120:3 35:16,18 37:10,12 175:15 176:12,18 foundation 306:3 120:4 124:4 38:18,22,24 39:8	128:24 131:19	303:13 342:14	1	·
136:15 138:10,22 172:15 317:2 150:25 151:17 139:14 145:20 146:12 151:21 130:14 170:22 215:23 157:22 159:16 224:18 235:8 224:18 235:8 224:18 235:8 166:13 167:5 274:7 280:5 308:25 336:5 functional 120:3 175:15 176:12,18 308:25 336:5 180:16 37:13 38:4,14,16 177:10 179:3 122:4 124:4 38:18,22,24 39:8	133:8 135:20		_	· · · · · · · · · · · · · · · · · · ·
139:14 145:20 found 65:20 75:2 157:16 214:25 22:25 23:7,13,17 146:12 151:21 130:14 170:22 215:23 24:2,7,9,20 25:19 157:22 159:16 224:18 235:8 function 179:11 29:20 30:14,21 166:13 167:5 274:7 280:5 functional 120:3 31:11 33:17 35:14 169:23 172:7,19 308:25 336:5 functioning 118:9 37:13 38:4,14,16 177:10 179:3 122:4 124:4 38:18,22,24 39:8	136:15 138:10,22	172:15 317:2	150:25 151:17	
146:12 151:21 130:14 170:22 215:23 157:22 159:16 224:18 235:8 function 179:11 162:9 164:17 252:24 270:16 332:23 166:13 167:5 274:7 280:5 functional 120:3 169:23 172:7,19 308:25 336:5 180:16 177:10 179:3 foundation 306:3 functioning 118:9 122:4 124:4 38:18,22,24 39:8	*	found 65:20 75:2		· · ·
157:22 159:16 162:9 164:17 166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3 224:18 235:8 252:24 270:16 274:7 280:5 308:25 336:5 foundation 306:3 180:16 120:3 120:3 120:				, , ,
162:9 164:17 166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3 252:24 270:16 274:7 280:5 308:25 336:5 functional 120:3 180:16 functioning 118:9 122:4 124:4 123:4 124:4 129:20 30:14,21 31:11 33:17 35:14 35:16,18 37:10,12 37:13 38:4,14,16 38:18,22,24 39:8				· · · · · · · · · · · · · · · · · · ·
166:13 167:5 169:23 172:7,19 175:15 176:12,18 177:10 179:3 274:7 280:5 308:25 336:5 foundation 306:3 functional 120:3 180:16 180:16 functioning 118:9 122:4 124:4 31:11 33:17 35:14 35:16,18 37:10,12 37:13 38:4,14,16 38:18,22,24 39:8				· · · · · · · · · · · · · · · · · · ·
169:23 172:7,19 175:15 176:12,18				
175:15 176:12,18 foundation 306:3 functioning 118:9 38:18,22,24 39:8				· · · · · · · · · · · · · · · · · · ·
177.10 170.3	,			· · ·
40:2,8,10,15,25	*			· · ·
				40:2,8,10,15,25

[gender - given] Page 23

			_
41:8,25 42:18,21	181:24 183:12,23	gendered 43:9	121:13 122:9,11
43:12,19 44:4,16	188:8,13,16,17	265:6	126:19 127:20
45:4,10,16,18	193:20,21 197:25	genderreport.ca	132:21 137:9
48:25,25 51:6,25	198:5,9 199:6,25	270:21	141:16 154:21
52:13,24 53:11,22	201:2,15 202:10	general 1:12 4:11	188:23 202:18
54:18 55:17 56:14	202:24 205:11	4:12 23:10 26:4	203:2 210:7
57:2 58:8,21,22	207:13 208:9,23	42:24 43:14 94:2	213:23 224:13
61:11,20 62:2	209:25 211:10	106:2 125:13	261:20 262:8
66:3 67:25 69:16	212:13 216:10	173:21 175:21	265:12,13 333:19
76:7,19 78:13	219:19 220:10,20	192:22 222:3	gill 4:3,7
79:25 80:3,14	220:21 226:23	233:2,4 261:18	girl 213:14 256:25
81:10,16 82:2,8	228:20 229:6	316:17 327:21	257:25
85:24 91:20 92:12	240:19 242:13,21	general's 6:15	girls 139:25
95:10,11 96:9	243:12,20 246:11	165:18 177:12	213:10 236:5
100:23 101:9	246:20 253:2	323:22	238:8 258:9 295:8
103:23 105:15,22	254:2,7,10,17,22	generalization	295:10
106:10,20,21	254:23 255:4,24	249:24	give 12:13,21
107:2,6,25 108:2	256:2,5,18 257:8	generally 15:24	13:15 16:20 20:5
108:14 109:2	257:12,17 258:8	26:11 30:13 39:5	25:13 31:12 45:6
110:23 112:10	258:16 259:7,16	45:21 46:22 63:12	49:2 71:10,25
113:24 114:2,10	263:4,18,22	76:20 98:25	72:3 73:16,21
114:24 125:12,20	264:19,23,24	102:20 126:8	89:24 97:24
128:2,4,6,15,21	265:16,19 268:5,8	157:7 167:18	103:17 115:16,16
131:15 134:21	272:8,19 284:5	180:9 192:8,24	121:17 130:12
135:3,9,19,23	285:11 290:15,18	196:18 197:13	150:5 153:24
136:10 137:4	293:9,13,21,23	221:8,9 227:21	157:25 177:12
138:8,13,19	294:19 301:12	246:4 289:15	186:23 191:5
139:11 140:23	304:11 305:21,22	290:2	203:22 207:15
145:8,13,14	308:18,18 310:3	generals 165:16	208:25 211:25
148:25 151:12	310:10 315:14,19	327:22	217:5,6 233:10
155:16,24 156:7	316:6,10,15,22	generate 131:21	245:6 251:6
156:10 157:20	317:6,18 318:3,7	generation 201:19	265:17 273:18
159:14 161:17	318:11,14,16,21	genetically 236:2	274:14 275:16
162:5,7 163:10,15	318:25 319:23	236:4 238:6,8	289:16 308:22
163:18 165:4	320:5,13,15,20	genital 197:20	329:23 334:24
166:15 167:25	321:4,5 323:7	genitalia 195:19	339:11 340:2
171:7,15,16	325:14 327:6,19	195:20	given 24:5,20
172:18,22,23	329:5 330:6	genitals 46:25	27:18 28:10 48:15
175:14 176:6,10	331:15 332:11	getting 48:10	59:17 79:24 98:12
177:8 178:22	333:17 334:5,9	54:16 87:7 88:5	130:21 156:13
179:6 180:7	344:12	95:4 118:5 121:10	172:24 179:16

[given - guys] Page 24

186:12 200:14	81:8 82:3 90:24	goodman 34:19	229:23 232:22
219:14 221:5	91:16 99:2,10,17	39:18	244:13 245:4,5,12
227:14 244:9	100:5,7 102:13	gotcha 305:20	245:14,22 246:3
261:24 274:8	103:12 105:8	gotten 330:11	253:7 260:7
277:18 304:7	110:6 121:9 127:2	government 135:6	268:15 269:25
347:9	136:22 148:2	214:10 215:3	273:23 283:24
gives 273:22	149:5 150:2 151:3	231:18	288:3 290:21
339:19,21	151:5 152:18	governor 218:11	303:12 332:17
giving 70:22 79:7	161:8 162:21	323:12 326:8,9	338:25
122:10 140:6	163:22 165:19,25	governors 218:18	groups 157:4
163:21 189:4,9	166:14 167:17,19	grant 94:24	230:16 243:25
208:19 252:2	168:3 172:11	grasp 178:5	245:20 268:23
258:2	173:25 175:6,7,8	grasped 202:19	grow 216:12
go 7:19 11:14,19	175:20,22,24,25	grasping 47:20	growing 267:5
19:3 53:24 58:4	176:2,4 180:25	333:21	338:17
60:13 63:6 68:9	181:4 186:3 192:3	great 57:14 58:2	gsullivan 3:25
76:23 80:4 91:11	192:6,7 196:4	102:8 127:2,14	guarantee 195:17
91:13 101:7	216:6 223:4,7	130:11,12,12	280:9
103:14 105:6	225:21 230:11,13	185:3 198:15	guaranteed
114:13 115:10	232:14 233:7,14	200:18 221:11	121:18
129:5 137:6 140:2	247:2 251:12,16	229:12 234:22	guess 17:13 36:14
161:2 170:3	265:20 266:15,16	266:13 308:4	48:23 55:25 58:13
182:13 191:7,14	266:17,18,20	315:25 316:19	59:22 67:12 74:4
192:6 216:14,15	283:6,11 285:22	339:20	100:5 116:5
222:8 223:2,9,18	285:23 287:20,20	green 257:20	184:24 209:21
239:18,24 245:2	289:5,9,24 291:7	green's 257:4	245:4 246:17
251:4 264:6	291:15,18 297:9	grew 257:12,17	guessing 53:16
267:14,19 270:5	297:10 301:7	266:12	guesstimate 33:15
272:11 278:7	305:25 308:23	grieving 83:20	96:12
289:7 302:11	316:13 320:9	gross 249:23	guesstimates
305:16 338:22	337:9,17 339:5,7	grossman 34:20	14:18
340:2	341:5	34:20	guidance 25:13
goal 44:6 322:2	good 5:1 7:4 9:7	ground 7:24	111:14
god 275:23	13:8 16:12 17:7	200:14 314:20	guide 289:2
goes 28:20 164:5,9	33:7 59:21 92:17	groundrules 7:20	guidelines 270:16
169:17 185:4	105:2,4 174:2	group 23:13 25:9	287:13,22,23
272:23	185:2 213:8	27:2 30:7 62:14	288:10,22
going 5:2 12:2	221:12,13 226:14	88:14 93:10	guru 49:25
25:12 29:4 49:18	237:19 276:3	117:23 134:16	guys 220:6
51:5 60:15,18	290:4 291:12	152:17 168:20	
65:23 71:20 73:20		173:17,21 225:11	

[h - high] Page 25

h	happy 92:24	125:22 126:3,23	help 17:5 25:11
	117:10,14 118:7	126:25 144:3	99:17 107:23
h 305:8 343:7	118:22,22,23,24	164:22,24 165:3	131:6 146:25
346:3	118:25 121:18	167:11 179:15	160:17 185:16
half 13:21,24	123:8,12 125:7	182:3 193:18	189:15 195:10
93:18 101:25	126:24 133:16	194:2,22 212:19	212:24 219:16
163:7	201:7 207:3 234:7	224:21 287:24	250:2 251:23
hall 260:6	247:4 319:11	289:2 293:14	264:16 279:19
halting 294:18	326:21	306:15,17 310:15	303:21 305:2
hand 155:18	hard 8:15 10:4	315:25 322:16	314:20 327:4
handbook 306:16	68:24 116:3	328:23	335:15
handful 64:6 74:8	199:15 221:15	healthcare 98:6	helped 52:5 123:5
78:4 257:15	237:3 289:13	181:9 333:15	124:15 148:4
293:24	309:11,12 333:20	334:3 343:21	218:15 219:9
handsomeness	harm 100:5	healthy 87:22	260:21 315:2
49:22	169:21 180:10	124:8,9 180:16	
happen 81:23	185:15 189:23	212:11	helpful 18:3,6 53:9 98:2 110:22
83:17 101:6		hear 6:25 15:12	211:15 217:18
159:18 162:21	211:24 218:22,24		
175:9 187:24	251:8 317:4	29:7 31:23 50:7	251:6 314:25
197:8 215:10	harm's 174:7	124:18 127:13	helping 38:10
256:4,11 289:24	harmed 218:11,15	221:24,25 261:4,7	207:2 219:22,25
happened 49:14	219:10 301:7,8	309:14 312:20	238:13 240:18
76:13 79:18 108:9	harmful 99:9,12	313:19 321:18	306:19 336:20
237:17 287:16	harming 43:2 82:3	327:11 333:24	helps 219:3 317:3
288:13 335:17	155:13 233:9	340:15	hereinbefore
happening 26:14	harms 139:23	heard 37:25 96:2	342:14
149:10,11,13	204:21 219:3	97:24 99:22	hereto 347:7
happens 103:15	hated 113:10,13	124:12 142:16	heroin 74:20,22,23
103:16 109:19	haunted 113:13	149:6 172:9	75:9 225:6,7
142:16 184:12	head 13:9 237:21	215:25 298:9	hesitating 16:24
200:22 216:5	303:3	304:5 328:4	28:16
218:14 274:20	heading 272:18	hearing 181:17,19	hesitation 31:23
278:5,11 326:15	health 23:11 39:25	199:15	heterogeneity
340:14	41:6,19 42:24	heart 278:7 336:7	145:24
happier 118:5,8	58:4 91:25 92:4,4	hearts 336:2	heterosexual
122:13,16 123:11	93:10 102:18,23	heavily 120:11	257:16 321:2
123:16 124:3	103:3,10,18 104:9	123:14,25,25	hidden 37:12
happily 127:21	104:12 117:4,17	hedging 67:12	hierarchy 240:11
happiness 123:9	118:10,15,18	held 2:4 11:24	240:15
125:12,14	119:10,16 121:21	223:13 293:20	high 101:20
120.12,1	121:24 124:24		137:13 154:4

189:5,7 194:23	hopefully 276:24	58:11,16,25 59:8	hour 17:21 59:17
212:21 216:16	276:25 296:14	63:13 66:6,20	93:18 95:5 147:23
296:6 335:3	340:3	72:2,4 73:16,22	159:4 316:20
higher 156:2	hoping 155:25	74:8 79:8 80:4,5	hour's 107:8
212:18 244:16	hormonal 84:19	82:9 86:4 87:20	hours 13:4,19 14:4
highlight 182:12	150:10 294:18	98:13 103:17	226:19 229:12
191:20	334:9	118:4,6,6,16,23,24	325:9
highlighted 65:19	hormone 35:24	119:11 120:8	hruz 305:8,12,14
71:13,21 149:23	36:12,14 44:7	121:5,14,17,22	306:4 307:2
150:3,9 191:3	45:2,9,15 53:13	122:3,11,16,23,24	hruz's 307:17
192:4 267:22	57:4 58:9 59:5	122:25 123:5,8,17	https 270:21
270:13	60:2,5 63:2,11,19	123:18 124:3,15	hum 8:15 33:16
highly 81:20	68:22 75:18,24	125:15 127:20	61:17
180:16 209:11	76:21 77:10 78:6	136:5,6 137:25	human 21:19 22:3
hint 74:22	79:17 82:18 83:15	148:2 150:22	109:3 110:2,3,10
hired 177:12,15,24	84:4 85:5 87:11	152:14 156:23,24	114:19 116:6,7,8
178:7	97:9 99:6 101:9	162:18,19,25	308:8 321:24
histories 112:25	101:15,16 102:5	163:5 166:17	hundred 285:20
241:23	105:17 117:3,8	167:24 168:4,6	hundreds 40:17
history 162:11,14	124:10 126:2,10	186:9 189:10	109:6
203:18 210:13	137:5,16 151:12	197:19 201:8,16	husband 38:9
241:2,3,4,22	164:13,16 166:25	206:5,12 216:8,21	hutchison 10:16
242:17 256:15	167:3 168:8	217:6 224:13,22	hyperbolic 326:6
311:21 312:5,6	169:14,19 171:8	226:3,16 227:19	i
320:15 338:12	172:18,24 187:5	243:23 244:3,20	icd 315:24 316:23
hit 64:23	192:9,25 196:19	244:23 251:17	idea 12:21 31:12
hold 196:6 221:22	197:14,23 198:8	258:3 259:23	38:17 90:20 92:18
holds 272:25	199:3,25 212:13	260:8,20 261:10	140:22 145:24
home 75:10 272:4	214:5,24 220:20	261:21 262:5,8	192:16 194:14
273:8 319:10	223:20 224:3	308:23 309:6	198:20 232:13
homosexual 51:17	225:21,24 226:23	320:19 324:24	275:18,22 299:7
256:14,22 257:18	227:4 229:24	338:8,23 339:13	323:17 325:6,12
301:19	242:5 243:11	340:3	339:22
honest 148:19	244:2 246:20	horrified 55:8	ideal 29:14 100:13
hope 147:13,16,20	259:25 261:23	hospital 167:14	158:4
155:11 161:23	300:2 306:2	272:25	ideally 167:7
164:21 167:9	324:18 327:6	hospitalizations	ideas 287:18
174:5 178:4	334:16 338:4	48:17 114:6,7	297:18,24 302:17
179:18 180:14,17	hormones 45:22	hospitals 76:18	303:8 306:15
180:18 195:25	46:20,24 49:3	hosted 2:5	identification
283:4 297:21	53:20 57:12,22		50:25 52:21 64:13

70:10 86:13	264:19,23,24	impressions 314:5	inconsistency
181:13 190:8	268:8,9 291:2	impressively	244:5
234:15 236:2,4	295:7,7 301:12	261:22	inconsistent 316:8
238:5,7 239:7	316:6,10 317:6	imprimatur 67:21	increase 139:24
272:10	ignorant 149:18	improper 249:18	168:10 280:10
identifications	ignored 94:3	improve 83:9	298:7
115:15 116:9	illness 103:23	144:3 155:15,23	increased 140:4
256:17	104:2 200:25	improved 120:7	increases 88:4,4
identified 15:10	201:4 293:15	121:2 124:6	increasing 138:8
86:24 121:14	illuminates 290:5	336:23	139:24 141:7,12
189:11 210:7	illustrate 289:11	improvement	184:13 258:24
254:10 256:14	illustrated 56:5	121:21 123:9	increasingly 268:6
257:8,13,17 258:7	imagine 28:11	169:7	incredible 225:14
258:8 259:7,16	233:3 299:13	improvements	incumbent 150:14
268:12,22	imagined 209:15	126:3	independent 47:10
identify 5:13	immediately 48:5	improves 120:5	129:9,13,16,21
50:15 111:2	79:7,8	179:11	277:10 281:8
112:12,13 114:23	immensely 117:14	improving 119:16	independently
143:2,8	immutable 298:5	imprudence 221:3	130:14 277:15
identities 51:22	impact 137:22	inaccurately	indicates 139:20
201:2 259:9,17	287:9	255:6	indicating 254:25
320:25	implications 85:8	incarceration	255:24
identity 15:19	150:12 153:7	142:21	indication 269:15
16:10,15 21:5	156:22 157:14	incidents 140:4	indications 179:14
23:14 24:7,20	180:5 217:23	inclined 84:9	233:8 248:23
27:20 28:22 38:12	251:22	include 14:10	indicators 88:13
40:8 42:18,21,22	implies 30:2	44:10 160:10	individual 147:15
43:12,19,25 49:10	imply 136:4	164:21 205:2	147:18 149:8
51:11,13,23,25,25	166:14	310:18	159:17 169:9
52:7,14 85:24	import 57:17 59:8	included 269:21	173:15,22 175:11
107:11,16,25	importance 317:3	includes 44:13	192:10 196:20
108:2,16,17,17	important 8:11	55:12 89:21	197:15 212:15
109:2,4,8,9 113:24	43:6 100:25	131:24 220:15	229:17 231:12,13
114:3,10 116:9,19	144:16,24 146:11	247:22	individually
125:20 140:18,19	180:21 274:17	including 33:4	167:19
140:20,23,24,25	290:13 312:5	71:16 204:8	individuals 39:15
166:16 168:2	320:11 322:11,12	250:16 294:17	39:22 76:19
179:6 180:7 188:8	322:13	300:20	254:21
189:13,14 216:10	imposing 174:16	inconclusive	indoctrination
240:20 242:13,21	impressed 94:12	244:21	50:24 94:6
253:2 254:7,8			

[industry - issues] Page 28

industry 298:15	216:21,22 217:13	284:12,13 288:24	introductory
influence 18:2	230:14 325:21	295:3 298:24	299:3
49:11 50:24	338:17 343:16	308:10 313:14,15	intuition 213:8
117:18 155:12	informer 156:20	342:21	investigate 36:9
220:5	informing 102:11	interests 46:2	323:3
influenced 50:14	203:3	211:9 339:25	investigating
influences 50:6	informs 151:17	interfering 180:13	327:5
51:10 52:13	216:7	international	investigation
inform 144:19	initial 113:12	141:19	38:10
147:7 157:13	136:6	internationally	investigative
160:2,17 216:6	initially 273:15	50:9	272:21
250:2	initials 92:21	internet 49:18	invitations 93:7
information 34:13	inmates 40:10	93:19	invited 93:9 94:14
48:22 90:5 129:19	inpatient 121:12	internist 206:23	involve 89:25
130:23 145:18	insistent 47:5 48:2	319:17	involved 21:22
159:10 196:22	78:16	interpret 162:17	78:22 157:8 167:8
197:6 208:19	insomnia 251:25	interpretation	167:13 173:19
236:15 241:21	252:2	314:16	233:25 241:6
260:12 314:8	instantly 117:10	interpreted 163:8	245:24 284:13
318:19,24 322:12	institution 24:13	163:9	286:23 287:2
339:20	303:6	interrupt 309:16	involvement 49:17
informed 10:2	institutions 147:17	interrupted	involves 38:11
83:12 86:9,23	189:6 296:7	303:13	involving 212:22
87:9 88:15 89:5	insurance 181:23	intervals 56:4	327:18 332:15
89:13 94:17,19	207:17 208:5	intervene 266:23	irb 135:6 231:5
109:21 119:21,23	insure 279:19	intervention	ireland 93:20
131:2 144:15	intelligence	100:20 236:13	isolation 43:3
145:18 146:10,14	101:20	253:9 266:18	101:22 108:6
146:15,22 147:14	intelligent 184:19	interventions	issue 12:14 18:25
148:6,18,19	intensive 18:12,18	150:11 156:25	24:7 27:3 30:6
149:21 150:18,25	intent 164:6	162:6 268:16	58:5 120:13,18
151:16 152:4,6,12	intention 52:2	286:2 334:9	152:22 162:2
153:2,25 154:3	176:9 177:6	interviewed 22:17	181:25 188:24
155:10 157:16	intentions 116:22	95:21	258:13 267:13
158:20 160:4	interactions	intimate 52:9	269:8 315:13,17
178:11 179:2	203:14	187:25	328:25 337:10,11
185:5 196:2	interest 76:16	intrafamilial	issues 11:13 15:19
199:21 200:3,11	94:16 212:7	264:17	16:10,15 22:7
202:6 203:22,25	interested 36:3	introduce 109:9	23:9,14 24:21
205:9 212:16	107:14,17 108:18	introduction	27:20 28:4 29:7,9
214:7 215:2,21	165:4 227:18	299:15	29:21 37:13 38:4

[issues - know] Page 29

	1		
42:21,22,23 45:19	188:19 197:4,5	184:13 189:7	88:19 91:22 92:10
45:20 93:23 94:11	205:20 206:5,6,7	206:19 207:5	96:12,24 99:18
94:13 107:4	249:14 252:5	219:6 244:13	100:23 101:18
110:11 172:25	juli 190:5 344:2	255:8 258:20	103:20,22 104:13
264:17,21 293:8	julia 91:5 92:10	259:5,25 269:2,3	104:19 109:5
293:13,22 302:6	julie 70:9,20	308:23 309:5	110:20 112:17
316:14,16 324:3	343:13	326:2	113:4 117:16
324:11 332:15	july 13:2 234:14	kill 308:24	118:13 119:5
item 235:16	235:3 344:7	kind 43:19 106:25	120:6,15,23 121:2
iv 316:7	jump 150:2	149:14 163:12	121:3 123:3,4
j	june 130:22 345:3	165:12 171:5	126:18,22 127:24
january 94:22	justify 278:17	173:5 187:12	129:4 131:9 132:7
111:4	k	193:25 200:5	132:15 136:14,16
jason 4:21	k 60:24	202:13 221:16	137:6 138:23
jeopardy 187:12	kalin 280:21 281:5	230:21,22 232:9	141:17 142:2,2,3,8
jm 1:4 5:12	281:9	242:3 260:24	142:11,14,18
joanna 1:7	karasic 10:19	284:16 285:25	143:24 144:17,25
job 122:9,12,12	karasic's 10:20	286:2 294:22	144:25 147:24
jobs 275:5	katz 37:21 39:18	310:25 311:24	149:14 154:5,21
jogging 59:14	keep 18:16 179:24	329:13	155:4 156:16,24
john 175:23,24	189:12,13 224:10	kinds 100:16	157:5 158:6,24
join 93:6 94:14	keeping 21:7,9,10	226:11 249:4	159:25 160:10
joined 6:6 93:17	197:9 302:17	267:5 283:2	162:16 165:9
jones 70:9,20	303:9	311:15	167:15 169:11
175:23,24 343:14	keeps 28:19	kink 113:21	170:12,23 171:20
journal 86:11	ken 253:18,21	116:21	171:23,25 174:24
194:8 274:19	265:22,25 294:13	kinky 116:21	175:16 179:25
276:18 277:23	294:25 295:3	knew 200:14	181:4 183:18
278:12 279:8	299:22	219:4	184:18 186:17
283:2 343:18	kenneth 292:13	know 7:6,17 9:5	187:23 188:9,13
journalist 271:11	kentucky 170:4	16:15 20:22 23:20	191:22 195:4
journals 282:3,3,5	keohane 70:8,20	32:3,3 34:2 35:6,7	200:23 201:17,22
judgment 47:12	343:13	38:10,21 39:9	201:23 203:2,4,13
75:13 85:9 146:23	kettles 318:17	41:3,21 47:11	203:20 204:13,23
158:15 185:2	kid 75:4 189:24	48:9 49:15 51:13	205:2,22 206:4,9,9
judgments 314:12	264:15 291:2	54:10,12 55:11,23	206:11,15,16,24
judicious 184:8,16	kids 111:16,17	58:24,25 59:5,9	207:18 209:8
184:19,22 185:4	112:5 135:8 136:7	60:2 62:13,15	215:10,14 217:18
185:12,17,18,24	153:25 163:14	64:16 65:20 68:24	217:19,25 218:3,4
186:6,6,8,13,25	165:25 170:10,16	70:3,5 76:11,12	218:4,13,17,21
187:5,9,11 188:18	170:18 171:17,18	81:6 86:16 88:10	219:2,14 220:3,25
107.5,7,11 100.10	170.10 171.17,10		

[know - lengthy] Page 30

221:3,11 225:6	Irmorringly 225.10	lower 261,22.22	low 241,12 15
229:14 231:13	knowingly 325:18	large 261:22,22 269:6	lay 241:12,15
	knowledge 59:25		lcooper 3:17
234:18 235:7	60:4 105:17	larger 220:4	
236:6 237:3	130:25 147:9	222:10 293:7	225:13,19 332:7
241:12,14,17,17	148:24 177:23	lasted 299:20	leader 26:24
246:4 247:3 248:2	186:19 189:20	late 111:4	leading 265:22
248:6 250:14	204:2,7 213:7	lately 287:6	learn 204:15
251:16 252:9	235:22 268:17	latest 287:25	209:13 313:5,6
255:14 256:4,12	276:23 288:2	288:2	learned 196:22
256:18 257:23,24	337:2	laugh 317:9	leave 217:19
258:2,11 259:5	knowledgeable	laughable 325:6	264:15,23 331:19
260:23 262:13,19	149:10 207:24	325:12	leaves 57:19
262:25 263:5,10	known 46:4,5 76:5	launch 201:7	leaving 315:3
264:5 265:17	77:6 104:21	law 6:22 154:24	led 281:5
267:4 270:6	109:24,25 120:25	155:4 162:2,4,10	left 12:5 75:5
271:18 274:23,25	144:22 156:21,21	162:12,15,17,22	159:12 214:18
275:14 277:2,12	194:6 216:20	163:3,7,20,24	245:12
280:18 282:7,14	250:18 309:2	164:5,6,9 165:7,15	legal 2:6 4:21
282:24 284:9,10	knows 88:9,21	165:15,22 166:9	154:19,23 157:25
284:18,24 285:4	103:13,14 104:18	166:11 168:12,12	158:8 329:23,23
285:16 286:8	110:15 132:13,19	168:14,14,16,23	330:2 345:23
287:2,5,6 288:12	145:2,3 148:21	169:8,17 170:23	legally 89:24
288:14,19 289:8	156:19 158:5	171:3,9,12,17	198:25
289:23 293:2	186:16 204:22	173:9 177:16,18	legislation 208:8
295:15 298:16	205:6 222:11,12	178:4 200:16	legislative 181:17
300:4 302:3,6	262:19	202:12 205:14	181:19 208:14
303:2,14,18,25	1	207:12,21 208:4,4	legislator 177:19
304:10,14,16,17	1 304:20	208:22 209:22	218:10 234:6
304:23 305:7,10	label 249:9,9,12	211:8 220:9,19	legislators 201:18
305:20,24 306:4	249:14,17 250:5	223:18 226:2	legislature 170:7
306:12 307:8,10	250:13,15,21	231:25 232:6,8,10	174:6 179:20
307:11 308:2,5	251:3,11,18	233:5 234:2	210:22
310:8,9,12 312:7,9	lack 116:17 284:3	241:19,20 328:2,9	legislatures
312:21,22 315:6,7		329:4,12,15,17,18	217:22 218:18
316:4 318:13	lacking 130:15 land 4:17 314:20	330:3 331:2,6	legitimacy 338:6
319:15 322:13,19		law.com 4:7	legitimate 180:4
323:16 324:2,5	landscape 96:18 96:23	lawsuit 137:12,13	legitimizes 339:18
326:3,10,14,17,22		lawyer 333:9	length 42:13 102:8
329:12 330:8	language 17:11	lawyer's 191:23	316:19 333:8
333:4 334:12	260:13,15 271:15	lawyers 217:22	lengthy 81:12
336:21 339:3	lappert 304:18	220:3	
	305:5,6		

[lesbian - levine] Page 31

lesbian 51:17,19	15:1 16:1 17:1	131:1 132:1,18,18	244:1 245:1 246:1
108:17	18:1 19:1 20:1	133:1 134:1 135:1	247:1 248:1 249:1
leslie 1:10 3:16 5:8	21:1 22:1 23:1	136:1 137:1 138:1	250:1 251:1 252:1
5:15 7:9 36:22	24:1 25:1 26:1	139:1 140:1 141:1	253:1 254:1 255:1
39:11 193:5	27:1 28:1 29:1	142:1 143:1 144:1	256:1 257:1 258:1
213:22	30:1 31:1 32:1	145:1 146:1 147:1	259:1 260:1 261:1
lesser 168:5	33:1 34:1 35:1	148:1 149:1 150:1	262:1 263:1 264:1
letter 44:7 45:2,8	36:1 37:1 38:1	151:1 152:1 153:1	265:1 266:1 267:1
45:14,22 46:8,10	39:1,15 40:1 41:1	154:1 155:1 156:1	268:1 269:1 270:1
46:13,14,21,22	42:1 43:1 44:1	157:1 158:1 159:1	271:1 272:1,7
47:7,8,16 48:3,7	45:1 46:1 47:1	160:1 161:1,13	273:1 274:1 275:1
48:11,15 49:2	48:1 49:1 50:1	162:1 163:1 164:1	276:1 277:1 278:1
63:14,19,25 66:17	51:1 52:1 53:1	165:1 166:1 167:1	279:1 280:1 281:1
67:2,21 68:12	54:1 55:1 56:1	168:1 169:1 170:1	282:1 283:1 284:1
69:7,10 73:23	57:1 58:1 59:1	171:1 172:1 173:1	285:1 286:1 287:1
75:17 80:7,22	60:1 61:1 62:1	174:1 175:1 176:1	288:1 289:1 290:1
81:11 83:14 85:10	63:1 64:1,9,10	177:1 178:1 179:1	291:1,20 292:1
86:3 95:13,19	65:1,5 66:1 67:1	180:1 181:1,8,15	293:1 294:1 295:1
96:3 98:14,21	68:1 69:1 70:1,6,8	182:1,17 183:1	296:1 297:1 298:1
99:8,8 100:4	70:16 71:1 72:1	184:1 185:1 186:1	299:1 300:1 301:1
102:6,11,17 103:3	73:1 74:1 75:1	187:1,16 188:1	302:1 303:1 304:1
103:4 227:10	76:1 77:1 78:1	189:1 190:1,3,4	305:1 306:1 307:1
308:17 338:24	79:1 80:1 81:1	191:1 192:1 193:1	308:1 309:1 310:1
339:9	82:1 83:1 84:1	194:1 195:1 196:1	311:1 312:1 313:1
letters 53:19 63:12	85:1 86:1,8,10	197:1 198:1 199:1	314:1 315:1,2
63:23 64:2 80:12	87:1 88:1 89:1	200:1 201:1 202:1	316:1 317:1 318:1
82:17 85:20 95:9	90:1 91:1 92:1	203:1 204:1 205:1	319:1 320:1 321:1
96:8 97:9,11,12,14	93:1 94:1 95:1	206:1 207:1 208:1	322:1,13 323:1
98:2,7,16,22 101:8	96:1 97:1 98:1	209:1 210:1 211:1	324:1 325:1 326:1
102:15 226:22	99:1 100:1 101:1	212:1 213:1 214:1	327:1 328:1,3
227:7 228:6	102:1 103:1 104:1	215:1 216:1 217:1	329:1,21 330:1
280:19 281:6	105:1 106:1 107:1	218:1 219:1 220:1	331:1 332:1 333:1
leukemia 267:4	108:1 109:1 110:1	221:1 222:1 223:1	334:1 335:1 336:1
leukemic 267:5	111:1 112:1 113:1	223:17 224:1	337:1,23 338:1
level 95:4 218:16	114:1 115:1 116:1	225:1 226:1 227:1	339:1 340:1,22
242:14 245:13,15	117:1 118:1 119:1	228:1 229:1 230:1	341:1 342:6 343:2
levels 177:21	120:1,14 121:1	231:1 232:1 233:1	343:8,9,11,12,15
levine 1:19 2:4 5:6	122:1 123:1 124:1	234:1,12,13 235:1	343:17,20,25
6:21 7:1,2,5,16	125:1 126:1 127:1	236:1 237:1 238:1	344:1,5,6,8,9,11
8:1 9:1 10:1 11:1	127:22 128:1	239:1,3,4 240:1	345:5 346:2,24
12:1 13:1 14:1	129:1,6 130:1	241:1 242:1 243:1	347:2,4,12

[levine's - m.d.] Page 32

levine's 154:7	346:19	long 7.7 (0.16	200.25 212.7
liars 322:4	lisa 238:24 272:22	long 7:7 68:16 79:2 84:16 85:23	308:25 313:7 320:23
liberties 3:13			looks 160:25
	272:24 273:5,12	85:23 89:2 104:25	
license 2:8,10	274:24 275:13	119:11 126:17	218:24 312:23,24
41:12 61:6 329:16	276:5 292:16	130:16,17 132:4	312:25
331:5,8 342:25	294:10 299:22,23	133:15 136:17	lose 220:4 282:15
licensee 41:17	list 90:11	139:20,22 153:5	331:5,14
licenses 328:12	listed 90:22 91:15	153:16 154:23	lost 99:24 100:9
329:8 330:5,14	listen 119:20	179:10 180:5,15	260:2 275:7
331:14 332:4	192:7 330:8,14	180:20 195:5	289:21 319:10
lie 321:22,25	listening 49:25	205:25 207:3	lot 29:25 50:13
lied 320:17	literally 163:8	214:16 215:18	178:23 183:19,21
lies 285:24	literature 79:5	221:11 237:20	213:18 233:8
life 81:17,19 84:13	139:20 252:8,10	248:10 251:14	238:17 245:7
90:20 101:17	252:11,13,16	256:24 266:25	252:2 306:13
104:24 109:12	254:5	318:9 322:25	313:6 314:22,24
119:25 127:2,6	litigation 323:19	longer 37:22 51:18	340:13
158:11 185:10	little 3:23 4:5,14	51:19 59:19 82:24	lots 335:4
203:17 215:18	6:12 16:18 23:22	130:2 196:17,21	love 110:5 188:3
217:7 241:6	25:12 80:10	227:4 228:6 261:9	224:16,17
251:13 265:6	113:18 127:9,11	look 50:12 82:4	loving 180:16
298:5 317:16	157:6 167:14	121:16 127:25	188:2
338:12	171:19 184:20	132:11,11 149:19	low 240:25 245:15
lifecycle 216:19,19	237:15,23 244:11	237:22 239:22	290:20 308:21
lifelong 101:3	257:25 258:8,9	243:21 262:14	lower 152:17
lifetime 87:19,21	274:10 281:10	272:2 273:9 280:3	216:11
96:11 113:5 217:4	283:20 298:18	280:4,4 282:18	lowering 117:13
liked 121:5 171:9	302:4 303:4 304:7	288:7,23 311:12	loyalty 224:16
likelihood 254:25	318:15	313:18 318:19	lumping 30:14
280:10	live 90:18 110:7	333:8	lunch 105:4,10
limitations 69:4	165:6,15 207:3	looked 230:11,13	lying 224:7
97:19 98:11	212:25 257:25	243:24 254:19	m
101:21 229:15,15	265:5 274:6 316:2	274:5 280:25	m 342:2,24
229:16 241:16	lived 256:6	287:5 308:19	m.d. 1:19 2:4 6:21
274:18 289:5	lives 78:17 150:12	looking 52:23	7:1 8:1 9:1 10:1
295:12,19 299:6	207:4 217:8	93:11 117:12,13	11:1 12:1 13:1
limited 148:16,17	living 96:5 113:15	129:23 172:15	14:1 15:1 16:1
227:20 242:22	127:21 142:21	195:20 219:11	17:1 18:1 19:1
limiting 207:17	llp 3:3	234:22 239:23	
line 55:24 148:22	london 137:14	256:20 270:12	20:1 21:1 22:1
346:4,7,10,13,16		272:17 274:12	23:1 24:1 25:1
			26:1 27:1 28:1

[m.d. - mark] Page 33

29:1 30:1 31:1	152:1 153:1 154:1	274:1 275:1 276:1	majors 84:22,23
32:1 33:1 34:1	155:1 156:1 157:1	277:1 278:1 279:1	maker 288:15
35:1 36:1 37:1	158:1 159:1 160:1	280:1 281:1 282:1	making 103:6
38:1 39:1 40:1	161:1 162:1 163:1	283:1 284:1 285:1	122:16 140:22
41:1 42:1 43:1	164:1 165:1 166:1	286:1 287:1 288:1	165:20 170:11
44:1 45:1 46:1	167:1 168:1 169:1	289:1 290:1 291:1	184:2 195:9
47:1 48:1 49:1	170:1 171:1 172:1	292:1 293:1 294:1	249:13 252:21
50:1 51:1 52:1	173:1 174:1 175:1	295:1 296:1 297:1	260:16,25 270:3
53:1 54:1 55:1	176:1 177:1 178:1	298:1 299:1 300:1	314:11
56:1 57:1 58:1	179:1 180:1 181:1	301:1 302:1 303:1	male 96:22 108:17
59:1 60:1 61:1	182:1 183:1 184:1	304:1 305:1 306:1	113:15 115:14
62:1 63:1 64:1	185:1 186:1 187:1	307:1 308:1 309:1	235:25 236:2
65:1 66:1 67:1	188:1 189:1 190:1	310:1 311:1 312:1	238:5,6 256:14
68:1 69:1 70:1	190:4 191:1 192:1	313:1 314:1 315:1	268:8
71:1 72:1 73:1	193:1 194:1 195:1	316:1 317:1 318:1	males 116:13,16
74:1 75:1 76:1	196:1 197:1 198:1	319:1 320:1 321:1	256:22
77:1 78:1 79:1	199:1 200:1 201:1	322:1 323:1 324:1	man 222:15
80:1 81:1 82:1	202:1 203:1 204:1	325:1 326:1 327:1	management
83:1 84:1 85:1	205:1 206:1 207:1	328:1 329:1 330:1	190:6,17 344:4
86:1 87:1 88:1	208:1 209:1 210:1	331:1 332:1 333:1	mandates 329:15
89:1 90:1 91:1	211:1 212:1 213:1	334:1 335:1 336:1	manpower 287:18
92:1 93:1 94:1	214:1 215:1 216:1	337:1 338:1 339:1	manuscript
95:1 96:1 97:1	217:1 218:1 219:1	340:1 341:1 342:6	278:12
98:1 99:1 100:1	220:1 221:1 222:1	343:2 344:1	march 74:14 87:5
101:1 102:1 103:1	223:1 224:1 225:1	macrichards	141:17 148:12
104:1 105:1 106:1	226:1 227:1 228:1	272:14,22,24	181:11 183:15
107:1 108:1 109:1	229:1 230:1 231:1	273:5,13 274:24	185:18 343:23
110:1 111:1 112:1	232:1 233:1 234:1	275:13 276:5	marchiano 238:24
113:1 114:1 115:1	235:1 236:1 237:1	mad 224:12	292:16 294:10
116:1 117:1 118:1	238:1 239:1 240:1	maintain 152:19	295:10,11 299:17
119:1 120:1 121:1	241:1 242:1 243:1	maintained	299:23
122:1 123:1 124:1	244:1 245:1 246:1	301:25	margaret 303:16
125:1 126:1 127:1	247:1 248:1 249:1	major 153:10	marginalized
128:1 129:1 130:1	250:1 251:1 252:1	180:10 277:16,24	104:22
131:1 132:1 133:1	253:1 254:1 255:1	278:25 300:20	maria 10:12
134:1 135:1 136:1	256:1 257:1 258:1	306:14 317:2	marijuana 101:23
137:1 138:1 139:1	259:1 260:1 261:1	majority 14:22	marital 86:11
140:1 141:1 142:1	262:1 263:1 264:1	21:2 31:2 139:5	343:19
143:1 144:1 145:1	265:1 266:1 267:1	139:13 146:6	mark 64:7 69:25
146:1 147:1 148:1	268:1 269:1 270:1	147:11 253:11	86:6 181:6 189:25
149:1 150:1 151:1	271:1 272:1 273:1	257:16 262:22	234:10 238:25

272:6 303:15,17	278:8	276:15 285:6,6	131:7,15 135:19
304:13,14	matters 98:19	286:25 299:18	135:25 136:11,24
marked 64:12	matthews 3:10 6:3	300:14 301:2	138:9,14,19
65:6 70:9 86:12	6:4	302:21 306:22	139:11 140:5,6
149:20 181:12	matthewss 3:11	307:15 309:17	142:7 143:10
190:7 234:14	maturation	312:8,17 314:22	144:11 145:13,15
239:6 272:9	188:23 244:12	314:23 319:14	148:25 154:15
market 224:2,22	290:11,12	326:9 330:4 331:4	156:10 157:20
226:3,9,15	maturational	333:8	159:14 161:17
marking 64:19	158:11 188:20	meaning 25:10	162:5 164:4
married 110:8	mature 85:16	54:22 79:8 80:25	165:14 166:2,3,23
321:2	196:3,3,9,14,15,16	203:15	168:24 174:3
marry 110:6	244:13	meaningful 67:7	175:14 176:7,10
masculine 115:18	maturity 84:13	meanings 67:11	177:8 178:22
115:24,24 116:20	85:7	67:13	180:10 181:23,24
124:2	maureen 1:25 2:7	means 17:18,19,20	183:12,23 186:4
masculinity 49:22	342:2,24	25:14 49:24 61:5	187:2,14,15
masculinization	mcfarland 271:25	90:21 152:15	194:25 202:10,24
119:2	272:14 275:14	188:18 230:6	204:12 205:11
masculinized	md 64:10 67:21	241:19 250:24	207:13 208:9,23
121:7	70:8 86:10 239:4	276:16 285:7	210:20 215:4
masochistic	309:24 339:18	295:17 329:18	216:20 217:20
113:21	343:9,13,18 344:9	meant 82:11	218:20 219:20
mason 91:5 92:10	mean 14:9 15:13	118:19 167:4	220:10,14 222:4
massachusetts	17:2,6 23:22 25:5	184:22 245:21	222:17 228:20
40:9	61:4 66:15,17	254:14	229:6 236:13
mastectomy 95:19	67:4 68:23 73:22	measure 209:2	243:20 259:14,16
95:25 96:4	78:10 79:9,10	media 5:4 50:13	269:12 285:11
master 272:25	84:24 85:13	50:18,22 52:5,11	296:19 297:13
masturbation	118:17,21 120:18	321:10,11	300:20 302:7
195:15,18	123:10 154:8	median 133:15	310:10 311:21
matches 242:13,21	162:13 166:9,24	medicaid 152:18	312:4,6 319:15
material 9:14 92:3	167:22,23 171:5	182:5 183:13	323:7 325:14
277:3 278:23	175:24 184:15,24	medical 54:5,9	327:19 328:25
279:11	185:2,11 186:3	55:6 56:21 57:24	329:5,7,9,14,16
math 13:9,14,17	206:25 228:22	73:2,10 84:21	330:6,9,20,21,22
matter 5:7 81:23	229:4 249:18,19	87:12 88:23 89:8	331:8,11,15 332:4
130:6 147:3	249:20 250:21,23	89:15 90:11 94:8	332:10
201:11,12 202:16	252:9 255:3 259:5	100:10,13 110:19	medicalize 125:23
213:10 222:4	263:7 264:8	111:22,23,24	medicalizing 79:3
227:24 232:16,19	273:12 276:10,14	128:2,4,16,22	140:24 179:6

180:6	42:24 58:4 93:10	methodologies	169:21,22 205:11
medically 52:25	99:20 102:18,23	129:24	209:24 214:3,22
53:12 55:4 56:14	103:3,10,18,23	methodologist	229:21 277:17
56:16,18 57:12	104:2,9,12 117:4	92:2	278:5 279:2
58:9,14 68:3 88:5	117:17 118:9,15	methodologists	318:20 324:18
336:6	118:18 119:10,16	273:23	325:15
medication 18:25	121:21,24 124:24	methodology	minority 262:22
210:15 236:23,24	125:22 126:3,22	230:17	minors 14:24
248:19 336:10	126:25 144:3	methods 313:10	24:21 27:11 30:15
medications 84:11	164:22,24 165:3	metropolitan	30:16,22 31:13,24
248:21,21	167:11 180:15	76:14	44:3,11,12,13
medicine 91:20	193:18 194:2,22	mic 155:21	46:17 47:14 53:6
117:16,17 167:6	200:24 201:4	michael 4:15 6:13	54:21 55:18,20
246:11 250:15	212:19 287:23	307:25 308:2	77:16,19 78:6
266:12 267:2	289:2 293:14,15	309:18 345:1	81:9 84:22 87:13
284:6,6 302:4	293:17 306:16	michael.cantrell	89:14 128:2,5,16
328:17 336:11	310:15 322:16	4:16 345:2	131:16 133:3,10
meet 11:3 39:4,6	328:23	microphones	134:22 135:3
41:23 42:7,12	mentally 124:5	124:20	136:10 138:9,14
45:21,23,23,24,24	200:21,21 318:11	mild 251:22	139:12 144:20
151:25 290:11	mention 10:8	266:14	145:8,12,15 149:2
305:14	41:22 42:6 83:25	millions 219:12	149:17 155:16,24
meeting 11:8	100:8 114:5	mind 48:10 74:15	156:12 161:17
324:10	258:10 295:22	113:8 128:10	162:6 176:11
meets 41:25	304:24 324:2	134:2 143:12	177:9 178:22
member 134:15	mentioned 27:5,14	196:11 307:16	181:25 182:7,8
310:7	27:17,24 33:22	322:2 326:15	183:12,24 198:5,9
members 268:23	34:3 37:4 57:8	333:10	199:5,25 202:10
285:18,20 294:11	58:23 60:21 74:2	mindful 8:16	207:13 208:10
318:25 320:4	77:8 95:15 172:10	191:13	211:6,10 212:14
memories 143:25	223:24 224:3	minds 299:9	219:17,20 220:11
memory 59:14	260:6 261:6 276:7	minimum 98:20	220:21 226:22
135:21 304:7	292:12 332:9	minor 14:16 30:23	228:20,23 229:5
men 236:3 238:6	mentions 152:8	32:23 33:4 38:13	232:2 243:11,20
256:14 257:19	merely 150:19	44:15,25 45:4	263:3 285:12
320:23,24	merit 278:3	63:20 64:3 77:10	294:19 300:2
men's 266:13	message 221:23	79:17,17 80:13,14	310:11 323:8
menstruation	met 7:6 44:17 45:4	80:23 89:18 90:4	329:6 330:7
180:12 252:4	102:2,9 106:15	90:9 105:14 106:9	331:16 332:11
mental 23:10	154:4 219:6	128:20 133:5	338:4
39:25 41:6,19	305:12	151:13 159:13	

[minus - need] Page 36

minus 137:5 205:5	moderator 302:21	morrison 109:5	names 209:17
minute 59:2 60:12	modern 248:23	mosaic 115:14	238:21
110:11 150:4	249:2	116:8,19 123:25	narcicisstic 155:8
161:5 222:9 240:4	modification	mother 1:7 60:12	narcon 75:10
297:3 330:15	279:2,2	227:15	narrative 314:8
minutes 25:8	modified 162:22	motivations	natal 111:3 112:12
58:12 74:3 79:9	222:14	108:21 140:8,9,10	112:15 114:24
79:10 125:24	modify 53:15	motives 36:6,19	143:2,8,14 240:19
151:10 210:18	174:20 185:24	mouth 155:19	242:12,13
213:25 229:12	moment 11:12	move 113:23	nation 328:20
291:12 294:25	71:15 143:23	189:7 193:5	national 141:18
295:18,21 299:20	150:6 235:10	335:16	229:9 232:21
299:21 315:3	265:20 327:12	moved 113:18	nationally 50:9
miriam 34:18,20	moments 240:17	114:13	nature 46:4 60:12
misadventures	monday 190:4	muddled 243:16	174:2
302:14	344:1	multicenter 231:3	naïve 224:15
miscommunicated	money 286:9	multiple 244:17	285:7
139:17	monitor 302:23	246:8 322:11	necessarily 20:17
miseducation	monitors 302:24	multiply 13:5,6,7	26:10 29:18 76:9
50:23	month 23:21,24	31:14	115:22 167:22
misinformed	25:5 56:4 259:22	multisite 229:9	226:13,14,17
325:19	291:21 327:23	231:15 249:5	229:4,21 250:21
missed 314:6	months 13:20	multistate 231:3	299:11
325:11	18:14,15 23:23	232:21	necessary 26:3
missing 148:23	31:3 35:11,12	n	68:3 159:11
missouri 170:4	38:2 39:9,10 42:8	n 3:1 4:1 60:24	173:21 231:17
mistake 283:19	42:9 48:12 54:11	230:25 303:19,23	281:17 347:6
301:18 302:10	54:11 69:22,23	303:24 343:1	need 8:19,25 9:4
mistakes 302:5	79:10 86:5,5 95:3	naivete 225:4	11:14 21:3 26:10
misunderstand	95:24 113:11	name 7:9,15 24:9	36:19 39:25 41:6
273:6	117:11 118:10,14	27:8,9 34:8,10,18	53:4 68:2 79:23
misunderstanding	165:8 168:5	37:14,17,17,20	87:24 88:8,10
116:17 250:8	183:19,20,21	60:22 91:12	104:15,16,17,20
misunderstood	205:23 259:24	271:25 273:5,13	110:20 115:12
139:15	264:9,10 266:21	273:16 275:13	119:22 120:9
mixed 17:23	277:7,8,9 306:8	289:19,19 298:23	127:18 128:16
mixture 24:21	moral 154:20	303:18,25 304:12	130:10 148:17,18
modal 340:16	morality 231:7	304:21	154:16 155:2
mode 278:15	morally 224:18	named 284:4	157:4,12,17 159:7
models 181:10	morning 5:1 7:4	337:25	161:2,2 173:19,24
343:22	7:12 11:7 148:11	337.20	184:25 189:14

[need - offered] Page 37

191:22 197:7	80:10 81:9 122:12	53:25 54:2 55:12	217:15 219:18,21
200:12,16 203:4	170:21 171:15,16	88:17,18 137:9	220:12 222:7
205:2 225:18	172:2,15,23	139:25 156:15	223:22 226:4
237:23 246:8	175:22 186:18	191:16 253:17,19	228:14 232:4
252:4 263:13	196:22 234:16	262:4 268:19	234:5 247:16
297:13 299:12	257:9	269:6,18,19,23	249:10 279:13
312:19 316:16	news 323:11	270:18	283:23 300:11,22
321:18,20 326:7	newspapers 282:6	numbers 13:3	306:11 307:19
336:7	nice 134:13 292:3	18:16 20:24 21:7	315:15 317:21
needed 37:25	303:7	29:2 56:8 141:6	319:3 320:7
102:15 107:4	night 251:4 319:10	184:14 230:24	324:20 326:2
232:25,25 303:6	nightmares 251:9	231:2 257:6	327:8 329:10,20
needing 291:5	nine 277:8 306:8	258:24 261:15,17	331:18 332:5
needs 8:12 164:4	nods 8:13	262:11	333:18
166:5 192:14	nodule 266:22	numerical 55:24	objecting 275:4
227:15 269:8	non 116:5,21	numerous 40:13	objection 119:18
285:5 326:8	125:3 186:6 253:9	nurse 41:10	143:11 191:23
negative 93:14	257:12 259:16	0	objections 215:7
122:20 174:14,14	normal 180:11,12	o 60:24	220:23 247:25
218:6 305:25	180:13 201:2	object 42:14 44:19	objective 313:8,9
neither 342:16,19	267:25	47:19 50:17 53:3	313:23 314:7
nervous 312:20,21	normality 116:18	62:11 81:14 83:2	315:8
neurosurgeon	normally 51:20	84:7 85:11,25	objectively 313:18
319:19	notary 2:10	90:7 100:11	obligated 160:14
neutral 218:13	347:13,19	101:13 105:24	obligation 160:15
never 13:2 20:25	note 345:10	121:25 126:12	obligations 147:15
30:10 47:15 60:7	noted 347:7	128:24 131:19	observe 268:5
80:18,21 81:3,6	notes 54:15	133:8.9 135:20	313:6,19
95:16 96:2 99:22	notice 2:6	136:15 138:10,22	obtaining 89:13
100:21 111:12	novak 27:9 60:22	139:14 145:20,24	obviously 18:15
126:24 186:2	61:20 63:9 77:9	146:12 151:21	233:22
209:15 215:21,24	77:19 78:3 79:16	157:22 159:16	occasion 79:22
215:24 217:10	80:19 226:21,25	162:9 164:17	occasionally 76:8
221:10 248:12	337:25 338:11	166:13 167:5	312:2
249:8 251:19	339:16 340:6,7	169:23 172:7,19	occupied 95:2
289:23 297:4,15	nuanced 260:24	175:15 176:12,18	october 272:8
304:5	nuances 188:6	177:10 179:3	344:12
new 3:5,5,15,15	number 7:18	187:7 199:9 200:6	offer 296:13
5:17,20,24 6:5	13:16 14:24 16:16	202:17 205:12	327:17 333:5
20:17 22:22 34:4	16:21 20:6 24:3	207:14 208:11	offered 163:11
50:25 75:6,7	33:4,9 40:14,17	211:11 214:13	333:3
		211.11 217.13	

offering 154:9	112:24 133:20	once 17:19 23:21	opposed 84:18
194:20	138:6 144:2 145:6	23:23 25:5 31:19	222:5 310:9
office 4:12 6:15	150:7 151:3 159:6	93:18 118:5	opposing 335:19
83:20 165:18,19	164:11 175:6	one's 38:12 107:10	337:5
177:12 323:22	177:3 181:14	140:18,19,20	optimism 174:2
officer 6:23	182:9,11,22 183:6	188:14	option 36:18
official 1:10	183:9 184:2	ones 10:10 157:18	options 36:7
302:18 303:9	190:20 191:25	172:4 248:24,24	160:16,17 338:21
oftentimes 37:12	193:10,14 202:21	249:2	oral 1:17 226:10
42:19 45:19 51:15	207:7 234:10,18	ongoing 19:10,21	orchiectomy 95:16
227:14 278:14	234:22 237:18	20:18 31:20 33:13	order 50:19
oh 34:24 44:9,9	240:2,8 243:8	40:13 75:14	157:12 158:16,19
49:12 59:13 67:25	247:9 250:10	338:14	230:23 281:17
100:18 125:5	251:15 255:6,17	online 268:6	307:20 312:3
139:18 144:5	262:16 270:3	onset 255:4 259:8	321:18
216:25 228:7	271:9 276:7	263:22 268:5	organization
239:20 248:20	282:11,20 291:10	open 86:15 190:10	91:24 92:5 271:10
272:14 282:5,12	293:6 305:7	234:19,21 299:9	271:13 283:22
311:5 315:22	337:15	335:25 336:7	284:20,22,24,25
319:9 320:8 327:9	oklahoma 170:4	operate 154:17	orgasm 195:18
327:10 334:12	old 19:5 32:14,16	330:20	orientation 42:22
ohio 21:5 75:11	83:13 85:15,15,15	operates 330:22	52:2 257:18
209:3,23 210:3,21	90:10,10,16 95:19	opined 306:10	original 9:23
211:10 330:9,21	96:4 111:6 112:21	opinion 9:24 65:4	281:6,12
oily 117:13	132:2,3,3 140:23	154:7 197:12	originally 10:20
okay 8:9,10,16,17	152:8 163:10	209:16,17 233:23	282:22
8:23,24 9:8,9,14	169:13 186:8,24	234:7,8 263:10	ought 110:17
9:19 10:23 11:3	187:3,6 189:10	286:15 329:24	257:25 286:20
13:15,23 14:5,21	195:8 201:6	330:3 333:7	outcome 180:15
15:11 19:25 20:21	213:10,11,14	opinions 120:20	268:3 339:8
29:3 33:3,10	217:6 224:9	120:21 326:20	outcomes 110:18
39:23 44:24 55:2	228:12,13 326:2,4	333:2,5	215:19 218:6,7
55:21 56:2 58:6	older 47:4 112:11	opioid 302:10	221:13,14 268:14
60:6 61:22 65:23	112:23 212:4	opioids 225:8,15	outdated 237:10
67:14 69:14,24	259:4,4	opponent 177:16	outgrow 267:12
71:5,8,19,20 72:11	olds 14:11,13 84:5	opportunities	outlaw 184:6,8
73:12 74:11 87:15	92:17 163:6,7	101:25	outlawed 187:10
87:17 89:4 91:6	164:13 168:15	opportunity 83:6	outlined 99:19
91:14 92:20 95:8	170:10 197:21	83:8 101:16	200:4 325:20
97:8 103:11	290:14	oppose 178:21	outpatient 23:10
106:24 110:21		334:8	

[outrageous - patient]

Page 39

0114magaaya 202.16	noin 75.14.14	333:12	nonticular 50.12
outrageous 282:16 outside 39:17	pain 75:14,14	parents 31:24,25	particular 59:12 60:8 61:13 66:6
	290:15,18,19,20	-	
106:20 309:13	panchankis 194:7	41:23 42:3 45:20	81:19 99:15
outweigh 128:5,22	279:22 280:3,12	52:20 55:7 57:19	107:16 222:13
129:25 130:17	280:13 282:23	59:9 62:18 75:8	284:7,8 307:16
131:3,16 133:2,22	panel 300:18	76:22 83:20 87:24	308:12
134:7 139:6 141:9	paper 91:6,14 93:4	88:7,22 89:18,22	particularly 78:8
outweighs 139:12	94:21,23,25 95:2,6	89:23,25 90:14	84:9 328:10
ovaries 213:13	95:12 142:12	111:5,8,16,17	parties 342:18
overall 125:13	143:22 144:15	113:8 144:20	partner 93:3
overarching	146:14 147:4,12	151:18 153:6,8	195:19
289:16	149:21 261:17,18	157:13,16,18,25	parts 93:21
overdose 74:20	262:14 277:6,19	158:2,4,5,9 159:13	pass 170:8 210:2
75:15	277:20,22 278:3,4	159:19 160:7,18	337:14 340:23
overlap 142:4	281:11,19,19	173:14,24 200:13	passage 71:8,21
override 214:11	295:15	201:5 207:10	73:6 184:5
215:4	papers 35:9 148:5	214:4,11,23 215:5	passed 171:12
overriding 289:16	187:17 282:20	224:8,12,17	202:11 209:23
overvalued 90:19	293:25 323:9,15	227:12 264:14,15	210:3 220:9
overwhelming	paradigm 299:4	264:16 265:13	passing 104:11
14:22	299:14	269:2 318:20	passion 90:17
owen 4:3 6:11	paradoxes 316:2,3	324:17,23 325:13	328:19 336:17,18
p	paragraph 65:19	325:22 327:5	passionate 156:18
p 3:1,1 4:1,1	69:3 150:3,9	338:12,19,22	229:18 232:18
304:20,20	153:20,21 235:7	339:23	242:4 336:16
p.m. 14:2 341:7	235:11,12,15,17	part 10:11 31:22	passionately
pa 4:3	235:18 239:25	31:22,25 37:6	158:22,23
package 194:24	240:3,5 241:3	38:9 41:20 48:16	passions 108:14
page 10:15 65:15	267:15,19,22	89:10 93:9 104:3	path 219:8
71:6,14 98:20,21	270:5,10,13	135:4,5 137:19	patient 13:18 18:4
149:22 182:10,12	283:10,15,16	155:14 183:13	21:16 23:25 26:22
,	parameters	209:20 216:22	32:10,15,17,23
182:19,25 183:3	136:19	222:10 229:6	33:2 36:10 38:7
184:3 190:21,25	paraphilic 42:23	232:13 264:7	39:2 42:6,11,19
191:7,10,12,15,21	paraphrase 292:3	293:6 312:7 313:3	43:8 45:14,17
191:24 239:14,18	pardon 34:9	participate 189:15	48:4 49:9 51:3
239:19 263:8	parent 16:4 32:18	232:2 288:16	57:7,16 60:8
272:20 346:4,7,10	32:21 111:13	participates 77:21	62:19 63:20 74:17
346:13,16,19	158:18 159:21	participation	75:19 80:23 83:7
paid 37:8 122:9	169:15 200:20	234:4 332:14	95:21 98:19,24
286:8 314:10	265:14 311:18		99:2,5 100:20,21
315:5			, , ,

[patient - people] Page 40

101:14,24 102:8 42:23 44:2,8 74:13 50:11 52:16 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:12 296:13 153:18 296:13 66:2,7 68:21 296:13 66:2,7 68:21 296:13 153:18 205:8,7 160:6,7 203:15 214:3,6,22 291:7 80:13 203:215 214:3,6,22 291:7 80:13 203:215 214:3,6,22 291:7 80:13 203:215 214:3,6,22 291:7 80:13 203:215 214:3,6,22 291:8 224:7,8 228:10 291:12 220:22 298:20 313:6,7,13 316:14 95:10 293:21 9339:21 300:16 101:8 206:21 9339:21 300:16 101:8 206:21 9339:21 300:16 101:8 206:21 9339:21 300:16 101:8 206:21 9339:21 300:16 101:8 206:21 9339:21 314:8,18 321:15 314:417 241:6 267:23 212:20 123:6,8,20 311:13 314:17 241:6 267:23 212:20 123:6,8,20 311:13 314:17 241:5 267:23 212:20 123:6,8,20 318:4,5 319:25 313:14 436:16 144:19 276:14,24 278:9 279:49,18 280:8 279:49,18 280:8 279:49,18 280:8 279:49,18 280:8 276:24 29:14 223:25 224:21 226:25 23:13,17 229:21 240:18			1	
106:20 109:16	,	,	-	,
120:12 122:6,22 124:6,7 132:6,7 55:4,7 56:13 58:7 144:18 153:18 61:23 62:3,6 63:2 158:5,7 160:6,7 64:4 66:2,7 68:21 169:2,8,15,20 69:16,17 77:10 203:15 214:3,6,22 78:22 79:17 80:13 224:7,8 228:10 81:22 82:16,22 241:8 244:9 89:6,14 92:12 260:16 264:9 93:14 95:10 289:20 313:6,7,13 100:16 101:8 314:8,18 321:15 322:19 339:21 307:14,23 106:3,9 322:19 339:21 317:2 118:13 41:16 51:10 66:19 117:2 118:13 41:16 51:10 66:19 17:2 118:13 117:2 118:13 118:4,5 319:25 311:23 312:14 143:6,16 144:19 241:8 243:12 133:51:14 146:6,6,23 15:17 150:16 146:9 147:19,21 133:5,12,16 14:4 146:6,6,23 15:17 150:16 146:9 147:19,21 133:5,12,16 14:4 163:1,21 17:9 199:1,6,19 20:6,10 20:14,17,21 21:15 223:25 224:21 225:17,21 26:15 248:18,20 255:2 27:15,19,22 28:3 30:16 311:8,9 36:12,13,16 38:4 4pub 305:8 pause 11:12 220:2 57:14,21 25:3 57:14,21 58:3 57:14,			I -	· ·
124:6,7 132:6,7		, ,	296:12	′
144:18 153:18 61:23 62:3,6 63:2 pause 11:12 220:2 57:14,21 58:3 158:5,7 160:6,7 64:4 66:2,7 68:21 pawn 209:10 59:23 61:7 71:23 169:2,8,15,20 69:16,17 77:10 203:15 214:3,6,22 78:22 79:17 80:13 200:23 289:17 76:6,8,24 78:12,15 203:15 214:3,6,22 80:14 81:7,8,9,21 200:23 289:17 79:8 80:3 85:5 79:8 80:3 85:5 241:8 244:9 89:6,14 92:12 pays 34:25 93:14 95:10 pays 34:25 99:24 100:8,25 289:20 313:6,7,13 100:16 101:8 206:21 99:24 100:8,25 99:24 100:8,25 314:8,18 321:15 105:14,23 106:3,9 206:21 99:24 100:8,25 99:24 100:8,25 322:19 339:21 107:5 109:9 110:2 206:21 206:21 102:21 103:24,25 patient's 32:18 113:3 114:25 257:24,319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 157:2,7 160:13,13 120:6,20 121:2,13 315:9 317:20 128:17 133:17 124:23 126:8,9 157:4,21 276:8,11 120:6,20 121:2,13 316:6,13,21 17:9 141:21 142:6,24 248:18,20 255:2 279:4,918 280:8	120:12 122:6,22	54:4,17,18,21 55:3	paucity 236:14	49:23 51:22 52:6
158:5,7 160:6,7 169:2,8,15,20 203:15 214:3,6,22 214:25 216:7 224:7,8 228:10 224:7,8 228:10 241:8 244:9 260:16 264:9 289:20 313:6,7,13 314:8,18 321:15 314:8,18 321:15 314:8,18 321:15 314:6 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:16 51:10 66:19 41:19 41:14 12:9 201:19 339:21 318:4,5 319:25 310:12 312:14 241:6 267:23 311:13 314:17 318:4,5 319:25 311:13 314:17 318:4,5 319:25 315:9 317:20 128:17 133:17 318:4,5 319:25 310:16 311:8,13 113:3,5,12,16 14:4 143:6,16 144:19 201:4,17,21 21:15 22:25 23:13,17 22:25 2	124:6,7 132:6,7	55:4,7 56:13 58:7	paul 305:8	53:16,18,19 55:16
169:2,8,15,20	144:18 153:18	61:23 62:3,6 63:2	pause 11:12 220:2	57:14,21 58:3
203:15 214:3,6,22 78:22 79:17 80:13 200:23 289:17 79:8 80:3 85:5 224:7,8 228:10 80:14 81:7,8,9,21 335:15 88:20 89:24 93:5 224:7,8 228:10 81:22 82:16,22 payments 152:20 93:8,19 94:11 241:8 244:9 89:6,14 92:12 pays 34:25 pois 34:25 98:14 97:25 98:7 260:16 264:9 93:14 95:10 payments 157:3,10 95:14 97:25 98:7 289:20 313:6,7,13 100:16 101:8 105:14,23 106:3,9 107:5 109:9 110:2 102:21 103:24,25 340:4,4 110:24 112:9 206:20 216:7 110:20 111:18,19 41:16 51:10 66:19 117:2 118:13 117:2 118:13 157:27, 160:13,13 115:31 117:6,9,19 41:16 210:12 119:4,14 120:7 157:27, 160:13,13 120:6,20 121:2,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 128:17 133:17 157:27, 160:13,13 120:6,20 121:2,13 318:4,5 319:25 144:21 142:6,24 279:4,9,18 280:8 14:4 12:1 142:6,24 320:3 321:14 143:6,16 144:19 279:4,9,18 280:8 14:4 142:8 147:7 16:6,13,21 17:9 199:21 240:18 <t< td=""><td>158:5,7 160:6,7</td><td>64:4 66:2,7 68:21</td><td>pawn 209:10</td><td>59:23 61:7 71:23</td></t<>	158:5,7 160:6,7	64:4 66:2,7 68:21	pawn 209:10	59:23 61:7 71:23
214:25 216:7 80:14 81:7,8,9,21 335:15 88:20 89:24 93:5 224:7,8 228:10 81:22 82:16,22 payments 152:20 93:8,19 94:11 241:8 244:9 89:6,14 92:12 pays 34:25 95:14 97:25 98:7 289:20 313:6,7,13 100:16 101:8 206:21 99:24 100:8,25 348:18 321:15 105:14,23 106:3,9 107:5 109:9 110:2 165:2 167:10 110:20 111:18,19 340:4,4 110:24 112:9 266:20 216:7 111:21 113:2 41:16 51:10 66:19 117:2 118:13 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 41:16 31:13 314:17 124:23 126:8,9 128:17 133:17 160:22 122:113,26:24 122:1143,20 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 129:23 13:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 276:14,24 278:9 132:4 137:9 140:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 282:21,25 290:21 156:45,1578,12 156:45,1578,12 156:45,1578,12 276:25 166:17 162:19,24 166:17 162:19,24	169:2,8,15,20	69:16,17 77:10	pay 35:8 157:4	76:6,8,24 78:12,15
224:7,8 228:10 81:22 82:16,22 payments 152:20 93:8,19 94:11 241:8 244:9 89:6,14 92:12 pays 34:25 93:8,19 94:11 260:16 264:9 93:14 95:10 pays 34:25 99:24 100:8,25 289:20 313:6,7,13 100:16 101:8 206:21 102:21 103:24,25 314:8,18 321:15 105:14,23 106:3,9 107:5 109:9 110:2 165:2 167:10 104:14,23 106:19 340:4,4 110:24 112:9 206:20 216:7 110:20 111:18,19 115:3 117:6,9,19 41:16 51:10 66:19 117:2 118:13 119:4,14 120:7 257:24 319:18 115:13 117:6,9,19 41:16 52:10 62:02 122:20 123:6,8,20 157:2,7 160:13,13 120:6,20 121:2,13 120:6,20 121:2,13 311:13 314:17 124:23 126:8,9 128:17 133:17 160:22 125:18,23 126:23 315:9 317:20 128:17 133:17 274:21 276:8,11 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patiently 150:16 203:2,12 12	203:15 214:3,6,22	78:22 79:17 80:13	200:23 289:17	79:8 80:3 85:5
241:8 244:9 89:6,14 92:12 pays 34:25 95:14 97:25 98:7 260:16 264:9 93:14 95:10 100:16 101:8 99:24 100:8,25 289:20 313:6,7,13 100:16 101:8 105:14,23 106:3,9 102:21 103:24,25 314:8,18 321:15 107:5 109:9 110:2 106:21 104:14,23 106:19 340:4,4 110:24 112:9 206:20 216:7 111:21 113:2 patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 pediatrician 92:11 110:20 111:18,19 67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 128:17 133:17 160:22 122:2 124:13,20 311:13 314:17 124:23 126:8,9 pediatrics 92:16 125:18,23 126:23 318:4,5 319:25 141:21 142:6,24 143:6,16 144:19 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 163:5,25 172:16 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 16:6,13,21 17:9<	214:25 216:7	80:14 81:7,8,9,21	335:15	88:20 89:24 93:5
260:16 264:9 93:14 95:10 pediatric 157:3,10 99:24 100:8,25 289:20 313:6,7,13 100:16 101:8 206:21 102:21 103:24,25 314:8,18 321:15 105:14,23 106:3,9 107:5 109:9 110:2 165:2 167:10 104:14,23 106:19 322:19 339:21 107:5 109:9 110:2 206:20 216:7 110:20 111:18,19 340:4,4 110:24 112:9 206:20 216:7 111:21 113:2 patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 pediatrician 118:4 119:10 67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 160:22 122:12 124:13,20 311:13 314:17 124:23 126:8,9 pediatrics 92:16 125:18,23 126:23 315:9 317:20 128:17 133:17 160:22 125:18,23 126:23 320:3 321:14 143:6,16 144:19 279:4,9,18 280:8 144:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 </td <td>224:7,8 228:10</td> <td>81:22 82:16,22</td> <td>payments 152:20</td> <td>93:8,19 94:11</td>	224:7,8 228:10	81:22 82:16,22	payments 152:20	93:8,19 94:11
289:20 313:6,7,13 314:8,18 321:15 32:19 339:21 340:4,4 patient's 32:18 41:16 51:10 66:19 67:16 210:12 241:6 267:23 315:9 317:20 315:9 317:20 318:4,5 319:25 320:3 321:14 patiently 150:16 patiently 10:20:13:11:13:13:13:13:13:13:13:13:13:13:13:	241:8 244:9	89:6,14 92:12	pays 34:25	95:14 97:25 98:7
314:8,18 321:15 105:14,23 106:3,9 pediatrician 92:11 104:14,23 106:19 322:19 339:21 107:5 109:9 110:2 165:2 167:10 110:20 111:18,19 340:4,4 110:24 112:9 206:20 216:7 111:21 113:2 patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 128:17 133:17 160:22 122:2 124:13,20 315:9 317:20 128:17 133:17 141:21 142:6,24 125:18,23 126:23 122:2 124:13,20 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 125:18,23 126:23 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 276:14,24 278:9 132:4 137:9 140:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 156:4,5 157:8,12 26:25 19:9,16,19 20:6,10 203:2,14 209:24 26:25 26:25 166:17 162:19,24	260:16 264:9	93:14 95:10	pediatric 157:3,10	99:24 100:8,25
322:19 339:21 107:5 109:9 110:2 165:2 167:10 110:20 111:18,19 340:4,4 110:24 112:9 206:20 216:7 111:21 113:2 patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 157:2,7 160:13,13 120:6,20 121:2,13 67:16 210:12 129:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 157:2,7 160:13,13 120:6,20 121:2,13 315:9 317:20 128:17 133:17 128:17 133:17 126:24 127:18 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patients 12:18,22 150:13 151:13,17 279:4,9,18 280:8 141:4 142:8 147:7 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 15:6,13,21 17:9 196:21 197:15 282:22,5 29:21 156:4,5 157,8,12 19:9,16,19 20:6,10 203:2,14 209:24 229:21 240:18 276:25 pending 9:5 163:9 164:7,8,12 22:25 23:13,17	289:20 313:6,7,13	100:16 101:8	206:21	102:21 103:24,25
340:4,4 110:24 112:9 206:20 216:7 111:21 113:2 patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 pediatricians 118:4 119:10 67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 160:22 122:2 124:13,20 315:9 317:20 128:17 133:17 pediatrics 92:16 125:18,23 126:23 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 146:9 147:19,21 276:14,24 278:9 132:4 137:9 140:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 276:25 163:9 164:7,8,12 20:14,17,21 21:15 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 195:16 168:19 170:1	314:8,18 321:15	105:14,23 106:3,9	pediatrician 92:11	104:14,23 106:19
patient's 32:18 113:3 114:25 257:24 319:18 115:13 117:6,9,19 41:16 51:10 66:19 117:2 118:13 pediatricians 118:4 119:10 67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 160:22 122:2 124:13,20 315:9 317:20 128:17 133:17 pediatrics 92:16 125:18,23 126:23 318:4,5 319:25 141:21 142:6,24 pediatrics 92:16 125:18,23 126:23 320:3 321:14 143:6,16 144:19 274:21 276:8,11 129:9,23 131:5 patiently 150:16 146:9 147:19,21 279:4,918 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14	322:19 339:21	107:5 109:9 110:2	165:2 167:10	110:20 111:18,19
41:16 51:10 66:19 117:2 118:13 pediatricians 118:4 119:10 67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 160:22 122:2 124:13,20 311:13 314:17 124:23 126:8,9 pediatrics 92:16 125:18,23 126:23 315:9 317:20 128:17 133:17 128:17 133:17 126:24 127:18 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 175:2 192:11,25 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 196:21 197:15 276:25 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 276:25 160:17 162:19,24 20:14,17,21 21:15 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 29:17,19 20:8:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 <t< td=""><td>340:4,4</td><td>110:24 112:9</td><td>206:20 216:7</td><td>111:21 113:2</td></t<>	340:4,4	110:24 112:9	206:20 216:7	111:21 113:2
67:16 210:12 119:4,14 120:7 157:2,7 160:13,13 120:6,20 121:2,13 241:6 267:23 121:20 123:6,8,20 160:22 122:2 124:13,20 311:13 314:17 124:23 126:8,9 pediatrics 92:16 125:18,23 126:23 315:9 317:20 128:17 133:17 pediatrics 92:16 125:18,23 126:23 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 196:21 197:15 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 201:4,17,21 21:15 223:25 224:21 26:25 163:9 164:7,8,12 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 <	patient's 32:18	113:3 114:25	257:24 319:18	115:13 117:6,9,19
241:6 267:23 121:20 123:6,8,20 160:22 122:2 124:13,20 311:13 314:17 124:23 126:8,9 128:17 133:17 126:24 127:18 315:9 317:20 128:17 133:17 126:24 127:18 126:24 127:18 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 <td>41:16 51:10 66:19</td> <td>117:2 118:13</td> <td>pediatricians</td> <td>118:4 119:10</td>	41:16 51:10 66:19	117:2 118:13	pediatricians	118:4 119:10
311:13 314:17 124:23 126:8,9 pediatrics 92:16 125:18,23 126:23 315:9 317:20 128:17 133:17 peer 154:6 274:19 126:24 127:18 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 160:17 162:19,24 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 27:15,19,22 28:3 310:16 311:8,9 19:15 20:15 21:7 192:15,16 194	67:16 210:12	119:4,14 120:7	157:2,7 160:13,13	120:6,20 121:2,13
315:9 317:20 128:17 133:17 peer 154:6 274:19 126:24 127:18 318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 156:4,5 157:8,12 16:6,13,21 17:9 196:21 197:15 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 276:25 160:17 162:19,24 20:14,17,21 21:15 223:25 224:21 29:1 40:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 29:21 240:18 195:16 168:19 170:14 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 36:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4	241:6 267:23	121:20 123:6,8,20	160:22	122:2 124:13,20
318:4,5 319:25 141:21 142:6,24 274:21 276:8,11 129:9,23 131:5 320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 24:19,24,25 25:9 247:11,14,21 195:16 168:19 170:14 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	311:13 314:17	124:23 126:8,9	pediatrics 92:16	125:18,23 126:23
320:3 321:14 143:6,16 144:19 276:14,24 278:9 132:4 137:9 140:7 patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 229:21 240:18 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 pensylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 3	315:9 317:20	128:17 133:17	peer 154:6 274:19	126:24 127:18
patiently 150:16 146:9 147:19,21 279:4,9,18 280:8 141:4 142:8 147:7 patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8	318:4,5 319:25	141:21 142:6,24	274:21 276:8,11	129:9,23 131:5
patients 12:18,22 150:13 151:13,17 281:23 282:3,6,13 147:7 148:11,14 13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 310:16 311:8,9 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	320:3 321:14	143:6,16 144:19	276:14,24 278:9	132:4 137:9 140:7
13:3,5,12,16 14:4 163:5,25 172:16 282:21,25 290:21 154:21 155:2,13 14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 16:6,13,21 17:9 196:21 197:15 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	patiently 150:16	146:9 147:19,21	279:4,9,18 280:8	141:4 142:8 147:7
14:6,16,23 15:17 175:2 192:11,25 peers 52:10 156:4,5 157:8,12 16:6,13,21 17:9 196:21 197:15 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	patients 12:18,22	150:13 151:13,17	281:23 282:3,6,13	147:7 148:11,14
16:6,13,21 17:9 196:21 197:15 276:25 160:17 162:19,24 19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	13:3,5,12,16 14:4	163:5,25 172:16	282:21,25 290:21	154:21 155:2,13
19:9,16,19 20:6,10 203:2,14 209:24 pending 9:5 163:9 164:7,8,12 20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	14:6,16,23 15:17	175:2 192:11,25	peers 52:10	156:4,5 157:8,12
20:14,17,21 21:15 223:25 224:21 penis 180:11 165:17 167:15 22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	16:6,13,21 17:9	196:21 197:15	276:25	160:17 162:19,24
22:25 23:13,17 229:21 240:18 195:16 168:19 170:14 24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	19:9,16,19 20:6,10	203:2,14 209:24	pending 9:5	163:9 164:7,8,12
24:19,24,25 25:9 247:11,14,21 pennsylvania 173:5,10,11,17,22 25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	20:14,17,21 21:15	223:25 224:21	penis 180:11	165:17 167:15
25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	22:25 23:13,17	229:21 240:18	195:16	168:19 170:14
25:17,21 26:15 248:18,20 255:2 181:17,20 208:18 174:8 175:8 27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	24:19,24,25 25:9	247:11,14,21	pennsylvania	173:5,10,11,17,22
27:15,19,22 28:3 310:16 311:8,9 people 17:2 18:7 180:17,23 192:13 28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	25:17,21 26:15	248:18,20 255:2	-	174:8 175:8
28:12,24 29:6,7,20 312:18 314:10 19:15 20:15 21:7 192:15,16 194:19 30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18	· ·	·	people 17:2 18:7	180:17,23 192:13
30:4,13,21 31:10 317:9 318:24 22:17,19 23:3 194:25 195:6 33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18			19:15 20:15 21:7	
33:4 35:13,18 336:17 24:6 25:18 27:18 196:2 197:19 36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18		317:9 318:24	22:17,19 23:3	
36:12,13,16 38:4 patrick 304:17,19 28:21 30:18 35:8 201:17 204:18		336:17	· · · · · · · · · · · · · · · · · · ·	196:2 197:19
	· ·	patrick 304:17,19	28:21 30:18 35:8	201:17 204:18
30.1 1,13 10.23 33.22 30.3 30.17 200.11 207.2,23	38:14,15 40:25		35:22 36:5 38:17	206:11 207:2,23
				•

[people - places] Page 41

211:24 212:2,10	perfect 225:8,17	101:18 102:3,5,14	phrased 216:24
212:11 213:6,19	perform 189:3	108:4,23,25 112:3	327:13
218:11 219:5,12	perfunctory	113:24 114:4,11	physical 43:4
225:11 226:9,10	152:25	115:22 122:8	66:19 166:4
236:16 238:12,14	period 81:12	125:7,14,16 127:8	224:20 313:5
241:12,15 243:25	119:11 147:3	127:10 140:11	328:23
248:9 251:24	153:5 227:9	142:22 165:9	physically 169:24
254:6,17 257:3,19	230:19 251:14	169:3 184:19	physician 38:19
258:15,24 259:4	253:16 256:24	189:12,13,17,18	41:10,11,14
259:13 260:7,10	268:2 293:20	224:25,25 225:5	156:15,17 266:10
261:8 262:2,4,19	309:4	241:7 276:16,18	physicians 129:11
263:25 267:12	periods 259:14	304:15,16 305:24	154:16 163:20
268:21 269:4,10	permanent 131:25	314:12,20 317:7	167:8 197:4,6
274:5,15 275:2,6	140:22 180:8	317:11,16 318:10	287:23 297:2,3
275:25 276:22	permanently	318:10 322:14	328:22
277:3 280:25	251:13	338:5,9	physiologic
281:14,15 282:24	permission 339:11	person's 34:10	164:18
284:11,17,24	permit 138:18	42:18 81:17,18	physiological
286:7,8 287:5,24	permitted 134:18	83:9 101:19,21	311:25 312:14
288:3 290:6,23,24	perplexed 184:21	119:25 251:13	physiology 251:12
293:5 296:6	persist 255:6,9	312:16	pick 297:2 306:25
297:25 299:23	persisted 256:10	personal 145:3	picked 8:14
301:3,7,19 302:20	persistence 252:11	156:18,18	279:23
303:6 306:21	persists 102:4	personality	picture 42:16
309:3,10,14	person 19:6 22:13	301:22	97:24
314:22,24 316:11	25:25 26:9,22	personally 16:22	piece 127:10
320:17,23 321:3	27:5,10 36:15	111:13 180:3	pieces 109:6,8
321:11,22,24	37:7 42:17 43:9	305:11	pill 117:19
322:3 324:15	43:13,18 45:22,23	persons 268:25	pittsburgh 59:16
326:7 330:13	45:23,24,24 48:9	perspective	pivot 16:12
332:18 334:14	48:15,16 51:2,12	216:20 217:5	place 76:6 77:6
335:2,4,18 336:4,5	51:14 56:20,22	perspectives	84:3 158:10
336:25 339:14	59:7,12,15 61:9	246:10	231:12 342:13
340:17	67:18,20,22,25	ph.d. 309:24	placebo 117:18,23
people's 260:13	74:15,24 81:25	ph.d.'s 129:12	123:22 230:19,20
296:12 298:7	82:5,9 83:10	phenomena	237:2,3,5,6 249:3
perceives 41:18	84:12 87:19 91:11	140:21	251:21
percentage 20:23	95:20,23 96:5	phenomenon	places 76:17,18
21:16 148:14	97:17 98:9,18	51:21 115:3 131:5	80:5,6 232:23
261:6	99:9,11,13,15,18	phrase 73:21	246:9 257:11
	99:19,21,21	129:2 196:11	296:6

[plaintiff - present]

Page 42

plaintiff 5:7	303:9 316:7	posture 312:24	predispose 216:17
plaintiffs 1:8 3:2	323:20 327:4	313:21	predominance
4:2 5:16,19,23 6:2	332:2,7,8	potential 203:17	295:8
6:5,12 7:11 9:25	' '	246:10 321:25	prefaces 193:17
· ·	policymakers		_
10:9 241:9 334:13	296:8	potentially 13:11	prefer 170:23
planning 60:11	polite 303:12	81:9	171:3 212:14,18
187:21	political 94:5,8	power 290:3	prefers 91:13
playing 115:10,11	209:9,10 301:16	powerful 189:3	pregnancy 107:20
please 5:13 7:14	326:16,20	246:7,7	158:12
8:16,20 21:12	politically 170:5	powerfully 306:21	preliminary
28:25 40:22 71:5	politician 177:19	practically 204:16	102:12
86:7 119:22	politicians 218:19	331:4	premature 93:15
182:10 183:5	politicized 209:11	practice 14:5	93:16
190:24 219:11	politics 233:22	20:23 21:2 23:3	prematurely
221:17,18 234:11	pontificating	23:11 24:7,14	57:23
238:22 272:6	241:8,9	27:11,16,19 28:3	preoccupied
286:21,21 304:8	pool 21:17 106:21	29:10,21 34:23	174:25 175:4
pleasure 188:9	population 254:17	37:6 39:18 60:21	213:2
195:15	255:2	61:10 64:15 66:2	preparation 10:21
pleasures 113:21	populations	73:2,10,14 80:20	prepare 9:20 11:4
pockets 298:18	212:10	81:5 198:21 199:4	11:9 12:7
podium 237:23	portions 1:15	201:16 248:25	prepared 98:10
point 9:4,8 23:21	position 114:19	266:16 332:10	preparing 234:16
40:17 48:4,15	156:7 178:16,18	practices 130:5	prepubertal 15:2
49:3 67:17 82:21	179:4,25 180:2,20	140:6 198:18,19	15:5,18,22 16:8
148:23 162:11,14	285:10 301:25	291:25 299:10,11	33:16,19 112:5,8
168:24 190:25	positions 221:16	332:20	252:24 258:20
197:22 205:5	300:13	practicing 12:25	263:17
226:20 242:15	positive 126:3	practitioner 41:10	prescribe 144:11
250:9 261:16	203:16 211:21	146:17 147:16	249:8
268:9 280:14	218:7	263:20	prescribed 66:4
pointing 280:20	possibility 57:23	practitioners	66:13 67:8 69:3
points 278:6 337:5	93:12 299:10	149:8 154:11	249:12 300:5
polarized 335:18	323:23	pre 258:5	prescribing
policies 302:18	possible 57:11	preceded 43:24	162:18
policy 129:17	124:17 125:25	precedent 154:24	prescription 59:18
131:20,22 132:10	187:20,25 205:19	precise 74:5	340:20
132:12,23 133:7	246:22	precisely 250:3	prescriptions
136:20 167:17	possibly 133:15	preclude 62:9	66:15
177:21,21 227:17	post 268:3	150:19	present 4:20 23:10
286:16 288:15	Pust 200.3	150.17	23:20 25:4,6 26:3
200.10 200.13			25.20 25.4,0 20.5
		l .	

[present - promise] Page 43

26.5 6 11 15 22	!!! 100.10	15.14	f 121.7
26:5,6,11,15,23	principle 180:10	problems 15:14	profession 131:7
27:2 32:10 62:13	principles 106:2	21:19,20,21 22:2	165:14 166:2,3
116:11 171:10	289:12,17 295:23	26:6,7,8,8 29:8	168:25 210:21
178:2 291:20	325:20 326:10	46:6 62:16 78:21	217:20 218:21
338:25	prior 150:16 192:6	88:24 90:12	professional 2:9
presentation	342:4	104:21,21 210:13	26:20 41:19 58:4
37:13 181:9	prison 115:4,5	216:4 317:12	103:3,10,19
343:21	328:12,15,24	335:7	104:10,13 126:23
presentations	prisoner 142:18	proceed 108:11	126:25 164:22,24
293:8	prisoners 115:2	proceedings 341:6	165:3 167:12
presented 16:4	private 24:13	342:11	196:8,10 305:15
22:15,16 25:21	224:10 289:22	process 19:8 39:2	342:3
281:4 294:13	privileged 288:13	59:3 87:10 89:5	professionals 26:5
presenters 292:11	probably 18:11	89:12,17,21	30:9 125:22
294:17	24:6 35:11,21	109:21 110:14	150:14 159:24
presenting 302:16	54:13 64:6 69:22	115:10 140:17	196:15 287:24
presents 285:2	74:20 79:21 95:4	146:10 147:20	289:2 306:17
preservation	107:8 123:22	150:18 151:2,15	professions 93:11
152:9	149:7,12 186:13	151:16 152:12	140:5
pressure 189:5	200:15 225:2	153:4 158:11,12	profile 201:13
presume 70:24	233:17 250:16	158:12,13,13	profound 150:11
170:18 178:3	256:12 259:8	162:23 163:6	193:22
248:2 273:7,9	267:7 273:16	174:3,3 184:13	profoundly 213:7
presumed 324:13	274:14 275:12	189:6,15 200:4	program 23:8
presuming 151:23	280:18 284:20	202:14 205:9,18	25:19 292:22,25
pretty 88:3 137:12	286:22 288:9	208:16 212:22,23	303:4
240:6,25	306:7,24	214:7 227:23	programs 80:2,3
prevent 9:11	problem 17:3,5,11	230:14,15 248:12	147:18
211:16	29:15 41:20 43:19	249:2 264:20	progress 337:12
preventing 168:17	62:12 76:16 79:3	279:4,9,18 281:10	prohibit 172:14
previous 40:6	94:18 104:4,8	281:23 282:23	prohibited 137:12
96:13 256:13	131:10 158:21	288:16 290:13	156:11 285:12,14
287:10 311:22	164:4,12,15,19,20	291:5 298:2	prohibiting
previously 31:15	165:24 175:21	331:23 338:16	138:13 205:15
40:24 174:9	188:14 203:17	processes 26:13	prohibits 162:5
primarily 36:2	210:10,12,17	107:12 108:3,10	proliferating
96:21,22 165:23	219:23 221:23	153:2 229:13	268:13
primary 41:9	222:17 265:2,3	267:6,25 289:11	prolonged 231:11
165:2 206:24	297:8 313:17	296:6	259:14
230:4,7,10 262:8	317:13 318:12	product 75:13	promise 95:23
287:22	321:13 338:13	107:11	

promised 102:5	170:7 186:25	282:8,8,14 284:21	psychologists
promote 198:15	187:5 205:8,10	293:11 294:3	275:8
promoting 179:15	228:6 247:11,13	300:21 302:7	psychology 116:6
188:20 198:17,20	247:20 314:4,14	315:21,23 316:12	189:20 267:10
199:3	323:18 329:5	316:17,24 317:10	296:20
pronouncement	330:6 332:3,11	319:6 320:4,12	psychopathic
291:4	339:13	334:18	301:21
pronouncements	provided 63:2	psychiatrist 12:17	psychopathology
124:19	71:7 149:2 155:16	12:20 22:22,22	83:12 153:11
proper 24:9	155:23 156:3	34:5,6,7 36:24	185:7,8,9 301:20
212:16	178:13 202:16	77:21 103:9	psychosexual
proponent 177:15	214:6 227:6	119:15,21 121:22	90:12
265:23	229:22 311:13	122:6 207:5 248:3	psychosocial
proportion 259:6	331:15	248:6,11 305:19	90:11
proposals 172:12	provider 39:25	309:22,23 310:14	psychotherapeutic
proposed 94:16	41:7 102:18	319:17	36:4 62:23 66:8
pros 46:3	providers 23:12	psychiatrists	84:18,20 135:24
prosecutor's	75:22 77:13 87:10	121:23 248:7	248:11 288:25
165:18	202:23 332:20	300:25	289:22 335:6
prosecutors 232:7	333:15 334:3	psychiatry 12:25	psychotherapist
proselytize 109:22	provides 329:4	194:9 238:17	67:22
prostate 266:14,23	providing 9:11	250:17 309:12,13	psychotherapists
267:2	19:10 35:24 90:6	313:15 316:2	290:9
protecting 212:8	145:8,14 146:7	322:21 336:13	psychotherapy
protection 4:11	149:16 178:21	psychodynamic	71:23 77:24 93:10
protocol 135:4	202:24 227:19	36:8	105:16,22 106:3
231:4 233:13	229:24 299:25	psychological	106:25 107:3,5
295:14	327:6 334:16	87:23 88:24	108:20 109:19
protocols 149:15	provision 310:10	106:11 140:10	110:12,16,25
proud 314:23	provisions 170:24	164:3,20 166:4,16	111:20 112:16
prove 205:21,23	171:4	171:13 188:15	114:12 136:4,11
240:13 281:19,20	prudence 221:2	189:21 210:10,11	136:18 138:17,20
339:16	psa 266:19,21,22	220:15 269:12	188:21 189:2
proven 174:13	pseudonym	290:15 294:5	227:22 235:25
206:6 298:6 299:7	272:23 275:2,10	311:19 313:23	236:20 237:4
provide 44:16	psyche 115:15	314:4	238:4,13,15
47:17 48:8 75:17	116:7	psychologically	240:18 242:2,20
84:17 102:17	psychiatric 41:13	169:22 210:14	248:7 289:3,8,14
145:17 151:12	42:15 48:17 98:5	psychologist 34:4	290:23 295:24
159:10 161:14	101:4 102:12	266:10	psychotic 318:14
168:23 169:19	114:6 121:12		

[pubertal - rate] Page 45

			T
pubertal 258:5	purpose 42:15	118:8,12 119:9	151:6 184:10
268:3	249:17,22	121:19,20 123:2	192:8 222:3
puberty 49:19	purposes 26:20	124:3 126:21	229:10 252:22
80:15,16,17 136:5	209:10	128:8,11 130:20	268:18 270:25
137:16,24 140:2	pursuant 2:6	130:21 131:11	299:18 341:2
153:24 156:23	pursue 226:2	132:16,22,24	quick 282:20
184:11 186:9	pursuing 55:23	133:20 142:18	quicker 84:19
197:19 198:4	put 17:15 28:2	146:4 147:10	quickly 72:2,4
227:14,19 243:22	82:22 109:20	151:22 153:3	79:9 144:11 170:9
244:3,8,20,23	128:25 174:7	166:19 175:17	189:8 202:25
253:3,14,15	186:9,10 187:11	177:3 178:8 181:5	quit 275:5,6
254:24 258:3	187:13 190:25	182:19 186:7	quite 12:20 272:12
259:10 300:5	199:22 227:9	187:14,15 190:11	quote 76:19
public 2:10 4:11	288:3 304:7 336:9	191:8,9,14 193:3	198:18
124:13,18 131:20	puts 277:4	197:10 199:2,24	quoted 261:16
131:22 132:10,12	putting 199:2	204:25 207:19	r
132:22 133:6	219:7 224:15	211:13,20 214:16	_
177:20 209:14,20	328:24	218:5,10 220:18	r 3:1 4:1 91:2
347:19	q	226:25 228:4,16	303:19,19,23,24
publication 279:8		230:3,4 233:13,16	303:24 304:20
283:10	qualified 207:25	237:13 243:2	305:8 342:1 346:3
publications 78:21	207:25	246:17,17,23	346:3
283:3 307:25	qualify 233:12	247:6 248:16	radiation 266:24
publish 231:14	241:19	254:13 255:10,13	ragon 4:3 6:11
287:20,21	quality 90:19	255:15,19 257:22	raised 203:7
published 87:3	212:19,21 289:18	258:14,22 259:12	raises 269:6
98:5 101:2 129:10	question 8:3,5,6,9	264:7 269:6	raising 158:13
237:8 242:17	8:18,21,22 9:6,7	279:15 283:5	173:2 184:9
257:5 259:19	10:5 12:8 17:8	285:4 302:15	ran 28:17
261:14 271:9,12	21:11 28:9 29:12	307:21 319:25	randomized
279:7,11 281:9	30:2 32:4,12	322:23 324:22	247:15,22 248:13
308:16	33:25 39:3 40:5,6	325:3,10 335:14	248:17 250:11
publishes 241:2	40:19,22 43:15	337:23 338:2	251:20
publishing 273:20	44:21,22 45:11	questioning 55:24	range 310:15
281:5	47:21 48:24 49:4	148:22	rapid 130:3
pull 272:5	49:7 50:20 51:8	questionnaires	137:23 144:10
_	53:5 56:7 60:11	313:22	268:5
pulse 312:16	79:12 82:13 83:4		rapidity 284:2
punish 325:22	83:16,22 89:21	questions 7:22	rare 79:22 115:13
punts 206:22	100:2 104:25	12:16 38:11 66:11	rate 215:20,23
purported 194:13	106:4 107:7 113:4	83:3 126:5,19	218:3,22 260:12
	116:24 117:21	128:19 145:22	260:14,16 261:4
	T7 '4 4 T		

[rate - record] Page 46

261:23 262:11 329:12 331:9 readmitted 142:20 reads 219:25 reasonale 114:18 174:17 234:23 239:11 256:23 329:11 308:5 335:12 reasonable ness 335:12 reasonable	0.41.00.040.44	220 12 221 2	11 44440	100 05 110 15
rates 141:14 reads 219:25 280:11 239:11 256:23 296:11 308:5 336:21 275:13 308:6 335:12 296:11 308:5 335:12 ratios 185:22 realize 84:14 reasoning 286:4 recognized 263:16 342:2,24 realized 180:19 restized 182:17 realized 180:19 recasons 95:18 320:16 338:20 recognizing reach 281:17 67:15 90:15 727:21 321:20 recognizing 17:12 recognizing 17:112 recognizing 17:12 recognizing 17:12 recognizing 17:12 recognizing 17:12 recognizing 17:12 recognizing 17:12				
225:14 309:7 336:21 real 273:5,13,16 275:13 reasonableness 308:6 296:11 308:5 335:12 296:11 308:5 335:12 ratios 185:22 reatios 185:22				
336:21 275:13 308:6 reasoning 286:4 recognized 263:16 ratto 1:25 2:7 342:2,24 realized 180:19 reasons 95:18 320:16 338:20 recognized 263:16 zerceptance 281:17 really 32:5 50:21 67:15 277:21 321:20 recognizing 171:12 recollection recollection 261:18 recollection 261:18 recollection recollection 261:18 recollection 261:18 recollection 272:24 68:18 1				
ratios 185:22 ratto realize log:3 188:7 realized reasons 95:18 reasons 97:21 125:17,21 recognizing recognized 263:16 338:20 recognizing reacceptance 981:17 reached 281:17 reached 227:5 100:24 102:24 103:21 116:3,23 120:5 read 9:24 10:811 116:3,23 120:5 read 9:24 10:811 116:3,23 120:5 112 35:9 65:23 163:13 165:16 11:2 35:9 65:23 163:13 165:16 11:2 35:9 65:23 163:13 165:16 16:24 66:9 71:11 169:6 186:8 17:15,20 72:6,13 200:23 202:2 87:6 93:5,8 138:3 203:22,24 211:14 150:8 151:4 211:15,20 215:12 161:21,25 182:16 221:5,15 237:5 182:25 183:2,3,15 245:4,6,12 248:12 25:17 253:14 191:5,10,22 192:3 25:17 253:14 267:21 270:9,11 299:2 301:14 271:8,13 272:16 273:6 276:19 288:10 306:5,24 307:21 311:21 realm 263:22 realm 263:22 readers 241:4 335:9 345:9 347:5 readers 241:4 335:9 37:5 readers 241:4 133:25 173:8,10 235:10 235:19 282:16 232:10 235:19 346:21 339:5,7 345:11 reading 10:6 91:7 193:5 209:15,16 346:6),12,15,18 232:10 235:19 346:21 346:21 recognize 36:18 65:8 67:17 70:18 11:22,25 12:3 recosning 286:4 reasons 95:18 recognizing 167:25 recognizing 17:122 recognizing 17:122 recognizing 167:25				
ratto 1:25 2:7 169:3 188:7 realized 180:19 reacceptance really 32:5 38:18 320:16 338:20 267:24 38:25 50:21 67:15 7:27:21 125:17,21 171:12 recognizing reach 281:17 67:15 90:15 reached 227:5 100:24 102:24 173:12 20 resignment 261:18 read 9:24 10:8,11 116:3,23 120:5 reassignment 193:19 recommend 62:5 read 9:24 10:8,11 152:14,22 162:20 152:14,22 162:20 recall 37:9 63:13 66:24 68:13,14,15 respect 65:24 66:9 71:11 169:6 186:8 138:11 176:24 163:13 165:16 63:18 100:25 62:24 68:13,14,15 71:15,20 72:6,13 200:23 20:2 138:11 176:24 161:21,25 182:16 181:18,21 190:17 receivel 345:18 98:12 101:3 147:2 recommendation 71:15,20 72:6,13 200:23 20:2 138:11 176:24 161:21,25 182:16 181:18,21 190:17 receivel 345:18 98:12 101:3 147:2 recommendation 63:5 80:7 90:3 98:12 101:3 147:2 recommendation 192:3 217:21 254:8 256:20 70:9 86:12 98:3 70:9 86:12 98:3				
342:2,24 realized 180:19 77:21 125:17,21 recognizing 267:24 38:25 50:21 67:15 277:21 321:20 recollection reache 281:17 67:15 90:15 reassignment 193:19 recollection reached 227:5 100:24 102:24 reassignment 193:19 recollection read 9:24 10:8,11 124:15 144:17 ressignment 193:19 recollection read 9:24 10:8,11 124:15 144:17 recall 37:9,17 71:22 82:9 84:20 ressuring 167:25 recall 37:9,17 71:22 82:9 84:20 recall 30:24 66:9 71:11 169:6 186:8 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 20:22 181:18,21 190:17 63:5 80:7 90:3 87:6 93:5,8 138:3 203:22,24 211:14 21:15,15 202:15:12 136:10 26:23 19:2: 2 182:25 221:5,15 237:5 136:10 26:23 101:5 137:8 288:2 19:2: 2 17:12 254:8 256:20 70:9 86:12 98:3 101:5 137:8 288:2 19:2: 2 17:12 254:8 256:20 70:9 86:12 98:			_	
reacceptance really 32:5 38:18 143:3,9 275:20 171:12 267:24 38:25 50:21 67:15 277:21 321:20 recollection zeach 281:17 67:15 90:15 reassignment 10:24 102:24 193:19 recollection z81:18 10:24 10:8,11 116:3,23 120:5 reassuring 167:25 62:24 68:13,14,15 read 9:24 10:8,11 10:12,14,18,20,25 152:14,22 162:20 recall 37:9 63:13 62:24 68:13,14,15 11:2 35:9 65:23 163:13 165:16 63:18 100:25 138:11 176:24 136:3 160:2,14,16 71:15,20 72:6,13 200:23 202:2 181:18,21 190:17 receipt 345:18 70:24 63:5 80:7 90:3 98:12 10:31 47:2 70:28 32:19		169:3 188:7	reasons 95:18	
267:24 38:25 50:21 67:15 277:21 321:20 recollection reach 281:17 67:15 90:15 reassignment 193:19 recommend 62:5 281:18 116:3,23 120:5 reassuring 167:25 62:24 68:13,14,15 7ecommend 62:5 read 9:24 10:8,11 124:15 144:17 rebutted 307:9,17 71:22 82:9 84:20 71:22 82:9 82:9 84:20 71:22 82:9 82:9 84:20 71:22 82:9 82:9 84:20 71:22 82:9 82:9 84:20 72:28:23 72:28:23 72:28:23 7	342:2,24	realized 180:19	97:21 125:17,21	recognizing
reach 281:17 67:15 90:15 reassignment 193:19 recommend 62:5 281:18 100:24 102:24 193:19 recommend 62:5 read 9:24 10:8,11 124:15 144:17 rebutted 307:9,17 71:22 82:9 84:20 10:12,14,18,20,25 152:14,22 162:20 recall 37:9 63:13 136:3 160:2,14,16 11:2 35:9 65:23 163:13 165:16 63:18 100:25 138:11 176:24 recall 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 202:2 181:18,21 190:17 receipt 345:18 98:12 101:3 147:2 recommendation 150:8 151:4 211:15,20 215:12 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 298:12 101:3 147:2 receive 80:15,17 recommendations 63:5 80:7 90:3 98:12 101:3 147:2 recommendations 101:5 137:8 288:2 294:23 101:5 137:8 288:2 294:23 294:23 101:5 137:8 288:2 294:23 294:23 101:5 137:8 288:2 294:23 101:5 137:8 288:2 294:23 101:5 137:8 288:2 294:23 101:5 137:8 288:2 294:23 101:5 137:	reacceptance	really 32:5 38:18	143:3,9 275:20	171:12
reached 227:5 100:24 102:24 193:19 recommend 62:5 281:18 116:3,23 120:5 reassuring 167:25 62:24 68:13,14,15 read 9:24 10:8,11 124:15 144:17 rebutted 307:9,17 71:22 82:9 84:20 11:2 35:9 65:23 163:13 165:16 63:18 100:25 136:3 160:2,14,16 65:24 66:9 71:11 169:6 186:8 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 202:2 138:11 176:24 63:58 80:7 90:3 87:6 93:5,8 138:3 203:22,24 211:14 211:15,20 215:12 receipt 345:18 98:12 101:3 147:2 161:21,25 182:16 221:5,15 237:5 136:10 226:23 98:12 101:3 147:2 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 recommendations 192:3 217:21 254:8 256:20 70:9 86:12 98:3 101:5 137:8 288:2 294:23 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 135:22 136:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 326:16 329:14 1	267:24	38:25 50:21 67:15	277:21 321:20	recollection
281:18 116:3,23 120:5 reassuring 167:25 62:24 68:13,14,15 read 9:24 10:8,11 124:15 144:17 rebutted 307:9,17 71:22 82:9 84:20 10:12,14,18,20,25 152:14,22 162:20 recall 37:9 63:13 136:3 160:2,14,16 65:24 66:971:11 169:6 186:8 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 202:2 183:11 176:24 receipt 345:18 790:3 87:6 93:5,8 138:3 203:22,24 211:14 211:15,20 215:12 receipt 345:18 98:12 101:3 147:2 161:21,25 182:16 221:5,15 237:5 136:10 226:23 98:12 101:3 147:2 recommendations 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 70:15 137:8 288:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 75:23 97:3,14 267:12 70:9,11 299:2 301:14 190:7 234:14 135:22 136:3 75:23 97:3,14 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 75:23 97:3,14 298:10 306:5,24 331:3 340:5,8 79:5 171:7 172:	reach 281:17	67:15 90:15	reassignment	261:18
read 9:24 10:8,11 124:15 144:17 rebutted 307:9,17 71:22 82:9 84:20 10:12,14,18,20,25 152:14,22 162:20 recall 37:9 63:13 136:3 160:2,14,16 65:24 66:9 71:11 169:6 186:8 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 20:2: 181:18,21 190:17 recommendation 87:6 93:5,8 138:3 203:22,24 211:14 receipt 345:18 98:12 101:3 147:2 161:21,25 182:16 211:15,20 215:12 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 receive 80:15,17 192:3 217:21 254:8 256:20 70:9 86:12 98:3 recommended 192:3 217:24 254:8 256:20 70:9 86:12 98:3 recommended 235:11,12,14,20 260:18 274:24 17:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 172:17 211:7 87:8 98:8	reached 227:5	100:24 102:24	193:19	recommend 62:5
10:12,14,18,20,25 152:14,22 162:20 recall 37:9 63:13 136:3 160:2,14,16 11:2 35:9 65:23 163:13 165:16 63:18 100:25 162:23 321:19 65:24 66:9 71:11 169:6 186:8 138:11 176:24 162:23 321:19 71:15,20 72:6,13 200:23 202:2 181:18,21 190:17 63:5 80:7 90:3 87:6 93:5,8 138:3 203:22,24 211:14 receipt 345:18 98:12 101:3 147:2 150:8 151:4 211:15,20 215:12 215:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 receive 40:11 101:5 137:8 288:2 192:3 217:21 254:8 256:20 228:23 294:23 192:3 217:21 254:8 256:20 270:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 12:12 67:8 68:5 69:2 235:11,12,14,20 260:18 274:24 117:3 12:1 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 273:6 276:19 326:16 329:14 239:5 244:2 272:9 138:16 148:2 298:10 306:5,24 331:3 340:5,8 75:5 1	281:18	116:3,23 120:5	reassuring 167:25	62:24 68:13,14,15
11:2 35:9 65:23 163:13 165:16 63:18 100:25 162:23 321:19 65:24 66:9 71:11 169:6 186:8 200:23 202:2 181:18,21 190:17 recommendation 87:6 93:5,8 138:3 203:22,24 211:14 211:15,20 215:12 181:18,21 190:17 receipt 345:18 98:12 101:3 147:2 161:21,25 182:16 221:5,15 237:5 136:10 226:23 98:12 101:3 147:2 2ecommendations 192:3 217:21 254:8 4,6,12 248:12 228:23 receive 80:15,17 136:10 226:23 294:23 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 101:5 137:8 288:2 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 7ecommending 333:6,9,11,12 28:16 51:7 74:13 229:5 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 296:10 335:12 337:19 178:11 343:16 <tr< td=""><td>read 9:24 10:8,11</td><td>124:15 144:17</td><td>rebutted 307:9,17</td><td>71:22 82:9 84:20</td></tr<>	read 9:24 10:8,11	124:15 144:17	rebutted 307:9,17	71:22 82:9 84:20
65:24 66:9 71:11 169:6 186:8 138:11 176:24 recommendation 71:15,20 72:6,13 200:23 202:2 181:18,21 190:17 63:5 80:7 90:3 87:6 93:5,8 138:3 203:22,24 211:14 receipt 345:18 98:12 101:3 147:2 150:8 151:4 211:15,20 215:12 receive 80:15,17 recommendations 161:21,25 182:16 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 receive 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 67:8 68:5 69:2 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 135:23 16:15 273:6 276:19 326:16 329:14 239:5 244:2 272:9 78:8 98:8 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 78:8 98:8 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 223:6 291:14,17 178:11 343:16 readers	10:12,14,18,20,25	152:14,22 162:20	recall 37:9 63:13	136:3 160:2,14,16
71:15,20 72:6,13 200:23 202:2 181:18,21 190:17 63:5 80:7 90:3 87:6 93:5,8 138:3 203:22,24 211:14 receipt 345:18 98:12 101:3 147:2 150:8 151:4 211:15,20 215:12 receive 80:15,17 recommendations 161:21,25 182:16 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 reason 26:21 223:19 225:23 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 recommends	11:2 35:9 65:23	163:13 165:16	63:18 100:25	162:23 321:19
87:6 93:5,8 138:3 203:22,24 211:14 receipt 345:18 98:12 101:3 147:2 150:8 151:4 211:15,20 215:12 receive 80:15,17 recommendations 161:21,25 182:16 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 receiving 58:25 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 105:10 161:10 86:9,23 144:15 <td>65:24 66:9 71:11</td> <td>169:6 186:8</td> <td>138:11 176:24</td> <td>recommendation</td>	65:24 66:9 71:11	169:6 186:8	138:11 176:24	recommendation
150:8 151:4 211:15,20 215:12 receive 80:15,17 recommendations 161:21,25 182:16 221:5,15 237:5 136:10 226:23 101:5 137:8 288:2 182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 326:16 329:14 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 receiving 58:25 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 223:6 291:14,17 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 <td< td=""><td>71:15,20 72:6,13</td><td>200:23 202:2</td><td>181:18,21 190:17</td><td>63:5 80:7 90:3</td></td<>	71:15,20 72:6,13	200:23 202:2	181:18,21 190:17	63:5 80:7 90:3
161:21,25 182:16 221:5,15 237:5 136:10 226:23 294:23 182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 326:16 329:14 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 receiving 58:25 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 28:16 51:7 74:13 229:5 7recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10	87:6 93:5,8 138:3	203:22,24 211:14	receipt 345:18	98:12 101:3 147:2
182:25 183:2,3,15 245:4,6,12 248:12 228:23 294:23 191:5,10,22 192:3 251:7 253:14 70:9 86:12 98:3 63:10 66:4,23 192:3 217:21 254:8 256:20 170:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 7ecommending 307:21 311:21 realm 263:22 72:17 211:7 87:8 98:8 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 23:6 291:14,17 146:14 149:21 readers 241:4 132:25 173:8,10 223:6 291:14,17 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 346:6,9,12,15,18 7ecognize 36:18 7:21 8:6	150:8 151:4	211:15,20 215:12	receive 80:15,17	recommendations
191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 72:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 146:14 149:21 335:9 256:8 285:21 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 346:6,9,12,15,18 721 8:6 11:15,20 232:10 235:19	161:21,25 182:16	221:5,15 237:5	136:10 226:23	101:5 137:8 288:2
191:5,10,22 192:3 251:7 253:14 received 64:11 recommended 192:3 217:21 254:8 256:20 70:9 86:12 98:3 63:10 66:4,23 235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 72:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 146:14 149:21 335:9 256:8 285:21 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 346:6,9,12,15,18 721 8:6 11:15,20 232:10 235:19	182:25 183:2,3,15	245:4,6,12 248:12	228:23	294:23
235:11,12,14,20 260:18 274:24 117:3 121:21 67:8 68:5 69:2 235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 72:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 46:14 149:21 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 record 5:2,14 7:14 7:21 8:6 11:15,20 232:10 235:19 346:6,9,12,15,18 65:8 67:17 70:18 7:21 8:6 11:15,20	191:5,10,22 192:3	251:7 253:14	received 64:11	recommended
235:21 240:4 276:25 288:19 142:7 181:11 75:23 97:3,14 267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 239:5 244:2 272:9 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 receiving 58:25 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 reason 26:21 223:19 225:23 recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 23:6 291:14,17 46:14 149:21 335:9 256:8 285:21 223:6 291:14,17 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 65:8 67:17 70:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	192:3 217:21	254:8 256:20	70:9 86:12 98:3	63:10 66:4,23
267:21 270:9,11 299:2 301:14 190:7 234:14 135:22 136:3 271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 326:16 329:14 331:3 340:5,8 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 receiving 58:25 340:6,7 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 record 5:2,14 7:14 7:21 8:6 11:15,20 193:5 209:15,16 346:6,9,12,15,18 65:8 67:17 70:18 11:22,25 12:3	235:11,12,14,20	260:18 274:24	117:3 121:21	67:8 68:5 69:2
271:8,13 272:16 315:2 316:15 239:5 244:2 272:9 138:16 148:2 273:6 276:19 326:16 329:14 326:16 329:14 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 46:14 149:21 335:9 256:8 285:21 23:6 291:14,17 146:14 149:21 reading 10:6 91:7 339:5,7 345:11 337:19 178:11 343:16 record 5:2,14 7:14 7:21 8:6 11:15,20 232:10 235:19 346:6,9,12,15,18 65:8 67:17 70:18 11:22,25 12:3		276:25 288:19	142:7 181:11	75:23 97:3,14
273:6 276:19 326:16 329:14 receiving 58:25 340:6,7 298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 28:16 51:7 74:13 223:19 225:23 recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 record 5:2,14 7:14 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:6,9,12,15,18 65:8 67:17 70:18 11:22,25 12:3	267:21 270:9,11	299:2 301:14	190:7 234:14	135:22 136:3
298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 reason 26:21 223:19 225:23 recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 65:8 67:17 70:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	271:8,13 272:16	315:2 316:15	239:5 244:2 272:9	138:16 148:2
298:10 306:5,24 331:3 340:5,8 59:5 171:7 172:6 recommending 307:21 311:21 realm 263:22 172:17 211:7 87:8 98:8 320:17 323:9,15 reason 26:21 223:19 225:23 recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 223:6 291:14,17 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	,	326:16 329:14	receiving 58:25	340:6,7
320:17 323:9,15 reason 26:21 223:19 225:23 recommends 333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	298:10 306:5,24	331:3 340:5,8		recommending
333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	307:21 311:21	realm 263:22	172:17 211:7	87:8 98:8
333:6,9,11,12 28:16 51:7 74:13 229:5 138:7 160:20 345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	320:17 323:9,15	reason 26:21	223:19 225:23	recommends
345:9 347:5 99:4 103:4 127:15 recess 60:17 reconsidering readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	·	28:16 51:7 74:13	229:5	138:7 160:20
readers 241:4 132:25 173:8,10 105:10 161:10 86:9,23 144:15 335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	1 ' ' '		recess 60:17	reconsidering
335:9 256:8 285:21 223:6 291:14,17 146:14 149:21 readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3				
readership 282:16 296:10 335:12 337:19 178:11 343:16 reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·
reading 10:6 91:7 339:5,7 345:11 reclaimed 268:7 record 5:2,14 7:14 193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3			· ·	
193:5 209:15,16 346:6,9,12,15,18 recognize 36:18 7:21 8:6 11:15,20 232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3	_			
232:10 235:19 346:21 65:8 67:17 70:18 11:22,25 12:3		· · · · · · · · · · · · · · · · · · ·		l '
			0	
33.12 33.11				· · · · · · · · · · · · · · · · · · ·

[record - reports] Page 47

84:24 85:2,3	ragion 80.8	relevant 191:6	reportedly 157:24
105:7,9,12 159:8	region 80:8 registered 2:9	194:18	repeatedly 157:24 203:6
161:9,12 193:3	309:3 342:3	reliability 241:21	
223:3,5,8,12,14,16		reliable 279:10,20	rephrase 20:15 129:3 166:19
243:3 272:18	regnerus 303:15 303:17	· · · · · · · · · · · · · · · · · · ·	220:18
		reliance 318:23 320:2	
291:16,19 337:18	regret 131:8		rephrasing 128:10
337:21 341:5	132:10 260:20	relieved 119:3	report 9:24,25
recorded 5:5	261:2 269:11	rely 311:9	10:12,14,15,18,21
recurring 30:20	regular 31:7 54:3	relying 273:19	10:24 41:16 65:4
54:20	regularly 17:4,16	remands 331:6	102:20 134:13,14
redone 47:2	17:17,18 264:10	remember 29:2	134:17 138:3,7
reduce 109:11	regulation 202:12	37:17,19 59:20	161:21 219:15,22
reduced 123:18	reidentify 115:2	70:22,25 71:2	219:25 244:16
reexamining	143:13	74:14 99:14	259:21 263:11,15
291:25	reintroduce 7:8	262:17,18,19,21	271:3,7,8 272:8,19
refer 36:11,15	reiyn 70:8,19	273:14 292:6	272:21 273:17,19
204:11 252:10	343:13	301:23 304:4	273:21,22 274:9
313:10	reject 277:16	305:3,4 307:5	274:17,22 283:11
reference 133:25	278:25	327:15 328:8	304:3,25 305:5
165:21 170:11	rejected 277:19,20	331:9	306:5 307:22
referenced 345:6	related 15:19	remembered	311:9,13 314:2
references 307:24	16:10,15 23:14	70:23	317:20 318:4,6,23
referred 253:13	28:4 209:2 293:9	remind 96:13	319:25 320:3,3,10
254:12	293:22 332:15	297:14	321:15,21 322:7
referring 39:19	relates 62:16	reminded 312:3	322:10,18,18
66:14 69:6 72:18	177:4	reminding 155:6,9	324:6 331:10
73:3 99:5 133:24	relating 92:3	remote 1:17	333:7,9,12 344:12
145:12 252:18	208:22 293:25	removal 329:15	reported 1:24 42:2
253:4,7 271:4	relationship 23:25	remove 87:22	reporter 2:8,9
315:18	31:20 36:4 48:6	213:9,13	6:19 7:21 8:14
refine 155:11	62:23 69:8 104:16	removed 195:12	90:25 342:3
refresh 64:24	109:15 188:4	removes 331:8	reporting 329:13
239:8	289:18 290:4,5	removing 132:2	reports 10:9 68:20
refuse 209:5	315:11 338:15	renal 19:6 95:15	129:13 141:16
refused 209:4,7	relationships	renew 330:14	161:20 176:5,8,15
regarding 176:6	62:17	repeat 21:11 40:21	176:17,25 177:4,5
240:18 241:25	relative 342:16,19	44:20 73:4 83:21	209:16,17 235:24
242:10	relatively 207:23	89:9 139:8,16,17	236:16,18 238:4
regardless 82:24	268:2 278:7	261:12 263:12	238:16,18 306:13
162:8	released 142:20	279:15	306:25 307:3,23
			333:11

	T	T	
reprehensible	respectable 290:5	review 37:2 71:16	right 11:10 13:10
224:19	respectful 303:5	113:5 129:16	13:13 14:6,17
represent 104:18	respectfully	139:19 154:6	15:6,7,20,21 29:10
104:20 109:24	307:13	231:5 268:10	29:21 30:7 31:21
110:13 132:19	respond 165:14	271:14 278:10	32:19 33:11 34:19
149:9 217:18	responds 188:8	279:5,9,18 280:8	36:25 37:7 38:6
334:14	278:13	281:23 282:14	39:20 47:18 48:3
representative	response 173:17	340:24 345:7	52:17 53:8 54:16
182:18	281:13 314:17	reviewed 112:25	54:21,23 56:10
represented	responsibility	129:22 183:20	57:9 60:3,23
188:16	103:6	270:15 271:6	61:12 65:16 68:17
reputation 79:24	responsible 195:8	274:19,21 276:8	69:12,18 77:11
301:8	195:9 212:5	276:11,14 282:3,6	78:7 87:8,13 90:2
require 102:23	rest 22:2 26:25	282:21,25 304:2	90:6,24 96:10,25
150:24 164:15	132:8,13 218:12	reviewer 278:13	97:2 106:17
168:22 319:16	restate 214:20	278:19 280:2,24	113:14 114:3
required 202:12	247:18	280:24	127:17 128:17
347:13	restrict 233:11,11	reviewers 276:24	134:19,22 139:7
requirements	result 51:6 117:5	277:6,25 278:16	141:24 146:3
147:4 158:8	121:22 248:23	278:23 279:24	151:4 154:13
200:10 203:24	289:9	280:23	156:12 158:7
requires 107:8	results 117:7	reviewing 54:15	159:21 161:13
126:18 132:10	231:14 244:4,6,15	210:12 273:25	181:22 182:7
318:6	244:19,19 281:2	reviews 71:17	183:24,25 191:4
reread 9:23,25	rethink 226:8	119:7 129:9,13	193:4 196:7,9,10
research 49:24	retraction 281:14	183:7 185:21	196:11 198:2,7
119:14 139:4	retransitioned	191:17 218:23	203:10 205:21,23
232:23 243:9,10	142:10,14	243:22,23	206:8 210:4 215:8
243:13 252:19	retrieve 143:25	revision 277:17,17	215:15 232:8
275:11 279:19	return 235:25	277:24	235:17 237:11
281:16	236:3 238:5,7	revisions 278:5	246:20,21 247:19
researchers 296:8	240:19 242:2,20	revisiting 178:25	248:4 249:25
residency 12:24	345:13,17	202:6	250:6 258:5
resolving 136:13	returned 113:14	revival 75:10	260:15 261:11
resource 328:21	142:21	revocation 328:11	262:16 270:23
respect 68:17	returning 242:12	rich 125:19	271:22 272:13
130:13 159:14	revascularize	richard 257:4,20	283:5 286:10
204:9 221:18	336:2	richness 109:10	292:19 294:4,7
229:13 230:24	reversed 137:19	rid 211:22	307:6,23 323:11
299:25	219:8	ridiculous 291:6	327:11 333:10

[rights - scientist] Page 49

• 14 040	202.4	156 12 150 4	156 10 150 04 05
rights 94:9	rows 293:4	156:13 159:4	156:19 158:24,25
rigor 250:25	rpr 1:25 342:24	167:6 172:20	177:14,23 178:6
rigorous 202:14	rule 7:24 222:6	184:24 185:13	179:16 180:17
rigors 248:13	ruled 84:5,9	193:23 201:10	185:5 186:12,15
ring 303:21	ruling 233:2	204:18,24 233:5	189:2,19 194:16
rise 298:13	run 16:2 26:18	258:25 286:18	198:14 203:5,13
risk 130:17 131:24	130:16,17 133:14	289:6 298:15	204:14,22 205:24
174:19 185:22	133:15,16 179:10	299:3 301:4 311:3	207:16 208:2
194:23 200:17	312:15 335:9	340:8	213:5 220:6 221:6
215:8,11 216:25	runs 121:11	says 65:24 71:21	222:11,12 225:10
217:3 218:24	rush 125:23	73:18 136:21	225:13,19 229:13
240:12	rutledge 1:10 5:9	154:25 158:25	229:14,16 232:16
risks 127:24,25	345:4 346:1 347:1	159:2 162:11	233:10 238:10
128:4,15,21 129:7	S	163:20 180:17	272:25 275:24
129:25 131:3,15	s 3:1 4:1 61:2 91:2	184:5 193:5	280:11 285:2,8,9
131:23 132:4	270:19 303:19,23	213:12 267:23	286:5,19,19
133:2,22 134:7	303:24 343:7	270:14,20 271:16	295:12,19 296:15
139:2,6,11 141:5,8	346:3	272:20 273:16	296:22 297:7
144:21 151:18	sad 102:20	274:22 282:12	298:10 299:5,6
174:21 198:15	sadly 59:7 111:23	296:23 314:12	326:12,18 332:7
203:5 214:8,8	sadomasochistic	322:6 331:2	335:14,22
215:2,13,16	113:20	scare 109:23	scientific 120:15
216:12 250:19	safe 155:12	scenario 84:6	135:4 139:19
robust 230:25	safety 228:19	scene 80:8,9	141:2,2 150:23
245:16 246:6		scheme 224:11	161:16 176:5
rock 3:23 4:5,14	sample 98:7 257:8 sasha 238:23	schizophrenia	204:6 235:23
6:12 80:10 167:14		222:22 324:16	236:11 238:3
rodgerson 3:6	292:16 294:10	school 82:4 114:13	240:9 242:19
rodgersonb 3:7	295:20	121:9	244:22 250:25
rogerson 5:21,22	satisfied 69:9	science 88:9,9,21	271:10,13 274:19
role 29:5 170:21	save 152:11	88:21 94:3,8	274:22 279:10
romantic 52:9	saw 15:4 31:6 54:3	104:18,19 110:14	283:2,22 284:14
188:4 207:4	58:15,17 98:7	119:22,23 120:10	284:19,22,23
room 75:11	113:8 307:24	120:19,21,23	285:3 287:25
103:15 293:3	saying 41:5 67:16	126:18 130:20	289:4 306:3
roommate 74:25	73:13 79:20 88:7	131:2,22 132:13	scientifically
75:2	90:23 102:13	132:15,19 141:10	163:17 168:18
rough 55:12	106:17 131:7	144:22 145:2,3	180:2 198:22
round 278:9	139:3 143:17	147:6,8 148:16,16	205:3 236:18
roundly 194:10	144:8 146:13	148:21 150:20	scientist 284:10
	147:12,22 151:9	151:19 156:14,16	
	154:2,2,14,18	<u> </u>	

[scientists - sessions] Page 50

	140.24 152.14 21	25.10.20.10.21.11	27.15.20.22	
scientists 230:24	149:24 153:14,21	25:18 30:18 31:11	sense 27:15 29:23	
282:2 283:25	158:3,18 159:3	31:18,19 33:6,18	68:4,15,16 84:8	
screen 64:24	160:4,11,20	53:23 54:8 55:11	139:2 150:24	
scroll 64:25 65:18	165:22 166:18	55:16 56:13 57:2	197:18 198:4	
71:6 149:22 182:9	168:6,12 173:24	57:21 58:8,21	213:18 220:4,17	
190:24 235:6	174:4,16 179:10	67:24 93:13 97:13	240:14 241:18	
scrolling 239:13	180:7,13,24	98:8 111:12,18,21	318:6,7 339:14	
scrutiny 141:3	182:20 188:20,24	112:7 113:22	sensitive 43:21	
se 265:16 316:10	189:12 190:12	115:2,3,7 117:4,6	78:25 81:17 166:3	
332:22	195:14,22 196:5	117:9 120:7,12,14	sent 63:10 280:22	
search 268:12	196:13 200:16	124:22 208:17	302:21 345:14	
second 12:14 37:7	201:8 206:18	215:21 227:13	sentence 67:10	
59:10 83:22 150:3	207:5 211:12,18	325:24	72:25 73:4,7	
150:8 260:5 261:5	211:24 215:17	sees 27:11 62:17	216:24 235:22	
270:25 287:4	216:4,10,14	62:18 77:18	270:12	
secondary 170:7	218:16,20 220:14	100:21	separate 117:22	
230:5,8,12	230:18,22 231:5	segm 91:15 92:20	125:11 129:21	
section 290:24	231:10 233:9	92:22,23,24,25	145:2 148:20	
see 13:16 14:12	237:21 239:19,21	94:20,23 283:8,11	156:17 173:11	
15:22 18:21 19:3	240:24 244:13,25	283:21 285:10,16	175:23 270:14	
19:9 23:13 28:13	245:8 246:5,25	285:17 286:11,24	286:5 317:6	
32:17 35:19 43:8	264:10 267:12	287:2,13,17	separately 135:13	
45:19,20 50:8	270:20 274:4,10	288:15,24 290:22	separating 317:15	
51:19 58:4 59:19	276:3 278:16	290:24 294:11	september 137:20	
61:24 65:6,7,19	279:15,24 290:21	310:7	sequences 74:16	
68:19 70:5,15,17	297:22 302:24	selects 76:24	series 56:5 132:12	
71:13 76:8 81:21	309:9 312:17,19	self 41:16 43:2	236:17 240:21	
81:23 84:3 86:17	314:5,18,19	82:3 122:20	241:22 243:5	
88:10,16 89:2	316:13 317:6,12	188:12,15,15	244:17,18 245:5	
90:13,22 91:14	317:17 318:10,12	311:9,13 313:2	293:8	
95:23 97:23 99:3	320:8,8 324:21	317:4,20 318:4,6	serious 42:20	
103:16 111:10	326:6 335:17,23	318:23 319:25	179:5,5 245:11	
115:6,20 116:4,24	336:14,23	320:3,10 322:7,10	serum 216:15	
117:24 120:9,12	seeing 62:14 74:21	322:18	serve 327:2	
120:22 121:4	122:6	seminal 301:15	service 121:12,12	
122:20 123:9	seeking 44:25 89:7	send 277:23	services 190:7,17	
124:5,17 125:11	89:15	278:22 282:10,19	344:4	
125:16 126:4,10	seen 13:4,25 14:15	328:15	session 32:21	
127:9,15,18	15:4,17 16:7 17:3	sends 276:21	289:23 302:22	
132:20 140:24	17:10 18:11 19:21	senior 4:10 22:13	sessions 302:25	
147:9,22,25	20:7 23:18 24:19	306:14		
Veritext Legal Solutions				

[set - sorry] Page 51

1 146 21 140 14	260 2 225 16	22 10 22 22 22 22	
set 146:21 148:14	268:2 337:16	22:18 23:23 33:22	socialize 265:17
155:25 158:5	shortening 217:8	35:11,22 39:10	socialized 172:23
159:23 160:9	shortly 259:9	42:9 48:12 51:21	socially 87:18 88:2
172:25 173:23	show 71:8 76:15	59:25 86:4 92:17	116:11 179:12
230:5 342:14	77:5 253:25	112:21 118:10,14	257:24
settings 262:9	265:21 296:23	140:17 165:8	society 91:19
276:9	showed 301:15	168:4 183:18	218:5 225:9 284:5
seven 22:21 23:3	showing 242:19	237:8 264:10	socioeconomic
23:12 25:18 51:21	shown 253:8,10	266:21 317:8,10	152:17
86:5 140:17	shows 243:14	317:12	sociology 309:25
280:19 281:6	sic 249:7	skeptical 285:21	softly 11:18
325:9	side 103:13 204:20	299:12	solely 213:2
sex 66:5 86:11	307:4	skepticism 204:14	solution 165:10,13
111:3 112:12,15	sign 63:12 141:3	296:22 308:14,15	167:21 170:3
114:24 136:5	232:24 340:24	skilled 129:23	solutions 2:6
137:16,24 143:2,8	345:12	skills 91:7	166:8,9,24,24
143:14 156:24	signature 239:14	skin 117:13	167:2,4 170:22
188:5 193:18,22	339:17 342:23	sleep 251:4,24	174:4,5 345:23
242:14,22 267:24	signed 63:24,24	slide 297:24	solved 164:4
338:23 343:18	64:3 98:15 345:20	slow 77:2 125:22	somebody 17:4
sexual 21:19 38:8	similar 20:23	143:25 267:5	30:23 34:22 40:2
38:12 42:21 51:23	21:16 84:6 129:3	321:21	41:8,25 67:3 69:8
51:25 52:7 108:8	171:25 209:2	slowed 137:9	86:4 146:25 152:7
116:9,19,22	234:8 274:21	small 14:23 20:24	213:20 225:11
153:12 184:6	278:5	smaller 14:24 54:2	234:2 252:3
188:3 216:10	simply 32:14	smoking 123:13	255:24 273:19
306:15,15 315:25	43:12 116:5	social 43:3 49:11	314:2 319:7
335:7	122:21 125:20	50:13,18,22 52:5,8	323:21 324:6
sexuality 306:16	204:6 322:24	52:10,11,16 60:25	someone's 121:24
sexually 22:4	331:19	61:2,7 62:8 66:5	somewhat 299:12
179:13	single 33:12	87:16 88:23 89:7	323:17 326:5
shake 312:17,18	240:21 241:21	89:15 92:16	son 111:11,12,13
share 64:15 234:8	243:5	101:22 103:9	147:22 224:13
283:25 290:10	sissy 257:5	108:6 140:9	319:12
sheet 345:11	sister 224:9,15	150:10,22 156:22	sophia 3:10 6:3
sherry 37:18	situation 96:18	166:5 171:13,15	sophisticated
shift 295:5 299:4	163:4 226:8 339:4	172:21 293:14	103:2
299:14 314:21	situations 165:20	296:20 298:8	soporific 251:23
short 18:12,18	173:7 267:11	302:5 312:8	sorry 15:12 19:3
84:15 100:19	six 14:2 15:5,17	321:10,11 325:24	32:22 34:19 40:18
133:14 248:10	16:8 18:14 21:20	337:24 338:8	42:6 54:12 73:7
155.17 270.10	10.0 10.17 21.20	331.27 330.0	12.0 57.12 13.1
-	77 '4 4 T	•	•

[sorry - status] Page 52

00 0 07 10 104 07	215.6	1 22 22	150 20 151 10
89:9 95:13 124:25	315:6	spread 33:23	150:20 151:18
131:14 135:15	speaking 7:25	stability 114:9	159:18 161:15
139:17 143:4	15:2 26:11 76:21	stabilize 216:9	177:13,13,20,21
155:7,18,20 172:8	102:21 227:21	stabilized 171:15	177:23 178:5
176:15 178:17,18	289:15 331:4	stable 85:23,24	179:16 181:23
182:13 192:5	special 80:2	168:2	183:13 187:10
199:13,17 204:4	302:21,23	staff 22:11,12 23:2	189:2 197:12
210:25 223:10	specialist 4:21	24:24 26:12,19,23	201:18 203:5,13
225:8 228:7	specialists 76:20	26:25,25 28:6	204:2,3 207:16
235:13 237:12	specialize 293:16	47:8 61:10,18	208:2,10,14 209:3
239:19 243:3,16	298:21	stand 99:4 124:20	212:7 214:9
272:15 283:12,16	specialized 79:25	standalone 338:5	219:16 220:9
292:23 303:16	specialty 21:18	standard 147:14	221:6 233:3,3,17
309:19,19 310:23	35:15	154:11 156:2	238:9 278:20
312:2 332:17	specific 261:17	198:16,17 202:8	295:11 303:20
sort 19:10 30:14	302:15	270:22 319:15	305:2 327:3 329:9
77:24 95:6 104:11	specifically 307:2	standardized	329:14 330:3,9,20
124:13 127:5	specifics 87:9	136:23	330:21,21 331:7
140:5 151:8 169:8	316:21	standards 71:24	331:11
222:3 224:9 256:8	speculate 50:20	72:5,17,18 73:17	stated 245:25
256:9 324:21	51:2	102:22 146:22,25	261:24
325:5	speculation	148:9,15 154:3	statement 133:24
sought 35:10	220:13 226:5	155:9 156:2	136:20 144:12,13
46:13 47:16	233:24 266:7	178:24 273:25	203:11 220:16
soul 204:14 296:22	spell 90:24	274:6,16 275:20	238:2 331:24
souls 85:17	spend 25:7 31:24	275:21,22 276:2	334:11
sound 7:2 11:13	49:23 316:20	288:8	statements 221:9
13:12 31:20 33:7	321:9	standing 85:23,23	states 1:1 5:10
97:2 313:2 314:23	spent 14:4 21:25	start 7:13 53:10	43:2 93:22 99:24
sounding 155:7	22:3 95:5 152:21	94:10 117:20	100:10 101:22
sounds 13:10	173:3 185:3	178:17 255:12	129:20,21 136:25
33:10 217:9	306:13 325:8	258:16 323:5	140:14 146:19
304:21	sperm 152:10	started 21:4 75:5	154:24 171:24
304.21	I		
source 224:4	sphere 326:16	193:4 243:8	172:12 186:20
	-	193:4 243:8 246:25 259:23	172:12 186:20 207:16 211:22
source 224:4	sphere 326:16		
source 224:4 sources 140:9,10	sphere 326:16 spironolactone	246:25 259:23	207:16 211:22
source 224:4 sources 140:9,10 322:11	sphere 326:16 spironolactone 168:7	246:25 259:23 260:7 297:11	207:16 211:22 231:16 233:22
source 224:4 sources 140:9,10 322:11 speak 12:9 47:4	sphere 326:16 spironolactone 168:7 spoke 11:17 60:20	246:25 259:23 260:7 297:11 starting 94:22	207:16 211:22 231:16 233:22 298:20 332:24
source 224:4 sources 140:9,10 322:11 speak 12:9 47:4 78:19 143:5	sphere 326:16 spironolactone 168:7 spoke 11:17 60:20 238:20 294:24	246:25 259:23 260:7 297:11 starting 94:22 182:20	207:16 211:22 231:16 233:22 298:20 332:24 statistical 281:8
source 224:4 sources 140:9,10 322:11 speak 12:9 47:4 78:19 143:5 155:20 173:9	sphere 326:16 spironolactone 168:7 spoke 11:17 60:20 238:20 294:24 295:2,17,20,25	246:25 259:23 260:7 297:11 starting 94:22 182:20 state 7:14 75:11	207:16 211:22 231:16 233:22 298:20 332:24 statistical 281:8 status 66:19

[statute - strong] Page 53

statute 331:13	96:1 97:1 98:1	218:1 219:1 220:1	339:1 340:1 341:1
stay 28:13 166:8	99:1 100:1 101:1	221:1 222:1 223:1	342:6 343:2,9,12
staying 47:13	102:1 103:1 104:1	224:1 225:1 226:1	343:17 344:1,6,9
119:17	105:1 106:1 107:1	227:1 228:1 229:1	345:5 346:2,24
stays 166:11	108:1 109:1 110:1	230:1 231:1 232:1	347:2,4,12
stenographically	111:1 112:1 113:1	233:1 234:1,13	sterility 131:25
342:12	114:1 115:1 116:1	235:1 236:1 237:1	sterilize 213:14
stent 336:9	117:1 118:1 119:1	238:1 239:1,4	sterilizing 152:13
step 233:15 317:2	120:1 121:1 122:1	240:1 241:1 242:1	stimulating
337:11	123:1 124:1 125:1	243:1 244:1 245:1	290:12
stephen 1:19 2:3	126:1 127:1 128:1	246:1 247:1 248:1	stop 36:17 141:3
5:6 6:21 7:1,16	129:1 130:1 131:1	249:1 250:1 251:1	162:18 163:14,16
8:1 9:1 10:1 11:1	132:1 133:1 134:1	252:1 253:1 254:1	174:15,17 175:6
12:1 13:1 14:1	135:1 136:1 137:1	255:1 256:1 257:1	184:14 191:19
15:1 16:1 17:1	138:1 139:1 140:1	258:1 259:1 260:1	203:8 225:25
18:1 19:1 20:1	141:1 142:1 143:1	261:1 262:1 263:1	stopped 21:9,10
21:1 22:1 23:1	144:1 145:1 146:1	264:1 265:1 266:1	215:9
24:1 25:1 26:1	147:1 148:1 149:1	267:1 268:1 269:1	stops 252:3
27:1 28:1 29:1	150:1 151:1 152:1	270:1 271:1 272:1	stories 127:13
30:1 31:1 32:1	153:1 154:1 155:1	273:1 274:1 275:1	268:19 269:20
33:1 34:1 35:1	156:1 157:1 158:1	276:1 277:1 278:1	322:14
36:1 37:1 38:1	159:1 160:1 161:1	279:1 280:1 281:1	story 25:8,10
39:1 40:1 41:1	162:1 163:1 164:1	282:1 283:1 284:1	straight 115:5
42:1 43:1 44:1	165:1 166:1 167:1	285:1 286:1 287:1	116:20 237:21
45:1 46:1 47:1	168:1 169:1 170:1	288:1 289:1 290:1	strange 44:22
48:1 49:1 50:1	171:1 172:1 173:1	291:1 292:1 293:1	strangio 3:18 5:18
51:1 52:1 53:1	174:1 175:1 176:1	294:1 295:1 296:1	5:18
54:1 55:1 56:1	177:1 178:1 179:1	297:1 298:1 299:1	street 3:4,14,22
57:1 58:1 59:1	180:1 181:1 182:1	300:1 301:1 302:1	4:13
60:1 61:1 62:1	183:1 184:1 185:1	303:1 304:1 305:1	strengthen 274:9
63:1 64:1,10 65:1	186:1 187:1 188:1	306:1 307:1 308:1	strengths 97:18
66:1 67:1 68:1	189:1 190:1,4	309:1 310:1 311:1	101:19
69:1 70:1,7 71:1	191:1 192:1 193:1	312:1 313:1 314:1	strict 150:23
72:1 73:1 74:1	194:1 195:1 196:1	315:1 316:1 317:1	236:11
75:1 76:1 77:1	197:1 198:1 199:1	318:1 319:1 320:1	strike 74:4 213:21
78:1 79:1 80:1	200:1 201:1 202:1	321:1 322:1 323:1	311:6
81:1 82:1 83:1	203:1 204:1 205:1	324:1 325:1 326:1	striking 199:10
84:1 85:1 86:1,10	206:1 207:1 208:1	327:1 328:1 329:1	strong 189:9
87:1 88:1 89:1	209:1 210:1 211:1	330:1 331:1 332:1	198:12 204:19
90:1 91:1 92:1	212:1 213:1 214:1	333:1 334:1 335:1	256:16 305:25
93:1 94:1 95:1	215:1 216:1 217:1	336:1 337:1 338:1	

[struggle - sure] Page 54

struggle 116:17	studying 233:6	207:3	summary 110:11
struggling 229:11	258:12	succinct 107:9	145:5
317:16	stuff 319:15	succinctly 306:20	summer 6:6
stuck 188:23	subcommittee	suddenly 288:18	supervise 22:8,18
student 116:6	182:4	sued 282:15	22:21 24:19 34:4
students 296:18	subject 10:7 94:21	suffer 22:4 126:13	34:22 35:19 37:22
296:19,19,20,21	232:17 233:6	126:14 162:6	40:15 43:8 61:6
studied 256:8	256:8,9 276:23	313:17	75:23
studies 117:22	277:2 284:15	suffered 66:2	supervised 22:10
118:3 129:11	326:6	suffering 185:11	37:5,8 39:16 40:7
149:4 186:22	subjective 313:10	211:17 296:11	supervising 19:15
193:16,22 194:5,6	321:14	297:9	29:5
194:7,9 195:3	subjectively	sufficient 42:13	supervision 20:2
197:7 236:22,23	116:11	138:21	22:6,23 29:4 35:2
237:4 243:24,25	subjectivities	sufficiently 171:18	35:8 37:8,10
244:4,17 245:18	315:12	suggest 291:8	40:12 226:16
245:19 246:8	subjectivity	294:17	supervisor 61:3
248:14 252:24	313:14 314:21	suggesting 171:5	support 45:9
253:5,6,8,10,17,19	315:9,10,10	suggestions	52:20 83:15 95:13
253:20,23,25	subjects 134:17	277:13	130:24 176:9
254:11,19 255:5	submission 276:21	suggests 187:17	177:7 200:3
256:13 259:18	submits 276:18	200:17	207:12 208:3
262:7 285:3	submitted 176:16	suicidal 104:23	219:16 302:8
301:15 335:16	235:3 239:12	suicidality 42:25	324:23 332:2,7
study 75:4 101:2	248:13 304:25	211:18 309:14	334:10,13
159:2 194:7,11,13	306:6	317:4	supported 52:15
216:2,3 229:10	submitting 176:8	suicide 74:18	66:5 67:9 210:20
230:17 231:3,6,7,8	176:24 177:5	75:12 121:15	247:21
231:8,11,15,20	subscribed 347:14	215:20,23 216:4	supporting 140:25
232:6,7,12 233:4	subsequent 335:15	298:7 308:17,20	153:23 285:24,25
236:13 244:5,15	subsequently	309:8 336:21	299:24
245:2,3,11,21,23	76:17 255:10	suicides 194:23	supportive 229:2
246:3,7 257:4,21	substance 104:22	309:3	301:13
260:5 261:5,14	211:18 322:8	sullcrom.com 3:7	supposed 299:19
262:7 270:18	substantial 334:20	3:9,11	suppress 168:9
271:17 276:11	338:14	sullivan 3:3,24	sure 7:20 16:18
277:21 279:22	subtle 29:25 38:11	5:22 6:1,4	26:3 28:25 37:16
280:13,25 281:2,3	success 127:13	summarize 255:5	40:23 41:9 49:16
286:4 295:13	136:19	300:6	56:23 59:11 60:3
336:5	successful 94:7	summarized	60:7 69:5 71:11
	127:17,18 136:12	145:25	73:6 75:15 79:21

[sure - talking] Page 55

85:14 89:14 99:17 100:6,18 105:5 143:814 180:55 143:81 44:19:15 135:25 139:9 144:18 146:16 151:7 167:4 182:14,23 184:2 191:5 193:11 228:3 229:19 237:16 245:10 232:24 134:35,20 252:21 253:6 134:23 135:2 270:3 291:13 246:12 296:4 296:4 296:4 296:4 296:4 296:4 293:19 296:4 296:4 293:19 233:13 136:24		I	I	I
114:8,14 129:15 135:25 139:9 144:18 146:16 151:7 167:4 178:14 180:24 182:14,23 184:2 191:5 193:11 228:3 229:19 237:16 245:10 237:16 245:10 252:21 253:6 260:14 263:8 270:3 291:13 296:4 104:4 104:4 195:11 150:22 197:20 19	85:14 89:11 99:17	surreptitiously	t	98:16 105:25
114:8, 14 129:15 135:25 139:9 134:18 146:16 151:7 167:4 178:14 180:24 182:14,23 184:2 182:14 193:11 228:3 229:19 237:16 245:10 133:24 134:3,5,20 252:21 253:6 234:23 135:2 260:14 263:8 246:12 246:12 246:12 246:12 246:12 246:12 246:14 252:7 283:6 302:13 296:4 switch 252:7 283:6 302:13 302:1			t 304:20 342:1.1	· ·
135:25 139:9 surrounding tab 64:8 70:2 86:7 134:18 164:11 166:7 216:25 151:7 167:4 susceptible 233:18 swallowing 117:10 swallowing 117:10 swallowing 117:10 swallowing 117:10 swallowing 117:10 swallowing 117:10 sweden 101:2 234:11 239:2 243:19 252:8,19 244:12 23:24 246:12 sweden 101:2 100:10 103:5 311:17,18,21 311:17,18,21 316:18 319:11 318:18 32:11 318:18 318:18 32:11 318:18 32:11<	,		I .	
151:7 167:4 178:14 180:24 178:14 180:24 182:14,23 184:2 191:5 193:11 190:6 129:14 133:24 134:3,5,20 134:23 135:2 140:12 186:22 226:14 263:8 226:12 234:11 139:2 136:18 139:11 323:24 324:4,12 326:17 330:15 144:17 150:4 152:10 10 155:18 156:7 161:6 111:9,19 127:23 128:14 133:21 142:17 150:4 152:13 184:7 193:23 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 156:25 192:10 104:2 123:19 194:3 196:20 197:14,24 surprise 97:7 surprised 191:3 267:3 208:21 308:2			′	
151:7 167:4 178:14 180:24 182:14,23 184:2 191:5 193:11 228:3 229:19 237:16 245:10 252:21 253:6 260:14 263:8 270:3 291:13 296:4 234:12 246:13 252:10 104:15 111:15 232:24 128:7 130:12 144:7 150:4 152:10,10 155:18 156:7 161:6 166:25 167:3 175:19 166:2 175:19 175:18 156:11 152:13 196:25 266:12 336:7 338:7 292:18 294:21 196:25 266:12 336:7 338:7 292:18 294:21 196:25 266:12 336:7 338:7 292:18 294:21 196:25 266:12 336:7 338:7 292:18 294:21 196:25 266:12 330:4 293:19		· ·		
178:14 180:24 swear 142:22 table 82:23 203:21 264:14 283:8 262:303:7 264:14 283:8 296:2 303:7 311:7,18,21 311:7,18,21 311:7,18,21 311:17,18,21 316:18 319:11 323:24 324:4,12 322:4 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 326:7 330:15 434:17 150:4 43:18 15:16 43:17 150:4 43:18 15:10 43:18 15:14 43:17 150:4 43:17 150:4 43:17 150:4 43:17 150:4 43:23 17:10:15:18 175:19 186:8 192:17 20:23 175:19 186:8 192:17 20:23 213:11 20:2 220:13:11 20:2 220:13:14		_		· ·
182:14,23 184:2 sweden 101:2 take 9:2 46:19 296:2 303:7 191:5 193:11 19:6 129:14 10:10 103:5 31:17,18,21 237:16 245:10 133:24 134:3,5,20 140:12 186:22 260:14 263:8 140:12 186:22 246:12 32:13 15:21 104:15 111:15 323:24 324:4,12 323:24 324:4,12 323:24 324:4,12 323:22 97:9111:6 32:16:18 319:11 32:21 68:7 30:13 140:12 186:22 246:12 32:17 30:12 144:17 150:4 150:21 150:24 150:21 150:25 156:7 161:6 111:9,19 127:23 128:14 133:21 128:14 133:21 128:14 133:21 128:14 133:21 128:14 133:21 128:14:17 150:4 150:25 167:3 128:14 133:21 128:14:17 150:4 150:15 16:6 150:15 16:6 150:15 16:6 166:25 167:3 175:19 186:8	178:14 180:24	_		264:14 283:8
191:5 193:11 228:3 229:19 119:6 129:14 102:10 103:5 136:18 319:11 102:10 103:5 104:15 111:15 132:24 32:44:12 102:10 103:5 104:15 111:15 132:24 32:44:12 102:10 103:5 104:15 111:15 128:17 130:15 120:8 125:16 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:15 120:8 125:16 120:8 125:15 120:2 120:2 120:2 120:2 120:2 120:2 120:2 120:2 120:2 120:2 120:2 120:1 120:2 120:1 120:2 120:1 120:2 120:1 1	182:14,23 184:2	swear 142:22		296:2 303:7
228:3 229:19 237:16 245:10 133:24 134:3,5,20 134:23 135:2 260:14 263:8 270:3 291:13 296:4 sweden's 135:11 104:4 surgeries 84:11 104:4 91:11 150:22 193:19,21,25 197:20 surgery 53:14,20 66:6 69:17 80:24 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 330:4 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 330:4 symptomatic 81:20 symptomatic 197:14,24 surgical 84:21 87:14,15 111:24 156:25 192:10 194:3 196:20 197:14,24 surgically 266:24 surprise 97:7 surprised 191:3 267:3 systematic 126:16 systemic 126:16 systemic 126:16 systemic 126:16 systemic 126:16 systemic 126:16 systems 152:3 102:10 103:5 104:15 111:15 120:8 125:15 128:7 130:12 128:14 133:21 144:17 150:4 111:90:155:18 128:10 105:518 128:7 130:12 128:14 133:21 129:13 120:23 226:17 330:15 128:7 130:12 221:16,21 222:25 221:16,21 222:25 221:16,21 222:25 221:16,21 222:25 226:19 238:13 241:25 242:10 2295:4,11,16 296:5 2297:17,18 298:12 2291:8,11 312:4,6,16 315:13 318:18 316:18 319:11 323:24 324:4,12 326:17 330:15 14ked 35:21 68:7 128:7 130:12 128:14 133:21 128:14 133:21 129:13 120:22 221:16,21 222:25 221:16,21 222:25 221:16,21 222:25 221:16,21 222:25 226:19 238:13 241:25 242:10 2295:4,11,16 296:5 2297:17,18 298:12 229:3 35:10 36:5 337:16 48:10,12 50:8 48:10,12	191:5 193:11	sweden 101:2		311:17,18,21
237:16 245:10 252:21 253:6 260:14 263:8 270:3 291:13 296:4 surgeon 41:11 104:4 surgeries 84:11 95:11 150:22 193:19,21,25 197:20 surgery 53:14,20 66:6 69:17 80:24 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 156:25 192:10 194:3 196:20 290:3 surgically 266:24 surprised 191:3 267:3 surprisingly 308:21 133:24 134:3,5,20 1104:15 111:15 120:8 125:15 120:8 125:15 128:7 130:12 128:7 130:12 128:7 130:12 128:10 155:18 150:10 155:18 150:10 155:18 156:7 161:6 166:25 167:3 175:19 186:8 192:17 210:23 213:11 220:2 221:16,21 222:25 226:19 238:13 241:25 242:10 295:4,11,16 296:5 297:17,18 298:12 298:13 302:10 318:18 323:24 324:4,12 326:17 330:15 talked 35:21 68:7 93:22 97:9 111:6 152:10,10 155:18 119:19,19 127:23 128:14 133:21 142:3 143:23 171:10 178:10 199:19 202:5 206:25 215:22 226:19 238:13 246:24 240:4 247:2,3 229:18 294:21 330:4 325:25 326:25 337:16 48:10,12 50:8 48:11 33:21 412:3 14	228:3 229:19	119:6 129:14		316:18 319:11
252:21 253:6 260:14 263:8 270:3 291:13 296:4 surgeon 41:11 104:4 surgeries 84:11 95:11 150:22 193:19,21,25 197:20 surgery 53:14,20 66:6 69:17 80:24 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 196:25 266:12 336:7 338:7 surgically 266:24 surprise 97:7 surprised 191:3 267:3 surprisingly 308:21 120:8 125:15 128:7 130:12 144:17 150:4 152:10,10 155:18 156:7 161:6 166:25 167:3 175:19 186:8 192:17 210:23 175:19 186:8 192:17 210:23 175:19 186:8 192:17 210:23 213:11 220:2 221:16,21 222:25 226:19 238:13 241:25 242:10 240:4 247:2,3 254:20 255:4 264:14 271:7 272:2 291:8,11 312:4,6,16 315:13 326:17 330:15 talked 35:21 68:7 93:22 97:9 111:6 166:25 167:3 175:19 186:8 192:17 210:23 221:16,21 222:25 226:19 238:13 241:25 242:10 240:4 247:2,3 254:0 255:4 299:18 294:21 300:4 325:25 326:25 337:16 talked 35:21 68:7 93:22 97:9 111:6 111:9,19 127:23 128:14 133:21 142:3 143:23 171:10 178:10 199:19 202:5 226:19 238:13 241:25 242:10 240:4 247:2,3 255:26 255:4 2298:13 302:10 318:18 talking 13:11 29:23 35:10 36:5 48:10,12 50:8 taken 5:6 48:21 60:17 82:23 94:4 105:10 122:7 158:3 161:10 199:19 202:5 226:19 238:13 241:25 242:10 240:4 247:2,3 255:25 326:25 337:16 taken 5:6 48:21 60:25 167:3 175:19 186:8 192:17 210:23 240:22 225:15:22 226:19 238:13 241:25 242:10 240:4 247:2,3 255:25 326:25 337:16 taken 5:6 48:21 60:25 167:3 175:19 186:8 192:17 210:23 240:22 225:15:22 226:19 238:13 241:25 242:10 240:4 247:2,3 255:26:25 237:13 13:12 241:25 242:10 240:4 247:2,3 255:25 326:25 237:13 13:13 241:25 242:10 240:4 247:2,3 255:25 326:25 237:14,16 296:5 246:14 271:7 272:2 291:8,11 104:4 23:14:3:23 241:25 242:10 240:4 247:2,3 255:25 326:25 237:14,20 240:4 247:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:4 27:2,3 249:12 24:10 240:14 27:17 279:22 291:8,11 299:3 35:10 36:5 48:10,12 20:1 24:12 22:10 24:12 23:10 24:12 22:10 24:	237:16 245:10	133:24 134:3,5,20		323:24 324:4,12
260:14 263:8 270:3 291:13 296:4 sweden's 135:11 swedish 216:2 switch 252:7 283:6 302:13 95:11 150:22 193:19,21,25 197:20 surgery 53:14,20 66:6 69:17 80:24 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 17:10 178:10 17:10 178:10 179:10 293:19 293:10:25 184:7 130:12 144:17 150:4 152:10,10 155:18 166:25 167:3 175:19 186:8 192:17 210:23 21:16,21 222:25 226:19 238:13 241:25 242:10 240:4 247:2,3 254:20 255:4 264:14 271:7 272:2 291:8,11 312:4,6,16 315:13 318:18 291:3 300:4 325:25 326:25 337:16 292:3 35:10 36:5 48:10,12 50:8 337:16 292:3 35:10 36:5 48:10,12 50:8 337:16 292:3 35:10 36:5 48:10,12 50:8 337:16 292:3 35:10 36:5 48:10,12 50:8 337:16 292:3 35:10 36:5 48:10,12 50:8 337:16 292:3 35:10 36:5 48:10,12 50:8 338:21 184:17 150:4 111:9,19 127:23 128:11 130:2 128:14 133:21 128:14 23:20 222:15 222:25 226:19 238:13 17:10 178:10 199:19 202:5 226:19 238:13 17:10 178:10 128:40,4 27:7 222:291:8,11 129:12 220:2 226:19 238:13 128:18	252:21 253:6	134:23 135:2		326:17 330:15
270:3 291:13 296:4 sweden's 135:11 swedish 216:2 switch 252:7 283:6 302:13 302:13 switching 303:14 195:11 150:22 193:19,21,25 197:20 surgery 53:14,20 66:6 69:17 80:24 82:10 97:3 99:16 99:21 102:5 150:11 152:13 184:7 193:23 196:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 152:10,10 155:18 156:7 161:6 166:25 167:3 175:19 186:8 192:17 210:23 213:11 220:2 221:16,21 222:25 226:19 238:13 241:25 242:10 240:4 247:2,3 254:20 255:4 264:14 271:7 272:2 291:8,11 312:4,6,16 315:13 325:25 326:25 337:16 taken 5:6 48:21 60:17 82:23 94:4 105:10 122:7 158:3 161:10 199:19 202:5 226:19 238:13 241:25 242:10 295:4,11,16 296:5 297:17,18 298:12 298:13 302:10 318:18 talking 13:11 299:23 35:10 36:5 48:10,12 50:8 535:,6 55:9 77:15 79:7 93:23,24,24 105:10 122:7 158:3 161:10 190:15 223:6 224:8 260:20 291:14,17 329:8 330:5 337:19 342:11 talk 15:14 22:24 47:2 59:19 97:16	260:14 263:8	140:12 186:22		talked 35:21 68:7
296:4 sweden's 135:11 swedish 216:2 152:10,10 155:18 111:9,19 127:23 surgeries 84:11 switch 252:7 283:6 156:7 161:6 128:14 133:21 128:14 133:21 95:11 150:22 switching 303:14 156:7 161:6 166:25 167:3 171:10 178:10 193:19,21,25 197:20 sworn 6:18,22 213:11 220:2 226:5 215:22 surgery 53:14,20 66:6 69:17 80:24 symposia 293:12 233:14 235:10 241:25 242:10 99:21 102:5 symposia 293:12 293:19 symposium 254:20 255:4 295:4,11,16 296:5 297:17,18 298:12 150:11 152:13 184:7 193:23 292:18 294:21 272:2 291:8,11 318:18 4alking 13:11 166:25 266:12 300:4 symptomatic 325:25 326:25 337:16 4alking 13:11 299:3 35:10 36:5 48:10,12 50:8 48:10,12 50:8 48:10,12 50:8 597:7 15 79:7 93:23,24,24 79:7 93:23,24,24 105:10 122:7 158:3 161:10 112:22 116:13,14 138:21 176:13 182:2 182:2 116:13,14 132:21 16:13,14 132:21 16:13,14 132:21 16:13,14 132:21 16:13,14 132:21 16:13,14	270:3 291:13	246:12		93:22 97:9 111:6
surgeon 41:11 swedish 216:2 104:4 switch 252:7 283:6 166:25 167:3 175:19 186:8 171:10 178:10 199:19 202:5 95:11 150:22 switching 303:14 175:19 186:8 192:17 210:23 179:10 178:10 199:19 202:5 206:25 215:22 226:19 238:13 233:14 235:10 199:19 202:5 206:25 215:22 226:19 238:13 241:25 242:10 240:4 247:2,3 295:4,11,16 296:5 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 298:13 302:10 318:18	296:4	sweden's 135:11		111:9,19 127:23
104:4 switch 252:7 283:6 166:25 167:3 142:3 143:23 surgeries 84:11 302:13 switching 303:14 175:19 186:8 171:10 178:10 95:11 150:22 310:13 175:19 186:8 192:17 210:23 206:25 215:22 197:20 sworn 6:18,22 342:6 347:14 221:16,21 222:25 226:19 238:13 surgery 53:14,20 symposia 293:12 293:19 233:14 235:10 240:4 247:2,3 241:25 242:10 82:10 97:3 99:16 symposia 293:12 293:19 254:20 255:4 297:17,18 298:12 99:21 102:5 symposium 238:12 291:21,25 291:8 294:21 300:4 325:25 326:25 337:16 184:7 193:23 292:18 294:21 300:4 325:25 326:25 337:16 318:18 8rigical 84:21 symptoms 97:20 104:2 123:19 104:2 123:19 60:17 82:23 94:4 105:10 122:7 158:3 16:10 190:15 223:6 53:5,6 55:9 77:15 79:7 93:23,24,24 94:2,11,13 112:3,4 190:15 223:6 32:13,13 136:24 224:8 260:20 291:14,17 329:8 166:22 168:21 176:13 182:2 183:22 192:20 116:22 16:16 <td>surgeon 41:11</td> <td>swedish 216:2</td> <td>· ·</td> <td>128:14 133:21</td>	surgeon 41:11	swedish 216:2	· ·	128:14 133:21
surgeries 84:11 302:13 switching 303:14 95:11 150:22 193:19,21,25 310:13 213:11 220:2 206:25 215:22 197:20 sworn 6:18,22 221:16,21 222:25 226:19 238:13 surgery 53:14,20 66:6 69:17 80:24 symposia 293:12 240:4 247:2,3 295:4,11,16 296:5 99:21 102:5 symposium 238:12 291:21,25 292:18 294:21 254:20 255:4 299:13 302:10 184:7 193:23 292:18 294:21 300:4 299:18 294:21 318:18 318:18 196:25 266:12 300:4 symptomatic 318:18 29:23 35:10 36:5 197:14,15 111:24 symptoms 97:20 60:17 82:23 94:4 105:10 122:7 79:7 93:23,24,24 194:3 196:20 syndrome 257:6 58:3 161:10 190:15 223:6 322:24 8260:20 152:24 153:7 197:14,24 surgically 266:24 32:13,13 136:24 224:8 260:20 152:24 153:7 190:15 223:6 320:3 330:5 337:19 330:5 337:19 166:22 168:21 190:13 20:3	104:4	switch 252:7 283:6		142:3 143:23
95:11 150:22 switching 303:14 310:13 192:17 210:23 199:19 202:5 206:25 215:22<	surgeries 84:11	302:13		171:10 178:10
193:19,21,25 197:20 sworn 6:18,22 342:6 347:14 symposia 293:12 240:4 247:2,3 295:4,11,16 296:5 297:17,18 298:12 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 318:18 298:13 302:10 298:13 302:10 318:18 298:13 302:10 318:18 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 318:18 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 318:18 298:13 302:10 298:13 302:10 318:18 298:13 30:10 318:18 298:13 30:10 318:18 298:13 30:10 318:18 298:13 30:10 318:18 298	95:11 150:22	switching 303:14		199:19 202:5
197:20 sworn 6:18,22 342:6 347:14 221:16,21 222:25 226:19 238:13 241:25 242:10 66:6 69:17 80:24 symposia 293:12 233:14 235:10 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 297:17,18 298:12 297:17,18 298:12 297:17,18 298:12 298:13 302:10 298:13 302:10 318:18 302:14 27:7 272:2 291:8,11 318:18 318:18 318:18 325:25 326:25 337:16 325:25 326:25 325:25 326:25 325:25 326:25 325:25 326:25 325:25 326:25 325:25 326:25 325:25 326:25	193:19,21,25	310:13		206:25 215:22
surgery 53:14,20 342:6 347:14 342:6 347:14 233:14 235:10 241:25 242:10 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 295:4,11,16 296:5 297:17,18 298:12 298:13 302:10 295:4,11,16 296:5 297:17,18 298:12 298:13 302:10 318:18 418 291:21 298:13 302:10 318:18 418 291:23 299:23 35:10 36:5 48:10,12 50:8 48:10,12 50:8 48:10,12 50:8 48:10,12 50:8 48:10,12 50:8 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 94:2,11,13 112:3,4 105:10 122:7 158:3 161:10 190:15 223:6 109:15 223:6 138:25 141:10 <	197:20	sworn 6:18,22		226:19 238:13
66:6 69:17 80:24 symposia 293:12 240:4 247:2,3 295:4,11,16 296:5 82:10 97:3 99:16 symposium 238:12 291:21,25 254:20 255:4 297:17,18 298:12 99:21 102:5 symposium 238:12 291:21,25 298:13 302:10 318:18 150:11 152:13 238:12 291:21,25 292:18 294:21 318:18 292:23 35:10 36:5 196:25 266:12 300:4 300:4 325:25 326:25 337:16 292:23 35:10 36:5 surgical 84:21 symptomatic 81:20 337:16 292:23 35:10 36:5 48:10,12 50:8 87:14,15 111:24 symptoms 97:20 104:2 123:19 60:17 82:23 94:4 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:15:13,14 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:7 93:23,24,24 79:15:13,14 79:7 93:23,24,24 79:15:13,14 79:7 93:23,24,24 79:11:11:11 79:7 93:23,24,24 79:11:11:11 79:7 93:23,24,24 79:11:11:11 79:7 93:23,24,24 79:11:11 7	surgery 53:14,20	342:6 347:14	· ·	241:25 242:10
82:10 97:3 99:16 293:19 293:13 293	66:6 69:17 80:24	symposia 293:12		295:4,11,16 296:5
99:21 102:5 symposium 238:12 291:21,25 264:14 271:7 298:13 302:10 150:11 152:13 30:4 318:18 318:18 196:25 266:12 300:4 300:4 325:25 326:25 335:10 36:5 336:7 338:7 symptomatic 81:20 37:16 48:10,12 50:8 48:10,12 50:8 87:14,15 111:24 symptoms 97:20 104:2 123:19 599:20 10 104:2 123:19 599:20 10 104:2 123:19 599:20 10 105:10 122:7 158:3 161:10 190:15 223:6 122:21 16:13,14 138:25 141:10 138:25 141:10 190:15 223:6 122:24 153:7 158:3 161:10 152:24 153:7 166:22 168:21 152:24 153:7 166:22 168:21 176:13 182:2 176:13 182:2 183:22 192:20 183:22 192:20 211:3 215:16,17 215:18,19,25 217:3 219:12 217:3 219:12	82:10 97:3 99:16			297:17,18 298:12
238:12 291:21,25 292:18 294:21 306:25 266:12 336:7 338:7 surgical 84:21 87:14,15 111:24 156:25 192:10 194:3 196:20 197:14,24 surgically 266:24 surprised 191:3 267:3 surprisingly 308:21 238:12 291:21,25 292:18 294:21 300:4 300:4 symptomatic 81:20 symptoms 97:20 104:2 123:19 syndrome 257:6 system 28:19 32:13,13 136:24 189:8 285:20 290:3 systematic 126:16 systems 152:3 238:12 291:21,25 272:2 291:8,11 312:4,6,16 315:13 325:25 326:25 337:16 taken 5:6 48:21 60:17 82:23 94:4 105:10 122:7 158:3 161:10 190:15 223:6 224:8 260:20 291:14,17 329:8 330:5 337:19 166:22 168:21 176:13 182:2 183:22 192:20 211:3 215:16,17 272:2 291:8,11 29:23 35:10 36:5 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 94:2,11,13 112:3,4 138:25 14lking 13:11 29:23 35:10 36:5 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 94:2,11,13 112:3,4 138:18 talking 13:11 29:23 35:10 36:5 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 105:10 122:7 158:3 16:10 190:15 223:6 224:8 260:20 291:14,17 329:8 330:5 337:19 166:22 168:21 176:13 182:2 183:22 192:20 211:3 215:16,17 272:2 291:8,11 29:23 35:10 36:5 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 112:22 116:13,14 138:25 141:10 190:15 223:6 224:8 260:20 291:14,17 329:8 330:5 337:19 166:22 168:21 176:13 182:2 183:22 192:20 211:3 215:16,17 272:2 291:8,11 29:23 35:10 36:5 48:10,12 50:8 53:5,6 55:9 77:15 79:7 93:23,24,24 105:10 122:7 158:3 16:10 190:15 223:6 224:8 260:20 291:14,17 329:8 330:5 337:19 166:22 168:21 176:13 182:2 176:13 182:2 272:2 291:8,11	99:21 102:5	symposium		298:13 302:10
184:7 193:23 292:18 294:21 312:4,6,16 315:13 talking 13:11 196:25 266:12 300:4 325:25 326:25 325:25 326:25 48:10,12 50:8 surgical 84:21 81:20 symptoms 97:20 53:5,6 55:9 77:15 53:5,6 55:9 77:15 79:7 93:23,24,24 156:25 192:10 104:2 123:19 syndrome 257:6 105:10 122:7 94:2,11,13 112:3,4 197:14,24 system 28:19 32:13,13 136:24 190:15 223:6 138:25 141:10 surgically 266:24 32:13,13 136:24 224:8 260:20 152:24 153:7 surprised 191:3 290:3 330:5 337:19 166:22 168:21 surprisingly systemic 126:16 342:11 176:13 182:2 surprisingly systemic 126:16 342:11 211:3 215:16,17 308:21 290:3 290:3 290:3 290:3 308:21 308:21 308:21 308:21 308:21	150:11 152:13			318:18
196:25 266:12 300:4 300:4 29:23 35:10 36:5 336:7 338:7 symptomatic 325:25 326:25 48:10,12 50:8 81:20 symptoms 97:20 53:5,6 55:9 77:15 53:5,6 55:9 77:15 194:3 196:20 syndrome 257:6 197:14,24 system 28:19 94:2,11,13 112:3,4 surgically 266:24 32:13,13 136:24 190:15 223:6 122:2 116:13,14 surprised 191:3 290:3 290:3 291:14,17 329:8 176:13 182:2 surprisingly 308:21 systemic 126:16 342:11 183:22 192:20 183:22 192:20 217:3 219:12	184:7 193:23	1	1	talking 13:11
336:7 338:7 symptomatic 8urgical 84:21 81:20 87:14,15 111:24 symptoms 97:20 156:25 192:10 104:2 123:19 194:3 196:20 syndrome 257:6 197:14,24 system 28:19 surgically 266:24 32:13,13 136:24 surprised 191:3 290:3 267:3 systematic 126:16 surprisingly systemic 126:16 308:21 systems 152:3 337:16 taken 5:6 48:21 60:17 82:23 94:4 105:10 122:7 158:3 161:10 190:15 223:6 224:8 260:20 152:24 153:7 290:3 330:5 337:19 30:5 337:19 166:22 168:21 176:13 182:2 183:22 192:20 211:3 215:16,17 215:18,19,25 217:3 210:12	196:25 266:12	300:4	· ·	
surgical 84:21 81:20 87:14,15 111:24 symptoms 97:20 156:25 192:10 104:2 123:19 60:17 82:23 94:4 79:7 93:23,24,24 194:3 196:20 syndrome 257:6 158:3 161:10 12:22 116:13,14 197:14,24 system 28:19 190:15 223:6 138:25 141:10 surprise 97:7 189:8 285:20 291:14,17 329:8 166:22 168:21 surprisingly systematic 126:16 342:11 183:22 192:20 308:21 systems 152:3 47:2 59:19 97:16 211:3 215:16,17	336:7 338:7	symptomatic		48:10,12 50:8
87:14,15 111:24 symptoms 97:20 79:7 93:23,24,24 156:25 192:10 104:2 123:19 105:10 122:7 194:3 196:20 system 28:19 158:3 161:10 197:14,24 32:13,13 136:24 190:15 223:6 surprise 97:7 189:8 285:20 291:14,17 329:8 surprised 191:3 290:3 330:5 337:19 267:3 systematic 126:16 342:11 surprisingly 308:21 systemic 126:16 342:11 talk 15:14 22:24 211:3 215:16,17 217:3 219:12	surgical 84:21			·
156:25 192:10 104:2 123:19 94:2,11,13 112:3,4 194:3 196:20 syndrome 257:6 158:3 161:10 112:22 116:13,14 197:14,24 32:13,13 136:24 190:15 223:6 138:25 141:10 surprise 97:7 189:8 285:20 291:14,17 329:8 152:24 153:7 surprised 191:3 290:3 330:5 337:19 166:22 168:21 surprisingly 308:21 systemic 126:16 342:11 138:22 192:20 211:3 215:16,17 215:18,19,25 217:3 210:12		symptoms 97:20		79:7 93:23,24,24
194:3 196:20 syndrome 257:6 103:10 122:7 197:14,24 system 28:19 158:3 161:10 138:25 141:10 surgically 266:24 32:13,13 136:24 224:8 260:20 152:24 153:7 surprised 191:3 290:3 291:14,17 329:8 166:22 168:21 surprisingly 308:21 systemic 126:16 342:11 183:22 192:20 systemic 126:16 342:11 211:3 215:16,17 257:3 219:12 217:3 219:12	· ·	, · ·		
197:14,24 system 28:19 surgically 266:24 32:13,13 136:24 surprise 97:7 189:8 285:20 surprised 191:3 290:3 267:3 systematic 126:16 surprisingly systemic 126:16 308:21 systemic 126:16 systems 152:3 talk 15:14 22:24 47:2 59:19 97:16 215:18,19,25 217:3 219:12	194:3 196:20			1
surgically 266:24 32:13,13 136:24 190.13 223.0 152:24 153:7 surprise 97:7 189:8 285:20 291:14,17 329:8 166:22 168:21 surprised 191:3 290:3 330:5 337:19 176:13 182:2 surprisingly 308:21 systemic 126:16 342:11 211:3 215:16,17 systems 152:3 47:2 59:19 97:16 215:18,19,25				
surprise 97:7 189:8 285:20 291:14,17 329:8 166:22 168:21 surprised 191:3 290:3 330:5 337:19 176:13 182:2 surprisingly systemic 126:16 342:11 183:22 192:20 surprisingly systemic 126:16 211:3 215:16,17 308:21 47:2 59:19 97:16 215:18,19,25		•		
surprised 191:3 290:3 330:5 337:19 176:13 182:2 surprisingly systemic 126:16 342:11 183:22 192:20 308:21 systemic 152:3 152:3 176:13 182:2 47:2 59:19 97:16 291:14,17 329:8 176:13 182:2 183:22 192:20 291:14,17 329:8 342:11 183:22 192:20 211:3 215:16,17 215:18,19,25 217:3 219:12		· · · · · · · · · · · · · · · · · · ·		
267:3 surprisingly 308:21 systematic 126:16 systemic 126:16 systems 152:3 systematic 126:16 47:2 59:19 97:16 183:22 192:20 211:3 215:16,17 215:18,19,25 217:3 219:12	_		· · · · · · · · · · · · · · · · · · ·	
surprisingly systemic 126:16 talk 15:14 22:24 211:3 215:16,17 308:21 systems 152:3 47:2 59:19 97:16 211:3 215:16,17	_			
308:21 systems 152:3 talk 13.14 22.24 47:2 59:19 97:16 215:18,19,25				
4/:2 59:19 9/:10				· · · · · · · · · · · · · · · · · · ·
9/:1/,18,19,20,22				
			97:17,18,19,20,22	

233:17 236:12	tell 27:21 38:16,20	139:20,22 142:4	202:22 209:2
242:16,18 250:11	46:20 49:13 54:15	153:16 180:5,15	323:19 327:17
254:16 283:17	66:14 87:7 122:5	195:5 205:25	345:9,18 347:8
303:11 307:11	122:17 124:6,7,21	215:18 248:10,10	testing 314:4
313:21 314:25	134:6 144:7	256:20 263:5,7	testosterone 48:14
316:20 326:12	148:10 198:13	266:2,5,8,11	48:21 56:21 57:9
talks 285:2 313:13	200:12 257:4	276:12 281:16	59:18 114:8
tangential 259:12	259:17 268:24	313:9	186:11 340:18
tangentially	269:19,23 279:21	terminology 66:12	tests 312:3,14
258:22	289:24 295:2	73:21 313:12	313:23
taught 204:9,13,17	297:20,22 311:15	terms 32:12 33:3	texas 323:3,7,12
tavistock 275:6	321:12 325:11	67:4,10 73:15	323:19 326:9
308:19 309:4	326:21 331:21	79:13 116:25	327:4
teach 155:2	telling 25:8 58:3	120:3 149:16	text 65:20 71:11
289:13 336:25	148:8 153:23	160:24 241:20	71:14,15 149:24
teaching 16:2,4	321:12,16,17	terrible 108:8	273:3
207:10	tells 39:2 45:17	267:18 301:17	textbook 306:14
team 22:19 23:4,6	46:19 120:19	terribly 115:9	320:18,20
23:18 24:8,9 40:8	160:5 298:23	120:8	thank 7:4 12:5
159:21,22,24	temporarily 34:15	test 266:20,21	17:7 21:13 40:20
164:21,25 167:8	123:21	311:19 312:10,13	45:12 49:7 68:19
167:12 205:16	temptations 57:14	312:19	72:14 82:14 87:17
227:18 273:23	ten 14:2 17:13,14	testified 14:15	91:18 95:8 110:21
teams 173:18	17:24 20:11,17	15:4 74:6 79:15	214:21 301:4
tease 55:13	27:25 30:18 31:5	96:7 120:2 141:23	328:2
technical 12:14	54:2,18 55:10,15	195:25 208:8,12	theme 293:13,18
teen 158:14 268:9	56:12,25 58:7,20	208:13	theoretical 83:5
teenage 22:24	132:6 206:12	testifies 6:23	theoretically
30:24 52:13	219:2 243:24	testify 177:25	83:14 84:2 169:25
teenager 14:9 32:2	275:8 277:8	178:7 207:12,20	196:15
32:6,10 50:6 55:9	297:17,24 298:8	208:21 342:7	therapeutic 26:7
62:20 88:3 113:18	298:12 306:8	testifying 148:7	48:6 212:22
teenager's 50:25	309:4 328:12	181:18 208:19	227:24 232:17
teenagers 14:8	tend 28:13 48:2	testimonies 209:14	264:20 268:15
23:9 26:2 31:4	131:3,16	testimony 8:12	therapeutics
46:22 49:18 259:4	tendency 101:23	9:12 12:10 36:23	225:20
321:9,12 334:17	tends 157:10	82:16 96:14 106:8	therapies 248:16
teens 27:6 175:13	term 18:12,18	131:14 139:10	294:18 295:23
308:18	69:15 79:2 84:15	144:7 161:15	therapist 25:11
teleconference 2:5	84:16 126:17	179:24 181:16	29:11 63:12
	132:4 133:15	191:24 195:2	185:14 311:22

[therapy - think] Page 57

therapy 19:11,21	271:16 273:8	71:19 74:2 75:9	200:16 201:23,24
35:25 36:12,14	274:17 278:5	75:20 76:5,6 77:8	202:7,19 203:23
44:7 45:3,9,15	288:6 290:22	77:18 79:11,15,21	205:15,19 209:7
53:13 57:4 58:10	299:8 301:11	79:21 85:12 87:10	209:18,22 211:9
59:5 60:2,5 63:3	313:4,4 316:6	90:15 92:5,15,16	211:24 212:8
63:11,19 68:10,22	319:18,19,20	92:22 93:2 98:9	213:5,25 214:18
75:18,25 77:10	336:16	99:16 100:3	215:3 217:23
78:6 79:18 82:18	things 10:3,6	101:11 102:13	219:23 220:2,14
83:15 84:4 85:6	46:23 83:10 85:13	105:19 106:2,15	220:16 221:5,16
86:12 87:12 97:10	101:5,18 108:23	111:4,15 112:24	223:17,23 225:6
99:6 105:17	108:24 114:20	113:16 114:2,2	225:12,18 226:6
110:14 117:3,8	115:21 132:4	119:3,22 122:4	226:20,24 227:17
124:10 126:2,10	151:24 152:21	125:21 126:20	227:21 228:17
137:5 151:12	157:24 159:7	128:12,13,25	230:23 232:5,6,8
164:14,16 167:2,3	160:5,11 179:13	132:14,21 134:13	232:11,20 233:5
169:14,19 171:8	179:14 180:14,22	134:24 136:2,19	233:16 237:25
172:18 187:6	180:25 187:19	137:14,19,22	241:10,13 243:23
192:25 199:3,25	188:10,11 192:21	142:18 143:24	247:6 250:4,7,14
212:13 214:5,24	195:6,24 196:9,11	144:9,16 147:18	251:8 253:14
220:20 223:21	204:15 209:7,11	148:9 149:4,6,11	254:5,13 256:12
224:3 225:21,24	209:14 211:16	151:8 152:4,14	257:6,14,21
226:24 227:4,10	216:17 218:19	153:8,14 154:4,10	259:11 261:3,8,15
227:15 229:24	221:4,13 231:19	154:23 156:2,25	262:13 263:9,9
242:5 243:11	244:8 274:21	159:3,25 160:3,21	266:6,8,11 269:7
246:21 248:9,12	296:16 298:9,13	162:10,21,21	270:2 271:12,25
289:11,12 297:8	301:5,6 311:16	163:2,7,13,15,22	275:7,12,12,15,17
300:2 324:18	314:6 317:15	164:6,14,18,19,20	275:19,25 276:11
327:7 331:15	326:20 330:23	164:24 165:5,16	279:14 281:6,24
338:4 343:19	think 9:13 10:16	165:23 167:16	283:4 284:20,23
thing 34:21 35:4	11:20 13:7 14:19	168:16 170:22	285:15,16,19
47:6 50:10 76:4	17:11 18:10 19:23	171:16,17 173:8,9	286:6,10,18
82:6 96:24 99:23	20:12 21:8,12	173:10,16,20,24	287:17 288:5
100:9,12,14,15	28:15,21,23 29:25	175:8,19 176:3	289:3 290:13,16
109:12,18 115:13	30:17,19 31:14	178:9 179:24	291:6 294:2
120:19 157:9	32:25 33:20,24,25	182:3 185:15,16	299:20 300:6,25
166:16 180:22	34:5 35:21 36:2	185:20 186:4,18	301:21 305:13,16
192:12 203:11	37:5,21 44:17,20	187:20,24 188:25	306:7 307:11,20
207:23 208:18	49:3,6 53:4,9 54:6	189:8,19 191:8	311:22 313:16
213:8 225:12	54:7,12,15 55:19	192:16 197:6,17	315:19 316:25
231:15 237:7	57:6,10 60:22	198:3,11,11	317:2,14,18 318:3
251:11 269:17	63:5 68:10 71:6	199:22 200:8,11	318:18 321:18

[think - trans] Page 58

		T	T
322:8,20,22	thoughtfulness	141:15 144:17	266:6 286:25
324:17,22 325:17	104:15 109:14	145:16 146:8	315:2 338:16
325:18,21,22	thousand 13:12	150:16 153:5,5	today's 130:25
326:22 328:10,14	threat 329:13	156:21 160:25	297:16
328:14,20 329:2	threatening 127:6	161:9,12 171:11	toggles 249:7
329:15 331:6,9,21	328:15 331:3	175:18 183:15	told 46:21 55:25
332:21 333:4,6,19	three 10:15 17:20	185:4 191:5,13	83:18 88:20 120:2
335:2 338:6	18:13,14 19:11,20	215:10 222:25	177:17 200:10
339:14 340:13	19:24 30:20 31:6	223:2,5,8,11,16	265:25 273:14
thinking 53:17	39:8 42:8 51:24	227:9 236:10	278:2
100:4 125:4,6	52:4 54:19 76:3	247:3,4 251:6,14	tom 176:2
168:22 209:12	80:2 88:20 95:21	253:12,16 256:24	tomorrow 169:18
228:2 269:3	95:24 98:20,21	259:14 287:19	324:8
thinks 113:14	108:25 111:10	291:16,19 299:4	tomorrow's
207:2 225:5 266:2	113:11 122:7	306:13 309:11,12	297:16
314:13	125:9 129:2	314:18 321:9,10	toni 109:5
third 143:24	162:20 169:5	322:14 328:4	top 80:24 183:2
175:18 199:16	201:25 233:14	333:20 335:20	184:4 287:7 329:2
264:17 265:10	264:9 265:8	337:18,21 341:4	topic 108:19
287:4	276:22 277:5,9,10	342:13 345:19	183:22 268:14
thirds 256:15	277:25 288:9	timeframe 79:14	284:8
thirty 132:7	298:22	345:8	topics 252:7
thorough 145:17	thromboembolism	times 7:18 20:12	295:18
145:18 150:25	215:13	22:16 31:15 49:14	total 16:8 31:6,17
151:14,16 152:6	throughput 189:7	52:22 95:22 96:10	244:5 259:24
200:3 214:7	thrust 94:3	97:4 102:2,2,3	touched 42:5
thoroughly 144:19	time 7:7 11:18	115:3 124:5 152:3	town 76:15,20
146:9 150:15	12:3,20,25 18:8	187:19 201:25	77:5
202:25 203:3	21:24 22:2 24:5	202:2 246:9	track 18:16 21:7
thought 51:16	24:20 27:18 28:10	249:11 282:8,9,14	21:10,10 28:20
83:10 115:7	31:24 33:23 42:10	timing 73:15	278:15
121:23 157:23	42:13 43:23 47:3	tired 333:20	trade 284:25
171:17 177:11	48:5,17,19 59:10	tissue 180:12	tradition 188:25
208:18 255:16	59:11 60:16,19	tissues 87:22	266:25
269:9 274:9,11	66:3 68:17 69:20	title 268:24 292:7	tragedies 131:24
321:4 328:13	70:21 71:10 74:12	today 7:12 9:12,16	trained 248:8
thoughtful 76:25	75:6,16,21 83:19	9:20 10:22 12:11	trajectory 217:7
92:13 109:14	95:3,5 104:15	142:2 157:24	trans 19:6 23:4,6
170:12 184:25	105:3,4,9,12	186:12,24 187:17	43:25 49:10,24,25
205:17	108:11 119:12	211:3 220:25	50:2,6,25 51:12,14
	122:10 140:16	221:12,13 265:10	52:13 57:14 74:24

[trans - truth] Page 59

75:2 86:24 100:14	150:19,21,22	117:5,7,11 128:22	251:21
108:5 111:8	156:23 187:2	134:25 135:8,11	trials 135:12
113:19 115:4,22	transitioned 52:25	140:7 149:16	228:18 229:3,7
116:5,5 121:14	53:12 54:10 55:4	160:15 163:14	232:3,9 234:4
142:22 147:24	56:15,16 57:24	169:5,17 172:6,15	247:15,23 249:3,4
157:12 189:11,13	88:5,25 89:2	172:16 173:4	250:12
189:17 194:25	131:6 170:14,16	174:10 179:20	trickle 296:15
209:19 210:7	215:24	184:9,23 187:2,22	tried 18:5 52:22
213:17 257:24	transitions 93:15	192:9,10 194:14	59:8 119:6,8
275:3,9 280:17	93:16	194:18,25 196:19	198:13 274:5
286:17 291:2	transsexual 46:7	196:20 197:14,15	tries 36:17
295:7 320:24	180:23	197:24,24 198:9	triglycerides
321:10 324:14	transsexualism	198:16 199:20	216:16
336:15	321:7	200:5 211:7 212:2	triple 249:3
transcribe 7:22	transvestitic	214:9 215:3,9,11	trouble 231:17
8:15	320:25	217:2,3,14 218:8	237:15,22 279:25
transcript 181:8	treat 222:19	219:3 222:13,17	330:11
181:16 190:3,14	243:11 248:18,20	228:24 229:22	troubles 15:15
342:11 343:20,25	294:18 310:14	230:15,21,22	319:8,9
345:6,20 347:5,8	322:3 333:16	233:12 259:15	troubling 108:23
transferred 75:7	334:9 336:6	260:2,4 261:9,23	true 61:15 62:19
transforming	treated 12:22 16:7	287:12 289:6	102:19 105:19
213:2	16:22,25 17:17	296:9 297:19,21	117:24 131:18
transgender 22:19	105:15 110:24	298:2,15 304:11	133:5 146:5
24:8 50:15,15	124:2 164:8,9	305:22 309:5	180:23 204:10
52:20 98:6 181:10	210:11 251:20	310:3 332:16	319:5 321:4,6
194:19 197:2	265:12,13,15	334:5,16,22 335:4	322:9 342:10
228:2 245:9 254:7	treating 17:16	336:22 338:20	347:8
257:14 259:9	18:7 32:24 66:2	treatments 130:4	truly 157:16 160:3
292:2 295:24	265:18	163:16,22 164:2	trust 13:14 94:2
298:14 321:23	treatment 12:18	168:17 171:11	166:2,2 168:24
343:22	16:13,25 17:22,25	172:2,24 179:22	190:23 204:11,13
transgendered	33:13 40:15 43:10	182:6 184:16	204:16 239:17
212:9	61:11 62:6,15,21	194:3,3,21 211:14	296:2,18,25 297:4
transition 52:16	62:24 63:8,11,15	217:10 236:23,24	297:6,12,14
54:5,9 55:6 56:22	63:16 68:2 76:22	247:10,13,20	trusting 109:15
66:5 87:12,14,15	80:2 81:25 84:18	269:12 296:13,14	trustworthy
87:16,19 88:2,13	84:19,20,21 94:4	298:6 306:2	156:20 240:12
89:7,8,15,16 92:17	98:23 99:9 101:10	treats 35:13	290:4 297:5,6,15
133:16 142:7	101:11,15,16	trial 70:24 229:20	truth 38:19 58:3
144:11 150:10,17	111:22,23,25	230:2 246:19	60:9 205:3,7

[truth - understood] Page 60

275:24 297:7	95:14 98:20	umm 72:7	108:21,22 115:12
321:16,22 322:5	108:22 110:7	unbeknownst	130:11 131:13
342:7,7,8	125:9 129:13	302:22	140:8 141:20
try 8:21 9:7 25:10	137:11,23 143:12	uncertain 56:9	144:6,14 151:7,10
29:16 36:17 47:22	143:15,19 144:3	114:19 141:6	152:23 153:6
56:10 107:9,21,25	148:5 162:20	160:6 169:12	161:24 162:4
108:12 109:9,23	165:11 169:20	195:5 213:6	163:19 178:14,20
110:13 117:22	172:8 173:16	uncertainties 58:2	179:23 184:12,20
155:15,20 185:16	175:19,22 183:18	156:14 261:25	192:19 195:10,14
195:10 224:2	186:14 187:21	uncertainty	200:2 202:21
237:18 335:19	189:11 193:16,21	114:17 286:3	203:23 205:7
trying 17:5,25	195:3 196:12,13	unclarified 287:22	214:2 220:6 229:4
27:15 43:7 53:24	196:23 205:23,24	unclear 129:9	229:20,25 233:21
57:17 67:3 72:9	206:8 221:4	130:16 132:9	237:12 239:23
79:14 82:19 92:8	227:12 238:12,12	139:21 163:17	241:5,13,16
106:24 109:22,22	256:15 257:13	193:17,24 194:16	250:10 252:18
112:24 113:5	259:18 265:9	209:12 219:4	255:21 263:6,7
127:9 132:18	270:14 280:22,25	uncomfortable	267:17 273:4,12
140:18 146:21,24	281:7,12 291:23	26:13,21 328:10	274:2,6 279:5,14
148:14,15 153:13	291:24 292:12,15	underestimated	279:16 281:20
155:10,23 156:5	309:5,6 315:11	262:4	283:20 309:21
163:14,16 173:5	334:25	undergo 157:20	322:4 326:23
182:4 193:8	typed 8:12	undergone 269:11	335:10 337:5
211:22,25 219:24	types 240:9	underlying 107:23	understanding
220:5 221:17	typical 35:4,7 50:6	108:3 200:24	50:12 69:6 78:17
289:10 296:10	90:16 99:23	265:2,3	79:15 88:8 96:17
320:21 331:21	u	underpinning	107:3,17 116:18
tsunami 140:4	u 91:2 303:19,23	150:21	135:17 136:9
turban's 10:24	303:24 305:8	understand 12:19	137:3 138:7,12,15
308:13	u.k. 119:5 129:14	14:6 21:3 25:11	139:4 145:7,11
turn 22:5 157:7	134:20 137:4,6	26:17 29:6 32:11	146:6 147:14
175:7 296:17	138:2,4 140:13	32:16 34:25 40:4	164:10 166:20
turned 97:6 224:2	259:21 261:14	43:7 46:2,4,6	173:6 174:21
turns 321:8	270:15 308:3	47:14,25 50:21	187:18 188:5
twice 17:18	ultimate 103:16	57:11 63:15,17	196:8 201:12
two 19:24 22:24	187:22	67:3,6 72:17	237:15 265:7
23:25 26:18 30:19	ultimately 43:11	73:12 79:23 82:15	338:18 339:10
31:6 35:11 39:4	225:2	82:19 85:7 87:7	understood 8:23
39:21,22 54:19	umbrella 154:16	87:25 88:11,22	18:17 29:3 32:15
57:6 76:3 83:3	154:17,19,20	92:9,19 98:11	79:13 139:9
88:18 93:4,18	175:25 222:10,19	105:13 106:25	240:16 249:15
	173.23 222.10,13		

[understood - visit] Page 61

282:2 287:10	unknown 75:8	vaginanlagty	vessels 336:3
327:25		vaginoplasty 195:14	vessels 550.5 video 4:21 5:5
	unproven 150:23		341:4
undertake 87:11 231:20	unquote 198:18,19 unrelated 108:19	vague 187:8	
		205:13 247:17,19	videoconference
undertaking	unsympathetic	300:23 315:16	1:17
150:17	165:19	vaguely 190:19	videographer 5:1
undervaluing	untrustworthy	331:3	6:8,17 11:22 12:2
122:19	270:17	valid 240:14	60:15,18 105:8,11
underwent 99:21	unusual 76:4	319:24 322:7	161:8,11 223:4,7
undisclosed	updates 287:25	valuation 62:22	223:11,15 291:15
287:21	upgrade 169:6	valuations 270:14	291:18 337:17,20
unease 97:22,22	uploaded 64:16,21	value 163:17	341:3
97:23	70:4	variable 253:15	videotape 2:3
uneasiness 108:6	urban 184:12	varied 21:2 125:19	videotaped 1:18
uneasy 78:24	urge 210:21	various 84:2 93:21	view 35:23 39:24
103:21	urged 335:8	93:25 108:12	81:16 128:20
unfortunately	urging 153:22	147:17 156:24	139:10 151:11,20
209:21	urologist 339:12	233:22 236:25	152:5 157:15
unhappiness	urology 267:2	244:18 246:8,9,9	159:11 160:22
125:13 218:3	use 17:25 33:14	268:23 308:11	175:10 187:4
unhappy 125:8	68:25 84:10 92:21	326:20 338:20	192:22 196:17,21
uniformity 285:19	92:24 96:12	varying 25:23	202:11 203:16
286:3	107:12 137:24	vast 139:5,13	214:3 217:10
union 3:13	145:21 184:8,16	vastly 262:3	236:7 249:15
unique 318:25	184:22 188:19	verbally 8:13	301:9,16 314:14
320:4	226:9 243:10	verification	314:17,19 328:25
unit 5:4 79:4	249:9,12,18,23	311:25	337:6
159:22 160:7,19	250:13,15,20,22	verify 311:12	viewed 276:20
united 1:1 5:10	251:2,3,9 266:6	314:5 345:9	views 122:20
93:22 99:24	274:25 276:17	veritext 2:5	130:25 158:3
100:10 129:20	292:19 313:12	345:14,23	178:12 221:19
136:25 140:14	326:3 334:8 335:5	veritext.com.	300:9,12,18,19
146:19 154:24	uses 250:5 279:9	345:15	305:25 334:4
186:19 231:16	usually 35:7 42:7	version 151:8	335:19
298:20	97:23 98:20 101:6	265:10	vintage 248:8
units 334:15	276:21 277:5,18	versions 265:9	vintages 25:23
universal 50:3	V	versus 5:8 17:4	violation 329:7
136:23	v 1:9 60:24 70:8	70:20 167:20	virginia 65:12
university 24:16	190:6 315:22	218:6 236:25	virtually 2:4
59:16 91:23 92:6	316:9,14 343:13	237:2 318:2	visit 127:22
273:2	344:3		340:19
	ידד.ט		

[vocal - witness] Page 62

vocal 268:6	185:23,24 186:5	watched 114:16	websites 49:25
vocational 207:3	191:4,11,19	114:16	268:13
vocationally	192:14,21 195:7	watchful 263:3,20	week 13:5,19,19
179:12	195:11,12,13	264:7,12,13,18	13:21,24 14:3
voice 115:16	199:18 203:11	265:8,23 266:9,11	17:19 26:18
117:14 216:11	206:10 209:9,10	266:16 267:8	323:21 324:8
vote 326:14	209:20 212:4	way 8:21 18:2	weeks 22:24 35:11
vs 345:4 346:1	213:12,15 218:7,8	29:14 30:20 31:7	93:18 111:10
347:1	227:21 235:21	46:11 52:6 53:2	237:9 323:25
vulnerabilities	238:21 247:3	53:13 55:13,14	weight 215:14
107:22	249:23 252:7	56:11,15 57:4	216:13
vulnerable 104:22	255:15 260:19,22	69:15 82:22 99:4	weightless 237:5
212:8,10	263:11 281:22	100:3 127:19	welcome 293:16
W	282:15 283:8,20	138:23 157:17	welfare 175:2
w 91:5	289:15 290:22	166:6,10,12	went 59:15 74:23
wait 8:8 267:12	296:2 309:16	168:14 174:7	74:24 95:16
waiting 64:20	315:7 316:19	175:5,5 178:19	122:11 127:19
263:3,20 264:8,12	321:23 326:16	184:11 199:22	147:22 206:11
264:13,18 265:8	336:17,21,24	223:20 225:16	316:23
265:23 266:9,11	340:18	228:25 231:9	west 3:22 4:4
266:17 267:8	wanted 118:6	235:6 236:11,11	65:12
waitlist 309:7	123:24 128:3	258:19 259:12	whoa 154:2,2,2
walked 315:4	183:10 192:2	280:9 293:16	wholeheartedly
want 11:11 12:16	193:11 227:13	299:3 307:5 308:7	336:19
16:17 29:9 32:11	237:11,24 239:22	316:24 319:10	willing 267:23
33:14 35:8 36:9	256:24 258:9	324:9 325:24	win 220:3
39:12 46:20,21	265:11 320:18	333:16	winded 104:25
47:6 61:15 67:6	324:3,12	ways 22:3 57:12	322:25
68:6 71:10 72:12	wanting 84:10	188:9 226:12	wisdom 178:3
73:9 74:4 76:6,11	102:4 139:25	257:2	179:6,17,19,21
76:12,21,24 78:18	274:7	we've 7:6 35:10	184:10 195:5
80:4 83:24 90:13	wants 30:6 67:19	71:6 97:8 152:11	217:25 231:6
103:2,4,5,8,8	71:25 101:14	185:3,21 229:10	250:17
110:8 126:5	102:9 104:5,7	278:17 302:5	wishes 115:25
132:17 133:4,12	189:24 217:21	340:9	withheld 48:21
149:9 150:4,8	265:5 274:25	weak 324:7	witness 6:17 7:3
151:7 153:15,22	war 232:14	weakening 114:3	11:17 64:17 65:3
154:10 170:21	warn 109:23	114:11	70:11 71:2 161:4
174:24 176:19,23	watch 266:15	weaknesses 97:19	176:19 237:20
174.24 170.19,23	267:6,11 314:15	web 1:17	303:20 327:3
183:3 184:4	314:16		332:24 337:14
105.5 104.4			

[witness - years] Page 63

			I
340:23 343:2	338:8	282:9,12 286:9	16:22 17:10,18
345:8,10,12,19	workers 312:8	287:3 306:19	18:10 19:5,12,15
witnesses 324:16	working 121:9	338:24 339:8	19:22 20:4,12,17
witnessing 330:19	127:7 288:18	writer 278:12,13	20:19 21:3,3
woman 95:14,20	works 92:4 153:6	writing 66:15,17	23:18 27:22 28:5
111:8 125:8	264:11 272:24	67:2 69:3 81:11	28:11,17 30:19
222:15 256:5,6,6	287:14 297:13	93:6 94:23 102:10	32:14,16 33:18,19
258:11 303:3	304:10 322:20,21	155:17 163:2	53:23 54:7,7,19
women 236:5	world 43:14	writings 144:7	55:16 57:3 58:9
238:9 268:7	113:19,20 116:4	written 53:19	58:23 84:5 85:15
wonder 285:23	116:24 120:4	80:12,22 82:17	85:15,15 87:4
wondering 202:4	146:20 154:5	85:20 86:10 93:8	90:10,10,16 92:17
woodwork 258:25	155:6,9 157:10,11	94:12 95:9 96:8	95:19 96:4 101:24
word 16:25 33:14	189:16 241:11	98:4,4,15 187:18	101:25 111:5,6
67:9 68:21,25	286:21 295:6	215:12 226:21	112:21 118:10,14
96:12 107:13	300:10 324:14	287:8 343:17	122:12 129:17
112:2 128:7,11	337:7,8	wrong 91:16	132:2,3,3 140:17
131:11 145:22	worried 88:11	205:21,23 249:21	140:23 141:18
184:20 185:24	285:22 290:8	273:6 278:2	152:8 163:6,7,10
186:3 199:16	worry 85:18	280:15	164:13 168:15
267:17 292:19	225:18 284:16	wrote 95:12,13,18	169:13 170:10
340:6	301:6	142:11 143:22	186:8,10,16,24
words 8:15 67:13	worrying 201:18	153:20 217:17	187:3,6 189:10
107:12 109:13	worth 122:8	236:6 237:7 281:9	197:21 201:6
129:2 142:23	185:16	281:14,16 287:3	213:10,11,14
183:16 225:8	worthy 231:20	295:15 333:7	217:6 224:9
331:2	wpath 72:18 73:17	335:5	228:12,13 236:7
work 13:4 19:14	102:22 275:20,25	X	259:20 260:9
22:6,8 32:9 56:3,6	288:7	x 1:5,14 260:20	261:15,19 290:14
61:7 66:8 94:2	wpath's 270:16	343:1,7	309:4 326:2,4
102:12 105:3	291:3	xi01165 2:8	330:16
111:15 122:17	wrap 221:20		years 13:22 18:21
168:13 275:3	write 45:8,22 46:8	y	18:23 20:8,13
280:16 284:16	46:10,14 67:20	yeah 24:4 28:7	30:24 31:10 33:6
296:20 298:19	68:12 69:7,10	54:22,25 71:9	33:11,21 40:11
309:18	73:23 83:14 86:3	199:17 242:24	48:19 51:21 63:4
worked 14:2 22:11	94:21 96:3 98:16	258:9 276:15	63:9,18 64:6 74:7
95:4 104:6,9	100:4 101:8 102:6	306:8 325:11	75:25 76:14 78:5
257:10 288:17	148:5 217:11	327:14	79:19 83:13 96:20
worker 60:25 61:2	242:6 275:10,11	year 13:17,20,23	102:3 110:7 118:7
62:9 103:9 337:25	277:3 281:13	13:25 14:11,13	118:11,14 122:3,7

[years - zucker] Page 64

440 # 4 # 5 * 5	
148:5 152:19	zeitgeist 197:9
162:20,20 164:14	zero 54:13,13
165:11 168:3	zoom 2:4
169:5,20 173:3	zucker 253:18,21
174:12 183:18	265:22,25 292:14
186:14 189:11	294:13,25 295:3
193:24 194:19	299:16,22 300:3
196:12,23 205:24	
206:8,9,12,19	
218:4 219:2	
233:14,15 248:25	
248:25 256:7,7,7	
257:7 260:20	
261:10 268:10	
275:7,8 288:7,9	
301:25 302:2,2	
309:2 328:12	
330:12,16,20	
yesterday 10:25	
york 3:5,5,15,15	
5:17,20,24 6:5	
22:23 34:4 80:10	
257:9	
young 26:2 61:14	
86:25 125:18	
150:13 168:18	
197:19 212:8	
268:7	
younger 27:6	
156:4 224:14	
254:10 256:19	
youth 130:5	
135:23 233:9	
254:2 286:17	
292:2 295:24	
youths 268:4	
Z	
z 91:2,2 305:8	
zeal 90:18	
zebras 252:6	

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.

Exhibit 7

Case 4:21-cv-00450-JM Document 156-7 Filed 06/22/22 Page 2 of 31

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION (313)414-4460. Lawrence_Przybysz@mied.uscourts.gov

Proceedings recorded by mechanical stenography. Transcript produced by computer-aided transcription.

APRIL DEBOER, ET AL.,

Plaintiffs,

HONORABLE BERNARD A. FRIEDMAN

. .

No. 12-10285

RICHARD SNYDER, ET AL.,

Defendants.

BENCH TRIAL

Monday, March 3, 2014

Appearances:

FOR THE PLAINTIFFS:

LESLIE COOPER, ESQ. CAROLE M. STANYAR, ESQ. DANA M. NESSEL, ESQ. KENNETH MOGILI, ESQ. ROBERT SEDLER, ESQ.

FOR THE DEFENDANTS:

TONYA C. JETER, ESQ. KRISTIN M. HEYSE, ESQ. JOSEPPH E. POTCHEN, ESQ. MICHELLE BRYA, ESQ. BETH M. RIVERS, ESQ. ANDREA J. JOHNSON, ESQ. MICHAEL L. PITT, ESQ.

To obtain a certified transcript, contact: Lawrence R. Przybysz, MA, CSR, RPR, RMR, CRR Official Federal Court Reporter Theodore Levin United States Courthouse 231 West Lafayette Boulevard, Room 718 Detroit, Michigan 48226

> Bench Trial Monday, March 3, 2014

> > I N D E X

Defendant's Case in Chief Page Vol.

Mark Regnerus, Ph. D.

Direct Examination By Ms. Heyse: 6 1

Certification of Reporter118

Bench Trial Monday, March 3, 2014 Δ

```
Detroit, Michigan
 2
                                 Monday, March 3, 2014
                                 1:00 p.m.
 5
                  THE COURT: Thank you. You may be seated,
 6
     who is the next witness?
                  MR. POTCHEN: Before we begin, I would like
 8
     to apologize I didn't bring this up before the break. Mr.
9
     Girgis was on the stand and he authenticated the book,
     What is Marriage? And we would like to move to admit this
1.0
11
     book. I mean, he's still in the courtroom if you would
     like to ask any questions about that. But to the extent
12
     that this Court ruled regarding his qualifications for an
1.3
14
      expert, we understand that, but --
                  THE COURT: I will admit it for the sole
     purpose -- is that he testified that this was his book and
16
17
     that this is a copy of that book. It was part of the voir
     dire to see whether or not he could testify.
19
                  MR. POTCHEN: Thank you, your Honor. And
20
     that's Defendant's Exhibit Number Four.
                  THE COURT: Very well. Okay.
21
                  MS. HEYSE: He is just right in the hall.
22
23
                  THE COURT: No worries. As I said, both
     side -- collegiality in terms of timing.
24
25
                  MS. HEYSE: Thank you, your Honor.
```

Case 4:21-cv-00450-JM Document 156-7 Filed 06/22/22 Page 3 of 31

Bench Trial Monday, March 3, 2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

THE COURT: Be kind enough to raise your 1 Q. Do you hold any other titles at the University of hand. Texas at Austin? 3 A. I am a research associate in the Population Research MARK REGNERUS, PH. D., Center being first duly sworn by the Court to tell Q. And are you tenured? 6 the truth, was examined and testified upon 6 A. I'm tenured. 7 their oath as follows: Q. And when were you tenured? 8 THE COURT: Come in and have a seat. Get ${\tt A.}\ {\tt I}$ was tenured in 2007. comfortable. when you have had an opportunity to be Q. And what are your duties with respect to the seated, give us your full name and spell the last name, 10 positions that you hold at the University of Texas? 11 11 A. I am responsible for up to four courses per year, THE WITNESS: My name is Mark Regnerus. Last 12 administrative duties. In terms of committees, chairs and 13 name spelling, R-e-g-n-e-r-u-s. 13 sitting on the committees, like admissions and things like 14 THE COURT: Thank you, very much. You may 14 that. 1.5 1.5 THE COURT: Like admissions? That is the 16 most important one, you would think. 17 17 THE WITNESS: Right. And I expected to have DIRECT EXAMINATION 18 BY MS HEYSE: 1.8 an ongoing research agenda. 19 Q. Good afternoon, Doctor Regnerus. 19 BY MS. HEYSE: 20 A. Good afternoon. Q. You mentioned you teach some courses at the 21 O. Doctor Regnerus, where are you employed? 21 university? 22 A. I'm employed at the University of Texas at Austin. THE COURT: I didn't hear the question. 23 Q. And what do you do there? 23 BY MS. HEYSE: A. I am an Associate Professor in sociology In the Q. You mentioned that you teach --25 Sociology Department. THE COURT: Pull the microphone closer. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Probably the base so you don't have to worry about moving your educational background -it Perfect A. My Master's and Ph.D. is from the University of 3 BY MS. HEYSE: North Carolina, Chapel Hill, in sociology. Q. You mentioned, Doctor, that you teach some courses THE COURT: Where? Blue? at the university. Can you tell us little bit about 5 THE WITNESS: North Carolina. Sky blue. Not 5 6 6 dark blue A. My primary course is the Introduction To Sociology THE COURT: That's right. I was just there 8 for undergraduates. It's a large course. Basically it 8 last week on the campus. covers the fundamentals of the discipline. And then I 9 A. Nice. Prior to that time I had my undergraduate 9 degree at Trinity Christian College, a small liberal arts 1.0 will teach as my secondary course sometimes I will teach a 10 graduate course in how to write for the social sciences. school outside Chicago, also in sociology. 11 11 And sometimes I will teach a sociology and religion 12 Q. What does the study of sociology entail? 1.3 course. I came in teaching because I'm interested in 13 A. Sociology is about sort of the influence of social sociology and religion, back in 2002. So I still teach forces on human behavior and then also how people, how 14 classes on it occasionally. But intro is my primary. 15 they operate in sort of social groups and things like that 15 16 Q. And you mentioned you have some administrative 16 and sort of the influence of sort of how social structures responsibilities. Can you explain that a little bit more? 17 change or don't change. And but then within that there A. Right. This semester I am on the, this year I'm on 18 are, you know, dozens of sort of subdisciplines where 19 the Admissions Committee Team. We review people who apply 19 people focus their attention one, say, for example, for the graduate program in sociology, offer admission to 20 religion or family or the economy and like that. 2.0 21 some of them. And the Executive Committee which is sort 21 Q. And where do you tend to focus your attention, of, we give counsel to the Chair of the Department on 22 Doctor Regnerus? A. In my research? certain matters that come before their attention. So, 23 23

24

25

O. Yes?

this is the kind of committee work we are talking about.

Q. Okay. Thank you. Can you tell us little bit about

24

25

A. As I said, I started at University of Texas

9

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

10

- 1 interested in sociology of religion, mapping religious
- 2 influences on human behavior with an emphasis on teenagers
- 3 because I was interested in the data from the National
- Longitudinal Study of Adolescent Health based at the
- 5 University of North Caroline where I went to school. But
- 6 I drifted away from that over the last few years. I wrote
- on religious influences on adolescent sexual behavior. At
- 8 that point I became interested in sort of the study of
- 9 sexual relationships and relationship formation. And so
- 10 that's what I have done since then.
 - Q. Can you give the Court an overview of your
- 12 employment history before coming to the University of
- 13 Texas?
- 14 A. Right. After I finished my Ph.D. in 2000 I was
- 15 employed for a year as a research associate at the
- 16 University of North Carolina. And then I went to Calvin
- 17 College in Grand Rapids for a year. I was the director of
- 18 the center for social research. And then from there I
- 19 went to Texas in 2002.
- 20 Q. You mentioned you teach an introduction to sociology
- 21 course at the University of Texas. What are some of the
- 22 topics that are covered in that particular course?
- 23 $\,$ $\,$ $\,$ $\,$ A. We give, I should say I gave introduction to the
 - basic research methods for sociologists, what sociologists
- 25 do. But then we go through some of the kinds of the key

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

- Q. And how many those touch on that topic?
 A. I think there are roughly six, six or seven that
- 3 talk about the relationship between parent and children
- 4 and especially the quality of interaction between parent
- 5 and child.
- 6 $\,$ Q. Do any of the peer reviewed articles address the
- 7 topic of social science research methods?
- 8 A. Right. Probably five or six would be characterized
- 9 as being about methods or methodological novelties, ways
- 10 of asking certain questions in different ways, yeah.
- 11 ${f Q}$. Have you published any books, Doctor Regnerus?
- 12 A. I published two books.
- Q. What are the topics of those books?
 - A. The first one which I briefly mentioned earlier was
- 15 on -- it's called Forbidden Fruit: Religion In The Lives,
- 16 Religion Sexual Behavior In The Lives Of American
- 17 Teenagers. That was 2007 from Oxford. The second one was
- 18 called Pre-Marital sex in America: How young Americans
- $19\,$ $\,$ meet, mate and think about marrying. That was 2011 from
- 20 Oxford.
- 21 Q. And were your books well received by your peers?
- 22 A. Generally speak, yeah. I had multiple reviews in
- 23 journals about those books. I think the last book had
- 24 one, you know, mediocre review but it had four or five
- 25 positive reviews.

- 1 aspects of sociology -- the socialization, how people
- 2 learn things, culture, what it is, how it changes, social
- 3 structure and how things change very slowly and often not
- 4 at all. And then we get a little bit later in the
- 5 semester we hit on things like family, population change,
- 6 some of the sort of more focused areas within sociology.
 7 Q. Does that course touch on the issues of same sex
- 8 marriage or parenting?
- 9 A. It does. Not extensively so, but it does.
- 10 Q. Have you published any peer review articles?
 - A. Yes. About 30 to 32, somewhere in there. 31.
- 12 $\,\,$ Q. Do any of them deal with issues that are relevant to
- 13 this trial?

1.5

- 14 A. Yes. A few.
 - Q. And how are they relevant?
- 16 A. One is on the New Family Structure Study which is --
- 17 that was something I published in 2012 which I'm sure we
- 18 will talk about. And the follow up which was not peer
- 19 reviewed but it was a response to critics of the original
- 20 study. So those are the two primary.
- 21 Q. Aside from those that specifically address
 - children's outcomes, what we are going to talk about
- 23 today, do you have -- to any of those address more general
- 24 topics of say, parent/child relationships?
- 25 A. Uh-huh.

12-10285; APRIL DEBOER, ET AL. V. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

12

- 1 Q. Have you ever been asked to review other peers'
- 2 work?
- 3 A. Yes.
- 4 Q. And how many times have you done that?
- 5 A. For journal article peer review I have done at least
- 6 three times as many as I have published. So, somewhere
- 7 between 90 and 120 I would say over the last 12 years.
- 8 $\,$ Q. Just out of curiosity have you done any peer review
- $9\,$ work since the release of the NFSS study?
- 10 A. Yes.
- 2 the issues of marriage or same sex marriage?
- 13 A. Same sex relationships, yes.
 - Q. Have you given any presentations, Doctor Regnerus?
- 15 **A.** I have.
- 16 Q. How many have you given?
- 17 A. Probably somewhere between 50 and 60, I would say.
- 18 Q. And what topics?
- 19 A. Oh, all manner of topics. As I said earlier my
- 20 research interests have changed somewhat. Most of the
- 21 articles that I have published are those 30, I had
- 22 presented in conference format at least at some point or
- 23 another, so --
- Q. Have you received any awards or recognition for your
- 25 work?

Mark Regnerus, Ph. D. - Direct

- A. Yes.
- Q. Okay. And what type of awards or recognition have
- you received?
- A. It's listed in the CV in detail. But 2001 there was
- ASA Section, the American Sociological Association section
- 6 on religion through a paper award for the year. I think I
- one that one twice. One was with co-authors. I think I
- won the ASA sections, Religion Section Student Award at
- one time and I think was runner up a couple times in the
- crime law and deviance section of the ASA student paper.
 - Q. And that's the American Sociological Association?
- 12 A. That is.
- 13 Q. ASA?
- 14 A. Yes.
- 1.5 Q. How many studies or data collection efforts have you
- 17 A. I have been a part of probably five or six data
- 1.8 collection efforts. National Longitudinal Study of
- 19 Adolescent Health and National Study for Family Growth.
- They each asked me to play a minor role in different
- 21 points in consulting on their survey questionnaire in one
- 22 particular section of that. The National Study Of Youth
- 23 And Religion I was more of a key part in that. Then the
- New Family Structure Study one I was principal
- investigator of. So I would say at least five in general

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

A. I give ideas to the staff about things that they

- should consider studying. There is a research associate
- or research assistant, I guess, that we co-author pieces
- with and he crunches numbers and I give him ideas about
- what he should consider doing. So it's ideation mainly, I
- 6 would say.
- Q. Can you give an example of the type of work that you
- do at the Austin Institute?
- 9 A. Well, we have -- one of the things we are interested
- in doing is sort of getting information out in creative $% \left(1\right) =\left(1\right) \left(1$
- ways speaking not just sort of the standard journal format 11
- but based on my suggestion and encouragement they created
- 1.3 an animated video of about nine minutes that focuses on
- the dynamics of the mating market.
- THE COURT: What kind of market?
- 16 THE WITNESS: The mating market. How people meet and fall in love and some marry or some don't. So
- that went up live in February and it's already got about
- 19 300,000 views. So, things like that. But also sort of
- regular academic papers. We call them research shorts 2.0
- where the research assistant will crunch some numbers and write a brief kind of on-line abstract of certain ideas.
- O. And just for the record, where is that available? 23
- 24 A. These things are on the web, the Austin students'
- website. 25

17

- that I have been part of either in a minor way or an
- extensive way. A project on religion and H.I.V. AIDS in
- Africa. That was several years ago. That was -- I was
- the co-investigator of that.
- Q. You touched on this a little bit, but how many of
- 6 these studies were you the principal investigator?
- A. Either principal or co of two, I would say.
- Q. Are you affiliated with the Austin Institute for the
- Study Of The Family And Culture?
- 10 A. I am.
 - Q. And how are you affiliated?
- A. I am a senior fellow.
 - Q. And what does the Austin Institute do?
- 14 A. We conduct research, social science research on
- 1.5 matters related to family, marriage, sexual behavior, that
- 16 general orbit of things.
 - O. When did you become a senior fellow?
- 1.8 A. I think it was late summer, early fall of 2013.
- 19 Q. Okay. And how did you get that position?
- 20 A. I was part of the founding of that institute and so
- 21 in discussion with other people who helped found it, it
- just made more sense for me to have a senior fellow
- 23 status, not in the sort of the running of the day-to-day
- 25 O. What does being a senior fellow entail?

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

16

- Q. Okay. Have you spoken to any legislature or
- legislative officials?
- A. I think it was back in November. I am not totally
- sure about the date of 2013, some Hawaiian legislators, I
- went out and talked to. I think there were four of them
- in advance of their, I think they had the same sex 6
- marriage bill going through both their house and Senate. 8 Q. What was the purpose of your speaking with them?
- A. They wanted to ask me questions about the New Family 9
- 1.0 Structure Study and my awareness of other population based
- 11 projects going on in the area about that.
- Q. And have you written or signed any Amicus briefs 12
- 1.3 regarding --
- 15 Q. -- regarding same sex marriage?
- 16 A. I have.
- 17 Q. At this time, if you will look at that very large
- 18 binder next to you and open it up to the tab for Exhibit
- 19 Five?

2.0

- A. My CV?
- 21 Q. Yes. Can you identify that for me, Doctor Regnerus?
- 22 A. Yes. That's my Curriculum Vitae.
- 23 O. I'm sorry?
- 24 A. My Curriculum Vitae.
- Q. Does that appear to be a true and accurate copy of 25

17

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

your Curriculum Vitae? parents have had same sex relationships, yes. O. And the outcomes for those individuals? A. Yes. But it was not the parent who reported the MS. HEYSE: Your Honor, I move for admission relationship. It was the child. of State Defendant's Exhibit Number Five. THE COURT: Any objection? Q. Thank you for clarifying. 6 MS. COOPER: No objection. 6 A. Adult child. 7 THE COURT: Received. Q. Can you tell the Court what methods you followed 8 BY MS. HEYSE: with regard to the NFSS? What type study was that? Q. Doctor Regnerus, can you explain the areas of A. Right. This was a large survey. We screened 15,058 expertise you will be testifying about today? 10 people, asked them a series of questions. The key focus A. I will be testifying about sociology in general, here was the question whether their mother or father, 12 survey research methods and measurement of sexual 12 while they were growing up, whether the mother or father 13 relationships and I presume the New Family Structure Study ever had a romantic relationship with a member of the same 14 and its articles. 14 sex. And we then interviewed extensively across a lot of 1.5 Q. Thank you. And more specifically within those areas 1.5 different domains, 2,988 people, including everyone who of the expertise, have you been asked to provide your 16 said yes to that particular question. And then I analyzed expert opinion regarding outcomes for children being 17 17 1.8 raised in same sex households, correct? 1.8 O. And why did you follow those methods? Is this a 19 A. Yes. That's correct. 19 typical or standard --Q. And did you, in fact, conduct a study called The New 20 A. Right. I don't think it was typical or standard. 21 Family Structure Study the acronym NFSS? 21 In this domain of study there are not very many very large 22 A. I did. population based samples out there because we are talking 23 Q. Did that study look at adult outcomes among children 23 about a fairly small population to begin with. So, the whose parents reported having a same sex relationships? interest was in sort of collecting a large enough number 25 A. I looked at adult children who reported their 25 of cases so that you didn't encounter a problem with too 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 20 small of samples to actually detect differences between sociology of sexual behaviors. groups which tended to be a problem certainly when you THE COURT: Okav. Counsel, do you have any think about studies that compare 18 kids. And, I mean, objection or voir dire? you are just not going to have enough cases to detect real MS. COOPER: No objection. differences that maybe exist in the population. 5 THE COURT: You may proceed. 5 Statistically you can't do that. So we want to collect a 6 6 MS. HEYSE: Thank you, your Honor. large population data set because there is not many of BY MS. STANYAR: 8 them on this broader topic. Q. Doctor Regnerus, I want to start out talking about Q. And what were your general findings? sampling and general research methods terminology. Okay? 9 9 A. Our general findings were that. 1.0 What is population based data? MS. COOPER: Objection. The witness has not 11 11 A. Population based data is about the sampling that is involved in this. There two broad different types of been qualified as an expert yet. 12 THE COURT: Yes. The objection is sustained. 1.3 1.3 sampling strategies when you want to talk -- to get He has gotten a little bit further. information about a group of people. There is probability 15 MS. HEYSE: Thank you, your Honor. Two based sampling and there is non-probability based sampling. 16 things, your Honor. I forget at the outset to provide you 16 with a copy. 17 17 So, for example, if I wanted to get a population 18 THE COURT: That's great. Just hand it to 18 based sample of the City of Detroit, you would want 19 19 everyone in Detroit to have an equal chance of being in MS. HEYSE: I apologize. it, in your sample. So that's a probability based study 2.0

21

22

23

24

25

your Honor, I move to qualify Doctor Regnerus as an expert

THE COURT: Nothing to worry about. Thank

MS. HEYSE: And, second, then at this time,

21

22

23

vou.

of a particular population. So you note underlying

trying to map is known. That's different than

population and then you can generate meaningful estimates

and statistics because the underlying population you are

non-probability based studies which might want to get at a

6

12

13

14

1.5

17

1.8

19

21

22

5

6

8

9

11

1.3

15 16

19

2.0

21

Mark Regnerus, Ph. D. - Direct

population but the methods they use don't allow them to population that you might be after. generalize to a larger population. So there is convenient samples, too, that are --O. Would an example of a population based probability we call them snowball samples where if I said I want to study be one that's nationally representative? talk to -- I want to survey Red Wings fans, you talk to A. A nationally representative study would be, its one, you say, do you know any other ones? My brother. population that speaks to, you know, the nation, right? 6 You talk to the brother. It's a snowball. You pick up So, there are a variety of these kinds of studies out cases along the way. So, you know, that's not a probability sample because not everybody has an equal Q. That would be one type? chance of being in it. They are opting in based and on A. Uh-huh. their own self selection and observation about it. So Q. And you touched a little bit on a non-probability it's not able to tell us about the real population that sample. Would an example of a non-probability sample be a 12 you are after like a probability study can. convenient sample? 13 Q. Okay. If these convenient sample studies are not A. Yes, correct. 14 able to tell you about the population as a whole, why are Q. Okay. 1.5 they used? A. Convenient samples are a type of non-probability 16 A. Well, there are different things you can learn from sample where you pick, I mean, you use variety of means to 17 convenient samples and I have used them in my own research in the past. I mean, depends on what you purported to do sort of collect the people that are going to be in your 1.8 study. It could be, you know, like you go in a coffee 19 with them, right? So the book I am slowly working on, we shop and you can pull off a tab. Would you like to be in talked to a hundred different 24 to 32 year olds. We this study? Or you see a billboard. We would like you 21 wanted 50 men, 50 women. So we call that a guota sample. for this study. That is a convenient sample. People opt Right? And we didn't use some sort of random method to into that. And since it's not really known what is the 23 get them in. We just want different people of different underlying probability that they would be picked randomly, kinds of jobs. And so it was a quota sample. But I can't it's difficult to generalize that to the broader generalize from that to knowing something about all 24 to 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 32 year olds. What I can say is I have learned something A. Depends on what the purpose -- what you are trying about the lives of these people. What I can't know from to accomplish. But ideal studies of this sort would be it is how similar they are or how different they are from large. I mean, you say how large? Large enough so that all 24 that 32 year olds. From that kind of thing and you could analyze, you can create sub-samples that are not hopefully in the same book, I lean on probability, 5 ten or fifteen people large. You know, hundreds and hundreds of cases drawn from a sampling strategy where nationally representative samples, survey data. So, it's 6 more, for me, that provides color commentary. You can go everybody in the underlying population you are trying to in-depth in people's lives and things like that but you 8 get at has an equal chance of getting in, equal chance of don't get a sense of what is going on among the large weighing in. I think that's the fairest way. 9 group that way. 1.0 Q. Would an ideal study be a random sampling? Q. So, in your opinion, should these convenient samples 11 be used to render opinions in social science? 12 Q. Okay. Why is that important? A. Not exclusively. I mean, they can inform us about 1.3 A. Random is just sort of, do the people who make up aspects of people's lives and relationships but I don't 14 this population have a equal shot at being part of it? I think you should make major decisions without getting a 15 think that's what random is about. And I think it's a sense of the underlying population and especially leaning 16 good thing, otherwise people, if people just opt in you on national representative data. 17 don't hear the average person. You hear the people who Q. So there a better method for rendering opinions in 18 are most interested in signing up for the study. social science? 19 Q. And in the ideal study, it would be representative? A. I think it's unwise to make major decisions without A. It would be representative of the underlying

21

22

23

24

25

leaning on large population based nationally 21 representative studies especially if you have something

that is -- has more of a broad or national scope to it. 23

24

25 Q. So is there such thing as an ideal study?

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

You can see how they changed. And you can see how, you 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

A. Ideally, ves. I mean, the benefits of measuring

people over time and revisiting them is a helpful thing.

population that you are trying to --

O. Would it be longitudinal?

1

6

8

12

13

14

1.5

17

19

20

21

22

23

25

replicability is ideal.

Mark Regnerus, Ph. D. - Direct

can see how people change or how trends emerge or fade Q. Why is that important? 1 over time if you talk to the same people or you give the A. So that you can sort of assess changes or trends, surveys questions. You first want them to be valid, good, same questions over ideally many years. I mean, one of the better studies that we hear about regularly is the 4 that they measure what they purport to measure. But general social survey. They ask the same questions, some seconding you want them to be comparable which is what is of which get out of date. They asked the same questions 6 replicability is about. since 1972. So you can kind of map how --Q. And why is this ideal study that you described THE COURT: Who is they? Who does that better than the convenient sample studies? study? A. I'm sorry. Could you say that again? THE WITNESS: The National Opinion Research Q. Why is the ideal study that we just talked about Center at University of Chicago. random, representative, longitudinal, replicable? Why is A. So quite often when you see in the newspaper some 12 that better than these convenient sample studies? sort of social survey, some change in American views on A. Because you actually know something about the this, that or the next thing, it will be from the general 14 underlying population you purport to talk about. So, what social survey. It's not asking the same people but it's 1.5 happens often is, and in a lot of convenient samples they asking a different group of people the same question over, 16 don't claim to do this, but people still tend to interpret every two years for since 1972. their data in that way because you see a study and you 18 BY MS HEYSE: 1.8 automatically kind of mentally accord it, this is a study Q. Would your ideal study also be replicable? 19 of all such and such. Even if they don't, even if the A. Ideally, yes. You know, when I have created survey 20 creators of the study are not claiming that. But a questions I will often sort of lean on other people who 21 convenient sample is like we learn something about who is have asked them so that if they have a national in the sample. Since we don't know their likelihood of representative survey and I have one, we can ask the same 23 inclusion because it's not a probability sample, we don't question and you can compare them over time. So, know if what they are like is what the underlying

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

population is like. So, there are some limitations to

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

what you can know from convenient samples. Q. So would it be fair to say can you learn a lot about individuals that are being studied? A. Is it fair to say -- I'm sorry? 5 O. You can learn a lot about the individuals being 6 studied? A. Sure. 8 Q. But not necessarily about the population or the 9 nation as a whole?

Q. Okay. In social science research is it important to have a clearly defined comparison group before you draw a conclusion regarding differences between those two groups?

A. Right. It's ideal. And people will disagree on the

construction of the comparison groups, but what you want 15 16 to be as clear about who is in this and who is not in this so that when other scientists come along and read your data they can sort of say, I see how you made that group

19 and I agree or disagree or I think we should do it a

different way. 2.0

A. Correct.

11

1.3

21 Q. What are controls in social science research?

22 A. Controls. Okay. So, when we talk about regression models, when we predict an outcome based on a set of 23

24 independent variables or a set of effects, usually we have in mind like the thing we are most interested in, like

what is the effect of X and Y? Net of other things,

right? When you say net of other things you are talking

about a set of controls. Usually sometimes they are 3

standard. Sometimes they are just things that you think

may influence an outcome but that are not critically

important to what you are interested in. So that what we 6

call controls. And most regression models employ some

8 sort of series of controls when they are doing that.

9 O. And why are they used?

1.0 A. In part because you want to sort of test sort of the

11 influence of X on Y and you might be hypothesizing it

exists independently of this set of controls. So, but 12

13 it's usually sort of a standard set of demographic things

you will often see. Other things that might affect the

15 outcome but that are not of interest to you or

16 different -- there is no sort of established protocol

17 about what must be a controlled variable in models. I

18 mean, some -- there are disputes in sociology, like should

19 you have 20 control variables? Some people call it

everything but the kitchen sink. Other people say, no, we

don't have all of those. Focus on just a handful. So 21

22 there is no protocol, but it's a common practice.

O. What are some the standard or common controls that 23

you mentioned? 24

25 A. Age, like as people age, they tend to do different

1

6

12

13

14

1.5

17 1.8

19

21

22

23

25

6

9

11

1.3

24

against.

Mark Regnerus, Ph. D. - Direct

things or think different things. So, gender or sex, But it suggests there is no differences between male, female, race and ethnicity and that's the sort of a parenting unit that, at least in one case, it lacks a the -- in sociology we often do mother's education as a genetic link to a child compared to parent units where proxy for social class of the family. Income, if you know there is a mother and a father and they are both the it, although a lot of people don't like to report their parents of that child and they stay in that relationship income. So sometimes that can be a little tricky. But 6 together. That had long been considered. I mean, in 1994 there is a standard -- those are standard controls. I think it was McLanahan and Sandefur in Wisconsin. And Q. Okay. Let's turn now to the American Psychological this was not a study of same sex parents, but it was about Association's position with regard to outcomes for single parent families. And they said, if we were going children. Are you familiar with their No Differences to design the ideal family, I mean, we would pick this Claim? sort of two parent ideal where there is two genetic A. In general, yes. connections to the child, two sources of -- resources for Q. Do you have an opinion on that No Difference Claim? the child and security and things like that. A. I think it's premature. In the social science of 14 So just to watch the social science discourse family which I have monitored off and on since I have been 1.5 change so rapidly on this subject struck me as in graduate school I have not been actively into it until 16 unscientific, premature, and worth -- I mean, scientists the last several years. But things historically did not are nothing if not tending to be a little skeptical when change very quickly in the study of families and parents 1.8 people purport rapid change in a paradigm. So it just and things like that. But they seem to have changed 19 strikes me as premature. rapidly in the last ten or fifteen years. And such that 20 Q. What type of studies does the APA rely onto support it seems premature to say that something that involves a 21 this No Differences Claim? reduced kinship, meaning somebody is not a biological A. There are probably other people who could speak to parent to the child, to claim there are no differences. 23 And it's important to clarify what the No Differences is

that a little more clearly. But my read on it is when it was issued, there was primarily non-probability samples. More psychology than sociology. And I'm not trying to

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

criticize the psychologists here, but I think it's wise if you are going make a statement on No Differences that you would want a variety of probability sample studies to be weighed in that. So there are more non-probability convenient samples studies than I would want to lean on in making that claim. Q. Okay. And do these non-probability convenience sample studies tend to be small in size? A. Not all of them. But most them, typically well under a hundred. Sometimes 78 or 44. Yeah. Typically under a hundred.

Q. Okay. And what is the problem with the small sample

A. The small sample size issue is, do you have, they call it statistical power, do you have the power to detect 16 real differences that might exist in the population but -and the smaller the sample size, the more difficult it

becomes to detect real differences. So you could, if you 19 had 20 cases of something versus 20 other cases, you could

say we don't detect any statistical difference between 2.0

21 this group of 20 and this group of 20. You could look at

face value, you can look at the numbers and they could

look dramatically different but they are not statistically 23

different because they are, it's called type two error,

the ability to detect statistically what might exist in

reality. So the smaller the sample size, the higher the

risk of making that kind of error is. So, the known

hypothesis, when you look at groups, you say there is no

differences, but you can make a mistake in saying I see no

differences when there actually exists -- your sample size

6 is too small to detect them.

9

1.0

12

1.3

Q. Would it be fair to say that bigger is better for

8 purposes of statistical power?

A. Generally bigger is better.

Q. Do the studies that the APA relies on, what type

11 comparison groups do they use?

A. That also varies widely. Some of the No Differences Claims have been about -- one I can remember is a matched sample of comparable sort of social demographics, but that was one of the Patterson pieces that exactly used the 44

16 cases in the Ad Health Study which is a probability study. 17 But the comparison group was some matched sample

18 out the same study, but they didn't tell us what they were 19 like. Right? I mean, were these kids from single parents or kids from step-parents? Have they had household

21 transitions in their lives? They didn't say. So some of 22

them are more clear about their comparison category being 23 heterosexual single mothers or heterosexual step-parents

24 arrangements. But in those studies there has been wide

25 variety of comparison groups used. Not -- I mean there is

Mark Regnerus, Ph. D. - Direct

not one stable reliable comparison group. A. I am not saying they are bad things. I am saying O. You mentioned this earlier, and I wanted to make they are typically recognized as concessions, sometimes sure it's clear for the record, you referred to something necessary, but sort of not the ideal what people want for called reduced kinship. Can you explain what that is? a child typically. A. Right. Reduced kinship is sort of the basic idea Q. What is the ideal. 6 that when a biological mother and father are not raising a 6 A. Married, mother and father, stably residing with the child together in the same household, some guys go off to child. the military, so, I mean, there is still an intact family Q. And why is that better than a reduced kinship even though dad or whoever is gone. But where the family relationship? has been broken up, the mother, biological mother, and 10 A. Well, better largely in the data historically but father are not actively in, you know, raising the child also back to that McLanahan and Sandefur comment, they 12 together at the same time. 12 talk about biological parents are less likely to abuse or 13 Q. Do you have any opinion with regard to children harm a child. It doesn't mean they never do, but on 14 being exposed to reduced kinship? 14 average, they are less likely than a step-parent 1.5 A. I think it's not the ideal. Now, we certainly 1.5 relationship. More likely to sacrifice for that child. didn't necessarily forbid diminished kinship 16 And just, in general, children flourish better in relationships, obviously. But states typically consider 17 households where mom and dad are together and married. them as concessions to, ideally -- I think about foster $\,$ 1.8 1.8 O. Turning back now to the studies that the APA relied 19 care. There is always that impulse to get foster children 19 on. Did some of those studies use a comparison group with back in the household with their mother and father. And reduced kinship? 21 so far as that is possible, states wish to do that. 21 A. Yes. I mean, many of them did. There was no 22 That's sort of this longstanding interest in kinship consistent -- there is not a consistent category that was 23 23 used as a comparison. Q. So just to be clear, are you saying that either Q. Do you see this as a problem or -step-parenting or adoption are bad things? A. I understand the impulse because there is, in a lot 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 of these same sex parents relationships, there is reduced completely a hundred percent accurate. kinship, I mean, almost by definition there, right? So So, that improves if you talk to say, teenagers. there is an impulse to compare them to something about themselves. Right? Teachers, teachers often can

comparable. At the same time, one runs the risk in this

declaring there is no difference in forgetting to compare

them to sort of kinship structures that are in tact and 6

original, biological. So I think we run the risk of not

remembering the structure that has been historically best

for children. So then when you get claims like No 9

Differences, I think they, you know, people hear this and

think they are just like anybody else. Well, anybody else 11

perhaps of diminished kinship structure which is not

1.3

16

Q. Are there also issues with source bias in these

small convenient samples relied on by the APA?

A. Yes. Source bias is who is doing the reporting on

the child in the study? Some of the times you are talking

about children who are young, too young to report for

19 themselves so the parents will report. But parents, you

when parents are talking about their kids and their 2.0

21 well-being, you know, I know about my kids. I am more apt

to paint them publicly as better than they, right? I say

my kids are good, right? But there is an impulse in 23

24 reporting about one's children to feel social desirability

bias, the impulse to say things about them that may not be

give what I call a little more objective perspective

although teachers have their own biases, but it's probably

ideal to wait until, I think to wait. That's why we did 6

to wait until they are out house so they can reflect on

their own lives and speak for themselves.

Q. So, Doctor Regnerus, are you saying there is no 9

1.0 benefit to the type of studies that the APA relied on?

11 A. I am not staying there is no benefits. Different

studies seek to do different things. Some studies kind of 12

1.3 are social psychological aspects of parent/child

relationships or parenting processes. So you can learn a

lot from the dynamics of different families from

16 convenient sample studies. What you cannot know is how

17 much they reflect an underlying population. So, if you

18 had ten same sex couples in a convenient sample you can

19 know a lot about those ten, but can you know how similar

20 those ten are to same sex couples a everywhere? I would

21 said the answer is no, not from a non-probability study.

22 Q. So given that critique, in your opinion, what type

of study is needed to definitively conclude there is no 23

24 difference?

A. What kind of study is needed? 25

37

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

A. A study as far as I am aware has not been done vet. The science in this domain as I said is new. People have been studying this for a while but just in the last year several years we have kind of started getting questions on 6 it and to national representative studies. I have a longitudinal study, something that tracks kids from, I was going to say from birth, but really you want people from before, when parents meet or get together, and track them through the birth of children into ideally into their adulthood and interview every few years.

So, and a large -- that would be a large study, a national representative study. I mean, it reminds me of, you know, day care was -- the affects of day care and kids is people have all sorts of opinions about that, but several years ago there was finally this Omnibus study of day care that had come to fruition, meaning they had done several different waves of this talking to parents, watching children, etc. So, it kind of clarified the story about day care and people's lives, kids' lives, that I think would be ideal and necessary really to get a sense of whether the No Differences line is true or with respect to what kind of kinship structure are we talking about No Differences.

THE COURT: What did the study say about day

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

those, 2000 some odd other people from different kinds of

household experiences, and asked them 80, 100 plus different questions about their life in the past, their

relationship with their parents, mother, father, how their

life is going now, questions about their employment

status, any interaction with the Criminal Justice System, 6

education. I think I had a question or two on religion.

A series of questions on sexual behavior. Just kind of

across the spectrum set of questions. 9

Q. Okay.

12

13

14

1.5

17

1.8

19

21

22

23

25

5

11

15

A. What was your original question? Did I answer it?

Q. Yes, you did. That's fine. What were your general

1.3 findings with regard to that study?

> A. My general findings with regard to the study is, I called into the question the No Differences Claim with

16 respect to the in tact biological family which is not

often used as the comparison category in a lot of these

convenient samples, when mom and dad are married, were

19 married and are married, even when the child is an adult,

compared to kids for whom their mother or their father had

2.0

had a same sex relationship. And out of 40 different outcomes we evaluated including things that they reflected

on their childhood and things that are current today. 25, 23

24 I might get the details mixed up, but 25 of the 40

different outcomes, there was a simple statistical

1

2 THE WITNESS: You know, I don't actually

recall the punch lines because my kids were really small

and in day care. But I was thinking it was a mixed bag

and it was not sort of -- they are not demonstrable. I

6 think the mother/child connections were a little weakened

but the kids didn't seem any worse for wear academically

for it. And socially, they were a little bit more

advanced. I think that was the punch line. But I just

10 remember it being an Omnibus study of day care that people

have been waiting for a long time.

12 BY MS. HEYSE:

Q. I want to talk about the New Family Structure Study

14 and I am going refer to it at the NFSS. Again, you were

1.5 the principal investigator for that study, correct?

O. And is this a large population based study?

1.8 A. It is. I mean, as large as we could make it. We

19 screened 15,000 people between the ages of 18 and 39.

15,058. Asked them a series of questions, one of which

21 was, you know, there are about adoption and things like

that. But one of which was, have your mother or father,

23 did the mother or father have a romantic relationship with

a member of the same sex while you were growing up with

another woman or another man? And we interviewed all

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

difference and always in the favor of the in tact

biological family. I think 24 of those held up after,

meaning they were still significant with a series of

controlled variables. The controlled variables were age,

race, ethnicity, mother's education, gender, their 5

6 perception about their family income while they were

growing up, a measure of whether they had been bullied as a child or during their growing up years, and a measure of

the gay friendliness of the state in which they were 9

1.0 residing now, measures of the different states. There was

11 scale I think the Los Angeles Times put out, one to five.

I used this as a control variable. 12

So even after those controls there was 24

14 differences between the kids who grew up in an in tact 15

biological family and kids for whom the mother had a same

16 sex relationship. There were fewer statistical

17 differences between kids whose father had a gay

relationship. Partly that is a function of the sample

19 size. We had 73 of those cases compared to 175 for the

mother, where the mother had a same sex relationship. 2.0

21 So when you get to smaller ends, you, of course,

22 you lose statistical power. So even if there were

23 differences, you would be less apt to detect that many of

24 them. There are fewer among the men. And they were less

likely to have lived with their father as well. So, then 25

41

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

they were with their mother. 1 that same household. 2 And then I also compared them with kids who grew THE WITNESS: They may not have been in same up in step-families or kids who had single parents. Now, 3 household. what we did is had a household roster where we asked who THE COURT: If there's divorce or separation. THE WITNESS: There was a great deal of did you live with at each year while you were growing up? 6 Who was in the household? And, I mean, there is a lot of 6 separation, ves. messy households out there. So even the step-parenting 7 THE COURT: Just curious. thing, we said, the step-parents might have came in at age A. Just to follow up on that. The screener question 16, might have come in at age two, right? Single parents was designed to be able to capture people for whom that where the mom never really, typically the mother, they 10 may have been true as well as people for whom, you know, lived with her and she didn't remarry. But we also no, I was -- my mother had me by assisted reproductive 12 compared kids who said their mom had a same sex 12 technology. We didn't ask whether that was true. They 13 relationship or the dad with kids that largely grew up in could have stayed with their mother and partner during 14 a single parent household or step-parenting household and 14 their entire growing years. 1.5 adopted before age two. --1.5 So that was the product of the decision we THE COURT: Define same sex relationship. 16 hammered out at the beginning like how do we -- we know 17 THE WITNESS: I mean, just from that screener 17 that like ART is not going to be common as a form of how 1.8 question where we said, while you were growing up did your 1.8 these kids came into being, but how can we make sure that 19 mother ever have a romantic relationship with another 19 gets included even though we don't expect it to be the 20 woman, I think, or it might have been phrased a member of 20 normative experience of kids. So that question was meant 21 the same sex. Did your father ever have a romantic 21 to be big enough to get in the fold everybody for whom, 22 relationship with a member of the same sex? you know, their parents had had a same sex relationship, 23 THE COURT: While you were growing up? 23 some of which lasted, some of which they started with, a THE WITNESS: During your growing up years. majority of which they did not start with. They started 25 $\ensuremath{{\bf THE}}$ $\ensuremath{{\bf COURT}}\colon$ So they may not have even been in 25 with a heterosexual union. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

> Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

43

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 4.4

THE COURT: Okay. I was just curious. Thank
you. You may continue.

MS. HEYSE: Thank you.

BY MS. HEYSE:

Q. I'm going to back you up a little bit, Doctor
Regnerus, and talk about how the NFSS came about. When
did you first begin working on the NFSS?

A. I think it was envisioned in 2010 at some point. I
want to say in the fall, but it might have been kicking
around in the summer.

Q. Go ahead.

A. It was not my brain child, but it came out of the 1.3 series of conversations that were involving me and eventually the funding agency, Witherspoon Institute, Princeton, New Jersey. And kind of the recognition that, 15 16 wow, the social science here doesn't have a lot of 17 probability based large samples, albeit, of a smallish population. There was a sense of a lot of social science 19 here based on small samples, the non-probability samples. There should be more on large samples, probability 2.0 21 samples.

22 So, I was finishing my second book at that time 23 and this was, you know, an idea that struck me as curious. 24 So I agreed to think more about it. And then there was a 25 meeting of several social scientists to talk about what

would social science in this domain of family look like? And out of that emerged, I mean, I proposed a project that eventually turned into the NFSS, although basically it was just this idea of we should do a big study, a big random 5 population based study in this area. But it didn't take real shape until January of 2011 when I had gotten several 6 consultants on board who met in Austin in January to talk 8 about sampling strategy which was kind of a big deal 9 because I had said, you know, the way that studies had 1.0 been done before, this was non-probability samples, etc. How should we be distinctive? So the assumption in the 11 room was, we have to have a probability sample, nationally representative. 13 14 And we talked about what should be on the

15 survey? But the primary thing was hammering out how are 16 we going to go about getting a nationally representative 17 sample? So I had a representative of the data collection 18 firm that I had already figured we should go with because 19 they are the largest in the country, present to tell us what he thought their data. I mean, the people in their 2.0 21 sample, how many people could -- what the sample sizes 22 would look like. So, that was January 2011.

And then at spring, we wrote the survey for it
and got it started in July. Most of the cases came in
early because -- they can collect data rather quickly on,

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

you know, cases that are easy to find, but we really sort Q. Were any deadlines placed on you by the Witherspoon of emphasized to them we want to find as many adopted kids and children who said their mother and father had a same A. You know, in all the e-mail that came out about this sex relationship. So we left it in the field for quite a study, there was one where Louise Tellez, who is the while. I mean, months and months until, I don't know, President of Witherspoon, had said it would be nice to 6 early 2012. Yes. Does that answer the question? 6 have this by the time the Supreme Court case is on. I Q. Uh-huh. You mentioned that Witherspoon Institute think that was back in 2010. I was oblivious of the funded the NFSS. Were there any -- was there any other Supreme Court cases. funding for the study? Q. I want to stop you there. What Supreme Court cases A. I don't know. Like half way along Witherspoon had are you referring to? 11 reached out to the Bradley Foundation to see if they would A. He just said Supreme Court cases. help. They are in Milwaukee. Also, a socially 12 13 conservative foundation. But, they said, sure, we will A. Or something like that. I had never considered that 14 help. I think they paid \$90,000 for it. 14 a deadline or a mandate of any sort, keeping in mind that 1.5 Q. You mentioned also conservative? 1.5 was 2010, well before anything came to the Supreme Court. A. Witherspoon, they are -- I think they originally But he said, you know, the emphasis is just on doing a started as kind of a Gradebooks Institute located next to good job. I always saw my goal as doing a good job. The 17 17 1.8 Princeton. But they are generally socially and 1.8 only deadline I worked with was internal because I had politically conservative. And they hadn't funded social 19 finished one book and was interested in starting another science research but they were interested in it and book on 24 to 32 year old relationship behaviors. 21 excited about the study possibility and agreed to fund it. 21 And I didn't want this to take forever. So, I 22 I agreed. I floated the idea and agreed to lead it if kept, you know, I think a lot, a lot of researchers say I they didn't tell me how to do it, nor would they have a 23 would like to be done by such and such a time so I can get clue how to do, you know, a probability based survey on with another project. I told them I would write them a report at the end of the project and that report was, in 25 study. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 my mind, a primary deliverable. And that just -- I had information on people's household experiences and child set deadlines for myself about when that report should get outcomes that they might find useful. But that was not written. And I had one of my colleagues at the University its intention. of Texas had agreed to, you know, co-author that report O. I think you mentioned earlier that you had some with me. And we were going to discuss all sorts of the 5 assistance or you were consulted with regard to drafting statistics and comment back and forth about what we saw in 6 the survey? A. Uh-huh. Q. Were you provided any directive from the Witherspoon 8 O. Is that correct?

9

11

Institute or anyone else for that matter about the results

1.0 of the study?

> A. No. I had told Witherspoon, well, they wouldn't have attempted to do that, but I told them I am going to

1.3 tell you whatever the data says. And, frankly, I had no

idea what the study would reveal.

Q. Doctor Regnerus, was the purpose of the NFSS to

16 inform the debate on same sex marriage?

A. Not to my -- in my estimation, it was not. I say in

the articles I have written about it, that it doesn't

19 primarily address, it's not intended to address political

and legal questions. I'm here addressing a legal 2.0

question. But that's not its intention. It's not its 21

primary strength I would say.

That said, it can be -- I mean, politicians and 23

24 legislators can, you know, they should have good

information and I think I wanted to provide quality

9 A. Yes.

1.0 $\mathbf{Q}.\$ Were there any individuals -- actually, can you tell

11 me who assisted with that survey?

A. Cynthia Osborne at the LBJ school in UT was the kind 12

of the co-investigator of sorts. She helped me with the 13

survey questionnaire and was more interested in it than

the average consultant. Back in January of 2011 we met in

design and broadly on the survey. Most of them, their

16 Austin with several people who offered advice on the

18 roles started and finished roughly then. I kept them

19

aware of what was going on at different points in time.

20 In the spring of 2012, I offered the data to them. Only a

21 couple of them wanted it at the time. So, does that help?

22 Q. Did you ask Doctor Gary Gates to consult on your

23 study?

17

24 A. I did ask him to consult. I asked Brandt (ph)

Powell of Indiana University to consult. I asked my 25

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

Michael Rosenfeld to consult. He gave me some good growing up, how secure did your family feel? Do you feel information but elected not to consult. Abbey Goldberg, you have any negative experience that you are still Susan Brown at Bowling Green. And it might be one or two working out with respect to the family? Your family of others. Tim Bidlar (ph), Southern Cal. origin, sexual partnerships, experience of sexual violence, just a bunch different domains. 40 total Q. Did Doctor gates decline your invitation? A. He did. 6 questions or 40 total variables. Q. How many outcomes were you evaluating in the survey Q. Who did your data collection, Doctor Regnerus? A. It's a research firm called Knowledge Networks. I A. We had no fixed idea. Just we had, wanted to have a think they're in Paolo Alto, in Washington. As far as I big survey of a lot of present and past stuff. And if I 10 can tell, they do the best on-line population based had to tally them up there is probably 80, 100 different nationally representative survey firm. They keep an distinctive outcomes. Some of them we pooled into 12 active data base of over 50,000 people that you can, you indexes. You could use them separately if you wanted to, 13 pay to sample those people. So, it's the best on-line 14 source of nationally representative data that's out there. Q. How many did you ultimately settle on when you 1.5 They get a lot of federal contracts, a lot of university A. I settled on 40 for the published article. 17 O. Did Professor Michael Rosenfeld also use that O. And how were those outcomes chosen? 1.8 particular data collection? A. To be a broad representation of their growing up 19 A. Yes, for how his How Couples Stay Together Project, years, their current life, and different kinds of domains, 20 which is a two year, three wave study. He might still be a little bit of, you know, experience with the Criminal 21 doing that study in different waves. But he used Justice System. I think we had, you know, smoking, Knowledge Networks for that. drinking behavior, how to get -- how do you get along with 23 Q. So you were able to analyze the data, Doctor your mother, parent/child. There is an index of sort of Regnerus. How many individuals reported growing up with a the security of your -- as you reflect upon your life 25 parent that had a same sex relationship? 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 A. We had 248 total out of the 15,048 who said, yes, my mother or my father had a romantic relationship with sure we touched on it. What is the household calendar?

Q. I just want to back up for a minute because I'm not

What was purpose of it? A. The household calendar is envisioned like an Excel file where you -- they had told us who had lived with them

5

at some point in their childhood and we automatically map onto this screen those names, those roles. If they said

the mother had a same sex partner, so that row comes in,

9 and each year while they were growing up. And we asked

1.0 them to tell, who did you live with at the different years

of your life until you left the household or turned 18? 11

And so they would click on like when -- they 12 13 could click saying I lived with my mother the entire time and it all goes in. But if they had lived with different

people or if mom had had a spouse that came, a husband 16 came, they would, if they left their mom to live with

17 their dad, we could X out until that age and then X in

18 they lived with their father. So that is how the

19 household calendar worked.

O. And if I understand you correctly, the majority of 2.0 21 the respondents in the NFSS were the product of a failed

heterosexual union?

A. Yes. And you can see from the slide that that is

23

24 the case

25 Q. For the folks that are not familiar with this graph,

someone of the same sex. 157 said that was true of their

mother. 73 said it was true their father.

O. So you observed more children reporting their mom

6 had a same sex relationship, correct?

A. That's correct.

6

11

13

14

1.5

17

1.8

19

21

22

8 Q. Were you able to -- if I can have the next slide,

9 please -- were you able to tell who those children lived

with and how were you able to tell?

11 A. Yes. I mean, this slide is of, well -- there is not

175. Not guite 175 filled out all of the household

1.3 calendar data. But of those that did, we were able to map

who grew up with who, when. Those are four of the most

common living arrangements. And you can tell that modal

16 means by which kids came into the world was with a

biological mother and father. And that union failed and

at some point after that they had -- that's when the

19 relationship, same sex relationship they are speaking of

2.0 occurred.

21 Another -- it looks like roughly 30 to 35

percent said at the time of their birth or age one they

were only with their biological mother. So, most of those 23

24 same sex relationships did not occur, the vast majority

did not occur at birth.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct

can you just explain what this represents? yeah, the joint custody kind of relationship, so far as I A. So, if you look at the pyramid, the triangle at the can tell. They could say, if they had joint custody, I bottom that starts -- this is the percentage of lived with my mother and I lived with my father, but they arrangements, the household arrangements, and on the were not in the same place. Q. Thank you. Did you use the acronyms LM and GF in bottom is the age and years of the child, the respondent who is now an adult. So you can see that over half said 6 your results? 6 when I was age one I was with my biological mother and A. I did in the initial, the July 2012 article, and I biological father. That is the darkest part of the bottom regret that. And I said that as much in the November group. Another share that gray area, said I lived with my followup because it seemed to conflate sexual orientation, biological mother only from. So that is almost all the 10 using it as adjective rather than a reflection of the 11 way up to 90 percent of the kids. relationship. 12 Then next to top haphazard row, those who said 12 In the original article in July 2012 I said, 13 they lived with their biological mother or mother's right when I described these acronyms I said, we shouldn't 14 partner, very few were born into that arrangement but the 14 assume this means that the parent is lesbian by their own 1.5 share of them that experienced it grew over time 1.5 self-reported orientation because we didn't talk to the especially, I mean, the modal age is 14. That is when the 16 parents and I didn't want to presume that the child -- I most people who said their mom had a same sex didn't want the child feeling like they had to out their 17 17 parent if their parent was not out. So I stated pretty 1.8 relationship, lived with mom and her partner, and that 1.8 19 goes to 18. It diminished a little bit. But teenage 19 clearly in the article, one should not read this as a years were when that maternal same sex relationship was description of orientation of their parents. 21 most likely to be residential for the kid. 21 But I regret doing that. And the origin was 22 O. What is the final category? that when I first got the data back, the first round of 23 A. The top, the biological mother, biological father, 23 the data back, I was like, I need some acronyms to start which is typically, so far as we can tell, probably a working through this and when I was coding the data. So joint custody kind of relationship. You spend time, but, 25 that is what I did. And I never really let it go. So I 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

> So what does one do with instability? Some people do control for it. And but my intention in the July 2012 article was -- so this is a mapping of a new 3 data set and a description of a data set and I characterized it that way in print. So I didn't think it was helpful to control for instability which in some ways,

you know, I mean, there is a debate about this. Does it

hide something or does it reveal something? I wanted to

9 map something.

1.0 One of the things I think sociology is best at

25

11 is its ability to describe social reality. And in the literature on same sex parenting, one could say that 13 rapidly moving to control for instability when instability is endemic, writes it off like it's a control variable. It's like we are not concerned about it. It doesn't

15

16 matter. And I thought that is not -- that doesn't really 17

do a service to trying to help people understand the lives 18 and households that we are describing. So I didn't elect

19 to do it in this study. It can be done. And the way I

framed it is that I made public and in November of 2012. 2.0

21 like five, four months, three months after this, the

article came out and saying there are different ways 23

people can evaluate this data and they are welcome to do 24

THE COURT: So, is this the place to take an

clarified in the November article. I shouldn't be

talk about these as mothers who have had lesbian

Q. And just so the record is clear, the LM

A. It stands for lesbian mother.

6

9

11

represents --

O. And then the GF?

A. Gay father.

relationships or fathers who had a gay relationship.

conflating this in the popular imagination even if I had

been clear in the article. So at that point I said let's

Q. Thank you. Did you control for family transitions

3

6

7

12

13

14

1.5

17

1.8

19

20

21

22

23

57

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

afternoon recess? that can't hear, raise your hand this time. Don't wait until we get to a break. Okay. You may proceed. THE WITNESS: Would you like me to address THE COURT: You can seque-way in? MS. HEYSE: I will make it work, your Honor. 4 THE COURT: No. Just look at counsel and then THE COURT: I am not in a hurry. We will 6 your voice will be directed to her and to those that are take a 15 minute recess and reconvene at quarter to. here and I can still hear. No problem. They are having a hard time, and I understand why. These microphones are MS. HEYSE: Thank you, your Honor. such. Talk to counsel. They will be able to hear and see (Recess from 2:15 p.m. until 2:30 p.m.) 10 you. For those that are hear, when you can't hear, don't THE COURT: Thank you. You may be seated. wait for a break. Raise your hand. Doctor, first of all, I never know, do the profs like to 12 MS. HEYSE: Thank you, your Honor. I be called doctor or professor? understand they were having trouble hearing me, too. THE WITNESS: I prefer my first name. 14 THE COURT: Oh, good. THE COURT: No, I can't do that. But I 1.5 MS. HEYSE: I will try to pay attention. understand. I am just curious. 16 THE COURT: Again, I'm sorry we had to wait THE WITNESS: Doctor is fine. to long. THE COURT: I'm going ask you to straighten 1.8 MS. HEYSE: Hopefully I will be closer. out your chair and kind of talk to counsel and right into 19 THE COURT: I will, too, now. I just the microphone. And I will tell you why. Usually I like 20 realized I am not talking in the microphone. to have face contact with you. But the people -- you 21 MS. HEYSE: Thank you. maybe seated, I'm sorry -- the people that are here are 22 BY MS HEYSE: having a difficult time hearing you. And also being able 23 Q. I just want to backtrack for a moment, Doctor to see you and so forth. So just talk to counsel and move Regnerus. Before the break we were actually taking a look your chair a little bit more. There you go. And those 25 at this graph and I want to just make it clear or have you 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

> Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

make it clear, what does this graph actually represent?

5

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

60

A. Right. It shows the sort of diversity of household occupants for children who said their mother had a same sex relationship. Clearly from that bottom piece you see is that from the left side, age one, 55 percent of kids 5 said they lived with biological mother and father when 6 they were age one and that diminishes all the way down to just a handful of cases well under 10 percent that was the case at age 18. 9 A lot of them lived with just their biological 11 mother only. And that's not necessarily the same people in the big gray block, but the same share roughly as at 1.3 age one lives with only their mother at age 18. And that share above it, this is the kind of thing where you are thinking about, when a child lives with his mom and her 15 16 same sex partner. Very few of them were born into that, right? It looks like we have -- there's only two cases so far as I can tell in the data where it's the case. And 19 along the way that number increases because either the mother begins to partner with somebody or a relationship 2.0 21 fails and she begins to partner with somebody and that peaks at age 14 where I think I want to say there was like 20 cases. I can't exactly recall where they are with 23 24 their mother and the partner in the same household. It 25 fluctuates over time.

This also gives you an indication of sort of the difficulty in tracking stability because it fluctuates over time in that mother and mother's partner unit. So the share of people who lived with their mom and her 5 partner for I think it was for over five years is like, I think it was like 30 cases or so. It diminishes. Over 6 ten years it's less than that and down to the entire 8 childhood is two cases, right? And people got upset about 9 that, saving, you know, this is not a comparison of kids 1.0 who lived their entire life. 11 I said, that's correct. But this is a population based study. This is what is going on in the 12 13 population of kids who are 18 to 39 years old now telling us who they lived with when. It doesn't purport to be a 15 study of something that is not the case in the broader 16 population. 17 So, it looks guite different than some of the 18 non-probability studies that begin with a proposed sample 19 of people who are with their mom and partner at birth. That's just uncommon in the population in this era. How 21 common it is today, I don't know. I don't think it's been 22 23 O. Sure. Does this graph tell you anything about the

a failed heterosexual union?

number of respondents of the NFSS that were the product of

24

25

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

A. On the left, you know, most at age one is when they start. The mother's partner moves into the household biological mother and father are together. Now, this does at some point. But that is never a large share of the not reflect their union status. Some of them were population. married. Some of them were not married. But this slide Q. Okay. Thank you. doesn't distinguish between that. A. The focus though is to get a portion of what is Q. And does it also indicate that a large majority of 6 really going on out there, regardless of what we thought 6 respondents from the NFSS were being raised at least might be going on. living with the single mom? Q. Okay. Thank you for explaining that. So what A. Yes. A lot. Right? I mean, of this population, comparison did you -- first comparison group did you right? Which is already a smallish minority. I mean, as 10 actually use for purposes of your results of the reporting I said earlier, that becomes the modal household unit your reports of the NFSS? where at probably at by age 10 or 11 the bio mom and dad 12 A. I used the in tact biological family where the mom 13 category has receded enough that the single mom, bio 13 and dad were together when the child was born and they are 14 mother only is pronounced then. So, the case where you 14 still together today. 1.5 live with mom and her partner is higher obviously then 1.5 Q. Okay. Why did you use that particular comparison at -- in the teenage years but it's never the modal 16 17 17 household circumstance. A. Because historically in the sociology of family it 1.8 O So this indicates that for whatever reason the 1.8 had been documented that a stable in tact mom and dad 19 children started out living with both bio mom and dad for 19 household has been the best context for children to a period of time and then ultimately? flourish in. So, I thought, well, why not? Why would you 21 A. That is the modal, the most common experience. 21 want to compare it against something less than what has 22 Q. And ultimately, the biological father left the home been -- had long been considered the ideal, right? 23 and mom was left to raise the kids? 23 Q. And I think you mentioned earlier in your testimony A. Who knows who left the home? It was mom and the that in doing that comparison in 24 of the 40 outcomes child, and then some share -- that's when you sort of, 25 when you had controlled the children, the respondents in 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 the NFSS that had been exposed to a same sex relationship, A. Repeat that. the outcomes were poorer from them when you compare them Q. I'm sorry. It's a longer question so I am happy to to the stably in tact opposite sex union? do that. What were some of the outcomes, some of the A. Correct. categories of outcomes where the children that were -- the O. Was there a particular comparison group that had parents had had a same sex relationship, were poorer than 5 those of children who were raised by the stably in tact 6 outcomes most similar to the children who lived for some 6 duration with their mother or father and same sex partner? biological? 8 A. Yeah. I got at this a little bit more firmly in the 8 A. Right. I can look it up and rattle them off or November followup in social science research where you rattle some of them off from memory. 9 9 split out more types of categories. Instead of 8, there 1.0 Q. Which are you more comfortable with? was 15. They compared most favorably, the ones where mom 11 A. I would rather look it up. Do you want that from lived, the respondent lived with the mom and partner for the original or the followup where I have more categories 1.3 some period of time, they compared most favorably to 1.3 including when the respondent lived with the mother and a single parents who did not have subsequent relationships 14 over the course -- before the child left the household. Q. I am looking for some examples. I don't need an 16 They compare also fairly favorably to the child who said 16 exhaustive list. A. Sure. their father had a gay relationship. And not that far 17 different, I mean, I think there was four differences, I 18 THE COURT: And tell us what you are looking 19 could look it up if you like, with step-parenting 19 at. Doctor. arrangements, although I would have to look that up to A. Sure. This is page 1372 of the November followup 2.0

21

22

23

24

25

Q. Okay. What were some of the outcomes if you recall

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

where children of parents who had a same sex relationship, 23

24 those outcomes were poorer than those of the children that

25 were raised?

confirm that.

21

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

partner. This is from Table One. After the set of

controls they are more likely to have received welfare while growing up. They were more likely to be currently

relationship with another woman and they lived with their

where I compared -- they said the mother had a

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

on public assistance, currently less likely to be 1 Study. currently employed full-time, more likely to be currently 2 Parental Sexual Relationships, Family unemployed, more likely to say they had an affair while Instability, and Subsequent Life Outcomes For Adult they were married or cohabiting, more likely to have had a Children, answering critics of the New Family Structure sexually transmitted infection. Study with additional analysis. Table Two has less educational attainment, less 6 Q. And is that your article, doctor Regnerus? safety or security if their family of origin that they are A. That's the November followup. reflecting on, more negative impact from their family of Q. Correct. Did you -- is that your original writing? A. Correct. The Table Three has greater marijuana use, 10 Q. And does that appear to be a true and accurate copy? greater frequency of smoking, frequency of having been 11 A. Yes. arrested or pled guilty to a non-minor offense. More 12 MS. HEYSE: At this time, I move for female sex partners among women. More male sex partners 13 admission of the State Defendant's Exhibit Number Seven, among men. 14 your Honor. Q. Can you just identify for the record what exhibit 1.5 THE COURT: Any objection? number that is, Doctor Regnerus? 16 MS. COOPER: No objection. 17 THE COURT: Number 17 is received. A. The tab number you mean? O. Correct. 18 BY MS HEYSE: A. That's seven. 19 Q. I guess while you have that book in front of you, Q. So State's Proposed Exhibit Seven. And can you Doctor Regnerus, if you can open it to Exhibit Tab Six? identify for the record what that document is, Doctor 21 Regneriis? Q. Can you identify that document for me? A. The title of it? Parental Same Sex Relationships. 23 A. By title? Family stability And Subsequent Life Outcomes For Adult Q. First identify what it is. Children. Answering Critics of the New Family Structure 25 A. It's the original NFSS based summary article that I 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 wrote which appeared in Social Sciences in July 2012. pretty emphatically as well. I don't make claims about Q. And very slowly, can you give us the title? the influence of sexual orientation, strong claims on any A. How Different Are The Adult Children Of Parents Who sort of outcome. It's more a focus on relationships. Have Same Sex Relationships: Findings From The New Family Partly it's a function of, you know, I don't think there Structure's Study. 5 is any standard way that social scientists have decided to 6

- Q. Okay. And does this appear to be a true and 6
- accurate copy of your article?
- 8

6

11

12

13

14

1.5

17

1.8

19

21

22

23

- 9 MS. HEYSE: I move at this time for the
- admission of State Defendant's Exhibit Number Six.
- THE COURT: Any objections to six, you mean?
- 17 was already received.
- 1.3 MS. HEYSE: Yes. We went backwards.
- MS. COOPER: No objection.
- 15 THE COURT: Very well. Received.
- 16 BY MS. HEYSE:
- Q. Doctor Regnerus, were there any limitations to the
- 19 A. Yes. As in all studies have their limitations, this
- is not a longitudinal study. It's cross-sectional. So 2.0
- you get a snapshot at one point in time. So it's not able
- to answer causal sort of claims about this causes this is
- to happen. And I stated that clearly in the article. 23
- 24 It is not a study of parental same sex
- orientation or sexual orientation. And I stated that

- document the orientation of parents in the literature as
- far as I can tell. Certainly not in the census it does
- not ask about orientation at all. So that's -- I'm losing
- track of the original question.
- 9
- 1.0 Q. I was asking if there were any limitations to the
- 11
- A. Right. It was not about -- not intended to be about 12
- 13 the orientation of parents. So it really is like snapshot
 - data, is able to answer certain things about what is going
- 15 on now without being able to say where it all came from.
- 16 Q. Okay. Were there any limitations with regard to the
- 17 age of the respondents?
- A. To some extent. I mean, they are 18 to 39. So
- 19 these are young adults. So some, I mean, they all at some
- level are removed from the household of origin. Most of 2.0
- them, I assume. If they had gone to like age 13 that 21
- 22 would have involved a lot more invasive human subjects
- 23 review, I suspect. So we didn't.
- 24 But also that's a different kind -- there I
- don't have the method of variance of asking kids who are 25

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

6

11

12

13

14

1.5

17

1.8

19

21

22

23

9

11

Mark Regnerus, Ph. D. - Direct

now out of the house. You have to blend it with kids who hard to decipher like the bio mother only category. Like are in the house. But, so that's, I mean, one could say did she -- was she in the union with a man for this? it's a limitation. I think it's a source of strength to Likely, I would say, but we don't know for sure. talk to people after they are done with their childhood, Q. And were you able to determine the percentage of respondents who were the product of an adoption? Q. We took a look at the graph but were you actually 6 A. Yes. There were statistics around adoption, either able to come up with a percentage of NFSS respondents that by strangers or family members before age two or after age were a product of the failed heterosexual union? two, by one person or two persons, yes. A. I think I said 55 percent is what that looks like at Q. Okay. Was there any potential for source bias in 10 the NESS? age one. ${\bf Q}_{\cdot}$ And were you able to determine a percentage of A. In so far as you are not talking to the parents of respondents who were the product of assisted reproductive 12 these children, I suppose. You are not getting reports technology or ART? from their employer and things like that. But you are A. We didn't ask about their origins. So I took an 14 getting a report from an adult about their own life. So I educated guess based on like whether the child was ever in 1.5 think less source bias than you might have with studies of the household with a father. So I thought that's unlikely to be the case. Or so I think in the original article my O. And you made the NFSS data available to the public? hunch is, I think I said 18 to 25 percent that is the 1.8 A. I did. maximum that was of a planned origin. Even though I still 19 Q. And when did you do that? think that's unlikely to all be assisted reproductive I think it was November 1st, 2012 or right around technology. I don't think very many is the bottom line. 21 that, give or take a few days. O. What else would it be if it's not -- if they don't Q. Why did you do that? fall within the ART category? 23 A. It might have been October 1st. October 1st or A. Surrogacy if it was among fathers. Yeah. So I November 1st. Because I had said I would. Because it's a don't think -- I think the number is fairly small. It's 25 scientific value to -- science moved forward, whether it's 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 a social science or natural science, if people share their A. It is. I mean, it's numerically a small population data and can, you know, everybody can have an open look at at face value. There are different estimates about the data. And, you know, it long aggravated me that there basically, how we are going to map this? Is this about had been data sets dealing with not just this subject but sexual identity? Is it about attraction? Is it about subject matters I am interested in that have not been made same sex behavior? There are different ways you might want to map this. I elected to map it by relationship public because they were funded privately. So nobody got 6 to know what their data says, right? So I was under no behavior, parental relationship behavior. Fairly obligation to release it because it was not federally 8 objective in some ways. funded data. But it's the right thing to do. 9 You ask somebody to say, tell when your mother Q. Not all researchers do that? 1.0 or father, have they had a romantic relationship? So I A. No. One of the primary data collection projects 11 consider that a fairly objective measure. Obviously, it's that has contributed to the literature around this subject coming from somebody who is offering that information. 12 is the National Longitudinal Lesbian Family Study. 13 But it's not like saying, do you think your father is gay Privately funded so far as I can tell. And never been or do you think your mother is a lesbian, which the child may or may not think that. The parent may or may not

16

17

18

19

2.0

21

22

23

24

25

self-identify as that.

1.3

released publicly. I don't know what wave it's on now but

16 now it's 20 some years old I think. And, you know, I

think it's now 21 published studies. So, I mean, it's

fair to say, yeah, there is a literature that says, that

19 often says no differences. But when you're talking about

21 studies based on a small end sample of 78 people and a 2.0

data set that's never been made public so nobody else can

evaluate it, I mean, it's -- I don't think that is a

scientific value. 23

24 Q. Thank you. Doctor Regnerus, is researching the same

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

sex community challenging?

in this era, from 18 to 39 year olds, I didn't want to 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

So I wanted to stick to relationship behavior.

And so I think we found 1.7 percent of the population had

a mother or father who said they had a mother or father

1.7 percent. So you know you are looking for a small

percentage of the population who would consider themselves

gay or lesbian, right? Not all of them have children. And

population to begin with and it's a share -- it's a

who had had a same sex romantic relationship.

73

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

make assumptions about how their parents or the kids would mentioned in mine, you saw diversity. Are you referring describe their parents' identity. So that's why we stuck to in the NFSS you were able to tell about diversity? with relationship behavior. That's long been my general A. Right. In the appendix I compared the general interest in the study of relationships is behavior, not percentages of a lot of different things to the current population study. I think I saw the University of Q. Okay. Is the same sex community as a whole very 6 Michigan, the National Study Of The Family Growth, 6 7 diverse? National Study Of Youth And Religion, Ad Health, all of A. It seems to me to be, yes. In both in the census them. So that's how you kind of show people that your and in the NFSS, and I think Mike Rosenfeld's census based data looks like other nationally representative population study, I think he said 43 -- something like 43 percent or 10 based samples. 11 39 percent of the population was of same sex couples in Q. Again, what was the percentage for minorities in the his case, were African-American or Hispanic. I think mine 12 NESS? 13 was 43 percent African-American or Hispanic. 13 A. In the NFSS, I think 43 percent. I think that was 14 Disproportionate compared to their shares in the 14 it, that were African-American or Latino. 1.5 population as a whole. But they also, African-American 1.5 Q. You mentioned the NLFSS. So that is a study that is and Latino same sex couples, according to the National 16 relied on by the APA for purposes of the No Differences 17 17 Study Of Family Growth, another population study, are more Claim 1.8 apt to have children and want to have children. So the 1.8 A. A couple times. 19 more you think about it, compared to the NLFSS which has, 19 Q. Okay. And so it's your opinion that the type of I think is 12 percent of the national lesbian family 20 diversity that you found in the NFSS and other studies is 21 study. I think 12 percent is non-white. 94 percent of 21 not reflected in those small convenient samples? 22 them have a college education. That's just not -- that's A. It is not. 23 not reflective the underlying population, which is why we 23 Q. That are relied on by the APA? wanted to go to population based studies. A. 94 percent. I think 30 percent of the US has a Q. Let me back you up just a little bit. I think you college education, I think. And this is 94 percent. But 25 25 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 it comes from how do they collect -- how do they gather relationship ended or, I mean, the person left the their sample? It was essentially a convenience sample. I household, the partner left the household or they turned think it included snowball aspects to it by putting up 18. Another 20 cases, that was for two years duration. advertisements in lesbian book stores in Washington, And then that number keeps shrinking all the way to like Boston and San Francisco. So they are apt to pick up only two cases where they spent the entire growing up people who frequent those book stores. Right? So, and vears together. Yes. 6 6 those three towns you would be more likely to be college So, I mean, the instability was notable. And educated. So, I mean, you get where the 8 for the fathers who had a gay relationship, it's even, you know, very few of them lived with dad and his partner for disproportionality comes from. But it's still like, that 9 9 1.0 is not an accurate reflection of the underlying population 1.0 a share of a year. 11 11 Q. So, so I understand you correctly, the NFSS showed that there was instability within? Q. So in your opinion, diversity is reflected at these 1.3 large population based studies? 1.3 A. Within the household, right, in terms of comings and goings. We are not exactly able to measure how often A. Yes, almost by definition since they are probability samples. That is a more accurate picture of what is going 15 these happened. It's possible the partner moved out but 16 on out there as a whole. 16 they were still in a relationship with them. Probably Q. Did the NFSS tell you anything about the stability 17 not. But we didn't measure when the relationship ended. of same sex couples? We measured who entered the household and how long did 19 A. Yes, it did. You look at sort of how many kids 19 they stay. lived with their mother and father for different -- or Q. Why did you measure that? 2.0 2.0

21

22

23

24

25

their mother and her same sex partner for how long. I

23

think there was a total of 85 who lived with mom and her

partner for at least some segment of one year. Right? I

think it was 31 of those 85 lived for only up to one year

with mom and a partner together before either the

A. It was actually upon the advice of one of our

consultants, I believe. And this is emerging family

studies. This is getting a household roster. Right?

families that people have. So, and if you take a look

Because there is a growing awareness of the complex

sort of saying I grew up in a step-parent family, when did A. For a couple reasons. One is that I have to be that start? Right? Obviously, if you are a step-parent sensitive to sample size. I was -- having looked at the you are no longer with your biological father or mother. household rosters, we were aware that stability was not When did your biological father or mother either leave or profound. So, I mean, unless I wanted to create ten one of the parents died? categories of a group that is only 175 large to begin I mean, so when did that start? Did it start at 6 with, and then your statistical power goes down to very 6 7 age two or age ten? Are you on your second step-dad or little and then you are in the same boat that everybody third step-mother? So the household roster was meant to else had been in except for the census. Right? And the capture some of that complexity. And I think it did. I census didn't ask about orientation or behavior. mean, I don't lean very heavily on the household roster in 10 So it was a judgment call with respect to sort 11 the first article because it's very complex. The first of both sample size and the reflection of how long a lot article is intended to be an overview of what we learned. 12 of those relationships had lasted or so far as we could 13 But a household roster data was there and for people to tell in terms of household. Not very many years. So they 14 analyze, make the data public and people can analyze it. 14 had a lot in common that those whose -- the mother had 1.5 Q. I want to follow up on a question or a point that 1.5 been in a relationship with another woman weren't the Judge made earlier. Did you include respondents --16 reporting extensive household experience with that person. 17 17 include in your results respondents that never lived with O. Were there any respondents of the NFSS that lived 1.8 their parents, same sex romantic partner? 1.8 with their parent and the parent's same sex partner 19 A. Yes. And then the November followup I distinguished 19 through age 18? the moms who did from the moms who did not, the kids whose A. Who? From the beginning? 21 mothers lived in the same household as a partner from the 21 O. Uh-huh. 22 mothers who didn't. But I did in the July article, yes. A. Yes. Two. There were some people for whom the 23 It was about split roughly fifty fifty. I think 90 said 23 relationship started later and was still ongoing at age they had not lived with their mother's partner. 85 did. 24 Q. Why did you include those people? 25 O. I mean, any respondents that lived with their parent 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 and same sex partner from birth to through age 18? 70 percent of the lesbian couples had broken up by eighth grade. So it was extensive instability in that data set. A. Yes. Two. Q. Two. Okay. And what were the outcomes like for Right? But once you control for it there is no differences. Right? A. Right. On average they looked pretty good. 5 So a lot of this debate and a lot of the 6 $\mathbf{Q}.\ \ \text{Are you aware of any other research regarding the}$ 6 criticism around this revolves around what you do you do stability of same sex couples? with instability, right? If you control for it, are you 8 A. Yes, I mean, Michael Rosenfeld attempted to tackle 8 saying, oh, well, we realize that it matters but our focus it in the census. And that's where Professor Allen and is on this other variable. But it's a live guestion. Is 9 9 Professor Pakaluk and Professor Price sort of contest how 1.0 there, you know, something -- is there something, you he deals with residential stability in the census. And he 11 know, systematically unstable about that kind of lops it off at sort of as to the last five years. And I arrangement? So, and one could say if you control for it 12 1.3 think Professor Allen and company say, why do you do that? 13 you are not shedding light on it. You are just sort of You are then giving a false sense of the instability. I pushing that out of sight. So I had I assessed that as mean, so there is a debate going on among them about that. 15 being an overview portrait of what is going on, 16 I mean, I also know in the Early Childhood 16 instability and all. Right? So --17 Longitudinal Study, The Kindergarten Cohort, which Daniel 17 Q. You mentioned that NFSS shows evidence of Potter published articles in the Journal of the Emerging 18 instability within same sex couples. And you mentioned 19 Family, July of 2012. Controlling for instability, he 19 the ECLS. Are you aware of the study by Anderson? doesn't find any differences. I think it's some sort of 20 A. The Norwegian Sweden study, right. 2.0 21 academic progress outcome. 21 $\mathbf{Q}.\$ Did that inform your decision or your opinion with But if you dig deeper into those cases, and 22 regard to the stability of same sex couples? that's public data, you find that there were no cases 23 A. Right. And I think Norway and Sweden might have 23

24

25

where the gay couple stayed together for eight years, I

think through kindergarten through eighth grade and

24

slightly different definitions of union and marriage. But

and they actually mapped sort of predictions for estimates much on that. That's interesting to look at. So it's for what they would expect in subsequent years. I think 94 percent college educated, overwhelmingly white, and in Boston, Washington and San Francisco, it's like you would they said we should expect lesbians, lesbian couples, lesbian marriage -- I'm not sure if they are marriages or say it's a privileged sample. Right? In terms of opportunities. And yet by wave five when the kids were on unions -- to break up at a rate of 30 percent over six 6 years. Gay couples, 20 percent over six years. And 6 average 17 years old, 40 of the 71 couples they had heterosexual couples, I want to say 12 percent over six tracked since the birth of the child had broken up. So years. So 30, 20, 12. it's 56 percent I think it is. Which struck me as higher Q. Thank you. than I would have expected in a sample of sort of A. That was -- I think that was Norwegian data. 10 privileged folks. Right? So, 56 percent by the time the Q. Did you also -kid was 17. 12 A. I think that might have been the Swedish data. 12 Q. I want to go back for a minute to --13 THE COURT: Why are they privileged? I don't 14 Q. Did Rosenfeld also have some research with regard to 14 get it. 1.5 the stability of same sex couples? 1.5 THE WITNESS: Overwhelmingly college A. In the How Couples Meet And Stav Together project 16 educated. Eighty-seven were white, etc. 17 17 which also used Knowledge Networks, and he presented that MS. HEYSE: Thank you. 1.8 at the Denver American Psychological Meeting in 2012. And 18 BY MS HEYSE: 19 he documented, I mean, he called it a lesbian effect on 19 Q. I want to go back to your response to my question instability in relationships. So after a variety of about how many of the children, the respondents from the 21 controls, he still found lesbian unions were more apt to 21 NFSS had lived with their parents and same sex partner 22 hreak anart from birth to age 18. So the two that actually --23 Q. And what about the NLFSS? 23 A. NLFSS, National Longitudinal Lesbian And Family Q. In your opinion, Doctor Regnerus, are two children Study. It's not a national study so I did not focus as enough to make any judgment on outcomes for -- let me 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 83 84 finish the question -- outcomes for children of same sex only -parent as a whole? A T was A. Right. I mean, two comes from 175, right? Or some Q. -- two? share of those did not fill out the household calendars. A. I didn't know what it expect really. But you would But most of them did. So, it's just long odds, right? I 5 think there would be more than two. mean, to get, to be those two kids who turned up fine, on ${\bf Q}.$ All right. I'm going it a turn here now and talk to 6 average, it's just sort of the odds were against them you a little bit about some of the criticisms that compared to the odds against -- I think, 40 percent of the 8 plaintiff's experts had lodged against the NFSS. We have sample was -- said their mothers and father were married mentioned names a couple times. I just want to make it 9 9 1.0 and still married today. Right? So, much taller odds to 1.0 clear for the record. Are you familiar with plaintiff's succeed and to witness that kind of stable union. expert witness, Doctor Michael Rosenfeld? 11 11 Q. So, in the NFSS, there were, if I understand you A. Yes. 12 1.3 correctly, there were two respondents that came from a 1.3 Q. Are you familiar with his work? stably coupled same sex household? A. Over the last several years, yes. I mean, with A. Correct. From the household roster that is what we 15 respect to this area, yes. 16 16 Q. Doctor Rosenfeld has criticized the NFSS because you 17 Q. Did your screening protocol somehow prevent these 17 did not control for instability. Do you have a reaction stably coupled same sex households from appearing in the to that criticism? 19 19 A. He criticized the data or my article? A. Not that I recall. No. If it had, there wouldn't O. The results. 2.0 2.0 21 be two, right? And I remember after the first criticism 21 A. Okay. So the article?

22

23

24

25

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Q. So you were surprised by the fact that there were

permutations possible and I didn't see any problem.

starting rolling in, I went right back to the screener

questionnaire and I tried to map out all of the

23

24

25

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

article which was to map, rather than explain away some

think that was the purpose of that original overview

A. Yes, I mean, I understand his complaint. I don't

6

13

14

1.5

17

1.8

19

20

21

22

23

25

5

8

9

13

16

19

2.0

21

25

Mark Regnerus, Ph. D. - Direct

things. And it intended to bring up the subject of why you have to go up to the Census to start talking about -such instability, right? So, as I point out, I already it doesn't get much bigger than that, right? I mean, talking about -- to document more stable relationships. had seen like the instability was endemic in the sample on average and not just the instability of the same sex But the Census does not ask about orientation or behavior. relationships, but the households in which the mother had So they do their own estimation. I think they do a good had a same sex relationship. There was -- most of them 6 job. But you can't figure out like how long mom and her had come from a heterosexual group, right? partner have been together. So there was relationship instability of all Q. When you are referring to, they do a good job, are sort, not just same sex. And I think it's an active you referring to -social scientific debate about what to think about that A. People who use the census to analyze relationships. and what to do about that, right? But in the -- for this Q. Any, in particular, you are referring to -case, Michigan is thinking about what it out to esteem in 12 I mean, both Gary Gates and Mike Rosenfeld used the the household of its average children. So, I think, it's census and Joe Price used the census and Doug Allen has helpful to see how children fare when mom and dad stay 14 used the Census. They have a lively debate about this together. I stated I think it was in the followup article 1.5 subject. And it all seems to hinge around household or in my report, there may be a gold standard, same sex 16 instability and what to make of it. To control for it household of stably coupled mothers or fathers, but no makes it disappear and go out your mind and say, it population based data that I have seen is vet able to 1.8 doesn't matter. I mean, or are you giving the impression widely consistently confirm evidence of it, right? It may 19 it doesn't matter. It matters profoundly. And I think we exist. Just maybe we have not collected large enough date 20 to people and to the public to sort of describe social or over time data or -- so, it might exist but we are not 21 reality any all its complexity. seeing it consistently in the population based data that Q. So given these questions surrounding stability and we have and that's been collected in the last several 23 the limitations with regard to studying same sex couples that you mentioned earlier, do you think it's just too new to make definitive conclusions? And, you know, you bump from mine up to like --12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 A. Absolutely. You think about all of the data being a study of children actually raised by same sex collection projects that ought to be done before one couples. settles a scientific question like this. I mean, you can A. Right. go back 20 to 30 years ago when people starting dabbling O. Do have you a reaction to that criticism? in this area. Most of it was convenient samples. The 5 A. Sure. I am aware of the tension around this. To say one is raised, does that mean you have spent your probability based sample discussions have been, I am 6 thinking, the last three years, four years, maybe at the entire household, your growing up years in the same most. Right? household with the same person? Increasingly American family lives are complicated. So you have got more people And then to say we settled this No Differences 9 question back in 2005 or 2006 when the APA thing came out, 1.0 coming and going. More people experiencing step-parents. we weren't even working with probability based large 11 More people experiencing single parenthood and things like samples at that time really. I mean, Ad Health Study had 12 that. 44 cases, I guess, right? Of same sex couples. But 44 is 13 Who is doing the raising in all these? If you not that large of a number, right? Of the statistical 14 primarily live with your mother but see your father on the power to detect genuine difference that might exist in the 15 weekend, is your father not raising you? I mean, I assume population is limited. 16 the father is raising you to some extent. So, raising, we So, it is very new. So it's intellectually 17 have got this mentality that it's consistent, stable

19

2.0

21

22

23

24

25

children.

usually it was frustrating to see social science close off a debate by claiming that it doesn't -- your screen has changed -- closing off a debate by saving this is settled when we haven't even corrected the ideal kind of data yet, right? And assess its limitations, census limitations.

Let's get some more before making wide scale changes of an 23

24 institution that has been around for time immemorial.

Q. Those experts have also criticized the NFSS as not

next best parenting structures to when mom and dad are 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

data, we didn't make a whole lot about it, is one of the

presence, right? And that's optimal, I'm sure, as the

data suggests. That may be different than influence,

children. Parental relationships can be influencing

right? And whereas all sorts of parents can be influencing

I mean, one of the things we noticed in the

89

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

married and stayed married, are that if mom divorces and occur? Did they break up again? So, the apples and oranges never recouples, right? Never recouples until the kid is suggests there is -- it's kind of dualist or binary when out of the house. I mean, because the child only the household rosters are complicated and people's lives experienced this one transition, right? Which is better are complicated. And with respect to the mothers who have than experiencing -- can often be better than experiencing had relationships with men of the same sex, the rosters 6 a second or third transition. Subsequent marriages fail 6 are all over the place. There is a lot of household at rates greater than first marriages. So instability movement. snowballs, really. So I maybe I'm getting away from your Q. Plaintiff's experts also criticized the NFSS as not original question. revealing anything about the well-being of children being Q. You're fine. Previous expert have also criticized raised in families created by gays and lesbians. So in 11 your use of stably in tact biological parents as a other words, ART or by donor insemination. Do you have a 12 comparison group saying you're comparing apples to 12 response to that? 13 oranges. Do you have a reaction to that? A. Well, the point was of that was to map social 14 A. Right. Really, it's -- everything except in stably 14 reality in the United States population based sample, 1.5 intact parents would be -- it's a kinship reduction, to 1.5 right? And that era -- there were clearly was probably not some extent. So, I mean, even as I said earlier, like 16 too many people who had children by artificial means, or figuring out, so what counts s a step-family? How long do 17 Assisted Reproductive Technology or insemination. 1.8 they have to live with their step-dad before he counts? 1.8 What we don't know is how many, as of today, 19 As raising, I mean -- so there is a lot of subjective 19 everybody assumes it's a lot more. We know that Assisted judgment calls in this stuff where you want to be clean Reproductive Technology accounts for one and a half 21 and clear about it. And we have eight categories. But 21 percent of all births today. And so, donor insemination 22 even in those comparison categories there is a lot -- it's or artificial technology, to say lesbian couples, what not just that the category of mom and her partner is 23 share of that 1.5 percent are theirs? I mean, it's complex. It is. I mean, a mother and her stepfather is certainly not half because they are not that numerous in complex. Stepfather, dad and a stepmother, is when did it 25 the population. It's some small share of 1.5 percent, so, 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 right. For that you kind of, the NLFSS gives information weaknesses. But in the case of something like some even though it's not a probability sample. You really -significant policy things at stake. I think you ought to to map sort of how the children who grew up who were donor error on the side of large data collection efforts inseminated, their origin, you want that, and you want underlying representative samples. that in a big survey. You want it to get a national 5 O. Thank you. portrait of what that looks like and that doesn't exist. 6 6 A. We do this when elections come up, right? CNN poll, Right? A lot of things in this domain do not exist yet. plus or minus 2 percent, who is voting for this or that 8 Q. Previous experts have testified that essentially 8 candidate? You want that to be representative of a state or a country. You don't want to say CNN poll of the 9 putting together a group, a collection of these small 9 convenient sample studies over time is just as good as one 10 people working in our office. That is not going to tell 11 large population based study. Do you have an opinion on 11 us anything about what to expect in terms of what is 12 probable among the collective. 1.3 A. They can be illuminating about certain dynamics. 1.3 Q. When was your article published in Social Science They not telling of what one should expect across the 14 Research, the NFSS results? population. I mean, it's a strange calculation to say, 15 A. July 2012. And followup was in November 2012. 16 you know, ten baseballs make a football. They are 16 Q. And what was the time line for publication of that different kinds of studies. 17 article? So, when we are dealing with questions of wide A. Tag line. I'm not sure what you're saying. 19 import, I will always think we should privilege these 19 Q. Do you recall when the Social Science Research nationally representative studies of which they exist. 20 actually received that article? 2.0 They are not cheap to do, but I think there is pressing 21 A. When I submitted it to them? 21 interests in it so they ought to be conducted. 22 So I don't usually say that or think about like 23 23 A. Okav. Late January, early February.

24

25

journal?

five of one thing equaling one or another. They are just

very different. They have their own strength and

24

Q. Okay. And do you recall when it was accepted by the

93

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

A. I would say sometime in the middle of March. Prompt. editor is not under any obligation to do. O. And would you agree that that time frame is Q. You mentioned that you had asked him to do that unusually fast? because you knew this was going to be sensitive. What do A. It was unusually fast. you mean by that? Q. Do you know why that happened? A. I asked him if he would consider it because some, A. I can only speculate. But the part that I 6 you know, quite often when I will submit an article I will 6 contributed to was that I was prompt in once I got reviews check in first with the editor like, would you even accept back, I was prompt in returning, you know, the edited a submission on this topic? Sometimes they don't take manuscript or a revised manuscript to the Journal. So I literature reviews. I have written one or two of those before, or studies -- if you are wondering, you just write didn't keep it with me for very long. I could have kept 10 11 it for months. I mean, one of my mantras that I learned the editor and say, are you accepting stuff like this? in graduate school, when you revise and submit a decision, 12 But social science research typically, historically has 13 you hurry up and you clear your desk and that's what you been known for publishing things that involve some sort of 14 focus on because that's your job is publishing. So, that 14 novel methodology or novel approach to a research 1.5 was my part. 1.5 question. So, that's why I thought of them. Right? And When I first contacted the editor of the journal 16 I had been a reviewer for them at various points in the to -- I knew this was a sensitive subject. Wanted to know 17 past and I found them easy to work with. if he would consider it. And I had asked for a speedy 1.8 1.8 O. What was the reaction to your article? review under the logic that I was still writing this 19 A. It was severe and swift. Surprised me. I knew it 20 report, this larger report. I was going to try to get an would stir the pot and some people would be upset. But it 21 overview study in. Maybe we could squeeze it in before 21 was clear that draft copies of the article had been 22 the large report that is due. And it's only due in my circulating for quite some time, from whatever source. I 23 head, right? Like March. And I pushed it back to May and 23 don't know. And so people had developed extensive I pushed it back to -- it was going to be September of critiques. One of the weird things, it felt like all a 2012. So I asked him for a speedy review of which an sudden everybody turned into a methodological purist with 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 this study when they left all sorts of methodological asked for outright retraction. Retraction is only in the challenges go in previous studies. So, I know a lot of case of outright fabrication. So that is not -- has not people were unhappy with it or unhappy with what it happened. But they complained about different aspects of implied or something. the study including the time line, including the use of 5 Q. Sure. You said that it was severe and swift. What the acronyms for which I definitely wanted to make that do you mean by that? What happened? right in the November followup. So, some legitimate 6 A. Well it came out in June 12, a few weeks early. criticisms of which there always are in studies, some that 8 That's why the on-line version. And, man, within a day I 8 I thought were a little over the top. was, you know, receiving complaints and there was stuff on O. Was there an audit conducted? 9 9 the web trying to take down this, the analyses, and we 1.0 A. There was, which is a very strange experience, very learned nothing from this article, etc. You learned unusual experience with respect to a social science study. 11 11 nothing from this article? Seems unlikely. I never heard of such a thing. I don't know why the editor agreed to do that. He was getting a lot of flack 1.3 Q. Was there an effort to get your article retracted? 1.3

14

15

16

17

A. Yes. Probably at a couple different times. Q. And do you know who led that effort? 16 A. Well, there was a blogosphere effort to do so, but I 17 know Gary Gates, I think, it was Gary Gates had got 200 people, a little over 200 people signed the letter. Only 19 a handful of them were family demographers. I went and looked and read their list and who that was. I mean. 2.0 21 family demographers, I think know better what this kind of data collection challenge is. Somebody once said creation is difficult. 23

18 agreed, who basically volunteered to do an audit and the 19 editor seemed to say, well, you can't -- we can't -- we 20 can't --21 MS. COOPER: Objection. Hearsay. 22 THE COURT: It's not for the truth of the 23 matter. It's for the state of mind. 24 THE WITNESS: I should continue? THE COURT: Do it from your perspective. 25

from what I could tell and that he did not expect. And

his who had -- who did not like me and has not liked me

decided, okay, I think it was an editorial board member of

for years, for whatever reason. I'm not really sure. Had

people complaining to the editor. I don't recall if they

Destruction is easy. There is a list, a letter of 200

24

97

Mark Regnerus, Ph. D. - Direct

THE WITNESS:

6

8

13

14

1.5

17

1.8

19

21

22

5

6

8

9

13

16

17

November, October.

- A. Sure. Can't be construed as being friendly. I mean, and he wasn't friendly, nor was he neutral. This is a person who has ranted in blogs for years about me and some other people, some other friends of mine, and gave the audit job to him which, you know, that doesn't seem to
- So, he and the editor turned over, so far as $\ensuremath{\mathsf{I}}$ can tell, the correspondence around the article. And he solicited University of Texas for all my grant expenditures on it and audited the process and concluded that he didn't think the article should be published. He thought it was deeply flawed, etc. And I'm not sure if it's just because I didn't control for instability or not. But, deeply flawed, etc. But concluded -- he could foresee why the editor would have made the decision. He had three reviews in hand that all said, publish. So, he seemed to exonerate the editor and then took off on a rant on the article itself which did not seem to be part of the audit. The audit is to review process, not to review the article. So that was done, I don't know, late summer of 2012. All very prompt. I mean, cooler heads would say let science work this out another time, right?. And I was still intending to release my data which I did in

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

reading the eight charges of a blogger from New York who

- sort of thing. They looked through my e-mail, and then I have to go in front of a little tribunal of four or five department chairs and the scientific misconduct officer
- Q. What was the ultimate result of that scientific misconduct?

is not an academic. Strange stuff.

- A. There are two processes to this. Misconduct review, and if they find ample evidence, they ask for a scientific misconduct investigation. The whole thing is supposed to operate in where both parties are going to be guiet. The blogger was not quiet. Right? So, but the end result is I appeared before this little tribunal and told them my side of the story. They evaluated it and recommended it to the Provost to dismiss the case and not open the scientific misconduct investigation. And the Provost
- Q. It was dismissed at that first stage of the process?
- 19
- O. Did all of this controversy surrounding the release 2.0
- 21 of your article, did that leave you to ultimately write
- that followup article.

accepted their decision.

- A. That was -- not inherently, but that was a request 23
- 24 from the editor of the social science research. He said,
- Mark, you know, you're getting a lot of criticism. I

- Q. Who conducted that audit?
 - A. Darren Sheraat (ph), Professor of Sociology at
- Southern Illinois.
 - Q. In your opinion, that was not an objective audit?
- A. I think that is an understatement.
- 6 Q. Was your article every retracted?
 - A. It was not.
 - Q. Did all -- well, strike that. Baking up a little
- bit. Was there also some allegation of misconduct that
- 10 resulted from the publication of the article?
- A. Let's see. June 12 had come out. By July 5th,
- 12 University of Texas Research Integrity Officer said, Mark,
- we are opening a scientific misconduct review of your
- case. And I'm like, you're kidding me. 14
- 1.5 THE COURT CLERK: Can you speak into the mike
- 16
- 17 A. By early July, the scientific integrity officer at
- 1.8 the University of Texas said, Mark, we have to open a
- 19 scientific misconduct review of you which stunned me. And
- it was a lie. We have had these allegations brought by
- 21 someone who is claiming scientific misconduct. We are
- bound to do them. This was from a blogger in New York who
- 23 had made outlandish accusations of me. Successfully got
- the university to put me under misconduct review, took all
- of my lap tops, hard drive, my computer, all records, that

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

- think I better open up some space in the November issue or
- whatever issue he had in mind for critics and for you to
- respond to your critics. So that is what he did.
- O. And was it November that that follow up was 5
 - published?
- A. It was. 6
- Q. And what did that followup say?
- 8 ${\bf A.}\ \ {\bf I}$ went back to the data and I looked at -- I sliced
- the pie some different ways. I had added seven different 9
- 1.0 categories that makes it more complex in some ways, but
- one of the key things I did was sort of split the children 11
- 12 whose mother had a same sex relationship into these two 13 groups. Ones who lived with mom and her partner and ones
- who did not. That makes sense. On average they look
- quite similar over the outcomes. But it has more clarity
- 16 in our mind about what the child -- what kind of situation
- they are in. 17
- 18 But even once where mom lived with the partner,
- 19 as I said, their relationship durations were not lengthy
- on average. I think it's 22 percent is the statistic 2.0
- 21 for -- of whom the $\ensuremath{\mathsf{mom}}\xspace^*s$ relationship was ongoing when
- they left the household at age 18. Otherwise they had,
- their household relationship had started, then stopped. 23
- 24 78 percent.
- 25 Q. You started touching on this earlier?

6

12

13

14

1.5

17 1.8

19

21

22

23

16

19

2.0

21

23 24

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

A. I'm sorry. There is more to that question. You it predict instability which then predicts poorer outcomes asked about the response. So there was that split. Then rather than mapping a direct influence from a maternal same sex relationship? I addressed the subject of what do there is also addressing the apples and oranges thing which I had done a few minutes ago, talking about foster you do with controlling for this thing? I mean, and then the issue of instability, is it care because some critics said same sex couples are more likely to adopt from foster care. Went back to the data, 6 a thing of the past or what do we know about it? And to the household rosters, because we had foster care as an that's where he talked about the Swedish data and option. And so far as I could tell, there was only seven Norwegian data. I mentioned Bidlars (ph) and Stacey in out of 21 cases where the child either left foster care to 2010 when they did the literature review said they noted go with mother's partner and mother or else they went into mostly this was from the convenience studies that lesbian foster care from that. I mean, otherwise foster care parents face a, quote, somewhat greater risk of splitting looked like randomly distributed across experiences in the 12 up due in part to their, quote, high standards of household. So I didn't think the foster care story was equality. what we were after. If you let me look, and I can briefly 14 I addressed that subject and people had said the summarize the other criticisms I addressed. 1.5 emphasis it is not a representative sample. This is -- we O. Sure, if that helps you recall. 16 should pay attention to Rosenfeld and the census, etc. A. In number seven. So I addressed the LM and GF thing This is garbage. And I said, it's not garbage. And it where I said I shouldn't have done that Classification 1.8 looks quite a bit like census estimates, NSFG Addressed the apples and oranges thing where it's like not 19 characteristics, etc. as easy as you might thing. They are complex household And the subject of mixed orientation marriages, structures. I addressed instability. Is it a controlled 21 which I don't know -- I don't always know, was this a variable or a pathway of analysis, right? marriage that ended. In the graph I showed and that is Other people would suggest a path analysis 23 from the November followup, what people were basically approach which I did not do. One could do it with the born in and what happened after that. But mixed data, so forth. This maternal same sex relationship, does 25 orientation marriages. Some are, yeah. Plenty are. I

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

104

didn't ask whether -- I just asked if the parents, the biological parents were divorced. Anyways, bisexuality was the subject -- I'm sure of these women are bisexual. Right? But one thing I did say in here, most of the time when in the cases of when the respondent lived with mom or 6 partner, she had exited an opposite sex union, entered a same sex union, either exited that -- or basically saying they didn't know, man, woman, man. So it looked more like 9 a former heterosexual union, now a same sex union. I addressed the subject but said it would be 11 impossible to tell. Those are the things that I sought to address in that. 1.3 Q. Thank you. So, again, turning now, you touched on this earlier and I want to circle back to it, in talking

science. In your opinion, Doctor Regnerus, what has the social science of same sex parents based on convenient samples taught us to date?

about the topic of this area being a new area of social

A. I think it taught us about the dynamics going on within same sex households. It's also shown us it's possible to be stably raised in lesbian couple households. And if it's possible, it doesn't show it's probable. I mean, these convenience samples are not -- you can get

what is possible from them. I think Paul Amato (ph)

brings this up in his response in the July article, you know. He said if it would have been terribly destructive we should have seen it by now, these convenience studies. We see it's possible. We don't get a sense of what the most likely outcome is. And you don't get that unless you 5 use probability based studies. 6

Q. Are you aware of other probability based studies 8 that have found sub-optimal outcomes for children raised in same sex homes?

9 1.0 A. I mean, in Rosenfeld's assessment of the census, he 11 disputes this with Price, Allen, Pakaluk. But you look at the raw numbers, the children who grow up in heterosexual 12 13 stably coupled heterosexual households fare better. It's comparable. Nothing statistically significantly different. That's one outcome. Academic progress in 16 school. Potter's longitudinal studies, that is also an 17 academic progress thing. This was 40 outcomes. So that 18 was lot to chew on. But the science really is young here. Think about this. This is the study that has come out with the most outcomes, right? Don't you think we should have more of these kinds of things?

19 2.0 21 22 One of the kind of mantras of responses to 23 critics didn't come from me, but from some people, said if 24 you don't like the study, go field your own population based national representative study and ask the questions 25

105

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

you like. I really think it's too early to tell a lot of relevant? Is it a controlled variable or is it something these things. And until we have more data I think it's to wrestle with? And I have some doubt on the side that rational and prudent of states to be very careful and to it's something to be open about and wrestle with rather privilege what we already know to be true about the stably than to control for and mask probably because I'm not coupled married opposite sex households and tread very making a claim that same sex orientation causes something, 6 carefully what we don't know to be true. 6 right? Q. Would Doug Allen's study of the Canadian census be 7 But to say, you know, the experience of parental another probability study that showed sub-optimal same sexual relationship was associated with, correlated outcomes? with greater household instability. And when you control A. It is. I read it and I wrote a brief thing about 10 for it and say there is no differences, you know, people it. It's not -- that kind of thing other people can 11 do that, but I don't think it has -- that certainly has 12 analyze because you had to apply to the Canadian 12 not shed light on the social reality of the children in 13 Government to look at it and he no longer has access to it those circumstances. 14 himself. But he found less optimal outcomes. So people 14 Q. You used the terminology, privilege, several times? 1.5 pushing back and forth on that study too. 1.5 A. Privilege samples? That sort of thing? O. And just to make it clear for the record, when you 16 O. You just mentioned we should privilege what we have 17 17 are talking about this debate between Doctor Rosenfeld and known 1.8 Doctors Price, Allen, Pakaluk, we are talking about the 1.8 A. Right. study of the United States census data regarding 19 Q. I want to make sure it's clear what you mean that we children's progress in school, correct? should privilege something? 21 A. Correct. 21 A. I mean, in this case, you know, I think the State of 22 Q. Okay. And do you have an opinion regarding that Michigan should tread carefully and privilege the 23 23 definition of marriage as between a man and woman because A. A modest opinion, you know, back to this sort of, historically, and still in this data set, you see that what are you going to do about instability? Is it it's the optimal child development environment for kids 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 108 into adulthood even. Right? Not just in their growing up Q. So that's a yes? years. So I think we should privilege what we can learn 2 A Yes from especially -- from these large data collection Q. Does that affiliation affect your research in any 3 projects in our decision making about what is prudent and what is best to do. 5 A. I would say people think it does in this stuff but I 5 don't see it, frankly. I mean, there is no Catholic way 6 Q. Doctor Regnerus, do you believe that this issue is 6 settled? So, in other words, there are no difference in of doing statistics or sampling strategy. I think, if outcomes between --8 anything, it shapes research questions I am interested in. A. No. But I'm not afraid of what data has to say. So I think it 9 9 Q. -- children of same sex couples and children of 1.0 shapes the kinds of things I study but not like the 11 opposite sex couples? 11 process of studying them. A. Nothing -- it's not that nothing can ever be Q. Do you have a belief about marriage, what it is or 1.3 settled, but we are definitely sort you in the novel 1.3 what it means? period of social science on relationships. I highly recommend more data collection efforts, prudence going 15 Q. What is that? 16 forward with respect to large scale social changes. But 16 A. I think that marriage is essentially a union between 17 we have not settled anything. I think is what we have 17 a man and a woman. It's intended to be permanent. learned is that it's possible to grow up in a same sex 18 Q. Are there specific norms of that relationship or 19 household and the children be fine. You will only learn 19 requirements of that relationship that you believe in?

2.0

21

22

23

24

25

25 A. I am Roman Catholic.

O. Doctor Regnerus, are you affiliated with any

if it's probable until you really track kids over time

with a lot of cases, far more cases than we have seen to

24 particular religion?

2.0

23

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

A. I mentioned permanence. On average, marriage is.

think partners expect sexual fidelity. I don't think people who marry want to or expect to cheat or leave. So

among younger people, is to expect to welcome children. I

I think it's built into the fabric of marriage, this sort of permanent you and me, and baby makes three kind of

6

11

12

13

14

1.5

17

1.8

19

21

22

23

109

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

mentality. And I think it's been true for a long time. in origin. It's fairly stable over time. It's Q. So that I am clear, so, three, for lack of a better cross-religion, cross-culture. term, requirements of marriage in your opinion are MS. COOPER: Objection. It's beyond the permanence, fidelity or exclusivity --A. Requirements? THE COURT: Sustained. Q. Components. Is that a better term? 6 BY MS. HEYSE: A. Components. Historically, generally speaking, 7 Q. Do you have an opinion about redefining marriage to stable components. I mean, we can error on polygamy. But include same sex couples? I think we moved away from that era. And I don't think A. I don't think it's a good idea. people on the average wish for that. Q. And did that opinion affect your research in any Q. I apologize for the terminology. So, again, three way? main components in your estimation are permanence, 12 A. No. Not in how I conducted the research. I mean, exclusivity and an expectation of producing children? it was -- the research question is a curiosity about how A. Right. That's not always the case with people but 14 children fare in same sex households but it didn't affect that's historically been part of the arrangement. And, 1.5 the conduct of it. I mean, if it did, then I wouldn't you know, you see in the data, I didn't create that in my 16 have gathered together a group of diverse consultants and have different people weigh in on how we are going do mind, but when you see permanence, I don't have a measure 17 of fidelity among the in tact biological families. 1.8 this. So, which I did those things. Permanence and, you know, children, I mean, the children 19 Q. Doctor Regnerus, your testimony and your work places flourish in that environment. a lot of emphasis on population based or probability O. What is your basis for that opinion or definition of 21 studies. Would that be accurate? marriage? A. Yes. I have done other things, but I always like doing things with large probability based studies.

23

25

9

that argument. But I don't think it's uniquely religious 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

A. I don't know. It's a pretty historically stable

basis. I don't think -- I mean, the Catholic Church likes

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Q. And you've been critical at least in your testimony

today to the extent that non-probability studies can

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

actually be used, correct? A. Not used in general, but used -- in this particular

case, to settle an intellectual dispute about No

Differences, I think it's unwise to lean on so many of

those or at least not exclusively. And the case in

general, I think you can learn about stability in same sex 6

couples households, but you don't want -- so I think you

should privilege larger non-probability samples to get 9

information about what is going on in the public and the

underlying population of both opposite sex and same sex 11

12 Q. So let me ask you this. If there were population

1.3 based studies that showed equivalent outcomes for children

raised by same sex couples and opposite sex biological

parents, would you reconsider your position with regard to

16 same second marriage?

17 A. Can you say that again?

Q. Sure. If there were population based studies that

19 show equivalent outcomes for children raised by same sex

couples and opposite sex biological parents, would you 2.0

21 consider your position about same sex marriage?

A. I mean, there are probability based studied that do

this. And even the NFSS in all fairness, 25 out of 40 23

24 outcomes where there are differences, it's not 40 out of

40. It's -- and even on the outcomes are there kids that

fare just fine and kids of opposite sex couples that are not faring fine. So it's a likelihood of occurrence. I

would want to see, certainly want to see more cases or 3

more studies. I think what is most likely to be changed

5 is my opinion about the No Differences thing, I mean, that

until we get a lot more evidence from probability based 6

studies I think we should be skeptical about that.

8 Q. So kind of up to wrap up your testimony from today,

Doctor Regnerus, based on the NFSS and your knowledge of

1.0 the research in this area, have you formed any opinions

11 relative to this case?

A. Right. I mean, I think the NFSS data together with

13 the disputes that go on around instability in the census

data and things like that suggest that it's prudent to --

for the state to retain its definition of marriage which

16 was the will of the people as between one man and one

17 woman. I think there is a wisdom in the people's

assessments here. And it's wisdom borne out in the data.

19 As I mentioned earlier, it's possible that there is a

stably coupled lesbian, you know, household type that just 2.0

21 doesn't show up in sufficient number of cases in

probability based data to make claims, and certainly not

23 to make major changes on it, right?

24 I mean, two kids, and those two kids are okay.

25 Well over a hundred. The odds are against it, right? And

113

Mark Regnerus, Ph. D. - Direct Monday/March-3-2014

nothing is preventing people from having unions and having That's not optimal. Right? So, I think the idea of children. But the state has to consider the entire esteeming a kinship structure that by its very definition population of people, not just one group or not just sort reduced in terms of a biological connection between child mother and father, I don't see why states would do that. of the most stable of a group. I mean, they have to consider the children as a whole and what is good for I mean, it's not the optimal context for flourishing for 6 them. And that's why I think with respect to the 6 children. It's a concession. I think states are prudent population based data that is available, some of it when they say, this is what is best. This is what we want highlighted here, the most prudent thing to do is wait and for our children. evaluate some of these changes over time before making any Q. In your opinion, Doctor Regnerus, can same sex radical moves around marriage. Marriage has been around a couples raise children? long time. We are in the process of overhauling it very A. Sure. 12 rapidly on modest information. 12 Q. In your opinion, is there any conclusive evidence 13 Q. And is that opinion -- let me back up. I want to that shows that there are no differences in outcomes for 14 make clear the opinions that you are expressing here 14 children growing up in households with same sex 1.5 today. Okay? In your opinion, Doctor Regnerus, what is 1.5 relationships? the ideal environment for raising children? 16 A. Sav that again. 17 17 A. When you are born into your married mother and O. Is there any conclusive evidence that there are no 1.8 father's life and they stay together, ideally, and into 1.8 differences in outcomes for children growing up in a 19 adulthood, right? I mean, that's the zero transitions, 19 household with same sex relationships? right? And kids fare best when they experience zero A. I don't think there is too many conclusive, too much 21 transition. Some transition can't be helped. Some 21 conclusive evidence that there are no differences. I 22 transitions, the parent gets violent. Things like that. think there are some outcomes or some measures. 23 But the states usually recognize it's a 23 relationship with the mother. But on average, I don't concession when we take a kid out of the household or a think we are anywhere near saying there is conclusive 25 parent decides to leave a household or the parent dies. evidence that there is no difference. APA disagrees, 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. 12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL. Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 Mark Regnerus, Ph. D. - Direct Monday/March-3-2014 116 right? But APA, they wrote this years before we started what you believe is the ideal environment for raising children? really focusing on some of these population based broad nationally representative studies. And I think you should A. I do, yes. privilege those kind of studies because they tell you what MS. HEYSE: I have no further questions. 5 is going on among the people, not just one small group. 5 THE COURT: Thank you, very much. I think we Q. In light of that fact, that you don't believe there 6 6 will start Cross-Examination tomorrow. Tell me, what is research and data to definitively answer that question witness do you have, the state has lined up? about child outcomes, do you have any opinion as to the 8 MS. HEYSE: We have Doctor Joseph Price wisdom of making decisions on these guestions without that 9 9 coming tomorrow. critical information? 1.0 THE COURT: Tell me what is his science. 11 A. I think in any business, they don't make critical 11 MS. HEYSE: He is -- economics, yes. decisions based on lack of information. I think nor THE COURT: Okay. And good. So in terms of 12 should governments. We have started adding to a new 1.3 1.3 timing, we will do Cross-Examination and then you will science. I mean, a new field, so to speak. Some call Doctor Price? interesting information. Didn't know what I would find. 15 MS. HEYSE: Correct. THE COURT: Okay. Any questions? 16 I think it's prudent to collect more data before one makes 16 any major conclusions on this. That doesn't seem to be 17 MS. NESSEL: I have a question regarding the movement of what is going on in the country. I mean, 18 Doctor Price. I was told by counsel there is a power 19 people are asking for change prior to ample information. 19 point presentation to accompany his testimony. We have I think it would be prudent and wise to be patient and map not received it and I was wondering if we could get a time 2.0 21 this out. Map it out in multiple data over time before 21 line. vou jump in. 22 THE COURT: Soon to have that.

24

25

marriage as between a man and a woman in order promote

O. So is it your opinion until we have that research

and data, it's prudent for the State of Michigan to define

23

had some similar incidents with plaintiff's counsel. We are happy to provide it to them. We are just doing some

MS. HEYSE: Sure. I am happy to do that. We

Case 4:21-cv-00450-JM Document 156-7 Filed 06/22/22 Page 31 of 31

Mark Regnerus, Ph. D. - Direct 117 118

Monday/March-3-2014

1	finalization.	1	CERTIFICATION
2	THE COURT: As soon as you get it, e-mail it	2	I, Lawrence R. Przybysz, official court reporter
3	to them.	3	for the United States District Court, Eastern District of
4	MS. HEYSE: I got Ms. Nessel's e-mail address	4	Michigan, Southern Division, appointed pursuant to the
5	to make sure I can get that to her.	5	provisions of Title 28, United States Code, Section 753,
6	THE COURT: Perfect. See you in the morning.	6	do hereby certify that the foregoing is a correct
7		7	transcript of the proceedings in the above-entitled cause
8		8	on the date hereinbefore set forth.
9		9	I do further certify that the foregoing
10		10	transcript has been prepared by me or under my direction.
11		11	
12		12	- (Tananana B. Barakana
13		13	s/Lawrence R. Przybysz Official Court Reporter
14		14	
15		15	
16		16	
17		17	
18		18	
19		19	
20		20	
21		21	
22		22	
23		23	
24		24	
25		25	

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

12-10285; APRIL DEBOER, ET AL. v. RICHARD SNYDER, ET AL.

Exhibit 8

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN

APRIL DEBOER, ET. AL.,

Plaintiffs.

Case Number: 12-10285 -v-

RICHARD SNYDER. ET. AL..

Defendants.

VOLUME 6 - AM SESSION

BENCH TRIAL

BEFORE THE HONORABLE BERNARD A. FRIEDMAN UNITED STATES DISTRICT JUDGE

UNITED STATES DISTRICT JODGE
100 U. S. Courthouse & Federal Building
231 West Lafayette Boulevard West
Detroit, Michigan 48226
TUESDAY, MARCH 4TH, 2014

APPEARANCES: For the Plaintiffs: Vickie L. Henry, Esq. Leslie Cooper, Esq. Carole M. Stanyar, Esq. Dana M. Nessel, Esq. Kenneth Mogill, Esq. Robert Sedler, Esq.

For the Defendants: Richard Snyder, Bill Schuette.

Tonya C. Jeter, Esq. Kristin M. Heyse, Esq. Joseph E. Potchen, Esq.

Lisa Brown Beth M. Rivers, Esq.

Andrea J. Johnson, Esq. Michael L. Pitt, Esq.

To Obtain Certified Transcript, Contact: JOAN L. MORGAN, OFFICIAL COURT REPORTER 734 812-2672

TNDEX

STATE DEFENDANTS' CASE

Preliminary Matters

WITNESS: PAGE:

MARK REGNERUS, Ph.D.

Cross-Examination by Ms. Cooper

EXHIBITS

RECEIVED:

None

Detroit, Michigan 2 Tuesday, March 4th, 2014 (At or about 9:00 a.m.) THE COURT: You may be seated. Just before our morning break, we'll talk a 6 little bit about scheduling so we have some idea. Doctor -- is he here? 8 9 MS. HEYSE: Plaintiffs have some preliminary 10 matters, your Honor. What do you have? 12 MS. NESSEL: Good morning your Honor. 13 When we recessed yesterday I brought to the 14 Court's attention the fact that Ms. Heyse had indicated to me that she intended to present a power point presentation for Joseph Price who is scheduled to be the witness after Dr. Regnerus today. THE COURT: Right. MS. NESSEL: I had asked for the presentation as quickly as possible. Despite the fact that we sent a couple emails requesting it following court, I did not receive an email with the presentation until like 10:28 last night.

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

I N D E X

15 16 17 18 19 20 21 22 23 The presentation involves many complex charts and graphs that I've never seen before. And the content of this 24 25 just from my quick review of it, it appears to include some

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 3 of 24

5

TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 content that was never in Dr. Prices' expert report. So I I'm happy to address this but before I do I just am requesting of the Court one of a number of remedies: want to take a brief moment. 3 Either that the Court strike the power point and not permit Your Honor had asked me to introduce members of that to be used or that Dr. Price instead of testifying our staff. after Dr. Regnerus which I think everybody assumes will be THE COURT: I did. today that he not testify until tomorrow which would give MS. HEYSE: They were able to come to court. me an opportunity to review all this matter. Or in the THE COURT: Please do. 8 alternative give an extensive, a lengthy, lengthy recess 8 MS. HEYSE: I do want to point out that one of our 9 9 following Dr. Regnerus' testimony so that I have an newest Assistant Attorney General is Scott Shimkus who is 1.0 opportunity to review all this because this is a lot of in the courtroom here today. THE COURT: Nice to see you. material and I've never seen it before. Obviously at 10:30 at night, you know, I was going to bed. MS. HEYSE: He has been a tremendous help to the THE COURT: Going to bed. This is an important team in preparing for the case so I did want to acknowledge 14 14 case. MS. NESSEL: I know. THE COURT: Good to have you. We're trying to get 16 THE COURT: Wait a minute. 16 everybody acknowledged. MS. NESSEL: I haven't had an opportunity to --MS. HEYSE: Thank you, so much for that 18 THE COURT: Ten thirty, you're suppose to take 1.8 opportunity, your Honor. 19 vour No-Doze. 19 And, again, I'm happy to address Ms. Nessel's 20 MS. NESSEL: I know. If it was over the counter, requests. She is absolutely right that we were unable to get her the power point until later in the evening So those are my requests to the Court, your vesterday. I don't dispute that. The fact of the matter is 23 that we left here, we went to meet with our witness who 24 24 THE COURT: What does the State have to say? came in from out of state, was able to go over the power MS. HEYSE: Good morning, your Honor. point with him, and finalize it so we could get them the 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014

final version.

2

6

8

9

1.3

14

15

16

18

19

23

24

25

BENCH TRIAL - VOLUME 6 - PART A

MARCH 4TH, 2014

Just to represent to your Honor, it certainly wasn't anything that was purposeful on our part. We got to it as I represented yesterday, got it to her as soon as we possibly could.

I would point out just a few things, your Honor, with regard to this matter. It is demonstrative evidence. Everything that is in that power point and I won't dispute the fact that there are quite a few slides. Everything that is in that power point is either contained in Dr. Price's report or his article that is going to be admitted. Again, it's demonstrative so we're not moving for admission, it's just something he's going to be discussing during his testimony.

I also point out for your Honor that, you know, we've had similar experiences with plaintiffs in this matter as well. We had some last minute changes from them with regard to two power points that we just bring to the Court's attention because quite frankly these things just happen in trial. So, you know, we would ask that we be allowed to use the power point. We certainly don't have any objection if Ms. Nessel needs additional time to prepare. We have no objection to that, your Honor, but we would ask that we be allowed to present the power point.

THE COURT: Okay. I think -- demonstrative

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014

BENCH TRIAL - VOLUME 6 - PART A

evidence is just that, it demonstrates or helps the witness demonstrate to the Court in an easier fashion. We had a policy that each side would exchange it as soon as they had it. Each side in this case has gotten along, the civility is great. I have no reason to believe that the State didn't get it to them -- to the plaintiffs as soon they could. So what we're going to do, we'll proceed. It's demonstrative, it's not anything else.

Ms. Nessel, if there comes a time when it becomes necessary to have more time, we'll certainly talk about. I have no problems with that. But I think -- let's see what it's all about. As I say, we've seen demonstrative evidence before. And, again, it's only to demonstrate and to help the Court and those are here understand the testimony.

It is limited, however, of course, to the report. If it exceeds the report then there would be I suspect an objection indicating that -- not so much demonstrative evidence but the testimony itself because the demonstrative evidence is not evidence.

So we'll proceed and take it one step at a time.

MS. NESSEL: May I just briefly, your Honor?

THE COURT: Yes.

6

8

1.3

14

16

18

19

20

21

22

23

2.4

25

MS. NESSEL: My only issue, your Honor, is that I won't know that until I see it presented since I haven't had an opportunity to review it. So that's why I'm asking

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 4 of 24

BENCH TRIAL - VOLUME 6 - PART A BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 to have some kind of lengthier recess so that I can at little longer lunch. Let's take a look. We're not going to least review the slides to know whether they were in the jam either side. I think each side throughout this whole report or not. It's very difficult as you can imagine the trial their intent wasn't to do anything to the other side. second that it appears for me then to know, you know, was Let's move on. Anything else? 4 it in the report --MS. STANYAR: No, your Honor. 6 THE COURT: But you know -- okay. I'm going to 6 THE COURT: Okay. Where's our witness? give you some time. But you know, it's in the report. It's We're not going to re-swear you, you're still 8 not what's on the screen that counts, it's what the expert 8 under oath. 9 testifies to. If he's testifying to something to whether it 9 Counsel, you may proceed. be on the screen or based upon his testimony, and it's not 1.0 MS. COOPER: Thank you. in his report then I would suspect that you're going to THE COURT: I don't know if the witness has met make an objection. You already know the report ${\rm I'm}$ sure backwards and forwards. So you will be able to make that 13 MARK REGNERUS, PH.D., HAVING BEEN DULY SWORN, TESTIFIED AS FOLLOWS: 14 objection. It has no bearing whatsoever to the 14 15 demonstrative evidence. It has to do with his sworn CROSS-EXAMINATION 16 testimony. 16 BY MS. COOPER: MS. NESSEL: I would only bring to the Court's Leslie Cooper. 18 attention, there's some very complex charts and graphs with 18 Good to see you live in person. 19 many, many numbers so I have to be able to go through the 19 Good morning 20 numbers to --Good morning. THE COURT: Let's take it one at a time. Let's Doctor Regnerus, you mentioned on Direct Exam vesterday that you asked two of the plaintiffs' expert 23 MS. NESSEL: All right. 23 witnesses, Michael Rosenfeld and Garv Gates to serve as 24 THE COURT: We'll see. We may get a break and it 24 consultants on your NFSS Study; is that right? may be right at the right time for lunch, and we may take a 2.5 Yes. DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TR}, 2014

1 Q And you consider Michael Rosenfeld to be well-regarded 2 professionally; is that right?

A Yes.

Q And you consider Gary Gates to be well-regarded in

5 lesbian and gay demography; correct?

6 A Yes.

7 Q Now, turning your opinions, it's not your opinion, is

 $\ensuremath{\mathtt{8}}$ it, that children raised by same sex parents necessarily

9 have poor outcomes; is that right?

10 A Would you restate that?

Q Sure. It's not your opinion is it that children raised

by same sex parents necessarily have poor outcomes; is that

13 right?

14 A Poorer outcomes.

15 Q Poorer outcomes.

16 A That is not my opinion.

17 Q And you agree that the social science of gay parenting

18 based on non-probability samples have taught us that it is

19 possible for children raised in same sex households to

20 develop normally; is that right?

21 A Yes.

Q In fact, you wrote in your -- in one of your NFSS

23 articles that most of the respondents in your own NFSS

24 Study report ample success and largely avoid problematic

25 physical and emotional difficulties regardless of their

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

parents' experiences; is that right?

2 $\,$ $\,$ A $\,$ It depends on the different outcomes. You know, some

outcomes that's certainly true.

THE COURT: Speak a little bit slower.

BY MS. COOPER:

7 "It's possible that there may be genuinely be two 8 gold standards of family stability and context for children

9 flourishing, a stably couple heterosexual household and a

10 stably couple homosexual household but no population base

11 sample analyses have yet been able to consistently confirm

2 wide evidence of the latter"; is that right?

13 A Yes, presuming you're directly quoting from --

14 Q Your report.

15 A The report, yes.

16 Q Okay. You have recognized that studies using non-

17 population base samples suggest that children in planned

gay, lesbian, bisexual families seem to fair comparatively

19 well; is that right?

A Could you repeat that once more?

21 Q Sure.

18

22 MS. HEYSE: Your Honor, I would ask that if we're 23 going to have lengthy quotes that Dr. Regnerus be able to

24 see a copy of what she's quoting from?

25 THE COURT: I think he has the report.

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 5 of 24

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A 14 TUESDAY, MARCH 4TH, 2014 That's correct. MS. COOPER: This was from the study itself. BY MS. COOPER: But you recognize that this is not necessarily true within the field of psychology; is that right? Do you have a copy of your NFSS Study? From the study itself? I know psychologists don't privilege those kind of The study itself? samples in the way that sociologists or certainly THE COURT: Do you remember what exhibit -demographers do. MS. HEYSE: Exhibit 6 from your original article. And your understanding is that most research in 8 THE COURT: Counsel, you can continue to ask him 8 psychology uses smaller non-representative samples; right? 9 9 questions, but just kind of refer him to the page. I wouldn't speak for all of psychology, but there are 1.0 BY MS. COOPER: plenty that privilege smaller samples for sure. Looking at page 766, the conclusion section. Okay. You had your deposition taken in January; is that right? Bottom of the first paragraph, if you'll read with me. 13 14 You reference that, 14 And you have a copy of your transcript there? I have "While previous studies suggest that children in 16 planned GLB families seem to fare comparatively well": is 16 If you turn with me to page 19. Line 19, that right? beginning there, "Ouestion: And is it true that most research in 18 A Yes. 1.8 Okay. Now you also believe that we should privilege 19 19 psychology uses smaller non-representative samples? 20 the collection of probability base data over other data; is "Answer: That is my understanding." Did I read that correctly? that right? 23 In your view, the hallmark of a rigorous study is a 23 Thank you. Now, yesterday on Direct testimony you 24 large representative pool of participants drawn from a 24 talked about your criticism of the research on gay parent population base random sample: is that right? families that was discussed in a report by the American 2.5 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 Psychological Association. Now that report was issued in That sample wasn't big enough to give you statistical 2 2005; is that correct? power to evaluate children raised from the beginning in same sex families; right? And you're aware that research on children of same sex That is correct. parents did not stop in 2005? You need a bigger group to do that. Correct 6 Definitely. That there has been research conducted since then? How many people do you think you would need to survey, 8 Δ Yes 8

9 Now, yesterday you testified that it's premature $\ensuremath{\mathsf{I}}$ think is the word you used to allow same sex marriage until we have large scale population base longitudinal studies on outcomes for children of same sex couples; is that right? Yeah, and I think the reference -- I could be mistaken 14 but the reference is to premature to settle the signs around this stuff. 15 16 Okay. You, yourself, did a large scale study of over 15,000 individuals in the NFSS; is that right? 18 We screened 15,000. Interviewed fully just under 19 3,000. You would call that a large scale study. 21 And after screening over 15,000 people you found only two who were raised from birth in a same sex parent family; 23 24 is that right? 25 That's correct.

to screen rather, to get a large enough group to study? 9 It depends a little bit on the outcome that you're 10 evaluating. If on average the outcomes at face value differ markedly, for example, the sample -- in adults whose mothers have same sex relationship, mothers -- adult 1.3 children whose mothers had a same sex relationship they 14 tend to report experiencing poverty or being on community 15 assistance at notably greater rates. It's like 70 percent 16 or something compared to closer to 10 to 20 percent for intact biological families. When you have a profound 18 difference one does not need lots of cases because there's 19 already a notable difference in the effect. But when you're detecting smaller effects then you need a larger number of 21 cases.

So like my reference yesterday to the CNN poll
where if two candidates are running neck and neck you need
a larger sample size to distinguish whether there's a

DEBOER, ET. AL. V SNYDER, ET. AL.

12-10285

BENCH TRIAL - VOLUME 6 - PART A

You're saying how much did it cost?

How much did it cost to do that survey?

TUESDAY, MARCH 4TH, 2014

1.8

more than -- ideally well over -- more than 50 or a 100. I think total about \$415,000. Okay. So if they need more than 50 or 100 let's say --So to screen -- your survey was not longitudinal, Ideally. It depends on the outcome and how different right it was just one assessment. So by my math to get 50 if your 15,000 people yielded So if it was -- you say 400 --8 only two to get 50 -- you can check my math -- you would 8 Four hundred fifteen is my recollection. Α 9 have to have 375,000 people screened? 9 So in order to screen say 375,000 people on multiple 1.0 1.0 I don't have to check your math, but it's -- it's a assessments can you even estimate the cost of that? Is it lot more than 15,000 to screen which indicates that we're in the tens of millions of dollars to fund that? 12 not only dealing with a small population among whom I can't offhand estimate, but it's not something that stability was comparatively rare in that era, but we're 13 the federal grant system can't handle if it wishes to study 14 also -- I mean, it calls for more data analysis. So this is 14 why people are interested in the census and what it has to 15 Is it common for researches to get grants in the tens 16 say on this, or the versions of the census, The American 16 and millions of dollars? Community Survey. But it raises an interest in new data A Well, I know that the Ad Health Project is now on it 18 collection. 1.8 way four or five, that was in the eight figures I know in terms of the grant. I mean, it's unusual but it's not 19 O Because the census data doesn't actually provide 19 20 information on child outcomes; right? unheard of for those large federally funded grants. And do you expect anyone would fund a tens of millions Not manv. School progress is one. of dollars study to assess whether children raised by same 23 23 sex parents fair any differently than children raised by 24 24 heterosexual couples when the professional groups in the Okav. How much did it cost you to do the project surveying or screening 15,000 people? fields of psychology, sociology and pediatrics have already 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 said we have sufficient research to answer this question of children and that's when we get into talking about 2 and we know the answer? 2 expectations -- assisted reproductive technology which is A One of the things I think it ought to be added to is very expensive and less expected among people of lower either an existing or an upcoming large federal grant and means. So it's not just about science around child there's a handful of them out there at any given time. I'm outcomes. It's also a science around common expectations not aware of what's out there right now. It could be tacked 6 and marriage. onto an existing children's study. So it's not -- for all T Q So either if we had the type of study you would 8 know it could be in the works, but I'm unaware of it. 8 require that still wouldn't be -- that wouldn't answer the 9 Q So in your opinion -- or is it your opinion that if 9 question and allow you to support same sex marriage. the type of study you describe, a nationally representative 10 A There are more aspects to it than just a large child large scale, longitudinal study if that type of study is outcome study for sure. never done because its cost prohibitive is it your view Now, I want to go back to your statement that there that we should just never allow same sex couples to marry? 1.3 may be two gold standards of family stability and context 14 for children flourishing, a stably coupled heterosexual 14 MS. HEYSE: Objection, your Honor, Calls for household and a stably coupled homosexual household but no 15 speculation. 15 16 THE COURT: He's an expert. He can testify. 16 population base sample analyses have yet been able to Well, there are other aspects to consider including consistently confirm wide evidence of the latter. That was 18 scientific aspects. I mentioned in a deposition and I think 18 your statement in your report; right? 19 I mentioned vesterday that marriage historically is about 19

20

21

22

23

2.4

25

less common especially in households of two women.

21

23

24

25

expectation of permanence, fidelity, and generally openness

and welcoming of children. Scientifically and studies that

we talked about yesterday permanence is -- permanence is

Expectations of fidelity are less common in households of

two men scientifically. And then you look at the welcoming

BENCH TRIAL - VOLUME 6 - PART A

if one is being -- in the other 70 to 30 you don't need

that many cases. But certainly more than two, certainly

TUESDAY, MARCH 4TH, 2014

A I'm going to ask you to repeat that one.

Now, are there population base studies that

develop as well as children of higher income parents?

Sure. Are there population base studies that

consistently confirm that children of low income couples

consistently confirm that children of low income couples

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 7 of 24

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014 develop as well as children of higher income couples? Typically insofar as it's associated with social class MS. HEYSE: Objection, your Honor. That's outside and life chances for children. 2 But you don't favor excluding low educated couples 3 the scope of his report. THE COURT: Again, he's an expert and it's crossfrom marriage; is that right? MS. HEYSE: Objection, your Honor. That's not examination. If he knows. Insofar as I know, ves. 6 relevant to these proceedings. BY MS. COOPER: THE COURT: Overruled. Again, it's cross-8 Confirming the equally good outcomes of children of 8 examination. 9 9 low income and high income parents? I do not. 1.0 Confirming that, no. I mean -- typically BY MS. COOPER: distinguishing that there are differences. And you don't favor excluding low income people from Q Right. So, in fact, studies show the opposite. It marriage; is that right? doesn't confirm that they are doing equally well, it 13 I do not. 14 confirms that children raised by low income parents don't 14 So it is not your view that marriage should be limited on average develop as well. 15 to those groups whose children are statistically most 16 A That's what I'm agreeing with. 16 likely to have positive child development outcomes. Okav. Are there population base studies that Can you say that again? 18 consistently confirm that children of non-college educated 1.8 It is not your view, is it, that marriage should be parents develop as well as children of college educated 19 19 limited to those groups whose children are statistically 20 parents? most likely to have positive outcomes? A I know less about that, but on average I would expect Correct, it's not. there to be differences. 22 And it is not your opinion that groups that are known Right. Studies actually show the opposite that kids of 23 from the scientific research to raise children who fair 24 non-college educated parents don't develop as well as 24 more poorly should be excluded from marriage. children of college educated parents. Right. 2.5 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 Okay. But in your view because there are, quote, outstanding 1 0 questions about whether children develop as well in same It's a function of sort -- they're more in line with 2 2 sex households compared to opposite households that same the longstanding criteria around marriage especially to the sex couples should not be allowed to marry? idea that marriage unites man and woman and the

A It's my view that the science here is very new whereas 6 the science around these other questions you've asked is notably older. So there's an intellectual debate going on though people would like to close it quickly, I think it 8 should still be open and it should be further investigated about the no differences debate. But as I mentioned just a little bit earlier it doesn't tackle the question of the hallmarks, the historic hallmarks of marriage. And that's a separate issue. We'll got to that. 14 MS. HEYSE: I'm going to object, your Honor, He should be able to finish his response. 15

16 THE COURT: He may complete his answer. I mean, it's not just about the science around child

18 outcomes. It's also the science around long-standing 19 expectations around marriage.

BY MS. COOPER:

21

25

Q So given -- you mentioned that the research on low

income and low educated couples is more longstanding, that

23 research actually confirms poor outcomes but you don't

24 favor excluding those groups.

A Right.

expectations around children because I think still today

6 half of all children that are born are unplanned. And

marriage for a very long time has served to unite the

parents, the biological parents of children in a union that 9 will be protective of that child whereas -- I mean --

MS. COOPER: Your Honor, it's non-responsive to

THE COURT: There's no question.

1.3 MS. COOPER: Thank you.

BY MS. COOPER: 14

Now, in your opinion and I think this was your

16 ultimate opinion in your expert report and I'm happy to

pull that out if you need but it's a sentence so you tell

18

8

19 In your opinion,

"It remains prudent for government to continue to 21 recognize marriage as a union of a man and a woman thereby 22 promoting what is known to be an ideal environment for

children"; is that right? 23

2.4 Yes.

25 Okay. Now, you recognize that same sex couples have

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 8 of 24

BENCH TRIAL - VOLUME 6 - PART A BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 children either through adoption or assisted reproduction you left home did either of your parents ever have a including in states like Michigan where they can't marry. romantic relationship with someone of the same sex"; is A Right. that right? And you recognize that excluding same sex couples from marriage does not prevent them from having children in And just for the record if I use "lesbian mother" or "gay father" terms I'm not using that to suggest anything That is true. about the sexual orientation of the individuals but those 8 And you're not aware of any data showing that allowing 8 are the terms used in the study so I may use that in 9 same sex couples to marry reduces the number of children 9 shorthand 1.0 who are raised in heterosexual biological parent families; 1.0 For example, if a respondent reports that her is that right? mother had a relationship with another woman for, say, six A I'm unaware of that. months but otherwise only had relationships with men that Q So, in fact, you acknowledged, did you not that you 13 individual would be put in the "lesbian mother" group; 14 don't actually know whether the exclusion of same sex 14 couples from marriage actually does anything to promote 15 Right, and in a followup I said it would be better to 16 what you consider to be the ideal environment for children. 16 talk about this category as mothers who've had lesbian A Right, we don't know except that it's an open relationships or fathers who had gay relationships. question. Moving forward there's more data to collect here. But this individual would still be in that category. 18 1.8 Right, because the relationship was a same sex one. 19 But vou don't know. 19 20 I don't know. Okay. And over half of the respondents you deemed to Okay. Now I want to ask you some questions about your fall into the "lesbian mother" category never actually NFSS Study. You noted yesterday that to be included in your lived in a same sex household; right? 23 "lesbian mother," or "gay father" groups the respondent had 23 Well, they didn't live in the household but their 24 to affirmatively answer the following question: 24 mother and her partner --"From when you were born until age 18 or until So that's ves. 2.5 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

A I don't purport to know how long the partnership

2 lasted

O But they never lived in an household where there was

a same sex couple living.

A Not according to them, yes, correct.

6 O Okav. And very few of the respondents that you deemed

to be children of a "gay father" ever lived in a same sex

8 counte household

1

9 In that era that was particularly uncommon.

So that's correct?

Did you say none of them ever --

No, no, very few.

Few. I want to say 23 percent lived for some share of

14 a year with their dad and his partner.

And you have noted that a majority of the respondents 15

you deemed to fall into the "lesbian mother" or "gay 16

father" group were the product of a failed heterosexual

18 union; correct?

19 A I said a majority, did you say?

20

21

Now, your primary heterosexual parent comparison group

23 or any of your heterosexual parent comparison groups were

24 not defined by asking the question did your parent ever

25 have a heterosexual relationship; right? That's not how you BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

1 established groups.

2 A That is correct.

Your primary comparison group was a group of

individuals who lived from birth to age 18 in an intact --

26

two biological parent family; is that right?

6 A According to them, ves.

Well, all of this is according to them.

8 A Yes

9 And this group which is called in shorthand IBF,

intact biological family, excluded all divorced, a single

parent, heterosexual families; right?

Excluded who?

1.3 Divorced people?

14 Right, I mean, they may have had a divorce before the

15 child came along. But the child experienced it as an intact

16 biological family for the duration of their childhood.

17 Okay. So any child who had experienced divorce was not

18 in that group.

19

And similarly any child who experienced single parent

21 family life, that was stripped away, not in that group.

22 Correct.

23 Okay. So the idea of intact biological family group

2.4 was defined by the stability of the families.

25 Yes. I did that intentionally because stability has

DEBOER, ET. AL. V SNYDER, ET. AL.

12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.

BENCH TRIAL - VOLUME 6 - PART A

That was not the criteria by which -- the criteria by

TUESDAY, MARCH 4TH, 2014

Okay.

0

3.0

29

comparison group was often unclear sometimes entirely. which I sorted them whether they had a same sex -- the parents had a same sex relationship. Historically, stability is a good thing, I wanted to make sure that we understood the comparison category was But that was the comparison. So that's a yes it was defined by it being a stable Now, the two respondents in the "lesbian mother" group who like the individuals in the "IBF" group lived from 8 family group. 8 9 9 birth to age 18 in an intact stable family appeared well Yes. 1.0 1.0 Okav. adjusted. By the way, we don't know how happy this group was. I On average. I don't recall them being notably either didn't make that -- are they together. 12 way. 13 Yesterday you testified they made --So on the one hand you compared the two groups -- two 0 14 of the groups in which a majority of the individuals had 14 15 been through a family breakup. That would be the "lesbian 15 And you recognize that I think you just said a few 16 mother" and "gay father" group. You compared them to a 16 moments ago that stability is associated with better group that was defined by its stability, the intact outcomes for children biological parent -- sorry, intact biological family group. 18 1.8 Right. A Could you repeat the first part of that? 19 19 And divorce is generally associated with poorer 20 Sure. You compared two groups in which the majority of 2.0 outcomes for children; is that right? the respondents had been through a family breakup. That would be the "lesbian mother" and "gay father" group. You 22 Now, yesterday you said you had no idea what the study compared them to a group that was defined by the stability 23 would reveal before the data came in. Are you saving you 24 of the group, the intact biological family group. 24 really had no idea that a sample in which most of the subjects experienced a family breakup would fair worse than 2.5 A Yes. 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 a comparison group where not a single one of the subjects 1 vesterday. 2 had experienced the family breakup because it was defined Q But I think you also mentioned the comparison to step 2 to exclude those individuals? families were very comparable? A What I mean by the statement is I had no idea what the A Slightly less but comparable. -- when the data was in the field how it would return in Q Okay. Now that actually wouldn't be surprising, would 6 terms of the number of people who had said their parents 6 it, given that in almost every case in the "lesbian mother" group the mother's same sex partner was not an original had same sex relationship or what their household calendars would look like. That's what I mean by I had no idea. member of the household. It was a later formed 8 Q But you recognize that in the era in which these 9 relationship. individuals grew up planned same sex parent families was A Sure Okay. Now, you made clear yesterday that you were not A It was, and I mention that in the study. making any claims about causation regarding child outcome Okay. Now, you said yesterday I think that individuals 1.3 in the NFSS Study; is that right?

14

15

16

18

19

20

21

22

23

2.4

25

Right.

about it.

parent; is that right?

ages 18 to 39; right?

Yes.

Α

split the pies a little bit more narrow the fewest

in the "lesbian mother" group had outcomes that were very

comparable to the individuals in the step family group; is

A If that's what I had said yesterday, I think -- step

I think what I said was in the followup study where I

differences between cases where adult children had a mom or

same sex relationship and they lived with their partner and

single parents who did not have subsequent partners. I

think that was the most close equation that I mentioned

14

15 16

18

19

20

21

23

24

25

that right?

BENCH TRIAL - VOLUME 6 - PART A

long been seen as a resource. And in a lot of the

literature in this area the exact stability of the

TUESDAY, MARCH 4TH, 2014

Okay. In fact, you agree that the sub-optimal outcomes

that you found in the "lesbian mother" and "gay father"

groups may not be due to the sexual orientation of the

Since I did not measure it, I cannot make a claim

Okay. Now, switching gears a little bit. I want to

So the data was collected in 2011 and 2012; right?

talk about the pool. So the respondents in the NFSS were

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 10 of 24

BENCH TRIAL - VOLUME 6 - PART A BENCH TRIAL - VOLUME 6 - PART A 34 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 0 You've got your NFSS article with you? Α So that means they were born from 1972, to 1993; that 2 0 window? If you would turn to page 756, and if you look with me at the bottom paragraph on that page, second sentence. At the time the individuals in the NFSS were being "Today's children of gay men and lesbian women are more apt to be 'planned' (that is, by using adoption, raised, you agree that stigma was more pronounced and 6 social support for lesbian and gay parents was far more IVF, or surrogacy) than as little as 15-20 years ago, when such children were more typically the products of 8 modest than it is today; is that right? 8 9 9 heterosexual unions." I would suspect so. I did not measure that. I mean, I measured how often they were bullied, things like that, but 1.0 1.0 You wrote that? one can presume so. A Yes 12 Q Now, in your article on the NFSS you noted that it is 12 Okay. Let's stay on page 756. Skip that. often the case and it certainly is true of the NFSS that a 13 On page 765, if you go to the third paragraph 14 gay or lesbian parent first formed a heterosexual union 14 from the bottom, last sentence, prior to coming out of the closet; right? 15 "Child outcomes in stable 'planned' GLB families 16 A Right. 16 and those that are the product of previous heterosexual unions are quite likely distinctive as previous studies And you also wrote that the NFSS may best capture what might be called "an earlier generation" of children of same 18 1.8 conclusions would suggest." You wrote that? 19 sex parents and includes among them many who witnessed a 19 20 failed heterosexual union." Yes. MS. HEYSE: Again, your Honor, I would just ask if 0 we're going to be reading from specific --22 And I followed it up with sort of -- we don't know how 23 THE COURT: I agree, and a little bit slower. 23 many of those actually are. 24 MS. COOPER: Sure, sure. 24 You don't believe that you can draw conclusions from BY MS. COOPER: your NESS Study about outcomes for children in planned 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 35 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 lesbian couple families; is that right? published that audit; isn't that right? 2 A If by "planned" you mean assisted reproductive I believe so. technology things like that, yeah. Now, are you familiar with a sociologist named Paul Q Okay. Now, that's families like the plaintiffs -well, actually families like many couples seeking to marry and form families together; is that right? 6 He's a professor of sociology at Penn State? 0 A I don't purport to know what share of that is true. 8 Okay. I think you emphasized this yesterday but I want 8 And you consider Paul Amato to be a well-regarded 9 to make sure we understand that the NFSS Study documented 9 scholar in family structure studies? differences statistically significant differences between 10 T do groups. In other words, in the groups in the so-called You consider him to be a level and level-headed lesbian mother group and those in the intact biological 12 family group, but it did not concern itself with the 1.3 Generally speaking. 14 14 magnitude of those differences. And you consider him to be a scholar who's right down Correct, and I stated in the article that was not my 15 the middle politically neither liberal, nor conservative? 15

16

17

18

19

20

21

22

23

24

25

0

-- the journal that published the study.

Q Now, you talked yesterday about the audit of the NFSS

Study conducted by the Journal Social Science Research that

A It was authorized by the journal. It was not conducted

O Authorized by the journal, okay. And you expressed

some views about the motives of the individual who wrote

the audit, but one question about this that I just don't

think was answered yesterday was -- it was the journal that

16

18

19

20

21

23

24

25

purpose.

by the journal.

So he served as a consultant?

He had struck me at one point. I have no idea if that

And, in fact, you asked Paul Amato to be one of the

MS. COOPER: I like to mark a document as an

is entirely accurate, but he strikes me as a moderate.

consultants on your study.

I did.
And he agreed?

He did.

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 11 of 24

BENCH TRIAL - VOLUME 6 - PART A

3.8

40

DEBOER, ET. AL. V SNYDER, ET. AL.

37

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 TUESDAY, MARCH 4TH, 2014 exhibit for identification. It's Exhibit 54. about your NFSS Study; is that right? 1 MS. HEYSE: Your Honor, I would just ask that we The source is a blog. I'm not sure what all of it is 2 verbatim, Paul Amato's words, and what is --3 be provided a copy. We have not seen it. THE COURT: I think counsel as a bunch of copies. Well, I'll direct your attention. Thank you for MS. HEYSE: If we could have a few minutes to clarifying. 6 review? This is not Paul Amato's blog. THE COURT: Sure. Show it to the witness so he can Understood. If you'll read with me. It says here --8 THE COURT: Tell him where you're reading. review it also. 8 9 MS. COOPER: I just want to find the right 9 MS. HEYSE: Your Honor, I would just note for the 1.0 record that we did agree to exchange exhibits in advance of 1.0 passage. the trial and this was not provided to us. BY MS COOPER. 12 THE COURT: Why was it not provided? If you look at the second paragraph from the top. MS. COOPER: This is being used for identification 13 First page? 14 to ask questions, and it was an exhibit that was used at 14 Yes. Second sentence, the deposition, they have it. "I regret that before writing that post" --16 THE COURT: Do you intend to introduce it? 16 Who wrote that? MS. COOPER: No. I'll clarify. The first three paragraphs in Italics are statements from somebody who wrote the blog, not 1.8 THE COURT: Okav. 1.8 MS. HEYSE: Oh, I'm sorrv. 19 19 attributable to Paul Amato 20 THE COURT: It's only for purposes of use, but not MS. HEYSE: I'm going to object, your Honor, to the extent this is hearsay. MS. COOPER: Not to admit. THE COURT: I'm not sure where she's going at. 23 THE COURT: Okav. 23 The first three were not written by --24 BY MS. COOPER: 24 MS. COOPER: I'm trying to direct Professor O So. Dr. Regnerus, this is a statement Paul Amato wrote Regnerus to the statement that this blogger says. 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 "There is a statement sent to me by Paul Amato THE COURT: Good. 2 which I agree to post" and then he posts the statement 2 BY MS. COOPER: 3 And who is he? "Thoughts on the Mark Regnerus 2012 Study by Paul THE COURT: Who is the blogger, is that your Amato." 6 question? Do you see that heading in bold? THE WITNESS: Yes. MS. COOPER: The blogger's name is Phil Cohen, I 8 8 So that's the beginning of the statement. 9 believe. This is something we looked at your deposition. So I'd like you to turn to page 3 of this BY MS. COOPER: Do you not recall identifying it? A Are there's 12 pages to this? I'm only seeing four. I do, yeah. I just don't know -- I can't identify on This is the first four. I didn't print the comments to this who wrote this top part. 1.3 the blog because -- I think, in fact, that may have been 14 14 something that counsel for defendants did not want to Okay. But the part I want to flag your attention to is 15 in the second paragraph it says -- this is not Paul Amato, 15 include in the exhibit. But either way I did not consider 16 this is the blogger. 16 that. "I regret that before" --THE COURT: The exhibit is just to ask him 18 MS. HEYSE: Your Honor, I'm going to object to the 18 19 extent of reading something into the record --19 MS. COOPER: It's just to feature the statement. 20 THE COURT: Sustained. 20 BY MS. COOPER: 21 The blogger said something and now what's your 21 Q So if you can go to page 3 with me. question? 22 Okay. If you would look at the second paragraph from MS. COOPER: I don't really care what the blogger 23 23 the bottom, okay, beginning with the second sentence, and 24 said, I just wanted to direct Professor Regnerus so the 2.4 read along with me, 25 statement from Paul Amato that is posted here. 25 "Many" --

DEBOER, ET. AL. V SNYDER, ET. AL.

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 12 of 24

BENCH TRIAL - VOLUME 6 - PART A 41 BENCH TRIAL - VOLUME 6 - PART A 42 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 MS. HEYSE: Your Honor, it's hearsay and she can't disingenuous to claim that the NFSS Study provides evidence that being raised by gay or lesbian parents is harmful to read it into the record. MS. COOPER: It's not for the truth. I want to ask children? him if he agrees with statements made by one of his own The question hinges around sort of what does it mean to be raised by, right? And I think we mentioned this a consultants about his study. THE COURT: For that purpose, you may. little bit yesterday and it says gay or lesbian parents. My BY MS. COOPER: mistake and acronyms notwithstanding I talk about parents 8 who have same sex relationship with no assumptions about "Many conservative observers have cited the Regnerus 8 9 study as if it provided evidence that being raised by gay 9 their orientation. So when he talks about being raised by or lesbian parents is harmful to children. This claim is which implies some degree of time I assume and household disingenuous because the study found no such thing. A presence I assume. But then he goes and uses gay or lesbian noteworthy example came from Regnerus himself who signed an as an adjective which I don't think -- I mean, I don't have amicus brief to the Supreme Court citing his study as 13 data on the orientation, it's harmful to children. I think 14 evidence against same sex marriage. This is curious because 14 the jury is out on this, figuratively speaking. What we on page 766 in his 2012 article, Regnerus stated that his need is -- the absence raises significant questions about 16 study was not intended to either affirm or undermine the 16 children who grow up in families where a parent has a same legal right to same sex marriage." sex relationship 18 And on page 768 of his response to the 1.8 What it doesn't answer his question about 19 commentaries in the same issue, he stated, 19 orientation, and it didn't come design to answer political 20 "That his data should not be used to press any questions. It came design to address an intellectual political program. Given these cautious early statements it is exasperating to see Regnerus later cite his own study as 22 O Okay. So he is correct in your view that -- sorry. He 23 evidence against same sex marriage." 23 is correct that you said the study was not intended to 24 So, first question about this: Is Professor Amato 24 either affirm or undermine the legal rights of same sex who is a consultant on your study correct to say that it is marriage? 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285

43

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014

Α That's what I wrote in the original study, yes.

Okay. Okay. Great.

2

6

8

19

21

23

24

25

Now, are you aware that yesterday the Chair of the Sociology Department at the University of Texas, your department, issued a statement posted on its website stating the following:

"Like all faculty" --

MS. HEYSE: Objection, your Honor. Hearsay.

MS. COOPER: I'm happy to provide a copy if you like. I'm not seeking to admit it again -- happy to show a copy if you don't have it.

12 MS. HEYSE: I don't have a copy.

1.3 THE COURT: And, again, it's only for purposes of 14 cross-examination.

MS. HEYSE: Thank you. 15

16 MS. COOPER: So I've marked this for

identification as Exhibit 55.

18 BY MS. COOPER:

So, if you'll read along with me, the statement says,

"Like all faculty Dr. Regnerus has the right to pursue his areas of research and express his point of view. However, Dr. Regnerus' opinions are his own. They do not reflect the views of the sociology department of the University of Texas at Austin. Nor do they reflect the

views of the American Sociological Association which takes

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

the position that the conclusions he draws from his study

of gay parenting are fundamentally flawed on conceptual and 2 methodological grounds and that findings from Dr. Regnerus'

work have been cited inappropriately in efforts to diminish

the civil rights and legitimacy of LBGTQ, partners and

their families. We encourage society as a whole to evaluate his claims."

There's additional material but I just wanted to

9 call your attention to that paragraph.

Were you aware of this statement?

Okav. And what is your reaction to that?

1.3 It's regrettable. I think the University has 14 characterized my academic freedom. I guess they have been

15 getting negative press probably about my appearance here,

16 and decided to make a statement which they had not made

before even though I had conducted the research -- the 18 process a few years ago. The article came out a year and a

19 half ago. I think they just wanted to distance themselves

from me which is sad. And I heard from some of my

21 colleagues that this was an inappropriate thing for the

22 department to do.

25

23 O And you are aware that The American Sociological

2.4 Association did submit a brief, an amicus brief in the U.S.

Supreme Court in the $\underline{\text{Windsor}}$ and $\underline{\text{Perry}}$ cases stating that

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 13 of 24

BENCH TRIAL - VOLUME 6 - PART A 45 BENCH TRIAL - VOLUME 6 - PART A 46 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 your study doesn't allow for conclusions about being raised If you look at the third paragraph from the bottom, and by -- the impact of being raised by same sex parents; is read along. It says, 2 that right? "Every study has its limitations and this one I'm aware of that. does, too. It is unable to track the household history of Okay. And I want to switch gears away from NFSS now children nor is it able to establish the circumstances of and your research and ask about another study. the birth of the children whose education is evaluated, You're familiar with a study done by Douglas that is, were they the product of a heterosexual union, Allen based on the Canadian Census that looks at high 8 8 adopted, or born via surrogate or assisted reproductive 9 9 school graduation rates? technology." 1.0 I've read and I wrote a little summary piece about it 1.0 You wrote that? but I'm not intimately familiar with that data. It cannot A T did be replicated so far as I can tell because it was Okay. And you have said that you would bet that given proprietary to the Canadian Census. 13 the time period in which these 17 to 22 year olds in 14 Okay. You mentioned that you wrote a little blog piece 14 Allen's study were born that many of the individuals who or a little article about that. 15 were in the same sex family group were the product of 16 16 former heterosexual unions; right? Did I say that? I don't think I said that. In that article you said that a limitation of this --Well, let's take a look at your deposition. 18 actually, let me show it to you so we don't have any 1.8 I may have said it. If you could point to the page? 19 confusion here 19 A 20 The document I've marked for identification as Would you agree with that now? Exhibit 56 called "A Married Mom and Dad Really Do Matter: А If you would repeat the question. New Evidence from Canada" that's the blog piece you wrote 22 Sure. You would bet that given the time period in 23 23 which the 17 to 22 year olds in Allen's study were born Yes. 24 24 many of the individuals who were in the same sex family Α group were the product of a former heterosexual union. 2.5 Okay. If you could turn with me to the second page. 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 47 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 Α It's likely given the timing. 1 BY MS. COOPER: 2 2 Again, we don't really have good data on sort of ART in the past. We really don't have good data on it at the five years or ten years? present. it. I've crunched it once. I don't recall offhand the 6 O Okav. But you think it's likely. Tt's likely. numbers. But it varies by, you know, age at marriage and

8 And you've said you suspect that planned same sex 9 couple families were not what the Allen study evaluated on average. I don't think he could, yeah. I mean --Okav. Now, there's been a lot of discussion about couple stability. So I want to ask you some questions about 14 that. 15 First of all, can you tell us generally what the 16 divorce rate for heterosexuals is in this country? A What do you mean by divorce rate? Rate per year, I 18 think it's two percent per year. 19 Isn't the data over sort of a ten-year period? MS. HEYSE: Your Honor, I'm going to object. 21 THE COURT: Let him answer. MS. COOPER: I'm sorry. I thought he was finished. 23 My apologies. Go ahead. 24 A My recollection is the divorce rate is, you know, it's 25 24,000 married women per year.

Q Okay. And is there data showing the divorce rate over, say, you know, percentages of marriages that fail at, say, A The National Study of Family and Growth is able to do things like that 9 Q But as a population as a whole looking at all 10 marriages you don't have a sense of what the divorce rate Over ten years, it would be guess work. Around 20 to 1.3 30 percent -- over five years? No, it be over ten or 15 14 years. It would really be guess work and it would be inappropriate for me to do that. 15 16 Okay. Now, you talked a lot about the issues of instability in the NFSS Study and the "lesbian mother" and 18 "gay father" groups. But there are two concepts that I 19 think got potentially blurred vesterday and I want to see 20 if we can clarify. The concepts of household instability on 21 the one hand, and couple instability on the other. So I 22 have a couple of guestions to help get at that. 23 So, I think your testimony made clear that individuals in the "lesbian mother" and "gay father" groups 2.4

experienced significant household instability, you'd agreed

25

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 14 of 24

BENCH TRIAL - VOLUME 6 - PART A 49 BENCH TRIAL - VOLUME 6 - PART A 50 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 with that; right? relationship lasted two years; is that right? A Right. A That is true, although I'm not sure why, you know, a 2 For example, you noted that a majority of the live-in relationship would suddenly, you know, end and the individuals in this group had started out life in a partner would not be the household. They may have moved, heterosexual mother father family that broke up; right? but I would presume most of them that when a partner leaves That's household instability, that's not about couple the household of the mother and her child that the instability. relationship has probably ceased, but I don't know that for 8 None of these are choices that children make, right? 8 sure. 9 Of course. But is that correct? 9 Now, in some of the cases that you only count two 1.0 years of living with the same sex partner because it was a That's who we are interviewing is the adult children. They're telling us who came and went. change of custody, right, the kid went, say, to live from Understood. So, again, that example, that in the mom's house to dad's house. So in that particular case the majority of the families, you know, the individuals in 13 couple may be together, may not be together; is that right? 14 "lesbian mother" and "gay father" group, the fact that they 14 True. That would require one to go into the actual came from a prior heterosexual union that broke up that's 15 individual household rosters and look at what happened in 16 an example of household instability but not an example of 16 different kids. same sex couple instability; is that right? O But is it correct that the fact that a particular 18 A Correct. If, in fact, those -- what broke was the 1.8 individual reports living two years with the same sex 19 opposite sex relationship. 19 couple and in some cases that has no bearing on the length 20 Which was a majority of the household -of time of the couple, it may be that the child left; That was the majority of the circumstances around there origins. It could be, although it's uncommon and general for a 23 Okav. Now, so, for example, in the NFSS the fact that 23 mother to lose -- you know, cede custody of her child some 24 a subject only spent say two years living in a same sex 24 household that doesn't necessarily mean that the couple 25 2.5 So none of the children in the NESS Study --12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 A Oh, I'm sure some of them did, but I don't know how don't think -- I don't know the state where they lived. But 2 there should have been cases where they lived in states O Let me start that again. Are you saying that none of where their mothers could married, right? the individuals in the "lesbian mother" group experienced a O Let me classify because I think I can be more precise change of custody from mom's custody to dad's? in the question.

A I didn't say that, no. I'm just saying it's less 6 common for a mother to lose custody in general. You can't 8 really tell lose custody. You just know that a child lived with mom or didn't live with mom. The child would report as an adult who he lived with at different years. So did any of the individuals in the "lesbian mother" group from the NSFF report a change from living with mom to

living with dad? I believe there are some cases. I don't recall how 14

15 many.

18

16 Okay. And also in some cases, you know, you stopped

counting when the child was 18, right, so you -- the fact

that an individual reports that mom's partner moved in when

19 they were 16 and then at 18 you're done counting; right?

A Right.

21 Okay. Now, the individuals in the NSFF were all raised

prior to marriage being an option for same sex couples

23 anywhere in the United States; is that right?

24

25 NFSS were 18 in 2011. So they should have been cases -- ${\tt I}$

6 None of the individuals in the NSFF were born

into families where couples, same sex couples could have

heen married: is that correct?

9 That is correct.

10 Okay. And you agree that marriage helps promotes

stability among heterosexual couples.

In general I think it reflects stability. People who

1.3 wish to make their union secure seek marriage. And marriage

14 generally speaking entails -- reflects some security and it

15 entails some security and puts up some barriers to break

16 up.

25

So it does help stabilize couples.

18 Conceptually, yes.

19 Conceptually.

21 In reality do you know?

22 There's something called self-selectivity like the

23 kinds of people who marry are the kind of people who are

2.4 more apt to stay together anyway. But generally speaking

it's understood that marriage both reflects and fosters

BENCH TRIAL - VOLUME 6 - PART A BENCH TRIAL - VOLUME 6 - PART A 54 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 security. relational stability tended to track towards, you know, Okav. So it reflects -- selects for stable couples and greater legal stability. also fosters stability in those couples; is that right? Q But for heterosexuals you recognize that it's not just the matter of selecting the most stable, marriage also Okay. And you have said you would expect greater helps foster stability. stability among married gay and lesbian couples than those 6 On average, yes. even in civil unions; is that right? Okay. Now, you mentioned yesterday that in the NFSS Can you point to where I said that? the household rosters, those are the calendars that you 8 8 9 Sure. Do you have your report? 9 talked about, right, they are complicated not just among 1.0 The report? I don't think I have the report. 1.0 the individuals in the "lesbian mother" and "gay father" I will mark this as 57. Again for identification only. group but also in other groups like the step family group If you'll turn with me to paragraph 49 of your and single parent family group; is that right? report. It's on page 13. 13 14 14 So there was instability for those individuals as 15 Now, just to give the context the previous paragraph 15 well? 16 you'll see is referencing a work by Michael Rosenfeld, a 16 study by Rosenfeld. In 49 you say, So there was instability in all the groups in the "In that study the highest stability rates appear 18 1.8 study except for the one that was defined by the stability among heterosexual married couples while notably better that would be the intact biological family group. 19 19 20 stability is located among married, gay and lesbian couples 2.0 Right. than among those in civil unions as would be expected." Okay. Now, you talked yesterday about your decision You wrote that? 22 not to control for family instability, that you didn't 23 think it was appropriate to do that, but you did 24 0 Okav. 24 effectively control for stability among the exclusively heterosexual parent groups by creating the intact 2.5 Which is a reflection of people who wish to have 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 biological family group; right? You separated out all the 1 0 I mean, the Census data doesn't provide that 2 stable ones. information; does it? A I didn't control for it. It is reflected in the A So far as I know. category. Q Okay. Now, you raised the issue of stability in same sex couple relationships but I think you started to touch O Okay. Still talking about the topic of couples

stability vesterday you cited some data from the UK where you said I think there were higher dissolution rates of civil partnerships of lesbians compared to gav men --8 A Yesterday, I don't saying anything about the UK vesterday. Oh, okay. I thought you did. My notes may be bad. You also talked yesterday about Michael Rosenfeld's study on school progress using the US Census; right? 14 15 16 And you identified this study as relevant to couples' stability I think the language you used, you said the study 18 controlled the way instability. 19 A Controlled for, ves. Q But just to clarify what he controlled for was whether 21 the child actually lived in the particular family structure at issue during the past five years; right?

on it before that there's a variety among groups in the 6 United States about divorce rates when I asked you a 8 question about the divorce rate. 9 So, for example, there are differences in divorce rates associated with race? Generally speaking, ves. 1.3 Different racial groups have different rates of 14 divorce. 15

So is it correct that African-Americans have a higher

And it is correct that interracial couples have higher

16

17

18

19

20

21

A On average although I'm not entirely -- I mean, I'm less clear with that.

22

Okay. And I think you mentioned yesterday that remarriages by what -- I understood it means second

2.4

rate of divorce than other racial groups?

risk of divorce than same race couples?

25 marriages?

He didn't actually control for couple breakups.

23

24

25

A Right.

Right.

BENCH TRIAL - VOLUME 6 - PART A BENCH TRIAL - VOLUME 6 - PART A 5.8 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 So you don't have an opinion about whether prior Α That remarriages fail at a higher rate than first divorce people should be allowed to get married? 0 I mean it exists. I don't think much about it. I don't marriages. have a strong opinion about that. Do you favor excluding African-Americans from marriage So if Michigan were to pass a law barring marriage by based on the elevated rate of divorce in that group? people who had been divorced you wouldn't have an opinion about that? 8 In fact, if there were population base data showing 8 MS. HEYSE: Objection, your Honor. It calls for 9 9 that African-Americans had a breakup rate that was higher speculation and he's answered the question. 1.0 1.0 THE COURT: Sustained. than that of same sex couples you would not favor excluding African-Americans from marriage. BY MS COOPER. MS. HEYSE: Objection, your Honor. Calls for Q Okay. It's not view then is it that groups -- the fact 13 that a group has an elevated divorce rate is a reason to speculation. 14 THE COURT: He's an expert. He can answer if he 14 exclude the group from marriage. 15 has an opinion. 15 16 A I don't. 16 Switching gears and focusing on issues of biological BY MS. COOPER: relatedness what I think you called diminished kinship vesterday. Just to make sure I'm clear with your terms when 18 O Okay. And do you favor excluding people who have 1.8 you talk about diminished kinship you mean the lack of a 19 previously already been married and divorced from 19 20 remarrying given the elevated rate of divorce for biological relationship between parent and child; is that remarriages? A I have no strong opinion on that. I tend to wish 22 Between mother, father and child, yes. 23 people would try to work it out. It's not always possible I 23 Between each parent and the child. 24 understand that, their original marriages. But I don't hold 24 А Right. a strong opinion on that. 2.5 2.5 Okay. And you assert that diminished kinship poses 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 59 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 risks to children; is that right? that we have data about whether that's outside the 2 biological couple or not. We're talking about pretty small A On average. On average. Okay. An example that you've given of diminished kinship would include couples who have children Q But the majority are heterosexual couples not same sex through donor sperm or donor ova; right? couples. It depends on -- I mean -- if it's a donation from 6 outside the couple, that would be a diminished kinship. And you don't have an opinion on whether the use of

8

Right. Somebody goes to a sperm bank or an egg donor 8 Some form of assisted reproductive technology are within the biological parents. That would be an example of diminished kinship? А Not if it's within the biological parents. 14 Right, but if it's outside of. 0 15 Correct. 16 And that includes both for heterosexual couples and same sex couples who have children in this way; is that 18

same sex couples who have children in this way; is that
right?
A Yes.
Q And you said the majority of children born through
assisted reproductive technology are raised by heterosexual
parents; is that right?
A By the numbers that should be the case, yes. Only one

to one and a half percent of all children born today are born via assisted reproductive technology. I don't know

I'm not a fan of that. I don't have a strong opinion. 1.3 I've never weighed in on the subject. 14 Okay. You don't have an opinion about whether it should be prohibited? 15 I'm not of fan of it, I'll tell you that. I don't have 16 a strong sense about the legal permission around it. I 18 think it diminishes kinship so we should privilege that 19 which enhances kinship between a mother, father and child. 20 Now, in support of the proposition that the lack of 21 biological relationship between parents and child poses a 22 risk to children you testified vesterday about comparative 23 rates of abuse by step parents compared to biological parents; right? 2.4 25 Can you say that one more time?

Meaning from a sperm bank let's say.

donor sperm, again, donor from outside the family whether the use of donor sperm or ova should be prohibited.

A From outside the family?

19

20

21

23

24

25

BENCH TRIAL - VOLUME 6 - PART A

62

61

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 TUESDAY, MARCH 4TH, 2014 Sure. That you -- in support of your proposition that remarries. lack of biological relationship between parents and child O Okav. poses a risk to children in support of that proposition you And in the -- the group of people for whom the child testified about comparative rates of abuse by step parents outcomes looked next best where kids for whom their mothers and biological parents; right? and fathers were married until one of them passed away. Okay. So, again, you identified data showing elevated Now, you testified there's an elevated risk of abuse risk of abuse in step families compared to biological 8 by step parents, right, compared to biological parents? families --8 9 Right, and --9 Outside the study. Not the NFSS. 1.0 1.0 Understood. But you don't favor prohibiting marriage by people who already have children, right? In other words, people who So you cited data showing elevated risk abuse in 12 are going to create step families despite the heightened step families compared to biological parent families, but risk to children in step families? 13 you don't favor excluding people who are going to create 14 A Step families come from different kinds of places. I 14 step families, in other words, people who already have mean, sometimes a parent dies and somebody remarries so children from remarrying. 16 they remarry into a step family, but through divorce, but 16 A What do you mean by people who are going to create through death. So step families are complicated as well. step families? 18 O So is it your understanding then that step families 1.8 People who have children -that form, you know, after a parent is widowed versus 19 19 A Right. 20 divorce that they don't have the same kind of risks? -- and want to marry someone. A I don't know if there's a difference in how those Right. Generally not, although, you know -- it is more outcomes work. I do know that, you know, it can be more 22 sympathetic when people have -- when a parent has died than 23 difficult to -- on a child to navigate step families and 23 -- as I said earlier it's nice when people try to work out 24 different custody arrangements which is not the case 24 their arrangements and not get a divorce in the first place typically when the parent dies and the surviving parent because that creates hostile instability for children. But. 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 63 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 in general, no. 1 Did I read that right? 2 Q So even a parent who has divorced, have children, А Right. 2 divorced, they'd like to remarry a new person, you don't Okay. Now, you agree that most heterosexual step think that should be barred. families are blended families; is that right? MS. HEYSE: Objection, your Honor. I believe A Meaning children come from both the marrying woman and 6 that's been asked and answered. 6 the marrying father? THE COURT: I'm not sure. He may answer. O Well, by "blended" -- we can look at your deposition 8 I have no, you know, strong opinion on the legality of 8 if you'd like, but let me ask you this way, by "blended" do 9 that. I mean, it's been around for time and memorial. So I you understand that term to mean the creation of a don't have a strong opinion about it. household out of previous failed households, or failed Okay. Now, I'd like to turn to your report, paragraph 28. Let me get you the page. It's at the bottom of page Some of them fail. Some of them, you know, one person 7, it begins. Paragraph 28. You got it? 1.3 was never married, and they marry somebody who had been 14 14 А Yes. married before, and they're blending something. They're not

15

16

18

19

21

23

2.4

25

have children.

children --

existing family.

Understood

let me pause, by that you mean if it's a reproductive

Okay. So, I'll start again.

"Yet, every child born to a couple via ART" and

"Yet, every child born to a couple via ART

('planned' gay or lesbian family) retains at least one non-

biological 'step' parent suggesting the more favorable

comparison group would not be the biologically intact

mother-father household, but heterosexual step families."

15

16

18

19

21

23

24

25

You say,

technology?

One of them might have been single.

always blending completely, you know, new families.

Sometimes one partner has children, sometimes they both

Sometimes blended marriages with no children.

talking about a new person coming in to somebody -- an

But it's blending two prior families whether they had

And in heterosexual step families you're generally

BENCH TRIAL - VOLUME 6 - PART A

You have diminished kinship but you don't have the

circumstances of the disruption of an existing family unit.

TUESDAY, MARCH 4TH, 2014

66

65

It's a little bit different, right. you had two single people who got married and neither had children; right? Step families --Okay. Now, you -- I believe in your deposition you Two single parents who -were not aware of research that looks at the well-being of Two single people with no children. children conceived through assisted reproduction using Two people. donor sperm or ova; is that right? 8 You have to have children, excuse me, to have a step 8 Population base data. 9 9 family; right? Right. You're not aware of studies on that? 1.0 Correct. Assisted reproductive technology, large population Okay. So step family among heterosexuals are, you basis, no, I'm not. know, a new person coming into an existing family with 12 What about other studies? Non-probability. children. 13 Non-probability ones, you know, where they're kind of 14 14 snowballed samples or something --15 Okay. And in planned same sex parent families you You're aware --16 don't have that circumstance; correct? 16 Right. NLFS is like that as far as I can tell. "Planned" as in assisted reproductive technology. Have you reviewed the research, the non-population 18 0 Correct. 18 base research that body of research on assisted reproduction whether it's heterosexual or same sex couples? 19 Δ Right 19 20 Okay. Now --By "review" you mean --But you still do have -- you know, somebody's not a biological parent of the child. Some of the NLFS studies I've read, not all of them. 23 That's the analogy, right, that's one is non-23 24 biologically related but --24 Outside of the NLFS have you read the research that So there's still diminished kinship. looks at -- compares children raised by donor -- let me ask 2.5 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 it this way. Can we turn to your deposition? If you will look at 2 Studies looking at a class of donor conceived page 43, please? If you would go to line 10 and I'll read 2 children and naturally conceived children, heterosexual with the question, beginning, families? Have you read that body of research? "Question: Are you familiar with the research on A Can you cite a particular author? children conceived through ART using donor egg or sperm I'm just asking if you've read a body of research? 6 6 with a heterosexual or gay parent family? I've read some examples I think out of England. "Answer: I don't believe there's any population 8 And are you aware of research showing then that 8 base data doing that. children conceived by donor insemination whether "Question: Are you aware of any research looking heterosexual parents or same sex parents fair no at such families? differently than naturally conceived children in those "Answer: I'm not. It may exist." studies? Right. I think I was referring to that, the population I don't recall comparison categories. I wouldn't want 1.3 base data. I was not aware of anything. I have looked at 14 14 to speak about any particular study unless I was looking at some non-population base data. it in front of me and looking at the sample sizes, and 15 Okay. 15 16 looking at how the comparison categories were constructed. 16 Referring to the population base aspect of it. Sometimes you can detect no differences in some of these If you'll turn to page 44, line 2, 18 small non-probability samples. And it's a function of 18 "Question: Sure. Do you know whether the non-19 diminished ability to detect real differences that exists. 19 biological parent" -- I'm sorry, Withdrawn, I often will look at the raw scores, right, and at least 20 Moving away from assisted reproduction, focusing

21

22

23

2.4

25

to do so. But I don't want to claim I know about a

see how the differences are in the simple difference level

even if they're not detecting any statistically significant

difference because they may not have the statistical power

particular study unless I'm looking at it in front of me.

21

23

24

25

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

If there are children -- yeah.

Okay. Now, you wouldn't use the term "step family" if

their children than two biological parent families.

on adoption. You are aware of research showing that in

adoptive families where the parents lack, both parents lack

a biological relationship with the children, that there's

research showing that adoptive parents invest more time in

BENCH TRIAL - VOLUME 6 - PART A 69 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 There's some research that suggest that, yes. I don't a strong opinion on -- I've thought very hard about it, who know if the research would all conclude that. should they go to, to one parent, two parents, single, I Okay. Now, you cite uncertainty about outcomes for mean -children of same sex parents as a basis to limit marriage So, do you have an opinion -- you said you don't have to heterosexual couples, but you have no opinion do you a strong opinion, do you have any opinion about whether whether lesbian and gay couples should be allowed to be lesbian and gay couples ought to be allowed to adopt adopt children? children? 8 Can you state that again? 8 I just haven't fashioned one. 9 9 You cite uncertainty about the outcomes for children You don't have one; is that right? 1.0 of same sex parents as a basis to limit marriage to A heterosexual couples, but you have no opinion on whether 0 Okay. So you have no opinion about whether a child lesbian and gay couples should be allowed to adopt 12 would be better off staying in the foster care system 13 rather than being adopted by two parents of the same sex? 14 A The uncertainty about -- I'm still trying to find the 14 A When you think about the State's interest in first part of that clause. sheltering children, most people think it's better to be 16 Q I can ask it differently. I can streamline this 16 out of the foster care system than in the foster care system. Otherwise -- some kids fair okay in the foster question for you. 18 A Okav. 18 system, but it's not the ideal. 19 Do you have an opinion on whether lesbian and gay 19 So you do have an opinion about whether children would 20 couples be allowed to adopt children? better off staying in foster care than being adopted by two I don't have a strong opinion that, no. parents of the same sex? Do you have any opinion? I think you asked me that at the deposition, I don't 23 The State looks to place children with families as a 23 recall what I said. I think I probably had no strong 24 means helping kids who are, you know, orphans -- looking --24 opinion on it.

12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.

it's a concession. The State looks to do that. I don't have

DEBOER, ET. AL. V SNYDER, ET. AL.

Do you have any opinion?

12-10285

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014

1 A No, I don't think so. 2

2.5

Okay. Now, in cases like the situation for plaintiffs

in this case where you have a child who is adopted into a

family headed by a same sex couple is that right that you

have no opinion about whether it's better for the child to

6 be adopted by just one of the adults or both? A Given that it's a concession in the first place and

not an ideal -- not ideal for the child to be apart from 8

its biological parents, but sometimes it's a necessary

concession, I don't believe I made a statement about the --

whether it's one or two. Is that what you're asking? I'm just asking do you have an opinion about in such

situations is it better for the child to be adopted by just

14 one of the two adults raising him or her --

Well, sometimes it's the biological child of one of 15

16 the two adults.

Okay. So a child who is adopted out of the foster care

18 system not related to either partner --

19

-- adopted into a family headed by a same sex couple

21 do you have an opinion whether it's better for that child

to have -- to be adopted by just one of those adults or

23 both of those adults?

24 I think I said at the deposition I didn't have an

25 opinion on that. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014

0 Okay. And is that correct, you don't have an opinion

2

2.5

Yeah, I haven't thought through all the permutations

and combinations so I don't.

So you don't have an opinion.

6 Right.

Okay. And similarly in situations where a child is

conceived into a lesbian couple family through assisted 8

9 reproduction you have no opinion about whether it's better

for the child to be able to adopted by the non-biological

parent to have a legal tie with both parents in the family?

I think you asked me again at the deposition I don't

1.3 have a strong formulated opinion on that.

14 I'm sorry, I didn't hear you.

I don't think I have a strong formulated opinion on 15

16 who should have legal connections and -- when kinship is

diminished.

18 Do you have any opinion?

19 I don't believe I listed one last time.

20 Do you have one now?

21

22 Okay. Now, in situations where a heterosexual couple

23 conceives using, say, donor sperm from a sperm bank, is it

2.4 right you have no opinion about whether it's beneficial to

25 the child to have a legal parent-child relationship with

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 20 of 24

BENCH TRIAL - VOLUME 6 - PART A

DEBOER, ET. AL. V SNYDER, ET. AL.

74

BENCH TRIAL - VOLUME 6 - PART A

DEBOER, ET. AL. V SNYDER, ET. AL.

TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 both parents in that family? link mom, dad and child biologically as well as socially. A I don't know the legalities of these things in terms O But you understand that there are families where's 2 of whose accorded legal status when the mother and father that's not the case. are already married and they go get assisted reproductive I understand that. technology, a donor insemination, I don't purport to know And you have no opinion about whether legal ties at all about how the legal parental rights work in that should be established with both parents -case. I mean, as I said before, I think it's less optimal MS. HEYSE: Objection, your Honor. This has been 8 to get donor inseminated because then you are giving --8 asked several times. taking in a diminished kinship, right, you're taking on 9 9 THE COURT: I'll sustain the objection. 1.0 that rather than working with parents to -- even by ART to 1.0 BY MS. COOPER: retain the genetic connection between mother, father and Q Moving on, switching gears, your position in favor of child. That's optimal. limiting marriage to heterosexual couples is not based Q So going back to the question for heterosexual couples 13 solely on the scientific research related to child outcomes 14 who are infertile and the way they have a child is to get 14 or couple stability; is it? sperm from a sperm bank do you have an opinion about 15 16 whether the non-biological father in that family should be 16 You've never been a fan of same sex marriage; isn't recognized as the legal father to the child born? that right? 18 A I've never fashioned an opinion on that. I presume 1.8 Correct. they are recognized, but I don't -- I'm not an expert in 19 19 And you were not a fan of same sex marriage before you 20 ART or adoption law. even started your work on the NFSS; is that right? So you have no opinion. Generally speaking, no. And that's because in your view marriage in much of Okav. Now --23 human history has privileged expectation of permanency, 24 My only opinion is that states have interest in 24 fidelity, and generally the anticipation of children and reducing diminished kinship, and seeking to heighten the you believe that doesn't comport with same sex marriage; is 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 that right? 0 I can't answer that, but you recognize this an alumni 2 profile. Q And you also agree as a matter of religious Yes, it's not recent. affiliation that sexual relationship outside of marriage Okay. I want to read some quotes attributable you in between a man and a woman are wrong; is that right? this profile. 6 A Can you state that last part again? 6 Sure Sure. That you also agree as a matter of our religious And you'll scroll down to -- six paragraphs down and affiliation that sexual relationships outside of a marriage 8 read along with me. 9 between a man and a woman are wrong? "As Christians our lives should reflect our Δ Yes relationship with God and our desire to glorify him." That doesn't really shape how I go about doing my "I've noticed that some Christian professors see social science, but I do hold that to be true. 1.3 a disconnect between their faith and their profession. I MS. COOPER: Non-responsive, your Honor. 14 14 believe that if your faith matters it should inform what THE COURT: Okay. 15 15 you teach and what you research." 16 BY MS. COOPER: 16 First of all, did I read that correctly? O This is marked for identification -- I believe we're 18 at Exhibit 59, another document. 18 Okay. If you go onto the next paragraph, it says, 19 Professor Regnerus, this document marked for 19 "I've had students here tell me that I'm the only identification as Exhibit 59, is that an alumni profile 20 Christian professor they've had. I'm not approved to share 21 from your alma mater? 21 the Gospel, but I don't necessarily hide my beliefs either. It is. 22 When I teach, I don't seek to break down or build any Q An alumni profile about you. 23 23 particular faith, but my world view colors what I do in the 24 It is. 2.4 classroom." 25 Do you know when that was published? 25 I want to skip down to a quote, again, in the

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 last paragraph of the page, on that yesterday; is that right? 1 "That's what I want my students to recognize the 2 Right. connection between my faith and my work." 3 0 Those people included Luis Tellez? If we could stop there and I just want to ask 4 you, is it right that your faith shapes your interest in He was the President of the Witherspoon Institute? researching sexual decision-making family and relationships? And you presume that the Witherspoon Institute is 8 Yeah, it's a source of interest, although, the genesis 8 against marriage for same sex couples? 9 of my interest in sexual behavior came from a chapter in a 9 I presume so. 1.0 book I was writing when the chapter got really long and 1.0 0 Tellez is also involved with the National Organization very interesting. Prior to that I hadn't been all that for Marriage? interested in studying sexual decision-making. 12 I have heard that. I have never -- I'm not familiar Q But you have said that your faith shapes your interest 13 with all the connections, but he has an affiliation of some 14 14 15 A Yeah, a lot of people when they get interested in 15 Now, that's an organization that advocates for 16 research topics it has some sort of personal connection to 16 limiting marriage to opposite sex couples? them A They do. O I want to --18 1.8 One of the people involved in these conversations that This is fairly an old document though. It doesn't you refer to about research possibilities was Maggie 19 19 20 really -- I've changed a little bit over ten plus years. 2.0 Gallagher; is that right? I'm probably not as -- I'm not as open about my faith as I might have once been. 22 Maggie Gallagher is a prominent advocate against Okav. Now, the idea for the NFSS Study emerged from a 23 marriage for same sex couples; is that right? 24 series of conversations you had with various people about 24 А Correct what research projects could be done. I think you touched 2.5 Now you attended a meeting in Washington, D.C., a grop 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 of people including Luis Tellez from Witherspoon and Maggie 0 Okay. They accepted it? 2 Gallagher among others; is that right? 2 They did. And they funded the study. Q And the purpose of that meeting was to discuss or to think about study possibilities in the area of marriage and Okay. I'd like to mark again for identification 6 relationships? 6 Exhibit 60 A Generally speaking what kind of research questions are Have you had a change to take a look? -- are good to be asked and answered in the broader domain. 8 Could you give me a minute? 9 I think that was -- do you have a date on that? 9 Q If you remember --MS. HEYSE: Your Honor, I just want to make clear I think in the deposition we said in the fall of 2009, you're not moving to admit? 12 MS. COOPER: No. 0 By the way was that the Heritage Foundation, that 1.3 MS. HEYSE: Okay. Thank you. 14 14 meeting? Okav. 15 I don't think it was. 15 BY MS. COOPER:

16

18

19

20

21

22

23

2.4

25

Austin.

right?

A I believe so. 23 Q Ultimately you submitted a proposal to Witherspoon to 24 fund the NFSS Study. 25 A Right.

DEBOER, ET. AL. V SNYDER, ET. AL.

of the meeting attendees of that D.C. meeting that you

Now, the Witherspoon Institute paid the expenses

16

18

19

20

21

Where was it?

A Some hotel.

attended?

12-10285

Hotel, okay.

DEBOER, ET. AL. V SNYDER, ET. AL.

21s, 2010 about the NFSS Study?

So this document that's been marked as Exhibit 60 for

identification is this an email in which Brad Wilcox is

responding to some questions you wrote him on September

Right. So this would be roughly -- yeah. Several

months before we fashioned the first meeting of people in

Q And just to be clear, Wilcox he's the person who

introduced you to Luis Tellez of Witherspoon; is that

BENCH TRIAL - VOLUME 6 - PART A

7.8

BENCH TRIAL - VOLUME 6 - PART A 81 BENCH TRIAL - VOLUME 6 - PART A 82 TUESDAY, MARCH 4TH, 2014 TUESDAY, MARCH 4TH, 2014 Right, roughly a year before that or something. I presume so. Okay. I think you need to speak up just a bit. 0 Okav. I'm sorry. I don't believe I ever -- I don't believe I ever got feedback after that. I saw people leaning. Some share of time before that, roughly a year. I'm just asking whether you wrote this. Okay. I want to call your attention to the bottom 6 paragraph. And, again, just before I read it, this is an Okay. And these are the same individuals, Luis Tellex email you wrote to Brad Wilcox, right, September 21st, 8 8 and Maggie Gallagher who were among others at the meeting 9 9 in Washington, D.C. you mentioned where you talked about 1.0 A Yes. ideas for studies? Okay. Bottom paragraph says, Right "I would like at some point to get more feedback 12 Okay. So you wanted to know what hopes Luis Tellez and from Luis and Maggie about the 'boundaries' around this 13 Maggie Gallagher had for your research project? 14 project, not just costs but also their optimal time lines 14 A I wanted to know what they -- when they anticipated 15 (for the coalition meeting, the data collection, et.) And 15 the results from this, and what it -- what they thought it 16 their hopes for what emerges from this project including 16 would like because we hadn't even met yet in January of the early report we discussed in D.C. Feel free to forward 2011, to start hammering out how are we going to sample this to them." 18 1.8 people, etc. 19 Did I read that right? 19 I was aware of, you know, what Witherspoon 20 thought about same sex marriage, but I was a skeptic at any Now the Luis that refers to Luis Tellez of data analysis project we took on could tackle what they might expect. So I wanted to know like if they had false 23 23 expectations for what this is capable is doing. It was 24 And Maggie is Maggie Gallagher, the advocate against 24 really intended to be a -- it's an intellectual question we same sex marriage? were answering. I think they would be surprised if -- I 2.5 2.5 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 1 didn't know if they would expect that it could answer a lot this referring to. I honestly don't. 2 more questions than I had a feeling it could. 2 Q You don't know what you meant when you wrote that? I don't. Unless it means -- it's probably a reference O At this point had Witherspoon already agreed to fund your study? to the pooling together of consultants and getting together A I don't honestly know. I'm -- I think the formal which we did in January of 2011. That's my best guess. funding came later. I don't recall. 6 O Consultants --Q Will it help you refresh your recollection if you I don't know what coalition meant to me at the time looked to what's numbered as point one, towards the top of 8 8 here. We did meet, a body of consultants in January of 2011 9 9 to hammer out like how we're going to do this study. A I think they probably had given me a voice go ahead, Q And you might -but we hadn't gotten cost estimates yet or anything like It might have been that, I'm not sure. that. I mention it at the bottom that, you know, costs. I You would have called the consultants on your study a didn't know how much it was going to cost and how much they 1.3 A coalition of consultants, yeah, I don't know. 14 14 thought they were capable of funding. Α In point one, you're asking we want to run this 15 0 Okay. 15 project through UT's PRC. I'm presuming 10 percent overhead 16 16 Α That would have made sense. is acceptable to Witherspoon. You're asking about details 17 0 There's not a question pending.

18

19

20

21

22

23

2.4

25

Institute?

A On the bottom

Q Okay. Now in the paragraph at the bottom we were

meeting. What coalition meeting were you referring to?

A The only coalition meeting I can recall is -- was in

the fall of 2009, the one I mentioned at the hotel. But I

don't know about -- I'm not sure what coalition meeting

looking at a moment ago, you reference the coalition

of costs and funding; right?

18

19

20

21

23

24

25

this page. Thanks for clarifying. The bottom email.

I'm going to mark for identification Exhibit 61.

email you received from Luis Tellez of the Witherspoon

So what's been marked as Exhibit 61 is this an

I'm sorry, yes. Below the line there are two emails on

BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH $4^{\rm TH}$, 2014 85 BENCH TRIAL - VOLUME 6 - PART A 86 TUESDAY, MARCH 4TH, 2014 Yes, I believe so. that you submitted the manuscript to the Journal before the And it's dated September -- sorry. September 22nd, data collection was completed; isn't that right? 0 A Ninety-eight percent completed basically and the findings were fairly robust. I mentioned when -- I sent Right. Okay. Now, in the body of it, are you talking about Paul Amato a copy of the manuscript after I submitted it, the NFSS Study they were funding? and said, I didn't think it was a big deal, put it in the Yeah. I mean, it didn't have a name yet. I don't think cue at the social science research. We were waiting on data it had a name. It was an idea at the time. The project that trickling in from Knowledge Networks, just a handful of 8 8 9 was going to get rolling starting in January of 2011. 9 cases. If Social Science Research was going to reject it 1.0 Okay. Now -- let's see. If you look he says, 1.0 then I wanted to know that sooner rather than later. "Move on it. Don't dilly dally etc. It would be Because you had an internal deadline in your head; 12 great to have this before a major decision of the Supreme 12 right? 13 Right, because I inserted this study -- before our Court"; is that right? 14 A Right, and before that he said don't get hung up with 14 report I was intending to write which I never did write. deadlines. Do it as right and best and think how you would 15 Okay. So the study is published in July, 2012, and 16 want it done which is always what I did. 16 online in June of that year; is that right? June 12 I think or 11. O I think you mentioned vesterday that you approached 18 Jim Wright at The Journal Social Science Research and asked 1.8 So this was before the Windsor and Perry cases were 19 him if he would consider reviewing your manuscript of the 19 heard in the H S Supreme Court? 20 NFSS Study and if he be speedy about it? I don't know the time tables of all that stuff. A Right, in part because I had a report that I intended 0 But you were able cite to the study -to write. I had my own internal deadlines around it. It 22 23 just kept getting shifted in the future and I wanted to get 23 -- in the amicus brief that you wrote --24 back to my other research projects. 24 A I don't remember --So you were so eager to have this published speedy Let me finish the question. 2.5 2.5 DEBOER, ET. AL. V SNYDER, ET. AL. DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 12-10285 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 87 BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014 THE COURT: Let her finish the question. said fine. 2 MS. COOPER: It's confusing for the reporter. So you gave that talk a day or so, a day or two before 2 BY MS. COOPER: the study was published, and Heritage gave you immediate

Q Okay. So you were able to cite and discuss the study in the amicus brief that you wrote to the Supreme Court in 6 Windsor and Perry in opposition to same sex marriage; is that right? 8 A True. It was a component of the amicus brief. There were more components to it than just this. Q A day or two before the NFSS Study was to be published

by the Journal, you gave a presentation at the Heritage Foundation about the findings of that study; is that right?

Yes, maybe a day before that or something like that.

Heritage Foundation is a conservative think tank in

14

Washington? 15

16 Right.

18

By the way, were they part of -- does that help

refresh your recollection about the coalition you

19

I don't believe that was the coalition I referring to.

21 That was -- I gave a talk I think Luis probably invited me

to do. I don't know for sure, I don't recall. But that

23 would not have been on my radar back in 2010. That was not

24 the coalition meeting. It was here's a study coming out,

25 would you like to give a talk at Heritage about it and I

training document suggesting talking points for you to use

when talking about the study?

6 A They gave it to me or sent it to me and I largely

ignored it.

8 O I've marked for identification Exhibit 62

MS. HEYSE: Your Honor, I'm going to object on a line of questions. Doctor Regnerus just -- if that's what she intends to do, Dr. Regnerus just testified that he

largely ignored this document.

THE COURT: You may renew your objection. I 1.3

14 haven't her guestion vet so it's hard for me to rule at

this point.

16 MS. COOPER: I will just clarify, he largely

ignored it, doesn't seem to take it off the table.

18 BY MS. COOPER:

22

25

19 Q I want to just first ask you is this the -- this

20 document has a few pages, four pages, and I want to focus

21 on the first two pages of the document. Is that the media

training document provided to you by Heritage?

A I presume so, but as I said I don't believe I used it. 23

2.4 It was recovered in some Freedom of Information Act request

out of some computer file of mine, but it was filed away

Case 4:21-cv-00450-JM Document 156-8 Filed 06/22/22 Page 24 of 24

Q If you look down on paragraph six paragraphs down 3 one of the key points to make that they provided for you 4 is, 5 "For many years" 5 break at 11:00. That's how they have their thing. Is to MS. HEYSE: Objection, your Honor. 6 okay? 7 THE COURT: Sustained. 7 MS. COOPER: Of course. 8 MS. HEYSE: Thank you. 8 THE COURT: I mean, do you want to finish read of the court reporters. That's why we to switch court reporters. That's why we to sw		BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014	89	BENCH TRIAL - VOLUME 6 - PART A TUESDAY, MARCH 4^{TH} , 2014	90
one of the key points to make that they provided for you is, "For many years" "For many years" "She ECOURT: Sustained. "She EYSE: Objection, your Honor. "THE COURT: Sustained. "She ECOURT: Sustained. "She ECOURT: Sustained. "She ECOURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You can't read from it. I think you "THE COURT: You need to take a break, let "THE COURT: We don't need to, but I think it' ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. "A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and filed it in some folder that eventually got discovered and "THE COURT: We don't need to, but I think it' "THE COURT: We don't need to, but I think it' "THE COURT: We don't need to, but I think it' "THE COURT: We don't need to, but I think it' "THE COURT: We don't need to, but I think it' "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don't need to a break, let "THE COURT: We don	1	and it's their words, not mine.	1	organization called the Austin Institute; is that right	?
4 is, "For many years" "For many years" "S. HEYSE: Objection, your Honor. "S. HEYSE: Objection, your Honor. "THE COURT: Sustained. "S. HEYSE: Thank you. "THE COURT: You can't read from it. I think you need a little more foundation in terms of the document. "BY MS. COOPER: If you need to take a break, let BY MS. COOPER: If you need to take a break, let BY MS. COOPER: If you need to take a break, let a understood, Professor Regnerus, you say you largely ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and "I have no recollection if I read it or not. Q So you're saying you never read it? A I have no recollection if I read it or not. Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	2	Q If you look down on paragraph six paragraphs	down 2	A Yes.	
break at 11:00. That's how they have their thing. Is to okay? THE COURT: Sustained. 8 MS. HEYSE: Thank you. 9 THE COURT: You can't read from it. I think you 10 need a little more foundation in terms of the document. 11 BY MS. COOPER: If you need to take a break, let take a break. 12 Q I understood, Professor Regnerus, you say you largely 13 ignored it. I didn't understand you to be saying you did 14 not read it, you did not consider it at all. 15 A Came over email because that's where it was had. I 16 filed it in some folder that eventually got discovered and 17 —— I mean, it's their words, not mine. 18 Q So you're saying you never read it? 19 A I have no recollection if I read it or not. 20 Q Okay. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Teller of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an	3	one of the key points to make that they provided for	you 3	THE COURT: Excuse, I'm sure you have some more	e to
MS. HEYSE: Objection, your Honor. THE COURT: Sustained. MS. HEYSE: Thank you. THE COURT: You can't read from it. I think you THE COURT: You can't read from it. I think you need a little more foundation in terms of the document. MS. COOPER: If you need to take a break, let take a break. Q I understood, Professor Regnerus, you say you largely ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and G So you're saying you never read it? A I have no recollection if I read it or not. Q Okay. A I fas almost two years ago, a year and a half ago. Q Now, apart from your interactions with Luis Tellez of discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	4	is,	4	go. We have to switch court reporters. That's why we ta	ke a
THE COURT: Sustained. MS. HEYSE: Thank you. THE COURT: You can't read from it. I think you need a little more foundation in terms of the document. In take a break. In the COURT: We don't need to take a break, let take a break. In take a break. In the COURT: We don't need to, but I think it' gond time. In the court is don't understand you to be saying you did to read it, you did not consider it at all. In the court is don't understand you to be saying you did to read it, you did not consider it at all. In the court is don't need to, but I think it' good time. In the court is don't need to, but I think it' good ti	5	"For many years"	5	break at 11:00. That's how they have their thing. Is the	at
MS. HEYSE: Thank you. THE COURT: You can't read from it. I think you need a little more foundation in terms of the document. MS. COOPER: It take a break. Q I understood, Professor Regnerus, you say you largely ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and If it is some folder that eventually got discovered and A I have no recollection if I read it or not. Q O kay. A It's almost two years ago, a year and a half ago. Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	6	MS. HEYSE: Objection, your Honor.	6	okay?	
THE COURT: You can't read from it. I think you need a little more foundation in terms of the document. 10	7	THE COURT: Sustained.	7	MS. COOPER: Of course.	
need a little more foundation in terms of the document. 10 MS. COOPER: If you need to take a break, let 11 BY MS. COOPER: 12 Q I understood, Professor Regnerus, you say you largely 13 ignored it. I didn't understand you to be saying you did 14 not read it, you did not consider it at all. 15 A Came over email because that's where it was had. I 16 filed it in some folder that eventually got discovered and 17 I mean, it's their words, not mine. 18 Q So you're saying you never read it? 19 A I have no recollection if I read it or not. 20 Q Okay. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 26 I take a break, let take a break, let take a break, let take a break. 26 THE COURT: We don't need to, but I think it' 18 at a quarter after. 19 (Court recessed, 11:00 a.m.) 27	8	MS. HEYSE: Thank you.	8	THE COURT: I mean, do you want to finish real	
BY MS. COOPER: Q I understood, Professor Regnerus, you say you largely ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and I mean, it's their words, not mine. Q So you're saying you never read it? A I have no recollection if I read it or not. It's almost two years ago, a year and a half ago. Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	9	THE COURT: You can't read from it. I think	you 9	quick? I don't know how much you have.	
12 Q I understood, Professor Regnerus, you say you largely 13 ignored it. I didn't understand you to be saying you did 14 not read it, you did not consider it at all. 15 A Came over email because that's where it was had. I 16 filed it in some folder that eventually got discovered and 17 I mean, it's their words, not mine. 18 Q So you're saying you never read it? 19 A I have no recollection if I read it or not. 20 Q Okay. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 26 THE COURT: We don't need to, but I think it' 18 good time. 19 Cokay. We'll take 15 minutes, and we'll record at a quarter after. 18 (Court recessed, 11:00 a.m.) 19 (Court recessed, 11:00 a.m.) 19 20 Q Okay. 20 A I have no recollection if I read it or not. 21 Q Now, apart from your interactions with Luis Tellez of 22 Witherspoon regarding the meeting in D.C. that you 23 discussed and the funding of your NFSS Study, you mentioned 24 yesterday that you also worked with him to create an	10	need a little more foundation in terms of the documen	nt. 10	MS. COOPER: If you need to take a break, let's	s
ignored it. I didn't understand you to be saying you did not read it, you did not consider it at all. A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and I mean, it's their words, not mine. Q So you're saying you never read it? A I have no recollection if I read it or not. Q Okay. It's almost two years ago, a year and a half ago. It's almost two years ago, a year and a half ago. Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	11	BY MS. COOPER:	11	take a break.	
not read it, you did not consider it at all. 14 Okay. We'll take 15 minutes, and we'll record and 15 at a quarter after. 16 filed it in some folder that eventually got discovered and 16 (Court recessed, 11:00 a.m.) 17 I mean, it's their words, not mine. 17 18 Q So you're saying you never read it? 18 A I have no recollection if I read it or not. 19 Q Okay. 20 A It's almost two years ago, a year and a half ago. 21 Q Now, apart from your interactions with Luis Tellez of 22 Witherspoon regarding the meeting in D.C. that you 23 discussed and the funding of your NFSS Study, you mentioned 24 yesterday that you also worked with him to create an 25	12	Q I understood, Professor Regnerus, you say you la	argely 12	THE COURT: We don't need to, but I think it's	а
A Came over email because that's where it was had. I filed it in some folder that eventually got discovered and I mean, it's their words, not mine. Q So you're saying you never read it? A I have no recollection if I read it or not. Q Okay. It's almost two years ago, a year and a half ago. X I t's almost two years ago, a year and a half ago. X Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an	13	ignored it. I didn't understand you to be saying you	did 13	good time.	
filed it in some folder that eventually got discovered and 16 (Court recessed, 11:00 a.m.) 17 I mean, it's their words, not mine. 18 Q So you're saying you never read it? 18 A I have no recollection if I read it or not. 19 Q Okay. 20 Q Asy. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 26 (Court recessed, 11:00 a.m.) 27 28 (Court recessed, 11:00 a.m.) 29	14	not read it, you did not consider it at all.	14	Okay. We'll take 15 minutes, and we'll reconve	ene
I mean, it's their words, not mine. Q So you're saying you never read it? 18 19 A I have no recollection if I read it or not. 19 Q Okay. 20 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 25	15	A Came over email because that's where it was had.	I 15	at a quarter after.	
18 Q So you're saying you never read it? 19 A I have no recollection if I read it or not. 20 Q Okay. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 26 27	16	filed it in some folder that eventually got discovere	ed and 16	(Court recessed, 11:00 a.m.)	
A I have no recollection if I read it or not. Q Okay. 19 20 Q Okay. 21 A It's almost two years ago, a year and a half ago. 22 Q Now, apart from your interactions with Luis Tellez of 23 Witherspoon regarding the meeting in D.C. that you 24 discussed and the funding of your NFSS Study, you mentioned 25 yesterday that you also worked with him to create an 25	17	I mean, it's their words, not mine.	17		
Q Okay. 20 21 A It's almost two years ago, a year and a half ago. 21 22 Q Now, apart from your interactions with Luis Tellez of 22 23 Witherspoon regarding the meeting in D.C. that you 23 24 discussed and the funding of your NFSS Study, you mentioned 24 25 yesterday that you also worked with him to create an 25	18	Q So you're saying you never read it?	18		
A It's almost two years ago, a year and a half ago. Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an 25	19	A I have no recollection if I read it or not.	19		
Q Now, apart from your interactions with Luis Tellez of Witherspoon regarding the meeting in D.C. that you discussed and the funding of your NFSS Study, you mentioned yesterday that you also worked with him to create an 25	20	Q Okay.	20		
Witherspoon regarding the meeting in D.C. that you 23 discussed and the funding of your NFSS Study, you mentioned 24 yesterday that you also worked with him to create an 25	21	A It's almost two years ago, a year and a half ago	21		
discussed and the funding of your NFSS Study, you mentioned 24 yesterday that you also worked with him to create an 25	22	Q Now, apart from your interactions with Luis Tell	ez of 22		
yesterday that you also worked with him to create an 25	23	Witherspoon regarding the meeting in D.C. that you	23		
	24	discussed and the funding of your NFSS Study, you men	ntioned 24		
12-10285 DEBOER, ET. AL. V SNYDER, ET. AL. 12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.	25	yesterday that you also worked with $\mathop{\mathtt{him}}\nolimits$ to create an	25		
		12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.		12-10285 DEBOER, ET. AL. V SNYDER, ET. AL.	

91

BENCH TRIAL - VOLUME 6 - PART A
TUESDAY, MARCH 4TM, 2014

CERTIFICATE

I, JOAN L. MORGAN, Official Court Reporter for the United States District Court for the Eastern District of Michigan, appointed pursuant to the provisions of Title 28, United States Code, Section 753, do hereby certify that the foregoing proceedings were had in the within entitled and number cause of the date hereinbefore set forth, and I do hereby certify that the foregoing transcript has been prepared by me or under my direction.

12 S:/ JOAN L. MORGAN, CSR 13 Official Court Reporter 14 Detroit, Michigan 48226

1

2

9

10

13 Official Court Reporter
14 Detroit, Michigan 48226
15
16
17
18
19
20
21
22
23
24
25 March 4th, 2014